{"dataset": [[0, "Rhabdomyolysis is an uncommon side effect of trabectedin which is used for the second line therapy of metastatic sarcoma after anthracycline and ifosfamide failure.", {"entities": [[0, 14, "Pathology"], [30, 41, "Pathology"], [45, 56, "Drug"], [102, 120, "Pathology"], [127, 140, "Drug"], [145, 155, "Drug"]]}], [1, "This side effect may be due to pharmacokinetic interactions caused by shared mechanisms of metabolism involving the cytochrome P450 (CYP) system in the liver.", {"entities": [[5, 16, "Pathology"], [116, 137, "Target"]]}], [2, "Here, for the first time in literature, we describe the unexpected onset of heavy toxicity, including rhabdomyolysis, after the fourth course of trabectedin in a patient with retroperitoneal liposarcoma who at the same time was taking an alternative herbal medicine suspected of triggering this adverse event.", {"entities": [[82, 90, "Pathology"], [102, 116, "Pathology"], [145, 156, "Drug"], [175, 202, "Pathology"], [295, 308, "Pathology"]]}], [3, "This is the case of a 56 year old Caucasian man affected by a relapsed de-differentiated liposarcoma who, after the fourth cycle of second-line chemotherapy with trabectedin, complained of sudden weakness, difficulty walking and diffuse muscle pain necessitating complete bed rest.", {"entities": [[22, 33, "Age"], [34, 43, "Ethnic group"], [44, 47, "Sex"], [62, 100, "Pathology"], [132, 173, "Drug"], [196, 204, "Pathology"], [206, 224, "Pathology"], [229, 248, "Pathology"]]}], [4, "Upon admission to our ward the patient showed grade (G) 4 pancytopenia and a marked increase in liver lytic enzymes, serum levels of myoglobin, creatine phosphokinase (CPK) and lactate dehydrogenase.", {"entities": [[46, 70, "Pathology"], [117, 142, "Parameter"], [144, 172, "Parameter"], [177, 198, "Parameter"]]}], [5, "No cardiac or kidney function injuries were present.", {"entities": [[3, 38, "Pathology"]]}], [6, "Based on these clinical and laboratory features, our conclusive diagnosis was of rhabdomyolysis induced by trabectedin.", {"entities": [[81, 95, "Pathology"], [107, 118, "Drug"]]}], [7, "The patient did not report any trauma or muscular overexertion and no co-morbidities were present.", {"entities": [[31, 37, "Pathology"], [41, 62, "Pathology"], [70, 84, "Pathology"]]}], [8, "He had not received any drugs during treatment with trabectedin, but upon further questioning the patient informed us he had been taking a folk medicine preparation of chokeberry (Aronia melanocarpa) daily during the last course of trabectedin and in the 2 subsequent weeks.", {"entities": [[52, 63, "Drug"], [168, 199, "Herb name"], [200, 205, "Frequency"], [232, 243, "Drug"]]}], [9, "One week after hospitalization and cessation of intake of chokeberry extract, CPK and other markers of myolysis slowly returned to standard range, and the patient noted a progressive recovery of muscle strength.", {"entities": [[58, 76, "Extraction process"], [78, 81, "Parameter"], [103, 111, "Pathology"]]}], [10, "The patient was discharged on day 14 when a blood transfusion and parenteral hydration gradually lowered general toxicity.", {"entities": [[105, 121, "Pathology"]]}], [11, "Progressive mobilization of the patient was obtained as well as a complete normalization of the laboratory findings.", {"entities": []}], [12, "The level of evidence of drug interaction leading to the adverse event observed in our patient was 2 (probable).", {"entities": [[57, 70, "Pathology"]]}], [13, "Furthermore, this report draws attention to a potential problem of particular concern, that of nutritional supplements and complementary and alternative drug interactions.", {"entities": [[18, 24, "Study"]]}], [14, "These are not widely recognized and can cause treatment failure.", {"entities": []}], [15, "Despite aggressive surgery and adjuvant radiotherapy, more than half of patients with soft tissue sarcoma develop a locally advanced or metastatic disease [1].", {"entities": [[86, 105, "Pathology"], [116, 154, "Pathology"]]}], [16, "Unfortunately there are very few active drugs for these patients.", {"entities": []}], [17, "By far the most relevant change in this scenario is trabectedin, a drug isolated from the marine microorganism Ecteinascidia turbinate.", {"entities": [[52, 63, "Drug"]]}], [18, "Trabectedin was approved in Europe in 2007 as a single agent for second-line therapy of soft tissue sarcomas, and its activity is mainly relevant in liposarcoma and leiomyosarcoma [2].", {"entities": [[0, 11, "Drug"], [88, 108, "Pathology"], [149, 160, "Pathology"], [165, 179, "Pathology"]]}], [19, "While adverse reactions to trabectedin treatment such as neutropenia and liver function test alterations are well-known, more education and data are needed on some of the rare side effects mediated by this drug, such as the potential induction of rhabdomyolysis.", {"entities": [[6, 23, "Pathology"], [27, 38, "Drug"], [57, 68, "Pathology"], [73, 104, "Pathology"], [176, 188, "Pathology"], [247, 261, "Pathology"]]}], [20, "A recent comprehensive safety analysis confirmed the uncommon occurrence of this side effect and also pointed out the need to avoid pharmacokinetic interactions with concomitant drugs caused by shared mechanisms of metabolism by the cytochrome P450 (CYP) system in the liver [3].", {"entities": [[81, 92, "Pathology"], [233, 261, "Target"]]}], [21, "We describe here the unexpected onset of heavy toxicity including rhabdomyolysis after the fourth course of trabectedin in a patient with retroperitoneal liposarcoma who at the same time was taking an alternative herbal medicine suspected of triggering this adverse event.", {"entities": [[66, 80, "Pathology"], [108, 119, "Drug"], [138, 165, "Pathology"], [258, 271, "Pathology"]]}], [22, "This report calls attention to a potential problem of particular concern, that of herbal-drug interaction.", {"entities": [[5, 11, "Study"]]}], [23, "This problem is not widely recognized and can cause treatment failure in patients without an immediately obvious clinical modification.", {"entities": []}], [24, "This is the case of a 56 year old Caucasian man from Montenegro whose cancer history began in April 2009 after the appearance of progressive abdominal pain due to a retroperitoneum mass measuring 5 \u00d7 8 cm.", {"entities": [[22, 33, "Age"], [34, 43, "Ethnic group"], [44, 47, "Sex"], [70, 76, "Pathology"], [129, 185, "Pathology"]]}], [25, "The patient\u2019s past medical record showed no relevant illness.", {"entities": []}], [26, "He was an ex heavy smoker and did not drink alcohol or use illicit drugs.", {"entities": []}], [27, "In May 2009 he underwent surgical removal of the abdominal mass achieving a complete margin negative (R0) resection.", {"entities": []}], [28, "Histological findings of lesion specimens highlighted a low-grade de-differentiated liposarcoma.", {"entities": [[56, 95, "Pathology"]]}], [29, "He then began follow-up.", {"entities": []}], [30, "In November 2011 a computed tomography (CT) scan detected a new retroperitoneal lesion measuring 5 \u00d7 10 cm whose imaging features clearly suggested relapsed liposarcoma.", {"entities": [[64, 86, "Pathology"], [148, 168, "Pathology"]]}], [31, "He therefore underwent another radical surgery and the second histological examination supported the diagnosis of G2 de-differentiated liposarcoma with myxoid areas.", {"entities": [[114, 164, "Pathology"]]}], [32, "Fluorescence in situ hybridization (FISH) analysis for oncogene murine double minute 2 (MDM2) status highlighted the amplification as highly specific diagnostic markers [4].", {"entities": []}], [33, "After only three months, a new recurrence occurred and owing to the brief relapse-free time he was not considered suitable for additional surgery.", {"entities": []}], [34, "Accordingly, he was treated with chemotherapy including three cycles of doxorubicin followed by three cycles of ifosfamide.", {"entities": [[72, 83, "Drug"], [112, 122, "Drug"]]}], [35, "In spite of chemotherapy, the lesion progressed rapidly reaching 16 \u00d7 10 cm and extending into the pre-aortic seat of the retro-peritoneum space.", {"entities": []}], [36, "In April 2012 the patient was referred to our Institute and underwent second line chemotherapy with trabectedin at a dose of 1.5 mg/m [2], administered as a 24-hour continuous intravenous infusion repeated every 21 days.", {"entities": [[70, 111, "Drug"], [115, 133, "Amount"], [206, 219, "Frequency"]]}], [37, "Intravenous premedication was normally used before trabectedin administration and included dexamethasone 12 mg, palenosetron 250 mcg and chlorphenamine maleate 10 mg. Due to the previous chemotherapy treatment, we decided to use prophylactic peg-G-CSF (granulocytes colony stimulating factor) administered the day after chemotherapy.", {"entities": [[51, 62, "Drug"], [91, 104, "Drug"], [105, 110, "Amount"], [112, 124, "Drug"], [125, 132, "Amount"], [137, 159, "Drug"], [160, 165, "Amount"], [229, 292, "Drug"]]}], [38, "Chemotherapy was well tolerated for the first three courses, and no abnormalities regarding hematological, liver and muscle enzyme levels were present.", {"entities": []}], [39, "At this time, the patient\u2019s Eastern Cooperative Oncology Group (ECOG) performance status was 0 and stable disease was documented by an abdominal CT scan examination.", {"entities": []}], [40, "Due to no alternative therapeutic options, we decided to continue chemotherapy with trabectedin.", {"entities": [[84, 95, "Drug"]]}], [41, "Two weeks after the fourth cycle of chemotherapy, the patient began to complain of sudden weakness, difficulty walking and diffuse muscle pain.", {"entities": [[83, 98, "Pathology"], [100, 118, "Pathology"], [123, 142, "Pathology"]]}], [42, "Some days after he was confined to complete bed rest as the muscle pain became unbearable.", {"entities": [[60, 71, "Pathology"]]}], [43, "For these reasons, the patient was urgently admitted to our ward and parenteral hydration and symptomatic therapy were initiated.", {"entities": []}], [44, "Laboratory tests found G4 pancytopenia and a marked increase in liver lytic enzymes.", {"entities": [[23, 38, "Pathology"]]}], [45, "At the same time, serum levels of myoglobin, creatine phosphokinase (CPK) and lactate dehydrogenase (LDH) showed an increase respectively of eighteen, eight and four times over the upper normal range value (Table\u00a01).", {"entities": [[18, 43, "Parameter"], [45, 73, "Parameter"], [78, 105, "Parameter"]]}], [46, "The absence of abnormalities on electrocardiogram and echocardiography ruled out cardiac etiology for the increased serum level of these enzymes.", {"entities": [[81, 97, "Pathology"]]}], [47, "No kidney function injury was present.", {"entities": [[3, 25, "Pathology"]]}], [48, "He did not report any trauma or muscular overexertion.", {"entities": [[22, 28, "Pathology"], [32, 53, "Pathology"]]}], [49, "Due to the absence of co-morbidity, the patient had not received any other drugs during treatment with trabectedin.", {"entities": [[103, 114, "Drug"]]}], [50, "After further questioning in a non-threatening fashion, the patient informed us that he had been taking a commercial folk medicine preparation of chokeberry juice (Aronia melanocarpa) daily during the last course of trabectedin and in the 2 weeks after.", {"entities": [[146, 183, "Herb name"], [184, 189, "Frequency"], [216, 227, "Drug"]]}], [51, "One week after hospitalization and stopping intake of chokeberry extract, CPK and other markers of myolysis slowly returned to standard range and the patient felt a progressive recovery of muscle strength.", {"entities": [[54, 72, "Extraction process"], [74, 77, "Parameter"], [99, 107, "Pathology"]]}], [52, "The patient was discharged on day 14 when blood transfusion and parenteral hydration gradually reduced general toxicity.", {"entities": [[103, 119, "Pathology"]]}], [53, "A progressive mobilization of the patient was obtained as well as a complete normalization of the laboratory findings (Table\u00a01).", {"entities": []}], [54, "Among mesenchymal tumors, liposarcoma has proven to be the most sensitive to the marine alkaloid trabectedin [2].", {"entities": [[6, 24, "Pathology"], [26, 37, "Pathology"], [81, 108, "Drug"]]}], [55, "This antitumor agent is used in second line therapy after anthracycline and ifosfamide failure.", {"entities": [[5, 20, "Drug"], [58, 71, "Drug"], [76, 86, "Drug"]]}], [56, "In this context, trabectedin acquires a central role in retroperitoneum liposarcoma which relapses very frequently and exhibits low response to few drugs.", {"entities": [[17, 28, "Drug"], [56, 83, "Pathology"]]}], [57, "The most common side effects of trabectedin include myelotoxicity and liver toxicity, mainly in the form of an increase of transaminase.", {"entities": [[16, 28, "Pathology"], [32, 43, "Drug"], [52, 65, "Pathology"], [70, 84, "Pathology"], [123, 135, "Parameter"]]}], [58, "Rhabdomyolysis is an uncommon side effect of trabectedin with an incidence of 0.5-0.7% [3,5].", {"entities": [[0, 14, "Pathology"], [30, 41, "Pathology"], [45, 56, "Drug"]]}], [59, "Nevertheless, it can have an important impact on the morbidity and mortality of patients, and lead to renal failure due to serum release of toxic muscle cell components.", {"entities": [[102, 115, "Pathology"]]}], [60, "Even if multivariate analysis does not identify any predictor factor of rhabdomyolysis developing, it is mandatory to avoid conditions which could trigger this occurrence such as direct trauma, seizures, extreme exertion, body-temperature extremes, muscle hypoxia, infections (sepsis and severe pneumonia) and endocrine disorders (hypothyroidism).", {"entities": [[72, 86, "Pathology"], [179, 192, "Pathology"], [194, 202, "Pathology"], [204, 220, "Pathology"], [222, 247, "Pathology"], [249, 263, "Pathology"], [265, 305, "Pathology"], [310, 346, "Pathology"]]}], [61, "Rhabdomyolysis is not a cumulative adverse effect of trabectedin because the majority of cases happen during the first 3 cycles, but the mechanism by which it may be caused is unknown.", {"entities": [[0, 14, "Pathology"], [35, 49, "Pathology"], [53, 64, "Drug"]]}], [62, "It is possible to deduce from safety analysis and case reports that a relevant risk issue is pharmacodynamic and pharmacokinetic drug interaction [6].", {"entities": [[50, 62, "Study"]]}], [63, "Beyond the pharmacodynamic interaction with substances of abuse such as alcohol and cocaine or medications like statins, concomitant treatments with drugs exerting a CYP inhibitor activity can increase serum trabectedin levels leading to toxicity.", {"entities": [[84, 91, "Herb name"], [112, 119, "Drug"], [149, 188, "Drug"], [208, 219, "Drug"], [238, 246, "Pathology"]]}], [64, "This is because trabectedin is eliminated through hepatic metabolism and CYP3A4 is the principal responsible enzyme mediating its degradation [7].", {"entities": [[16, 27, "Drug"], [73, 79, "Target"]]}], [65, "As known, cancer patients are likely to experience drug interactions due to the increased number and types of chemotherapeutic drugs, their combinations in oncology practice and their narrow therapeutic index, the achievement of a prolonged life expectancy, and the common use of a broad range of ancillary medications to prevent and/or treat cancer-related syndromes and treatment-induced toxicity [8].", {"entities": [[10, 16, "Pathology"], [343, 367, "Pathology"], [372, 398, "Pathology"]]}], [66, "In some cases, a drug interaction may result from an unexpected source, such as herbs or vitamins, which most patients do not consider to be drugs.", {"entities": []}], [67, "Given the lack of effectiveness, many cancer patients treated with conventional therapies also try 'alternative' cancer treatments even when beneficial effects have not been proven [9].", {"entities": [[38, 44, "Pathology"], [113, 119, "Pathology"]]}], [68, "There are many challenges related to alternative medication as a treatment for cancer, not the least toxicity related to the interaction with conventional chemotherapy.", {"entities": [[79, 85, "Pathology"]]}], [69, "Despite the increasing use of these alternative medications among cancer patients, the breadth of their side effects is not always well known and is still seldom addressed, therefore these patients risk being more harmed than helped by these compounds [10,11].", {"entities": [[66, 72, "Pathology"], [104, 116, "Pathology"]]}], [70, "In Table\u00a02 the most common herbal medicines involved in pharmacokinetic interactions with chemotherapeutic drugs via CYP are reported.", {"entities": [[117, 120, "Target"]]}], [71, "An overview of the most common herbal medicines involved in pharmacokinetic CYP interactions with chemotherapeutic drugs In our patient this \u201cnatural foe\u201d was chokeberry (Aronia melanocarpa) extract derived from the black fruit of this shrub.", {"entities": [[76, 79, "Target"], [159, 190, "Herb name"], [191, 198, "Extraction process"], [216, 227, "Herb name"]]}], [72, "This berry has a long tradition in European and North American folk medicine [19].", {"entities": [[5, 10, "Herb name"]]}], [73, "It is a relatively concentrated source of flavonoids such as quercetin, and is also reported to strongly inhibit CYP3A4 activity in the liver.", {"entities": [[42, 52, "Herb name"], [61, 70, "Herb name"], [113, 119, "Target"]]}], [74, "Consequently it is capable of increasing the bioavailability of different chemotherapeutic agents [20].", {"entities": [[74, 97, "Drug"]]}], [75, "Furthermore, the polyphenol anthocyanins in these berries are proven to have antioxidant properties which positively influence several risk factors for cardiovascular disease as well as anti-proliferative or protective effects against colon cancer [21,22].", {"entities": [[17, 40, "Herb name"], [50, 57, "Herb name"], [152, 174, "Pathology"], [235, 247, "Pathology"]]}], [76, "Several other substances such as sorbitol and polyphenols like laetrile advocated by some as a \u201ccure\u201d or a \u201cpreventative\u201d for cancer are burdened by considerable doubt about their safety, and there are no proven beneficial effects for cancer patients [7].", {"entities": [[33, 41, "Herb name"], [46, 57, "Herb name"], [63, 71, "Herb name"], [126, 132, "Pathology"], [235, 241, "Pathology"]]}], [77, "From a clinical-pharmacological point of view, due to the evidence concerning decreased activities of enzymatic markers of CYP after forced feeding of chokeberry juice [23], the adverse event observed in our patient was secondary to the herbal-chemotherapy interaction with a level of evidence of 2 (probable) [24].", {"entities": [[123, 126, "Target"], [151, 167, "Extraction process"], [178, 191, "Pathology"]]}], [78, "Moreover, as the patient took a commercial preparation of chokeberry juice which did not provide information on the amounts of its compounds, it cannot be excluded that other interactions might have occurred such as the inhibition of transport mechanisms, the activation of the death receptor and other unknown mechanisms.", {"entities": [[58, 74, "Extraction process"]]}], [79, "Thus these potential interactions could occur not only with trabectedin but also with other chemotherapies.", {"entities": [[60, 71, "Drug"]]}], [80, "The development of medication databases linked to electronic screening programs is a useful tool that could help health professionals to identify dangerous herbal-drug combinations in the oncology setting [26].", {"entities": []}], [81, "Furthermore, in the presence of unexpected toxicity during conventional anticancer treatment, the simultaneous use by the patient of alternative drugs should be suspected.", {"entities": [[72, 92, "Drug"]]}], [82, "So a thorough medication history, enquiring about nutritional supplements and over-the-counter drugs, may help raise some red flags about potential interactions with chemotherapy.", {"entities": []}], [83, "Written informed consent was obtained from the patient for the publication of this report.", {"entities": []}], [84, "CYP: Cytochrome P450; CT: Computed tomography; MDM2: Oncogene murine double minute 2; peg-G-CSF: Pegylated granulocytes colony stimulating factor; ECOG: Eastern Cooperative Oncology Group; CPK: Creatine phosphokinase; LDH: Lactate dehydrogenase; ALT: Alanine transaminase; AST: Aspartate transaminase.", {"entities": [[0, 20, "Target"], [86, 145, "Drug"], [189, 216, "Parameter"], [218, 244, "Parameter"], [246, 271, "Parameter"], [273, 300, "Parameter"]]}], [85, "The authors declare that they have no competing interests.", {"entities": []}], [86, "SS, MG and VL treated and clinically evaluated the patient, SS and MG drafted the manuscript and were principle authors of the paper, VL and AA contributed to draft the manuscript.", {"entities": []}], [87, "All authors contributed to manuscript revision and approved the final manuscript.", {"entities": []}], [88, "The pre-publication history for this paper can be accessed here:           We would like to thank Caroline Oakley and Silvana Valerio for their assistance in the preparation of this manuscript.", {"entities": []}], [89, "Cannabis products that contain the tetrahydrocannabinol (THC) cannabinoid are emerging as promising therapeutic agents for the treatment of medical conditions such as chronic pain.", {"entities": [[0, 8, "Herb name"], [35, 73, "Herb name"], [167, 180, "Pathology"]]}], [90, "THC elicits psychoactive effects through modulation of dopaminergic neurons, thereby altering levels of dopamine in the brain.", {"entities": [[0, 3, "Herb name"], [55, 76, "Target"]]}], [91, "This case report highlights the complexity associated with medicinal cannabis and the health risks associated with its use.", {"entities": [[69, 77, "Herb name"]]}], [92, "A 57-year-old male with Parkinson\u2019s disease was experiencing worsening tremors and vivid hallucinations despite therapy optimization attempts.", {"entities": [[2, 13, "Age"], [14, 18, "Sex"], [24, 43, "Pathology"], [61, 78, "Pathology"], [83, 103, "Pathology"]]}], [93, "It was discovered that the patient took cannabis for chronic back pain, and a pharmacogenomics (PGx) test indicated the presence of variants for the COMT and HTR2A genes.", {"entities": [[40, 48, "Herb name"], [53, 70, "Pathology"]]}], [94, "These variants could increase dopamine levels and predispose patients to visual hallucinations.", {"entities": [[73, 94, "Pathology"]]}], [95, "Once the cannabis was discontinued, the patient\u2019s hallucinations began to slowly dissipate.", {"entities": [[9, 17, "Herb name"], [50, 64, "Pathology"]]}], [96, "Cannabis use continues to expand as it gains more acceptance legally and medicinally, but cannabis can affect the response to drugs.", {"entities": [[0, 8, "Herb name"], [90, 98, "Herb name"]]}], [98, "These conditions support the importance of considering herb\u2013drug interactions and PGx data when performing a medication safety review.", {"entities": []}], [99, "The use of medical cannabis has steadily gained popularity over the last several years.", {"entities": [[19, 27, "Herb name"]]}], [101, "While the role of cannabis in medicine continues to expand, it is imperative to consider cannabis effects and potential drug interactions.", {"entities": [[18, 26, "Herb name"], [89, 97, "Herb name"]]}], [102, "Research has demonstrated that THC and CBD are substrates of the cytochrome P450 (CYP) enzymes CYP2C9 and CYP2C19, and thus, will increase the risk for drug\u2013drug interactions [4].", {"entities": [[31, 34, "Herb name"], [39, 42, "Herb name"]]}], [103, "Additionally, THC has been shown to elicit its psychoactive effects through modulation of dopaminergic neurons, thereby altering levels of dopamine in different areas of the brain [5].", {"entities": [[14, 17, "Herb name"], [90, 110, "Target"]]}], [104, "Appropriate dopamine levels are vital, as the nervous system utilizes dopamine for the regulation of several physiological functions (e.g., mood, motor, cognitive) [6].", {"entities": []}], [105, "Enzymes and transporters, such as the catechol-O-methyltransferase (COMT) enzyme and dopamine transporters, help regulate the level of dopamine in the synapses [6].", {"entities": []}], [106, "The COMT gene is responsible for producing the COMT enzyme, which acts as a metabolizing enzyme for dopamine [6].", {"entities": []}], [107, "Therefore, genetic alterations of COMT and other relevant genes affecting dopamine can potentially alter how an individual responds to THC [7].", {"entities": [[135, 138, "Herb name"]]}], [108, "Low levels of dopamine in specific brain regions have been found to be associated with certain conditions, such as Parkinson\u2019s disease (PD).", {"entities": [[115, 139, "Pathology"]]}], [109, "PD is a neurodegenerative disease caused by the death of dopamine-producing neurons in the substantia nigra, which is a part of the midbrain responsible for coordinating movement [8].", {"entities": [[0, 2, "Pathology"], [8, 33, "Pathology"]]}], [110, "Neuronal death in this region results in low dopamine concentrations; therefore, treatment strategies for PD often involve initiating medications (e.g., carbidopa-levodopa, ropinirole, entacapone) that result in increased concentrations of dopamine to improve movement control [8].", {"entities": [[106, 108, "Pathology"], [153, 171, "Drug"], [173, 183, "Drug"], [185, 195, "Drug"]]}], [111, "Concomitant intake of cannabis and drugs used in the treatment of PD can significantly modulate dopamine concentrations.", {"entities": [[22, 30, "Herb name"], [66, 68, "Pathology"]]}], [112, "The case described herein demonstrates the importance of considering the pharmacokinetic and pharmacodynamic effects of cannabis and an individual\u2019s pharmacogenomic (PGx) data when evaluating a patient\u2019s medication regimen for therapeutic response and/or adverse drug events.", {"entities": [[120, 128, "Herb name"], [255, 274, "Pathology"]]}], [113, "A 57-year-old male with a past diagnosis of PD began treatment with a new primary care physician (PCP).", {"entities": [[2, 13, "Age"], [14, 18, "Sex"], [44, 46, "Pathology"]]}], [114, "In addition to PD, the patient\u2019s past medical history includes spinal stenosis, vitamin D deficiency, frequent falls, a history of nicotine and alcohol dependence, mild kidney disease, and chronic neck, back, and shoulder pain.", {"entities": [[15, 17, "Pathology"], [63, 78, "Pathology"], [80, 100, "Pathology"], [102, 116, "Pathology"], [164, 183, "Pathology"], [189, 226, "Pathology"]]}], [115, "The patient had spinal surgery approximately two years ago, during which he developed complications (i.e., delirium) from anesthesia, causing him to remain hospitalized for an additional month.", {"entities": [[107, 115, "Pathology"]]}], [116, "During his initial meeting with the PCP, the patient reported experiencing worsening tremors, body pain, and vivid visual hallucinations encompassing small children and flying objects, which the patient claimed to have been seeing for over two years.", {"entities": [[75, 92, "Pathology"], [94, 103, "Pathology"], [109, 136, "Pathology"], [240, 249, "Duration"]]}], [117, "This patient was also prescribed rivastigmine, as Lewy body dementia was recently included as a differential diagnosis due to the presence of these hallucinations.", {"entities": [[33, 45, "Drug"], [50, 68, "Pathology"], [148, 162, "Pathology"]]}], [118, "Upon evaluation of the patient\u2019s past medical history and medications, changes were made to his drug regimen to better control his symptoms, which included increasing the doses for carbidopa-levodopa and rivastigmine (Figure 1).", {"entities": [[181, 199, "Drug"], [204, 216, "Drug"]]}], [119, "The patient\u2019s tremors began to slowly diminish with his new medication regimen; however, his vivid hallucinations were still present.", {"entities": [[14, 21, "Pathology"], [93, 113, "Pathology"]]}], [120, "Upon further inquisition at a subsequent visit, the PCP discovered that approximately two years ago the patient had been advised to chronically use cannabis to manage his chronic back pain.", {"entities": [[148, 156, "Herb name"], [171, 188, "Pathology"]]}], [121, "On average, the patient reported smoking approximately 3 g of cannabis per week.", {"entities": [[55, 58, "Amount"], [62, 70, "Herb name"], [71, 80, "Frequency"]]}], [122, "The new PCP promptly recommended the cessation of cannabis, as its use with other medications could be contributing to his vivid hallucinations.", {"entities": [[50, 58, "Herb name"], [123, 143, "Pathology"]]}], [123, "The patient\u2019s interdisciplinary team continued to evaluate his hallucinations and tremors after discontinuation of cannabis, which was confirmed with a negative drug screen.", {"entities": [[63, 77, "Pathology"], [82, 89, "Pathology"], [115, 124, "Herb name"]]}], [124, "The patient reported that his hallucinations began to diminish slowly over time.", {"entities": [[30, 44, "Pathology"]]}], [125, "As more time elapsed, his hallucinations of children and flying objects changed to seeing only floating dots.", {"entities": [[26, 40, "Pathology"]]}], [126, "Considering the improvement in hallucinations was observed following discontinuation of cannabis, rivastigmine was discontinued as it was determined that the patient\u2019s hallucinations were likely not due to Lewy body dementia.", {"entities": [[31, 45, "Pathology"], [88, 96, "Herb name"], [98, 110, "Drug"], [168, 182, "Pathology"], [206, 224, "Pathology"]]}], [127, "During a follow-up encounter two months later, the patient reported that his hallucinations had disappeared, and control of his tremors had improved further.", {"entities": [[77, 91, "Pathology"], [128, 135, "Pathology"]]}], [128, "The clinical pharmacist recommended dose increases of carbidopa-levodopa to help control his tremors still present early in the morning (Figure 1).", {"entities": [[54, 72, "Drug"], [93, 100, "Pathology"]]}], [129, "A PGx test was also ordered to help determine if a genetic component could explain why this patient experienced such vivid hallucinations from cannabis.", {"entities": [[117, 137, "Pathology"], [143, 151, "Herb name"]]}], [130, "Upon reception of the PGx results (Table 1), the pharmacist observed that the patient was homozygous for the COMT variant (rs4680 AA (Met/Met); this variant is associated with low enzyme (COMT) activity due to a decreased production of the enzyme.", {"entities": []}], [131, "Such a decrease in COMT activity is associated with higher levels of catecholamines (i.e., dopamine) in the brain.", {"entities": []}], [132, "To manage his chronic pain (after cessation of cannabis), the patient was prescribed celecoxib and lidocaine topical patches for back, neck, and shoulder pain.", {"entities": [[14, 28, "Pathology"], [47, 55, "Herb name"], [85, 94, "Drug"], [99, 108, "Drug"], [129, 158, "Pathology"]]}], [133, "However, his PCP determined that additional medication for pain control was warranted.", {"entities": []}], [134, "Given that patient was identified as a CYP2D6 intermediate metabolizer (Table 1; CYP2D6*1/*4), the clinical pharmacist recommended prescribing an opioid that does not utilize the CYP2D6 pathway (e.g., morphine) to decrease the risk of pharmacotherapy failure and/or possible adverse drug events.", {"entities": [[146, 152, "Drug"], [201, 209, "Drug"], [275, 294, "Pathology"]]}], [135, "The use of cannabis products for medical purposes continues to expand as research develops.", {"entities": [[11, 19, "Herb name"]]}], [136, "The patient under consideration in this case report was initially recommended cannabis for analgesia due to chronic back pain.", {"entities": [[78, 86, "Herb name"], [108, 125, "Pathology"]]}], [137, "Guidance is currently available regarding medical cannabis use for the treatment of chronic pain, suggesting that cannabis-based drugs can be considered when all other treatment options have failed [1].", {"entities": [[84, 96, "Pathology"], [114, 122, "Herb name"]]}], [138, "CBD and THC are the two most prominent cannabinoids found in cannabis and have been used to treat multiple sclerosis spasms, neuropathic and cancer pain, nausea, and insomnia [4].", {"entities": [[0, 3, "Herb name"], [8, 11, "Herb name"], [39, 51, "Herb name"], [61, 69, "Herb name"], [107, 123, "Pathology"], [125, 152, "Pathology"], [154, 160, "Pathology"], [166, 174, "Pathology"]]}], [139, "CBD has been utilized as an anxiolytic and the U.S. Food and Drug Administration has approved the CBD oral solution (Epidiolex THC is the main psychoactive cannabinoid in cannabis as both the parent molecule and its 11-hydroxy-delta-9-tetrahydrocannabinol (11-OH-THC) metabolite produce euphoric effects [13].", {"entities": [[0, 3, "Herb name"], [98, 115, "Extraction process"], [117, 130, "Herb name"], [156, 167, "Herb name"], [171, 179, "Herb name"], [216, 267, "Herb name"]]}], [140, "THC does not provide analgesic effects, but its 11-carboxy-delta-9-tetrahydrocannabinol (11-COOH-THC, psychotropically inactive) metabolite possesses anti-inflammatory and analgesic properties [13].", {"entities": [[0, 3, "Herb name"], [48, 100, "Herb name"]]}], [141, "The non-psychoactive analogue of THC, CBD, another cannabinoid found in cannabis, has also shown analgesic and anti-inflammatory effects [14].", {"entities": [[33, 36, "Herb name"], [38, 42, "Herb name"], [51, 62, "Herb name"], [72, 80, "Herb name"]]}], [142, "THC is metabolized by CYP enzymes in the liver, particularly CYP3A4 and CYP2C9 [4,15].", {"entities": [[0, 3, "Herb name"]]}], [143, "CBD is mainly metabolized by CYP3A4 and CYP2C19, and at higher oral doses (5 mg/kg/day), can inhibit CYP2C9 and to a lesser extent CYP1A2 [8,11,16].", {"entities": [[0, 3, "Herb name"], [74, 82, "Amount"], [101, 107, "Target"], [131, 137, "Target"]]}], [144, "Concomitant administration of prescribed medications with cannabis engenders a risk of potential herb\u2013drug CYP450 interactions (Figure 2).", {"entities": [[58, 66, "Herb name"]]}], [145, "Therefore, any drug with a stronger affinity for the CYP2C9, CYP2C19 or CYP3A4 enzymes than THC or CBD, if administered at the same time, could affect their disposition and result in an herb\u2013drug interaction [4,17].", {"entities": [[92, 95, "Herb name"], [99, 102, "Herb name"]]}], [146, "These interactions could lead to increased CBD or THC concentrations and possibly lower concentrations of THC\u2019s metabolites [4,17].", {"entities": [[43, 46, "Herb name"], [50, 53, "Herb name"], [106, 123, "Herb name"]]}], [147, "Furthermore, CYP2C9 and CYP2C19 are both polymorphic enzymes with differing functions that could modulate cannabis exposure if genetic variants are present (which was excluded as a contributing factor for this case) (Table 1) [15,18].", {"entities": [[106, 114, "Herb name"]]}], [148, "Although studies investigating the use of cannabis for pain demonstrated mixed results, there is emerging evidence supporting the benefit of cannabis for pain [19,20,21].", {"entities": [[42, 50, "Herb name"], [55, 59, "Pathology"], [141, 149, "Herb name"], [154, 158, "Pathology"]]}], [149, "Numerous factors can explain discrepancies between study results such as pain models, healthy subjects vs. patients, routes of administration (inhalation vs. oral), and sources of the product [19,20,21].", {"entities": [[73, 77, "Pathology"], [86, 93, "Pathology"]]}], [150, "The utility of cannabis use remains under debate as there is no approved indication, formulation, or dosage for pain.", {"entities": [[15, 23, "Herb name"]]}], [151, "Further research is needed to better understand the efficacy, dose\u2013response effects, routes of administration and side-effect or safety profiles associated with such products.", {"entities": [[114, 125, "Pathology"]]}], [152, "Side effects and safety profiles should be considered for both routes of administrations.", {"entities": [[0, 12, "Pathology"]]}], [153, "PD is characterized by the death of dopamine-producing neurons, specifically in the substantia nigra, which impacts an individual\u2019s ability to control their movements [8].", {"entities": [[0, 2, "Pathology"]]}], [154, "Treatment strategies to combat PD motor symptoms include drugs such as dopamine precursors (e.g., carbidopa-levodopa), dopamine agonists (e.g., ropinirole), COMT inhibitors (e.g., entacapone), and monoamine oxidase B inhibitors (e.g., rasagiline) [8].", {"entities": [[31, 33, "Pathology"], [71, 117, "Drug"], [119, 155, "Drug"], [157, 191, "Drug"], [197, 246, "Drug"]]}], [155, "Additionally, visual hallucinations are a common non-motor symptom observed in patients with PD, and they typically result from long-term use or dose increases of PD drugs [8].", {"entities": [[14, 35, "Pathology"], [93, 95, "Pathology"], [163, 165, "Pathology"]]}], [156, "The cause of these particular hallucinations can be multifactorial but there is evidence attributing them to high levels of dopamine [22].", {"entities": [[30, 44, "Pathology"]]}], [157, "In this patient\u2019s case, the medical team considered the patient\u2019s PD medication regimen and disease progression when attempting to identify the cause of hallucinations while managing worsening tremors.", {"entities": [[66, 68, "Pathology"], [153, 167, "Pathology"], [183, 200, "Pathology"]]}], [158, "The clinical presentation suggested that the patient was not receiving enough dopamine from his medications to control his tremors supporting the proposed increased dose of carbidopa-levodopa.", {"entities": [[123, 130, "Pathology"], [173, 191, "Drug"]]}], [159, "In addition, the dose of rivastigmine was increased to improve cognitive and functional abilities and diminish visual hallucinations [23].", {"entities": [[25, 37, "Drug"], [111, 132, "Pathology"]]}], [160, "These pharmacotherapy interventions improved his tremors; however, his vivid hallucinations were not alleviated which warranted further consideration.", {"entities": [[49, 56, "Pathology"], [71, 91, "Pathology"]]}], [161, "The endocannabinoid system (ECS) is an essential regulator of dopamine levels [4,24].", {"entities": []}], [162, "The ECS is a neuromodulatory system able to regulate several neurons (e.g., dopamine) [4,24,25].", {"entities": []}], [163, "THC acts as a receptor agonist for receptors in the ECS, known as cannabinoid receptor 1 (CB1R) and cannabinoid receptor 2 (CB2R) [4,5,24].", {"entities": [[0, 3, "Herb name"], [66, 95, "Target"], [100, 129, "Target"]]}], [164, "CB1Rs are found predominately in the brain and are located on many neurons presynaptically, as well as postsynaptically [26].", {"entities": [[0, 5, "Target"]]}], [165, "In regards to dopamine neurons, inhibitory neurotransmitters such as gamma-aminobutyric acid (GABA) act on dopamine neurons to regulate and reduce dopamine release into the synapses [5,24,25].", {"entities": [[147, 155, "Parameter"]]}], [166, "When CB1Rs on presynaptic neurons are activated, inhibitory neurotransmitter levels are reduced and dopamine levels increase [5,24,25].", {"entities": [[5, 10, "Target"], [100, 115, "Parameter"]]}], [167, "When THC binds in the striatum and cortex, the euphoric feeling associated with THC occurs; however, abnormal levels of dopamine in the striatal and limbic regions of the brain have been observed in patients experiencing psychotic symptoms, including hallucinations [5,24,27].", {"entities": [[5, 8, "Herb name"], [80, 83, "Herb name"], [251, 265, "Pathology"]]}], [168, "A small percentage of people have been shown to experience psychotomimetic effects with low-dose THC in the presence of genetic polymorphisms [7].", {"entities": [[97, 100, "Herb name"]]}], [169, "The COMT gene is responsible for producing the COMT enzyme, which acts as a metabolizing enzyme for dopamine [6].", {"entities": []}], [170, "The COMT enzyme demonstrates the importance of dopamine regulation within the prefrontal cortex, as there are fewer available dopamine transporters in this region of the brain [28].", {"entities": []}], [171, "In COMT, a common polymorphism can occur due to a change from the amino acid valine (Val) to a methionine (Met) [Val158Met], which results in a reduction in dopamine metabolism [29].", {"entities": []}], [172, "Therefore, carriers of the Met variant experience higher dopamine concentrations in synapses [29].", {"entities": []}], [173, "Studies in healthy individuals with the COMT wild-type have been shown to metabolize dopamine up to four times faster than those with COMT Met/Met, deeming individuals homozygous for Met as having low COMT enzyme activity [28].", {"entities": [[11, 18, "Pathology"]]}], [174, "Interestingly, the patient\u2019s PGx results (Table 1) reported a genotype for COMT Met/Met, therefore higher levels of dopamine in his synapses would be expected.", {"entities": []}], [175, "Research has been conducted to evaluate the effects of the COMT Val158Met polymorphism and the use of cannabis on the risk for psychosis [28,30].", {"entities": [[102, 110, "Herb name"]]}], [176, "In healthy individuals, there is an observed correlation between cannabis use in those with COMT Val/Val and increased risk for psychosis [28,30].", {"entities": [[3, 10, "Pathology"], [65, 73, "Herb name"], [128, 137, "Pathology"]]}], [177, "This genotype is also associated with lower levels of prefrontal dopamine; therefore, this observation is thought to be due to higher levels of phasic dopamine transmission, which aids in the development of psychotic symptoms [28].", {"entities": [[207, 225, "Pathology"]]}], [178, "Additionally, a previous study evaluated patients with PD and their subsequent reactions to cannabis use, reporting that one out of five patients experienced hallucinations [12].", {"entities": [[55, 57, "Pathology"], [92, 100, "Herb name"], [158, 172, "Pathology"]]}], [179, "Given these studies and considering THC can also increase dopamine levels, extra care should be exercised in carriers of the Met variant in regards to cannabis use [31].", {"entities": [[36, 39, "Herb name"], [58, 66, "Parameter"], [151, 159, "Herb name"]]}], [180, "Furthermore, this patient was reported to have a single nucleotide polymorphism on the HTR2A gene, resulting in altered serotonin 2A (5-HT2A) receptor function (Table 1).", {"entities": []}], [181, "While there is a lack of clinical studies with the 5-HT2A receptor and cannabis, research has demonstrated that the CB1R is expressed on serotonin neurons; therefore, the binding of THC to this receptor increases neuronal firing [32].", {"entities": [[25, 41, "Study"], [71, 79, "Herb name"], [116, 120, "Target"], [182, 185, "Herb name"]]}], [182, "In pre-clinical studies, the CB1R and 5-HT2A have been shown to form a heteromer that could be responsible for altered homeostasis of the serotonin system [33].", {"entities": [[3, 23, "Study"], [29, 33, "Target"]]}], [183, "This type of serotonin receptor is commonly found in the prefrontal cortex and evidence has suggested that alterations in receptor function have demonstrated association with mood disorders and psychosis [25].", {"entities": [[175, 189, "Pathology"], [194, 203, "Pathology"]]}], [184, "Several studies have proven that cannabinoids affect the serotonergic system; however, the data regarding the relationship between cannabis and HTR2A and its subsequent effects are limited [25].", {"entities": [[33, 45, "Herb name"], [131, 139, "Herb name"]]}], [185, "The PGx test results identified the patient as a CYP2D6 intermediate metabolizer, which is heavily involved in the metabolism of several opioid drugs utilized for pain (e.g., codeine, tramadol, hydrocodone, oxycodone) [34].", {"entities": [[137, 143, "Drug"], [175, 182, "Drug"], [184, 192, "Drug"], [194, 205, "Drug"], [207, 216, "Drug"]]}], [186, "Guidelines are available for CYP2D6 and select opioids, which state that individuals with CYP2D6 intermediate metabolizer status may experience altered effects (e.g., possible adverse drug events, increased risk for pharmacotherapy failure) when compared to CYP2D6 normal metabolizers [34].", {"entities": [[47, 54, "Drug"], [176, 195, "Pathology"]]}], [187, "Given this patient\u2019s genetic results, guidelines, and current pain status, the clinical pharmacist suggested morphine as an alternative, as it does not utilize CYP2D6 for metabolism [34].", {"entities": [[62, 66, "Pathology"], [109, 117, "Drug"]]}], [188, "Studies have been conducted evaluating pain sensitivity in individuals with COMT genotype Val/Met and Met/Met, reporting that those with this polymorphism have an increased pain sensitivity [35].", {"entities": [[39, 43, "Pathology"], [173, 177, "Pathology"]]}], [189, "In addition, low COMT activity has demonstrated association with increased opioid analgesia and opioid side effects (e.g., nausea, vomiting) [35].", {"entities": [[75, 91, "Drug"], [96, 102, "Drug"], [103, 115, "Pathology"], [123, 129, "Pathology"], [131, 139, "Pathology"]]}], [190, "Considering these studies and the patient\u2019s COMT genotype, if an opioid were to be prescribed, starting a low dose opioid and monitoring for any medication-related side effects would be suggested.", {"entities": [[164, 176, "Pathology"]]}], [191, "There are additional genetic polymorphisms proven to affect an individual\u2019s reaction to THC, such as the Taq1A polymorphism in the dopamine receptor gene; however, these data were not available for the patient at the time of these interventions.", {"entities": [[88, 91, "Herb name"]]}], [192, "[7].", {"entities": []}], [193, "Cannabis use has been demonstrated to have an impact on dopamine concentrations in the brain, resulting in side effects like hallucinations.", {"entities": [[0, 8, "Herb name"], [56, 64, "Parameter"], [107, 119, "Pathology"], [125, 139, "Pathology"]]}], [194, "In a condition like PD, many interactions and their subsequent side effects can occur when combining cannabis with dopamine-promoting drugs and the genetic variants that affect dopamine.", {"entities": [[20, 22, "Pathology"], [63, 75, "Pathology"], [115, 139, "Drug"], [177, 185, "Parameter"]]}], [195, "This patient case demonstrates the importance of considering cannabis use when evaluating for potential drug\u2013drug and drug\u2013gene interactions in an individual\u2019s regimen.", {"entities": [[61, 69, "Herb name"]]}], [196, "Considering all drug-use (e.g., prescribed, recreational, over-the-counter drugs), along with an individual\u2019s PGx results when evaluating a patient allows for a safer and more accurate approach when completing comprehensive assessments.", {"entities": []}], [197, "The authors want to thank Katie Meyer for her assistance.", {"entities": []}], [198, "The authors would also like to thank Pamela Dow and Dana Filippoli, for their comprehensive review and comments on this manuscript.", {"entities": []}], [199, "Publisher\u2019s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.", {"entities": []}], [200, "Conceptualization, N.D.T.-P., D.T., A.M. and V.M.", {"entities": []}], [201, "; writing\u2014original draft preparation, K.P., N.D.T.-P. and D.T.", {"entities": []}], [202, "; writing\u2014review and editing, K.P., N.D.T.-P., D.T., A.H., V.M.", {"entities": []}], [203, "and J.T.", {"entities": []}], [204, "; supervision, D.T., A.M., N.A., V.M.", {"entities": []}], [205, "and J.T.", {"entities": []}], [206, "All authors have read and agreed to the published version of the manuscript.", {"entities": []}], [207, "This research received no external funding.", {"entities": []}], [208, "Not applicable.", {"entities": []}], [209, "Informed consent was obtained from all subjects involved in the study.", {"entities": []}], [210, "Not applicable.", {"entities": []}], [211, "The authors declare no conflict of interest.", {"entities": []}], [212, "Drug and Symptom Change Timeline.", {"entities": []}], [213, "Summary of Affinity and CYP Metabolic Pathways.", {"entities": []}], [214, "Patient\u2019s Pharmacogenomics Test Results.", {"entities": []}], [215, "Academic Editor: Roja Rahimi The worldwide using of herb products and the increasing potential herb-drug interaction issue has raised enthusiasm on discovering the underlying mechanisms.", {"entities": []}], [216, "Previous review indicated that the interactions may be mediated by metabolism enzymes and transporters in pharmacokinetic pathways.", {"entities": []}], [217, "On the other hand, an increasing number of studies found that genetic variations showed some influence on herb-drug interaction effects whereas these genetic factors did not draw much attention in history.", {"entities": [[62, 80, "Parameter"], [150, 165, "Parameter"]]}], [218, "We highlight that pharmacogenomics may involve the pharmacokinetic or pharmacodynamic pathways to affect herb-drug interaction.", {"entities": []}], [219, "We are here to make an updated review focused on some common herb-drug interactions in association with genetic variations, with the aim to help safe use of herbal medicines in different individuals in the clinic.", {"entities": [[20, 37, "Study"], [104, 122, "Parameter"]]}], [220, "Herbal medicinal products (HMPs) belong to a main part of complementary and alternative medicine (CAM).", {"entities": [[0, 32, "Herb name"]]}], [221, "The National Center for Complementary and Alternative Medicine (NCCAM) has defined CAM as those health care practices not currently considered an integral part of conventional medicine [1].", {"entities": []}], [222, "During the past two decades, the world has witnessed an increased rate of conventional medicines integrated with CAM for treatment.", {"entities": [[7, 27, "Duration"]]}], [223, "It was estimated that in 1990 about one-third of the US population used unconventional therapies and the expenditures on this amount to $13.7 billion [2], whereas in 2007 approximately 38 percent of American adults (83 million) are using some form of CAM for their health, and the expenditures reached $34 billion [1].", {"entities": [[199, 207, "Ethnic group"]]}], [224, "Correspondingly the funding for NCCAM has reached $124.125 million in 2013, much more than that was in 1998 ($19.5 million) when it was established [1].", {"entities": []}], [225, "In eastern Asia, countries that have a tradition use of oriental herb medicine for centuries, the prevalence of CAM use is much higher.", {"entities": [[79, 92, "Duration"]]}], [226, "In Japan, the use of CAM in the general population had been reported to be 76% [3].", {"entities": []}], [227, "In China, 93.4% of cancer patients reported having used CAM in 2009-2010 [4].", {"entities": [[19, 25, "Pathology"]]}], [228, "In South Korean population reported a range from 29% to 83% [5].", {"entities": [[3, 15, "Ethnic group"]]}], [229, "The prevalence of HMPs and other forms of CAM for treatment have its reasons.", {"entities": [[18, 22, "Herb name"]]}], [230, "Conventional medicines are relatively more expensive, more difficult, and inconvenience of access and sometimes more likely to get side effects, toxicities, and incomplete efficacy.", {"entities": [[131, 143, "Pathology"], [145, 155, "Pathology"]]}], [231, "CAM, such as traditional Chinese medicine (TCM), though empirical, has been used for centuries and proved to be effective.", {"entities": [[25, 32, "Ethnic group"]]}], [232, "In developing countries like China patients, especially those in rural areas, are more likely to choose HMPs as main medicine for treatment.", {"entities": [[104, 108, "Herb name"]]}], [233, "In developed countries or areas like Japan, the increased use of CAM has promoted the government approval of 148 traditional Japanese (or Chinese) herbal medicines listed on the \u201cNational Health Insurance Drug Tariff\u201d [6].", {"entities": [[125, 133, "Ethnic group"], [138, 145, "Ethnic group"]]}], [234, "Western countries, however, in most cases use herb prescriptions as dietary supplements or as part of a traditional medicine, and this trend is still rising.", {"entities": []}], [235, "This increased the chance of concurrently use of herbs and conventional drugs.", {"entities": []}], [236, "Similar to drug-drug interactions, the multicomponent herbs can exert their effects on pharmacokinetics and consequently lead to herb-drug interactions (HDIs) [7].", {"entities": [[35, 59, "Herb name"], [87, 103, "Parameter"]]}], [237, "Understanding the exact mechanism of each extract of an herb that affects drug's absorption, distribution, metabolism, and excretion (ADME) properties is incomplete at the moment.", {"entities": [[74, 150, "Parameter"]]}], [238, "A review of previous studies indicated that pharmacogenetic factors may help to explain the HDIs effect and give us instructions for rational drug administration.", {"entities": [[44, 67, "Parameter"]]}], [239, "The incidences of herb products to affect drug responses maybe more often in the clinic than expected for it is more easy for patients to conduct self-administration without informing their health care providers.", {"entities": []}], [240, "Some of the interactions may have a beneficial effect by increasing drug efficacy or diminishing potential side effects.", {"entities": [[68, 81, "Parameter"], [107, 119, "Pathology"]]}], [241, "For example, combined therapy of garlic (250\u2009mg/kg) with captopril demonstrated higher synergistic action with respect to fall in blood pressure and ACE inhibition [8]; patients received silymarin (140\u2009mg three times daily) in combination with conventional desferrioxamine therapy showed beneficial effects on thalassemia patients [9].", {"entities": [[33, 39, "Herb name"], [41, 50, "Amount"], [57, 66, "Drug"], [130, 144, "Parameter"], [149, 152, "Target"], [187, 196, "Drug"], [198, 204, "Amount"], [205, 222, "Frequency"], [257, 280, "Drug"], [310, 321, "Pathology"]]}], [242, "However, more often the potential side-effect and outcome influence may be brought about by combination use of HMPs and conventional drugs, and these circumstances are always difficult to predict.", {"entities": [[34, 45, "Pathology"], [111, 115, "Herb name"]]}], [243, "Previous studies identified various mechanisms of pharmacokinetic HDIs, mainly mediated by drug-metabolizing enzymes and transporters [10].", {"entities": []}], [244, "Most of them are substrates of cytochrome P450s (CYPs) and/or P-glycoprotein (P-gp) [11].", {"entities": [[31, 54, "Target"], [62, 83, "Target"]]}], [245, "An important fact is that most of these affected drugs have very narrow therapeutic indices.", {"entities": []}], [246, "So, adverse drug reactions, toxicities, and treatment failure are more likely to occur when they are integrated with herbs.", {"entities": [[4, 26, "Pathology"], [28, 38, "Pathology"]]}], [247, "To date an increasing number of studies in evaluating HDIs have been reported [11].", {"entities": []}], [248, "CYP enzymes can be induced by various herbs.", {"entities": [[0, 11, "Target"]]}], [249, "As the author discussed, St. John's wort may pharmacokinetically interact with clozapine through inducing a number of CYP450 enzymes such as CYP3A4, CYP1A2, CYP2C9, and CYP2C19, which are responsible for clozapine metabolism.", {"entities": [[25, 40, "Herb name"], [79, 88, "Drug"], [118, 132, "Target"], [141, 147, "Target"], [149, 155, "Target"], [157, 163, "Target"], [169, 176, "Target"], [204, 213, "Drug"]]}], [250, "Recently, an in vivo study showed that coadministration of a single dose of baicalin, a Chinese medicine isolated from Scutellaria baicalensis, resulted in a dose-dependent decrease of midazolam in its clearance (CL) from 25%\u2009to 34%, while it increased in AUC Most of study reported that HDIs mechanisms are associated with pharmacokinetics and pharmacodynamics related genes, mainly including CYP450 enzymes and/or P-glycoprotein (P-gp) [11, 17] and also UDP-glucuronosyltransferases (UGTs) [18].", {"entities": [[76, 84, "Herb name"], [88, 95, "Ethnic group"], [119, 142, "Herb name"], [185, 194, "Drug"], [202, 216, "Parameter"], [222, 225, "Amount"], [229, 232, "Amount"], [256, 259, "Parameter"], [394, 408, "Parameter"], [416, 437, "Parameter"], [456, 491, "Parameter"]]}], [251, "For more details we can refer to the reviews [11, 19, 20].", {"entities": []}], [252, "Some studies found that herb induced expression changes of genes may have some specificity; for instance, it was reported that coadministration of Marsdenia tenacissima extract (MTE) with gefitinib significantly decreased the in vitro intrinsic clearance (Clint) of gefitinib by 2.6- and 4.0-fold for CYP2D6 and CYP3A4, respectively, but did not affect other CYP450s [21]; another study reported that hyperoside could selectively inhibit CYP2D6 activity in a dose dependent manner and might cause herb-drug interactions when coadministrated with CYP2D substrates [22].", {"entities": [[147, 182, "Herb name"], [188, 197, "Drug"], [226, 262, "Parameter"], [266, 275, "Drug"], [279, 283, "Amount"], [288, 296, "Amount"], [301, 307, "Target"], [312, 318, "Target"], [359, 366, "Parameter"], [401, 411, "Herb name"], [438, 444, "Target"], [546, 562, "Parameter"]]}], [253, "However, whole herbs like garlic, St. John's wort, Gingko, and so forth are complex compounds.", {"entities": [[26, 32, "Herb name"], [34, 49, "Herb name"], [51, 57, "Herb name"]]}], [254, "Various confounding factors driving the pharmacokinetic profiles of them are considered to be a crucial factor when evaluating HDIs.", {"entities": []}], [255, "In these cases we should make sure the confounding factors are at the same levels in the research situations.", {"entities": []}], [256, "While evaluating the pharmacokinetic synergy effects of different ingredients in a whole herb on HDIs remains a big challenge so far.", {"entities": []}], [257, "Previous studies have made us believe that the genetic involvement in the pharmacokinetic pathways may help us to understand this effect.", {"entities": []}], [258, "Recent pharmacogenomics studies in the following and cases listed in Tables 1 and 2 of these pharmacokinetics and pharmacodynamics related genes may help explain the individual differences in HDIs.", {"entities": [[93, 144, "Parameter"]]}], [259, "Genetic polymorphisms have long been studied and believed to involve pharmacokinetic and pharmacodynamic pathways that cause individual difference in drug responses [47].", {"entities": [[0, 21, "Parameter"]]}], [260, "Herbal medicines are actually a combination of potentially biologically active compounds possessing various inherent pharmacological activities.", {"entities": []}], [261, "The metabolism of these compounds usually occurs by the same mechanisms as that of drugs.", {"entities": []}], [262, "Pharmacokinetic interactions mediated by drug-metabolizing enzymes or transporters are involved in many herb-drug interactions [48], and as the concentrations of the herbal extract and the drug may determine the degree of DHI, polymorphisms in the drug-metabolizing enzyme genes (listed in Table 1) and transporter genes (listed in Table 2) that alter the systemic exposure to the substrate drugs or active components of herbs may affect the risk of interaction [10, 48, 49].", {"entities": [[140, 193, "Parameter"], [227, 320, "Parameter"], [377, 396, "Target"], [400, 426, "Target"]]}], [263, "On the other hand, drug metabolism or transport has alternative pathways.", {"entities": []}], [264, "When poor metabolizer genotype or inhibition of an enzyme may lead to the drug metabolized by another pathway enzymes, which may be more sensitive to their native substrates, then it may cause the competition metabolism of drugs or herbs and eventually HDIs difference.", {"entities": [[5, 30, "Parameter"]]}], [265, "So conducting pharmacogenomics studies on HDIs may help to illuminate the fundamental mechanisms underlying the HDIs.", {"entities": []}], [266, "In the following, we reviewed pharmacogenomics studies, mainly from clinic study, on some important herb products that have been reported to have HDIs.", {"entities": [[30, 54, "Study"], [68, 80, "Study"]]}], [267, "St. John's wort is an herb most commonly used for depression and conditions that sometimes go along with depression such as anxiety, tiredness, loss of appetite, and trouble in sleeping.", {"entities": [[0, 15, "Herb name"], [50, 60, "Pathology"], [105, 115, "Pathology"], [124, 185, "Pathology"]]}], [268, "There is some strong scientific evidence that it is effective for mild to moderate depression.", {"entities": [[66, 93, "Pathology"]]}], [269, "Currently it is displayed that 95 drugs (296 brand and generic names) are known to have a major interaction with St. John's wort.", {"entities": [[113, 128, "Herb name"]]}], [270, "After administration of St John's wort, the AUC Ginkgo is often used for memory disorders including Alzheimer's disease.", {"entities": [[24, 38, "Herb name"], [44, 47, "Parameter"], [48, 54, "Herb name"], [73, 89, "Pathology"], [100, 119, "Pathology"]]}], [271, "It is also used for conditions that seem to be due to reduced blood flow in the brain, especially in older people.", {"entities": [[54, 85, "Pathology"]]}], [272, "These conditions include memory loss, headache, ringing in the ears, vertigo, difficulty concentrating, mood disturbances, and hearing disorders.", {"entities": [[25, 144, "Pathology"]]}], [273, "The decrease was greater in CYP2C19 PMs ( Baicalin is a flavone glucuronide purified from the medical plant Radix scutellariae through uridine diphosphate glucuronidation.", {"entities": [[28, 35, "Parameter"], [42, 50, "Herb name"], [108, 126, "Herb name"], [135, 170, "Parameter"]]}], [274, "Nowadays, baicalin has begun to be used in bilirubin lowering therapy, both prescribed and over the counter, in China.", {"entities": [[10, 18, "Herb name"], [43, 52, "Parameter"]]}], [275, "The mean changes in AUC ratio of bupropion was lower for subjects with CYP2B6 Garlic is widely used around the world for its pungent flavor as a seasoning or condiment.", {"entities": [[20, 29, "Parameter"], [33, 42, "Drug"], [71, 77, "Parameter"], [78, 84, "Herb name"]]}], [276, "There is some scientific evidence that garlic can lower high cholesterol after a few months of treatment.", {"entities": [[39, 45, "Herb name"], [61, 72, "Parameter"], [79, 91, "Duration"]]}], [277, "Garlic seems to also lower blood pressure in people with high blood pressure and possibly slow \u201chardening of the arteries.\u201d There is also some evidence that eating garlic might reduce the chance of developing some cancers such as cancer of the colon and possibly stomach cancer and prostate cancer.", {"entities": [[0, 6, "Herb name"], [27, 41, "Parameter"], [62, 76, "Parameter"], [96, 121, "Pathology"], [164, 170, "Herb name"], [214, 221, "Pathology"], [230, 249, "Pathology"], [263, 277, "Pathology"], [282, 297, "Pathology"]]}], [278, "Coadministration of garlic did not significantly alter warfarin pharmacokinetics or pharmacodynamics.", {"entities": [[20, 26, "Herb name"], [55, 63, "Drug"]]}], [279, "However, subjects with the VKORC1 wild-type genotype showed an increase in the S-warfarin EC50 when warfarin was administered with garlic [50].", {"entities": [[27, 52, "Parameter"], [79, 89, "Drug"], [90, 94, "Parameter"], [100, 108, "Drug"], [131, 137, "Herb name"]]}], [280, "Grapefruit juice, and grapefruit in general, is a potent inhibitor of the cytochrome P450 CYP3A4 enzyme, which can affect the metabolism of a variety of drugs, increasing their bioavailability.", {"entities": [[0, 16, "Extraction process"], [22, 32, "Herb name"], [70, 103, "Parameter"], [177, 192, "Parameter"]]}], [281, "In some cases, this can lead to a fatal interaction with drugs like astemizole or terfenadine.", {"entities": [[68, 78, "Drug"], [82, 93, "Drug"]]}], [282, "Grapefruit juice treatment significantly increased total AUC of lansoprazole in CYP2C19 PMs ( Cranberry juice is the juice of the cranberry.", {"entities": [[0, 16, "Extraction process"], [57, 60, "Parameter"], [64, 76, "Drug"], [80, 87, "Parameter"], [94, 103, "Herb name"], [104, 109, "Extraction process"], [117, 122, "Extraction process"], [130, 139, "Herb name"]]}], [283, "Cranberry juice contains phytochemicals, which may help prevent cancer and cardiovascular disease.", {"entities": [[0, 9, "Herb name"], [10, 15, "Extraction process"], [25, 39, "Herb name"], [64, 97, "Pathology"]]}], [284, "Cranberry juice is high in oxalate and has been suggested to increase the risk for developing kidney stones, although more recent studies have indicated it may lower the risk.", {"entities": [[0, 9, "Herb name"], [10, 15, "Extraction process"], [27, 34, "Herb name"], [94, 107, "Pathology"]]}], [285, "Cranberry significantly increased the area under the INR-time curve by 30% when administered with warfarin without altering pharmacokinetics or plasma protein binding of S- or R-warfarin, and this effect is dependent on VKORC11173T>C polymorphism.", {"entities": [[0, 9, "Herb name"], [34, 67, "Parameter"], [71, 74, "Amount"], [98, 106, "Drug"], [170, 186, "Drug"], [220, 246, "Parameter"]]}], [286, "This case gives us an example of pharmacodynamic pathway gene polymorphisms that can be involved in the herb-drug interaction.", {"entities": []}], [287, "Tianqi Jiangtang is an herb widely used for diabetes treatment in China.", {"entities": [[0, 16, "Herb name"], [44, 52, "Pathology"]]}], [288, "Many of these herbal medicines are correlated with diabetes-related parameters.", {"entities": [[51, 59, "Pathology"]]}], [289, "For example, Rhizoma Coptidis and astragalin in Radix Astragali reduce glucose, similar to Diformin.", {"entities": [[13, 29, "Herb name"], [34, 44, "Herb name"], [48, 63, "Herb name"], [71, 78, "Parameter"], [91, 99, "Drug"]]}], [290, "Berberine in Rhizoma Coptidis improves some glycemic parameters.", {"entities": [[0, 9, "Herb name"], [13, 29, "Herb name"], [44, 63, "Parameter"]]}], [291, "Ginsenoside Re in Radix Ginseng has significant antihyperglycemic effects.", {"entities": [[0, 14, "Herb name"], [18, 31, "Herb name"], [48, 65, "Pathology"]]}], [292, "The rs1142345 (A>G) SNP in the thiopurine S-methyltransferase (TPMT) gene was significantly associated with the hypoglycemic effect of the drug (P = 0.001, FDR P = 0.043).", {"entities": [[0, 73, "Parameter"], [112, 124, "Pathology"]]}], [293, "The \u201cG\u201d allele frequencies of rs1142345 in the healthy (subjects reverted from IGT to normal glucose tolerance), maintenance (subjects still had IGT), and deterioration (subjects progressed from IGT to T2D) groups were 0.094, 0.214, and 0.542, respectively.", {"entities": [[0, 39, "Parameter"], [47, 54, "Pathology"], [79, 82, "Pathology"], [93, 110, "Parameter"], [145, 148, "Pathology"], [195, 198, "Pathology"], [202, 205, "Pathology"], [219, 224, "Amount"], [226, 231, "Amount"], [237, 242, "Amount"]]}], [294, "Rs1142345 was also significantly associated with the hypoglycemic effect of the drug between the healthy and maintenance groups (P = 0.027, OR = 4.828) and between the healthy and deterioration groups (P = 0.001, OR = 7.811).", {"entities": [[0, 9, "Parameter"], [53, 65, "Pathology"], [97, 104, "Pathology"], [168, 175, "Pathology"]]}], [295, "Therefore, rs1142345 was associated with the clinical effect of traditional hypoglycemic herbs.", {"entities": [[11, 20, "Parameter"], [76, 88, "Pathology"]]}], [296, "This is the first study to utilize the ADME gene chip in the pharmacogenetic study of traditional herbs [35].", {"entities": []}], [297, "Due to the limitations of conventional drugs, the use of herbal medicinal products (HMPs) as a CAM integrated with drugs for treatment has been increasing, this eventually will contribute to a rising incidence of herb-drug interactions.", {"entities": [[57, 89, "Herb name"]]}], [298, "However, because of variability in herbal product composition, uncertainty of the causative constituents, and often scant knowledge of causative constituent pharmacokinetics, the mechanisms underlie herb-drug interactions remain an understudied area, and evaluation of herbal product interaction liability is still a big challenge [19].", {"entities": []}], [299, "Studies showed that these HDIs are mediated mainly by metabolism enzymes and transporters in the pharmacokinetic pathways.", {"entities": [[54, 89, "Parameter"]]}], [300, "Polymorphisms in these pharmacokinetic pathways related genes can contribute to the individual difference of HDIs effect.", {"entities": [[0, 13, "Parameter"]]}], [301, "We make an updated review with respect to pharmacogenomics related HDIs on some important herb products and call for a vigilance of using these drug for therapy when the patient is taking medication with narrow therapeutic indices.", {"entities": []}], [302, "Currently, there is still a lack of effective method to predict HDIs in the clinic; the main obstacles are laid by the multiconstituents of an herb.", {"entities": []}], [303, "In the near future years, scientist in this area should focus on identifying individual constituents from herbal products, characterizing pharmacokinetics and pharmacodynamics of each individual constituents, discovering the fundamental genetic bases that eventually facilitate prospective identification of herb-drug interactions.", {"entities": [[106, 121, "Herb name"]]}], [304, "Here we reviewed a definite involvement of pharmacogenomics in HDIs; some other mechanism, such as epigenetic regulations, that is, a recent hotspot area, is also supposed to take part in it.", {"entities": []}], [305, "The National Institute of Health (NIH) and similar organizations in other countries have increased the financial support for scientific investigation on safety use of herb medicines.", {"entities": []}], [306, "This trend will promote the herb medicines more normalization as that of drugs, and the progress may promote finding new effective drugs from extracts of herbs.", {"entities": []}], [307, "With respect to the wide and increasing use of herb drugs and their benefits, and with the progress in pharmacogenomics and pharm-chemistry, we are still optimistic on this area.", {"entities": []}], [308, "This work was supported by the National Scientific Foundation of China (nos.", {"entities": []}], [309, "81273595 and 81373489) and the National High Technology Research and Development Program of China, \u201c863\u201d Project (no.", {"entities": []}], [310, "2012AA02A517 and no.", {"entities": []}], [311, "2012AA02A518).", {"entities": []}], [312, "The authors declare no conflict of interests.", {"entities": []}], [313, "Metabolic enzyme gene polymorphisms and HDIs.", {"entities": [[0, 35, "Parameter"]]}], [314, "AUC: concentration-time curve; EMs: extensive metabolizer; PM: poor metabolizer.", {"entities": [[0, 29, "Parameter"]]}], [315, "Transporter gene polymorphisms and HDIs.", {"entities": [[0, 30, "Parameter"]]}], [316, "This study evaluated the effects of Newbouldia laevis and Cassia abbreviata extracts on CYP450 enzyme activity.", {"entities": [[36, 53, "Herb name"], [58, 75, "Herb name"], [76, 84, "Extraction process"], [88, 94, "Target"]]}], [317, "Recombinant CYP450 enzyme and fluorogenic substrates were used for evaluating inhibition, allowing the assessment of herb\u2013drug interactions (HDI).", {"entities": [[12, 18, "Target"]]}], [318, "Phytochemical fingerprinting was performed using UPLC-MS.", {"entities": []}], [319, "The herbal extracts were risk ranked for HDI based on the IC African populations have used herbal medicines for many centuries.", {"entities": [[11, 19, "Extraction process"], [58, 60, "Parameter"], [61, 68, "Ethnic group"]]}], [320, "Knowledge regarding specific plants and parts of these plants and their function in disease treatment is traditionally passed on from one generation to the next.", {"entities": []}], [321, "With the boom in conventional therapeutic drugs, the utilization of herbal remedies sometimes in combination with other medications has increased tremendously over the last decade [1,2].", {"entities": []}], [322, "It has been demonstrated over the years that herbal remedies possess great therapeutic potential in managing and treating a number of diseases including malaria, hypertension, HIV/AIDS, and cancer.", {"entities": [[153, 160, "Pathology"], [162, 174, "Pathology"], [176, 179, "Pathology"], [180, 184, "Pathology"], [190, 196, "Pathology"]]}], [323, "The use of herbal remedies is especially relevant in developing countries [3,4] due to their affordability and accessibility compared to orthodox health interventions.", {"entities": []}], [324, "Evidence available shows that there are potential interactions between drugs and herbs, some with fatal clinical outcomes [5,6,7].", {"entities": []}], [325, "Despite these fatal herb-drug clinical outcomes, there is still limited information on monitoring herb\u2013drug interactions [8].", {"entities": []}], [326, "Newbouldia laevis (family Bignoniaceae) and Cassia abbreviata (family Fabaceae) are medicinal herbal plants that are used in Western and Southern African countries for the treatment and management of many conditions.", {"entities": [[0, 39, "Herb name"], [44, 79, "Herb name"], [125, 153, "Ethnic group"]]}], [327, "Newbouldia laevis, also known as the tree of life or boundary tree, is a shrub or small tree that grows in West African countries such as Ghana, Nigeria, and Benin.", {"entities": [[0, 17, "Herb name"], [107, 119, "Ethnic group"]]}], [328, "Local names for this shrub include Faangum in Cameroon, Sasanemasa/Sesemasa or Esisimansa in Ghana, Lifui in Togo, and Akoko in Nigeria.", {"entities": [[35, 42, "Herb name"], [56, 75, "Herb name"], [79, 89, "Herb name"], [100, 105, "Herb name"], [119, 124, "Herb name"]]}], [329, "The leaves, stems, and roots are used to treat conditions such as malaria, convulsions, cancer, dyslipidemia, diabetes, hemorrhoids, constipation, peptic ulcer, and cough [9,10].", {"entities": [[4, 10, "Herb part"], [12, 17, "Herb part"], [23, 28, "Herb part"], [66, 73, "Pathology"], [75, 86, "Pathology"], [88, 94, "Pathology"], [96, 108, "Pathology"], [110, 118, "Pathology"], [120, 131, "Pathology"], [133, 145, "Pathology"], [147, 159, "Pathology"], [165, 170, "Pathology"]]}], [330, "Cassia abbreviata is a medium-sized tree that grows in most parts of Africa, especially utilized in Southern African countries such as Botswana, South Africa, Uganda, Zambia, and Zimbabwe.", {"entities": [[0, 17, "Herb name"], [100, 116, "Ethnic group"]]}], [331, "Local names for this shrub include Muremberembe in Zimbabwe, Mahemba in Tanzania, and Monepenepe in Botswana and South Africa.", {"entities": [[35, 47, "Herb name"], [61, 68, "Herb name"], [86, 96, "Herb name"]]}], [332, "The leaves, stems, and roots are used to treat and/or manage a number of diseases such as malaria, diabetes, ulcers, headaches, diarrhoea, constipation, and skin diseases [11,12], and are believed to possess anti-HIV activity [13].", {"entities": [[4, 10, "Herb part"], [12, 17, "Herb part"], [23, 28, "Herb part"], [90, 97, "Pathology"], [99, 107, "Pathology"], [109, 115, "Pathology"], [117, 126, "Pathology"], [128, 137, "Pathology"], [139, 151, "Pathology"], [157, 170, "Pathology"]]}], [333, "Despite the advances made in Western medicine, there are many diseases with no cure and so herbal medicines become the default treatment option.", {"entities": []}], [334, "However, in many cases, herbal medicines are used concurrently with conventional drugs, raising the risk for adverse drug reactions (ADRs) through the alteration of the pharmacokinetic and pharmacodynamics profiles through herb\u2013drug interactions (HDI).", {"entities": [[109, 138, "Pathology"]]}], [335, "Drug-metabolizing enzymes (DMEs) play a very important role in the metabolism of xenobiotics including therapeutic drugs.", {"entities": []}], [336, "The cytochrome P450 (CYP450) family of enzymes especially plays an important role in the biotransformation of about 70% of xenobiotics and other endogenous substances [14].", {"entities": [[4, 28, "Target"]]}], [337, "The composition of herbal medicines is complicated as they contain a number of different phytochemicals and other substances that give them their therapeutic potential.", {"entities": []}], [338, "Notwithstanding the complicated composition of herbal medicines, most of their metabolism is also dependent on DMEs, including the CYP450 enzymes, which might affect the metabolism of other administered drugs, leading to potentially increased risk of HDI [15,16].", {"entities": [[131, 145, "Target"]]}], [339, "There are more than 57 cytochrome P-450 genes identified in humans, with the CYP1, CYP2, and CYP3 families contributing to most of the biotransformation of xenobiotics (including therapeutic drugs) [17,18].", {"entities": [[23, 39, "Target"], [77, 81, "Target"], [83, 87, "Target"], [93, 97, "Target"]]}], [340, "This study concentrated on investigating the effects of potential interaction between extracts from Newbouldia laevis and Cassia abbreviata on CYP1A2, CYP2C9, and CYP2C19 activities.", {"entities": [[86, 94, "Extraction process"], [100, 117, "Herb name"], [122, 139, "Herb name"], [143, 149, "Target"], [151, 157, "Target"], [163, 170, "Target"]]}], [341, "CYP1A2 is responsible for the metabolism of drugs including theophylline, caffeine, imipramine, paracetamol, and phenacetin [19].", {"entities": [[0, 6, "Target"], [60, 72, "Drug"], [84, 94, "Drug"], [96, 107, "Drug"], [113, 123, "Drug"]]}], [342, "Among the substrates of CYP2C9 is the anticoagulant warfarin, non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen, diclofenac, and naproxen, the hypoglycemic agent tolbutamide, phenytoin, and the angiotensin-II receptor antagonist losartan.", {"entities": [[24, 30, "Target"], [38, 60, "Drug"], [62, 108, "Drug"], [117, 126, "Drug"], [128, 138, "Drug"], [144, 152, "Drug"], [158, 188, "Drug"], [190, 199, "Drug"], [209, 252, "Drug"]]}], [343, "CYP2C19 metabolizes a number of commonly used drugs including benzodiazepine diazepam, the proton pump inhibitor omeprazole, propranolol, and the antidepressant amitriptyline [19].", {"entities": [[0, 7, "Target"], [62, 85, "Drug"], [87, 123, "Drug"], [125, 136, "Drug"], [146, 174, "Drug"]]}], [344, "Despite the long-term use of Newbouldia laevis and Cassia abbreviata by several African populations for various ailments, their effects on cytochrome P450 and information on their potential to cause herb-drug interaction (HDI) by inhibition of cytochrome P450 has not been reported.", {"entities": [[29, 46, "Herb name"], [51, 68, "Herb name"], [80, 87, "Target"], [139, 154, "Target"], [244, 259, "Target"]]}], [345, "This study therefore investigated the inhibition profiles of extracts from two medicinal plants, Newbouldia laevis and Cassia abbreviata, on three major CYP450 enzymes, CYP1A2, CYP2C9, and CYP2C19, using recombinant human CYP450 enzymes.", {"entities": [[61, 69, "Extraction process"], [97, 114, "Herb name"], [119, 136, "Herb name"], [153, 167, "Target"], [169, 175, "Target"], [177, 183, "Target"], [189, 196, "Target"], [222, 236, "Target"]]}], [346, "Enzyme kinetic studies were carried out to determine the inhibitory mechanisms of Newbouldia laevis and Cassia abbreviata.", {"entities": [[0, 22, "Study"], [82, 99, "Herb name"], [104, 121, "Herb name"]]}], [347, "The potential of these two herbal plants to cause HDI was also evaluated.", {"entities": []}], [348, "Phytofingerprinting was performed in order to evaluate the profile of possible phytocompounds in both Newbouldia laevis and Cassia abbreviata.", {"entities": [[102, 119, "Herb name"], [124, 141, "Herb name"]]}], [349, "The potency of extracts from Newbouldia laevis (NL) and Cassia abbreviata (CA) to cause inhibition of CYP1A2, CYP2C9, and CYP2C19 activity using the rCYP enzymes was investigated.", {"entities": [[15, 23, "Extraction process"], [29, 51, "Herb name"], [56, 78, "Herb name"], [102, 108, "Target"], [110, 116, "Target"], [122, 129, "Target"], [149, 161, "Target"]]}], [350, "Figure 1 shows the inhibition profiles of NL and CA on CYP1A2, CYP2C9, and CYP2C19.", {"entities": [[42, 44, "Herb name"], [49, 51, "Herb name"], [55, 61, "Target"], [63, 69, "Target"], [75, 82, "Target"]]}], [351, "IC Single point concentrations of the plant extracts at 50 \u00b5g/mL were pre-incubated with or without NADPH and the percentage residual activity compared (Figure 2).", {"entities": [[0, 2, "Parameter"], [44, 52, "Extraction process"], [100, 105, "Target"]]}], [352, "Medicinal plant extracts that were pre-incubated with NADPH showed a significant reduction (p < 0.05) in percent activity of CYP1A2, depicting its TDI potency without the possibility of enzyme recovery; this was not observed for CYP2C9 and CYP2C19 enzyme activities.", {"entities": [[16, 24, "Extraction process"], [54, 59, "Target"], [125, 131, "Target"], [229, 235, "Target"], [240, 247, "Target"]]}], [353, "The IC Extracts of NL and CA showed a TDI potency (dashed line) with an IC CYP1A2, CYP2C9, and CYP2C19 activity were inactivated in a reversible and time-dependent manner by extracts of NL and CA.", {"entities": [[4, 6, "Parameter"], [7, 15, "Extraction process"], [19, 21, "Herb name"], [26, 28, "Herb name"], [72, 74, "Parameter"], [75, 81, "Target"], [83, 89, "Target"], [95, 102, "Target"], [174, 182, "Extraction process"], [186, 188, "Herb name"], [193, 195, "Herb name"]]}], [354, "Linear regression analysis of the time course was used to determine the K A non-targeted approach was used in order to provide information about all possible metabolites present in the analysed samples.", {"entities": []}], [355, "The gradient parameters were adjusted by systematically changing the percentage of solvents to be able to determine as many compounds as possible.", {"entities": []}], [356, "The chromatograms obtained (Figure 8) showed the retention times of the various compounds that were found in the extracts.", {"entities": [[113, 121, "Extraction process"]]}], [357, "Using fragmentation data, and available databases, possible compounds that might be found in the extracts were proposed for CA (Table 1) and NL (Table 2).", {"entities": [[97, 105, "Extraction process"], [124, 126, "Herb name"], [141, 143, "Herb name"]]}], [358, "Selected structures of these polyphenols are shown in Figure 9 and Figure 10 for Cassia abbreviata and Newbouldia laevis respectively.", {"entities": [[29, 40, "Herb name"], [81, 98, "Herb name"], [103, 120, "Herb name"]]}], [359, "It is becoming a common occurrence for in vitro data from HDI studies to be used to predict in vivo HDI risk [21,22,23].", {"entities": [[39, 47, "Study"]]}], [360, "Therefore, in this study, the putative GIT concentration that serves as the inhibitor concentration was calculated as shown in Table 3.", {"entities": []}], [361, "Since the intestinal absorption and plasma concentration of each test compound are not known and with the knowledge that herbal extracts have different bioavailability [24], the bioavailable concentration was estimated using the % yield (weight extracted powdered material/weight of original starting material) to give the soluble extract available in the GIT tract.", {"entities": [[128, 136, "Extraction process"], [152, 167, "Parameter"], [178, 204, "Parameter"], [323, 338, "Extraction process"]]}], [362, "With this knowledge, differential bioavailable concentration was calculated as seen in Table 3.", {"entities": [[34, 60, "Parameter"]]}], [363, "The IC The therapeutic efficacy of medicinal herbal plants is well acknowledged in both developed and developing countries.", {"entities": [[4, 6, "Parameter"]]}], [364, "Medicinal plants from different countries mostly lack valid documentation on their safety, efficacy, manufacturing standards, and quality control.", {"entities": []}], [365, "Given the varied amounts of compounds found in medicinal herbal plants, standardization parameters and development of marker profiles of commonly used medicinal plants are very important for maintaining the quality of herbal remedies and also provide knowledge on the optimal concentrations of the various bio-constituents [25,26].", {"entities": []}], [366, "Despite being natural, medicinal plant extracts are not free from risks and interactions with other drugs and herbs, which may lead to significant public health consequences including the possibility of being fatal [5,6].", {"entities": [[39, 47, "Extraction process"]]}], [367, "Traditionally, whole plants or mixtures of medicinal plants are used rather than isolated compounds from these plants.", {"entities": []}], [368, "Evidence indicates that crude plant extracts often have greater in vitro and/or in vivo therapeutic activity than isolated constituents at an equivalent dose.", {"entities": [[24, 44, "Extraction process"]]}], [369, "The aim of this study therefore was to evaluate the CYP450 inhibition activities of Newbouldia laevis and Cassia abbreviata extracts commonly used in West and Southern Africa for the treatment and/or management of common communicable and non-communicable diseases.", {"entities": [[52, 58, "Target"], [84, 101, "Herb name"], [106, 123, "Herb name"], [124, 132, "Extraction process"]]}], [370, "It was observed that extracts from these two plants had differential inhibitory effects on CYP1A2, 2C9, and 2C19.", {"entities": [[21, 29, "Extraction process"], [91, 112, "Target"]]}], [371, "This could be used for initial assessment of the potential risk of HDI, which would bring awareness and educate the public and/or patients on the dangers of co-use of herbal medicinal remedies and conventional medications.", {"entities": []}], [372, "Drug interactions can result in clinical fatalities; thus, in the drug discovery process, guidelines and opinions have been published by the FDA, EMA, and pharmaceutical industries [27,28] for the conducting of drug\u2013drug interaction (DDI) studies to help target drugs that are likely to cause interactions at the early stages so that such entities can be either discontinued or modified before further processing.", {"entities": [[211, 246, "Study"]]}], [373, "The potential interactions of herbal remedies with prescribed or over-the-counter drugs has been a major safety concern for clinicians and public health practitioners, as such interactions are difficult to predict and also, generally, there is a lack of available information on the composition of herbs and their pharmacological actions [29].", {"entities": []}], [374, "With the tremendous surge in the acceptance of and public interest in herbal medicinal remedies, researchers are adopting the guidelines and opinions proposed for DDI studies to study HDI.", {"entities": [[163, 174, "Study"]]}], [375, "This is helpful with labelling purposes for commercially available herbal products and also to caution patients from combining herbal remedies with known conventional medications [30].", {"entities": []}], [376, "There is limited information currently available regarding the potential of Newbouldia laevis and Cassia abbreviata to interact with clinically prescribed drugs.", {"entities": [[76, 93, "Herb name"], [98, 115, "Herb name"]]}], [377, "This is a safety issue as these herbal plant remedies are commonly used by certain populations.", {"entities": []}], [378, "This study therefore looked at the drug interaction potential of N. laevis and C. abbreviata extracts on three major cytochrome P450 enzymes, CYP1A2, CYP2C9, and CYP2C19.", {"entities": [[65, 74, "Herb name"], [79, 92, "Herb name"], [93, 101, "Extraction process"], [117, 140, "Target"], [142, 148, "Target"], [150, 156, "Target"], [162, 169, "Target"]]}], [379, "Newbouldia laevis extract showed a strong reversible inhibitory effect on CYP1A2 and CYP2C9 enzyme activities whilst exhibiting a moderate reversible inhibition on CYP2C19.", {"entities": [[0, 17, "Herb name"], [18, 25, "Extraction process"], [74, 80, "Target"], [85, 91, "Target"], [164, 171, "Target"]]}], [380, "Cassia abbreviata extract showed a strong reversible inhibitory effect on CYP1A2, CYP2C9, and CYP2C19 enzyme activities.", {"entities": [[0, 17, "Herb name"], [18, 25, "Extraction process"], [74, 80, "Target"], [82, 88, "Target"], [94, 101, "Target"]]}], [381, "The implication is that there is a possibility of enzyme recovery should the herbal extracts inactivate these CYPs.", {"entities": [[84, 92, "Extraction process"], [110, 114, "Target"]]}], [382, "Time-dependent inhibition of CYP450 enzymes that is caused by NCEs is of great concern because such compounds can cause clinically relevant DDI or HDI [31].", {"entities": [[29, 43, "Target"]]}], [383, "The TDI of a CYP enzyme refers to the change in inhibition potency of a NCE as a result of a dosing period that leads to formation of inhibitory metabolites and mechanism-based inhibition [32].", {"entities": [[4, 7, "Parameter"], [13, 23, "Target"]]}], [384, "The use of the IC The differential reversible and irreversible inhibition of CYP1A2, CYP2C9, and CYP2C19 enzymes by Newbouldia laevis and Cassia abbreviata extracts implies that patients who are on prescribed drugs that have narrow therapeutic ranges (for example, theophylline, caffeine, imipramine, paracetamol, phenacetin-CYP1A2, warfarin, non-steroidal anti-inflammatory drugs (NSAIDs), tolbutamide, phenytoin, losartan-CYP2C9, diazepam, omeprazole, propranolol, amitriptyline-CYP2C19, or over-the-counter drugs that are metabolized by similar CYP450 enzymes) stand a risk of having HDI, which can lead to clinical consequences.", {"entities": [[15, 17, "Parameter"], [77, 83, "Target"], [85, 91, "Target"], [97, 104, "Target"], [116, 133, "Herb name"], [138, 155, "Herb name"], [156, 164, "Extraction process"], [265, 277, "Drug"], [289, 299, "Drug"], [301, 312, "Drug"], [314, 324, "Drug"], [325, 331, "Target"], [333, 341, "Drug"], [343, 389, "Drug"], [391, 402, "Drug"], [404, 413, "Drug"], [415, 423, "Drug"], [424, 430, "Target"], [432, 440, "Drug"], [442, 452, "Drug"], [454, 465, "Drug"], [467, 480, "Drug"], [481, 488, "Target"], [548, 562, "Target"]]}], [385, "The TDI effects of these herbals is felt when patients chronically use them because sufficient intermediary metabolites may be generated and this can be deleterious to consumers concomitantly taking conventional medications, as stated earlier.", {"entities": []}], [386, "Single point screening for the effects of pre-incubation with NADPH was performed on CYP1A2, CYP2C9, and CYP2C19.", {"entities": [[62, 67, "Target"], [85, 91, "Target"], [93, 99, "Target"], [105, 112, "Target"]]}], [387, "Data showed significant effects of pre-incubation of Newbouldia laevis extracts on CYP1A2 enzyme activity but not CYP2C9 and CYP2C19 enzyme activities.", {"entities": [[53, 70, "Herb name"], [71, 79, "Extraction process"], [83, 89, "Target"], [114, 120, "Target"], [125, 132, "Target"]]}], [388, "Cassia abbreviata extracts, however, exhibited significant effects on CYP1A2 and CYP2C19 enzyme activities after pre-incubation with NADPH but not CYP2C9 enzyme activity.", {"entities": [[0, 17, "Herb name"], [18, 26, "Extraction process"], [70, 76, "Target"], [81, 88, "Target"], [133, 138, "Target"], [147, 153, "Target"]]}], [389, "These results combined with the TDI potencies imply that these herbs\u2019 inhibitory effects may either be increased or reduced after pre-incubation.", {"entities": []}], [390, "The weakening inhibition potency could be due to recovery of enzyme activity since the inhibition potency of the herbs weakens with time regardless of the concentration applied, whilst the increase in inhibitory potency could be due to the interaction of the herb with CYP450 enzymes during pre-incubation.", {"entities": [[269, 283, "Target"]]}], [391, "Following the inactivation of CYP1A2, CYP2C9, and CYP2C19, the inactivation parameters were determined.", {"entities": [[30, 36, "Target"], [38, 44, "Target"], [50, 57, "Target"]]}], [392, "The kinetic parameters for the inactivation of CYP1A2 by Newbouldia laevis and Cassia abbreviata extracts were: K Herbal medicines consist of multi-phytochemical constituents with different physicochemical properties.", {"entities": [[47, 53, "Target"], [57, 74, "Herb name"], [79, 96, "Herb name"], [97, 105, "Extraction process"]]}], [393, "The risk of HDI of orally administered herbal remedies depends on the bioavailable fraction of the phyto-constituents [34], which may or may not permeate through membrane barriers.", {"entities": []}], [394, "Due to the multi-phyto nature of herbals, their bio-availabilities are variable depending on the constituents [24].", {"entities": [[48, 66, "Parameter"]]}], [395, "Prediction of in vivo HDI using in vitro results [21,23,35,36] gives preliminary information that can caution patients to be wary of combination therapies of herbals with conventional medications and also for pharmaceutical companies and researchers to get baseline information guiding further investigation.", {"entities": [[32, 40, "Study"]]}], [397, "This study assessed the risk of HDI on CYP1A2, CYP2C9, and CY2C19 activities and predicted these herbals can cause HDIs in vivo to a significant extent, with the assumption that at least one phyto-constituent is absorbed to cause HDI.", {"entities": [[39, 45, "Drug"], [47, 53, "Drug"], [59, 65, "Drug"]]}], [398, "Profiling of herbal extracts for the phyto-constituents is a critical step in elucidating the possible mechanisms for HDI potential.", {"entities": [[20, 28, "Extraction process"]]}], [399, "Based on the UPLC-MS data obtained, the crude extracts of Newbouldia laevis and Cassia abbreviata are composed of several different phenolic compounds.", {"entities": [[40, 54, "Extraction process"], [58, 75, "Herb name"], [80, 97, "Herb name"], [132, 150, "Herb name"]]}], [400, "The UPLC-MS profiles indicated the presence of at least 10 polyphenolic candidates including catechins and potent antioxidant flavonoids, which likely give these herbs their therapeutic effects.", {"entities": [[59, 82, "Herb name"], [93, 102, "Herb name"], [114, 136, "Herb name"]]}], [401, "Epidemiological studies of polyphenols suggest that consumption of polyphenol-rich herbs and beverages may contribute to the prevention of diseases including cancers, cardiovascular diseases, osteoporosis, neurodegenerative diseases, and diabetes [38,39].", {"entities": [[0, 23, "Study"], [27, 38, "Herb name"], [67, 88, "Herb name"], [158, 165, "Pathology"], [167, 190, "Pathology"], [192, 204, "Pathology"], [206, 232, "Pathology"], [238, 246, "Pathology"]]}], [402, "However, some of these polyphenols are known to inhibit CYP450 [40,41,42,43].", {"entities": [[23, 34, "Herb name"], [56, 62, "Target"]]}], [403, "It is therefore possible that the interactions observed in this study may be related to some of the constituents that are in these herbs.", {"entities": []}], [404, "Inhibition and kinetic reactions were carried out in Black costar 96-well plates bought from Thermo Fischer Scientific (Pittsburgh, PA, USA).", {"entities": []}], [405, "\u03b1-naphthoflavone, furafylline, sulphaphenazole, and miconazole were purchased from Sigma-Aldrich (St. Louis, MO, USA).", {"entities": [[18, 29, "Drug"], [31, 46, "Drug"], [52, 62, "Drug"]]}], [406, "Vivid The leaves of Newbouldia laevis (UCC/BS/689) and Cassia abbreviata (UB/B/151) were obtained with the assistance of traditional herbal practitioners and authenticated by a botanist from the University of Cape Coast herbarium.", {"entities": [[10, 16, "Herb part"], [20, 37, "Herb name"], [55, 72, "Herb name"]]}], [407, "Voucher specimens were kept at the University of Cape Coast herbarium.", {"entities": []}], [408, "The plant material was air-dried at room temperature and ground into a fine powder.", {"entities": []}], [409, "Extraction was performed using water to mimic the indigenous mode of extraction.", {"entities": []}], [410, "Powdered plant material (10 g) was added to 100 mL of distilled water, heated for one hour at 60 \u00b0C, and allowed to extract for 72 h with 24 h decanting of supernatant and refilling with the same volume of distilled water on solid residue.", {"entities": []}], [411, "Supernatants were pooled, centrifuged (14,000\u00d7 g, 10 min), and filtered using a filter paper (8 \u00b5m, Whatman International LTD, Maidstone, UK).", {"entities": []}], [412, "Filtrates were freeze-dried using a Virtis sentry freeze dryer (the Virtis Company, NC, Gardiner, NY, USA) and the dried powder stored in airtight containers at \u201320\u00b0C until subsequent experiments.", {"entities": []}], [413, "The determination of reversible inhibition was carried out as reported in a previous study with slight modification [23].", {"entities": []}], [414, "An initial study of two-point screening indicated that 100 \u00b5g/mL exhibited the maximum inhibitory effect on CYP1A2, CYP2C9, and CY2C19.", {"entities": [[108, 114, "Target"], [116, 122, "Target"], [128, 134, "Target"]]}], [415, "Reconstitution of extracts in subsequent experiments were performed with 100 \u00b5g/mL concentration as the highest concentration.", {"entities": [[18, 26, "Extraction process"]]}], [416, "Briefly, serial dilutions (1:3) of the medicinal plant extracts from a concentration of 100 \u00b5g/mL were pre-incubated with a mixture of CYP 450 BACULOSOME The procedure followed was similar to that used for the screening of CYP450 inhibition with a slight modification that included employing the curve shift method by Berry and Zhao [20].", {"entities": [[55, 63, "Extraction process"], [135, 142, "Target"], [223, 229, "Target"]]}], [417, "Plant extracts with a starting concentration of 100 \u00b5g/mL were serially diluted (1:3) in black costar 96-well plates.", {"entities": [[6, 14, "Extraction process"]]}], [418, "The black costar plates were divided into two halves.", {"entities": []}], [419, "One half contained a reaction mixture made of BACULOSOME The method used is a slight modification of the CYP450 inhibition and TDI determinations according to the method of Krippendorff et al.", {"entities": [[105, 111, "Target"]]}], [420, "[44].", {"entities": []}], [421, "Briefly, serial dilutions of the extracts were added to a mixture of regeneration system, NADP Phytofingerprinting was performed on the extracts using a Waters Acquity UPLC system (Waters Corporation, Milford, MA, USA) with an Acquity BEH C18 column (2.1 mm \u00d7 100 mm, 1.7 \u00b5m particle size) incorporating a binary pump, vacuum degasser, autosampler, column oven, and Micromass Xevo tandem quadrupole mass spectrometric detector (QTOF xevo G2; Waters micromass, Manchester, UK) equipped with ESI probe.", {"entities": [[33, 41, "Extraction process"], [90, 94, "Target"], [136, 144, "Extraction process"]]}], [422, "Gradient elution was performed at a flow rate of 0.1 mL/min throughout at injection volumes of 10 \u00b5L.", {"entities": []}], [423, "Gradient parameters were adjusted by systematically changing the percentage organic modifier at initial conditions, and/or the isocratic hold period at initial conditions, and/or gradient steepness.", {"entities": []}], [424, "Electrospray mass spectra data were recorded on a negative ionization mode for a mass range m/z 100 to m/z 1500 at a collision energy of 50 V. Relative quantification of some constituents of the extracts was performed as stated previously [23].", {"entities": []}], [425, "Standards of epicatechin, catechin, chlorogenic acid, caffeic acid, and p-coumaric acid were used to generate calibration curves and quantities derived from the calibration curves.", {"entities": [[13, 24, "Herb name"], [26, 34, "Herb name"], [36, 52, "Herb name"], [54, 66, "Herb name"], [72, 87, "Herb name"]]}], [426, "Calibration curve ranges for each reference compound ranged from 0.1 to 100 \u00b5g/mL.", {"entities": []}], [427, "Data generated were exported into an Excel spreadsheet and the amount of metabolite formed at the various concentrations relative to the control (residual activity) was calculated using the equation below:  Percentage residual activity was plotted against the log-transformed concentrations of the extracts and positive inhibitors.", {"entities": [[298, 306, "Extraction process"]]}], [428, "Non-linear regression analysis was used for the sigmoid curve fitting and IC The natural logarithm of the percentage remaining activity was plotted against the pre-incubation times at each extract concentration to obtain K All values are expressed as Mean \u00b1 SEM.", {"entities": [[74, 76, "Parameter"], [189, 196, "Extraction process"]]}], [429, "Comparisons for significance were performed using unpaired t-test with p < 0.05 considered statistically significant.", {"entities": []}], [430, "Most patients in developed and developing countries consume herbal medicines for reasons already elucidated in addition to conventional medicines.", {"entities": []}], [431, "This study has evaluated the inhibitory potencies of Newbouldia laevis and Cassia abbreviata on CYP1A2, CYP2C9, and CYP2C19 activities.", {"entities": [[53, 70, "Herb name"], [75, 92, "Herb name"], [96, 102, "Target"], [104, 110, "Target"], [116, 123, "Target"]]}], [432, "It is observed that these two herbs caused differential inhibition of the CYPs and are likely to cause HDI.", {"entities": [[74, 78, "Target"]]}], [433, "This study gives information on two herbs that have been used for decades and this may be used to caution patients to desist from combining them with other conventional medications.", {"entities": []}], [434, "Research reported in this publication was supported by the National Research Foundation (NRF) under an Indigenous Knowledge Systems Research Grant.", {"entities": []}], [435, "The views and opinions expressed are not those of the NRF but of the authors of the material published.", {"entities": []}], [436, "NET is funded by an NRF grant-holder linked bursary.", {"entities": []}], [437, "Sample Availability: Samples of the compounds are not available from the authors.", {"entities": []}], [438, "Collet Dandara, Dee Blackhurst, Ambroise Wonkam, and Nicholas Ekow Thomford, contributed to the design of the study.", {"entities": []}], [439, "All authors have materially participated in the manuscript preparation.", {"entities": []}], [440, "Nicholas Ekow Thomford performed the laboratory and data analysis.", {"entities": []}], [441, "Nicholas Ekow Thomford and Collet Dandara wrote the draft manuscript and interpretation of data.", {"entities": []}], [442, "Dennis Chopera, Dee Blackhurst, Ambroise Wonkam, and Kevin Dzobo commented.", {"entities": []}], [443, "All authors reviewed the final manuscript.", {"entities": []}], [444, "The authors declare no conflict of interest.", {"entities": []}], [445, "Inhibition profiles (IC Inhibitory effects of 50 \u00b5g/mL concentration of Newbouldia laevis (NL) and Cassia abbreviata (CA) after pre-incubation with NADPH.", {"entities": [[21, 23, "Parameter"], [72, 94, "Herb name"], [99, 121, "Herb name"], [148, 153, "Target"]]}], [446, "(A): CYP1A1; (B): CYP2C9 and (C): CYP2C19, * Significant p value.", {"entities": [[5, 11, "Target"], [18, 24, "Target"], [34, 41, "Target"]]}], [447, "IC Time-dependent inhibition (TDI) classification of medicinal plant extracts on CYP1A2, CYP2C9, and CYP219 activity based on the IC Double reciprocal plots of K Double reciprocal plots of K Double reciprocal plots of K Profiles of crude extracts of Cassia abbreviata (CA) and Newbouldia laevis (NL) after UPLC-MS analysis.", {"entities": [[0, 34, "Parameter"], [69, 77, "Extraction process"], [81, 87, "Target"], [89, 95, "Target"], [101, 107, "Target"], [130, 132, "Parameter"], [232, 246, "Extraction process"], [250, 272, "Herb name"], [277, 299, "Herb name"]]}], [448, "(A,B) represent chromatograms for CA and NL respectively.", {"entities": [[34, 36, "Herb name"], [41, 43, "Herb name"]]}], [451, "Compounds identified in extracts of Cassia abbreviata (CA).", {"entities": [[24, 32, "Extraction process"], [36, 58, "Herb name"]]}], [452, "Compounds identified in extract of Newbouldia laevis (NL).", {"entities": [[24, 31, "Extraction process"], [35, 57, "Herb name"]]}], [453, "Calculation of herbal medicine concentration in the gut.", {"entities": []}], [454, "Note: GIT, Gastrointestinal tract, Putative GIT concentration = dose/ estimated gut fluid volume of 250 mL, estimated bioavailable concentration = (% yield \u00d7 putative GIT concentration)/100.", {"entities": [[118, 144, "Parameter"]]}], [455, "In vivo prediction of HDI from in vitro data for CYP1A2, CYP2C9, and CYP2C19.", {"entities": [[31, 39, "Study"], [49, 55, "Target"], [57, 63, "Target"], [69, 76, "Target"]]}], [456, "Note: HDI, herb-drug interaction, inhibitor concentration = estimated bioavailable concentration (\u00b5g/mL), * the likelihood of a clinically relevant interaction when these herbal extracts are taken is based on the assumption that the % yield serves as the bioavailable fraction, which was used in estimating the bioavailable concentration in the gut and also if there is complete absorption.", {"entities": [[34, 57, "Parameter"], [60, 96, "Parameter"], [178, 186, "Extraction process"], [311, 337, "Parameter"]]}], [457, "Experimental conditions involved in fluorogenic assay.", {"entities": []}], [458, "Herb-drug interactions (HDI) has become important due to the increasing popularity of natural health product consumption worldwide.", {"entities": []}], [459, "HDI is difficult to predict as botanical drugs usually contain complex phytochemical-mixtures, which interact with drug metabolism.", {"entities": [[31, 46, "Herb name"]]}], [460, "Currently, there is no specific pharmacological tool to predict HDI since almost all in vitro-in vivo-extrapolation (IVIVE) Drug-Drug Interaction (DDI) models deal with one inhibitor-drug and one victim-drug.", {"entities": []}], [461, "The objectives were to modify-two IVIVE models for the prediction of in vivo interaction between caffeine and furanocoumarin-containing herbs, and to confirm model predictions by comparing the DDI predictive results with actual human data.", {"entities": [[97, 105, "Herb name"], [110, 141, "Herb name"]]}], [462, "Different hepatic inlet inhibitor concentration ([I] 5-methoxypsoralen 8-methoxypsoralen area-under-curve (from time zero to infinity) ratio body weight concentration-addition model maximum concentration cytochrome P450 drug-drug interaction geometric mean fold-error herb-drug interaction human liver microsomes hepatic inlet inhibitor concentration isopimpinellin in vitro-in vivo extrapolation natural logarithm common logarithm mechanism-based inhibitor standard deviation time-dependent inhibitor", {"entities": [[10, 47, "Parameter"], [53, 88, "Herb name"], [89, 140, "Parameter"], [141, 152, "Parameter"], [153, 166, "Parameter"], [182, 203, "Parameter"], [204, 219, "Parameter"], [313, 350, "Parameter"], [351, 365, "Herb name"]]}], [463, "Academic Editor: Youn Chul Kim Many active components of herbal products are small organic anions, and organic anion transporters were previously demonstrated to be a potential site of drug-drug interactions.", {"entities": [[36, 97, "Herb name"], [103, 129, "Parameter"]]}], [464, "In this study, we assessed the inhibitory effects of six hydrophilic components of the herbal medicine Danshen, lithospermic acid, protocatechuic acid, rosmarinic acid, salvianolic acid A, salvianolic acid B, and tanshinol, on the function of the murine organic anion transporters, mOat1 and mOat3.", {"entities": [[57, 222, "Herb name"], [243, 297, "Target"]]}], [465, "Kinetic analysis demonstrated that LSA, RMA, and SAA were competitive inhibitors.", {"entities": [[35, 52, "Herb name"]]}], [466, "Despite this long history of medicinal use, the issue of which component(s) is (are) responsible for its therapeutic effects, and the precise biochemical mechanisms underlying their absorption, distribution, and elimination, remain largely unknown.", {"entities": []}], [467, "Increasingly, six hydrophilic compounds, lithospermic acid (LSA), protocatechuic acid (PCA) (in this work we use the abbreviation PCA to designate protocatechuic acid.", {"entities": [[18, 91, "Herb name"], [130, 133, "Herb name"], [147, 166, "Herb name"]]}], [468, "Some previous reports have used PCA to refer to protocatechuic aldehyde.", {"entities": [[14, 21, "Study"], [32, 35, "Herb name"], [48, 71, "Herb name"]]}], [469, "Since these compounds are organic, small in size (154\u2013718\u2009Da), and exist as anions at physiological pH, it is possible that they are substrates and/or inhibitors of the organic anion transport pathway that exists in organs such as the kidney, liver, intestine, and choroid plexus [7].", {"entities": [[86, 102, "Parameter"], [165, 200, "Parameter"]]}], [470, "We now know that this organic anion transport pathway is actually a complex system of transport proteins that belong to a variety of gene families.", {"entities": [[22, 53, "Parameter"], [86, 104, "Parameter"]]}], [471, "Members of the solute carrier (SLC) superfamily, composed of ~55 gene families containing almost 400 identified transporters, are an important component of this pathway [7\u20139].", {"entities": [[11, 47, "Parameter"], [112, 124, "Parameter"]]}], [472, "Of particular interest for the Danshen components examined in this work is the SLC22 (organic cation/anion/zwitterion transporters) family, which includes both the organic cation transporters and the organic anion transporters (OATs).", {"entities": [[27, 49, "Herb name"], [75, 138, "Parameter"], [160, 233, "Parameter"]]}], [473, "Members of the OAT family are found in virtually every barrier tissue in the body and mediate the transepithelial flux (absorption, distribution, and elimination) of a multitude of endogenous and xenobiotic compounds [7\u20139].", {"entities": [[11, 25, "Parameter"], [94, 216, "Parameter"]]}], [474, "Typical endogenous OAT substrates include sulfated steroid conjugates, indoxyl sulfate, uric acid, and acidic metabolites of monoamine neurotransmitters.", {"entities": [[8, 33, "Parameter"], [42, 152, "Parameter"]]}], [475, "Currently, there are 29 putative SLC22 family members, 18 of which are believed to be OATs.", {"entities": [[33, 38, "Parameter"], [86, 90, "Parameter"]]}], [476, "Of those, transport activity has been demonstrated for eleven, OAT1-10 and URAT1 [7, 9].", {"entities": [[10, 28, "Parameter"], [63, 70, "Parameter"], [75, 80, "Parameter"]]}], [477, "OATs expressed in the proximal tubule cells of the kidney mediate the blood to urine secretory flux and urine to blood reabsorptive flux of substrate compounds [7\u20139].", {"entities": [[0, 4, "Parameter"], [66, 99, "Parameter"], [104, 159, "Parameter"]]}], [478, "Since these compounds are negatively charged, OATs provide a passageway through which they can readily cross the lipid bilayer of cells.", {"entities": [[46, 50, "Parameter"]]}], [479, "Substrate entry into proximal tubule cells from the blood across the basolateral membrane is energized by exchange for intracellular \u03b1-ketoglutarate (i.e., organic anion/dicarboxylate exchange).", {"entities": [[119, 148, "Parameter"], [156, 192, "Parameter"]]}], [480, "In humans and rodents this process involves the basolateral exchangers and organic anion transporter 1 (Oat1; Slc22a6) and 3 (Oat3; Slc22a8) [11, 12].", {"entities": [[44, 70, "Parameter"], [75, 140, "Parameter"]]}], [481, "OAT-mediated exit of organic anions from the cell into the urine is accomplished via facilitated diffusion using the electrochemical gradient.", {"entities": [[0, 3, "Parameter"], [21, 35, "Parameter"]]}], [482, "There appears to be distinct species differences between rodents and humans in terms of OATs targeted to the apical membrane of proximal tubule cells.", {"entities": [[88, 92, "Parameter"]]}], [483, "For example, while both species express Urat1 (Slc22a12), humans also have OAT4 (SLC22A9; no current rodent ortholog), whereas rodents have Oat5 (Slc22a19; no human ortholog identified) [7, 9].", {"entities": [[40, 56, "Parameter"], [75, 88, "Parameter"], [140, 154, "Parameter"]]}], [484, "The basolateral uptake transporters Oat1 and Oat3 share a high degree of amino acid sequence identity (mOat1 versus mOat3 = 48% and hOAT1 versus hOAT3 = 50%).", {"entities": [[0, 49, "Parameter"], [63, 101, "Parameter"], [103, 108, "Parameter"], [116, 121, "Parameter"], [124, 127, "Amount"], [132, 137, "Parameter"], [145, 150, "Parameter"], [153, 156, "Amount"]]}], [485, "This protein homology likely contributes to the greatly overlapping substrate profiles exhibited by these two transporters.", {"entities": [[110, 122, "Parameter"]]}], [486, "However, despite this general similarity, the individual affinities for the same substrate often differ greatly between Oat1 and Oat3 [7].", {"entities": [[120, 124, "Parameter"], [129, 133, "Parameter"]]}], [487, "Further, unique substrates that interact with Oat1, but not with Oat3 (and vice-versa) have been identified [7].", {"entities": [[46, 50, "Parameter"], [65, 69, "Parameter"]]}], [488, "Preclinical in vivo studies utilizing knockout mouse lines have also demonstrated that, in terms of renal transport function, expression of Oat1 does not fully compensate for loss of Oat3 (and vice-versa) [13\u201316].", {"entities": [[0, 27, "Study"], [140, 144, "Parameter"], [183, 187, "Parameter"]]}], [489, "The aim of the present study was to characterize the effects of six active hydrophilic Danshen components on the transport activity of mOat1 and mOat3.", {"entities": [[87, 105, "Herb name"], [109, 150, "Parameter"]]}], [490, "Danshen components producing the greatest inhibition were examined further in studies designed to elucidate the mechanism of inhibition (competitive versus noncompetitive versus uncompetitive).", {"entities": [[0, 18, "Herb name"]]}], [491, "Combining this information with dose response data, we derived inhibitory constants (K  The Danshen components LSA, PCA, RMA, SAA, SAB, and TSL (\u226596% purity) were obtained from Tauto Biotech (Shanghai, China).", {"entities": [[63, 86, "Parameter"], [88, 143, "Herb name"]]}], [492, "Their chemical structures are illustrated in Figure 1.", {"entities": []}], [493, "Tritiated PAH ([ Derivation of the stably transfected Chinese hamster ovary (CHO) cell lines expressing mOat1 (CHO-mOat1), mOat3 (CHO-mOat3), and the empty vector (FRT) transfected control cell line (CHO-FRT) was described previously [13, 15].", {"entities": [[0, 13, "Parameter"], [54, 61, "Ethnic group"], [104, 121, "Parameter"], [123, 140, "Parameter"]]}], [494, "In brief, 2 \u00d7 10 Data are reported as mean \u00b1 S.D.", {"entities": []}], [495, "or mean \u00b1 S.E.M.", {"entities": []}], [496, "as indicated.", {"entities": []}], [497, "Statistical differences were assessed using one-way ANOVA followed by post hoc analysis with Dunnett's t-test or using Student's unpaired t-test, as indicated (\u03b1 = 0.05).", {"entities": []}], [498, "Initially, an uptake assay with excess (1\u2009mM) Danshen components was performed to identify which, if any, of the compounds might interact with mOat1 (Figure 2(a)).", {"entities": [[40, 44, "Amount"], [46, 64, "Herb name"], [143, 148, "Parameter"]]}], [499, "Each of the Danshen components, LSA, PCA, RMA, SAA, SAB, and TSL, significantly inhibited PAH uptake in CHO-mOat1 cells (P < 0.001) under these conditions.", {"entities": [[8, 64, "Herb name"], [90, 100, "Parameter"]]}], [500, "LSA, SAB, and TSL produced approximately 70\u201385% inhibition, whereas PCA, RMA, and SAA, each reduced PAH accumulation to background level (>95% inhibition), similar to the prototypical OAT inhibitor, probenecid.", {"entities": [[0, 17, "Herb name"], [41, 47, "Amount"], [48, 58, "Parameter"], [68, 85, "Herb name"], [100, 116, "Parameter"], [138, 142, "Amount"], [143, 153, "Parameter"], [167, 209, "Drug"]]}], [501, "SAB and TSL produced approximately 53% and 55% inhibition, respectively.", {"entities": [[0, 11, "Herb name"], [35, 38, "Amount"], [43, 46, "Amount"], [47, 57, "Parameter"]]}], [502, "Although PCA exhibited as potent inhibition as LSA, RMA, and SAA, it is not a major component in Danshen preparations.", {"entities": [[9, 12, "Herb name"], [47, 64, "Herb name"], [97, 117, "Herb name"]]}], [503, "Our previous work with CHO-mOat3 cells showed that ES accumulation was linear through the first 5\u2009min and that ES exhibited a K  To allow direct comparison of inhibition potencies of LSA, RMA, and SAA for mOat1 and mOat3, experiments were conducted to determine the inhibition constant (K  Many natural products, which are extracted from living organisms, have beneficial biological or pharmacological activities and have been used as medicines throughout the world for more than 1,000 years.", {"entities": [[23, 32, "Parameter"], [51, 53, "Parameter"], [96, 101, "Duration"], [111, 113, "Parameter"], [126, 127, "Parameter"], [183, 200, "Herb name"], [205, 210, "Target"], [215, 220, "Target"], [262, 288, "Parameter"], [466, 491, "Duration"]]}], [504, "Today, they are often used as first-line therapeutics, dietary supplements, or complementary/alternative medicines, and it is reported that ~20% of adults in the United States are taking an herbal product [20].", {"entities": [[190, 204, "Herb name"]]}], [505, "Over the last decade a number of studies have identified transporter proteins, including OATs, as sites of drug-drug and natural product-drug interactions.", {"entities": [[57, 93, "Parameter"]]}], [506, "For example, the dietary polyphenol, ellagic acid, which exhibits beneficial antioxidant and anticancer properties, was demonstrated to be one of the most potent inhibitors of hOAT1 (IC Danshen, a traditional herbal medicine, continues to be used in the treatment of angina, myocardial ischemia, and other cardiovascular diseases throughout the world including Asia, Europe, and North America [1].", {"entities": [[13, 49, "Herb name"], [77, 114, "Pathology"], [176, 181, "Target"], [186, 224, "Herb name"], [267, 329, "Pathology"]]}], [507, "Thus, the strength of interaction of each compound could be quantified independently versus the merged effects of a mixture containing all of the compounds.", {"entities": []}], [508, "Similarly, since the transporters were expressed in isolation, the interaction of each individual compound with each individual transporter could be specifically assessed versus the in vivo situation where multiple transporter proteins are expressed simultaneously in a tissue, and the measured response is possibly an amalgamation of the activities of multiple transporter proteins.", {"entities": [[17, 33, "Parameter"], [128, 139, "Parameter"], [215, 235, "Parameter"], [362, 382, "Parameter"]]}], [509, "The rank order of their potencies was different between the two transporters with RMA \u2248 SAA > LSA for mOat1 and RMA > SAA \u2248 LSA for mOat3.", {"entities": [[82, 85, "Herb name"], [88, 91, "Herb name"], [94, 97, "Herb name"], [102, 107, "Target"], [112, 115, "Herb name"], [118, 121, "Herb name"], [124, 127, "Herb name"], [132, 137, "Target"]]}], [510, "A separate study in rats found that spiking additional SAA into Danshen preparations increased the AUC of SAB (82.4%) and TSL (26.7%) and markedly reduced their clearances (46.8% and 32.9% for SAB and TSL, resp.)", {"entities": [[0, 24, "Study"], [55, 58, "Herb name"], [64, 84, "Herb name"], [95, 102, "Parameter"], [106, 109, "Herb name"], [111, 116, "Amount"], [122, 125, "Herb name"], [127, 132, "Amount"], [161, 171, "Parameter"], [173, 178, "Amount"], [183, 188, "Amount"], [193, 196, "Herb name"], [201, 204, "Herb name"]]}], [511, "[26].", {"entities": []}], [512, "As we determined that SAA was a potent competitive mOat1/mOat3 inhibitor, and SAB and TSL can interact with mOat1 and mOat3, our data suggest that these in vivo results may be explained by competition for transport on Oat1/Oat3.", {"entities": [[22, 25, "Herb name"], [51, 56, "Target"], [57, 62, "Target"], [78, 81, "Herb name"], [86, 89, "Herb name"], [108, 113, "Parameter"], [118, 123, "Parameter"], [205, 227, "Parameter"]]}], [513, "It is known that after oral administration in healthy volunteers, the majority of RMA exists as such conjugated forms, as well [30, 31].", {"entities": [[46, 53, "Pathology"], [82, 85, "Herb name"]]}], [514, "Currently, there are no reports on characterization of LSA and SAA metabolites in human plasma, while SAA might undergo methylation and glucuronidation in rats [32].", {"entities": [[24, 31, "Study"], [55, 78, "Herb name"], [102, 105, "Herb name"], [120, 131, "Parameter"], [136, 151, "Parameter"]]}], [515, "Therefore, studies elucidating the metabolic pathways of these compounds are needed such that potential interactions of their metabolites with Oat1 and/or Oat3 can be examined.", {"entities": [[143, 147, "Parameter"], [155, 159, "Parameter"]]}], [516, "In addition, there are other transporter families known to interact with small organic anions, for example, the multidrug resistance-associated proteins (MRPs, ABCC family) and the organic anion transporting polypeptides (OATPs, SLCO family).", {"entities": [[29, 49, "Parameter"], [73, 93, "Herb name"], [108, 172, "Parameter"], [177, 241, "Parameter"]]}], [517, "For the most part these latter two transporter families and the OATs have fairly distinct substrate interactions; however, the possibility that they also may contribute to the overall clinical pharmacokinetic profile of Danshen components in vivo needs to be considered until investigated directly.", {"entities": [[35, 55, "Parameter"], [60, 68, "Parameter"], [220, 238, "Herb name"]]}], [518, "Finally, the amount of each active component in Danshen preparations varies with different cultivation regions and manufacturing processes [4].", {"entities": [[48, 68, "Herb name"]]}], [519, "The variation of RMA in raw plant material was observed to be ~16-fold between different growing regions, and the dose of RMA ranged from 4.1 to 160\u2009mg (~40 fold) in injectable dosage forms produced by different manufacturers [4, 5].", {"entities": [[17, 20, "Herb name"], [24, 42, "Extraction process"], [122, 125, "Herb name"], [133, 151, "Amount"]]}], [520, "In a clinical study, the C  Chemical structures of six active hydrophilic Danshen components.", {"entities": [[3, 19, "Study"], [51, 92, "Herb name"]]}], [521, "MW: molecular weight.", {"entities": []}], [522, "In order to calculate K   K   K  Estimated \u03b1 values from mixed inhibition model analysis for LSA, RMA, and SAA.", {"entities": [[22, 23, "Parameter"], [26, 27, "Parameter"], [30, 31, "Parameter"], [93, 110, "Herb name"]]}], [523, "Values are reported as mean.", {"entities": []}], [524, "The S.E.M.", {"entities": []}], [525, "is not applicable in this analysis.", {"entities": []}], [526, "Estimated K  Values are reported as mean \u00b1\u2009S.E.M.", {"entities": [[0, 11, "Parameter"]]}], [527, "(n = 3).", {"entities": []}], [528, "No significant differences between K", {"entities": []}], [529, "Despite increasing recognition of potential untoward interactions between herbal products and conventional medications, a standard system for prospective assessment of these interactions remains elusive.", {"entities": [[74, 89, "Herb name"], [94, 118, "Drug"]]}], [530, "Effects of St John's wort and CYP2C9 genotype on the pharmacokinetics and pharmacodynamics of gliclazide H Xu,1 K M Williams,2 W S Liauw,2 M Murray,1 R O Day,2 and A J McLachlan1,3,* Author information Article notes Copyright and License information PMC Disclaimer Go to: Abstract Background and purpose:  Patients commonly take complementary medicines in conjunction with conventional drugs without clear evidence of safety or the risk of herb\u2013drug interactions.", {"entities": [[11, 25, "Herb name"], [30, 36, "Target"], [94, 104, "Drug"]]}], [531, "The aim of this study was to assess potential pharmacokinetic (PK) and pharmacodynamic (PD) interactions between St John's wort and gliclazide in healthy subjects with different cytochrome P450 2C9 (CYP2C9) genotypes.", {"entities": [[113, 127, "Herb name"], [132, 142, "Drug"], [146, 162, "Pathology"], [178, 206, "Target"]]}], [532, "Experimental approach:  A crossover controlled study was conducted in 21 healthy subjects.", {"entities": [[24, 52, "Study"], [70, 89, "Cohort"]]}], [533, "Each received gliclazide (80\u2009mg) either alone or during 15 days treatment with St John's wort.", {"entities": [[14, 24, "Drug"], [26, 31, "Amount"], [49, 63, "Duration"], [79, 93, "Herb name"]]}], [535, "CYP2C9*2 and CYP2C9*3 alleles were identified using PCR followed by restriction enzyme digestion analysis.", {"entities": [[0, 29, "Target"]]}], [536, "The mean ratio and 90% confidence interval (CI) of gliclazide AUC0\u2212\u221e and CL/F were 0.67 (0.55\u20130.81) and 1.50 (1.24\u20131.81), respectively, after St John's wort treatment.", {"entities": [[51, 61, "Drug"], [62, 68, "Parameter"], [73, 77, "Parameter"], [83, 99, "Amount"], [104, 120, "Amount"], [142, 156, "Herb name"]]}], [537, "St John's wort decreased gliclazide t 1/2, with mean ratio and 90% CI of 0.85 (0.74\u20130.93).", {"entities": [[0, 14, "Herb name"], [25, 35, "Drug"], [36, 41, "Parameter"]]}], [539, "Conclusions and implications:  Treatment with St John's wort significantly increases the apparent clearance of gliclazide which is independent of CYP2C9 genotype.", {"entities": [[46, 60, "Herb name"], [85, 107, "Parameter"], [111, 121, "Drug"], [146, 152, "Target"]]}], [540, "People with diabetes receiving this combination should be closely monitored to evaluate possible signs of reduced efficacy.", {"entities": [[12, 20, "Pathology"]]}], [541, "Keywords: pharmacokinetics, pharmacodynamics, gliclazide, St John's wort, CYP2C9, genotype Go to: Introduction  The incidence of type 2 diabetes is increasing in the community.", {"entities": [[46, 56, "Drug"], [58, 72, "Herb name"], [74, 80, "Target"], [129, 144, "Pathology"]]}], [542, "Dietary modification and hypoglycaemic medicines such as gliclazide have important roles in the control of diabetes and the prevention of secondary complications of this disease.", {"entities": [[25, 48, "Drug"], [57, 67, "Drug"], [107, 115, "Pathology"]]}], [543, "Recent survey data indicate that 52% of Australian consumers had used complementary and alternative medicines in 2004 (MacLennan et al., 2006).", {"entities": [[7, 13, "Study"], [40, 50, "Ethnic group"]]}], [544, "Approximately, half of these consumers also took prescription medicines at the same time (Kristoffersen et al., 1996; MacLennan et al., 2006).", {"entities": []}], [545, "Furthermore, 31% of diabetic patients have been reported to take alternative medicines, most in conjunction with conventional medicines (Ryan et al., 2001).", {"entities": [[20, 28, "Pathology"]]}], [546, "St John's wort (Hypericum perforatum) is one of the most widely used herbal medicines in Western countries, and it has been used for centuries for a variety of diseases, but most commonly for depression (Ryan et al., 2001).", {"entities": [[0, 37, "Herb name"], [192, 202, "Pathology"]]}], [547, "A systematic review of clinical trials concluded that St John's wort interacts with many medicines, including many clinically important drugs such as warfarin and cyclosporin, leading to reduced effectiveness (Mills et al., 2004).", {"entities": [[0, 38, "Study"], [54, 68, "Herb name"], [150, 158, "Drug"], [163, 174, "Drug"]]}], [548, "Gliclazide (1-(3-azabicyclo[3.3.0]oct-3-yl)-3-para-tolylsulphonylurea) is a most widely used sulphonylurea drug for type 2 diabetes (Figure 1).", {"entities": [[0, 70, "Drug"], [93, 106, "Drug"], [116, 131, "Pathology"]]}], [549, "The clinical use of gliclazide is initiated at 40\u2009mg daily and may increase up to 320\u2009mg daily in divided doses.", {"entities": [[20, 30, "Drug"], [47, 52, "Amount"], [53, 58, "Frequency"], [82, 88, "Amount"], [89, 94, "Frequency"]]}], [550, "It has high bioavailability (approximately 100%) from tablets and gliclazide's absorption is not affected by food (Shima et al., 1982; Hong et al., 1998).", {"entities": [[12, 27, "Parameter"], [29, 47, "Amount"], [66, 76, "Drug"]]}], [551, "Compared to other sulphonylureas, gliclazide has an intermediate half-life of approximately 11\u2009h (Campbell et al., 1991; Park et al., 2003).", {"entities": [[18, 32, "Drug"], [34, 44, "Drug"], [65, 74, "Parameter"]]}], [552, "Gliclazide is extensively metabolized in the liver (Davis et al., 2000) to at least eight identified metabolites (Oida et al., 1985; Campbell et al., 1991; Taylor et al., 1996).", {"entities": [[0, 10, "Drug"]]}], [553, "Tolylmethyl hydroxylation (to form methyl-hydroxy-gliclazide) followed by oxidation to the corresponding carboxylic acid (to form carboxygliclazide) is the major metabolic pathway of gliclazide.", {"entities": [[35, 60, "Drug"], [130, 147, "Drug"], [183, 193, "Drug"]]}], [554, "These two metabolites account for 59% of the dose recovered in urine 96\u2009h later (Oida et al., 1985).", {"entities": []}], [555, "Hydroxylation of the azabicyclo-octyl moiety has the potential to form seven monohydroxylated metabolites.", {"entities": []}], [556, "Four of these metabolites (6\u03b1, 6\u03b2, 7\u03b1 and 7\u03b2 positions) have been identified in urine, which represented 1, 20, 6 and 14% of urinary recovered dose 96\u2009h after dose, respectively (Oida et al., 1985).", {"entities": []}], [557, "Gliclazide metabolites have no hypoglycaemic activity and plasma concentrations are very low, representing only a small fraction of gliclazide concentrations in vivo (Campbell et al., 1980; Lupo and Bataille, 1987).", {"entities": [[0, 10, "Drug"], [132, 142, "Drug"], [158, 165, "Study"]]}], [558, "There is no evidence that transporters are involved in gliclazide disposition.", {"entities": [[55, 65, "Drug"]]}], [559, "Elliot et al.", {"entities": []}], [560, "(2007) recently identified the human cytochrome P450 catalysing the rate-limiting pathways of gliclazide metabolism and found that cytochrome P450 2C9 (CYP2C9) is the major contributor to gliclazide metabolic clearance, although CYP2C19 may also be involved in tolymethyl hydroxylation of gliclazide.", {"entities": [[37, 52, "Target"], [94, 104, "Drug"], [131, 159, "Target"], [188, 198, "Drug"], [229, 236, "Target"], [289, 299, "Drug"]]}], [561, "An external file that holds a picture, illustration, etc.", {"entities": []}], [562, "Object name is 0707685f1.jpg Figure 1  Chemical structure of gliclazide.", {"entities": [[61, 71, "Drug"]]}], [563, "CYP2C9 is a polymorphic enzyme with 29 variant alleles described (www.cypalleles.ki.se/).", {"entities": [[0, 6, "Target"]]}], [564, "The three most common alleles are CYP2C9*1 (wild-type), CYP2C9*2 and CYP2C9*3.", {"entities": [[34, 42, "Target"], [56, 64, "Target"], [69, 77, "Target"]]}], [565, "CYP2C9*2 and CYP2C9*3 alleles are associated with lower enzyme activity both in vitro and in vivo (Lee et al., 2002; Soga et al., 2004; Topic et al., 2004).", {"entities": [[0, 8, "Target"], [13, 21, "Target"], [77, 85, "Study"], [90, 97, "Study"]]}], [566, "CYP2C9 polymorphism also plays an important role in individual differences in hypoglycaemic effects of sulphonylurea agents (Kirchheiner et al., 2005).", {"entities": [[0, 6, "Target"], [103, 123, "Drug"]]}], [567, "The CYP2C9*2/*2 genotype carriers have a lower apparent clearance (CL/F) of glyburide compared to the individuals with CYP2C9*1/*1, but this contrast is not seen with the other sulphonylurea drugs.", {"entities": [[4, 15, "Target"], [47, 72, "Parameter"], [76, 85, "Drug"], [119, 130, "Target"], [177, 196, "Drug"]]}], [568, "The carriers of one or two CYP2C9*3 alleles tend to have lower CL/F for most of the sulphonylurea drugs.", {"entities": [[27, 43, "Target"], [63, 67, "Parameter"], [84, 103, "Drug"]]}], [569, "However, there are only limited clinical data available on gliclazide pharmacokinetics and/or pharmacodynamics in relation to CYP2C9 genotype groups despite the suggestion that individual gene differences are potentially important factors that determine a patient's response to therapy.", {"entities": [[59, 69, "Drug"], [126, 132, "Target"]]}], [570, "The aims of this study were to investigate the effects of St John's wort on the pharmacokinetics and pharmacodynamics of gliclazide in healthy subjects and to identify sources of individual variation by examining gliclazide pharmacokinetics and pharmacodynamics in relation to CYP2C9 polymorphisms.", {"entities": [[58, 72, "Herb name"], [121, 131, "Drug"], [135, 151, "Pathology"], [213, 223, "Drug"], [277, 283, "Target"]]}], [571, "Go to: Methods Subjects  This study was approved by the St Vincent's Hospital and University of Sydney Human Research Ethics Committees (Sydney, Australia).", {"entities": []}], [572, "Health status was assessed by medical history, physical examination and routine laboratory tests (including fasting blood glucose concentration).", {"entities": [[108, 143, "Parameter"]]}], [573, "Pharmacogenetic study (PCR-RFLP analysis)  Saliva (2\u2009ml) or blood samples (4\u2009ml) were obtained from each subject.", {"entities": []}], [574, "DNA was extracted and used to detect the different alleles of CYP2C9.", {"entities": [[51, 68, "Target"]]}], [575, "Genomic DNA was isolated from saliva using Oragene DNA Self-Collection Kit (DNA Genotek, Ottawa, ON, Canada) or blood using Qiagen blood kit (Qiagen, Doncaster, VIC, Australia).", {"entities": []}], [576, "Detection of the CYP2C9*2 and CYP2C9*3 alleles were carried out using a polymerase chain reaction based restriction fragment length polymorphism (polymerase chain reaction-RFLP) analysis.", {"entities": [[17, 25, "Target"], [30, 38, "Target"]]}], [577, "The primers and restriction sites (AvaII restriction site for the CYP2C9*2 allele, NsiI and KpnI for the CYP2C9*3 allele) used in the present study were as described by Sullivan-Klose et al.", {"entities": [[66, 81, "Target"], [105, 120, "Target"]]}], [578, "(1996).", {"entities": []}], [579, "Subjects in whom neither CYP2C9*2 nor CYP2C9*3 was detected were characterized as CYP2C9 wild type (*1/*1).", {"entities": [[25, 33, "Target"], [38, 46, "Target"], [82, 88, "Target"]]}], [580, "Briefly, PCR was performed in a final reaction volume of 50\u2009\u03bcl, which included 20\u2009\u03bcl 2.5 \u00d7 HotMasterMix (Eppendorf, Westbury, NY, USA), approximately 250\u2009ng of human genomic DNA and the primer pairs (0.25\u2009\u03bcM).", {"entities": []}], [581, "PCR amplification was performed with an initial melting step at 94\u2009\u00b0C for 2\u2009min, followed by 35 cycles of denaturation at 94\u2009\u00b0C for 30\u2009s, annealing at 55\u2009\u00b0C for CYP2C9*2 (59\u2009\u00b0C for CYP2C9*3) for 30\u2009s and extension at 72\u2009\u00b0C for 30\u2009s. Upon completion of 35 cycles, the reaction was continued at 72\u2009\u00b0C for 10\u2009min for final extension.", {"entities": []}], [582, "Aliquots of each PCR reaction (16\u2009\u03bcl for AvaII and NsiI, 10\u2009\u03bcl for KpnI) were subjected to restriction enzyme analysis with 20\u2009U AvaII (CYP2C9*2) and NsiI (CYP2C9*3) or 10\u2009U KpnI (CYP2C9*3).", {"entities": []}], [583, "After overnight incubation at 37\u2009\u00b0C, digested products were separated by electrophoresis using 2% agarose gels (Progen, Darra, QLD, Australia) run at 110\u2009V for 60\u2009min for CYP2C9*2 or 2.5% agarose gels run at 110\u2009V for 50\u2009min for CYP2C9*3; the gels were stained with ethidium bromide and the restriction fragments were visualized (Gel Doc, Bio-Rad, Segrate, Milan, Italy).", {"entities": [[171, 179, "Target"], [229, 237, "Target"]]}], [584, "Clinical study  A sequential crossover two-treatment study was performed, with at least a 4-day washout period between the two treatments.", {"entities": [[0, 14, "Study"], [16, 58, "Study"]]}], [585, "After an overnight fast, a single dose of 80\u2009mg gliclazide (Diamicron, Servier Laboratories, Hawthorn, VIC, Australia) was administered either alone or, on the last day (Day 15) treatment, with 300\u2009mg St John's wort (Kira, LI 160 extract, Lichtwer Pharma, Berlin, Germany) given three times a day.", {"entities": [[42, 47, "Amount"], [48, 58, "Drug"], [60, 69, "Drug"], [194, 200, "Amount"], [201, 215, "Herb name"], [217, 237, "Herb name"], [279, 296, "Frequency"]]}], [586, "An oral 75\u2009g dose of glucose (Glucaid Clear, Fronine, Riverstone, NSW, Australia) was given 0.5\u2009h after gliclazide intake.", {"entities": [[8, 12, "Amount"], [104, 114, "Drug"]]}], [587, "Food and drink (with the exception of water) were not allowed for the first 4\u2009h after gliclazide intake.", {"entities": [[86, 96, "Drug"]]}], [588, "All participants were asked not to drink caffeine-containing beverages and to refrain from grapefruit from the day before until 2 days after taking gliclazide.", {"entities": [[41, 49, "Herb name"], [91, 101, "Herb name"], [148, 158, "Drug"]]}], [589, "Venous blood (EDTA tube) was taken for gliclazide and insulin quantification at 0, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 36 and 48\u2009h after gliclazide administration.", {"entities": [[39, 49, "Herb name"], [54, 61, "Parameter"], [145, 155, "Drug"]]}], [590, "Plasma was obtained by centrifugation at 1500\u2009g for 15\u2009min and stored at \u221220\u2009\u00b0C before the assay.", {"entities": []}], [591, "Capillary blood samples were used to measure glucose levels at 0, 0.5, 1, 1.5, 2, 2.5, 3 and 4\u2009h after gliclazide administration.", {"entities": [[45, 59, "Parameter"], [103, 113, "Drug"]]}], [592, "Analytical methods  Plasma gliclazide concentrations were measured by reversed-phase HPLC using a C18 column (150 \u00d7 4.6\u2009mm) by the method of Park et al.", {"entities": [[27, 37, "Drug"]]}], [593, "(2004) with minor modifications.", {"entities": []}], [594, "The separation was achieved using a mobile phase of 40\u2009mM KH2PO4 (pH 4.6, 56%) and acetonitrile (44%) at a flow rate of 1.2\u2009ml\u2009min\u22121 with UV detection at a wavelength of 227\u2009nm.", {"entities": []}], [595, "In brief, 0.5\u2009ml of plasma, 20\u2009\u03bcl of glibenclamide (internal standard, 50\u2009\u03bcg\u2009ml\u22121) and 0.5\u2009ml of acetonitrile was transferred to a 10\u2009ml plastic tube.", {"entities": [[37, 50, "Drug"]]}], [596, "After vortexing for 10\u2009s, chloroform (4\u2009ml) was added followed by vigorous shaking (1\u2009min) and then centrifugation at 1500\u2009g for 15\u2009min.", {"entities": []}], [597, "The lower organic layer (3\u2009ml) was transferred into a 5\u2009ml glass tube and dried under a stream of nitrogen at 40\u2009\u00b0C.", {"entities": []}], [598, "The residue was reconstituted with mobile phase (150\u2009\u03bcl), vortex mixed for 20\u2009s, then transferred to a microcentrifuge tube and centrifuged at 1500\u2009g for 2\u2009min, and 50\u2009\u03bcl of the upper layer was taken for HPLC analysis.", {"entities": []}], [599, "The limit of detection for gliclazide was 50\u2009ng\u2009ml\u22121.", {"entities": [[27, 37, "Drug"]]}], [600, "The intraday and interday coefficients of variation for gliclazide were all less than 11% at concentrations of 0.5, 3 and 8\u2009\u03bcg\u2009ml\u22121 (n=5).", {"entities": [[56, 66, "Drug"]]}], [601, "Plasma insulin concentration was determined using the Coat-A-Count 125I-labelled radioimmunoassay (Bio-Mediq DPC, Los Angeles, CA, USA).", {"entities": [[0, 28, "Parameter"]]}], [602, "Capillary blood glucose concentration was measured immediately after each sample was taken using a commercial glucose meter (Roche ACCU-CHEK Go, Castle Hill, NSW, Australia).", {"entities": [[0, 37, "Parameter"]]}], [603, "The AUC was extrapolated to infinity (AUCt\u2013\u221e) using Ct/kel, where Ct is the last measured gliclazide concentration and kel is the elimination rate constant determined from the terminal slope of the log concentration\u2013time plot.", {"entities": [[4, 7, "Parameter"], [38, 44, "Parameter"], [90, 100, "Drug"]]}], [604, "Elimination half-life (t1/2) was calculated as ln\u20092/kel.", {"entities": [[0, 28, "Parameter"]]}], [605, "The maximum concentration (Cmax) and the time to Cmax (tmax) were obtained by the inspection of the concentration\u2013time data.", {"entities": [[0, 32, "Parameter"], [37, 60, "Parameter"]]}], [606, "The CL/F was calculated as dose/AUC0\u2013\u221e.", {"entities": [[4, 8, "Parameter"]]}], [607, "The glucose and insulin concentrations were measured to determine the pharmacodynamic effects.", {"entities": [[4, 38, "Parameter"]]}], [608, "The incremental area under the blood glucose and insulin concentration\u2013time curves (AUC0\u20134) were calculated to adjust for the individual variation of the baseline glucose concentrations using the approach described by Park et al.", {"entities": [[16, 91, "Parameter"], [163, 185, "Parameter"]]}], [609, "(2003).", {"entities": []}], [610, "The maximum glucose and insulin concentration after glucose loading was determined by observation of the concentration\u2013time data.", {"entities": [[0, 45, "Parameter"]]}], [611, "Statistical analysis  All data are presented as mean\u00b1s.d.", {"entities": []}], [612, "and 95% confidence interval (CI) except tmax, which is presented as median and range.", {"entities": [[40, 44, "Parameter"]]}], [613, "The pharmacokinetic parameters with and without St John's wort treatment were compared using the paired Student's t-test.", {"entities": [[48, 62, "Herb name"]]}], [614, "The mean residual error was calculated using ANOVA (Stata 5.0, Stata Corp, College Station, TX, USA) of log-transformed parameters considering treatment and used to calculate the 90% CI of the ratio of log-transformed pharmacokinetic parameters comparing control (gliclazide alone) and treatment phase (gliclazide and St John's wort).", {"entities": [[264, 274, "Drug"], [303, 313, "Drug"], [318, 332, "Herb name"]]}], [615, "A 90% CI that did not include 1.0 was considered significantly different.", {"entities": []}], [616, "The mean ratio (n=21) and 90% CI of gliclazide AUC0\u2013\u221e and CL/F are shown in Table 1.", {"entities": [[36, 46, "Drug"], [47, 53, "Parameter"], [58, 62, "Parameter"]]}], [617, "After St John's wort treatment, gliclazide Cmax decreased by 22%, whereas the CL/F increased by nearly 50%.", {"entities": [[6, 20, "Herb name"], [32, 42, "Drug"], [43, 47, "Parameter"], [78, 82, "Parameter"]]}], [618, "Furthermore, the mean t1/2 of gliclazide after St John's wort treatment decreased from 10.3 to 8.7\u2009h. An external file that holds a picture, illustration, etc.", {"entities": [[22, 26, "Parameter"], [30, 40, "Drug"], [47, 61, "Herb name"]]}], [619, "Object name is 0707685f2.jpg Figure 2  Mean plasma gliclazide concentration\u2013time profile in control and St John's wort treatment phases.", {"entities": [[51, 61, "Drug"], [104, 118, "Herb name"]]}], [620, "Error bars represent s.d.", {"entities": []}], [621, "(n=21).", {"entities": []}], [622, "An external file that holds a picture, illustration, etc.", {"entities": []}], [623, "Ratio is presented as mean and 90% CI, and all others are presented as mean and 95% CI.", {"entities": []}], [624, "Effects of St John's wort on pharmacodynamics of gliclazide  Glucose concentration increased after the intake of 75\u2009g glucose in each phase of this study.", {"entities": [[11, 25, "Herb name"], [49, 59, "Drug"], [61, 82, "Parameter"]]}], [625, "Gliclazide initially lowered glucose concentrations, which returned to baseline 2.5\u2009h after glucose intake.", {"entities": [[0, 10, "Drug"], [29, 51, "Parameter"]]}], [626, "The mean incremental glucose concentration showed a trend towards a decrease after St John's wort treatment, but this difference did not reach statistical significance (Table 2 and Figure 4a).", {"entities": [[83, 97, "Herb name"]]}], [627, "Similarly, the mean insulin incremental concentration increased slightly in the St John's wort phase of the study compared to the control phase (Table 2 and Figure 4b).", {"entities": [[11, 53, "Parameter"], [80, 94, "Herb name"]]}], [628, "There was considerable interindividual variation observed for both glucose and insulin concentration\u2013time profiles.", {"entities": [[67, 114, "Parameter"]]}], [629, "An external file that holds a picture, illustration, etc.", {"entities": []}], [630, "Data are presented as mean\u00b1s.d., except for tmax data, which are given as median and range.", {"entities": [[44, 48, "Parameter"]]}], [631, "Pharmacogenetic results  All subjects were genotyped for CYP2C9 genes (Table 3).", {"entities": [[57, 69, "Target"]]}], [632, "The subjects were grouped into three categories *1/*1 (wild type), *1/*2 or *2/*2, and *1/*3 to compare the pharmacokinetic parameters.", {"entities": []}], [633, "There was slightly lower CL/F of gliclazide in subjects carrying the CYP2C9*2 allele, but the difference did not reach statistical significance (Figure 5).", {"entities": [[25, 29, "Parameter"], [33, 43, "Drug"], [69, 84, "Target"]]}], [634, "An external file that holds a picture, illustration, etc.", {"entities": []}], [635, "Object name is 0707685f5.jpg Figure 5  Gliclazide apparent clearance (CL/F) of three groups of CYP2C9 genotypes in gliclazide only phase.", {"entities": [[39, 49, "Target"], [50, 75, "Parameter"], [95, 101, "Target"], [115, 125, "Drug"]]}], [636, "(\u2018\u2014' indicates mean in each group, the solid circle represents a subject with CYP2C9*2/*2 genotype).", {"entities": [[78, 89, "Target"]]}], [637, "Table 3  Genotype frequency and gliclazide CL/F in 21 subjects in gliclazide only phase CYP2C9 genotype\tSamples (n)\tFrequency (%)\tGliclazide CL/F (ml\u2009h\u22121\u2009kg\u22121) *1/*1\t11\t52.4\t24.0 (19.0\u201328.9) *1/*2 or\t6\t28.6\t18.5 (15.2\u201321.7) *2/*2\t1\t4.8\t  *1/*3\t3\t14.3\t25.4 (20.4\u201330.5) Open in a separate window Abbreviation: CL/F, apparent clearance.", {"entities": [[32, 42, "Drug"], [43, 47, "Parameter"], [51, 62, "Cohort"], [66, 76, "Drug"], [88, 94, "Target"], [130, 140, "Drug"], [141, 145, "Parameter"], [308, 332, "Parameter"]]}], [638, "Data shown was not to represent population frequency; data are presented as median and range.", {"entities": []}], [639, "Go to: Discussion and conclusions  The mean CL/F of gliclazide in subjects possessing the CYP2C9*2 allele (homozygous and heterozygous combined) was approximately 25% lower than that observed in wild-type subjects.", {"entities": [[44, 48, "Parameter"], [52, 62, "Drug"], [90, 144, "Target"]]}], [640, "In similar studies, the CL/F ratios in subjects possessing at least one copy of the CYP2C9*2 allele (compared with wild-type subjects) were 0.88 for tolbutamide (Kirchheiner et al., 2002a) and 0.9 for glyburide (Kirchheiner et al., 2002b).", {"entities": [[24, 28, "Parameter"], [84, 99, "Target"], [149, 160, "Drug"], [201, 210, "Drug"]]}], [641, "Furthermore, the CL/F of gliclazide in subjects who were heterozygous for the CYP2C9*3 allele was not significantly different from wild-type subjects in the present study, which is consistent with the reported findings for glyburide (Kirchheiner et al., 2002b).", {"entities": [[17, 21, "Parameter"], [25, 35, "Drug"], [78, 93, "Target"], [223, 232, "Drug"]]}], [642, "By contrast, for carriers of the CYP2C9*3 allele, the CL/Fs of glipizide (Kidd et al., 1999) and tolbutamide (Kirchheiner et al., 2002a) were significantly different from wild-type subjects, with ratios of 0.18 and 0.58, respectively.", {"entities": [[33, 48, "Target"], [54, 59, "Parameter"], [63, 72, "Drug"], [97, 108, "Drug"]]}], [643, "Compared with wild-type individuals, the clearances of tolbutamide (Kirchheiner et al., 2002a) and glyburide (Kirchheiner et al., 2002b) were decreased by 50\u201384% in those carrying the CYP2C9*3/*3 genotype and by 41\u201354% in those of CYP2C9*2/*3 genotype.", {"entities": [[41, 51, "Parameter"], [55, 66, "Drug"], [99, 108, "Drug"], [184, 195, "Target"], [231, 242, "Target"]]}], [644, "In a study by Holstein et al.", {"entities": []}], [645, "(2005), the clinical implications of CYP2C9 genotype in people receiving sulphonylurea agents were examined.", {"entities": [[37, 43, "Target"], [73, 93, "Drug"]]}], [646, "It was found that the CYP2C9*2/*3 and CYP2C9*3/*3 genotypes were associated with a higher risk of experiencing severe hypoglycaemia (Holstein et al., 2005).", {"entities": [[22, 33, "Target"], [38, 49, "Target"], [118, 131, "Pathology"]]}], [647, "However, these genotypes were not found in the present study population, which is compatible with the reported frequencies in Caucasians of the CYP2C9*2 and CYP2C9*3 alleles of 0.014 and 0.04, respectively (Lee et al., 2002); thus, the impact of these genotypes on gliclazide pharmacokinetics could not be evaluated.", {"entities": [[126, 136, "Ethnic group"], [144, 152, "Target"], [157, 165, "Target"], [265, 275, "Drug"]]}], [648, "The apparent differences in the impact of the CYP2C9 genotype on the clearance of drug substrates may be attributable in part to contributions from other CYPs.", {"entities": [[46, 61, "Target"], [69, 78, "Parameter"], [154, 158, "Target"]]}], [649, "Thus, evidence has been presented that CYP2C19 can also oxidize tolbutamide, at least in vitro, although the in vivo significance is uncertain (Lasker et al., 1998; Wester et al., 2000).", {"entities": [[39, 46, "Target"], [64, 75, "Drug"], [86, 94, "Study"]]}], [650, "CYP2C9 is believed to be the principal enzyme involved in gliclazide elimination by tolylmethyl hydroxylation, but CYP2C19 may also contribute (Elliot et al., 2007).", {"entities": [[0, 6, "Target"], [58, 68, "Drug"], [115, 122, "Target"]]}], [651, "Accordingly, the potential contributions of CYP2C19 allelic variants to the pharmacokinetics of oral hypoglycaemic agents such as tolbutamide and gliclazide cannot be excluded, and this might explain the lack of concordance between CYP2C9 genotype and gliclazide clearance.", {"entities": [[44, 51, "Target"], [101, 121, "Drug"], [130, 141, "Drug"], [146, 156, "Drug"], [232, 238, "Target"], [252, 262, "Drug"], [263, 272, "Parameter"]]}], [652, "A recent study investigated the relative influence of CYP2C9 and CYP2C19 genetic polymorphisms on the pharmacokinetics of gliclazide in healthy Chinese subjects (Zhang et al., 2007).", {"entities": [[54, 60, "Target"], [65, 72, "Target"], [122, 132, "Drug"], [136, 143, "Pathology"], [144, 151, "Ethnic group"]]}], [653, "These researchers suggest a greater role for CYP2C19 polymorphisms than has been reported previously.", {"entities": [[45, 52, "Target"]]}], [654, "The major aim of the present study was to evaluate the impact of St John's wort treatment on gliclazide pharmacokinetics and pharmacodynamics.", {"entities": [[65, 79, "Target"], [93, 103, "Drug"]]}], [656, "Park et al.", {"entities": []}], [657, "(2003) reported a 70% reduction of gliclazide AUC and fourfold increase of CL/F of gliclazide after 6 days of rifampicin treatment.", {"entities": [[35, 45, "Drug"], [46, 49, "Parameter"], [75, 79, "Parameter"], [83, 93, "Drug"], [100, 106, "Duration"], [110, 120, "Drug"]]}], [658, "Induction of CYP2C9 is the most likely mechanism responsible for the effects of rifampicin and St John's wort.", {"entities": [[13, 19, "Target"], [80, 90, "Drug"], [95, 109, "Herb name"]]}], [659, "However, it is noteworthy that altered gliclazide pharmacokinetics in response to co-administered St John's wort was somewhat similar in subjects carrying CYP2C9 variant alleles.", {"entities": [[39, 49, "Drug"], [98, 112, "Herb name"], [155, 161, "Target"]]}], [660, "Despite the observed pharmacokinetic changes for gliclazide, there was no apparent change in the incremental AUC0\u20134 for either glucose or insulin after St John's wort treatment.", {"entities": [[49, 59, "Drug"], [109, 115, "Parameter"], [152, 166, "Parameter"]]}], [661, "This finding is in contrast to the observations of Park et al.", {"entities": []}], [662, "(2003) who investigated the interaction between rifampicin and gliclazide.", {"entities": [[48, 58, "Drug"], [63, 73, "Drug"]]}], [663, "The reason for the discrepancy is unclear, but may relate to differences in the magnitude of the induction between St John's wort and rifampicin.", {"entities": [[115, 129, "Herb name"], [134, 144, "Drug"]]}], [664, "The extent of induction of gliclazide clearance and the decrease in AUC produced by St John's wort may have been insufficient to alter the pharmacodynamic response in individuals with normal insulin regulation.", {"entities": [[27, 37, "Drug"], [38, 47, "Parameter"], [68, 71, "Parameter"], [84, 98, "Herb name"]]}], [665, "However, there may have been additional environmental factors, such as diet (Shaw, 2006), that could have contributed to the minimal impact on pharmacodynamics in the present study.", {"entities": []}], [666, "The extent to which gliclazide clearance was influenced by co-administered St John's wort varied considerably between subjects.", {"entities": [[20, 30, "Drug"], [31, 40, "Parameter"], [75, 89, "Herb name"]]}], [667, "Pronounced increases in CL/F were observed in a few subjects showing efficient induction of CYP2C9, but the majority of individuals exhibited relatively small changes, whereas in four subjects, gliclazide clearance decreased somewhat after treatment with St John's wort.", {"entities": [[24, 28, "Parameter"], [92, 98, "Target"], [194, 204, "Drug"], [205, 214, "Parameter"], [255, 269, "Herb name"]]}], [668, "The adherence to St John's wort treatment was established by regular telephone contact and confirmed by interview, which corroborated the compliance records submitted immediately after completion of the study.", {"entities": [[17, 31, "Herb name"]]}], [669, "Therefore, we speculated that such variation in response might be related to differences in the inducibility of the CYP2C9 gene between individuals.", {"entities": [[116, 127, "Target"]]}], [670, "The mechanism underlying the St John's wort\u2013gliclazide interaction has not been established unequivocally.", {"entities": [[29, 43, "Herb name"], [44, 54, "Drug"]]}], [671, "However, St John's wort has been shown to induce the CYP3A4 gene and to increase the clearance of many CYP3A4 substrates, for example, indinavir (Piscitelli et al., 2000), simvastatin (Sugimoto et al., 2001), cyclosporin (Bauer et al., 2003) and midazolam (Dresser et al., 2003).", {"entities": [[9, 23, "Herb name"], [53, 59, "Target"], [85, 94, "Parameter"], [103, 109, "Target"], [135, 144, "Drug"], [172, 183, "Drug"], [209, 220, "Drug"], [246, 255, "Drug"]]}], [673, "Interestingly, the extent of the interaction between St John's wort and the CYP3A4 substrate cyclosporin has been shown to be related to hyperforin content (Mai et al., 2004).", {"entities": [[53, 67, "Herb name"], [76, 82, "Target"], [93, 104, "Drug"], [137, 147, "Herb name"]]}], [674, "In the present study, a hyperforin-rich St John's wort extract LI 160 (Kira) was used (Wurglics et al., 2001), which is most likely to have mediated the induction of CYP2C9 and led to altered gliclazide pharmacokinetics observed in this study.", {"entities": [[24, 34, "Herb name"], [40, 76, "Herb name"], [166, 172, "Target"], [192, 202, "Drug"]]}], [675, "Although CYP2C9 appears to be the major enzyme involved in gliclazide metabolism, the contributions of CYP2C19 and possibly CYP2C18 cannot be excluded (Elliot et al., 2007).", {"entities": [[9, 15, "Target"], [59, 69, "Drug"], [103, 110, "Target"], [124, 131, "Target"]]}], [676, "Therefore, in addition to the CYP2C9 induction by St John's wort, the induction of CYP2C19 and possibly CYP2C18 may contribute to the observed decrease in gliclazide AUC.", {"entities": [[30, 36, "Target"], [50, 64, "Herb name"], [83, 90, "Target"], [104, 111, "Target"], [155, 165, "Drug"], [166, 169, "Parameter"]]}], [677, "The effect of St John's wort on CYP2C9 induction has been studied with several drugs.", {"entities": [[14, 28, "Herb name"], [32, 38, "Target"]]}], [678, "Our previous studies demonstrated that St John's wort constituents induced the metabolism of S-warfarin, another CYP2C9 substrate (Jiang et al., 2004).", {"entities": [[39, 53, "Herb name"], [93, 103, "Drug"], [113, 119, "Target"]]}], [679, "Wang et al.", {"entities": []}], [680, "(2001) studied the prototypic sulphonylurea, tolbutamide, under conditions of short-term and long-term St John's wort co-administration but, somewhat surprisingly, neither of these treatments influenced the pharmacokinetic parameters of tolbutamide (Wang et al., 2001).", {"entities": [[30, 43, "Drug"], [45, 56, "Drug"], [103, 117, "Herb name"], [237, 248, "Drug"]]}], [681, "However, the hyperforin content of the St John's wort preparation used by these researchers was not clearly defined, so that comparisons with the present study are not straightforward.", {"entities": [[13, 23, "Herb name"], [39, 53, "Herb name"]]}], [682, "Despite the finding that allelic variants of CYP2C9 contribute to gliclazide pharmacokinetic differences, there are additional pharmacodynamic factors that could account for interindividual differences in glucose and insulin concentrations in response to gliclazide treatment.", {"entities": [[45, 51, "Target"], [66, 76, "Drug"], [205, 239, "Parameter"], [255, 265, "Drug"]]}], [683, "Further study on variations of those genes involved in pharmacodynamic differences may help to better understand the findings of the present study.", {"entities": []}], [684, "St John's wort significantly decreased gliclazide AUC0\u2013\u221e, which was probably due to induction of CYP2C9 and/or CYP2C19.", {"entities": [[0, 14, "Herb name"], [39, 49, "Drug"], [50, 56, "Parameter"], [97, 103, "Target"], [111, 118, "Target"]]}], [685, "Variant alleles of CYP2C9 did not appear to mediate differences in gliclazide clearance or glucose-lowering effects.", {"entities": [[19, 25, "Target"], [67, 77, "Drug"], [78, 87, "Parameter"]]}], [686, "Further investigations in people with diabetes will improve our understanding of the impact of pharmacogenetics on gliclazide pharmacokinetics and provide further insight into its optimal clinical usage and the effects of herbal remedies on the pharmacokinetics and pharmacodynamics of prescription medicines.", {"entities": [[38, 46, "Pathology"], [115, 125, "Drug"]]}], [687, "Recommended by Anne M. Larson There are a growing number of cases detailing acute hepatic necrosis in patients taking black cohosh (Cimicifuga racemosa), an over-the-counter herbal supplement for management of menopausal symptoms.", {"entities": [[76, 98, "Pathology"], [118, 151, "Herb name"], [210, 229, "Pathology"]]}], [688, "Our aim is to illustrate two cases of liver injury following the use of black cohosh characterized by histopathological features mimicking autoimmune hepatitis.", {"entities": [[38, 50, "Pathology"], [72, 84, "Herb name"], [139, 159, "Pathology"]]}], [689, "Both patients reported black cohosh use for at least six months and had no evidence of another cause of liver disease.", {"entities": [[23, 35, "Herb name"], [40, 63, "Duration"], [104, 117, "Pathology"]]}], [690, "Their liver biopsies showed a component of centrilobular necrosis consistent with severe drug-induced liver injury.", {"entities": [[89, 114, "Pathology"]]}], [691, "In addition, the biopsies showed characteristics of autoimmune-like liver injury with an interface hepatitis dominated by plasma cells.", {"entities": [[52, 80, "Pathology"], [89, 108, "Pathology"]]}], [692, "Although serum markers for autoimmune hepatitis were not particularly elevated, both patients responded to corticosteroids, supporting an immune-mediated component to the liver injury.", {"entities": [[27, 47, "Pathology"], [107, 122, "Drug"], [171, 183, "Pathology"]]}], [693, "Liver injury following the use of black cohosh should be included in the list of differential diagnoses for chronic hepatitis with features mimicking autoimmune hepatitis.", {"entities": [[0, 12, "Pathology"], [34, 46, "Herb name"], [108, 125, "Pathology"], [150, 170, "Pathology"]]}], [694, "Black cohosh (Cimicifuga racemosa) is an herbal supplement that is sold over-the-counter for management of menopausal symptoms, menstrual irregularities, and arthritis.", {"entities": [[0, 33, "Herb name"], [107, 126, "Pathology"], [128, 152, "Pathology"], [158, 167, "Pathology"]]}], [695, "There are now a number of manuscripts indicating liver injury from black cohosh [1\u20137].", {"entities": [[49, 61, "Pathology"], [67, 79, "Herb name"]]}], [696, "Here, we present two patients who developed a drug-induced liver injury following the use of black cohosh characterized by centrilobular necrosis and histologic features mimicking autoimmune hepatitis (AIH) who improved with corticosteroid therapy.", {"entities": [[46, 71, "Pathology"], [93, 105, "Herb name"], [180, 205, "Pathology"], [225, 247, "Drug"]]}], [697, "The case series was approved by the Institutional Review Board at the University of Illinois at Chicago.", {"entities": []}], [698, "A 42-year-old woman presented to her primary care provider with a two-month history of progressive malaise, nausea, vomiting, and dizziness.", {"entities": [[2, 13, "Age"], [14, 19, "Sex"], [66, 75, "Duration"], [87, 106, "Pathology"], [108, 114, "Pathology"], [116, 124, "Pathology"], [130, 139, "Pathology"]]}], [699, "On physical examination, she had mild icterus and no stigmata of chronic liver disease.", {"entities": [[38, 45, "Pathology"], [65, 86, "Pathology"]]}], [700, "Her only comorbidity was hypothyroidism.", {"entities": [[25, 39, "Pathology"]]}], [701, "Her medications included black cohosh, which she was taking for 6 months, and levothyroxine 0.05\u2009mg daily.", {"entities": [[25, 37, "Herb name"], [60, 72, "Duration"], [78, 91, "Drug"], [92, 99, "Amount"]]}], [702, "She discontinued black cohosh when her symptoms began.", {"entities": [[17, 29, "Herb name"]]}], [703, "She had no family history of liver or autoimmune disease.", {"entities": [[29, 56, "Pathology"]]}], [704, "She denied any alcohol or drug use.", {"entities": [[15, 34, "Pathology"]]}], [705, "Her total bilirubin level was 3.1\u2009mg/dL (normal 0.8\u20131.2), alanine transaminase (ALT) 1457\u2009U/L (normal 5\u201340), aspartate transaminase (AST) 696\u2009U/L (normal 10\u201340), alkaline phosphatase (ALP) 94\u2009U/L (normal 30\u2013120\u2009U/L), and international normalized ratio (INR) 1.2 (normal 0.8\u20131.2).", {"entities": [[4, 19, "Parameter"], [30, 55, "Amount"], [58, 84, "Parameter"], [85, 107, "Amount"], [109, 137, "Parameter"], [138, 159, "Amount"], [162, 187, "Parameter"], [189, 214, "Amount"], [221, 257, "Parameter"], [258, 278, "Amount"]]}], [706, "Further laboratories showed no serological evidence of active hepatitis A, B, or C infection.", {"entities": [[55, 92, "Pathology"]]}], [707, "Serological titers for acute cytomegalovirus (CMV) and Epstein Barr virus (EBV) were negative.", {"entities": [[23, 49, "Pathology"], [55, 78, "Pathology"]]}], [708, "Antinuclear antibody (ANA) was 1 : 40 and smooth muscle antibody was modestly elevated at 1 : 80.", {"entities": [[0, 25, "Parameter"], [31, 37, "Amount"], [42, 64, "Parameter"], [90, 96, "Amount"]]}], [709, "Ceruloplasmin was in the normal range.", {"entities": [[0, 13, "Parameter"]]}], [711, "A liver biopsy was performed which prompted a referral to the liver center at the University of Illinois.", {"entities": []}], [712, "The liver biopsy was remarkable for necrosis around terminal hepatic venules, lobular disarray, mild ballooning, apoptosis, Kupffer cell reactivity, mild cholangiolar proliferation, and interface hepatitis remarkable for numerous plasma cells and eosinophils.", {"entities": [[186, 205, "Pathology"]]}], [713, "A repeat antismooth muscle antibody was normal at 1 : 20.", {"entities": []}], [714, "Prednisone treatment was initiated.", {"entities": [[0, 10, "Drug"]]}], [715, "A follow-up liver biopsy was performed after three months.", {"entities": [[39, 57, "Duration"]]}], [716, "At this time, the liver histology demonstrated chronic hepatitis with fibroinflammatory expansion of portal tracts by moderate plasma cell rich interface hepatitis, rare periportal hepatocyte apoptosis, and mild cholangiolar proliferation (Figures 1(a) and 1(b)).", {"entities": [[47, 64, "Pathology"], [144, 163, "Pathology"], [170, 191, "Parameter"]]}], [717, "The patient was started on azathioprine.", {"entities": [[27, 39, "Drug"]]}], [719, "A repeat liver biopsy after fifteen months showed marked improvement with only minimal portal lymphocytes and no other significant histopathological changes.", {"entities": [[22, 42, "Duration"], [87, 105, "Parameter"]]}], [720, "The liver function test values remained normal at 15 months and at 40 months following the acute episode.", {"entities": [[50, 59, "Duration"], [67, 76, "Duration"]]}], [721, "The clinicopathological features of Case 1 are illustrated in Tables 1, 2, and 3.", {"entities": []}], [722, "A 53-years-old woman presented to our liver center for evaluation of elevated liver enzymes detected at a health screening fair four months earlier.", {"entities": [[2, 14, "Age"], [15, 20, "Sex"], [128, 147, "Duration"]]}], [723, "She had no risk factors for viral hepatitis, no family history of liver disease, and denied any alcohol consumption.", {"entities": [[28, 43, "Pathology"]]}], [724, "Although she was initially asymptomatic, she developed right upper quadrant abdominal pain, fatigue, and lower extremity edema by the time of her presentation.", {"entities": [[55, 90, "Pathology"], [92, 99, "Pathology"], [105, 126, "Pathology"]]}], [725, "Her medical history was remarkable only for irritable bowel syndrome.", {"entities": [[44, 68, "Pathology"]]}], [726, "Her medications within the past year included dicyclomine for abdominal cramps as needed, an herbal supplement which contains soy protein and black cohosh for menopausal symptoms, and occasional over the counter nonsteroidal anti-inflammatory drugs (NSAIDs) for pain.", {"entities": [[46, 57, "Drug"], [62, 78, "Pathology"], [126, 137, "Herb name"], [142, 154, "Herb name"], [159, 178, "Pathology"], [212, 256, "Drug"]]}], [727, "She discontinued these medications on the advice of her primary care physician.", {"entities": []}], [728, "Laboratories showed a total bilirubin of 2.0\u2009mg/dL, ALT 443\u2009U/L, AST 478\u2009U/L, ALP 188\u2009U/L, and an INR of 2.0.", {"entities": [[22, 37, "Parameter"], [41, 50, "Amount"], [52, 55, "Parameter"], [56, 63, "Amount"], [65, 68, "Parameter"], [69, 76, "Amount"], [78, 81, "Parameter"], [82, 89, "Amount"], [98, 101, "Parameter"], [105, 108, "Amount"]]}], [729, "Serological tests for antinuclear, antismooth muscle, antiliver kidney microsomal, and antimitochondrial antibodies were negative.", {"entities": [[22, 115, "Parameter"]]}], [730, "An ultrasound demonstrated patent portal and hepatic veins and a normal appearing liver.", {"entities": []}], [731, "Her liver biopsy was remarkable for centrilobular necrosis with moderate cholangiolar proliferation and plasma cell rich interface and lobular hepatitis.", {"entities": [[135, 152, "Pathology"]]}], [732, "The patient was started on 40\u2009mg of prednisone daily.", {"entities": [[27, 32, "Amount"], [36, 46, "Drug"]]}], [733, "Liver function test values improved to a total bilirubin of 1.4\u2009mg/dL, ALT of 60\u2009U/L, AST 50\u2009U/L, and ALP 153\u2009U/L after two weeks and normalized after five weeks of therapy.", {"entities": [[41, 56, "Parameter"], [60, 69, "Amount"], [71, 74, "Parameter"], [78, 84, "Amount"], [86, 89, "Parameter"], [90, 96, "Amount"], [102, 105, "Parameter"], [106, 113, "Amount"], [114, 129, "Duration"], [145, 161, "Duration"]]}], [734, "The clinicopathological features of Case 2 are illustrated in Tables 1, 2, and 4.", {"entities": []}], [735, "The Naranjo causality score for adverse drug reactions [8] was applied to the cases described here.", {"entities": [[32, 54, "Pathology"]]}], [736, "As shown in Table 5, the current case studies individually achieved a Naranjo score of 3 and were both categorized as \u201cpossible adverse drug reaction\u201d, in a scale encompassing a minimum score of zero, or \u201cdoubtful adverse drug reaction\u201d to a maximum score of \u22659, or \u201cdefinite adverse drug reaction.\u201d While the current case studies showed histopathological features of autoimmune hepatitis, neither fulfilled a diagnosis of \u201cprobable AIH\u201d or \u201cdefinite AIH\u201d based on the Hennes simplified criteria for diagnosis of AIH [10].", {"entities": [[128, 149, "Pathology"], [214, 235, "Pathology"], [276, 297, "Pathology"], [368, 388, "Pathology"], [433, 436, "Pathology"], [451, 454, "Pathology"], [513, 516, "Pathology"]]}], [737, "Briefly, Case 1 had an ANA titer of up to 1 : 80 (score 2), no available immunoglobulin titers (no score), a liver histology compatible with AIH (score 1), and absence of viral hepatitis (score 2), with a total score of 5.", {"entities": [[73, 87, "Parameter"], [141, 144, "Pathology"], [171, 186, "Pathology"]]}], [738, "Case 2 had a score of 1-0-1-2 = 4, on a scale where a score of \u22656 was designated \u201cprobable AIH\u201d, and \u22657 as \u201cdefinite AIH.\u201d Botanical dietary supplements are used commonly in the United States and are generally perceived to be safe [11].", {"entities": [[91, 94, "Pathology"], [117, 120, "Pathology"]]}], [739, "In one study, nearly one half of persons reported use of at least one agent to their primary provider [12].", {"entities": []}], [740, "A major difficulty in studying black cohosh is uncertainty regarding the composition of the various black cohosh products.", {"entities": [[31, 43, "Herb name"], [100, 112, "Herb name"]]}], [741, "Black cohosh itself contains a number of secondary compounds including phenolic derivatives and triterpene glycosides [13].", {"entities": [[0, 12, "Herb name"], [71, 91, "Herb name"], [96, 117, "Herb name"]]}], [742, "Phytoestrogens were postulated to play a role in black cohosh binding to estrogen receptors, but the presence of these compounds is controversial.", {"entities": [[0, 14, "Herb name"], [49, 61, "Herb name"], [73, 91, "Target"]]}], [743, "In one study, chromatographic analysis of 11 commercial black cohosh products showed that three were actually Asian Actea species [13].", {"entities": [[56, 68, "Herb name"], [110, 115, "Ethnic group"], [116, 121, "Herb name"]]}], [744, "An analysis of the remaining eight products found variability in the composition of triterpene glycosides and phenolic constituents.", {"entities": [[84, 105, "Herb name"], [110, 131, "Herb name"]]}], [745, "More importantly, not a single product contained a phytoestrogen.", {"entities": [[51, 64, "Herb name"]]}], [746, "Thus, the mechanism by which black cohosh might impact on alleviating menopausal symptoms is not well understood.", {"entities": [[29, 41, "Herb name"], [70, 89, "Pathology"]]}], [747, "Other possibilities include binding to yet-to-be-defined receptors or effects on the central nervous system [14].", {"entities": []}], [748, "Whether black cohosh is effective in controlling vasomotor symptoms of menopause is controversial as well.", {"entities": [[8, 20, "Herb name"], [71, 80, "Pathology"]]}], [749, "The American College of Obstetrics and Gynecology included black cohosh as a possible remedy for the vasomotor symptoms of menopause [15].", {"entities": [[4, 12, "Ethnic group"], [59, 71, "Herb name"], [123, 132, "Pathology"]]}], [750, "A large randomized-blinded trial of one-year duration found no difference between black cohosh and placebo in controlling vasomotor symptoms [16].", {"entities": [[8, 32, "Study"], [36, 44, "Duration"], [82, 94, "Herb name"]]}], [751, "Moreover, a recent review did not recommend long-term use due to the absence of safety evaluation [17].", {"entities": []}], [752, "There are a growing number of case reports of hepatotoxicity in patients taking black cohosh (Table 6) [1\u20137].", {"entities": [[46, 60, "Pathology"], [80, 92, "Herb name"]]}], [753, "Most described acute hepatic necrosis, although three articles of them detailed a case with clinical features of autoimmune hepatitis after black cohosh use [1, 2, 5].", {"entities": [[15, 37, "Pathology"], [113, 133, "Pathology"], [140, 152, "Herb name"]]}], [754, "The clinicopathological features of the cases in the current series have a fascinating combination of findings.", {"entities": []}], [755, "Both patients presented with an acute hepatitis displaying prominent centrilobular necrosis consistent with severe drug-induced liver injury.", {"entities": [[32, 47, "Pathology"], [115, 140, "Pathology"]]}], [756, "While autoantibodies were low titer or absent, the histology showed characteristics of autoimmune hepatitis with a plasma cell rich interface and lobular hepatitis.", {"entities": [[6, 20, "Parameter"], [87, 107, "Pathology"], [146, 163, "Pathology"]]}], [757, "In addition, both patients responded to corticosteroids, supporting an immune mediated component to the liver injury.", {"entities": [[40, 55, "Drug"], [104, 116, "Pathology"]]}], [758, "Determining the risk of black cohosh hepatotoxicity is further complicated by variability in both dosage and number of other botanical herbal supplements contained in some preparations.", {"entities": [[24, 36, "Herb name"], [37, 51, "Pathology"]]}], [759, "As an example, in the case reported by Lontos [4], the preparation of black cohosh included 4 other botanicals: ground ivy, golden seal, gingko, and oat seeds.", {"entities": [[70, 82, "Herb name"], [112, 122, "Herb name"], [124, 135, "Herb name"], [137, 143, "Herb name"], [149, 158, "Herb name"]]}], [760, "While liver injury remains unreported with the use of the last 3 botanicals, ground ivy contains a known hepatotoxin, pulegone.", {"entities": [[77, 87, "Herb name"], [118, 126, "Herb name"]]}], [761, "This case culminated in liver failure despite discontinuation of the herbal supplement [4].", {"entities": [[24, 37, "Pathology"]]}], [762, "Drug interactions might further potentiate negative outcomes resulting from hepatoxicity due to herbal supplements.", {"entities": [[76, 88, "Herb name"]]}], [763, "Herbal supplements such as venencapsan and black cohosh, and prescription drugs specifically rosiglitazone, ritonavir, and valproic acid, have had reported drug interactions with levothyroxine [1, 9, 18\u201322].", {"entities": [[27, 38, "Herb name"], [43, 55, "Herb name"], [93, 106, "Drug"], [108, 117, "Drug"], [123, 136, "Drug"], [179, 192, "Drug"]]}], [765, "As earlier stated, both cases of the current study were also assigned \u201cpossible causality\u201d by Naranjo scale [8].", {"entities": []}], [766, "Although no clinical or animal pharmacokinetic or toxicological information were identified in the Mahady review, it led to the inclusion of a cautionary statement on black cohosh products which was not previously required [9].", {"entities": [[167, 179, "Herb name"]]}], [767, "Despite such development, the use of botanical dietary supplements is generally viewed by the public as safe [11].", {"entities": []}], [768, "Providers are encouraged to screen patients about their consumption of botanical herbal supplements and to assess for any evidence of liver injury [1].", {"entities": [[134, 146, "Pathology"]]}], [769, "Timely discontinuation of hepatotoxic agents and, in some cases, early initiation of immunotherapy might prevent significant liver injury or could even be life saving [4].", {"entities": [[85, 98, "Drug"], [125, 137, "Pathology"]]}], [770, "The validity of reported cases of liver injury due to black cohosh illustrated in Table 6 has been disputed.", {"entities": [[34, 46, "Pathology"], [54, 66, "Herb name"]]}], [771, "Concerns that led to this uncertainty included cases in which the timing of liver injury occurred at a relatively short interval following exposure to black cohosh [2, 6, 7], presence of comorbidities such as cholelithhiasis [6] or concomittant use of drugs other than black cohosh that could have potentially triggered the adverse drug reaction [3, 4, 7], or the notion that some of the reported cases [2], including Case 1 of the current study (also reported by Mahady [23]), were indeed examples of autoimmune hepatitis rather than adverse drug reactions.", {"entities": [[151, 163, "Herb name"], [209, 224, "Pathology"], [269, 281, "Herb name"], [324, 345, "Pathology"], [502, 522, "Pathology"], [535, 557, "Pathology"]]}], [772, "Nonetheless, application of the Naranjo causality score to these case reports found possible cause for adverse drug reaction [8].", {"entities": [[103, 124, "Pathology"]]}], [773, "Further, autoimmune hepatitis is one of the known outcomes of drug-induced liver injury.", {"entities": [[9, 29, "Pathology"], [62, 87, "Pathology"]]}], [774, "The immune mechanism is precipitated by a drug or a metabolite acting as a hapten covalently binding to host cellular protein, converting into an immunogen [24] and thereby eliciting an autoimmune response.", {"entities": []}], [775, "Outcomes illustrating an association of chronic hepatitis with autoimmune features developing following the use of the botanical supplement black cohosh need to be emphasized.", {"entities": [[40, 57, "Pathology"], [140, 152, "Herb name"]]}], [776, "Here we described two cases of liver injury following the use of black cohosh characterized by chronic hepatitis with centrilobular necrosis and an interface activity dominated by plasma cells.", {"entities": [[65, 77, "Herb name"], [95, 140, "Pathology"]]}], [777, "While the histopathology in both cases was compatible with autoimmune hepatitis, clinical evidence for an autoimmune etiology was lacking.", {"entities": [[59, 79, "Pathology"]]}], [778, "Nonetheless both cases improved upon withdrawal of the drug and immunosuppressive therapy, indicating that there was at least in part a drug-induced immunological basis to the liver injury.", {"entities": [[64, 89, "Drug"], [176, 188, "Pathology"]]}], [779, "The current case studies, and three other published cases of liver injury following the use of black cohosh, share similar histological characteristics [1, 2, 5].", {"entities": [[61, 73, "Pathology"], [95, 107, "Herb name"]]}], [780, "Hepatic manifestations following the use of black cohosh should therefore be added to the list of differential diagnoses of hepatic necrosis culminating in chronic hepatitis mimicking autoimmune hepatitis.", {"entities": [[44, 56, "Herb name"], [124, 140, "Pathology"], [156, 173, "Pathology"], [184, 204, "Pathology"]]}], [781, "This liver biopsy from Case 1 displays chronic hepatitis remarkable for its dense interface activity with cholangiolar proliferation (1a) (\u00d7200) and sheets of plasma cells and apoptosis (1b) (\u00d7600).", {"entities": [[39, 56, "Pathology"]]}], [782, "Current case studies: clinical features and medications.", {"entities": []}], [783, "LFTs: Liver function tests.", {"entities": []}], [784, "RUQ: Right upper quadrant.", {"entities": []}], [785, "CLD: Chronic liver disease.", {"entities": [[0, 26, "Pathology"]]}], [786, "OTC: Over the counter drug.", {"entities": []}], [787, "NSAID: Nonsteroidal anti-inflammatory drug.", {"entities": [[0, 42, "Drug"]]}], [788, "Current case studies: past medical history, serological tests, and other pertinent laboratory data.", {"entities": []}], [789, "Duration of Illness and black cohosh use, liver function tests, autoimmune markers, histology, and treatment.", {"entities": [[24, 36, "Herb name"]]}], [790, "Duration of Illness and black cohosh use, liver function tests, autoimmune markers and histology.", {"entities": [[24, 36, "Herb name"]]}], [791, "Naranjo [8] Causality Scale for Adverse Drug Reactions.", {"entities": [[32, 54, "Pathology"]]}], [792, "Scoring: >9 : definite adverse drug reaction (ADR).", {"entities": [[23, 49, "Pathology"]]}], [793, "5\u20138 : probable ADR.", {"entities": [[15, 18, "Pathology"]]}], [794, "1\u20134 : possible ADR.", {"entities": [[15, 18, "Pathology"]]}], [795, "0 : doubtful ADR.", {"entities": [[13, 16, "Pathology"]]}], [796, "Similarities and differences among current case studies and published cases of black cohosh hepatotoxicity.", {"entities": [[79, 91, "Herb name"], [92, 106, "Pathology"]]}], [797, "*Cases adapted from Table 1 Lynch [5]; ALF: Acute liver failure; RUQ: Right upper quadrant pain.", {"entities": [[44, 63, "Pathology"]]}], [798, "OLT: Orthotopic liver transplant; LF: Liver failure.", {"entities": [[34, 51, "Pathology"]]}], [799, "Academic Editor: Min Li  Polygonum capitatum has unique curative effects on the urinary system.", {"entities": [[25, 44, "Herb name"]]}], [800, "In fact, many Polygonum capitatum-based preparations are currently used in the clinic.", {"entities": [[14, 33, "Herb name"]]}], [801, "In China, the combination of levofloxacin (LVFX) with a Chinese herbal preparation derived from Polygonum capitatum has been used for the clinical treatment of urinary system diseases, which can improve the curative effects and reduce the side effects of LVFX.", {"entities": [[29, 48, "Drug"], [56, 63, "Ethnic group"], [96, 115, "Herb name"], [239, 251, "Pathology"], [255, 259, "Drug"]]}], [802, "However, the herb-drug interaction (HDI) between these drugs has not been reported and the effect of Polygonum capitatum on the in vivo process of LVFX is unclear.", {"entities": [[101, 120, "Herb name"], [147, 151, "Drug"]]}], [803, "In this article, a sensitive ultraperformance liquid chromatography-tandem mass spectroscopy (UPLC-MS/MS) method was developed to evaluate the effects of the combined application of LVFX and the Polygonum capitatum extract on tissue distribution and excretion.", {"entities": [[182, 186, "Drug"], [195, 214, "Herb name"]]}], [804, "Thereafter, the method was validated for selectivity, accuracy, precision, linearity, lower limit of quantification (LLOQ), dilution integrity, recovery, and matrix effect.", {"entities": []}], [805, "Based on tissue distribution, LVFX could diffuse into all of the tested tissues, with significant differences in the content of each tissue between the coadministration group and single administration group.", {"entities": [[30, 34, "Drug"]]}], [806, "At 48\u2009h after the combination was orally administered, the urinary cumulative excretion of LVFX decreased from 20.69% to 11.84% while its fecal cumulative excretion decreased from 26.08% to 13.28%.", {"entities": [[59, 87, "Parameter"], [91, 95, "Drug"], [138, 164, "Parameter"]]}], [807, "Our results suggest that a drug interaction exists between the two drugs in the process of distribution and excretion.", {"entities": []}], [808, "This study provides important experimental evidence for further studies on the clinical efficacy and mechanism of the Polygonum capitatum extract and LVFX.", {"entities": [[118, 137, "Herb name"], [150, 154, "Drug"]]}], [809, "For thousands of years, traditional Chinese medicine has been widely used in China to treat diseases.", {"entities": [[36, 43, "Ethnic group"]]}], [810, "With the development of modern medicine, more and more people are trying to combine herbs and western medicines clinically to explore new medication options [1\u20133].", {"entities": []}], [811, "A reasonable herb-drug interaction (HDI) can enhance efficacy and reduce adverse reactions [4].", {"entities": [[73, 90, "Pathology"]]}], [812, "For example, the combination of Eugenia jambolana extract and sitagliptin caused significant improvement in the comorbidities associated with diabetes mellitus compared to sitagliptin treatment alone [5].", {"entities": [[32, 49, "Herb name"], [62, 73, "Drug"], [142, 159, "Pathology"], [172, 183, "Drug"]]}], [813, "Pittosporum angustifolium Lodd.", {"entities": [[0, 30, "Herb name"]]}], [814, "extracts also potentiated the activity of conventional antibiotics, without significantly affecting the toxicity of the combination [6].", {"entities": []}], [815, "However, the composition of Chinese herbal medicine is complex, and there is little information about the pharmacokinetics of many phytochemicals present in herbal medicine.", {"entities": [[28, 35, "Ethnic group"]]}], [816, "When used with western medicine especially, coadministration of herbs and conventional medicines will lead to increased potential risks of herbs interacting with the medicine; for example, combining ginseng with warfarin could increase the risk of bleeding in patients on chronic warfarin therapy [7], which represents huge challenges in terms of safety of the medication.", {"entities": [[199, 206, "Herb name"], [212, 220, "Drug"], [248, 256, "Pathology"], [280, 288, "Drug"]]}], [817, "Therefore, it is essential to evaluate the safety and effectiveness of HDI and drugs by studying the pharmacokinetics of the drug in vivo when combining herbs with western medicine.", {"entities": []}], [818, "Levofloxacin (LVFX) is used to treat numerous bacterial infections belonging to the third-generation fluoroquinolone antibiotic family [8].", {"entities": [[0, 19, "Drug"], [84, 127, "Drug"]]}], [819, "In fact, it is safe and effective and is widely employed to treat diseases such as community-acquired pneumonia, acute bacterial sinusitis, complicated urinary tract infections, and acute pyelonephritis [9\u201311].", {"entities": [[102, 111, "Pathology"], [113, 138, "Pathology"], [140, 176, "Pathology"], [182, 202, "Pathology"]]}], [820, "Because of the widespread use of this drug, its incidence of adverse reactions has increased.", {"entities": [[61, 78, "Pathology"]]}], [821, "These adverse effects including abdominal discomfort, diarrhea, vomiting, headache, skin rash, pruritus, and headache are commonly identified during clinical treatment [12\u201314].", {"entities": [[6, 21, "Pathology"], [32, 52, "Pathology"], [54, 62, "Pathology"], [64, 72, "Pathology"], [74, 82, "Pathology"], [84, 93, "Pathology"], [95, 103, "Pathology"], [109, 117, "Pathology"]]}], [822, "Thus, in clinics in China, many doctors opt to prescribe a combination of LVFX and a Chinese patent drug to enhance its efficacy and reduce its adverse effects.", {"entities": [[74, 78, "Drug"], [85, 92, "Ethnic group"], [144, 159, "Pathology"]]}], [823, "Polygonum capitatum is derived from Polygonum capitatum Buch.-Ham.", {"entities": [[0, 19, "Herb name"], [36, 55, "Herb name"]]}], [824, "ex D.Don and is a well-known Miao medicine that is widely used to treat different urinary system diseases [15].", {"entities": []}], [825, "Some drugs that are derived from Polygonum capitatum are presently used in the clinic such as Relinqing\u00ae granule and Milins\u00ae capsules [16].", {"entities": [[33, 52, "Herb name"], [94, 104, "Herb name"], [105, 124, "Herb name"]]}], [826, "Relinqing\u00ae granule, a unilateral preparation derived from Polygonum capitatum, is the best-selling Chinese patent drug for the treatment of urinary diseases and has been included in Chinese pharmacopoeia 2015 [17].", {"entities": [[0, 18, "Herb name"], [58, 77, "Herb name"], [99, 106, "Ethnic group"], [182, 189, "Ethnic group"]]}], [827, "For patients with urinary system infection, Relinqing\u00ae granule from Polygonum capitatum is usually combined with LVFX.", {"entities": [[18, 42, "Pathology"], [44, 62, "Herb name"], [68, 87, "Herb name"], [113, 117, "Drug"]]}], [828, "Several clinical prospective studies reported that the combination of a Chinese herbal preparation derived from Polygonum capitatum and LVFX is more effective and can thus enhance their efficacy to treat patients with urinary system infection, shorten the course of treatment, reduce the adverse effects of antibiotics, and exhibit a significant synergistic effect [18\u201320].", {"entities": [[8, 36, "Study"], [72, 79, "Ethnic group"], [112, 131, "Herb name"], [136, 140, "Drug"], [218, 242, "Pathology"], [288, 303, "Pathology"]]}], [829, "However, published studies have mainly focused on the clinical curative effect after the two drugs are combined.", {"entities": []}], [830, "To our knowledge, some information regarding the tissue distribution and excretion of LVFX combined with Polygonum capitatum is lacking.", {"entities": [[86, 90, "Drug"], [105, 124, "Herb name"]]}], [831, "Furthermore, the interactions and mechanism of the active ingredients in HDI are unclear.", {"entities": []}], [832, "In vivo distribution studies are crucial in drug research as they can be performed to demonstrate the pharmacokinetic features of a drug [21, 22].", {"entities": [[0, 28, "Study"]]}], [833, "In particular, investigating drug distribution throughout the whole body is critical as it provides insights into the accumulation and metabolism of drugs in a particular tissue [23].", {"entities": []}], [834, "In the present work, we examined the tissue distribution and excretion behavior of the single administration of LVFX or its combination with Polygonum capitatum.", {"entities": [[112, 116, "Drug"], [141, 160, "Herb name"]]}], [835, "In addition, we established an LC\u2013MS/MS method to simultaneously determine LVFX in tissue homogenate, urine, and feces after the oral administration of LVFX and Polygonum capitatum.", {"entities": [[75, 79, "Drug"], [152, 156, "Drug"], [161, 180, "Herb name"]]}], [837, "Therefore, the potential HDI in rats was examined via tissue distribution and excretion studies to comprehensively reveal its safety, predict its mechanism, and clarify its clinical applicability.", {"entities": []}], [838, "Polygonum capitatum was extracted with water according to the Chinese pharmacopeia [17].", {"entities": [[0, 19, "Herb name"], [62, 69, "Ethnic group"]]}], [839, "LVFX (purity: 97.3%) and puerarin (purity: 95.4%) standards were obtained from the National Institutes for Food and Drug Control (Beijing, China).", {"entities": [[0, 4, "Drug"], [25, 33, "Herb name"]]}], [840, "Methanol, formic acid, and acetonitrile (HPLC-grade) were purchased from Merck Co. (Darmstadt, Germany).", {"entities": []}], [841, "Distilled water was obtained from Watsons Group Co. Ltd. (Hong Kong, PR China).", {"entities": []}], [842, "All other chemicals were of analytical grade.", {"entities": []}], [843, "An ACQUITY I-Class UPLC system with a conditional autosampler and an Acquity I-Class UPLC BEH C Mass spectrometric detection was performed with an XEVO TQS Triple-Quadrupole Tandem Mass Spectrometer (Waters Corp, Milford, MA, USA) equipped with an electrospray ionization (ESI) source.", {"entities": []}], [844, "The mass spectrometer parameters were capillary voltage, 3.0\u2009kV; capillary ionization voltage, 3\u2009kV; ion source temperature, 120\u00b0C; spray gas and backflush gas, N Sprague\u2013Dawley rats (230\u2009\u00b1\u200920\u2009g) were supplied by Changsha Tianqin Biotechnology Co. Ltd. (Changsha, China; certificate No.", {"entities": []}], [845, "SCXK (Xiang) 2014-0010).", {"entities": []}], [846, "All studies were approved by the Animal Ethics Committee at Guizhou Medical University and conducted in accordance with the guidelines of the Committee on the Care and Use of Laboratory Animals in China.", {"entities": []}], [847, "The stock solutions of LVFX were separately weighed and dissolved in methanol to obtain the final concentration of 1.002\u2009mg/mL.", {"entities": [[23, 27, "Drug"]]}], [848, "An appropriate amount of puerarin was dissolved in methanol and diluted to obtain the IS solution (20\u2009ng/mL).", {"entities": [[25, 33, "Herb name"]]}], [849, "The stock solutions of LVFX were successively diluted to the following concentrations to generate the calibration curves: 5.01\u201315,030.00\u2009ng/mL, 5.01\u201310,020.00\u2009ng/mL, and 5.01\u20131002.00\u2009ng/mL.", {"entities": [[23, 27, "Drug"]]}], [850, "Quality control (QC) samples containing 10.02, 100.20, and 5010.00\u2009ng/mL of LVFX were prepared for the tissue distribution study, 10.02, 200.40, and 4008.00\u2009ng/mL of LVFX for the urinary excretion study, and 10.02, 20.04, and 200.40\u2009ng/mL of LVFX for the fecal excretion study.", {"entities": [[76, 80, "Drug"], [166, 170, "Drug"], [242, 246, "Drug"]]}], [851, "All stock and working solutions were stored at 4\u00b0C and brought to room temperature before use.", {"entities": []}], [852, "The tissues were cut on ice and mixed evenly.", {"entities": []}], [853, "Each weighed tissue was homogenized in physiological saline (1\u2009:\u20094, w/v) after thawing.", {"entities": []}], [854, "The corresponding tissue homogenate with no drug was used as the blank homogenate.", {"entities": []}], [855, "One milliliter of tissue homogenate and the bladder homogenates were centrifuged (5000\u2009rpm, 4\u00b0C, 8\u2009min).", {"entities": []}], [856, "Thereafter, 50\u2009\u03bcL of the IS solution (puerarin, 20\u2009ng/mL in methanol) and 50\u2009\u03bcL of 2% formic acid were added to 100\u2009\u03bcL of the rat tissue homogenate.", {"entities": [[38, 46, "Herb name"]]}], [857, "For protein precipitation, 400\u2009\u03bcL of methanol was added to the protein sample, vortexed for 1\u2009min, sonicated for 10\u2009min, and centrifuged at 12,000\u2009rpm for 10\u2009min at 4\u00b0C.", {"entities": []}], [858, "The supernatant was collected in a centrifuge tube and dried at 37\u00b0C with N Feces were crushed with a grinder.", {"entities": []}], [859, "Thereafter, 0.5\u2009g of the feces was homogenized with physiological saline (1\u2009:\u20098, w/v), vortexed for 2\u2009min, sonicated for 10\u2009min, and centrifuged at 5000\u2009rpm for 10\u2009min at 4\u00b0C.", {"entities": []}], [860, "The supernatant was then collected in a centrifuge tube.", {"entities": []}], [861, "A 100\u2009\u03bcL volume of rat urine or fecal homogenate was diluted 100-fold with the corresponding blank matrix.", {"entities": []}], [862, "Thereafter, 50\u2009\u03bcL of the IS solution (puerarin, 20\u2009ng/mL in methanol) and 50\u2009\u03bcL of 2% formic acid were added to 100\u2009\u03bcL of the diluted rat urine or fecal homogenate.", {"entities": [[38, 46, "Herb name"]]}], [863, "For protein precipitation, 800\u2009\u03bcL of methanol was added to the protein sample, vortexed for 1\u2009min, sonicated for 10\u2009min, and centrifuged at 12,000\u2009rpm for 10\u2009min at 4\u00b0C.", {"entities": []}], [864, "The supernatant was then collected in a centrifuge tube and used in the UPLC-MS/MS analysis.", {"entities": []}], [865, "The specificity of the method was evaluated by analyzing a blank rat liver tissue homogenate, adding LVFX and IS to this blank, and collecting the tissue homogenate at 30\u2009min after oral administration.", {"entities": [[101, 105, "Drug"], [110, 112, "Herb name"]]}], [866, "As described in Section 2.4, a standard curve was established to evaluate the linearity by plotting the relationship between the peak area ratio (y) of the analyte and IS and the standard concentration (x) of the analyte using 1/x The precision and accuracy of the test were determined by analyzing the quality control samples of the five replicates at three concentration levels (low, medium, and high) on the same day (intraday) and three consecutive days (interday).", {"entities": []}], [867, "The extraction recovery of the analyte was evaluated by comparing the peak area ratio of the low concentration, medium concentration, and high concentration of the pretreated QC samples to the peak area ratio of the supernatant containing the same concentration of the standard solution.", {"entities": []}], [868, "The matrix effect was evaluated by comparing the peak area of the analyte in the spiked sample postextraction, with the peak area of the analyte dissolved in the same concentration of methanol.", {"entities": []}], [869, "Five replicate analyses were performed on the QC samples.", {"entities": []}], [870, "The stability of the analytes was determined using low, medium, and high concentrations (n\u2009=\u20095 for each concentration level) under different conditions: 6\u2009h at room temperature, three freeze (\u221220\u00b0C) and thaw (room temperature) cycles, and storage at 4\u00b0C for 12\u2009h. The dilution integrity of the test was determined by analyzing the high-concentration samples in the ultralinear range (urine: 1,002.00\u2009\u03bcg/mL; feces: 100.20\u2009\u03bcg/mL) following 100-fold dilution with the blank rat matrix.", {"entities": []}], [871, "A result within \u00b115% should be achieved to satisfy the deviation between the measured result and the labeled amount.", {"entities": []}], [872, "For the tissue distribution study, Sprague\u2013Dawley rats were randomly divided into two groups, with 24 rats in each group.", {"entities": []}], [873, "Group one was administered 42\u2009mg\u00b7kg For the urinary and fecal study, Sprague\u2013Dawley rats were randomly divided into two groups (6 rats/group).", {"entities": []}], [874, "Group one was administered 42\u2009mg\u00b7kg Data are presented as mean\u2009\u00b1\u2009standard deviation (SD).", {"entities": []}], [875, "Statistical analysis was performed using the statistical software package, Statistical Product and Service Solutions (SPSS 11.5, SPSS Inc., Chicago, IL, USA).", {"entities": []}], [876, "Factorial analysis of variance was used for comparison between groups.", {"entities": []}], [877, "A P value <0.05 was considered to indicate statistical significance, while P values <0.01 indicated very significant difference.", {"entities": []}], [878, "Figure 1 shows the chromatograms of a blank tissue homogenate sample, a tissue homogenate sample with LVFX and IS, and a chromatogram obtained from a sample of rat tissue homogenate 30\u2009min after the addition of the LVFX and IS.", {"entities": [[102, 106, "Drug"], [215, 219, "Drug"], [224, 226, "Herb name"]]}], [879, "Based on the retention time, the endogenous substances in the tissue did not interfere with the determination of the analyzed components, indicating the good specificity of the experimental conditions.", {"entities": []}], [880, "As described in Section 2.4, a standard curve was established to examine linearity by plotting the relationship between the peak area ratio (y) of the analyte and IS and the standard concentration (x) of the analyte using 1/x The precision and accuracy of LVFX are shown in Table 3.", {"entities": [[256, 260, "Drug"]]}], [881, "The intra- and interday precision and accuracy of LVFX were assessed by analyzing the quality control (QC) samples at three concentrations in five duplicates.", {"entities": [[50, 54, "Drug"]]}], [882, "The relative standard deviations of the intraday and interday measurements were less than 15%.", {"entities": []}], [883, "These data indicate that the values are within the acceptable range and that the method used is accurate and precise.", {"entities": []}], [884, "The mean extraction recovery and the matrix effect of LVFX are shown in Table 4.", {"entities": [[54, 58, "Drug"]]}], [885, "Based on our findings, the developed method is acceptable and accurate for analyzing LVFX in complex matrices.", {"entities": [[85, 89, "Drug"]]}], [886, "Table 5 shows the stability data of LVFX.", {"entities": [[36, 40, "Drug"]]}], [887, "The stability of the analytes was determined using low, medium, and high concentrations (n\u2009=\u20095) under different conditions: 6\u2009h at room temperature, three freeze-thaw cycles from \u221220\u00b0C to 20\u00b0C, and storage at 4\u00b0C for 12\u2009h. Based on our findings, the analytes were stable under routine laboratory conditions.", {"entities": []}], [888, "The dilution integrity of LVFX in urine and fecal are shown in Table 6.", {"entities": [[26, 30, "Drug"]]}], [889, "The diluted samples were analyzed using a calibration curve to derive their integrities, which were within the acceptable limit of \u00b115%.", {"entities": []}], [890, "This finding demonstrates that the developed method could be applied for higher concentrations that exceed the linear ranges during quantitative analysis.", {"entities": []}], [891, "The content of LVFX in the heart, liver, spleen, lung, kidney, stomach, intestine, and bladder is shown in Figure 2, respectively.", {"entities": [[15, 19, "Drug"]]}], [892, "Compared to the single administration group, the tissue content of the group administered the combination was significantly decreased (P < 0.01).", {"entities": []}], [893, "Further, when different administration methods were employed, a significant difference was found in the concentration of LVFX in tissues with time (P < 0.01).", {"entities": [[121, 125, "Drug"]]}], [894, "As the data were statistically significant, the concentration of LVFX in tissue could be affected by the drug delivery mode and interaction time.", {"entities": [[65, 69, "Drug"]]}], [895, "From 30\u2009min to 2\u2009h, a prolongation in the residence time of LVFX in the liver and stomach of rats occurred relative to that of LVFX alone.", {"entities": [[60, 64, "Drug"], [127, 131, "Drug"]]}], [896, "Such findings demonstrate that elimination in the liver and stomach was reduced after combination treatment.", {"entities": []}], [897, "Figure 3 showed the excretion of LVFX in urine and feces.", {"entities": [[33, 37, "Drug"]]}], [898, "At 48\u2009h after the oral administration of a single dose of LVFX (42\u2009mg/kg), and the combination of the Polygonum capitatum extract (1.86\u2009g/kg) plus LVFX (42\u2009mg/kg) and the urinary cumulative excretion of LVFX was 20.69% and 11.84%, while its fecal cumulative excretion was 26.08% and 13.28%, respectively.", {"entities": [[58, 62, "Drug"], [64, 72, "Amount"], [102, 121, "Herb name"], [131, 140, "Amount"], [147, 151, "Drug"], [153, 161, "Amount"], [203, 207, "Drug"]]}], [899, "In the present study, we established a rapid, simple, and sensitive UPLC-MS/MS method.", {"entities": []}], [900, "Thereafter, we opted to apply this method to determine the tissue distribution and excretion changes when LVFX was combined with Polygonum capitatum.", {"entities": [[106, 110, "Drug"], [129, 148, "Herb name"]]}], [901, "Previously, our research group showed that Relinqing\u00ae granule, a unilateral preparation derived from Polygonum capitatum, could significantly change the main pharmacokinetic parameters of ciprofloxacin in rats [24], with a decrease in AUC After drugs enter the blood circulation, they are distributed to the tissues of the body and blood.", {"entities": [[43, 61, "Herb name"], [101, 120, "Herb name"], [188, 201, "Drug"], [235, 238, "Parameter"]]}], [902, "Understanding the characteristics of the tissue distribution of a drug will enable the identification of its target organs and the prediction of its pharmacological effect, which are significant for expanding its clinical use [25, 26].", {"entities": []}], [903, "In this experiment, we investigated the distribution of LVFX in rats for 0.25, 0.5, 2, and 6\u2009h using two drug delivery modes including the absorption phase, equilibrium phase, and elimination phase, which were selected according to the preliminary experimental results.", {"entities": [[56, 60, "Drug"]]}], [904, "The tissue distribution of LVFX is shown in Figure 2.", {"entities": [[27, 31, "Drug"]]}], [905, "The drug could be detected in 15\u2009min within the single administration group and the combination group.", {"entities": []}], [906, "Thus, LVFX was demonstrated to be rapidly and widely distributed in each tissue under the two different drug delivery modes.", {"entities": [[6, 10, "Drug"]]}], [907, "The content of tissues in the combined treatment group was significantly reduced relative to that of the single-treated group (P < 0.01).", {"entities": []}], [908, "Polygonum capitatum may inhibit the entrance of LVFX into blood, thereby directly affecting its distribution rate in the tissue.", {"entities": [[0, 19, "Herb name"], [48, 52, "Drug"]]}], [909, "Generally, multiple mechanisms may be responsible for the HDI of a specific drug.", {"entities": []}], [910, "Traditional Chinese medicine mainly causes pharmacokinetic interactions by inhibiting or inducing drug-metabolizing enzymes and transporters, which play a decisive role in the absorption, distribution, metabolism, and excretion of drugs [27].", {"entities": [[12, 19, "Ethnic group"]]}], [911, "The cytochrome P450 (CYP450) system and the efflux drug transporter, P-glycoprotein (P-gp), play an indispensable role in most HDIs, and more than half of oral Chinese medicine may interact with the CYP system [28].", {"entities": []}], [912, "According to the literature, the chemical constituents of the Polygonum capitatum extract mainly include flavonoids and phenolic acids [29, 30].", {"entities": [[62, 81, "Herb name"], [105, 115, "Herb name"], [120, 134, "Herb name"]]}], [913, "Flavonoids can regulate efflux transporters such as p-gp, MRPs, and BCRP [31].", {"entities": [[0, 10, "Herb name"], [52, 56, "Target"], [58, 62, "Target"], [68, 72, "Target"]]}], [914, "Previously, LVFX, ciprofloxacin, and other quinolones were demonstrated to be the substrates of P-gp [32] and our research group revealed that Polygonum capitatum could induce CYP2C9 and CYP3A4 [15].", {"entities": [[12, 16, "Drug"], [18, 31, "Drug"], [43, 53, "Drug"], [143, 162, "Herb name"], [176, 182, "Target"], [187, 193, "Target"]]}], [915, "Thus, after the two drugs were combined, the tissue distribution behavior of LVFX in vivo was altered.", {"entities": [[77, 81, "Drug"]]}], [916, "The interaction between the two drugs may be related to the metabolic enzymes and transporters in vivo.", {"entities": []}], [917, "Therefore, we will carry out a future study on the metabolic enzymes and transporters to determine whether the absorption and distribution of LVFX was altered by the involvement of efflux transporters and metabolic enzymes.", {"entities": [[142, 146, "Drug"]]}], [918, "LVFX excretion in urine and feces is shown in Figure 3.", {"entities": [[0, 4, "Drug"]]}], [919, "When the Polygonum capitatum extract and LVFX were combined, their cumulative excretion rate in urine and feces was significantly different from that of LVFX alone (P < 0.01).", {"entities": [[9, 28, "Herb name"], [41, 45, "Drug"], [153, 157, "Drug"]]}], [920, "After the Polygonum capitatum extract and LVFX were orally administered, the urinary cumulative excretion of LVFX decreased from 20.69\u2009\u00b1\u20094.26% to 11.84\u2009\u00b1\u20094.21%, thereby depicting the absorption of the drug followed by its transportation to tissues and organs during blood circulation.", {"entities": [[10, 29, "Herb name"], [42, 46, "Drug"], [109, 113, "Drug"]]}], [921, "According to the results of tissue distribution, drug content of the kidney was significantly reduced after the two drugs were combined, thereby causing a decrease in the excretion of LVFX in urine.", {"entities": [[184, 188, "Drug"]]}], [922, "Current reports showed that Relinqing\u00ae granule from Polygonum capitatum is usually combined with LVFX to enhance their efficacy to treat patients with urinary system infection.", {"entities": [[28, 46, "Herb name"], [52, 71, "Herb name"], [97, 101, "Drug"], [151, 175, "Pathology"]]}], [923, "At present, our current studies at the pharmacokinetic level may not be able to explain this problem strongly.", {"entities": []}], [924, "However, drug interactions can be divided into pharmacokinetic interactions and pharmacodynamic interactions.", {"entities": []}], [925, "At the pharmacodynamic level, how drugs cause the body to function, the mechanism of action is comprehensive and complex.", {"entities": []}], [926, "We speculate whether it is because of the synergistic inhibitory effect of the two drugs on the pathogenic bacteria [33, 34], such as reducing the ability of bacteria to adhere to the urothelial cells, speeding the passage of pathogenic bacteria out of the body, results in improved efficacy, but these speculations need to be confirmed by further experiments.", {"entities": []}], [927, "In addition, the fecal cumulative excretion decreased from 26.08\u2009\u00b1\u20094.16% to 13.28\u2009\u00b1\u20093.98% at 48\u2009h after oral administration.", {"entities": []}], [928, "These results suggest that the Polygonum capitatum extract has an effect on the excretion of LVFX in urine and feces.", {"entities": [[31, 50, "Herb name"], [93, 97, "Drug"]]}], [929, "However, a further study is required to elucidate the causes and effects of the emergence of these phenomena.", {"entities": []}], [930, "Herein, we developed an LC\u2013MS/MS method to determine LVFX in rat biological samples after the combined oral administration of the Polygonum capitatum extract and LVFX.", {"entities": [[53, 57, "Drug"], [130, 149, "Herb name"], [162, 166, "Drug"]]}], [931, "Thereafter, we successfully applied this method to a tissue distribution and excretion study in rats.", {"entities": []}], [932, "To our knowledge, this is the first study to evaluate the tissue distribution and excretion of Polygonum capitatum extract and LVFX when coadministered to rats.", {"entities": [[95, 114, "Herb name"], [127, 131, "Drug"]]}], [933, "Based on our findings, the content of LVFX in tissues and excretion samples was significantly reduced when combined with the Polygonum capitatum extract.", {"entities": [[38, 42, "Drug"], [125, 144, "Herb name"]]}], [934, "Moreover, we demonstrated the herb-drug interactions of this drug combination.", {"entities": []}], [935, "Nonetheless, a further research on the in vivo HDI between the Polygonum capitatum extract and LVFX should be conducted to provide a substantial foundation for investigating the suitability of this combination for clinical applications.", {"entities": [[63, 82, "Herb name"], [95, 99, "Drug"]]}], [936, "This work was supported by the National Natural Science Foundation of China (grant no.", {"entities": []}], [937, "81760675/U1812403); Guizhou Science and Technology Department (grant nos.", {"entities": []}], [938, "[2019] 2777/5660, [2018]4006, and [2017]5601); Guiyang Science and Technology Bureau (grant no.", {"entities": []}], [939, "[2017]30-29); and Guizhou Education Department (no.", {"entities": []}], [940, "KY[2017]073).", {"entities": []}], [941, "The data used to support the findings of this study are included within the article.", {"entities": []}], [942, "The authors declare that there are no conflicts of interest regarding the publication of this paper.", {"entities": []}], [943, "Typical chromatograms.", {"entities": []}], [944, "(a) Blank tissue homogenate; (b) blank tissue homogenate spiked with LVFX and IS; (c) rat tissue homogenate collected at 30\u2009min after oral administration of LVFX.", {"entities": [[69, 73, "Drug"], [157, 161, "Drug"]]}], [945, "(1) LVFX; (2) puerarin.", {"entities": [[4, 8, "Drug"], [14, 22, "Herb name"]]}], [946, "The content of LVFX in rat tissue homogenate of single and coadministration group at four different time points (mean\u2009\u00b1\u2009SD).", {"entities": [[15, 19, "Drug"]]}], [947, "Compared with single group:  Urinary and fecal cumulative excretion ratio of LVFX after oral administration to rats (n\u2009=\u20096).", {"entities": [[77, 81, "Drug"]]}], [948, "(a) Urinary excretion.", {"entities": []}], [949, "(b) Fecal excretion.", {"entities": []}], [950, "Mass spectrum parameters of the analyte and puerarin (IS).", {"entities": [[44, 52, "Herb name"]]}], [951, "Calibration curves, linear ranges, correlation coefficients, and LLOQ of LVFX in rat tissues and urine and fecal samples.", {"entities": [[73, 77, "Herb name"]]}], [952, "Precision and accuracy of LVFX in rat liver tissues, urine, and feces (n\u2009=\u20095).", {"entities": [[26, 30, "Drug"]]}], [953, "Recovery and matrix effect of LVFX in rat liver tissues, urine, and feces (n\u2009=\u20095).", {"entities": [[30, 34, "Drug"]]}], [954, "Stability of LVFX under different storage conditions (n\u2009=\u20095).", {"entities": [[13, 17, "Drug"]]}], [955, "Dilution integrity of LVFX in urine and fecal samples (n\u2009=\u20095).", {"entities": [[22, 26, "Drug"]]}], [956, "Patients commonly take complementary medicines in conjunction with conventional drugs without clear evidence of safety or the risk of herb\u2013drug interactions.", {"entities": []}], [957, "The aim of this study was to assess potential pharmacokinetic (PK) and pharmacodynamic (PD) interactions between St John's wort and gliclazide in healthy subjects with different cytochrome P450 2C9 (CYP2C9) genotypes.", {"entities": [[113, 127, "Herb name"], [132, 142, "Drug"], [146, 153, "Pathology"], [178, 216, "Parameter"]]}], [958, "Each received gliclazide (80\u2009mg) either alone or during 15 days treatment with St John's wort.", {"entities": [[14, 24, "Drug"], [26, 31, "Amount"], [49, 63, "Duration"], [79, 93, "Herb name"]]}], [959, "The mean ratio and 90% confidence interval (CI) of gliclazide AUC Treatment with St John's wort significantly increases the apparent clearance of gliclazide which is independent of CYP2C9 genotype.", {"entities": [[51, 61, "Drug"], [62, 65, "Parameter"], [81, 95, "Herb name"], [120, 142, "Parameter"], [146, 156, "Drug"], [181, 196, "Parameter"]]}], [960, "People with diabetes receiving this combination should be closely monitored to evaluate possible signs of reduced efficacy.", {"entities": [[12, 20, "Pathology"]]}], [961, "Chemical structure of gliclazide.", {"entities": [[22, 32, "Drug"]]}], [962, "Error bars represent s.d.", {"entities": []}], [963, "(n=21).", {"entities": []}], [964, "Gliclazide apparent clearance (CL/F) of three groups of CYP2C9 genotypes in gliclazide only phase.", {"entities": [[0, 10, "Drug"], [11, 36, "Parameter"], [56, 72, "Parameter"], [76, 86, "Drug"]]}], [965, "(\u2018\u2014' indicates mean in each group, the solid circle represents a subject with CYP2C9*2/*2 genotype).", {"entities": [[78, 98, "Parameter"]]}], [966, "Data shown was not to represent population frequency; data are presented as median and range.", {"entities": []}], [967, "Edited by: Emilio Clementi, University of Milano, Italy Reviewed by: Paavo Honkakoski, University of Eastern Finland, Finland; Oliver Burk, Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Germany; Paul Cos, Antwerp University, Belgium This article was submitted to Pharmaceutical Medicine and Outcomes Research, a section of the journal Frontiers in Pharmacology.", {"entities": []}], [968, "Labisia pumila (Kacip Fatimah) is a popular herb in Malaysia that has been traditionally used in a number of women\u2019s health applications such as to improve libido, relieve postmenopausal symptoms, and to facilitate or hasten delivery in childbirth.", {"entities": [[0, 30, "Herb name"], [109, 114, "Sex"], [156, 162, "Parameter"], [172, 195, "Pathology"]]}], [969, "In addition, the constituents of this plant have been reported to possess anticancer, antioxidant, and anti-inflammatory properties.", {"entities": [[13, 43, "Herb name"], [74, 84, "Pathology"], [103, 120, "Pathology"]]}], [970, "Clinical studies have indicated that cytochrome P450s (CYPs), P-glycoprotein (P-gp), and Pregnane X receptor (PXR) are the three main modulators of drug-drug interactions which alter the absorption, distribution, and metabolism of drugs.", {"entities": [[0, 16, "Study"], [37, 60, "Parameter"], [62, 83, "Parameter"], [89, 114, "Parameter"], [187, 236, "Parameter"]]}], [971, "Given the widespread use of Kacip Fatimah in dietary supplements, the current study focuses on determining the potential of its constituents to affect the activities of CYPs, P-gp, or PXR using in vitro assays which may provide useful information toward the risk of herb-drug interaction with concomitantly used drugs.", {"entities": [[28, 41, "Herb name"], [151, 187, "Parameter"], [194, 209, "Study"]]}], [972, "Six compounds isolated from the roots of L. pumila (2 saponins and 4 alkyl phenols) were tested, in addition to the methanolic extract.", {"entities": [[28, 37, "Herb part"], [41, 82, "Herb name"], [112, 134, "Extraction process"]]}], [973, "The alkyl phenols inhibited CYP3A4 (TDI), CYP2C9, and 2C19 (reversible) while saponins inhibited P-gp and PXR.", {"entities": [[0, 17, "Herb name"], [28, 58, "Target"], [78, 86, "Herb name"], [97, 109, "Target"]]}], [974, "In conclusion, L. pumila and its constituents showed significant modulation of all three regulatory proteins (CYPs, P-gp, and PXR) suggesting a potential to alter the pharmacokinetic and pharmacodynamic properties of conventional drugs if used concomitantly.", {"entities": [[15, 45, "Herb name"], [110, 129, "Target"]]}], [975, "Labisia pumila (Blume) Fern.-Vill., locally termed as Kacip Fatimah (KF), is a popular herb in South East Asian countries.", {"entities": [[0, 34, "Herb name"], [54, 72, "Herb name"], [95, 111, "Ethnic group"]]}], [976, "It belongs to the Myrsinaceae family.", {"entities": [[14, 36, "Herb name"]]}], [977, "Recently it has been identified as one of the top five herbs used in Malaysia for treating variety of ailments (Karimi et al., 2013).", {"entities": [[102, 110, "Pathology"]]}], [978, "Traditionally, KF is mainly used in a wide spectrum of women\u2019s health related issues; the effects are presumed as attributable to the presence of estrogen-like compounds.", {"entities": [[15, 17, "Herb name"], [55, 60, "Sex"], [146, 169, "Herb name"]]}], [979, "KF is often taken during and after pregnancy for its beneficial effects on uterine function and delivery.", {"entities": [[0, 2, "Herb name"], [35, 44, "Parameter"], [75, 104, "Parameter"]]}], [980, "The primary route of administration of KF is oral, whereby the leaves, roots, or whole plant are boiled in water and consumed.", {"entities": [[39, 41, "Herb name"], [59, 76, "Herb part"], [97, 112, "Extraction process"]]}], [981, "Additionally, it is sold commercially in the form of herbal tea, powder, capsules, and tablets in many countries (Abdul Kadir et al., 2012).", {"entities": [[53, 94, "Extraction process"]]}], [982, "Clinical studies have also suggested the usefulness of KF extract in treating postmenopausal symptoms (Abdul Kadir et al., 2012) with no acute toxicity (Singh et al., 2009).", {"entities": [[0, 16, "Study"], [55, 65, "Herb name"], [78, 101, "Pathology"], [137, 151, "Pathology"]]}], [983, "Furthermore, the extract and constituents of KF have been shown to possess anticancer, antioxidant, anti-osteoporosis, and anti-inflammatory properties (Nadia et al., 2012; Fathilah et al., 2013).", {"entities": [[13, 47, "Herb name"], [75, 151, "Pathology"]]}], [984, "Due to the increasing popularity and wide spread use of herbal supplements throughout the world, there is a potential risk of herb-drug interactions when these supplements are taken in combination with conventional drugs, as there is often limited standardization of dose of herbal supplements taken.", {"entities": [[56, 74, "Herb name"], [202, 220, "Drug"]]}], [985, "This is evident by the increasing reports of clinical cases of toxicity caused by herb-drug interactions (Chen et al., 2011, 2012).", {"entities": [[34, 59, "Study"], [63, 71, "Pathology"]]}], [986, "Early identification of drug interaction potential of herbal supplements and their constituents will aid in lowering the risk of herb-drug interactions.", {"entities": []}], [987, "It is widely documented that CYPs, P-gp, and PXR are the three main modulators of drug-drug interactions as these are involved in affecting the pharmacokinetic and pharmacodynamic properties of xenobiotics (Alissa, 2014).", {"entities": [[29, 48, "Parameter"], [194, 205, "Drug"]]}], [988, "Despite the use of KF as a herbal medicine, limited studies exist in literature for its drug interaction potential.", {"entities": [[19, 42, "Herb name"]]}], [989, "A recent study has indicated that different extracts of L. pumila show potent inhibition of CYPs, specifically CYP2C isoforms (Pan et al., 2012).", {"entities": [[44, 65, "Herb name"], [92, 125, "Target"]]}], [990, "However, there are no studies identifying the chemical constituents of KF responsible for CYP inhibition.", {"entities": [[71, 73, "Herb name"], [90, 93, "Target"]]}], [991, "As part of our phytochemical studies on medicinal plants, several constituents have been isolated from the roots of L. pumila; these belong to various chemical classes, including saponins, alkyl phenols, cerebroside, glycerogalactolipids, and lipids (Ali and Khan, 2011).", {"entities": [[15, 56, "Study"], [103, 112, "Herb part"], [116, 125, "Herb name"], [179, 249, "Herb name"]]}], [992, "In the extension of these studies, the current investigation focuses on determining the potential of KF methanolic extract and its constituents to affect the activities of major drug metabolizing enzymes (CYP 3A4, 2D6, 1A2, 2C9, and 2C19), P-gp, and PXR using in vitro assays which may provide useful information toward the risk of herb-drug interactions with concomitantly used drugs.", {"entities": [[101, 103, "Herb name"], [104, 122, "Extraction process"], [178, 253, "Parameter"], [260, 275, "Study"]]}], [993, "The inhibition of CYP 3A4, 2D6, 1A2, 2C9, and 2C19 was determined by employing C-DNA baculovirus expressed recombinant enzymes and specific fluorescent substrates.", {"entities": [[18, 50, "Target"], [79, 126, "Parameter"]]}], [994, "The inhibition of P-gp was determined in hMDR1-MDCK-II (Madin-Darby canine kidney) and MDCK-II cells by using two widely used substrates calcein-AM and digoxin.", {"entities": [[18, 22, "Target"], [137, 147, "Herb name"], [152, 159, "Drug"]]}], [995, "Modulation of PXR activity was monitored through a reporter gene assay in HepG2 cells transfected with PXR plasmid DNA and a luciferase reporter plasmid PCR5.", {"entities": [[14, 26, "Parameter"], [103, 118, "Parameter"]]}], [996, "Additionally, we used FDA guided assumptions (Zhang et al., 2009) to predict the likelihood of the KF extract and its constituents to cause herb drug interactions (HDI) in vivo.", {"entities": [[99, 109, "Herb name"]]}], [997, "Madin-Darby canine kidney-II (parental) and hMDR1-MDCK-II (transfected) cell lines were a gift from Dr. Gottesman (NIH, Bethesda, USA).", {"entities": []}], [998, "Dulbecco\u2019s Modified Eagle Medium (DMEM), Minimal Essential Medium (MEM), Hanks balanced salt solution (HBSS), HEPES, Trypsin EDTA, Penicillin-streptomycin, and Sodium Pyruvate were from GIBCO BRL (Invitrogen Corp., Grand Island, NY, USA).", {"entities": [[73, 108, "Extraction process"], [110, 115, "Extraction process"], [117, 129, "Extraction process"], [131, 154, "Drug"], [160, 175, "Extraction process"]]}], [999, "Fetal bovine serum (FBS) was from Hyclone Lab Inc. (Logan, UT, USA).", {"entities": [[0, 24, "Extraction process"]]}], [1000, "CYP1A2/CEC, CYP2C9/MFC, CYP3A4/BQ, CYP2C19/CEC, and CYP2D6/AMMC high throughput inhibitor screening kits were from BD Gentest (Woburn, MA, USA).", {"entities": [[0, 63, "Parameter"]]}], [1001, "Transwell plates (12 mm diameter, 0.4 \u03bcM pore size) were from Costar Corp. (Cambridge, MA, USA).", {"entities": []}], [1002, "All other chemicals were from Sigma Chem.", {"entities": []}], [1003, "Co., (St. Louis, MO, USA).", {"entities": []}], [1004, "Radio labeled digoxin [ Parental and transfected MDCK-II cells were grown in DMEM supplemented with 10% FBS, 1% non-essential amino acids, 1%  The assay for reversible inhibition was conducted in a total volume of 200 \u03bcL in 96-well microplates.", {"entities": [[14, 21, "Drug"], [100, 103, "Amount"], [104, 107, "Extraction process"], [109, 111, "Amount"], [112, 137, "Herb name"], [139, 141, "Amount"], [214, 220, "Amount"]]}], [1005, "The assay conditions, enzyme and substrate concentrations were similar as reported earlier (Crespi et al., 1997; Manda et al., 2013).", {"entities": [[22, 57, "Parameter"]]}], [1006, "Test samples or positive controls were serially diluted in a solution (100 \u03bcL) of cofactors mix, control protein (0.05 mg of protein/mL), and G-6-PDH to achieve six concentrations (100-0.4 \u03bcM or \u03bcg/mL).", {"entities": [[71, 77, "Amount"], [82, 95, "Parameter"], [97, 112, "Parameter"], [114, 135, "Amount"], [142, 149, "Parameter"], [165, 179, "Parameter"], [181, 200, "Amount"]]}], [1007, "Reaction was initiated by the addition of enzyme substrate mixture (100 \u03bcL) followed by incubation for 15, 30, or 45 min.", {"entities": [[42, 66, "Parameter"], [68, 74, "Amount"], [99, 120, "Duration"]]}], [1008, "Fluorescence was measured on Spectramax M5 plate reader (Molecular Devices, Sunnyvale, CA, USA) at specified excitation and emission wavelengths for each substrate.", {"entities": [[0, 12, "Parameter"]]}], [1009, "IC Time dependent inhibition (TDI) of CYPs was measured as described earlier by Sekiguchi et al.", {"entities": [[3, 42, "Parameter"]]}], [1010, "(2009).", {"entities": []}], [1011, "IC The pSG5-hPXR expression vector was provided generously by Dr. Steven Kliewer (University of Texas Southwestern Medical Center, Dallas, TX, USA; Lehmann et al., 1998) and the reporter plasmid CYP3A4-PXR response element (PXRE)-LUC (containing the proximal 0/\u2013362 and distal 7208/7797 PXRE regions fused upstream of luciferase; Goodwin et al., 1999) was a kind gift from Dr. Christopher Liddle (University of Sydney, Westmead, NSW, Australia).", {"entities": [[3, 34, "Parameter"], [174, 233, "Parameter"]]}], [1012, "The modulation of PXR activity by test samples was determined in HepG2 cells transiently transfected with pSG5-PXR (25 \u03bcg) and PCR5 plasmid DNA (25 \u03bcg) by electroporation at 180 V, 1 pulse for 70 msec.", {"entities": [[18, 30, "Parameter"], [106, 114, "Parameter"], [116, 121, "Amount"], [127, 143, "Parameter"], [145, 150, "Amount"], [181, 182, "Amount"], [183, 188, "Parameter"], [193, 200, "Duration"]]}], [1013, "The cells were plated in 96-well plates at a density of 50,000 cells per well.", {"entities": []}], [1014, "After 24 h, test samples and drug controls were added at various concentrations.", {"entities": [[0, 10, "Duration"], [65, 79, "Parameter"]]}], [1015, "After additional 24 hour incubation, the media was aspirated and 40 \u03bcL of luciferase reagent (Promega Corporation, Madison, WI, USA) was added to each well and luminescence was measured on Spectramax M5 plate reader (Molecular Devices, Sunnyvale, CA, USA).", {"entities": [[17, 24, "Duration"], [65, 70, "Amount"], [74, 92, "Extraction process"]]}], [1016, "The fold induction in luciferase activity in the treated cells was calculated in comparison to vehicle treated cells.", {"entities": [[22, 41, "Parameter"]]}], [1017, "The cytotoxicity of test samples toward HepG2 cells was also determined by measuring the cell viability using the CellTiter 96 AQ The assay was performed as described previously (Rautio et al., 2006).", {"entities": [[4, 16, "Pathology"], [89, 103, "Parameter"]]}], [1018, "Cells were seeded in 96-well plates at 70,000 cells/well in 200 \u03bcL of culture medium.", {"entities": []}], [1019, "The medium was changed at 24 h after seeding and the assay was performed 48 h later.", {"entities": [[26, 30, "Duration"], [73, 83, "Duration"]]}], [1020, "The EC The assay conditions were similar as described earlier (Rautio et al., 2006) with some modifications.", {"entities": []}], [1021, "The cells were seeded at a density of 120,000 cells/well in 12-well Transwell plates and cultured for 3 days.", {"entities": [[102, 108, "Duration"]]}], [1022, "The IC All assumptions to predict the HDI potential of KF methanolic extract and its constituents were according to previously published report (Awortwe et al., 2014).", {"entities": [[55, 57, "Herb name"], [58, 76, "Extraction process"]]}], [1023, "The % yield was calculated from the amounts extracted from the KF roots (Ali and Khan, 2011).", {"entities": [[63, 65, "Herb name"], [66, 71, "Herb part"]]}], [1024, "We then compared the in vitro IC All values are represented as mean \u00b1 SD (n = 3).", {"entities": []}], [1025, "The data were analyzed by one way ANOVA, followed by Dunnett\u2019s multiple comparison tests using GraphPad Prism Version 5, (San Diego, CA, USA).", {"entities": []}], [1026, "P < 0.05 was considered to be statistically significant.", {"entities": []}], [1027, "The two major classes of compounds isolated from the roots of KF are alkyl phenols and triterpene glycosides (saponins) as reported earlier (Ali and Khan, 2011).", {"entities": [[49, 58, "Herb part"], [62, 64, "Herb name"], [69, 119, "Herb name"]]}], [1028, "We have determined the effect of methanolic extract of KF and its six constituents (4 alkyl phenols and 2 saponins, Figure 1 on major CYPs using specific fluorescent substrates and recombinant enzymes.", {"entities": [[33, 51, "Extraction process"], [55, 57, "Herb name"], [84, 114, "Herb name"], [134, 138, "Parameter"], [154, 200, "Parameter"]]}], [1029, "Chemical structures of two saponins and four alkyl phenols isolated from the roots of Labisia pumila.", {"entities": [[23, 58, "Herb name"], [73, 82, "Herb part"], [86, 100, "Herb name"]]}], [1030, "The methanolic extract and alkyl phenolic compounds showed dose dependent inhibition of CYP3A4, 2C9, and 2C19 (Figures 2\u20134) while saponins did not affect the activity of these enzymes.", {"entities": [[0, 22, "Extraction process"], [27, 51, "Herb name"], [88, 109, "Target"], [130, 138, "Herb name"], [154, 183, "Parameter"]]}], [1031, "The data are represented as mean \u00b1 SD of 3 independent experiments (n = 2 in each experiment).", {"entities": []}], [1032, "The test samples were pre-incubated for 30 min with the co-factors, control protein, and specific enzymes before substrates were added.", {"entities": [[40, 46, "Duration"], [52, 66, "Parameter"], [68, 83, "Parameter"], [89, 105, "Parameter"], [113, 123, "Parameter"]]}], [1033, "The data are represented as mean \u00b1 SD of 3 independent experiments (n = 2 in each experiment).", {"entities": []}], [1034, "The data are represented as mean \u00b1 SD of 3 independent experiments (n = 2 in each experiment).", {"entities": []}], [1035, "IC Next, we determined the inhibition of P-gp by the extract of L. pumila and the constituents by using the two widely used probes calcein-AM and digoxin (Rautio et al., 2006).", {"entities": [[41, 45, "Target"], [49, 94, "Herb name"], [131, 141, "Herb name"], [146, 153, "Drug"]]}], [1036, "Equations used in evaluating EC The second probe used to determine the P-gp inhibition was radiolabelled digoxin [ Dose-response curves of P-gp inhibition by methanol extract (A) of Labisia pumila roots, its two saponin constituents (B\u2013C) and positive control cyclosporin A (D), determined by calculating the basolateral to apical transport (%) of  Finally, we looked at the modulation of PXR activity by the extract and the constituents using a reporter gene assay in HepG2 cells.", {"entities": [[71, 75, "Target"], [105, 112, "Drug"], [139, 143, "Target"], [158, 174, "Extraction process"], [182, 196, "Herb name"], [197, 202, "Herb part"], [212, 232, "Herb name"], [260, 273, "Drug"], [305, 344, "Parameter"], [389, 401, "Parameter"], [405, 437, "Herb name"]]}], [1037, "These results suggest that there is no effect on the PXR activation by KF extract or its constituents.", {"entities": [[49, 67, "Parameter"], [71, 101, "Herb name"]]}], [1038, "These results indicate that L. pumila and its constituents significantly modulate the activity of PXR and thereby could affect the downstream genes involved in PXR signaling.", {"entities": [[28, 58, "Herb name"], [82, 101, "Parameter"], [160, 173, "Parameter"]]}], [1039, "Ketoconazole (KTZ) was used as a positive control in the inhibition assay.", {"entities": [[0, 18, "Drug"]]}], [1040, "*P < 0.05, **P < 0.01, and ***P < 0.001, determined by One way ANOVA, followed by Dunnett\u2019s multiple comparison tests.", {"entities": []}], [1041, "The data are represented as mean \u00b1 SD of triplicate measurements in three independent experiments.", {"entities": []}], [1042, "Since the intestinal absorption or plasma concentrations are not known for the test compounds, we made an assumption that all of the compounds are completely absorbed (100% bioavailable) from the GI tract.", {"entities": [[6, 31, "Parameter"], [35, 56, "Parameter"], [168, 172, "Amount"], [173, 185, "Parameter"]]}], [1043, "Based on this, the predicted GI and plasma concentrations of the compounds were calculated as shown in Tables 2 and 3.", {"entities": [[15, 74, "Parameter"]]}], [1044, "There is increasing evidence that the global use of herbal supplements for the treatment of a wide spectrum of ailments has been on the rise.", {"entities": [[111, 119, "Pathology"]]}], [1045, "Concurrently, there are more clinical cases of toxicity caused by concomitant administration of herbal supplements with conventional medicines (Colalto, 2010).", {"entities": [[47, 55, "Pathology"]]}], [1046, "This risk is mainly attributed due to the lack of research on the drug interaction potential of herbal medicines and their constituents.", {"entities": [[96, 135, "Herb name"]]}], [1047, "Such studies are needed to identify the potential herbs which may cause drug interactions and may help in reducing the risk of clinical toxicity (Chen et al., 2012).", {"entities": [[127, 144, "Pathology"]]}], [1048, "Furthermore, it is also of significant value to identify the constituents responsible for causing drug interactions.", {"entities": []}], [1049, "This will also enable us to identify the potential herbs which have similar chemical composition that may cause drug interactions.", {"entities": []}], [1050, "Based on the FDA guidelines related to the drug interaction, identifying compounds which interact with drug metabolizing enzymes and e\ufb04ux transporters are of paramount importance since they play a major role in altering the pharmacokinetics and pharmacodynamics of majority of conventional drugs (Huang et al., 2008).", {"entities": [[103, 128, "Parameter"], [133, 150, "Parameter"]]}], [1051, "Accordingly, the current study is focused on studying a widely used herb KF and some of its chemical constituents for the possibility of herb-drug interaction mediated by modulating the activities of CYPs, P-gp, and PXR using in vitro methods.", {"entities": [[73, 75, "Herb name"], [182, 219, "Parameter"]]}], [1052, "In the present study, the methanolic extract of KF and its constituents showed a moderate inhibition of CYP2D6 and 1A2 at higher concentrations.", {"entities": [[22, 44, "Extraction process"], [48, 71, "Herb name"], [104, 118, "Target"], [129, 143, "Parameter"]]}], [1053, "It is unlikely that most of these compounds will accumulate to such high physiological concentrations after oral intake.", {"entities": [[73, 101, "Parameter"]]}], [1054, "However, saponins isolated from Panax notoginseng were found to induce CYP1A2 with no inhibitory effect on the activity of other CYPs (Liu et al., 2012).", {"entities": [[9, 49, "Herb name"], [71, 77, "Target"], [107, 133, "Parameter"]]}], [1055, "These differences toward CYP3A4 activity may be attributed to the differences in the chemical composition of the extracts used in separate studies.", {"entities": [[25, 40, "Parameter"]]}], [1056, "Time dependent inhibitors are categorized as mechanism based inhibitors.", {"entities": []}], [1057, "Such inhibitors are generally considered to have more profound clinical effects compared to reversible inhibitors as they form strong covalent bonds and thereby inactivate the CYPs (Riley et al., 2007; Venkatakrishnan et al., 2007).", {"entities": [[172, 180, "Parameter"]]}], [1058, "In order to find out if the methanolic extract or the constituents cause any TDI, the shift in IC P-gp is known to contain multiple binding sites and consequently multiple probe substrates are recommended to determine if a compound is an inhibitor (Martin et al., 2000).", {"entities": [[24, 46, "Extraction process"], [98, 102, "Parameter"], [172, 188, "Parameter"]]}], [1059, "We used calcein-AM and digoxin as our probe substrates as they are known to bind two different binding pockets of P-gp (Rautio et al., 2006).", {"entities": [[8, 18, "Herb name"], [23, 30, "Drug"], [114, 118, "Parameter"]]}], [1061, "However, using digoxin as the substrate, much more potent inhibition of P-gp was seen.", {"entities": [[15, 22, "Drug"], [72, 76, "Target"]]}], [1062, "A similar trend was seen with verapamil which showed more potency in the digoxin assay, in accordance to previous report (Rautio et al., 2006).", {"entities": [[30, 39, "Drug"], [73, 80, "Drug"]]}], [1063, "Our results indicate that the components of KF exhibit similar mechanism of P-gp inhibition as verapamil.", {"entities": [[44, 46, "Herb name"], [76, 80, "Target"], [95, 104, "Drug"]]}], [1064, "Inhibition of P-gp and PXR by the methanol extract could be attributed to the presence of saponins while inhibition of CYPs could be due to alkyl phenols.", {"entities": [[14, 26, "Target"], [30, 50, "Extraction process"], [90, 98, "Herb name"], [119, 123, "Target"], [140, 153, "Herb name"]]}], [1065, "Taken together, concomitant use of L. pumila (KF) with conventional drugs could cause a possibility of drug-herb interaction.", {"entities": [[35, 49, "Herb name"], [55, 73, "Drug"]]}], [1066, "Further studies are warranted in this direction.", {"entities": []}], [1067, "The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.", {"entities": []}], [1068, "The United States Department of Agriculture, Agricultural Research Service, Specific Cooperative Agreement No.", {"entities": []}], [1069, "58-6408-1-603 and the United States Food and Drug Administration (FDA; Grant No.", {"entities": []}], [1070, "1U01FD004246-3) are acknowledged for partial support of this work.", {"entities": []}], [1071, "The opinions expressed herein are attributable to the authors only, and do not represent the position of the FDA or any government agency.", {"entities": []}], [1072, "Holista Biotech Sdn Bhd, Malaysia, is also acknowledged for partial support and providing the authenticated plant material but Holista did not contribute to this report, nor does the work represent their opinions.", {"entities": []}], [1073, "Cytochrome P450 enzymes Food and Drug Administration human hepatocellular carcinoma human multidrug resistance-1-transfected Madin-Darby canine kidney Madin-Darby canine kidney Lucifer yellow P-glycoprotein Pregnane X receptor Time dependent inhibition.", {"entities": [[0, 23, "Parameter"], [74, 83, "Pathology"], [192, 206, "Parameter"], [207, 226, "Parameter"]]}], [1074, "Rooibos extract, due to its glucose and lipid lowering effects, has potential as a nutraceutical for improvement of metabolic dysfunction.", {"entities": [[0, 7, "Herb name"], [8, 15, "Extraction process"], [116, 137, "Pathology"]]}], [1075, "Potential herb-drug interactions as a result of the use of natural products are of increasing concern.", {"entities": []}], [1076, "Cytochrome P450 enzymes, CYP2C8, CYP2C9, and CYP3A4, are important in the metabolism of hypoglycemic drugs, such as thiazolidinediones (TZDs) and sulfonylureas, and hypocholesterolemic drugs, such as atorvastatin.", {"entities": [[0, 23, "Target"], [25, 31, "Target"], [33, 39, "Target"], [45, 51, "Target"], [88, 106, "Drug"], [116, 141, "Drug"], [146, 159, "Drug"], [165, 190, "Drug"], [200, 212, "Drug"]]}], [1077, "This study investigated the effects of rooibos extracts, prepared from \u201cunfermented\u201d and \u201cfermented\u201d rooibos plant material and two of the major bioactive compounds, Z-2-(\u03b2- Aspalathus linearis (Burm.f.)", {"entities": [[39, 46, "Herb name"], [47, 55, "Extraction process"], [72, 83, "Extraction process"], [90, 99, "Extraction process"], [101, 108, "Herb name"], [166, 193, "Herb name"]]}], [1078, "Dahlg.", {"entities": []}], [1079, "(Fabaceae), a legume commonly referred to as rooibos, is a member of the fynbos biome native to the Western Cape region of South Africa.", {"entities": [[1, 9, "Herb name"], [45, 52, "Herb name"]]}], [1080, "The plant is processed to produce \u201cunfermented\u201d (green; unoxidised) and \u201cfermented\u201d (oxidised) rooibos, mainly for consumption as herbal tea [1].", {"entities": [[34, 67, "Extraction process"], [72, 94, "Extraction process"], [95, 102, "Herb name"], [137, 140, "Herb name"]]}], [1081, "Furthermore, rooibos extracts have been demonstrated to improve insulin resistance and related metabolic disturbances [7,8].", {"entities": [[13, 20, "Herb name"], [21, 29, "Extraction process"], [64, 82, "Pathology"], [95, 117, "Pathology"]]}], [1082, "The anti-diabetic [9,10], anti-obesity [11], and cardio-protective effects [12,13,14] of rooibos extracts are of specific relevance given the global increase in the prevalence of diabetes and obesity [15,16,17].", {"entities": [[89, 96, "Herb name"], [97, 105, "Extraction process"], [179, 187, "Pathology"], [192, 199, "Pathology"]]}], [1083, "These health promoting effects of rooibos have been attributed to its flavonoids including aspalathin, isoorientin, orientin, rutin, and nothofagin, as well as the phenylpropenoid glucoside, Z-2-(\u03b2- The use of natural products to improve general health or to treat a range of conditions has escalated in both developed and developing countries [26,27].", {"entities": [[34, 41, "Herb name"], [70, 80, "Herb name"], [91, 101, "Herb name"], [103, 114, "Herb name"], [116, 124, "Herb name"], [126, 131, "Herb name"], [137, 147, "Herb name"], [164, 189, "Herb name"]]}], [1084, "Natural products are perceived to be safer and without unwanted side effects attributed to conventional medicines.", {"entities": [[64, 76, "Pathology"]]}], [1085, "This perception is greatly based on anecdotal evidence often without scientific verification.", {"entities": []}], [1086, "Regardless, many plant-based nutraceuticals, including those derived from rooibos, are currently being developed or are already in use.", {"entities": [[74, 81, "Herb name"]]}], [1087, "The safety and efficacy of such nutraceuticals as supplements and adjunctive therapies to chronic medications, specifically those used to treat metabolic disorders, such as type 2 diabetes and hyperlipidemia, have often not been established.", {"entities": [[144, 163, "Pathology"], [173, 188, "Pathology"], [193, 207, "Pathology"]]}], [1088, "The adjunctive use of natural products with chronic medications for these metabolic disorders could potentially induce adverse herb-drug interactions.", {"entities": [[74, 93, "Pathology"]]}], [1089, "Cytochrome P450 (CYP) enzymes are mainly responsible for the metabolism of drugs and other compounds including phytochemicals in the liver, kidney and intestines.", {"entities": [[0, 29, "Target"]]}], [1090, "Approximately 80% of conventional drugs are metabolized by specific enzymes (CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A4) belonging to subfamilies, CYP1, CYP2, and CYP3 [28,29].", {"entities": [[77, 83, "Target"], [85, 91, "Target"], [93, 100, "Target"], [102, 108, "Target"], [110, 116, "Target"], [122, 128, "Target"], [156, 160, "Target"], [162, 166, "Target"], [172, 176, "Target"]]}], [1091, "Metformin, a first-line anti-diabetic drug, is metabolized by CYP2C11, CYP2D1, and CYP3A1/2, while glyburide and pioglitazone, other known hypoglycemic drugs, are metabolized by CYP2C9, CYP3A4, and CYP2C8.", {"entities": [[0, 9, "Drug"], [24, 42, "Drug"], [62, 69, "Target"], [71, 77, "Target"], [83, 91, "Target"], [99, 108, "Drug"], [113, 125, "Drug"], [139, 157, "Drug"], [178, 184, "Target"], [186, 192, "Target"], [198, 204, "Target"]]}], [1092, "Atorvastatin used to treat hypercholesterolemia is metabolized by CYP3A4.", {"entities": [[0, 12, "Drug"], [27, 47, "Pathology"], [66, 72, "Target"]]}], [1093, "Inhibition of these specific CYPs by phytochemicals can affect the pharmacodynamics of these drugs, leading to toxicity or, alternatively, reduced efficacy [30].", {"entities": [[29, 33, "Target"]]}], [1094, "When two substrates (phytochemicals and drugs) compete for the same receptor site, the more potent inhibitor will exert control over the weaker inhibitor, thus resulting in decreased metabolism of the respective substrate and, in the case where the drug is the weaker inhibitor, alter its pharmacodynamic properties [30].", {"entities": []}], [1095, "Most drugs and xenobiotics including dietary polyphenols have the ability to bind to CYP3A4 as substrates.", {"entities": [[45, 56, "Herb name"], [85, 91, "Target"]]}], [1096, "The chemical structure of polyphenols and, specifically, their functional groups play an important role in their metabolism.", {"entities": [[26, 37, "Herb name"]]}], [1097, "Flavonoids, common in the diet, are responsible for the modulation of the clinically relevant CYP2C8, CYP2C9, and CYP3A4 enzymes [31].", {"entities": [[0, 10, "Herb name"], [94, 100, "Target"], [102, 108, "Target"], [114, 120, "Target"]]}], [1098, "This modulation can alter drug metabolism through changes in the expression or activity of CYP enzymes, thereby affecting the plasma concentration of co-administered chronic medications [31].", {"entities": [[91, 102, "Target"]]}], [1099, "Content values for the individual compounds of the extracts are embedded in the respective chromatograms.", {"entities": []}], [1100, "GRT contained substantially higher levels of flavonoids than FRE, largely due to its high aspalathin content.", {"entities": [[0, 3, "Extraction process"], [45, 55, "Herb name"], [61, 64, "Extraction process"], [90, 100, "Herb name"]]}], [1101, "It was the major compound in GRT, comprising ca.", {"entities": [[29, 32, "Extraction process"]]}], [1102, "12% of the extract, compared to 0.36% of FRE.", {"entities": [[41, 44, "Extraction process"]]}], [1103, "Compounds present in GRT at >1% were nothofagin, orientin, isoorientin, and quercetin-3-O-robinobioside.", {"entities": [[21, 24, "Extraction process"], [37, 47, "Herb name"], [49, 57, "Herb name"], [59, 70, "Herb name"], [76, 103, "Herb name"]]}], [1104, "The PPAG content of GRT and FRE were 0.42% and 0.71%, respectively.", {"entities": [[4, 8, "Herb name"], [20, 23, "Extraction process"], [28, 31, "Extraction process"]]}], [1105, "Qualitative screening of extracts and compounds was used to identify potential inhibitory effects on CYP2C8, CYP2C9 and CYP3A4.", {"entities": [[101, 107, "Target"], [109, 115, "Target"], [120, 126, "Target"]]}], [1106, "The organic solvents such as methanol, acetonitrile and DMSO showed no inhibitory effects on the respective enzymes (Supplementary Materials, Figure S1a\u2013c).", {"entities": []}], [1107, "Quercetin, sulfaphenazole, and ketoconazole were the selected positive inhibitors for CYP2C8, CYP2C9, and CYP3A4, respectively.", {"entities": [[0, 9, "Herb name"], [11, 25, "Drug"], [31, 43, "Drug"], [86, 92, "Target"], [94, 100, "Target"], [106, 112, "Target"]]}], [1108, "GRT and FRE inhibited the reaction rate of CYP2C8, CYP2C9, and CYP3A4 as measured over 30 min (Figure 2a\u2013c).", {"entities": [[0, 3, "Extraction process"], [8, 11, "Extraction process"], [43, 49, "Target"], [51, 57, "Target"], [63, 69, "Target"]]}], [1109, "ASP showed 24% inhibition of CYP2C9 at 100 \u00b5g/mL and 23% inhibition of CYP3A4 at 200 \u00b5g/mL activity, while PPAG had no effect on any of these enzymes.", {"entities": [[0, 3, "Herb name"], [29, 35, "Target"], [71, 77, "Target"], [107, 111, "Herb name"]]}], [1110, "GRT and FRE showed strong inhibition of CYP2C8 activity (7.69 \u00b1 8.85 \u00b5g/mL and 8.93 \u00b1 8.88 \u00b5g/mL, respectively) (Figure 3a).", {"entities": [[0, 3, "Extraction process"], [8, 11, "Extraction process"], [40, 46, "Target"]]}], [1111, "Both extracts moderately inhibited CYP3A4 activity (31.33 \u00b1 4.69 \u00b5g/mL and 51.44 \u00b1 4.31 \u00b5g/mL, respectively) (Figure 3b), while ASP displayed weak inhibition of CYP3A4 activity (69.57 \u00b1 4.03 \u00b5g/mL) (Figure 3b).", {"entities": [[35, 41, "Target"], [128, 131, "Herb name"], [161, 167, "Target"]]}], [1112, "GRT and FRE reduced the remaining CYP2C8 activity in a moderate to strong concentration-dependent manner from 25 \u00b5g/mL (70.1% and 82.1%, respectively; p < 0.001), 50 \u00b5g/mL (31% and 39.7%, respectively; p < 0.001), and 100 \u00b5g/mL (15.9% and 18.1%, respectively; p < 0.001) (Figure 4a).", {"entities": [[0, 3, "Extraction process"], [8, 11, "Extraction process"], [34, 40, "Target"]]}], [1113, "ASP significantly inhibited CYP2C8 activity, albeit that the percentage remaining activity at 50 and 100 \u00b5g/mL was still at 84.4% and 85.5%, respectively.", {"entities": [[0, 3, "Herb name"], [28, 34, "Target"]]}], [1114, "PPAG, ASP, GRT, and FRE did not significantly affect CYP2C9 enzyme activity (Figure 4b).", {"entities": [[0, 4, "Herb name"], [6, 9, "Herb name"], [11, 14, "Extraction process"], [20, 23, "Extraction process"], [53, 59, "Target"]]}], [1115, "ASP, GRT, and FRE reduced CYP3A4 activity at 25 \u00b5g/mL (62.9%, 36.9% and 61.4%, respectively; p < 0.001), 50 \u00b5g/mL (44.5%, 13.5% and 29.7%, respectively; p < 0.001), and 100 \u00b5g/mL (28.1%, 1.7% and 9.2%, respectively; p < 0.001) (Figure 4c).", {"entities": [[0, 3, "Herb name"], [5, 8, "Extraction process"], [14, 17, "Extraction process"], [26, 32, "Target"]]}], [1116, "Time-dependent screening determines the inactivation of enzymes by the ligand or metabolites of the ligand generated over time.", {"entities": []}], [1117, "Both GRT and FRE showed time-dependent inhibition of CYP2C8 activity (Figure 5a).", {"entities": [[5, 8, "Extraction process"], [13, 16, "Extraction process"], [53, 59, "Target"]]}], [1118, "GRT showed a slight increase (p < 0.01) in inhibition of CYP2C9 activity after approximately 15 min, however, this inhibitory effect was more noticeable than for the positive inhibitor, sulfaphenazole (Figure 5b).", {"entities": [[0, 3, "Extraction process"], [57, 63, "Target"], [186, 200, "Drug"]]}], [1119, "PPAG demonstrated time-dependent inhibition (p < 0.05) of only CYP3A4 (Figure 5c).", {"entities": [[0, 4, "Herb name"], [63, 69, "Target"]]}], [1120, "ASP indicated no time-dependent inhibitory activity.", {"entities": [[0, 3, "Herb name"]]}], [1121, "An interesting finding, however, is the time-dependent inhibition of CYP3A4 activity by GRT (p < 0.01) and FRE (p < 0.01), displaying a similar effect to that of erythromycin (Figure 5c).", {"entities": [[69, 75, "Target"], [88, 91, "Extraction process"], [107, 110, "Extraction process"]]}], [1122, "The prevalent use of natural products for the treatment of various medical conditions has increased the potential of medicinal herbs to interact with conventional drugs when consumed concomitantly [32,33].", {"entities": []}], [1123, "Interactions between components of herbal medicines and drugs could alter the pharmacodynamics and pharmacokinetics of the latter, leading to adverse reactions and toxic effects or reduced drug efficacy [34,35,36,37,38].", {"entities": [[142, 159, "Pathology"], [164, 177, "Pathology"]]}], [1124, "Herbal extracts contain many constituents that can contribute to their effects at different concentrations [39].", {"entities": []}], [1125, "These constituents include various bioactive compounds that can either activate or inhibit CYP3A4 [31].", {"entities": [[91, 97, "Target"]]}], [1126, "Echinacea purpurea, a known plant-based product with constituents such as caffeic acid derivatives, amides, flavonoids, and glycosides, displayed weak inhibitory effects of CYP3A4 activity with IC Recent studies demonstrated the potential use of rooibos extracts [8,11] and compounds, such as ASP [19] and PPAG [24,25], as anti-diabetic and/or anti-obesity nutraceuticals.", {"entities": [[0, 18, "Herb name"], [74, 86, "Herb name"], [100, 106, "Herb name"], [108, 118, "Herb name"], [124, 134, "Herb name"], [173, 179, "Target"], [194, 196, "Parameter"], [246, 253, "Herb name"], [254, 262, "Extraction process"], [293, 296, "Herb name"], [306, 310, "Herb name"]]}], [1127, "Plant extracts containing high levels of polyphenols are expected to have inhibitory effects on various CYPs including CYP2C8, CYP2C9, CYP2D6, and CYP3A4 [28,42].", {"entities": [[41, 52, "Herb name"], [104, 108, "Target"], [119, 125, "Target"], [127, 133, "Target"], [135, 141, "Target"], [147, 153, "Target"]]}], [1128, "Of these, CYP3A4 is commonly involved in herb-drug interactions as it metabolizes about 50% of clinically-prescribed medications [42,43,44].", {"entities": [[10, 16, "Target"]]}], [1129, "Results obtained by Matsuda et al.", {"entities": []}], [1131, "No details of the type of rooibos tea (unfermented or fermented) used to prepare the infusion for feeding to the rats were provided.", {"entities": [[26, 37, "Target"], [39, 50, "Extraction process"], [54, 63, "Extraction process"], [85, 93, "Extraction process"]]}], [1132, "For the present study, two extracts of rooibos, GRT and FRE, were tested for their ability to inhibit selected CYPs.", {"entities": [[39, 46, "Herb name"], [48, 51, "Extraction process"], [56, 59, "Extraction process"], [111, 115, "Target"]]}], [1133, "GRT containing higher levels of polyphenols, in particular ASP (12.78% compared to 0.36%), demonstrated a more potent inhibition of CYP3A4 activity than FRE with IC CYP2C9 plays a role in the oxidation of xenobiotic and endogenous compounds and is responsible for the metabolism of 15%\u201320% of drugs undergoing phase I metabolism [52,53].", {"entities": [[0, 3, "Extraction process"], [32, 43, "Herb name"], [59, 62, "Herb name"], [132, 138, "Target"], [153, 156, "Extraction process"], [165, 171, "Target"]]}], [1134, "CYP2C9 is also involved in the metabolic clearance of therapeutic drugs such as oral hypoglycemics (pioglitazone, glyburide, and tolbutamide), cyclooxygenase-2 anti-inflammatories (celecoxib, ibuprofen, and naproxen), and oral anti-coagulants (warfarin) [29,30,51,54].", {"entities": [[0, 6, "Target"], [80, 98, "Drug"], [100, 112, "Drug"], [114, 123, "Drug"], [129, 140, "Drug"], [143, 179, "Drug"], [181, 190, "Drug"], [192, 201, "Drug"], [207, 215, "Drug"], [222, 242, "Drug"], [244, 252, "Drug"]]}], [1135, "Changes in metabolic activity caused by genetic variants in CYP2C9 play a major role in the pathogenesis caused by adverse drug reactions [55].", {"entities": [[60, 66, "Target"], [115, 137, "Pathology"]]}], [1136, "Patients with low enzyme activity are at risk of adverse drug reactions from these CYP2C9 substrates [56].", {"entities": [[49, 71, "Pathology"], [83, 89, "Target"]]}], [1137, "We were unable to demonstrate a concentration dependent inhibitory effect for the extracts and ASP.", {"entities": [[95, 98, "Herb name"]]}], [1138, "However, a partial time-dependent decrease in CYP2C9 activity was shown for GRT and FRE with GRT demonstrating stronger inhibitory potential than the competitive CYP2C9 inhibitor, sulfaphenazole.", {"entities": [[46, 52, "Target"], [76, 79, "Extraction process"], [84, 87, "Extraction process"], [93, 96, "Extraction process"], [162, 168, "Target"], [180, 194, "Drug"]]}], [1139, "When time-dependent inhibition is the major mode of action, the inhibitory effect of such a compound will be more prolonged specifically when multiple dosing is administered, such as the case for chronic medication [57].", {"entities": []}], [1140, "Rooibos extracts, but not ASP or PPAG, when taken concomitantly with drugs, such as sulfonylureas, and specifically glyburide, could result in an exaggerated pharmacodynamic effect, thereby causing an increased risk of hypoglycemia [58,59].", {"entities": [[0, 7, "Herb name"], [8, 16, "Extraction process"], [26, 29, "Herb name"], [33, 37, "Herb name"], [84, 97, "Drug"], [116, 125, "Drug"], [219, 231, "Pathology"]]}], [1141, "A strong concentration- and time-dependent inhibition of CYP2C8 activity was observed for both GRT and FRE.", {"entities": [[57, 63, "Target"], [95, 98, "Extraction process"], [103, 106, "Extraction process"]]}], [1142, "However, ASP and PPAG had no effect on CYP2C8.", {"entities": [[9, 12, "Herb name"], [17, 21, "Herb name"], [39, 45, "Target"]]}], [1143, "This suggests that other phytochemicals or synergistic interactions of constituents in the extract account for this inhibitory effect.", {"entities": []}], [1144, "For compounds with the same basic flavonoid structure, the difference in inhibitory effect is related to their hydrophobicity [46].", {"entities": [[34, 43, "Herb name"]]}], [1145, "Molecules more soluble in water do not make good substrates for P450 enzymes.", {"entities": [[64, 76, "Target"]]}], [1146, "Both ASP and PPAG are water-soluble.", {"entities": [[5, 8, "Herb name"], [13, 17, "Herb name"]]}], [1147, "Other structural features of flavonoids that are important for their effect on CYPs are hydroxyl substitution (number and position) and the presence of double bonds [60].", {"entities": [[29, 39, "Herb name"], [79, 83, "Extraction process"]]}], [1148, "Luteolin, containing several hydroxyl groups on the A- and B-rings, inhibit metabolism of drugs such as midazolam, whereas tangeretin, also a flavone, but without free hydroxyl groups on the A- and B-ring (i.e., methoxylated), increases midazolam metabolism [46].", {"entities": [[0, 8, "Herb name"], [104, 113, "Drug"], [123, 133, "Herb name"], [142, 149, "Herb name"], [237, 246, "Drug"]]}], [1149, "Clinically, this could lead to increased concentrations of TZDs present in the circulation, thereby potentially altering their therapeutic dose.", {"entities": [[59, 63, "Drug"]]}], [1150, "This study demonstrates that GRT and FRE inhibited CYP2C8 and CYP3A4 activity in a dose- and time-dependent manner, whilst inhibiting CYP2C9 activity in a time-dependent manner only.", {"entities": [[29, 32, "Extraction process"], [37, 40, "Extraction process"], [51, 57, "Target"], [62, 68, "Target"], [134, 140, "Target"]]}], [1151, "ASP could only be implicated in CYP3A4 inhibition.", {"entities": [[0, 3, "Herb name"], [32, 38, "Target"]]}], [1152, "PPAG did not display any inhibitory activities.", {"entities": [[0, 4, "Herb name"]]}], [1153, "These results indicate that rooibos extracts may potentially cause herb-drug interactions when co-administered with substrates or drugs metabolized by these P450 enzymes.", {"entities": [[28, 35, "Herb name"], [36, 44, "Extraction process"], [157, 169, "Target"]]}], [1154, "This will include chronic medications, such as hypoglycemics (TZDs and sulfonylureas) and hypolipidemics (atorvastatin and simvastatin).", {"entities": [[47, 60, "Drug"], [62, 66, "Drug"], [71, 84, "Drug"], [90, 104, "Drug"], [106, 118, "Drug"], [123, 134, "Drug"]]}], [1155, "As part of the drug discovery pipeline, it is important to demonstrate the potential of new therapeutics to interact with CYPs at a pre-clinical stage to avoid withdrawal once it enters the market.", {"entities": [[122, 126, "Target"], [132, 150, "Study"]]}], [1156, "Future research should identify possible phytoconstituents of rooibos likely implicated in the observed interactions.", {"entities": [[62, 69, "Herb name"]]}], [1157, "In addition, a pharmaceutical-grade unfermented rooibos extract, Afriplex GRT (GRT), with a high aspalathin (ca.", {"entities": [[36, 63, "Extraction process"], [65, 77, "Herb name"], [79, 82, "Extraction process"], [97, 107, "Herb name"]]}], [1158, "12%) content was also included in the study.", {"entities": []}], [1159, "HPLC-diode array detection (DAD) quantification of the individual flavonoid and PPAG content of GRT was performed according to the method of Beelders et al.", {"entities": [[66, 75, "Herb name"], [80, 84, "Herb name"], [96, 99, "Extraction process"]]}], [1160, "[61], as previously used for FRE (Figure 1b) [8].", {"entities": [[29, 32, "Extraction process"]]}], [1161, "Z-2-(\u03b2- Ketoconazole, sulfaphenazole, erythromycin, quercetin, and solvents methanol, acetonitrile, and dimethyl sulfoxide (DMSO), were purchased from Sigma-Aldrich (St. Louis, MO, USA).", {"entities": [[8, 20, "Drug"], [22, 36, "Drug"], [38, 50, "Drug"], [52, 61, "Herb name"]]}], [1162, "Black Costar 96-well plates were obtained from Thermo Fischer Scientific (Pittsburgh, PA, USA).", {"entities": []}], [1163, "Vivid The effect of organic solvents such as methanol, acetonitrile and DMSO on Vivid Compounds, PPAG and ASP, and the rooibos extracts, GRT and FRE, were screened for their inhibitory effects on CYP2C8, CYP2C9, and CYP3A4 using one-point screening kinetics.", {"entities": [[97, 101, "Herb name"], [106, 109, "Herb name"], [119, 126, "Herb name"], [127, 135, "Extraction process"], [137, 140, "Extraction process"], [145, 148, "Extraction process"], [196, 202, "Target"], [204, 210, "Target"], [216, 222, "Target"]]}], [1164, "Stock solutions (10 mg/mL) were prepared by diluting the extracts and compounds in distilled water.", {"entities": []}], [1165, "Briefly, inhibitors, extracts, and compounds were pre-incubated with either CYP2C8 or CYP2C9 at a concentration of 100 \u00b5g/mL, or CYP3A4 at a concentration of 200 \u00b5g/mL.", {"entities": [[76, 82, "Target"], [86, 92, "Target"], [129, 135, "Target"]]}], [1166, "In a black Costar 96-well plate, 3 \u00b5L of extracts or compounds (100 \u00b5g/mL) were added to 57 \u00b5L of reaction buffer.", {"entities": []}], [1167, "As per the manufacturer\u2019s instruction, 50 \u00b5L of Vivid A three-fold serial dilution of PPAG, ASP, GRT, and FRE was added to CYP2C8 and CYP2C9 (concentration range 100\u20130.41 \u00b5g/mL) and CYP3A4 (concentration range 200\u20130.82 \u00b5g/mL) to determine their respective IC Time-dependent inhibition (TDI) using the respective serial dilutions employed for IC Stock solutions (10 mg/mL) of PPAG, ASP, GRT, and FRE were prepared by dissolving the extracts and compounds in distilled water.", {"entities": [[86, 90, "Herb name"], [92, 95, "Herb name"], [97, 100, "Extraction process"], [106, 109, "Extraction process"], [123, 129, "Target"], [134, 140, "Target"], [182, 188, "Target"], [256, 290, "Parameter"], [342, 344, "Parameter"], [375, 379, "Herb name"], [381, 384, "Herb name"], [386, 389, "Extraction process"], [395, 398, "Extraction process"]]}], [1168, "Thereafter, 3 \u00b5L of extracts or compounds (100 \u00b5g/mL) were added to 57 \u00b5L of reaction buffer in a black Costar 96-well plate.", {"entities": []}], [1169, "The following concentrations, 100, 50, 25, 10, and 5 \u00b5g/mL were added to the plate in duplicate.", {"entities": []}], [1170, "Inhibition of CYP2C8, CYP2C9, and CYP3A4 BACULOSOMES The data generated were exported to an Excel (Microsoft Headquarters, One Microsoft Way, Redmond, WA, USA) worksheet and the amount of metabolite formed at various concentrations relative to the control was calculated using the following equation:  The relative percentage activity was plotted against the log transformed concentrations of the extracts, compounds and positive controls, i.e.", {"entities": [[14, 20, "Target"], [22, 28, "Target"], [34, 40, "Target"]]}], [1171, "quercetin (positive CYP2C8 inhibitor), sulfaphenazole (positive CYP2C9 inhibitor), and ketoconazole (positive CYP3A4 inhibitor).", {"entities": [[0, 9, "Herb name"], [20, 26, "Target"], [39, 53, "Drug"], [64, 70, "Target"], [87, 99, "Drug"], [110, 116, "Target"]]}], [1172, "A sigmoid curve was then fitted using a non-linear regression curve fit, dose response inhibition analysis was performed, and IC Data are means \u00b1 SEM.", {"entities": [[126, 128, "Parameter"]]}], [1173, "The percentage remaining activity was analysed using two-way ANOVA with p < 0.05 considered significant.", {"entities": []}], [1174, "Statistical analyses were performed using GraphPad Prism This in vitro study indicated that combining nutraceuticals containing rooibos extracts with drugs metabolized by CYP2C8 and CYP3A4 could potentially alter the pharmacodynamics and safety of these drugs.", {"entities": [[62, 76, "Study"], [128, 135, "Herb name"], [136, 144, "Extraction process"], [171, 177, "Target"], [182, 188, "Target"]]}], [1175, "These findings still have to be confirmed in vivo.", {"entities": [[42, 49, "Study"]]}], [1176, "This research was funded in part by the National Research Foundation (NRF) Thuthuka Programme (Grant 99381) and the Biomedical Research and Innovation Platform of the South African Medical Research Council.", {"entities": []}], [1177, "Afriplex GRT\u2122 was provided by Afriplex, Paarl, South Africa.", {"entities": [[0, 13, "Herb name"]]}], [1178, "Sample Availability: Aspalathin is available from commercial sources.", {"entities": [[21, 31, "Herb name"]]}], [1179, "Click here for additional data file.", {"entities": []}], [1180, "Supplementary materials can be accessed at:  Charles Awortwe and Christo Muller contributed to the design of the study.", {"entities": []}], [1181, "Oelfah Patel and Charles Awortwe performed the laboratory experiments and data analysis.", {"entities": []}], [1182, "Oelfah Patel and Christo Muller wrote the manuscript.", {"entities": []}], [1183, "Elizabeth Joubert provided the extracts and compositional data and gave input relating to the phytochemical aspects.", {"entities": []}], [1184, "Johan Louw provided aspalathin and PPAG and contributed to writing the manuscript.", {"entities": [[35, 39, "Herb name"]]}], [1185, "Bernd Rosenkranz helped with the pharmaceutical interpretation.", {"entities": []}], [1186, "All authors reviewed the manuscript.", {"entities": []}], [1187, "The authors declare no conflict of interest.", {"entities": []}], [1188, "The founding sponsors had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, and in the decision to publish the results.", {"entities": []}], [1189, "HPLC chromatograms of (a) FRE (fermented rooibos extract) and (b) GRT (unfermented rooibos extract) at 288 and 350 nm (solid and dotted lines, respectively).", {"entities": [[26, 57, "Extraction process"], [66, 99, "Extraction process"]]}], [1190, "Content values of compounds are expressed as g/100 g extract (1, PPAG (Z-2-(\u03b2-D-glucopyranosyloxy)-3-phenylpropenoic acid), 2, isoorientin; 3, orientin; 4, ASP (aspalathin); 5, quercetin-3-O-robinobioside; 6, vitexin; 7, hyperoside; 8, rutin; 9, isovitexin; 10, isoquercetrin; 11, luteolin-7-O-glucoside, and 12, nothofagin).", {"entities": [[65, 122, "Herb name"], [127, 138, "Herb name"], [143, 151, "Herb name"], [156, 172, "Herb name"], [177, 204, "Herb name"], [209, 216, "Herb name"], [221, 231, "Herb name"], [236, 241, "Herb name"], [246, 256, "Herb name"], [262, 275, "Herb name"], [281, 303, "Herb name"], [313, 323, "Herb name"]]}], [1191, "Qualitative screening of drugs, compounds and extracts based on their inhibitory potency of Vivid Percentage remaining activity of (a) CYP2C8 and (b) CYP3A4 after 30 min co-incubation with ASP (aspalathin), GRT (unfermented rooibos extract) and FRE (fermented rooibos extract) with NADPH and substrates.", {"entities": [[135, 141, "Target"], [150, 156, "Target"], [189, 205, "Herb name"], [207, 240, "Extraction process"], [245, 276, "Extraction process"], [282, 287, "Target"]]}], [1192, "Data are the average values of two independent assays done in duplicate (n = 4).", {"entities": []}], [1193, "Percentage remaining activity of (a) CYP2C8; (b) CYP2C9 and (c) CYP3A4 following 30 min pre-incubation with PPAG (Z-2-(\u03b2- Screening of PPAG (Z-2-(\u03b2- Structures of (a) aspalathin and (b) phenylpyruvic acid glucoside (PPAG) where R = \u03b2-", {"entities": [[37, 43, "Target"], [49, 55, "Target"], [64, 70, "Target"], [108, 112, "Herb name"], [135, 139, "Herb name"], [167, 177, "Herb name"], [186, 221, "Herb name"]]}], [1194, "The median age was 46 years (interquartile range, 41 to 50), and the median body weight was 76 kg (interquartile range, 68 to 92).", {"entities": [[19, 27, "Age"], [50, 58, "Age"], [76, 87, "Parameter"], [92, 97, "Amount"], [120, 128, "Amount"]]}], [1195, "Echinacea was well tolerated, and all participants completed the study.", {"entities": [[0, 9, "Herb name"]]}], [1196, "The GMR for etravirine coadministered with E. purpurea relative to etravirine alone was 1.07 (90% CI, 0.81 to 1.42) for the maximum concentration, 1.04 (90% CI, 0.79 to 1.38) for the area under the concentration-time curve from 0 to 24 h, and 1.04 (90% CI, 0.74 to 1.44) for the concentration at the end of the dosing interval.", {"entities": [[0, 7, "Parameter"], [12, 22, "Drug"], [43, 54, "Herb name"], [67, 77, "Drug"], [88, 92, "Amount"], [102, 114, "Amount"], [120, 145, "Parameter"], [147, 151, "Amount"], [161, 173, "Amount"], [179, 222, "Parameter"], [223, 237, "Duration"], [243, 247, "Amount"], [257, 269, "Amount"], [275, 326, "Parameter"]]}], [1197, "In conclusion, the coadministration of E. purpurea with etravirine was safe and well tolerated in HIV-infected patients; our data suggest that no dose adjustment for etravirine is necessary.", {"entities": [[39, 50, "Herb name"], [56, 66, "Drug"], [98, 110, "Pathology"], [166, 176, "Drug"]]}], [1198, "Go to: INTRODUCTION  More than half of HIV-infected patients express interest in taking some kind of complementary therapy in addition to their antiretroviral regimens at some point during the course of treatment (15, 16, 19).", {"entities": [[39, 51, "Pathology"], [144, 167, "Drug"]]}], [1199, "These patients usually choose dietary and herbal supplements and take them without medical supervision.", {"entities": [[30, 60, "Herb name"]]}], [1200, "Nonetheless, such botanical supplements may influence the activity of various enzymes and transporters involved in the absorption, distribution, and metabolism of antiretroviral drugs, putting patients at risk of potential herb-drug interactions (11, 14).", {"entities": [[78, 102, "Parameter"], [163, 183, "Drug"]]}], [1201, "Echinacea preparations rank among the herbal remedies most commonly taken by HIV-infected patients (2, 3, 13), probably because of their hypothesized immunostimulant properties (20, 21).", {"entities": [[0, 22, "Herb name"], [38, 53, "Herb name"], [77, 89, "Pathology"], [150, 165, "Pathology"]]}], [1202, "Constituents of Echinacea purpurea have the potential to interact with cytochrome P450, providing a reason to suspect herb-drug interactions involving CYP3A4 substrates, including many antiretroviral agents (1, 10, 18).", {"entities": [[16, 34, "Herb name"], [71, 86, "Parameter"], [151, 157, "Parameter"], [185, 206, "Drug"]]}], [1204, "The magnitude of this potential interaction could be ameliorated by using etravirine in combination with a ritonavir-boosted protease inhibitor (12).", {"entities": [[74, 84, "Drug"], [107, 143, "Drug"]]}], [1205, "However, there is a growing interest in using etravirine once daily without a protease inhibitor (8; P. Echeverr\u00eda, A. Bonjoch, J. Puig, R. Paredes, G. Sirera, J. R. Santos, J. Molt\u00f3, B. Clotet, and E. Negredo, presented at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy, 2011), a scenario where possible CYP3A4 induction might be more relevant.", {"entities": [[46, 56, "Drug"], [57, 67, "Frequency"], [76, 96, "Drug"], [332, 338, "Parameter"]]}], [1206, "The objective of the present study was therefore to evaluate the potential of E. purpurea to interact with etravirine in the absence of ritonavir.", {"entities": [[78, 89, "Herb name"], [107, 117, "Drug"], [136, 145, "Drug"]]}], [1207, "Go to: MATERIALS AND METHODS  Study design.", {"entities": []}], [1208, "Patients on concomitant treatment with ritonavir or other CYP3A4 inhibitors or with a history of suboptimal treatment adherence were excluded.", {"entities": [[39, 48, "Drug"], [58, 64, "Target"]]}], [1210, "W064636A; Arkopharma) at a dosage of 500 mg every 8 h from days 1 to 14.", {"entities": [[37, 43, "Amount"], [44, 53, "Frequency"], [54, 71, "Duration"]]}], [1211, "All pills came from a single lot, which was externally controlled and certified to contain 100% of the labeled content of E. purpurea.", {"entities": [[122, 133, "Herb name"]]}], [1212, "Antiretroviral treatment remained unchanged.", {"entities": [[0, 24, "Drug"]]}], [1213, "On both days, etravirine was taken with a standard 550-kcal breakfast whose composition was 43% carbohydrate, 39% fat, and 18% protein.", {"entities": [[14, 24, "Herb name"], [92, 95, "Amount"], [96, 108, "Parameter"], [110, 113, "Amount"], [114, 117, "Parameter"], [123, 126, "Amount"], [127, 134, "Parameter"]]}], [1214, "Demographic and clinical variables (age, body weight and height, and use of concomitant drugs, including over-the-counter medications) were recorded.", {"entities": [[36, 39, "Parameter"], [41, 52, "Parameter"], [57, 63, "Parameter"]]}], [1215, "To enhance adherence to scheduled clinical visits and the treatment protocol, patients were provided with a visit calendar.", {"entities": []}], [1216, "Apart from days 0 and 14, drug intake was not directly observed; adherence was assessed by means of a diary, in which the patient recorded medication intake, and by pill count on day 14.", {"entities": []}], [1217, "Analytical and pharmacokinetic analysis.", {"entities": []}], [1218, "Blood samples for etravirine determinations were collected into K-ethylenediaminetetraacetic acid\u2013containing 10-ml tubes.", {"entities": [[18, 28, "Drug"], [64, 97, "Extraction process"], [109, 114, "Amount"]]}], [1219, "Chromatographic separation was performed on a Sunfire C18 column (particle size 5 \u03bcm, 4.6 by 150 mm; Waters) protected by a SecurityGuard C18 column (4.0 by 3.0 mm; Phenomenex).", {"entities": []}], [1220, "The fluorescence detector was set at 299 and 396 nm for excitation and emission wavelengths, respectively.", {"entities": [[37, 40, "Amount"], [45, 51, "Amount"], [56, 91, "Parameter"]]}], [1221, "The drug was extracted from plasma by liquid-liquid extraction with tert-butyl methyl ether.", {"entities": [[68, 91, "Extraction process"]]}], [1222, "The method was linear over the range of 0.01 to 2.40 mg/liter.", {"entities": []}], [1223, "The intraday and interday coefficients of variation were less than 10%.", {"entities": []}], [1224, "Our laboratory subscribes to the external quality assurance program organized by the Association for Quality Assessment in Therapeutic Drug Monitoring and Clinical Toxicology of Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands (6).", {"entities": []}], [1226, "Maximum concentrations (Cmax), and the concentrations at the end of the dosing interval (C24), were obtained by inspection of the concentration data.", {"entities": [[0, 29, "Parameter"], [35, 93, "Parameter"], [130, 143, "Parameter"]]}], [1227, "Statistical analysis.", {"entities": []}], [1228, "Data analysis was carried out using SPSS version 15.0 statistical software.", {"entities": []}], [1229, "Pharmacokinetic parameters were natural log-transformed before analysis, and confidence intervals (CIs) for means (and for the difference between two means) were constructed on the natural log scale based on an analysis of variance (ANOVA) model with treatment as a fixed effect.", {"entities": [[0, 26, "Parameter"]]}], [1230, "The results were then exponentiated and reported with 90% CIs.", {"entities": []}], [1231, "A power calculation indicated that 15 patients would provide an 80% chance of detecting a 25% difference in the AUC0\u201324 for etravirine at a level of significance of 0.05 (P value).", {"entities": [[112, 119, "Parameter"], [124, 134, "Drug"]]}], [1232, "Overall, 10 (66.7%) were males, and 4 (26.7%) were coinfected with hepatitis C virus (HCV).", {"entities": [[25, 30, "Sex"], [67, 90, "Pathology"]]}], [1233, "The median age was 46 years (interquartile range, 41 to 50), and the median body weight was 76 kg (interquartile range, 68 to 92).", {"entities": [[19, 27, "Age"], [50, 58, "Age"], [76, 87, "Parameter"], [92, 97, "Amount"], [120, 128, "Amount"]]}], [1234, "Other antiretroviral drugs being taken in addition to etravirine included tenofovir-emtricitabine (10 patients) and abacavir-lamivudine (5 patients).", {"entities": [[6, 26, "Drug"], [54, 64, "Drug"], [74, 97, "Drug"], [116, 135, "Drug"]]}], [1235, "The median CD4+ T cell count was 799 cells/mm3 (range, 541 to 946).", {"entities": [[11, 28, "Parameter"], [33, 46, "Amount"], [55, 65, "Amount"]]}], [1236, "The echinacea preparation was well tolerated, and all participants completed the study.", {"entities": [[0, 25, "Herb name"]]}], [1237, "This patient was considered to be a poor metabolizer/outlier, and he was excluded from the pharmacokinetic analysis.", {"entities": []}], [1238, "Despite once-daily dosing of etravirine without boosted protease inhibitors, etravirine trough concentrations remained consistently above the median protein-binding-adjusted 50% effective concentration (EC50) for wild-type HIV (0.004 mg/liter) (5) in all participants (Fig.", {"entities": [[8, 18, "Frequency"], [29, 39, "Drug"], [48, 75, "Drug"], [77, 87, "Drug"], [95, 109, "Parameter"], [138, 208, "Parameter"], [223, 226, "Pathology"], [228, 242, "Amount"]]}], [1239, "2).", {"entities": []}], [1240, "An external file that holds a picture, illustration, etc.", {"entities": []}], [1241, "Error bars represent 90% confidence intervals.", {"entities": []}], [1242, "ETR, etravirine; GMR, geometric mean ratio; CI, confidence interval; Cmax, maximum concentration; AUC0\u201324, area under the concentration-time curve from 0 to 24 h after dosing; C24, concentration at the end of the dosing interval.", {"entities": [[0, 15, "Drug"], [17, 42, "Parameter"], [69, 96, "Parameter"], [98, 174, "Parameter"], [176, 228, "Parameter"]]}], [1243, "An external file that holds a picture, illustration, etc.", {"entities": []}], [1244, "The gray lines represent individual values, and the black line represents the geometric mean.", {"entities": []}], [1245, "Go to: DISCUSSION  Our findings show that E. purpurea does not significantly affect the pharmacokinetics of etravirine in HIV-infected patients and therefore is not likely to put the patients at a significant herb-drug interaction risk.", {"entities": [[42, 53, "Herb name"], [108, 118, "Drug"], [122, 134, "Pathology"]]}], [1246, "The concern that E. purpurea might induce CYP3A4 activity in patients on antiretroviral agents, which are metabolized by this enzyme, is based on previous studies that found that midazolam exposure decreased by nearly 25% in the presence of an echinacea preparation (10, 18).", {"entities": [[17, 28, "Herb name"], [42, 57, "Parameter"], [73, 94, "Drug"], [179, 188, "Drug"], [244, 265, "Herb name"]]}], [1247, "However, two recent studies in individuals taking echinacea with boosted protease inhibitors found no significant interaction (17, 18).", {"entities": [[50, 59, "Herb name"], [65, 92, "Drug"]]}], [1248, "One study was performed in healthy volunteers who received lopinavir-ritonavir (18), and the other was conducted in HIV-infected patients taking darunavir-ritonavir (17).", {"entities": [[27, 34, "Pathology"], [59, 78, "Drug"], [116, 128, "Pathology"], [145, 164, "Drug"]]}], [1249, "Three factors are relevant to interpreting our results.", {"entities": []}], [1250, "First, in addition to CYP3A4 induction at the liver by E. purpurea, inhibition at the intestinal lumen has also been reported (10) and could also offset the potential induction of hepatic CYP3A4.", {"entities": [[22, 28, "Target"], [55, 66, "Herb name"], [180, 194, "Target"]]}], [1251, "Second, etravirine is a CYP3A4 inducer itself, and it could have masked potential induction of CYP3A by echinacea.", {"entities": [[8, 18, "Drug"], [24, 30, "Target"], [95, 100, "Target"], [104, 113, "Herb name"]]}], [1252, "Third, discrepancies between the labeled and the actual content of active constituents have been reported for many botanical preparations, to the extent that commercial products have not contained the labeled herb at all in some cases (7, 9).", {"entities": [[115, 137, "Herb name"]]}], [1253, "To avoid an effect of this potential limitation within our study, we purchased a single lot of E. purpurea from Arkopharma, which is a leader in the botanical supplement market in Europe.", {"entities": [[95, 106, "Herb name"]]}], [1254, "This company is externally controlled and has been granted the Good Manufacturing Practices certificate by the AFSSAPS (a French health products safety agency).", {"entities": [[122, 128, "Ethnic group"]]}], [1255, "Although etravirine is licensed for twice-daily dosing and for use in combination with a boosted protease inhibitor (12), the patients in this study were receiving 400 mg of etravirine once daily without a boosted protease inhibitor.", {"entities": [[9, 19, "Drug"], [36, 47, "Frequency"], [89, 115, "Drug"], [164, 170, "Amount"], [174, 184, "Drug"], [185, 195, "Frequency"], [204, 232, "Drug"]]}], [1256, "Interest in this off-label etravirine dosing regimen has emerged in the clinical setting (8; P. Echeverr\u00eda, A. Bonjoch, J. Puig, R. Paredes, G. Sirera, J. R. Santos, J. Molt\u00f3, B. Clotet, and E. Negredo, presented at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy, 2011).", {"entities": [[27, 37, "Drug"]]}], [1257, "We conclude that the coadministration of E. purpurea with etravirine is safe and well tolerated in HIV-infected patients.", {"entities": [[41, 52, "Herb name"], [58, 68, "Drug"], [99, 111, "Pathology"]]}], [1258, "Our data suggest that no dose adjustment for etravirine is necessary in this scenario.", {"entities": [[45, 55, "Drug"]]}], [1259, " Phytochemical-mediated modulation of cytochrome P-450 activity may underlie many herb-drug interactions.", {"entities": [[38, 54, "Target"]]}], [1260, "Single time-point, phenotypic metabolic ratios were used to determine whether long-term supplementation of goldenseal (Hydrastis canadensis), black cohosh (Cimicifuga racemosa), kava kava (Piper methysticum), or valerian (Valeriana officinalis) extracts affected CYP1A2, CYP2D6, CYP2E1, or CYP3A4/5 activity.", {"entities": [[107, 140, "Herb name"], [142, 176, "Herb name"], [178, 207, "Herb name"], [212, 244, "Herb name"], [263, 269, "Target"], [271, 277, "Target"], [279, 285, "Target"], [290, 298, "Target"]]}], [1261, "For each subject, a 30-day washout period was interposed between each supplementation phase.", {"entities": []}], [1262, "Probe drug cocktails of midazolam and caffeine, followed 24 hours later by chlorzoxazone and debrisoquine were administered before (baseline) and at the end of supplementation.", {"entities": [[24, 33, "Drug"], [38, 46, "Herb name"], [75, 88, "Drug"], [93, 105, "Drug"]]}], [1263, "Pre- and post-supplementation phenotypic trait measurements were determined for CYP3A4/5, CYP1A2, CYP2E1, and CYP2D6 using 1-hydroxymidazolam/midazolam serum ratios (1-hour sample), paraxanthine/caffeine serum ratios (6-hour sample), 6-hydroxychlorzoxazone/chlorzoxazone serum ratios (2-hour sample), and debrisoquine urinary recovery ratios (8-hour collection), respectively.", {"entities": [[80, 88, "Target"], [90, 96, "Target"], [98, 104, "Target"], [110, 116, "Target"], [123, 151, "Drug"], [182, 203, "Herb name"], [234, 270, "Drug"], [305, 317, "Drug"]]}], [1264, "The content of purported \u201cactive\u201d phytochemicals was determined for each supplement.", {"entities": []}], [1265, "Comparisons of pre- and post-supplementation phenotypic ratio means revealed significant inhibition (~40%) of CYP2D6 (difference = \u22120.228; 95% CI = \u22120.268 to \u22120.188) and CYP3A4/5 (difference = \u22121.501; 95% CI = \u22121.840 to \u22121.163) activity for goldenseal.", {"entities": [[110, 116, "Target"], [170, 178, "Target"], [241, 251, "Herb name"]]}], [1266, "Kava produced significant reductions (~40%) in CYP2E1 only (difference = \u22120.192; 95% CI = \u22120.325 to \u22120.060).", {"entities": [[0, 4, "Herb name"], [47, 53, "Target"]]}], [1267, "Black cohosh also exhibited statistically significant inhibition of CYP2D6 (difference = \u22120.046; 95% CI = \u22120.085 to \u22120.007), but the magnitude of the effect (~7%) did not appear clinically relevant.", {"entities": [[0, 12, "Herb name"], [68, 74, "Target"]]}], [1268, "No significant changes in phenotypic ratios were observed for valerian.", {"entities": [[62, 70, "Herb name"]]}], [1269, "Botanical supplements containing goldenseal strongly inhibited CYP2D6 and CYP3A4/5 activity in vivo, while kava inhibited CYP2E1 and black cohosh weakly inhibited CYP2D6.", {"entities": [[33, 43, "Herb name"], [63, 69, "Target"], [74, 82, "Target"], [107, 111, "Herb name"], [122, 128, "Target"], [133, 145, "Herb name"], [163, 169, "Target"]]}], [1270, "Accordingly, serious adverse interactions may result from the concomitant ingestion of goldenseal supplements and drugs that are CYP2D6 and CYP3A4/5 substrates.", {"entities": [[87, 97, "Herb name"], [129, 135, "Target"], [140, 148, "Target"]]}], [1271, "Kava kava and black cohosh may interact with CYP2E1 and CYP2D6 substrates, respectively.", {"entities": [[0, 9, "Herb name"], [14, 26, "Herb name"], [45, 51, "Target"], [56, 62, "Target"]]}], [1272, "Valerian appears less likely to produce CYP-mediated herb-drug interactions.", {"entities": [[0, 8, "Herb name"]]}], [1273, "The effect of Echinacea purpurea on the pharmacokinetics of docetaxel Andrew K L Goey,1 Irma Meijerman,2 Hilde Rosing,3 Jacobus A Burgers,4 Marja Mergui-Roelvink,5 Marianne Keessen,5 Serena Marchetti,5 Jos H Beijnen,1,3 and Jan H M Schellens1,5 Author information Article notes Copyright and License information PMC Disclaimer Go to: Abstract Aims  The herbal medicine Echinacea purpurea (E. purpurea) has been shown to induce cytochrome P450 3A4 (CYP3A4) both in vitro and in humans.", {"entities": [[14, 32, "Herb name"], [60, 69, "Drug"], [369, 387, "Herb name"], [427, 455, "Target"]]}], [1274, "This study explored whether E. purpurea affects the pharmacokinetics of the CYP3A4 substrate docetaxel in cancer patients.", {"entities": [[28, 39, "Herb name"], [76, 82, "Target"], [93, 102, "Drug"], [106, 112, "Pathology"]]}], [1275, "In both cycles, pharmacokinetic parameters of docetaxel were determined.", {"entities": [[46, 55, "Drug"]]}], [1276, "Results  Before and after supplementation with E. purpurea, the mean area under the plasma concentration\u2013time curve of docetaxel was 3278 \u00b1 1086 and 3480 \u00b1 1285 ng ml\u22121 h, respectively.", {"entities": [[47, 58, "Herb name"], [69, 115, "Herb name"], [119, 128, "Drug"]]}], [1277, "This result was statistically not significant.", {"entities": []}], [1278, "Nonsignificant alterations were also observed for the elimination half-life (from 30.8 \u00b1 19.7 to 25.6 \u00b1 5.9 h, P = 0.56) and maximum plasma concentration of docetaxel (from 2224 \u00b1 609 to 2097 \u00b1 925 ng ml\u22121, P = 0.30).", {"entities": [[66, 75, "Parameter"], [125, 153, "Parameter"], [157, 166, "Drug"]]}], [1279, "Conclusions  The multiple treatment of E. purpurea did not significantly alter the pharmacokinetics of docetaxel in this study.", {"entities": [[39, 50, "Herb name"], [103, 112, "Drug"]]}], [1280, "The applied E. purpurea product at the recommended dose may be combined safely with docetaxel in cancer patients.", {"entities": [[12, 23, "Herb name"], [84, 93, "Drug"], [97, 103, "Pathology"]]}], [1281, "Keywords: clinical trial, CYP3A4, docetaxel, Echinacea purpurea, herb\u2013drug interactions, pharmacokinetics WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT      The herbal immunostimulant Echinacea purpurea (E. purpurea) is widely used among cancer patients.", {"entities": [[10, 24, "Study"], [26, 32, "Target"], [34, 43, "Drug"], [45, 63, "Herb name"], [179, 211, "Drug"], [233, 239, "Pathology"]]}], [1282, "E. purpurea has been shown to induce cytochrome P450 3A4 (CYP3A4) in vitro and in clinical studies.", {"entities": [[0, 11, "Herb name"], [37, 65, "Target"], [66, 74, "Study"], [82, 98, "Study"]]}], [1283, "CYP3A4 is extensively involved in the metabolism of many anticancer drugs, such as docetaxel.", {"entities": [[0, 6, "Target"], [57, 73, "Drug"], [83, 92, "Drug"]]}], [1284, "WHAT THIS STUDY ADDS      This is the first clinical study to investigate the pharmacokinetic interaction between E. purpurea and an anticancer drug metabolized by CYP3A4.", {"entities": [[44, 58, "Study"], [114, 125, "Herb name"], [133, 148, "Drug"], [164, 170, "Target"]]}], [1285, "The commercially available E. purpurea extract did not significantly alter the pharmacokinetics of docetaxel.", {"entities": [[27, 38, "Herb name"], [99, 108, "Drug"]]}], [1286, "The applied E. purpurea formulation at the recommended dose may be combined safely with docetaxel and presumably also with other anticancer drugs primarily metabolized by CYP3A4.", {"entities": [[12, 23, "Herb name"], [88, 97, "Drug"], [129, 145, "Drug"], [171, 177, "Target"]]}], [1287, "Go to: Introduction  The use of complementary and alternative medicines among cancer patients and the associated risk of herb\u2013drug interactions have increased over recent years [1, 2].", {"entities": [[78, 84, "Pathology"]]}], [1288, "Especially for anticancer drugs, which usually have narrow therapeutic windows, these interactions could have serious consequences, such as an increased risk of toxicities or undertreatment.", {"entities": [[15, 31, "Drug"]]}], [1289, "Among cancer patients, Echinacea is a widely used herbal supplement.", {"entities": [[6, 12, "Pathology"], [23, 32, "Herb name"]]}], [1290, "Echinacea was also reported to be the second-most popular pharmacological complementary and alternative medicines agent among cancer patients enrolled into phase I clinical trials [4].", {"entities": [[0, 9, "Herb name"], [126, 132, "Pathology"], [164, 179, "Study"]]}], [1292, "The most common species of Echinacea are Echinacea angustifolia, Echinacea pallida and Echinacea purpurea (E. purpurea).", {"entities": [[27, 36, "Herb name"], [41, 63, "Herb name"], [65, 82, "Herb name"], [87, 119, "Herb name"]]}], [1293, "The components of Echinacea responsible for the pharmacological effects are caffeic acid derivatives, alkylamides, polysaccharides and glycoproteins [7].", {"entities": [[18, 27, "Herb name"], [76, 100, "Herb name"], [102, 113, "Herb name"], [115, 130, "Herb name"], [135, 148, "Herb name"]]}], [1294, "Of these components, caffeic acid derivatives and the more bioavailable alkylamides are found in ethanolic liquid extracts for medicinal use [8].", {"entities": [[21, 45, "Herb name"], [72, 83, "Herb name"], [97, 122, "Extraction process"]]}], [1295, "The use of Echinacea by cancer patients may interfere with their conventional chemotherapy via interactions with the cytochrome P450 (CYP) 3A4 isoenzyme system.", {"entities": [[11, 20, "Herb name"], [24, 30, "Pathology"], [117, 159, "Target"]]}], [1296, "This enzyme system is involved in the metabolism of many anticancer drugs.", {"entities": [[57, 73, "Drug"]]}], [1297, "Both in supersomes and in hepatocytes, it has been shown that Echinacea extracts have the potential to inhibit CYP3A4 in vitro [9, 10].", {"entities": [[62, 80, "Herb name"], [111, 117, "Target"], [118, 126, "Study"]]}], [1298, "There are indications that Echinacea is also capable of inducing CYP3A4.", {"entities": [[27, 36, "Herb name"], [65, 71, "Target"]]}], [1299, "Induction of CYP3A4 by E. purpurea has been shown in healthy volunteers, in whom the systemic exposure to the CYP3A4 probe midazolam was significantly decreased after supplementation with E. purpurea for 28 days [11].", {"entities": [[13, 19, "Target"], [23, 34, "Herb name"], [53, 60, "Pathology"], [110, 116, "Target"], [123, 132, "Drug"], [188, 199, "Herb name"], [200, 211, "Duration"]]}], [1300, "In another clinical study with midazolam in healthy volunteers, E. purpurea also affected CYP3A4 function [12].", {"entities": [[11, 25, "Study"], [31, 40, "Drug"], [44, 51, "Pathology"], [64, 75, "Herb name"], [90, 96, "Target"]]}], [1301, "In this study on volunteers, the systemic clearance of intravenous (IV) midazolam was significantly increased, which reflects induction of hepatic CYP3A4 activity, while intestinal CYP3A4 was not significantly affected, as shown by the lack of significant alterations in oral clearance of orally administered midazolam [12].", {"entities": [[33, 51, "Parameter"], [72, 81, "Drug"], [139, 153, "Target"], [170, 187, "Target"], [271, 285, "Parameter"], [309, 318, "Drug"]]}], [1302, "In a third clinical study, no significant effect of E. purpurea on midazolam pharmacokinetics was reported in healthy volunteers [13].", {"entities": [[11, 25, "Study"], [52, 63, "Herb name"], [67, 76, "Drug"], [110, 117, "Pathology"]]}], [1303, "Thus, both in vitro and clinical results showed that E. purpurea has the potential to affect CYP3A4, but results concerning inhibition and induction are inconsistent.", {"entities": [[11, 19, "Study"], [24, 32, "Study"], [53, 64, "Herb name"], [93, 99, "Target"]]}], [1304, "An anticancer drug for which systemic exposure may be affected via CYP3A4 modulation by E. purpurea is docetaxel.", {"entities": [[3, 18, "Drug"], [67, 73, "Target"], [88, 99, "Target"], [103, 112, "Drug"]]}], [1305, "Docetaxel has, among other indications, been approved for the treatment of locally advanced or metastatic breast cancer, nonsmall cell lung cancer and hormone-refractory metastatic prostate cancer at doses ranging from 75 to 100 mg m\u22122, administrated as a 1 h IV infusion every 3 weeks.", {"entities": [[0, 9, "Drug"], [75, 119, "Pathology"], [121, 146, "Pathology"], [151, 196, "Pathology"], [219, 231, "Amount"], [256, 271, "Duration"], [272, 285, "Frequency"]]}], [1306, "Pharmacokinetic interactions between docetaxel and E. purpurea could be expected, because docetaxel is extensively metabolized by CYP3A4.", {"entities": [[37, 46, "Drug"], [51, 62, "Herb name"], [90, 99, "Drug"], [130, 136, "Target"]]}], [1307, "As docetaxel is administered intravenously, hepatic CYP3A4 is mainly involved in its metabolism.", {"entities": [[3, 12, "Drug"], [44, 58, "Target"]]}], [1308, "Expected induction of hepatic CYP3A4 by E. purpurea may lead to decreased plasma levels of docetaxel.", {"entities": [[22, 36, "Target"], [40, 51, "Herb name"], [91, 100, "Drug"]]}], [1309, "For docetaxel, systemic exposure has shown to be a good predictor for its efficacy and toxicity [14].", {"entities": [[4, 13, "Drug"]]}], [1310, "Thus, CYP3A4 induction by E. purpurea could lead to undertreatment in patients receiving docetaxel chemotherapy.", {"entities": [[6, 12, "Target"], [26, 37, "Herb name"], [89, 111, "Drug"]]}], [1311, "Currently, no clinical studies concerning pharmacokinetic interactions between E. purpurea and anticancer drugs have been reported.", {"entities": [[14, 30, "Study"], [79, 90, "Herb name"], [95, 111, "Drug"]]}], [1312, "Results of the present study may provide valuable information about the safety of concomitant use of E. purpurea with other anticancer agents metabolized by CYP3A4.", {"entities": [[101, 112, "Herb name"], [124, 141, "Drug"], [157, 163, "Target"]]}], [1313, "In the present study, the primary objective was to determine the effect of E. purpurea on the pharmacokinetics of docetaxel.", {"entities": [[75, 86, "Herb name"], [114, 123, "Drug"]]}], [1314, "The secondary objective was to assess the effect of E. purpurea supplementation on safety parameters, such as grade 3 and 4 toxicities induced by docetaxel [according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE, version 3.0)].", {"entities": [[52, 63, "Herb name"], [124, 134, "Pathology"], [146, 155, "Drug"], [179, 185, "Pathology"], [228, 242, "Pathology"]]}], [1315, "Go to: Methods Patients  This clinical study was performed at the Netherlands Cancer Institute (NKI, Amsterdam, The Netherlands).", {"entities": [[30, 44, "Study"], [78, 84, "Pathology"]]}], [1316, "Patients with histological or cytological proof of cancer for whom treatment with docetaxel was considered to be of therapeutic benefit (e.g.", {"entities": [[51, 57, "Pathology"], [82, 91, "Drug"]]}], [1317, "advanced breast, gastric, oesophagus, bladder, prostate, ovarian, nonsmall cell lung, head and neck cancer) were included.", {"entities": [[0, 106, "Pathology"]]}], [1318, "Other inclusion criteria were as follows: age \u2265 18 years, performance status \u2264 2 according to the World Health Organization scale, life expectancy > 3 months, absolute neutrophil count \u2265 1.5 \u00d7 109 l\u22121, platelet count \u2265 100 \u00d7 109 l\u22121, haemoglobin level \u2265 6.0 mmol l\u22121, hepatic function as defined by serum bilirubin \u2264 1.5 times the upper limit of normal and alanine aminotransferase and aspartate aminotransferase \u2264 2.5 times the upper limit of normal, renal function as defined by serum creatinine \u2264 1.5 times the upper limit of normal or creatinine clearance \u2265 50 ml min\u22121, able and willing to swallow and retain oral medication, to comply with the protocol procedures and to follow dietary restrictions.", {"entities": [[42, 56, "Age"], [168, 184, "Parameter"], [185, 200, "Amount"], [202, 216, "Parameter"], [217, 232, "Amount"], [234, 251, "Parameter"], [252, 266, "Amount"], [299, 314, "Parameter"], [357, 381, "Parameter"], [386, 412, "Parameter"], [481, 497, "Parameter"], [539, 559, "Parameter"], [560, 573, "Amount"]]}], [1319, "Patients were excluded in the event of any treatment with investigational drugs within 30 days before the start of the study or the use of herbal supplements within 6 weeks prior to study treatment.", {"entities": [[87, 94, "Duration"], [165, 172, "Duration"]]}], [1320, "Other exclusion criteria were as follows: alcoholism, drug addiction, psychotic disorders leading to non-adequate follow-up, concomitant use of multidrug resistance and CYP3A-modulating drugs, uncontrolled infectious disease, HIV-1 or HIV-2 type patients, unresolved (>grade 1) toxicities of previous chemotherapy, bowel obstruction or motility disorders that may influence the absorption of drugs, pregnancy, chronic use of H2-receptor antagonists or proton pump inhibitors, neurological disease that may render a patient at increased risk for peripheral or central neurotoxicity and presence of symptomatic cerebral or leptomeningeal metastases.", {"entities": [[54, 68, "Pathology"], [70, 89, "Pathology"], [169, 174, "Target"], [193, 224, "Pathology"], [226, 231, "Pathology"], [235, 240, "Pathology"], [315, 332, "Pathology"], [336, 354, "Pathology"], [399, 408, "Pathology"], [425, 448, "Drug"], [452, 474, "Drug"], [476, 496, "Pathology"], [545, 580, "Pathology"], [609, 646, "Pathology"]]}], [1321, "The study (EudraCT number: 2008-000886-41) has been approved by the Medical Ethical Committee of the NKI, and all patients provided written informed consent prior to study entry.", {"entities": []}], [1322, "All patients were treated between April 2009 and March 2010.", {"entities": []}], [1323, "Drug administration  Docetaxel (Taxotere\u00ae; Aventis Pharma SA, Antony Cedex, France) was administered intravenously and was supplied in a 15 ml clear glass vial containing 2 ml of a 40 mg ml\u22121 docetaxel solution in polysorbate 80.", {"entities": [[21, 30, "Drug"], [32, 41, "Drug"], [192, 201, "Drug"]]}], [1324, "Standard docetaxel pretreatment consisted of oral dexamethasone 8 mg two times daily for three consecutive days: 1 day before, on the day of docetaxel administration and 1 day after.", {"entities": [[9, 18, "Drug"], [50, 63, "Drug"], [64, 68, "Amount"], [69, 84, "Frequency"], [85, 111, "Duration"], [141, 150, "Drug"]]}], [1325, "Furthermore, commercially available E. purpurea drops were used (A. Vogel Echinaforce\u00ae, batch 08 K0302; Biohorma BV, Elburg, The Netherlands).", {"entities": [[36, 53, "Herb name"], [65, 86, "Herb name"]]}], [1326, "These drops were labelled to contain 95% aerial parts and 5% roots of E. purpurea.", {"entities": [[41, 53, "Parameter"], [61, 66, "Parameter"], [70, 81, "Herb name"]]}], [1327, "Study design and procedures  On day 1, all patients received docetaxel at an absolute dose of 135 mg given as a 60 min IV administration (cycle 1).", {"entities": [[61, 70, "Drug"], [94, 100, "Amount"], [112, 118, "Duration"]]}], [1328, "The dose of 135 mg was based on a safe dose of 75 mg m\u22122 and a mean body surface area of 1.8 m2.", {"entities": [[12, 18, "Duration"], [47, 56, "Amount"]]}], [1329, "From day 7 until the morning of day 22, the patients ingested 20 drops of the E. purpurea extract three times daily.", {"entities": [[62, 70, "Amount"], [78, 89, "Herb name"], [98, 115, "Frequency"]]}], [1330, "On day 22, the second cycle of docetaxel was administered according to the same dosing schedule as on day 1 (Figure 1).", {"entities": [[31, 40, "Drug"]]}], [1331, "The follow-up of each patient ended with an end-of-treatment visit 3 weeks after day 22.", {"entities": []}], [1332, "An external file that holds a picture, illustration, etc.", {"entities": []}], [1333, "Object name is bcp0076-0467-f1.jpg Figure 1  Study design.", {"entities": []}], [1334, "Abbreviation is as follows: PK, pharmacokinetics Docetaxel analysis  Blood samples for assessment of docetaxel pharmacokinetics were drawn at predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 7, 10, 24 and 48 h after the start of the docetaxel infusion.", {"entities": [[49, 58, "Drug"], [101, 110, "Drug"], [224, 233, "Drug"]]}], [1335, "Blood was collected in heparinized tubes and centrifuged at 1500g for 10 min at 4\u00b0C.", {"entities": []}], [1336, "Subsequently, plasma was separated and stored at \u221220\u00b0C until analysis.", {"entities": []}], [1337, "Docetaxel plasma levels were quantified using a validated liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS) assay with a lower limit of quantification of 0.25 ng ml\u22121 [15].", {"entities": [[0, 9, "Drug"]]}], [1338, "Analysis of E. purpurea constituents: alkylamides  In order to check the compliance to E. purpurea intake, patients had to keep diaries.", {"entities": [[12, 23, "Herb name"], [38, 49, "Herb name"], [87, 98, "Herb name"]]}], [1339, "In addition, they were called at regular intervals by the research team, and single blood samples were collected in heparinized tubes on days 7, 14 and 22.", {"entities": []}], [1340, "In a subset of four patients, the pharmacokinetics of alkylamides were studied by collection of blood samples at t = 0, 0.5, 1 and 2 h after administration of E. purpurea.", {"entities": [[15, 28, "Cohort"], [54, 65, "Herb name"], [159, 170, "Herb name"]]}], [1341, "Plasma was separated after centrifugation at 1500g for 10 min at 4\u00b0C and stored at \u221220\u00b0C until quantitative analysis of dodeca-2E,4E,8Z,10E/Z-tetraenoic acid isobutylamides (DTAI) using a validated LC-MS/MS assay [16].", {"entities": []}], [1342, "Pharmacokinetic analysis  Pharmacokinetic parameters were calculated using noncompartmental analysis with R software (version 2.10.1; R Development Core Team, Vienna, Austria) by employing validated scripts.", {"entities": []}], [1343, "The following pharmacokinetic parameters of docetaxel were calculated: area under the plasma concentration\u2013time curve from time zero to infinity (AUC0\u2013\u221e), elimination half-life (t1/2) and maximum plasma concentration (Cmax).", {"entities": [[44, 53, "Drug"], [71, 153, "Parameter"], [155, 183, "Parameter"], [188, 223, "Parameter"]]}], [1344, "Statistical analysis  For each patient, the values of AUC0\u2013\u221e, t1/2 and Cmax of docetaxel in cycle 1 (before E. purpurea) were compared with values obtained in cycle 2 (after E. purpurea).", {"entities": [[54, 60, "Parameter"], [62, 66, "Parameter"], [71, 75, "Parameter"], [79, 88, "Drug"], [108, 119, "Herb name"], [174, 185, "Herb name"]]}], [1345, "After logarithmic transformation of these parameters, Student's paired t-test (\u03b1 = 0.05) was performed by use of R. Docetaxel-related adverse events  Docetaxel-related adverse events during cycles 1 and 2 were registered according to NCI CTCAE version 3.0.", {"entities": [[116, 125, "Drug"], [134, 148, "Pathology"], [150, 159, "Drug"], [168, 182, "Pathology"]]}], [1346, "Adverse events were considered as docetaxel related when rated as \u2018possibly\u2019, \u2018probably\u2019 or \u2018definitely\u2019 related by the investigator.", {"entities": [[0, 14, "Pathology"], [34, 43, "Drug"]]}], [1347, "Go to: Results Patients  Eleven patients were included (Table 1), of whom one patient needed to be replaced because the second docetaxel course was not administered due to her deteriorated physical condition.", {"entities": [[25, 40, "Cohort"], [127, 136, "Drug"]]}], [1348, "Hence, in total 10 patients were eligible for evaluation.", {"entities": [[16, 27, "Cohort"]]}], [1349, "Table 1  Patient characteristics (n = 11) Gender\t \u2003Female\t2 \u2003Male\t9 Age (years)\t \u2003Median\t58 \u2003Range\t42\u201367 Race\t \u2003Caucasian\t11 World Health Organization performance status\t \u20030\t5 \u20031\t3 \u20032\t3 Primary tumour\t \u2003Ovarian\t5 \u2003Nonsmall cell lung carcinoma\t2 \u2003Endometrium\t1 \u2003Unknown primary tumour\t2 \u2003Oesophageal\t1 Open in a separate window Effect of E. purpurea on the pharmacokinetics of docetaxel  In Figure 2, the mean plasma concentration\u2013time curves of docetaxel in the absence and presence of E. purpurea are presented.", {"entities": [[34, 40, "Cohort"], [51, 57, "Sex"], [61, 65, "Sex"], [68, 104, "Age"], [105, 121, "Ethnic group"], [186, 210, "Pathology"], [214, 242, "Pathology"], [246, 257, "Pathology"], [261, 298, "Pathology"], [337, 348, "Herb name"], [376, 385, "Drug"], [445, 454, "Drug"], [486, 497, "Herb name"]]}], [1350, "The individual differences in docetaxel AUC0\u2013\u221e are depicted in Figure 3.", {"entities": [[30, 39, "Drug"], [40, 46, "Parameter"]]}], [1351, "In five patients, an increase of the AUC0\u2013\u221e of docetaxel was observed after supplementation with E. purpurea, while in the other five patients the AUC0\u2013\u221e decreased.", {"entities": [[3, 16, "Cohort"], [37, 43, "Parameter"], [47, 56, "Drug"], [97, 108, "Herb name"], [129, 142, "Cohort"], [147, 153, "Parameter"]]}], [1352, "The mean values of pharmacokinetic parameters of docetaxel are shown in Table 2.", {"entities": [[49, 58, "Drug"]]}], [1353, "Intake of E. purpurea did not result in statistically significant changes in AUC0\u2013\u221e, Cmax and t1/2 of docetaxel.", {"entities": [[10, 21, "Herb name"], [77, 83, "Parameter"], [85, 89, "Parameter"], [94, 98, "Parameter"], [102, 111, "Drug"]]}], [1354, "An external file that holds a picture, illustration, etc.", {"entities": []}], [1355, "Object name is bcp0076-0467-f2.jpg Figure 2  Mean (\u00b1 SD) plasma concentration\u2013time curves for docetaxel alone and after E. purpurea supplementation (n = 10).", {"entities": [[94, 103, "Drug"], [120, 131, "Herb name"]]}], [1356, "An external file that holds a picture, illustration, etc.", {"entities": []}], [1357, "Object name is bcp0076-0467-mu1.jpg, docetaxel 135 mg; An external file that holds a picture, illustration, etc.", {"entities": [[37, 46, "Drug"], [47, 53, "Amount"]]}], [1358, "Object name is bcp0076-0467-mu2.jpg, docetaxel 135 mg + E. purpurea An external file that holds a picture, illustration, etc.", {"entities": [[37, 46, "Drug"], [47, 53, "Amount"], [56, 67, "Herb name"]]}], [1359, "Object name is bcp0076-0467-f3.jpg Figure 3  Individual values of the area under the plasma concentration\u2013time curve extrapolated to infinity (AUC0\u2013\u221e) for docetaxel before and after E. purpurea supplementation (n = 10) Table 2  Summary of docetaxel pharmacokinetic parameters Parameter\tDay 1: docetaxel alone\tDay 22: with pretreatment of E. purpurea\tP value AUC0\u2013\u221e (ng ml\u22121 h)\t3278 \u00b1 1086\t3480 \u00b1 1285\t0.51 Cmax (ng ml\u22121)\t2224 \u00b1 609\t2097 \u00b1 925\t0.30 t1/2 (h)\t30.8 \u00b1 19.7\t25.6 \u00b1 5.9\t0.56 Open in a separate window  Pharmacokinetic data are given as means \u00b1 SD and were obtained on day 1 (docetaxel alone) and day 22 (14 days after start of Echinacea purpurea).", {"entities": [[70, 150, "Parameter"], [155, 164, "Drug"], [182, 193, "Herb name"], [211, 217, "Cohort"], [239, 248, "Drug"], [293, 302, "Drug"], [338, 349, "Herb name"], [358, 364, "Parameter"], [406, 410, "Parameter"], [448, 452, "Parameter"], [585, 594, "Drug"], [637, 655, "Herb name"]]}], [1360, "The P values were obtained from Student's paired t test.", {"entities": []}], [1361, "Docetaxel-related adverse events  The incidence of docetaxel-related adverse events differed between the two docetaxel courses.", {"entities": [[0, 9, "Drug"], [18, 32, "Pathology"], [51, 60, "Drug"], [69, 83, "Pathology"], [109, 118, "Drug"]]}], [1362, "During the course without E. purpurea, 24 adverse events (grade 1\u20132, 22 events; and grade 3\u20134, two events) were reported in nine patients, while 16 adverse events (grade 1\u20132, 15 events; and grade 3\u20134, one event) occurred in six patients in the course after E. purpurea supplementation.", {"entities": [[26, 37, "Herb name"], [42, 56, "Pathology"], [124, 137, "Cohort"], [224, 236, "Cohort"], [257, 268, "Herb name"]]}], [1363, "However, in the majority of the patients the incidence of docetaxel-related adverse events did not correlate with changes in the AUC0\u2013\u221e of docetaxel.", {"entities": [[58, 67, "Drug"], [76, 90, "Pathology"], [129, 135, "Parameter"], [139, 148, "Drug"]]}], [1364, "The most common adverse events were fatigue (cycle 1, five events; and cycle 2, four events), alopecia (five events in both cycles), rash (cycle 1, three events; and cycle 2, one event) and allergic reaction (cycle 1, two events; and cycle 2, one event), and were mostly of grade 1\u20132.", {"entities": [[16, 30, "Pathology"], [36, 43, "Pathology"], [94, 102, "Pathology"], [133, 137, "Pathology"], [190, 207, "Pathology"]]}], [1365, "Adherence to E. purpurea intake  Adherence was confirmed by inspection of patients' diaries, telephone calls and inspection of returned bottles.", {"entities": [[13, 24, "Herb name"]]}], [1366, "Bioanalysis of alkylamides in plasma samples was less applicable to demonstrate adherence.", {"entities": [[15, 26, "Herb name"]]}], [1367, "Several bioanalytical assays have been developed for quantification of alkylamides such as undeca-2-ene-8,10-diynoic acid isobutylamide [17] and DTAI [16].", {"entities": [[71, 82, "Herb name"], [91, 135, "Herb name"], [145, 149, "Herb name"]]}], [1368, "In the present study, DTAI, the most abundant alkylamides in E. purpurea, were determined.", {"entities": [[22, 26, "Herb name"], [46, 57, "Herb name"], [61, 72, "Herb name"]]}], [1369, "Unfortunately, in the majority of the patients' samples collected at random time points on days 14 and 22, DTAI plasma levels were below the lower limit of quantification of 0.01 ng ml\u22121.", {"entities": [[107, 111, "Herb name"]]}], [1370, "Pharmacokinetic blood sampling from 0 until 2 h after ingestion of E. purpurea revealed that DTAI had already reached the lower limit of quantification after 2 h [16].", {"entities": [[67, 78, "Herb name"], [93, 97, "Herb name"]]}], [1371, "Go to: Discussion  Based on significant induction of CYP3A4 by E. purpurea in previous clinical studies with midazolam [11, 12], the pharmacokinetic interaction between E. purpurea and docetaxel was investigated in the present clinical study.", {"entities": [[53, 59, "Target"], [63, 74, "Herb name"], [87, 103, "Study"], [109, 118, "Drug"], [169, 180, "Herb name"], [185, 194, "Drug"], [227, 241, "Study"]]}], [1372, "In contrast to the significant interaction in our clinical study with the herbal antidepressant St John's wort and docetaxel [18], E. purpurea did not significantly affect systemic exposure to docetaxel in the present study.", {"entities": [[50, 64, "Study"], [96, 110, "Herb name"], [115, 124, "Drug"], [131, 142, "Herb name"], [193, 202, "Drug"]]}], [1373, "Intraindividual changes in AUC (Figure 3) were in line with an estimated intraindividual variability in docetaxel clearance of 25% [19].", {"entities": [[27, 30, "Parameter"], [104, 113, "Drug"]]}], [1374, "There are no clear explanations for the more remarkable 93% increase in AUC0\u2013\u221e in one patient.", {"entities": [[72, 78, "Parameter"]]}], [1375, "The incidence of docetaxel-related adverse events, however, did not increase in this patient (data not shown).", {"entities": [[17, 26, "Drug"], [35, 49, "Pathology"]]}], [1376, "Compared with the clinical studies in which significant induction of CYP3A4 by E. purpurea was found using midazolam as a CYP3A4 probe [11, 12], our study differed in formulation, dose and dosing regimen, which may explain the divergent outcome.", {"entities": [[18, 34, "Study"], [69, 75, "Target"], [79, 90, "Herb name"], [107, 116, "Drug"], [122, 128, "Target"]]}], [1377, "First, in the study of Penzak et al.", {"entities": []}], [1378, "[11], E. purpurea was administered for a longer time period (28 days).", {"entities": [[6, 17, "Herb name"], [61, 68, "Duration"]]}], [1379, "In the study of Gorski et al.", {"entities": []}], [1380, "[12], however, a shorter supplementation period (8 days) was applied, but the dosing frequency was higher (four times daily).", {"entities": [[49, 55, "Duration"], [107, 123, "Frequency"]]}], [1381, "Second, comparison between the contents of the E. purpurea formulations used in the midazolam studies [11, 12] and in the present study is complicated.", {"entities": [[47, 58, "Herb name"], [84, 93, "Drug"]]}], [1382, "The formulations of Penzak et al.", {"entities": []}], [1383, "[11] and Gorski et al.", {"entities": []}], [1384, "[12] contained 500 and 400 mg E. purpurea extract, respectively.", {"entities": [[15, 29, "Amount"], [30, 41, "Herb name"]]}], [1385, "Our commercial product was only labelled to contain 95% aerial parts and 5% roots of E. purpurea, and no information was provided about the total amount of extract used.", {"entities": [[56, 68, "Herb part"], [76, 81, "Herb part"], [85, 96, "Herb name"]]}], [1386, "Previously, this formulation has been shown to contain 18\u201334 \u03bcg ml\u22121 DTAI [5, 9].", {"entities": [[55, 68, "Amount"], [69, 73, "Herb name"]]}], [1387, "In contrast, contents of DTAI or other alkylamides in the extracts used in the midazolam studies [11, 12] were not specified.", {"entities": [[25, 29, "Herb name"], [39, 50, "Herb name"], [79, 88, "Drug"]]}], [1388, "Due to these differences in specifications and the absence of clinical interaction studies with Echinaforce\u00ae and midazolam, the effects of Echinaforce\u00ae on midazolam pharmacokinetics remain unknown.", {"entities": [[62, 90, "Study"], [96, 108, "Herb name"], [113, 122, "Drug"], [139, 151, "Herb name"], [155, 164, "Drug"]]}], [1389, "Besides differences in the amounts and phytochemical content of E. purpurea extracts, differences in their origin may also have contributed to the conflicting clinical outcomes.", {"entities": [[64, 75, "Herb name"]]}], [1390, "For example, alkylamide content is known to vary considerably across different parts of E. purpurea plants [20], and DTAI are more abundant in roots than in leaves.", {"entities": [[13, 23, "Herb name"], [88, 99, "Herb name"], [117, 121, "Herb name"], [143, 148, "Herb part"], [157, 163, "Herb part"]]}], [1391, "Consequently, the root extract used by Gorski et al.", {"entities": [[18, 22, "Herb part"]]}], [1392, "[12] was likely to contain more DTAI than our product and could exert a more potent effect on CYP3A4.", {"entities": [[32, 36, "Herb name"], [94, 100, "Herb name"]]}], [1393, "The ability of alkylamides and E. purpurea extracts to induce CYP3A4, however, is inconclusive according to in vitro data.", {"entities": [[15, 26, "Herb name"], [31, 42, "Herb name"], [62, 68, "Target"], [108, 116, "Study"]]}], [1394, "Recently, Modarai et al.", {"entities": []}], [1395, "have shown that E. purpurea extract and isolated alkylamides did not significantly induce CYP3A4 in HepG2 cells [21].", {"entities": [[16, 27, "Herb name"], [49, 60, "Herb name"], [90, 96, "Target"]]}], [1396, "However, the lack of an effect on CYP3A4 could be explained by the use of HepG2 cells.", {"entities": [[34, 40, "Target"]]}], [1397, "It has been shown previously that LS180 cells are to be preferred over HepG2 cells to study CYP3A4 induction, because LS180 cells show higher CYP3A4 expression [22].", {"entities": [[92, 98, "Target"], [142, 148, "Target"]]}], [1398, "In LS180 cells, our group has shown significant induction of CYP3A4 by isolated alkylamides and E. purpurea extracts using a gene reporter assay, which is a reliable method to assess the CYP3A4 induction potential of compounds [23].", {"entities": [[61, 67, "Target"], [80, 91, "Herb name"], [96, 107, "Herb name"], [187, 193, "Target"]]}], [1399, "Induction of CYP3A4 became significant (P < 0.05) at relatively high concentrations of 10 and 100 \u03bcg ml\u22121 alkylamides and E. purpurea extract (data not shown).", {"entities": [[13, 19, "Target"], [106, 117, "Herb name"], [122, 141, "Herb name"]]}], [1400, "In addition to the moderate CYP3A4-inducing properties of E. purpurea, its systemic exposure could be insufficient to induce hepatic CYP3A4 significantly in the present study.", {"entities": [[28, 34, "Target"], [58, 69, "Herb name"], [133, 139, "Target"]]}], [1401, "For example, pharmacokinetic analysis of DTAI indicated that plasma levels of these major alkylamides were undetectable or in the lower range of the calibration curve (<0.08 ng ml\u22121) halfway through the supplementation period.", {"entities": [[41, 45, "Herb name"], [90, 101, "Herb name"]]}], [1402, "In addition, DTAI were also rapidly eliminated within 2 h after intake.", {"entities": [[13, 17, "Herb name"]]}], [1403, "This finding indicates that the absence of DTAI in plasma samples collected during the study was caused by low systemic absorption and rapid elimination of DTAI.", {"entities": [[43, 47, "Herb name"], [156, 160, "Herb name"]]}], [1404, "As plasma levels of DTAI were not quantifiable or hardly quantifiable throughout the study period on days 14 and 22, compliance with E. purpurea supplementation could not be checked by pharmacokinetic analysis of DTAI.", {"entities": [[20, 24, "Herb name"], [133, 144, "Herb name"], [213, 217, "Herb name"]]}], [1405, "However, inspection of patient diaries and returned bottles of E. purpurea indicated that patients ingested their drops according to the schedule.", {"entities": [[63, 74, "Herb name"]]}], [1406, "Besides the dosing regimen and content of the applied E. purpurea product, docetaxel pretreatment with dexamethasone may also have contributed to the lack of a significant effect of E. purpurea on the pharmacokinetics of docetaxel.", {"entities": [[54, 65, "Herb name"], [75, 84, "Drug"], [103, 116, "Drug"], [182, 193, "Herb name"], [221, 230, "Drug"]]}], [1407, "Dexamethasone is a known inducer of CYP3A4 [24].", {"entities": [[0, 13, "Drug"], [36, 42, "Target"]]}], [1408, "Assuming induction of CYP3A4 by dexamethasone, systemic exposure to docetaxel could have been decreased already in both courses, thus making the inductive effect of E. purpurea during the second course less noticeable.", {"entities": [[22, 28, "Target"], [32, 45, "Drug"], [68, 77, "Drug"], [165, 176, "Herb name"]]}], [1409, "However, results regarding clinical effects of dexamethasone on CYP3A4 are conflicting.", {"entities": [[47, 60, "Drug"], [64, 70, "Target"]]}], [1410, "A significant pharmacodynamic interaction has been shown between dexamethasone and the CYP3A4 substrate lapatinib [25], while dexamethasone did not significantly alter docetaxel pharmacokinetics in Asian patients [26].", {"entities": [[65, 78, "Drug"], [87, 93, "Target"], [104, 113, "Drug"], [126, 139, "Drug"], [168, 177, "Drug"], [198, 203, "Ethnic group"]]}], [1411, "Presumably, these differences in outcomes resulted from differences in exposure to dexamethasone.", {"entities": [[83, 96, "Drug"]]}], [1412, "In the lapatinib study, the median duration of treatment with dexamethasone was 11 days [25], which was substantially longer than the 3 day treatment period with dexamethasone in the study with docetaxel in Asians [26].", {"entities": [[7, 16, "Herb name"], [62, 75, "Drug"], [80, 87, "Duration"], [134, 139, "Duration"], [162, 175, "Drug"], [194, 203, "Drug"], [207, 213, "Ethnic group"]]}], [1413, "These data suggest that treatment with dexamethasone for 3 days in the present study would have had only a modest inductive effect on CYP3A4.", {"entities": [[39, 52, "Drug"], [57, 63, "Duration"], [134, 140, "Target"]]}], [1414, "While this study focused on CYP3A4, the drug efflux transporter P-glycoprotein (P-gp, ABCB1) is also involved in the pharmacokinetics of docetaxel.", {"entities": [[28, 34, "Target"], [40, 92, "Target"], [137, 146, "Drug"]]}], [1415, "In accordance with CYP3A4, P-gp is also regulated by the nuclear pregnane X receptor.", {"entities": [[19, 25, "Target"], [27, 31, "Target"], [57, 84, "Target"]]}], [1416, "Consequently, upregulation of P-gp by E. purpurea could have resulted in decreased plasma levels of docetaxel.", {"entities": [[30, 34, "Target"], [38, 49, "Herb name"], [100, 109, "Drug"]]}], [1417, "In clinical practice, however, the role of P-gp in docetaxel pharmacokinetics does not seem to be relevant.", {"entities": [[3, 20, "Study"], [43, 47, "Target"], [51, 60, "Drug"]]}], [1418, "For example, the potent P-gp inhibitors R101933 [27, 28] and zosuquidar [29] did not significantly alter plasma levels of docetaxel in cancer patients.", {"entities": [[24, 28, "Target"], [61, 71, "Drug"], [122, 131, "Drug"], [135, 141, "Pathology"]]}], [1419, "Furthermore, there were no significant associations between several P-gp polymorphisms and docetaxel clearance [30].", {"entities": [[68, 72, "Target"], [91, 100, "Drug"]]}], [1420, "Moreover, E. purpurea is unlikely to affect P-gp function, because no significant interactions were found in clinical studies with Echinacea extracts and the sensitive P-gp substrates fexofenadine [11] and digoxin [31].", {"entities": [[10, 21, "Herb name"], [44, 48, "Target"], [109, 125, "Study"], [131, 140, "Herb name"], [168, 172, "Target"], [184, 196, "Drug"], [206, 213, "Target"]]}], [1421, "Significant clinical interactions between E. purpurea and the CYP3A4 and CYP3A5 substrate midazolam indicate that E. purpurea also has the potential to interact with CYP3A5.", {"entities": [[42, 53, "Herb name"], [62, 68, "Target"], [73, 79, "Target"], [90, 99, "Drug"], [114, 125, "Herb name"], [166, 172, "Target"]]}], [1422, "Corresponding to CYP3A4, the polymorphic CYP3A5 enzyme is also regulated by pregnane X receptor and is involved in the metabolism of docetaxel [32].", {"entities": [[17, 23, "Target"], [41, 47, "Target"], [76, 95, "Target"], [133, 142, "Drug"]]}], [1423, "However, potential CYP3A5 induction is not likely to affect docetaxel pharmacokinetics significantly, because the affinity of docetaxel for CYP3A4 is approximately 10 times higher than for CYP3A5 [33].", {"entities": [[19, 25, "Target"], [60, 69, "Drug"], [126, 135, "Drug"], [140, 146, "Target"], [189, 195, "Target"]]}], [1424, "In agreement with this finding, no significant correlation was observed between the inactive CYP3A5*3 genotype, which is present in the majority of Caucasians, and docetaxel clearance in cancer patients [26, 30].", {"entities": [[93, 101, "Target"], [148, 158, "Ethnic group"], [164, 173, "Drug"], [187, 193, "Pathology"]]}], [1425, "This study was not planned in a randomized crossover design.", {"entities": [[32, 59, "Study"]]}], [1426, "Considering the risk of tumour progression, randomization was not in the interest of patients with advanced cancer.", {"entities": [[24, 30, "Pathology"], [99, 114, "Pathology"]]}], [1427, "Patients randomized to the group starting with E. purpurea intake would then have to wait for 14 days prior to receiving their first cycle of docetaxel.", {"entities": [[47, 58, "Herb name"], [94, 101, "Duration"], [142, 151, "Drug"]]}], [1428, "The absence of randomization may be seen as a limitation of this study.", {"entities": []}], [1429, "However, the fixed treatment sequence in this study is not likely to introduce substantial bias to the pharmacokinetic results.", {"entities": []}], [1430, "No significant period effect of docetaxel exposure is expected based on data published in the literature [34, 35].", {"entities": [[32, 41, "Drug"]]}], [1431, "A modest intrapatient variability of the AUC0\u201324 h of docetaxel (mean ratio of cycle 2 to cycle 1 was 1.11 \u00b1 0.14) was reported after repeated administration of docetaxel administered over 1 h at a dose of 55 mg m\u22122 every 3 weeks [34].", {"entities": [[41, 50, "Parameter"], [54, 63, "Drug"], [161, 170, "Drug"], [206, 215, "Amount"], [216, 229, "Frequency"]]}], [1432, "Accordingly, a similar intrapatient variability was reported after repeated 3 weekly administration of docetaxel dosed at 100 mg m\u22122 over 1 h [35].", {"entities": [[76, 99, "Frequency"], [103, 112, "Drug"], [122, 132, "Amount"], [133, 141, "Duration"]]}], [1433, "In addition, the pharmacokinetic end-points in the present study are objective outcomes; therefore, biased results by learning effects are very unlikely.", {"entities": []}], [1434, "Furthermore, before the start of the second docetaxel treatment, patients underwent physical examination, and laboratory values were checked to ensure that inclusion and exclusion criteria were still met.", {"entities": [[44, 53, "Drug"]]}], [1435, "It can thus be assumed that patients' basic medical conditions were comparable between the two cycles.", {"entities": []}], [1436, "Carryover effects were also not likely to affect the pharmacokinetic results, because docetaxel levels were not quantifiable in the predose plasma samples of cycle 2.", {"entities": [[86, 95, "Drug"]]}], [1437, "Thus, the washout period of 3 weeks was adequate.", {"entities": [[28, 35, "Duration"]]}], [1438, "Furthermore, a validated LC-MS/MS assay for docetaxel analysis was used, and for every patient the plasma samples of both cycles were analysed within the same analytical run.", {"entities": [[44, 53, "Drug"]]}], [1439, "The sequence of treatment was therefore not likely to affect the bioanalysis of docetaxel.", {"entities": [[80, 89, "Drug"]]}], [1440, "It should be noted that the outcome of this study applies only to the specific E. purpurea formulation and dose used in the present study.", {"entities": [[79, 90, "Herb name"]]}], [1441, "As stated above, alkylamide distribution varies in different parts of E. purpurea plants [20] and also in several liquid E. purpurea preparations [36].", {"entities": [[17, 27, "Herb name"], [70, 81, "Herb name"], [121, 132, "Herb name"]]}], [1442, "Thus, the risk of CYP3A4-mediated interactions may be product dependent.", {"entities": [[18, 24, "Target"]]}], [1443, "In conclusion, our findings showed that at the recommended dose and schedule of a commercially available E. purpurea extract no statistically significant interference with docetaxel pharmacokinetics could be demonstrated.", {"entities": [[105, 116, "Herb name"], [172, 181, "Drug"]]}], [1444, "This result indicates that the applied E. purpurea formulation may be combined safely with docetaxel.", {"entities": [[39, 50, "Herb name"], [91, 100, "Drug"]]}], [1445, "Go to: Acknowledgments  This work was supported by the Dutch Cancer Society [UU 2007\u20133795].", {"entities": [[61, 67, "Pathology"]]}], [1446, "We would like to thank Roel Maas-Bakker (Department of Pharmaceutical Sciences, Division of Pharmacoepidemiology & Clinical Pharmacology, Utrecht University) for his technical assistance in the in vitro experiments performed at Utrecht University.", {"entities": [[194, 214, "Study"]]}], [1447, "Go to: Competing Interests  All authors have completed the Unified Competing Interest form at http://www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare: support from the Dutch Cancer Society for the submitted work; no financial relationships with any organizations that might have an interest in the submitted work in the previous 3 years; no other relationships or activities that could appear to have influenced the submitted work.", {"entities": [[223, 229, "Pathology"]]}], [1448, "Previous in vitro studies have reported the inhibitory effect of green tea on p-glycoprotein (p-gp) encoded by ABCB1.", {"entities": [[65, 74, "Herb name"], [78, 116, "Target"]]}], [1449, "This study aimed to investigate the effect of green tea on the pharmacokinetics of digoxin, a typical probe drug of p-gp.", {"entities": [[46, 55, "Herb name"], [83, 90, "Drug"]]}], [1450, "Sixteen healthy volunteers participated in this study.", {"entities": [[0, 26, "Cohort"]]}], [1451, "At Day 1, 0.5 mg of digoxin was administered via oral route.", {"entities": [[10, 16, "Amount"], [20, 27, "Drug"]]}], [1452, "After a 14-day washout period, 630 mg of green tea catechins (GTC) was administered via oral route, followed by 0.5 mg of digoxin 1 hour later.", {"entities": [[31, 37, "Amount"], [41, 66, "Herb name"], [112, 118, "Amount"], [122, 129, "Drug"]]}], [1453, "From Day 16 through Day 28, 630 mg of GTC was administered alone.", {"entities": [[28, 34, "Amount"], [38, 41, "Herb name"]]}], [1454, "At Day 29, 630 mg of GTC and 0.5 mg of digoxin were administered in the same way as Day 15.", {"entities": [[11, 17, "Amount"], [21, 24, "Herb name"], [29, 35, "Amount"], [39, 46, "Drug"]]}], [1455, "Blood samples for the pharmacokinetic assessments of digoxin were collected up to 8 hours after each dose.", {"entities": [[53, 60, "Drug"]]}], [1456, "Pharmacokinetic parameters were estimated by noncompartmental analysis.", {"entities": []}], [1457, "Area under the curve (AUC) and peak plasma concentration (C Fifteen subjects completed the study.", {"entities": [[0, 26, "Parameter"], [31, 56, "Parameter"], [60, 76, "Cohort"]]}], [1458, "Compared to digoxin alone, the concomitant administration of digoxin and GTC significantly reduced the systemic exposure of digoxin: geometric mean ratios (GMR) and 90% confidence intervals (CI) of area under the concentration\u2013time curve from time 0 to the last measurable time (AUC This study demonstrates that the coadministration of GTC reduces the systemic exposure of digoxin regardless of pretreatment of GTC.", {"entities": [[12, 19, "Drug"], [61, 68, "Drug"], [73, 76, "Herb name"], [124, 131, "Drug"], [198, 237, "Parameter"], [279, 282, "Parameter"], [336, 339, "Herb name"], [373, 380, "Drug"], [411, 414, "Herb name"]]}], [1459, "Green tea is one of the most popular beverages in Asia.", {"entities": [[0, 9, "Herb name"]]}], [1461, "Importantly, the concurrent use of a drug and green tea can alter the concentration of the drug, as the green tea catechins (GTC) can potentially interact with drug-metabolizing enzymes or transporters.", {"entities": [[46, 55, "Herb name"], [104, 129, "Herb name"]]}], [1463, "Knop et al8 also demonstrated the inhibition of various transporters by EGCG via an in vitro study.", {"entities": [[72, 76, "Herb name"]]}], [1464, "Misaka et al9 reported in a clinical study that green tea ingestion greatly reduces the systemic exposure of nadolol by inhibiting OATP1A2-mediated uptake.", {"entities": [[28, 42, "Study"], [48, 57, "Herb name"], [109, 116, "Drug"], [131, 154, "Target"]]}], [1465, "In contrast to the OATP transporters that exhibit significant interactions with GTC, p-glycoprotein (p-gp) has not been reported to interact with GTC in a study involving human subjects.", {"entities": [[19, 36, "Target"], [80, 83, "Herb name"], [85, 106, "Target"], [146, 149, "Herb name"]]}], [1466, "P-gp is the well-characterized efflux transporter which is located in various organs such as the intestine, kidney, and liver to efflux drugs out of cells.10,11 We used digoxin to evaluate the effect of GTC on P-gp in vivo.", {"entities": [[0, 4, "Target"], [169, 176, "Drug"], [203, 206, "Herb name"], [210, 214, "Target"]]}], [1468, "The US Food and Drug Administration recommended digoxin as one of the most suitable substrates for p-gp studies.14 To investigate the effect of green tea on the pharmacokinetics of digoxin, we conducted an open-label, 3-treatment, 3-period, fixed-sequence study.", {"entities": [[48, 55, "Drug"], [99, 103, "Target"], [144, 153, "Herb name"], [181, 188, "Drug"], [206, 261, "Study"]]}], [1469, "Digoxin was given on Day 1, followed by a 14-day washout period, and given with GTC on Day 15; then, GTC was given for 13 days from Day 16 through 28, as a pretreatment; and digoxin and GTC were given concomitantly on Day 29.", {"entities": [[0, 7, "Drug"], [80, 83, "Herb name"], [101, 104, "Herb name"], [115, 126, "Duration"], [174, 181, "Drug"], [186, 189, "Herb name"]]}], [1470, "For each treatment, plasma concentrations of digoxin were measured to compare its systemic exposure between treatments.", {"entities": [[45, 52, "Drug"]]}], [1471, "Genotyping of ABCB1 gene encoding p-gp was also performed to identify the effect of genotype in the inhibition of p-gp by GTC.", {"entities": [[34, 38, "Target"], [114, 118, "Target"], [122, 125, "Herb name"]]}], [1472, "This study was conducted in healthy Korean volunteers, aged 19\u201355 years who agreed to refrain from any food containing green tea during whole study duration.", {"entities": [[36, 42, "Ethnic group"], [55, 71, "Age"], [119, 128, "Herb name"]]}], [1473, "Volunteers were screened by a physical examination, a 12-lead electrocardiogram, and clinical laboratory tests, and those who showed any abnormal findings could not participate in this study.", {"entities": []}], [1474, "The volunteers who had any significant past medical history or allergy to green tea constituents were excluded.", {"entities": [[63, 70, "Pathology"], [74, 83, "Herb name"]]}], [1475, "Also, volunteers who had taken any agent that was reported to inhibit or induce transporter p-gp in the prior 2 weeks were excluded from this study.", {"entities": [[80, 96, "Target"]]}], [1476, "To investigate the effect of GTC on the pharmacokinetics of digoxin, an open-label, 3-treatment, fixed-sequence study was conducted (Figure 1) in Konkuk University Medical Center.", {"entities": [[29, 32, "Herb name"], [60, 67, "Drug"], [72, 117, "Study"]]}], [1477, "The Institutional Review Boards of Konkuk University Medical Center (IRB No KUH1280094) approved the study protocol, and written informed consent was obtained from all subjects before study enrollment.", {"entities": []}], [1478, "All procedures were performed in accordance with the recommendations of the Declaration of Helsinki and Good Clinical Practices.", {"entities": []}], [1479, "At Day 1, all the subjects were orally administered a 0.5 mg digoxin tablet.", {"entities": [[54, 60, "Amount"], [61, 68, "Drug"]]}], [1480, "After a 14-day washout period, they were administered 630 mg of green tea extract followed by 0.5 mg digoxin 1 hour later.", {"entities": [[54, 60, "Amount"], [64, 81, "Extraction process"], [94, 100, "Amount"], [101, 108, "Drug"]]}], [1481, "From Day 16 through 28, subjects only received 630 mg of GTC.", {"entities": [[47, 53, "Amount"], [57, 60, "Herb name"]]}], [1482, "At Day 29, the subjects were administered a 630 mg capsule of green tea extract followed by 0.5 mg digoxin 1 hour later, just like Day 15.", {"entities": [[44, 50, "Amount"], [62, 79, "Extraction process"], [92, 98, "Amount"], [99, 106, "Drug"]]}], [1484, "From the screening to the completion of the study, foods containing green tea constituents or grapefruit juice were not allowed.", {"entities": [[68, 77, "Herb name"], [94, 110, "Extraction process"]]}], [1485, "Concomitant medications were allowed only if it was not reported to induce or inhibit p-gp.", {"entities": [[86, 90, "Target"]]}], [1486, "For the analysis of digoxin pharmacokinetics, blood samples (8 mL) were taken predose and 1, 1.5, 2, 4, 6, and 8 hours after the administration of digoxin.", {"entities": [[20, 27, "Drug"], [147, 154, "Drug"]]}], [1487, "Plasma was obtained by centrifugation at 3,000 rpm for 10 minutes and transferred into 3 polypropylene tubes.", {"entities": []}], [1488, "Plasma samples obtained after receiving digoxin were additionally transferred into 2 polypropylene tubes containing ascorbate-EDTA solution (20% ascorbic acid and 0.1% EDTA in 0.4 M NaH The peak plasma concentration (C Plasma concentrations of digoxin were determined using a Cobas Integra 800 automated analyzer (Roche Diagnostics, Rotkreuz, Switzerland).", {"entities": [[40, 47, "Drug"], [190, 215, "Parameter"], [244, 251, "Drug"]]}], [1489, "The limit of detection was 0.3 ng/mL, and the measuring range was 0.3\u20135.0 ng/mL, defined by linearity.", {"entities": []}], [1490, "For this assay, intermediate precision was 3.9%\u20139.7% and cross-reactivities with structurally related or potentially coadministered compounds (canrenone, dehydroisoandrosterone, digitoxose, estradiol, estriol, hydrocortisone, 11-hydroxyprogesterone, 17-hydroxyprogesterone, prednisolone, prednisone, progesterone, and spironolactone) were under 0.03%.", {"entities": [[143, 152, "Drug"], [154, 176, "Drug"], [178, 188, "Drug"], [190, 199, "Drug"], [201, 208, "Drug"], [210, 224, "Drug"], [226, 248, "Drug"], [250, 272, "Drug"], [274, 286, "Drug"], [288, 298, "Drug"], [300, 312, "Drug"], [318, 332, "Drug"]]}], [1491, "EGCG, ECG, EGC, and EC were analyzed from plasma using liquid\u2013liquid extraction method15 and their concentrations were calculated with a liquid chromatography-tandem mass spectrometry (LC-MS/MS).", {"entities": [[0, 4, "Herb name"], [6, 9, "Herb name"], [11, 14, "Herb name"], [20, 22, "Herb name"]]}], [1492, "Briefly, 1 mL of ethyl acetate was added to 100 \u00b5L plasma and ascorbic acid-EDTA solution 10:1 (v/v) mixture with 10 \u00b5L ethyl gallate (1 \u00b5g/mL) as internal standard and vortexed for 15 minutes and centrifuged at 4,500 rpm for 20 minutes.", {"entities": []}], [1493, "After initial collection of 850 \u00b5L of the supernatant, the remaining precipitate was repeatedly processed under the same conditions for further extraction, and 600 \u00b5L of the supernatant was additionally obtained.", {"entities": []}], [1494, "The final 1,450 \u00b5L was concentrated at 35\u00b0C for 60 minutes.", {"entities": []}], [1495, "After evaporation, the pellet was reconstituted with 100 \u00b5L of 15% acetonitrile containing 0.3% acetic acid and centrifuged at 13,000 rpm for 10 minutes, and 5 \u00b5L of the supernatant was injected into LC-MS/MS.", {"entities": []}], [1496, "Analysis was carried out through UPLC (ACQUITY\u2122 Binary UPLC system, Waters, Milford, MA, USA) coupled XEVO TQ-MS (Waters).", {"entities": []}], [1497, "The samples were eluted in a gradient mobile phase consisting of water containing 0.3% acetic acid (A) and acetonitrile containing 0.3% acetic acid (B) with conditions as follow; A 98%\u201370% (0\u20134 minutes), 70% (4\u20137 minutes), 70%\u20132% (7\u20137.1 minutes), 2% (7.1\u20138 minutes), 2%\u201398% (8\u20138.1 minutes), 98% (8.5\u201310 minutes).", {"entities": []}], [1498, "The monitored M/Z values of the parent and product ions under the positive electrospray mode of ECG, EGC, EC, and internal standard (IS) injected into MS through the Atlantis T3 (4.6\u00d750 mm \u00d73 \u00b5m) C18 (Waters) column were 443.10 \u2192 123.00, 307.20 \u2192 151.00, 291.20 \u2192 139.00, and 199.00 \u2192 127.03, respectively.", {"entities": [[96, 99, "Herb name"], [101, 104, "Herb name"], [106, 108, "Herb name"]]}], [1499, "The confirmation ion from negative mode of EGCG was detected 457.20 \u2192 168.98.", {"entities": [[43, 47, "Herb name"]]}], [1500, "Instrumental settings of the ionization were as follows: capillary voltage 2 kV; capillary source temperature at 150\u00b0C; desolvation gas temperature at 625\u00b0C; cone voltages 25 V for EGCG and ECG, 20 V for EGC and EC, 18 V for ethyl gallate; collision energy 25 V for EGCG, 15 V for ECG and EGC, 12 V for ethyl gallate.", {"entities": [[181, 185, "Herb name"], [190, 193, "Herb name"], [204, 207, "Herb name"], [212, 214, "Herb name"], [225, 238, "Herb name"], [266, 270, "Herb name"], [281, 284, "Herb name"], [289, 292, "Herb name"], [303, 316, "Herb name"]]}], [1501, "Using this LC-MS/MS method, a calibration curve range was generated by 0.1\u201350 ng/mL for EC and 1\u2013500 ng/mL for EGCG, ECG, and EGC.", {"entities": [[88, 90, "Herb name"], [111, 115, "Herb name"], [117, 120, "Herb name"], [126, 129, "Herb name"]]}], [1502, "Lower limit of quantification was determined as the lowest concentration of the calibration curve.", {"entities": []}], [1504, "DNA was isolated from the 200 \u00b5L of whole blood samples using a QIAamp DNA Blood Mini Kit (Qiagen, Germantown, MD, USA).", {"entities": []}], [1505, "The concentrations of purified DNAs were quantified by absorbance spectroscopy (260 and 280 nm) between 1.8 and 2.0 using a Nanodrop 2000 (Thermo Fisher Scientific, Waltham, MA, USA).", {"entities": []}], [1506, "The identification of genotyping was performed for 4 single-nucleotide polymorphisms (SNPs) in ABCB1, namely C3435T (rs1045642), C1236T (rs1128503), G2677A (rs2032582), and G2677T (rs2032582).", {"entities": []}], [1507, "The PCR reaction mixture consisted of 1 \u00b5L of isolated DNA, 5 \u00b5L of 2\u00d7 TagMan Universial PCR master mix, 0.5 \u00b5L of 20\u00d7 Drug Metabolism Genotyping assay mix, and 3.5 \u00b5L of DNase-free water.", {"entities": []}], [1508, "Genotyping was carried out using the Taqman SNP Genotyping Assays.", {"entities": []}], [1509, "DNA amplification was performed by real-time PCR using a Light Cycler 96\u2122 (Roche) under the following protocol: initial denaturation at 60\u00b0C for 60 seconds and at 95\u00b0C for 600 seconds, followed by a 45-cycle amplification step that consists of denaturation at 95\u00b0C for 15 seconds and annealing/extension at 60\u00b0C for 60 seconds, and final cooling at 60\u00b0C for 60 seconds.", {"entities": []}], [1510, "To compare C To evaluate the effect of catechin exposure on digoxin transport, correlation between percent change of digoxin AUC SAS A total of 16 subjects (11 males and 5 females) were enrolled in this study.", {"entities": [[39, 47, "Herb name"], [60, 67, "Drug"], [117, 124, "Drug"], [125, 128, "Parameter"], [144, 180, "Cohort"]]}], [1511, "One male subject withdrew his consent after Day 15, and so 15 subjects completed the study.", {"entities": [[4, 8, "Sex"], [59, 70, "Cohort"]]}], [1512, "The mean age of subjects was 23.1\u00b12.8 years (mean \u00b1 SD), and weight was 68.8\u00b110.8 kg.", {"entities": [[4, 43, "Age"]]}], [1513, "The baseline characteristics are presented in Table 1.", {"entities": []}], [1514, "Sixteen subjects reported 27 adverse events.", {"entities": [[0, 16, "Cohort"], [29, 43, "Pathology"]]}], [1515, "Of these, 20 were symptoms related to upper respiratory tract infection such as headache, cough, rhinorrhea, pharyngitis, and sputum.", {"entities": [[38, 71, "Pathology"], [80, 88, "Pathology"], [90, 95, "Pathology"], [97, 107, "Pathology"], [109, 120, "Pathology"], [126, 132, "Pathology"]]}], [1516, "There were 7 cases of adverse events unrelated to upper respiratory tract infection, including single cases of nausea, constipation, and insomnia and 4 cases of headache.", {"entities": [[22, 36, "Pathology"], [50, 83, "Pathology"], [111, 117, "Pathology"], [119, 131, "Pathology"], [137, 145, "Pathology"], [161, 169, "Pathology"]]}], [1517, "Among those adverse events, nausea and constipation were considered possibly related to GTC.", {"entities": [[12, 26, "Pathology"], [28, 34, "Pathology"], [39, 51, "Pathology"], [88, 91, "Herb name"]]}], [1518, "All the adverse events were mild in intensity and resolved without any treatment.", {"entities": [[8, 22, "Pathology"]]}], [1519, "Compared to the single administration of digoxin (Day 1), the concomitant administration of digoxin and GTC was associated with a significant reduction in systemic exposure of digoxin (Day 15): AUC The concentration\u2013time profiles of EC, EGC, ECG, and EGCG and the pharmacokinetics parameters are presented in Figure 4 and Table 3.", {"entities": [[41, 48, "Drug"], [92, 99, "Drug"], [104, 107, "Herb name"], [176, 183, "Drug"], [194, 197, "Parameter"], [233, 235, "Herb name"], [237, 240, "Herb name"], [242, 245, "Herb name"], [251, 255, "Herb name"]]}], [1520, "All the 4 kinds of catechins showed peak level at 1 hour after administering digoxin, ie, 2 hours after receiving GTC.", {"entities": [[19, 28, "Herb name"], [77, 84, "Drug"], [114, 117, "Herb name"]]}], [1521, "EGCG accounted for the largest part of total catechins, followed by ECG.", {"entities": [[0, 4, "Herb name"], [45, 54, "Herb name"], [68, 71, "Herb name"]]}], [1522, "The concentrations of EGC and EC were very low compared to EGCG or ECG.", {"entities": [[22, 25, "Herb name"], [30, 32, "Herb name"], [59, 63, "Herb name"], [67, 70, "Herb name"]]}], [1523, "There was no correlation between its AUC In the comparisons between genotypes in ABCB1, dominant and recessive models were applied depending on the distribution of each polymorphism among the subjects: the dominant model (wild-type + heterozygote variant vs homozygote variant) was used for C1236T genotypes and the recessive model (wild-type vs heterozygote + homozygote variant) for G2677A and G2677T genotypes.", {"entities": [[37, 40, "Parameter"]]}], [1524, "In case of C3435T, wild-type was compared with heterozygous variant due to the absence of homozygous variant.", {"entities": []}], [1525, "To identify the effect of ABCB1 genotype on the pharmacokinetic alteration of digoxin by GTC, we compared the percentage changes from Day 1 (digoxin alone treatment) of AUC This study investigated the effect of GTC on the pharmacokinetics of digoxin.", {"entities": [[78, 85, "Drug"], [89, 92, "Herb name"], [141, 148, "Drug"], [169, 172, "Parameter"], [211, 214, "Herb name"], [242, 249, "Drug"]]}], [1526, "Compared with digoxin alone, concomitant administration with GTC reduced C Apparently, these findings are not consistent with the known role of p-gp in drug absorption and elimination.", {"entities": [[14, 21, "Drug"], [61, 64, "Herb name"], [144, 148, "Target"]]}], [1527, "P-gp is abundantly expressed on the luminal membrane of enterocytes, hepatocytes facing biliary canaliculi, and renal proximal tubular epithelial cells, so that it interrupts the absorption of substrate drugs and facilitate their excretion.", {"entities": [[0, 4, "Target"]]}], [1529, "Surprisingly, the coadministration of GTC reduced the systemic exposure of digoxin in this study.", {"entities": [[38, 41, "Herb name"], [75, 82, "Drug"]]}], [1530, "Distinct from other catechins, EC has been reported to enhance the efflux function of p-gp possibly by binding to an allosteric site of p-gp that increases its activity.17 Although the AUC In this study, a 630 mg capsule of green tea extract containing 300 mg of catechins was used as the source of GTC.", {"entities": [[20, 29, "Herb name"], [31, 33, "Herb name"], [86, 90, "Target"], [136, 140, "Target"], [185, 188, "Parameter"], [206, 212, "Amount"], [224, 241, "Extraction process"], [253, 259, "Amount"], [263, 272, "Herb name"], [299, 302, "Herb name"]]}], [1532, "Given the variable amount of catechins contained in green tea products and the differing chemical compositions of catechins, our finding might not generalize to every case of concomitant administration of digoxin and a green tea product.", {"entities": [[29, 38, "Herb name"], [52, 61, "Herb name"], [114, 123, "Herb name"], [205, 212, "Drug"], [219, 228, "Herb name"]]}], [1533, "In particular, systemic exposure of digoxin may not be reduced at all if digoxin is taken with a green tea product containing a very small amount of catechins.", {"entities": [[36, 43, "Drug"], [73, 80, "Drug"], [97, 106, "Herb name"], [149, 158, "Herb name"]]}], [1534, "There are some limitations in this study.", {"entities": []}], [1535, "This study was designed to collect blood sample up to 8 hours post-dose.", {"entities": []}], [1536, "Since the terminal elimination half-life of digoxin is 26\u201345 hours,23 blood sampling for 8 hours is not sufficient for evaluating pharmacokinetic characteristics of the elimination phase.", {"entities": [[44, 51, "Drug"]]}], [1537, "Despite the lack of data from the elimination phase, collection of more blood samples beyond 8 hours after administration of digoxin is unlikely to have made a difference for the following reasons.", {"entities": [[125, 132, "Drug"]]}], [1538, "First, it is highly unlikely that digoxin and GTC have significant interaction in the intestinal lumen at 8 hours after administration because most of the digoxin and GTC will have been absorbed by that time.", {"entities": [[34, 41, "Drug"], [46, 49, "Herb name"], [155, 162, "Drug"], [167, 170, "Herb name"]]}], [1539, "Second, the concentrations of catechins reported in previous studies on the inhibitory effect of catechins on organic anion transporters were much higher than the plasma concentrations of EGCG found in our subjects.", {"entities": [[30, 39, "Herb name"], [97, 106, "Herb name"], [188, 192, "Herb name"]]}], [1540, "Roth et al7 reported that the IC We observed that concomitant administration of GTC significantly reduces the systemic exposure of digoxin, with or without pretreatment with GTC.", {"entities": [[80, 83, "Herb name"], [131, 138, "Drug"], [174, 177, "Herb name"]]}], [1541, "Our findings suggest that caution might be needed in case of prescribing digoxin to a patient taking green tea or green tea supplement on a regular basis.", {"entities": [[73, 80, "Drug"], [101, 110, "Herb name"], [114, 134, "Herb name"]]}], [1542, "This study did not investigate the mechanism for the finding.", {"entities": []}], [1543, "Further studies are needed on the role of each green tea ingredient or other digoxin transporters to clarify the green tea\u2013digoxin interaction.", {"entities": [[47, 56, "Herb name"], [77, 84, "Drug"], [113, 122, "Herb name"], [123, 130, "Drug"]]}], [1544, "This work was supported by the National Research Foundation of Korea (NRF) grant (No NRF-2017R1D1A1B03035766).", {"entities": []}], [1545, "Dr Kim was supported by a training program grant from the Korea Healthcare Technology R&D Project, Ministry for Health & Welfare, Republic of Korea (HI14C2339).", {"entities": []}], [1546, "Disclosure          The authors report no conflicts of interest in this work.", {"entities": []}], [1547, "Study design.", {"entities": []}], [1548, "Notes: Arrows indicate the single dose of digoxin (0.5 mg oral).", {"entities": [[42, 49, "Drug"], [51, 57, "Amount"]]}], [1549, "Blood samples were taken on days 1, 15, and 29 for pharmacokinetics.", {"entities": []}], [1550, "Plasma concentration\u2013time profiles of digoxin.", {"entities": [[38, 45, "Drug"]]}], [1551, "Notes: \u2022 Digoxin alone (Day 1); \u25a1 digoxin + GTC (Day 15); \u25b2 digoxin + GTC + GTC pretreatment (Day 29).", {"entities": [[9, 16, "Drug"], [34, 41, "Drug"], [44, 47, "Herb name"], [60, 67, "Drug"], [70, 73, "Herb name"], [76, 79, "Herb name"]]}], [1552, "Abbreviation: GTC, green tea catechins.", {"entities": [[14, 38, "Herb name"]]}], [1553, "Plot of individual pharmacokinetic parameters of digoxin per the treatment (Day 1, digoxin alone; Day 15, digoxin + GTC; Day 29, digoxin + GTC + GTC pretreatment).", {"entities": [[49, 56, "Drug"], [83, 90, "Drug"], [106, 113, "Drug"], [116, 119, "Herb name"], [129, 136, "Drug"], [139, 142, "Herb name"], [145, 148, "Herb name"]]}], [1554, "Abbreviations: C Plasma concentration\u2013time profiles of catechins on (A) Day 15 (digoxin + GTC) and (B) Day 29 (digoxin + GTC + GTC pretreatment).", {"entities": [[55, 64, "Herb name"], [80, 87, "Drug"], [90, 93, "Herb name"], [111, 118, "Drug"], [121, 124, "Herb name"], [127, 130, "Herb name"]]}], [1555, "Note: Time 0 hour means the time of digoxin administration, ie, 1 hour after GTC administration.", {"entities": [[36, 43, "Drug"], [77, 80, "Herb name"]]}], [1556, "Abbreviations: EC, (\u2212)-epicatechin; EGC, (\u2212)-epigallocatechin; ECG, (\u2212)-epicatechin gallate; EGCG, (\u2212)-epigallocatechin gallate; GTC, green tea catechin.", {"entities": [[15, 34, "Herb name"], [36, 61, "Herb name"], [63, 91, "Herb name"], [93, 127, "Herb name"], [129, 152, "Herb name"]]}], [1557, "Relationship between the catechin AUC Abbreviations: AUC Subject baseline characteristics at the start of the study Note: Data are presented as mean \u00b1 SD for continuous variables and as ratios for categorical variables.", {"entities": [[25, 33, "Herb name"], [34, 37, "Parameter"], [53, 56, "Parameter"]]}], [1558, "Pharmacokinetic parameters of digoxin according to treatment              Note:            Comparisons between Day 1 and Day 15 or between Day 1 and Day 29.", {"entities": [[30, 37, "Drug"]]}], [1559, "Abbreviations: GTC, green tea catechin; T Pharmacokinetic parameters of catechins Abbreviations: GTC, green tea catechin; EC, (\u2212)-epicatechin; EGC, (\u2212)-epigallocatechin; ECG, (\u2212)-epicatechin gallate; EGCG, (\u2212)-epigallocatechin gallate; C Pharmacokinetic parameters of digoxin in each treatment according to genotype and treatment              Note:            Comparisons of the % changes from Day 1 between genotypes (wild-type vs variant genotype).", {"entities": [[15, 38, "Herb name"], [72, 81, "Herb name"], [97, 120, "Herb name"], [122, 141, "Herb name"], [143, 168, "Herb name"], [170, 198, "Herb name"], [200, 234, "Herb name"], [268, 275, "Drug"]]}], [1560, "Abbreviations: AUC", {"entities": [[15, 18, "Parameter"]]}], [1561, "We aimed to investigate the effects of red ginseng extract (RGE) on the expression of efflux transporters and to study the pharmacokinetics of representative substrate.", {"entities": [[39, 64, "Herb name"]]}], [1562, "mRNA and protein levels of multidrug resistance-associated protein2 (Mrp2), bile salt export pump (Bsep), and P-glycoprotein (P-gp) in the rat liver were measured via real-time polymerase chain reaction and Western blot analysis.", {"entities": [[27, 74, "Target"], [76, 104, "Target"], [110, 131, "Target"]]}], [1563, "Ginsenosides concentrations from the rat plasma were also monitored using a liquid chromatography\u2013tandem mass spectrometry (LC\u2013MS/MS) system.", {"entities": [[0, 12, "Herb name"]]}], [1564, "Plasma concentrations of ginsenoside Rb1, Rb2, Rc, and Rd following repeated administration of RGE for 1 and 2 weeks were comparable but significantly higher than those after single administration of RGE.", {"entities": [[25, 36, "Herb name"], [37, 40, "Herb name"], [42, 45, "Herb name"], [47, 49, "Herb name"], [55, 57, "Herb name"], [68, 91, "Frequency"], [95, 98, "Herb name"], [99, 116, "Duration"], [175, 196, "Frequency"], [200, 203, "Herb name"]]}], [1565, "These dosing regimens did not induce significant biochemical abnormalities in the liver, kidneys, and lipid homeostasis.", {"entities": []}], [1566, "In the RGE repeated oral administration groups, the mRNA and protein levels of Mrp2 significantly decreased.", {"entities": [[7, 10, "Herb name"], [11, 39, "Frequency"], [79, 83, "Target"]]}], [1567, "Accordingly, we investigated the changes in the pharmacokinetics of methotrexate, a probe substrate for Mrp2, following intravenous administration of 3 mg/kg methotrexate to rats in the RGE 1-week repeated oral administration group, compared to that in the control group.", {"entities": [[68, 80, "Drug"], [104, 108, "Target"], [150, 157, "Amount"], [158, 170, "Drug"], [186, 189, "Herb name"], [190, 196, "Duration"], [197, 225, "Frequency"]]}], [1568, "Biliary excretion, but not urinary excretion, of methotrexate decreased in the RGE repeated administration group, compared to that in the control group.", {"entities": [[0, 17, "Parameter"], [27, 44, "Parameter"], [49, 61, "Drug"], [79, 82, "Herb name"], [83, 106, "Frequency"]]}], [1571, "Pharmacokinetic herb\u2013drug interaction between RGE and methotrexate might occur owing to the decrease in the mRNA and protein levels of Mrp2.", {"entities": [[46, 49, "Herb name"], [54, 66, "Drug"], [135, 139, "Target"]]}], [1572, "Ginseng (the roots and rhizomes of Panax ginseng C.A.", {"entities": [[0, 7, "Herb name"], [13, 18, "Herb part"], [23, 31, "Herb part"], [35, 48, "Herb name"]]}], [1573, "Meyer) has been extensively used for more than 2000 years in East Asian countries [1,2].", {"entities": [[61, 71, "Ethnic group"]]}], [1574, "Red ginseng extract (RGE) is produced from 6-year-old fresh ginseng by steaming and drying, which leads to biochemical transformation of various ginsenosides [3].", {"entities": [[0, 25, "Herb name"], [60, 67, "Herb name"], [71, 90, "Extraction process"], [145, 157, "Herb name"]]}], [1575, "Ginsenosides are considered the major active pharmacological constituents of ginseng.", {"entities": [[0, 12, "Herb name"], [77, 84, "Herb name"]]}], [1576, "They have been shown to exhibit anti-neoplastic, anti-hypertensive, anti-diabetic, anti-inflammatory, anti-oxidant, anti-allergic, neuroprotective, and immunological effects [4,5,6,7].", {"entities": []}], [1577, "Similar to other herbal medicines, ginseng products are frequently co-administered with prescribed Western medications.", {"entities": [[35, 42, "Herb name"]]}], [1578, "Accordingly, the potential for pharmacokinetic herb\u2013drug interactions between ginseng and concomitantly administered drugs should be evaluated since they may result in toxicity or treatment failure [8].", {"entities": [[78, 85, "Herb name"]]}], [1579, "Ginseng could alter the activity of cytochrome P450 (CYP) enzymes, the most important drug-metabolizing enzymes, which can affect the pharmacokinetics and efficacy of the co-administered drug.", {"entities": [[0, 7, "Herb name"], [36, 57, "Target"]]}], [1580, "Two-week red ginseng treatment (10 mL of concentrated red ginseng extracts, dried ginseng 64%) weakly inhibited CYP2C9, CYP2D6, and CYP 3A4 activity, whereas it weakly induced CYP2D6 activity [10].", {"entities": [[0, 8, "Duration"], [9, 20, "Herb name"], [54, 74, "Herb name"], [76, 81, "Extraction process"], [82, 89, "Herb name"], [112, 118, "Target"], [120, 126, "Target"], [132, 139, "Target"], [176, 182, "Target"]]}], [1581, "Besides inhibition or induction of CYP, the modulation of drug-transporters is also an important mechanism for herb\u2013drug interaction [11,12,13].", {"entities": [[35, 38, "Target"]]}], [1582, "Drug efflux transporters such as multidrug resistance-associated protein (Mrp), bile salt export pump (Bsep), and P-glycoprotein (P-gp) play important roles in the efflux of their substrates from the cells, thereby protecting the cells against these high concentrations of substrates, reducing intestinal absorption, or facilitating excretion of the substrate drugs [14].", {"entities": [[0, 24, "Target"], [33, 78, "Target"], [80, 108, "Target"], [114, 135, "Target"]]}], [1583, "Moreover, alteration of efflux transporter activity or expression could affect the tissue distribution, systemic disposition, and intestinal absorption of substrate drugs, thereby affecting their efficacy [15,16].", {"entities": []}], [1584, "Despite the growing understanding of the role of the transport system in the pharmacokinetics, drug response, and herb\u2013drug interactions, the effects of red ginseng on the efflux transporters have not yet been fully elucidated.", {"entities": [[153, 164, "Herb name"], [172, 191, "Target"]]}], [1585, "A clinical study reported that red ginseng exhibited limited effects on P-gp function following 2-weeks repeated administration of red ginseng product in humans [10].", {"entities": [[2, 16, "Study"], [31, 42, "Herb name"], [72, 76, "Target"], [96, 103, "Duration"], [104, 127, "Frequency"], [131, 142, "Herb name"]]}], [1586, "Therefore, in the present study, we investigated the effects of single or repeated administration of RGE on efflux transporters and examined the potential changes in the pharmacokinetics of their substrate drugs.", {"entities": [[101, 104, "Herb name"], [108, 127, "Target"]]}], [1587, "Of these, Mrp2 drew our interest because it is mainly involved in the pharmacokinetics and renal and biliary elimination of its substrate anions as well as amphipathic drugs that conjugate with glucuronide, sulfate, and glutathione (GSH) [17,18].", {"entities": [[10, 14, "Target"], [91, 120, "Parameter"]]}], [1589, "GSH facilitates the biliary excretion of amphipathic drugs via Mrp2 through the conjugation reaction and also acts as a regulator of redox homeostasis [21].", {"entities": [[0, 3, "Herb name"], [20, 37, "Parameter"], [63, 67, "Target"]]}], [1590, "RGE has been shown to be effective in reducing oxidative stress through the Nrf2 signaling pathway [7,22].", {"entities": [[0, 3, "Herb name"], [76, 98, "Target"]]}], [1591, "Nrf2 is a transcriptional factor that regulates Mrp2 expression [21], suggesting herb\u2013drug interaction between red ginseng and Mrp2 substrates.", {"entities": [[0, 4, "Target"], [48, 52, "Target"], [111, 122, "Herb name"], [127, 131, "Target"]]}], [1592, "To measure ginsenoside concentrations, we developed analytical methods for quantification of 14 ginsenosides in diluted RGE and rat plasma samples with slight modification of a previously described method [23].", {"entities": [[11, 22, "Herb name"], [96, 108, "Herb name"], [112, 119, "Extraction process"], [120, 123, "Herb name"]]}], [1593, "Among the 14 ginsenosides tested, eight ginsenosides (Rb1, Rb2, Rc, Rd, Rg3, Re, Rh1, and Rg1) could be quantitated in the diluted RGE.", {"entities": [[13, 25, "Herb name"], [40, 52, "Herb name"], [54, 57, "Herb name"], [59, 62, "Herb name"], [64, 66, "Herb name"], [68, 70, "Herb name"], [72, 75, "Herb name"], [77, 79, "Herb name"], [81, 84, "Herb name"], [90, 93, "Herb name"], [123, 130, "Extraction process"], [131, 134, "Herb name"]]}], [1594, "Peaks of the other six ginsenosides (Rh2, F2, compound K, protopanaxadiol, F1, and protopanaxatriol) were not detected since these ginsenosides are minor components and are biological metabolites of Rb1, Rb2, Re, or Rg1 that could be produced via metabolism in the gut microflora [24,25].", {"entities": [[23, 35, "Herb name"], [37, 40, "Herb name"], [42, 44, "Herb name"], [46, 56, "Herb name"], [58, 73, "Herb name"], [75, 77, "Herb name"], [83, 99, "Herb name"], [131, 143, "Herb name"], [199, 202, "Herb name"], [204, 207, "Herb name"], [209, 211, "Herb name"], [216, 219, "Herb name"]]}], [1595, "The contents of ginsenosides could differ depending on the preparation procedure for RGE (steaming and drying conditions); however, the contents of major ginsenosides, such as Rb1, Rb2, Rc, and Rg3, were comparable to previously reported values [26,27].", {"entities": [[16, 28, "Herb name"], [85, 88, "Herb name"], [154, 166, "Herb name"], [176, 179, "Herb name"], [181, 184, "Herb name"], [186, 188, "Herb name"], [194, 197, "Herb name"]]}], [1596, "Ginsenoside contents in RGE used in this study are summarized in Table 1.", {"entities": [[0, 11, "Herb name"], [24, 27, "Herb name"]]}], [1597, "Rb1 content was the highest (0.19%), and Rb2, Rc, and Rg3 contents were 0.09%, 0.1%, and 0.13%, respectively.", {"entities": [[0, 3, "Herb name"], [41, 44, "Herb name"], [46, 48, "Herb name"], [54, 57, "Herb name"]]}], [1598, "Rd, Re, and Rh1 contents in RGE were in the range of 0.05\u20130.06%.", {"entities": [[0, 2, "Herb name"], [4, 6, "Herb name"], [12, 15, "Herb name"], [28, 31, "Herb name"]]}], [1599, "After RGE was orally administered to rats at single or multiple doses for 1 or 2 weeks, the plasma concentrations of ginsenosides were also monitored.", {"entities": [[6, 9, "Herb name"], [70, 86, "Duration"], [117, 129, "Herb name"]]}], [1600, "Among the 14 ginsenosides monitored, only four ginsenosides (Rb1, Rb2, Rc, and Rd) could be quantitated (Table 2); however, the other 10 ginsenoside peaks were not detected in rat plasma.", {"entities": [[13, 25, "Herb name"], [47, 59, "Herb name"], [61, 64, "Herb name"], [66, 69, "Herb name"], [71, 73, "Herb name"], [79, 81, "Herb name"], [137, 148, "Herb name"]]}], [1601, "The representative multiple reaction monitoring (MRM) chromatograms for the four identified ginsenosides (Rb1, Rb2, Rc, and Rd) and five unidentified ginsenosides (Rg3, compound K, Re, Rh1, and Rg1) are shown in Figure 1.", {"entities": [[92, 104, "Herb name"], [106, 109, "Herb name"], [111, 114, "Herb name"], [116, 118, "Herb name"], [124, 126, "Herb name"], [150, 162, "Herb name"], [164, 167, "Herb name"], [169, 179, "Herb name"], [181, 183, "Herb name"], [185, 188, "Herb name"], [194, 197, "Herb name"]]}], [1602, "Plasma concentrations of ginsenosides Rb1, Rb2, and Rc following single oral administration (SA) of RGE were comparable to each other and greater than the plasma concentrations of Rd (Table 2).", {"entities": [[25, 37, "Herb name"], [38, 41, "Herb name"], [43, 46, "Herb name"], [52, 54, "Herb name"], [65, 96, "Frequency"], [100, 103, "Herb name"], [180, 182, "Herb name"]]}], [1603, "Repeated administration of RGE for 1 week (1WRA) resulted in an increase in plasma ginsenoside concentrations, compared to those in the SA group; however, they were not significantly different from those in the 2WRA group (Table 2).", {"entities": [[0, 23, "Frequency"], [27, 30, "Herb name"], [31, 48, "Duration"], [83, 94, "Herb name"], [136, 138, "Frequency"], [211, 215, "Duration"]]}], [1604, "The results suggested that ginsenosides accumulated in the plasma because of their long elimination half-life (t Because of the potential of drug interactions between herbal medicines and efflux transporters, we measured the mRNA expression of efflux transporters, such as Bsep, P-gp, Mrp1, and Mrp2 in the liver tissues from rats in the control, SA, 1WRA, and 2WRA groups (Figure 2).", {"entities": [[27, 39, "Herb name"], [88, 109, "Parameter"], [273, 277, "Target"], [279, 283, "Target"], [285, 289, "Target"], [295, 299, "Target"], [347, 349, "Frequency"], [351, 355, "Duration"], [361, 365, "Duration"]]}], [1605, "The expression of P-gp, and Bsep did not change; however, Mrp1 expression slightly decreased in both single- and multiple-dose RGE-treated groups although it did not reach statistical significance.", {"entities": [[18, 22, "Target"], [28, 32, "Target"], [58, 62, "Target"], [127, 130, "Herb name"]]}], [1606, "Mrp2 expression slightly decreased in the SA group but significantly decreased in the repeated-dose RGE-treated groups.", {"entities": [[0, 4, "Target"], [42, 44, "Frequency"], [86, 99, "Frequency"], [100, 103, "Herb name"]]}], [1607, "There was no significant difference in Mrp2 expression between the 1WRA and 2WRA groups.", {"entities": [[39, 43, "Target"], [67, 71, "Duration"], [76, 80, "Duration"]]}], [1608, "Based on the plasma ginsenoside concentrations and mRNA expression level, further comparison studies were performed among the control, SA, and 1WRA groups.", {"entities": [[20, 31, "Herb name"], [135, 137, "Frequency"], [143, 147, "Duration"]]}], [1609, "To confirm the decrease in the mRNA expression of Mrp2 in the repeated-dose RGE-treated groups, Western blot analysis was performed using the liver tissues collected from rats in the control, SA, and 1WRA groups.", {"entities": [[50, 54, "Target"], [76, 79, "Herb name"], [192, 194, "Frequency"], [200, 204, "Duration"]]}], [1610, "As shown in Figure 3, Mrp2 protein levels significantly decreased in the liver tissues of rats in the 1WRA group, compared to that in the control group.", {"entities": [[22, 26, "Target"], [102, 106, "Duration"]]}], [1611, "Next, we investigated the effects of RGE on the biliary excretion of Mrp2 substrate drug in rats.", {"entities": [[37, 40, "Herb name"], [69, 73, "Target"]]}], [1612, "Methotrexate was selected as a representative substrate for Mrp2 because 62% and 27% of methotrexate intravenous dose is excreted into the bile and urine, respectively, within 3 h mainly by Mrp2 [31].", {"entities": [[0, 12, "Drug"], [60, 64, "Target"], [88, 100, "Drug"], [190, 194, "Target"]]}], [1613, "Pharmacokinetic parameters of methotrexate related to its excretion were presented in Figure 4 and Table 4.", {"entities": [[30, 42, "Drug"]]}], [1614, "We observed delayed disposition of methotrexate from the plasma (Figure 4), including an increase in t Since methotrexate underwent the least metabolism [31], disposition from the plasma could be attributed to its excretion via the liver and kidney.", {"entities": [[35, 47, "Drug"], [109, 121, "Drug"]]}], [1615, "Multiple-dose administration of red ginseng decreased the biliary excretion, but not the urinary excretion, of methotrexate (Figure 4B,C) and consequently, CL RGE treatment at a daily dose of 1.5 g/kg for 1 week resulted in steady-state plasma concentrations of major ginsenosides, such as Rb1, Rb2, Rc, and Rd (Table 2).", {"entities": [[32, 43, "Herb name"], [58, 75, "Parameter"], [89, 106, "Parameter"], [111, 123, "Drug"], [156, 158, "Parameter"], [159, 162, "Herb name"], [178, 183, "Frequency"], [192, 200, "Amount"], [201, 211, "Duration"], [268, 280, "Herb name"], [290, 293, "Herb name"], [295, 298, "Herb name"], [300, 302, "Herb name"], [308, 310, "Herb name"]]}], [1616, "In addition, this treatment did not induce biochemical abnormalities in the liver, kidneys, and lipid homeostasis in rats (Table 3).", {"entities": []}], [1617, "The plasma concentration of Rb1 was the highest among the ginsenosides detected in rat plasma after oral administration of RGE, followed by Rb2, Rc, and Rd, which was similar to the rank of the ginsenoside content in RGE used in this study (Table 1 and Table 2).", {"entities": [[28, 31, "Herb name"], [58, 70, "Herb name"], [123, 126, "Herb name"], [140, 143, "Herb name"], [145, 147, "Herb name"], [153, 155, "Herb name"], [194, 205, "Herb name"], [217, 220, "Herb name"]]}], [1618, "However, other ginsenosides, such as Rg3, Re, and Rh1, were not detected in rat plasma despite their high content in RGE (Table 1 and Table 2).", {"entities": [[15, 27, "Herb name"], [37, 40, "Herb name"], [42, 44, "Herb name"], [50, 53, "Herb name"], [117, 120, "Herb name"]]}], [1619, "Although the underlying mechanisms need to be explored, limited intestinal permeability, short plasma half-life, and intestinal instability owing to the biotransformation and pH-dependent degradation of Rg3, Re, and Rh1 [32,33,34], compared to Rb1, Rb2, Rc, and Rd, might contribute to this finding.", {"entities": [[95, 111, "Parameter"], [203, 206, "Herb name"], [208, 210, "Herb name"], [216, 219, "Herb name"], [244, 247, "Herb name"], [249, 252, "Herb name"], [254, 256, "Herb name"], [262, 264, "Herb name"]]}], [1620, "Repeated RGE treatment decreased the mRNA and protein expression of Mrp2; however, it did not modulate the expression of Bsep and P-gp in the liver (Figure 2 and Figure 3).", {"entities": [[9, 12, "Herb name"], [68, 72, "Target"], [121, 125, "Target"], [130, 134, "Target"]]}], [1621, "Nuclear receptors, such as farnesoid X receptor (FXR, also known as bile acid receptor) and pregnane X receptor (PXR), are known as major regulators of the expression of Bsep and P-gp, respectively [35].", {"entities": [[27, 87, "Target"], [92, 117, "Target"], [170, 174, "Target"], [179, 183, "Target"]]}], [1622, "The expression of Mrp2 has been shown to be regulated through transcriptional and post-transcriptional regulation via activation of the Nrf2 and cAMP-dependent protein kinase A (PKA) signaling pathways [5].", {"entities": [[18, 22, "Target"], [136, 140, "Target"], [145, 182, "Target"]]}], [1623, "Repeated administration of RGE reduced Mrp2 expression; however, the expression of Bsep and P-gp did not change, suggesting that multiple-dose RGE treatment might affect the Nrf2 pathway.", {"entities": [[27, 30, "Herb name"], [39, 43, "Target"], [83, 87, "Target"], [92, 96, "Target"], [143, 146, "Herb name"], [174, 186, "Target"]]}], [1624, "This might subsequently contribute to the decrease in Mrp2 mRNA and protein expression, and the increase in the plasma concentration of MTX, an Mrp2 probe substrate drug, by decreasing its elimination and biliary excretion following repeated administration of RGE (Figure 4).", {"entities": [[54, 58, "Target"], [136, 139, "Drug"], [144, 148, "Target"], [205, 222, "Parameter"], [260, 263, "Herb name"]]}], [1625, "Therefore, it could be concluded that multiple-dose administration of RGE could induce herb\u2013drug interactions with various Mrp2 substrate drugs by reducing the hepatobiliary elimination of the Mrp2 substrates, xenobiotics, and their conjugated metabolites, which should be considered when Mrp2 substrate drugs are co-administered with RGE.", {"entities": [[70, 73, "Herb name"], [123, 127, "Target"], [160, 185, "Parameter"], [193, 197, "Target"], [289, 293, "Target"], [335, 338, "Herb name"]]}], [1626, "In addition, MTX has been used as a chemotherapeutic and immunosuppressive agent for treatment of leukemia, lymphoma, rheumatoid arthritis, and Crohn\u2019s disease [24].", {"entities": [[13, 80, "Drug"], [98, 106, "Pathology"], [108, 116, "Pathology"], [118, 138, "Pathology"], [144, 159, "Pathology"]]}], [1627, "In particular, the beneficial effects of red ginseng products for reducing the symptoms of rheumatoid arthritis have been proven in animals and humans [24,25,26,27,36].", {"entities": [[41, 52, "Herb name"], [91, 111, "Pathology"]]}], [1628, "Therefore, the use of MTX and red ginseng alone or in combination is highly plausible for treatment of rheumatoid arthritis.", {"entities": [[22, 25, "Drug"], [30, 41, "Herb name"], [103, 123, "Pathology"]]}], [1629, "Repeated high doses of red ginseng could decrease Mrp2 expression, which is crucial for the elimination of MTX.", {"entities": [[23, 34, "Herb name"], [50, 54, "Target"], [107, 110, "Drug"]]}], [1630, "Therefore, in conclusion, this study showed that the herb\u2013drug interactions between red ginseng and MTX occurred via Mrp2 regulation changes in rats, but clinical significance thereof should be determined with follow-up studies.", {"entities": [[84, 95, "Herb name"], [100, 103, "Drug"], [117, 121, "Target"]]}], [1631, "Methotrexate was purchased from Sigma-Aldrich (St. Louis, MO, USA).", {"entities": [[0, 12, "Drug"]]}], [1632, "Analytical standard ginsenosides were purchased from Ambo Institute (Daejeon, Korea).", {"entities": [[20, 32, "Herb name"]]}], [1633, "Male Sprague\u2212Dawley rats (7\u20138 weeks, 220\u2212250 g) were purchased from Samtako Co. (Osan, Korea).", {"entities": [[0, 4, "Sex"]]}], [1634, "All animal procedures were approved by the Animal Care and Use Committee of Kyungpook National University (Approval No.", {"entities": []}], [1635, "2017-0021) and carried out in accordance with the National Institutes of Health guidance for the care and the use of laboratory animals.", {"entities": []}], [1636, "Rats in the control group received water (2 mL/kg as a vehicle treatment) orally at 9 a.m. for 7 days by oral gavage.", {"entities": [[91, 101, "Duration"]]}], [1637, "Two hours after the last treatment of RGE, abdominal arterial blood (about 5 mL) and liver tissues were collected from rats in all groups.", {"entities": [[38, 41, "Herb name"]]}], [1638, "The liver tissues were snap-frozen for analysis of the mRNA and protein expression of efflux transporters.", {"entities": []}], [1639, "The plasma samples were used for measurement of plasma ginsenoside concentrations and biochemical parameters.", {"entities": [[55, 66, "Herb name"]]}], [1640, "The biochemical parameters such as ALT, AST, triglycerides, plasma cholesterol levels, free fatty acids, blood urea nitrogen and serum creatinine were measured from the service of Seoul Clinical Laboratories (Yongin, Korea) using UV spectrophotometric assay kits from Young-Dong Diagnostics Co. (Yongin, Korea).", {"entities": [[35, 38, "Parameter"], [40, 43, "Parameter"], [45, 58, "Parameter"], [60, 85, "Parameter"], [87, 103, "Parameter"], [105, 124, "Parameter"], [129, 145, "Parameter"]]}], [1641, "Lyphocheck assayed chemistry control (normal and abnormal standards; Bio-Rad, Hercules, CA, USA) were used as positive control and YD calibrator (Young-Dong Diagnostics Co.) was used for external calibration.", {"entities": []}], [1642, "Ginsenoside concentrations in RGE and plasma samples were analyzed using an Agilent 6470 triple quadrupole liquid chromatography\u2013tandem mass spectrometry (LC\u2013MS/MS) system (Agilent, Wilmington, DE, USA) equipped with an Agilent 1260 high-performance liquid chromatography (HPLC) system according to the previously published method [23].", {"entities": [[0, 11, "Herb name"], [30, 33, "Herb name"]]}], [1643, "Briefly, diluted RGE samples (50 \u03bcL) and plasma samples (50 \u03bcL) were protein-precipitated with methanol 200 \u03bcL containing berberine (0.5 ng/mL; used as an internal standard).", {"entities": [[17, 20, "Herb name"]]}], [1644, "Aliquots (10 \u03bcL) of the supernatant were injected into the LC\u2013MS/MS system for the analysis of ginsenosides.", {"entities": [[95, 107, "Herb name"]]}], [1645, "Ginsenosides were separated on a Synergi Polar RP column (2 \u00d7 150 mm, 4 \u03bcm particle size; Phenomenex) using a mobile phase consisting of water (A) and methanol (B) containing 0.1% formic acid at a flow rate of 0.3 mL/min.", {"entities": [[0, 12, "Herb name"]]}], [1646, "The solvent gradient program was as follows: (1) 0\u20131 min, 70 % B; (2) 1\u20136.5 min, 90 % B; (3) 6.5\u20137 min, 80% B; and (4) 7\u201314 min, 70% B. Quantification of a separated ginsenoside peak was performed using MRM mode at m/z 1131.6 \u2192 365.1 for Rb1 (retention time (rt) = 4.1 min), m/z 1101.6 \u2192 335.1 for Rb2 (rt = 5.0 min) and Rc (rt = 4.2 min), m/z 969.9 \u2192 789.5 for Rd (rt = 5.1 min) and Re (rt = 1.8 min), m/z 823.5 \u2192 365.1 for Rf (rt = 2.7 min), m/z 824 \u2192 643.6 for Rg1 (T Total RNA was extracted from liver samples (100 mg) using Qiazol (Qiagen, Valencia, CA, USA), according to the vendor\u2019s protocol.", {"entities": [[166, 177, "Herb name"], [238, 241, "Herb name"], [298, 301, "Herb name"], [321, 323, "Herb name"], [362, 364, "Herb name"], [384, 386, "Herb name"], [425, 427, "Herb name"], [464, 467, "Herb name"]]}], [1647, "The concentration of total RNA was determined by Nano Vue Plus (GE healthcare Korea, Seoul, Korea).", {"entities": []}], [1648, "RT-PCR of Mrp1, Mrp2, Bsep, and P-gp was performed using a LightCycler 96 real-time PCR system (Roche, Carlsbad, CA, USA) as previously described [21,37].", {"entities": [[10, 14, "Target"], [16, 20, "Target"], [22, 26, "Target"], [32, 36, "Target"]]}], [1649, "Primers were designed using ProbeFinder as follows: 5\u2032-tgagggtggagaaaaggttg-5\u2032 and 5\u2032-aaacccagggtgagagatga-3\u2032 for Mrp1 (NM_022281.2); 5\u2032-aatacatgaccttttggtgtttctg-5\u2032 and 5\u2032-acgaaaccgatcagcaactt-3\u2032 for Mrp2 (NM_012833.2); 5\u2032-gggcagtcacacccatctac-5\u2032 and 5\u2032-ctttatcgaggagtgaaaaagtcc-3\u2032 for Bsep (NM_031760.1); 5\u2032-cacagaccgtcagcgaca-5\u2032 and 5\u2032-caatgcccgtgtaatagtaggc-3\u2032 for P-gp (NM_012623.2).", {"entities": [[114, 118, "Target"], [201, 205, "Target"], [287, 291, "Target"], [369, 373, "Target"]]}], [1650, "Protein expression of Mrp2, Bsep, and P-gp was measured as previously described [21].", {"entities": [[22, 26, "Target"], [28, 32, "Target"], [38, 42, "Target"]]}], [1651, "Briefly, total protein was obtained by homogenizing 100 mg of liver samples with equal volume of a tissue lysis buffer.", {"entities": []}], [1652, "Protein samples (30\u201350 \u00b5g) were loaded and separated by sodium dodecyl sulfate\u2013polyacrylamide gel electrophoresis (SDS-PAGE) on a 4\u201315% gradient gel (Bio-Rad).", {"entities": []}], [1653, "Separated proteins were transferred onto a Potran 0.45 \u03bcm nitrocellulose membrane (GE Healthcare).", {"entities": []}], [1654, "The membrane was blocked with 5% bovine serum albumin in Tris-buffered saline containing 0.1% Tween20 (TBST) (Biosesang, Seoul, Republic of Korea) for 1 h and incubated with primary antibody at 4 \u00b0C for 12 h. Primary antibodies were used as follows: anti-Mrp2 antibody (ab203397, dilution 1:1000, Abcam, San Francisco, CA, USA), anti-Bsep antibody (ab217532, dilution 1:1000, Abcam), anti-P-gp antibody (E1Y7S, dilution 1:1000, Cell signaling technology, Danvers, MA, USA) and beta-actin antibody (1:1000, Cell signaling technology).", {"entities": [[255, 259, "Target"], [334, 338, "Target"], [389, 393, "Target"]]}], [1655, "The membrane was rinsed twice with TBST at 25 \u00b0C and treated with horseradish peroxidase-labeled anti-rabbit IgG antibody (Santa Cruz Biotechnology, Dallas, TX, USA).", {"entities": []}], [1656, "Protein bands were visualized using a Luminata Forte enhanced chemiluminescence system (Millipore, Burlington, MA, USA), and beta-actin served as the loading control.", {"entities": []}], [1657, "Pharmacokinetic study of methotrexate was performed as previously described [21].", {"entities": [[25, 37, "Drug"]]}], [1658, "Briefly, the femoral arteries, femoral veins, and bile duct of rats in the control and 1WRA groups were cannulated with PE50 or PE10 polyethylene tubing (Jungdo, Seoul, Korea) under anesthesia.", {"entities": [[87, 91, "Duration"]]}], [1659, "Pharmacokinetic studies started 2 h after the last RGE treatment.", {"entities": [[51, 54, "Herb name"]]}], [1660, "Methotrexate solution (3 mg/kg in phosphate-buffered saline) was injected intravenously to rats.", {"entities": [[0, 12, "Drug"], [23, 30, "Amount"]]}], [1661, "Blood samples (about 150 \u03bcL) were collected from the femoral artery at 0, 0.03, 0.08, 0.25, 0.5, 1, 2, 4, and 6 h after the methotrexate injection.", {"entities": [[124, 136, "Drug"]]}], [1662, "Bile samples were collected at 1 and 2 h and every 2 h up to 12 h through the bile cannula.", {"entities": []}], [1663, "Urine samples were also collected every 4 h up to 12 h through urinary bladder.", {"entities": []}], [1664, "Aliquots (50 \u03bcL) of plasma, bile, and urine samples were added to 250 \u03bcL of acetonitrile containing 2 ng/mL of propranolol (IS).", {"entities": []}], [1665, "After vortexing for 10 min and centrifugation at 10,000\u00d7 g for 10 min, an aliquot (1 \u03bcL) of the supernatant was injected directly into the Agilent 6430 triple quadrupole LC\u2013MS/MS system, according to the previously described method [21].", {"entities": []}], [1666, "Briefly, methotrexate and propranolol (IS) were eluted at 2.1 and 2.7 min, respectively, on a Synergi Polar RP column.", {"entities": [[9, 21, "Drug"]]}], [1667, "Mobile phase consisted of water (0.1% formic acid):acetonitrile (0.1% formic acid) = 20:80 (v/v) and eluted at a rate of 0.25 mL/min.", {"entities": []}], [1668, "Quantitation was carried out at m/z 455.2 \u2192 308.1 for methotrexate and m/z 260 \u2192 116 for IS in the positive ionization mode.", {"entities": [[54, 66, "Drug"]]}], [1669, "Pharmacokinetic parameters were calculated by non-compartmental analysis using WinNonlin version 2.0 software (Pharsight, Certara, NJ, USA).", {"entities": []}], [1670, "Statistical comparisons were performed by t-test using the Statistical Package for the Social Sciences (SPSS Inc., Chicago, IL, USA).", {"entities": []}], [1671, "A p value < 0.05 was considered statistically significant.", {"entities": []}], [1672, "This research was funded by a grant of the Korea Institute of Planning and Evaluation for Technology in Food, Agriculture, Forestry and Fisheries (IPET) through Export Promotion Technology Development Program, funded by Ministry of Agriculture, Food and Rural Affairs (MAFRA) (No.", {"entities": []}], [1673, "316017-3).", {"entities": []}], [1674, "Sample Availability: Red ginseng extract are available from the authors.", {"entities": [[21, 40, "Herb name"]]}], [1675, "Conceptualization, M.-K.C.", {"entities": []}], [1676, "and I.-S.S.; methodology, investigation, and data interpretation, S.L., M.K., M.-K.C., and I.-S.S.; writing\u2014original draft preparation, S.L.", {"entities": []}], [1677, "; writing\u2014review and editing and supervision, M.-K.C.", {"entities": []}], [1678, "and I.-S.S.; funding acquisition, I.-S.S.", {"entities": []}], [1679, "The authors declare no conflict of interest.", {"entities": []}], [1680, "Representative multiple reaction monitoring (MRM) chromatograms of ginsenosides Rb1, Rb2, Rc, Rd, Rg3, compound K (Comp K), Re, Rh1, Rg1, and berberine (internal standard, IS) in (A) rat blank plasma, (B) standard ginsenosides (20 ng/mL) spiked in rat blank plasma, and (C) plasma samples following single oral administration of RGE (1.5 g/kg).", {"entities": [[67, 79, "Herb name"], [80, 83, "Herb name"], [85, 88, "Herb name"], [90, 92, "Herb name"], [94, 96, "Herb name"], [98, 101, "Herb name"], [103, 122, "Herb name"], [124, 126, "Herb name"], [128, 131, "Herb name"], [133, 136, "Herb name"], [142, 151, "Herb name"], [214, 226, "Herb name"], [299, 310, "Frequency"], [329, 332, "Herb name"], [334, 342, "Amount"]]}], [1681, "mRNA expression level of multidrug resistance-associated protein 1 (Mrp1), Mrp2, bile salt export pump (Bsep), and P-glycoprotein (P-gp) in the liver of rats in the control, single administration (SA), and repeated administration of RGE (1.5 g/kg, PO) for 7 days (1WRA) and 14 days (2WRA) groups.", {"entities": [[25, 73, "Target"], [75, 79, "Target"], [81, 109, "Target"], [115, 136, "Target"], [197, 199, "Frequency"], [206, 229, "Frequency"], [233, 236, "Herb name"], [238, 246, "Amount"], [252, 269, "Duration"], [274, 288, "Duration"]]}], [1682, "Hrpt1 was used as an internal standard.", {"entities": []}], [1683, "Each bar represents the mean \u00b1 SD from four rats per group.", {"entities": []}], [1684, "* p < 0.05, significant compared with SA group by Student\u2019s t-test.", {"entities": [[38, 40, "Frequency"]]}], [1685, "Protein expression of Mrp2 in the liver of rats in the control (lanes A, B, and C), SA (lanes D, E, and F), and 1WRA (lanes G, H, and I) groups.", {"entities": [[22, 26, "Target"], [84, 86, "Frequency"], [112, 116, "Duration"]]}], [1686, "\u03b2-actin served as a loading control.", {"entities": []}], [1687, "Quantitative analysis of Western blot results is shown in the lower panel.", {"entities": []}], [1688, "Each bar represents the mean \u00b1 SD of three independent densitometric analyses.", {"entities": []}], [1689, "* p < 0.05, significant compared with SA group by Student\u2019s t-test.", {"entities": [[38, 40, "Frequency"]]}], [1690, "(A) Plasma concentration-time profile, (B) biliary excretion, and (C) urinary excretion of methotrexate following intravenous injection of methotrexate at a dose of 3 mg/kg in rats from the control and 1WRA groups of RGE (1.5 g/kg, PO).", {"entities": [[43, 60, "Parameter"], [70, 87, "Parameter"], [91, 103, "Drug"], [139, 151, "Drug"], [165, 172, "Amount"], [202, 206, "Duration"], [217, 220, "Herb name"], [222, 230, "Amount"]]}], [1691, "Data represent the means \u00b1 SD (n = 3 or 4 rats/group).", {"entities": []}], [1692, "Contents of ginsenosides in RGE.", {"entities": [[12, 24, "Herb name"], [28, 31, "Herb name"]]}], [1693, "Data are expressed as mean \u00b1 SD from triplicated measurements of ginsenosides in RGE.", {"entities": [[65, 77, "Herb name"], [81, 84, "Herb name"]]}], [1694, "ND: Not detected.", {"entities": []}], [1695, "RGE: Red ginseng extract.", {"entities": [[0, 3, "Herb name"], [5, 24, "Herb name"]]}], [1696, "Data are expressed as mean \u00b1 SD from four rats of control, SA, 1WRA, and 2WRA groups.", {"entities": [[59, 61, "Frequency"], [63, 67, "Duration"], [73, 77, "Duration"]]}], [1697, "* p < 0.05, significant compared with SA group by Student\u2019s t-test.", {"entities": [[38, 40, "Frequency"]]}], [1698, "ND: Not detected.", {"entities": []}], [1699, "RGE: red ginseng extract.", {"entities": [[0, 3, "Herb name"], [5, 24, "Herb name"]]}], [1700, "Data are expressed as mean \u00b1 SD from three rats of control and 1WRA groups.", {"entities": [[63, 67, "Frequency"]]}], [1701, "HDL: high-density lipoprotein; LDL: low-density lipoprotein.", {"entities": [[0, 3, "Parameter"], [5, 29, "Parameter"], [31, 34, "Parameter"], [36, 59, "Parameter"]]}], [1702, "Pharmacokinetic parameters of methotrexate following intravenous injection of methotrexate at a dose of 3 mg/kg.", {"entities": [[30, 42, "Drug"], [78, 90, "Drug"], [104, 111, "Amount"]]}], [1703, "Data are expressed as mean \u00b1 SD from four rats of control and six rats of 1WRA groups.", {"entities": [[37, 85, "Cohort"]]}], [1704, "* p < 0.05, significant compared with SA group by Student\u2019s t-test.", {"entities": [[38, 40, "Frequency"]]}], [1705, "C", {"entities": []}], [1706, "The first two authors contributed equally to this work.", {"entities": []}], [1707, "Context: Danshen tablets (DST), an effective traditional Chinese multi-herbal formula, are often combined with atorvastatin calcium (AC) for treating coronary heart disease in the clinic.", {"entities": [[9, 30, "Herb name"], [57, 64, "Ethnic group"], [111, 136, "Drug"], [150, 172, "Pathology"]]}], [1708, "Objective: This study investigated the effects of DST on the pharmacokinetics of AC and the potential mechanism.", {"entities": [[50, 53, "Herb name"], [81, 83, "Drug"]]}], [1709, "Materials and methods: The pharmacokinetics of AC (1\u2009mg/kg) with or without pretreatment of DST (100\u2009mg/kg) were investigated using LC-MS/MS.", {"entities": [[47, 49, "Drug"], [51, 58, "Amount"], [92, 95, "Herb name"], [97, 106, "Amount"]]}], [1710, "The effects of DST (50\u2009\u03bcg/mL) on the metabolic stability of AC were also investigated using rat liver microsome incubation systems.", {"entities": [[15, 18, "Herb name"], [20, 28, "Amount"], [60, 62, "Drug"]]}], [1711, "Results: The results indicated that C Discussion and conclusions: This study indicated that the main components in DST could accelerate the metabolism of AC in rat liver microsomes and change the pharmacokinetic behaviors of AC.", {"entities": [[115, 118, "Herb name"], [154, 156, "Drug"], [225, 227, "Drug"]]}], [1712, "So these results showed that the herb-drug interaction between DST and AC might occur when they were co-administered.", {"entities": [[63, 66, "Herb name"], [71, 73, "Drug"]]}], [1713, "Therefore, the clinical dose of AC should be adjusted when DST and AC are co-administered.", {"entities": [[32, 34, "Drug"], [59, 62, "Herb name"], [67, 69, "Drug"]]}], [1714, "Atorvastatin, a synthetic and lipophilic statin, inhibits 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, the rate-limiting enzyme in cholesterol biosynthesis (Dybro et\u00a0al.", {"entities": [[0, 12, "Drug"], [58, 115, "Target"]]}], [1715, "2016; Eng et\u00a0al.", {"entities": []}], [1716, "2016; Cruz-Correa et\u00a0al.", {"entities": []}], [1717, "2017; Dennison et\u00a0al.", {"entities": []}], [1718, "2017).", {"entities": []}], [1719, "Atorvastatin is commonly prescribed for the treatment of hypercholesterolemia and for the prevention of coronary heart disease (Kadam et\u00a0al.", {"entities": [[0, 12, "Drug"], [57, 77, "Pathology"], [104, 140, "Pathology"]]}], [1720, "2016; Liu et\u00a0al.", {"entities": []}], [1721, "2016; Bautista et\u00a0al.", {"entities": []}], [1722, "2017; Kasabri et\u00a0al.", {"entities": []}], [1723, "2017; Kashihara et\u00a0al.", {"entities": []}], [1724, "2017).", {"entities": []}], [1726, "2016; Shu et\u00a0al.", {"entities": []}], [1727, "2016; Wang et\u00a0al.", {"entities": []}], [1728, "2016).", {"entities": []}], [1729, "Most of the statins, except pravastatin, are metabolized by the cytochrome P450 (CYP) enzymes (Wei and Zhang 2015; Hsiao et\u00a0al.", {"entities": [[12, 19, "Drug"], [28, 39, "Drug"]]}], [1730, "2016).", {"entities": []}], [1731, "Interactions involving CYP are therefore possible.", {"entities": []}], [1732, "For example, itraconazole has been shown to increase the area under the plasma concentration-time curve (AUC) of atorvastatin acid and lactone by three- and four-fold, respectively (Higgins et\u00a0al.", {"entities": [[13, 25, "Drug"], [57, 109, "Parameter"], [113, 130, "Drug"]]}], [1733, "2014; Dybro et\u00a0al.", {"entities": []}], [1734, "2016).", {"entities": []}], [1735, "Danshen tablets (DST), an effective traditional Chinese multi-herbal formula, are widely used in treating cardiovascular diseases (Shi et\u00a0al.", {"entities": [[0, 20, "Herb name"], [48, 55, "Ethnic group"], [106, 129, "Pathology"]]}], [1736, "2016; Yin et\u00a0al.", {"entities": []}], [1737, "2016; Zhang et\u00a0al.", {"entities": []}], [1738, "2016; Yao et\u00a0al.", {"entities": []}], [1739, "2017).", {"entities": []}], [1740, "As we know, atorvastatin calcium (AC) and DST are often simultaneously used for treating coronary heart disease in Chinese clinics.", {"entities": [[12, 37, "Drug"], [42, 45, "Herb name"], [89, 111, "Pathology"], [115, 122, "Ethnic group"]]}], [1741, "However, it is unknown whether there is an interaction between AC and DST.", {"entities": [[63, 65, "Drug"], [70, 73, "Herb name"]]}], [1742, "A better understanding of the pharmacokinetic interaction between DST and AC would help link data from pharmacological assays to clinical effects, thus facilitating the design of rational dosage regimens and avoiding the occurrence of adverse reactions (Yang et\u00a0al.", {"entities": [[66, 69, "Herb name"], [74, 76, "Drug"], [235, 252, "Pathology"]]}], [1743, "2011).", {"entities": []}], [1744, "This study investigates the effects of DST on the pharmacokinetics of AC in rats, and to clarify the herb-drug interaction potential between DST and AC.", {"entities": [[39, 42, "Herb name"], [70, 72, "Drug"], [141, 144, "Herb name"], [149, 151, "Drug"]]}], [1745, "Standards of AC (purity\u2009>98%) and simvastatin (purity\u2009>98%) was purchased from the National Institute for the Control of Pharmaceutical and Biological Products (Beijing, China).", {"entities": [[13, 15, "Drug"]]}], [1746, "This animal experimental protocol was approved by the Animal Ethics Committee of the Second Military Medical University.", {"entities": []}], [1747, "Male Sprague\u2013Dawley rats weighing 220\u2013250\u2009g were supplied by Sino\u2013British Sippr/BK Lab Animal Ltd (Shanghai, China).", {"entities": [[0, 4, "Sex"]]}], [1748, "The rats were maintained in an air-conditioned animal quarter at 22\u2009\u00b1\u20092\u2009\u00b0C and 50\u2009\u00b1\u200910% relative humidity.", {"entities": []}], [1749, "Water and food (Laboratory Rodent Chow, Shanghai, China) were allowed ad libitum.", {"entities": []}], [1750, "The animals were acclimatized to the facilities for five days, and then fasted with free access to water for 12\u2009h prior to each experiment.", {"entities": [[52, 61, "Duration"], [109, 113, "Duration"]]}], [1751, "The analysis was performed on an Agilent 1290 series liquid chromatography system (Agilent Technologies, Palo Alto, CA, USA) that included a binary pump, an on-line vacuum degasser, a surveyor autosampling system, a column temperature controller and an Agilent 6460 triple-quadrupole mass spectrometer (Agilent Technologies, CA, USA) with Turbo Ion spray, which is connected to the liquid chromatography system.", {"entities": []}], [1752, "The Agilent MassHunter B 4.0 (Agilent Technologies, CA, USA) software was used to control the equipment and for data acquisition.", {"entities": []}], [1753, "The chromatographic analysis of AC was performed on a Waters X-Bridge C18 column (Milford, MA, USA) (3.0\u2009\u00d7\u2009100\u2009mm, i.d.", {"entities": [[32, 34, "Drug"]]}], [1754, "; 3.5\u2009\u03bcm) at room temperature.", {"entities": []}], [1755, "The mobile phase was water (containing 0.1% formic acid) and acetonitrile (30:70, v:v) at a flow rate of 0.4\u2009mL/min.", {"entities": []}], [1756, "The mass scan mode was the positive MRM mode.", {"entities": []}], [1757, "The precursor ion and product ion were m/z 559.2 \u2192 440.2 for AC and m/z 419.9 \u2192 199.4 for the simvastatin, respectively.", {"entities": [[61, 63, "Drug"], [94, 105, "Drug"]]}], [1758, "The collision energy for AC and simvastatin were 30 and 25\u2009eV, respectively.", {"entities": [[25, 27, "Drug"], [32, 43, "Drug"]]}], [1759, "The MS/MS conditions were optimized as follows: fragmentor, 140\u2009V; capillary voltage, 4\u2009kV; nozzle voltage, 500\u2009V; nebulizer gas pressure (N The stock solution of AC and simvastatin were prepared in methanol at a concentration of 2.00 and 1.00\u2009mg/mL, respectively.", {"entities": [[163, 165, "Drug"], [170, 181, "Drug"]]}], [1760, "The stock solutions of atorvastatin were further diluted with methanol to give a series of standard solution in the range of 5\u20132500\u2009ng/mL, from which the spiked plasma samples were prepared by appropriate dilution.", {"entities": [[23, 35, "Drug"]]}], [1761, "Quality control (QC) samples were prepared at low (2\u2009ng/mL), medium (50\u2009ng/mL) and high (400\u2009ng/mL) concentrations in the same way as the plasma samples for calibration.", {"entities": []}], [1762, "Each plasma sample (100\u2009\u03bcL) was spiked with 10\u2009\u03bcL of the simvastatin (0.5\u2009\u03bcg/mL).", {"entities": [[57, 68, "Drug"], [70, 79, "Amount"]]}], [1763, "The mixture was then extracted with 190\u2009\u03bcL of acetonitrile by vortexing for 1\u2009min, and centrifuged at 12,000\u2009rpm for 10\u2009min.", {"entities": []}], [1764, "The supernatant was removed into an injection vial, and a 3\u2009\u03bcL aliquot was injected into the LC-MS/MS system for analysis.", {"entities": []}], [1765, "The method validation assays were performed according to the United States Food and Drug Administration (FDA) guidelines.", {"entities": []}], [1766, "Specificity was investigated by analyzing six individual blank rat plasma samples, which were compared to those obtained by the spiking analyte and IS into the corresponding blank plasma sample to monitor interference.", {"entities": []}], [1767, "For the calibration curve, nine concentrations of calibration standards (1, 2, 5, 10, 20, 50, 100, 200 and 500\u2009ng/mL) were processed and determined as described above.", {"entities": []}], [1768, "The calibration curves for AC were constructed by plotting peak area ratios of the analyte to simvastatin against plasma concentrations.", {"entities": [[27, 29, "Drug"], [94, 105, "Drug"]]}], [1769, "The lower limit of quantification (LLOQ) was determined as the concentration of the analyte with a signal-to-noise ratio of 10.", {"entities": []}], [1770, "To determine intra-day precision and accuracy, six replicates of QC samples at low, medium and high concentration levels (2, 50, and 400\u2009ng/mL) were prepared and analyzed on the same day.", {"entities": []}], [1771, "Inter-day precision and accuracy were evaluated on three independent days.", {"entities": []}], [1772, "The intra- and inter-day precisions were expressed as the relative standard deviation (RSD) value and the accuracy as the RE value.", {"entities": []}], [1773, "The extraction recovery was determined by calculating the ratio of QC (2, 50, and 400\u2009ng/mL) samples obtained against those originally spiked in the blank plasma; this step was replicated six times.", {"entities": []}], [1774, "The matrix effect was evaluated by comparing the solution spiked with the blank processed matrix with the solution at three different QC concentrations; this step was replicated six times.", {"entities": []}], [1775, "The extraction recovery and matrix effect of the IS were also determined.", {"entities": []}], [1777, "The long-term stability was assessed by storing the QC samples at \u221240\u2009\u00b0C for 15\u2009days.", {"entities": [[77, 84, "Duration"]]}], [1778, "For pharmacokinetic study in vivo, 12 rats were equally randomized to two groups, six rats in each group, including AC-only group (1\u2009mg/kg) (A) and AC (1\u2009mg/kg)\u2009+\u2009DST (100\u2009mg/kg) group (B).", {"entities": [[20, 33, "Study"], [116, 118, "Drug"], [131, 138, "Amount"], [148, 150, "Drug"], [152, 159, "Amount"], [162, 166, "Herb name"], [167, 177, "Amount"]]}], [1779, "The AC and DST fraction powders were all homogenized in water solution with a mortar and pestle.", {"entities": [[4, 6, "Drug"], [11, 14, "Herb name"]]}], [1780, "Blood samples (0.25\u2009mL) were collected into a heparinized tube via the oculi chorioideae vein before drug administration and at 0.083, 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12 and 24\u2009h after drug administration.", {"entities": []}], [1781, "After centrifuging at 3500\u2009rpm for 10\u2009min, the supernatant was obtained and frozen at \u221240\u2009\u00b0C until analysis.", {"entities": []}], [1782, "Plasma data was subjected to non-compartmental pharmacokinetic analysis by using DAS version 3.0 (BioGuider Co., Shanghai, China), and parameters were calculated.", {"entities": []}], [1783, "The maximum plasma concentration (C Rat liver microsomes were used to determine the metabolic rate of AC.", {"entities": [[102, 104, "Drug"]]}], [1784, "The assay conditions and reaction mixtures were similar as reported previously (Qi et\u00a0al.", {"entities": []}], [1785, "2013; Qin et\u00a0al.", {"entities": []}], [1786, "2014).", {"entities": []}], [1787, "The reaction mixture was incubated at 37\u2009\u00b0C for 5\u2009min and then AC (100\u2009\u03bcM) was added.", {"entities": [[48, 53, "Duration"], [63, 65, "Drug"]]}], [1788, "The effects of DST on the metabolic rate of AC was investigated by adding 50\u2009\u03bcg/mL of DST to rat liver microsomes and preincubating for 30\u2009min at 37\u2009\u00b0C, and then AC (100\u2009\u03bcM) was added.", {"entities": [[15, 18, "Herb name"], [44, 46, "Drug"], [74, 82, "Amount"], [86, 89, "Herb name"], [136, 142, "Duration"], [162, 164, "Drug"], [165, 172, "Amount"]]}], [1789, "Aliquots of 30\u2009\u03bcL were collected from reaction volumes at 0, 1, 3, 5, 15, 30 and 60\u2009min and 60\u2009\u03bcL ice-cold acetonitrile was added to terminate the reaction, and then the sample preparation method was the same as the plasma sample preparation method and determined by LC-MS/MS.", {"entities": []}], [1790, "The half-life (t Experimental values are expressed as mean\u2009\u00b1\u2009SD.", {"entities": []}], [1791, "Statistical analysis of results obtained from clinical study was performed using Student\u2019s paired t-test.", {"entities": []}], [1792, "Differences were considered statistically significant when p values were <0.05.", {"entities": []}], [1793, "Statistical analysis was conducted using Graph-Pad Prism version 3.0 for Windows (San Diego, CA, USA).", {"entities": []}], [1794, "Due to the heterogeneous nature of plasma, a sample pretreatment procedure is often needed to remove protein and potential interfering substances before the LC-MS/MS analysis.", {"entities": []}], [1795, "Currently, the most widely used biological sample preparation methods are protein precipitation, solid phase extraction and liquid-liquid extraction.", {"entities": []}], [1796, "All of these sample pretreatment methods were investigated to achieve good resolution and high recovery of the analyte from spiked biological matrices.", {"entities": []}], [1797, "Finally, protein precipitation was selected for AC.", {"entities": [[48, 50, "Drug"]]}], [1798, "The highest recovery was obtained using acetonitrile as a protein precipitant.", {"entities": []}], [1799, "In the present study, the selectivity was examined using independent plasma samples from six different rats.", {"entities": []}], [1800, "As shown in Figure 1, no obvious interference was observed in the representative chromatogram of a blank plasma sample at the retention times of the analyte and IS.", {"entities": []}], [1801, "(A) Representative chromatograms of blank plasma; (B) blank plasma spiked with AC (1) and simvastatin (2).", {"entities": [[79, 81, "Drug"], [90, 101, "Drug"]]}], [1802, "Linearity for AC was obtained over the concentration range of 1\u2013500\u2009ng/mL.", {"entities": [[14, 16, "Drug"]]}], [1803, "A typical calibration curve was y\u2009=\u20090.0157x\u2009+ 0.00312 (r The precision and accuracy data for the plasma samples are presented in Table 1.", {"entities": []}], [1804, "The intra- and inter-day precision values (RSD) were less than 10%, and the accuracy (RE) ranged from \u22126.89 to 8.00%.", {"entities": []}], [1805, "These data indicated that the accuracy and precision of the method were satisfactory.", {"entities": []}], [1806, "The intra-day and inter-day precision and accuracy of AC in plasma samples (n\u2009=\u20096).", {"entities": [[54, 56, "Drug"]]}], [1807, "The matrix effects were examined to assess the possibility of ion suppression or enhancement.", {"entities": []}], [1808, "The matrix effects ranged from 91.25 to 95.68% for AC over the three levels of QC samples.", {"entities": [[51, 53, "Drug"]]}], [1809, "The results indicated that no obvious matrix effects were present.", {"entities": []}], [1810, "The overall mean recoveries of AC in plasma at the three different concentration levels were found to be 87.65\u201393.51% with a RSD less than 10%, which indicated that the extraction procedure was consistent and reproducible.", {"entities": [[31, 33, "Drug"]]}], [1811, "The results of the short-term stability, auto-sampler stability, freeze and thaw stability and long-term stability are shown in Table 2.", {"entities": []}], [1812, "It was demonstrated that the stability offered by this method was satisfactory, with the REs and RSD for all samples within the general assay acceptability criteria.", {"entities": []}], [1813, "These results showed that the samples were sufficiently stable to allow for routine analysis as part of the pharmacokinetic study of AC.", {"entities": [[133, 135, "Drug"]]}], [1814, "Stability of AC in plasma samples (n\u2009=\u20093).", {"entities": [[13, 15, "Drug"]]}], [1815, "The mean concentration-time curve of AC in the two treatments is shown in Figure 2, and all the pharmacokinetic parameters are shown in Table 3.", {"entities": [[9, 33, "Parameter"], [37, 39, "Drug"]]}], [1816, "The results indicated that the C The mean concentration-time curves in rat plasma after oral administration of single AC or both AC and DST.", {"entities": [[118, 120, "Drug"], [129, 131, "Drug"], [136, 139, "Herb name"]]}], [1817, "Pharmacokinetic parameters of AC in male Sprague\u2009\u2212\u2009Dawley rats following oral administration of AC alone or both AC and DST.", {"entities": [[30, 32, "Drug"], [36, 40, "Sex"], [96, 98, "Drug"], [113, 115, "Drug"], [120, 123, "Herb name"]]}], [1818, "p\u2009<\u20090.05 indicate significant differences from the control.", {"entities": []}], [1819, "As we know, the metabolism of AC was mainly modulated by CYP3A4 enzymes, and therefore, in this research, the effects of DST on the metabolic stability of AC were further investigated in rat liver microsomes in vitro.", {"entities": [[30, 32, "Drug"], [121, 124, "Herb name"], [155, 157, "Drug"]]}], [1820, "The metabolic stability of AC was 42.5\u2009\u00b1\u20096.1\u2009min, while the metabolic stability was decreased (25.7\u2009\u00b1\u20095.2\u2009min) in the presence of DST.", {"entities": [[27, 29, "Drug"], [130, 133, "Herb name"]]}], [1821, "The results indicated that the main components in DST could accelerate the metabolism of AC in rat liver microsomes and change the pharmacokinetic behaviors of AC.", {"entities": [[50, 53, "Herb name"], [89, 91, "Drug"], [160, 162, "Drug"]]}], [1822, "Therefore, we infer that DST could also affect the pharmacokinetic profiles of other statins (simvastatin, lovastatin) as they were also metabolized by the CYP3A4 enzymes, and herb-drug interactions should also occur when they are co-administered.", {"entities": [[25, 28, "Herb name"], [85, 92, "Drug"], [94, 105, "Drug"], [107, 117, "Drug"]]}], [1823, "In conclusion, the results indicated that DST could influence the pharmacokinetic behavior of AC when they are co-administered.", {"entities": [[42, 45, "Herb name"], [94, 96, "Drug"]]}], [1824, "The main ingredients in DST could accelerate the metabolism of AC in rat liver microsomes, and the metabolic stability of AC was decreased, which may be one of the reasons resulting in pharmacokinetic interactions when they are co-administered.", {"entities": [[24, 27, "Herb name"], [63, 65, "Drug"], [122, 124, "Drug"]]}], [1825, "Therefore, the clinical dose of AC should be adjusted when DST and AC are co-administered.", {"entities": [[32, 34, "Drug"], [59, 62, "Herb name"]]}], [1826, "The authors of this manuscript declare no conflict of interest.", {"entities": []}], [1827, " Edited by:   Reviewed by:    These authors have contributed equally to this work and share first authorship This article was submitted to Ethnopharmacology, a section of the journal Frontiers in Pharmacology  Background: Digoxin is one of the most widely and commonly used cardiac drug, which plays an irreplaceable role in treating heart failure and arrhythmia.", {"entities": [[222, 229, "Drug"], [334, 347, "Pathology"], [352, 362, "Pathology"]]}], [1828, "Its effective plasma drug concentration is close to the toxic concentration, and large individual differences in the effects of the drug have been observed.", {"entities": []}], [1829, "Most of the reported drug interactions are with Western drugs.", {"entities": []}], [1830, "However, there are many combinations of traditional Chinese medicine (TCM) and Western drugs, TCM interacting with digoxin comprises monomer components, single medicines, and Chinese patent medicines.", {"entities": [[52, 59, "Ethnic group"], [115, 122, "Drug"], [175, 182, "Ethnic group"]]}], [1831, "Aim of the study: We aimed i) to provide an overview of the TCM formulations affecting the pharmacology of digoxin and their mechanisms of action and ii) to provide a theoretical reference for the safe and rational use of digoxin in combination with TCM in clinical practice and to avoid ADRs.", {"entities": [[107, 114, "Drug"], [222, 229, "Drug"], [288, 292, "Pathology"]]}], [1832, "Methods: A literature search of electronic databases, including PubMed, MEDLINE, Cochrane Library, Web of Science, China National Knowledge Infrastructure, and WANFANG Data, was performed to search for articles published between 1 January 1960, and 1 August 2022.", {"entities": []}], [1833, "Search terms used included \u201cdigoxin,\u201d \u201ctraditional Chinese medicine,\u201d \u201cChinese patent medicine,\u201d and \u201cadverse reactions\u201d and their combinations.", {"entities": [[28, 35, "Drug"], [51, 58, "Ethnic group"], [71, 78, "Ethnic group"], [102, 119, "Pathology"]]}], [1834, "Results: A total of 49 articles were obtained, including clinical reports, pharmacological experiments and in vitro experiments.", {"entities": []}], [1835, "The mechanisms of action affecting the pharmacology of digoxin are complex.", {"entities": [[55, 62, "Drug"]]}], [1836, "TCM formulations may affect the pharmacology of digoxin in vivo by influencing gastrointestinal motility or gastric juice pH, regulating P-glycoprotein levels, exerting cumulative pharmacological effects, and enhancing the sensitivity of the heart to digoxin.", {"entities": [[48, 55, "Drug"], [79, 104, "Parameter"], [108, 124, "Parameter"], [126, 158, "Parameter"], [251, 258, "Drug"]]}], [1837, "Although studies have shown that some TCM formulations interact with digoxin, they may be influenced by the complexity of the composition and the pharmacological effects of the TCM, the sensitivity of digoxin concentration determination methods, etc.", {"entities": []}], [1838, "The results of existing studies are controversial and further in-depth studies are required.", {"entities": []}], [1839, "Conclusion: Combinations of digoxin and TCM formulations are commonly used.", {"entities": [[28, 35, "Drug"]]}], [1840, "This article serves as a reference to understand the interactions between TCM formulations and digoxin to avoid the occurrence of ADRs and improve the efficacy and safety of digoxin.", {"entities": [[95, 102, "Drug"], [130, 134, "Pathology"], [174, 181, "Drug"]]}], [1841, "Digoxin is a pure preparation derived from the leaves of Digitalis lanata Ehrh (Maohuayangdihuang).", {"entities": [[0, 7, "Drug"], [57, 98, "Herb name"]]}], [1842, "It is a cardiac glycoside commonly used in clinical practice for the treatment of heart failure, atrial fibrillation, and other arrhythmias (Srinivasan et al., 2020).", {"entities": [[82, 95, "Pathology"], [97, 116, "Pathology"], [128, 139, "Pathology"]]}], [1843, "There is significant individual variation in patient response to digoxin therapy, and an important reason for this variation is that the disposition and sensitivity of patients to the drug vary greatly.", {"entities": [[65, 72, "Drug"]]}], [1844, "Digoxin shows large individual variation in vivo.", {"entities": [[0, 7, "Drug"]]}], [1846, "Moreover, its efficacy is influenced by several factors (Liu et al., 2016), including drug interactions.", {"entities": []}], [1847, "Digoxin is one of the 10 drugs with the most drug interactions, and the incidence of adverse reactions (ADRs) due to interactions is as high as 27% (Sun, 1982).", {"entities": [[0, 7, "Drug"], [85, 109, "Pathology"]]}], [1848, "Most of these reports and studies are on combinations with Western drugs.", {"entities": []}], [1849, "In this paper, we summarize the interactions of digoxin with other drugs and their mechanisms of action from a pharmacological point of view by summarizing basic research, clinical studies, treatment guidelines and monographs, to provide a reference for its safe clinical use.", {"entities": [[48, 55, "Drug"], [172, 188, "Study"]]}], [1850, "A literature search of electronic databases, including PubMed, MEDLINE, Cochrane Library, Web of Science, China National Knowledge Infrastructure, and WANFANG Data, was performed to search for articles published between 1 January 1960 and 1 August 2022.", {"entities": []}], [1851, "Search terms used included \u201cdigoxin\u201d, \u201cChinese medicine\u201d, \u201ctraditional Chinese medicine\u201d, \u201cChinese patent medicine\u201d, \u201cadverse reactions\u201d and their combinations.", {"entities": [[28, 35, "Drug"], [71, 78, "Ethnic group"], [91, 98, "Ethnic group"], [118, 135, "Pathology"]]}], [1852, "The inclusion criteria included the following: a.", {"entities": []}], [1853, "Clear literatures on the experimental and clinical research on the interactions between TCM formulations and digoxin.", {"entities": [[109, 116, "Drug"]]}], [1854, "b. Literatures written in English and Chinese.", {"entities": [[38, 45, "Ethnic group"]]}], [1855, "The exclusion criteria were as follows: a. Literatures without mechanisms of interactions between TCM formulations and digoxin; b.", {"entities": [[119, 126, "Drug"]]}], [1856, "Literature review, expert experience introduction and other types of literature; c. For the content of the repeatedly published literature.", {"entities": []}], [1857, "A total of 49 articles were obtained, including clinical reports, pharmacological experiments and in vitro experiments which were reviewed to determine the mechanism of interactions between TCM and digoxin.", {"entities": [[198, 205, "Drug"]]}], [1858, "Oral and injectable digoxin formulations exist.", {"entities": [[20, 27, "Drug"]]}], [1859, "Because the injection is prone to ADRs and is only suitable for patients with severe heart failure requiring immediate treatment, oral formulations are more frequently used.", {"entities": [[34, 38, "Pathology"], [78, 98, "Pathology"]]}], [1860, "Thus, this article focuses on the pharmacokinetic processes of oral formulations.", {"entities": []}], [1861, "Digoxin is absorbed orally through the small intestine, with incomplete and irregular absorption.", {"entities": [[0, 7, "Drug"]]}], [1862, "The absorption rate is about 75%, the onset of action is at 0.5\u20132\u00a0h, the peak plasma concentration is observed at 2\u20133\u00a0h, and the maximum effect is observed at 4\u20138\u00a0h. After absorption, it is widely distributed to various tissues, such as the heart, bone, muscle, liver, and kidney (Bai et al., 2014).", {"entities": [[73, 98, "Parameter"]]}], [1863, "In addition, some bacteria present in the gastrointestinal tract may affect the pharmacokinetic parameters of digoxin.", {"entities": [[110, 117, "Drug"]]}], [1864, "Drug transporters are among the main factors affecting the in vivo disposal of drugs.", {"entities": []}], [1865, "P-glycoprotein (P-gP), which belongs to the superfamily of ATP-binding cassette (ABC) transporters, is the main efflux protein in humans.", {"entities": []}], [1866, "P-gP is mainly expressed on capillary endothelial cells in the small intestine, liver, kidney, and blood-brain barrier (Thiebaut et al., 1987).", {"entities": []}], [1867, "Its main function is to excrete intracellular toxic substances and exogenous substances such as drugs through the gastrointestinal tract, bile, or urine.", {"entities": []}], [1868, "Since the activity of P-gP can affect the plasma concentration, bioavailability, tissue distribution, and liver and kidney clearance rate (CL) of the drug (Herfindal et al., 2011), during co-administration, certain drugs can act as substrates, P-gP inhibitors, or P-gP inducers, causing changes in the plasma concentration of the co-administered drugs leading to interactions.", {"entities": [[42, 62, "Parameter"], [64, 79, "Parameter"], [81, 100, "Parameter"], [106, 142, "Parameter"], [244, 248, "Target"], [264, 268, "Target"], [302, 322, "Parameter"]]}], [1869, "Digoxin is a substrate of P-gP.", {"entities": [[0, 7, "Drug"], [26, 31, "Target"]]}], [1870, "P-gP mediates the renal excretion of digoxin while promoting the absorption process in the small intestine (Mamidi, et al., 2017).", {"entities": [[0, 4, "Target"], [37, 44, "Drug"]]}], [1872, "Digoxin belongs to cardiac glycosides and has a positive inotropic effect.", {"entities": [[0, 7, "Drug"]]}], [1873, "It acts directly on myocardial cells, inhibits Na Low blood potassium level is the most important factor affecting digoxin toxicity (Du et al., 2016).", {"entities": [[47, 49, "Target"], [115, 122, "Drug"]]}], [1874, "Blood potassium levels are positively correlated with cardiomyocyte potassium channel permeability, and low potassium levels inhibit cardiomyocyte potassium outflow, leading to increased cardiac autoregulation and inducing cardiac arrhythmias caused by cardiac glycosides.", {"entities": [[0, 22, "Parameter"], [223, 242, "Pathology"]]}], [1875, "Endogenous digoxin substances are present in neonates and patients with renal dysfunction, and these substances may lead to elevated or false-positive digoxin plasma concentration monitoring results.", {"entities": [[11, 18, "Drug"], [58, 66, "Pathology"], [72, 89, "Pathology"], [151, 158, "Drug"]]}], [1876, "Patients with higher body weight have a large V Pharmacogenomic studies of digoxin revealed that polymorphisms at certain loci can affect the metabolism and action of digoxin.", {"entities": [[0, 8, "Pathology"], [40, 71, "Study"], [75, 82, "Drug"], [167, 174, "Drug"]]}], [1877, "Yan et al.", {"entities": []}], [1878, "Based on our analysis of the literature, the mechanism of interaction between TCM formulations and digoxin is as follows: A.", {"entities": [[99, 106, "Drug"]]}], [1879, "Effect of TCM on Pharmacodynamics mechanism of digoxin iii) synergistic drug effects may occur, increasing the risk of digoxin poisoning; iv) they may enhance the sensitivity of the heart to digoxin and increase the risk of poisoning; and v) they may antagonize the ADRs caused by digoxin (Figure 1).", {"entities": [[47, 54, "Drug"], [119, 126, "Drug"], [191, 198, "Drug"], [266, 270, "Pathology"], [281, 288, "Drug"]]}], [1880, "Schematic diagram of the mechanism of action between digoxin and traditional Chinese medicine.", {"entities": [[53, 60, "Drug"], [77, 84, "Ethnic group"]]}], [1881, "TCM formulations containing tropane alkaloids, such as belladonna tablets, increase the absorption and accumulation of cardiac glycosides in muscle tissue because of the relaxing effect of tropane alkaloids on smooth muscle tissue and reduced gastrointestinal motility, especially in patients with heart failure who are sensitive to the effects of cardiac glycosides and prone to toxic reactions.", {"entities": [[28, 45, "Herb name"], [55, 73, "Herb name"], [88, 137, "Parameter"], [189, 206, "Herb name"], [243, 268, "Parameter"], [284, 292, "Pathology"], [298, 311, "Pathology"]]}], [1882, "Two groups were given gastrin and normal saline respectively in addition to  Wheat bran is the seed coat of the grass plant wheat, which harmonizes the middle and benefits the spleen (Wu et al., 2014).", {"entities": [[77, 87, "Herb name"]]}], [1883, "TCM extracts: A study on the effect of citronellal on intestinal absorption of digoxin in vivo and in vitro was carried out.", {"entities": [[39, 50, "Herb name"], [54, 75, "Parameter"], [79, 86, "Drug"], [87, 107, "Study"]]}], [1884, "In vivo, digoxin was administered intravenously to control rats and citronellal pretreated experimental rats, and in vitro, the transcellular transport of   Single TCM: Single TCM formulations that are capable of inhibiting or downregulating P-gP include Conioselinum anthriscoides \u201cChuanxiong\u201d (Chuanxiong), Vernonia amygdalina (Biantaobanjiuju), Tapinanthus sessilifolius, Carica papaya (Mugua) and Ginkgo biloba L. (Yinxing).", {"entities": [[9, 16, "Drug"], [68, 79, "Herb name"], [242, 246, "Target"], [255, 307, "Herb name"], [309, 346, "Herb name"], [348, 373, "Herb name"], [375, 396, "Herb name"], [401, 427, "Herb name"]]}], [1885, "In addition to inhibiting P-gP expression by affecting intracellular Ca  Chinese patent medicine and decoction: Wuzhi Tablet is an ethanolic extract preparation of S. chinensis (Turcz.)", {"entities": [[26, 30, "Target"], [73, 80, "Ethnic group"], [112, 124, "Herb name"], [131, 160, "Extraction process"], [164, 176, "Herb name"]]}], [1886, "Baill.", {"entities": []}], [1887, "(Wuweizi), which is a commonly used hepatoprotective drug (Xin et al., 2011).", {"entities": [[1, 8, "Herb name"]]}], [1888, "In combination with digoxin, S. chinensis (Turcz.)", {"entities": [[20, 27, "Drug"], [29, 41, "Herb name"]]}], [1889, "Baill.", {"entities": []}], [1890, "Baill.", {"entities": []}], [1891, "(Wuweizi) alcohol B is the strongest.", {"entities": [[0, 19, "Herb name"]]}], [1892, "Experiments in mice have shown that the AUC of digoxin is increased by gavage and intravenous injection.", {"entities": [[40, 43, "Parameter"], [47, 54, "Drug"]]}], [1893, "Shaoyaogancao decoction is described in Zhang Zhongjing\u2019s Treatise on Febrile Diseases.", {"entities": [[0, 23, "Herb name"], [70, 86, "Pathology"]]}], [1894, "It consists of two herbs, Paeonia lactiflora Pall (Baishao) and Glycyrrhiza glabra L. (Gancao).", {"entities": [[26, 59, "Herb name"], [64, 94, "Herb name"]]}], [1895, "Some studies suggest that TCM formulations with induction effects on P-gP include silymarin, auraptene, Bupleurum chinense DC.", {"entities": [[69, 73, "Target"], [82, 91, "Herb name"], [93, 102, "Herb name"], [104, 125, "Herb name"]]}], [1897, "Silymarin significantly induces mRNA expression of P-gP and may decrease the bioavailability of digoxin and reduce its efficacy (Wang, 2019), but a study from the University of Mississippi showed no significant effect of silymarin on pharmacokinetic parameters such as AUC, C Homology of medicine and food means that food and medicine have the same efficacy and no clear boundary in regulating human physiological function, and have the homology of source, composition and theory (Jia et al., 2021).", {"entities": [[0, 9, "Herb name"], [32, 55, "Target"], [77, 92, "Parameter"], [96, 103, "Drug"], [221, 230, "Herb name"], [269, 272, "Parameter"]]}], [1898, "Medicinal and edible homologous varieties interacting with digoxin include Citrus juices, Purple grape, Green tea and Areca catechu L. (Dasuan).", {"entities": [[59, 66, "Drug"], [75, 88, "Herb name"], [90, 102, "Herb name"], [104, 113, "Herb name"], [118, 143, "Herb name"]]}], [1899, "Citrus juices such as orange juice, lemon juice, grape juice, and grapefruit juice contain a variety of flavonoid components with similar modulatory activity on digoxin transport as P-gP inhibitors, but the strength and characteristics of the effects depend on the distribution and classification of the flavonoid components (Xu et al., 2003).", {"entities": [[22, 34, "Herb name"], [36, 47, "Herb name"], [49, 60, "Herb name"], [66, 82, "Herb name"], [104, 113, "Herb name"], [161, 168, "Drug"], [182, 186, "Target"], [304, 313, "Herb name"]]}], [1900, "Purple grape is widely used for its health effects such as antioxidant activity, free radical scavenging, and anti-aging effects, and a study on the effect of purple grape on the pharmacokinetic parameters of digoxin in rats have confirmed that purple grape juice can inhibit P-gP in the gastrointestinal tract wall, and when used in combination with digoxin, it can increase pharmacokinetic parameters such as AUC (92.27%, 18.37 \u00b1 1.67\u00a0ng\u00a0h/mL to 35.32 \u00b1 5.58\u00a0ng\u00a0h/mL) and C  Venenum bufonis (Chansu) is the dried white pulp secreted from the skin glands and post-auricular glands of the Chinese toad or the black orbital toad, family Toadidae.", {"entities": [[0, 12, "Herb name"], [159, 171, "Herb name"], [209, 216, "Drug"], [245, 263, "Herb name"], [276, 280, "Target"], [351, 358, "Drug"], [411, 414, "Parameter"], [416, 468, "Amount"], [589, 596, "Ethnic group"]]}], [1901, "The composition is complex, and the main components are toad toxin and toad venom ligands, all of which have the structure of cardiac glycosides of the toad steroidal dienolactone type, and animal experiments and clinical practice have proved that toad crisp, toad toxin, and toad venom ligands have cardiotonic effects, and their properties of action are similar to those of digitalis, but the cardiotonic effect is weaker (Dong, 2009; Chen, 2014).", {"entities": [[376, 385, "Drug"]]}], [1902, "The crude venom of toad and one of its main components, toad venom ling, can enhance electrically driven contraction of isolated rat atria, constrict rat aortic rings, inhibit Na Commonly used Chinese patent medicines containing Venenum bufonis (Chansu) include Shexiangbaoxin Pill, Houtongxiaoyan Pill, Liushen Pill, Lushen Pill, and Jiuxin Pill.", {"entities": [[193, 200, "Ethnic group"]]}], [1903, "These compounds are classified as \u201ctoad venom dienolide,\u201d which is similar to digoxin in chemical structure and therefore elicits a digoxin-like immune response and inhibits Na  Nerium oleander L. (Jiazhutao) is a common cause of poisoning in Southeast Asia.", {"entities": [[78, 85, "Drug"], [132, 139, "Drug"], [178, 208, "Herb name"]]}], [1904, "All parts of the N. oleander L. (Jiazhutao) shrub contain cardiac glycoside components that inhibit Na  Periploca sepium Bunge (Xiangjiapi) is widely used in Chinese medicine for the treatment of cardiac dysfunction, and its component periplocymarin has a strong cardiac glycoside structure with a strong affinity for Na  Panax ginseng C.A.Mey.", {"entities": [[17, 43, "Herb name"], [100, 102, "Target"], [104, 139, "Herb name"], [158, 165, "Ethnic group"], [196, 215, "Pathology"], [235, 249, "Herb name"], [318, 320, "Target"], [322, 335, "Herb name"]]}], [1905, "(Renshen) can strengthen the heart, raise the blood pressure, improve coronary flow, increase the body\u2019s ability to resist hypoxia, reduce myocardial oxygen consumption, protect and repair cardiomyocytes, and exert certain anti-arrhythmic effects.", {"entities": [[1, 8, "Herb name"], [46, 60, "Parameter"]]}], [1906, "Some of its molecular structures are similar to those of digitalis glycosides, which are commonly used clinically in combination with digoxin for the treatment of coronary heart disease, heart failure, etc.", {"entities": [[57, 77, "Drug"], [134, 141, "Drug"], [163, 185, "Pathology"], [187, 200, "Pathology"]]}], [1907, "The combined therapeutic effects can enhance each other.", {"entities": []}], [1908, "However, some studies have shown that P. ginseng (Renshen) does not affect the determination of serum digoxin (Chow et al., 2003).", {"entities": [[38, 58, "Herb name"], [102, 109, "Drug"]]}], [1909, "A study on the effect of Shenmai Injection on digoxin blood concentration and pharmacokinetic parameters in dogs with heart failure showed that there are differences in the pharmacokinetic effects of different doses on digoxin, all of which tend to shorten digoxin t Ephedrine, the main component in Ephedra sinica Stapf (Caomahuang), has excitatory effects on cardiac \u03b1 and \u03b2 receptors, which excite the myocardium and enhance myocardial contractility.", {"entities": [[25, 42, "Herb name"], [46, 53, "Drug"], [118, 131, "Pathology"], [219, 226, "Drug"], [257, 264, "Drug"], [300, 333, "Herb name"]]}], [1910, "When combined with digoxin, E. sinica Stapf (Caomahuang) can enhance both the cardiotonic effects of digoxin and the toxic effects of digoxin on the heart, which can lead to toxic reactions including premature ventricular contractions, arrhythmia, and heart failure (Dong, 2009; Chen, 2014).", {"entities": [[19, 26, "Drug"], [28, 56, "Herb name"], [101, 108, "Drug"], [134, 141, "Drug"], [200, 234, "Pathology"], [236, 246, "Pathology"], [252, 265, "Pathology"]]}], [1911, "Common Chinese patent medicines containing E. sinica Stapf include Jizhi syrup, Maxinzhike tablets, Tongxuanlifei pills, and Xiaokening tablets.", {"entities": [[7, 14, "Ethnic group"], [43, 58, "Herb name"], [67, 78, "Herb name"], [80, 98, "Herb name"], [100, 120, "Herb name"], [125, 143, "Herb name"]]}], [1912, "High serum Ca Commonly used clinical single Chinese medicines containing calcium include Os Draconis (Longgu), Os Tigris (Hugu), Os Pardi (Baogu), antler (Lujiao), rhinoceros horn (Xijiao), Saigae Tataricae Cornu (Lingyangjiao), Bubali Cornu (Shuiniaojiao), magnetitum (Cishi), alumen (Baifan), Gypsum Fibrosum (Shigao), stalactitum (Zhongrushi), ophicalcitum (Huaruishi), fluoritum (Zishiying), hematite (Daizheshi), Natrii Sulfas (Mangxiao), calamina (Luganshi), talcum (Huashi), chalcanthitum (Danfan), Haliotidis Concha (Shijueming), Ostreae Concha (Muli), Margaritifera Concha (Zhenzhumu), ark shell (Walengzi), Concha Meretricis Seu Cyclinae (Haigeqiao), cuttlebone (Haipiaoxiao), pangolin scales (Chuanshanjia), Testudinis Carapacis Et Plastri (Guijia), Turtle Carapace (Biejia),  The Qiliqiangxin capsule is a Chinese patent medicine for the treatment of chronic congestive heart failure (Chen and Pang, 2014).", {"entities": [[44, 51, "Ethnic group"], [89, 109, "Herb name"], [111, 127, "Herb name"], [129, 145, "Herb name"], [147, 162, "Herb name"], [164, 188, "Herb name"], [190, 227, "Herb name"], [229, 256, "Herb name"], [258, 276, "Herb name"], [278, 293, "Herb name"], [295, 319, "Herb name"], [321, 345, "Herb name"], [347, 371, "Herb name"], [373, 394, "Herb name"], [396, 416, "Herb name"], [418, 442, "Herb name"], [444, 463, "Herb name"], [465, 480, "Herb name"], [482, 504, "Herb name"], [506, 536, "Herb name"], [538, 559, "Herb name"], [561, 593, "Herb name"], [595, 615, "Herb name"], [617, 659, "Herb name"], [661, 685, "Herb name"], [687, 717, "Herb name"], [719, 759, "Herb name"], [761, 785, "Herb name"], [792, 812, "Herb name"], [818, 825, "Ethnic group"], [863, 895, "Pathology"]]}], [1913, "Its ingredients, C. rotundus L. (Fuzi) and Descurainia sophia (L.) Webb ex Prantl (Tinglizi), contain cardiac glycoside components, such as strophanthigenin, evomonoside, and helveticoside, which have different degrees of cardiac strengthening effects (Ma and Gao, 2004; Wang et al., 2013).", {"entities": [[17, 38, "Herb name"], [43, 66, "Herb name"], [67, 92, "Herb name"], [140, 156, "Herb name"], [158, 169, "Herb name"], [175, 188, "Herb name"]]}], [1914, "The patients over 80\u00a0years old (27.5%) were more likely to be poisoned by the increase of digoxin concentration than those under 60\u00a0years old (15.30%), the proportion of digoxin poisoning in 60\u201380\u00a0years old patients (17.57%) was also higher than that under 60\u00a0years old (15.30%), but there was no statistical significance (Ye et al., 2019).", {"entities": [[4, 12, "Pathology"], [18, 30, "Age"], [90, 97, "Drug"], [129, 141, "Age"], [170, 177, "Drug"], [191, 206, "Age"], [207, 215, "Pathology"], [257, 269, "Age"]]}], [1915, "TCM formulations containing cardiac glycosides, such as  The main component of   Angelica sinensis (Oliv.)", {"entities": [[28, 46, "Herb name"], [81, 106, "Herb name"]]}], [1916, "Diels (Danggui), C. pinnatifida Bunge (Shanzha), and Calculus Bovis (Niuhuang) can antagonize digoxin-induced arrhythmias.", {"entities": [[0, 16, "Herb name"], [17, 47, "Herb name"], [53, 78, "Herb name"], [94, 101, "Drug"], [110, 121, "Pathology"]]}], [1917, "Diels (Danggui) has antiarrhythmic effects and can antagonize digoxin-induced arrhythmias when combined with digoxin (Yang et al., 2019).", {"entities": [[0, 15, "Herb name"], [62, 69, "Drug"], [78, 89, "Pathology"], [109, 116, "Drug"]]}], [1918, "Li Xin et al.", {"entities": []}], [1919, "used the duration of QRS interval prolongation, ventricular precontraction, ventricular tachycardia, and ventricular fibrillation as markers of arrhythmia to study the effects of C. pinnatifida Bunge (Shanzha) extract on digoxin-induced arrhythmias, and the results showed that the ventricular arrhythmias in the digoxin-induced experimental group of rats all decreased after the administration of C. pinnatifida Bunge (Shanzha) extract, indicating that the flavonoid glycoside and flavane polymers in C. pinnatifida Bunge (Shanzha) extract can antagonize digoxin-induced arrhythmias (Li and Huang, 2016), which may be related to their ability to dilate blood vessels, lower blood pressure, slow down the heart rhythm, and improve the cardiovascular system (Zhang et al., 2021).", {"entities": [[48, 100, "Pathology"], [105, 129, "Pathology"], [144, 154, "Pathology"], [179, 209, "Herb name"], [221, 228, "Drug"], [237, 248, "Pathology"], [282, 305, "Pathology"], [313, 320, "Drug"], [398, 428, "Herb name"], [458, 477, "Herb name"], [482, 498, "Herb name"], [502, 532, "Herb name"], [556, 563, "Drug"], [572, 583, "Pathology"], [675, 689, "Parameter"], [705, 717, "Parameter"]]}], [1920, "2-Aminoethanesulfonic acid (taurine) is a sulfur-containing non-protein amino acid isolated from Calculus Bovis.", {"entities": []}], [1921, "In a study in dogs, an initial dose of 35\u00a0\u03bcg/kg digoxin was administered intravenously to dogs with severed vagus nerves, followed by 17.5\u00a0\u03bcg every half hour until the electrocardiogram T-wave reversal and premature beats started to show toxic reactions, after which 2-aminoethanesulfonic acid was injected into the femoral vein at 0.5\u00a0mmoL/kg every 15\u00a0min.", {"entities": [[39, 47, "Amount"], [48, 55, "Drug"], [134, 141, "Amount"], [332, 343, "Amount"], [344, 356, "Frequency"]]}], [1922, "The results showed that the electrocardiogram returned to normal, probably because 2-aminoethanesulfonic acid was converted to acyl thiourea intracellularly, reducing the digoxin-induced arrhythmia (Read and Welty, 1963).", {"entities": [[171, 178, "Drug"], [187, 197, "Pathology"]]}], [1923, "In conclusion, TCM interacting with digoxin comprises monomer components, single medicines, and Chinese patent medicines.", {"entities": [[36, 43, "Drug"], [96, 103, "Ethnic group"]]}], [1924, "They can influence the pharmacokinetic process and pharmacodynamics of digoxin, resulting in changes in pharmacokinetic parameters, enhanced efficacy and even poisoning of digoxin.", {"entities": [[71, 78, "Drug"], [172, 179, "Drug"]]}], [1925, "Some of the above changes are clear, while others are speculated to have potential risks through the mechanism of action, which need further study and confirmation.", {"entities": []}], [1926, "The following table summarizes and analyzes the interaction between Chinese medicine and digoxin from the aspects of the outcome, types of Chinese medicine, research objects, influence mechanism and changes in pharmacokinetic parameters of digoxin (See Table 1).", {"entities": [[68, 75, "Ethnic group"], [89, 96, "Drug"], [139, 146, "Ethnic group"], [240, 247, "Drug"]]}], [1927, "Interactions between TCM formulations and digoxin, and the underlying mechanisms.", {"entities": [[42, 49, "Drug"]]}], [1928, "Digoxin is a cardiac glycoside drug commonly used in clinical practice for the treatment of heart failure, atrial fibrillation, and other arrhythmias, with a low therapeutic index, a narrow safety range, and large individual differences.", {"entities": [[0, 7, "Drug"], [92, 105, "Pathology"], [107, 126, "Pathology"], [138, 149, "Pathology"]]}], [1929, "Therefore, clinicians and pharmacists need to understand the interactions between digoxin and TCM formulations to avoid the occurrence of ADRs or even toxic reactions and promote the rational clinical use of drugs.", {"entities": [[82, 89, "Drug"], [138, 142, "Pathology"]]}], [1930, "In this paper, we summarize interactions with digoxin and their mechanisms.", {"entities": [[46, 53, "Drug"]]}], [1931, "The mechanisms of TCM interactions with digoxin are summarized from the following five perspectives (Figure 2).", {"entities": [[40, 47, "Drug"]]}], [1932, "Interactions between TCM formulations and digoxin.", {"entities": [[42, 49, "Drug"]]}], [1933, "C. anthriscoides \u201cChuanxiong\u201d influences Ca Medicinal and edible homologous substances are edible and medicinal Chinese herbal medicines used in TCM and diet therapy based on the guidance of the concept of homologous medicine and food.", {"entities": [[0, 29, "Herb name"], [112, 119, "Ethnic group"]]}], [1934, "For example, the ancients used edible bark in nature and processed it into food to replace food to satisfy hunger, which played a role in satisfying and curing diseases.", {"entities": []}], [1935, "The buds, seedlings, leaves, or flowers of medicinal plants with the homology of medicine and food in wood are processed into drinks, which have good taste, and can play a role in healthcare and conditioning discomfort symptoms after long-term use.", {"entities": [[4, 8, "Herb part"], [10, 19, "Herb part"], [21, 27, "Herb part"], [32, 39, "Herb part"], [208, 227, "Pathology"]]}], [1936, "With the rapid development of social economy, modern life makes people have higher expectations and pursuit for physical and mental health.", {"entities": []}], [1937, "Medicinal varieties with the homology of medicine and food should be paid attention to.", {"entities": []}], [1938, "Most medicinal plants with the homology of medicine and food are gentle in nature, warm in nature and sweet in taste.", {"entities": []}], [1939, "When the bias of medicine is greater than that of food, it will inevitably affect the balance of qi, blood, yin and yang of the human body (Jia et al., 2021).", {"entities": []}], [1940, "The homology of medicine and food does not mean that medicine and food are the same.", {"entities": []}], [1941, "In practical application, special attention should be paid to the difference between medicine and food.", {"entities": []}], [1942, "Excessive or improper consumption can easily lead to toxicity (bias).", {"entities": [[53, 61, "Pathology"]]}], [1943, "While knowing its edible value, we should also pay attention to its medicinal value, so as to avoid drug interaction and affect the treatment of diseases.", {"entities": []}], [1944, "Synergistic drug effects increase the risk of digoxin poisoning: Venenum bufonis has a cardiac glycoside structure, inhibits Na  Enhanced sensitivity of the heart to digoxin and increased risk of toxicity: G. glabra L. (Gancao) has deoxycorticosterone-like effects, which can \u201cconserve sodium and drain potassium,\u201d easily causing hypokalemia, increasing the sensitivity of myocardium to digoxin, and inducing digoxin toxicity in therapeutic doses.", {"entities": [[46, 53, "Drug"], [65, 80, "Herb name"], [87, 104, "Herb name"], [125, 127, "Target"], [166, 173, "Drug"], [196, 204, "Pathology"], [206, 227, "Herb name"], [387, 394, "Drug"], [409, 416, "Drug"], [417, 425, "Pathology"]]}], [1945, "Antagonize digoxin-induced ADR: A. sinensis (Oliv.)", {"entities": [[11, 18, "Drug"], [32, 51, "Herb name"]]}], [1946, "Diels (Danggui) has anti-arrhythmic effects; C. pinnatifida Bunge (Shanzha) extract contains flavonoid glycosides and flavane polymers that can dilate blood vessels, lower the blood pressure, and slow down the heart rhythm; 2-aminoethanesulfonic acid is converted to acyl thiourea intracellularly, reducing the cellular response to digoxin-induced arrhythmia.", {"entities": [[0, 15, "Herb name"], [45, 75, "Herb name"], [93, 113, "Herb name"], [118, 134, "Herb name"], [176, 190, "Parameter"], [210, 222, "Parameter"], [332, 339, "Drug"], [348, 358, "Pathology"]]}], [1947, "All the above herbs can antagonize the arrhythmic toxic reactions induced by digoxin.", {"entities": [[77, 84, "Drug"]]}], [1948, "Although a lot of experience has been accumulated in the clinical application of digoxin over the years, limited research has been conducted on its possible interactions with TCM formulations.", {"entities": [[81, 88, "Drug"]]}], [1949, "The mechanisms of interaction between TCM formulations and digoxin have been basically elucidated in terms of pharmacokinetics and pharmacodynamics in cells, animals, and humans.", {"entities": [[59, 66, "Drug"]]}], [1950, "Based on the reported pharmacological effects and existing research results, some Chinese herbal medicines may have potential interaction with digoxin.", {"entities": [[82, 89, "Ethnic group"], [143, 150, "Drug"]]}], [1951, "The following problems were found in the present analysis: i) Existing studies on the effects of TCM formulations on P-gP mainly focus on a certain component or a single drug, while few studies have been conducted on Chinese patent medicines containing these components.", {"entities": [[117, 121, "Target"], [217, 224, "Ethnic group"]]}], [1952, "ii) Studies have been conducted on the interactions of TCM extracts with digoxin, but the specific components of the extracts were not identified.", {"entities": [[73, 80, "Drug"]]}], [1953, "For example, a study showed that a small molecule component of the water-soluble part of B. chinense DC.", {"entities": [[89, 104, "Herb name"]]}], [1954, "(Chaihu) has an induction effect on P-gP, but its water-soluble part contains a variety of monosaccharides, oligosaccharides, amino acids, and other components, and it is not clear which component causes the interaction.", {"entities": [[1, 7, "Herb name"], [36, 41, "Target"], [91, 106, "Herb name"], [108, 124, "Herb name"], [126, 137, "Herb name"]]}], [1955, "iii) The results of the interactions between Chinese patent medicines, TCM formulations, and digoxin are inconsistent.", {"entities": [[45, 52, "Ethnic group"], [93, 100, "Drug"]]}], [1956, "For example, P. ginseng C.A.Mey.", {"entities": [[13, 32, "Herb name"]]}], [1957, "enhances the effect of digoxin, but Shenmai injection (a Chinese patent medicine containing P. ginseng C.A.Mey.)", {"entities": [[23, 30, "Drug"], [36, 53, "Herb name"], [57, 64, "Ethnic group"], [92, 112, "Herb name"]]}], [1958, "These discrepancies may be related to the formulation of the Chinese patent medicine, the dose, the assay method, and other factors; further study is necessary.", {"entities": [[61, 68, "Ethnic group"]]}], [1959, "iv) The pharmacological effects of TCM formulations are complex, and most of the current studies have been conducted in cells and animals.", {"entities": []}], [1960, "Whether TCM formulations that can regulate P-gP also interfere with human digoxin plasma concentration needs further clinical validation.", {"entities": [[43, 47, "Target"], [74, 81, "Drug"]]}], [1961, "In view of the above problems in the research of the interaction between TCM and digoxin, the following solutions are put forward: 1) Because of the complex components of TCM, the pharmacology of some TCMs has not been clarified.", {"entities": [[81, 88, "Drug"]]}], [1962, "It is suggested that network pharmacology should be used to clarify the components and mechanism of TCM in the future.", {"entities": []}], [1963, "2) For Chinese medicines found to have exact or potential interaction with digoxin, it is suggested to study from different levels of monomer, single medicine, ready-for-use TCM or prescription in the future to confirm whether the action with digoxin is related to a certain component, a certain medicine, mutual compatibility, processing and other factors.", {"entities": [[7, 14, "Ethnic group"], [75, 82, "Drug"], [243, 250, "Drug"]]}], [1964, "3) At present, most of the research data come from animal experiments or cells.", {"entities": []}], [1965, "For TCMs that have interaction found in vitro studies, it is suggested to further conduct clinical research to provide basis for the safe combination of digoxin and TCMs.", {"entities": [[37, 53, "Study"], [153, 160, "Drug"]]}], [1966, "4) The combination of Chinese and Western medicine is not only simply adding Chinese medicine with Western medicine, but it should also be a combination of the theoretical basis and scientific medication principles.", {"entities": [[22, 29, "Ethnic group"], [77, 84, "Ethnic group"]]}], [1967, "Digoxin mainly passes through glomerular filtration and is excreted in its original form in human body.", {"entities": [[0, 7, "Drug"]]}], [1968, "Considering the narrow therapeutic window of digoxin, the effective therapeutic dose is not easy to determine, and it is prone to poor efficacy or toxic reactions (Englund et al., 2004).", {"entities": [[45, 52, "Drug"]]}], [1969, "Therefore, when combining digoxin with one or more P-gP inhibitors, clinicians or pharmacists should consider the patient\u2019s condition, the TCM components, the interactions between digoxin and TCM formulations, and the compatibility between drugs.", {"entities": [[26, 33, "Drug"], [51, 55, "Target"], [114, 123, "Pathology"], [180, 187, "Drug"]]}], [1970, "With the popularization of TCM and the improvement of living standards, elderly patients who have been taking digoxin for a long time tend to take TCM on their own.", {"entities": [[80, 88, "Pathology"], [110, 117, "Drug"]]}], [1971, "Digoxin has a narrow safety range, i.e., the therapeutic and toxic doses are close to each other, and it is associated with large individual differences.", {"entities": [[0, 7, "Drug"]]}], [1972, "Drug interactions have a great effect on digoxin plasma concentration and cause toxic reactions.", {"entities": [[41, 48, "Drug"]]}], [1973, "The composition of TCM formulations is complex.", {"entities": []}], [1974, "Therefore, the interactions between TCM formulations and digoxin are difficult to elucidate, and they are easily ignored by physicians.", {"entities": []}], [1975, "Doctors and pharmacists should screen patients for the TCM formulations mentioned in this paper that have interactions with digoxin, monitor the use of interacting drugs such as those containing flavonoids or calcium, those affecting P-gP, and herbal medicines with cardiac potency, and adjust the type and dose of medication according to the monitoring results and clinical symptoms to prevent or reduce the occurrence of ADRs and improve efficacy and safety.", {"entities": [[38, 46, "Pathology"], [124, 131, "Drug"], [195, 205, "Herb name"], [234, 238, "Target"], [423, 427, "Pathology"]]}], [1976, "WZ and TH wrote the manuscript.", {"entities": []}], [1977, "WZ, TH, Z-ZW, and B-BJ searched for related studies.", {"entities": []}], [1978, "B-BJ and LZ proofread the manuscript.", {"entities": []}], [1979, "S-YX and X-ZD guided the writing and critically revised the manuscript.", {"entities": []}], [1980, "All authors have read and approved the final version of the manuscript.", {"entities": []}], [1981, "The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.", {"entities": []}], [1982, "All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers.", {"entities": []}], [1983, "Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.", {"entities": []}], [1984, "Centella asiatica Water Extract Shows Low Potential for Cytochrome P450\u2013Mediated Drug Interactions Kirsten M. Wright, Armando Alcazar Magana, Ronald M. Laethem, Caroline L. Moseley, Troy T. Banks, Claudia S. Maier, Jan F. Stevens, Joseph F. Quinn, and Amala Soumyanathcorresponding author Author information Article notes Copyright and License information PMC Disclaimer See \"Natural Products: Experimental Approaches to Elucidate Disposition Mechanisms and Predict Pharmacokinetic Drug Interactions\" in volume 48 on page 956.", {"entities": [[0, 17, "Herb name"], [18, 31, "Extraction process"], [56, 71, "Parameter"]]}], [1985, "See \"National Center for Complementary and Integrative Health Perspectives on Clinical Research Involving Natural Products\" in volume 48 on page 963.", {"entities": []}], [1986, "Go to: Abstract  Centella asiatica (CA) shows considerable promise for development as a botanical drug for cognitive decline.", {"entities": [[17, 39, "Herb name"], [107, 124, "Pathology"]]}], [1987, "Its primary bioactive components include triterpene glycosides asiaticoside and madecassoside and their corresponding aglycones asiatic acid and madecassic acid.", {"entities": [[41, 75, "Herb name"], [80, 93, "Herb name"], [118, 160, "Herb name"]]}], [1988, "Exploration of the bioactivity of CA\u2019s caffeoylquinic acids is ongoing.", {"entities": [[34, 59, "Herb name"]]}], [1989, "CAW-R61J was assessed for induction potential of CYP1A2, CYP2B6, and CYP3A4 using transporter-certified cryopreserved human hepatocytes in sandwich culture.", {"entities": [[0, 8, "Herb name"], [49, 55, "Target"], [57, 63, "Target"], [69, 75, "Target"]]}], [1990, "No induction was observed up to 16.7 \u00b5g/ml CAW-R61J (equivalent to 1.1 \u00b5M asiaticoside, 0.8 \u00b5M madecassoside, 0.09 \u00b5M asiatic acid, and 0.12 \u00b5M madecassic acid).", {"entities": [[32, 42, "Amount"], [43, 51, "Herb name"], [67, 73, "Amount"], [74, 86, "Herb name"], [88, 94, "Amount"], [95, 108, "Herb name"], [110, 117, "Amount"], [118, 130, "Herb name"], [136, 143, "Amount"], [144, 159, "Herb name"]]}], [1991, "Reversible and time-dependent inhibitory effects of CAW-R61J on CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4/5 were evaluated using human liver microsomes.", {"entities": [[52, 60, "Herb name"], [64, 70, "Target"], [72, 78, "Target"], [80, 86, "Target"], [88, 94, "Target"], [96, 103, "Target"], [105, 111, "Target"], [117, 125, "Target"]]}], [1992, "CAW-R61J showed weak reversible inhibition of most of the P450 forms tested, with the strongest being CYP2C9 (IC50 of 330 \u00b5g/ml).", {"entities": [[0, 8, "Herb name"], [58, 68, "Target"], [102, 108, "Target"], [110, 114, "Parameter"], [118, 127, "Amount"]]}], [1993, "CAW-R61J (\u22641000 \u00b5g/ml) was not a time-dependent inhibitor of any of these P450 enzymes.", {"entities": [[0, 8, "Herb name"], [10, 21, "Amount"], [74, 86, "Target"]]}], [1994, "In summary, CAW-R61J had no, or only a weak impact, on P450 induction and inhibition in vitro.", {"entities": [[12, 20, "Herb name"], [55, 59, "Target"]]}], [1995, "SIGNIFICANCE STATEMENT  A preparation of Centella asiatica is currently under clinical development for the prevention or treatment of cognitive decline.", {"entities": [[41, 58, "Herb name"], [134, 151, "Pathology"]]}], [1996, "The US Food and Drug Administration required an evaluation of its potential for drug interactions mediated through drug-metabolizing enzymes.", {"entities": []}], [1997, "This in vitro study revealed minimal induction or inhibition of a range of P450 enzymes, including CYP3A4, by the C. asiatica extract, suggesting a low potential for drug interactions modulated by P450 metabolism.", {"entities": [[0, 19, "Study"], [75, 87, "Target"], [99, 105, "Target"], [114, 133, "Herb name"], [197, 212, "Parameter"]]}], [1998, "Go to: Introduction  Over 80% of the world\u2019s population uses botanical medicines (herbal medicines) (Ekor, 2014).", {"entities": []}], [1999, "Many view these medicines as benign because they are of natural origin; however, because their constituents may be metabolized through the same enzymatic pathways as pharmaceutical agents, there is a potential for herb-drug interactions.", {"entities": []}], [2000, "Reported outcomes of such interactions include low drug efficacy, serious toxic reactions to the drug component, and death (Ekor, 2014; Feltrin and Oliveira Sim\u00f5es, 2019; Liu et al., 2019; Maadarani et al., 2019; Suroowan and Mahomoodally, 2019).", {"entities": [[66, 89, "Pathology"], [117, 122, "Pathology"]]}], [2001, "The most important class of enzymes involved in human drug metabolism is cytochrome P450 (P450), which occurs as a superfamily of related monooxygenase forms responsible for oxidative metabolism of xenobiotics and endogenous compounds (Nebert et al., 2013).", {"entities": [[73, 95, "Parameter"], [138, 157, "Parameter"]]}], [2002, "The major forms are CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4/5.", {"entities": [[20, 81, "Parameter"]]}], [2003, "Metabolic drug interactions normally occur between two or more drugs such that the addition of the perpetrator drug alters the systemic levels of the victim drug (Lin and Lu, 1998; Bohnert et al., 2016).", {"entities": []}], [2004, "For example, induction of P450 forms by herbal components could increase the clearance of the victim drug, thus causing decreased therapeutic efficacy (Shi and Klotz, 2012).", {"entities": [[26, 36, "Target"], [73, 105, "Parameter"]]}], [2005, "Conversely, P450 inhibition by phytochemicals could cause circulating levels of the victim drug to rise to toxic levels (Shi and Klotz, 2012).", {"entities": [[12, 16, "Target"], [107, 112, "Pathology"]]}], [2006, "Investigation of herb-drug interactions is undoubtedly a public health priority to ensure the safe use of herbal interventions (Borse et al., 2019).", {"entities": []}], [2007, "The US Food and Drug Administration (FDA) has issued guidance for studying metabolic drug interactions in vitro using specific tools and methods (U.S. Food and Drug Administration, 2020).", {"entities": []}], [2008, "As the use of herbal healthcare products increases worldwide, it is important to apply the techniques traditionally used for small molecules to determine whether these products have the potential to induce or inhibit P450 forms in humans.", {"entities": [[217, 227, "Target"]]}], [2009, "Centella asiatica (L.) Urban (Apiaceae) (CA), commonly known as gotu kola, is a botanical reputed in Ayurvedic medicine to increase intelligence and memory (Kapoor, 1990).", {"entities": [[0, 73, "Herb name"], [123, 155, "Pathology"]]}], [2010, "Triterpene glycosides asiaticoside and madecassoside and their corresponding aglycones, asiatic acid and madecassic acid, collectively known as centelloids, are regarded as the predominant bioactive compounds of CA (Brinkhaus et al., 2000), although recent studies by our group suggest a therapeutic role for its caffeoylquinic acid constituents (Gray et al., 2014, 2017b).", {"entities": [[0, 155, "Herb name"], [212, 214, "Herb name"], [313, 345, "Herb name"]]}], [2011, "These include modulation of antioxidant pathways and improved mitochondrial function (Gray et al., 2016, 2018c; Matthews et al., 2019).", {"entities": [[28, 48, "Parameter"], [62, 84, "Parameter"]]}], [2012, "In addition, similar extracts have been shown to modify brain structure by increasing dendritic arborization of hippocampal neurons (Gray et al., 2017b, 2018b), potentially contributing to the observed cognitive changes.", {"entities": [[21, 29, "Extraction process"], [86, 131, "Parameter"], [202, 219, "Pathology"]]}], [2013, "CA extracts and compounds have been reported to be weak inhibitors of some phase I drug-metabolizing P450 enzymes in vitro (Pan et al., 2010, 2011; Seeka et al., 2012; Savai et al., 2015a,b; Kar et al., 2017).", {"entities": [[0, 11, "Herb name"], [101, 113, "Parameter"]]}], [2014, "In rats, administration of a CA product (composition not provided) increased plasma maximum concentration (14.34%), area under the curve (23%), and elimination half-life (13.81%) of amitriptyline (Khurshid et al., 2018), a substrate of CYP2C19 and CYP2D6 in humans (Mifsud Buhagiar et al., 2019).", {"entities": [[29, 31, "Herb name"], [77, 105, "Parameter"], [107, 113, "Amount"], [116, 136, "Parameter"], [138, 141, "Amount"], [148, 169, "Parameter"], [171, 177, "Amount"], [182, 195, "Drug"], [236, 243, "Parameter"], [248, 254, "Parameter"]]}], [2015, "These studies suggest that CA components may cause drug interactions resulting from altered phase I metabolism of coadministered drugs.", {"entities": [[27, 40, "Herb name"]]}], [2016, "None of the aforementioned studies investigated the effects on drug-metabolizing enzymes of the type of extract (CAW) used in our preclinical studies and in our current phase I (NCT03929250, NCT03937908) and proposed phase II clinical trials investigating CAW as a botanical drug for cognitive decline.", {"entities": [[113, 116, "Herb name"], [130, 149, "Study"], [217, 241, "Study"], [256, 259, "Herb name"], [284, 301, "Pathology"]]}], [2017, "During our application for Investigational New Drug status for CAW, the FDA asked us to investigate potential interactions with P450 enzymes.", {"entities": [[63, 66, "Herb name"], [128, 140, "Parameter"]]}], [2018, "CYP3A4, CYP2D6, and CYP2C19 are of particular interest.", {"entities": [[0, 6, "Parameter"], [8, 14, "Parameter"], [20, 27, "Parameter"]]}], [2019, "The cognitively impaired, elderly target population for CAW may be taking cholinesterase inhibitors donepezil or galantamine, which are substrates for CYP3A4 and CYP2D6 (Noetzli and Eap, 2013; Coin et al., 2016), or drugs for other health conditions, many of which are substrates of CYP3A4 (Zhou et al., 2007).", {"entities": [[4, 24, "Pathology"], [56, 59, "Herb name"], [74, 124, "Drug"], [151, 157, "Parameter"], [162, 168, "Parameter"], [283, 289, "Parameter"]]}], [2020, "The composition of plant extracts can vary considerably depending on genetic factors, cultivation conditions, and processing methods (Figueiredo, 2017), and this in turn can affect their biologic properties.", {"entities": []}], [2021, "In the present study, in vitro P450 induction potential of CYP1A2, CYP2B6, and CYP3A4 by CAW-R61J was studied using human hepatocytes in sandwich culture (LeCluyse et al., 2000; LeCluyse, 2001).", {"entities": [[31, 35, "Target"], [59, 65, "Target"], [67, 73, "Target"], [79, 85, "Target"], [89, 97, "Herb name"]]}], [2022, "Hepatocytes cultured in this format are responsive to nuclear receptor agonists and maintain important transporter function necessary for proper drug disposition (Yang et al., 2016).", {"entities": [[54, 70, "Parameter"]]}], [2023, "Reversible and time-dependent inhibition of P450 forms by CAW-R61J was investigated using standard methods with pooled human liver microsomes (Stresser et al., 2014; Bohnert et al., 2016).", {"entities": [[44, 54, "Target"], [58, 66, "Herb name"]]}], [2024, "Go to: Materials and Methods  Materials.", {"entities": []}], [2025, "Acetaminophen-d4, azamulin, bupropion hydrocholoride, flumazenil, furafylline, hydroxybupropion-d6, 4\u2032-hydroxy mephenytoin-d3, ketoconazole, (S)-mephenytoin, N-desethylamodiaquine-d5, paroxetine hydrochloride, phenacetin, sertraline hydrochloride, N,N\u2032,N\u2032\u2032-triethylenethiophosphoramide, ticlopidine hydrochloride, and tienilic acid were from Toronto Research Chemicals (North York, ON, Canada).", {"entities": [[0, 16, "Drug"], [18, 26, "Drug"], [28, 52, "Drug"], [54, 64, "Drug"], [66, 77, "Drug"], [79, 125, "Drug"], [127, 139, "Drug"], [141, 156, "Drug"], [158, 182, "Drug"], [184, 208, "Drug"], [210, 220, "Drug"], [222, 246, "Drug"], [248, 285, "Drug"], [287, 312, "Drug"], [318, 331, "Drug"]]}], [2026, "\u03b1-Naphthoflavone and NADP+ were obtained from Cayman Chemicals (Ann Arbor, MI).", {"entities": [[0, 16, "Parameter"], [21, 26, "Parameter"]]}], [2027, "LC-MS\u2013grade acetonitrile, LC-MS\u2013grade methanol, and formic acid American Chemical Society reagent were purchased from Fisher Scientific (Pittsburgh, PA).", {"entities": [[12, 24, "Extraction process"], [38, 46, "Extraction process"], [52, 63, "Extraction process"], [64, 72, "Ethnic group"]]}], [2028, "Imported C. asiatica herb, consisting of dried aerial parts, was purchased from Oregon\u2019s Wild Harvest (lot numbers 180700075 and 180600069; Redmond, OR).", {"entities": [[9, 25, "Herb name"], [41, 59, "Herb part"]]}], [2029, "The commercial reference phytochemical standards asiatic acid, asiaticoside, madecassic acid, madecassoside, 5-O-caffeoylquinic acid, 4-O-caffeoylquinic acid, 3-O-caffeoylquinic acid, 1,3-dicaffeoylquinic acid, 1,5-dicaffeoylquinic acid, 3,5-dicaffeoylquinic acid, and quinic acid were purchased from Toronto Research Chemicals; 3,4-dicaffeoylquinic acid and 4,5-dicaffeoylquinic acid were purchased from Chromadex (Irvine, CA).", {"entities": [[49, 280, "Herb name"], [329, 354, "Herb name"], [359, 384, "Herb name"]]}], [2030, "C. asiatica Plant Material and Preparation of CAW-R61J.", {"entities": [[0, 17, "Herb name"]]}], [2031, "Two batches of C. asiatica (lot numbers 180600069 and 180700075; CA1 and CA2, respectively) were purchased from Oregon's Wild Harvest (Redmond, OR) for clinical trial product manufacture.", {"entities": [[15, 26, "Herb name"], [152, 166, "Study"]]}], [2032, "Plant identity was verified by visual inspection, Fourier-transform Infrared spectroscopy, and thin-layer chromatography in comparison with earlier lots of C. asiatica (Soumyanath et al., 2012; Gray et al., 2016), reference standards of characteristic chemical components, and the literature (Bonfill et al., 2006).", {"entities": [[156, 167, "Herb name"]]}], [2033, "The material was extracted by Ashland Industries (Kearny, NJ) in two lots.", {"entities": []}], [2034, "Aliquots of the two filtrates were shipped to Oregon Health & Science University (OHSU, Portland, OR), where they were frozen and lyophilized, yielding 21.4% from dried CA for CAW-R61F (extraction lot 1) and 23.9% from dried CA for CAW-R61H (extraction lot 2).", {"entities": [[152, 157, "Amount"], [163, 184, "Herb name"], [208, 213, "Amount"], [219, 240, "Herb name"]]}], [2036, "This ratio mimicked that used in the clinical trial product manufacture, which was performed using the major part of the water extracts.", {"entities": [[37, 51, "Study"], [117, 135, "Extraction process"]]}], [2037, "Since the chemical composition of CA raw material can vary, we used the specific CAW-R61J extract used to make our clinical trial product in this study.", {"entities": [[34, 40, "Herb name"], [81, 97, "Herb name"], [115, 129, "Study"]]}], [2038, "Voucher samples of the original dried plant materials CA1 and CA2 have been deposited at the Oregon State University Herbarium (OSC-V-258630, OSC-V-258631, respectively), and voucher samples of dried plant materials and CAW extracts (CAW-R61F, CAW-R61H, and CAW-R61J) are held at OHSU.", {"entities": [[32, 65, "Herb name"], [194, 215, "Herb name"], [220, 232, "Herb name"], [234, 242, "Herb name"], [244, 252, "Herb name"], [258, 266, "Herb name"]]}], [2039, "CAW-R61J Fingerprinting.", {"entities": [[0, 8, "Herb name"]]}], [2040, "The bioactive centelloids and caffeoylquinic acid compounds in CAW-R61J test material were identified and quantified using the area under the curve of the precursor ion (MS1 quantification) using LC-HRMS at Oregon State University (Corvallis, OR) by comparison against co-chromatographed commercial reference standards as previously described (Alcazar-Magana et al., 2020).", {"entities": [[14, 71, "Herb name"], [123, 168, "Parameter"]]}], [2041, "In addition toMS1- quantification of known compounds, untargeted LC-HRMS analysis of all the materials was performed.", {"entities": []}], [2042, "Analytical data on accurate mass (high resolution), isotopic pattern, retention time, and relative peak area of all components detected using both negative and positive electrospray ionization mode were recorded as \u201cfingerprints\u201d of the CAW-R61J extract.", {"entities": [[233, 253, "Herb name"]]}], [2043, "Data-dependent acquisition mode was conducted using a Shimadzu Nexera ultra-performance liquid chromatography system (Columbia, MD) connected to an AB SCIEX TripleTOF 5600 mass spectrometer (Framingham, MA) equipped with a TurboSpray electrospray ionization source.", {"entities": []}], [2044, "Chromatographic separation was achieved using an Inertsil Phenyl-3 column (4.6 mm \u00d7 150 mm; GL Sciences, Torrance, CA).", {"entities": []}], [2045, "The injection volume was 10 \u00b5l, and three technical replicates were carried out.", {"entities": [[0, 20, "Parameter"], [25, 30, "Amount"]]}], [2046, "A gradient with solvent A (water containing 0.1% v/v formic acid) and B (methanol containing 0.1% v/v formic acid) was used with a flow rate of 0.4 ml/min in a 35-minute chromatographic run.", {"entities": [[27, 32, "Extraction process"], [44, 52, "Amount"], [53, 64, "Extraction process"], [73, 81, "Extraction process"], [93, 101, "Amount"], [102, 113, "Extraction process"], [129, 140, "Parameter"], [144, 154, "Frequency"], [160, 169, "Duration"]]}], [2047, "Solvent gradient started at 5% B at 0 to 1 minute and was followed by 5%\u201330% B from 1 to 10 minutes, then 30%\u2013100% B from 10 to 20 minutes, held at 100% B from 20 to 25 minutes, then returned to 5% B from 25 to 30 minutes, and then the column was equilibrated with 5% B until 35 minutes.", {"entities": [[28, 30, "Amount"], [36, 49, "Duration"], [70, 76, "Amount"], [84, 99, "Duration"], [106, 114, "Amount"], [117, 138, "Duration"], [148, 152, "Amount"], [155, 176, "Duration"], [195, 197, "Amount"], [200, 221, "Duration"], [265, 267, "Duration"]]}], [2048, "Samples were filtered (Ultrafree-UFC 30GVNB 0.22-\u03bcm spin filter; Fisher Scientific) prior to transfer to high-performance liquid chromatography vials.", {"entities": []}], [2049, "HPLC-MS/MS of caffeoylquinic acids was performed on an Applied Biosystems Qtrap5500 LC-MS instrument (Framingham, MA).", {"entities": [[14, 34, "Herb name"]]}], [2050, "Chromatographic separation was achieved using a Zorbax Eclipse plus C8 Rapid Resolution column (4.6 mm \u00d7 150 mm, 3.5 \u03bcm; Agilent, Foster City, CA) fitted with a Zorbax Eclipse plus C8 Rapid Resolution precolumn (4.6 mm \u00d7 12.5 mm, 5 \u03bcm; Agilent).", {"entities": []}], [2051, "The injection volume was 5 \u00b5l.", {"entities": []}], [2052, "Solvent gradient increased from 10% to 25% B from 0 to 4.5 minutes, to 40% B by 10 minutes, and to 95% B from 10 to 11 minutes.", {"entities": [[32, 35, "Amount"], [39, 42, "Amount"], [45, 66, "Duration"], [71, 74, "Amount"], [80, 90, "Duration"], [99, 102, "Amount"], [105, 126, "Duration"]]}], [2053, "After holding at 95% B from 11 to 16 minutes, composition returned to 10% B by 16.2 minutes and was re-equilibrated at 10% B until 21 minutes.", {"entities": [[17, 20, "Amount"], [23, 44, "Duration"], [70, 73, "Amount"], [119, 122, "Amount"]]}], [2054, "MS/MS was carried out with electrospray ionization in negative ion mode; transitions monitored were monocaffeoylquinic acids (353/191) and dicaffeoylquinic acids (515/191).", {"entities": [[100, 124, "Herb name"], [139, 161, "Herb name"]]}], [2055, "Analysis of the centelloids was performed on an Applied Biosystems Qtrap 4000 LC-MS instrument.", {"entities": [[16, 27, "Herb name"]]}], [2056, "Chromatographic separation was achieved using a Poroshell 120 EC-C18 column (3-mm \u00d7 50 mm, 2.7 \u03bcm; Agilent) fitted with a Poroshell 120 EC-C18 guard column (3 mm \u00d7 5 mm, 2.7 \u03bcm; Agilent).", {"entities": []}], [2057, "The injection volume was 20 \u00b5l.", {"entities": []}], [2058, "Solvent gradient increased from 40% B to 60% B from 0 to 2 minutes and then increased to 95% B by 3.5 minutes.", {"entities": [[32, 35, "Amount"], [41, 44, "Amount"], [47, 66, "Duration"], [89, 92, "Amount"]]}], [2060, "MS/MS was carried out in positive ion mode; transitions monitored were asiatic acid (506/453), madecassic acid (522/451), asiaticoside (976/452), and madecassoside (992/486).", {"entities": [[44, 65, "Parameter"], [71, 83, "Herb name"], [85, 92, "Amount"], [95, 110, "Herb name"], [112, 119, "Amount"], [122, 134, "Herb name"], [136, 143, "Amount"], [150, 163, "Herb name"]]}], [2061, "Asiatic acid and madecassic acid were monitored as ammonium adducts.", {"entities": [[0, 12, "Herb name"], [17, 32, "Herb name"], [51, 59, "Parameter"]]}], [2063, "Compounds of interest were quantified by reference to calibration curves.", {"entities": []}], [2064, "Hepatocytes.", {"entities": []}], [2065, "Human hepatocyte culture transporter-certified human hepatocytes were prepared in-house at BioIVT (Baltimore, MD).", {"entities": []}], [2066, "The hepatocyte pellet was resuspended in BioIVT QualGro Seeding Medium (BioIVT), and the viability was determined using trypan blue exclusion and a hemocytometer (Fisher Scientific).", {"entities": [[120, 131, "Parameter"]]}], [2067, "The hepatocytes were diluted to a density of 0.8\u20131.0 \u00d7 106 viable cells/ml and seeded (0.5 ml/well) onto Corning BioCoat Collagen I 24-well plates (Fisher Scientific).", {"entities": [[34, 41, "Parameter"], [45, 74, "Amount"], [87, 98, "Amount"], [121, 129, "Parameter"]]}], [2068, "The cells were allowed to attach for 18\u201324 hours and were then overlaid with Hepatocyte Induction Medium supplemented with 0.25 mg/ml Corning Matrigel (Fisher Scientific) for 18\u201324 hours.", {"entities": [[33, 48, "Duration"], [123, 133, "Amount"], [171, 186, "Duration"]]}], [2069, "After the overlay, the medium was aspirated, and cultures were treated with compounds.", {"entities": []}], [2070, "All control compounds were made as 1000\u00d7 stocks in DMSO and diluted 1:1000 in Hepatocyte Induction Medium.", {"entities": [[51, 55, "Parameter"]]}], [2071, "The final concentration of the control compounds was 0.1% DMSO, 25 \u00b5M flumazenil, 50 \u00b5M omeprazole, 1000 \u00b5M phenobarbital, or 10 \u00b5M rifampicin.", {"entities": [[10, 48, "Parameter"], [53, 57, "Amount"], [58, 62, "Parameter"], [64, 69, "Amount"], [70, 80, "Drug"], [82, 87, "Amount"], [88, 98, "Drug"], [100, 107, "Amount"], [108, 121, "Drug"], [126, 131, "Amount"], [132, 142, "Drug"]]}], [2072, "A stock solution of CAW-R61J was made in Hepatocyte Induction Medium at 1 mg/ml and was used to make a dosing solution of 50 \u00b5g/ml.", {"entities": [[20, 28, "Herb name"], [72, 79, "Amount"], [122, 130, "Amount"]]}], [2073, "The 50-\u00b5g/ml solution was serially diluted (1:3) in Hepatocyte Induction Medium to yield 0.02, 0.07, 0.2, 0.6, 1.9, 5.6, 16.7, or 50 \u00b5g/ml.", {"entities": [[4, 12, "Amount"], [89, 138, "Amount"]]}], [2074, "DMSO was added to the CAW-R61J dosing solutions to 0.1% (v/v) such that all treatment conditions contained 0.1% DMSO.", {"entities": [[0, 4, "Parameter"], [22, 30, "Herb name"], [51, 61, "Amount"], [107, 111, "Amount"], [112, 116, "Parameter"]]}], [2075, "All conditions for each donor were carried out in triplicate with treatment every 24 hours for a total exposure period of 72 hour.", {"entities": [[82, 90, "Duration"], [122, 129, "Duration"]]}], [2076, "TABLE 1  Donor demographics for hepatocytes used in the study Donor\tAge\tSex\tRace\tViability (%) XVN\t57\tM\tCaucasian\t93 IWM\t46\tM\tCaucasian\t93 BXW\t73\tF\tCaucasian\t90 Open in a separate window  F, female; M, male.", {"entities": [[81, 94, "Parameter"], [99, 101, "Age"], [102, 103, "Sex"], [104, 113, "Ethnic group"], [114, 116, "Amount"], [121, 123, "Age"], [124, 125, "Sex"], [126, 135, "Ethnic group"], [136, 138, "Amount"], [143, 145, "Age"], [146, 147, "Sex"], [148, 157, "Ethnic group"], [158, 160, "Amount"], [188, 197, "Sex"], [199, 206, "Sex"]]}], [2077, "Determination of ATP Content in Hepatocyte Cultures.", {"entities": [[17, 20, "Parameter"]]}], [2078, "Cells from donor XVN were cultured as described above.", {"entities": []}], [2079, "On days 2\u20134 of culture, hepatocytes were treated in triplicate with culture medium containing positive control (25 \u00b5M tamoxifen), vehicle control (0.1% DMSO), or CAW-R61J (20, 250, or 1000 \u00b5g/ml).", {"entities": [[112, 117, "Amount"], [118, 127, "Drug"], [147, 151, "Amount"], [152, 156, "Parameter"], [162, 170, "Herb name"], [172, 174, "Amount"], [176, 179, "Amount"], [184, 194, "Amount"]]}], [2080, "After exposure, culture plates were harvested for ATP analysis.", {"entities": [[50, 53, "Parameter"]]}], [2081, "Cellular content of ATP was determined using the CellTiter-Glo Assay Kit provided by Promega (Madison, WI) per the manufacturer\u2019s instructions.", {"entities": [[20, 23, "Parameter"]]}], [2082, "A sample of fresh culture medium was included as a no-cell control, and luminescence of all samples was recorded using a Biotek Synergy 4 microplate reader (Winooski, VT).", {"entities": []}], [2083, "Determination of P450 mRNA Levels in Cultured Hepatocytes.", {"entities": [[17, 33, "Parameter"]]}], [2084, "After incubation with the P450 probe substrate cocktail, the cultures were washed 2\u00d7 with 0.5 ml/well Hank\u2019s balanced salt solution (HBSS).", {"entities": [[26, 30, "Parameter"], [90, 101, "Amount"], [102, 138, "Extraction process"]]}], [2085, "Plates were thawed at ambient temperature.", {"entities": []}], [2086, "Lysates were thawed, and total RNA was isolated from each treatment group using the RNeasy 96 Kit (Qiagen) following the manufacturer\u2019s instructions.", {"entities": []}], [2087, "Isolated RNA was quantified using Quant-iT RiboGreen RNA Assay Kit (Thermo Fisher Scientific) following the manufacturer\u2019s instructions.", {"entities": []}], [2088, "Total RNA (500 ng) was converted to cDNA following the manufacturer\u2019s procedure for the High Capacity cDNA Reverse Transcription Kit (Thermo Fisher Scientific) on a MiniAmp Plus thermocycler (Thermo Fisher Scientific).", {"entities": [[0, 9, "Parameter"], [11, 17, "Amount"], [36, 40, "Parameter"]]}], [2089, "cDNA from human hepatocyte cultures was analyzed from each reverse transcription reaction using the gene-specific TaqMan assays (Thermo Fisher Scientific) for CYP1A2, CYP2B6, and CYP3A4.", {"entities": [[159, 165, "Parameter"], [167, 173, "Parameter"], [179, 185, "Parameter"]]}], [2090, "Glyceraldehyde-3-phosphate dehydrogenase was used as an endogenous control for gene expression analysis.", {"entities": [[0, 40, "Parameter"]]}], [2091, "Amplifications were performed on a ViiA 7 Real-Time Polymerase Chain Reaction System (Thermo Fisher Scientific) in relative quantification mode for 45 amplification cycles using standard conditions for TaqMan-based assays.", {"entities": []}], [2092, "Threshold cycle (Ct) determinations were performed by the ViiA 7 system software for both target and endogenous control genes.", {"entities": []}], [2093, "Relative-fold mRNA content was determined for each treatment group relative to the endogenous control gene expression and the calibrator (0.1% DMSO vehicle control).", {"entities": [[0, 26, "Parameter"], [138, 142, "Amount"], [143, 147, "Parameter"]]}], [2094, "Determination of P450 Activity in Hepatocyte Cultures.", {"entities": [[17, 30, "Parameter"]]}], [2095, "At the end of the treatment period, CYP1A2, CYP2B6, and CYP3A4/5 activity was determined in situ using a method based on Pelletier et al.", {"entities": [[36, 73, "Parameter"]]}], [2096, "(2013).", {"entities": []}], [2097, "The treatment medium was aspirated, and the cultures were washed 2\u00d7 with 0.5 ml of HBSS and then incubated with 0.3 ml/well HBSS containing a P450 probe substrate cocktail for CYP1A2 (100 \u00b5M phenacetin), CYP2B6 (500 \u00b5M bupropion), and CYP3A4 (10 \u00b5M midazolam).", {"entities": [[65, 79, "Amount"], [83, 87, "Extraction process"], [112, 123, "Amount"], [124, 128, "Extraction process"], [142, 146, "Parameter"], [176, 182, "Parameter"], [184, 190, "Amount"], [191, 201, "Drug"], [204, 210, "Parameter"], [212, 218, "Amount"], [219, 228, "Drug"], [235, 241, "Parameter"], [243, 248, "Amount"], [249, 258, "Drug"]]}], [2098, "Sample Preparation for LC-MS/MS Analysis.", {"entities": []}], [2099, "Internal standard solution (300 \u00b5l containing 200 nM d4-acetaminophen, 200 nM d6-hydroxybupropion, and 200 nM d4-1\u2032-hydroxymidazolam in 100% MeOH) was added to each sample (100 \u00b5l) in a 96-well deep-well plate.", {"entities": [[28, 34, "Amount"], [46, 52, "Amount"], [53, 69, "Drug"], [71, 77, "Amount"], [78, 97, "Drug"], [103, 109, "Amount"], [110, 132, "Amount"], [136, 140, "Amount"], [141, 145, "Extraction process"], [173, 179, "Amount"]]}], [2100, "After shaking for 15 minutes, the samples were transferred to a Whatman 96-well Unifilter 25-\u00b5m 0.45-\u00b5m melt-blown polypropylene filter plate (7770-0062; Whatman) stacked on a 96-well deep-well plate.", {"entities": [[14, 28, "Duration"]]}], [2101, "Samples were filtered into the deep-well plate by centrifugation.", {"entities": []}], [2102, "The sample filtrate was evaporated to dryness and reconstituted in 150 \u00b5l of sample diluent (30:70 methanol:5 mM ammonium acetate) and mixed for at least 10 minutes on a plate shaker.", {"entities": [[67, 73, "Amount"], [93, 129, "Extraction process"], [141, 164, "Duration"]]}], [2103, "The reconstituted samples were transferred to a Millipore 0.45-\u00b5m filter plate (MSHVN45; Millipore) and filtered into a Costar 3957 plate by centrifugation.", {"entities": []}], [2104, "Plates were sealed with a silicone cap mat prior to LC-MS/MS analysis.", {"entities": []}], [2105, "LC-MS/MS Analysis.", {"entities": []}], [2106, "LC-MS/MS was conducted using a Thermo Fisher Scientific Vanquish system (Palo Alto, CA) connected to a Thermo Fisher Scientific TSQ Quantis Triple Quadrupole mass spectrometer equipped with an OptaMax NG ionization source and heated electrospray ionization probe.", {"entities": []}], [2107, "Chromatographic separation was achieved using a Thermo Scientific Hypersil Gold C18 column (50 mm \u00d7 1 mm, 1.9 \u00b5m; Bellefont, PA).", {"entities": []}], [2108, "The injection volume was 2 \u00b5l, and three technical replicates were carried out.", {"entities": []}], [2109, "The gradient started at 10% B, increasing to 100% B over 1 minute, holding at 100% B for 1 minute, and then returning to 10% B. Analytes (probe substrate metabolites) and internal standards were detected using electrospray ionization in positive ion mode (Table 2).", {"entities": [[24, 27, "Amount"], [45, 49, "Amount"], [78, 82, "Amount"], [85, 97, "Duration"], [121, 124, "Amount"]]}], [2110, "Determination of Reversible P450 Inhibition in HLM.", {"entities": [[28, 32, "Parameter"]]}], [2111, "Pooled HLMs (n = 150, mixed sex, lot IGF) obtained from BioIVT were used.", {"entities": [[37, 40, "Parameter"]]}], [2112, "A 4\u00d7 stock solution (4 mg/ml) of CAW-R61J in 100 mM potassium phosphate buffer, pH 7.4 (KPi), was made and was diluted to give a series of 4\u00d7 stock solutions.", {"entities": [[21, 28, "Amount"], [33, 41, "Herb name"], [45, 51, "Amount"], [52, 78, "Extraction process"], [80, 82, "Parameter"], [83, 86, "Amount"]]}], [2113, "The reaction components and conditions for each P450 are given in Table 3.", {"entities": [[48, 52, "Parameter"]]}], [2114, "The final organic solvent in all incubations was \u22641% DMSO and \u22640.9% of methanol and/or acetonitrile.", {"entities": [[49, 52, "Amount"], [53, 57, "Parameter"], [62, 67, "Amount"], [71, 99, "Extraction process"]]}], [2115, "A solvent control was carried out for each condition to 100% control activity.", {"entities": []}], [2116, "All reactions were terminated by the addition of an equal volume of acetonitrile containing stable-labeled internal standard (Table 2).", {"entities": [[68, 80, "Extraction process"]]}], [2117, "The samples were vortexed and centrifuged for 5 minutes to sediment the precipitated protein.", {"entities": [[42, 55, "Duration"]]}], [2118, "Cleared supernatants were transferred to fresh plates and used for the quantitation of the appropriate P450 probe substrate metabolite (Table 2) by LC-MS/MS as described earlier.", {"entities": [[103, 107, "Parameter"]]}], [2119, "Determination of P450 Time-Dependent Inhibition in HLM.", {"entities": [[17, 47, "Parameter"]]}], [2120, "Lot IGF of HLM was used as above.", {"entities": [[4, 7, "Parameter"]]}], [2121, "Potential TDI of P450 enzyme activity by CAW-R61J was determined using the shift in IC50 values between 30-minute preincubations in the presence and absence of NADPH.", {"entities": [[0, 37, "Parameter"], [41, 49, "Herb name"], [84, 88, "Parameter"], [104, 113, "Duration"], [160, 165, "Parameter"]]}], [2122, "Preincubation reactions were assembled in 96-well plates containing HLM (1 mg/ml), CAW-R61J or control, and KPi (Table 9).", {"entities": [[83, 91, "Herb name"]]}], [2123, "All reactions were terminated by the addition of an equal volume of acetonitrile containing stable-labeled internal standard (Table 2).", {"entities": [[68, 80, "Extraction process"]]}], [2124, "The samples were vortexed and centrifuged for 5 minutes to sediment the precipitated protein.", {"entities": [[42, 55, "Duration"]]}], [2125, "Cleared supernatants were transferred to fresh plates and used for the quantitation of the appropriate P450 probe substrate metabolite (Table 2) by LC-MS/MS as described earlier.", {"entities": [[103, 107, "Parameter"]]}], [2126, "Unless otherwise specified, all results were expressed as the means \u00b1 S.D.", {"entities": []}], [2127, "of triplicate determinations.", {"entities": []}], [2129, "P450 mRNA Induction Data Analysis.", {"entities": [[0, 19, "Parameter"]]}], [2130, "The Ct values (the fractional cycle number at which the fluorescence passes the fixed threshold) were determined as described above.", {"entities": [[4, 6, "Parameter"], [15, 95, "Parameter"]]}], [2131, "Each target gene sample was normalized (\u0394Ct) by subtracting the Ct for its corresponding endogenous control (glyceraldehyde-3-phosphate dehydrogenase).", {"entities": [[40, 43, "Parameter"], [64, 66, "Parameter"], [109, 149, "Parameter"]]}], [2132, "In addition, the \u0394\u0394Ct was determined for positive control inducers and the test articles by subtracting the \u0394Ct of its corresponding solvent control.", {"entities": [[17, 21, "Parameter"], [108, 111, "Parameter"]]}], [2133, "Fold changes in target gene expression were determined by taking 2 to the power of the \u0394\u0394Ct (2\u2212\u0394\u0394Ct).", {"entities": [[87, 91, "Parameter"], [93, 99, "Parameter"]]}], [2134, "For comparison of mRNA responses, the percent of treatment induction response as compared with the positive control induction response was calculated using eq.", {"entities": [[18, 32, "Parameter"], [34, 77, "Parameter"], [95, 134, "Parameter"]]}], [2135, "1, where CYP mRNA FOCSample is the mRNA fold over control (FOC) value of the CAW-R61J\u2013treated samples, CYP mRNA FOCVehicle is the mRNA FOC value of 0.1% DMSO\u2013treated samples, and CYP mRNA FOCPos Con is the mRNA FOC value of positive control\u2013treated samples.", {"entities": [[9, 27, "Parameter"], [77, 85, "Herb name"], [103, 122, "Parameter"], [148, 152, "Amount"], [153, 157, "Parameter"], [179, 198, "Parameter"]]}], [2136, "To signify induction, a threshold of 2-fold over the vehicle control response and at least 20% of the relevant positive control response was used, a threshold proposed by the FDA (U.S. Food and Drug Administration, 2020).", {"entities": [[11, 20, "Parameter"], [91, 94, "Parameter"]]}], [2137, "equation image (1)  Statistical significance was determined by ordinary one-way ANOVA and the Bonferroni multiple comparisons test with 0.1% as the control.", {"entities": []}], [2138, "Differences with P values > 0.05 were considered significant.", {"entities": []}], [2139, "To determine the EC50 and maximal effect (Emax) values, the data from concentration-response (FOC values) curves were fitted to a four-parameter sigmoid (Hill) model, according to eq.", {"entities": [[17, 21, "Parameter"], [26, 47, "Parameter"], [70, 105, "Parameter"]]}], [2140, "2. equation image (2)  P450 Activity Induction Data Analysis.", {"entities": [[23, 46, "Parameter"]]}], [2141, "Activity of CYP1A2, CYP2B6, and CYP3A4/5 was determined in picomoles per minute per 106 plated hepatocytes.", {"entities": [[12, 18, "Parameter"], [20, 26, "Parameter"], [32, 40, "Parameter"]]}], [2142, "The fold induction over the control was calculated by dividing the activity in the treated sample by the vehicle control activity and multiplying by 100.", {"entities": []}], [2143, "To determine the percentage of the positive control, the eq.", {"entities": []}], [2144, "3 was used, where CYP Activity FOCSample is the activity FOC values of the CAW-R61J\u2013treated samples, CYP Activity FOCVehicle is the activity FOC values of the 0.1% DMSO\u2013treated samples, and CYP Activity FOCPos Con is the activity FOC value of positive control\u2013treated samples.", {"entities": [[18, 40, "Parameter"], [75, 83, "Herb name"], [101, 124, "Parameter"], [159, 163, "Amount"], [164, 168, "Parameter"], [190, 209, "Parameter"]]}], [2145, "equation image (3)  To signify induction, a threshold of 40% of the positive control response was used, a threshold proposed by Fahmi et al.", {"entities": [[31, 40, "Parameter"], [57, 60, "Amount"]]}], [2146, "(2010).", {"entities": []}], [2147, "P450 Inhibition Data Analysis.", {"entities": [[0, 4, "Target"]]}], [2148, "The peak area ratio (PAR) of probe substrate metabolite to internal standard was determined for all the P450 inhibition samples.", {"entities": [[0, 25, "Parameter"], [104, 108, "Target"]]}], [2149, "The values for the vehicle-treated control samples were taken as 100% P450 activity and compared with the treated samples to determine the percentage of P450 activity.", {"entities": [[65, 69, "Amount"], [70, 83, "Parameter"], [153, 166, "Parameter"]]}], [2150, "The PAR of the treated samples was divided by the PAR of the control and multiplied by 100 to get the percentage of control activity.", {"entities": [[0, 30, "Parameter"], [46, 68, "Parameter"], [87, 90, "Amount"]]}], [2151, "To determine the IC50 values, the concentration-response (percentage control value) curves were fitted to a four-parameter sigmoid (Hill) model, according to eq.", {"entities": [[13, 28, "Parameter"], [30, 83, "Parameter"]]}], [2152, "2 above (substituting logEC50 for logIC50).", {"entities": [[22, 29, "Parameter"], [34, 41, "Parameter"]]}], [2153, "The percent TDI is the net time-dependent inhibition and was determined by taking the percent inhibition of the positive TDI control in the presence of NADPH during the 30-minute preincubation and subtracting the percent inhibition of the positive TDI control in the absence of NADPH.", {"entities": [[0, 15, "Parameter"], [82, 104, "Parameter"], [152, 157, "Parameter"], [169, 178, "Duration"], [209, 231, "Parameter"], [278, 283, "Parameter"]]}], [2154, "Graph Plotting Software.", {"entities": []}], [2155, "All curve fitting was carried out using Prism 8.0.2 (GraphPad Software, San Diego, CA).", {"entities": []}], [2157, "The composition of CAW-R61J used in this study with respect to characteristic centelloid and caffeoylquinic acid components was determined using precursor ion quantification by LC-HRMS (Table 4).", {"entities": [[19, 27, "Herb name"], [78, 88, "Herb name"], [93, 112, "Herb name"]]}], [2158, "Detailed untargeted LC-HRMS fingerprint of CAW-R61J, recorded using positive and negative electrospray ionization, is available upon request to the corresponding author.", {"entities": [[43, 51, "Herb name"]]}], [2159, "TABLE 4  CAW-R61J composition Compound\tAmount of Compound (mg/g Dry Extract) Asiaticoside\t64.13 \u00b1 0.78 Madecassoside\t47.26 \u00b1 6.22 Asiatic acid\t2.75 \u00b1 0.02 Madecassic acid\t3.49 \u00b1 0.26 5-O-Caffeoylquinic acid\t1.47 \u00b1 0.01 4-O-Caffeoylquinic acid\t0.54 \u00b1 0.01 3-O-Caffeoylquinic acid\t2.21 \u00b1 0.08 1,5-Dicaffeoylquinic acid\t0.40 \u00b1 0.01 1,3-Dicaffeoylquinic acid\t0.50 \u00b1 0.01 3,4-Dicaffeoylquinic acid\t1.19 \u00b1 0.04 3,5-Dicaffeoylquinic acid\t1.05 \u00b1 0.01 4,5-Dicaffeoylquinic acid\t1.25 \u00b1 0.03 Open in a separate window  Evaluation of Cytotoxicity Prior to P450 Induction Studies.", {"entities": [[9, 17, "Herb name"], [59, 75, "Herb name"], [77, 89, "Herb name"], [90, 102, "Amount"], [103, 116, "Herb name"], [117, 129, "Amount"], [130, 142, "Herb name"], [143, 154, "Amount"], [155, 170, "Herb name"], [171, 182, "Amount"], [183, 206, "Herb name"], [207, 218, "Amount"], [219, 242, "Herb name"], [243, 254, "Amount"], [255, 278, "Herb name"], [279, 290, "Amount"], [291, 316, "Herb name"], [317, 328, "Amount"], [329, 354, "Herb name"], [355, 366, "Amount"], [367, 392, "Herb name"], [393, 404, "Amount"], [405, 430, "Herb name"], [431, 442, "Amount"], [443, 468, "Herb name"], [469, 480, "Amount"], [522, 534, "Parameter"], [544, 548, "Parameter"]]}], [2160, "SCHHs were treated with 20, 250, or 1000 \u00b5g/ml CAW-R61J for 72 hours, and ATP levels were measured.", {"entities": [[24, 26, "Amount"], [28, 31, "Amount"], [36, 46, "Amount"], [47, 55, "Herb name"], [56, 68, "Duration"], [74, 84, "Parameter"]]}], [2161, "The positive control, 25 \u00b5M tamoxifen, caused significant deterioration of the cultures and a complete loss of ATP from the cultures (Fig.", {"entities": [[22, 27, "Amount"], [28, 37, "Drug"], [111, 114, "Parameter"]]}], [2162, "1).", {"entities": []}], [2163, "We have previously used 50 \u00b5g/ml of CAW-R61J with no observed cellular stress in studies with neuroblastoma cells and primary neurons (Gray et al., 2014, 2015, 2017a,b).", {"entities": [[24, 32, "Amount"], [36, 44, "Herb name"]]}], [2165, "An external file that holds a picture, illustration, etc.", {"entities": []}], [2166, "Object name is dmd.120.090860f1.jpg Fig.", {"entities": []}], [2167, "1.", {"entities": []}], [2169, "ATP levels were measured and normalized to the ATP content in the 0.1% DMSO vehicle control.", {"entities": [[0, 10, "Parameter"], [47, 50, "Parameter"], [66, 70, "Amount"], [71, 75, "Parameter"]]}], [2170, "***P < 0.001; n = 3 per treatment.", {"entities": []}], [2171, "Centelloid and Caffeoylquinic Acid Stability in Medium and Hepatocyte Cell Culture.", {"entities": [[0, 10, "Herb name"], [15, 34, "Herb name"]]}], [2172, "The centelloids were easily detectable in samples held at both temperatures.", {"entities": [[0, 15, "Herb name"], [63, 75, "Parameter"]]}], [2173, "Differences in the size of the percent change are likely due to their relative abundance in CAW (Table 4).", {"entities": [[92, 95, "Herb name"]]}], [2174, "Samples of the culture media during hepatocyte incubations were taken at 6 and 24 hours after the last addition of CAW-R61J and were compared with the original dosing solutions (CAW-R61J 5.6, 16.7 and 50 \u00b5g/ml) for the content of some known components using LC-HRMS (Table 5).", {"entities": [[115, 123, "Herb name"], [178, 186, "Herb name"], [187, 190, "Amount"], [192, 196, "Amount"], [201, 209, "Amount"]]}], [2176, "All of the caffeoylquinic acids were detected in the 50-\u00b5g/ml dose of CAW-R61J, but their levels had reduced considerably (>50%) by 6 hours.", {"entities": [[7, 31, "Herb name"], [53, 61, "Amount"], [70, 78, "Herb name"], [124, 127, "Amount"], [132, 139, "Duration"]]}], [2177, "Madecassoside, madecassic acid, asiaticoside, and asiatic acid were easily detectable in the samples at all starting concentrations.", {"entities": [[0, 13, "Herb name"], [15, 30, "Herb name"], [32, 44, "Herb name"], [50, 62, "Herb name"], [117, 131, "Parameter"]]}], [2178, "The centelloid glycosides madecassoside and asiaticoside showed modest increases over 24 hours.", {"entities": [[0, 56, "Herb name"], [86, 94, "Duration"]]}], [2179, "TABLE 5  Metabolic stability of CAW-R61J components during the final 24 h of SCHH treatment Compound\t5.6 \u00b5g/ml CAW-R61J\t16.7 \u00b5g/ml CAW-R61J\t50 \u00b5g/ml CAW-R61J Time 0 Amount of Compound (ng/ml)\t% of Time 0\tTime 0 Amount of Compound (ng/ml)\t% of Time 0\tTime 0 Amount of Compound (ng/ml)\t% of Time 0 6 h\t24 h\t6 h\t24 h\t6 h\t24 h 5-O-Caffeoylquinic acid\t0.7 \u00b1 0.1\t70\t0\t4 \u00b1 1\t92\t0\t9 \u00b1 1\t46\t32 4-O-Caffeoylquinic acid\tBLQ\tBLQ\tBLQ\tBLQ\tBLQ\tBLQ\t20 \u00b1 1\t0\t0 3-O-Caffeoylquinic acid\tBLQ\tBLQ\tBLQ\tBLQ\tBLQ\tBLQ\t13 \u00b1 1\t0\t0 1,5-Dicaffeoylquinic acid\tBLQ\tBLQ\tBLQ\t0.9 \u00b1 0.1\t0\t0\t3.8 \u00b1 0.1\t30\t0 1,3-Dicaffeoylquinic acid\tBLQ\tBLQ\tBLQ\t0.7 \u00b1 0.1\t0\t0\t3.7 \u00b1 0.1\t29\t28 3,4-Dicaffeoylquinic acid\t4 \u00b1 1\t0\t0\t11 \u00b1 1\tBLQ\tBLQ\t41 \u00b1 5\t31\t21 3,5-Dicaffeoylquinic acid\tBLQ\tBLQ\tBLQ\tBLQ\tBLQ\tBLQ\t17 \u00b1 1\t0\t0 4,5-Dicaffeoylquinic acid\tBLQ\tBLQ\tBLQ\tBLQ\tBLQ\tBLQ\t28 \u00b1 2\t0\t0 Quinic acid\t38 \u00b1 2\t101\t149\t102 \u00b1 4\t106\t153\t303 \u00b1 10\t95\t131 Madecassoside\t155 \u00b1 3\t100\t121\t367 \u00b1 44\t125\t145\t1222 \u00b1 129\t104\t116 Asiaticoside\t123 \u00b1 18\t97\t113\t383 \u00b1 38\t113\t130\t1402 \u00b1 152\t92\t101 Asiatic acid\t17 \u00b1 3\t81\t63\t27 \u00b1 2\t76\t41\t69 \u00b1 3\t65\t19 Madecassic acid\t11 \u00b1 2\t76\t54\t43 \u00b1 1\t80\t60\t136 \u00b1 6\t91\t88 Open in a separate window  BLQ, below the limit of quantitation.", {"entities": [[32, 40, "Herb name"], [69, 73, "Duration"], [101, 110, "Amount"], [111, 119, "Herb name"], [120, 130, "Amount"], [131, 139, "Herb name"], [140, 148, "Amount"], [149, 157, "Herb name"], [165, 191, "Parameter"], [211, 237, "Parameter"], [257, 284, "Parameter"], [323, 346, "Herb name"], [385, 408, "Herb name"], [444, 467, "Herb name"], [503, 528, "Herb name"], [570, 595, "Herb name"], [638, 663, "Herb name"], [702, 727, "Herb name"], [763, 788, "Herb name"], [824, 835, "Herb name"], [883, 896, "Herb name"], [949, 961, "Herb name"], [1013, 1025, "Herb name"], [1065, 1080, "Herb name"]]}], [2180, "Effect of CAW-R61J on mRNA Expression in SCHH.", {"entities": [[10, 18, "Herb name"], [22, 37, "Parameter"]]}], [2181, "Treatment of SCHH with the positive control P450 inducers (10 \u00b5M rifampicin, 1000 \u00b5M phenobarbital, and 50 \u00b5M omeprazole) resulted in significant increases in mRNA levels for the appropriate target gene in every donor (Table 6).", {"entities": [[44, 48, "Target"], [59, 64, "Amount"], [65, 75, "Drug"], [77, 84, "Amount"], [85, 98, "Drug"], [104, 109, "Amount"], [110, 120, "Drug"], [159, 170, "Parameter"]]}], [2182, "The negative control (25 \u00b5M flumazenil) did not cause significant induction of any mRNA signal above the vehicle control, indicating a responsive test system (Table 6).", {"entities": [[22, 27, "Amount"], [28, 38, "Drug"], [83, 94, "Parameter"]]}], [2183, "Treatment with CAW-R61J (0.02\u201350 \u00b5g/ml) did not result in the induction of CYP1A2, CYP2B6, or CYP3A4 mRNA with any donor (Fig.", {"entities": [[15, 23, "Herb name"], [25, 38, "Amount"], [75, 105, "Target"]]}], [2184, "2A).", {"entities": []}], [2186, "TABLE 6  Induction of P450 mRNA in SCHH after treatment of 72 h with DMSO, flumazenil, omeprazole, phenobarbital, or rifampicin P450\tConcentration\tXVN\tIWM\tBXW Fold over Vehicle Control\t% Positive Control\tFold over Vehicle Control\t% Positive Control\tFold over Vehicle Control\t% Positive Control Mean\tS.D.", {"entities": [[22, 31, "Target"], [59, 63, "Duration"], [69, 73, "Parameter"], [75, 85, "Drug"], [87, 97, "Drug"], [99, 112, "Drug"], [117, 127, "Drug"], [128, 146, "Parameter"]]}], [2187, "Mean\tS.D.", {"entities": []}], [2188, "Mean\tS.D.", {"entities": []}], [2189, "Mean\tS.D.", {"entities": []}], [2190, "Mean\tS.D.", {"entities": []}], [2191, "Mean\tS.D.", {"entities": []}], [2192, "1A2\t0.1% DMSO\t1.3\t0.89\t0.0\t1.2\t1.5\t1.6\t0.0\t24\t1.0\t0.046\t0.0\t0.18 25 \u00b5M Flumazenil\t3.8\tNA\t3.3\tNA\t0.91\t0.080\t\u22128.6\t1.2\t1.8\t0.59\t3.0\t2.3 50 \u00b5M Omeprazole\t77***\tNA\t100\tNA\t8.2***\t1.8\t100\t27\t26***\t1.8\t100\t7.0 2B6\t0.1% DMSO\t1.0\t0.045\t0.0\t0.41\t1.0\t0.037\t0.0\t0.16\t1.1\t0.41\t0.0\t2.8 25 \u00b5M Flumazenil\t1.4\t0.11\t3.4\t0.99\t1.7\t0.16\t3.2\t0.73\t1.9\t0.38\t6.0\t2.6 1000 \u00b5M Phenobarbital\t12***\t1.3\t100\t11\t23***\t7.6\t100\t34\t16***\t2.7\t100\t18 3A4\t0.1% DMSO\t1.0\t0.18\t0.0\t0.46\t1.0\t0.045\t0.0\t0.18\t1.0\t0.20\t0.0\t1.4 25 \u00b5M Flumazenil\t1.7\t0.26\t1.9\t0.67\t1.2\t0.065\t0.93\t0.26\t2.0\t0.25\t6.7\t1.7 10 \u00b5M Rifampicin\t40***\t4.9\t100\t12***\t26\t4.8\t100\t19\t16***\t0.40\t100\t2.7 Open in a separate window  NA, not applicable; n = 2.", {"entities": [[4, 8, "Amount"], [9, 13, "Parameter"], [65, 70, "Amount"], [71, 81, "Drug"], [133, 138, "Amount"], [139, 149, "Drug"], [206, 210, "Amount"], [211, 215, "Parameter"], [271, 276, "Amount"], [277, 287, "Drug"], [341, 348, "Amount"], [349, 362, "Drug"], [418, 422, "Amount"], [423, 427, "Parameter"], [482, 487, "Amount"], [488, 498, "Drug"], [554, 559, "Amount"], [560, 570, "Drug"]]}], [2193, "***P < 0.0001.", {"entities": []}], [2194, "An external file that holds a picture, illustration, etc.", {"entities": []}], [2195, "Object name is dmd.120.090860f2.jpg Fig.", {"entities": []}], [2196, "2.", {"entities": []}], [2198, "Fold change of P450 mRNA (A) or P450 activity (B) is plotted relative to the vehicle control (0.1% DMSO) after treatment with CAW-R61J for 72 hours.", {"entities": [[15, 24, "Parameter"], [32, 45, "Parameter"], [94, 98, "Amount"], [99, 103, "Parameter"], [126, 134, "Herb name"], [135, 147, "Duration"]]}], [2199, "Data shown are the means and S.E.", {"entities": []}], [2200, "of a triplicate determination in three individual hepatocyte donors.", {"entities": []}], [2201, "\u25cf, donor XVN; \u25a0, donor IWM; \u25b2, donor BXW; #, n = 2 for donor XVN.", {"entities": []}], [2202, "Data from the 50-\u03bcg/ml condition is not shown due to cytotoxicity being observed at this concentration.", {"entities": [[14, 22, "Amount"], [53, 65, "Pathology"], [89, 102, "Parameter"]]}], [2203, "Effect of CAW-R61J on Enzyme Activity.", {"entities": [[10, 18, "Herb name"], [22, 37, "Parameter"]]}], [2204, "The effect of CAW-R61J on the enzymatic activity levels of CYP1A2, CYP2B6, and CYP3A4 was examined in parallel with the mRNA levels described above.", {"entities": [[14, 22, "Herb name"], [26, 85, "Parameter"], [116, 131, "Parameter"]]}], [2205, "Both mRNA and activity data were gathered from a single well of SCHH.", {"entities": [[5, 9, "Parameter"], [14, 22, "Parameter"]]}], [2206, "The positive control P450 inducers (50 \u00b5M omeprazole, 1000 \u00b5M phenobarbital, and 10 \u00b5M rifampicin) resulted in significant increases in activity levels for the appropriate target genes with all three donors (Table 7).", {"entities": [[21, 25, "Target"], [36, 41, "Amount"], [42, 52, "Drug"], [54, 61, "Amount"], [62, 75, "Drug"], [81, 86, "Amount"], [87, 97, "Drug"], [136, 151, "Parameter"]]}], [2207, "The negative control (25 \u00b5M flumazenil) did not cause significant induction of enzyme activity above the vehicle control, indicating a responsive test system (Table 7).", {"entities": [[22, 27, "Amount"], [28, 38, "Drug"], [79, 94, "Parameter"]]}], [2208, "CAW-R61J treatment did not result in the induction of CYP1A2, CYP2B6, or CYP3A4 activity in hepatocytes from any donor (Fig.", {"entities": [[0, 8, "Herb name"], [54, 88, "Parameter"]]}], [2209, "2B).", {"entities": []}], [2211, "2A).", {"entities": []}], [2212, "TABLE 7  Induction of P450 activity in SCHH after treatment of 72 h with DMSO, flumazenil, omeprazole, phenobarbital, or rifampicin P450\tConcentration\tXVN\tIWM\tBXW Fold over Vehicle Control\t% Positive Control\tFold over Vehicle Control\t% Positive Control\tFold over Vehicle Control\t% Positive Control Mean\tS.D.", {"entities": [[22, 35, "Parameter"], [63, 67, "Duration"], [73, 77, "Parameter"], [79, 89, "Drug"], [91, 101, "Drug"], [103, 116, "Drug"], [121, 131, "Drug"], [132, 150, "Parameter"]]}], [2213, "Mean\tS.D.", {"entities": []}], [2214, "Mean\tS.D.", {"entities": []}], [2215, "Mean\tS.D.", {"entities": []}], [2216, "Mean\tS.D.", {"entities": []}], [2217, "Mean\tS.D.", {"entities": []}], [2218, "1A2\t0.1% DMSO\t1.0\t0.087\t0.0\t0.41\t1.0\t0.13\t0.0\t0.91\t1.0\t0.051\t0.0\t0.38 25 \u00b5M Flumazenil\t1.4\t0.21\t2.0\t1.0\t1.3\t0.13\t2.4\t0.91\t1.5\t0.62\t3.5\t4.6 50 \u00b5M Omeprazole\t22***\t2.1\t100\t9.7\t15***\t1.4\t100\t10\t14***\t1.8\t100\t14 2B6\t0.1% DMSO\t1.0\t0.082\t0.0\t2.0\t1.0\t0.069\t0.0\t2.9\t1.0\t0.11\t0.0\t3.3 25 \u00b5M Flumazenil\t1.0\t0.083\t0.99\t2.0\t1.1\t0.090\t4.0\t3.8\t1.2\t0.092\t6.4\t2.8 1000 \u00b5M Phenobarbital\t5.1***\t0.44\t100\t11\t3.4***\t0.49\t100\t21\t4.3***\t0.17\t100\t5.3 3A4\t0.1% DMSO\t1.0\t0.036\t0.0\t0.46\t1.0\t0.070\t0.0\t0.90\t1.0\t0.45\t0.0\t10 25 \u00b5M Flumazenil\t1.1\t0.095\t1.1\t1.2\t1.1\t0.10\t1.2\t1.3\t0.92\t0.28\t\u22121.8\t6.4 10 \u00b5M Rifampicin\t8.8***\t0.49\t100\t6.3\t8.8***\t0.22\t100\t2.8\t5.3***\t1.8\t100\t42 Open in a separate window ***P < 0.0001.", {"entities": [[4, 8, "Amount"], [9, 13, "Parameter"], [70, 75, "Amount"], [76, 86, "Drug"], [139, 144, "Amount"], [145, 155, "Drug"], [212, 216, "Amount"], [217, 221, "Parameter"], [275, 280, "Amount"], [281, 291, "Drug"], [347, 354, "Amount"], [355, 368, "Drug"], [431, 435, "Amount"], [436, 440, "Parameter"], [495, 500, "Amount"], [501, 511, "Drug"], [566, 571, "Amount"], [572, 582, "Drug"]]}], [2219, "Cytotoxicity of CAW-R61J during SCHH Culture.", {"entities": [[0, 12, "Pathology"], [16, 24, "Herb name"]]}], [2220, "; data not shown).", {"entities": []}], [2221, "The concentration of 50 \u00b5g/ml did show signs of cytotoxicity at the latest time point; therefore, the data for this concentration are not included in Fig.", {"entities": [[0, 17, "Parameter"], [21, 29, "Amount"], [48, 60, "Pathology"], [116, 129, "Parameter"]]}], [2222, "2.", {"entities": []}], [2223, "Evaluation of Reversible P450 Inhibition.", {"entities": [[25, 29, "Target"]]}], [2224, "3; Table 8) in a manner consistent with the literature (Ring et al., 1996; Suzuki et al., 2002; Emoto et al., 2003; Walsky et al., 2006; VandenBrink et al., 2011; Zhao et al., 2012; Thu et al., 2017).", {"entities": []}], [2225, "CAW-R61J was found to be a relatively weak reversible inhibitor for most of the P450s tested.", {"entities": [[0, 8, "Herb name"], [80, 85, "Target"]]}], [2226, "The strongest reversible inhibition was against CYP2C9 (IC50 330 \u00b5g/ml), and the least inhibition was against CYP1A2 and CYP2B6 (IC50 > 1000 \u00b5g/ml).", {"entities": [[48, 54, "Target"], [56, 60, "Parameter"], [61, 70, "Amount"], [110, 116, "Target"], [121, 127, "Target"], [129, 133, "Parameter"], [134, 146, "Amount"]]}], [2227, "Dose-response curves are shown in Fig.", {"entities": []}], [2228, "3 for CYP3A4, CYP2D6, and CYP2C19.", {"entities": [[6, 12, "Parameter"], [14, 20, "Parameter"], [26, 33, "Parameter"]]}], [2229, "An external file that holds a picture, illustration, etc.", {"entities": []}], [2230, "Object name is dmd.120.090860f3.jpg Fig.", {"entities": []}], [2231, "3.", {"entities": []}], [2232, "Data shown are the means \u00b1 S.D.", {"entities": []}], [2233, "of triplicate determinations.", {"entities": []}], [2234, "CAW-R61J was not found to be a time-dependent inhibitor for any of the P450s tested up to 1000 \u00b5g/ml (Table 9).", {"entities": [[0, 8, "Herb name"], [71, 76, "Target"], [90, 100, "Amount"]]}], [2235, "For all P450 forms examined, there was virtually no difference between the dose-response curves with or without NADPH (Fig.", {"entities": [[8, 18, "Parameter"], [112, 117, "Parameter"]]}], [2236, "4).", {"entities": []}], [2237, "A shift of 1.5-fold in the IC50 that is NADPH- and time-dependent is the commonly used threshold to indicate time-dependent inhibition.", {"entities": [[27, 31, "Parameter"], [40, 46, "Parameter"]]}], [2238, "An external file that holds a picture, illustration, etc.", {"entities": []}], [2239, "Object name is dmd.120.090860f4.jpg Fig.", {"entities": []}], [2240, "4.", {"entities": []}], [2241, "Potential TDI of P450 enzyme activity by CAW-R61J was determined using the shift in IC50 values between 30-minute preincubations in the presence and absence of NADPH.", {"entities": [[10, 37, "Parameter"], [41, 49, "Herb name"], [84, 88, "Parameter"], [104, 113, "Duration"], [160, 165, "Parameter"]]}], [2242, "All reactions were performed in triplicate.", {"entities": []}], [2243, "Data shown are the means \u00b1 S.D.", {"entities": []}], [2244, "of triplicate determinations.", {"entities": []}], [2245, "Go to: Discussion  After several studies on the inhibitory potential of CA extracts and compounds, this is the first study investigating the effects of the specific type of CA extract (CAW-R61J; a hot water extract) prepared for use in our preclinical, phase I, and phase II clinical studies on P450 enzymes.", {"entities": [[72, 83, "Herb name"], [173, 193, "Herb name"], [195, 214, "Extraction process"], [240, 291, "Study"], [295, 307, "Parameter"]]}], [2246, "Plant extracts are complex, and their composition will vary depending on the source material and extraction method.", {"entities": [[0, 14, "Herb name"]]}], [2247, "Although the results of this study are specific to CAW-R61J, a range of doses were tested in an effort to encompass the variable levels of water-extractable compounds that may occur between this specific extract and other similarly prepared aqueous extracts.", {"entities": [[51, 59, "Herb name"], [139, 166, "Extraction process"], [241, 257, "Extraction process"]]}], [2248, "CAW-R61J was characterized by LC-HRMS to be able to relate its effects on P450 activity to specific concentrations of known active compounds.", {"entities": [[0, 8, "Herb name"], [74, 87, "Parameter"]]}], [2249, "Of these, the centelloids have a limited distribution in the plant kingdom, whereas the caffeoylquinic acids are common in numerous plants used in food and beverages.", {"entities": [[10, 25, "Herb name"], [84, 108, "Herb name"]]}], [2250, "This makes consideration of the effects of the centelloids on P450 induction and inhibition of particular importance.", {"entities": [[43, 58, "Herb name"], [62, 66, "Target"]]}], [2251, "In our preliminary studies, CAW-R61J did cause some cytotoxicity in the hepatocyte cultures at higher concentrations, which was unexpected based on data from previous neuroblastoma and primary neuron cell culture studies in which up to 200 \u00b5g/ml of CAW-R61J has been used (Soumyanath et al., 2012; Gray et al., 2015, 2017a,b).", {"entities": [[7, 26, "Study"], [28, 36, "Herb name"], [52, 64, "Pathology"], [102, 116, "Parameter"], [236, 245, "Amount"], [249, 257, "Herb name"]]}], [2252, "Because of this observation, it was decided that for the induction study, 50 \u00b5g/ml would be used as the highest concentration.", {"entities": [[74, 82, "Amount"], [112, 125, "Parameter"]]}], [2253, "However, because of toxicity observed at this concentration, only the data up to 16.7 \u03bcg/ml (the next-highest concentration tested) are considered.", {"entities": [[20, 28, "Pathology"], [46, 59, "Parameter"], [81, 91, "Amount"], [110, 123, "Parameter"]]}], [2254, "CAW-R61J, applied at up to 16.7 \u00b5g/ml, was found not to induce CYP1A2, CYP2B6, or CYP3A4 in SCHH.", {"entities": [[0, 8, "Herb name"], [27, 37, "Amount"], [63, 69, "Target"], [71, 77, "Target"], [82, 88, "Target"]]}], [2255, "Nevertheless, no induction of the enzymes was observed at the nontoxic or mildly cytotoxic concentrations of the extract tested.", {"entities": [[62, 70, "Pathology"], [74, 90, "Pathology"]]}], [2256, "Metabolic stability of the known CA compounds in media and during the induction experiment was examined.", {"entities": [[33, 45, "Herb name"]]}], [2257, "Although the caffeoylquinic acids were not stable throughout the dosing period, the centelloids were easily detectable and were relatively stable.", {"entities": [[9, 33, "Herb name"], [80, 95, "Herb name"]]}], [2258, "Caffeoylquinic acids degraded in medium alone over 24 hours, showing that their loss in SCHH incubations was not due to cellular metabolism alone.", {"entities": [[0, 20, "Herb name"], [51, 59, "Duration"]]}], [2259, "It can be noted (Table 5) that 24-hour recovery values for the triterpene glycosides exceed 100%.", {"entities": [[31, 38, "Duration"], [59, 84, "Herb name"], [92, 96, "Amount"]]}], [2260, "This may have been due to their release from breakdown of larger sugar-containing moieties.", {"entities": []}], [2261, "The aglycones do reduce in concentration over the 24-hour period, potentially because of metabolism, since they do not contain chemically labile functional groups.", {"entities": [[0, 13, "Herb name"], [27, 40, "Parameter"], [50, 64, "Duration"]]}], [2262, "Because of the stability of the centelloids, the relatively unique and suspected main active constituents of CA, it was decided to not carry out additional dosing during each 24-hour incubation period.", {"entities": [[28, 111, "Herb name"], [175, 182, "Duration"]]}], [2263, "At the end of the last dosing period of 16.7 \u03bcg/ml, the triterpene glycosides asiaticoside and madecassoside were present at approximately 1.1 and 0.8 \u00b5M, respectively, whereas the free aglycones asiatic acid and madecassic acid were present at 0.09 and 0.12 \u00b5M, respectively.", {"entities": [[40, 50, "Amount"], [52, 108, "Herb name"], [139, 142, "Amount"], [147, 153, "Amount"], [177, 228, "Herb name"], [245, 249, "Amount"], [254, 261, "Amount"]]}], [2264, "However, since they are ubiquitous in dietary plants, their effects on P450 are less significant than those of the centelloids.", {"entities": [[38, 52, "Herb name"], [71, 75, "Target"], [111, 126, "Herb name"]]}], [2265, "CAW-R61J (\u22641000 \u00b5g/ml) was not a time-dependent inhibitor of any P450 form tested.", {"entities": [[0, 8, "Herb name"], [10, 21, "Amount"], [65, 74, "Target"]]}], [2266, "However, it did exhibit weak, reversible inhibition of most P450 forms tested, with the greatest inhibition being of CYP2C9 (IC50 330 \u00b5g/ml) and the least inhibition of CYP1A2 and CYP2B6 (IC50 > 1000 \u00b5g/ml).", {"entities": [[60, 70, "Target"], [117, 123, "Target"], [125, 129, "Parameter"], [130, 139, "Amount"], [169, 175, "Target"], [180, 186, "Target"], [188, 192, "Parameter"], [195, 205, "Amount"]]}], [2267, "These results are consistent with previous phase I metabolic reaction studies in which a CA methanolic extract weakly inhibited human CYP3A4 (IC50 226 \u00b5g/ml), CYP2D6 (IC50 140 \u00b5g/ml), CYP2C9 (IC50 185 \u00b5g/ml), and CYP1A2 (IC50 289 \u00b5g/ml) (Kar et al., 2017).", {"entities": [[43, 77, "Study"], [89, 91, "Herb name"], [92, 110, "Extraction process"], [134, 140, "Parameter"], [142, 146, "Parameter"], [147, 156, "Amount"], [167, 171, "Parameter"], [172, 181, "Amount"], [184, 190, "Parameter"], [192, 196, "Parameter"], [197, 206, "Amount"], [213, 219, "Parameter"], [221, 225, "Parameter"], [226, 235, "Amount"]]}], [2268, "Similar results were observed with a CA methanolic extract in human liver microsomes (IC50 60\u2013109 \u00b5g/ml) (Savai et al., 2015b).", {"entities": [[37, 39, "Herb name"], [40, 58, "Extraction process"], [86, 90, "Parameter"], [91, 103, "Amount"]]}], [2270, "In human P450 forms expressed by Escherichia coli, the ethanol and dichloromethane extracts showed a higher inhibitory effect on CYP2C19, CYP2C9, CYP2D6, and CYP3A4 (IC50 17\u2013466 \u00b5g/ml) compared with the water (IC50 230\u2013615 \u00b5g/ml) or hexane (IC50 113\u2013397 \u00b5g/ml) extracts (Pan et al., 2010, 2011).", {"entities": [[9, 19, "Target"], [51, 91, "Extraction process"], [129, 164, "Target"], [166, 170, "Parameter"], [171, 183, "Amount"], [199, 208, "Extraction process"], [210, 214, "Parameter"], [215, 228, "Amount"], [233, 239, "Extraction process"], [241, 245, "Parameter"], [246, 259, "Amount"]]}], [2272, "This reinforces the need to investigate the specific botanical extract of interest for its P450 inhibitory and induction potential prior to clinical testing.", {"entities": [[91, 95, "Target"]]}], [2273, "Purified centelloids are weak inhibitors in human liver microsomes and human P450 forms expressed by E. coli of CYP2C19, CYP3A4, CYP2D6, and CYP2C9.", {"entities": [[9, 20, "Herb name"], [77, 81, "Parameter"], [112, 147, "Parameter"]]}], [2274, "Madecassic and asiatic acids were found to be more potent (IC50 61- > 495 \u00b5M and IC50 68\u2013139 \u00b5M, respectively) than asiaticoside (IC50 1116- > 1564 \u00b5M) (Pan et al., 2010, 2011; Savai et al., 2015b).", {"entities": [[0, 28, "Herb name"], [59, 63, "Parameter"], [64, 76, "Amount"], [81, 85, "Parameter"], [86, 95, "Amount"], [116, 128, "Herb name"], [130, 134, "Parameter"], [135, 150, "Amount"]]}], [2275, "This difference in potency has been proposed to be due to varying degrees of lipophilicity and hydrogen bonding between the aglycones and the glycosides (Pan et al., 2010).", {"entities": [[120, 133, "Herb name"], [138, 152, "Herb name"]]}], [2276, "Standard inhibitors of these P450 forms have considerably lower IC50 values (0.01\u20135.3 \u00b5M; Table 8), indicating just how weak these centelloids are as P450 inhibitors.", {"entities": [[29, 39, "Parameter"], [64, 68, "Parameter"], [77, 88, "Amount"], [131, 142, "Herb name"], [150, 154, "Parameter"]]}], [2277, "The observed lowest IC50 for CAW-R61J in this study (CYP2C9; 330 \u00b5g/ml) is equivalent to 16 \u00b5M madecassoside, 22.1 \u00b5M asiaticoside, 1.9 \u00b5M asiatic acid, and 2.3 \u00b5M madecassic acid.", {"entities": [[20, 24, "Parameter"], [29, 37, "Herb name"], [53, 59, "Parameter"], [61, 70, "Amount"], [89, 94, "Amount"], [95, 108, "Herb name"], [110, 117, "Amount"], [118, 130, "Herb name"], [132, 138, "Amount"], [139, 151, "Herb name"], [157, 163, "Amount"], [164, 179, "Herb name"]]}], [2278, "These concentrations are well below the IC50 values observed when testing the purified centelloids as described above.", {"entities": [[40, 44, "Parameter"], [87, 98, "Herb name"]]}], [2279, "Thus, other components in CAW-R61J must be responsible for, or contribute to, the inhibitory effects on CYP2C9, or the centelloids may act synergistically to inhibit CYP2C9.", {"entities": [[26, 34, "Herb name"], [104, 110, "Target"], [115, 130, "Herb name"], [166, 172, "Target"]]}], [2280, "It has been suggested that an IC50 of less than 100 \u03bcg/ml (for extracts) or 100 \u03bcM (for active constituents) should be classified as potent inhibition that could lead to undesirable herb-drug interactions (Obach, 2000; Pan et al., 2011).", {"entities": [[30, 34, "Parameter"], [48, 57, "Amount"], [76, 82, "Amount"]]}], [2281, "By this measure, CAW-R61J is not a potent P450 inhibitor, and it also showed no evidence of P450 induction.", {"entities": [[17, 25, "Herb name"], [42, 46, "Target"], [92, 96, "Target"]]}], [2282, "Based on the centelloid content of CAW-R61J, we expect similar plasma concentrations for these compounds in our clinical studies using this extract.", {"entities": [[9, 43, "Herb name"], [63, 104, "Parameter"], [112, 128, "Study"]]}], [2283, "Again, these levels are lower than the concentrations of these compounds found at the lowest IC50 of CAW-R61J (CYP2C9; 330 \u00b5g/ml).", {"entities": [[35, 72, "Parameter"], [93, 97, "Parameter"], [101, 109, "Herb name"], [111, 117, "Parameter"], [119, 128, "Amount"]]}], [2284, "Ultimately, the clinical relevance of the weak P450 inhibition seen in this study will depend on the IC50 values of the as yet unknown inhibitory CAW-R61J compounds and their in vivo concentration achieved in humans.", {"entities": [[47, 51, "Target"], [101, 105, "Parameter"], [146, 154, "Herb name"], [175, 196, "Parameter"]]}], [2285, "In making these comparisons, it will be important to consider the unbound fraction (rather than total concentration) of each compound in vitro and in plasma.", {"entities": [[62, 82, "Parameter"]]}], [2286, "However, based on the results of the present study, it is expected that administration of the proposed doses of CAW-R61J (up to 4 g) would not cause clinically significant P450 induction or inhibition resulting in herb-drug interactions in humans.", {"entities": [[112, 120, "Herb name"], [128, 131, "Amount"], [172, 176, "Target"]]}], [2287, "Future studies could focus on identifying the CA compounds associated with the weak P450 inhibition seen in the present study, evaluating their IC50 values, and comparing these with systemic concentrations achieved in humans.", {"entities": [[46, 58, "Herb name"], [84, 88, "Target"], [144, 148, "Parameter"], [182, 205, "Parameter"]]}], [2288, "Bioassay (P450 inhibition)-guided fractionation could be performed to isolate and identify these molecules.", {"entities": [[10, 14, "Target"]]}], [2289, "Once identified, these compounds could be excluded from extracts developed for clinical use of CA if their IC50 values and human plasma levels suggest a clinically relevant inhibitory potential.", {"entities": [[95, 97, "Herb name"], [107, 111, "Parameter"], [123, 142, "Parameter"]]}], [2290, "It will also be important to examine possible interactions of CA derivatives with phase II drug-metabolizing enzymes.", {"entities": [[62, 64, "Herb name"], [82, 116, "Parameter"]]}], [2291, "CA extract (ECa-223) administered orally to male and female rats at 10, 100, and 1000 mg/kg per day for 90 days did not alter the activity of hepatic phase II metabolizing enzymes uridine diphosphate glucuronosyltransferase, glutathione S-transferase, and NADPH:quinone oxidoreductase (Seeka et al., 2017).", {"entities": [[0, 20, "Herb name"], [44, 48, "Sex"], [53, 59, "Sex"], [68, 70, "Amount"], [72, 75, "Amount"], [81, 91, "Amount"], [92, 99, "Frequency"], [100, 111, "Duration"], [126, 284, "Parameter"]]}], [2292, "Hepatic sulfotransferase activity was not changed in female rats, whereas a previous study had found a decrease in sulfotransferase activity in male rats treated with ECa-223 (Seeka et al., 2017).", {"entities": [[0, 33, "Parameter"], [53, 59, "Sex"], [115, 140, "Parameter"], [144, 148, "Sex"], [167, 174, "Herb name"]]}], [2293, "However, no studies were found on the effects of CA derivatives on phase II drug metabolism in humans or human-derived test systems.", {"entities": [[49, 51, "Herb name"]]}], [2294, "Principal investigator.", {"entities": []}], [2295, "Our objective was to investigate the steady-state pharmacokinetic and pharmacodynamic interaction between the antidepressive herbal medicine St John's wort and the antidiabetic drug metformin.", {"entities": [[110, 124, "Pathology"], [125, 155, "Herb name"], [160, 191, "Drug"]]}], [2296, "The addition of St John's wort decreased the area under the glucose concentration\u2013time curve [702 (95% confidence interval, 643\u2013761) vs. 629\u2009min*mmol/L (95% confidence interval, 568\u2013690), P = 0.003], and this effect was caused by a statistically significant increase in the acute insulin response.", {"entities": [[16, 30, "Herb name"], [41, 92, "Parameter"], [94, 97, "Amount"], [137, 151, "Amount"], [280, 296, "Parameter"]]}], [2297, "St John's wort improves glucose tolerance by enhancing insulin secretion independently of insulin sensitivity in healthy male subjects taking metformin.", {"entities": [[0, 14, "Herb name"], [24, 41, "Parameter"], [55, 72, "Parameter"], [90, 109, "Parameter"], [113, 120, "Pathology"], [121, 125, "Sex"], [142, 151, "Drug"]]}], [2298, "Fimasartan, amlodipine, and hydrochlorothiazide are commonly used in combination therapies as antihypertensive drugs.", {"entities": [[0, 10, "Drug"], [12, 22, "Drug"], [28, 47, "Drug"], [94, 116, "Drug"]]}], [2299, "This study aimed to develop and validate an analytical method for fimasartan, its active and major metabolite fimasartan-amide, amlodipine, and hydrochlorothiazide in rat plasma using liquid chromatography-tandem mass spectrometry (LC-MS/MS).", {"entities": [[66, 76, "Drug"], [110, 126, "Drug"], [128, 138, "Drug"], [144, 163, "Drug"]]}], [2300, "The standard calibration curves for fimasartan (1\u2013500 ng/mL), its active and major metabolite fimasartan-amide (0.3\u2013100 ng/mL), amlodipine (0.5\u2013200 ng/mL), and hydrochlorothiazide (5\u20135000 ng/mL) were linear with R For the management of hypertension, approximately 70% of patients with hypertension take two or more antihypertensive drugs for effective blood pressure control.", {"entities": [[36, 46, "Drug"], [94, 110, "Drug"], [128, 138, "Drug"], [160, 179, "Drug"], [236, 248, "Pathology"], [285, 297, "Pathology"], [315, 337, "Drug"], [352, 366, "Parameter"]]}], [2301, "Among these combination drugs, calcium channel blockers, angiotensin II receptor antagonists, and thiazide diuretics are the most commonly used [1].", {"entities": [[31, 55, "Drug"], [57, 92, "Drug"], [98, 116, "Drug"]]}], [2302, "Fimasartan is an angiotensin II receptor antagonist that has been approved in Korea and several Latin American countries for the treatment of mild-to-moderate hypertension.", {"entities": [[0, 51, "Drug"], [142, 171, "Pathology"]]}], [2303, "It has often been prescribed in combination with amlodipine and/or hydrochlorothiazide in patients with hypertension, as these combination therapies exhibit additive effects [2,3,4].", {"entities": [[49, 59, "Drug"], [67, 86, "Drug"], [104, 116, "Pathology"]]}], [2304, "In addition, fimasartan-amlodipine combination has led to similar adverse events compared with either monotherapy and resulted in a high compliance rate (>90%).", {"entities": [[13, 23, "Drug"], [24, 34, "Drug"], [66, 80, "Pathology"]]}], [2305, "Based on these advantages, fimasartan is increasingly used in multiple combination therapies [4].", {"entities": [[27, 37, "Drug"]]}], [2306, "The combined use of drugs with different mechanisms of action may provide advantages in terms of efficacy and tolerability; however, it also increases the possibility of drug\u2013drug interactions (DDIs).", {"entities": []}], [2307, "Therefore, the tolerability and safety of combination drugs were evaluated in the context of their DDI potential.", {"entities": []}], [2308, "Co-administration of fimasartan and amlodipine did not result in substantial changes in the pharmacokinetics of either drug after multiple oral doses [3].", {"entities": [[21, 31, "Drug"], [36, 46, "Drug"]]}], [2309, "Similarly, no clinically relevant DDIs have been reported for the combination of fimasartan and hydrochlorothiazide, although fimasartan has a slight potential to increase the urinary excretion of hydrochlorothiazide [5].", {"entities": [[81, 91, "Drug"], [96, 115, "Drug"], [126, 136, "Drug"], [176, 193, "Parameter"], [197, 216, "Drug"]]}], [2310, "A fixed-dose triple combination of fimasartan/amlodipine/hydrochlorothiazide 60/10/25 mg exhibited pharmacokinetic profiles similar to those of the corresponding doses of the three drugs [6].", {"entities": [[35, 45, "Drug"], [46, 56, "Drug"], [57, 76, "Drug"], [77, 88, "Amount"]]}], [2311, "In addition, a physiologically based pharmacokinetic (PBPK) model for fimasartan, amlodipine, and hydrochlorothiazide was developed by Rhee et al., and they predicted no remarkable DDIs using this PBPK model when fimasartan (120\u2013240 mg) was co-administered with amlodipine (10 mg) and hydrochlorothiazide (25 mg), which is consistent with the observed clinical data [1].", {"entities": [[70, 80, "Drug"], [82, 92, "Drug"], [98, 117, "Drug"], [213, 223, "Drug"], [225, 235, "Amount"], [262, 272, "Drug"], [274, 279, "Amount"], [285, 304, "Drug"], [306, 311, "Amount"]]}], [2312, "In addition to combination therapy, the use of herbal supplements is continuously increasing.", {"entities": []}], [2313, "Recent studies disclosed that approximately 76% and 60% of adults in the USA and Europe, respectively, consume herbal supplements, and 25% of the herbal-drug consumers also take prescribed drugs [7,8], which increases the possibility of herb\u2013drug interactions and may trigger the adverse effects of antihypertensive drugs.", {"entities": [[280, 295, "Pathology"], [299, 321, "Drug"]]}], [2314, "Adverse events of fimasartan were reported in 2.35% of patients.", {"entities": [[0, 14, "Pathology"], [18, 28, "Drug"]]}], [2315, "The most frequent events were dizziness (1.55%), headache (0.52%), abdominal pain, nausea, diarrhea, and coughing [9].", {"entities": [[30, 39, "Pathology"], [49, 57, "Pathology"], [67, 81, "Pathology"], [83, 89, "Pathology"], [91, 99, "Pathology"], [105, 113, "Pathology"]]}], [2316, "One case of angioedema was reported in 14,571 patients [9].", {"entities": [[12, 22, "Pathology"]]}], [2317, "In addition, a case report described a 73-year-old patient with fimasartan-induced liver injury.", {"entities": [[13, 26, "Study"], [39, 50, "Age"], [64, 74, "Drug"], [83, 95, "Pathology"]]}], [2318, "Liver biopsy revealed hepatocellular necrosis and it was scored as a highly probable drug-induced liver injury [10,11].", {"entities": [[22, 45, "Pathology"], [98, 110, "Pathology"]]}], [2319, "Recently, an outcome study was conducted to evaluate the effects of early BP control and correction of metabolic abnormalities on future cardiovascular outcomes, relative to low-risk hypertension.", {"entities": [[183, 195, "Pathology"]]}], [2320, "Fimasartan reduced pulse pressure\u2014a predictor of cardiovascular events\u2014in the elderly (by \u22128.2 \u00b1 0.3 mmHg) and nonelderly (by \u22127.0 \u00b1 0.2 mmHg) (p < 0.0001), after adjusting for confounding factors, which indicates a higher efficacy in the elderly than that in the nonelderly [12,13].", {"entities": [[0, 10, "Drug"], [19, 33, "Parameter"], [49, 70, "Pathology"]]}], [2321, "Moreover, in a clinical study, \u201cFANTASTIC\u201d, to evaluate the rate of change in albuminuria in patients with diabetic chronic kidney disease, treatment with fimasartan for 6 months reduced albuminuria by more than 30%, which is expected to lower the risk of chronic kidney disease progression (compared with losartan).", {"entities": [[15, 29, "Study"], [78, 89, "Parameter"], [107, 138, "Pathology"], [155, 165, "Drug"], [166, 178, "Duration"], [187, 198, "Parameter"], [256, 278, "Pathology"], [306, 314, "Drug"]]}], [2322, "Based on these clinical outcomes, fimasartan can be recommended for patients with hypertension and chronic kidney disease [4,14].", {"entities": [[34, 44, "Drug"], [82, 94, "Pathology"], [99, 121, "Pathology"]]}], [2323, "The rapidly growing fimasartan market and combination trends may increase the risk of developing DDIs.", {"entities": [[20, 30, "Drug"]]}], [2324, "Therefore, we aimed to develop sensitive and simple analytical methods to monitor the pharmacokinetic features of fimasartan, amlodipine, and hydrochlorothisazide, the most frequently prescribed combination.", {"entities": [[114, 124, "Drug"], [126, 136, "Drug"], [142, 162, "Drug"]]}], [2325, "In addition, to understand the effect of fimasartan metabolism, we included an analytical method for the major and active metabolite of fimasartan, fimasartan-amide (oxidative desulfuration or BR-A-557, Figure 1) [15].", {"entities": [[41, 51, "Drug"], [136, 146, "Drug"], [148, 164, "Drug"]]}], [2327, "It also has adaptogenic effects in the modulation of immune function and cardiovascular functions [16,17,18].", {"entities": []}], [2328, "Ginsenosides are responsible for the therapeutic efficacy of RGE [19,20,21] and, therefore, individual ginsenosides such as Rg3, compound K, protopanax diol, and protopanaxatriol and ginseng products have been under clinical evaluation or drug development process [7,16].", {"entities": [[0, 12, "Herb name"], [61, 64, "Herb name"], [103, 115, "Herb name"], [124, 127, "Herb name"], [129, 139, "Herb name"], [141, 156, "Herb name"], [162, 178, "Herb name"], [183, 190, "Herb name"], [216, 235, "Study"]]}], [2329, "Rg3-enriched Korean ginseng products have shown remarkable anti-hypertensive effects in spontaneously hypertensive rats [26,27].", {"entities": [[0, 27, "Herb name"], [102, 114, "Pathology"]]}], [2330, "In addition to the beneficial effect of ginseng products with respect to the anti-hypertensive effect, the drug\u2013drug interaction potential between ginseng and anti-hypertensive drugs needs to be evaluated as combination therapy with drugs having different modes of action is often prescribed, especially as therapeutic drugs are taken along with health supplements.", {"entities": [[40, 47, "Herb name"], [147, 154, "Herb name"], [159, 182, "Drug"]]}], [2331, "Therefore, we aimed to investigate the pharmacokinetic interactions between RGE\u2014an extract from dried root of ginseng of 6 years and more than 60% of dried ginseng content\u2014and a triple anti-hypertensive drug combination (fimasartan, amlodipine, and hydrochlorothiazide) in rats.", {"entities": [[76, 79, "Herb name"], [96, 106, "Herb part"], [110, 117, "Herb name"], [156, 163, "Herb name"], [221, 231, "Drug"], [233, 243, "Drug"], [249, 268, "Drug"]]}], [2332, "RGE\u2014an extract from dried root of ginseng of 6 years and more than 60% of dried ginseng content, 13.2 mg marker ginsenosides (GRb1 + GRg1 + GRg3), and 34.7 mg total ginsenosides per gram extract\u2014was purchased from the Punggi Ginseng Cooperative Association (Youngjoo, Kyungpook, Korea) [29,30,31,32].", {"entities": [[0, 3, "Herb name"], [20, 30, "Herb part"], [34, 41, "Herb name"], [74, 79, "Extraction process"], [80, 87, "Herb name"], [97, 104, "Amount"], [112, 124, "Herb name"], [126, 130, "Herb name"], [133, 137, "Herb name"], [140, 144, "Herb name"], [151, 158, "Amount"], [165, 177, "Herb name"]]}], [2333, "Amlodipine besylate, hydrochlorothiazide, and berberine hydrochloride (IS) were purchased from Sigma-Aldrich Chemical Co. (St. Louis, MO, USA).", {"entities": [[0, 19, "Drug"], [21, 40, "Drug"]]}], [2334, "Fimasartan potassium trihydrate (fimasartan) and the oxidized desulfurized metabolite of fimasartan (fimasartan-amide) were obtained from Boryung Pharm.", {"entities": [[0, 44, "Drug"], [53, 118, "Drug"]]}], [2335, "Co. Ltd. (Seoul, Korea).", {"entities": []}], [2336, "All other chemicals and solvents were of reagent or analytical grade.", {"entities": []}], [2337, "Fimasartan, fimasartan-amide, amlodipine, and hydrochlorothiazide levels in each sample were determined using an Agilent 6470 Triple Quadrupole LC-MS/MS system (Agilent, Wilmington, DE, USA).", {"entities": [[0, 10, "Drug"], [12, 28, "Drug"], [30, 40, "Drug"], [46, 65, "Drug"]]}], [2338, "An isocratic mobile phase, which consisted of a mixture of water and acetonitrile (30:70, v/v) and contained 0.1% formic acid, was used at a flow rate of 0.20 mL/min to elute the analytes from the rat plasma matrix.", {"entities": []}], [2339, "Separation was performed using a Synergi Polar RP column (150 \u00d7 4.6 mm, 4 \u03bcm particle size; Pheonomenex, Torrance, CA, USA).", {"entities": []}], [2340, "The analytes were monitored using multiple reaction monitoring (MRM) mode, and the optimized mass conditions are listed in Table 1.", {"entities": []}], [2341, "Before starting sample analysis, the simultaneous analytical method was validated by evaluating the selectivity, linearity, accuracy, precision, recovery, and matrix effect.", {"entities": []}], [2342, "Three concentrations of quality control (QC) samples were prepared at low, medium, and high concentrations in the range of the standard calibration curves.", {"entities": []}], [2343, "Calibration curves for a mixture of fimasartan, fimasartan-amide, amlodipine, and hydrochlorothiazide were prepared using the internal standard method.", {"entities": [[36, 46, "Drug"], [48, 64, "Drug"], [66, 76, "Drug"], [82, 101, "Drug"]]}], [2344, "Briefly, aliquots (50 \u03bcL in acetonitrile) of seven different concentrations of the standard curve mixture that contained fimasartan (1, 2, 5, 20, 50, 200, and 500 ng/mL), fimasartan-amide (final concentrations of 0.3, 1, 2, 5, 20, 50, and 100 ng/mL), amlodipine (0.5, 2, 5, 20, 50, 100, and 200 ng/mL), and hydrochlorothiazide (5, 20, 50, 200, 500, 2000, and 5000 ng/mL) were dried under gentle nitrogen gas stream and reconstituted with 50 \u03bcL rat blank plasma.", {"entities": [[121, 131, "Drug"], [171, 187, "Drug"], [251, 261, "Drug"], [307, 326, "Drug"]]}], [2345, "Then, 150 \u03bcL acetonitrile containing 1 ng/mL berberine (IS) was added to the reconstituted standard curves.", {"entities": []}], [2346, "After vortexing for 10 min and centrifuging for 10 min at 16,000\u00d7 g, an aliquot (15 \u03bcL) of the supernatant was injected into the LC-MS/MS system.", {"entities": []}], [2347, "The linearity of the calibration standard was calculated from the peak height ratio of the analytes to the IS using the weight-adjusted method (1/x The precision and accuracy of the inter- and intra-day assays were assessed by five or six measurements of three QC samples of fimasartan, fimasartan-amide, amlodipine, and hydrochlorothiazide.", {"entities": [[275, 285, "Drug"], [287, 303, "Drug"], [305, 315, "Drug"], [321, 340, "Drug"]]}], [2348, "Precision was evaluated using the coefficient of variation (CV, %) of five or six QC sample measurements.", {"entities": []}], [2349, "Accuracy was calculated by dividing the measured QC concentration by the spiked QC concentration.", {"entities": []}], [2350, "Extraction recovery was calculated by comparing the peak areas of the three QC samples in the pre-extraction samples with those of the post-extraction blank plasma spiked with the corresponding QC samples.", {"entities": []}], [2351, "Matrix effects were determined by comparing the peak area obtained from the post-extraction blank plasma spiked with three QC concentrations of the mixture of fimasartan, fimasartan-amide, amlodipine, and hydrochlorothiazide and the peak area from the corresponding concentration of the blank solution.", {"entities": [[159, 169, "Drug"], [171, 187, "Drug"], [189, 199, "Drug"], [205, 224, "Drug"]]}], [2352, "The stabilities of fimasartan, fimasartan-amide, amlodipine, and hydrochlorothiazide in rat plasma were tested under various conditions.", {"entities": [[19, 29, "Drug"], [31, 47, "Drug"], [49, 59, "Drug"], [65, 84, "Drug"]]}], [2353, "Bench-top stability was calculated by comparing QC samples stored for 12 h at 25 \u00b0C with the untreated QC samples.", {"entities": []}], [2354, "For freeze\u2013thaw stability, QC samples were analyzed after three freeze\u2013thaw cycles.", {"entities": []}], [2355, "One cycle of the freeze\u2013thaw process involved storing the QC samples at \u221280 \u00b0C for >12 h and thawing at 25 \u00b0C for 6 h. After three freeze\u2013thaw cycles, the concentrations of the QC samples were determined using freshly prepared calibration standards.", {"entities": []}], [2356, "Post-preparative stability was evaluated by comparing the extracted QC samples maintained in the autosampler at 6 \u00b0C for 24 h (compared with the untreated QC samples).", {"entities": []}], [2357, "Male Sprague-Dawley rats aged seven weeks (Samtako, Osan, Korea) were acclimatized for one week in an animal facility at Kyungpook National University.", {"entities": [[0, 4, "Sex"]]}], [2358, "Food and water were provided ad libitum.", {"entities": []}], [2359, "All animal experiments were approved by the Institutional Animal Care and Use Committee of Kyungpook National University (approval no.", {"entities": []}], [2360, "KNU 2017-0044).", {"entities": []}], [2361, "To investigate the DDIs among fimasartan, amlodipine, and hydrochlorothiazide, rats were randomly divided into a combination group (n = 6) and a single group (n = 6, for individual drug administration).", {"entities": [[30, 40, "Drug"], [42, 52, "Drug"], [58, 77, "Drug"]]}], [2362, "The femoral arteries and veins of the rats were cannulated with PE50 polyethylene tubing (Jungdo, Seoul, Korea) under anesthesia with zoletil and lompun (50 and 5 mg/kg, respectively, intramuscular injection), and heparinized saline (10 U/mL) was used to prevent blood clotting.", {"entities": []}], [2363, "Pharmacokinetic studies were initiated after recovery from anesthesia.", {"entities": []}], [2364, "Each rat in the combination group received a mixture of fimasartan (3 mg/kg), amlodipine (5 mg/kg), and hydrochlorothiazide (5 mg/kg) dissolved in saline containing 10% DMSO.", {"entities": [[56, 66, "Drug"], [68, 75, "Amount"], [78, 88, "Drug"], [90, 97, "Amount"], [104, 123, "Drug"], [125, 132, "Amount"]]}], [2365, "The rats in the single group orally received individual drug solutions at the same dose as present in the triple mixture solution.", {"entities": []}], [2366, "Blood samples were collected through the femoral artery at 0, 0.25, 0.5, 1, 2, 4, 8, and 24 h following the oral administration of fimasartan, amlodipine, and hydrochlorothiazide.", {"entities": [[131, 141, "Drug"], [143, 153, "Drug"], [159, 178, "Drug"]]}], [2367, "After centrifugation of the blood samples at 8000\u00d7 g for 1 min, 50 \u03bcL aliquots of the plasma samples were stored at \u221280 \u00b0C until analysis.", {"entities": []}], [2368, "Rats were randomly divided into three groups, i.e., control (n = 6, vehicle treatment), single (n = 6, 1.5 g/kg), and multiple RGE treatments (n = 6, 1.5 g/kg for 7 days).", {"entities": [[103, 111, "Amount"], [127, 130, "Herb name"], [150, 158, "Amount"], [159, 169, "Duration"]]}], [2369, "Importantly, rats in the multiple RGE group received RGE suspension (1.5 g/kg/3 mL/day) for 7 days via oral gavage, while rats in the single RGE treatment group received water (3 mL/kg) for 6 days via oral gavage and RGE suspension (1.5 g/kg/3 mL) via oral gavage on the day 7.", {"entities": [[34, 37, "Herb name"], [53, 56, "Herb name"], [69, 82, "Amount"], [88, 98, "Duration"], [141, 144, "Herb name"], [177, 184, "Amount"], [186, 196, "Duration"], [217, 220, "Herb name"], [233, 246, "Amount"]]}], [2370, "The control group received water (3 mL/kg) for seven days by oral gavage.", {"entities": [[34, 41, "Amount"], [43, 57, "Duration"]]}], [2371, "One hour after the last RGE treatment, rats received a mixture of fimasartan, amlodipine, and hydrochlorothiazide at doses of 3, 5, and 5 mg/kg, respectively, by oral gavage.", {"entities": [[24, 27, "Herb name"], [66, 76, "Drug"], [78, 88, "Drug"], [94, 113, "Drug"], [126, 143, "Amount"]]}], [2372, "Subsequently, blood samples were collected via the femoral artery at 0, 0.25, 0.5, 1, 2, 4, 8, and 24 h. After centrifugation of the blood samples at 8000\u00d7 g for 1 min, 50 \u03bcL aliquots of the plasma samples were stored at \u221280 \u00b0C until analysis.", {"entities": []}], [2373, "Plasma samples (50 \u03bcL) were then mixed with 150 \u03bcL acetonitrile containing 1 ng/mL berberine (IS).", {"entities": []}], [2374, "After vortexing for 10 min and centrifuging for 10 min at 16,000\u00d7 g, an aliquot (15 \u03bcL) of the supernatant was injected into the LC-MS/MS system.", {"entities": []}], [2375, "Randomly divided rats received vehicle (control group, n = 4), single (1.5 g/kg, n = 4), or multiple RGE treatments (1.5 g/kg for 7 days, n = 4).", {"entities": [[71, 79, "Amount"], [101, 104, "Herb name"], [117, 125, "Amount"], [126, 136, "Duration"]]}], [2376, "The procedure was the same as described previously.", {"entities": []}], [2377, "The jejunal segments were then isolated and rinsed using pre-warmed saline.", {"entities": []}], [2378, "Subsequently, they were mounted in the tissue holder of a Navicyte easy mount Ussing chamber (Warner Instruments, Holliston, MA, USA) and acclimated in Hank\u2019s balanced salt solution (HBSS, pH 7.4) for 15 min with continuous oxygenation (95% O\u2082/5% CO\u2082).", {"entities": []}], [2379, "An intestinal permeability study was performed by adding 1 mL HBSS containing fimasartan, amlodipine, or hydrochlorothiazide (10 \u03bcM each) on the donor side and 1 mL fresh HBSS on the receiver side.", {"entities": [[78, 88, "Drug"], [90, 100, "Drug"], [105, 124, "Drug"]]}], [2380, "Then, a 400 \u03bcL aliquot was withdrawn from the receiver side every 30 min for 2 h, and an equal volume of pre-warmed fresh HBSS was added to replenish the lost volume.", {"entities": []}], [2381, "For amlodipine analysis, 50 \u03bcL aliquots were mixed with 150 \u03bcL acetonitrile containing 1 ng/mL berberine (IS).", {"entities": [[4, 14, "Drug"]]}], [2382, "After vortexing for 10 min and centrifuging for 10 min at 16,000\u00d7 g, an aliquot (15 \u03bcL) of the supernatant was injected into the LC-MS/MS system.", {"entities": []}], [2383, "Pharmacokinetic parameters were calculated using non-compartmental analyses and compared using the Kruskal\u2013Wallis test.", {"entities": []}], [2384, "p < 0.05 was considered significant.", {"entities": []}], [2385, "To optimize the electrospray ionization conditions for fimasartan, fimasartan-amide, amlodipine, and hydrochlorothiazide, each compound was directly injected into the mass spectrometer ionization source.", {"entities": [[55, 65, "Drug"], [67, 83, "Drug"], [85, 95, "Drug"], [101, 120, "Drug"]]}], [2386, "The ionization mode and mass transition from Q1 to Q3 were selected based on the product ion scan results of authentic standards and previously published reports (Figure 1).", {"entities": []}], [2387, "Fimasartan, fimasartan-amide, and amlodipine had optimal ionization in the positive mode, whereas hydrochlorothiazide showed optimal ionization in the negative mode (Table 1).", {"entities": [[0, 10, "Drug"], [12, 28, "Drug"], [34, 44, "Drug"], [98, 117, "Drug"]]}], [2388, "Optimized MRM transitions and MS/MS conditions for the analytes are listed in Table 1 and Figure 1, respectively.", {"entities": []}], [2389, "These conditions were consistent with those presented in previous reports [15,33,34,35,36].", {"entities": []}], [2390, "Selectivity was confirmed in male Sprague-Dawley rat plasma of eight different origins and was assessed by comparing the blank plasma peak response with that of plasma spiked with the lower limit of quantification (LLOQ) of fimasartan, fimasartan-amide, amlodipine, and hydrochlorothiazide (Table 1).", {"entities": [[29, 33, "Sex"], [224, 234, "Drug"], [236, 252, "Drug"], [254, 264, "Drug"], [270, 289, "Drug"]]}], [2391, "The signal-to-noise ratios of each analyte of the LLOQ were all over 10.", {"entities": []}], [2392, "Figure 2 shows the chromatograms of the blank matrix and those of fimasartan, fimasartan-amide, amlodipine, and hydrochlorothiazide spiked at the LLOQ or rat plasma samples 1 h after oral administration of fimasartan, amlodipine, and hydrochlorothiazide.", {"entities": [[66, 76, "Drug"], [78, 94, "Drug"], [96, 106, "Drug"], [112, 131, "Drug"], [206, 216, "Drug"], [218, 228, "Drug"], [234, 253, "Drug"]]}], [2393, "The peak retention times for fimasartan, fimasartan-amide, amlodipine, hydrochlorothiazide, and the IS were 3.1, 2.7, 3.2, 2.2, and 4.6 min, respectively.", {"entities": [[29, 39, "Drug"], [41, 57, "Drug"], [59, 69, "Drug"], [71, 90, "Drug"]]}], [2394, "The results showed no disturbance peaks derived from rat blank plasma at the retention times of fimasartan, fimasartan-amide, amlodipine, hydrochlorothiazide, and IS under our MS/MS analysis conditions (Figure 2).", {"entities": [[96, 106, "Drug"], [108, 124, "Drug"], [126, 136, "Drug"], [138, 157, "Drug"]]}], [2395, "Linearity was evaluated using calibration curves of the mixture of fimasartan, fimasartan-amide, amlodipine, and hydrochlorothiazide (Table 1).", {"entities": [[67, 77, "Drug"], [79, 95, "Drug"], [97, 107, "Drug"], [113, 132, "Drug"]]}], [2396, "The calibration curves showed good linearity in the ranges 1\u2013500 ng/mL (for fimasartan), 0.3\u2013100 ng/mL (for fimasartan-amide), 0.5\u2013200 ng/mL (for amlodipine), and 5\u20135000 ng/mL (for hydrochlorothiazide), with a correlation coefficient (R Table 2 summarizes the intra- and inter-day precision and accuracy of fimasartan, fimasartan-amide, amlodipine, and hydrochlorothiazide.", {"entities": [[76, 86, "Drug"], [108, 124, "Drug"], [146, 156, "Drug"], [181, 200, "Drug"], [307, 317, "Drug"], [319, 335, "Drug"], [337, 347, "Drug"], [353, 372, "Drug"]]}], [2397, "Precision was assessed as CV (%) for all analytes and the values were in the range of 2.38\u20136.77% in the intra-day batch and 1.96\u20137.75% in the inter-day batch.", {"entities": []}], [2398, "Accuracy is expressed as a percentage (%) of the concentrations determined from the calibration curve over the nominal concentrations.", {"entities": []}], [2399, "The accuracy of all analytes was in the range of 87.94\u2013109.6% in the intra-day batch and 98.15\u2013107.2% in the inter-day batch.", {"entities": []}], [2400, "The accuracy of the QC sample was obtained through back calculations from the equations of the standard curve.", {"entities": []}], [2401, "Owing to slight variations in the analytical process (e.g., changes in recovery during preparation of a biological sample and variability in the performance of the analytical instrument), there may be cases where the response of a QC sample is higher than that of a standard curve sample, but the inter- and intra-day accuracy in Table 2 were within the acceptance criteria for accuracy (i.e., 85~115%) according to the Guideline of Bioanalytical method validation from FDA, EMA, and ICH [37].", {"entities": []}], [2402, "Table 3 summarizes the extraction recoveries and matrix effects.", {"entities": []}], [2403, "The extraction recoveries for fimasartan, fimasartan-amide, amlodipine, and hydrochlorothiazide were high and reproducible in the range of extraction recovery (75.92\u201396.73%) and CV (4.14\u201313.4%).", {"entities": [[30, 40, "Drug"], [42, 58, "Drug"], [60, 70, "Drug"], [76, 95, "Drug"]]}], [2404, "Therefore, the protein precipitation method\u2014employing three volumes of acetonitrile\u2014utilized in this study could efficiently extract fimasartan, fimasartan-amide, amlodipine, and hydrochlorothiazide from rat plasma.", {"entities": [[133, 143, "Drug"], [145, 161, "Drug"], [163, 173, "Drug"], [179, 198, "Drug"]]}], [2405, "The matrix effects ranged from 34.11% to 37.08% with a CV range of 9.44\u201313.6% for fimasartan, from 6.628% to 8.030% with a CV range of 8.90\u201310.9% for fimasartan-amide, from 39.87 to 49.35% with a CV range of 9.11\u201313.2% for amlodipine, and from 9.192% to 12.29% with a CV range of 6.73\u201311.1% for hydrochlorothiazide.", {"entities": [[82, 92, "Drug"], [150, 166, "Drug"], [223, 233, "Drug"], [295, 314, "Drug"]]}], [2406, "The results suggested that the co-eluting substances showed substantial matrix effects on the ionization of the analytes.", {"entities": []}], [2407, "However, the matrix effects were stable for the three QC concentrations in the six samples of each plasma matrix.", {"entities": []}], [2408, "Therefore, we conclude that our sample preparation process can be used to analyze the concentrations of fimasartan, fimasartan-amide, amlodipine, and hydrochlorothiazide in rat plasma samples.", {"entities": [[104, 114, "Drug"], [116, 132, "Drug"], [134, 144, "Drug"], [150, 169, "Drug"]]}], [2409, "The extraction recovery and matrix effects of the IS were also high and reproducible (Table 3).", {"entities": []}], [2410, "The results of the stability experiments are presented in Table 4.", {"entities": []}], [2411, "The precision and accuracy for the bench-top stability, the post-preparative stability, and the three cycles of freeze\u2013thaw stability were lower than 15%.", {"entities": []}], [2412, "These results provide evidence that fimasartan, fimasartan-amide, amlodipine, and hydrochlorothiazide in rat plasma samples were stable for up to 6 h at 25 \u00b0C (bench-top stability).", {"entities": [[36, 46, "Drug"], [48, 64, "Drug"], [66, 76, "Drug"], [82, 101, "Drug"]]}], [2413, "Moreover, they were stable for 24 h in the autosampler tray after sample treatment and remained stable for three freeze\u2013thaw cycles.", {"entities": []}], [2414, "First, we compared the pharmacokinetics of fimasartan, fimasartan-amide, amlodipine, and hydrochlorothiazide in rats, following their oral administration (as monotherapy or combination dose) (Figure 3).", {"entities": [[43, 53, "Drug"], [55, 71, "Drug"], [73, 83, "Drug"], [89, 108, "Drug"]]}], [2415, "The plasma concentration profiles of fimasartan, fimasartan-amide, amlodipine, and hydrochlorothiazide were very similar, regardless of whether these drugs were orally administered individually or simultaneously as combination doses (3, 5, and 5 mg/kg for fimasartan, amlodipine, and hydrochlorothiazide, respectively).", {"entities": [[37, 47, "Drug"], [49, 65, "Drug"], [67, 77, "Drug"], [83, 102, "Drug"], [234, 251, "Amount"], [256, 266, "Drug"], [268, 278, "Drug"], [284, 303, "Drug"]]}], [2416, "Pharmacokinetic parameters, such as C To investigate the herb\u2013drug interactions between RGE and the antihypertensive drugs, the pharmacokinetic parameters of fimasartan, amlodipine, and hydrochlorothiazide in control rats were compared with those in rats that were orally administered a single dose of RGE and multiple doses of RGE for one week (Figure 4 and Table 6).", {"entities": [[88, 91, "Herb name"], [100, 122, "Drug"], [158, 168, "Drug"], [170, 180, "Drug"], [186, 205, "Drug"], [302, 305, "Herb name"], [328, 331, "Herb name"], [332, 344, "Duration"]]}], [2417, "The plasma profile of fimasartan was similar, and pharmacokinetic parameters, such as C The T To investigate whether the decreased permeability caused by repeated RGE treatment was specific for amlodipine, we also measured the intestinal permeability of fimasartan and hydrochlorothiazide.", {"entities": [[22, 32, "Drug"], [163, 166, "Herb name"], [194, 204, "Drug"], [254, 264, "Drug"], [269, 288, "Drug"]]}], [2418, "The P Fimasartan is effective at reducing blood pressure.", {"entities": [[6, 16, "Drug"], [42, 56, "Parameter"]]}], [2419, "In large clinical studies, fimasartan showed an excellent safety profile and, when combined with hydrochlorothiazide or amlodipine, it showed a better effect with respect to controlling blood pressure than that of monotherapy.", {"entities": [[9, 25, "Study"], [27, 37, "Drug"], [97, 116, "Drug"], [120, 130, "Drug"], [186, 200, "Parameter"]]}], [2420, "It has beneficial effects with respect to protecting against major adverse cardiovascular events and its renoprotective effects in hypertensive diabetic chronic kidney disease are under evaluation [4,12,14,38].", {"entities": [[67, 96, "Pathology"], [131, 175, "Pathology"]]}], [2421, "Preclinical studies have demonstrated organ-protective effects of fimasartan [4].", {"entities": [[0, 19, "Study"], [66, 76, "Drug"]]}], [2422, "These results suggest that fimasartan is an attractive candidate for the treatment of hypertension and suggest the increasing use of fimasartan monotherapy and combination therapy.", {"entities": [[27, 37, "Drug"], [86, 98, "Pathology"], [133, 143, "Drug"]]}], [2423, "Fimasartan and its combination drugs have been introduced into the market in form of the following formulations: Kanarb Jung et al.", {"entities": [[0, 10, "Drug"]]}], [2424, "[6] investigated the pharmacokinetic interactions of triple combinations of fimasartan, amlodipine, and hydrochlorothiazide.", {"entities": [[76, 86, "Drug"], [88, 98, "Drug"], [104, 123, "Drug"]]}], [2425, "For this, they applied two different sample preparation methods including protein precipitation for fimasartan/amlodipine and liquid\u2013liquid extraction for hydrochlorothiazide.", {"entities": [[100, 110, "Drug"], [111, 121, "Drug"], [155, 174, "Drug"]]}], [2426, "In this study, we developed simple and simultaneous analytical method for fimasartan, fimasartan-amide (a major metabolite of fimasartan), amlodipine, and hydrochlorothiazide in rat plasma using the protein precipitation method; therefore, it has advantages of a simple sample pretreatment procedures and a shortened run time.", {"entities": [[74, 84, "Drug"], [86, 137, "Drug"], [139, 149, "Drug"], [155, 174, "Drug"]]}], [2427, "In addition, we included the analysis of a major active metabolite of fimasartan, fimasartan-amide, which is expected to be easily applied to efficacy and pharmacokinetic-pharmacodynamic studies of antihypertensive combination drugs as well.", {"entities": [[43, 98, "Drug"], [198, 232, "Drug"]]}], [2428, "Finally, to the best of our knowledge, this is the first validated report of an LC-MS/MS method for the simple and simultaneous determination of fimasartan, fimasartan-amide, amlodipine, and hydrochlorothiazide from rat plasma.", {"entities": [[145, 155, "Drug"], [157, 173, "Drug"], [175, 185, "Drug"], [191, 210, "Drug"]]}], [2429, "A number of analytical methods for monitoring individual fimasartan, amlodipine, or hydrochlorothiazide in plasma samples using tandem mass did not use the quantitative and qualitative MRM trace.", {"entities": [[57, 67, "Drug"], [69, 79, "Drug"], [84, 103, "Drug"]]}], [2430, "We also used the same MRM condition as previously published reports [39,40] and the product ion mass spectra from fimasartan, amlodipine, and hydrochlorothiazide showed different mass fragmentation patterns (Figure 1).", {"entities": [[114, 124, "Drug"], [126, 136, "Drug"], [142, 161, "Drug"]]}], [2431, "In addition, in a selectivity evaluation, we confirmed that there were no interfering peaks in the individual substance compared with all four substances spiked in blank rat plasma.", {"entities": []}], [2432, "However, the use of two MRM traces would have increased the quality and usability of the analytical method, as it provides more certainty in identifying the analytes among the existing exogenous and endogenous structural analogues [41].", {"entities": []}], [2433, "Therefore, it is necessary to apply and validate two MRM trace methods for fimasartan and fimasartan-amide, amlodipine, and hydrochlorothiazide in our future analysis.", {"entities": [[75, 85, "Drug"], [90, 106, "Drug"], [108, 118, "Drug"], [124, 143, "Drug"]]}], [2434, "We then applied our analytical method to evaluate the pharmacokinetic interactions among the triple combination of these drugs and the effect of RGE treatment on the same.", {"entities": [[145, 148, "Herb name"]]}], [2435, "Pharmacokinetic interactions among the triple combination drugs were evaluated by comparing oral monotherapy of fimasartan, amlodipine, and hydrochlorothiazide, as well as the oral administration of the triple mixture with the corresponding dose.", {"entities": [[112, 122, "Drug"], [124, 134, "Drug"], [140, 159, "Drug"]]}], [2436, "The results indicated no interaction in the pharmacokinetic parameters of the orally administered triple combination compared with those of the individual components (Figure 3 and Table 5).", {"entities": []}], [2437, "When compared with the previous pharmacokinetic results of antihypertensive drugs, pharmacokinetic parameters such as C Next, we evaluated the interactions between RGE and the triple combination.", {"entities": [[59, 81, "Drug"], [164, 167, "Herb name"]]}], [2438, "No significant difference was observed in the pharmacokinetic parameters of fimasartan, fimasartan-amide, amlodipine, and hydrochlorothiazide (except for the T Our validated analytical method for fimasartan, its active metabolite fimasartan-amide, amlodipine, and hydrochlorothiazide can be easily extrapolated to pharmacokinetic, efficacy, and toxicokinetic studies.", {"entities": [[76, 86, "Drug"], [88, 104, "Drug"], [106, 116, "Drug"], [122, 141, "Drug"], [196, 206, "Drug"], [230, 246, "Drug"], [248, 258, "Drug"], [264, 283, "Drug"], [345, 366, "Study"]]}], [2439, "In an application study, we successfully assessed the pharmacokinetic interactions between these triple combination drugs and co-administered drugs and herbal supplements.", {"entities": []}], [2440, "In conclusion, using a triple combination of anti-hypertensive drugs and simultaneous analytical methods, we conducted efficient drug interaction and pharmacokinetic studies using fewer animals.", {"entities": [[45, 68, "Drug"], [150, 173, "Study"]]}], [2441, "Publisher\u2019s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.", {"entities": []}], [2442, "Conceptualization, M.-K.C.", {"entities": []}], [2443, "and I.-S.S.; methodology, S.-Y.J., J.-H.J.", {"entities": []}], [2444, "and J.-H.P.", {"entities": []}], [2445, "; validation, S.-Y.J., J.-H.J.", {"entities": []}], [2446, "and J.-H.P.", {"entities": []}], [2447, "; formal analysis, S.-Y.J.", {"entities": []}], [2448, "and M.P.", {"entities": []}], [2449, "; investigation, S.-Y.J., J.-H.J., J.-H.P., J.L.", {"entities": []}], [2450, "and M.P.", {"entities": []}], [2451, "; writing\u2014original draft preparation, S.-Y.J., J.-H.J., J.-H.P., J.L.", {"entities": []}], [2452, "and M.P.", {"entities": []}], [2453, "; writing\u2014review and editing, M.-K.C.", {"entities": []}], [2454, "and I.-S.S.; supervision, M.-K.C.", {"entities": []}], [2455, "and I.-S.S.; project administration, I.-S.S.; funding acquisition, I.-S.S. All authors have read and agreed to the published version of the manuscript.", {"entities": []}], [2456, "The animal study protocol was approved by the Institutional Animal Care and Use Committee of Kyungpook National University (protocol code KNU 2017-0044 and date of approval 6 April 2017).", {"entities": [[4, 16, "Study"]]}], [2457, "Not applicable.", {"entities": []}], [2458, "Not applicable.", {"entities": []}], [2459, "The authors declare no conflict of interest.", {"entities": []}], [2460, "Structure and product ion mass spectra of (A) fimasartan, (B) fimasartan-amide, (C) amlodipine, and (D) hydrochlorothiazide.", {"entities": [[46, 56, "Drug"], [62, 78, "Drug"], [84, 94, "Drug"], [104, 123, "Drug"]]}], [2461, "Representative multiple reaction monitoring (MRM) chromatogram of fimasartan, fimasartan-amide, amlodipine, hydrochlorothiazide, and IS (berberine) in (A) blank rat plasma; (B) rat blank plasma spiked with standard solution at a lower limit of quantification (LLOQ); and (C) rat plasma samples at 1 h following oral administration of fimasartan, amlodipine, and hydrochlorothiazide.", {"entities": [[66, 76, "Drug"], [78, 94, "Drug"], [96, 106, "Drug"], [108, 127, "Drug"], [334, 344, "Drug"], [346, 356, "Drug"], [362, 381, "Drug"]]}], [2463, "Data represent the mean \u00b1 standard deviation (n = 5).", {"entities": []}], [2465, "Data represent the mean \u00b1 standard deviation (n = 5).", {"entities": []}], [2466, "Comparison of (A) T MS/MS parameters for the detection and standard calibration curves for fimasartan, fimasartan-amide, amlodipine, and hydrochlorothiazide.", {"entities": [[91, 101, "Drug"], [103, 119, "Drug"], [121, 131, "Drug"], [137, 156, "Drug"]]}], [2467, "Intra- and inter-day precision and accuracy of fimasartan, fimasartan-amide, amlodipine, and hydrochlorothiazide.", {"entities": [[47, 57, "Drug"], [59, 75, "Drug"], [77, 87, "Drug"], [93, 112, "Drug"]]}], [2468, "Data represented as mean and CV from five or six independent experiments.", {"entities": []}], [2469, "Extraction recoveries and matric effects for the determination of fimasartan, fimasartan-amide, amlodipine, and hydrochlorothiazide.", {"entities": [[66, 76, "Drug"], [78, 94, "Drug"], [96, 106, "Drug"], [112, 131, "Drug"]]}], [2470, "Data represented as mean and CV from six independent experiments.", {"entities": []}], [2471, "Stability of fimasartan, fimasartan-amide, amlodipine, and hydrochlorothiazide.", {"entities": [[13, 23, "Drug"], [25, 41, "Drug"], [43, 53, "Drug"], [59, 78, "Drug"]]}], [2472, "Data represented as mean and CV from three independent experiments.", {"entities": []}], [2473, "Pharmacokinetic parameters of fimasartan, fimasartan-amide, amlodipine, and hydrochlorothiazide in rats that were orally administered monotherapy or a combination of fimasartan (3 mg/kg), amlodipine (5 mg/kg), and hydrochlorothiazide (5 mg/kg).", {"entities": [[30, 40, "Drug"], [42, 58, "Drug"], [60, 70, "Drug"], [76, 95, "Drug"], [166, 176, "Drug"], [178, 185, "Amount"], [188, 198, "Drug"], [200, 207, "Amount"], [214, 233, "Drug"], [235, 242, "Amount"]]}], [2476, "Highly active antiretroviral therapy (HAART) has greatly improved health parameters of HIV infected individuals.", {"entities": [[0, 44, "Drug"], [87, 99, "Pathology"]]}], [2477, "However, there are several challenges associated with the chronic nature of HAART administration.", {"entities": [[76, 81, "Drug"]]}], [2478, "For populations in health transition, dual use of medicinal plant extracts and conventional medicine poses a significant challenge.", {"entities": []}], [2479, "There is need to evaluate interactions between commonly used medicinal plant extracts and antiretroviral drugs used against HIV/AIDS.", {"entities": [[90, 110, "Drug"], [124, 127, "Pathology"], [128, 132, "Pathology"]]}], [2480, "Efavirenz (EFV) and nevirapine (NVP) are the major components of HAART both metabolized by CYP2B6, an enzyme that can potentially be inhibited or induced by compounds found in medicinal plant extracts.", {"entities": [[0, 15, "Drug"], [20, 36, "Drug"], [65, 70, "Drug"], [91, 97, "Target"]]}], [2481, "The purpose of this study was to evaluate the effects of extracts of selected commonly used medicinal plants on CYP2B6 enzyme activity.", {"entities": [[112, 118, "Target"]]}], [2482, "Recombinant human CYP2B6 was used to evaluate inhibition, allowing the assessment of herb-drug interactions (HDI) of medicinal plants Hyptis suaveolens, Myrothamnus flabellifolius, Launaea taraxacifolia, Boerhavia diffusa and Newbouldia laevis.", {"entities": [[18, 24, "Target"], [134, 151, "Herb name"], [153, 179, "Herb name"], [181, 202, "Herb name"], [204, 221, "Herb name"], [226, 243, "Herb name"]]}], [2483, "The potential of these medicinal extracts to cause HDI was ranked accordingly for reversible inhibition and also classified as potential time-dependent inhibitor (TDI) candidates.", {"entities": []}], [2484, "The most potent inhibitor for CYP2B6 was Hyptis suaveolens extract (IC It has been shown unequivocally that antiretroviral therapy (ART) reduces HIV/AIDS mortality and prolongs life.", {"entities": [[30, 36, "Target"], [41, 58, "Herb name"], [59, 66, "Extraction process"], [68, 70, "Parameter"], [108, 136, "Drug"], [145, 148, "Pathology"], [149, 153, "Pathology"]]}], [2485, "However, attention has now shifted from reduction in mortality to improvement of the quality of life for people taking ART [1,2].", {"entities": [[119, 122, "Drug"]]}], [2486, "Across the world, there are huge disparities in health systems, thus, HIV/AIDS patients in different geographical regions receive different ART regimens mostly due to the different cost of the more than 30 antiretroviral (ARV) drugs approved by the US FDA.", {"entities": [[70, 73, "Pathology"], [74, 78, "Pathology"], [140, 143, "Drug"], [206, 232, "Drug"]]}], [2487, "In resource constrained settings, the most commonly used ARV drugs include nevirapine (NVP) and efavirenz (EFV) which form the backbone of highly active antiretroviral therapy (HAART) regimens; thus, quite a number of patients use these two drugs during treatment [3,4].", {"entities": [[57, 66, "Drug"], [75, 91, "Drug"], [96, 111, "Drug"], [139, 183, "Drug"]]}], [2488, "Africa is a continent with a high prevalence of HIV/AIDS making up approximately 67% of the world\u2019s population of HIV infected people [5].", {"entities": [[48, 51, "Pathology"], [52, 56, "Pathology"], [114, 126, "Pathology"]]}], [2489, "Most ARV drugs used in Africa include EFV and NVP.", {"entities": [[5, 14, "Drug"], [38, 41, "Drug"], [46, 49, "Drug"]]}], [2491, "Both EFV and NVP are relatively affordable when compared to other ARV drugs [6]; hence, they are widely used in many African countries.", {"entities": [[5, 8, "Drug"], [13, 16, "Drug"], [66, 75, "Drug"], [117, 124, "Ethnic group"]]}], [2492, "EFV and NVP are substrates of the CYP2B6 enzyme [7,8] and plasma concentrations of these two ARVs are affected by changes in levels and activity of CYP2B6.", {"entities": [[0, 3, "Drug"], [8, 11, "Drug"], [34, 40, "Target"], [93, 97, "Drug"], [148, 154, "Target"]]}], [2493, "CYP3A4 also metabolizes these two drugs but its contribution appears to be marginal [9].", {"entities": [[0, 6, "Target"]]}], [2494, "EFV and NVP have been associated with a number of side effects including liver damage, nausea, vomiting, fever, diarrhoea, dyslipidemia and headache [10].", {"entities": [[0, 3, "Drug"], [8, 11, "Drug"], [50, 62, "Pathology"], [73, 85, "Pathology"], [87, 93, "Pathology"], [95, 103, "Pathology"], [105, 110, "Pathology"], [112, 121, "Pathology"], [123, 135, "Pathology"], [140, 148, "Pathology"]]}], [2495, "CYP2B6 enzyme metabolizes many commonly used drugs including bupropion, propofol and cyclophosphamide which should not be given together with EFV or NVP, to avoid drug-drug interactions.", {"entities": [[0, 6, "Target"], [61, 70, "Drug"], [72, 80, "Drug"], [85, 101, "Drug"], [142, 145, "Drug"], [149, 152, "Drug"]]}], [2496, "Among populations in health transition, especially those in resource-constrained countries, patients often make use of herbal medicinal plants in the management and treatment of several diseases in addition to use of conventional drugs [11].", {"entities": []}], [2497, "HIV infection is an epidemic in resource constrained countries, particularly in sub-Sahara Africa; thus, it is inevitable that there is dual use of HAART and herbal medicinal plants.", {"entities": [[0, 13, "Pathology"], [148, 153, "Drug"]]}], [2498, "Herbal medicine is much cheaper and readily available in most settings.", {"entities": []}], [2499, "There is substantial evidence supporting the potential of medicinal plants in combating diseases, especially in developing countries [12,13,14,15].", {"entities": []}], [2500, "Although effective in the treatment of some diseases, the mechanisms of action for most herbal medicines remain largely unknown.", {"entities": []}], [2501, "A wide range of compounds (including phytochemicals) have been extracted from some of these medicinal plants so it is not inconceivable to be able to predict possible effects of herbal medicines on enzymes, such as CYP2B6, that metabolize commonly used drugs including EFV and NVP [16,17,18].", {"entities": [[215, 221, "Target"], [269, 272, "Drug"], [277, 280, "Drug"]]}], [2502, "Some patients take herbal medicines and conventional medicines at the same time in a bid to get better more quickly, potentiating risk of herb\u2013drug interaction (HDI) [19].", {"entities": []}], [2503, "In spite of the wide use of herbal medications among HIV/AIDs patients taking EFV or NVP-based HAART, data on their pharmacokinetic and pharmacodynamics properties in humans remain lacking or scant [11,20].", {"entities": [[53, 56, "Pathology"], [57, 61, "Pathology"], [78, 81, "Drug"], [85, 88, "Drug"], [95, 100, "Drug"]]}], [2504, "Clinically significant interaction of herbs with prescribed medications via drug metabolism may worsen the health condition of patients if not detected earlier during treatment.", {"entities": []}], [2505, "Cytochrome P450 enzymes (CYP450) are responsible for the metabolism of nearly 75% of phase I-dependent metabolism of clinically used drugs [21].", {"entities": [[0, 32, "Target"]]}], [2506, "Relative expression of CYP2B6 ranges from 2% to 10% of the total hepatic content [22,23,24] and contributes to a significant proportion of drug metabolism [25].", {"entities": [[23, 29, "Target"]]}], [2507, "Genetic polymorphism in CYP2B6 have been implicated in variations in the activity of the enzyme in metabolizing xenobiotics [26].", {"entities": [[24, 30, "Target"]]}], [2508, "Inhibition of CYP2B6 by any drug, conventional and/or herbal, is likely to present in a similar manner as portrayed by polymorphisms that result in deficient enzyme activity.", {"entities": [[14, 20, "Target"]]}], [2509, "Thus, when herbal medicines are co-administered with ARV drugs, the possibility of herb-ARV drug interaction might be clinically significant and may lead to significant morbidity and mortality.", {"entities": [[53, 62, "Drug"], [88, 96, "Drug"]]}], [2510, "The purpose of this study was to evaluate the inhibition of CYP2B6 enzyme activity by selected medicinal plant extracts used by HIV patients to treat HIV-associated opportunistic infections.", {"entities": [[60, 66, "Target"], [128, 131, "Pathology"], [150, 189, "Pathology"]]}], [2511, "The medicinal plant extracts evaluated were extracted from Hyptis suaveolens, Boerhavia diffusa, Newbouldia laevis, Launaea taraxacifolia and Myrothamnus flabellifolius.", {"entities": [[20, 28, "Extraction process"], [59, 76, "Herb name"], [78, 95, "Herb name"], [97, 114, "Herb name"], [116, 137, "Herb name"], [142, 168, "Herb name"]]}], [2512, "This study provides us with an opportunity to understand the effects of five medicinal plants\u2014Hyptis suaveolens, Boerhavia diffusa, Newbouldia laevis, Launaea taraxacifolia and Myrothamnus flabellifolius\u2014on CYP2B6 activity.", {"entities": [[94, 111, "Herb name"], [113, 130, "Herb name"], [132, 149, "Herb name"], [151, 172, "Herb name"], [177, 203, "Herb name"], [207, 213, "Target"]]}], [2513, "Data presented here can help to increase awareness among current and future patients of the potential effects of dual use of conventional drugs that are metabolized xenobiotic metabolising enzymes such as CYP2B6 and the above herbal medicinal plants.", {"entities": [[205, 211, "Target"]]}], [2514, "Our data shows that, indeed, for most of these herbal compounds, there is need for caution when co-administering them with other medications.", {"entities": []}], [2515, "The potential of each medicinal plant extract to inhibit activity of recombinant human CYP2B6 is presented in Figure 1 and Table 1.", {"entities": [[38, 45, "Extraction process"], [87, 93, "Target"]]}], [2516, "Four of the medicinal plant extracts inhibited CYP2B6 activity in a concentration dependent manner.", {"entities": [[28, 36, "Extraction process"], [47, 53, "Target"]]}], [2517, "The potency of inhibition exhibited by the extracts was in the order of Hyptis suaveolens (HS) > Myrothamnus flabellifolius (MF) > Boerhavia diffusa (BD) > Launaea taraxacifolia (LT).", {"entities": [[43, 51, "Extraction process"], [72, 94, "Herb name"], [97, 128, "Herb name"], [131, 153, "Herb name"], [156, 182, "Herb name"]]}], [2518, "Newbouldia laevis did not show any concentration dependent inhibitory effects.", {"entities": [[0, 17, "Herb name"]]}], [2519, "IC The IC IC The % yield and concentration per dose was calculated as shown in Table 2.", {"entities": [[0, 2, "Parameter"], [7, 9, "Parameter"], [10, 12, "Parameter"]]}], [2520, "Since the intestinal absorption and plasma concentrations of each test compound are not known, and with the knowledge that herbal extracts have different bioavailability [28], the estimated bioavailable concentration was calculated using the % yield to give the soluble extract available in the GI tract.", {"entities": [[130, 138, "Extraction process"], [154, 169, "Parameter"], [190, 216, "Parameter"], [262, 277, "Extraction process"]]}], [2521, "Calculation of herbal medicine concentration in the gut.", {"entities": []}], [2522, "Note: GIT, Gastrointestinal tract, estimated bioavailable concentration = (% yield \u00d7 putative GIT concentration)/100.", {"entities": [[45, 71, "Parameter"]]}], [2523, "Using this assumption, the putative GIT concentration was calculated as shown in Table 2 and Table 3.", {"entities": []}], [2524, "The IC In vivo prediction of HDI from in vitro for CYP2B6.", {"entities": [[4, 6, "Parameter"], [7, 14, "Study"], [38, 46, "Study"], [51, 57, "Target"]]}], [2525, "Note: HDI, herb-drug interaction, inhibitor concentration = estimated bioavailable concentration (\u00b5g/mL), * the likelihood of a clinically relevant interaction when four of these herbal extracts are taken is based on the assumption that the % yield serves as the bioavailable fraction which was used in estimating the bioavailable concentration in the gut and also if there is complete absorption.", {"entities": [[34, 57, "Parameter"], [70, 96, "Parameter"], [186, 194, "Extraction process"], [318, 344, "Parameter"]]}], [2526, "The IC A fold decrease in IC Time dependent inhibition (TDI) classification of medicinal plant extract incubation based on IC Extracts of Hyptis suaveolens (HS), Boerhavia diffusa (BD), Myrothamnus flabellifolius (MF) and Launaea taraxacifolia (LT) on recombinant CYP2B6.", {"entities": [[4, 6, "Parameter"], [95, 102, "Extraction process"], [123, 125, "Parameter"], [126, 134, "Extraction process"], [138, 160, "Herb name"], [162, 184, "Herb name"], [186, 217, "Herb name"], [222, 248, "Herb name"], [264, 270, "Target"]]}], [2527, "The bars represent ratio of IC Specific concentrations of the plant extracts were pre-incubated with or without NADPH and the percentage residual activity was compared (Figure 3).", {"entities": [[28, 30, "Herb part"], [68, 76, "Extraction process"], [112, 117, "Target"]]}], [2528, "Medicinal plant extracts that were pre-incubated with NADPH showed a reduction in the percentage activity of CYP2B6 compared to those without NADPH with a significant effect observed for the Launaea taraxacifolia extract indicating its time dependent inhibitory potency without the possibility of enzyme activity recovery.", {"entities": [[16, 24, "Extraction process"], [54, 59, "Target"], [109, 115, "Target"], [142, 147, "Target"], [191, 212, "Herb name"], [213, 220, "Extraction process"]]}], [2529, "Hyptis suaveolens (HS), Boerhavia diffusa (BD), Myrothamnus flabellifolius (MF) and Launaea taraxacifolia (LT) on recombinant CYP2B6 after pre-incubation with or without NADPH for 30 min.", {"entities": [[0, 22, "Herb name"], [24, 46, "Herb name"], [48, 79, "Herb name"], [84, 110, "Herb name"], [126, 132, "Target"], [170, 175, "Target"], [176, 186, "Duration"]]}], [2530, "Percentage residual activities were plotted against respective fractions.", {"entities": []}], [2531, "Two-tailed unpaired t-test was used to compare the percentage residual activity of each fraction with p < 0.05 considered significant.", {"entities": []}], [2532, "Inhibitory effects of 50 \u00b5g/mL of each extract after pre-incubation in the presence and absence of NADPH.", {"entities": [[39, 46, "Extraction process"], [99, 104, "Target"]]}], [2533, "** Significant p value.", {"entities": []}], [2534, "The relative quantification of phenolic compounds after UPLC-MS was performed using XCMS data analysis software.", {"entities": [[31, 49, "Herb name"]]}], [2535, "Table 4 shows the relative quantification of the phenolic compounds analyzed using MS detection expressed in mg\u00b7kg Quantification of compounds identified in herbal extracts using MS detection.", {"entities": [[49, 67, "Herb name"], [164, 172, "Extraction process"]]}], [2536, "Note: values are expressed as mg\u00b7kg Structures of the phenolic compounds identified and quantified from crude herbal extracts (1) Caffeic acid; (2) Catechin; (3) Chlorogenic acid; (4) Epicatechin; (5) p-Coumaric acid.", {"entities": [[54, 72, "Herb name"], [104, 125, "Extraction process"], [130, 142, "Herb name"], [148, 156, "Herb name"], [162, 178, "Herb name"], [184, 195, "Herb name"], [201, 216, "Herb name"]]}], [2537, "The use of medicinal plants for therapeutic purpose is a globally known phenomenon.", {"entities": []}], [2538, "When adverse effects are experienced or cure fails, like in the case of HIV infection and cancer, limited resources could be used to promote the use of herbal medicines.", {"entities": [[5, 20, "Pathology"], [72, 85, "Pathology"], [90, 96, "Pathology"]]}], [2539, "Thus, studies such as this one, which seek to scientifically validate the safety of herbal medicines, are imperative.", {"entities": []}], [2540, "Herbal medicine is being used for the treatment of a wide spectrum of disease conditions including cardiovascular and viral disease, cancer and diabetes [29].", {"entities": [[99, 131, "Pathology"], [133, 139, "Pathology"], [144, 152, "Pathology"]]}], [2541, "There is increasing evidence to also show that there is concomitant use of herbal medicines with conventional medicines which leads to clinical complications resulting from herb\u2013drug interactions [11,19,30].", {"entities": []}], [2542, "Studies on the drug interaction potential of herbal medicines, especially those that have been in use for centuries, will help to create an awareness of the potential for complications [31,32].", {"entities": []}], [2543, "It is also imperative that identification of the phytochemical constituents in these herbal medicines be performed to identify those likely to cause drug interactions.", {"entities": []}], [2544, "The advantage of phytochemical profiling is that similar drug interacting constituents could be identified in other related herbs that are used for therapeutic purposes and that necessary mechanistic studies are performed on them.", {"entities": []}], [2545, "Guidelines from the FDA relating to drug interaction and identification of compounds which interact with drug metabolizing enzymes and transporters is of high value since these compounds play a major role in affecting the pharmacokinetic and pharmacodynamics profiles of allopathic medications [33].", {"entities": []}], [2546, "In this study, five herbal medicines commonly taken to treat and manage the effects of HIV/AIDS or its comorbidities by patients were evaluated for their ability to modulate activity of CYP2B6 in vitro using recombinant human CYPs.", {"entities": [[87, 90, "Pathology"], [91, 95, "Pathology"], [186, 192, "Target"], [193, 201, "Study"], [226, 230, "Target"]]}], [2547, "Crude extracts of the herbal medicines were used because since patients take these extracts in their crude from, it became important that the effect of the crude form is evaluated.", {"entities": [[0, 14, "Extraction process"], [83, 111, "Extraction process"]]}], [2548, "The method of extraction used for this study was also performed to mimic the indigenous mode of extraction using water.", {"entities": []}], [2549, "The study showed that Launaea taraxacifolia Hyptis suaveolens, Boerhavia diffusa and Myrothamnus flabellifolius extracts caused a concentration-dependent inhibition in CYP2B6.", {"entities": [[22, 43, "Herb name"], [44, 61, "Herb name"], [63, 80, "Herb name"], [85, 111, "Herb name"], [112, 120, "Extraction process"], [168, 174, "Target"]]}], [2550, "The US FDA, EMA and pharmaceutical industries have published opinion documents and guidelines for the conduct of drug enzyme inhibition studies [34,35,36] which include reversible and time dependent inhibition profiles of new chemical entities (NCE).", {"entities": []}], [2551, "A reversible inhibition profile was thus conducted for the herbal extracts.", {"entities": [[66, 74, "Extraction process"]]}], [2552, "It was observed that Hyptis suaveolens, Myrothamnus flabellifolius, Launaea taraxacifolia and Boerhavia diffusa had a reversible inhibitory effect on the activity of CYP2B6.", {"entities": [[21, 38, "Herb name"], [40, 66, "Herb name"], [68, 89, "Herb name"], [94, 111, "Herb name"], [166, 172, "Target"]]}], [2553, "Newbouldia laevis, however, did not show any significant inhibitory effects on the activity of CYP2B6 based on the concentration range assessed.", {"entities": [[0, 17, "Herb name"], [95, 101, "Target"]]}], [2554, "Based on the recommended dosage taken by patients, the GIT concentration was calculated and % yield used to estimate the bioavailable concentration (Table 2) and the possibility of causing HDI in vivo determined.", {"entities": [[121, 147, "Parameter"], [193, 200, "Study"]]}], [2555, "Here, a comparison was made between the amount of extract in the gut and the IC According to US FDA, EMA and pharmaceutical industries guidelines on the conduct of drug enzyme inhibition studies [34,36,38], NCE that show significant reversible inhibition should also be assessed for time dependent inhibitory (TDI) effects.", {"entities": [[50, 57, "Extraction process"], [77, 79, "Parameter"]]}], [2556, "The IC Launaea taraxacifolia has been used for centuries in West African countries such as Ghana and Nigeria as a vegetable and also for managing dyslipidemia and liver diseases [42] which are complications of HIV/AIDS, its comorbidities [43,44,45,46] and HAART [10,47,48,49].", {"entities": [[4, 6, "Parameter"], [7, 28, "Herb name"], [60, 72, "Ethnic group"], [146, 158, "Pathology"], [163, 177, "Pathology"], [210, 213, "Pathology"], [214, 218, "Pathology"], [256, 261, "Drug"]]}], [2557, "Patients on HAART regimens containing EFV and NVP are likely to experience adverse drug effects from Launaea taraxacifolia when used together.", {"entities": [[12, 17, "Drug"], [38, 41, "Drug"], [46, 49, "Drug"], [75, 95, "Pathology"], [101, 122, "Herb name"]]}], [2558, "In resource-limited settings, Launaea taraxacifolia is a commonly used vegetable; thus, herb\u2013drug interactions are highly likely to be reported.", {"entities": [[30, 51, "Herb name"]]}], [2559, "Although the study analyzed effects of the crude herbal extracts as taken by patients and did not evaluate the effects of the individual phytochemical constituents or fractions, UPLC-MS was used to quantify some phenolic compounds known for their therapeutic effects and some that have been implicated in CYP inhibition.", {"entities": [[43, 64, "Extraction process"], [212, 230, "Herb name"], [305, 308, "Target"]]}], [2560, "Quantification of catechin, p-coumaric acid, caffeic acid, epicatechin and chlorogenic acid was performed with known standards and analyzed using XCMS data analysis software.", {"entities": [[18, 26, "Herb name"], [28, 43, "Herb name"], [45, 57, "Herb name"], [59, 70, "Herb name"], [75, 91, "Herb name"]]}], [2561, "Extract from Launaea taraxacifolia showed high content of chlorogenic acid (1662.98 mg\u00b7kg Miconazole nitrate was purchased from Sigma-Aldrich (St. Louis, MO, USA).", {"entities": [[0, 7, "Extraction process"], [13, 34, "Herb name"], [58, 74, "Herb name"], [90, 108, "Drug"]]}], [2562, "Black costar 96 well plates were obtained from Thermo Fischer Scientific (Pittsburgh, PA, USA).", {"entities": []}], [2563, "Vivid The following plants Hyptis suaveolens (UCC/BS/687), Boerhavia diffusa (UCC/BS/688), Newbouldia laevis (UCC/BS/689) and Launaea taraxacifolia (UCC/BS/690), Table 5, used in the study were obtained and authenticated by botanists from the University of Cape Coast and samples were kept in the herbarium in the department of Biological sciences with voucher numbers as indicated.", {"entities": [[27, 44, "Herb name"], [59, 76, "Herb name"], [91, 108, "Herb name"], [126, 147, "Herb name"]]}], [2564, "Myrothamnus flabellifolius, Table 5, was obtained from Zimbabwe and authenticated by a botanist.", {"entities": [[0, 26, "Herb name"]]}], [2565, "Leaves of the plants were air dried and made into a powder using mortar and pestle.", {"entities": [[0, 6, "Herb part"]]}], [2566, "Ethical approval was obtained from the University of Cape Town Human Research Ethics committee with number HREC REF: 826/2014.", {"entities": []}], [2567, "Herbal plants and their medicinal value.", {"entities": []}], [2568, "A sample of 10 g of leaves from each plant was prepared in 100 mL of distilled water and heated for one hour at 60 \u00b0C to mimic the indigenous mode of extraction.", {"entities": [[20, 26, "Herb part"]]}], [2569, "The material was allowed to extract for 72 h at room temperature during which supernatant was decanted every 24 h and the solid residue reconstituted in the same volume of purified water for the extraction process to be repeated.", {"entities": [[36, 44, "Duration"], [103, 113, "Frequency"]]}], [2570, "The supernatants were pooled and centrifuged (14,000\u00d7 g, 10 min) and filtered using filter paper (8 \u00b5m, Whatman International LTD, Maidstone, UK).", {"entities": []}], [2571, "The filtrates were freeze-dried using a Virtis sentry freeze dryer (the Virtis Company, NC, Gardiner, NY, USA) and the resulting powders were weighed.", {"entities": []}], [2572, "The dried extracts were stored in an airtight container and stored at \u221220 \u00b0C until needed for use.", {"entities": [[4, 18, "Extraction process"]]}], [2573, "The medicinal plant extracts were screened for inhibitory effects on CYP2B6 using a two point screening assay that used two concentrations of the extracts, 10 \u00b5g/mL and 100 \u00b5g/mL, respectively.", {"entities": [[20, 28, "Extraction process"], [69, 75, "Target"], [146, 154, "Extraction process"]]}], [2574, "The assays were performed using the Vivid Determination of time-dependent inhibition (TDI) followed the same procedure as that of the IC In order to identify and quantify constituents in the medicinal plant extracts, chromatographic separation was performed on a Waters Acquity UPLC system (Waters Corporation, Milford, MA, USA) coupled to a PDA detector and Synapt G2 (ESI negative) following the procedure described by Farag and Wessjohann [55].", {"entities": [[134, 136, "Herb part"], [207, 215, "Extraction process"]]}], [2575, "Quantification of glycosylated derivatives of epicatechin, catechin, chlorogenic acid, caffeic acid and p-coumaric acid was calculated from calibration curves of epicatechin, catechin, chlorogenic acid, and caffeic acid and p-coumaric acid standards, respectively.", {"entities": [[18, 42, "Herb name"], [46, 57, "Herb name"], [59, 67, "Herb name"], [69, 85, "Herb name"], [87, 99, "Herb name"], [104, 119, "Herb name"], [162, 173, "Herb name"], [175, 183, "Herb name"], [185, 201, "Herb name"], [207, 219, "Herb name"], [224, 239, "Herb name"]]}], [2576, "Calibration curves for each reference compound ranged from 0.1 to 100 \u00b5g/mL.", {"entities": []}], [2577, "The data generated was exported into an excel spreadsheet and the amount of metabolite formed at the various concentrations relative to the control (residual activity) was calculated using Equation (1)  The percentage residual activity was plotted against the log transformed concentrations of the medicinal plant extracts and the miconazole (positive CYP2B6 inhibitor).", {"entities": [[314, 322, "Extraction process"], [331, 341, "Drug"], [352, 358, "Target"]]}], [2578, "A sigmoid curve was then fitted using non-linear regression analysis and the IC Y: remaining CYP2B6 activity (percentage of control), [I]: concentration of medicinal plant extract, H: Hill coefficient.", {"entities": [[77, 79, "Parameter"], [93, 99, "Target"], [172, 179, "Extraction process"]]}], [2579, "The difference between the calculated IC The assumptions to risk rank the HDI potential of all extracts used in this study was done according to the method of Awortwe et al.", {"entities": [[38, 40, "Parameter"], [95, 103, "Parameter"]]}], [2580, "[57].", {"entities": []}], [2581, "Percentage yield of each extract was calculated from amounts extracted from each herbal plant material.", {"entities": [[25, 32, "Extraction process"]]}], [2582, "To predict the likelihood of medicinal plant extracts interacting with hepatic CYP2B6, two assumptions were made: firstly, that extracts were completely soluble in the human Gastro intestinal tract (GIT) fluid volume of 250 mL.", {"entities": [[45, 53, "Extraction process"], [79, 85, "Target"], [128, 136, "Extraction process"]]}], [2583, "The commonly used dose of the various extracts was estimated to be 200\u2013400 mg. Based on the recommended dose used in humans, an estimated concentration per dose in GIT depending on the % yield was calculated; Secondly, that adequate amount of each extract enters the hepatic portal vein to interact with CYP2B6, if the IC We have shown that some of the medicinal plant extracts that have been used traditionally to cure different diseases may need to be carefully considered in the era of HAART treatment, especially when considering regimens containing EFV and NVP because of the effects of these herbal treatments on CYP2B6, an enzyme that is necessary in the deposition of many therapeutically used drugs.", {"entities": [[38, 46, "Extraction process"], [67, 77, "Amount"], [248, 255, "Extraction process"], [304, 310, "Target"], [319, 321, "Parameter"], [369, 377, "Extraction process"], [489, 504, "Drug"], [554, 557, "Drug"], [562, 565, "Drug"], [619, 625, "Target"]]}], [2584, "Research reported in this publication was supported by the National Research Foundation (NRF) under an Indigenous Knowledge Systems (IKS) Research Grant to Collet Dandara.", {"entities": []}], [2585, "The views and opinions expressed are not those of the NRF but of the authors of the material published.", {"entities": []}], [2586, "Nicholas Ekow Thomford is funded by an NRF grant-holder linked bursary from the IKS research grant awarded to Collet Dandara.", {"entities": []}], [2587, "Sample Availability: Not available.", {"entities": []}], [2588, "Collet Dandara, Ambroise Wonkam, Nicholas Ekow Thomford, Michelle Skelton, Dee Blackhurst and Faustina Adu contributed to the design of the study.", {"entities": []}], [2589, "All authors have materially participated in the manuscript preparation.", {"entities": []}], [2590, "Nicholas Ekow Thomford and Charles Awortwe performed the laboratory and data analysis.", {"entities": []}], [2591, "Collet Dandara and Nicholas Ekow Thomford wrote the draft manuscript and interpretation of data.", {"entities": []}], [2592, "Denis Chopera, Kevin Dzobo, Ambroise Wonkam, Dee Blackhurst and Michelle Skelton commented.", {"entities": []}], [2593, "All authors reviewed the final manuscript.", {"entities": []}], [2594, "The authors declare no conflict of interest.", {"entities": []}], [2595, "These authors contributed equally to this work.", {"entities": []}], [2596, "These authors contributed equally to this work.", {"entities": []}], [2597, "Galgeuntang (GGT), a traditional herbal medicine, is widely co-administered with acetaminophen (AAP) for treatment of the common cold, but this combination has not been the subject of investigation.", {"entities": [[0, 16, "Herb name"], [81, 100, "Drug"], [122, 133, "Pathology"]]}], [2598, "Therefore, we investigated the herb\u2013drug interaction between GGT and AAP by population pharmacokinetics (PKs) modeling and simulation studies.", {"entities": [[61, 64, "Herb name"], [69, 72, "Drug"], [123, 141, "Study"]]}], [2599, "Ephedrine (EPD), the only GGT component detected, was identified using a one-compartment model.", {"entities": [[0, 15, "Herb name"], [26, 29, "Herb name"]]}], [2600, "The PKs of AAP were described well by a one-compartment model and exhibited two-phase absorption (rapid followed by slow) and first-order elimination.", {"entities": [[11, 14, "Drug"]]}], [2601, "The model showed that EPD significantly influenced the PKs of AAP.", {"entities": [[22, 25, "Herb name"], [62, 65, "Drug"]]}], [2602, "The simulation results showed that at an AAP dose of 1000 mg \u00d7 4 times daily, the area under the concentration versus time curve of AAP increased by 16.4% in the presence of GGT compared to AAP only.", {"entities": [[41, 44, "Drug"], [53, 60, "Amount"], [63, 77, "Frequency"], [82, 128, "Parameter"], [132, 135, "Drug"], [174, 177, "Herb name"], [190, 193, "Drug"]]}], [2603, "In conclusion, the PKs of AAP were affected by co-administration of GGT.", {"entities": [[26, 29, "Drug"], [68, 71, "Herb name"]]}], [2604, "Therefore, when AAP is combined with GGT, adverse effects related to overdose of AAP could be induced possibly.", {"entities": [[16, 19, "Drug"], [37, 40, "Herb name"], [42, 57, "Pathology"], [81, 84, "Drug"]]}], [2605, "Herbal medicines are widely used alone or in combination with synthetic drugs.", {"entities": []}], [2606, "Co-administration of herbal medicines and synthetic drugs may result in drug interactions, which could affect efficacy of treatment [1].", {"entities": []}], [2607, "Indeed, a large number of over-the-counter combinations of synthetic and herbal drugs is used to treat mild conditions, despite the dearth of data on their interactions.", {"entities": []}], [2608, "Galgeuntang (GGT), a traditional herbal medicine, is extracted from the herbs Puerariae Radix, Ephedra sinica, Paeonia albiflora, Glycyrrhiza uralensis Fisch, Zingiber officinale Roscoe, Cinnamomum cassia, and Ziziphus jujuba.", {"entities": [[0, 17, "Herb name"], [78, 93, "Herb name"], [95, 109, "Herb name"], [111, 128, "Herb name"], [130, 157, "Herb name"], [159, 185, "Herb name"], [187, 204, "Herb name"], [210, 225, "Herb name"]]}], [2609, "According to Korean Herbal Pharmacopoeia (2013), puerarin, ephedrine, paeoniflorin, glycyrrhetic acid, and (6)-shogaol are confirmed as marker compounds of GGT.", {"entities": [[13, 19, "Ethnic group"], [49, 57, "Herb name"], [59, 68, "Herb name"], [70, 82, "Herb name"], [84, 101, "Herb name"], [107, 118, "Herb name"], [156, 159, "Herb name"]]}], [2610, "As a result of its anti-inflammatory, anti-pyretic, analgesic [2], antioxidant [3], and anti-influenza virus [4] activities, GGT has been used to treat the common cold.", {"entities": [[125, 128, "Herb name"]]}], [2611, "In addition, GGT has been reported to modulate atopic dermatitis [5] and chronic rhinosinusitis [6].", {"entities": [[13, 16, "Herb name"], [47, 64, "Pathology"], [73, 95, "Pathology"]]}], [2612, "GGT is frequently co-administered with Tylenol (acetaminophen) to treat the common cold in East Asia.", {"entities": [[0, 3, "Herb name"], [39, 62, "Drug"], [76, 87, "Pathology"]]}], [2613, "Although regulatory agencies approved both drugs based on their efficacy and safety, no clinical study of this combination has been conducted.", {"entities": [[88, 102, "Study"]]}], [2614, "Herbal medicines contain a variety of components, making them susceptible to interactions with other drugs.", {"entities": []}], [2615, "Such interactions can alter the pharmacokinetics (absorption, distribution, metabolism, and excretion) of co-administered drugs.", {"entities": []}], [2616, "GGT with five major ingredients also possesses chance of drug interactions when co-administering with other drugs.", {"entities": [[0, 3, "Herb name"]]}], [2617, "A number of in vitro studies investigated the influence of GGT and GGT components on cytochrome (CYP) 450 and predicted its drug interactions [7,8,9,10,11,12,13,14,15,16,17,18,19].", {"entities": [[15, 28, "Study"], [59, 62, "Herb name"], [67, 70, "Herb name"], [85, 105, "Target"]]}], [2618, "For example, GGT reportedly inhibits CYP2C19, CYP2D6, and CYP2E1 [16].", {"entities": [[13, 16, "Herb name"], [37, 44, "Target"], [46, 52, "Target"], [58, 64, "Target"]]}], [2619, "Glycyrrhetic acid completely inhibits CYP3A4 [12], and paeoniflorin inhibits the activity of CYP1A2 in vivo [17].", {"entities": [[0, 17, "Herb name"], [38, 44, "Target"], [55, 67, "Herb name"], [93, 99, "Target"]]}], [2620, "Wu et al.", {"entities": []}], [2621, "[8] reported that ephedrine induces CYP1A2 activity.", {"entities": [[18, 27, "Herb name"], [36, 42, "Target"]]}], [2622, "Moreover, puerarin inactivates CYP2C19, CYP2D6, and CYP1A2 [10].", {"entities": [[10, 18, "Herb name"], [31, 38, "Target"], [40, 46, "Target"], [52, 58, "Target"]]}], [2623, "Acetaminophen (AAP) metabolism mainly occurs in the liver and a lesser extent in the kidney and intestine [20].", {"entities": [[0, 19, "Drug"]]}], [2624, "AAP is primarily metabolized to AAP glucuronide and AAP sulfate, and with a minor fraction to N-acetyl-p-benzoquinone imine (NAPQI) [21].", {"entities": [[0, 3, "Drug"], [32, 35, "Drug"], [52, 55, "Drug"]]}], [2625, "NAPQI is highly reactive and mediates AAP-related hepatotoxicity.", {"entities": [[38, 41, "Drug"], [50, 64, "Pathology"]]}], [2626, "Several CYP450 (CYP3A4, CYP1A2, CYP2D6, CYP2A6, and CYP2E1) were reported to convert AAP to NAPQI [21].", {"entities": [[85, 88, "Drug"]]}], [2627, "Therefore, when GGT and AAP are co-administered, a potential herb\u2013drug interaction might occur and be mediated by CYP450.", {"entities": [[16, 19, "Herb name"], [24, 27, "Drug"], [114, 120, "Target"]]}], [2628, "It possibly results in increasing NAPQI level and consequently causes hepatotoxicity.", {"entities": [[70, 84, "Pathology"]]}], [2629, "However, no clinical study has been performed to evaluate such interaction to date.", {"entities": [[12, 26, "Study"]]}], [2630, "Therefore, our study was conducted to investigate the effect of GGT on PKs of AAP by performing population pharmacokinetics and simulation studies.", {"entities": [[64, 67, "Herb name"], [78, 81, "Drug"], [128, 146, "Study"]]}], [2631, "GGT tablets (640 mg) were purchased from Kyungbang Pharmaceutical Company (394 Namdong-daero, Namdong-gu, Incheon, Republic of Korea).", {"entities": [[0, 3, "Herb name"], [13, 19, "Amount"]]}], [2632, "The inclusion and exclusion criteria were provided in the Supplementary Material Table S1.", {"entities": []}], [2633, "All participants gave their informed consent before participating the study.", {"entities": []}], [2634, "The study was performed in accordance with the Declaration of Helsinki, and the protocol was approved by the Ethics Committee of Daejeon Korean Hospital of Daejeon University (Project identification no.", {"entities": []}], [2635, "DCDC_18_01, approved on 3 January 2018).", {"entities": []}], [2636, "Each participant received three treatments with a 7 \u00b1 1-day washout period in-between.", {"entities": []}], [2637, "The treatment schedule was as follows: period 1, (G1) single-dose AAP 500 mg (2 tablets); period 2, (G2) combination of AAP 500 mg (2 tablets) and GGT 640 mg (12 tablets); and period 3, (G3) single-dose GGT 640 mg (12 tablets).", {"entities": [[54, 65, "Frequency"], [66, 69, "Drug"], [70, 76, "Amount"], [120, 123, "Drug"], [124, 130, "Amount"], [147, 150, "Herb name"], [151, 157, "Amount"], [191, 202, "Frequency"], [203, 206, "Herb name"], [207, 213, "Amount"]]}], [2638, "A dose of 1000 mg AAP (equal to 2 tablets) was used in this study because in clinical practice, AAP is recommended at 1000 mg for the treatment of the common cold.", {"entities": [[10, 17, "Amount"], [18, 21, "Drug"], [96, 99, "Drug"], [118, 125, "Amount"], [151, 162, "Pathology"]]}], [2639, "To enhance efficacy of AAP, GGT is suggested in combination with AAP, and the maximum recommended dose of GGT is 12 tablets per day.", {"entities": [[23, 26, "Drug"], [28, 31, "Herb name"], [65, 68, "Drug"], [106, 109, "Herb name"]]}], [2640, "Therefore, we applied this dose of GGT in our study.", {"entities": [[35, 38, "Herb name"]]}], [2641, "After screening (days \u221228 to \u22121), participants underwent a baseline assessment (day 0).", {"entities": []}], [2642, "All participants fasted from 10 p.m. on the night prior to the day of drug administration.", {"entities": []}], [2643, "During period 1, participants were given the drug at 8 a.m. and resided in the study center for at least 7 h for sample collection.", {"entities": [[105, 108, "Duration"]]}], [2644, "In periods 2 and 3, the subjects stayed in the center for at least 30 h for PK analysis.", {"entities": [[67, 71, "Duration"]]}], [2645, "The study design is shown in Figure 1.", {"entities": []}], [2646, "Blood samples were analyzed by high-performance liquid chromatography-tandem mass spectrometry (Agilent 1100 HPLC; AB Science API2000).", {"entities": []}], [2648, "The calibration curves for AAP and EPD were linear at 50 to 10,000 ng/mL and 50 to 2500 ng/mL, respectively (R Non-compartmental PK analysis was performed using Phoenix WinNonlin (version 8.2.0.4383, Certera LP).", {"entities": [[27, 30, "Drug"], [35, 38, "Herb name"]]}], [2649, "The PK parameters were compared between the two groups by Mann\u2013Whitney U-test (IBM SPSS Statistics Version 24).", {"entities": []}], [2650, "The level of statistical significance was set at \u03b1 = 0.05 for all tests.", {"entities": []}], [2651, "The area under the concentration\u2013time profile curve from zero to the last time point (AUC A population PK analysis was conducted by nonlinear mixed-effects modeling (NONMEM, version 7.4.1).", {"entities": [[4, 51, "Parameter"], [86, 89, "Parameter"]]}], [2652, "PK parameters and interindividual and residual variabilities were estimated using first order conditional estimation with interaction.", {"entities": []}], [2653, "The model was modified in a sequential manner to identify that which best fit the data.", {"entities": []}], [2654, "The model was chosen based on the OFV and plots of goodness of fit.", {"entities": []}], [2655, "IIV was described using an exponential error model (Equation (1)): After development of optimal AAP model, a covariate analysis was conducted to assess additional variables as determinants of the variability in the PK estimate.", {"entities": [[96, 99, "Drug"]]}], [2656, "The co-administered drug (GGT) was considered a covariate.", {"entities": [[26, 29, "Herb name"]]}], [2657, "Covariate was tested using forward selection (p < 0.05) and backward elimination (p < 0.01) processes with likelihood ratio test to determine whether GGT affects the PKs of AAP.", {"entities": [[150, 153, "Herb name"], [173, 176, "Drug"]]}], [2658, "The effect of GGT on PKs of AAP was tested by linear, exponential, and power function models.", {"entities": [[14, 17, "Herb name"], [28, 31, "Drug"]]}], [2659, "The differences between OFV of each model and the base model were calculated.", {"entities": []}], [2660, "During forward selection, a covariate was selected if it showed at least a decrease of 3.84 in OFV.", {"entities": []}], [2661, "In backward elimination, an increase of at least 6.64 unit of OFV was set as criteria for retaining a covariate.", {"entities": []}], [2662, "The final model was validated by VPC and nonparametric bootstrapping.", {"entities": []}], [2663, "The parameter estimates of the bootstrap samples were re-estimated and the median and 95% confidence intervals were compared with those estimated using the final model.", {"entities": []}], [2664, "For VPCs, the estimated parameter and the final model were used to simulate 1000 data sets, and the observed data were overlaid on the simulated median and 90% prediction intervals.", {"entities": []}], [2665, "To mimic the recommended dose based on the status of patients, AAP dose is suggested from 1000 mg to the maximum dose of 1000 mg \u00d7 4 times (8 tablets) per day for treatment of the common cold [22,23].", {"entities": [[63, 66, "Drug"], [90, 97, "Amount"], [121, 128, "Amount"], [131, 158, "Frequency"], [180, 191, "Pathology"]]}], [2666, "Therefore, two simulation scenarios were used to evaluate the magnitude of any interaction, (AAP 1000 mg once daily + GGT 7680 mg once daily) and (AAP 1000 mg \u00d7 4 times daily + GGT 7680 mg once daily) in a week.", {"entities": [[93, 96, "Drug"], [97, 104, "Amount"], [105, 115, "Frequency"], [118, 121, "Herb name"], [122, 129, "Amount"], [130, 140, "Frequency"], [147, 150, "Drug"], [151, 158, "Amount"], [161, 174, "Frequency"], [177, 180, "Herb name"], [181, 188, "Amount"], [189, 199, "Frequency"], [206, 210, "Duration"]]}], [2667, "The effect of GGT on the PKs of AAP was assessed by monitoring the AUC Among the components of GGT, only EPD (Ephedra sinica) was detected under our analysis.", {"entities": [[14, 17, "Herb name"], [32, 35, "Drug"], [67, 70, "Parameter"], [95, 98, "Herb name"], [105, 125, "Herb name"]]}], [2668, "Therefore, we investigated the interaction between AAP and EPD.", {"entities": [[51, 54, "Drug"], [59, 62, "Herb name"]]}], [2669, "Figure 2 shows the mean plasma concentration versus (vs.) time profiles of AAP administered alone (group 1, G1) and AAP co-administered with GGT (group 2, G2).", {"entities": [[75, 78, "Drug"], [116, 119, "Drug"], [141, 144, "Herb name"]]}], [2670, "Table 2 summaries PK parameters of AAP in the presence or absence of GGT according to non-compartmental analysis (NCA) results.", {"entities": [[35, 38, "Drug"], [69, 72, "Herb name"]]}], [2671, "The area under the concentration\u2013time curve from time zero to infinity (AUC One- and two-compartment with first-order elimination and absorption were initially tested in development AAP model.", {"entities": [[4, 43, "Parameter"], [72, 75, "Parameter"], [182, 185, "Drug"]]}], [2672, "The objective function values (OFV) of those models are listed in Table 3.", {"entities": []}], [2673, "One-compartment model gave an OFV of 1493.", {"entities": []}], [2674, "When two-compartment was applied, the OFV increased by 34.6 units comparing to one-compartment model.", {"entities": []}], [2675, "Therefore, one-compartment was used in the next step.", {"entities": []}], [2676, "Variety of absorption models was tested to describe absorption process of AAP.", {"entities": [[74, 77, "Drug"]]}], [2677, "Gastric emptying (GE) was firstly modelled in absorption phase of AAP owing to the dependence of AAP absorption on rate of GE [24].", {"entities": [[0, 21, "Parameter"], [66, 69, "Drug"], [97, 100, "Drug"], [123, 125, "Parameter"]]}], [2678, "Another simple GE model was also taken into consideration due to sparse absorption data.", {"entities": [[15, 17, "Parameter"]]}], [2679, "In which, absorption phase was modelled with two periods, initially rapid absorbed (represented by k In the covariate analysis, the effect of co-administration EPD on the principal PK parameters (apparent clearance (CL/F), absorption rate (k Incorporation of EPD significantly reduced the interindividual variability (IIV) and OFV (p < 0.05).", {"entities": [[160, 163, "Herb name"], [196, 221, "Parameter"], [223, 238, "Parameter"], [259, 262, "Herb name"]]}], [2680, "IIV of V/F and k The parameter estimates and 95% confidence intervals for the parameters were calculated (Table 5).", {"entities": []}], [2681, "All estimates obtained from the final model were comparable to the bootstrap estimates (n = 1000) and were within the 95% bootstrap confidence intervals.", {"entities": []}], [2682, "Figure 5 shows the result of visual predictive check (VPC) (n = 1000) for AAP.", {"entities": [[74, 77, "Drug"]]}], [2683, "Overall, the VPC suggested that the final model adequately describes the distribution of AAP concentration.", {"entities": [[89, 92, "Drug"]]}], [2684, "The simulated median represented the trend of the observed concentration.", {"entities": []}], [2685, "In addition, the majority of the observed values fell within the 90% prediction intervals.", {"entities": []}], [2686, "Simulations were performed 1000 times using the developed model to assess the effect of GGT on PKs of AAP.", {"entities": [[88, 91, "Herb name"], [102, 105, "Drug"]]}], [2687, "AAP at 1000 once a day or 1000 mg \u00d7 4 times a day was administered in the presence or absence of GGT (7680 mg) daily.", {"entities": [[0, 3, "Drug"], [12, 22, "Frequency"], [26, 33, "Amount"], [36, 49, "Frequency"], [97, 100, "Herb name"], [102, 109, "Amount"], [111, 116, "Frequency"]]}], [2688, "The drugs were given consecutively over 1 week.", {"entities": [[35, 46, "Duration"]]}], [2689, "The result was provided in the Table 6.", {"entities": []}], [2690, "The median predicted AAP plasma concentrations are shown in Figure 6 and Figure 7.", {"entities": [[21, 24, "Drug"]]}], [2691, "The PKs of AAP were best described by a one-compartment and first-order elimination and two-period absorption phases.", {"entities": [[11, 14, "Drug"]]}], [2692, "EPD, the only component of GGT detected, was identified as a covariate in the model.", {"entities": [[0, 3, "Herb name"], [27, 30, "Herb name"]]}], [2693, "The CL/F, V/F, k In our study, GE was applied to describe absorption process of AAP due to the dependence of AAP absorption on the rate of GE [24].", {"entities": [[31, 33, "Parameter"], [80, 83, "Drug"], [109, 112, "Drug"], [139, 141, "Parameter"]]}], [2694, "A biphasic GE pattern was modelled, in which a fraction of total administered drug (f Since the dependence of AAP absorption on GE rate [24], absorption of AAP is susceptible to factors which can change GE rate, such as food or concomitant intake.", {"entities": [[11, 13, "Parameter"], [110, 113, "Drug"], [128, 130, "Parameter"], [156, 159, "Drug"], [203, 205, "Parameter"]]}], [2695, "In this study, for GGT 7680 mg, a total of 12 tablets were co-administered with AAP.", {"entities": [[19, 22, "Herb name"], [23, 30, "Amount"], [80, 83, "Drug"]]}], [2696, "Those of tablet intake was enough to stimulate gastro-intestinal (GI) mobility under fasting condition, so the k In our population PK result, GGT increased V/F while it had no effect on CL/F of AAP, and sequentially resulted in an increase in t An increase in t According to this equation, AR is 1.18 and 1.63 in AAP alone group and combined group (AAP + GGT), respectively.", {"entities": [[142, 145, "Herb name"], [194, 197, "Drug"], [313, 316, "Drug"], [349, 352, "Drug"], [355, 358, "Herb name"]]}], [2697, "The extent of drug accumulation in AAP alone group is lower than that of combined group.", {"entities": [[35, 38, "Drug"]]}], [2698, "It results in an increase in AUC of AAP in combined group comparing to that in AAP alone group at dose of 1000 mg \u00d7 4 times per day with an increase of approximately 116.4% of AUC A total of 1000 mg \u00d7 4 times per day of AAP was applied in the simulation scenario because it is the highest recommended dose of AAP for treatment of the common cold [22,23].", {"entities": [[29, 32, "Parameter"], [36, 39, "Drug"], [79, 82, "Drug"], [106, 113, "Amount"], [116, 131, "Frequency"], [176, 179, "Parameter"], [191, 198, "Amount"], [201, 216, "Frequency"], [220, 223, "Drug"], [309, 312, "Drug"], [334, 345, "Pathology"]]}], [2699, "As reference, patients can use 1000 mg AAP every 6 h, and should not take more than 4000 mg in 24 h. In addition, AAP was reported to follow linear pharmacokinetics for doses of less or equal to 18 mg/kg [31].", {"entities": [[14, 22, "Pathology"], [31, 38, "Amount"], [39, 42, "Drug"], [43, 52, "Frequency"], [84, 91, "Amount"], [114, 117, "Drug"], [195, 203, "Amount"]]}], [2700, "Therefore, it is appropriate to extrapolate PKs of AAP 1000 mg \u00d7 4 times per day from AAP 1000 mg.", {"entities": [[51, 54, "Drug"], [55, 62, "Amount"], [65, 80, "Frequency"], [86, 89, "Drug"], [90, 97, "Amount"]]}], [2701, "In addition to investigating the effect of EPD on PKs of AAP, we also checked the impact of AAP on PKs of EPD, in which AAP as perpetrator and EPD as victim.", {"entities": [[43, 46, "Herb name"], [57, 60, "Drug"], [92, 95, "Drug"], [106, 109, "Herb name"], [120, 123, "Drug"], [143, 146, "Herb name"]]}], [2702, "The NCA results and plot of concentration vs. time profile of EPD with/without AAP was provided in Supplementary Materials Table S3 and Figure S1, respectively.", {"entities": [[62, 65, "Herb name"], [79, 82, "Drug"]]}], [2703, "NCA results showed that there was no statistically significant difference between two groups, (EPD alone) and (EPD + AAP) (p > 0.05).", {"entities": [[95, 98, "Herb name"], [111, 114, "Herb name"], [117, 120, "Drug"]]}], [2704, "Therefore, AAP was concluded to have no effect on PKs of EPD.", {"entities": [[11, 14, "Drug"], [57, 60, "Herb name"]]}], [2705, "Pseudoephedrine (P-EPD), a stereoisomer of EPD, is widely combined with AAP in a fixed dose of many commercial products for treatment common cold, headache, fever, etc.", {"entities": [[0, 22, "Herb name"], [43, 46, "Herb name"], [72, 75, "Drug"], [134, 145, "Pathology"], [147, 155, "Pathology"], [157, 162, "Pathology"]]}], [2706, "[32].", {"entities": []}], [2707, "P-EPD and EPD show a relatively similar in physiochemical properties, such as same solubility (8.26 mg/mL for both) [33,34], similar lipophilicity (logP = 1.13 for EPD [35], 0.89 for P-EPD [36]), etc.", {"entities": [[0, 5, "Herb name"], [10, 13, "Herb name"], [164, 167, "Herb name"], [185, 188, "Herb name"]]}], [2708, "As physiochemical properties mainly govern PK properties of drugs in the body [37], PKs of P-EPD are comparable to PKs of EPD.", {"entities": [[91, 96, "Herb name"], [122, 125, "Herb name"]]}], [2709, "As EPD has effects on PKs of AAP, P-EPD could have an interaction with AAP.", {"entities": [[3, 6, "Herb name"], [29, 32, "Drug"], [34, 39, "Herb name"], [71, 74, "Drug"]]}], [2710, "Therefore, caution should be necessary when taking a combination of P-EPD and AAP, especially in multiple dosage regimen.", {"entities": [[68, 73, "Herb name"], [78, 81, "Drug"]]}], [2711, "This study had several limitations.", {"entities": []}], [2712, "Movement of AAP from the stomach to the small intestine is a determinant of its absorption.", {"entities": [[12, 15, "Drug"]]}], [2713, "In our study, subjects were fasted to exclude any effect of food on AAP absorption.", {"entities": [[68, 71, "Drug"]]}], [2714, "However, food is typically consumed when a medicine is taken and the impact of food on AAP absorption should be taken into consideration.", {"entities": [[87, 90, "Drug"]]}], [2715, "Moore et al.", {"entities": []}], [2716, "[38] reported that food delays the absorption of AAP.", {"entities": [[49, 52, "Drug"]]}], [2717, "In the fed condition, the T This study is the first study to describe the herb\u2013drug interaction between GGT and AAP.", {"entities": [[104, 107, "Herb name"], [112, 115, "Drug"]]}], [2718, "The developed model is adequately described the PKs of AAP in presence or absence of GGT.", {"entities": [[55, 58, "Drug"], [85, 88, "Herb name"]]}], [2719, "Co-administered with GGT decreased k Publisher\u2019s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.", {"entities": [[21, 24, "Herb name"]]}], [2720, "The following are available online at  Click here for additional data file.", {"entities": []}], [2721, "Conceptualization, S.J.P., J.-w.C., Y.C.P., and H.-y.Y.", {"entities": []}], [2722, "; data analysis, Q.T.T., H.-m.B., L.T.N., S.J.P., J.-w.C., Y.C.P., and H.-y.Y.", {"entities": []}], [2723, "; performing clinical trial, S.J.P.", {"entities": []}], [2724, "and Y.C.P.", {"entities": []}], [2725, "; performing modeling, Q.T.T., H.-m.B., L.T.N., J.-w.C., and H.-y.Y.", {"entities": []}], [2726, "; qualifying modeling S.J.", {"entities": []}], [2727, "and H.-y.Y.", {"entities": []}], [2728, "; writing\u2014original draft preparation, Q.T.T., S.J.P., J.-w.C., Y.C.P., and H.-y.Y.", {"entities": []}], [2729, "; writing\u2014review and editing, Q.T.T., S.J.P., H.-m.B., L.T.N., D.T.C., H.V.N., J.-w.C., Y.C.P., and H.-y.Y.", {"entities": []}], [2730, "All authors have read and agreed to the published version of the manuscript.", {"entities": []}], [2731, "This study was supported by research funds from Chungnam National University (CNU) and also supported by Institute of Information & communications Technology Planning & Evaluation (IITP) grant funded by the Korea government (MSIT) (No.2020-0-01441, Artificial Intelligence Convergence Research Center (Chungnam National University)) and by a grant of the Korea Healthcare technology R&D Project, Ministry for Health & Welfare Affairs, Republic of Korea (grant number: HI15C0006) and by a grant of National Research Foundation of Korea (Grant number : NRF-2018R1C1B6007898), Republic of Korea.", {"entities": []}], [2732, "The authors declare no conflict of interest.", {"entities": []}], [2733, "Scheme of the clinical trial.", {"entities": [[14, 28, "Study"]]}], [2734, "PK, pharmacokinetics.", {"entities": []}], [2735, "Comparison of plasma concentration\u2013time profiles of acetaminophen (AAP) after administration alone or co-administration with Galgeuntang (GGT).", {"entities": [[52, 71, "Drug"], [125, 142, "Herb name"]]}], [2736, "Each point represents the mean and standard deviation.", {"entities": []}], [2737, "Scheme of the base model with two periods of absorption phase.", {"entities": []}], [2738, "CL, clearance.", {"entities": []}], [2739, "Goodness of fit plots of the final AAP model.", {"entities": [[35, 38, "Drug"]]}], [2740, "Empty circle: observation, solid line: reference line (y = x line for individual predicted concentrations (IPRED) or predicted concentrations (PRED) vs. observation plots, y = 0 for Time or IPRED vs. conditional weight residual (CWRES) plots), dash line: regression line.", {"entities": []}], [2741, "Visual predictive check (VPC) plot of the final model for AAP observations.", {"entities": [[58, 61, "Drug"]]}], [2742, "Empty circles: observed AAP concentration; pink area: 95% confidence intervals of median predicted concentration; gray areas: 95% confidence intervals of 5th and 95th percentile predicted concentration.", {"entities": [[24, 27, "Drug"]]}], [2743, "Simulation result of 1000 mg AAP administered alone (A) or co-administered with GGT (B) in a week.", {"entities": [[21, 28, "Amount"], [29, 32, "Drug"], [80, 83, "Herb name"], [93, 97, "Duration"]]}], [2744, "Black solid lines: median simulated concentration; shaded bands: 90% percent confidence interval for 1000 replicates simulation.", {"entities": []}], [2745, "Simulation result of 1000 mg \u00d7 4 times per day of AAP administered alone (A) or co-administered with GGT (B) in a week.", {"entities": [[21, 28, "Amount"], [31, 46, "Frequency"], [50, 53, "Drug"], [101, 104, "Herb name"], [114, 118, "Duration"]]}], [2746, "Black solid lines: median simulated concentration; shaded bands: 90% percent confidence interval for 1000 replicates simulation.", {"entities": []}], [2747, "The content of major ingredients in Galgeuntang.", {"entities": [[36, 47, "Herb name"]]}], [2748, "Non-compartmental analysis (NCA) result of pharmacokinetic (PK) parameters of AAP.", {"entities": [[78, 81, "Drug"]]}], [2749, "AUC Model development of AAP.", {"entities": [[0, 3, "Parameter"], [25, 28, "Drug"]]}], [2750, "\u0394OFV, change in objective function value.", {"entities": []}], [2751, "Summary of covariate model building steps.", {"entities": []}], [2752, "\u0394OFV, change in objective function value; DF: degree of freedom; K Parameter estimates of the final covariate model and bootstrap result for AAP.", {"entities": [[141, 144, "Drug"]]}], [2753, "COV NCA results of simulated AAP in steady state.", {"entities": [[29, 32, "Drug"]]}], [2754, "* AUC", {"entities": [[2, 5, "Parameter"]]}], [2755, "PMCID: PMC1858666 NIHMSID: NIHMS19443 PMID: 15974642 Clinical Assessment of Botanical Supplementation on Cytochrome P450 Phenotypes in the Elderly: St. John\u2019s wort, Garlic oil, Panax ginseng, and Ginkgo biloba Bill J. Gurley, PhD.,1 Stephanie F. Gardner, PharmD, EdD.,2 Martha A. Hubbard, MS,1 D. Keith Williams, PhD.,3 W. Brooks Gentry, MD,4 Yanyan Cui, PhD,5 and Catharina Y. W. Ang, PhD.5 Author information Copyright and License information PMC Disclaimer The publisher's final edited version of this article is available at Drugs Aging Go to: Abstract INTRODUCTION Objectives  Elderly patients are more likely to ingest prescription medications concurrently with botanical supplements, therefore, they may be vulnerable to herb-drug interactions.", {"entities": [[53, 72, "Study"], [105, 120, "Target"], [148, 163, "Herb name"], [165, 175, "Herb name"], [177, 190, "Herb name"], [196, 209, "Herb name"]]}], [2756, "Phytochemical-mediated modulation of cytochrome P-450 (CYP) activity may underlie many herb-drug interactions.", {"entities": [[37, 59, "Target"]]}], [2757, "Some evidence suggests that CYP activity may decrease in the elderly.", {"entities": [[28, 31, "Target"]]}], [2758, "If so, herb-mediated changes in CYP activity may take on greater clinical relevance in this population.", {"entities": [[32, 35, "Target"]]}], [2759, "Single time-point, phenotypic metabolic ratios were used to determine whether long-term supplementation of St. John\u2019s wort, garlic oil, Panax ginseng, and Ginkgo biloba affected CYP1A2, CYP2D6, CYP2E1, or CYP3A4 activity in elderly subjects.", {"entities": [[107, 122, "Herb name"], [124, 134, "Herb name"], [136, 149, "Herb name"], [155, 168, "Herb name"], [178, 184, "Target"], [186, 192, "Target"], [194, 200, "Target"], [205, 211, "Target"]]}], [2760, "Probe drug cocktails of midazolam, caffeine, chlorzoxazone, and debrisoquine were administered before and at the end of supplementation.", {"entities": [[24, 33, "Drug"], [35, 43, "Drug"], [45, 58, "Drug"], [64, 76, "Drug"]]}], [2761, "Pre- and postsupplementation phenotypic ratios were determined for CYP3A4, CYP1A2, CYP2E1, and CYP2D6 using 1-hydroxymidazolam/midazolam serum ratios (1-hr), paraxanthine/caffeine serum ratios (6-hr), 6-hydroxychlorzoxazone/chlorzoxazone serum ratios (2-hr), and debrisoquine urinary recovery ratios (8-hr), respectively.", {"entities": [[67, 73, "Target"], [75, 81, "Target"], [83, 89, "Target"], [95, 101, "Target"], [108, 126, "Drug"], [127, 136, "Drug"], [151, 155, "Duration"], [158, 170, "Herb name"], [171, 179, "Herb name"], [194, 198, "Duration"], [201, 223, "Drug"], [224, 237, "Drug"], [252, 256, "Duration"], [263, 275, "Drug"], [301, 305, "Duration"]]}], [2762, "The content of purported \u201cactive\u201d phytochemicals was determined for each supplement.", {"entities": []}], [2763, "RESULTS  Comparisons of pre- and post-St. John\u2019s wort phenotypic ratios revealed significant induction of CYP3A4 (~140%) and CYP2E1 activity (~28%).", {"entities": [[38, 53, "Herb name"], [106, 112, "Target"], [125, 131, "Target"]]}], [2764, "Garlic oil inhibited CYP2E1 activity by approximately 22%.", {"entities": [[0, 10, "Herb name"], [21, 27, "Target"]]}], [2765, "P. ginseng inhibition of CYP2D6 was statistically significant, but the magnitude of the effect (~7%) did not appear clinically relevant.", {"entities": [[0, 10, "Herb name"], [25, 31, "Target"]]}], [2766, "None of the supplements tested in this study appeared to affect CYP1A2 activity.", {"entities": [[64, 70, "Target"]]}], [2767, "CONCLUSIONS  Elderly subjects, like their younger counterparts, are susceptible to herb-mediated changes in CYP activity, especially those involving St. John\u2019s wort.", {"entities": [[108, 111, "Target"], [149, 164, "Herb name"]]}], [2768, "Pharmacokinetic herb-drug interactions stemming from alterations in CYP activity may adversely affect drug efficacy and/or toxicity.", {"entities": [[68, 71, "Herb name"]]}], [2769, "When compared to earlier studies that employed young subjects, the data suggest that some age-related changes in CYP responsivity to botanical supplementation may exist.", {"entities": [[113, 116, "Target"]]}], [2770, "Concomitant ingestion of botanical supplements with prescription medications, therefore, should be strongly discouraged in the elderly.", {"entities": []}], [2771, "Go to: INTRODUCTION  The concomitant use of botanical supplements and conventional medications has engendered a growing medical concern over possible herb-drug interactions.", {"entities": []}], [2772, "[1\u20137] Recent surveys indicate that 24\u201336% of all consumers use botanical products on a regular basis.", {"entities": [[13, 20, "Study"]]}], [2773, "[1\u20133,8,9] Still other surveys indicate that herbal supplement usage is prevalent among patients taking prescription medications,[10\u201312] with many individuals greater than 65 years of age.", {"entities": [[22, 29, "Study"], [158, 186, "Age"]]}], [2774, "[12\u201315] Given that the elderly constitute the largest demographic with regard to prescription medication use, they may also exhibit an increased risk for herb-drug interactions.", {"entities": []}], [2775, "Phytochemical-mediated changes in human drug metabolizing enzyme activity may underlie many herb-drug interactions.", {"entities": []}], [2776, "Recently, a host of prospective clinical investigations have examined the ability of various botanical supplements to modulate human cytochrome P-450 (CYP) activity;[16\u201321] yet, none have examined these effects in elderly subjects.", {"entities": [[20, 55, "Study"], [133, 155, "Target"]]}], [2777, "The practice of self-medicating with botanical supplements is common among elderly subjects,[1,13] and the products most frequently consumed include garlic, Ginkgo biloba, ginseng, and St. John\u2019s wort.", {"entities": [[149, 155, "Herb name"], [157, 170, "Herb name"], [172, 179, "Herb name"], [185, 200, "Herb name"]]}], [2778, "[9\u201312,14,15] Accordingly, these four supplements were selected for examination in the current study.", {"entities": []}], [2779, "To date, St. John\u2019s wort, a dietary supplement with antidepressant properties, appears to be the most problematic botanical with regard to CYP-mediated herb-drug interactions.", {"entities": [[9, 24, "Herb name"], [139, 142, "Target"]]}], [2780, "[4\u20137] Hyperforin, a phytochemical component of St John\u2019s wort, is a ligand for the steroid xenobiotic receptor (SXR) and thus acts as a potent inducer of CYP3A4 and MDR1 gene expression.", {"entities": [[6, 16, "Herb name"], [47, 61, "Herb name"], [83, 116, "Target"], [154, 160, "Target"], [165, 174, "Target"]]}], [2781, "[22,23] Due to the overwhelming number of prescription medications that are substrates for both CYP3A4 and the drug efflux pump, P-glycoprotein (the gene product of MDR1), their effectiveness can be greatly diminished when used concomitantly with St. John\u2019s wort.", {"entities": [[96, 102, "Target"], [129, 143, "Target"], [165, 169, "Target"], [247, 262, "Herb name"]]}], [2782, "Garlic, commonly used for treatment of hypercholesterolemia, also appears to modulate CYP activity in vivo.", {"entities": [[0, 6, "Herb name"], [39, 59, "Pathology"], [86, 89, "Target"]]}], [2784, "[17] Ginkgo biloba is frequently used as an alternative adjunctive treatment for mild senile dementia although its effectiveness is suspect.", {"entities": [[5, 18, "Herb name"], [81, 101, "Pathology"]]}], [2785, "[25,26] Accordingly, its use is rising among elderly patients.", {"entities": []}], [2786, "[13\u201315,26] Studies in young volunteers indicate, however, that ginkgo\u2019s effect on CYP activity is minimal, and similar findings have also been presented for Panax ginseng.", {"entities": [[63, 69, "Herb name"], [82, 85, "Target"], [157, 170, "Herb name"]]}], [2787, "[17,18,27] Nevertheless, the growing popularity of herbal supplement use together with evidence of herb-mediated changes in drug metabolism, suggest that elderly consumers may be especially vulnerable to herb-drug interactions.", {"entities": []}], [2788, "Moreover, age-related changes have been observed in the pharmacokinetics of several CYP substrates,[28\u201330] as well as certain CYP enzymes,[29,30] thus the question remains as to whether such effects may extend to botanical supplements and their effect on drug metabolism in the elderly.", {"entities": [[84, 87, "Target"]]}], [2789, "Evaluating changes in the clearance of various probe drugs (medications that are substrates for specific CYP enzymes) has become a widely accepted methodology for assessing possible CYP-mediated drug-drug interactions.", {"entities": [[105, 108, "Target"], [182, 185, "Target"]]}], [2790, "[31\u201333] Recently, a rapid and reliable in vivo screening method that utilizes single-time point phenotypic metabolic ratios was described for identifying botanical supplements capable of modulating CYP activity.", {"entities": [[39, 56, "Study"], [198, 201, "Target"]]}], [2791, "[17] Although not intended to supplant traditional concentration-time profiles as a means of determining drug clearance, phenotypic metabolic ratios can provide reasonable estimates of probe drug clearance, thereby allowing in vivo evaluations of multiple CYP enzymes and multiple botanical supplements by means of a limited blood sampling scheme.", {"entities": [[224, 243, "Study"], [256, 259, "Target"]]}], [2792, "This method was previously used to assess the effects of long-term supplementation with St. John\u2019s wort, garlic oil, P. ginseng, and G. biloba on CYP1A2, CYP2D6, CYP2E1, and CYP3A4 activity in young, healthy volunteers.", {"entities": [[88, 103, "Herb name"], [105, 115, "Herb name"], [117, 127, "Herb name"], [133, 142, "Herb name"], [146, 152, "Target"], [154, 160, "Target"], [162, 168, "Target"], [174, 180, "Target"], [200, 207, "Pathology"]]}], [2793, "Botanical supplements containing extracts of Citrus aurantium, milk thistle, saw palmetto, and Echinacea purpurea have also been evaluated by this technique.", {"entities": [[45, 61, "Herb name"], [63, 75, "Herb name"], [77, 89, "Herb name"], [95, 113, "Herb name"]]}], [2794, "[34] The purpose of the current study was to utilize single-time point phenotypic ratios as an instrument for determining the effects of St. John\u2019s wort, garlic oil, P. ginseng, and G. biloba on CYP activity in elderly, healthy volunteers.", {"entities": [[137, 152, "Herb name"], [154, 164, "Herb name"], [166, 176, "Herb name"], [182, 191, "Herb name"], [195, 198, "Target"], [220, 227, "Pathology"]]}], [2795, "Go to: MATERIALS AND METHODS Study subjects  The University of Arkansas for Medical Sciences Human Research Advisory Committee (Little Rock, AR) approved this study protocol and all participants provided written informed consent before commencing the study.", {"entities": []}], [2796, "Twelve elderly adults (6 males, 6 females) (age, mean \u00b1 SD = 67 \u00b1 5.2 years; weight, 79.8 \u00b1 14.4 kg) participated in the study and all subjects were in good health as indicated by medical history, routine physical examination, and clinical laboratory testing.", {"entities": [[0, 42, "Cohort"], [44, 75, "Age"], [149, 163, "Pathology"]]}], [2797, "All subjects were extensive metabolizers of CYP2D6 as confirmed by debrisoquine urinary recovery screenings.", {"entities": [[44, 50, "Target"], [67, 79, "Drug"]]}], [2798, "[31] All subjects were nonsmokers, ate a normal diet, and were not using botanical dietary supplements.", {"entities": []}], [2799, "With the exception of 2 female subjects taking conjugated estrogens/medroxyprogesterone acetate (Prempro\u2122, 0.3 mg) no other participants were using prescription or nonprescription medications.", {"entities": [[24, 30, "Sex"], [47, 105, "Drug"], [107, 113, "Amount"]]}], [2800, "Subjects were asked to abstain from alcohol, caffeine, fruit juices, cruciferous vegetables, and charbroiled meat throughout the study.", {"entities": [[55, 67, "Extraction process"]]}], [2801, "Adherence to these restrictions was further emphasized five days before each probe drug administration.", {"entities": []}], [2802, "Subjects were also asked to refrain from taking prescription and nonprescription medications during supplementation periods, and any medication use during this time was brought to the investigators\u2019 attention.", {"entities": []}], [2803, "Documentation of compliance to these restrictions was achieved through the use of a food/medication diary.", {"entities": []}], [2804, "This was an open-label study randomized for supplementation sequence.", {"entities": [[9, 39, "Study"]]}], [2805, "Each supplementation period lasted twenty-eight days and was followed by a 30-day washout period.", {"entities": [[35, 52, "Duration"]]}], [2806, "This randomly assigned sequence of supplementation followed by washout was repeated until each subject had received all four botanical supplements (Figure 1).", {"entities": []}], [2807, "Telephone and electronic mail reminders were used to facilitate compliance, while pill counts and supplementation usage records were used to verify compliance.", {"entities": []}], [2808, "An external file that holds a picture, illustration, etc.", {"entities": []}], [2809, "Object name is nihms19443f1.jpg Figure 1  Supplementation and washout scheme.", {"entities": []}], [2810, "Arrows indicate days of probe drug administration.", {"entities": []}], [2811, "On the day of each scheduled probe drug administration, all subjects reported to the General Clinical Research Center at the University of Arkansas for Medical Sciences.", {"entities": []}], [2812, "CYP1A2, CYP2D6, CYP2E1 and CYP3A4 phenotypes were assessed before (Days \u20131, 0) and at the end of each supplementation phase (Days 27, 28) (Figure 1).", {"entities": [[0, 6, "Target"], [8, 14, "Target"], [16, 22, "Target"], [27, 33, "Target"]]}], [2813, "Forty-eight hours before supplementation (Day \u20131) each subject received an oral dose of caffeine (100 mg), and midazolam (8 mg).", {"entities": [[88, 96, "Herb name"], [98, 104, "Amount"], [111, 120, "Drug"], [122, 126, "Amount"]]}], [2814, "For the first two hours after midazolam administration, blood pressure, heart rate, respiration rate and pulse oximeter readings were obtained every 15 minutes.", {"entities": [[30, 39, "Drug"], [56, 70, "Parameter"], [72, 82, "Parameter"], [84, 100, "Parameter"], [105, 110, "Parameter"], [143, 159, "Frequency"]]}], [2815, "Blood samples (10 mL) were collected at 1 and 6 hours after probe drug administration and separated by centrifugation (1133 \u00d7 g) to obtain serum for determining CYP3A4 and CYP1A2 activity.", {"entities": [[161, 167, "Target"], [172, 178, "Target"]]}], [2816, "To avoid potential interference from midazolam and caffeine, CYP2E1 and CYP2D6 phenotypes were assessed twenty-four hours later.", {"entities": [[37, 46, "Drug"], [51, 59, "Herb name"], [61, 67, "Target"], [72, 78, "Target"]]}], [2817, "[35] The day before supplementation (Day 0), subjects emptied their bladder prior to receiving an oral dose of chlorzoxazone (500 mg) and debrisoquine (5 mg).", {"entities": [[111, 124, "Drug"], [126, 132, "Amount"], [138, 150, "Drug"], [152, 156, "Amount"]]}], [2818, "Blood samples were then obtained at 2 hours and urine was collected for eight hours, at which time the volume was recorded and a 10-milliliter aliquot stored for analysis.", {"entities": []}], [2819, "All samples were stored frozen at \u221270\u00b0C until analyzed.", {"entities": []}], [2820, "Phenotypes were again assessed on supplementation Days 27 (CYP1A2, CYP3A4) and 28 (CYP2D6, CYP2E1).", {"entities": [[59, 65, "Target"], [67, 73, "Target"], [83, 89, "Target"], [91, 97, "Target"]]}], [2821, "The CYP modulatory capability of each botanical supplement was evaluated by comparing individual differences in phenotype before and at the end of 28 days of supplementation.", {"entities": [[4, 7, "Target"], [147, 154, "Duration"]]}], [2822, "Analytical methods  Serum concentrations of caffeine and paraxanthine were quantified by high performance liquid chromatography (HPLC) with ultraviolet absorbance detection per the method of Holland et al.", {"entities": [[44, 52, "Herb name"], [57, 69, "Herb name"]]}], [2823, "[36] Chlorzoxazone and 6-hydroxychlorzoxazone serum concentrations were measured by HPLC using ultraviolet absorbance detection as previously described by Frye and Stiff.", {"entities": [[5, 18, "Drug"], [23, 45, "Drug"]]}], [2824, "[37] The HPLC method described by Frye and Branch employing fluorescence detection was utilized for the quantitation of debrisoquine and 4-hydroxydebrisoquine in urine.", {"entities": [[120, 132, "Drug"], [137, 158, "Drug"]]}], [2825, "[38] A previously described modification of the HPLC method of Sautou et al.", {"entities": []}], [2826, "[39] was used to determine serum concentrations of midazolam and 1-hydroxymidazolam.", {"entities": [[51, 60, "Drug"], [65, 83, "Drug"]]}], [2827, "[17] To optimize the recovery of 6-hydroxychlorzoxazone and 1-hydroxymidazolam, serum samples (250 \u03bcL) for these probe drugs were incubated with \u03b2-glucuronidase (250 \u03bcL, 1800 units per mL) for 2.5 hours at 37\u00b0C.", {"entities": [[33, 55, "Drug"], [60, 78, "Drug"], [145, 160, "Target"]]}], [2828, "Phytochemical analysis  The phytochemical content of each supplement was independently analyzed for specific \u201cmarker compounds\u201d by high performance liquid chromatography (HPLC).", {"entities": []}], [2830, "Quantitative determination of hyperforin, adhyperforin, and several other phytochemical components of St. John\u2019s wort was achieved by HPLC using photodiode array detection with confirmation via mass spectrometry according to the method of Liu et al.", {"entities": [[30, 40, "Herb name"], [42, 54, "Herb name"], [102, 117, "Herb name"]]}], [2831, "[40] Hyperforin serum concentrations, obtained two hours after St. John\u2019s wort administration on day 27, were determined by HPLC using solid-phase extraction and ultraviolet absorption detection per the method of Cui et al.", {"entities": [[5, 15, "Herb name"], [63, 78, "Herb name"]]}], [2832, "[41]  Panax ginseng was analyzed for ginsenosides Rb1, Rb2, Rc, Rd, Re, Rf, and Rg at the National Center for Natural Products Research (University of Mississippi, University, MS.) by use of a proprietary gradient HPLC method.", {"entities": [[6, 19, "Herb name"], [37, 49, "Herb name"], [50, 53, "Herb name"], [55, 58, "Herb name"], [60, 62, "Herb name"], [64, 66, "Herb name"], [68, 70, "Herb name"], [72, 74, "Herb name"], [80, 82, "Herb name"]]}], [2833, "In brief, capsules were weighed and the contents transferred to a 15 mL polystyrene conical tube containing 3mL of water:acetonitrile (15:85).", {"entities": []}], [2834, "The samples were sonicated for 15 minutes, centrifuged at 1550 rpm, and the supernatant transferred to a 10 mL volumetric flask.", {"entities": []}], [2835, "After repeating this process twice, the volumetric flask was diluted to final volume with the extraction solution.", {"entities": []}], [2836, "Each sample was then filtered through a 0.45 \u03bcm Nylon membrane filter and a 50 \u03bcL aliquot was injected onto the HPLC column.", {"entities": []}], [2837, "The HPLC system consisted of a Waters 2695 Alliance Separations Module equipped with a 996 photodiode array detector (Waters Corp. Milford, MA).", {"entities": []}], [2838, "Ginsenosides were purchased from Chromadex (Santa Ana, CA) and separated on a Luna C18 column (150 \u00d7 3.0 mm; 5 \u03bcm particle size) (Phenomenex, Torrance, CA) using gradient elution at a flow rate of 0.7 mL/minute and a detection wavelength of 205 nm.", {"entities": [[0, 12, "Herb name"]]}], [2839, "The mobile phase consisted of (A) water:acetonitrile (85:15, v/v); (B) water:acetonitrile (25:75, v/v); (C) water:acetonitrile (50:50, v/v); and (D) methanol.", {"entities": []}], [2840, "The gradient elution as follows:100% A to 100% B in 30 minutes, and then to 100% C after an additional 30 minutes.", {"entities": []}], [2841, "Each run was followed by an 8 minute wash with 100% D and a re-equilibration period of 10 minutes.", {"entities": []}], [2842, "Peaks were assigned by a comparison of retention times and ultraviolet absorption spectra.", {"entities": []}], [2843, "Chromatographic data was collected and analyzed using the Millennium software system (Waters Corp., Milford, MA).", {"entities": []}], [2844, "Retention times for ginsenosides Re, Rg1, Rf, Rb1, Rb2, Rc, and Rd were 28, 29, 42.5, 46.3, 47.3, 48.3, and 50.5 minutes, respectively.", {"entities": [[20, 32, "Herb name"], [33, 35, "Herb name"], [37, 40, "Herb name"], [42, 44, "Herb name"], [46, 49, "Herb name"], [51, 54, "Herb name"], [56, 58, "Herb name"], [64, 66, "Herb name"]]}], [2845, "Using standard curves covering the range of 22.5 to 160 \u03bcg/mL, relative standard deviations for inter- and intra-day analyses were less than 5%.", {"entities": []}], [2846, "The limit of quantitation for the various ginsenosides ranged from 22.5 \u03bcg/mL for Rb2 to 40 \u03bcg/mL for Rd.", {"entities": [[42, 54, "Herb name"], [82, 85, "Herb name"], [102, 104, "Herb name"]]}], [2847, "Percent recoveries for all ginsenosides exceeded 99%.", {"entities": [[27, 39, "Herb name"]]}], [2848, "[42] Simultaneous detection of terpene lactones and flavonoid aglycones in Ginkgo biloba was achieved by HPLC with evaporative light scattering detection as described by Li and Fitzloff.", {"entities": [[31, 47, "Herb name"], [52, 71, "Herb name"], [75, 88, "Herb name"]]}], [2849, "[43] Phenotype Assessment  Serum ratios of 1-hydroxymidazolam/midazolam determined one hour after dosing were used to estimate CYP3A4 activity.", {"entities": [[43, 61, "Drug"], [62, 71, "Drug"], [127, 133, "Target"]]}], [2850, "[44] CYP1A2 phenotypes were determined from paraxanthine/caffeine serum ratios obtained at six hours.", {"entities": [[5, 11, "Target"], [44, 56, "Herb name"], [57, 65, "Herb name"]]}], [2852, "[32,33] Statistics  A repeated measures ANOVA model was fit for each phenotype response using SAS Proc Mixed software (SAS Institute, Inc. Cary, N.C.).", {"entities": []}], [2853, "Since pre-and post-supplementation phenotypic ratios were determined in each subject for all four supplements, a covariance structure existed for measurements within subjects.", {"entities": []}], [2854, "Sex, supplement, and supplement-by-sex terms were estimated for each phenotype using a Huynh-Feldt covariance structure fit.", {"entities": []}], [2855, "If supplement-by-sex interaction terms for a specific phenotypic measure were significant at the 5% level, the focus of the post-supplementation minus pre-supplementation response was assessed according to sex.", {"entities": []}], [2856, "If the supplement-by-sex interaction was not statistically significant, responses for both sexes were combined.", {"entities": []}], [2857, "Additionally, a power analysis was performed to estimate the ability to detect significant post- minus pre-supplementation effects.", {"entities": []}], [2858, "All four phenotype models obtained at least 80% power at the 5% level of significance to detect a Cohen effect size of 1.0 to 1.32 standard deviation units.", {"entities": []}], [2859, "[45] Go to: RESULTS General Experimental Observations  All subjects completed the study and no serious adverse events occurred during the course of the investigation.", {"entities": []}], [2860, "An external file that holds a picture, illustration, etc.", {"entities": []}], [2861, "Object name is nihms19443f2.jpg Figure 2  Comparison of pre- and post-supplementation phenotypic ratios (1-hydroxymidazolam/midazolam) for CYP3A4.", {"entities": [[105, 123, "Drug"], [124, 133, "Drug"], [139, 145, "Target"]]}], [2862, "Gray circles = individual values, Black circles = group means.", {"entities": []}], [2863, "Astersisks = statistically significant difference from baseline.", {"entities": []}], [2864, "An external file that holds a picture, illustration, etc.", {"entities": []}], [2865, "Object name is nihms19443f5.jpg Figure 5  Comparison of pre- and post-supplementation phenotypic ratios (paraxanthine/caffeine) for CYP1A2.", {"entities": [[105, 117, "Herb name"], [118, 126, "Herb name"], [132, 138, "Target"]]}], [2866, "Gray circles = individual values, Black circles = group means.", {"entities": []}], [2867, "Table I  Pre- and Postsupplementation Phenotypic Ratios (means, 95% confidence intervals) Phenotypic Ratio (CYP)\tSupplement\tPresupplementation (mean and 95% CI)\tPostsupplementation.", {"entities": []}], [2868, "Chronic administration of G. biloba and P. ginseng had no modulatory effects on CYP2E1 (Fig 4C, D).", {"entities": [[26, 35, "Herb name"], [40, 50, "Herb name"], [80, 86, "Target"]]}], [2869, "An external file that holds a picture, illustration, etc.", {"entities": []}], [2870, "Object name is nihms19443f4.jpg Figure 4  Comparison of pre- and post-supplementation phenotypic ratios (6-hydroxychlorzoxazone/chlorzoxazone) for CYP2E1.", {"entities": [[105, 127, "Drug"], [128, 141, "Drug"], [147, 153, "Target"]]}], [2871, "Gray circles = individual values, Black circles = group means.", {"entities": []}], [2872, "Asterisks = statistically significant difference from baseline.", {"entities": []}], [2873, "Twenty-eight days of P. ginseng administration produced a statistically significant decrease (p = 0.003) in debrisoquine urinary recovery ratios of 7% (Fig 3D, Table I), however, this effect was not considered clinically relevant.", {"entities": [[0, 17, "Duration"], [21, 31, "Herb name"], [108, 120, "Drug"]]}], [2874, "An external file that holds a picture, illustration, etc.", {"entities": []}], [2875, "Object name is nihms19443f3.jpg Figure 3  Comparison of pre- and post-supplementation phenotypic ratios (8-hour debrisoquine urinary recovery ratios) for CYP2D6.", {"entities": [[112, 124, "Drug"], [154, 160, "Target"]]}], [2876, "Gray circles = individual values, Black circles = group means.", {"entities": []}], [2877, "While moderate differences in pre- and post-supplementation paraxanthine/caffeine serum ratios were observed for specific individuals, no statistically significant differences in mean values were noted, suggesting that 28 days of supplementation had little effect on CYP1A2 activity (Fig 5, A\u2013D).", {"entities": [[60, 72, "Drug"], [73, 81, "Drug"], [219, 226, "Duration"], [267, 273, "Target"]]}], [2878, "Throughout the study period no statistically significant differences in mean baseline phenotypic ratios were observed for CYP1A2, CYP2D6, CYP2E1, or CYP3A4.", {"entities": [[122, 128, "Target"], [130, 136, "Target"], [138, 144, "Target"], [149, 155, "Target"]]}], [2879, "In, addition, no sex-related changes in CYP phenotypes were noted for any of the supplements.", {"entities": [[40, 43, "Target"]]}], [2880, "Phytochemical content  Table II depicts the content of various phytochemicals present in the supplements used for this study.", {"entities": []}], [2881, "Based on a hyperforin content of 5.34 mg/g, each subject ingested approximately 4.8 mg daily.", {"entities": [[11, 21, "Herb name"], [80, 86, "Amount"], [87, 92, "Frequency"]]}], [2882, "Mean serum hyperforin concentrations determined on day 28, one hour after oral midazolam administration, were 51.3 \u00b1 10.7 ng/mL.", {"entities": [[11, 21, "Herb name"], [79, 88, "Drug"]]}], [2883, "No significant difference in hyperforin serum concentration was noted between males (51.2 \u00b1 10.4 ng/mL) and females (51.3 \u00b1 12.1 ng/mL).", {"entities": [[29, 39, "Herb name"]]}], [2884, "Serum concentrations of phytochemicals present in the other supplements were not determined.", {"entities": []}], [2885, "Table II  Content of phytochemical marker compounds for botanical supplements.", {"entities": []}], [2886, "Previously, this approach had been used to document CYP3A4 induction as evidenced by significant elevations in 1-hydroxymidazolam/midazolam ratios following St. John\u2019s wort supplementation.", {"entities": [[52, 58, "Target"], [111, 129, "Drug"], [130, 139, "Drug"], [157, 172, "Herb name"]]}], [2887, "[17] The single-time point phenotypic ratio approach confirmed what other investigators observed with St. John\u2019s wort when more conventional \u201carea-under-the-curve\u201d methods were utilized to determine midazolam clearance.", {"entities": [[102, 117, "Herb name"], [142, 162, "Parameter"], [199, 208, "Drug"], [209, 218, "Parameter"]]}], [2888, "[16] The method also demonstrated that an absence of change in mean phenotypic ratios following botanical supplementation could be interpreted as a lack of effect on CYP activity.", {"entities": [[166, 169, "Target"]]}], [2890, "[18\u201321] More recently, this methodology has demonstrated that goldenseal supplementation inhibits CYP2D6 and CYP3A4 activity in vivo.", {"entities": [[62, 72, "Herb name"], [98, 104, "Target"], [109, 115, "Target"], [125, 132, "Study"]]}], [2891, "[46] Thus, a range of herb-mediated effects on CYP activity (e.g.", {"entities": [[47, 50, "Target"]]}], [2892, "induction, inhibition, or no effect) can be differentiated with single time-point phenotypic ratios.", {"entities": []}], [2893, "It must be emphasized, however, that single-time point phenotypic ratios simply provide estimates of probe drug clearance.", {"entities": []}], [2894, "Yet, even with this limitation, the method\u2019s distinct advantage lies in an ability to evaluate multiple CYP enzymes and multiple botanical supplements in vivo while using a limited blood-sampling scheme.", {"entities": [[104, 107, "Target"], [151, 158, "Study"]]}], [2895, "These findings are in close agreement with those reported previously for a cohort of young volunteers who underwent an identical study protocol.", {"entities": []}], [2896, "[17] The present results suggest that, like their younger counterparts, elderly subjects are equally susceptible to botanical-mediated changes in CYP activity, especially those involving St. John\u2019s wort.", {"entities": [[146, 149, "Target"], [187, 202, "Herb name"]]}], [2897, "A 141% increase in the mean phenotypic ratio following a 28-day course of St. John\u2019s wort (Figure 2A) is a testament to the magnitude of CYP3A4 induction among elderly users of this botanical.", {"entities": [[57, 63, "Duration"], [74, 89, "Herb name"], [137, 143, "Target"]]}], [2898, "A comparison of St. John\u2019s wort\u2019s effect on CYP3A4 phenotypic ratios for both young and elderly subjects is depicted in Figure 6.", {"entities": [[16, 31, "Herb name"], [44, 50, "Target"]]}], [2899, "It is interesting to note the similarity in magnitude of the effect (98% in young versus 141% in elderly) despite a 2.5 fold difference in daily-administered hyperforin dose (12.2 mg in young versus 4.8 mg in elderly).", {"entities": [[139, 144, "Frequency"], [158, 168, "Herb name"], [175, 182, "Amount"], [199, 205, "Amount"]]}], [2900, "Moreover, this discrepancy in hyperforin dosing yielded closely matching serum concentrations (42.6 ng/mL in young versus 51.2 ng/mL in elderly).", {"entities": [[30, 40, "Herb name"], [95, 105, "Amount"], [122, 132, "Amount"]]}], [2901, "An external file that holds a picture, illustration, etc.", {"entities": []}], [2902, "Object name is nihms19443f6.jpg Figure 6  Effect of St. John\u2019s wort on CYP3A4 phenotype in young (A) and elderly (B) subjects.", {"entities": [[52, 67, "Herb name"], [71, 77, "Target"]]}], [2903, "Mean age for young subjects was 25 years, mean age for elderly subjects was 67 years.", {"entities": [[32, 40, "Age"], [76, 84, "Age"]]}], [2904, "(See Gurley et al.17 for description of original study involving young volunteers.)", {"entities": []}], [2905, "HMDZ = 1-hydroxymidazolam, MDZ = midazolam.", {"entities": [[0, 4, "Drug"], [7, 25, "Drug"], [27, 30, "Drug"], [33, 42, "Drug"]]}], [2906, "Gray circles = individual values, Black circles = group means.", {"entities": []}], [2907, "Asterisks = statistically significant difference from baseline.", {"entities": []}], [2908, "Reprinted with permission from Elsevier Press.", {"entities": []}], [2909, "It is unknown whether hyperforin exhibits age-related differences in pharmacokinetics; however, similar serum concentrations between the two age groups, despite disparate doses, suggest that hyperforin clearance may be reduced in elderly subjects.", {"entities": [[22, 32, "Herb name"], [191, 201, "Herb name"]]}], [2910, "Age-related reductions in the hepatic clearance of several medications have been noted previously.", {"entities": [[30, 47, "Parameter"]]}], [2911, "[28\u201330] Such changes are believed to result from reduced liver blood flow and/or diminished liver weight in the elderly, and not necessarily from alterations in CYP activity.", {"entities": [[161, 164, "Target"]]}], [2912, "[28\u201330] If such is the case with hyperforin, elderly consumers may be more vulnerable to the CYP3A4 inductive effects of St. John\u2019s wort.", {"entities": [[33, 43, "Herb name"], [93, 99, "Target"], [121, 136, "Herb name"]]}], [2913, "In other words, relatively small doses of hyperforin may produce significant induction of CYP3A4 activity in elderly consumers.", {"entities": [[42, 52, "Herb name"], [90, 96, "Target"]]}], [2914, "This is important since most St. John\u2019s wort products do not provide a label claim for hyperforin content, but instead are standardized to another phytochemical, hypericin.", {"entities": [[29, 44, "Herb name"], [87, 97, "Herb name"], [162, 171, "Herb name"]]}], [2915, "Hypericin, although easily quantifiable, has no antidepressive activity or ability to induce CYP3A4.", {"entities": [[0, 9, "Herb name"], [93, 99, "Target"]]}], [2916, "Moreover, St. John\u2019s wort supplements standardized for hypericin exhibit considerable variability with regard to hyperforin content.", {"entities": [[10, 25, "Herb name"], [55, 64, "Herb name"], [113, 123, "Herb name"]]}], [2917, "[40,47\u201349] The practical implications of these findings would seem to render all St. John\u2019s wort products as potent inducers of CYP3A4 in elderly patrons.", {"entities": [[81, 96, "Herb name"], [128, 134, "Target"]]}], [2919, "[23]  In addition to its effect on CYP3A4, our data indicate that St. John\u2019s wort appears to induce CYP2E1 in elderly subjects.", {"entities": [[35, 41, "Target"], [66, 81, "Herb name"], [100, 106, "Target"]]}], [2920, "This finding also corroborates the results of an earlier study in young individuals.", {"entities": []}], [2921, "[17] However, unlike the profound increase in CYP2E1 metabolic ratios reported for younger subjects, the magnitude of the effect was tempered in the elderly (110% increase in young versus 26% increase in elderly).", {"entities": [[46, 52, "Target"]]}], [2922, "A tempering of CYP2E1 induction could reflect individual variability in enzyme response or it may point toward an age-related reduction in CYP2E1 activity.", {"entities": [[15, 21, "Target"], [139, 145, "Target"]]}], [2924, "[51,52] Unlike CYP3A4, CYP2E1 induction is not SXR-mediated; therefore, if hyperforin is the inducing agent then it must act through other mechanisms, perhaps as a ligand for other transcription factors or via posttranslational stabilization of the enzyme.", {"entities": [[15, 21, "Target"], [23, 29, "Target"], [47, 50, "Target"], [75, 85, "Herb name"]]}], [2925, "[53] Other phytochemicals besides hyperforin may also be involved (see Table 2).", {"entities": [[34, 44, "Herb name"]]}], [2926, "Regardless of the induction mechanism, no interactions involving St. John\u2019s wort and other CYP2E1 substrates have been reported.", {"entities": [[65, 80, "Herb name"], [91, 97, "Target"]]}], [2927, "This lack of interaction may stem from inadequate reporting of suspected cases, or the paucity of orally administered drugs that are CYP2E1 substrates.", {"entities": [[133, 139, "Target"]]}], [2928, "Nevertheless, several inhalation anesthetics (e.g.", {"entities": [[22, 44, "Drug"]]}], [2929, "enflurane, sevoflurane, methoxyflurane) are metabolized by CYP2E1 and their halogenated byproducts can produce liver injury.", {"entities": [[0, 9, "Drug"], [11, 22, "Drug"], [24, 38, "Drug"], [59, 65, "Target"], [111, 123, "Pathology"]]}], [2930, "[54] Thus, a potential interaction may exist between these agents and St. John\u2019s wort.", {"entities": [[70, 85, "Herb name"]]}], [2931, "[42] The difference in extent of inhibition between the two age groups hints at either an age-related diminution in CYP2E1 responsivity or a dissimilarity in allyl sulfide content between the garlic supplements.", {"entities": [[116, 122, "Target"], [158, 171, "Herb name"], [192, 198, "Herb name"]]}], [2932, "A number of case reports have documented possible interactions between G. biloba and warfarin.", {"entities": [[12, 24, "Study"], [71, 80, "Herb name"], [85, 93, "Drug"]]}], [2933, "[11,12] Such an interaction is particularly relevant to elderly patients on anticoagulant therapy.", {"entities": [[76, 97, "Drug"]]}], [2934, "This interaction appears attributable to the inhibition of platelet activating factor by various ginkgolides.", {"entities": [[59, 85, "Target"], [97, 108, "Herb name"]]}], [2935, "[59] A CYP-mediated explanation for the Ginkgo/warfarin interaction seems less plausible based on the present data.", {"entities": [[40, 46, "Herb name"], [47, 55, "Drug"]]}], [2936, "These current findings mirror those reported by our group in an earlier study of G. biloba supplementation in young adults.", {"entities": [[81, 90, "Herb name"]]}], [2937, "[17] In addition, our results corroborate those of Duche et al, who observed that 13 days of G. biloba extract administration to human volunteers had no effect on the pharmacokinetics of antipyrine, a non-specific probe of hepatic microsomal drug oxidation.", {"entities": [[82, 89, "Duration"], [93, 110, "Herb name"], [187, 197, "Drug"]]}], [2938, "[60] Furthermore, Markowitz et al noted that 14 days of G. biloba supplementation in normal volunteers did not affect the pharmacokinetics of the CYP2D6 substrate, dextromethorphan, or the CY3A4 substrate, alprazolam.", {"entities": [[45, 52, "Duration"], [56, 65, "Herb name"], [146, 152, "Target"], [164, 180, "Drug"], [189, 194, "Target"], [206, 216, "Drug"]]}], [2939, "[18] Taken together these findings indicate that herb-drug interactions attributable to G. biloba are not the result of phytochemical-mediated effects on CYP isoforms.", {"entities": [[88, 97, "Herb name"], [154, 157, "Target"]]}], [2940, "Like G. biloba, Panax ginseng appears to have little effect on the activities of the specific CYP isoforms investigated in this study.", {"entities": [[5, 14, "Herb name"], [16, 29, "Herb name"], [94, 97, "Target"]]}], [2941, "Although we observed a statistically significant decrease in debrisoquine urinary recovery ratios (~7%) after P. ginseng supplementation, this seemingly minor inhibitory effect on CYP2D6 is not likely to be clinically relevant.", {"entities": [[61, 73, "Drug"], [110, 120, "Herb name"], [180, 186, "Target"]]}], [2942, "These findings too are analogous to those reported in young subjects supplemented with P. ginseng for either 14 or 28 days.", {"entities": [[87, 97, "Herb name"], [109, 122, "Duration"]]}], [2943, "[17,20] Therefore, P. ginseng supplementation seems unlikely to pose clinically significant interactions with drugs that are substrates for CYP1A2, CYP2D6, CYP2E1, or CYP3A4.", {"entities": [[19, 29, "Herb name"], [140, 146, "Target"], [148, 154, "Target"], [156, 162, "Target"], [167, 173, "Target"]]}], [2944, "Its effect on other prominent CYP isoforms, however, remains to be evaluated in vivo.", {"entities": [[30, 33, "Target"], [77, 84, "Study"]]}], [2945, "Clinical evidence from warfarin patients hints at a possible interaction between ginseng species and CYP2C9 substrates.", {"entities": [[0, 8, "Study"], [23, 31, "Drug"], [81, 88, "Herb name"], [101, 107, "Target"]]}], [2946, "Janetzky reported a case involving a patient on warfarin therapy in which the International Normalized Ratio (INR) was reduced during P. ginseng supplementation.", {"entities": [[18, 24, "Study"], [48, 56, "Drug"], [78, 114, "Parameter"], [134, 144, "Herb name"]]}], [2947, "[61] More recently, a randomized trial involving 20 subjects receiving warfarin, demonstrated that 14 days of P. quinquefolius also reduced both INR values and warfarin plasma concentrations.", {"entities": [[20, 38, "Study"], [49, 60, "Cohort"], [71, 79, "Drug"], [99, 106, "Duration"], [110, 126, "Herb name"], [145, 148, "Parameter"], [160, 168, "Drug"]]}], [2948, "[62] CYP2C9 is the principal isoform involved in the biotransformation of warfarin (more particularly the active enantiomer, S-warfarin) and the aforementioned reports hint strongly at a ginseng-mediated induction of this enzyme.", {"entities": [[5, 11, "Target"], [74, 82, "Drug"], [127, 135, "Drug"], [160, 167, "Study"], [187, 194, "Herb name"]]}], [2949, "The use of ginseng supplements, therefore, should be discouraged in patients on warfarin therapy.", {"entities": [[11, 18, "Herb name"], [80, 88, "Drug"]]}], [2950, "Go to: CONCLUSION  Prescription drug use is greatest among elderly adults and recent surveys indicate that usage of botanical supplements is rapidly increasing among this population.", {"entities": []}], [2951, "Our data demonstrate that botanical dietary supplements can modulate drug metabolism and, in turn, adversely affect the pharmacokinetics of a variety of medications used in the elderly.", {"entities": [[99, 115, "Pathology"]]}], [2952, "Therefore, botanical supplements, when taken concomitantly with conventional medications, can give rise to serious herb-drug interactions.", {"entities": []}], [2953, "This may be especially true when multiple drugs and multiple supplements are ingested concurrently.", {"entities": []}], [2954, "St. John\u2019s wort is particularly problematic on account of its ability to induce CYP3A4, an enzyme involved in the biotransformation of more than 50% of all prescription medications.", {"entities": [[0, 15, "Herb name"], [80, 86, "Target"]]}], [2955, "Other supplements (e.g.", {"entities": []}], [2956, "ginseng species) may also pose a risk for pharmacokinetic herb-drug interactions in the elderly.", {"entities": [[0, 7, "Herb name"]]}], [2957, "Accordingly, health care providers should question their patients about dietary supplement use and discourage concomitant administration of botanical supplements with prescription medications.", {"entities": []}], [2958, "Effect of dehusked Garcinia kola seed on the overall pharmacokinetics of quinine in healthy Nigerian volunteers Sharon I. Igbinoba, PhD,1,* Cyprian O. Onyeji, PhD,2 Moses A. Akanmu, PhD,3 Julius O. Soyinka, PhD,2 Srirama Sarma V.V Pullela, PhD,4 James M. Cook, PhD,4 and Thomas I. Nathaniel, PhD5 Author information Copyright and License information PMC Disclaimer The publisher's final edited version of this article is available at J Clin Pharmacol Go to: Abstract  We investigated the effect of concurrent ingestion of Garcinia kola seed on the pharmacokinetics of quinine.", {"entities": [[10, 32, "Herb name"], [33, 37, "Herb part"], [73, 80, "Drug"], [84, 91, "Pathology"], [92, 100, "Ethnic group"], [522, 535, "Herb name"], [536, 540, "Herb part"], [568, 575, "Drug"]]}], [2959, "Blood samples were collected and analyzed for plasma quinine and its metabolite, (3-hydroxyquinine) using a validated HPLC method.", {"entities": [[53, 60, "Drug"], [82, 98, "Drug"]]}], [2960, "Concurrent administration of quinine with G. kola reduced quinine tmax by 48% (group A), mean Cmax by 19% and 26% in groups A and B, and slight reduction in mean AUC0\u2013\u221e of quinine in both groups.", {"entities": [[29, 36, "Drug"], [42, 49, "Herb name"], [58, 65, "Drug"], [66, 70, "Parameter"], [94, 98, "Parameter"], [162, 168, "Parameter"], [172, 179, "Drug"]]}], [2961, "3-hydroxyquinine Cmax also reduced by 29% and 32%; AUC0\u2013\u221e by 13% and 9% respectively.", {"entities": [[0, 16, "Drug"], [17, 21, "Parameter"], [51, 57, "Parameter"]]}], [2962, "The point estimates of the T/R ratio of the geometric means for all Cmax obtained and only the AUC0\u2013\u221e at a higher dose of G. kola were outside the 80\u2013125% bioequivalence range.", {"entities": [[68, 72, "Parameter"], [95, 101, "Parameter"], [122, 129, "Herb name"]]}], [2963, "In conclusion, an herb-drug interaction was noted with concurrent quinine and G. kola administration.", {"entities": [[66, 73, "Drug"], [78, 85, "Herb name"]]}], [2964, "Keywords: Garcinia kola, Quinine, 3-Hydroxyquinine, Pharmacokinetics, Drug-herb interactions  Use of natural products such as herbs and supplements for health maintenance has become very popular, raising the potential for interactions when administered in combination with prescription drugs.", {"entities": [[10, 23, "Herb name"], [25, 32, "Drug"], [34, 50, "Drug"]]}], [2965, "[1, 2] Garcinia kola seed commonly called bitter kola is a highly valued ingredient in African ethno-medicine and is used in the management and treatment of several ailments such as coughs, cold, voice hoarseness, aphrodisiac, and liver diseases.", {"entities": [[7, 20, "Herb name"], [21, 25, "Herb part"], [42, 53, "Herb name"], [182, 188, "Pathology"], [190, 194, "Pathology"], [196, 212, "Pathology"], [214, 225, "Pathology"], [231, 245, "Pathology"]]}], [2966, "[3, 4] It is also relevant in traditional medicine, cultural and social ceremonies in many parts of West and Central Africa.", {"entities": []}], [2967, "[4, 5] The seed is often ingested as a dietary supplement, and some proprietary dietary supplements of G. kola seed or its extract, alone or in combination with other phytochemicals are now used in the management of several clinical conditions.", {"entities": [[11, 15, "Herb part"], [103, 110, "Herb name"], [111, 115, "Herb part"]]}], [2968, "[4] Studies on phytochemical analysis of G. kola seeds [6\u201311] reveal benxophenones, xanthones, alkaloids, phenols, tannins and saponins, kolaviron a biflavonoid complex, and metallic ions such as aluminum, magnesium, calcium and copper as major chemical components of G. kola.", {"entities": [[41, 48, "Herb name"], [49, 54, "Herb part"], [69, 82, "Herb name"], [84, 93, "Herb name"], [95, 104, "Herb name"], [106, 113, "Herb name"], [115, 122, "Herb name"], [127, 135, "Herb name"], [137, 146, "Herb name"], [149, 168, "Herb name"], [268, 275, "Herb name"]]}], [2969, "The seeds or its extracts have been reported to modulate the pharmacokinetics of some drugs in humans and alter the activities of cytochrome P450 in vitro [12\u201316].", {"entities": [[4, 9, "Herb part"], [130, 145, "Target"], [146, 154, "Study"]]}], [2970, "Assessment of in vitro CYP inhibition of natural products is important for predicting product-drug interactions if these products are taken concomitantly.", {"entities": [[14, 22, "Study"], [23, 26, "Target"]]}], [2971, "In this context, herb-drug interaction studies are necessary to determine the absence or presence of such in vivo drug interactions.", {"entities": [[106, 113, "Study"]]}], [2972, "[17] The continued relevance of quinine in malaria therapy in sub-Saharan Africa [18] raises the possibility of its concomitant use with other natural therapeutic agents.", {"entities": [[32, 39, "Drug"], [43, 50, "Pathology"]]}], [2973, "The customary use of G. kola in certain regions in Western African countries coupled with the prevalence of malaria in this geographical region suggest that there is a possibility of the concurrent use G. kola and quinine.", {"entities": [[21, 28, "Herb name"], [108, 115, "Pathology"], [202, 209, "Herb name"], [214, 221, "Drug"]]}], [2974, "This may result in a potential herb-drug interaction with serious consequences, such as therapeutic failure or toxicity.", {"entities": []}], [2975, "Such interaction could occur at any stage of the pharmacokinetic process.", {"entities": []}], [2976, "[19] Indeed, quinine has been demonstrated both in vivo and in vitro as a substrate for CYP3A enzyme [20\u201324].", {"entities": [[13, 20, "Drug"], [48, 55, "Study"], [60, 68, "Study"], [88, 93, "Target"]]}], [2977, "This enzyme is responsible for the formation of 3-hydroxyquinine, a major metabolite of quinine [21, 22] and the metabolism of at least 50 % of clinically administered drugs [25] making it an important enzyme.", {"entities": [[48, 64, "Drug"], [88, 95, "Drug"]]}], [2978, "Despite the extensive consumption and use of G. kola in folkloric remedies for the treatment of various diseases, [3\u20134, 10] the interactions of G. kola, with prescription medications has not been fully investigated.", {"entities": [[45, 52, "Herb name"], [144, 151, "Herb name"]]}], [2979, "In the current study, we analyzed the potential interaction between G. kola ingestion and quinine disposition in healthy volunteers.", {"entities": [[68, 75, "Herb name"], [90, 97, "Drug"], [113, 120, "Pathology"]]}], [2980, "Our analysis determined whether the concurrent ingestion of G. kola with oral quinine administration elicited a pharmacokinetic interaction.", {"entities": [[60, 67, "Herb name"], [78, 85, "Drug"]]}], [2982, "[22] Go to: METHODS Subjects  Before the commencement of the studies, ethical approval was obtained from the Obafemi Awolowo University Teaching Hospital Complex Research Ethics Board and Safety Committee and conducted in accordance with good clinical practice guidelines and the Declaration of Helsinki.", {"entities": []}], [2983, "We used the amount of G. kola to be taken to randomly divide twenty four healthy Nigeria men and women into two groups of twelve volunteers.", {"entities": [[22, 29, "Herb name"], [61, 72, "Cohort"], [73, 80, "Pathology"], [81, 88, "Ethnic group"], [89, 92, "Sex"], [97, 102, "Sex"]]}], [2984, "Volunteers recruited were non smokers and were not on any other medication or continuous medication for at least two weeks prior to commencement of the study.", {"entities": []}], [2985, "Pregnancy, breastfeeding, histories of hypersensitivity to quinine or similar agents, or adverse side effects from taking G. kola seeds were also used as exclusion criteria for the study.", {"entities": [[0, 9, "Pathology"], [11, 24, "Pathology"], [39, 55, "Pathology"], [59, 66, "Drug"], [89, 109, "Pathology"], [122, 129, "Herb name"], [130, 135, "Herb part"]]}], [2986, "Participants were certified healthy by a physician based on medical history, clinical examination, and laboratory tests and they gave their written informed consent to comply with the study protocol.", {"entities": [[28, 35, "Pathology"]]}], [2987, "Study design and G. kola and quinine administration  A two phase study was employed in two separate studies.", {"entities": [[17, 24, "Herb name"], [29, 36, "Drug"], [53, 70, "Study"]]}], [2988, "Each phase of the study was a randomized, open label, two-step pharmacokinetic cross over design with a wash out period of two weeks between treatments.", {"entities": [[28, 119, "Study"]]}], [2989, "Participants were randomly divided into two groups (A and B) of 12 persons each.", {"entities": []}], [2990, "In the first phase, after an overnight fast, each subject in the respective groups received a single oral dose of 600 mg quinine sulphate tablets (Maderich Ltd, Surrey, England).", {"entities": [[114, 120, "Amount"], [121, 137, "Drug"]]}], [2991, "The second phase of the study commenced a week after drug administration.", {"entities": []}], [2992, "Garcinia kola seeds used in these studies were obtained locally in Ile \u2013 Ife (South-western part of Nigeria) and were certified in the herbarium of the Department of Pharmacognosy, Obafemi Awolowo University, Nigeria.", {"entities": [[0, 13, "Herb name"], [14, 19, "Herb part"]]}], [2993, "Participants in group A ingested 12.5 g of dehusked G. kola seed once daily for seven days while those in group B received 12.5 g of dehusked G. kola seeds twice daily for six days and once on day 7.", {"entities": [[33, 39, "Amount"], [43, 59, "Herb name"], [60, 64, "Herb part"], [65, 75, "Frequency"], [76, 90, "Duration"], [123, 129, "Amount"], [133, 149, "Herb name"], [150, 155, "Herb part"], [156, 167, "Frequency"], [168, 198, "Duration"]]}], [2994, "The choice of ingesting kola twice daily was to evaluate if a higher dose of G. kola ingestion is associated with further changes on quinine kinetics.", {"entities": [[24, 28, "Herb name"], [29, 40, "Frequency"], [77, 84, "Herb name"], [133, 140, "Drug"]]}], [2995, "Doses of G. kola in this study were chosen based on the consumption pattern from a survey conducted prior to this present study and reports from doses employed in previous studies, both in rats and in man.", {"entities": [[9, 16, "Herb name"], [83, 89, "Study"]]}], [2996, "[9, 27\u201328] Prolonged administration of G. kola ensured that a possible induction of enzyme activity by G. kola could be evaluated since it is known that enzyme inhibition may occur with the first dose of the inhibitor [29\u201330], while an inducer can cause an increase in enzyme activity over time usually at a relatively higher dose of the inducing agent.", {"entities": [[39, 46, "Herb name"], [103, 110, "Herb name"]]}], [2997, "[31] During the seventh day of bitter kola administration, coinciding with the end of the wash out period, each participant after an overnight fast received bitter kola concomitantly with the administration of a single oral dose of 600 mg quinine sulphate tablets.", {"entities": [[31, 42, "Herb name"], [157, 168, "Herb name"], [232, 238, "Amount"], [239, 255, "Drug"]]}], [2998, "Tolerability assessments included physical examinations, supine blood pressure, pulse rate and adverse-events (AE) monitoring using investigators' questionnaires and subjects' spontaneous reports.", {"entities": [[57, 78, "Parameter"], [80, 90, "Parameter"], [95, 109, "Pathology"]]}], [2999, "Sample collection  Venous blood samples (5ml) was collected into heparinised tubes at time zero (just before the administration of quinine sulphate tablets)) and at 1, 2, 3,4, 6, 8, 12, 24, 36 and 48 h after each participant received quinine alone or concurrently with the scheduled dose of G. kola.", {"entities": [[131, 147, "Drug"], [234, 241, "Drug"], [291, 298, "Herb name"]]}], [3000, "For pharmacokinetic assay, the blood sample was centrifuged (3000 g for 10 mins) and the resulting plasma was stored at \u221220 \u00b0C until the time of drug analysis.", {"entities": []}], [3001, "Drug Analysis  A slight modification of an earlier reported HPLC method [32] was used to assay for quinine and its major metabolite, 3-hydroquinine in the plasma samples.", {"entities": [[99, 106, "Drug"], [133, 147, "Drug"]]}], [3002, "The HPLC system consisted of an Agilent 1200 series HPLC system (Agilent Technologies, Santa Clara, California, USA) fitted with an isocratic pump (model G1341A).The variable wavelength detector [Agilent Technologies; standard version (model G1341B)] was set at 254 nm.", {"entities": []}], [3003, "Chromatographic separation was achieved with an Eclipse XDB-C18 reverse phase HPLC column, (5\u00b5m particle size and 150 \u00d7 4.6 mm, i.d.).", {"entities": []}], [3004, "The mobile phase consisting of (methanol: acetonitrile: 0.02M KH2PO4 buffer (15:15: 70) containing 0.64 ml of perchloric acid (70 % w/w, density 1.664 g/ml) to give a pH of 2.6 was run at a flow rate of 1.6 ml/min.", {"entities": []}], [3005, "Primaquine (3.0 \u00b5g/ml) was used as the internal standard.", {"entities": []}], [3006, "Data acquisition was enabled by LC3D Chemstation software and windows 2000 for system Control.", {"entities": []}], [3007, "Sample extraction involved protein precipitation with perchloric acid, followed by basification with 5 M NaOH and subsequent extraction using diethylether and back extraction into 0.1M HCl.", {"entities": []}], [3008, "Calibration procedure has been previously reported.", {"entities": []}], [3009, "[32] Briefly, retention times of 3-hydroxyquinine, quinine and internal standard were 1.5, 2.7 and 6.7 min respectively.", {"entities": [[33, 49, "Drug"], [51, 58, "Drug"]]}], [3010, "The Standard curve used in this study was linear over the concentrations range (0.25 \u2013 4.0 \u00b5g/ml) for both quinine and metabolite.", {"entities": [[107, 114, "Drug"]]}], [3011, "The coefficient of determination was 0.999 and 0.9995 for quinine and 3 hydroxyquinine respectively.", {"entities": [[58, 65, "Drug"], [70, 86, "Drug"]]}], [3012, "The limit of quantitation was 0.37\u00b5g/ml and 0.5\u00b5g/ml for quinine and for 3-hydroxyquinine respectively.", {"entities": [[57, 64, "Drug"], [73, 89, "Drug"]]}], [3013, "Intraday and inter-day precision for both quinine and 3-hydroxyquinine ranged from 2.37 to 3.17 % and 1.49 to 3.51 %, respectively.", {"entities": [[42, 49, "Drug"], [54, 70, "Drug"]]}], [3014, "Recovery was not less than 93.9 % for quinine and 73.4 % for 3-HQN, while accuracy for both quinine and its metabolite ranged between 93.1 % and 105.9 %.", {"entities": [[38, 45, "Drug"], [61, 66, "Drug"], [92, 99, "Drug"]]}], [3015, "Pharmacokinetic Analysis  Cmax (peak plasma concentration), tmax (time to Cmax), were estimated by visual inspection of the plasma concentration-time profiles.", {"entities": [[26, 58, "Parameter"], [60, 79, "Parameter"]]}], [3016, "Other pharmacokinetics parameters such as AUC (0\u201348h) (area under the plasma concentration time curve), AUC0\u2013\u221e (area under the plasma concentration time curve from zero to infinity), T1/2 (terminal half-life), and Cl/F (apparent oral clearance), for quinine and 3-HQN were calculated by standard noncompartmental analysis using WinNonLin Standard Edition, version 1.5 Scientific Consultant Inc, Apex, NC, USA) using individual plasma concentration profile.", {"entities": [[42, 102, "Parameter"], [104, 181, "Parameter"], [183, 208, "Parameter"], [214, 244, "Parameter"], [250, 257, "Drug"], [262, 267, "Drug"]]}], [3017, "AUC (0\u201348h) were determined by the linear trapezoidal method to last sample time point.", {"entities": [[0, 11, "Parameter"]]}], [3018, "The area from the last datum point (Ct) to infinity was obtained as Ct/\u03b2.", {"entities": []}], [3019, "Linear regression analysis of the terminal phase of the log concentration-time profile was used to calculate the elimination rate constant (\u03b2).", {"entities": []}], [3020, "Elimination half life (T1/2\u03b2) was computed from the elimination rate constant (\u03b2) as 0.693/\u03b2.", {"entities": [[0, 29, "Parameter"]]}], [3021, "Cl/F was determined from dose/ AUC0\u2013\u221e.", {"entities": [[0, 4, "Parameter"], [31, 37, "Parameter"]]}], [3022, "Metabolic ratio was computed using the AUC0\u2013\u221e met/AUC0\u2013\u221e drug.", {"entities": [[39, 45, "Parameter"], [50, 56, "Parameter"]]}], [3023, "Statistical Analysis  Data were analysed using Minitab 17 by Lead Technologies, Inc. Pharmacokinetics parameters of quinine and 3-hydroxyquinine were summarized by descriptive statistics.", {"entities": [[116, 123, "Drug"], [128, 144, "Drug"]]}], [3024, "The 90% confidence intervals (CIs) were constructed for the ratios of the geometric means of quinine with G. kola (T) and quinine alone (R) using a two one sided t-test for the primary pharmacokinetic end points [Cmax and AUC0\u2013\u221e of both quinine and 3 hydroxyquinine] and the metabolic ratio of 3-hydroxyquinine to quinine.", {"entities": [[93, 100, "Drug"], [106, 113, "Herb name"], [122, 129, "Drug"], [213, 217, "Parameter"], [222, 228, "Parameter"], [237, 244, "Drug"], [249, 265, "Drug"], [294, 310, "Drug"], [314, 321, "Drug"]]}], [3025, "The exponents of the ratios of the geometric means multiplied by 100 (point estimates) and that of the 90% CIs were computed.", {"entities": []}], [3026, "Bioequivalence was established if the 90% CIs were entirely within the 80\u2013125% range and therefore no interaction was noted between periods.", {"entities": []}], [3027, "The age and weight [mean \u00b1 SD (range)] of group A was [24.00 \u00b1 2.00 (21 \u2013 28 years); 62.25 \u00b1 7.77 (55 \u2013 78 kg)] and group B was [23 .92 \u00b1 3.06 (20\u201331years); 61.00 \u00b1 7.80(46 \u2013 77 kg)].", {"entities": [[55, 83, "Age"], [129, 155, "Age"]]}], [3028, "Figures 1 and \u200band22 present the mean plasma concentration over time for quinine and 3-hydroxyquinine following oral administration of single oral doses of 600 mg of quinine sulphate before and after concurrent administration of scheduled dose of G. kola.", {"entities": [[73, 80, "Drug"], [85, 101, "Drug"], [156, 162, "Amount"], [166, 182, "Drug"], [247, 254, "Herb name"]]}], [3029, "Table 1 (Group A) summarizes the pharmacokinetic parameters (mean \u00b1 SD) for quinine and 3-hydroxyquinine following single oral administration of 600 mg dose of quinine sulphate tablet to each of 12 participants before and after each volunteer received G. kola (12.5 g) once daily for 7 days.", {"entities": [[76, 83, "Drug"], [88, 104, "Drug"], [145, 151, "Amount"], [160, 176, "Drug"], [195, 210, "Cohort"], [252, 259, "Herb name"], [261, 267, "Amount"], [269, 279, "Frequency"], [280, 290, "Duration"]]}], [3030, "Concurrent intake of G. kola with quinine resulted in reduction in peak plasma concentration (Cmax) and an increase in time to reach Cmax (tmax) of quinine.", {"entities": [[21, 28, "Herb name"], [34, 41, "Drug"], [67, 99, "Parameter"], [119, 144, "Parameter"], [148, 155, "Drug"]]}], [3031, "Specifically, tmax of quinine increased significantly by 48 %.", {"entities": [[14, 18, "Parameter"], [22, 29, "Drug"]]}], [3032, "(p < 0.05).", {"entities": []}], [3033, "Quinine and 3-hydroxyquinine Cmax reduced by 19 % and 29 % respectively.", {"entities": [[0, 7, "Drug"], [12, 28, "Drug"], [29, 33, "Parameter"]]}], [3034, "The Cmax of both quinine and its metabolite with and without G. kola administration were not bioequivalent as they fell outside the bioequivalence range of 80\u2013125%.", {"entities": [[4, 8, "Parameter"], [17, 24, "Drug"], [61, 68, "Herb name"]]}], [3035, "The exposure (AUC0\u2013\u221e) to quinine and 3-hydroxyquinine, and also the metabolic ratio compared to baseline were bioequivalent (Table 2).", {"entities": [[14, 20, "Parameter"], [25, 32, "Drug"], [37, 53, "Drug"]]}], [3036, "Other parameters such as T1/2 and CL/F for quinine were comparable to baseline (p>0.05).", {"entities": [[25, 29, "Parameter"], [34, 38, "Parameter"], [43, 50, "Drug"]]}], [3037, "An external file that holds a picture, illustration, etc.", {"entities": []}], [3038, "Object name is nihms785321f1.jpg Figure 1  Mean plasma concentration versus time profiles for quinine and 3-hydroxyquinine following single oral administration of 600mg dose of quinine sulphate tablet to 12 volunteers before and after each volunteer received G. kola (12.5 g) once daily for 7 days (Group A) An external file that holds a picture, illustration, etc.", {"entities": [[94, 101, "Drug"], [106, 122, "Drug"], [163, 168, "Amount"], [177, 193, "Drug"], [204, 217, "Cohort"], [259, 266, "Herb name"], [268, 274, "Amount"], [276, 286, "Frequency"], [287, 297, "Duration"]]}], [3040, "Quinine tmax increased by 27 % with concomitant intake of G. kola.", {"entities": [[0, 7, "Drug"], [8, 12, "Parameter"], [58, 65, "Herb name"]]}], [3041, "The Cmax of quinine and 3-hydroxyquinine decreased by 26 and 32 % respectively when compared to baseline.", {"entities": [[4, 8, "Parameter"], [12, 19, "Drug"], [24, 40, "Drug"]]}], [3042, "The AUC0\u2013\u221e of quinine was slightly reduced by about 9 %.", {"entities": [[4, 10, "Parameter"], [14, 21, "Drug"]]}], [3043, "Shown in Table 2 are the point estimate of T/R of Cmax and AUC0\u2013\u221e for both quinine and 3-hydroxyquinine.", {"entities": [[50, 54, "Parameter"], [59, 65, "Parameter"], [75, 82, "Drug"], [87, 103, "Drug"]]}], [3044, "The Cmax of quinine and 3-hydroxyquinine, and also the AUC0\u2013\u221e of quinine fell outside the bioequivalence range of 80\u2013125% when quinine was administered with G. kola on a twice-daily regimen.", {"entities": [[4, 8, "Parameter"], [12, 19, "Drug"], [24, 40, "Drug"], [55, 61, "Parameter"], [65, 72, "Drug"], [127, 134, "Drug"], [157, 164, "Herb name"], [170, 181, "Frequency"]]}], [3045, "Adverse effects of quinine  A questionnaire was designed and administered to the volunteers to record any observed side effects or adverse reaction during the study.", {"entities": [[0, 15, "Pathology"], [19, 26, "Drug"], [115, 127, "Pathology"], [131, 147, "Pathology"]]}], [3046, "The physician who assessed the volunteers for fitness to participate was also on site during drug administration and sample collection.", {"entities": []}], [3047, "No adverse drug reaction was experienced that warranted discontinuation from the study.", {"entities": []}], [3048, "Blood pressure and pulse rate were monitored as drastic changes may be pointer to more serious adverse reaction to quinine.", {"entities": [[0, 14, "Parameter"], [19, 29, "Parameter"], [95, 111, "Pathology"], [115, 122, "Drug"]]}], [3049, "Following quinine administration, participants in the phase one of these studies tolerated the drug but presented with slight dizziness (18 participants), nausea (14 participants), headache (7 participants) and ringing sensation in the ear (4 participants).", {"entities": [[10, 17, "Drug"], [119, 135, "Pathology"], [155, 161, "Pathology"], [181, 189, "Pathology"], [211, 239, "Pathology"]]}], [3050, "Interestingly, in the second phase, quinine was better tolerated.", {"entities": [[36, 43, "Drug"]]}], [3051, "Precisely, only 3 participants complained of very light dizziness.", {"entities": [[50, 65, "Pathology"]]}], [3052, "There were no other complaints of adverse reactions reported by the volunteers Go to: DISCUSSION  A major goal of an interaction study is to determine whether there is any increase or decrease in exposure to the substrate in the presence of the interacting drug, because this has a potential to influence therapy outcome.", {"entities": [[34, 51, "Pathology"]]}], [3053, "In this study, the Cmax and AUC0\u2013\u221e consistently reduced (Figures 1 and \u200band2)2) while tmax increased (Table 1) for both quinine and metabolite at both doses of G. kola.", {"entities": [[19, 23, "Parameter"], [28, 34, "Parameter"], [86, 90, "Parameter"], [120, 127, "Drug"], [160, 167, "Herb name"]]}], [3054, "These observations suggest that co-administration of quinine and G. kola may have decreased and delayed the absorption of quinine.", {"entities": [[53, 60, "Drug"], [65, 72, "Herb name"], [122, 129, "Drug"]]}], [3055, "Furthermore, our findings (Table 2) clearly indicate there was a pharmacokinetic interaction between quinine and G. kola as evidenced from the 90 % confidence intervals of point estimates for Cmax of quinine and 3-hydroxyquinine which fell outside the 80 \u2013 125 % range in both groups.", {"entities": [[101, 108, "Drug"], [113, 120, "Herb name"], [192, 196, "Parameter"], [200, 207, "Drug"], [212, 228, "Drug"]]}], [3056, "Thus, an herb - drug interaction was noted with only the higher dose of G. kola as evidenced from the Cmax and AUC0\u2013\u221e of quinine which were both reduced and not bioequivalent in the presence of 12.5mg twice daily dose of G. kola when compared with the baseline values.", {"entities": [[72, 79, "Herb name"], [102, 106, "Parameter"], [111, 117, "Parameter"], [121, 128, "Drug"], [194, 200, "Amount"], [201, 212, "Frequency"], [221, 228, "Herb name"]]}], [3057, "This suggests a dose dependent interaction may have occurred between G. kola and quinine.", {"entities": [[69, 76, "Herb name"], [81, 88, "Drug"]]}], [3058, "A plausible explanation for this occurrence may be that the presence of higher amount of G. kola (known to be rich in fiber) in the gut may have altered the systemic bioavailability of quinine.", {"entities": [[89, 96, "Herb name"], [118, 123, "Herb name"], [166, 181, "Parameter"], [185, 192, "Drug"]]}], [3059, "The metabolite exposure was considered important since it has been reported to contribute 5\u201312 % of the antimalarial action of quinine.", {"entities": [[127, 134, "Drug"]]}], [3060, "The precise therapeutic window however remains uncertain as various factors have been reported to affect the pharmacokinetic and therapeutic response of quinine.", {"entities": [[153, 160, "Drug"]]}], [3061, "[34, 35] In these present studies, the pharmacokinetic parameters of a single dose administration of quinine were in concordance with values reported in literature [36, 37].", {"entities": [[101, 108, "Drug"]]}], [3062, "Interestingly, we observed that during drug administration and blood sample collection, the incidences of adverse reactions to quinine was greatly reduced when G. kola was co-administered with quinine.", {"entities": [[106, 123, "Pathology"], [127, 134, "Drug"], [160, 167, "Herb name"], [193, 200, "Drug"]]}], [3063, "Precisely, in the first phase, when quinine was administered alone, all the twenty four participants (100 %) complained of one or more mild adverse effects which were transient.", {"entities": [[36, 43, "Drug"], [76, 100, "Cohort"], [140, 155, "Pathology"]]}], [3064, "However, in the second phase when quinine and G. kola were concurrently administered it was much more tolerated.", {"entities": [[34, 41, "Drug"], [46, 53, "Herb name"]]}], [3065, "Out of the twenty four participants who participated in the study, only 3 participants (12.5 %) complained of slight dizziness while the other volunteers had no complaints of adverse reaction whatsoever to quinine.", {"entities": [[117, 126, "Pathology"], [175, 191, "Pathology"], [206, 213, "Drug"]]}], [3066, "Indeed, the reduction in Cmax and AUC0\u2013\u221e of quinine and its metabolite after concomitant intake of quinine with G. kola as observed in the current studies suggest a possible reduction in toxic effects or adverse effects of quinine.", {"entities": [[25, 29, "Parameter"], [34, 40, "Parameter"], [44, 51, "Drug"], [99, 106, "Drug"], [112, 119, "Herb name"], [187, 200, "Pathology"], [204, 219, "Pathology"], [223, 230, "Drug"]]}], [3067, "This observation is in agreement with previous report where higher plasma concentrations of quinine are associated with manifestations of toxic effects.", {"entities": [[47, 53, "Study"], [92, 99, "Drug"], [138, 151, "Pathology"]]}], [3068, "[35]  There are several reports of other commonly consumed supplements with significant effects on drug bioavailability and disposition.", {"entities": [[24, 31, "Study"], [104, 119, "Parameter"]]}], [3069, "For example, kola nut has been reported to cause a significant decrease in the plasma concentration of halofantrine and its metabolite when co-administered [28] and Tamarindus indica the major component of a local drink widely taken in the Northern part of Nigeria has been reported to significantly decrease the bioavailability of aspirin in healthy human subjects.", {"entities": [[13, 17, "Herb name"], [18, 21, "Herb part"], [103, 115, "Drug"], [165, 182, "Herb name"], [313, 328, "Parameter"], [332, 339, "Drug"], [343, 350, "Pathology"]]}], [3070, "[38]  Although, the exact mechanism responsible for the delayed and decreased absorption of quinine in the presence of G. kola in this current study is not known, it is possible that quinine may have interacted through complex formation with the trace metals or flavonoids usually found in G. kola [6, 11] as evidenced from a significant reduction in the Cmax and tmax of quinine but no significant change in parameters which are indicative of interference with elimination.", {"entities": [[92, 99, "Drug"], [119, 126, "Herb name"], [183, 190, "Drug"], [262, 272, "Herb name"], [290, 297, "Herb name"], [355, 359, "Parameter"], [364, 368, "Parameter"], [372, 379, "Drug"]]}], [3071, "Since knowledge of the mechanism for interactions makes it possible to predict and prevent pharmacokinetic drug interactions [39], further studies are necessary to investigate the different mechanisms of interactions leading to a decrease in the plasma concentrations of quinine when co-administered with G. kola.", {"entities": [[271, 278, "Drug"], [305, 312, "Herb name"]]}], [3072, "To determine whether the extracts of G. kola seeds influence Phase I and Phase II drug metabolizing enzymes [12\u201314] we also evaluated the possible modulation of enzyme activity by G. kola by using the metabolic ratio of quinine in plasma [26] as a measure of the assessment of metabolism of quinine to 3-hydroxyquinine by CYP3A, in both groups.", {"entities": [[37, 44, "Herb name"], [180, 187, "Herb name"], [220, 227, "Drug"], [291, 298, "Drug"], [302, 318, "Drug"], [322, 327, "Target"]]}], [3073, "The metabolic ratio of 3-hydroxyquinine to quinine did not change significantly in the presence of G. kola suggesting that the activity of CYP3A in metabolising 3-hydroxyquinine to quinine was not significantly modulated in the presence of G. kola.", {"entities": [[23, 39, "Drug"], [43, 50, "Drug"], [99, 106, "Herb name"], [139, 144, "Target"], [161, 177, "Drug"], [181, 188, "Drug"], [240, 247, "Herb name"]]}], [3074, "Moreover, parameters such as T1/2 and CL/F of quinine that relates to elimination in both study groups were also not altered significantly in the presence of G. kola.", {"entities": [[29, 33, "Parameter"], [38, 42, "Parameter"], [46, 53, "Drug"], [158, 165, "Herb name"]]}], [3075, "We argue that the observed reduction in the plasma concentrations of quinine in healthy volunteers in the presence of G. kola may not be due to a metabolic interaction or interference but rather a potential reduction in absorption.", {"entities": [[69, 76, "Drug"], [80, 87, "Pathology"], [118, 125, "Herb name"]]}], [3076, "It is possible that CYP3A activity on quinine metabolism in humans is not significantly affected by co-administration of G. kola.", {"entities": [[20, 25, "Target"], [38, 45, "Drug"], [121, 128, "Herb name"]]}], [3077, "Co-administration of oral quinine and G. kola seeds resulted in a reduction in the peak plasma concentrations and exposure of quinine and its major metabolite, 3 hydroxyquinine.", {"entities": [[26, 33, "Drug"], [38, 45, "Herb name"], [46, 51, "Herb part"], [83, 109, "Parameter"], [126, 133, "Drug"], [160, 176, "Drug"]]}], [3078, "The absorption of quinine was delayed as evidenced from an increase in the Tmax of quinine.", {"entities": [[18, 25, "Drug"], [75, 79, "Parameter"], [83, 90, "Drug"]]}], [3079, "A pharmacokinetic herb-drug interaction was seen with the Cmax of quinine and its metabolite at both doses of G. kola seed and with quinine exposure (AUC0\u2013\u221e) at only the higher dose of G. kola seed.", {"entities": [[58, 62, "Parameter"], [66, 73, "Drug"], [110, 117, "Herb name"], [118, 122, "Herb part"], [132, 139, "Drug"], [150, 156, "Parameter"], [185, 192, "Herb name"], [193, 197, "Herb part"]]}], [3080, "Therefore, caution may need to be exercised with the ingestion of G. kola when on oral quinine therapy.", {"entities": [[66, 73, "Herb name"], [87, 94, "Drug"]]}], [3081, "Competing Interests: Co-author Nceba Gqaleni is employed by AIK Innovations (Pty) Ltd.", {"entities": []}], [3082, "There are no patents, products in development or marketed products to declare.", {"entities": []}], [3083, "This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.", {"entities": []}], [3084, "Conceived and designed the experiments: DW KG KW MMG NG JS PB QJ WRF.", {"entities": []}], [3085, "Performed the experiments: DW KG KW MMG JS PB.", {"entities": []}], [3086, "Analyzed the data: KW DW.", {"entities": []}], [3087, "Contributed reagents/materials/analysis tools: JS QJ.", {"entities": []}], [3088, "Wrote the paper: DW KG KW MMG NG JS PB QJ WRF.", {"entities": []}], [3089, "Sutherlandia frutescens (L.) R. Br.", {"entities": [[0, 35, "Herb name"]]}], [3090, "is widely used as an over the counter complementary medicine and in traditional medications by HIV seropositive adults living in South Africa; however the plant\u2019s safety has not been objectively studied.", {"entities": [[95, 111, "Pathology"]]}], [3092, "In Stage 1 56 participants were randomized to S. frutescens 400, 800 or 1,200 mg twice daily or matching placebo for 24 weeks.", {"entities": [[46, 59, "Herb name"], [60, 63, "Amount"], [65, 68, "Amount"], [72, 80, "Amount"], [81, 92, "Frequency"], [113, 125, "Duration"]]}], [3093, "In Stage 2 77 additional participants were randomized to either 1,200 mg S. frutescens or placebo.", {"entities": [[64, 72, "Amount"], [73, 86, "Herb name"]]}], [3094, "In the final analysis data from Stage 1 and Stage 2 were combined such that 107 participants were analysed (54 in the S. frutescens 1,200 mg arm and 53 in the placebo arm).", {"entities": [[76, 92, "Cohort"], [118, 131, "Herb name"], [132, 140, "Amount"]]}], [3095, "A possible interaction between S. frutescens and IPT needs further evaluation, and may presage antagonistic interactions with other herbs having similar biochemical (antioxidant) properties.", {"entities": [[31, 44, "Herb name"], [49, 52, "Drug"]]}], [3096, "No other safety issues relating to consumption of S. frutescens in this cohort were identified.", {"entities": [[50, 63, "Herb name"]]}], [3097, "ClinicalTrials.gov  Data contain potentially identifying information and is ethically restricted from being shared in the public domain.", {"entities": []}], [3098, "Data are available upon request from the corresponding author, pending ethical approval.", {"entities": []}], [3099, "The human immunodeficiency virus (HIV) pandemic has placed unprecedented demands on healthcare services in sub-Saharan Africa.", {"entities": [[0, 38, "Pathology"]]}], [3100, "In South Africa an estimated 5.26 million individuals (about 10% of the population) are living with HIV infection [1].", {"entities": [[100, 113, "Pathology"]]}], [3101, "The South African government implemented the World Health Organization\u2019s (WHO) recommendation that antiretroviral therapy (ART) be started when individuals\u2019 CD4 T-lymphocyte count falls below 350 cells /\u03bcL [2]; however the average CD4 count of patients who start ART remains <150 cell/\u03bcL, with many patients deferring ART for a variety of reasons including lack of capacity within the South African public health service [3\u20136].", {"entities": [[4, 17, "Ethnic group"], [99, 127, "Drug"], [157, 179, "Parameter"], [186, 205, "Amount"], [219, 240, "Parameter"], [263, 266, "Drug"], [275, 287, "Amount"], [318, 321, "Drug"], [385, 398, "Ethnic group"]]}], [3102, "As in most countries, many South Africans use traditional, complementary and alternative medicines (TCAM) and/or consult with traditional health practitioners (THPs) [7\u20139].", {"entities": [[27, 41, "Ethnic group"]]}], [3103, "More than 50% of adults in KwaZulu-Natal attending public sector facilities for ART initiation disclose using TCAM [10], and similar levels of TCAM use by HIV positive individuals may occur worldwide [11].", {"entities": [[80, 83, "Drug"], [155, 167, "Pathology"]]}], [3104, "Sutherlandia frutescens is an indigenous southern African plant widely used to treat a variety of conditions including those associated with HIV infection (S1 Fig) [8, 12].", {"entities": [[0, 23, "Herb name"], [41, 57, "Ethnic group"], [141, 154, "Pathology"]]}], [3105, "A variety of properties of S. frutescens and anecdotal reports suggest benefit in HIV seropositive patients [12]; however the plant is not registered by the South African Medicines Control Council (MCC) for specific indications.", {"entities": [[27, 40, "Herb name"], [82, 98, "Pathology"], [157, 170, "Ethnic group"]]}], [3106, "No toxicity of S. frutescens was observed in either vervet monkeys at doses of up to 80 mg/kg dried powder over 3 months, or in healthy volunteers taking 400 mg dried powder twice daily for 24 weeks [14,15].", {"entities": [[3, 11, "Pathology"], [15, 28, "Herb name"], [85, 93, "Amount"], [94, 106, "Extraction process"], [107, 120, "Duration"], [128, 135, "Pathology"], [154, 160, "Amount"], [161, 173, "Extraction process"], [174, 185, "Frequency"], [186, 198, "Duration"]]}], [3107, "However, the safety and possible attributes of S. frutescens in HIV-seropositive adults are unknown.", {"entities": [[47, 60, "Herb name"], [64, 80, "Pathology"]]}], [3109, "HIV seropositive adults were recruited from clinics in the Edendale Hospital catchment area and evaluated at the Edendale Hospital Research Unit.", {"entities": [[0, 16, "Pathology"]]}], [3110, "This state-funded hospital serves 860,000 individuals living in urban and rural communities in the uMgungundlovu District of KwaZulu-Natal, South Africa.", {"entities": []}], [3111, "The demographic profile is similar to other high HIV prevalence settings in the province with an antenatal HIV seroprevalence of 42.2% in 2010 [18].", {"entities": [[49, 52, "Pathology"], [97, 110, "Pathology"]]}], [3112, "Close collaborations have developed between hospital staff and local THPs, especially relating to the management of HIV infection and tuberculosis.", {"entities": [[116, 129, "Pathology"], [134, 146, "Pathology"]]}], [3113, "This Stage I/II study evaluated S. frutescens in healthy HIV seropositive adults using a double-blind, randomized, placebo-controlled design with a two-stage statistical selection theory design [19, 20].", {"entities": [[32, 45, "Herb name"], [49, 73, "Pathology"], [89, 193, "Study"]]}], [3114, "In Stage 1, 56 participants were randomized to one of three doses of S. frutescens (400, 800, 1200 mg) or placebo, taken twice daily for 24 weeks.", {"entities": [[69, 82, "Herb name"], [84, 87, "Amount"], [89, 92, "Amount"], [94, 101, "Amount"], [121, 132, "Frequency"], [133, 145, "Duration"]]}], [3115, "Interim analyses to determine which active study arm (i.e., 400, 800 or 1200 mg) should be continued in Stage 2 were conducted after at least twelve participants in each arm had completed the study.", {"entities": [[60, 63, "Amount"], [65, 68, "Amount"], [72, 79, "Amount"]]}], [3116, "The most promising dose level was identified by comparing the number of participants in each arm with regard to clinical adverse events and evidence of treatment failure.", {"entities": [[19, 29, "Parameter"], [112, 135, "Pathology"]]}], [3117, "Treatment failure was defined as follows: having either a decline in the primary outcomes of weight loss (>5% body mass) or CD4 T-lymphocyte (>20 cells/\u03bcL associated with percentage CD4 decline); having a score decrease of \u2265 20 points on any subscale score from the secondary outcome measure of the Medical Outcomes Study HIV Health Survey (MOS-HIV); or duration of infection more than 10 days of active infections during the 6 month trial (acquired on-study infections).", {"entities": [[93, 99, "Parameter"], [106, 109, "Amount"], [110, 119, "Parameter"], [124, 140, "Parameter"], [142, 154, "Amount"], [171, 185, "Parameter"], [322, 325, "Pathology"], [366, 375, "Pathology"], [376, 393, "Duration"], [397, 414, "Pathology"], [426, 433, "Duration"], [434, 439, "Study"], [459, 469, "Pathology"]]}], [3118, "In the interim analysis changes in weight and CD4 count were similar across the arms.", {"entities": [[35, 41, "Parameter"], [46, 55, "Parameter"]]}], [3119, "Unfavourable infection outcomes were observed in three of twelve participants in the 1200mg group, in six of fourteen participants in the placebo group, and in seven of twelve participants in the 400mg group.", {"entities": [[0, 31, "Pathology"], [85, 91, "Amount"], [196, 201, "Amount"]]}], [3120, "With respect to the MOS-HIV, failure differences were found between placebo and 1200 mg, favouring the 1200mg group.", {"entities": [[80, 87, "Amount"], [103, 109, "Amount"]]}], [3121, "The study proceeded to Stage 2 in which placebo was compared with the highest dose evidenced to have no significant safety issues, have fewer failures than the placebo arm, and believed to be of the greatest potential benefit (i.e.", {"entities": [[78, 82, "Parameter"]]}], [3122, "1,200 mg).", {"entities": [[0, 8, "Amount"]]}], [3123, "was sourced from a commercial grower (Afriplex, Paarl, South Africa) and ground to a uniform powder.", {"entities": [[85, 99, "Extraction process"]]}], [3124, "Four hundred milligrams of study product powder were packed into standard opaque 20 mm by 6 mm capsules by a GMP certified manufacturer (Ferlot Manufacturing Packaging (Pty) Ltd, Jeffreys Bay, South Africa).", {"entities": [[0, 23, "Amount"], [41, 47, "Extraction process"], [81, 103, "Extraction process"]]}], [3125, "The physicochemical properties of the study product were monitored annually by visual observation and high performance liquid chromatography measurement of Sutherlandioside B, canavanine and \u03b3-amino butyric acid biomarkers.", {"entities": [[0, 51, "Parameter"], [156, 211, "Herb name"]]}], [3126, "Rigorous blinding procedures were developed to ensure that neither the participants nor study staff who worked directly with participants were able to link study product assignment with research subject.", {"entities": []}], [3127, "These practices conformed to the NCCAM/NIH Guidance on Natural Product Integrity and, substantively, the Guidelines for Complementary Medicines recently promulgated by the Republic of South Africa Department of Health and MCC [21,22].", {"entities": []}], [3128, "At the baseline visit eligible participants were sequentially assigned a participant identification number (PIN) which had already been randomly linked to study arm and study product dispensing number by the off-site study statistician; randomization was stratified by gender.", {"entities": []}], [3129, "Study staff and participants did not have access to the randomization tables linking PIN to product dispensing number.", {"entities": []}], [3130, "The full inclusion / exclusion criteria are shown in S1 Table.", {"entities": []}], [3131, "In addition to the consent documents, standardized questionnaires to evaluate quality of life, psychological distress and depression were translated into isiZulu and validated using procedures already described [23,24].", {"entities": [[95, 117, "Pathology"], [122, 132, "Pathology"]]}], [3132, "Stage 1 ran from May 2008 to July 2009 (interim analysis) and Stage 2 from August 2010 to December 2011 (study completion).", {"entities": [[12, 38, "Duration"], [70, 103, "Duration"]]}], [3133, "Study procedures were conducted by registered nurses and medical practitioners.", {"entities": []}], [3134, "At baseline participants had a physical examination and electrocardiogram, had weight, height and skin fold thickness measured, and were prescribed a multivitamin for two months.", {"entities": [[79, 85, "Parameter"], [87, 93, "Parameter"], [98, 117, "Parameter"], [150, 162, "Herb name"], [163, 177, "Duration"]]}], [3135, "To support adherence, study product was transferred into pill boxes by study staff, and adherence was measured by counting the number of capsules returned at each visit.", {"entities": []}], [3136, "Participants returned to the clinic at weeks 2, 4, 8, 12, 16, 20 and 24.", {"entities": []}], [3137, "Study questionnaires were administered by a study nurse at baseline and weeks 4, 12 and 24.", {"entities": []}], [3138, "Haematological and biochemical parameters were repeated at weeks 4, 8, 12 and 24, and the physical examination and electrocardiogram was repeated at weeks 12 and 24 and at other visits in response to symptoms.", {"entities": [[0, 41, "Parameter"], [200, 208, "Pathology"]]}], [3139, "As consumption of S. frutescens has been anecdotally associated with systemic lupus erythematosis [25], serum anti-nuclear factor (ANF) was measured at baseline and weeks 12 and 24 and participants were screened for symptoms suggestive of vasculitis at each scheduled clinical review.", {"entities": [[18, 31, "Herb name"], [69, 97, "Pathology"], [104, 135, "Parameter"], [216, 249, "Pathology"]]}], [3140, "Skin fold thickness and weight was repeated at every visit.", {"entities": [[0, 19, "Parameter"], [24, 30, "Parameter"]]}], [3141, "Body mass index was calculated using the height measurement obtained at screening.", {"entities": [[0, 15, "Parameter"], [41, 47, "Parameter"]]}], [3142, "Participants with unresolved medical issues were re-evaluated 4 weeks after exiting the study.", {"entities": [[18, 43, "Pathology"], [62, 75, "Duration"]]}], [3143, "Adverse events were graded using the standardized criteria developed by the NIH division of AIDS [26].", {"entities": [[0, 14, "Pathology"], [92, 96, "Pathology"]]}], [3144, "Participants with a CD4 T-lymphocyte count of <350 cells/\u03bcL had a repeat count taken six weeks later; those found to have a second count of <350 cells/\u03bcL had the option of exiting the study and starting antiretroviral therapy.", {"entities": [[20, 42, "Parameter"], [46, 59, "Amount"], [85, 100, "Duration"], [140, 153, "Amount"], [203, 225, "Drug"]]}], [3145, "Duration of those adverse events likely to be due to infection were collected prospectively in Stage 2.", {"entities": [[18, 32, "Pathology"], [53, 62, "Pathology"]]}], [3146, "Study participants were asked to contact the study site at the onset of symptoms and were tracked regularly by telephone until resolution.", {"entities": [[72, 80, "Pathology"]]}], [3147, "Aetiology of infection events (viral, bacterial, fungal or protozoal) was determined by study physicians using standardized guidelines (S1 Text).", {"entities": [[13, 69, "Pathology"]]}], [3148, "The adverse event log was used similarly to infer aetiology of infection events occurring in Stage 1.", {"entities": [[4, 17, "Pathology"], [63, 79, "Pathology"]]}], [3149, "Primary and secondary outcomes were analysed using an intention to treat analysis based on treatment assignment to groups.", {"entities": []}], [3150, "Analyses of the primary outcome, effect of treatment on infection (Mean BOI and Total Days BOI), were accomplished using independent t-tests using per protocol analyses.", {"entities": [[56, 65, "Pathology"], [67, 75, "Parameter"], [80, 94, "Parameter"]]}], [3151, "For secondary outcomes, profile plots for participants in each group across the 24 week observation period were generated.", {"entities": [[80, 87, "Duration"]]}], [3152, "The secondary measures were analysed by fitting a mixed effects model to assess interaction effects of group over time (group and observation period as fixed effects) clustered within individual (participants as a random effect) on all continuous outcomes.", {"entities": []}], [3153, "Analyses were conducted using STATA 11.0 SE (StataCorp LP, College Station TX) to derive full maximum-likelihood and variance estimates with model assumptions confirmed through the analysis of residuals.", {"entities": []}], [3154, "Adherence to assigned study medication was calculated by subtracting the number of capsules returned from the number dispensed, dividing this figure by 6 multiplied by the number of days between visits, and expressing the result as a percentage.", {"entities": [[83, 91, "Extraction process"]]}], [3155, "Differences in adherence between arms were compared using the Wilcoxon-Mann-Whitney test.", {"entities": []}], [3156, "The Biomedical Research Ethics Committee of the University of KwaZulu-Natal reviewed and approved the study protocol and amendments, and further approval to conduct the study was obtained from the KwaZulu-Natal Department of Health and the South African MCC, the Research Ethics Committees of Stellenbosch University, the University of the Western Cape, the University of Missouri and by the U.S. National Institutes of Health.", {"entities": [[240, 253, "Ethnic group"]]}], [3157, "All participants gave written informed consent in their home language.", {"entities": []}], [3158, "Compliance with the study protocol was evaluated by an independent study monitor and study data were regularly assessed by an independent Data Safety Monitoring Board at the University of Cape Town.", {"entities": []}], [3159, "Participant screening, enrolment and randomization are shown in Fig 1.", {"entities": []}], [3160, "Fifty- six participants (50 women [89%] and 6 men [11%]) were enrolled into Stage 1, and 55 participants\u2019 data were included in the interim analysis.", {"entities": [[28, 33, "Sex"], [46, 49, "Sex"]]}], [3161, "In Stage 2, 77 participants were randomized to either S. frutescens 1,200 mg or placebo.", {"entities": [[54, 67, "Herb name"], [68, 76, "Amount"]]}], [3162, "At the completion of Stage 2 data from the 1,200 mg and placebo groups from both stages were combined for the final analysis.", {"entities": [[43, 51, "Amount"]]}], [3163, "In total, 54 participants were randomized to the S. frutescens 1,200 mg arm and 53 to the placebo arm, with 49 (92%) participants in the S. frutescens 1,200 mg arm and 48 participants (90%) in the placebo arm completing the study.", {"entities": [[49, 62, "Herb name"], [63, 71, "Amount"], [137, 150, "Herb name"], [151, 159, "Amount"]]}], [3164, "Thirty one participants in each arm were prescribed isoniazid preventive therapy (IPT).", {"entities": [[52, 86, "Drug"]]}], [3165, "Participant characteristics at baseline were similar in the two arms and are shown in Table 1; about 80% in each arm were female.", {"entities": [[60, 68, "Study"], [122, 128, "Sex"]]}], [3166, "Adherence to study product was high (>80% in all participants who completed the study), and there were no significant differences in adherence across study arms (P-value 0.98).", {"entities": []}], [3167, "Biochemical and haematological parameters did not change significantly over the course of the study, irrespective of group (Table 2).", {"entities": [[0, 41, "Parameter"]]}], [3168, "P-values for change in glucose measurements were assessed as being not clinically significant.", {"entities": [[23, 30, "Parameter"]]}], [3169, "On serial electrocardiograms the PR interval, QRS duration and corrected QT interval (QTc) were similar in both arms (S2 Table).", {"entities": [[29, 44, "Parameter"], [46, 58, "Parameter"], [63, 90, "Parameter"], [107, 116, "Study"]]}], [3170, "Abbreviations: HDL (high density lipoprotein); LDL (low density lipoprotein) *P-value for interaction effect of groups over time.", {"entities": [[15, 45, "Parameter"], [47, 76, "Parameter"]]}], [3171, "Adverse events classified by system (S3 Table) were evenly distributed between the two arms, as were adverse events caused by infection (Table 3).", {"entities": [[0, 14, "Pathology"], [83, 91, "Study"], [101, 115, "Pathology"], [126, 135, "Pathology"]]}], [3172, "Two serious adverse events occurred, both in participants on the S. frutescens arm: one participant had a positive urine pregnancy test followed two weeks later by spontaneous miscarriage; and one participant was hospitalized with shingles and early varicella dissemination that resolved completely with intravenous acyclovir.", {"entities": [[12, 26, "Pathology"], [65, 78, "Herb name"], [121, 130, "Parameter"], [145, 154, "Duration"], [164, 187, "Pathology"], [231, 239, "Pathology"], [244, 273, "Pathology"], [304, 325, "Drug"]]}], [3173, "Neither was judged to be related to the study product.", {"entities": []}], [3174, "Five participants on the S. frutescens arm and one participant on the placebo arm developed a positive anti-nuclear factor during the study period, two of who reverted to negative.", {"entities": [[25, 38, "Herb name"], [103, 122, "Parameter"]]}], [3175, "Two participants with a positive ANF at baseline tested negative during the study period.", {"entities": [[33, 36, "Parameter"]]}], [3176, "None of the participants developed vasculitis, and none needed to start antiretroviral therapy within 24 weeks of the baseline visit.", {"entities": [[35, 45, "Pathology"], [72, 94, "Drug"], [102, 110, "Duration"]]}], [3177, "Abbreviation: BOI (burden of infection) Total and mean BOI was greater in the S. frutescens arm (Table 3), with statistical significance being due to two participants who were diagnosed with tuberculosis while taking IPT.", {"entities": [[14, 39, "Parameter"], [40, 58, "Parameter"], [78, 91, "Herb name"], [191, 203, "Pathology"], [217, 220, "Drug"]]}], [3178, "No other cases of tuberculosis occurred on the study.", {"entities": [[18, 30, "Pathology"]]}], [3179, "Mean body mass index and skin fold thickness did not change significantly in the two arms (S4 Table).", {"entities": [[0, 20, "Parameter"], [25, 44, "Parameter"], [81, 89, "Study"]]}], [3180, "*P-value for interaction effect of groups over time.", {"entities": []}], [3181, "Mean scores for depression, perceived stress and most HIV symptoms (MOS-HIV) did not differ between the two arms of the study after controlling for baseline variability (S5 Table).", {"entities": [[16, 26, "Pathology"], [28, 44, "Pathology"], [49, 76, "Pathology"]]}], [3182, "There were however, statistically significant interaction effects (differences between groups over time) for the Social (P-value < 0.01) and Mental Health (P-value 0.03) measures, although the differences were of small magnitude and appeared to reflect slightly different changes in trajectory from baseline values.", {"entities": []}], [3183, "This is the first study to rigorously evaluate an African traditional and complementary medicine in adults living with HIV infection, using well established ethical and regulatory norms.", {"entities": [[50, 57, "Ethnic group"], [119, 132, "Pathology"]]}], [3184, "This study responds to calls by the WHO and others to rigorously evaluate African traditional medicines in the context in which they are used with the knowledge and support of THPs [7\u201312, 15\u201317, 27\u201329], and provide a precedent and guidance for the conduct of future clinical trials of African TCAM practices.", {"entities": [[74, 81, "Ethnic group"], [266, 281, "Study"], [285, 292, "Ethnic group"]]}], [3185, "When compared to placebo S. frutescens did not impact CD4 T-lymphocyte count, however duration of secondary infection in participants consuming S. frutescens 1,200 mg was longer than that observed in those on placebo due to two participants developing tuberculosis while taking S. frutescens, despite taking isoniazid.", {"entities": [[25, 38, "Herb name"], [54, 76, "Parameter"], [98, 117, "Pathology"], [144, 157, "Herb name"], [158, 166, "Amount"], [252, 264, "Pathology"], [278, 291, "Herb name"], [308, 317, "Drug"]]}], [3186, "The possible interaction that reduces the efficacy of IPT requires further evaluation.", {"entities": [[54, 57, "Drug"]]}], [3187, "This requires further study but, if experimentally supported, could substantially advance strategies for the prevention of tuberculosis and reduce development of drug resistance in regions where TCAM use occurs concurrently with IPT.", {"entities": [[123, 135, "Pathology"], [162, 177, "Parameter"], [229, 232, "Drug"]]}], [3188, "This study has several limitations.", {"entities": []}], [3189, "Asymptomatic HIV-positive adults were enrolled at a single site in KwaZulu-Natal.", {"entities": [[0, 25, "Pathology"]]}], [3190, "Inclusion of participants with more advanced HIV disease may have changed study findings in unpredictable ways; however known interactions between S. frutescens and antiretroviral medications precluded their inclusion in this study [27, 28].", {"entities": [[45, 56, "Pathology"], [147, 160, "Herb name"], [165, 191, "Drug"]]}], [3191, "Inclusion of participants with diabetes and/or adrenal imbalances may have revealed other effects of S. frutescens but was outside the scope of this study [35, 36].", {"entities": [[31, 39, "Pathology"], [47, 65, "Pathology"], [101, 114, "Herb name"]]}], [3192, "The majority of participants in this study were women; this gender bias for enrolment in clinical studies is a limiting factor, but has been observed in multiple other contexts.", {"entities": [[48, 53, "Sex"], [89, 105, "Study"]]}], [3193, "Further, different ways of preparing S. frutescens for consumption may alter the chemistry and availability of any bioactive components.", {"entities": [[37, 50, "Herb name"], [77, 135, "Parameter"]]}], [3194, "Based on data from Stage 1, duration of infection and BOI were used as secondary endpoints in Stage 2.", {"entities": [[40, 49, "Pathology"], [54, 57, "Parameter"]]}], [3195, "Data on duration of infection therefore needed to be retrospectively collected from Stage 1 source documents using adverse event start/stop dates.", {"entities": [[20, 29, "Pathology"], [115, 128, "Pathology"]]}], [3196, "Monitoring for infectious events was less intense in Stage 1 and the duration of infection relied on participant recollection at scheduled study visits.", {"entities": [[15, 32, "Pathology"], [81, 90, "Pathology"]]}], [3197, "However these limitations would have equally affected both arms of the study in Stage 1 participants whose data were carried forward into the final analysis and data on infection events requiring hospitalization or antibiotic treatment would have been captured.", {"entities": [[54, 76, "Study"], [169, 185, "Pathology"], [196, 211, "Parameter"], [215, 235, "Drug"]]}], [3198, "Data from this study suggests that S. frutescens at doses of up to 2,400 mg daily does not causes significant adverse effects in HIV seropositive adults; however possible interactions between S. frutescens and isoniazid require further study.", {"entities": [[35, 48, "Herb name"], [67, 75, "Amount"], [76, 81, "Frequency"], [110, 125, "Pathology"], [129, 145, "Pathology"], [192, 205, "Herb name"], [210, 219, "Drug"]]}], [3199, "(PDF) Click here for additional data file.", {"entities": []}], [3200, "(PDF) Click here for additional data file.", {"entities": []}], [3201, "(DOCX) Click here for additional data file.", {"entities": []}], [3202, "(PDF) Click here for additional data file.", {"entities": []}], [3203, "(DOCX) Click here for additional data file.", {"entities": []}], [3204, "(DOCX) Click here for additional data file.", {"entities": []}], [3205, "(DOCX) Click here for additional data file.", {"entities": []}], [3206, "(DOCX) Click here for additional data file.", {"entities": []}], [3207, "(PDF) Click here for additional data file.", {"entities": []}], [3208, "This study was registered with the U.S. National Institutes of Health (Clinical Trial Number NCT00549523).", {"entities": [[71, 85, "Study"]]}], [3209, "The full protocol is available at  The study funded by Grant U19 AT003264 (PI W Folk) from the National Center for Complementary and Alternative Medicines, the Office of Dietary Supplements and the Fogarty International Center, National Institutes of Health.", {"entities": []}], [3210, "The content is solely the responsibility of the authors and does not necessarily represent the official views of the sponsors.", {"entities": []}], [3211, "We gratefully acknowledge the contributions and support of the study participants, and many in the International Center for Indigenous Phytotherapy Studies, the University of Cape Town, the University of the Western Cape where the study was based, and the University of Missouri.", {"entities": []}], [3212, "We appreciate the support of the KwaZulu-Natal Department of Health, the Data Safety Monitoring Board (M. Blockman, C. Orrell, R. Madsen, D. Ngubane, A. Dhai), G Maartens, KwaZulu-Natal Traditional Health Practitioners (T.D.", {"entities": []}], [3213, "Buthelezi, S.W.", {"entities": []}], [3214, "Ndlovu, V.F.", {"entities": []}], [3215, "Shange, M.A.", {"entities": []}], [3216, "Thabethe, D.A.", {"entities": []}], [3217, "Mkhwanazi, B.L Nkomo-Gwala, T. Hlongwane, T. Mdlalose), and M.E Makhathini (liaison), D Shoemaker and K Rudeen (University of Missouri,) and K Doherty (Vanderbilt University).", {"entities": []}], [3218, "Edendale Research Team: Z Magcaba, L Maziya, L Ngubane, L Mbhele, W Hall, L Bishop, B Thembela.", {"entities": []}], [3219, "The prevalence of herb\u2013drug interactions and herb's adverse effects may be serious in susceptible population such as patients with chronic kidney disease (CKD).", {"entities": [[52, 67, "Pathology"], [131, 159, "Pathology"]]}], [3220, "In this study, we planned to determine the usage prevalence of herbal products and herb\u2013drug interactions in CKD patients.", {"entities": [[109, 112, "Pathology"]]}], [3221, "A cross-sectional prospective study was conducted on CKD and posttransplant patients with a history of using herbal supplements in Isfahan, Iran.", {"entities": [[0, 35, "Study"], [53, 56, "Pathology"]]}], [3222, "The patients were subjected to a validated checklist, containing demographic and clinical information.", {"entities": []}], [3223, "The knowledge of herbal use, side effects, and herb\u2013drug interactions was assessed based on patients' responses.", {"entities": [[29, 41, "Pathology"]]}], [3224, "Data were reported as prevalence (percent) of the occurrence.", {"entities": []}], [3225, "The prevalence of herbal supplement usage among CKD patients was 18.6% in this study.", {"entities": [[48, 51, "Pathology"]]}], [3226, "The majority of the study population were in the age range of 50\u201370 years (61.5%).", {"entities": [[62, 73, "Age"]]}], [3227, "Hypertension (34.36%) was the most common cause of kidney failure, while diabetes mellitus (21.80%) took the second place.", {"entities": [[0, 12, "Pathology"], [51, 65, "Pathology"], [73, 90, "Pathology"]]}], [3228, "The most frequently used unformulated medicinal herb was Echium (Echium amoenum) (15.27%), and the most commonly used formulated herbal products were anticough and mucolytic based on Thymus vulgaris (24.27%).", {"entities": [[57, 80, "Herb name"], [183, 198, "Herb name"]]}], [3229, "Eighteen patients (4.5%) used herbal mix with unknown entity and sources.", {"entities": []}], [3230, "In this study, ginseng has the most possible interactions with prescription drugs (18 interactions), while this interaction (with clopidogrel, warfarin, and heparin) was severe in six cases.", {"entities": [[15, 22, "Herb name"], [130, 141, "Drug"], [143, 151, "Drug"], [157, 164, "Drug"]]}], [3231, "The present study provided the information on possible herb\u2013drug interactions in CKD patients on herbal usage.", {"entities": [[81, 84, "Pathology"]]}], [3232, "Since the issue of using herbal products may be arbitrarily in the majority of the patients, and considering the importance of adverse reactions or major interactions, health-care providers should play an active role to identify these cases and inform the patients regarding herbal product safety, adverse effects, and possible interactions.", {"entities": [[127, 144, "Pathology"], [298, 313, "Pathology"]]}], [3233, "Chronic kidney disease (CKD) is a global public health problem with an increasing incidence and a lot of economic burden for treatment.", {"entities": [[0, 28, "Pathology"]]}], [3234, "Kidney failure may lead to a variety of complications such as cardiovascular disease, renal osteodystrophy, and renal anemia.", {"entities": [[0, 14, "Pathology"], [62, 84, "Pathology"], [86, 106, "Pathology"], [112, 124, "Pathology"]]}], [3235, "According to the National Kidney Foundation classification, end-stage renal disease (ESRD) is called when the glomerular filtration rate is <15 ml/min/1.73 m Complementary medicine is a combination of a variety of medical therapies that may be used alongside conventional medicine in the treatment of disease.", {"entities": [[60, 90, "Pathology"], [110, 136, "Parameter"], [140, 157, "Amount"]]}], [3236, "Alternative medicine is defined as the use of such alternative methods instead of conventional medicine.", {"entities": []}], [3237, "In majority of traditional medicine sources, CAM is classified as an alternative medicine system such as Ayurveda and Unani; mind\u2013body interventions such as yoga; biologically based therapies such as herbal and dietary supplement therapy; manipulative and body-based methods such as massage therapy; and energy therapy such as reiki.", {"entities": []}], [3238, "Biologically treatments are based mostly on natural products which are not proven.", {"entities": []}], [3239, "However, a large number of these therapies have been shown that they are not safe and can be harmful due to their interactions with other drugs which are used contemporaneously.", {"entities": []}], [3240, "[4] An important marker to assess the efficacy of selected treatment and also to predict undesirable outcomes risk is health-related quality of life.", {"entities": []}], [3241, "In the population of dialysis patients, impaired quality of life is well-defined, although data are far less in CKD patients.", {"entities": [[112, 115, "Pathology"]]}], [3242, "[1] Patients with CKD turn to use different modalities of CAM to treat a variety of complications because of chronic nature of the disease, and the poor quality of life, but yet there is a lack of data on CKD patients' usage of CAM.", {"entities": [[18, 21, "Pathology"], [205, 208, "Pathology"]]}], [3243, "[5] In general, physicians and health-care providers are not aware of using CAM modalities by the patients.", {"entities": []}], [3244, "[67] Only 50% of dialysis patients discussed about their CAM usage to physicians.", {"entities": []}], [3245, "[9] About 2.9% of the patients with CKD had a history of CAM usage before renal failure, whereas 25.2% of them had used CAM after disease occurred.", {"entities": [[36, 39, "Pathology"], [74, 87, "Pathology"]]}], [3246, "[7] A study showed that 63% of patients with CKD were willing to use some type of CAM therapies.", {"entities": [[45, 48, "Pathology"]]}], [3247, "[10] Another study demonstrated that CAM usage is common among dialysis (57%) and transplant patients (49%); while 28.1% of CKD patients used herbals after kidney failure, 13.2% were currently continuing herbals.", {"entities": [[124, 127, "Pathology"], [156, 170, "Pathology"]]}], [3248, "[9] The prevalence of medication interactions with CAM products (mainly healthy food) was reported to be about 40% for CKD patients using this type of CAM modality.", {"entities": [[119, 122, "Pathology"]]}], [3249, "[8] The high rate of herb\u2013drug interactions is reported, but yet the mechanism to explain them is unknown.", {"entities": []}], [3250, "The chance of herb\u2013drug interactions is more likely than drug\u2013drug interactions, and this is related to various bioactive entities provided in herbals.", {"entities": []}], [3251, "[11] Supplement usage can also affect CKD and transplant patients due to electrolyte changes, pharmacokinetic interactions, and effect on immune system or producing toxic metabolites.", {"entities": [[38, 41, "Pathology"]]}], [3252, "[12] CKD patients may use a vast of medications due to the chronic nature of their disease, while most patients do not inform health-care providers about their herbal product usage which leads to the risk of herbal's adverse effects and interactions.", {"entities": [[5, 8, "Pathology"], [217, 232, "Pathology"]]}], [3253, "[678] This clarifies the positive role of health-care team to alert the patients about these side effects and avoid life-threating interactions.", {"entities": [[93, 105, "Pathology"]]}], [3254, "A dynamic role of health-care team and specially nephrologists to educate patients taking CAM and supplements may help to prevent possible interactions and adverse effect.", {"entities": [[156, 170, "Pathology"]]}], [3255, "[1314] In this study, we planned to determine the usage prevalence of herbal products and herb\u2013drug interactions in patients with kidney diseases.", {"entities": []}], [3256, "These findings may highlight the main issues for health-care professionals to care about herbal product usage in CKD patients.", {"entities": [[113, 116, "Pathology"]]}], [3257, "A cross-sectional study was conducted in the nephrology units and clinics of Alzahra and Noor educational hospitals affiliated to Isfahan University of Medical Sciences in Isfahan, Iran, for a period of 8 months between February and October 2018.", {"entities": [[0, 23, "Study"]]}], [3258, "The determination of sample size was based on the previously reported prevalence of complementary medicine use in the literature;[15] accordingly, the study was continued to recruit 400 CKD and posttransplant patients who had been using medicinal herbs and herbal products during their kidney disease.", {"entities": [[182, 185, "Cohort"], [186, 189, "Pathology"]]}], [3259, "In this study, CKD was defined as having any kind of kidney diseases for more than 3 months,[16] and the time span of positive history of herbal medicine use was from the diagnosis of the patient's kidney disease.", {"entities": [[15, 18, "Study"]]}], [3260, "After obtaining institutional ethics committee approval (project number and ethics code: 294155) from the university research affairs, patients' demographic information (sex, age, educational status, occupational status, and marital status) were collected from patients' hospital records or by direct interviewing of patients and filled in a specially designed form for this study.", {"entities": []}], [3261, "The educational status was categorized as follows: illiterate, primary school education (school education till 8 years), high school education (12 years), postdiploma education (14 years), Master of Science (16 years), and PhD level.", {"entities": []}], [3262, "The occupational status had the following categorization: Without financial income (without job, homeworker, and student) and with financial income (recruitment job and retired).", {"entities": []}], [3263, "The occupational status was finally interpreted regarding financial income.", {"entities": []}], [3264, "Marital status was categorized as single or married.", {"entities": []}], [3265, "A 3-item newly researcher-designed checklist was applied.", {"entities": []}], [3266, "The first section consisted of the patients' demographic information, the second section was about disease-related information, including cause of renal failure, other comorbidities, and drug history in the past 2 months, while the third part consisted of herbal and supplemental usage by the patient, route of administration, how to advise it, where to buy from, and evaluation of herbal effects by the patient her- or himself.", {"entities": [[147, 160, "Pathology"]]}], [3267, "The first question to start interview was asked to clear if the patient had herbal usage or not.", {"entities": []}], [3268, "If the answer was yes, questions were continued to find the type of the herbs as well as other chemical medications which were being used in order to detect any possible drug\u2013herb interactions, according to the reliable references.", {"entities": []}], [3269, "[171819] The information on possible herb\u2013drug interactions were obtained from different references which are declared following each interaction [Table 1].", {"entities": []}], [3270, "Each interview took 10\u201320 min to complete.", {"entities": []}], [3271, "Possible herb-drug interactions among the study population *Total frequency of herb interaction\u201d shows the number of patients who used the herb and drug concomitantly in the study population, **The significance of drug-herb interactions is not classified in the relevant references, nor the literature; data in this column are presented according to the authors\u2019 interpretation.", {"entities": []}], [3272, "To determine the influence of age, gender, comorbidities, educational status, and occupational status on the tendency to herbal usage, the Chi-square test was utilized to assess the influence.", {"entities": []}], [3273, "P < 0.05 was considered statistically significant.", {"entities": []}], [3274, "A total of 2153 CKD and posttransplant patients have been interviewed upon study objectives; of these, 400 patients who declared to be CAM users were included.", {"entities": [[11, 15, "Cohort"], [16, 19, "Pathology"]]}], [3275, "Accordingly, the prevalence of herbal supplement use among the study patients was about 18.6%.", {"entities": []}], [3276, "This population consisted of 261 males and 139 females, with the majority in the age range of 50\u201370 years (61.5%).", {"entities": [[33, 38, "Sex"], [47, 54, "Sex"], [94, 105, "Age"]]}], [3277, "Regarding CAM nonusers, the majority were in the age group of 20\u201360 years with the male/female ratio of 73/27 percent.", {"entities": [[62, 73, "Age"], [83, 87, "Sex"], [88, 94, "Sex"]]}], [3278, "Table 2 shows the demographic characteristics of the study population.", {"entities": []}], [3279, "Regarding causes of renal failure, hypertension (34.4%) was the most common cause of failure, and diabetes mellitus (21.8%) was the second most.", {"entities": [[20, 33, "Pathology"], [35, 47, "Pathology"], [98, 115, "Pathology"]]}], [3280, "It is notable that 11.89% of the patients had hypertension and diabetes contemporaneously.", {"entities": [[46, 58, "Pathology"], [63, 89, "Pathology"]]}], [3281, "The others (13.23%) consisted of congenital kidney disease, polycystic kidney disease, drug-induced renal failure, and acute kidney injury.", {"entities": [[33, 58, "Pathology"], [60, 85, "Pathology"], [87, 113, "Pathology"], [119, 138, "Pathology"]]}], [3282, "As shown in Table 2, among demographic characteristics, age, sex, and the status of financial income were the influential parameters which determined the tendency of patients to herbal usage.", {"entities": []}], [3283, "With this regard, female patients more than 60 years old and patients with no financial income had more tendency to use herbal supplements.", {"entities": [[18, 24, "Sex"], [44, 52, "Age"]]}], [3284, "Demographic characteristics of the study population (n=2153) *Chi-square test was used to assess the influence of each parameter on the tendency to herbal usage, **The occupational status was interpreted regarding financial income: without financial income (without job, homeworker, and student) and with financial income (recruitment job and retired).", {"entities": [[53, 59, "Cohort"]]}], [3285, "CAM=Complementary and alternative medicine, mainly herbal products As illustrated in Table 3, the most frequently used unformulated herb was Echium (Echium amoenum) (15.27%), while the most commonly used formulated herbal products were anticough and mucolytic based on Thymus vulgaris (24.27%).", {"entities": [[141, 164, "Herb name"], [269, 284, "Herb name"]]}], [3286, "Top 10 formulated herbal products and unformulated medicinal herbs used by the study patients Eighteen patients used herbal mix with unknown sources involving that they did not know what kind of herb they were using; however, the most common reason they were using these unknown herbs was for controlling obesity (50%).", {"entities": [[94, 111, "Cohort"], [305, 312, "Pathology"]]}], [3287, "Other top most used herbs, whether formulated or unformulated herbal products, are depicted in Table 3.", {"entities": []}], [3288, "The most common reason for which these CKD patients used herbal products was for common cold and respiratory symptoms (32.58%), followed by 19.13% for gastrointestinal problems and 11.69% for kidney and urinary disorders.", {"entities": [[39, 42, "Pathology"], [88, 117, "Pathology"], [192, 220, "Pathology"]]}], [3289, "Herb\u2013drug interactions are depicted in Table 1.", {"entities": []}], [3290, "Ginseng was found to have most interactions with prescription drugs (18 interactions).", {"entities": [[0, 7, "Herb name"]]}], [3291, "The interaction was severe in 6 cases (with clopidogrel, warfarin, and heparin), while the most possible interaction mechanism was found to be the effect on coagulation process.", {"entities": [[44, 55, "Drug"], [57, 65, "Drug"], [71, 78, "Drug"]]}], [3292, "One important interaction was found between Hypericum perforatum and cyclosporine which may lead to reduce the effectiveness of cyclosporine.", {"entities": [[44, 64, "Herb name"], [69, 81, "Drug"], [128, 140, "Drug"]]}], [3293, "The majority of the patients identified as herbal users were in the age range of 50\u201370 years, and herbal usage prevalence was high among this age range.", {"entities": [[81, 92, "Age"]]}], [3294, "This finding was similar to Birdee et al.", {"entities": []}], [3295, "'s study,[25] which reported that the trend was more prevalent among middle-aged (50\u201364) patients compared to other age groups.", {"entities": [[82, 87, "Age"]]}], [3296, "The CKD occurrence in this age range was more due to diabetes and hypertension.", {"entities": [[4, 7, "Pathology"], [53, 61, "Pathology"], [66, 79, "Pathology"]]}], [3297, "Different factors may affect herbal supplement usage, such as age, sex, geographic region, duration of disease, race, and socioeconomic status.", {"entities": []}], [3298, "In our study, we evaluate the trend to herbal usage regarding age, gender, occupational status, marital status, educational status, duration of chronic disease, or years passed transplant.", {"entities": []}], [3299, "Demographic factors such as gender, age, and the status of financial income had a significant impact on herbal usage, while comorbidities and duration of disease were found to be the most highlighted reason for herbal supplement usage.", {"entities": []}], [3300, "Differences in the study population and their geographic location lead to different results achieved in studies on herbal usage.", {"entities": []}], [3301, "There is a fact that patients using CAM were hesitant to inform the physicians about it.", {"entities": []}], [3302, "Physicians' disapproval is one reason for CAM users not to disclose to the physicians about their CAM consumption.", {"entities": []}], [3303, "[2526] Iranian borage (E. amoenum) as unformulated and anticough syrups as formulated herbal products were the most used ones in our study population, while common cold and respiratory problems were determined to be the main indications for this trend.", {"entities": [[7, 34, "Herb name"]]}], [3304, "Iranian borage, native to the northern part of Iran and Caucasus, is one of the important medicinal herbs in Iranian traditional medicine mainly being used for variety of effects such as demulcent, anti-inflammatory, antioxidant, analgesic, and sedative, especially for treating common cold and anxiety.", {"entities": [[0, 14, "Herb name"], [109, 116, "Ethnic group"], [286, 290, "Pathology"], [295, 302, "Pathology"]]}], [3305, "This herb has no serious side effects in usual doses applied for its therapeutic effects.", {"entities": [[25, 37, "Pathology"]]}], [3306, "[27] In the study performed by Roozbeh et al.", {"entities": []}], [3307, "in 2013, Cichorium intybus was introduced as the most used herbal product for gastrointestinal disorders.", {"entities": [[9, 26, "Herb name"], [78, 104, "Pathology"]]}], [3308, "[14] Garlic was reported as the most commonly used herb in a Turkish study.", {"entities": [[5, 11, "Herb name"]]}], [3309, "[9] Panax ginseng appeared to have the most possible drug\u2013herb interactions mainly with anticoagulant agents.", {"entities": [[4, 17, "Herb name"]]}], [3310, "This herb is used mostly for boosting immune system as well as sexual power enhancement.", {"entities": []}], [3311, "The most serious possible interaction was between Panax ginseng and warfarin which is a powerful anticoagulant agent usually used after heart attack.", {"entities": [[50, 63, "Herb name"], [68, 76, "Drug"], [136, 148, "Pathology"]]}], [3312, "This interaction leads international normalized ratio (INR) to be reduced, and the possibility of coagulation may be increased in clinical setting.", {"entities": [[23, 59, "Parameter"]]}], [3313, "[28] In this study population, dangerous interactions found where the posttransplant patients take their immunosuppressive regimen and also use H. perforatum or Echinacea, which both finally could lead to kidney graft rejection.", {"entities": [[144, 157, "Herb name"], [161, 170, "Herb name"], [205, 227, "Pathology"]]}], [3314, "H. perforatum could inhibit the reuptake of several neurotransmitters.", {"entities": [[0, 13, "Herb name"], [32, 69, "Target"]]}], [3315, "In our study, Hypericum had shown a life-threatening interaction with cyclosporin, an immunosuppressive agent which uses after kidney transplant.", {"entities": [[14, 23, "Herb name"], [70, 81, "Drug"]]}], [3316, "This serious interaction decreases cyclosporine's serum level (with possible rejection in some cases) by inducing CYP3A4 enzyme.", {"entities": [[35, 47, "Drug"], [114, 120, "Target"]]}], [3317, "In the study performed by Borrelli and Izzo in 2009, the interaction between H. perforatum and cyclosporine was mentioned as the most well-documented herb\u2013drug interactions among patients of renal and liver transplant.", {"entities": [[77, 90, "Herb name"], [95, 107, "Drug"]]}], [3318, "[29] These interactions are common since CKD patients use many drugs for various conditions at the same time.", {"entities": [[41, 44, "Pathology"]]}], [3319, "The usage of herbal products could be harmful for CKD patients because of nephrotoxicity or changes in kidney hemodynamic.", {"entities": [[50, 53, "Pathology"], [74, 88, "Pathology"]]}], [3320, "Furthermore, electrolyte abnormalities by herbs could change the kidney performance.", {"entities": [[13, 38, "Pathology"]]}], [3321, "[1819] The fact that most patients do not inform health-care providers about their herbal product usage which leads to the risk of herbal's adverse effects and interactions.", {"entities": [[140, 155, "Pathology"]]}], [3322, "[678] Furthermore, a study by Kelak et al.", {"entities": []}], [3323, "in 2018 showed that the attitude of patients toward herbal drug usage is an important factor to inform the health-care team about their consumption.", {"entities": []}], [3324, "[30] This clarifies the positive role of health-care team to alert the patients about these side effects and avoid life-threating interactions.", {"entities": [[92, 104, "Pathology"]]}], [3325, "Our study has highlighted the main issues for health-care professionals to care about herbal product usage in CKD patients.", {"entities": [[110, 113, "Pathology"]]}], [3326, "More researches in other CKD and posttransplant populations may clarify more possible interactions between herbal products and prescribed medications.", {"entities": [[25, 28, "Pathology"]]}], [3327, "The present study provided useful information on possible herb\u2013drug interactions in CKD patients using medicinal herbs concomitant with conventional drug regimen.", {"entities": [[84, 87, "Pathology"]]}], [3328, "Ginseng was found to be the herb which may mostly have an interaction with prescribed medications.", {"entities": [[0, 7, "Herb name"]]}], [3329, "Age and educational status were determinative factors which may influence on herbal product usage.", {"entities": []}], [3330, "The majority of the patients were using herbal products to treat or relieve symptoms of common cold and respiratory disorders.", {"entities": [[95, 99, "Pathology"], [104, 125, "Pathology"]]}], [3331, "Due to the possibility of important interactions, health-care team should play an active role to inform the patient about herbal product safety, adverse effects, and possible interactions.", {"entities": [[145, 160, "Pathology"]]}], [3332, "Discussing about herbal usage by physicians to the CKD and post-transplant patients, need more encourage by health-care providers which can be achieved by more efficacious education on risks and benefits of herbal therapy.", {"entities": [[51, 54, "Pathology"]]}], [3333, "All authors contributed the idea of research, design of study, data analysis and manuscript preparation.", {"entities": []}], [3334, "Nil.", {"entities": []}], [3335, "There are no conflicts of interest.", {"entities": []}], [3336, "Liver toxicity during temozolomide chemotherapy caused by Chinese herbs Thomas Melchardt,1 Teresa Magnes,1 Lukas Weiss,1 Michael Grundbichler,1 Michael Strasser,2 Clemens Hufnagl,1 Martin Moik,1 Richard Greil,1 and Alexander Eglecorresponding author1 Author information Article notes Copyright and License information PMC Disclaimer Go to: Abstract Background  Complementary and alternative medicine is often used by patients with malignant glioma.", {"entities": [[0, 14, "Pathology"], [22, 47, "Drug"], [58, 65, "Ethnic group"], [431, 447, "Pathology"]]}], [3337, "Although several interactions of various alternative agents with chemotherapy are known, none has been described for temozolomide so far.", {"entities": [[117, 129, "Drug"]]}], [3338, "Case presentation  We report the case of severe liver toxicity with jaundice during radiochemotherapy with temozolomide likely due to interaction with a popular Chinese herbal formula after surgery for glioblastoma.", {"entities": [[0, 4, "Study"], [22, 37, "Study"], [41, 62, "Pathology"], [68, 76, "Pathology"], [107, 119, "Drug"], [161, 168, "Ethnic group"], [202, 214, "Pathology"]]}], [3339, "After cessation of the herbal formula as well as the chemotherapy liver enzymes slowly normalized.", {"entities": []}], [3340, "Due to tumor progression the patient was retreated with temozolomide for 5 cycles without toxicity.", {"entities": [[7, 12, "Pathology"], [56, 68, "Drug"], [69, 81, "Duration"]]}], [3341, "Because of further progression combination treatment of bevacizumab and irinotecan was started and again no liver toxicity was observed.", {"entities": [[56, 67, "Drug"], [72, 82, "Drug"], [108, 122, "Pathology"]]}], [3342, "Conclusions  We conclude that the observed toxicity with jaundice was probably caused by an interaction of this popular Chinese formula and temozolomide.", {"entities": [[43, 51, "Pathology"], [57, 65, "Pathology"], [120, 127, "Ethnic group"], [140, 152, "Drug"]]}], [3343, "This is the first report about a relevant interaction of temozolomide and any herbal formula.", {"entities": [[18, 24, "Study"], [57, 69, "Drug"]]}], [3344, "Keywords: Temozolomide, Chinese herbs, Interaction, Liver toxicity, Hepatitis Go to: Background  Complementary and alternative medicine (CAM) is frequently used by glioblastoma patients [1] but treating physicians are often left uninformed about its use.", {"entities": [[10, 22, "Drug"], [24, 31, "Ethnic group"], [52, 66, "Pathology"], [68, 77, "Pathology"], [164, 176, "Pathology"]]}], [3345, "These patients are potentially at increased risk for herb-drug interactions resulting in increased toxicity due to higher serum levels of cytostatics on the one hand or undertreatment due to decreased efficacy caused by lower serum levels on the other hand.", {"entities": [[138, 149, "Drug"]]}], [3346, "Go to: Case presentation  A 56 year old female Caucasian patient was diagnosed with a temporal-parietal glioblastoma WHO IV\u00b0 after further evaluation for cephalea.", {"entities": [[7, 11, "Study"], [28, 39, "Age"], [40, 46, "Sex"], [47, 56, "Ethnic group"], [84, 124, "Pathology"], [154, 162, "Pathology"]]}], [3347, "Complete resection was performed using 5-aminolevulinic acid guided surgery and postoperative magnetic resonance investigation showed a small rest tumor.", {"entities": [[39, 60, "Drug"], [147, 152, "Pathology"]]}], [3348, "The patient had a Karnofsky performance status scale of 90% after resection without neurological deficiencies and was referred to our department for further treatment with radiotherapy and temozolomide (TEM).", {"entities": [[84, 109, "Pathology"], [189, 201, "Drug"]]}], [3349, "Co-medication consisted of dexamethason 4 mg per day because of edema, pantoprazol, levetiracetam and mirtazapine because of depression.", {"entities": [[27, 39, "Drug"], [40, 44, "Amount"], [45, 52, "Frequency"], [64, 69, "Pathology"], [71, 82, "Drug"], [84, 97, "Drug"], [102, 113, "Drug"], [125, 135, "Pathology"]]}], [3350, "Further medical history consisted of hypertension and recurrent cutaneous herpes infections.", {"entities": [[37, 49, "Pathology"], [54, 91, "Pathology"]]}], [3351, "Adjuvant concomitant radiochemotherapy (RCT) was started with an absolute dose of 140 mg TEM per day 4 weeks after primary resection.", {"entities": [[82, 88, "Amount"], [89, 92, "Drug"], [93, 100, "Frequency"], [101, 108, "Duration"]]}], [3352, "Furthermore, prophylactic valaciclovir was prescribed.", {"entities": [[26, 38, "Drug"]]}], [3353, "Treatment was initially well tolerated and the steroid was tampered.", {"entities": [[43, 54, "Drug"]]}], [3354, "Unfortunately, TEM had to be stopped after 32 days of treatment and 24 fractions of radiotherapy because of grade II\u00b0 thrombopenia and increasing liver enzymes.", {"entities": [[15, 18, "Drug"], [43, 63, "Duration"], [108, 130, "Pathology"], [135, 159, "Pathology"]]}], [3355, "Mirtazapine, valaciclovir and pantoprazol were paused and radiotherapy was completed as planned after 30 fractions.", {"entities": [[0, 11, "Drug"], [13, 25, "Drug"], [30, 41, "Drug"]]}], [3356, "Because of further increasing liver enzymes and jaundice (bilirubin: 16.7 mg/dl; AST: 263 U/l; ALT: 585 U/l) the patient was hospitalized and underwent further evaluation including exclusion of viral hepatitis, Epstein-Barr virus or cytomegalovirus-infection, computed tomography scan as well as autoantibody screening to exclude an autoimmune hepatitis.", {"entities": [[19, 43, "Pathology"], [48, 56, "Pathology"], [58, 67, "Parameter"], [69, 79, "Amount"], [81, 84, "Parameter"], [86, 93, "Amount"], [95, 98, "Parameter"], [100, 107, "Amount"], [194, 209, "Pathology"], [211, 229, "Pathology"], [233, 258, "Pathology"], [333, 353, "Pathology"]]}], [3357, "Endoscopic retrograde endoscopy excluded pathology of the biliary or pancreatic ductal system.", {"entities": [[41, 93, "Pathology"]]}], [3358, "A negative herpes polymerase chain reaction ruled out systemic herpes infection and levetiracetam was reduced in the absence of seizures with the intention to reduce co-medications.", {"entities": [[54, 79, "Pathology"], [84, 97, "Drug"], [128, 136, "Pathology"]]}], [3359, "After repeated and detailed conversations the patient reported the use of Chinese herbs as a decoction twice daily for 2 weeks between the beginning of the RCT and the diagnosis of increasing liver enzymes.", {"entities": [[74, 81, "Ethnic group"], [93, 102, "Extraction process"], [103, 114, "Frequency"], [115, 126, "Duration"], [156, 159, "Study"], [181, 205, "Pathology"]]}], [3360, "Following the diagnosis of glioblastoma a general practitioner specialized in CAM recommended the use of a modified form of the Chinese herbal formula called Bu Zhong Yi Qi Wan (11 different herbs) compiled by a local pharmacy, which is commonly used in Chinese CAM.", {"entities": [[27, 39, "Pathology"], [128, 135, "Ethnic group"], [158, 197, "Herb name"]]}], [3361, "Four weeks after cessation of TEM and the Chinese herbs the liver enzymes started to decrease, but it took about 3 months to normalization of the bilirubin level (Figure 1).", {"entities": [[30, 33, "Drug"], [42, 49, "Ethnic group"], [113, 121, "Duration"], [146, 161, "Parameter"]]}], [3362, "An external file that holds a picture, illustration, etc.", {"entities": []}], [3363, "Object name is 1472-6882-14-115-1.jpg Figure 1  Course of liver enzymes during primary radiochemotherapy with temozolomide and re-exposition for 5 cycles after first diagnosis of glioblastoma.", {"entities": [[110, 122, "Drug"], [179, 191, "Pathology"]]}], [3364, "Unfortunately, a [18 F]-fluorethylenthyrosin positron emission tomography positive residual tumor was detected 2 months after the end of radiotherapy.", {"entities": [[92, 97, "Pathology"]]}], [3365, "Therefore, despite normalization of the liver parameters was still pending we decided to restart TEM after repeated briefing of the patient to omit any CAM, because we were convinced that this toxic hepatitis was primarily caused by the addition of this Chinese herbal formula.", {"entities": [[97, 100, "Drug"], [193, 208, "Pathology"], [254, 261, "Ethnic group"]]}], [3366, "Thus, TEM with an absolute dose of 250 mg per day for 5 days every 4 weeks was re-introduced, supportive medication with valaciclovir and 500 mg bi-daily levetiracetam remained unchanged.", {"entities": [[6, 9, "Drug"], [35, 41, "Amount"], [42, 49, "Frequency"], [50, 60, "Duration"], [61, 74, "Frequency"], [121, 133, "Drug"], [138, 144, "Amount"], [145, 153, "Frequency"], [154, 167, "Drug"]]}], [3367, "We continued treatment for 5 cycles of TEM without any increase of the liver parameters or any other toxicity except for mild cytopenia.", {"entities": [[23, 35, "Duration"], [39, 42, "Drug"], [121, 135, "Pathology"]]}], [3368, "Thereafter the patient did not want to continue treatment despite response, because she desired to undergo further complementary treatment.", {"entities": []}], [3369, "Unfortunately, 3 months after cessation of therapy symptomatic progression due to large edema was diagnosed and combination treatment of bevacizumab and irinotecan was initiated.", {"entities": [[15, 23, "Duration"], [82, 93, "Pathology"], [137, 148, "Drug"], [153, 163, "Drug"]]}], [3370, "No liver toxicity or any other severe side effect was observed after 3 months of treatment.", {"entities": [[3, 17, "Pathology"], [38, 49, "Pathology"], [69, 77, "Duration"]]}], [3371, "Go to: Conclusion  Liver toxicity is a known but very rare side effect of TEM [2].", {"entities": [[19, 33, "Pathology"], [59, 70, "Pathology"], [74, 77, "Drug"]]}], [3372, "Reexpositions to TEM in our patient showed that toxic hepatitis was not causally related to TEM treatment alone or caused by the combination with valaciclovir or levetiracetam.", {"entities": [[17, 20, "Drug"], [48, 63, "Pathology"], [92, 95, "Drug"], [146, 158, "Drug"], [162, 175, "Drug"]]}], [3373, "Thus, we conclude that the observed liver toxicity was caused by the concomitant intake of the popular Chinese herbal formula, Bu Zhong Yi Qi Wan, in combination with TEM.", {"entities": [[36, 50, "Pathology"], [103, 110, "Ethnic group"], [127, 145, "Herb name"], [167, 170, "Drug"]]}], [3374, "Some direct hepatotoxicity by the herbal formula itself seems unlikely, because in traditional Chinese medicine Bu Zhong Yi Qi Wan is thought to be protective to the liver, but cannot be completely ruled out.", {"entities": [[12, 26, "Pathology"], [95, 102, "Ethnic group"], [112, 130, "Herb name"]]}], [3375, "To exclude an unknown toxic product in the formula we asked for some remnants of this formula, but unfortunately it was totally used up by the patient.", {"entities": []}], [3376, "Furthermore, the Chinese herbs were recommended by a physician not involved in the management of the patient and probable not familiar with GBM.", {"entities": [[17, 24, "Ethnic group"], [140, 143, "Pathology"]]}], [3377, "Due to that we were primarily not aware of this possible interaction and this delayed clarification of this case.", {"entities": [[108, 112, "Study"]]}], [3378, "This herbal formula consists of several different herbs and the exact composition varies frequently in CAM.", {"entities": []}], [3379, "The detailed list of herbs taken by our patient is shown in Table 1 and comprises at least two herbs Huang Qi and Huang Qin with relevant cytochrome P450 3A4 (CYP3A4) inhibition [3,4].", {"entities": [[101, 109, "Herb name"], [114, 123, "Herb name"], [138, 166, "Target"]]}], [3380, "The effect and safety of temozolomide was not addressed in patients with severe hepatic impairment in clinical trials, but no dose adjustment is recommended in these patients according to manufacturer\u2019s labeling.", {"entities": [[25, 37, "Drug"], [73, 98, "Pathology"], [102, 117, "Study"]]}], [3381, "TEM is nonenzymatically converted to the active alkylating metabolite in all tissues and excreted with the urine, therefore CYP isoenzymes are thought to play a minor role up to now.", {"entities": [[0, 3, "Drug"], [124, 138, "Target"]]}], [3382, "Nevertheless, the distribution of single nucleotide polymorphisms of the CYP450 system is different in Chinese compared to other populations [5].", {"entities": [[73, 79, "Target"], [103, 110, "Ethnic group"]]}], [3383, "This would in part explain, why such an interaction is observed in Europe but not in China so far despite integration of TEM in the national insurance schedule in China [6].", {"entities": [[121, 124, "Drug"]]}], [3384, "Furthermore, Chinese medicine comprises hundreds if not thousands of preparations.", {"entities": [[13, 20, "Ethnic group"]]}], [3385, "It may well slip the attention of physicians if a broad background of intake is assumed.", {"entities": []}], [3386, "Table 1  Modified form of the Chinese herbal formula called Bu Zhong Yi Qi Wan Chinese name\tName and species Dang Shen\tRadix Codonopsitis Zhi Gan Cao\tRadix Glycyrrhizae Bai Zhun\tRhizoma Atractylodes macrocephala Huang Qi\tRadix Astragali Chen Pi\tCitrus reticulata Chai Hu\tRadix Bupleuri Sheng Ma\tRhizoma Cimicifugae Dang Gui\tRadix Angelicae sinensis Ge Gen\tRadix Puerariae Du Zhong\tCortex eucommiae Huang Qin\tRadix Scutellariae Open in a separate window  Furthermore, liver toxicity due to pantoprazol or mirtazapine seems unlikely, because they were started 6 weeks before the start of RCTX without any toxicity and the overall low incidence of liver toxicity of these drugs.", {"entities": [[30, 37, "Ethnic group"], [60, 78, "Herb name"], [109, 118, "Herb name"], [119, 137, "Herb name"], [138, 149, "Herb name"], [150, 168, "Herb name"], [169, 177, "Herb name"], [178, 211, "Herb name"], [212, 220, "Herb name"], [221, 236, "Herb name"], [237, 244, "Herb name"], [245, 262, "Herb name"], [263, 270, "Herb name"], [271, 285, "Herb name"], [286, 294, "Herb name"], [295, 314, "Herb name"], [315, 323, "Herb name"], [324, 348, "Herb name"], [349, 355, "Herb name"], [356, 371, "Herb name"], [372, 380, "Herb name"], [381, 397, "Herb name"], [398, 407, "Herb name"], [408, 426, "Herb name"], [467, 481, "Pathology"], [489, 500, "Drug"], [504, 515, "Drug"], [558, 565, "Duration"], [586, 590, "Study"], [645, 659, "Pathology"]]}], [3387, "Nevertheless, while the exact mechanism remains unclear, we still observed a severe liver toxicity with the combination of TEM and a popular Chinese formula, which is not reported up to now in the literature.", {"entities": [[84, 98, "Pathology"], [123, 126, "Drug"], [141, 148, "Ethnic group"]]}], [3388, "In face of the frequent use of CAM and Chinese herbs in patients with malignant glioma we want to alert cancer physicians about this possible side effect.", {"entities": [[39, 46, "Ethnic group"], [70, 86, "Pathology"], [104, 110, "Pathology"], [142, 153, "Pathology"]]}], [3389, "We hope to inspire the discussion about the safety of any herbal formulas in combination with cytotoxic therapies and encourage physicians to seek faithful conversations dealing with the use of CAM in cancer patients.", {"entities": [[201, 216, "Pathology"]]}], [3390, "There are several reports on the detrimental effects of CAM on the efficacy of chemotherapeutic agents such as St. John\u2019s wort with irinotecan or imatinib [7] or ascorbic acid and green tea with bortezomib [8,9] to name but a few.", {"entities": [[18, 25, "Study"], [79, 102, "Drug"], [111, 126, "Herb name"], [132, 142, "Drug"], [146, 154, "Drug"], [162, 175, "Herb name"], [180, 189, "Herb name"], [195, 205, "Drug"]]}], [3391, "Therefore, we think that a comprehensive management of our patients should also include education about the risk of interactions with herbal formulas.", {"entities": []}], [3392, "Pharmacodynamic interaction of warfarin with cranberry but not with garlic in healthy subjects M I Mohammed Abdul,1 X Jiang,1,5 K M Williams,2 R O Day,3,4 B D Roufogalis,1 W S Liauw,2 H Xu,1 and A J McLachlan1,5,* Author information Article notes Copyright and License information PMC Disclaimer Go to: Abstract Background and purpose:  Patients commonly take complementary medicines in conjunction with warfarin yet evidence supporting the safety or the risk of a herb\u2013drug interaction is lacking.", {"entities": [[31, 39, "Drug"], [45, 54, "Herb name"], [68, 74, "Herb name"], [78, 85, "Pathology"], [404, 412, "Drug"]]}], [3393, "The aim of this study was to investigate the possible impact of two commonly used herbal medicines, garlic and cranberry, on the pharmacokinetics and pharmacodynamics of warfarin in healthy male subjects.", {"entities": [[100, 106, "Herb name"], [111, 120, "Herb name"], [170, 178, "Drug"], [182, 189, "Pathology"], [190, 194, "Sex"]]}], [3394, "A single dose of 25\u2009mg warfarin was administered alone or after 2 weeks of pretreatment with either garlic or cranberry.", {"entities": [[0, 13, "Frequency"], [17, 22, "Amount"], [23, 31, "Drug"], [100, 106, "Herb name"], [110, 119, "Herb name"]]}], [3395, "Key results:  Cranberry significantly increased the area under the INR\u2013time curve by 30% when administered with warfarin compared with treatment with warfarin alone.", {"entities": [[14, 23, "Herb name"], [48, 81, "Parameter"], [112, 120, "Drug"], [150, 158, "Drug"]]}], [3396, "Cranberry did not alter S- or R-warfarin pharmacokinetics or plasma protein binding.", {"entities": [[0, 9, "Herb name"], [24, 40, "Drug"]]}], [3397, "Co-administration of garlic did not significantly alter warfarin pharmacokinetics or pharmacodynamics.", {"entities": [[21, 27, "Herb name"], [56, 64, "Drug"]]}], [3398, "Both herbal medicines showed some evidence of VKORC1 (not CYP2C9) genotype-dependent interactions with warfarin, which is worthy of further investigation.", {"entities": [[46, 52, "Target"], [58, 64, "Target"], [103, 111, "Drug"]]}], [3399, "Conclusions and implications:  Cranberry alters the pharmacodynamics of warfarin with the potential to increase its effects significantly.", {"entities": [[31, 40, "Herb name"], [72, 80, "Drug"]]}], [3400, "Co-administration of warfarin and cranberry requires careful monitoring.", {"entities": [[21, 29, "Drug"], [34, 43, "Herb name"]]}], [3401, "Keywords: warfarin, garlic, cranberry, herb\u2013drug interactions, pharmacokinetic, pharmacodynamic, platelet aggregation, genotype Go to: Introduction  There is increasing evidence and clinical concern regarding herb\u2013drug interactions (Mills et al., 2004).", {"entities": [[10, 18, "Drug"], [20, 26, "Herb name"], [28, 37, "Herb name"], [97, 117, "Parameter"]]}], [3402, "Warfarin has been implicated in almost 50 herb\u2013drug interactions (Ernst, 2002), and Ramsay et al.", {"entities": [[0, 8, "Drug"]]}], [3403, "(2005) found that 58% patients who take warfarin also consumed herbal medicines, which have the potential to interact with the anticoagulant.", {"entities": [[40, 48, "Drug"], [123, 140, "Drug"]]}], [3404, "Despite increased awareness of the potential of herb\u2013drug interactions, the lack of rigorous clinical evidence regarding the significance and possible mechanisms involved provides a challenge for clinicians and consumers to make rational decisions about the safe combination of complementary and conventional medicines.", {"entities": []}], [3405, "Garlic is one of the most widely used herbal medicines and is commonly ingested by people receiving warfarin (Ramsay et al., 2005).", {"entities": [[0, 6, "Herb name"], [100, 108, "Drug"]]}], [3406, "In vitro studies with the garlic constituent, allicin, and its degradation products indicate that these compounds possess antiplatelet effects (Lawson et al., 1992; Briggs et al., 2000).", {"entities": [[0, 16, "Study"], [26, 32, "Herb name"], [46, 53, "Herb name"]]}], [3407, "The combination of garlic and warfarin has been implicated in episodes of bleeding in patient case reports (Burnham, 1995; German et al., 1995).", {"entities": [[19, 25, "Herb name"], [30, 38, "Drug"], [94, 106, "Study"]]}], [3408, "There is conflicting evidence from in vitro (Ariga et al., 1981; Apitz-Castro et al., 1983) and in vivo (Piscitelli et al., 2002; Markowitz et al., 2003) studies concerning the effects of garlic formulations that release allicin on the inhibition of drug-metabolizing enzyme activity.", {"entities": [[35, 43, "Study"], [96, 103, "Study"], [188, 194, "Herb name"]]}], [3409, "Taken together, the evidence provides a basis for concern that allicin-containing garlic formulations have the potential to interact with warfarin through pharmacokinetic and/or pharmacodynamic mechanisms.", {"entities": [[63, 70, "Herb name"], [82, 88, "Herb name"], [138, 146, "Drug"]]}], [3410, "Cranberry is among the top 10 herbs sold in the United States (Blumenthal, 2003), where it is most commonly used to help prevent urinary tract infections (Bailey et al., 2007; Jepson and Craig, 2008).", {"entities": [[0, 9, "Herb name"], [129, 153, "Pathology"]]}], [3411, "However, there has been an increasing number of case reports of life-threatening interactions between cranberry and warfarin (Suvarna et al., 2003; ADRAC, 2004; Grant, 2004; MHRA and CSM, 2004; Rindone and Murphy, 2006).", {"entities": [[48, 60, "Study"], [102, 111, "Herb name"], [116, 124, "Drug"]]}], [3412, "One fatal case report described a patient with a significantly elevated international normalized ratio (INR) taking both warfarin and cranberry (Suvarna et al., 2003).", {"entities": [[10, 21, "Study"], [72, 108, "Parameter"], [121, 129, "Drug"], [134, 143, "Herb name"]]}], [3413, "Despite these data, cranberry and its constituents lack clear evidence to support a putative mechanism for an interaction with warfarin.", {"entities": [[20, 29, "Herb name"], [127, 135, "Drug"]]}], [3414, "Recent clinical studies, which have attempted to address the clinical significance of both pharmacokinetic and pharmacodynamic interactions between cranberry and warfarin, have been inconclusive (Greenblatt et al., 2006; Grenier et al., 2006; Li et al., 2006b; Lilja et al., 2007).", {"entities": [[7, 23, "Study"], [148, 157, "Herb name"], [162, 170, "Drug"]]}], [3415, "Genetic factors contribute to variability in warfarin response.", {"entities": [[45, 53, "Drug"]]}], [3416, "Differences in disposition of S-warfarin have been attributed to genetic variability of CYP2C9 (cytochrome P450 2C9; Kirchheiner and Brockmoller, 2005).", {"entities": [[30, 40, "Drug"], [88, 115, "Target"]]}], [3417, "Studies on the genetic variability in vitamin K epoxide reductase subunit 1 gene (VKORC1) reported it to be involved in warfarin resistance.", {"entities": [[38, 89, "Target"], [120, 128, "Drug"]]}], [3418, "Patients with the variant type VKORC1 (CT or TT alleles) have been found to require a significantly lower warfarin dose compared with people with wild-type VKORC1 (CC allele) (Li et al., 2006a).", {"entities": [[31, 56, "Target"], [106, 114, "Drug"], [156, 174, "Target"]]}], [3419, "However, there is no evidence regarding the possible impact of genotype on the interaction between warfarin and other drugs or herbal medicines.", {"entities": [[99, 107, "Drug"]]}], [3420, "The aim of this open-label randomized crossover study was to investigate the impact of two commonly used herbal medicines, garlic and cranberry, on the pharmacokinetics and pharmacodynamics (PKPD) of warfarin in healthy male subjects of known CYP2C9 and VKORC1 genotype.", {"entities": [[16, 53, "Study"], [123, 129, "Herb name"], [134, 143, "Herb name"], [200, 208, "Drug"], [212, 219, "Pathology"], [220, 224, "Sex"], [243, 249, "Target"], [254, 260, "Target"]]}], [3421, "This trial is registered with Australian New Zealand Clinical Trial Registry (ACTRN12607000054415), available at the URL \u2018http://www.anzctr.org.au/trial_view.aspx?ID=81647'.", {"entities": [[30, 40, "Ethnic group"]]}], [3422, "Go to: Methods Herbal medicines  Garlic (Allium sativum) product selection involved analyses of a number of commercially available enteric-coated products.", {"entities": [[33, 56, "Herb name"]]}], [3423, "Tablets were assessed for their allicin-releasing characteristics using the USP dissolution Apparatus II according to the USP method described in delayed-release garlic tablets with a modified tablet/solution ratio.", {"entities": [[32, 39, "Herb name"], [162, 168, "Herb name"]]}], [3424, "Garliplex 2000 enteric-coated garlic tablets, labelled as containing 2000\u2009mg of fresh garlic bulb equivalent to 3.71\u2009mg of allicin per tablet, were selected for use in this study.", {"entities": [[0, 44, "Herb name"], [69, 76, "Amount"], [86, 92, "Herb name"], [93, 97, "Herb part"], [112, 119, "Amount"], [123, 130, "Herb name"]]}], [3425, "Subjects received one tablet twice daily in accordance with dosage recommended by the German Commission E (Blumenthal and Busse, 1998).", {"entities": [[18, 28, "Herb name"], [29, 40, "Frequency"]]}], [3426, "Cranberry (Vaccinium macrocarpon) juice concentrate formulations from a number of commercial products were qualitatively analysed using thin layer chromatography to identify the presence and to compare relative intensities of mercetin, quercetin, kaempherol, anthocyanins and resverterol as a marker for their relative composition in different commercial products (Upton et al., 2002).", {"entities": [[0, 33, "Herb name"], [34, 51, "Extraction process"], [226, 234, "Herb name"], [236, 245, "Herb name"], [247, 257, "Herb name"], [259, 271, "Herb name"], [276, 287, "Herb name"]]}], [3427, "Quercetin and anthocyanins were found in all brands.", {"entities": [[0, 9, "Herb name"], [14, 26, "Herb name"]]}], [3428, "Subjects received two capsules three times daily, which is equivalent to 57\u2009g of fruit per day.", {"entities": [[18, 30, "Amount"], [31, 48, "Frequency"], [73, 77, "Amount"]]}], [3429, "Study design  The study was approved by the Human Research Ethics Committees at St Vincent's Hospital (Darlinghurst, NSW, Australia) and at the University of Sydney (Sydney, NSW, Australia).", {"entities": []}], [3430, "Subjects who gave written consent to participate in the study were selected after a full medical history, physical examination and clinical laboratory evaluation.", {"entities": []}], [3431, "Subjects with any medical condition that could alter warfarin effects, including any clotting disorders, hepatic dysfunction or platelet dysfunction were excluded from the study.", {"entities": [[53, 61, "Drug"], [85, 103, "Pathology"], [105, 124, "Pathology"], [128, 148, "Pathology"]]}], [3432, "Selected subjects were randomly allocated to three treatment groups to receive a single oral dose of 25\u2009mg rac-warfarin (Coumadin 5 \u00d7 5\u2009mg tablets) after an overnight fast (of at least 10\u2009h) either alone or after 2 weeks of pretreatment with either cranberry juice concentrate capsules or enteric-coated garlic tablets.", {"entities": [[101, 106, "Amount"], [107, 129, "Drug"], [134, 138, "Amount"], [249, 258, "Herb name"], [259, 276, "Extraction process"], [304, 310, "Herb name"]]}], [3433, "Dosing with herbal medicines continued for 7 days after warfarin administration until the last blood sample was drawn.", {"entities": [[39, 49, "Duration"], [56, 64, "Drug"]]}], [3434, "Subjects were subsequently crossed over to other treatments following a washout period of 2 weeks.", {"entities": [[90, 97, "Duration"]]}], [3435, "During the study, the subject's adherence to medicines, well-being and adverse events were assessed using regular mobile phone calls/text messages and e-mail contact.", {"entities": [[71, 85, "Pathology"]]}], [3436, "Blood samples were collected before (\u221248, \u221224 and 0\u2009h) and at 1, 2, 4, 8, 12, 24, 48, 72, 96, 120, 144 and 168\u2009h after warfarin administration into sodium citrate tubes for INR and clotting factor activity measurement, and EDTA tubes for HPLC analysis of warfarin enantiomers.", {"entities": [[119, 127, "Drug"], [173, 176, "Parameter"], [181, 205, "Parameter"], [255, 263, "Drug"]]}], [3437, "Plasma was harvested by centrifugation at 1500\u2009g for 15\u2009min and stored at \u221270\u2009\u00b0C until further analysed.", {"entities": []}], [3438, "CYP2C9 genotyping  EDTA blood samples were stored at \u221220\u2009\u00b0C until genomic DNA extraction (Qiagen, Doncaster, VIC, Australia).", {"entities": [[0, 6, "Target"]]}], [3439, "The polymorphisms of CYP2C9 were detected by PCR-based on restriction fragment length polymorphism (PCR-RFLP) analysis.", {"entities": [[21, 27, "Target"]]}], [3440, "The primers and restriction sites for CYP2C9*2 and CYP2C9*3 allele used in this study were as described by Sullivan-Klose et al.", {"entities": [[38, 46, "Target"], [51, 59, "Target"]]}], [3441, "(1996).", {"entities": []}], [3442, "VKORC1 genotyping  The VKORC1 1173T>C polymorphism was detected using allelic discrimination real-time PCR as described by Li et al.", {"entities": [[0, 6, "Target"], [23, 29, "Target"]]}], [3443, "(2006a) with minor modifications.", {"entities": []}], [3444, "TaqMan Universal PCR master mix was used with cycle conditions at 50\u2009\u00b0C for 2\u2009min, 95\u2009\u00b0C for 10\u2009min, followed by 50 cycles at 92\u2009\u00b0C for 15\u2009s, 60\u2009\u00b0C for 90\u2009s, and an end point plate read performed on an 7000 real-time PCR system (Applied Biosystems, Melbourne, VIC, Australia).", {"entities": []}], [3445, "Warfarin enantiomer concentration analysis  Plasma samples obtained from each of the blood samples taken at different times after warfarin dosing in each treatment were analysed using a validated chiral HPLC assay (Jiang et al., 2004).", {"entities": [[0, 8, "Drug"], [130, 138, "Drug"]]}], [3446, "In brief, plasma (0.5\u2009mL) was acidified with 0.5\u2009M sulphuric acid (350\u2009\u03bcL) and extracted with an organic solvent mixture (hexane: dichloromethane, 5:1 v/v).", {"entities": []}], [3447, "After roller bed mixing and centrifugation, the organic layer was removed, evaporated to dryness under nitrogen and reconstituted with acetonitrile (200\u2009\u03bcL) before HPLC analysis.", {"entities": []}], [3448, "The HPLC system comprised a silica-bonded \u03b2-cyclodextrin column with a mobile phase of acetonitrile/acetic acid/triethylamine (500:1.35:1.00, v/v/v) pumped at a flow rate of 1\u2009mL\u2009min\u22121 with fluorescence detection (excitation and emission wavelengths 310 and 400\u2009nm, respectively).", {"entities": []}], [3449, "Inter- and intra-assay precision and accuracy for warfarin enantiomers were within 15% when expressed as coefficient of variation.", {"entities": [[50, 58, "Drug"]]}], [3450, "Extraction recovery of both S-warfarin and R-warfarin was within the range of 86\u201393%.", {"entities": [[28, 38, "Drug"], [43, 53, "Drug"]]}], [3451, "The lower limit of quantification was 36.9\u2009ng\u2009mL\u22121 for both enantiomers of warfarin.", {"entities": [[75, 83, "Drug"]]}], [3452, "Plasma protein binding  The unbound fraction of S-warfarin and R-warfarin in plasma samples was investigated using a validated ultrafiltration method (Jiang et al., 2004) based on the assumption that warfarin fraction unbound concentration is independent of concentration up to 25\u2009\u03bcg\u2009mL\u22121 of rac-warfarin as demonstrated by (Banfield et al., 1983).", {"entities": [[48, 58, "Drug"], [63, 73, "Drug"], [200, 208, "Drug"], [292, 304, "Drug"]]}], [3453, "In brief, rac-warfarin (15\u2009\u03bcg) was added to plasma samples (1\u2009mL) from each subject obtained by pooling samples collected between 1 and 8, 12 and 72, and 96 and 168\u2009h after the warfarin dose.", {"entities": [[10, 22, "Drug"], [177, 185, "Drug"]]}], [3454, "Unbound warfarin enantiomers were separated by ultrafiltration (Centrifree YM-30; Millipore; Australia Pty Ltd, North Ryde, NSW, Australia) with centrifugation at 1500\u2009g for 20\u2009min.", {"entities": [[8, 16, "Drug"]]}], [3455, "Ultrafiltrate was assayed using the validated chiral HPLC assay described above.", {"entities": []}], [3456, "The unbound fraction was calculated as the ratio of ultrafiltrate to plasma warfarin enantiomer concentrations.", {"entities": [[76, 84, "Drug"]]}], [3457, "Platelet aggregation  Platelet aggregation was assessed on blood samples (within 3\u2009h of blood collection) collected 24\u2009h prior to warfarin administration (\u221224\u2009h) in each treatment period using a whole blood aggregometer (Chrono-par; Chrono-log Corp., Havertown, Pennsylvania, USA; Edward Keller Australia Pty Ltd, Hallam, VIC, Australia).", {"entities": [[0, 20, "Parameter"], [22, 42, "Parameter"], [130, 138, "Drug"]]}], [3458, "Briefly, whole blood (0.5\u2009mL) was diluted twofold with freshly prepared normal saline and incubated at 37\u2009\u00b0C for at least 6\u2009min.", {"entities": []}], [3459, "Platelet aggregation was induced by four different agents; ADP (10\u2009\u03bcM), arachidonic acid (0.5\u2009mM), collagen (2\u2009\u03bcg\u2009mL\u22121) and ristocetin (1\u2009mg\u2009mL\u22121).", {"entities": [[0, 20, "Parameter"]]}], [3460, "A change in impedance (\u03a9) was recorded for at least 6\u2009min.", {"entities": []}], [3461, "International normalized ratio  International normalized ratio was measured at each blood sampling time before and after warfarin dosing using a BFT II analyser.", {"entities": [[0, 30, "Parameter"], [32, 62, "Parameter"], [121, 129, "Drug"]]}], [3462, "Briefly, plasma (50\u2009\u03bcL) was incubated (1\u2009min, 37\u2009\u00b0C) in a cuvette, to which human thromboplastin reagent (100\u2009\u03bcL, thromborel S) was added.", {"entities": []}], [3463, "INR was calculated and displayed as a function of time taken for a change in impendence.", {"entities": [[0, 3, "Parameter"]]}], [3464, "Factor II, Factor VII and Factor X activity  The activity of the clotting Factor II, Factor VII and Factor X was measured in pooled plasma samples obtained over the collection periods from \u221248 to 0, 1 to 12, 24 to 72 and 96 to 168\u2009h after warfarin dosing either alone or after pretreatment with cranberry juice extract.", {"entities": [[0, 9, "Parameter"], [11, 21, "Parameter"], [26, 43, "Parameter"], [45, 83, "Parameter"], [85, 95, "Parameter"], [100, 108, "Parameter"], [239, 247, "Drug"], [295, 304, "Herb name"], [305, 318, "Extraction process"]]}], [3465, "Clotting factor activity was assessed using the BFT II analyser.", {"entities": [[0, 24, "Parameter"]]}], [3466, "In brief, clotting time of the diluted pooled plasma sample (1:20) was measured following the addition of factor-deficient plasma.", {"entities": [[10, 23, "Parameter"]]}], [3467, "Percentage factor activity for each sample was obtained from a standard curve constructed using different dilutions of standard human plasma of known factor activity and clotting time.", {"entities": [[170, 183, "Parameter"]]}], [3468, "Control plasma of known activity for all factors was used to establish the accuracy of the method, which was found to be within 2% of the nominal value.", {"entities": []}], [3469, "Data analysis  The pharmacodynamic response to warfarin was assessed using the area under the international normalized ratio\u2013time curve (AUCINR) calculated using the trapezoidal rule, INR at baseline (INR0) before warfarin administration and maximum observed INR (INRmax) after warfarin administration.", {"entities": [[47, 55, "Drug"], [79, 144, "Parameter"], [184, 206, "Parameter"], [214, 222, "Drug"], [242, 271, "Parameter"], [278, 286, "Drug"]]}], [3470, "Clotting factor activities are presented as the percentage decrease in activity from baseline for each pooled sample in different treatment periods.", {"entities": [[0, 26, "Parameter"]]}], [3471, "The pharmacokinetic parameters for the warfarin enantiomers were estimated using both non-compartmental and population PKPD modelling methods.", {"entities": [[39, 47, "Drug"]]}], [3472, "The elimination rate constant (kel) was obtained from the slope of the terminal portion of the logarithmic concentration\u2013time curve for S-warfarin and R-warfarin.", {"entities": [[0, 35, "Parameter"], [136, 146, "Drug"], [151, 161, "Drug"]]}], [3473, "The half-life was calculated as ln\u20092/kel, the apparent clearance (CL/F) as dose/AUC0\u2212\u221e and the apparent volume of distribution (V/F) as CL/kel.", {"entities": [[4, 13, "Parameter"], [66, 70, "Parameter"], [80, 86, "Parameter"], [136, 142, "Parameter"]]}], [3474, "The maximum concentration (Cmax) and the time it occurred (tmax) were determined by observation.", {"entities": [[0, 32, "Parameter"], [59, 63, "Parameter"]]}], [3475, "To elucidate the mechanism of the herb\u2013drug interaction further, pharmacokinetic and pharmacodynamic data from each arm of the study were analysed using the nonlinear mixed-effects modelling programme (NONMEM VI), using the first-order conditional estimation method with interaction.", {"entities": []}], [3476, "The modelling approach used in this study has been described by Jiang et al.", {"entities": []}], [3477, "(2006).", {"entities": []}], [3478, "In brief, a two-compartment pharmacokinetic model was used to describe S-warfarin concentration\u2013time data and an indirect pharmacodynamic model described the relationship between percentage of prothrombin complex activity (PCA; which was derived from the INR data in this study) and S-warfarin concentration.", {"entities": [[71, 81, "Drug"], [193, 226, "Parameter"], [255, 258, "Parameter"], [283, 293, "Drug"]]}], [3479, "The development and evaluation of this model has been described previously (Jiang et al., 2006).", {"entities": []}], [3480, "Herbal medicine treatment was evaluated as a possible influential covariate on both pharmacokinetic and pharmacodynamic parameters.", {"entities": []}], [3481, "Materials  Garliplex 2000 enteric-coated garlic tablets (Golden Glow Pty Ltd, VA, QLD, Australia), GNC cranberry juice concentrate (General Nutrition Company, Melbourne, VIC, Australia) and rac-warfarin (Coumadin 5 \u00d7 5\u2009mg tablets; Boots HealthCare Australia Pty Ltd, North Ryde, NSW, Australia).", {"entities": [[41, 47, "Herb name"], [103, 112, "Herb name"], [113, 130, "Extraction process"], [190, 202, "Drug"], [204, 212, "Drug"], [217, 229, "Amount"]]}], [3482, "TaqMan Universal PCR master mix (Applied Biosystems); silica-bonded \u03b2-cyclodextrin column (Cyclobond I 2000; Astec, Alltech Associates Australia Pty Ltd, Baulkham Hills, NSW, Australia).", {"entities": []}], [3483, "BFT II analyzer, thromborel S and factor-deficient and control plasma (Dade Behring Diagnostics Pty Ltd, Lane Cove, NSW, Australia).", {"entities": []}], [3484, "Statistical analysis  Preliminary analyses indicated that 12 subjects in a crossover study provides an 80% chance of detecting a 20% difference in the AUC0\u2212\u221e of S-warfarin at P<0.05 level of significance, which is in agreement with our previous study (Jiang et al., 2004).", {"entities": [[58, 69, "Cohort"], [73, 90, "Study"], [151, 157, "Parameter"], [161, 171, "Drug"]]}], [3485, "A difference of greater than 20% was considered to be clinically significant.", {"entities": []}], [3486, "Pharmacokinetic and pharmacodynamic parameters calculated after warfarin alone (control) and after warfarin with herbal medicines (intervention) were logarithmically transformed and reported as the geometric mean ratio (intervention to control) and 90% confidence interval (CI) of the ratio.", {"entities": [[64, 72, "Drug"], [99, 107, "Drug"]]}], [3487, "If 90% CI of ratios fell within the range of 0.8\u20131.25, then the variation in the parameter was considered to be clinically insignificant.", {"entities": []}], [3488, "The residual mean square error used to calculate the 90% CI for each logarithmically transformed parameter for each treatment was obtained using ANOVA (Stata 5.0; Stata Corp., College Station, Texas, USA) with nested parameters in treatment and sequence order.", {"entities": []}], [3489, "Go to: Results  Twenty-three subjects were screened for entry into the study and of these seven subjects did not meet the entry criteria.", {"entities": [[16, 37, "Cohort"]]}], [3490, "Sixteen subjects were randomized to treatment, two were lost to follow-up and two chose to discontinue.", {"entities": [[0, 16, "Cohort"]]}], [3491, "Twelve subjects completed the study (four subjects per treatment arm).", {"entities": [[0, 15, "Cohort"]]}], [3492, "The mean (and range) age, weight and height of the subjects were 23 years (20\u201335 years), 68\u2009kg (54\u201381\u2009kg) and 1.75\u2009m (1.65\u20131.85\u2009m), respectively.", {"entities": [[65, 87, "Age"]]}], [3493, "Seven subjects were Caucasians and five subjects were Asian (including three people of Indian origin).", {"entities": [[0, 14, "Cohort"], [20, 30, "Ethnic group"], [35, 48, "Cohort"], [54, 59, "Ethnic group"], [71, 83, "Cohort"], [87, 93, "Ethnic group"]]}], [3494, "Nine subjects were of the CYP2C9*1/*1 genotype and three were of the CYP2C9*1/*2 genotype.", {"entities": [[0, 13, "Cohort"], [26, 37, "Target"], [69, 80, "Target"]]}], [3495, "Four subjects were VKORC1 wild-type (CC) and eight subjects carried variant VKORC1 alleles including six with CT and two with TT alleles.", {"entities": [[0, 13, "Cohort"], [19, 40, "Target"], [45, 59, "Cohort"], [76, 90, "Target"]]}], [3496, "No subjects experienced major bleeding or INR readings above 4.", {"entities": [[30, 38, "Pathology"], [42, 45, "Parameter"]]}], [3497, "Two subjects in the cranberry\u2013warfarin treatment arm experienced rashes and one subject had evidence of nasal bleeding (presence of dried blood in his nose) at approximately 72\u2009h after warfarin treatment.", {"entities": [[0, 12, "Cohort"], [20, 29, "Herb name"], [30, 38, "Drug"], [65, 71, "Pathology"], [76, 87, "Cohort"], [104, 118, "Pathology"], [185, 193, "Drug"]]}], [3498, "Subjects on garlic reported the characteristic garlic odour and one subject complained of lip dryness.", {"entities": [[12, 18, "Herb name"], [47, 53, "Herb name"], [90, 101, "Pathology"]]}], [3499, "No adverse events were reported with warfarin-alone treatment.", {"entities": [[3, 17, "Pathology"], [37, 45, "Drug"]]}], [3500, "Pharmacodynamic end points  Figure 1 shows the INR\u2013time profile after warfarin dosing either alone or following pretreatment with cranberry or garlic.", {"entities": [[47, 50, "Parameter"], [70, 78, "Drug"], [130, 139, "Herb name"], [143, 149, "Herb name"]]}], [3501, "Neither garlic nor cranberry pretreatment affected the baseline INR, suggesting that these herbal medicines do not have a significant independent effect on the clotting system (Table 1).", {"entities": [[8, 14, "Herb name"], [19, 28, "Herb name"], [64, 67, "Parameter"], [160, 175, "Target"]]}], [3502, "An external file that holds a picture, illustration, etc.", {"entities": []}], [3503, "Object name is bjp2008210f1.jpg Figure 1  International normalized ratio of prothrombin time (INR) vs time profile (n=12) after a single oral dose of warfarin (25\u2009mg) alone, and after multiple dose of cranberry juice concentrate capsules and after multiple dose of enteric-coated garlic tablets.", {"entities": [[42, 98, "Parameter"], [150, 158, "Drug"], [160, 165, "Amount"], [201, 210, "Herb name"], [211, 228, "Extraction process"], [280, 286, "Herb name"]]}], [3504, "*Statistically and clinically significant difference.", {"entities": []}], [3505, "Cranberry juice concentrate pretreatment significantly increased the mean AUCINR by approximately 30% (Table 1).", {"entities": [[0, 9, "Herb name"], [10, 27, "Extraction process"], [74, 80, "Parameter"]]}], [3506, "Moreover, the majority of the subjects displayed an increase in AUCINR in response to warfarin after cranberry pretreatment (Figure 2).", {"entities": [[64, 70, "Parameter"], [86, 94, "Drug"], [101, 110, "Herb name"]]}], [3507, "There was a trend towards a greater decrease in the activity of clotting Factor II, Factor VII and Factor X when warfarin was co-administered with cranberry (Figures 3a\u2013c).", {"entities": [[64, 82, "Target"], [84, 94, "Target"], [99, 107, "Target"], [113, 121, "Drug"], [147, 156, "Herb name"]]}], [3508, "However, this did not reach statistical significance (data not shown).", {"entities": []}], [3509, "Co-administration of garlic and warfarin did not significantly affect AUCINR (Table 1).", {"entities": [[21, 27, "Herb name"], [32, 40, "Drug"], [70, 76, "Parameter"]]}], [3510, "Furthermore, 2 weeks of pretreatment with garlic or cranberry had no effect on platelet aggregation.", {"entities": [[13, 20, "Duration"], [42, 48, "Herb name"], [52, 61, "Herb name"], [79, 99, "Parameter"]]}], [3511, "An external file that holds a picture, illustration, etc.", {"entities": []}], [3512, "Object name is bjp2008210f2.jpg Figure 2  Individual area under the international normalized ratio (INR)\u2013time curve (AUCINR) of subjects receiving warfarin alone or after pretreatment with cranberry.", {"entities": [[53, 124, "Parameter"], [147, 155, "Drug"], [189, 198, "Herb name"]]}], [3513, "A majority of subjects showed a tendency towards an increase in AUCINR following cranberry and warfarin treatment in comparison with warfarin alone.", {"entities": [[64, 70, "Parameter"], [81, 90, "Herb name"], [95, 103, "Drug"], [133, 141, "Drug"]]}], [3514, "However, two subjects exhibited a decrease in AUCINR.", {"entities": [[9, 21, "Cohort"], [46, 52, "Parameter"]]}], [3515, "An external file that holds a picture, illustration, etc.", {"entities": []}], [3516, "Object name is bjp2008210f3.jpg Figure 3  Percentage clotting activity vs midpoint time profiles for (a) Factor II, (b) Factor VII and (c) Factor X during warfarin treatment alone or after cranberry pretreatment.", {"entities": [[53, 70, "Parameter"], [105, 115, "Target"], [120, 130, "Target"], [139, 147, "Target"], [155, 163, "Drug"], [189, 198, "Herb name"]]}], [3517, "Mean and s.d.", {"entities": []}], [3518, "(error bars) are presented.", {"entities": []}], [3519, "Pharmacokinetic end points  The plasma concentration\u2013time profiles of S-warfarin or R-warfarin were unaltered when rac-warfarin was co-administered with either cranberry juice concentrate or garlic (Figures 4a and b; Table 2).", {"entities": [[70, 80, "Drug"], [84, 94, "Drug"], [115, 127, "Drug"], [160, 169, "Herb name"], [170, 187, "Extraction process"], [191, 197, "Herb name"]]}], [3520, "Plasma unbound fraction of warfarin enantiomers was not affected by concomitant administration of garlic or cranberry juice concentrate (Table 2).", {"entities": [[27, 35, "Drug"], [98, 104, "Herb name"], [108, 117, "Herb name"], [118, 135, "Extraction process"]]}], [3521, "An external file that holds a picture, illustration, etc.", {"entities": []}], [3522, "Object name is bjp2008210f4.jpg Figure 4  Plasma concentration\u2013time profile of (a) S-warfarin and (b) R-warfarin after a single oral dose of warfarin (25\u2009mg) alone, or after multiple doses of cranberry juice concentrate capsules given along with single dose of warfarin and after multiple doses of enteric-coated garlic tablets.", {"entities": [[83, 93, "Drug"], [102, 112, "Drug"], [141, 149, "Drug"], [151, 156, "Amount"], [192, 201, "Herb name"], [202, 219, "Extraction process"], [261, 269, "Drug"], [313, 319, "Herb name"]]}], [3523, "Table 2  Pharmacokinetic parameters of S-warfarin and R-warfarin  \tMean (95% CI)\tGeometric mean ratio (90% CI)  \tWarfarin only\tWarfarin and cranberry\tWarfarin and garlic\tWarfarin and cranberry/warfarin only\tWarfarin and garlic/warfarin only S-warfarin \u2003tmax (h)\t1.4 (1.1\u20131.6)\t1.9 (1.1\u20132.7)\t1.3 (1.1\u20131.6)\tNA\tNA \u2003Cmax (\u03bcg\u2009mL\u22121)\t1.8 (1.7\u20131.9)\t1.7 (1.5\u20132.0)\t1.9 (1.5\u20132.2)\t0.94 (0.67\u20131.29)\t1.06 (0.77\u20131.47) \u2003t1/2 (h)\t38.6 (35.7\u201341.5)\t34.9 (31.0\u201338.8)\t41.2 (35.1\u201347.3)\t0.94 (0.79\u20131.12)\t0.99 (0.83\u20131.18) \u2003AUC (\u03bcg\u2009mL\u22121\u2009h)\t60.3 (54.5\u201366.1)\t63.0 (57.3\u201368.8)\t65.5 (55.3\u201375.6)\t1.04 (0.94\u20131.67)\t1.06 (0.95\u20131.19) \u2003CL/F (mL\u2009h\u22121)\t213 (193\u2013232)\t204 (183\u2013224)\t202 (175\u2013229)\t0.89 (0.80\u20130.99)\t1.05 (0.94\u20131.17) \u2003Fraction unbound (fu)\t0.010 (0.007\u20130.013)\t0.010 (0.007\u20130.014)\t0.011 (0.008\u20130.014)\t1.00 (0.75\u20131.25)\t1.12 (0.39\u20131.84)  \t \t \t \t \t  R-warfarin \u2003tmax (h)\t1.4 (1.1\u20131.6)\t1.9 (1.1\u20132.7)\t1.8 (0.7\u20132.9)\tNA\tNA \u2003Cmax (\u03bcg\u2009mL\u22121)\t1.8 (1.7\u20132.0)\t1.7 (1.5\u20131.9)\t1.9 (1.5\u20132.2)\t0.90 (0.67\u20131.21)\t1.02 (0.8\u20131.4) \u2003t1/2 (h)\t55.6 (46.2\u201365.0)\t47.7 (41.5\u201353.9)\t52.6 (47.4\u201357.9)\t0.93 (0.80\u20131.08)\t0.98 (0.84\u20131.14) \u2003AUC (\u03bcg\u2009mL\u22121\u2009h)\t108.7 (90.0\u2013127.3)\t105.8 (91.7\u2013119.9)\t105.0 (96.3\u2013113.7)\t1.0 (0.9\u20131.1)\t0.99 (0.87\u20131.13) \u2003CL/F (mL\u2009h\u22121)\t123 (106\u2013140)\t124 (109\u2013139)\t121 (112\u2013131)\t0.87 (0.75\u20130.99)\t0.96 (0.84\u20131.11) \u2003Fraction unbound (fu)\t0.006 (0.004\u20130.007)\t0.005 (0.004\u20130.007)\t0.006 (0.004\u20130.007)\t0.95 (0.72\u20131.18)\t1.04 (0.80\u20131.29) Open in a separate window Abbreviations: AUC, area under the plasma concentration\u2013time curve; CI, confidence interval; CL, clearance; CL/F, apparent clearance; Cmax, maximum concentration; F, bioavailability; NA, not applicable; tmax, time to Cmax.", {"entities": [[39, 49, "Drug"], [54, 64, "Drug"], [113, 121, "Drug"], [127, 135, "Drug"], [140, 149, "Herb name"], [150, 158, "Drug"], [163, 169, "Herb name"], [170, 178, "Drug"], [183, 192, "Herb name"], [193, 201, "Drug"], [207, 215, "Drug"], [220, 226, "Herb name"], [227, 235, "Drug"], [241, 251, "Drug"], [253, 257, "Parameter"], [311, 315, "Parameter"], [498, 501, "Parameter"], [600, 604, "Parameter"], [819, 829, "Drug"], [831, 835, "Parameter"], [889, 893, "Parameter"], [979, 983, "Parameter"], [1074, 1077, "Parameter"], [1179, 1183, "Parameter"], [1427, 1478, "Parameter"], [1505, 1518, "Parameter"], [1520, 1544, "Parameter"], [1546, 1573, "Parameter"], [1575, 1593, "Parameter"], [1615, 1633, "Parameter"]]}], [3524, "Pharmacokinetic\u2013pharmacodynamic modelling  The population PKPD parameter estimates for warfarin are presented in the Table 3.", {"entities": [[87, 95, "Drug"]]}], [3525, "The NONMEM analysis confirmed the lack of an effect of herbal medicine treatment on pharmacokinetic parameters and highlighted a significant effect of cranberry treatment on warfarin pharmacodynamic parameters.", {"entities": [[151, 160, "Herb name"], [174, 182, "Drug"]]}], [3526, "The PKPD model displayed a significantly lower NONMEN-derived objective function (\u0394OFV=\u22126.765) when cranberry treatment was included as covariate on S-warfarin EC50.", {"entities": [[100, 109, "Herb name"], [149, 159, "Drug"], [160, 164, "Parameter"]]}], [3527, "The mean ratio of S-warfarin EC50 (90% CI; n=12) for cranberry vs control was 0.85 (0.77\u20130.94) indicating that treatment with cranberry juice concentrate significantly increased the sensitivity of S-warfarin, reflecting a lower EC50 value for S-warfarin.", {"entities": [[18, 28, "Drug"], [29, 33, "Parameter"], [53, 62, "Herb name"], [126, 135, "Herb name"], [136, 153, "Extraction process"], [197, 207, "Drug"], [228, 232, "Parameter"], [243, 253, "Drug"]]}], [3528, "Using the final PKPD model, it was possible to generate posterior Bayesian estimates of S-warfarin EC50 (presented as mean\u00b1s.d., n=12), which were 443\u00b1212\u2009ng\u2009mL\u22121 in subjects receiving warfarin only, 376\u00b1184\u2009ng\u2009mL\u22121 when warfarin was co-administered with cranberry and 486\u00b1275\u2009ng\u2009mL\u22121 during garlic co-administration.", {"entities": [[88, 98, "Drug"], [99, 103, "Parameter"], [185, 193, "Drug"], [221, 229, "Drug"], [255, 264, "Herb name"], [292, 298, "Herb name"]]}], [3529, "Table 3  Population pharmacokinetic and pharmacodynamic parameter estimates derived from the combined data from all treatment arms Parameter\tEstimates\tBetween-subject variability (CV %)\tBetween-occasion variability (CV %)  \tStructural model ka (h\u22121)\t3.15 (fixed)\t59% (fixed)\t\u2014 CL/F (mL\u2009h\u22121)\t208\t13%\t10% VC/F (mL)\t6440\t15%\t14% Q/F (mL\u2009h\u22121)\t849\t\u2014\t\u2014 VP/F (mL)\t3120\t\u2014\t\u2014 t1/2,PCA (h)\t16\t\u2014\t\u2014 EC50,S (ng\u2009mL\u22121)\t397\t52%\t21% PCA0 (%)\t89\t10%\t\u2014 aRatio for cranberry on EC50,S\t0.85\t\u2014\t\u2014 aRatio for garlic on EC50,S\t1.04\t\u2014\t\u2014  \t \t \t  Residual variability\t\u03c3exp, S-warfarin (CV %)\t\u03c3add, S-warfarin (s.d.)", {"entities": [[277, 281, "Parameter"], [444, 453, "Herb name"], [484, 490, "Herb name"], [545, 555, "Drug"], [569, 579, "Drug"]]}], [3530, "(ng\u2009mL\u22121)\t\u03c3add, PCA (s.d.)", {"entities": []}], [3531, "(%)  \t15%\t6\t7% Open in a separate window Abbreviations: CL, clearance; CL/F, apparent clearance; CV, coefficient of variation; EC50,S, concentration of S-warfarin that produces 50% inhibition of PCA; F, bioavailability; ka, absorption rate constant; PCA, prothrombin complex activity; PCA0, PCA in the absence of warfarin; Q, distributional clearance between the compartments; t1/2,PCA, half-life of prothrombin complex activity; VC, volume of distribution in central compartment; VP, volume of distribution in peripheral compartment; \u03c3add, PCA, variance for PCA residual variability of additive model; \u03c3add, S-warfarin, variance for S-warfarin residual variability of additive model; \u03c3exp, S-warfarin, variance for S-warfarin residual variability of exponential model.", {"entities": [[56, 69, "Parameter"], [71, 95, "Parameter"], [127, 198, "Parameter"], [200, 218, "Parameter"], [220, 248, "Parameter"], [250, 283, "Parameter"], [285, 321, "Parameter"], [323, 375, "Parameter"], [377, 428, "Parameter"], [430, 479, "Parameter"], [481, 533, "Parameter"], [609, 619, "Drug"], [634, 644, "Drug"], [691, 701, "Drug"], [716, 726, "Drug"]]}], [3532, "The impact of herbal medicine treatment was evaluated as a ratio of the treatment to control on specific parameters (e.g., EC50,S); \u2014, not evaluated.", {"entities": []}], [3533, "aGeometric mean ratio intervention to control.", {"entities": []}], [3534, "Impact of CYP2C9 and VKORC1 genotype  Subjects with the CT and TT allele for the VKORC1 gene exhibited significantly lower S-warfarin EC50 values (derived from posterior Bayesian estimates) compared with people with the CC genotype when warfarin was administered alone or in combination with either cranberry or garlic (Table 4).", {"entities": [[10, 16, "Target"], [21, 27, "Target"], [56, 72, "Target"], [81, 87, "Target"], [123, 133, "Drug"], [134, 145, "Parameter"], [220, 231, "Target"], [237, 245, "Drug"], [299, 308, "Herb name"], [312, 318, "Herb name"]]}], [3535, "Subject numbers are smaller but it is apparent that people with the CT and TT genotypes had a significant reduction in S-warfarin EC50 when warfarin was co-administered with cranberry juice extract but no effect was noted during garlic treatment compared with warfarin only (genomic mean ratios).", {"entities": [[68, 87, "Target"], [119, 129, "Drug"], [130, 134, "Parameter"], [140, 148, "Drug"], [174, 183, "Herb name"], [184, 197, "Extraction process"], [229, 235, "Herb name"], [260, 268, "Drug"]]}], [3536, "In contrast, subjects with the VKORC1 wild-type genotype showed an increase in the S-warfarin EC50 when warfarin was administered with garlic (Table 4).", {"entities": [[31, 56, "Target"], [83, 93, "Drug"], [94, 98, "Parameter"], [104, 112, "Drug"], [135, 141, "Herb name"]]}], [3537, "Table 4  EC50 of S-warfarin and VKORC1 genotype  \tEC50 (95% CI)\tGeometric mean ratio (90% CI)  \tWarfarin only\tWarfarin and cranberry\tWarfarin and garlic\tWarfarin and cranberry/warfarin only\tWarfarin and garlic/warfarin only CC (n=4, 33%)\t648 (511\u2013785)\t611 (551\u2013671)\t791 (572\u20131010)\t0.96 (0.85\u20131.06)\t1.22* (1.11\u20131.34) CT (n=6, 50%)\t379\u00b1 (239\u2013519)\t276.8\u00b1 (178\u2013375)\t379\u00b1 (150\u2013608)\t0.78* (0.63\u20130.92)\t1.01 (0.94\u20131.08) TT (n=2, 17%)\t228\u00b1 (174\u2013281)\t202\u00b1 (168\u2013236)\t194\u00b1 (72\u2013316)\t0.89* (0.84\u20130.94)\t0.81 (0.53\u20131.10) Open in a separate window Abbreviations: CI, confidence interval; VKORC1, vitamin K epoxide reductase subunit 1.", {"entities": [[17, 27, "Drug"], [32, 47, "Target"], [50, 54, "Parameter"], [96, 104, "Drug"], [110, 118, "Drug"], [123, 132, "Herb name"], [133, 141, "Drug"], [146, 152, "Herb name"], [153, 161, "Drug"], [166, 175, "Herb name"], [176, 184, "Drug"], [190, 198, "Drug"], [203, 209, "Herb name"], [210, 218, "Drug"], [571, 616, "Target"]]}], [3538, "*Statistically and clinically significant difference between treatment arm and control arm for subjects of particularly genotype.", {"entities": []}], [3539, "\u00b1Statistically different from the CC genotype (P<0.03, Student's unpaired t-test) in a particular treatment arm.", {"entities": []}], [3540, "The CL/F of S-warfarin tended to be higher in people with the CYP2C9 wild-type when compared with people with CYP2C9*1/*2 variant.", {"entities": [[4, 8, "Parameter"], [12, 22, "Drug"], [62, 68, "Target"], [110, 121, "Target"]]}], [3541, "There was no CYP2C9 genotype\u2013herb\u2013drug interaction for the CL/F of S-warfarin when subjects received warfarin with either cranberry or garlic (Table 5).", {"entities": [[13, 19, "Target"], [59, 63, "Parameter"], [67, 77, "Drug"], [101, 109, "Drug"], [122, 131, "Herb name"], [135, 141, "Herb name"]]}], [3542, "Table 5  S-warfarin apparent clearance (mL\u2009h\u22121) and CYP2C9 genotype  \tS-warfarin apparent clearance (95% CI)\tGeometric mean ratio (90% CI)  \tWarfarin only\tWarfarin and cranberry\tWarfarin and garlic\tWarfarin and Cranberry/warfarin only\tWarfarin and garlic/warfarin only *1/*1 (n=9, 75%)\t220 (197\u2013244)\t208 (182\u2013234)\t215 (187\u2013244)\t0.94 (0.88\u20131.01)\t0.97 (0.91\u20131.03) *1/*2 (n=3, 25%)\t189 (170\u2013209)\t190 (167\u2013212)\t164 (116\u2013212)\t1.00 (0.91\u20131.10)\t0.85 (0.62\u20131.07) Open in a separate window Abbreviations: CI, confidence interval; CYP2C9, cytochrome P450 2C9 gene.", {"entities": [[9, 19, "Drug"], [20, 38, "Parameter"], [52, 67, "Target"], [70, 80, "Drug"], [81, 99, "Parameter"], [141, 149, "Drug"], [155, 163, "Drug"], [168, 177, "Herb name"], [178, 186, "Drug"], [191, 197, "Herb name"], [198, 206, "Drug"], [211, 220, "Herb name"], [221, 229, "Drug"], [235, 243, "Drug"], [248, 254, "Herb name"], [255, 263, "Drug"], [521, 553, "Target"]]}], [3543, "Go to: Discussion  This study investigated the pharmacodynamic and pharmacokinetic interaction of warfarin with cranberry juice concentrate and enteric-coated garlic tablets.", {"entities": [[98, 106, "Drug"], [112, 121, "Herb name"], [122, 139, "Extraction process"], [159, 165, "Herb name"]]}], [3544, "However, cranberry did not alter the pharmacokinetics of either S-warfarin or R-warfarin nor did 2 weeks of pretreatment with cranberry juice extract affect platelet aggregation.", {"entities": [[9, 18, "Herb name"], [64, 74, "Drug"], [78, 88, "Drug"], [97, 104, "Duration"], [126, 135, "Herb name"], [136, 149, "Extraction process"], [157, 177, "Parameter"]]}], [3545, "The lack of a pharmacokinetic interaction between warfarin and cranberry is in agreement with the findings of the study by Greenblatt et al.", {"entities": [[50, 58, "Drug"], [63, 72, "Herb name"]]}], [3546, "(2006).", {"entities": []}], [3547, "They demonstrated that cranberry did not affect CYP2C9 enzyme activity in vivo (assessed by flurbiprofen metabolism).", {"entities": [[23, 32, "Herb name"], [48, 54, "Target"], [71, 78, "Study"], [92, 104, "Drug"]]}], [3548, "However, these researchers only used a single dose of cranberry juice.", {"entities": [[54, 63, "Herb name"], [64, 69, "Extraction process"]]}], [3549, "Lilja et al.", {"entities": []}], [3550, "(2007) also investigated the effect of pretreatment with cranberry juice for 5 days on warfarin pharmacokinetics and found no clinically significant change in the AUC of S-warfarin.", {"entities": [[57, 66, "Herb name"], [67, 72, "Extraction process"], [73, 83, "Duration"], [87, 95, "Drug"], [163, 166, "Parameter"], [170, 180, "Drug"]]}], [3551, "This lack of an effect of cranberry on drug metabolism is supported by the study by Grenier et al.", {"entities": [[26, 35, "Herb name"]]}], [3552, "(2006), who found no pharmacokinetic interaction between a single dose of cranberry juice and cyclosporine.", {"entities": [[74, 83, "Herb name"], [84, 89, "Extraction process"], [94, 106, "Drug"]]}], [3553, "The hepatic enzyme CYP3A4 is known to be involved in the metabolism of cyclosporine and in the metabolism of R-warfarin (Wittkowsky, 2003).", {"entities": [[19, 25, "Target"], [71, 83, "Drug"], [109, 119, "Drug"]]}], [3554, "The results of the present study on the pharmacodynamic interaction between warfarin and cranberry are in contrast to the recent studies performed by Li et al.", {"entities": [[76, 84, "Drug"], [89, 98, "Herb name"]]}], [3555, "(2006b) and Ansell et al.", {"entities": []}], [3556, "(2008).", {"entities": []}], [3557, "In these studies no significant change in the warfarin response was observed during concomitant administration of cranberry juice.", {"entities": [[46, 54, "Drug"], [114, 123, "Herb name"], [124, 129, "Extraction process"]]}], [3558, "However, these studies have a number of limitations including a relatively small sample size, Li et al.", {"entities": []}], [3559, "(2006b) included 7 patients with atrial fibrillation, whereas Ansell et al.", {"entities": [[17, 27, "Cohort"], [33, 52, "Pathology"]]}], [3560, "(2008) included 14 patients with diverse medical indications in intervention group.", {"entities": [[16, 27, "Cohort"]]}], [3561, "Details regarding patient characteristics, concomitant medicines taken by patients and the nature and strength of the cranberry juice were omitted by Ansell et al.", {"entities": [[118, 127, "Herb name"], [128, 133, "Extraction process"]]}], [3562, "(2008).", {"entities": []}], [3563, "Lilja et al.", {"entities": []}], [3564, "(2007) concluded that there were no pharmacodynamic interactions between warfarin and cranberry juice, but they employed a low dose of warfarin (10\u2009mg), which made this end point difficult to assess.", {"entities": [[73, 81, "Drug"], [86, 95, "Herb name"], [96, 101, "Extraction process"], [135, 143, "Drug"], [145, 150, "Amount"]]}], [3565, "The studies by Li et al.", {"entities": []}], [3566, "(2006b) and Lilja et al.", {"entities": []}], [3567, "(2007) also include a relatively short duration of cranberry pretreatment (7 days or less).", {"entities": [[51, 60, "Herb name"], [75, 89, "Duration"]]}], [3568, "The data available from case reports suggest that a longer pretreatment period with cranberry is needed to detect changes in INR (Grant, 2004).", {"entities": [[24, 36, "Study"], [84, 93, "Herb name"], [125, 128, "Parameter"]]}], [3569, "Despite these negative findings, case reports on interactions between cranberry and warfarin continue to be published (Paeng et al., 2007).", {"entities": [[33, 45, "Study"], [70, 79, "Herb name"], [84, 92, "Drug"]]}], [3570, "We believe the randomized crossover design, the higher (25\u2009mg) single warfarin dose, the 2-week pretreatment with herbal medicines of known quality along with rigorous investigation of pharmacokinetic and pharmacodynamic end points give this study advantages over previous studies in this regard.", {"entities": [[11, 42, "Study"], [56, 61, "Amount"], [70, 78, "Drug"], [89, 95, "Duration"]]}], [3571, "In this study, we used a population PKPD modelling approach to elucidate further the nature of the interaction between warfarin and cranberry.", {"entities": [[119, 127, "Drug"], [132, 141, "Herb name"]]}], [3572, "The findings of this analysis suggested that subjects were more sensitive to the effects of warfarin when it was co-administered with cranberry.", {"entities": [[92, 100, "Drug"], [134, 143, "Herb name"]]}], [3573, "This confirmed that the interaction between cranberry and warfarin was pharmacodynamic in nature.", {"entities": [[44, 53, "Herb name"], [58, 66, "Drug"]]}], [3575, "Previous studies have suggested that Factor II and Factor X significantly contribute to the clinical effects of warfarin (Mahe et al., 2006; Sarode et al., 2006).", {"entities": [[37, 46, "Target"], [51, 59, "Target"], [112, 120, "Drug"]]}], [3576, "Each of the clotting factors investigated displayed a trend consistent with increased sensitivity to warfarin when administered during cranberry treatment.", {"entities": [[12, 28, "Target"], [101, 109, "Drug"], [135, 144, "Herb name"]]}], [3577, "This finding is also consistent with the INR observations during this phase of the study.", {"entities": [[41, 44, "Parameter"]]}], [3578, "Case reports of warfarin and cranberry have been reviewed and some authors have concluded lack of causality of these cases (Pham and Pham, 2007).", {"entities": [[0, 12, "Study"], [16, 24, "Drug"], [29, 38, "Herb name"]]}], [3579, "Some authors have suggested that the interaction may be dose or dose form dependent (as most patients in case reports ingested cranberry juice) (Aston et al., 2006).", {"entities": [[105, 117, "Study"], [127, 136, "Herb name"], [137, 142, "Extraction process"]]}], [3580, "The cranberry juice concentrate used in this study has been shown to exhibit chemical and therapeutic similarities with cranberry juice (Stothers, 2002; Upton et al., 2002).", {"entities": [[4, 13, "Herb name"], [14, 31, "Extraction process"], [120, 129, "Herb name"], [130, 135, "Extraction process"]]}], [3581, "However, there is a lack of consistency in the dose of cranberry used in clinical trials, and the equivalence between cranberry juice and concentrate has not been established (Jepson and Craig, 2008).", {"entities": [[55, 64, "Herb name"], [73, 88, "Study"], [118, 127, "Herb name"], [128, 133, "Extraction process"], [138, 149, "Extraction process"]]}], [3582, "Cytochrome P450 2C9 and VKORC1 genotype account for the major proportion of the variability in warfarin response (Sconce et al., 2005).", {"entities": [[0, 19, "Target"], [24, 39, "Target"], [95, 103, "Drug"]]}], [3583, "However, relatively little is known about the significance of genotype in interactions with other drugs or herbal medicines.", {"entities": []}], [3584, "This study found that subjects with less functional VKORC1 variants (CT and TT alleles) have significantly lower S-warfarin EC50 values derived from the PKPD modelling (Li et al., 2006a).", {"entities": [[52, 87, "Target"], [113, 123, "Drug"], [124, 128, "Parameter"]]}], [3585, "Furthermore, this study provides the first evidence that both cranberry and garlic interactions with warfarin are dependent on VKORC1 genotype.", {"entities": [[62, 71, "Herb name"], [76, 82, "Herb name"], [101, 109, "Drug"], [127, 142, "Target"]]}], [3586, "Subjects who carry the VKORC1 variant type (CT and TT alleles) were more prone to interactions with warfarin and cranberry; cranberry significantly increased the effects of warfarin (decrease in EC50 suggesting the need to lower warfarin dose).", {"entities": [[23, 62, "Target"], [100, 108, "Drug"], [113, 122, "Herb name"], [124, 133, "Herb name"], [173, 181, "Drug"], [195, 199, "Parameter"], [229, 237, "Drug"]]}], [3587, "Furthermore, there is preliminary evidence to suggest that people with the VKORC1 wild-type genotype are more prone to interactions between warfarin and garlic in that garlic significantly decreased the effects of warfarin.", {"entities": [[75, 100, "Target"], [140, 148, "Drug"], [153, 159, "Herb name"], [168, 174, "Herb name"], [214, 222, "Drug"]]}], [3588, "In this study, garlic had no effect on warfarin pharmacokinetics or pharmacodynamics and we found no effect on platelet aggregation induced by ADP, arachidonic acid, collagen or ristocetin.", {"entities": [[15, 21, "Herb name"], [39, 47, "Drug"], [111, 131, "Parameter"]]}], [3590, "(2006) in patients receiving an aged-garlic extract and warfarin.", {"entities": [[32, 51, "Herb name"], [56, 64, "Drug"]]}], [3591, "Whereas these researchers used a different garlic formulation to that employed in the present study, they also found no change in clinical effects of warfarin between patients receiving garlic and warfarin and patients on placebo and warfarin (Macan et al., 2006).", {"entities": [[43, 49, "Herb name"], [150, 158, "Drug"], [186, 192, "Herb name"], [197, 205, "Drug"], [234, 242, "Drug"]]}], [3592, "Evidence from four subjects with the wild-type VKORC1 genotype suggests that people with this genotype exhibit a pharmacodynamic interaction with garlic that induces a significant decrease in warfarin response.", {"entities": [[14, 27, "Cohort"], [37, 53, "Target"], [146, 152, "Herb name"], [192, 200, "Drug"]]}], [3593, "Garlic remains a widely used remedy by people who are also taking warfarin (Ramsay et al., 2005) with some suggestion that it confers beneficial cardiovascular effects (Kannar et al., 2001), and, hence, INR monitoring is likely to remain a safety initiative in people receiving this combination.", {"entities": [[0, 6, "Herb name"], [66, 74, "Drug"], [203, 206, "Parameter"]]}], [3594, "This observation warrants further investigation.", {"entities": []}], [3595, "This study is the first of its kind to explore VKORC1 gene variation and interactions with warfarin.", {"entities": [[47, 53, "Target"], [91, 99, "Drug"]]}], [3596, "Relatively small sample size for each genotype is one of the limitations of this study and could be the reason for the variable results.", {"entities": []}], [3597, "Hence, further future studies are needed to confirm these findings.", {"entities": []}], [3598, "In conclusion, this study comprehensively addressed the various possible mechanisms of interactions between warfarin and two commonly used herbal medicines.", {"entities": [[108, 116, "Drug"]]}], [3599, "Treatment with cranberry juice extract for 2 weeks significantly increased the sensitivity of healthy male subjects to warfarin without influencing the pharmacokinetics of warfarin enantiomers.", {"entities": [[15, 24, "Herb name"], [25, 30, "Extraction process"], [43, 50, "Duration"], [94, 101, "Pathology"], [102, 106, "Sex"], [119, 127, "Drug"], [172, 180, "Drug"]]}], [3600, "These findings, when taken together with recent case reports, strongly suggest that patients who are co-administered cranberry and warfarin should be closely monitored, or preferably cranberry should be avoided in such patients.", {"entities": [[48, 60, "Study"], [117, 126, "Herb name"], [131, 139, "Drug"], [183, 192, "Herb name"]]}], [3601, "By contrast garlic (at least when presented as an enteric-coated tablet dose form) did not have significant effects on platelet aggregation or the pharmacodynamics or pharmacokinetics of warfarin in healthy male subjects.", {"entities": [[12, 18, "Herb name"], [119, 139, "Parameter"], [187, 195, "Drug"], [199, 206, "Pathology"], [207, 211, "Sex"]]}], [3602, "Both herbal medicines showed some evidence of VKORC1 genotype-dependent interactions with warfarin, which is worthy of further investigation.", {"entities": [[46, 52, "Target"], [90, 98, "Drug"]]}], [3603, "Current address: Drug Metabolism and Pharmacokinetics, Covance Laboratories Inc., Madison, WI, USA Patients commonly take complementary medicines in conjunction with warfarin yet evidence supporting the safety or the risk of a herb\u2013drug interaction is lacking.", {"entities": [[166, 174, "Drug"]]}], [3604, "The aim of this study was to investigate the possible impact of two commonly used herbal medicines, garlic and cranberry, on the pharmacokinetics and pharmacodynamics of warfarin in healthy male subjects.", {"entities": [[100, 106, "Herb name"], [111, 120, "Herb name"], [170, 178, "Drug"], [182, 189, "Pathology"], [190, 194, "Sex"]]}], [3605, "A single dose of 25\u2009mg warfarin was administered alone or after 2 weeks of pretreatment with either garlic or cranberry.", {"entities": [[0, 13, "Frequency"], [17, 22, "Amount"], [23, 31, "Drug"], [58, 71, "Duration"], [100, 106, "Herb name"], [110, 119, "Herb name"]]}], [3606, "Cranberry significantly increased the area under the INR\u2013time curve by 30% when administered with warfarin compared with treatment with warfarin alone.", {"entities": [[0, 9, "Herb name"], [34, 67, "Parameter"], [71, 74, "Amount"], [98, 106, "Drug"], [136, 144, "Drug"]]}], [3607, "Cranberry did not alter S- or R-warfarin pharmacokinetics or plasma protein binding.", {"entities": [[0, 9, "Herb name"], [24, 40, "Drug"], [61, 83, "Parameter"]]}], [3608, "Both herbal medicines showed some evidence of VKORC1 (not CYP2C9) genotype-dependent interactions with warfarin, which is worthy of further investigation.", {"entities": [[46, 52, "Parameter"], [58, 64, "Parameter"], [103, 111, "Drug"]]}], [3609, "Cranberry alters the pharmacodynamics of warfarin with the potential to increase its effects significantly.", {"entities": [[0, 9, "Herb name"], [41, 49, "Drug"]]}], [3610, "Co-administration of warfarin and cranberry requires careful monitoring.", {"entities": [[21, 29, "Drug"], [34, 43, "Herb name"]]}], [3611, "Individual area under the international normalized ratio (INR)\u2013time curve (AUC Percentage clotting activity vs midpoint time profiles for (a) Factor II, (b) Factor VII and (c) Factor X during warfarin treatment alone or after cranberry pretreatment.", {"entities": [[0, 78, "Parameter"], [90, 107, "Parameter"], [142, 151, "Parameter"], [157, 167, "Parameter"], [176, 184, "Parameter"], [192, 200, "Drug"], [226, 235, "Herb name"]]}], [3612, "Mean and s.d.", {"entities": []}], [3613, "(error bars) are presented.", {"entities": []}], [3614, "Warfarin pharmacodynamic end points following the different treatments Abbreviations: CI, confidence interval; INR, international normalized ratio of prothrombin time; INR Pharmacokinetic parameters of S-warfarin and R-warfarin Abbreviations: AUC, area under the plasma concentration\u2013time curve; CI, confidence interval; CL, clearance; CL/F, apparent clearance; C Population pharmacokinetic and pharmacodynamic parameter estimates derived from the combined data from all treatment arms Abbreviations: CL, clearance; CL/F, apparent clearance; CV, coefficient of variation; EC The impact of herbal medicine treatment was evaluated as a ratio of the treatment to control on specific parameters (e.g., EC Geometric mean ratio intervention to control.", {"entities": [[0, 8, "Drug"], [111, 166, "Parameter"], [168, 171, "Parameter"], [202, 212, "Drug"], [217, 227, "Drug"], [243, 294, "Parameter"], [296, 319, "Parameter"], [321, 334, "Parameter"], [336, 360, "Parameter"], [501, 514, "Parameter"], [516, 540, "Parameter"]]}], [3615, "EC Abbreviations: CI, confidence interval; VKORC1, vitamin K epoxide reductase subunit 1.", {"entities": [[43, 88, "Parameter"]]}], [3616, "S-warfarin apparent clearance (mL\u2009h Abbreviations: CI, confidence interval; CYP2C9, cytochrome P450 2C9 gene.", {"entities": [[0, 10, "Drug"], [11, 35, "Parameter"], [76, 108, "Parameter"]]}], [3617, "Academic Editor: Igho J. Onakpoya In recent popular publications as well as in widely used information websites directed to cancer patients, valerian is claimed to have a potential of adverse interactions with anticancer drugs.", {"entities": [[124, 139, "Pathology"], [141, 149, "Herb name"], [210, 226, "Drug"]]}], [3618, "This questions its use as a safe replacement for, for example, benzodiazepines.", {"entities": [[63, 78, "Drug"]]}], [3619, "A review on the interaction potential of preparations from valerian root (Valeriana officinalis L. root) was therefore conducted.", {"entities": [[59, 67, "Herb name"], [68, 72, "Herb part"], [74, 98, "Herb name"], [99, 103, "Herb part"]]}], [3620, "A data base search and search in a clinical drug interaction data base were conducted.", {"entities": []}], [3621, "Thereafter, a systematic assessment of publications was performed.", {"entities": []}], [3622, "Seven in vitro studies on six CYP 450 isoenzymes, on p-glycoprotein, and on two UGT isoenzymes were identified.", {"entities": [[9, 22, "Study"]]}], [3623, "However, the methodological assessment of these studies did not support their suitability for the prediction of clinically relevant interactions.", {"entities": []}], [3624, "In addition, clinical studies on various valerian preparations did not reveal any relevant interaction potential concerning CYP 1A2, 2D6, 2E1, and 3A4.", {"entities": [[13, 29, "Study"], [41, 49, "Herb name"]]}], [3625, "Available animal and human pharmacodynamic studies did not verify any interaction potential.", {"entities": [[10, 50, "Study"]]}], [3626, "The interaction potential of valerian preparations therefore seems to be low and thereby without clinical relevance.", {"entities": [[29, 37, "Herb name"]]}], [3627, "We conclude that there is no specific evidence questioning their safety, also in cancer patients.", {"entities": [[81, 96, "Pathology"]]}], [3628, "Valerian \u201ccan interfere in an unwanted way with the oncological cancer therapy\u201d or valerian \u201ccan diminish the efficacy of cancer therapeutics.\u201d Statements like these can be found in published features on complementary medicine for cancer patients (Sloan Kettering Center 2012 [1]).", {"entities": [[0, 8, "Herb name"], [64, 70, "Pathology"], [83, 91, "Herb name"], [122, 128, "Pathology"], [231, 246, "Pathology"]]}], [3629, "In a very popular book on integrative oncology published by Sparreboom and Baker [2], it is stated that it is known for some herbal drugs that they can influence the activity of the cytochrome system and thereby may change the effect of chemotherapy.", {"entities": [[237, 249, "Drug"]]}], [3630, "It is further stated that cancer patients often have difficulties to sleep and are restless, so that they can use herbal drugs such as valerian in order to avoid chemically defined sedatives and hypnotics as they fear becoming addicted.", {"entities": [[26, 41, "Pathology"], [53, 74, "Pathology"], [135, 143, "Herb name"]]}], [3631, "However, they state that warnings that valerian (Valeriana officinalis) may stimulate CYP 3A4.", {"entities": [[39, 47, "Herb name"], [49, 70, "Herb name"], [86, 93, "Target"]]}], [3632, "This would reduce the effect of several cytostatic substances.", {"entities": []}], [3633, "For tamoxifen, the plasma level is reduced by CYP3A4 inductors, while inhibitors of CYP2D6 can lower the level of active metabolites, both leading to reduced efficacy.", {"entities": [[4, 13, "Drug"]]}], [3634, "In case of cyclophosphamide, metabolic activation by CYP2D6 is necessary that is increased by inductors of this isoenzyme.", {"entities": [[11, 27, "Drug"]]}], [3635, "The plasma level of several other cytostatic substances is lowered by CYP3A4 inductors.", {"entities": []}], [3636, "Examples are the epipodophyllotoxin derivative teniposide, camptothecin, tyrosine kinase inhibitors like imatinib, taxanes like paclitaxel and docetaxel, and vinca alkaloids like vincristine.", {"entities": [[17, 57, "Drug"], [59, 71, "Drug"], [73, 99, "Drug"], [105, 113, "Drug"], [115, 122, "Drug"], [128, 138, "Drug"], [143, 152, "Drug"], [158, 173, "Herb name"], [179, 190, "Drug"]]}], [3637, "CYP3A4 inductors also may reduce the activity of alkylating substances like ifosfamide and some antitumor antibiotics [2].", {"entities": [[76, 86, "Drug"], [96, 117, "Drug"]]}], [3638, "In several websites directed to patients ( More than 70% of all cancer patients are very interested in herbal drugs.", {"entities": [[32, 40, "Pathology"], [64, 79, "Pathology"]]}], [3639, "However, many of them do not inform their oncologist about their use [3, 4].", {"entities": []}], [3640, "As 19 to 75% of all cancer patients suffer from sleep disturbances [5], warnings against the use of valerian preparations have a high impact on these patients.", {"entities": [[48, 66, "Pathology"], [100, 108, "Herb name"], [150, 158, "Pathology"]]}], [3641, "However, it has to be ascertained that warnings that valerian may cause interactions with other medicines are backed by valid evidence supporting such an assumption and that they are therefore scientifically correct.", {"entities": [[53, 61, "Drug"]]}], [3642, "Therefore, we conducted a review in order to assess the interaction potential of valerian.", {"entities": [[81, 89, "Herb name"]]}], [3643, "The clinical relevance of acute as well as chronic sleep disorders is obvious: epidemiological data show that they affect approximately one-third of the adult population [6, 7].", {"entities": [[26, 66, "Pathology"]]}], [3644, "Treatment is indicated in about 15% of these cases [8, 9].", {"entities": []}], [3645, "Insomnia, defined as insufficient quantity or quality of sleep resulting in compromised daytime alertness and activity, is a common condition.", {"entities": [[0, 8, "Pathology"]]}], [3646, "It can result in serious adverse consequences, including attention and memory impairment, depression, falls, and perceived reduced quality of life [10].", {"entities": [[17, 45, "Pathology"], [57, 88, "Pathology"], [90, 100, "Pathology"], [102, 107, "Pathology"]]}], [3647, "To the most common treatments of insomnia belong drugs [11], this however bears some problems.", {"entities": [[33, 41, "Herb name"]]}], [3648, "Benzodiazepines and imidazopyridines offer only short-term relief, while data on their long-term efficacy are scarce.", {"entities": [[0, 15, "Drug"], [20, 36, "Drug"]]}], [3649, "Both drug classes have significant adverse effects such as serious psychomotor symptoms, behavioral aberrations, memory impairment resulting in injuries, respiratory depression, rebound insomnia, and paradoxical agitation.", {"entities": [[35, 50, "Pathology"], [59, 78, "Pathology"], [89, 111, "Pathology"], [113, 130, "Pathology"], [154, 176, "Pathology"], [178, 194, "Pathology"], [200, 221, "Pathology"]]}], [3650, "Especially for benzodiazepines, the potential for abuse is high [10].", {"entities": [[15, 30, "Drug"]]}], [3651, "Therefore, the National Institutes of Health consensus conference strongly discouraged chronic treatment of insomnia with benzodiazepines already in 2005 [11].", {"entities": [[108, 116, "Pathology"], [122, 137, "Drug"]]}], [3652, "Sedating antihistamines, such as diphenhydramine, the active ingredient in most over-the-counter sleep aids, are associated with cognitive impairment, daytime drowsiness, and anticholinergic effects.", {"entities": [[0, 23, "Drug"], [33, 48, "Drug"], [129, 149, "Pathology"], [151, 169, "Pathology"], [175, 198, "Pathology"]]}], [3653, "There is no evidence-based data available on their efficacy improving insomnia or prolonging sleep.", {"entities": [[70, 78, "Pathology"], [82, 98, "Pathology"]]}], [3654, "It therefore was recommended that they should be avoided in the elderly [10, 12].", {"entities": []}], [3655, "Finally, antidepressants used for treating insomnia, such as trazodone, can produce dangerous and life-threatening adverse events due to their anticholinergic, cardiovascular, and neurologic actions [10, 12].", {"entities": [[9, 24, "Drug"], [43, 51, "Pathology"], [61, 70, "Drug"], [115, 129, "Pathology"]]}], [3656, "Herbal substances improving insomnia, such as valerian, hops, or passion flower, are well-known sleep aids.", {"entities": [[28, 36, "Pathology"], [46, 54, "Herb name"], [56, 60, "Herb name"], [65, 79, "Herb name"]]}], [3657, "While marketed as food in the US, they are authorized or registered as medicines in Europe and many other regions, being mostly used in self-medication and holding widespread appeal, presumably because of their lower cost and higher range of safety when compared to chemically defined pharmaceuticals [13].", {"entities": []}], [3658, "Among these, the roots of valerian (Valeriana officinalis L.) are the most familiar ones, especially in Europe.", {"entities": [[17, 22, "Herb part"], [26, 34, "Herb name"], [36, 60, "Herb name"]]}], [3659, "They improve the subjective experience of sleep when taken in the evening over a period of one or two weeks [14].", {"entities": [[91, 107, "Duration"]]}], [3660, "The constituents of valerian root include, among others, valepotriates (iridoids) and volatile oil, including monoterpenes and sesquiterpenes (valerenic acids).", {"entities": [[20, 28, "Herb name"], [29, 33, "Herb part"], [57, 81, "Herb name"], [110, 122, "Herb name"], [127, 159, "Herb name"]]}], [3661, "Commercially available extracts are free from valepotriates [15].", {"entities": [[46, 59, "Herb name"]]}], [3662, "Recommended daily doses of valerian root extracts are about 600\u2009mg, usually taken as capsules or tablets.", {"entities": [[12, 17, "Frequency"], [27, 35, "Herb name"], [36, 40, "Herb part"], [60, 66, "Amount"]]}], [3663, "Several controlled clinical trials with various valerian extracts are available, and also a meta-analysis on eighteen randomized placebo-controlled trails was published.", {"entities": [[48, 56, "Herb name"], [118, 154, "Study"]]}], [3664, "Its qualitative results suggest that valerian would be effective for a subjective improvement of insomnia, although its effectiveness could not be demonstrated with quantitative or objective measurements [16].", {"entities": [[37, 45, "Herb name"], [97, 105, "Pathology"]]}], [3665, "In a study conducted in cancer patients, an improvement in the primary variable, a sleep quality index based mainly on objective parameters, could not be demonstrated; however, fatigue and sleep problems were significantly improved [17].", {"entities": [[24, 39, "Pathology"], [177, 184, "Pathology"], [189, 203, "Pathology"]]}], [3666, "The clinical studies available show an excellent short-term tolerability, and from several decades of clinical use within the frame of pharmacovigilance systems no data questioning its long-term safety have evolved, while prospective data are missing [18].", {"entities": [[4, 20, "Study"]]}], [3667, "In contrast to classical sedatives, valerian extracts did not impair the ability to drive or to use machines, neither after single [19\u201322] nor after repeated doses [23].", {"entities": [[36, 44, "Herb name"]]}], [3668, "Reports of putative adverse reactions are extremely rare and include one case of hepatic symptoms after prolonged treatment and one case of cardiac symptoms after discontinuation of a long-term treatment with very high doses, which were interpreted as a withdrawal reaction [24, 25].", {"entities": []}], [3669, "In both case reports, outcome was benign, causality was questionable, and characteristics of the extract preparations were not provided.", {"entities": []}], [3670, "While the side effect profile therefore is benign, a potential for adverse drug interactions has been claimed by some reviews [26], while other reviews did not [18, 27\u201332], so that a reevaluation of the existing evidence is necessary.", {"entities": [[10, 21, "Pathology"]]}], [3671, "For evaluation of the scientific data on the interaction potential of valerian (Valeriana officinalis L.), published data (experimental in vitro and in vivo studies, pharmacovigilance data from its long standing use as an authorized medicinal drug or supplement) were assessed and evaluated for identifying data on possible drug-herb interactions (Table 1).", {"entities": [[79, 105, "Herb name"], [136, 164, "Study"]]}], [3672, "A search with the search terms (valerian or valeriana) was conducted in the databases MEDLINE and TOXLIT, via DIMDI (Cologne, Germany).", {"entities": [[32, 40, "Herb name"], [44, 53, "Herb name"]]}], [3674, "In all cases, where a relevance to the subject could thereby not be clearly ruled out, full-text articles were assessed and, as far as relevant, included into the review.", {"entities": []}], [3675, "Additionally MedIQ [33], a leading online database for the assessment of potential interactions in pharmacotherapy, was searched.", {"entities": []}], [3676, "Thereafter cross-referencing was conducted in order to identify and close potential gaps.", {"entities": []}], [3677, "Studies were assessed for completeness and validity of data on material and methods, on the potential clinical relevance of the results and on potential bias in the presentation of results and conclusions.", {"entities": []}], [3678, "Eligible and included were all scientific publications on interactions of Valeriana officinalis L. root and preparations thereof.", {"entities": [[74, 98, "Herb name"], [99, 103, "Herb part"]]}], [3679, "Among these are altogether 21 original publications.", {"entities": []}], [3680, "11 of them present data from in vitro studies on pharmacokinetic interactions.", {"entities": [[29, 45, "Study"]]}], [3681, "One of these publications [34] contains, in addition, data on animal studies.", {"entities": [[62, 76, "Study"]]}], [3682, "Two publications [35, 37] present clinical studies on pharmacokinetic interactions.", {"entities": [[34, 50, "Study"]]}], [3683, "8 studies are available on the subject of pharmacodynamic interactions, thereof two in vitro and three animal studies, one clinical study, and in addition two case reports.", {"entities": [[84, 117, "Study"], [119, 137, "Study"]]}], [3684, "Predicting pharmacokinetic herb-drug interactions is difficult because the pharmacological actions of the interacting drugs are often not related.", {"entities": []}], [3685, "This is also the case with the subject of this review, valerian as a treatment of insomnia, and chemically defined cytostatic therapies.", {"entities": [[55, 63, "Herb name"], [82, 90, "Pathology"], [115, 135, "Drug"]]}], [3686, "Herb-drug interactions can occur on the levels of absorption, distribution, metabolism, or excretion and can change the amount and duration of the availability of a drug at the site of action.", {"entities": []}], [3687, "The interactions due to drug metabolism can be, as mentioned above, based on phase 1 metabolism (mainly involving cytochrome P 450 isoenzymes) or, rather rare, on phase 2 metabolism involving, for example, P-glycoproteins (P-gp), which is relevant for outward bound transport processes, for example, in the intestinal wall, or on conjugation, for example, with glucuronic acid [43].", {"entities": []}], [3688, "In case that a specific herb-drug interaction is identified, its clinical significance depends on the degree of accumulation and the therapeutic window of the respective drug [44].", {"entities": []}], [3689, "Also the dosage, time of administration, galenic properties, and coadministration as well as intrinsic and extrinsic factors may be of importance.", {"entities": []}], [3690, "Budzinski et al.", {"entities": []}], [3691, "An IC Lefebvre et al.", {"entities": []}], [3692, "[39] determined the in vitro effects of 14 commercially available single entity and combination herbal products containing extracts of valerian root, on CYP 3A4-mediated metabolism and on P-gp transport.", {"entities": [[135, 143, "Herb name"], [144, 148, "Herb part"]]}], [3693, "The extracts were prepared by extracting 100\u2009mg of the powdered commercial preparations with 1\u2009mL of water and 70% ethanol or acetonitrile and characterized by determination of total valerenic acids by HPLC.", {"entities": []}], [3694, "In a proportion of 1\u20135% of total assay volume, most extracts showed an inhibition to different extents.", {"entities": []}], [3695, "Six extracts had some inhibitory effects on P-gp.", {"entities": [[44, 48, "Target"]]}], [3696, "The authors concluded that \u201cthere is wide variation in commercially available samples of valerian root.", {"entities": [[89, 97, "Herb name"], [98, 102, "Herb part"]]}], [3697, "The findings from this study suggest that valerian root may have an initial inhibitory effect, when taken with therapeutic products.", {"entities": [[42, 50, "Herb name"], [51, 55, "Herb part"]]}], [3698, "Further work is warranted to determine whether valerian root can affect other CYP 450 isozymes and how the results of this in vitro investigation can be extrapolated to in vivo situations.\u201d Indeed, several of the tested preparations are insufficiently characterized, as only the valerenic acid content is provided.", {"entities": [[47, 55, "Herb name"], [56, 60, "Herb part"], [279, 293, "Herb name"]]}], [3699, "In addition, only one rather high concentration of each extract was tested and, again, a fluorometric method was used, which is highly susceptible to interference by fluorescent herbal components.", {"entities": []}], [3700, "These limitations do not allow valid extrapolations with respect to a clinical relevance of the results.", {"entities": []}], [3701, "The aim of a further study was to evaluate the in vitro effect of commercially available valerian medicinal products on the metabolic activities of the CYP 450 isoenzymes 1A2, 2D6, and 3A4.", {"entities": [[89, 97, "Herb name"]]}], [3702, "The herbal extract concentrations used in in vitro metabolic systems were claimed to cover the whole range of herbal concentrations occurring in vivo.", {"entities": []}], [3703, "Dose dependent and statistically significant increases in CYP 2D6 and CYP 3A4 were observed only with two concentrations (0.188\u2009mg/mL and 1.875\u2009mg/mL).", {"entities": [[58, 65, "Target"], [70, 77, "Target"]]}], [3704, "The authors postulate an allosteric antagonism but also clearly point to the limitations of their study, as hepatocytes from only one donor were used.", {"entities": []}], [3705, "Therefore, the well-known polymorphisms in the CYP superfamily were not covered.", {"entities": []}], [3706, "In another study, the effect of valerian, valerian/hops extracts, and valerenic acid on the glucuronide conjugation of various substrates (17\u03b1-estradiol, acetaminophen, morphine, and testosterone) was determined using human liver microsomes [41].", {"entities": [[32, 40, "Herb name"], [42, 50, "Herb name"], [70, 84, "Herb name"], [139, 152, "Drug"], [154, 167, "Drug"], [169, 177, "Drug"], [183, 195, "Drug"]]}], [3707, "Test substance was a valerian capsule (250\u2009mg extract corresponding to 3.48\u2009mg valerenic acid per capsule, further specification not available), which was extracted with 80% methanol (5\u2009mL/capsule).", {"entities": [[21, 29, "Herb name"], [79, 93, "Herb name"]]}], [3708, "Also, the activities of UGT 1A1 and UGT 2B7 were tested in the presence of 2.5 or 5.0\u2009mL of valerian or valerian/hops extract per 250\u2009mL final incubation volume.", {"entities": [[24, 31, "Parameter"], [36, 43, "Parameter"], [92, 100, "Herb name"], [104, 112, "Herb name"]]}], [3709, "Valerenic acid significantly inhibited the glucuronidation by both microsomes and UGTs with the rather high concentration of 1\u2009mg/mL.", {"entities": [[0, 14, "Drug"], [82, 86, "Parameter"]]}], [3710, "Due to this fact and the very high glucuronidation capacity of the liver, a clinical relevance of these results cannot be assumed.", {"entities": []}], [3711, "Mohamed at al.", {"entities": []}], [3712, "[42] used an UGT 1A1 assay to test a commercially available valerian preparation (\u22650.1% valerenic acid; extraction medium 70% ethanol, recommended daily dose 1000\u2009mg) for inhibition of human estradiol-3-O-glucuronidation (E-3-G) in the same concentrations as Hellum et al.", {"entities": [[60, 68, "Herb name"], [88, 102, "Herb name"], [147, 152, "Frequency"], [158, 165, "Amount"], [191, 228, "Target"]]}], [3713, "[36].", {"entities": []}], [3714, "E-3-G was quantified by HPLC.", {"entities": [[0, 5, "Target"]]}], [3715, "Daily before going to bed, participants took two tablets, with 500\u2009mg valerian extract each (extraction solvent ethanol 70%, valerenic acid content 5.51\u2009mg/tablet), for 14 subsequent days.", {"entities": [[0, 5, "Frequency"], [63, 69, "Amount"], [70, 78, "Herb name"], [125, 139, "Herb name"], [169, 187, "Duration"]]}], [3716, "This dose is well within the range of recommended doses for valerian preparations.", {"entities": [[60, 68, "Herb name"]]}], [3717, "The probe drugs dextromethorphan (30\u2009mg; CYP 2D6 activity) and alprazolam (2\u2009mg; CYP 3A4 activity) were administered orally at baseline and after treatment with valerian, and dextromethorphan to dextrorphan metabolic ratios and alprazolam pharmacokinetics were determined.", {"entities": [[16, 32, "Drug"], [34, 39, "Amount"], [63, 73, "Drug"], [75, 80, "Amount"], [161, 169, "Herb name"], [175, 191, "Drug"], [195, 206, "Drug"], [228, 238, "Drug"]]}], [3718, "The ratio of dextromethorphan to dextrorphan increased slightly but significantly from 0.214 to 0.254.", {"entities": [[13, 29, "Drug"], [33, 44, "Drug"]]}], [3719, "The maximum concentration of alprazolam was moderately increased for about 20% from 25 to 31\u2009ng/mL (P < 0.05).", {"entities": [[29, 39, "Drug"]]}], [3720, "This change is therefore within the frame of 80% to 125% rated as equivalent by FDA.", {"entities": []}], [3721, "Bioavailability of other medicines would therefore not be relevantly diminished and therapeutic efficacy of a therapy not questioned.", {"entities": []}], [3722, "Changes of other pharmacokinetic parameters were not detected.", {"entities": []}], [3723, "In conclusion valerian in therapeutic doses is unlikely to produce clinically relevant effects on CYP 2D6 and CYP 3A4 pathways which could diminish the therapeutic efficacy of other drugs.", {"entities": [[14, 22, "Herb name"], [98, 105, "Target"], [110, 117, "Target"]]}], [3724, "Before and after the test period, the activities of CYP 3A4/5 (1-hydroxymidazolam/midazolam serum ratio), CYP 1A2 (paraxanthine/caffeine serum ratio), CYP 2E1 (hydroxychlorzoxazone/chlorzoxazone serum ratio), and CYP 2D6 (debrisoquine urinary recovery ratio) were determined.", {"entities": [[82, 91, "Drug"], [115, 127, "Drug"], [128, 136, "Drug"], [181, 194, "Drug"], [222, 234, "Drug"]]}], [3725, "All subjects were nonsmokers and extensive metabolizers of CYP 2D6.", {"entities": []}], [3726, "No changes at all in phenotypic ratios were observed.", {"entities": []}], [3727, "The daily dose applied in this study was corresponding to 1.5\u2009g drug, which is in the lower range of doses recommended, for example, in the monograph of the HMPC.", {"entities": [[4, 9, "Frequency"], [58, 63, "Amount"]]}], [3728, "Despite that, the fact that there was not even a tendency of an effect in the CYP isoenzymes tested underlines the assumption of the lack of an interaction potential in CYP enzymes.", {"entities": []}], [3729, "Pharmacodynamic interactions include the concurrent administration of drugs having the same or opposing pharmacologic actions and also the change of the sensitivity or the responsiveness of the tissues to one drug, induced by another one.", {"entities": []}], [3730, "Many of these interactions can be predicted from knowledge of the pharmacology of each drug.", {"entities": []}], [3731, "They were proposed for valerian mainly with drugs influencing vigilance such as codeine, citalopram, and benzodiazepines.", {"entities": [[23, 31, "Herb name"], [80, 87, "Drug"], [89, 99, "Drug"], [105, 120, "Drug"]]}], [3732, "A presumable interaction with benzodiazepines, which are positive allosteric modulators on GABA-receptors, is based on in vitro data suggesting GABAergic mechanisms of action of valerian extracts [49, 50].", {"entities": [[30, 45, "Drug"], [91, 105, "Target"], [178, 186, "Herb name"]]}], [3733, "These studies however are inconclusive and require independent replication.", {"entities": []}], [3734, "In rats an in vivo study was conducted on interactions between valerian root tincture (ethanol 100%, 1\u2009:\u200910, not further characterized, daily therapeutic dose 3060\u2009mg for an adult human) and haloperidol with respect to impaired liver or kidney functions.", {"entities": [[14, 24, "Study"], [63, 71, "Herb name"], [72, 76, "Herb part"], [136, 141, "Frequency"], [159, 166, "Amount"], [191, 202, "Drug"]]}], [3735, "Valerian tincture was applied with the drinking water (1%, corresponding to an extract dose of 200\u2013250\u2009mg/kg bw/d).", {"entities": [[0, 17, "Herb name"], [95, 113, "Amount"]]}], [3736, "Haloperidol (38\u2009mg/kg bw) was applied intramuscularly once every 4 weeks over 12 weeks beginning after 15 days of treatment with valerian [51].", {"entities": [[0, 11, "Drug"], [13, 24, "Amount"], [54, 58, "Frequency"], [59, 72, "Frequency"], [78, 86, "Duration"], [103, 110, "Duration"], [129, 137, "Herb name"]]}], [3737, "While renal effects were lacking, in some of the parameters measured in liver homogenates, slight and statistically significant deviations from control values were observed, suggesting an additive effect of haloperidol and valerian, however of questionable relevance.", {"entities": [[207, 218, "Drug"], [223, 231, "Herb name"]]}], [3738, "Authors concluded that in humans a possible toxic additive effect would occur only at supratherapeutic doses.", {"entities": []}], [3739, "The same working group evaluated the effect of valerian in a rat model of orofacial dyskinesia using the same application procedure as described above.", {"entities": [[47, 55, "Herb name"], [74, 94, "Pathology"]]}], [3740, "Valerian did not influence orofacial dyskinesia induced by haloperidol.", {"entities": [[0, 8, "Herb name"], [27, 47, "Pathology"], [59, 70, "Drug"]]}], [3741, "Also oxidative stress parameters were not changed [52].", {"entities": []}], [3742, "In another in vivo study on mice [53], 25\u2009mg/kg of a valerian root dry extract was combined with 25\u2009mg/kg of a liquorice extract (both prepared with ethanol 70%, not further characterized) or the benzodiazepine alprazolam (0.7\u2009mg/kg).", {"entities": [[14, 24, "Study"], [39, 47, "Amount"], [53, 61, "Herb name"], [62, 66, "Herb part"], [97, 105, "Amount"], [111, 120, "Herb name"], [196, 221, "Drug"], [223, 232, "Amount"]]}], [3743, "Tests were conducted in an elevated plus maze.", {"entities": []}], [3744, "Valerian and alprazolam, rather than liquorice, significantly increased time spent in the open arm, pointing to an anxiolytic effect.", {"entities": [[0, 8, "Herb name"], [13, 23, "Drug"], [37, 46, "Herb name"]]}], [3745, "The effect of alprazolam, combined with liquorice or valerian, was significantly increased compared to each of the single substances.", {"entities": [[14, 24, "Drug"], [40, 49, "Herb name"], [53, 61, "Herb name"]]}], [3746, "The authors discuss an improved bioavailability, for example, due to an increased gastrointestinal absorption induced by liquorice.", {"entities": [[32, 47, "Parameter"], [121, 130, "Herb name"]]}], [3747, "The relevance in humans remains unclear.", {"entities": []}], [3748, "The results were not presented in detail but indicated that the two drugs act independently from each other.", {"entities": []}], [3749, "Interactions with respect to heart rate and parameters of psychic strain could not be demonstrated [54].", {"entities": []}], [3750, "A possible pharmacodynamic interaction of valerian preparations with other drugs is supported only by two case reports.", {"entities": [[42, 50, "Herb name"]]}], [3751, "A 40-year-old male patient had taken lorazepam (2\u2009mg/d) for two month without side effects.", {"entities": [[2, 9, "Age"], [14, 18, "Sex"], [37, 46, "Drug"], [48, 54, "Amount"], [60, 69, "Duration"], [78, 90, "Pathology"]]}], [3752, "Then he additionally took for two days an infusion of valerian root two hours before bedtime and, just before going to bed, an infusion of valerian root and passion flower herb (dose unknown) without side effects.", {"entities": [[30, 38, "Duration"], [54, 62, "Herb name"], [63, 67, "Herb part"], [127, 135, "Extraction process"], [139, 147, "Herb name"], [148, 152, "Herb part"], [200, 212, "Pathology"]]}], [3753, "On the third day he took, instead of the infusion, three tablets containing a combination of valerian root extract (300\u2009mg) and passion flower root and herb extracts (350\u2009mg; no further information available) before bedtime.", {"entities": [[41, 49, "Extraction process"], [93, 101, "Herb name"], [102, 106, "Herb part"], [116, 122, "Amount"], [128, 142, "Herb name"], [143, 147, "Herb part"], [167, 173, "Amount"]]}], [3754, "He thereafter suffered from transient mild handshaking and drowsiness [55].", {"entities": [[28, 54, "Pathology"], [59, 69, "Pathology"]]}], [3755, "It was suspected that these symptoms were caused by an interaction between the herbal drugs and lorazepam, as they ceased after stopping herbal treatment.", {"entities": [[96, 105, "Herb name"]]}], [3756, "It is however questionable to ascribe the adverse event to valerian alone as the herbal preparation also contained a root and herb extract of passion flower, for which monographs are lacking.", {"entities": [[59, 67, "Herb name"], [117, 121, "Herb part"], [142, 156, "Herb name"]]}], [3757, "As the symptoms are also potential adverse effects of lorazepam itself, and no other similar cases have been described since then, and also a coincidence cannot be ruled out.", {"entities": [[35, 50, "Pathology"], [54, 63, "Drug"]]}], [3758, "Another patient (39-year-old female) had taken for two month a daily dose of two tablets of a St. John's wort preparation and one tablet of a valerian preparation and additionally Loperamide [56].", {"entities": [[8, 15, "Pathology"], [17, 24, "Age"], [29, 35, "Sex"], [51, 60, "Duration"], [63, 68, "Frequency"], [94, 109, "Herb name"], [142, 150, "Herb name"], [180, 190, "Drug"]]}], [3759, "After this time, she was hospitalized with a severe delirium.", {"entities": [[45, 61, "Pathology"]]}], [3761, "The authors proposed an interaction between the herbal drugs and Loperamide, involving MAO-inhibitory properties.", {"entities": [[65, 75, "Drug"], [87, 90, "Target"]]}], [3762, "Given that none of these herbal medicines has been proven to have MAO-inhibitory properties, while induction of delirium, and a positive drug screening on opioids was reported, the assumption of an involvement of the valerian preparation does not seem to be plausible.", {"entities": [[66, 69, "Target"], [112, 120, "Pathology"], [155, 162, "Drug"], [217, 225, "Herb name"]]}], [3763, "A good understanding of the mechanisms of drug-drug interactions is essential for assessing and minimizing clinical risks.", {"entities": []}], [3764, "Indeed many drug interactions are a result of inhibition or induction of CYP enzymes.", {"entities": []}], [3765, "This is especially true for many antineoplastic substances.", {"entities": []}], [3766, "However, interactions on P-glycoprotein and conjugation mechanisms should not be neglected.", {"entities": []}], [3767, "Additionally, pharmacodynamic interactions have to be considered.", {"entities": []}], [3768, "Herbal medicinal drugs consist of multiple components.", {"entities": []}], [3769, "The complex nature of herbal drugs can provide broader information on multiple interaction mechanisms and the results may change due to environmental or manufacturing differences.", {"entities": []}], [3770, "More information is obtained than that with a single pure natural substance.", {"entities": []}], [3771, "During the past decade, several potential mechanisms of interactions of valerian preparations, involving CYP enzymes, P-glycoprotein, and UGTs, have been studied in vitro [36, 38\u201342, 46].", {"entities": [[72, 80, "Herb name"], [105, 116, "Target"], [118, 132, "Target"], [138, 142, "Target"], [154, 170, "Study"]]}], [3772, "Some of these studies pointed to a possible drug interaction potential by valerian extracts.However, critical assessment of these studies suggests that the clinical relevance of the findings is questionable due to various methodological limitations (Table 1).", {"entities": [[74, 82, "Herb name"]]}], [3773, "This is underlined by the available clinical interaction studies on CYP isoenzymes, which do not indicate a relevant drug interaction potential of valerian in healthy volunteers [35, 37].", {"entities": [[36, 64, "Study"], [147, 155, "Herb name"], [159, 166, "Pathology"]]}], [3774, "In this context also the amiability of in vitro data to the situation in humans should be addressed.", {"entities": []}], [3775, "Especially the open questions of in vivo bioavailability and of the metabolism of extract components relevant for in vitro effects often prevent reliable extrapolations from in vitro to in vivo data.", {"entities": [[41, 56, "Parameter"]]}], [3776, "As in vitro and in vivo correlations usually are not available, results from in vitro interaction studies on herbal medical drugs may not simply be transferred to the in vivo situation.", {"entities": [[80, 105, "Study"]]}], [3777, "For valerian, and similarly also for Echinacea, Ginkgo, and hawthorn, clinically relevant interactions are lacking in in vivo studies, despite in vitro studies pointing to drug interactions in vivo.", {"entities": [[4, 12, "Herb name"], [37, 46, "Herb name"], [48, 54, "Herb name"], [60, 68, "Herb name"], [121, 134, "Study"], [146, 159, "Study"]]}], [3778, "Since for herbal extracts a positive in vitro and in vivo correlation of data on drug bioavailability is rare, results from in vitro studies should be carefully interpreted [57].", {"entities": [[86, 101, "Parameter"]]}], [3779, "Also the interpretation of metabolic studies in animals of different species should be critically evaluated, as often dosages far above those applied to humans are used and also regarding the enzyme variations in the species.", {"entities": [[27, 44, "Study"]]}], [3780, "As for pharmacodynamic interactions of valerian, neither animal studies nor human data provide solid information for a possible risk [51, 52, 54].", {"entities": [[39, 47, "Herb name"], [57, 71, "Study"]]}], [3781, "Also the case reports are by no means convincing [55, 56].", {"entities": []}], [3782, "At present therefore a relevant risk of pharmacodynamic interactions is not proven by valid clinical observations.", {"entities": []}], [3783, "Altogether, this review could not identify studies showing a clinically relevant interaction effect of valerian.", {"entities": [[103, 111, "Herb name"]]}], [3784, "This confirms pharmacovigilance reviews of herbal medicinal products, which do not mention valerian at all [58\u201360] or claim valerian as safe [16, 27\u201331].", {"entities": [[91, 99, "Herb name"], [124, 132, "Herb name"]]}], [3785, "Block et al.", {"entities": []}], [3786, "[5] specifically pointed out that valerian is safe and efficient in patients undergoing cancer therapy.", {"entities": [[34, 42, "Herb name"], [68, 76, "Pathology"]]}], [3787, "That therapeutic safety regarding interactions is high in valerian and is mentioned in the respective monograph of the HMPC [18] and also in a fact sheet of the Office of Dietary Supplements at the NIH [32].", {"entities": [[58, 66, "Herb name"]]}], [3788, "In a data base for interactions of medicinal drugs (MedIQ), the rating \u201cweak interaction\u201d is given for CYP-isoenzymes, P-gp, and UGT, based on in vitro data.", {"entities": [[103, 117, "Target"], [119, 123, "Target"], [129, 132, "Target"]]}], [3789, "However, this rating is apparently the result of a merely formalistic approach and not the result from an analysis of the clinical relevance of these data.", {"entities": []}], [3790, "The use of valerian preparations is very common in patients with cancer, who often receive medicines with a narrow therapeutic window.", {"entities": [[11, 19, "Herb name"]]}], [3791, "It was claimed as not being safe with regards to interactions in earlier scientific reviews.", {"entities": []}], [3792, "A critical analysis of interaction data and experimental setups in papers addressed to CYP 450 isoenzymes and P-gp as targets showed limited in vitro interactions.", {"entities": [[87, 105, "Target"], [111, 112, "Target"]]}], [3793, "However, the relevance of herb-drug interactions becomes apparent only during clinical use.", {"entities": []}], [3794, "So the available studies on interactions on CYP 450 enzymes do not reveal clinically relevant interactions.", {"entities": [[44, 59, "Target"]]}], [3795, "Also the studies and other data on pharmacodynamic interactions do not support the assumption of clinically relevant interactions.", {"entities": []}], [3796, "Further adverse effects, if any, seem to be very rare and reversible.", {"entities": [[8, 23, "Pathology"]]}], [3797, "In summary, it can be concluded that warnings regarding a specific risk of interactions of valerian are without any recent evidence.", {"entities": [[91, 99, "Herb name"]]}], [3798, "Instead, valerian turns out to be an advisable treatment option, as it has a more favorable safety profile than chemically defined hypnotics and as it also improves subjective parameters of sleep quality.", {"entities": [[9, 17, "Herb name"]]}], [3799, "Warnings directed to cancer patients, in whom restless nights are responsible for continued disruption of well-being and for further impairment of health, to abstain from its use, should therefore be substantiated and specifically take the comedication into account.", {"entities": [[21, 36, "Pathology"]]}], [3800, "Otherwise, they are likely to do more harm than good.", {"entities": []}], [3801, "The authors declare that there is no conflict of interests regarding the publication of this paper.", {"entities": []}], [3802, "Potential pharmacokinetic interactions of valerian according to the published literature.", {"entities": [[42, 50, "Herb name"]]}], [3803, "The conclusions by the respective authors, the ratings given by MedIQ ( CYP: cytochrome P450; UGT: uridine 5\u2032-diphosphate glucuronosyltransferase.", {"entities": []}], [3804, "Phytochemical-mediated modulation of cytochrome P450 enzymes (CYPs) may underlie many herb-drug interactions.", {"entities": []}], [3805, "This study\u2019s purpose was to assess the effects of milk thistle and black cohosh supplementation on CYP3A activity and compare them to a clinically recognized inducer, rifampin, and inhibitor, clarithromycin.", {"entities": [[50, 62, "Herb name"], [67, 79, "Herb name"], [99, 104, "Target"], [167, 175, "Drug"], [192, 206, "Herb name"]]}], [3806, "Healthy volunteers were randomly assigned to receive a standardized milk thistle (900 mg) or black cohosh (80 mg) supplement for 14 days.", {"entities": [[0, 7, "Pathology"], [68, 80, "Herb name"], [82, 88, "Amount"], [93, 105, "Herb name"], [107, 112, "Amount"], [129, 136, "Duration"]]}], [3807, "Subjects also received rifampin (600 mg) and clarithromycin (1000 mg) for 7 days as positive controls for CYP3A induction and inhibition, respectively.", {"entities": [[23, 31, "Drug"], [33, 39, "Amount"], [45, 59, "Drug"], [61, 68, "Amount"], [74, 80, "Duration"], [106, 111, "Target"]]}], [3808, "Midazolam was administered orally before and after each supplementation and control period.", {"entities": [[0, 9, "Drug"]]}], [3809, "The effects of milk thistle, black cohosh, rifampin, and clarithromycin on midazolam pharmacokinetics were determined using noncompartmental techniques.", {"entities": [[15, 27, "Herb name"], [29, 41, "Herb name"], [43, 51, "Drug"], [57, 71, "Drug"], [75, 84, "Drug"]]}], [3810, "Unlike those observed for rifampin and clarithromycin, midazolam pharmacokinetics were unaffected by milk thistle or black cohosh.", {"entities": [[26, 34, "Drug"], [39, 53, "Drug"], [55, 64, "Drug"], [101, 113, "Herb name"], [117, 129, "Herb name"]]}], [3811, "Milk thistle and black cohosh appear to have no clinically relevant effect on CYP3A activity in vivo.", {"entities": [[0, 12, "Herb name"], [17, 29, "Herb name"], [78, 83, "Target"]]}], [3812, "Financial support: None.", {"entities": []}], [3813, "Venlafaxine is a serotonin-norepinephrine reuptake inhibitor used as an antidepressant.", {"entities": [[0, 86, "Drug"]]}], [3814, "Interindividual variability and herb-drug interactions can lead to drug-induced toxicity.", {"entities": [[67, 88, "Pathology"]]}], [3815, "We report the case of a 35-year-old female patient diagnosed with synchronous pneumonitis and acute cardiomyopathy attributed to venlafaxine.", {"entities": [[24, 35, "Age"], [36, 42, "Sex"], [66, 114, "Pathology"], [129, 140, "Drug"]]}], [3816, "The patient sought medical attention due to dyspnea and dry cough that started three months after initiating treatment with venlafaxine for depression.", {"entities": [[44, 65, "Pathology"], [79, 91, "Duration"], [124, 135, "Drug"], [140, 150, "Pathology"]]}], [3817, "The patient was concomitantly taking Centella asiatica and Fucus vesiculosus as phytotherapeutic agents.", {"entities": [[37, 54, "Herb name"], [59, 76, "Herb name"]]}], [3818, "Chest CT angiography and chest X-ray revealed parenchymal lung disease (diffuse micronodules and focal ground-glass opacities) and simultaneous dilated cardiomyopathy.", {"entities": [[46, 70, "Pathology"], [144, 166, "Pathology"]]}], [3819, "Ecocardiography revealed a left ventricular ejection fraction (LVEF) of 21%.", {"entities": [[27, 68, "Parameter"], [72, 75, "Amount"]]}], [3820, "A thorough investigation was carried out, including BAL, imaging studies, autoimmune testing, right heart catheterization, and myocardial biopsy.", {"entities": []}], [3821, "After excluding other etiologies and applying the Naranjo Adverse Drug Reaction Probability Scale, a diagnosis of synchronous pneumonitis/cardiomyopathy associated with venlafaxine was assumed.", {"entities": [[114, 152, "Pathology"], [169, 180, "Drug"]]}], [3822, "After venlafaxine discontinuation, there was rapid improvement, with regression of the radiological abnormalities and normalization of the LVEF.", {"entities": [[6, 17, "Drug"], [83, 113, "Pathology"], [139, 143, "Parameter"]]}], [3823, "This was an important case of drug-induced cardiopulmonary toxicity.", {"entities": [[30, 67, "Pathology"]]}], [3824, "Here, we also discuss why macrophage-dominant phospholipidosis was the most likely mechanism of toxicity in this case.", {"entities": [[26, 62, "Parameter"], [96, 104, "Pathology"]]}], [3825, "Drug-induced lung and heart disease can result from individual drug toxicity or drug-to-drug interactions, with impairment of kinetics and metabolization.", {"entities": [[0, 35, "Pathology"], [63, 76, "Pathology"], [112, 153, "Pathology"]]}], [3826, "We report the third case of a patient with synchronous interstitial pneumonitis and acute cardiomyopathy induced by venlafaxine, with a new insight regarding the potential lesion mechanism.", {"entities": [[43, 104, "Pathology"], [116, 127, "Drug"], [172, 178, "Pathology"]]}], [3827, "A 35-year-old female patient presented with progressive dyspnea over the previous three months, New York Heart Association (NYHA) functional class III, myalgia, and dry cough.", {"entities": [[0, 13, "Age"], [14, 20, "Sex"], [44, 63, "Pathology"], [82, 94, "Duration"], [152, 159, "Pathology"], [165, 174, "Pathology"]]}], [3828, "She was hospitalized and submitted to CT angiography of the chest, which excluded pulmonary thromboembolic disease but revealed hazy parenchymal micronodules, thickening of interlobular septa, and subtle bilateral areas of ground-glass attenuation, mainly in the upper lobes, without adenopathies or pleuropericardial effusion (Figure 1).", {"entities": [[82, 114, "Pathology"], [128, 157, "Pathology"], [159, 191, "Pathology"], [223, 247, "Pathology"], [284, 296, "Pathology"], [300, 326, "Pathology"]]}], [3829, "A chest X-ray revealed a mixed (reticular and micronodular) pattern and cardiomegaly (Figure 2).", {"entities": [[72, 84, "Pathology"]]}], [3830, "Simultaneously, she was diagnosed with subacute severe heart failure due to a dilated cardiomyopathy.", {"entities": [[39, 68, "Pathology"], [78, 100, "Pathology"]]}], [3831, "The patient had a history of depression and was started on a slow-release formulation of venlafaxine three months prior.", {"entities": [[29, 39, "Pathology"], [89, 100, "Drug"], [101, 113, "Duration"]]}], [3832, "For the last year, she had been taking Centella asiatica and Fucus vesiculosus as phytotherapeutic supplements for weight loss.", {"entities": [[0, 17, "Duration"], [39, 56, "Herb name"], [61, 78, "Herb name"], [115, 121, "Parameter"]]}], [3833, "The patient had no history of smoking, alcohol use, or illicit drug use.", {"entities": [[30, 37, "Parameter"], [39, 50, "Parameter"], [55, 71, "Parameter"]]}], [3834, "Previous medical examinations had been negative for heart disease, and there was neither a relevant family history nor a history of occupational exposure.", {"entities": [[52, 65, "Pathology"]]}], [3836, "Heart catheterization revealed normal coronary arteries and a cardiac index of 2.36 L .", {"entities": [[60, 75, "Parameter"], [79, 85, "Amount"]]}], [3837, "min Pulmonary function test results were normal.", {"entities": []}], [3838, "Renal and hepatic parameters, complement proteins, and urinary sediment were all normal.", {"entities": [[0, 28, "Parameter"], [30, 49, "Parameter"], [55, 71, "Parameter"]]}], [3839, "The serological panel was negative for HIV, syphilis, Mycoplasma sp., Coxiella sp., cytomegalovirus, Epstein-Barr virus, parvovirus B19, and HHV-6.", {"entities": [[39, 42, "Pathology"], [44, 52, "Pathology"], [54, 68, "Pathology"], [70, 82, "Pathology"], [84, 99, "Pathology"], [101, 119, "Pathology"], [121, 135, "Pathology"], [141, 146, "Pathology"]]}], [3840, "The results of testing for autoimmune disease were unremarkable.", {"entities": [[27, 45, "Pathology"]]}], [3841, "Bronchoscopy results were normal.", {"entities": []}], [3842, "The BAL fluid presented normal cellularity, a low CD4/CD8 lymphocyte ratio (0.7), and a massive presence of foamy macrophages (Figure 3).", {"entities": [[31, 42, "Parameter"], [50, 74, "Parameter"], [76, 79, "Amount"], [108, 125, "Parameter"]]}], [3843, "The microbiological study on BAL fluid was negative.", {"entities": []}], [3844, "No transbronchial lung biopsies were obtained, because of ventricular tachycardia during the examination.", {"entities": [[58, 81, "Pathology"]]}], [3845, "The patient was started on standard therapy without improvement.", {"entities": []}], [3846, "Inotropic support was then initiated.", {"entities": []}], [3847, "However, no improvement was seen over the course of a week.", {"entities": [[52, 58, "Duration"]]}], [3848, "At that time, the decision was made to discontinue venlafaxine.", {"entities": [[51, 62, "Drug"]]}], [3849, "Two weeks later, an HRCT revealed notorious improvement, with only a few centrilobular nodules remaining in the right lower lobe.", {"entities": [[0, 9, "Duration"], [73, 94, "Pathology"]]}], [3850, "Together with that radiological upswing, there was an overall improvement, and the LVEF was up to 35% at discharge.", {"entities": [[83, 87, "Parameter"], [98, 101, "Amount"]]}], [3851, "Four months later, the patient presented with an LVEF close to normal (50%), NYHA functional class I, maintaining only mild left ventricle enlargement (60/40 mm), and mild mitral regurgitation.", {"entities": [[0, 17, "Duration"], [49, 53, "Parameter"], [71, 74, "Amount"], [77, 100, "Parameter"], [124, 150, "Pathology"], [152, 160, "Amount"], [172, 192, "Pathology"]]}], [3852, "Most of the cardiac medications were therefore discontinued.", {"entities": [[12, 31, "Drug"]]}], [3853, "There have been various reports on adverse effects related to venlafaxine.", {"entities": [[35, 50, "Pathology"], [62, 73, "Drug"]]}], [3854, "Acute and subacute interstitial pneumonitis have been reported The diagnosis of drug-induced interstitial lung disease is hindered by its clinical nonspecificity, interindividual variations, the confounding effect of comorbidities, and treatment with multiple medications.", {"entities": [[0, 43, "Pathology"], [80, 118, "Pathology"]]}], [3855, "The cytochrome P450 (CYP) superfamily is present in human lung tissue and participates in the enzymatic inactivation of numerous xenobiotics.", {"entities": [[0, 37, "Parameter"], [129, 140, "Target"]]}], [3856, "Venlafaxine is an antidepressant that is metabolized to O-desmethylvenlafaxine (ODV) by the isoenzyme CYP2D6 and, to a lesser extent, by CYP3A4.", {"entities": [[0, 32, "Drug"], [56, 84, "Drug"], [88, 108, "Parameter"], [137, 143, "Parameter"]]}], [3857, "Drug-induced phospholipidosis (DIP) is characterized by intracellular accumulation of phospholipids in various body tissues and formation of lamellar bodies, leading to a foamy macrophage appearance at light microscopy.", {"entities": [[0, 35, "Pathology"], [86, 99, "Parameter"], [177, 187, "Parameter"]]}], [3858, "Although DIP can occur from hours to months after the beginning of treatment, Another typical feature of DIP is its reversibility after drug discontinuation.", {"entities": [[9, 12, "Pathology"], [28, 43, "Duration"], [105, 108, "Pathology"]]}], [3859, "The present case details the occurrence of cardiopulmonary toxicity, which was probably associated with venlafaxine.", {"entities": [[43, 67, "Pathology"], [104, 115, "Drug"]]}], [3860, "The case occurred in a previously healthy 35-year-old patient submitted to exhaustive investigation after the exclusion of other possible causes.", {"entities": [[34, 41, "Pathology"], [42, 53, "Age"]]}], [3861, "Only two similar cases have been reported in the literature.", {"entities": []}], [3862, "The strong temporal connection between the drug intake and the clinical manifestations and, conversely, between the drug discontinuation and the rapid improvement in lung abnormalities and heart function, provides additional support for that hypothesis.", {"entities": [[166, 184, "Pathology"], [189, 203, "Parameter"]]}], [3863, "For ethical reasons, rechallenge with venlafaxine was not carried out.", {"entities": [[38, 49, "Drug"]]}], [3864, "After an objective analysis, considering the Naranjo Adverse Drug Reaction Probability Scale, A DIP could be the mechanism of toxicity, because venlafaxine is a potential CAD, as well as because there were striking quantities of foamy macrophages in the BAL fluid, a low CD4/CD8 T lymphocyte ratio in the blood and BAL fluid, and features that were consistent with a \"macrophage-dominant phospholipidosis\" subtype pattern.", {"entities": [[96, 99, "Pathology"], [126, 134, "Pathology"], [144, 155, "Drug"], [235, 246, "Parameter"], [250, 263, "Parameter"], [271, 297, "Parameter"], [315, 324, "Parameter"], [368, 404, "Pathology"]]}], [3865, "The present case highlights the importance of high clinical suspicion for the timely recognition of drug-induced cardiopulmonary toxicity, especially in cases of initially unexplained disease.", {"entities": [[100, 137, "Pathology"], [184, 191, "Pathology"]]}], [3866, "Prompt discontinuation of the drug usually results in remarkable clinical and prognostic improvement.", {"entities": []}], [3867, "The authors would like to thank Professor V\u00edtor Sobral of the Department of Chemistry of the University of Coimbra for his vital contribution in the analysis of the chemical structure of venlafaxine.", {"entities": [[187, 198, "Drug"]]}], [3868, "A vers\u00e3o completa em portugu\u00eas deste artigo est\u00e1 dispon\u00edvel em www.jornaldepneumologia.com.br A venlafaxina \u00e9 um inibidor de recapta\u00e7\u00e3o de serotonina e noradrenalina utilizado como antidepressivo.", {"entities": []}], [3869, "A variabilidade individual ou intera\u00e7\u00f5es entre fitoter\u00e1picos e f\u00e1rmacos podem causar toxicidade induzida por drogas.", {"entities": []}], [3870, "Relatamos o caso de uma paciente de 35 anos diagnosticada com pneumonite intersticial e miocardiopatia dilatada atribu\u00eddas \u00e0 venlafaxina.", {"entities": []}], [3871, "A paciente procurou atendimento m\u00e9dico devido a dispneia e tosse seca, que come\u00e7aram tr\u00eas meses ap\u00f3s iniciar tratamento com venlafaxina para depress\u00e3o.", {"entities": []}], [3872, "Concomitantemente tomava suplementos fitoter\u00e1picos contendo Centella asiatica e Fucus vesiculosus.", {"entities": []}], [3873, "A radiografia e a CT de t\u00f3rax revelaram doen\u00e7a pulmonar parenquimatosa (micron\u00f3dulos difusos e opacidades em vidro fosco) e, simultaneamente, foi diagnosticada uma miocardiopatia por ecocardiograma, que revelou uma fra\u00e7\u00e3o de eje\u00e7\u00e3o ventricular esquerda (FEVE) de 21%.", {"entities": []}], [3874, "Uma investiga\u00e7\u00e3o ampla foi realizada, incluindo LBA, estudos de imagem, detec\u00e7\u00e3o de doen\u00e7as autoimunes, cateterismo card\u00edaco direito e bi\u00f3psia mioc\u00e1rdica.", {"entities": []}], [3875, "Ap\u00f3s a exclus\u00e3o de outras etiologias e a aplica\u00e7\u00e3o da Escala de Probabilidade de Rea\u00e7\u00f5es Adversas a Medicamentos de Naranjo, foi assumido o diagn\u00f3stico de pneumonite/miocardiopatia s\u00edncronas associadas \u00e0 venlafaxina.", {"entities": []}], [3876, "J\u00e1 foi demonstrado que os suplementos fitoter\u00e1picos utilizados pela paciente podem inibir a isoenzima do complexo enzim\u00e1tico citocromo P450, respons\u00e1vel pelo metabolismo da venlafaxina.", {"entities": []}], [3877, "Ap\u00f3s a descontinua\u00e7\u00e3o da venlafaxina, verificou-se uma r\u00e1pida melhora cl\u00ednica com regress\u00e3o das altera\u00e7\u00f5es radiol\u00f3gicas e normaliza\u00e7\u00e3o da FEVE.", {"entities": []}], [3878, "Este \u00e9 um importante caso de toxicidade cardiopulmonar induzida por droga.", {"entities": []}], [3879, "A administra\u00e7\u00e3o circunstancial de inibidores da isoenzima CYP2D6 e a presen\u00e7a de um fen\u00f3tipo de metaboliza\u00e7\u00e3o lenta de CYP2D6 podem ter resultado na acumula\u00e7\u00e3o t\u00f3xica da venlafaxina e na manifesta\u00e7\u00e3o cl\u00ednica subsequente.", {"entities": []}], [3880, "Aqui, \u00e9 discutida a hip\u00f3tese de a fosfolipidose macrof\u00e1gica ser o mecanismo de toxicidade.", {"entities": []}], [3881, "Doen\u00e7a pulmonar e card\u00edaca induzida por drogas pode resultar da toxicidade dos f\u00e1rmacos para o indiv\u00edduo ou da intera\u00e7\u00e3o entre f\u00e1rmacos, com comprometimento da cin\u00e9tica e do metabolismo.", {"entities": []}], [3882, "Relatamos o terceiro caso de paciente com pneumonite intersticial e miocardiopatia dilatada induzidas pela venlafaxina, com uma nova percep\u00e7\u00e3o sobre o potencial mecanismo de les\u00e3o.", {"entities": []}], [3883, "Paciente do sexo feminino, 35 anos de idade, apresentava dispneia progressiva nos \u00faltimos tr\u00eas meses, classe funcional III da New York Heart Association (NYHA), mialgia e tosse seca.", {"entities": []}], [3884, "Foi internada e submetida a angiografia por TC de t\u00f3rax, que excluiu doen\u00e7a tromboemb\u00f3lica pulmonar mas revelou micron\u00f3dulos parenquimatosos indistintos, espessamento dos septos interlobulares e \u00e1reas de atenua\u00e7\u00e3o em vidro fosco bilaterais e sutis, principalmente nos lobos superiores, sem adenopatias ou derrame pleuroperic\u00e1rdico (Figura 1).", {"entities": []}], [3885, "A radiografia de t\u00f3rax revelou padr\u00e3o misto (reticular e micronodular) e cardiomegalia (Figura 2).", {"entities": []}], [3886, "Simultaneamente, foi diagnosticada com insufici\u00eancia card\u00edaca subaguda grave causada por miocardiopatia dilatada.", {"entities": []}], [3887, "Apresentava hist\u00f3ria de depress\u00e3o e havia iniciado tratamento com uma formula\u00e7\u00e3o de libera\u00e7\u00e3o lenta de venlafaxina h\u00e1 tr\u00eas meses.", {"entities": []}], [3888, "Desde o ano anterior, estava tomando suplementos fitoter\u00e1picos de Centella asiatica e Fucus vesiculosus para perda de peso.", {"entities": []}], [3889, "N\u00e3o apresentava hist\u00f3ria de tabagismo, de uso de \u00e1lcool ou de uso de drogas il\u00edcitas.", {"entities": []}], [3890, "Exames m\u00e9dicos anteriores haviam sido negativos para doen\u00e7as card\u00edacas, e n\u00e3o havia hist\u00f3ria familiar relevante nem hist\u00f3ria de exposi\u00e7\u00e3o ocupacional.", {"entities": []}], [3891, "O exame f\u00edsico revelou apirexia, hipotens\u00e3o leve e SpO O eletrocardiograma mostrou ritmo sinusal normal, batimentos ventriculares prematuros e invers\u00e3o da onda T em V4-V6, conhecida como \"tens\u00e3o\"; uma fra\u00e7\u00e3o de eje\u00e7\u00e3o ventricular esquerda (FEVE) de 21% foi identificada na angiografia de radionucl\u00eddeos; tamb\u00e9m foram encontradas dilata\u00e7\u00e3o biatrial, dilata\u00e7\u00e3o grave do ventr\u00edculo esquerdo (71/60 mm) e fun\u00e7\u00e3o sist\u00f3lica global gravemente comprometida (FEVE = 20%); dilata\u00e7\u00e3o moderada do ventr\u00edculo direito com comprometimento sist\u00f3lico - excurs\u00e3o sist\u00f3lica do plano anular da valva tric\u00faspide de 15 mm (valor normal, 15-20 mm), velocidade de S' de 0,06 m/s (valor normal, > 0,15 m/s) - e regurgita\u00e7\u00f5es funcionais mitral e tric\u00faspide graves foram encontradas no ecocardiograma.", {"entities": []}], [3892, "O cateterismo card\u00edaco revelou art\u00e9rias coron\u00e1rias normais e \u00edndice card\u00edaco de 2,36 L .", {"entities": []}], [3893, "min Os resultados dos testes de fun\u00e7\u00e3o pulmonar foram normais.", {"entities": []}], [3894, "Por\u00e9m, a capacidade de difus\u00e3o mostrou-se um pouco diminu\u00edda (PaO O hemograma apresentou par\u00e2metros inflamat\u00f3rios normais, eutireoidismo e n\u00edvel de pept\u00eddeo natriur\u00e9tico cerebral de 963,6 pg/mL (valor normal, < 100 pg/mL).", {"entities": []}], [3895, "Os par\u00e2metros renais e hep\u00e1ticos, as prote\u00ednas do complemento e o sedimento urin\u00e1rio estavam todos normais.", {"entities": []}], [3896, "O painel sorol\u00f3gico foi negativo para HIV, s\u00edfilis, Mycoplasma sp., Coxiella sp., citomegalov\u00edrus, v\u00edrus Epstein-Barr, parvov\u00edrus B19 e HHV-6.", {"entities": []}], [3897, "Os resultados dos testes para doen\u00e7as autoimunes foram normais.", {"entities": []}], [3898, "Os resultados da broncoscopia foram normais.", {"entities": []}], [3899, "O LBA apresentou celularidade normal, rela\u00e7\u00e3o de linf\u00f3citos CD4/CD8 diminu\u00edda (0,7) e presen\u00e7a maci\u00e7a de macr\u00f3fagos espumosos (Figura 3).", {"entities": []}], [3900, "O estudo microbiol\u00f3gico do LBA foi negativo.", {"entities": []}], [3901, "N\u00e3o foram obtidas bi\u00f3psias pulmonares transbr\u00f4nquicas, em raz\u00e3o de taquicardia ventricular durante o exame.", {"entities": []}], [3902, "Foi iniciado o tratamento padr\u00e3o, sem melhora.", {"entities": []}], [3903, "Foi ent\u00e3o iniciado suporte inotr\u00f3pico.", {"entities": []}], [3904, "Por\u00e9m, nenhuma melhora foi observada ao longo de uma semana.", {"entities": []}], [3905, "Na \u00e9poca, tomou-se a decis\u00e3o de descontinuar a venlafaxina.", {"entities": []}], [3906, "Duas semanas depois, a TCAR revelou uma melhora not\u00f3ria, com a perman\u00eancia de apenas alguns n\u00f3dulos centrolobulares no lobo inferior direito.", {"entities": []}], [3907, "Juntamente com essa recupera\u00e7\u00e3o radiol\u00f3gica, verificou-se uma melhora geral, e a FEVE foi at\u00e9 35% na alta hospitalar.", {"entities": []}], [3908, "Quatro meses depois, a paciente apresentava FEVE pr\u00f3xima \u00e0 normal (50%), classe funcional I da NYHA, apresentando somente dilata\u00e7\u00e3o leve do ventr\u00edculo esquerdo (60/40 mm) e regurgita\u00e7\u00e3o mitral leve.", {"entities": []}], [3909, "A maioria dos medicamentos card\u00edacos foi, portanto, descontinuada.", {"entities": []}], [3910, "V\u00e1rios trabalhos relatam efeitos adversos relacionados \u00e0 venlafaxina.", {"entities": []}], [3911, "H\u00e1 relatos de pneumonite intersticial aguda e subaguda O diagn\u00f3stico da doen\u00e7a pulmonar intersticial induzida por drogas \u00e9 dificultado por sua inespecificidade cl\u00ednica, por variabilidades individuais, pelo efeito de confus\u00e3o causado por comorbidades e pelo tratamento com m\u00faltiplos medicamentos.", {"entities": []}], [3912, "A superfam\u00edlia do citocromo P450 (CYP) est\u00e1 presente no tecido pulmonar humano e participa da inativa\u00e7\u00e3o enzim\u00e1tica de in\u00fameros xenobi\u00f3ticos.", {"entities": []}], [3913, "A venlafaxina \u00e9 um antidepressivo que \u00e9 metabolizado em O-desmetilvenlafaxina (ODV) pela isoenzima CYP2D6 e, em menor escala, pela CYP3A4.", {"entities": []}], [3914, "A fosfolipidose induzida por drogas \u00e9 caracterizada pelo ac\u00famulo intracelular de fosfolip\u00eddios em v\u00e1rios tecidos corporais e pela forma\u00e7\u00e3o de corpos lamelares, levando a uma apar\u00eancia espumosa dos macr\u00f3fagos \u00e0 microscopia de luz.", {"entities": []}], [3915, "Embora a fosfolipidose induzida por drogas possa ocorrer horas ou meses ap\u00f3s o in\u00edcio do tratamento, Outra caracter\u00edstica t\u00edpica da fosfolipidose induzida por drogas \u00e9 a sua reversibilidade ap\u00f3s a descontinua\u00e7\u00e3o da droga.", {"entities": []}], [3916, "O presente caso detalha a ocorr\u00eancia de toxicidade cardiopulmonar, provavelmente associada \u00e0 venlafaxina.", {"entities": []}], [3917, "O caso ocorreu em uma paciente previamente h\u00edgida de 35 anos de idade que foi submetida a investiga\u00e7\u00e3o exaustiva ap\u00f3s a exclus\u00e3o de outras poss\u00edveis causas.", {"entities": []}], [3918, "Apenas dois casos semelhantes foram relatados na literatura.", {"entities": []}], [3919, "Reconhecemos a administra\u00e7\u00e3o concomitante de dois medicamentos fitoter\u00e1picos sabidamente inibidores da isoenzima espec\u00edfica do metabolismo da venlafaxina, o que explicaria o ac\u00famulo de venlafaxina e ODV a n\u00edveis t\u00f3xicos.", {"entities": []}], [3920, "A forte rela\u00e7\u00e3o temporal entre a administra\u00e7\u00e3o da droga e as manifesta\u00e7\u00f5es cl\u00ednicas e, inversamente, entre a descontinua\u00e7\u00e3o da droga e a r\u00e1pida melhora das altera\u00e7\u00f5es pulmonares e da fun\u00e7\u00e3o card\u00edaca fornece suporte adicional a essa hip\u00f3tese.", {"entities": []}], [3921, "Por raz\u00f5es \u00e9ticas, n\u00e3o foi feita reexposi\u00e7\u00e3o \u00e0 venlafaxina.", {"entities": []}], [3922, "Ap\u00f3s uma an\u00e1lise objetiva, considerando-se a Escala de Probabilidade de Rea\u00e7\u00f5es Adversas a Medicamentos de Naranjo, Uma fosfolipidose induzida por drogas poderia ser o mecanismo de toxicidade, pois a venlafaxina \u00e9 uma droga anfif\u00edlica cati\u00f4nica em potencial, e tamb\u00e9m porque havia grandes quantidades de macr\u00f3fagos espumosos no LBA, rela\u00e7\u00e3o de linf\u00f3citos T CD4/CD8 diminu\u00edda no sangue e no LBA e caracter\u00edsticas consistentes com um padr\u00e3o do subtipo \"fosfolipidose macrof\u00e1gica\".", {"entities": []}], [3923, "O presente caso destaca a import\u00e2ncia da alta suspei\u00e7\u00e3o cl\u00ednica para o reconhecimento oportuno da toxicidade cardiopulmonar induzida por drogas, especialmente em casos de doen\u00e7a inicialmente inexplic\u00e1vel.", {"entities": []}], [3924, "A descontinua\u00e7\u00e3o imediata da droga geralmente resulta em not\u00e1vel melhora cl\u00ednica e do progn\u00f3stico.", {"entities": []}], [3925, "Os autores agradecem o Professor V\u00edtor Sobral do Departamento de Qu\u00edmica da Universidade de Coimbra sua vital contribui\u00e7\u00e3o na an\u00e1lise da estrutura qu\u00edmica da venlafaxina.", {"entities": []}], [3926, "Apoio financeiro: Nenhum.", {"entities": []}], [3927, "Trabalho realizado no Servi\u00e7o de Pneumologia, na Unidade de Tratamento de Insufici\u00eancia Card\u00edaca Avan\u00e7ada do Servi\u00e7o de Cardiologia e no Servi\u00e7o de Anatomopatologia, Centro Hospitalar e Universit\u00e1rio de Coimbra, Coimbra, Portugal.", {"entities": []}], [3928, "Various treatments are used to relieve menopausal symptoms for women.", {"entities": [[39, 58, "Pathology"], [63, 68, "Sex"]]}], [3929, "However, herbal substances are frequently used as complementary and alternative therapies as other treatments can increase ovarian and breast cancer risk.", {"entities": [[123, 148, "Pathology"]]}], [3930, "While the herbal substances\u2019 therapeutic effect is essential, the safety of their use is considered more important.", {"entities": []}], [3931, "This study aims to confirm the safety of red ginseng and herb extract complex (RHC), which are used to relieve menopausal symptoms.", {"entities": [[41, 52, "Herb name"], [57, 83, "Herb name"], [111, 130, "Pathology"]]}], [3932, "Subjects were administered with 2\u00a0g RHC or placebo daily for 12\u00a0wk.", {"entities": [[32, 35, "Amount"], [36, 39, "Herb name"], [57, 66, "Duration"]]}], [3933, "Adverse reactions, female hormonal changes, and uterine thickness were observed and recorded on wk 0, 6, and 12.", {"entities": [[0, 17, "Pathology"], [19, 42, "Pathology"], [48, 65, "Pathology"]]}], [3934, "Hematologic and blood chemistry tests were also conducted.", {"entities": []}], [3935, "The reactions of the subjects who received RHC or placebo at least once were analyzed.", {"entities": [[43, 46, "Herb name"]]}], [3936, "A total of six adverse reactions occurred in the RHC group, while nine occurred in the placebo group; common reactions observed in both groups were genital, subcutaneous tissue, and vascular disorders.", {"entities": [[15, 32, "Pathology"], [49, 52, "Herb name"], [148, 200, "Pathology"]]}], [3937, "However, there was no statistically significant difference between the administration groups (p\u00a0=\u00a00.5695), and no severe adverse reactions occurred in both groups.", {"entities": [[121, 138, "Pathology"]]}], [3938, "This study confirms the safety of daily intake of 2\u00a0g of RHC for 12\u00a0wk by menopausal women.", {"entities": [[50, 53, "Amount"], [57, 60, "Herb name"], [61, 70, "Duration"], [74, 84, "Pathology"], [85, 90, "Sex"]]}], [3939, "Efforts have been made to alleviate menopause symptoms using edible crops or alternative foods like bioequivalent hormones and herbs.", {"entities": [[36, 45, "Pathology"]]}], [3940, "According to Posadzki et\u00a0al.", {"entities": []}], [3941, "[3], it was reported that 32.9% of postmenopausal women use complementary and alternative therapies, and of these, herbal substances are the most frequently used (34.6%).", {"entities": [[26, 31, "Amount"], [35, 49, "Pathology"], [50, 55, "Sex"], [163, 168, "Amount"]]}], [3942, "On the one hand, most clinical studies on complementary and alternative therapies, including phytoestrogens, have failed to prove their effects on menopausal symptoms [4].", {"entities": [[22, 38, "Study"], [93, 107, "Herb name"], [147, 166, "Pathology"]]}], [3943, "On the other hand, there are reports that some substances, such as isoflavone, black cohosh (Cimicifuga heracleifolia), or St. John's wort (Hypericum perforatum), are effective in alleviating menopausal symptoms [[5], [6], [7]].", {"entities": [[67, 77, "Herb name"], [79, 118, "Herb name"], [123, 161, "Herb name"], [192, 211, "Pathology"]]}], [3944, "Despite the varied results of the studies on the substances used in complementary and alternative therapies, these substances are still widely used.", {"entities": []}], [3945, "A 2002 Women's Health Initiative (WHI) study [8] confirmed that an increased risk of coronary artery disease, stroke, breast cancer, and venous thromboembolism of the long-term hormone therapy outweighed the benefits of reducing hot flashes, fractures, and colorectal cancer.", {"entities": [[7, 12, "Sex"], [85, 108, "Pathology"], [110, 116, "Pathology"], [118, 131, "Pathology"], [137, 159, "Pathology"], [177, 192, "Drug"], [229, 240, "Pathology"], [242, 251, "Pathology"], [257, 274, "Pathology"]]}], [3946, "In addition, long-term hormone administration increases the risks of uterine cancer and bleeding.", {"entities": [[69, 83, "Pathology"], [88, 96, "Pathology"]]}], [3947, "It also causes an increased number of blood clotting factors produced by the liver, and that weight gain, edema, irregular bleeding, breast pain, and digestive disorders can also develop [9,10].", {"entities": [[15, 60, "Pathology"], [93, 104, "Pathology"], [106, 111, "Pathology"], [113, 131, "Pathology"], [133, 144, "Pathology"], [150, 169, "Pathology"]]}], [3948, "Since then, various studies on red ginseng have been carried out to develop an alternative to hormone therapy.", {"entities": [[31, 42, "Herb name"], [94, 109, "Drug"]]}], [3949, "The various effects of red ginseng can be explained by its adaptogen activity, which nonspecifically increases the body's resistance to external stress and maintains homeostasis by normalizing overall biological functions [11,12].", {"entities": [[23, 34, "Herb name"], [145, 151, "Pathology"]]}], [3950, "Red ginseng has been recognized by the Korean Ministry of Food and Drug Safety (MFDS) [13] for its functions in immunity enhancement, fatigue improvement, blood circulation improvement, memory enhancement, antioxidant activity, and beneficial effects on menopausal women's health.", {"entities": [[0, 11, "Herb name"], [39, 45, "Ethnic group"], [134, 141, "Pathology"], [254, 264, "Pathology"], [265, 270, "Sex"]]}], [3951, "In addition to red ginseng, nine other functional ingredients that relieve menopausal symptoms were approved by the MFDS.", {"entities": [[15, 26, "Herb name"], [75, 94, "Pathology"]]}], [3952, "However, one of these functional ingredients' safety became a critical issue in the functional food market.", {"entities": []}], [3953, "As a result, securing the safety of functional foods became an essential factor.", {"entities": []}], [3954, "Therefore, this study assessed the safety of the 12-wk administration of red ginseng complex (red ginseng and other plant extracts mixture) in menopausal women.", {"entities": [[49, 54, "Duration"], [73, 84, "Herb name"], [94, 105, "Herb name"], [143, 153, "Pathology"], [154, 159, "Sex"]]}], [3955, "The present study was conducted with the approval of the Institutional Review Board of Konkuk University (IRB# KUH 1040083).", {"entities": []}], [3956, "Ethical approval includes agreed processes for obtaining consent from or on behalf of all participants.", {"entities": []}], [3957, "Postmenopausal women with menopausal symptoms, who signed a consent form for the human study, were assessed based on test criteria through a visit evaluation.", {"entities": [[0, 14, "Pathology"], [15, 20, "Sex"], [26, 45, "Pathology"]]}], [3958, "The selected subjects were randomly assigned to the RHC or placebo groups based on their registration order.", {"entities": [[52, 55, "Herb name"]]}], [3959, "The inclusion criteria were as follows: 1) menopausal women aged 45\u201360\u00a0yr old (amenorrhea for more than 12\u00a0mo), 2) women with a modified Kupperman Index (MKI) score of 20 or higher, and 3) women who signed the informed consent form for participating in this study.", {"entities": [[43, 53, "Pathology"], [54, 59, "Sex"], [65, 77, "Age"], [79, 89, "Pathology"], [90, 109, "Duration"], [115, 120, "Sex"], [128, 158, "Parameter"], [168, 170, "Amount"], [189, 194, "Sex"]]}], [3960, "Meanwhile, the exclusion criteria were: 1) women who became menopausal from surgery or chemotherapy; 2) women who underwent hysterectomy; 3) women with a history of endometrial hyperplasia or endometrial, breast, or sex hormone\u2013related cancers; 4) women with uncontrolled hypertension (160/100\u00a0mmHg or higher); 5) women with uncontrolled diabetes mellitus (fasting blood sugar 180\u00a0mg/dL or higher, or cases of starting or changing medication due to diabetes within 3\u00a0mo); 6) uncontrolled thyroid patients; 7) women who have had severe migraines within the last year or who have been diagnosed with thromboembolism, cerebrovascular disease, or serious cardiovascular disease; 8) women with atypical uterine bleeding after 1\u00a0yr of menopause; 9) women who have taken sleep inducers, antidepressants, selective estrogen receptor modulators, antihyperlipidemic drugs, antithrombotic drugs (Aspirin, Warfarin, and Clopidogrel), bisphosphonates, or calcitonin within 4\u00a0wk; 10) women who have taken plant hormones (isoflavone, flaxseed, pomegranate, horseradish, white sorghum, red shamrock, and red ginseng products) in the form of supplements or medicines within 4\u00a0wk; 11) women who have continuously taken functional foods and herbal medicines that could affect bone health, blood lipid lipids (triglyceride and cholesterol), and blood circulation within 4\u00a0wk; 12) women who were administered female hormone formulations within 6\u00a0mo; 13) women with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels exceeding 3 times the laboratory's normal upper limit; 14) women with creatinine levels exceeding 2 times the laboratory's normal upper limit; 15) women with a history of drug or alcohol abuse; 16) women who have performed intensive exercises (more than 10\u00a0h) within 3\u00a0mo; 17) women with hypersensitivity to the test drug or its ingredients; 18) women with clinically significant abnormalities based on mammographies or Pap smears (Category 0 or higher than 3 of Breast Imaging Reporting and Data System (BI-RADS)) is confirmed (in the case of BI-RADS Category 0, subject registration is possible after confirming additional test results; in the case of Pap smear, atypical squamous cell of undetermined significance can be registered); 19) women who have participated in other clinical trials within 1\u00a0mo of the start of the current study or who are planning to participate in another clinical trial during the study period; and, 20) in cases where the researchers decided that the subject is unsuitable to participate in this study.", {"entities": [[43, 48, "Sex"], [60, 70, "Pathology"], [76, 83, "Pathology"], [87, 99, "Drug"], [104, 109, "Sex"], [124, 136, "Pathology"], [141, 146, "Sex"], [165, 188, "Pathology"], [192, 243, "Pathology"], [248, 253, "Sex"], [259, 284, "Pathology"], [286, 298, "Amount"], [314, 319, "Sex"], [325, 355, "Pathology"], [357, 376, "Parameter"], [377, 386, "Amount"], [449, 457, "Pathology"], [458, 469, "Duration"], [475, 495, "Pathology"], [509, 514, "Sex"], [528, 544, "Pathology"], [545, 565, "Duration"], [598, 613, "Pathology"], [615, 638, "Pathology"], [651, 673, "Pathology"], [678, 683, "Sex"], [698, 714, "Pathology"], [715, 725, "Duration"], [729, 738, "Pathology"], [743, 748, "Sex"], [764, 778, "Drug"], [780, 795, "Drug"], [797, 835, "Drug"], [837, 861, "Drug"], [863, 883, "Drug"], [885, 892, "Drug"], [894, 902, "Drug"], [908, 919, "Drug"], [922, 937, "Drug"], [942, 952, "Drug"], [953, 964, "Duration"], [970, 975, "Sex"], [1007, 1017, "Herb name"], [1019, 1027, "Herb name"], [1029, 1040, "Herb name"], [1042, 1053, "Herb name"], [1055, 1068, "Herb name"], [1070, 1082, "Herb name"], [1088, 1099, "Herb name"], [1150, 1161, "Duration"], [1167, 1172, "Sex"], [1290, 1302, "Parameter"], [1307, 1318, "Parameter"], [1343, 1354, "Duration"], [1360, 1365, "Sex"], [1388, 1394, "Sex"], [1416, 1427, "Duration"], [1433, 1438, "Sex"], [1444, 1474, "Parameter"], [1478, 1510, "Parameter"], [1577, 1582, "Sex"], [1588, 1598, "Parameter"], [1665, 1670, "Sex"], [1689, 1710, "Pathology"], [1716, 1721, "Sex"], [1762, 1776, "Duration"], [1778, 1789, "Duration"], [1795, 1800, "Duration"], [1806, 1822, "Pathology"], [1864, 1869, "Sex"], [2259, 2264, "Sex"], [2296, 2311, "Study"], [2312, 2323, "Duration"], [2404, 2418, "Study"]]}], [3961, "This study was designed as a randomized, double-blind, placebo-controlled human study.", {"entities": [[27, 85, "Study"]]}], [3962, "For volunteers who signed the consent form to participate in this study, demographic, medical, and medication history surveys, physical examination, vital signs, physical measurements, laboratory tests, mammography or Pap smear, and MKI were performed.", {"entities": []}], [3963, "If the inclusion/exclusion criteria were met, the volunteer was registered through randomization.", {"entities": []}], [3964, "Subjects assigned to the RHC and placebo group received the test drug or placebo drug for 12\u00a0wk; the assignment ratio was 1 RHC group: 1 placebo group.", {"entities": [[25, 28, "Herb name"], [86, 95, "Duration"], [124, 127, "Herb name"]]}], [3965, "After the baseline visit, the subjects returned after the 6th and 12th wk of test substance administration.", {"entities": [[48, 73, "Duration"]]}], [3966, "Subjects are assigned to Groups A and B based on the pre-made allocation code of the block randomization method in the order of their participation in the clinical trial.", {"entities": [[155, 169, "Study"]]}], [3967, "The size of each block is either 6 or 12, and the ratio of each group is 1:1.", {"entities": []}], [3968, "The randomization table is a permutation of random numbers (random number of A or B) generated through SAS system's randomization program sequentially applied from subject number 1 created.", {"entities": []}], [3969, "The subjects were instructed to take 2 tablets of the test substance (test drug or placebo drug) with water twice a day for 12\u00a0wk (2 tablets of 500\u00a0mg taken twice daily, 30\u00a0min before breakfast and dinner to reduce the interaction with food and increase the bioavailability).", {"entities": [[37, 46, "Amount"], [108, 119, "Frequency"], [120, 129, "Duration"], [131, 150, "Amount"], [157, 168, "Frequency"], [170, 176, "Duration"], [258, 273, "Parameter"]]}], [3970, "A 500\u00a0mg tablet of the test drug contained 375\u00a0mg red ginseng extract, 102.6\u00a0mg plant extract (peony, baekchuk, bokryeong, bamboo leaf, angelica), 22.4\u00a0mg other excipients (hydroxypropylmethylcellulose (C After randomization, 60 subjects in the RHC group and 60 subjects in the placebo group who took the test substance at least once were analyzed.", {"entities": [[2, 8, "Amount"], [43, 49, "Amount"], [50, 69, "Herb name"], [71, 79, "Amount"], [95, 100, "Herb name"], [102, 110, "Herb name"], [112, 121, "Herb name"], [123, 134, "Herb name"], [136, 144, "Herb name"], [147, 154, "Amount"], [226, 237, "Cohort"], [245, 248, "Herb name"], [259, 270, "Cohort"]]}], [3971, "Information on adverse reactions was evaluated by non-directive questioning on each visit during the study period.", {"entities": [[15, 32, "Pathology"]]}], [3972, "In addition, the subjects reported voluntarily during or between visits, and physical examination, laboratory tests, or other evaluations were carried out.", {"entities": []}], [3973, "During the investigation of adverse reactions, the date of onset and disappearance, the degree and result of the adverse reaction, the measures are taken in relation to the test substance and the causal relationship with the test substance, the name of the drug other than the test substance, and treatment of adverse reactions were included.", {"entities": [[28, 45, "Pathology"], [113, 129, "Pathology"], [310, 327, "Pathology"]]}], [3974, "At each visit, adverse reactions were checked, and all adverse reactions detected were monitored continuously until the relevant adverse reactions disappeared, stabilized, or the situation became explanatory.", {"entities": [[15, 32, "Pathology"], [55, 72, "Pathology"], [129, 146, "Pathology"]]}], [3975, "All observed adverse reactions were coded according to the medical dictionary for regulatory activities (MedDRA), and all adverse reactions during the study period were calculated and compared using the number of subjects and the number of occurrences.", {"entities": [[13, 30, "Pathology"], [122, 139, "Pathology"]]}], [3976, "Moreover, the relevance to the test substance (test drug and control drug) and the severity of the adverse reactions were analyzed and presented.", {"entities": [[99, 116, "Pathology"]]}], [3977, "The relationship between the test substance and the adverse reaction was assessed by each subject as \u201cPossibly related,\u201d \u201cProbably related,\u201d \u201cDefinitely related,\u201d or \u201cUnknown.\u201d Meanwhile, the adverse reactions reported as \u201cUnknown\u201d were treated as relevant to the test substance, and detailed information was presented separately.", {"entities": [[52, 68, "Pathology"], [192, 209, "Pathology"]]}], [3978, "For clinical pathology tests (hematologic and blood chemistry tests), the subjects\u2019 general health status was evaluated by conducting clinical pathology tests during the baseline and 12th wk after administering the test substance (or during the dropout visit).", {"entities": [[183, 196, "Duration"]]}], [3979, "Subjects were instructed to come to the hospital after 8\u00a0h of fasting on the day of the examination.", {"entities": [[49, 58, "Duration"]]}], [3980, "Vital signs (blood pressure and pulse) were measured during the baseline visit and on the 6th and 12th wk after taking the test substance.", {"entities": [[13, 27, "Parameter"], [32, 37, "Parameter"], [83, 105, "Duration"]]}], [3981, "Changes in blood estradiol (E2), follicle-stimulating hormone (FSH), luteinizing hormone (LH), and endometrial thickness were measured during the baseline and the 12th wk after taking the test substance.", {"entities": [[11, 31, "Parameter"], [33, 67, "Parameter"], [69, 93, "Parameter"], [99, 120, "Parameter"], [159, 170, "Duration"]]}], [3982, "Statistical analysis was performed using SAS (version 9.4, SAS Institute, Cary, North Caroline, USA).", {"entities": []}], [3983, "For demographic evaluation and safety evaluation analysis, a two-sided test was performed with a significance level of 0.05.", {"entities": []}], [3984, "For the p-values of all analyses, a p-value of <0.05 was considered significant.", {"entities": []}], [3985, "The proportion of subjects with an adverse reaction between groups was calculated and analyzed using the Chi-square test or Fisher's exact test.", {"entities": []}], [3986, "For hematologic and blood chemistry test results, vital signs (blood pressure and pulse), bodyweight test results, blood E2, FSH, LH, and endometrial thickness, the intragroup comparison of the differences before and after intake was performed by paired t-test or Wilcoxon signed-rank test.", {"entities": [[63, 77, "Parameter"], [82, 87, "Parameter"], [90, 100, "Parameter"], [115, 123, "Parameter"], [125, 128, "Parameter"], [130, 132, "Parameter"], [138, 159, "Parameter"]]}], [3987, "In addition, the comparison between the RHC and the placebo groups was evaluated to determine if there is a statistically significant difference by performing a two-sample t-test or Wilcoxon rank-sum test depending on the satisfaction of normality.", {"entities": [[40, 43, "Herb name"]]}], [3988, "Between December 2018 and October 2019, a total of 120 participants were screened.", {"entities": [[0, 38, "Duration"], [51, 67, "Cohort"]]}], [3989, "The number of retaining participants and justification for dropping out in each phase were shown in the CONSORT flow diagram (Fig.\u00a01).", {"entities": []}], [3990, "The study evaluation included all subjects who consumed the test substance at least once after randomization, and Table\u00a01 compares the subjects\u2019 demographic information and characteristics before administration.", {"entities": []}], [3991, "The examination of demographic information and characteristics before consumption showed no statistically significant difference between the intake groups.", {"entities": []}], [3992, "CONSORT flow diagram of subjects selection and allocation.", {"entities": []}], [3993, "Demographic information and pre-administration characteristics of human subjects.", {"entities": []}], [3994, "p-value by Wilcoxon rank-sum test.", {"entities": []}], [3995, "p-value by Chi-square test.", {"entities": []}], [3996, "p-value by Fisher's exact test.", {"entities": []}], [3997, "The incidence and number of adverse reactions occurring after consuming the test substance are presented in Table\u00a02.", {"entities": []}], [3998, "A total of 6 cases occurred in the RHC group, and adverse reactions included gastrointestinal disorders (1.67%), musculoskeletal disorders, connective tissue disorders (1.67%), nervous system disorders (1.67%), genital and breast disorders (1.67%), skin and subcutaneous tissue disorders (1.67%), and vascular disorders (1.67%).", {"entities": [[35, 38, "Herb name"], [50, 67, "Pathology"], [77, 103, "Pathology"], [105, 110, "Amount"], [113, 138, "Pathology"], [140, 167, "Pathology"], [169, 174, "Amount"], [177, 201, "Pathology"], [203, 208, "Amount"], [211, 239, "Pathology"], [241, 246, "Amount"], [249, 287, "Pathology"], [289, 294, "Amount"], [301, 319, "Pathology"], [321, 326, "Amount"]]}], [4000, "Others were microbial contamination (1.67%), nervous system disorders (1.67%), and renal and urinary disorders (1.67%).", {"entities": [[12, 35, "Pathology"], [37, 42, "Amount"], [45, 69, "Pathology"], [71, 76, "Amount"], [83, 110, "Pathology"], [112, 117, "Amount"]]}], [4001, "However, there was no statistically significant difference between the administration groups (p\u00a0=\u00a00.5695).", {"entities": []}], [4002, "No severe adverse reactions occurred in either the RHC or placebo groups, and two patients in the placebo group dropped out due to adverse reactions.", {"entities": [[10, 27, "Pathology"], [51, 54, "Herb name"], [131, 148, "Pathology"]]}], [4003, "Adverse reactions and symptoms.", {"entities": [[0, 17, "Pathology"]]}], [4004, "Cumulative count (number of cases).", {"entities": []}], [4005, "The symptom severity of adverse reactions and their relevance to the test substance are in Table\u00a0S1.", {"entities": [[24, 41, "Pathology"]]}], [4006, "In investigating the severity of adverse reactions during the study period, 6 cases in the RHC group and 9 cases in the placebo group were mild.", {"entities": [[33, 50, "Pathology"], [91, 94, "Herb name"]]}], [4007, "In terms of the relevance to the test substance, 1 case of \u201cprobably related\u201d and 5 cases of \u201cnot related\u201d were reported by subjects in the RHC group, and 2 cases of \u201cprobably related,\u201d 1 case of \u201cpossibly related,\u201d and 6 cases of \u201cnot related\u201d were reported by subjects.", {"entities": [[140, 143, "Herb name"]]}], [4008, "There was no statistically significant difference between the two groups (p\u00a0=\u00a00.7363).", {"entities": []}], [4009, "Table\u00a0S2 shows the adverse reactions that cannot be excluded from the relevance to the test substance.", {"entities": []}], [4010, "Based on the table, the RHC group has one case of gastrointestinal disorder, while the placebo group has one case each of gastrointestinal, nervous system, skin and subcutaneous tissue, and vascular disorders.", {"entities": [[24, 27, "Herb name"], [50, 75, "Pathology"], [122, 208, "Pathology"]]}], [4011, "In the RHC group, one subject fully recovered from gastrointestinal disorder without receiving a related treatment.", {"entities": [[7, 10, "Herb name"], [51, 76, "Pathology"]]}], [4012, "In addition, one subject with pruritus and hot flash and another subject with headache fully recovered after discontinuation of administration in the placebo group.", {"entities": [[30, 38, "Pathology"], [43, 52, "Pathology"], [78, 86, "Pathology"]]}], [4013, "It is noteworthy that no severe adverse reactions were observed in this study.", {"entities": [[32, 49, "Pathology"]]}], [4014, "A clinical pathology test was performed during the baseline and 12th wk of administration.", {"entities": [[64, 71, "Duration"]]}], [4015, "In addition, hematologic and blood chemistry tests were carried out (Table\u00a03, Table\u00a04).", {"entities": []}], [4016, "Hematologic examination.", {"entities": []}], [4017, "Compared between groups, p-value for two-sample t-test.", {"entities": []}], [4018, "Compared between groups; p-value for Wilcoxon rank-sum test.", {"entities": []}], [4019, "Compared within groups, p-value for paired t-test.", {"entities": []}], [4020, "Compared within groups; p-value for Wilcoxon signed-rank test.", {"entities": []}], [4021, "Blood chemistry test.", {"entities": []}], [4022, "AST, aspartate aminotransferase; GOT, glutamic-oxaloacetic transaminase; ALT, alanine aminotransferase; GPT, glutamic pyruvic transaminase; Na, sodium; K, potassium; Cl, chlorine; Ca, calcium; CK, creatine kinase; BUN, blood urea nitrogen; \u03b3-GPT, gamma-glutamyl transpeptidase.", {"entities": [[0, 31, "Parameter"], [33, 71, "Parameter"], [73, 102, "Parameter"], [104, 138, "Parameter"], [140, 150, "Parameter"], [152, 164, "Parameter"], [166, 178, "Parameter"], [180, 191, "Parameter"], [193, 212, "Parameter"], [214, 238, "Parameter"], [240, 276, "Parameter"]]}], [4023, "Compared between groups, p-value for two-sample t-test.", {"entities": []}], [4024, "Compared between groups, p-value for Wilcoxon rank-sum test.", {"entities": []}], [4025, "Compared within groups, p-value for paired t-test.", {"entities": []}], [4026, "Compared within groups; p-value for Wilcoxon signed-rank test.", {"entities": []}], [4027, "The result of analysis of the amount of hematocrit change in the hematologic test shows that after 12\u00a0wk of consumption, hematocrit levels decreased by 1.00%\u00a0\u00b1\u00a01.54% in the RHC group (p\u00a0<\u00a00.0001) and decreased by 0.17%\u00a0\u00b1\u00a01.87% in the placebo group (p\u00a0=\u00a00.5004), showing a statistically significant difference between the groups (p\u00a0=\u00a00.0136).", {"entities": [[40, 50, "Parameter"], [99, 104, "Duration"], [121, 138, "Parameter"], [152, 165, "Amount"], [173, 176, "Herb name"], [213, 226, "Amount"]]}], [4028, "Meanwhile, the analysis of the change in the mean corpuscular volume showed that after 12\u00a0wk of consumption, it decreased by 0.57\u00a0\u00b1\u00a01.46\u00a0fL in the RHC group (p\u00a0=\u00a00.0063) and increased by 0.53\u00a0\u00b1\u00a04.07\u00a0fL in the placebo group (p\u00a0=\u00a00.6590), indicating that there was no statistically significant difference between the groups (p\u00a0=\u00a00.0046).", {"entities": [[87, 92, "Duration"], [125, 139, "Amount"], [147, 150, "Herb name"], [187, 201, "Amount"]]}], [4029, "Thus, the change was within the normal range, and there was no statistically significant difference between the groups after 12\u00a0wk of consumption in other hematologic and blood chemistry test measurements.", {"entities": [[125, 130, "Duration"]]}], [4030, "Table\u00a0S3 shows the analysis results of vital signs (blood pressure and pulse) and body weight.", {"entities": [[52, 66, "Parameter"], [71, 76, "Parameter"], [82, 93, "Parameter"]]}], [4031, "In the systolic blood pressure change analysis, the observed pressure decreased by 3.53\u00a0\u00b1\u00a08.71\u00a0mmHg (p\u00a0=\u00a00.0054) in the RHC group and 5.40\u00a0\u00b1\u00a010.35\u00a0mmHg (p\u00a0=\u00a00.0003) in the placebo group, showing no statistically significant difference between the two groups, after the 6-wk drug administration.", {"entities": [[7, 30, "Parameter"], [83, 99, "Amount"], [120, 123, "Herb name"], [134, 151, "Amount"], [269, 273, "Duration"]]}], [4032, "However, after 12\u00a0wk of consumption, the pressure increased by 1.56\u00a0\u00b1\u00a011.08\u00a0mmHg (p\u00a0=\u00a00.2999) in the RHC group, while it decreased by 3.70\u00a0\u00b1\u00a010.83\u00a0mmHg (p\u00a0=\u00a00.0151) in the placebo group, indicating a statistically significant difference between the groups (p\u00a0=\u00a00.0136).", {"entities": [[15, 20, "Duration"], [41, 49, "Parameter"], [63, 80, "Amount"], [101, 104, "Herb name"], [134, 151, "Amount"]]}], [4033, "All changes were within the normal range, and there was no statistically significant difference between the two groups after 6 and 12\u00a0wk of consumption in the results of the pulse, diastolic blood pressure, and body weight analyses.", {"entities": [[125, 136, "Duration"], [170, 179, "Parameter"], [181, 205, "Parameter"], [211, 222, "Parameter"]]}], [4034, "Meanwhile, the changes in E2, FSH, and LH levels showed no significant difference in both groups after 12\u00a0wk compared to baseline (Table\u00a05), and there was no statistically significant difference between the groups.", {"entities": [[26, 28, "Parameter"], [30, 33, "Parameter"], [39, 48, "Parameter"], [103, 108, "Duration"]]}], [4035, "As for the amount of change in endometrial thickness at baseline and 12\u00a0wk, there were no significant differences between baseline and 12\u00a0wk for each group and between the RHC and placebo groups.", {"entities": [[31, 52, "Parameter"], [69, 74, "Duration"], [135, 140, "Duration"], [172, 175, "Herb name"]]}], [4036, "Changes in estradiol (E2), follicle-stimulating hormone (FSH), luteinizing hormone (LH), and endometrial thickness.", {"entities": [[11, 25, "Parameter"], [27, 61, "Parameter"], [63, 87, "Parameter"], [93, 114, "Parameter"]]}], [4037, "E2, estradiol; FSH, follicle-stimulating hormone; LH, luteinizing hormone.", {"entities": [[0, 13, "Parameter"], [15, 48, "Parameter"], [50, 73, "Parameter"]]}], [4038, "Compared between groups, p-value for two-sample t-test.", {"entities": []}], [4039, "Compared between groups, p-value for the Wilcoxon rank sum test.", {"entities": []}], [4040, "Compared within groups; p-value for Wilcoxon signed-rank test.", {"entities": []}], [4041, "In this study, the safety of RHC, a mixture of red ginseng and herb extract, which has been proven to be effective for menopausal symptoms, was assessed.", {"entities": [[29, 75, "Herb name"], [119, 129, "Pathology"]]}], [4042, "Safety was confirmed by menopausal women's daily consumption of 2\u00a0g RHC for 12\u00a0wk.", {"entities": [[24, 34, "Pathology"], [35, 40, "Sex"], [64, 67, "Amount"], [68, 71, "Herb name"], [72, 81, "Duration"]]}], [4043, "As for the number of adverse reactions during the study period, six adverse reactions were reported in the RHC group and nine adverse reactions in eight placebo group subjects.", {"entities": [[21, 38, "Pathology"], [68, 85, "Pathology"], [107, 110, "Herb name"], [126, 143, "Pathology"]]}], [4044, "However, there was no statistically significant difference between the groups, and there were no severe adverse reactions in either group.", {"entities": [[104, 121, "Pathology"]]}], [4045, "In the RHC group, there was only one case of an adverse reaction that could not be excluded from the relevance to the test substance, gastrointestinal disorder, which was naturally improved.", {"entities": [[7, 10, "Herb name"], [48, 64, "Pathology"], [134, 159, "Pathology"]]}], [4046, "In the placebo group, three cases were reported, and it was confirmed that all of them were fully cured.", {"entities": []}], [4047, "Hematocrit and systolic blood pressure were significantly decreased in both groups at 12\u00a0wk, but all changes were within the normal range.", {"entities": [[0, 10, "Parameter"], [15, 38, "Parameter"], [83, 91, "Duration"]]}], [4048, "The average postmenopause period accounts for more than one-third of a woman's lifespan, and the loss of ovarian function causes physical and psychological changes due to the decrease in sex hormones, and some overlook menopause symptoms as part of the aging process.", {"entities": [[12, 25, "Pathology"], [71, 76, "Sex"], [93, 121, "Pathology"], [187, 199, "Parameter"], [219, 228, "Pathology"]]}], [4049, "Currently, the number of women at least 60\u00a0yr old with symptoms of menopause is increasing significantly due to an increase in the elderly population because of worldwide aging.", {"entities": [[25, 30, "Sex"], [40, 49, "Age"], [67, 76, "Pathology"]]}], [4050, "Considering that life expectancy will be further extended in the future, treatment of menopausal symptoms in the menopausal period is essential for maintaining health and quality of life for women [19].", {"entities": [[86, 96, "Pathology"], [113, 123, "Pathology"], [160, 166, "Pathology"], [191, 196, "Sex"]]}], [4051, "However, an increasing number of patients seek complementary and alternative therapies because of the risk of developing breast cancers and other harmful effects on the cardiovascular system when used long-term [20].", {"entities": [[121, 135, "Pathology"], [146, 161, "Pathology"]]}], [4052, "As a complementary and alternative therapy, various products containing plant estrogens, also called phytoestrogens, are consumed by women.", {"entities": [[72, 115, "Herb name"], [133, 138, "Sex"]]}], [4053, "Phytoestrogens have a chemical structure similar to that of the female hormone estrogen and act similarly to estrogen in the body.", {"entities": [[0, 14, "Herb name"], [64, 70, "Sex"], [71, 87, "Parameter"], [109, 117, "Parameter"]]}], [4054, "Examples include isoflavones, abundantly found in soybeans and ingredients extracted from C.\u00a0heracleifolia, evening primrose, red clover, and pomegranate [21].", {"entities": [[17, 28, "Herb name"], [50, 58, "Herb name"], [90, 106, "Herb name"], [108, 124, "Herb name"], [126, 136, "Herb name"], [142, 153, "Herb name"]]}], [4055, "Although red ginseng does not contain phytoestrogens, it is effective for menopausal symptoms as it can reduce the KI, which scores menopausal symptoms like hot flashes, sweating, and depression without affecting female hormones [18] and improved sexual function [22].", {"entities": [[9, 20, "Herb name"], [38, 52, "Herb name"], [74, 93, "Pathology"], [115, 117, "Parameter"], [132, 151, "Pathology"], [157, 168, "Pathology"], [170, 178, "Pathology"], [184, 194, "Pathology"], [213, 219, "Sex"]]}], [4056, "Moreover, among various diseases developed after menopause, red ginseng has been proven to be effective for improving cardiovascular disease [18], reducing cholesterol [23], reducing oxidative stress [24], and treating mental disorders by reducing stress hormones [25].", {"entities": [[49, 58, "Pathology"], [60, 71, "Herb name"], [118, 140, "Pathology"], [156, 167, "Parameter"], [219, 235, "Pathology"], [248, 263, "Parameter"]]}], [4057, "Red ginseng shows various effects because it contains ginsenosides, polysaccharides, peptides, alkaloids, phenols and phenolic compounds, essential oils, and polyacetylenes.", {"entities": [[0, 11, "Herb name"], [54, 66, "Herb name"], [68, 83, "Herb name"], [85, 93, "Herb name"], [95, 104, "Herb name"], [106, 113, "Herb name"], [118, 136, "Herb name"], [138, 152, "Herb name"], [158, 172, "Herb name"]]}], [4058, "These components interact with each other to maintain homeostasis in the body [26].", {"entities": []}], [4059, "In addition, red ginseng is thought to alleviate menopausal symptoms due to hormonal imbalance by maintaining the body's homeostasis during the menopausal period as these components work together.", {"entities": [[13, 24, "Herb name"], [49, 68, "Pathology"], [144, 154, "Pathology"]]}], [4060, "Even natural substances with tremendous effects are useless if they cause side effects.", {"entities": [[74, 86, "Pathology"]]}], [4061, "As with all pharmaceuticals, safety is the most important consideration.", {"entities": []}], [4062, "Therefore, as a traditional complementary and alternative therapy that can alleviate menopausal symptoms, 12\u00a0wk of RHC consumption may be considered safe for the human body.", {"entities": [[85, 104, "Pathology"], [106, 111, "Duration"], [115, 118, "Herb name"]]}], [4063, "In general, there are many studies on the safety of intake of red ginseng and dietary supplements for 12\u00a0wk, but this study was conducted with less than 120 subjects and observations for a short period of 12\u00a0wk.", {"entities": [[62, 73, "Herb name"], [98, 107, "Duration"], [143, 165, "Cohort"], [183, 210, "Duration"]]}], [4064, "In conclusion, the intake of RHC as a traditional complementary and alternative therapy of menopausal syndrome at a daily dose of 2\u00a0g for 12\u00a0wk was safe in menopausal women.", {"entities": [[29, 32, "Herb name"], [91, 110, "Pathology"], [114, 133, "Frequency"], [134, 143, "Duration"], [156, 166, "Pathology"], [167, 172, "Sex"]]}], [4065, "However, further research is needed on the safety of RHC intake for a long period in large-scale menopausal subjects.", {"entities": [[53, 56, "Herb name"], [97, 107, "Pathology"]]}], [4066, "The following is the Supplementary data to this article: All persons who have made substantial contributions to the work reported in the manuscript (e.g., technical help, writing and editing assistance, general support), but who do not meet the criteria for authorship, are named in the Acknowledgements and have given us their written permission to be named.", {"entities": []}], [4067, "If we have not included an Acknowledgements, then that indicates that we have not received substantial contributions from non-authors.", {"entities": []}], [4068, "Supplementary data to this article can be found online at", {"entities": []}], [4069, "These authors contributed equally to this work.", {"entities": []}], [4070, "Celastrol, a quinone methide triterpene isolated from Tripterygium wilfordii Hook F., has various biochemical and pharmacological activities, and is now being developed as a promising anti-tumor agent.", {"entities": [[0, 39, "Herb name"], [54, 84, "Herb name"], [184, 200, "Drug"]]}], [4071, "Inhibitory activity of compounds towards UDP-glucuronosyltransferase (UGT) is an important cause of clinical drug-drug interactions and herb-drug interactions.", {"entities": [[41, 74, "Target"]]}], [4072, "The aim of the present study is to investigate the inhibition of celastrol towards two important UDP-glucuronosyltransferase (UGT) isoforms UGT1A6 and UGT2B7.", {"entities": [[65, 74, "Herb name"], [97, 157, "Target"]]}], [4073, "Recombinant UGT isoforms and non-specific substrate 4-methylumbelliferone (4-MU) were used.", {"entities": [[12, 15, "Target"]]}], [4074, "The results showed that celastrol strongly inhibited the UGT1A6 and 2B7-mediated 4-MU glucuronidation reaction, with 0.9 \u00b1 0.1% and 1.8 \u00b1 0.2% residual 4-MU glucuronidation activity at 100 \u03bcM of celastrol, respectively.", {"entities": [[24, 33, "Herb name"], [57, 110, "Target"], [195, 204, "Herb name"]]}], [4075, "Furthermore, inhibition kinetic study (Dixon plot and Lineweaver-Burk plot) demonstrated that celastrol noncompetitively inhibited the UGT1A1-mediated 4-MU glucuronidation, and competitively inhibited UGT2B7-catalyzed 4-MU glucuronidation.", {"entities": [[13, 37, "Study"], [94, 103, "Herb name"], [135, 171, "Target"], [201, 238, "Target"]]}], [4076, "The inhibition kinetic parameters (Ki) were calculated to be 0.49 \u03bcM and 0.045 \u03bcM for UGT1A6 and UGT2B7, respectively.", {"entities": [[86, 92, "Target"], [97, 103, "Target"]]}], [4077, "At the therapeutic concentration of celastrol for anti-tumor utilization, the possibility of celastrol-drug interaction and celastrol-containing herbs-drug interaction were strongly indicated.", {"entities": [[36, 45, "Herb name"], [93, 102, "Herb name"], [124, 133, "Herb name"]]}], [4078, "However, given the complicated nature of herbs, these results should be viewed with more caution.", {"entities": []}], [4080, "Celastrol (Figure 1), a quinone methide triterpene, is one of active components isolated from Tripterygium wilfordii Hook F. [2].", {"entities": [[0, 50, "Herb name"], [94, 124, "Herb name"]]}], [4081, "Celastrol has been widely used to effectively treat autoimmune diseases, chronic inflammation, asthma, and neurodegenerative diseases [3,4,5,6].", {"entities": [[0, 9, "Herb name"], [52, 71, "Pathology"], [73, 93, "Pathology"], [95, 101, "Pathology"], [107, 133, "Pathology"]]}], [4082, "Additionally, the anti-tumor activity of celastrol has been drawing much attention [7,8].", {"entities": [[41, 50, "Herb name"]]}], [4083, "The structure of celastrol.", {"entities": [[17, 26, "Herb name"]]}], [4084, "Herb-induced adverse effects are a major cause that limits the clinic utilization of herbal medicines.", {"entities": [[0, 28, "Pathology"]]}], [4085, "The metabolic behaviour of herbal components plays a key role in herbs\u2019 adverse effects, including metabolic activation-induced herb toxicity and metabolic enzymes inhibition-based herb-drug interactions [9].", {"entities": [[72, 87, "Pathology"]]}], [4086, "For metabolic enzymes inhibition-based herb-drug interactions, inhibition of cytochrome P450 (CYP) by herbal constituents has been widely investigated and regarded as a major reason, because CYPs are involved in the metabolism of most clinical drugs [10].", {"entities": [[77, 98, "Target"], [191, 195, "Target"]]}], [4087, "Additionally, many selective probe reactions of CYPs can be effectively utilized to investigate the inhibition of herbal constituents towards various CYP isoforms.", {"entities": [[48, 52, "Target"], [150, 162, "Target"]]}], [4088, "In the past years, these probe reactions have been employed to find many herbal ingredients strongly inhibiting CYP isoforms, including ginsenosides [11], corynoline [12], curcumenol [13], and flavonoids [14].", {"entities": [[112, 124, "Target"], [136, 148, "Herb name"], [155, 165, "Herb name"], [172, 182, "Herb name"], [193, 203, "Herb name"]]}], [4089, "The human uridine glucuronosyltransferases (UGTs) are phase II conjugation enzymes that can conjugate various endogenous substances and exogenous compounds [15].", {"entities": [[10, 49, "Target"]]}], [4090, "Glucuronidation reactions catalyzed by UGTs account for >35% of all phase II drug metabolism [16].", {"entities": [[39, 43, "Target"]]}], [4091, "Many important endogenous substances can be conjugated by UGTs, such as bilirubin, steroid hormones, thyroid hormones, bile acids, and fat-soluble vitamins [17,18].", {"entities": [[58, 62, "Target"]]}], [4092, "Therefore, more attention should be paid to the inhibition of UGTs by herbal components because the influence of UGT-mediated reactions can result in serious herb-drug interactions.", {"entities": [[62, 66, "Target"], [113, 135, "Target"]]}], [4093, "Different from CYPs, limited probe substances have been found for UGT-mediated glucuronidation reaction, which has strongly limited the study of the inhibition of compounds towards UGT activity.", {"entities": [[15, 19, "Target"], [66, 103, "Target"], [181, 184, "Target"]]}], [4094, "Therefore, evaluation of inhibition of compounds towards UGT isoforms was always carried out using recombinant UGTs and nonspecific substrates [19,20,21].", {"entities": [[57, 69, "Target"], [111, 115, "Target"]]}], [4095, "To date, the inhibitory potential of celastrol towards UGT isoforms remains unclear.", {"entities": [[37, 46, "Herb name"], [55, 67, "Target"]]}], [4096, "In the present study, the inhibitory effect of celastrol towards two important UGT isoforms (UGT1A6 and UGT2B7) was investigated.", {"entities": [[47, 56, "Herb name"], [79, 111, "Target"]]}], [4097, "Dixon and Lineweaver-Burk plots were used to determine the inhibition type.", {"entities": []}], [4098, "In Dixon plot and Lineweaver-Burk plot, we can determine the inhibition kinetic type through evaluating the intersection of the lines in the plots.", {"entities": []}], [4099, "When the intersection is in the second quadrant and vertical axis for Dixon and Lineweaver-Burk plots respectively, the inhibition type is competitive.", {"entities": []}], [4100, "When the intersection is in the horizontal axis, the inhibition type is noncompetitive.", {"entities": []}], [4101, "As shown in Figure 2, at 100 \u03bcM of celastrol, the residual activity of UGT1A6 and UGT2B7-mediated 4-MU glucuronidation was 0.9 \u00b1 0.1% and 1.8 \u00b1 0.2% of control group.", {"entities": [[35, 44, "Herb name"], [71, 118, "Target"]]}], [4102, "Furthermore, inhibition kinetic analysis was carried out to determine the inhibition type and kinetic parameters.", {"entities": []}], [4103, "The results showed that celastrol exhibited concentration-dependent inhibitory behaviour towards UGT1A6 and UGT2B7-catalyzed 4-MU glucuronidation.", {"entities": [[24, 33, "Herb name"], [97, 145, "Target"]]}], [4104, "Dixon plot (Figure 3A) and Lineweaver-Burk plot (Figure 3B) showed that celastrol noncompetitively inhibited UGT1A6- mediated 4-MU glucuronidation.", {"entities": [[72, 81, "Herb name"], [109, 146, "Target"]]}], [4105, "The second plot (Figure 3C) using slope (obtained from Lineweaver-Burk plot) vs. celastrol concentration showed that the inhibition kinetic parameter (Ki) was 0.49 \u03bcM.", {"entities": [[81, 90, "Herb name"]]}], [4106, "Different from the inhibition type of UGT1A6, Dixon plot (Figure 4A) and Lineweaver-Burk plot (Figure 4B) demonstrated that the inhibition of UGT2B7 by celastrol best fit the competitive inhibition type, and Ki was calculated to be 0.045 \u03bcM (Figure 4C).", {"entities": [[38, 44, "Target"], [142, 148, "Target"], [152, 161, "Herb name"]]}], [4107, "Initial screening of the inhibition of celastrol (100 \u03bcM) towards UGT1A6 and 2B7-mediated 4-MU glucuronidation.", {"entities": [[39, 48, "Herb name"], [66, 110, "Target"]]}], [4108, "The experiment was performed in duplicate.", {"entities": []}], [4109, "UGT1A6 is a major UGT isoform in human liver that glucuronidates various drugs, toxins, and endogenous substrates, including acetaminophen, benzopyrene, and serotonin [22,23].", {"entities": [[0, 6, "Target"], [125, 138, "Drug"]]}], [4110, "The alteration of UGT1A6 activity may have important pharmacological, toxicological and physiological consequences.", {"entities": [[18, 24, "Target"]]}], [4111, "For example, 120-fold variability of UGT1A6 expression in human liver might result in 13-fold variablity in serotonin glucuronidation [24].", {"entities": [[37, 43, "Target"]]}], [4112, "UGT2B7, one of the most important UGT isoforms, has been demonstrated to be involved in the glucuronidation of several physiologically important endogenous compounds such as steroid hormones, bile acids, retinoids and fatty acids.", {"entities": [[0, 6, "Target"]]}], [4113, "Additionally, it can metabolize many drugs including clofibric acid and valproic acid [25].", {"entities": [[72, 85, "Drug"]]}], [4114, "The glucuronidation of some drugs (e.g., zidovudine, morphine, etc.)", {"entities": [[41, 51, "Drug"], [53, 61, "Drug"]]}], [4115, "is exclusively metabolized by UGT2B7.", {"entities": [[30, 36, "Target"]]}], [4116, "Inhibition kinetic analysis of celastrol (Cela) towards UGT1A6-catalyzed 4-MU glucuronidation.", {"entities": [[31, 47, "Herb name"], [56, 93, "Target"]]}], [4117, "(A) Dixon plot of Cela\u2019s inhibition towards UGT1A6-catalyzed 4-MU glucuronidation.", {"entities": [[18, 22, "Herb name"], [44, 81, "Target"]]}], [4119, "(C) Second plot using slope (obtained from Lineweaver-Burk plot) vs. the concentration of Cela.", {"entities": [[90, 94, "Herb name"]]}], [4120, "When celastrol is employed as an anti-tumor agent, the effective dose is approximately 1\u201310 \u03bcM, which is much higher than inhibition concentration of celastrol towards UGT1A1 and UGT2B7.", {"entities": [[5, 14, "Herb name"], [33, 49, "Drug"], [87, 94, "Amount"], [150, 159, "Herb name"], [168, 174, "Target"], [179, 185, "Target"]]}], [4121, "Additionally, as a promising anti-cancer agent, celastrol is likely to be administered with multiple drugs.", {"entities": [[29, 46, "Drug"], [48, 57, "Herb name"]]}], [4122, "Therefore, high attention should be given to the celastrol-associated drug-drug interaction due to the inhibition of UGT1A1 and UGT2B7.", {"entities": [[117, 123, "Target"], [128, 134, "Target"]]}], [4123, "However, when evaluating the celastrol-containing herbs-drugs interaction, these results should be explained with caution because complicated herbs\u2019 factors might influence the results.", {"entities": [[29, 38, "Herb name"]]}], [4124, "For example, processing of herbs and many environmental factors (soil, altitude, seasonal variation in temperature, length of daylight, rainfall patterns, shade) can influence the quantity of celastrol in herbs, which might strongly alleviate the celastrol-containing herbs-drugs interaction.", {"entities": [[192, 201, "Herb name"], [247, 256, "Herb name"]]}], [4125, "The previous study performed by Du et al.", {"entities": []}], [4126, "showed that many environmental factors (e.g., average precipitation per year, accumulative irradiation time, the soil nitrogen content) could influence the celastrol concentration in Tripterygium wilfordii Hook F. [26].", {"entities": [[156, 165, "Herb name"], [183, 213, "Herb name"]]}], [4127, "Therefore, these factors should be considered when explaining our present results.", {"entities": []}], [4128, "Inhibition kinetic analysis of celastrol (Cela) towards UGT2B7-catalyzed 4-MU glucuronidation.", {"entities": [[31, 47, "Herb name"], [56, 93, "Target"]]}], [4129, "(A) Dixon plot of Cela\u2019s inhibition towards UGT2B7-catalyzed 4-MU glucuronidation.", {"entities": [[18, 22, "Herb name"], [44, 81, "Target"]]}], [4131, "(C) Second plot using slope (obtained from Lineweaver-Burk plot) vs. the concentration of cela.", {"entities": [[90, 94, "Herb name"]]}], [4132, "Celastrol (purity \u2265 98%) was purchased from Weikeqi Biotechnology Co. Ltd (Sichuan, China).", {"entities": [[0, 9, "Herb name"]]}], [4133, "4-methylumbelliferone (4-MU), 4-methylumbelliferone-\u03b2- The probe substrate for all the UGT isoforms tested was 4-MU which is a non-selective substrate of UGTs.", {"entities": [[87, 99, "Target"], [154, 158, "Target"]]}], [4134, "Incubation with each UGT isoform was carried out as previously reported [25].", {"entities": [[21, 32, "Target"]]}], [4135, "The mixture (200 \u03bcL total volume) contained recombinant UGTs (final concentration: 0.025 and 0.05 mg/mL for UGT1A6 and UGT2B7) 5 mM UDPGA, 5 mM MgCl Our study indicates the possible occurrence of celastrol-drug interactions or celastrol-containing herbs-drug interactions due to the strong inhibition of celastrol towards UGT1A6 and UGT2B7.", {"entities": [[56, 60, "Target"], [196, 205, "Herb name"], [227, 236, "Herb name"], [304, 313, "Herb name"], [322, 328, "Target"], [333, 339, "Target"]]}], [4136, "However, given the complicated nature of herbs, these results should be viewed with more caution.", {"entities": []}], [4137, "Sample Availability: Sample of the compound celastrol is available from the authors.", {"entities": []}], [4138, "The purpose of this study was to investigate the herb\u2013drug interactions involving red ginseng extract (RGE) or ginsenoside Rc with valsartan, a substrate for organic anion transporting polypeptide (OATP/Oatp) transporters.", {"entities": [[82, 107, "Herb name"], [111, 125, "Herb name"], [131, 140, "Drug"], [158, 221, "Target"]]}], [4140, "The therapeutic benefits of ginseng include anti-diabetic and anti-inflammatory effect and anti-oxidative response on chronic liver disease [3,4,5,6,7,8].", {"entities": [[28, 35, "Herb name"], [118, 139, "Pathology"]]}], [4141, "Ginseng is also commonly used due to its potential as a chemo-preventive agent and adjuvant therapy [9].", {"entities": [[0, 7, "Herb name"]]}], [4142, "These pharmacological activities have also been observed for various ginsenosides mainly present in ginseng products [4].", {"entities": [[69, 81, "Herb name"], [100, 107, "Herb name"]]}], [4143, "Due to the growing use of herbal medicine and convenience of taking herbal formulations, herb\u2013drug interactions caused by the co-administration of herbal medicine with therapeutic drugs have also rapidly increased from 13.8% in 2010 to 17.3% in 2013 among adverse drug reactions in China [10].", {"entities": [[256, 278, "Pathology"]]}], [4144, "The most frequently reported cases of herb\u2013drug interactions include the modulation of drug metabolizing enzymes and transporters by herbal medicines and the causative pharmacokinetic alterations of co-administered therapeutic drugs that may acts as substrates for drug metabolizing enzymes and transporters [8,11].", {"entities": [[20, 34, "Study"]]}], [4145, "In case of ginseng interactions, it was reported that no herb\u2013drug interaction between single oral dose of Korean red ginseng extract (RGE) (0.5\u20132.0 g/kg) and the probe substrates for five cytochrome P450 (CYP) enzymes (i.e., CYP1A2, 2C9, 2C19, 2D6, 3A) in mouse [12].", {"entities": [[11, 18, "Herb name"], [107, 113, "Ethnic group"], [114, 139, "Herb name"], [141, 153, "Amount"], [189, 218, "Target"], [226, 252, "Target"]]}], [4146, "Repeated oral administration of RGE (0.5 g/kg for 2 weeks in mice and 85 mg total ginsenosides for 2 weeks in human) did not alter the metabolic activity of above 5 CYP enzymes in the mouse liver [13] and could not induce clinically significant interaction in human [14,15].", {"entities": [[32, 35, "Herb name"], [37, 45, "Amount"], [46, 57, "Duration"], [70, 75, "Amount"], [82, 94, "Herb name"], [95, 106, "Duration"], [165, 176, "Target"]]}], [4147, "In a study conducted by Malati et al.", {"entities": []}], [4148, "[16], Korean ginseng (0.5 g capsule twice daily for 28 days) induced CYP3A activity and decrease plasma concentration of midazolam following oral administration of 8 mg midazolam.", {"entities": [[6, 12, "Ethnic group"], [13, 20, "Herb name"], [22, 27, "Amount"], [36, 47, "Frequency"], [48, 59, "Duration"], [69, 74, "Target"], [121, 130, "Drug"], [164, 168, "Amount"], [169, 178, "Drug"]]}], [4149, "The expression levels of organic anion transporter 1 (Oat1) and Oat3 in the kidney and P-glycoprotein (P-gp) in the liver were increased by the repeated administration of RGE (30\u2013300 mg/kg for 2 weeks) in mice, which were accompanied with the dose dependent decrease in the area under the plasma concentration-time curve (AUC) of fexofenadine, a substrate for P-gp [17].", {"entities": [[25, 59, "Target"], [64, 68, "Target"], [87, 108, "Target"], [171, 174, "Herb name"], [176, 188, "Amount"], [189, 200, "Duration"], [274, 326, "Parameter"], [330, 342, "Drug"], [360, 364, "Target"]]}], [4150, "Repeated RGE treatment was reported to decrease multidrug resistance-related protein 2 (Mrp2) mRNA and protein expression, consequently decreasing the biliary excretion of methotrexate and increasing plasma concentration [8].", {"entities": [[9, 12, "Herb name"], [48, 93, "Target"], [94, 98, "Target"], [172, 184, "Drug"]]}], [4151, "Intestinal and hepatic organic cation transporter 1 (Oct1) expression was increased and decreased, respectively, in rats following repeated administration of RGE (1.5 g/kg for 7 days) [19].", {"entities": [[23, 58, "Target"], [158, 161, "Herb name"], [163, 171, "Amount"], [172, 182, "Duration"]]}], [4152, "Although repeated administration of RGE suggested modulation of transporter activity, the systematic pharmacokinetic ginseng-drug interaction on drug transporters and clinical evidence is still limited [20].", {"entities": [[36, 39, "Herb name"], [117, 124, "Herb name"]]}], [4153, "In addition to ginseng products, individual ginsenosides can also modulate drug-metabolizing enzymes or transporters.", {"entities": [[15, 22, "Herb name"], [44, 56, "Herb name"]]}], [4154, "For example, Rb1, the most abundant ginsenoside in RGE, was found to significantly inhibit CYP2C9 (IC The inhibitory effects of ginsenosides on drug transporters were evaluated using HEK293 cells overexpressing OCT1, OCT2, OAT1, OAT3, OATP1B1, OATP1B3 and HEK293-mock cells.", {"entities": [[13, 16, "Herb name"], [36, 47, "Herb name"], [51, 54, "Herb name"], [91, 97, "Target"], [99, 101, "Parameter"], [128, 140, "Herb name"], [211, 215, "Target"], [217, 221, "Target"], [223, 227, "Target"], [229, 233, "Target"], [235, 242, "Target"], [244, 251, "Target"]]}], [4155, "First, we measured the uptake of probe substrates into respective transporters in the presence of typical inhibitors of the transporters for the system validation (Figure 1).", {"entities": []}], [4156, "Triethylammonium (TEA) inhibited OCT1 and OCT2 with IC We then evaluated the modulation of drug transporters by ginsenosides.", {"entities": [[33, 37, "Target"], [42, 46, "Target"], [52, 54, "Parameter"], [112, 124, "Target"]]}], [4157, "We found that ginsenosides selectively inhibited OATP transport activities but not OCTs and OATs.", {"entities": [[14, 26, "Herb name"], [49, 53, "Target"], [83, 87, "Target"], [92, 96, "Target"]]}], [4158, "Ginsenosides Rb1, Rb2, Rc, Rd, Rg3, compound K, Rh2, PPD, PPT, and Rh1 had IC Based on the significant inhibitory effect of ginsenosides on OATP1B1 and OATP1B3, we further evaluated the in vivo herb\u2013drug interaction using a substrate drug for both OATP1B1 and OATP1B3.", {"entities": [[0, 12, "Herb name"], [13, 16, "Herb name"], [18, 21, "Herb name"], [23, 25, "Herb name"], [27, 29, "Herb name"], [31, 34, "Herb name"], [36, 46, "Herb name"], [48, 51, "Herb name"], [53, 56, "Herb name"], [58, 61, "Herb name"], [67, 70, "Herb name"], [75, 77, "Parameter"], [124, 136, "Herb name"], [140, 147, "Target"], [152, 159, "Target"], [248, 255, "Target"], [260, 267, "Target"]]}], [4159, "Valsartan was selected as a substrate for both OATP1B1 and OATP1B3 (Figure 4).", {"entities": [[0, 9, "Drug"], [47, 54, "Target"], [59, 66, "Target"]]}], [4160, "Valsartan uptake by HEK293 cells expressing OATP1B1 and OATP1B3 was increased by 19.8-fold and 26.1-fold, respectively, compared with the uptake by HEK293-mock cells.", {"entities": [[0, 9, "Drug"], [44, 51, "Target"], [56, 63, "Target"]]}], [4162, "The contribution of Oatp transporters in the hepato-biliary excretion was about 70\u201385% in both rats and human [29,30].", {"entities": [[20, 37, "Target"]]}], [4163, "The results suggest that valsartan could be used as a model drug for investigating OATP (in human) or Oatp (in rats)-mediated herb\u2013drug interaction between valsartan and RGE or ginsenosides.", {"entities": [[25, 34, "Drug"], [83, 87, "Target"], [102, 106, "Target"], [156, 165, "Drug"], [170, 173, "Herb name"], [177, 189, "Herb name"]]}], [4164, "We initially investigated the effect of rifampin on the valsartan pharmacokinetics following the intravenous injection of valsartan at a dose of 1 mg/kg as a positive control group and the results were shown in Figure 5A and Table 2.", {"entities": [[40, 48, "Drug"], [56, 65, "Drug"], [122, 131, "Drug"], [145, 152, "Amount"]]}], [4165, "The plasma concentration of valsartan was increased by co-treatment with rifampin, a typical inhibitor of OATP or Oatp transporters.", {"entities": [[28, 37, "Drug"], [73, 81, "Drug"], [106, 110, "Target"], [114, 131, "Target"]]}], [4166, "Thus, pharmacokinetic parameters such as the area under the plasma concentration-time curve (AUC To explain the lack of herb\u2013drug interaction between RGE and valsartan, we measured the plasma concentrations of ginsenosides following repeated administration of RGE using the previously developed analytical method by LC-MS/MS [19,31].", {"entities": [[41, 91, "Parameter"], [93, 96, "Parameter"], [150, 153, "Herb name"], [158, 167, "Drug"], [210, 222, "Herb name"], [260, 263, "Herb name"]]}], [4167, "Among the 14 ginsenosides examined (Rb1, Rb2, Rc, Rd, Rh2, Rg3, F2, compound K, PPD, Re, Rh1, Rg1, F1, and PPT), 6 ginsenosides were detected in the plasma samples and the plasma concentrations of the 6 ginsenosides are shown in Figure 6.", {"entities": [[13, 25, "Herb name"], [36, 39, "Herb name"], [41, 44, "Herb name"], [46, 48, "Herb name"], [50, 52, "Herb name"], [54, 57, "Herb name"], [59, 62, "Herb name"], [64, 66, "Herb name"], [68, 78, "Herb name"], [80, 83, "Herb name"], [85, 87, "Herb name"], [89, 92, "Herb name"], [94, 97, "Herb name"], [99, 101, "Herb name"], [107, 110, "Herb name"], [115, 127, "Herb name"], [203, 215, "Herb name"]]}], [4168, "The ginsenosides Rh2, Rg3, F2, and compound K (intermediate metabolites of PPD-type ginsenosides [32], were not detected.", {"entities": [[4, 16, "Herb name"], [17, 20, "Herb name"], [22, 25, "Herb name"], [27, 29, "Herb name"], [35, 45, "Herb name"], [75, 96, "Herb name"]]}], [4169, "PPD, a final metabolite of PPD-type ginsenosides, was detected in the rat plasma and showed a slow elimination process (Figure 6E and Table 3).", {"entities": [[0, 3, "Herb name"], [27, 48, "Herb name"]]}], [4170, "Similarly, Re, Rh1, Rg1, and F1 (PPT-type ginsenosides and their intermediate metabolites [32]) were not detected in the rat plasma.", {"entities": [[11, 13, "Herb name"], [15, 18, "Herb name"], [20, 23, "Herb name"], [29, 31, "Herb name"], [33, 54, "Herb name"]]}], [4171, "PPT, a final metabolite of PPT-type ginsenosides, was detected and also showed a slow elimination process (Figure 6F and Table 3).", {"entities": [[0, 3, "Herb name"], [27, 48, "Herb name"]]}], [4172, "As shown in Table 3. the maximum plasma concentrations of Rb1, Rb2, Rc, Rd, PPD, and PPT were 17.84 \u00b1 2.34 ng/mL (15.8 nM), 10.02 \u00b1 1.04 ng/mL (9.1 nM), 11.67 \u00b1 2.49 (10.6 nM), 5.10 \u00b1 0.74 ng/mL (5.3 nM), 20.56 \u00b1 9.47 ng/mL (48.4 nM), and 16.97 \u00b1 8.99 ng/mL (38.5 nM), respectively.", {"entities": [[25, 54, "Parameter"], [58, 61, "Herb name"], [63, 66, "Herb name"], [68, 70, "Herb name"], [72, 74, "Herb name"], [76, 79, "Herb name"], [85, 88, "Herb name"], [94, 112, "Amount"], [114, 121, "Amount"], [124, 142, "Amount"], [144, 150, "Amount"], [153, 165, "Amount"], [167, 174, "Amount"], [177, 194, "Amount"], [196, 202, "Amount"], [205, 223, "Amount"], [225, 232, "Amount"], [239, 257, "Amount"], [259, 266, "Amount"]]}], [4173, "These concentrations might be far below the IC We further investigated herb\u2013drug interaction between valsartan and individual ginsenoside.", {"entities": [[44, 46, "Parameter"], [101, 110, "Drug"], [126, 137, "Herb name"]]}], [4174, "At first, the inhibitory effect of ginsenoside Rb1, Rb2, and Rc on the OATP1B1 and OATP1B3-mediated valsartan uptake was measured.", {"entities": [[35, 46, "Herb name"], [47, 50, "Herb name"], [52, 55, "Herb name"], [61, 63, "Herb name"], [71, 78, "Target"], [83, 90, "Target"], [100, 109, "Drug"]]}], [4175, "Ginsenoside Rb1, Rb2, and Rc was selected considering its stability and high plasma concentation in rat plasma (based on Figure 6) and in human plasma [31,33] as well as its low IC Next, we investigated whether the high plasma concentration of individual ginsenoside (Rc) above the IC To investigate the cause of the minimal herb\u2013drug interaction between Rc and valsartan, we measured the plasma and liver distribution of Rc following intravenous injection of Rc.", {"entities": [[0, 11, "Herb name"], [12, 15, "Herb name"], [17, 20, "Herb name"], [26, 28, "Herb name"], [178, 180, "Parameter"], [255, 271, "Herb name"], [282, 284, "Parameter"], [355, 357, "Herb name"], [362, 371, "Drug"], [422, 424, "Herb name"], [460, 462, "Herb name"]]}], [4176, "As shown in Figure 9A, Rc was not widely distributed to the liver; thus, the liver concentration of Rc was lower than the plasma concentration of Rc and the liver-to-plasma concentration ratio of Rc was in the range of 0.13\u20130.2.", {"entities": [[23, 25, "Herb name"], [100, 102, "Herb name"], [146, 148, "Herb name"], [196, 198, "Herb name"]]}], [4177, "In addition, these tri-glycosylated ginsenosides showed high protein binding in rat plasma and liver homogenates (Figure 9B).", {"entities": [[19, 48, "Herb name"]]}], [4178, "When calculated free Rc concentration in our system, free Rc concentration was estimated to be 0.08\u20130.34 \u03bcM in the rat plasma and 0.07\u20130.14 \u03bcM in the rat liver.", {"entities": [[21, 23, "Herb name"], [58, 60, "Herb name"], [95, 107, "Amount"], [130, 142, "Amount"]]}], [4179, "As Oatp transporters are located in the sinusoidal membrane of hepatocytes, the low hepatic distribution and high protein binding of Rc may contribute to the negative inhibitory effect of Rc on Oatp transporters in vivo, which might result in the negligible pharmacokinetic interaction between Rc and valsartan.", {"entities": [[3, 20, "Target"], [133, 135, "Herb name"], [188, 190, "Herb name"], [194, 211, "Target"], [294, 296, "Herb name"], [301, 310, "Drug"]]}], [4180, "Similarly, limited herb\u2013drug interaction between valsartan and ginsenoside Rb1 and Rb2 would be expected based on their similarity in the structure, protein binding features, and inhibitory effect on OATP transporters (Figure 7 and Figure 9B, Table 1).", {"entities": [[49, 58, "Drug"], [63, 74, "Herb name"], [75, 78, "Herb name"], [83, 86, "Herb name"], [200, 204, "Target"]]}], [4181, "In the present study, the inhibitory effect of 12 ginsenosides (Rb1, Rb2, Rc, Rd, compound K, Rg3, Rh2, PPD, PPT, Re, Rg1, and Rh1) on HEK293 cells overexpressing drug transporters such as OCT1, OCT2, OAT1, OAT3, OATP1B1, and OATP1B3 was evaluated.", {"entities": [[50, 62, "Herb name"], [64, 67, "Herb name"], [69, 72, "Herb name"], [74, 76, "Herb name"], [78, 80, "Herb name"], [82, 92, "Herb name"], [94, 97, "Herb name"], [99, 102, "Herb name"], [104, 107, "Herb name"], [109, 112, "Herb name"], [114, 116, "Herb name"], [118, 121, "Herb name"], [127, 130, "Herb name"], [189, 193, "Target"], [195, 199, "Target"], [201, 205, "Target"], [207, 211, "Target"], [213, 220, "Target"], [226, 233, "Target"]]}], [4182, "The transport activity of OCT1, OCT2, OAT1, and OAT3 was not modulated by the 12 ginsenosides.", {"entities": [[26, 30, "Target"], [32, 36, "Target"], [38, 42, "Target"], [48, 52, "Target"], [81, 93, "Herb name"]]}], [4183, "However, Rb1, Rb2, Rc, Rd, Rg3, compound K, and Rh2 (PPD-type ginsenosides) inhibited OATP1B1 with IC This possible herb\u2013drug interaction led us to investigate OATP-mediated in vivo pharmacokinetic herb\u2013drug interactions because OATPs play important roles in the intestinal absorption and hepatic uptake of various therapeutic reagents.", {"entities": [[9, 12, "Herb name"], [14, 17, "Herb name"], [19, 21, "Herb name"], [23, 25, "Herb name"], [27, 30, "Herb name"], [32, 42, "Herb name"], [48, 51, "Herb name"], [53, 74, "Herb name"], [86, 93, "Target"], [99, 101, "Parameter"], [160, 164, "Target"], [229, 234, "Target"]]}], [4184, "And a lot of clinically relevant herb\u2013drug interactions and drug-drug interactions have been reported to be caused by the inhibition of OATPs [34].", {"entities": [[136, 141, "Target"]]}], [4185, "For example, gemfibrozil and cyclosporine can increase the plasma exposure of pravastatin, pitavastatin, and atorvastatin through the inhibition of hepatic OATPs [34].", {"entities": [[13, 24, "Drug"], [29, 41, "Drug"], [78, 89, "Drug"], [91, 103, "Drug"], [109, 121, "Drug"], [148, 161, "Target"]]}], [4186, "Green tea and its marker component, epigallocatechin gallate, can also suppress the absorption of naldolol and rosuvastatin via the inhibition of intestinal OATP [35].", {"entities": [[0, 9, "Herb name"], [36, 60, "Herb name"], [98, 106, "Drug"], [111, 123, "Drug"], [146, 161, "Target"]]}], [4187, "Given the importance of OATP (in human) and Oatp (in rat) in the pharmacokinetics and biliary excretion of valsartan [29,30], we monitored Oatp-mediated in vivo herb\u2013drug interactions using valsartan as a substrate for Oatps in rats.", {"entities": [[24, 28, "Target"], [44, 48, "Target"], [107, 116, "Drug"], [139, 143, "Target"], [190, 199, "Drug"], [219, 224, "Target"]]}], [4188, "The results revealed that the repeated administration of RGE and high dose of Rc did not significantly induce herb\u2013drug interactions involving valsartan (Figure 5 and Figure 8).", {"entities": [[57, 60, "Herb name"], [78, 80, "Herb name"], [143, 152, "Drug"]]}], [4189, "Among PPD-type ginsenosides that inhibited in vitro OATP function, ginsenosides Rb1, Rb2, and Rc demonstrated high affinity for OATP1B3 inhibition (1.9\u20135.1 \u03bcM for OATP1B3; Figure 7).", {"entities": [[6, 27, "Herb name"], [43, 51, "Study"], [52, 56, "Target"], [67, 79, "Herb name"], [80, 83, "Herb name"], [85, 88, "Herb name"], [94, 96, "Herb name"], [128, 135, "Target"], [148, 158, "Amount"], [163, 170, "Target"]]}], [4190, "The plasma concentration was ranged from 7.8 \u03bcM to 34.1 \u03bcM but unbound fraction of tri-glycosylated PPD-type ginsenosides (Rb1, Rb2, and Rc) was very low (0.1\u20130.2% in rat plasma, 0.4\u20130.5% in rat liver; Figure 9B).", {"entities": [[83, 121, "Herb name"], [123, 126, "Herb name"], [128, 131, "Herb name"], [137, 139, "Herb name"]]}], [4191, "Moreover, the tri-glycosylated ginsenosides are hydrophilic and bulky and, thus, they are difficult to be readily distributed in the liver tissue.", {"entities": [[14, 43, "Herb name"]]}], [4192, "Taken together, high protein binding and limited liver distribution of tri-glycosylated PPD-type ginsenosides (Rb1, Rb2, and Rc) might contribute to the lack of in vivo pharmacokinetic herb\u2013drug interactions involving valsartan in rats although their plasma concentration was maximized following repeated intravenous injection of single ginsenoside.", {"entities": [[71, 109, "Herb name"], [111, 114, "Herb name"], [116, 119, "Herb name"], [125, 127, "Herb name"], [218, 227, "Drug"], [337, 348, "Herb name"]]}], [4193, "Jiang et al.", {"entities": []}], [4194, "[23] reported that the unbound fraction of PPD-type ginsenosides was very low (0.4\u20130.9% in Rb1, Rc, and Rd) in the human plasma.", {"entities": [[43, 64, "Herb name"], [91, 94, "Herb name"], [96, 98, "Herb name"], [104, 106, "Herb name"]]}], [4195, "Based on the similarity in the structure and protein binding features between rats and human and inhibitory effect on OATP transporters of Rb1, Rb2, and Rc, limited herb\u2013drug interaction between valsartan and ginsenoside Rb1, Rb2, and Rc would be expected in human.", {"entities": [[118, 122, "Target"], [139, 142, "Herb name"], [144, 147, "Herb name"], [153, 155, "Herb name"], [195, 204, "Drug"], [209, 220, "Herb name"], [221, 224, "Herb name"], [226, 229, "Herb name"], [235, 237, "Herb name"]]}], [4196, "In case of co-administration of valsartan and rifampin, a significant drug interaction between valsartan and rifampin was found (Figure 5A) because unbound concentration of rifampin (4.7\u201322.9 \u03bcM) would exceed the IC Clinical herb\u2013drug interactions between ginseng or ginsenosides and OATP1B1 or OATP1B3 have not been fully investigated.", {"entities": [[32, 41, "Drug"], [46, 54, "Drug"], [95, 104, "Drug"], [109, 117, "Drug"], [173, 181, "Drug"], [183, 194, "Amount"], [213, 215, "Parameter"], [256, 263, "Herb name"], [267, 279, "Herb name"], [284, 291, "Target"], [295, 302, "Target"]]}], [4198, "In addition, 82-year-old male patient who took atorvastatin (80 mg), atenolol (50 mg), and aspirin (100 mg) reported drug-induced liver injury after concomitant ginseng intake.", {"entities": [[13, 24, "Age"], [25, 29, "Sex"], [47, 59, "Drug"], [61, 66, "Amount"], [69, 77, "Drug"], [79, 84, "Amount"], [91, 98, "Drug"], [100, 106, "Amount"], [117, 142, "Pathology"], [161, 168, "Herb name"]]}], [4199, "The patient\u2019s symptoms regarding liver injury were resolved within 2 months after the cessation of both atorvastatin and the ginseng product [42].", {"entities": [[33, 45, "Pathology"], [60, 75, "Duration"], [104, 116, "Drug"], [125, 132, "Herb name"]]}], [4200, "After that, the case of liver injury might be deduced by the impaired elimination of atorvastatin through the inhibition of CYP3A4 and/or OATP1B1 activity by ginseng product [42].", {"entities": [[24, 36, "Pathology"], [85, 97, "Drug"], [124, 130, "Target"], [138, 145, "Target"], [158, 165, "Herb name"]]}], [4201, "The benefits of ginseng and ginsenosides have been reported in cardiovascular diseases [2].", {"entities": [[16, 23, "Herb name"], [28, 40, "Herb name"], [63, 86, "Pathology"]]}], [4202, "Ginseng is also widely used for individuals with cardiovascular risk factors such as hypertension and hypercholesterolemia [2].", {"entities": [[0, 7, "Herb name"], [85, 97, "Pathology"], [102, 122, "Pathology"]]}], [4203, "The ginsenoside Rc has been found to have analgesic, anti-allergic, anti-tumor, and sedative effects [43].", {"entities": [[4, 18, "Herb name"]]}], [4204, "The ginsenoside Rc may also be a strong anti-diabetic agent because it can markedly enhance glucose uptake [44].", {"entities": [[4, 18, "Herb name"]]}], [4205, "Therefore, in conclusion, the findings showing the lack of herb\u2013drug interactions between RGE or ginsenoside Rc and valsartan would provide useful information for patients taking anti-hypertensive, anti-diabetics, anti-tumor drugs such as valsartan and repaglinide that are substrate for OATPs transporters.", {"entities": [[90, 93, "Herb name"], [97, 111, "Herb name"], [116, 125, "Drug"], [179, 196, "Drug"], [198, 212, "Drug"], [214, 230, "Drug"], [239, 248, "Drug"], [253, 264, "Drug"], [288, 293, "Target"]]}], [4206, "RGE was purchased from the Punggi Ginseng Cooperative Association (Youngjoo, Kyungpook, Korea).", {"entities": [[0, 3, "Herb name"]]}], [4207, "The ginsenosides Rb1, Rb2, Rc, Rd, Rg1, Rg3, Rh1, Rh2, compound K, Re, PPD, and PPT were purchased from the Ambo Institute (Daejeon, Korea).", {"entities": [[4, 16, "Herb name"], [17, 20, "Herb name"], [22, 25, "Herb name"], [27, 29, "Herb name"], [31, 33, "Herb name"], [35, 38, "Herb name"], [40, 43, "Herb name"], [45, 48, "Herb name"], [50, 53, "Herb name"], [55, 65, "Herb name"], [67, 69, "Herb name"], [71, 74, "Herb name"], [80, 83, "Herb name"]]}], [4208, "Berberine, caffeine, valsartan, probenecid, rifampin, TEA, sodium dodecyl sulfate (SDS), and Hank\u2019s balanced salt solution (HBSS) were obtained from Sigma-Aldrich (St. Louis, MO, USA).", {"entities": [[0, 9, "Herb name"], [11, 19, "Herb name"], [21, 30, "Drug"], [32, 42, "Drug"], [44, 52, "Drug"], [54, 57, "Herb name"]]}], [4209, "Dulbecco\u2019s modified Eagle\u2019s medium (DMEM), fetal bovine serum (FBS), non-essential amino acids, and poly-D-lysine-coated 96-well plates were purchased from Corning Life Sciences (Woburn, MA, USA).", {"entities": []}], [4211, "HEK293 cells overexpressing drug transporters and HEK293-mock cells were seeded in poly-D-lysine-coated 96-well plates at a density of 10 To examine the effects of ginsenosides and typical inhibitors on transporter activity, aliquots (100 \u03bcL) of HBSS containing the probe substrate and ginsenosides or typical inhibitors were added to the cells after aspirating pre-incubated HBSS.", {"entities": [[164, 176, "Herb name"], [286, 298, "Herb name"]]}], [4212, "The concentrations and probe substrates were as follows: 0.1 \u03bcM [ The uptake of valsartan 5 (\u03bcM)was measured for 5 min immediately after adding aliquots (100 \u03bcL) of HBSS containing 5 \u03bcM valsartan in the presence or absence of rifampin (1\u2013100 \u03bcM) or tri-glycosylated PPD-type ginsenosides (Rb1, Rb2, and Rc; 0.1\u2013100 \u03bcM) to the HEK293-mock cells and HEK293-OATP1B1 and \u2013OAPT1B3 cells after aspirating pre-incubated HBSS.", {"entities": [[80, 89, "Drug"], [186, 195, "Drug"], [226, 234, "Drug"], [249, 287, "Herb name"], [289, 292, "Herb name"], [294, 297, "Herb name"], [303, 305, "Herb name"], [355, 362, "Target"], [368, 375, "Target"]]}], [4213, "After 5 min incubation, the cells were washed three times with 100 \u03bcL of ice-cold HBSS, followed by lysing with 300 \u03bcL of 80% ice-cold methanol containing berberine 0.05 ng/mL and 0.1% formic acid for 15 min.", {"entities": [[155, 164, "Herb name"]]}], [4214, "After the centrifugation of cell lysate samples (16,000\u00d7 g, 5 min, 4 \u00b0C), aliquots (4 \u03bcL) of cell lysate samples were injected into LC-MS/MS system for the analysis of valsartan.", {"entities": [[168, 177, "Drug"]]}], [4215, "Transporter mediated uptake of probe substrates or valsartan was calculated by subtracting the uptake rate of probe substrates or valsartan into HEK293-mock cells from that into HEK293 cells expressing respective transporters.", {"entities": [[51, 60, "Drug"], [130, 139, "Drug"]]}], [4216, "Male Sprague-Dawley rats (6\u20137-weeks old, 220\u2013250 g) were purchased from Samtako Co. (Osan, Korea).", {"entities": [[0, 4, "Sex"], [26, 39, "Age"]]}], [4217, "The animals were acclimatized for 1 week in an animal facility at Kyungpook National University.", {"entities": []}], [4218, "Food and water were provided ad libitum.", {"entities": []}], [4219, "All animal procedures were approved by the Animal Care and Use Committee of Kyungpook National University (Approval No.", {"entities": []}], [4220, "KNU 2017-21 and KNU 2019-83).", {"entities": []}], [4221, "To calculate and compare the pharmacokinetic parameters of valsartan and ginsenosides, we performed repeated blood sampling through the retro-orbital puncture under isoflurane anesthesia.", {"entities": [[59, 68, "Drug"], [73, 85, "Herb name"]]}], [4222, "During the experimental procedure, rats did not suffer from any significant injury or infection.", {"entities": [[76, 82, "Pathology"], [86, 95, "Pathology"]]}], [4223, "The rats were randomly divided into the control and rifampin groups.", {"entities": [[52, 60, "Drug"]]}], [4224, "The rifampin group was orally administered with rifampin solution (20 mg/2 mL/kg, dissolved in DMSO: saline = 2:8, v/v) and the control group received only the vehicle via oral gavage.", {"entities": [[4, 12, "Drug"], [48, 56, "Drug"], [67, 80, "Amount"]]}], [4225, "Valsartan was injected intravenously to both groups via the tail vein at 1 mg/mL/kg (dissolved in DMSO: saline = 2:8, v/v).", {"entities": [[0, 9, "Drug"], [73, 83, "Amount"]]}], [4226, "Blood samples were collected via the retro-orbital vein at 0.25, 0.5, 1, 2, 4, 8, and 24 h following valsartan dosing.", {"entities": [[101, 110, "Drug"]]}], [4227, "After the centrifugation of blood samples (16,000\u00d7 g, 10 min, 4 \u00b0C), aliquots (50 \u03bcL each) of plasma samples were stored at \u201380 \u00b0C until the analysis of valsartan.", {"entities": [[153, 162, "Drug"]]}], [4228, "The rats were randomly divided into the control and RGE groups.", {"entities": [[52, 55, "Herb name"]]}], [4229, "The control group received distilled water for 7 days via oral gavage.", {"entities": [[43, 53, "Duration"]]}], [4230, "After 1 h following the last RGE treatment, valsartan was injected intravenously to both groups via the tail vein at 1 mg/mL/kg (dissolved in DMSO: saline = 2:8, v/v).", {"entities": [[29, 32, "Herb name"], [44, 53, "Drug"], [117, 127, "Amount"]]}], [4231, "Blood samples were collected via the retro-orbital vein at 0.25, 0.5, 1, 2, 4, 8, 24, 30, and 48 h after valsartan dosing.", {"entities": [[105, 114, "Drug"]]}], [4232, "After centrifugation of the blood samples at 16,000\u00d7 g for 10 min, aliquots (50 \u03bcL each) of plasma samples were stored at \u221280 \u00b0C until the analysis of ginsenosides and valsartan.", {"entities": [[151, 163, "Herb name"], [168, 177, "Drug"]]}], [4233, "The rats were randomly divided into the control and Rc groups.", {"entities": [[52, 54, "Herb name"]]}], [4234, "The Rc group was injected with Rc solution (3 mg/mL/kg, dissolved in saline) intravenously via the tail vein for 5 consecutive days.", {"entities": [[4, 6, "Herb name"], [31, 33, "Herb name"], [44, 54, "Amount"], [109, 131, "Duration"]]}], [4235, "The control group received saline (1 mL/kg) for 5 consecutive days via the tail vein.", {"entities": [[35, 42, "Amount"], [44, 66, "Duration"]]}], [4236, "After 1 h following the last Rc treatment, valsartan was injected intravenously via the femoral vein at 1 mg/kg.", {"entities": [[29, 31, "Herb name"], [43, 52, "Drug"], [104, 111, "Amount"]]}], [4237, "Blood samples were collected via the retro-orbital vein at 0.17, 0.33, 0.67, 1.5, 2, 4, 8, 24, and 48 h after valsartan dosing.", {"entities": [[110, 119, "Drug"]]}], [4238, "After centrifugation of the blood samples (16,000\u00d7 g, 10 min, 4 \u00b0C), aliquots (50 \u03bcL each) of plasma samples were stored at \u221280 \u00b0C until the analysis of the ginsenoside Rc and valsartan.", {"entities": [[157, 171, "Herb name"], [176, 185, "Drug"]]}], [4239, "The rats were injected with Rc solution (3 mg/mL/kg, dissolved in saline) via the tail vein.", {"entities": [[28, 30, "Herb name"], [41, 51, "Amount"]]}], [4240, "Blood samples were collected from the abdominal artery, and the liver tissue was immediately excised, gently washed with ice-cold saline, and weighed after the rats were euthanized at 2, 12, and 48 h after intravenous injection of Rc.", {"entities": [[231, 233, "Herb name"]]}], [4241, "The blood samples were centrifuged (16,000\u00d7 g, 10 min, 4 \u00b0C) and the liver tissue samples were homogenized with four volumes of saline.", {"entities": []}], [4242, "Aliquots (50 \u03bcL each) of plasma and liver homogenates were stored at \u221280 \u00b0C until the analysis of the ginsenoside Rc.", {"entities": [[102, 116, "Herb name"]]}], [4243, "The protein binding of Rb1, Rb2, and Rc (1 \u03bcM) in rat plasma and liver homogenate was determined using a rapid equilibrium dialysis kit (ThermoFisher Scientific Korea, Seoul, Korea) according to the manufacturer\u2019s instructions.", {"entities": [[23, 26, "Herb name"], [28, 31, "Herb name"], [37, 39, "Herb name"], [41, 45, "Amount"]]}], [4244, "Briefly, 100 \u03bcL of rat plasma and 10% liver homogenate samples containing Rb1, Rb2, or Rc (1 \u03bcM) were added to the sample chamber of a semipermeable membrane (molecular weight cut-off 8000 Da) and 300 \u03bcL of HBSS was added to the outer buffer chamber.", {"entities": [[74, 77, "Herb name"], [79, 82, "Herb name"], [87, 89, "Herb name"], [91, 95, "Amount"]]}], [4245, "Four hours after incubation at 37 \u00b0C on a shaking incubator at 300 rpm, aliquots (50 \u03bcL) were collected from both the sample and buffer chambers and treated with equal volumes of fresh HBSS and plasma, respectively, to match the sample matrices.", {"entities": []}], [4246, "The matrix-matched samples (100 \u03bcL) were mixed with 300 \u03bcL of 80% ice-cold methanol containing berberine 0.05 ng/mL and 0.1% formic acid for 15 min.", {"entities": [[95, 104, "Herb name"]]}], [4247, "After centrifugation (16,100\u00d7 g, 5 min, 4  Plasma protein binding was calculated using the following equation [47].", {"entities": []}], [4248, "Tissue protein binding was calculated using the following equations, and a dilution factor (D as a value of 10) was used since we used 10% liver homognenates [47,48].", {"entities": []}], [4249, "The concentration of valsartan was analyzed using a modified Liquid chromatography\u2013mass spectrometry (LC-MS/MS) method as previously reported by Yamashiro et al.", {"entities": [[21, 30, "Drug"]]}], [4250, "[29] using an Agilent 6470 Triple Quad LC\u2013MS/MS system (Agilent, Wilmington, DE, USA).", {"entities": []}], [4251, "Briefly, aliquots (50 \u03bcL) of plasma samples were mixed with 350 \u03bcL of an internal standard (IS) solution (berberine 0.05 ng/mL in methanol) and the mixtures were vortexed for 15 min.", {"entities": [[106, 115, "Herb name"]]}], [4252, "After centrifugation (16,100\u00d7 g, 5 min, 4 \u00b0C), 100 \u03bcL of the supernatant was transferred to a clean tube, evaporated and an aliquot (4 \u03bcL) from the sample was injected into LC-MS/MS system.", {"entities": []}], [4253, "The samples were eluted through a Synergy Polar RP column (2.0 mm \u00d7 150 mm, 4 \u00b5m particle size) (Phenomenex, Torrance, CA, USA) using a mobile phase consisting of methanol and water (75:25, v/v) with 0.1% formic acid at a flow rate of 0.2 mL/min.", {"entities": []}], [4254, "Valsartan and berberine (IS) were detected at a retention time (T The concentration of compound K was analyzed using a modified LC-MS/MS method of Jin et al.", {"entities": [[0, 9, "Drug"], [14, 23, "Herb name"], [87, 97, "Herb name"]]}], [4255, "[31] using an Agilent 6470 Triple Quad LC\u2013MS/MS system (Agilent, Wilmington, DE, USA).", {"entities": []}], [4256, "For the detection of Rb1, Rb2, Rc, Rd, Re, Rg1, Rh2, and Rg3, aliquots (50 \u03bcL) of plasma and liver homogenates were mixed with 350 \u03bcL of IS solution (0.05 ng/mL berberine in methanol) and vortexed for 15 min.", {"entities": [[21, 24, "Herb name"], [26, 29, "Herb name"], [31, 33, "Herb name"], [35, 37, "Herb name"], [39, 41, "Herb name"], [43, 46, "Herb name"], [48, 51, "Herb name"], [57, 60, "Herb name"], [161, 170, "Herb name"]]}], [4257, "After centrifugation (16,100\u00d7 g for 5 min, 4 \u00b0C), 200 \u03bcL of the supernatant was transferred to a clean tube and evaporated.", {"entities": []}], [4258, "The residue was reconstituted with 100 \u03bcL of 70% methanol consisting of 0.1% formic acid.", {"entities": []}], [4259, "An aliquot (20 \u03bcL) from the sample was injected into the LC-MS/MS system.", {"entities": []}], [4260, "The samples were eluted through a Synergy Polar RP column (2.0 mm \u00d7 150 mm, 4 \u00b5m particle size) (Phenomenex, Torrance, CA, USA) with a gradient mobile phase consisting of 0.1% formic acid in water (phase A) and 0.1% formic acid in methanol (phase B) as follows: 69% of phase B for 0\u20132.0 min, 69\u201385% of phase B for 2.0\u20134.0 min, and 85\u201369% of phase B for 6.0\u20136.5 min at a flow rate of 0.27 mL/min.", {"entities": []}], [4261, "The ginsenosides Rb1, Rb2, Rc, Rd, Re, Rg1, Rh2, Rg3, and berberine (IS) were detected at m/z 1131.6 \u2192 365.1 (for Rb1, T For the detection of Rh1, compound K, PPD, and PPT, aliquots (50 \u03bcL) of plasma and liver homogenates were mixed with 50 \u03bcL of IS solution (25 ng/mL caffeine in water) and 600 \u03bcL of methyl tertiary-butyl ether (MTBE), vortexed for 15 min, and centrifuged at 16,100\u00d7 g for 5 min.", {"entities": [[4, 16, "Herb name"], [17, 20, "Herb name"], [22, 25, "Herb name"], [27, 29, "Herb name"], [31, 33, "Herb name"], [35, 37, "Herb name"], [39, 42, "Herb name"], [44, 47, "Herb name"], [49, 52, "Herb name"], [58, 67, "Herb name"], [114, 117, "Herb name"], [142, 145, "Herb name"], [147, 157, "Herb name"], [159, 162, "Herb name"], [168, 171, "Herb name"], [269, 277, "Herb name"]]}], [4262, "After freezing the aqueous layer at \u221280 \u00b0C for 2 h, the upper organic layer was transferred to a clean tube and evaporated to dryness.", {"entities": []}], [4263, "The residue was reconstituted with 150 \u03bcL of 85% methanol.", {"entities": []}], [4264, "An aliquot (20 \u03bcL) from the sample was injected into the LC-MS/MS system.", {"entities": []}], [4265, "The samples were eluted through an Omega Polar C18 column (2.1 mm \u00d7 100 mm, 3 \u00b5m particle size) (Phenomenex, Torrance, CA, USA) using a mobile phase consisting of 0.1% formic acid in water: 0.1% formic acid in methanol (15:85, v/v) at a flow rate of 0.2 mL/min.", {"entities": []}], [4266, "The ginsenosides Rh1, Rh2, compound K, PPD, PPT, and caffeine (IS) were detected at m/z 603.4 \u2192 423.4 (for Rh1, T In the inhibition studies, the uptake rate of substrate by HEK293 cells overexpressing the respective transporters was used as the control (100%) and the uptake rate of substrates in the presence of typical inhibitors or ginsenosides expressed as a percentage of the control.", {"entities": [[4, 16, "Herb name"], [17, 20, "Herb name"], [22, 25, "Herb name"], [27, 37, "Herb name"], [39, 42, "Herb name"], [44, 47, "Herb name"], [53, 61, "Herb name"], [107, 110, "Herb name"], [335, 347, "Herb name"]]}], [4267, "The inhibition data were fitted to an inhibitory effect model [26] using Sigma plot (version 10.0; Systat Software Inc., San Jose, CA, USA).", {"entities": []}], [4268, "IC Pharmacokinetic parameters were calculated from plasma concentration-time profile using non-compartment analysis of WinNonlin (version 5.1; Pharsights, Cary, NC, USA).", {"entities": [[0, 2, "Parameter"]]}], [4269, "The statistical significance was assessed by t-test using Statistical Package for the Social Sciences (version 24.0; SPSS Inc., Chicago, IL, USA).", {"entities": []}], [4270, "Sample Availability: Not available.", {"entities": []}], [4271, "Conceptualization: I.-S.S.; methodology, J.-H.J, S.J., and M.-K.C.", {"entities": []}], [4272, "; validation, J.-H.J, S.J., and M.-K.C.", {"entities": []}], [4273, "; formal analysis, W.L.", {"entities": []}], [4274, "; investigation, J.-H.J, S.L., W.L., S.J., M.K., C.H.S., and I.-S.S.; writing\u2014original draft preparation, J.-H.J.", {"entities": []}], [4275, "and I.-S.S.; writing\u2014review and editing, M.-K.C.", {"entities": []}], [4276, "and I.-S.S.; supervision, I.-S.S.; project administration, I.-S.S.; funding acquisition, I.-S.S. All authors have read and agreed to the published version of the manuscript.", {"entities": []}], [4277, "This research was supported by Kyungpook National University Development Project Research Fund, 2018.", {"entities": []}], [4278, "The authors declare no conflict of interest.", {"entities": []}], [4279, "Inhibitory effect of typical inhibitors on the (A) OCT1, (B) OCT2, (C) OAT1, (D) OAT3, (E) OATP1B1, and (F) OATP1B3-mediated uptake.", {"entities": [[51, 55, "Target"], [61, 65, "Target"], [71, 75, "Target"], [81, 85, "Target"], [91, 98, "Target"], [108, 115, "Target"]]}], [4280, "Transporter mediated uptake of probe substrate were calculated by subtracting the uptake in HEK293-mock cells from the uptake in HEK293 cells overexpressing respective transporters.", {"entities": []}], [4281, "The concentrations and probe substrates were as follows: 0.1 \u03bcM [ Inhibitory effect of Rb1, Rb2, Rc, Rd, compound K, Rg3, Rh2, PPD, PPT, Re, Rg1, and Rh1 on the OATP1B1-mediated transport of [ Inhibitory effect of Rb1, Rb2, Rc, Rd, compound K, Rg3, Rh2, PPD, PPT, Re, Rg1, and Rh1 on the OATP1B3-mediated uptake of [ (A) Uptake of valsartan (5 \u03bcM) by HEK293-mock cells and HEK293 cells expressing OATP1B1 and OATP1B3.", {"entities": [[57, 63, "Amount"], [87, 90, "Herb name"], [92, 95, "Herb name"], [97, 99, "Herb name"], [101, 103, "Herb name"], [105, 115, "Herb name"], [117, 120, "Herb name"], [122, 125, "Herb name"], [127, 130, "Herb name"], [132, 135, "Herb name"], [137, 139, "Herb name"], [141, 144, "Herb name"], [150, 153, "Herb name"], [161, 168, "Target"], [214, 217, "Herb name"], [219, 222, "Herb name"], [224, 226, "Herb name"], [228, 230, "Herb name"], [232, 242, "Herb name"], [244, 247, "Herb name"], [249, 252, "Herb name"], [254, 257, "Herb name"], [259, 262, "Herb name"], [264, 266, "Herb name"], [268, 271, "Herb name"], [277, 280, "Herb name"], [288, 295, "Herb name"], [331, 340, "Drug"], [342, 346, "Amount"], [397, 404, "Target"], [409, 416, "Target"]]}], [4283, "Data points represent the mean \u00b1 SD from triplicate measurements.", {"entities": []}], [4284, "*p < 0.05 compared with HEK293-mock cells.", {"entities": []}], [4285, "(A) Plasma concentration-time profile of valsartan in the control and rifampin (20 mg/kg) groups following intravenous injection of valsartan at a dose of 1 mg/kg in rats.", {"entities": [[41, 50, "Drug"], [70, 78, "Drug"], [80, 88, "Amount"], [132, 141, "Drug"], [155, 162, "Amount"]]}], [4286, "Data points represent the mean \u00b1 SD of four different rats per group.", {"entities": []}], [4287, "Plasma concentration-time profiles of the ginsenosides (A) Rb1, (B) Rb2, (C) Rc, (D) Rd, (E) PPD, and (F) PPT in the rat plasma after 1-week repeated administration of red ginseng extract (RGE).", {"entities": [[42, 54, "Herb name"], [59, 62, "Herb name"], [68, 71, "Herb name"], [77, 79, "Herb name"], [85, 87, "Herb name"], [93, 96, "Herb name"], [106, 109, "Herb name"], [134, 140, "Duration"], [168, 193, "Herb name"]]}], [4288, "Data represent the mean \u00b1 SD of four rats.", {"entities": []}], [4291, "Data points represent the mean \u00b1 SD from triplicate measurements.", {"entities": []}], [4292, "(A) Plasma concentration-time profile of valsartan in the control and Rc groups following intravenous injection of valsartan at a dose of 1 mg/kg.", {"entities": [[41, 50, "Drug"], [70, 72, "Herb name"], [115, 124, "Drug"], [138, 145, "Amount"]]}], [4293, "(B) Plasma concentration-time profile of Rc in the Rc group.", {"entities": [[41, 43, "Herb name"], [51, 53, "Herb name"]]}], [4294, "Data points represent the mean \u00b1 SD of three different rats per group.", {"entities": []}], [4295, "(A) Plasma (\u25cf) and liver (\u25cb) concentrations of Rc following intravenous injection of Rc at a dose of 3 mg/kg.", {"entities": [[47, 49, "Herb name"], [85, 87, "Herb name"], [101, 108, "Amount"]]}], [4296, "(B) Protein binding of Rb1, Rb2, and Rc in the rat plasma and liver homogenates using a rapid equilibrium dialysis device.", {"entities": [[23, 26, "Herb name"], [28, 31, "Herb name"], [37, 39, "Herb name"]]}], [4297, "Data were expressed as the mean \u00b1 SD of three different rats or triplicated measurements.", {"entities": []}], [4298, "Inhibitory effect of ginsenosides on drug transporters.", {"entities": [[21, 33, "Herb name"]]}], [4299, "NI: No significant inhibition; >100: weak inhibition but IC Pharmacokinetic parameters of valsartan following intravenous injection of valsartan at a dose of 1 mg/kg in rats.", {"entities": [[57, 59, "Parameter"], [90, 99, "Drug"], [135, 144, "Drug"], [158, 165, "Amount"]]}], [4300, "Data represent mean \u00b1 SD of four rats per group.", {"entities": []}], [4301, "* p < 0.05 compared with control group.", {"entities": []}], [4302, "T Pharmacokinetic parameters of ginsenosides in the rat plasma after 1-week repeated administration of red ginseng extract (RGE).", {"entities": [[32, 44, "Herb name"], [69, 75, "Duration"], [103, 128, "Herb name"]]}], [4303, "Data represent mean \u00b1 SD of four rats per group.", {"entities": []}], [4304, "AUC: area under the plasma concentration-time curve from 0 to 48 h C Pharmacokinetic parameters of valsartan and Rc following intravenous injection of valsartan at a dose of 1 mg/kg in rats.", {"entities": [[0, 26, "Parameter"], [99, 108, "Drug"], [113, 115, "Herb name"], [151, 160, "Drug"], [174, 181, "Amount"]]}], [4305, "Data represent mean \u00b1 SD of three rats per group T", {"entities": []}], [4306, "Given the high prevalence of anxiety and restlessness in younger women, oral contraceptives and Silexan will likely be co-administered.", {"entities": [[29, 53, "Pathology"], [65, 70, "Sex"], [72, 91, "Drug"], [96, 103, "Herb name"]]}], [4307, "It exceeds the quality definition of the pharmacopoeial monograph with respect to items that are important for efficacy and tolerability.", {"entities": []}], [4308, "Randomised controlled clinical trials have demonstrated that Silexan is a potent anxiolytic drug with superior efficacy compared with placebo in subsyndromal anxiety disorder [2].", {"entities": [[0, 37, "Study"], [61, 68, "Herb name"], [81, 91, "Pathology"], [145, 174, "Pathology"]]}], [4309, "In generalised anxiety disorder (GAD), Silexan was found to be comparably efficacious as lorazepam [3] and at least as efficacious as paroxetine.", {"entities": [[3, 37, "Pathology"], [39, 46, "Herb name"], [89, 98, "Drug"], [134, 144, "Drug"]]}], [4311, "While Silexan is a complex, multi-ingredient mixture, its anxiolytic properties have been ascribed in particular to linalool and linalyl acetate [4].", {"entities": [[6, 13, "Herb name"], [58, 68, "Pathology"], [116, 144, "Herb name"]]}], [4312, "Anxiety disorders are by far the most prevalent psychiatric conditions in Western Europe and the USA [5, 6].", {"entities": [[0, 17, "Pathology"], [48, 70, "Pathology"]]}], [4313, "Their prevalence in women is at least twice as high as in men [7, 8].", {"entities": [[20, 25, "Sex"], [58, 61, "Sex"]]}], [4314, "Since the prevalence of anxiety disorders tends to decrease rather than to increase with age [9], a substantial proportion of the patients who seek treatment for anxiety are women of childbearing potential who may be practising oral contraception.", {"entities": [[24, 41, "Pathology"], [162, 169, "Pathology"], [174, 179, "Sex"], [183, 205, "Parameter"], [228, 246, "Drug"]]}], [4315, "The steroid hormones contained in oral contraceptives are metabolised mainly through hydroxylation in the liver.", {"entities": [[0, 53, "Drug"], [85, 98, "Parameter"]]}], [4316, "Drugs that induce the cytochrome P450 (CYP) enzyme system, notably CYP3A4, reduce the bioavailability by increasing the first-pass metabolism of the oral contraceptive steroids and may therefore impair their efficacy, leading to breakthrough bleeding and, possibly, unwanted pregnancy [10, 11].", {"entities": [[18, 73, "Target"], [82, 101, "Parameter"], [116, 176, "Parameter"], [208, 216, "Parameter"], [229, 250, "Pathology"], [266, 284, "Parameter"]]}], [4317, "A comprehensive list of drugs that induce CYP has been published by Rendic [12].", {"entities": [[42, 45, "Target"]]}], [4318, "They include several anticonvulsants and broad spectrum antibiotics, rifampicin, griseofulvin, and anti-retroviral drugs.", {"entities": [[21, 120, "Drug"]]}], [4319, "Bioavailability is the rate and extent to which the active substance or active moiety is absorbed from a pharmaceutical form and becomes available at the site of action [13].", {"entities": [[0, 15, "Parameter"]]}], [4320, "As the use of herbal preparations increases in the general population, the potential for herb\u2013drug interactions also increases.", {"entities": [[14, 33, "Herb name"]]}], [4321, "Therefore, herbal products must be assessed for their efficacy and safety, including their potential for interactions with other drugs [14].", {"entities": [[11, 26, "Herb name"], [54, 73, "Parameter"]]}], [4322, "Since women of childbearing potential who practise oral contraception represent an important part of the target population for which Silexan is intended, it is important to investigate whether the herbal drug may have an effect on the bioavailability and efficacy of oral contraceptives.", {"entities": [[6, 11, "Sex"], [15, 37, "Parameter"], [51, 69, "Drug"], [133, 140, "Herb name"], [193, 208, "Herb name"], [231, 286, "Parameter"]]}], [4323, "Although a clinical study showed no induction of the CYP enzymes 1A2, 2C9, 2C19, 2D6 and 3A4 [15], suggesting that no increased activity in metabolization of contraceptive ingredients occurs during co-administration of Silexan, some examples of inhibition of phase-II enzymes, mainly UDP-glucuronosyltransferases (UGTs), by co-administered herbal drugs (e. g., Williams et al.", {"entities": [[9, 25, "Study"], [49, 92, "Parameter"], [128, 183, "Parameter"], [219, 226, "Herb name"], [259, 319, "Target"], [340, 352, "Herb name"]]}], [4324, "[16]) do exist.", {"entities": []}], [4325, "All subjects provided written informed consent.", {"entities": []}], [4326, "The principles of Good Clinical Practice and the Declaration of Helsinki were adhered to.", {"entities": []}], [4327, "rifampicin, dexamethasone, barbiturates, anticonvulsants, St. John\u2019s wort); any drugs known to inhibit CYP3A4 (e.g.", {"entities": [[0, 56, "Drug"], [58, 73, "Herb name"], [103, 109, "Target"]]}], [4328, "ketoconazole, verapamil, cimetidine, macrolides); any broad-spectrum antibiotics; and long-acting, injectable or implant hormonal therapy within 26\u00a0weeks prior to the screening visit, as well as any oral contraceptives other than the investigational treatment.", {"entities": [[0, 137, "Drug"], [145, 153, "Duration"], [199, 218, "Drug"]]}], [4329, "During randomised treatment, the subjects had to take one capsule of Silexan or placebo per day in the morning unchewed.", {"entities": [[54, 65, "Amount"], [69, 76, "Herb name"], [88, 95, "Frequency"]]}], [4330, "A daily dose of 160\u00a0mg corresponds to twice the currently recommended dose of the marketed product.", {"entities": [[0, 12, "Frequency"], [16, 22, "Amount"]]}], [4331, "Microgynon The study participants had to complete at least 2 cycles of oral contraception with Microgynon Study schedule    EE ethinyl estradiol, LNG levonorgestrel, PK pharmacokinetics, PL placebo, SIL Silexan During randomised treatment, weekly visits were scheduled on days 7, 14, 21, and 28 of each cycle.", {"entities": [[0, 10, "Drug"], [71, 105, "Drug"], [124, 164, "Drug"], [166, 185, "Parameter"], [199, 210, "Herb name"]]}], [4332, "For each visit, a deviation of\u00a0\u00b11\u00a0day was permitted.", {"entities": [[31, 37, "Duration"]]}], [4333, "After subjects were determined as eligible for the trial, they were randomised to treatment with Silexan followed by placebo, or vice versa, at a ratio of 1:1.", {"entities": [[47, 56, "Study"], [97, 104, "Herb name"]]}], [4334, "Fixed block randomisation was used; however, the investigator was not informed about the random block size until completion of the trial.", {"entities": [[127, 136, "Study"]]}], [4335, "A biometrician otherwise not involved in the trial generated the code using a validated computer program.", {"entities": [[41, 50, "Study"]]}], [4336, "Upon inclusion into randomised treatment, each subject received the lowest available number.", {"entities": []}], [4337, "Tests for AUC\u03c4 and C  In the absence of other guidance, the assessment of the pharmacological interacting potential of Silexan was based on the same approach as when testing for bioequivalence [21]: the absence of a clinically relevant PK interaction between Silexan and EE or LNG was concluded if the 90\u00a0% confidence intervals for the AUC\u03c4 ratios (Silexan/placebo) determined from the ANOVA models were included within the standard 80\u2013125\u00a0% equivalence range.", {"entities": [[10, 14, "Parameter"], [19, 20, "Parameter"], [119, 126, "Herb name"], [178, 192, "Parameter"], [259, 266, "Herb name"], [271, 280, "Drug"], [336, 340, "Parameter"], [349, 356, "Herb name"]]}], [4338, "Since the confidence intervals for the AUC\u03c4 ratios of both hormones were required to fall within the pre-specified equivalence range simultaneously, type I error level adjustment for multiple testing was not required.", {"entities": [[35, 50, "Parameter"], [54, 67, "Drug"]]}], [4340, "When the true AUC\u03c4 ratio between Silexan and placebo is between 0.95 and 1.05, a sample size of 20 subjects will have at least 80\u00a0% power for rejecting the null hypothesis predicting an interaction between Silexan and EE or LNG according to the above criteria.", {"entities": [[14, 24, "Parameter"], [33, 40, "Herb name"], [56, 77, "Amount"], [96, 107, "Cohort"], [206, 213, "Herb name"], [218, 227, "Drug"]]}], [4341, "In order to compensate for study participants who did not complete both treatment phases, a total of 24 subjects were to be randomised.", {"entities": [[90, 112, "Cohort"]]}], [4342, "All randomised subjects completed the study as scheduled.", {"entities": []}], [4343, "All treated subjects were analysed for safety.", {"entities": []}], [4344, "Two subjects were excluded from all PK and pharmacodynamic (PD) analyses; one took prohibited concomitant medication and one missed one dose of Microgynon The randomised study participants were aged between 21 and 37\u00a0years (mean\u00a0\u00b1\u00a0standard deviation [SD] 27.3 \u00b1\u00a04.1\u00a0years) and had a body mass index ranging between 19.3 and 26.8\u00a0kg/m According to capsule counting, compliance with Silexan or placebo was 100\u00a0% in 23 of the 24 subjects.", {"entities": [[83, 116, "Drug"], [144, 154, "Drug"], [199, 222, "Age"], [255, 271, "Age"], [281, 298, "Parameter"], [307, 333, "Amount"], [381, 388, "Herb name"], [419, 434, "Cohort"]]}], [4345, "One woman took one additional capsule during the first treatment period and left out one during the second.", {"entities": [[4, 9, "Sex"], [15, 37, "Amount"]]}], [4346, "The numerical results are presented in Table 2.", {"entities": []}], [4347, "The only case of an active follicle-like structure (>13\u00a0mm follicular growth accompanied by estradiol production) was observed during placebo treatment.", {"entities": [[52, 58, "Amount"], [59, 76, "Parameter"], [92, 101, "Parameter"]]}], [4348, "During randomised treatment, 36 AEs were reported by 17 of the 24 women (70.8\u00a0%) under co-administration of Microgynon It is important to investigate whether anxiolytic drugs may modify the bioavailability and the clinical efficacy of oral contraceptives with steroid hormones.", {"entities": [[32, 35, "Pathology"], [66, 71, "Sex"], [108, 118, "Drug"], [158, 174, "Drug"], [186, 205, "Parameter"], [210, 231, "Parameter"], [235, 276, "Drug"]]}], [4349, "Since about one-third of the women in the study sample were mild smokers (subjects smoking more than ten cigarettes per day were excluded from participation), this might have contributed to large inter-individual variability in plasma concentrations, notably in EE.", {"entities": [[29, 34, "Sex"], [65, 72, "Parameter"], [83, 90, "Parameter"], [91, 115, "Amount"], [116, 123, "Frequency"], [228, 249, "Parameter"], [262, 264, "Drug"]]}], [4350, "Since the null hypothesis could be rejected and an interaction could be excluded in accordance with the pre-specified criteria, an introduction of bias due to the inclusion of mild smokers can also be excluded.", {"entities": [[181, 188, "Parameter"]]}], [4351, "The measured individual follicle sizes were always within the range expected during adequate ovarian suppression [23], and a follicle size exceeding a threshold value of 13\u00a0mm was observed only once in a woman receiving placebo.", {"entities": [[24, 38, "Parameter"], [123, 138, "Parameter"], [170, 175, "Amount"], [204, 209, "Sex"]]}], [4352, "AEs observed during this trial in healthy volunteers were never more than moderately severe and temporary; abnormal laboratory values were more often related to the study procedures (e.g., to frequent blood sampling) than to study medication intake.", {"entities": [[0, 3, "Pathology"], [25, 30, "Study"], [34, 41, "Pathology"]]}], [4353, "Among the events assessed to be potentially attributable to Silexan, the only effect that was observed in more than one subject but also not during placebo treatment was eructation.", {"entities": [[60, 67, "Herb name"], [170, 180, "Pathology"]]}], [4354, "Mild gastrointestinal disorders are among the known side effects of Silexan, but were always tolerable and did not interfere with treatment compliance.", {"entities": [[0, 31, "Pathology"], [52, 64, "Pathology"], [68, 75, "Herb name"]]}], [4355, "This study was work for hire supported by Dr. Willmar Schwabe GmbH & Co. KG, Karlsruhe, Germany (sponsor).", {"entities": []}], [4356, "AD and SS are employees of Dr. Willmar Schwabe GmbH & Co. KG.", {"entities": []}], [4357, "No further conflict of interest is declared.", {"entities": []}], [4358, "Medical writing support was provided by Andreas V\u00f6lp, psy consult scientific services, Frankfurt, Germany.", {"entities": []}], [4359, "This paper aimed to evaluate the effect of herbal mixture (Mentha spicata, Zingiber officinale, Cinnamomum zeylanicum, and Citrus sinensis) only and along with clomiphene citrate (CC) compared to CC on serum antioxidants, glycemic status, menstrual regulation, and rate of pregnancy.", {"entities": [[59, 73, "Herb name"], [75, 94, "Herb name"], [96, 117, "Herb name"], [123, 138, "Herb name"], [160, 183, "Drug"], [196, 198, "Drug"]]}], [4360, "They were randomly allocated into group 1 (n = 20) who received routine dose of CC pills (50\u2013150 mg) for three menstrual cycles from the fifth day of menstruation for five days; group 2 (n = 20) who consumed herbal mixture daily (700 mg); and group 3 (n = 20) who used up herbal mixture along with CC for 3 months.", {"entities": [[80, 82, "Drug"], [90, 99, "Amount"], [101, 176, "Duration"], [223, 228, "Frequency"], [230, 236, "Frequency"], [298, 300, "Drug"], [301, 313, "Duration"]]}], [4361, "Catalase (CAT), glutathione peroxidase (GPx), superoxide dismutase (SOD), malondialdehyde (MDA), fasting blood sugar (FBS), insulin, and homeostatic model assessment for insulin resistance (HOMA-IR) were measured in their blood samples.", {"entities": [[0, 14, "Parameter"], [16, 44, "Parameter"], [46, 72, "Parameter"], [74, 95, "Parameter"], [97, 122, "Parameter"], [124, 131, "Parameter"], [137, 198, "Parameter"]]}], [4362, "No statistically significant differences were observed between the three groups in terms of socio-demographic characteristics.", {"entities": []}], [4363, "After intervention, however, the levels of CAT in group 2 (adjusted mean difference (aMD): = 9.0; confidence interval (CI) 95% = 1.1\u201316.9) and group 3 (aMD = 12.2; CI 95% = 4.5\u201319.9), GPx in group 2 (aMD = 986.1; CI 95% = 141.1\u20131831.1) and group 3 (aMD = 1781.2; CI 95% = 960.7\u20132601.8), and SOD in group 2 (aMD = 55.1; CI 95% = 26.0\u201384.2) increased.", {"entities": [[43, 46, "Parameter"], [184, 187, "Parameter"], [291, 294, "Parameter"]]}], [4364, "While FBS in group 3 (aMD = \u22128.7; CI 95% = \u221214.7 to \u22122.7), insulin in group 2 (aMD = \u22125.6; CI 95% = \u221210.8 to \u22120.4), and HOMA-IR in group 2 (aMD = \u22121.3; CI 95% = \u22122.4 to \u22120.2) significantly decreased compared to the group 1.", {"entities": [[6, 9, "Parameter"], [59, 66, "Parameter"], [120, 127, "Parameter"]]}], [4365, "To summarize, herbal mixture supplements along with CC have beneficial effects on serum antioxidant levels, as well as glycemic biomarkers of infertile PCOS, menstrual regulation, and pregnancy rate.", {"entities": [[52, 54, "Drug"], [82, 106, "Parameter"], [142, 156, "Pathology"]]}], [4366, "Polycystic ovary syndrome (PCOS) is recognized as a leading cause of infertility with the incidence of 6\u201326% among women at child bearing age [1].", {"entities": [[0, 32, "Pathology"], [69, 80, "Pathology"], [115, 120, "Sex"]]}], [4367, "Clinical manifestations of PCOS as a heterogeneous endocrine disorder are anovulation, hyperandrogenism, amenorrhea or oligomenorrhea, hirsutism, acne, obesity, and dyslipidemia [2].", {"entities": [[27, 31, "Pathology"], [37, 69, "Pathology"], [74, 85, "Pathology"], [87, 103, "Pathology"], [105, 115, "Pathology"], [119, 133, "Pathology"], [135, 144, "Pathology"], [146, 150, "Pathology"], [152, 159, "Pathology"], [165, 177, "Pathology"]]}], [4368, "Polycystic ovary syndrome has been associated with oxidative stress (OS) and metabolic factors, for instance insulin resistance, obesity, and diabetes [3,4].", {"entities": [[0, 25, "Pathology"], [51, 72, "Pathology"], [109, 127, "Pathology"], [129, 136, "Pathology"], [142, 150, "Pathology"]]}], [4369, "Oxidative stress can affect female fertility by influencing ovulation, fertilization, embryo development, and implantation [5].", {"entities": [[0, 16, "Pathology"], [28, 34, "Sex"]]}], [4370, "Although reactive oxygen species (ROS) and reactive nitrogen species (RNS) as examples of OS play physiological roles in cellular signaling pathways at low concentrations, they may damage cellular functions in excess levels [6].", {"entities": [[9, 38, "Target"], [43, 74, "Target"], [90, 92, "Pathology"]]}], [4371, "Reactive oxygen species are derived from molecular oxygen, and include oxygen ions, free radicals (chemical species with unpaired electrons), and peroxides [3].", {"entities": [[0, 23, "Target"]]}], [4372, "Oxidative stress is dramatically increased in PCOS patients, when oxidant/antioxidant status is measured by circulating serum markers, including catalase (CAT), glutathione peroxidase (GPx), superoxide dismutase (SOD), and malondialdehyde (MDA) [3].", {"entities": [[0, 16, "Pathology"], [46, 50, "Pathology"], [145, 159, "Parameter"], [161, 189, "Parameter"], [191, 217, "Parameter"], [223, 244, "Parameter"]]}], [4373, "However, OS is also correlated with insulin resistance by impairing glucose uptake in muscle and adipose tissue [7].", {"entities": [[9, 11, "Pathology"], [36, 54, "Pathology"]]}], [4374, "In vivo and in vitro studies have demonstrated that an excess level of OS results in impaired insulin secretion and insulin resistance [8].", {"entities": [[0, 28, "Study"], [71, 73, "Pathology"], [116, 134, "Pathology"]]}], [4375, "However, antioxidant treatment may ameliorate insulin sensitivity in insulin resistant patients [9].", {"entities": [[69, 86, "Pathology"]]}], [4376, "But whether high levels of OS in PCOS patients derive from PCOS or other potential complications still remains undetermined [10].", {"entities": [[27, 29, "Pathology"], [33, 37, "Pathology"], [59, 63, "Pathology"]]}], [4377, "Of the most prevalent medications to treat PCOS is clomiphene citrate (CC), long-term consumption of which causes endometrial thickness [11].", {"entities": [[43, 47, "Pathology"], [51, 74, "Drug"], [114, 135, "Pathology"]]}], [4378, "Since CC has a structural similarity to estrogen compounds, it binds to estrogen receptors and suppresses the endometrial E2 which plays an important role in endometrial growth and maturation [12].", {"entities": [[6, 8, "Drug"], [40, 48, "Target"], [72, 90, "Target"], [110, 124, "Target"]]}], [4379, "Therefore, use of an herbal agent with antioxidant and polyphenolic properties without significant side effects helps to treat PCOS as a disease of antioxidant deficiency [13].", {"entities": [[55, 67, "Herb name"], [99, 111, "Pathology"], [127, 131, "Pathology"]]}], [4380, "Cinnamomum zeylanicum nees (Cinnamon) from the Lauraceae family has been known for its antioxidant and anti-inflammatory properties [14].", {"entities": [[0, 63, "Herb name"]]}], [4381, "Cinnamon extract can be used as an antioxidant due to its phenolic content particularly cinnamaldehyde, which improves level of SOD, GPx, CAT, and reduces MDA concentration, as well as increase rate of pregnancy [15,16].", {"entities": [[0, 8, "Herb name"], [58, 66, "Herb name"], [88, 102, "Herb name"], [128, 131, "Parameter"], [133, 136, "Parameter"], [138, 141, "Parameter"], [155, 158, "Parameter"]]}], [4382, "Furthermore, it decreases insulin and blood glucose markedly [17].", {"entities": [[26, 33, "Parameter"], [38, 51, "Parameter"]]}], [4383, "Citrus Sinensis (L.) Osbeck from Rutaceae family mainly contains hesperidin, polymethoxylated flavonoids (PMF), and terpenoids (limonene and linalool), and these phenolic bioactive compounds indicate considerable cytoprotective effects against OS [18].", {"entities": [[0, 48, "Herb name"], [65, 75, "Herb name"], [77, 110, "Herb name"], [116, 126, "Herb name"], [128, 136, "Herb name"], [141, 149, "Herb name"], [162, 170, "Herb name"], [244, 246, "Pathology"]]}], [4384, "Moreover, hesperidin in C. sinensis increases the levels of antioxidants including SOD and CAT, and decreases the MDA level [19].", {"entities": [[10, 20, "Herb name"], [24, 35, "Herb name"], [83, 86, "Parameter"], [91, 94, "Parameter"], [114, 117, "Parameter"]]}], [4385, "Major components of Zingiber officinale Roscoe (ginger) from Zingiberaceae family are zingiberene, camphene, and p-cineole, which show antioxidant, anti-cancer, anti-clotting, and anti-inflammatory properties [20,21].", {"entities": [[20, 81, "Herb name"], [86, 97, "Herb name"], [99, 107, "Herb name"], [113, 122, "Herb name"]]}], [4387, "In vitro and in vivo studies have confirmed that ginger enhances the levels of SOD, CAT, and GP Although aforesaid studies have illustrated the potency of each herb, there are hypotheses that the mixture of these herbs may have more potent antioxidant efficacy.", {"entities": [[0, 28, "Study"], [49, 55, "Herb name"], [79, 82, "Target"], [84, 87, "Target"], [93, 95, "Target"]]}], [4388, "However, to the best of our knowledge, no study has subjected its effect on PCOS.", {"entities": [[76, 80, "Pathology"]]}], [4389, "Therefore, the aims of this study were to compare the efficacy of four herbal mixtures with CC on serum antioxidants (CAT, GP The dried plant samples consisting of the leaves of M. spicata, rhizomes of Z. officinale, bark of C. zeylanicum, and peels of C. sinensis were provided from the Herbal Medicine Market and identified at the Department of Pharmacognosy, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran.", {"entities": [[92, 94, "Drug"], [118, 121, "Parameter"], [123, 125, "Parameter"], [168, 174, "Herb part"], [178, 188, "Herb name"], [190, 198, "Herb part"], [202, 215, "Herb name"], [217, 221, "Herb part"], [225, 238, "Herb name"], [244, 249, "Herb part"], [253, 264, "Herb name"]]}], [4390, "The different plant samples were thoroughly powdered and sieved.", {"entities": [[44, 52, "Extraction process"]]}], [4391, "The powders were mixed with 5 (250 mg): 4 (200 mg): 3 (150 mg): 2 (100 mg) weight ratios of spearmint, ginger, cinnamon, and C. sinensis, respectively.", {"entities": [[4, 11, "Extraction process"], [92, 101, "Herb name"], [103, 109, "Herb name"], [111, 119, "Herb name"], [125, 136, "Herb name"]]}], [4392, "Finally, obtained powder was used for preparation of 700 mg capsules.", {"entities": [[18, 24, "Extraction process"], [53, 59, "Amount"]]}], [4393, "The methanolic extract was obtained from 72 g of herbal mixture powder using the maceration method with 700 mL methanol (MeOH) during three consecutive days.", {"entities": [[4, 22, "Extraction process"], [64, 70, "Extraction process"], [81, 91, "Extraction process"]]}], [4394, "The obtained extract was filtered and dried using a rotary evaporator at 45 \u00b0C.", {"entities": []}], [4395, "The yielded methanolic extract was 12.04 g. Free radical scavenging activity of methanolic extract was measured using DPPH (2, 2-diphenyl-1-picrylhydrazyl) method.", {"entities": [[12, 30, "Extraction process"], [80, 98, "Extraction process"]]}], [4396, "The extract was dissolved in methanol to prepare a stock solution with the concentration of 10 mg/10 mL.", {"entities": []}], [4397, "Serial dilutions (0.5, 0.25, 0.125, 0.625, 0.313, and 0.156 mg/mL) were made to reduce the concentrations.", {"entities": []}], [4398, "Two mL of diluted solution was mixed with 2 mL of 0.08 mg/mL DPPH solution and was allowed to stay for 30 min for any reaction.", {"entities": []}], [4399, "The ultraviolet (UV)-visible absorbance was set at 517 nm by Thermo Fisher spectrophotometer (Walthman, MA, USA).", {"entities": []}], [4400, "The reduction percentage was recorded against the extract concentration to compute RC50 values (the concentration of extract that provides 50% loss of DPPH activity).", {"entities": [[83, 87, "Parameter"]]}], [4401, "Quercetin was used as the positive control and the experiment was performed in triplicate [27].", {"entities": [[0, 9, "Herb name"]]}], [4402, "Total antioxidant activity was determined by the ferric reducing antioxidant potential (FRAP) following the method of Benzie and Strain with some modifications.", {"entities": []}], [4403, "This method is based on the reduction of Fe (III)-TPTZ (ferric 2,4,6-tripyridyl-s triazine complex) by antioxidants to Fe (II)-TPTZ (ferrous form).", {"entities": []}], [4404, "Light blue reagent clarifies the presence of Fe (III)\u2013TPTZ, and changing it to dark blue after interaction with antioxidants illustrates the presence of Fe (II)\u2013TPTZ in the reagent.", {"entities": []}], [4405, "To this end, FRAP stock solution was prepared freshly by mixing TPTZ (10 mM), HCl (40 mM), and FeCl3 (20 mM) in an acetate buffer (300 mM, pH 3.6).", {"entities": []}], [4406, "Next, 900 \u00b5L of FRAP reagent was allowed to react with 30 \u00b5L of plant extract for 30 min in a test tube.", {"entities": []}], [4407, "The tube was vortexed and placed in bain-marie to reach 37 \u00b0C.", {"entities": []}], [4408, "The standard calibration curve was obtained by using different concentrations of FeSO Total amount of the phenolic components was determined by Folin-Ciocalteau method.", {"entities": [[106, 125, "Herb name"]]}], [4409, "One mL of methanolic extract (5 mg/mL in acetone-water solution) was mixed with 200 \u00b5L of Folin-Ciocalteau reagent and 1 mL of 2% Na Total flavonoids were determined using the AlCl The herbal mixture powder (120 g) was exposed to hydrodistillation using a Clevenger type apparatus for about 4 h. Then, the obtained dark yellow oil was dried over anhydrous sodium sulfate, measured, and stored in a dark glass at 4 \u00b0C for further analyses.", {"entities": [[10, 28, "Extraction process"], [139, 149, "Herb name"]]}], [4410, "The essential oil (0.5% w/w) was assessed on the dry weight basis.", {"entities": [[4, 17, "Extraction process"]]}], [4411, "Gas chromatography\u2013mass spectrometry (GC\u2013MS) and gas chromatography with flame ionization detector (GC\u2013FID) analyses were performed on a Shimadzu GC-MSQP-5050A and GC-17A equipped with a DB-1 fused silica column (60 m \u00d7 0.25 mm i.d., 0.25 \u00b5m film thickness), with an oven temperature of 50 \u00b0C rising to 260 \u00b0C at a rate of 3 \u00b0C/min.", {"entities": []}], [4412, "The total running time for a sample was about 82 min.", {"entities": []}], [4413, "Helium was used as the carrier gas at a flow rate of 1.3 mL/min.", {"entities": []}], [4414, "The essential oil was diluted 1:100 in n-hexane and 1 \u00b5L was injected into the column.", {"entities": [[4, 17, "Extraction process"]]}], [4415, "Split ratio, ionization energy, scan time, and acquisition mass range were 1:33, 70 eV, 1 s, and 30\u2013600 amu, respectively.", {"entities": []}], [4416, "Identification of the essential oil components was based on the comparison of the standard alkanes (C8\u2013C20) from Sigma-Aldrich (St. Louis, MO, USA) with the retention times and mass spectral data, and computer matching with the NIST 21, NIST 107, and WILEY 229 library by comparing the fragmentation patterns of the mass spectra with those reported in the library [29].", {"entities": [[22, 35, "Extraction process"]]}], [4417, "This single-blind, parallel randomized clinical trial was authorized by the Ethics Committee of Tabriz University of Medical Sciences (code: TBZMED.REC.1394.576) on 26 November 2015, and was registered in the Iranian Registry of Clinical Trials (IRCT201509295563N7) on 9 January 2016.", {"entities": [[5, 53, "Study"]]}], [4418, "They were also asked to keep their daily intake of food during three months of study.", {"entities": [[35, 40, "Frequency"], [56, 75, "Duration"]]}], [4419, "Compliance of the subjects was followed up via phone consultation every week.", {"entities": [[66, 76, "Frequency"]]}], [4420, "The subjects were randomly allocated into the three groups: group 1 (n = 20) received routine dose of CC pills (50\u2013150 mg) for three menstrual cycles from the fifth day of menstruation for five days; group 2 (n = 20) consumed 700 mg herbal mixture capsule daily; and group 3 used up 700 mg herbal mixture capsule along with CC for three months.", {"entities": [[102, 104, "Drug"], [112, 121, "Amount"], [123, 198, "Duration"], [226, 232, "Amount"], [256, 261, "Frequency"], [283, 289, "Amount"], [324, 326, "Drug"], [327, 343, "Duration"]]}], [4421, "The participants were divided into three groups by random allocation software (RAS/ version 1.0.0, M Saghaei, Isfahan, Iran) [31] through randomized blocks of three and six with an allocation ratio of 1:1:1 by a person who was not involved in the study.", {"entities": []}], [4422, "For allocation concealment, according to sequence generation opaque and sealed envelopes numbered from 1 to 75; each contain a letter designating the allocation.", {"entities": []}], [4423, "The first envelope was dedicated to first participant and this process was followed to the end of the research.", {"entities": []}], [4424, "Only the statistician was blind to the study.", {"entities": []}], [4425, "Ten mL of blood samples was collected twice from antecubital veins in the morning after an overnight fasting, on the second day of the women\u2019s menstrual cycle; first, as the pre-intervention, and second, as the post intervention (three months later).", {"entities": [[135, 140, "Sex"]]}], [4426, "The blood samples were centrifuged for 10 min at 4000 rpm to separate the serum.", {"entities": []}], [4427, "The extracted serum was divided into four aliquots and kept frozen at \u221270 \u00b0C until assay.", {"entities": []}], [4428, "Serum MDA levels were measured by thiobarbituric acid (TBA) test with \u00b10.01 \u00b5Mol/L sensitivity.", {"entities": [[0, 9, "Parameter"]]}], [4429, "Concentration of plasma MDA was determined with a spectrophotometric detector at 532 nm.", {"entities": [[17, 27, "Parameter"]]}], [4430, "A 1,1\u2032,3,3\u2032-tetramethoxypropane was used to construct the calibration curve as the standard [32] (reference value: 0.54\u20131.32 pg/mL).", {"entities": []}], [4431, "In addition, serum SOD levels were measured by colorimetric method using an ELISA kit (RANDOX, Antrim, North Ireland UK) according to the manufacturers\u2019 instruction.", {"entities": [[13, 22, "Parameter"]]}], [4432, "Sensitivity of the assay was \u00b1 0.01 IU/mL (Cat.", {"entities": []}], [4433, "No.", {"entities": []}], [4434, "(SD) = 124; reference value: 164\u2013240 IU/mL).", {"entities": []}], [4435, "Moreover, serum GPx levels were measured by UV method using the ELISA kit (RANDOX).", {"entities": [[10, 19, "Parameter"]]}], [4436, "Sensitivity of this assay was \u00b1 1.15 IU/mL (Cat.", {"entities": []}], [4437, "No.", {"entities": []}], [4438, "RS 2318; reference value: 4171\u201310881 IU/mL).", {"entities": []}], [4439, "Furthermore, serum CAT levels were measured by immunoturbimetric assay using an ELISA commercial kit according to the manufacturers\u2019 protocol (CUSABIO Kit, WUHAN HUAMEI BIOTECH Co., Ltd. Wuhan, China).", {"entities": [[13, 22, "Parameter"]]}], [4440, "Sensitivity of the assays was \u00b1 3.9 pg/mL (Cat.", {"entities": []}], [4441, "No.", {"entities": []}], [4442, "CSB-E13635h; reference value: 19.8\u201366.4 pg/mL).", {"entities": []}], [4443, "Insulin concentration was determined through a fully automated chemiluminescence assay (LIAISON C-Peptide, Byk-Sangtec; reference value: 3.21\u201316.32 \u00b5IU/mL) [33].", {"entities": [[0, 21, "Parameter"]]}], [4444, "Blood glucose level (FBS) was measured by enzymatic methods using commercial kits (Pars Azemun, Isfahan, Iran) and the auto-analyzer system (Selectra E, Vitalab, Netherlands; reference value: 70\u2013115 mg/dL).", {"entities": [[0, 25, "Parameter"]]}], [4445, "Homeostatic model assessment for insulin resistance (HOMA-IR) was calculated according to  Volume of ovary, numbers as well as size of follicles were probed by vaginal ultrasound (5 MHz Ulramark 4 Plus; Advanced Technology Laboratories, Bothell, WA, USA).", {"entities": [[0, 61, "Parameter"]]}], [4446, "The participants were also asked to complete a checklist encompassing the side effects of medications during the intervention.", {"entities": [[74, 86, "Pathology"]]}], [4447, "Normality of all quantitative variables for each of the groups was confirmed using the Kolmogorov-Smirnov test.", {"entities": []}], [4448, "Descriptive statistics, including the frequency and percentage, and measures of central tendency and dispersion, including the mean and standard deviation (SD), were also used to describe the study variable.", {"entities": []}], [4449, "Moreover, the results were analyzed using one-way analysis of variance (ANOVA) with a post-hoc Tukey test for baseline quantitative variables.", {"entities": []}], [4450, "The paired t-test was also applied for comparison of quantitative data before and after the trial within the 3 groups, and analysis of covariance (ANCOVA) was used for between-group analysis after intervention adjusted for baseline values.", {"entities": []}], [4451, "p-Value \u2264 0.05 was considered statistically significant.", {"entities": []}], [4452, "The data were analyzed by SPSS software, version 22.0 (SPSS Inc., Chicago, IL, USA).", {"entities": []}], [4453, "In this study, the total methanolic extract was obtained from the herbal mixture powder which was 12.04 g. Then, the levels of DPPH, FRAP, TPC, and TFC were measured from this methanolic extract.", {"entities": [[25, 43, "Extraction process"], [176, 194, "Extraction process"]]}], [4454, "Herbal mixture showed potent antioxidant activity (RC50: 0.018 \u00b1 0.0007 mg/mL) in comparison to quercetin (RC50: 0.004 \u00b1 0.0001 mg/mL) as the positive control; this activity could be attributed to the presence of phenolic structures in the extract.", {"entities": [[51, 55, "Parameter"], [96, 105, "Herb name"], [213, 221, "Herb name"]]}], [4455, "The methanolic extract of herbal mixture had the ability to decrease TPRZ-Fe (III) to TPTZ-Fe (II), and FRAP values for methanolic extract of herbal mixture was 720 \u00b1 35 \u00b5mol Fe (II)/g, which was lower than that of quercetin (2880 \u00b1 41 \u00b5mol Fe (II)/g) as the standard antioxidant.", {"entities": [[4, 22, "Extraction process"], [120, 138, "Extraction process"], [215, 224, "Herb name"]]}], [4457, "The amount of extracted essential oil was 0.5% w/w, which was assessed on the dry weight basis.", {"entities": [[14, 37, "Extraction process"]]}], [4458, "The GC\u2013MS and GC\u2013FID analysis of the herbal powder essential oil indicated that the phytochemicals of the essential oil, including sesquiterpenes and derivatives (55.49%), aldehydes (19.38%), and monoterpenes (15.45%) were the main groups of oil components.", {"entities": [[51, 64, "Extraction process"], [106, 119, "Extraction process"], [131, 145, "Herb name"], [172, 181, "Herb name"], [196, 208, "Herb name"], [242, 245, "Extraction process"]]}], [4459, "Moreover, it was shown that zingiberene (13.58%), \u03b1-curcumene (10.77%), \u03b2-sesquiphellandrene (9.86%), \u03b1-farnesene (5.30%), and \u03b2-bisabolene (5.93%), isolated from ginger with sesquiterpenes hydrocarbons, were the most abundant components in essential oil of herbal mixture powder.", {"entities": [[28, 39, "Herb name"], [50, 61, "Herb name"], [72, 92, "Herb name"], [102, 113, "Herb name"], [127, 139, "Herb name"], [163, 169, "Herb name"], [175, 202, "Herb name"], [241, 254, "Extraction process"]]}], [4460, "In the same way, cinnamic aldehyde (13.06%) was separated from cinnamon with the organic compounds of aldehyde, and pulegone (5.61%) was extracted from spearmint with monoterpene structure.", {"entities": [[17, 34, "Herb name"], [63, 71, "Herb name"], [102, 110, "Herb name"], [116, 124, "Herb name"], [152, 161, "Herb name"], [167, 178, "Herb name"]]}], [4461, "No substance was extracted that could be related to C. sinensis, which might be due to its lowest dosage (Table 2, Figure 1).", {"entities": [[52, 63, "Herb name"]]}], [4462, "Based on our results, the antioxidant activity increased proportionally to the levels of polyphenol component, and a tremendous effect was seen on the treatment of PCOS regarding antioxidant activity.", {"entities": [[89, 99, "Herb name"], [164, 168, "Pathology"]]}], [4463, "Therefore, in standardization of herbal mixture, different proportions of each herbal powder were mixed, and phenolic and flavonoid contents were measured.", {"entities": [[109, 117, "Herb name"], [122, 131, "Herb name"]]}], [4464, "Moreover, the highest levels of phenolic and flavonoid contents were obtained in the weight ratios of 5 (250 mg) spearmint): 4 (200 mg) ginger: 3 (150 mg) cinnamon: 2 (100 mg) C. sinensis in comparison with other ratios.", {"entities": [[32, 40, "Herb name"], [45, 54, "Herb name"], [113, 122, "Herb name"], [136, 142, "Herb name"], [155, 163, "Herb name"], [176, 187, "Herb name"]]}], [4465, "Then, 75 participants were randomly allocated into 3 groups including group 1: CC (n = 25); group 2: herbal mixture (n = 25); and group 3: CC with herbal mixture (n = 25).", {"entities": [[6, 21, "Cohort"], [79, 81, "Drug"], [139, 141, "Drug"]]}], [4466, "Twenty-two women out of 25 in group 1, 23 out of 25 in group 2, and 24 out of 25 in group 3 received allocated interventions.", {"entities": []}], [4467, "However, 3, 2, and 1 of them in groups 1, 2, and 3, respectively, did not feel comfortable enough to participate.", {"entities": []}], [4468, "During the follow-up stage, 2 participants in group 1 were lost to be followed up with because of consuming other medication along with treatment, 3 of them in group 2 discontinued intervention on account of deciding to get treated with intrauterine insemination (IUI) or in vitro fertilization (IVF), and 2 of them in group 3 did not take an initial blood test, while 2 of them wanted to be treated with IUI or IVF.", {"entities": []}], [4469, "Finally, 60 participants (n = 20 in each group) finalized the intervention and their blood samples were analyzed at the end of three months (Figure 2).", {"entities": [[9, 24, "Cohort"], [127, 139, "Duration"]]}], [4470, "Before intervention, there were no significant differences between groups in terms of socio-demographic characteristics.", {"entities": []}], [4471, "The mean (SD) age was 25.7(4.1) years; the mean (SD) marital age was 20.2 (3.5) years, and the mean (SD) infertility history was 3.9 (3.0) years.", {"entities": [[0, 37, "Age"]]}], [4472, "Likewise, the mean (SD) weight was 73.8 (11.4) kg, and the mean (SD) BMI was 27.5 (3.8) kg/m Before intervention, there were no significant differences between groups regarding the serum levels of CAT (p = 0.725), GPx (p = 0.751), SOD (p = 0.793), and MDA (p = 0.835).", {"entities": [[55, 92, "Parameter"], [197, 200, "Parameter"], [214, 217, "Parameter"], [231, 234, "Parameter"], [252, 255, "Parameter"]]}], [4473, "After intervention, however, with adjusting baseline values, significant differences were observed between groups in terms of CAT (p = 0.001), GPx (p < 0.001), and SOD (p < 0.001) levels except for MDA (p = 0.420).", {"entities": [[126, 129, "Parameter"], [143, 146, "Parameter"], [164, 167, "Parameter"], [198, 201, "Parameter"]]}], [4474, "In a binary comparison, the CAT levels in group 2 (aMD = 9.0; CI 95% = 1.1\u201316.9, p = 0.021) and group 3 (aMD = 12.2; CI 95% = 4.5\u201319.9, p < 0.001), the GPx levels in group 2 (aMD = 986.1; CI 95% = 141.1\u20131831.1, p = 0.017) and group 3 (aMD = 1781.2; CI 95% = 960.7\u20132601.8, p < 0.001), and the SOD levels in group 2 (aMD = 55.1; CI 95% = 26.0\u201384.2, p < 0.001) and group 3 (aMD = 55.9; CI 95% = 27.5\u201384.2, p < 0.001) significantly increased in comparison with group 1.", {"entities": [[28, 31, "Parameter"], [152, 155, "Parameter"], [292, 295, "Parameter"]]}], [4475, "However, the binary comparison displayed no significant decrease in the MDA levels in group 2 (aMD = \u22120.1; CI 95% = \u22120.4 to 0.1, p = 0.502) and group 3 (aMD = \u22120.1; CI 95% = \u22120.4 to 0.1, p = 0.725).", {"entities": [[72, 75, "Parameter"]]}], [4476, "In addition, the binary comparison indicated no significant difference in the SOD, GPx, CAT, and MDA levels between groups 2 and 3 (p > 0.05).", {"entities": [[78, 81, "Parameter"], [83, 86, "Parameter"], [88, 91, "Parameter"], [97, 100, "Parameter"]]}], [4477, "Yet, in within-group analysis, a significant increase was observed after intervention compared to baseline considering the serum levels of CAT in group 2 (mean difference (MD) = 8.6; CI 95% = 1.9\u201315.2, p = 0.014) and group 3 (MD = 12.8; CI 95% = 6.5\u201319.1, p < 0.001), GPx in group 2 (MD = 1063.3; CI 95% = 509.7\u20131616.9, p < 0.001) and group 3 (MD = 1682.3; CI 95% = 794.3\u20132570.3, p < 0.001), and SOD in group 2 (MD = 49.2; CI 95% = 29.1\u201369.2, p < 0.001) and group 3 (MD = 54.1; CI 95% = 27.4\u201380.8, p < 0.001).", {"entities": [[139, 142, "Parameter"], [268, 271, "Parameter"], [396, 399, "Parameter"]]}], [4478, "Meanwhile, serum levels of MDA in group 2 (MD = \u20130.4; CI 95% = \u22120.6 to \u22120.2, p < 0.001) and group 3 (MD = \u22120.3; CI 95% = \u22120.5 to \u22120.1, p = 0.004) significantly decreased.", {"entities": [[27, 30, "Parameter"]]}], [4479, "Moreover, no significant difference was observed in group 1 in terms of CAT, SOD, and MDA levels (p > 0.05) except for GPx level (MD= \u221252.3; CI 95% = \u2212100.8 to \u20133.7, p = 0.036), which reduced remarkably (Table 4).", {"entities": [[72, 75, "Parameter"], [77, 80, "Parameter"], [86, 89, "Parameter"], [119, 122, "Parameter"]]}], [4480, "Before intervention, there were no significant differences between groups in terms of serum levels of insulin (p = 0.135) and HOMA-IR (p = 0.188) except for FBS (p = 0.003).", {"entities": [[86, 109, "Parameter"], [126, 133, "Parameter"], [157, 160, "Parameter"]]}], [4481, "After intervention, however, with adjusting baseline values, significant differences were observed in terms of FBS (p = 0.003), insulin (p = 0.029), and HOMA-IR (p = 0.017) levels.", {"entities": [[111, 114, "Parameter"], [128, 135, "Parameter"], [153, 160, "Parameter"]]}], [4482, "In the binary comparison, a significant decrease was seen in serum levels of FBS (aMD = \u22128.7; CI 95%= \u221214.7 to 2.7, p = 0.002) in group 3, insulin (aMD = \u22125.6; CI 95% = \u221210.8 to \u22120.4, p = 0.029) in group 2, and HOMA-IR (aMD = \u22121.3; CI 95% = \u22122.4 to \u22120.2, p = 0.013) in group 2 in comparison with group 1.", {"entities": [[77, 80, "Parameter"], [139, 146, "Parameter"], [211, 218, "Parameter"]]}], [4483, "Moreover, the binary comparison indicated no significant difference in the FBS level (p = 0.212) in group 2, the insulin level (p = 0.842) in group 3, and the HOMA-IR level (p = 0.403) in group 3 compared to group 1.", {"entities": [[75, 84, "Parameter"], [113, 126, "Parameter"], [159, 172, "Parameter"]]}], [4484, "Furthermore, based on our results from the binary comparison between groups 2 and 3 (p > 0.05), there was no significant difference in the FBS, insulin, and HOMA-IR levels.", {"entities": [[139, 142, "Parameter"], [144, 151, "Parameter"], [157, 164, "Parameter"]]}], [4485, "Additionally, in within-group analysis, no significant decrease was detected after intervention compared to baseline regarding the serum levels of FBS (MD = \u22126.4; CI 95%= \u221210.5 to \u22122.3, p = 0.004) in group 3, insulin (MD = \u22124.3; CI 95% = \u22127.7 to \u22122.2, p < 0.001) in group 2, and HOMA-IR (MD = \u22121.0; CI 95% = \u22121.4 to \u22120.4, p = 0.002) in group 2; yet, in the within-group comparison, there were no significant differences in the FBS levels in groups 1 and 2, the insulin levels in groups 1 and 3, and the HOMA-IR levels in groups 1 and 3 (p > 0.05, Table 5).", {"entities": [[147, 150, "Parameter"], [209, 216, "Parameter"], [279, 286, "Parameter"], [427, 430, "Parameter"], [461, 468, "Parameter"], [503, 510, "Parameter"]]}], [4486, "Ultrasonography for PCOS women on the second day of menstrual cycle after three-month treatment demonstrated no significant variations in the number, size of basal antral follicle count (AFC), and volume of ovary in all three groups that were 10\u201312, 2\u201312 mm, and 10 cm Our results also showed that after intervention, in groups 1, 2, and 3, 35%, 22.2%, and 35% had oligomenorrhea versus 65% (p = 0.014), 55.6% (p = 0.014), and 100% (p < 0.001) at the baseline.", {"entities": [[20, 24, "Pathology"], [25, 30, "Sex"], [74, 95, "Duration"], [164, 191, "Parameter"]]}], [4487, "Furthermore, after intervention, 25% of women in group 1 had amenorrhea versus 45% at the baseline (p = 0.46), and 25% in group 3 had amenorrhea versus 65% at the baseline (p = 0.005).", {"entities": [[40, 45, "Sex"], [61, 71, "Pathology"], [134, 144, "Pathology"]]}], [4488, "However, after intervention, in group 2, 16.7% had amenorrhea versus 33.3% at the baseline; though the difference between the groups was not significant (p = 0.083).", {"entities": [[51, 61, "Pathology"]]}], [4489, "Meanwhile, no side effects were reported in all three study groups during the 12 weeks of intervention.", {"entities": [[14, 26, "Pathology"], [78, 86, "Duration"]]}], [4490, "According to our results presented in Table 1, herbal mixture showed potent antioxidant activity, as well as total phenol and flavonoid content.", {"entities": [[115, 121, "Herb name"], [126, 135, "Herb name"]]}], [4491, "Based on previous studies, the antioxidant activity of extracts could mainly be attributed to the polyphenolic compounds [34].", {"entities": [[98, 120, "Herb name"]]}], [4492, "The FRAP assay is widely used to determine the antioxidant compounds in dietary polyphenols [35].", {"entities": [[80, 91, "Herb name"]]}], [4493, "In fact, polyphenols determine the antioxidant activity, and this positive relationship renders a trend in many medicinal plants [36].", {"entities": [[9, 20, "Herb name"]]}], [4494, "It has been proven that cinnamon contains a great variety of flavonoids and polyphenols with free-radical-scavenging properties and antioxidant activities [37].", {"entities": [[24, 32, "Herb name"], [61, 71, "Herb name"], [76, 87, "Herb name"]]}], [4495, "Ginger with a wide range of antioxidants and polyphenol compounds such as \u03b2-carotene, ascorbic acid, terpenoids, alkaloids, and polyphenols like flavonoids, flavone glycosides, and rutin is regarded the greatest source of phytochemical antioxidants [38].", {"entities": [[0, 6, "Herb name"], [45, 65, "Herb name"], [74, 84, "Herb name"], [86, 99, "Herb name"], [101, 111, "Herb name"], [113, 122, "Herb name"], [128, 139, "Herb name"], [145, 155, "Herb name"], [157, 175, "Herb name"], [181, 186, "Herb name"]]}], [4496, "Phenolic phytochemicals of spearmint significantly enhance the antioxidant defense [39].", {"entities": [[0, 23, "Herb name"], [27, 36, "Herb name"]]}], [4497, "Peel of C. sinensis is also very rich in phenolic compounds, including flavonoids and phenolic acids, which can be consumed as natural antioxidants [40].", {"entities": [[0, 4, "Herb part"], [8, 19, "Herb name"], [41, 59, "Herb name"], [71, 81, "Herb name"], [86, 100, "Herb name"]]}], [4498, "The GC\u2013MS and GC\u2013FID analyses in Table 2 showed the presence of zingiberene (13.58%), \u03b1-curcumene (10.77%), \u03b2-sesquiphellandrene (9.86%), \u03b1-farnesene (5.30%), and \u03b2-bisabolene (5.93%) with sesquiterpene hydrocarbons in ginger; cinnamic aldehyde (13.06%) with the organic compounds of aldehyde in cinnamon, and finally, pulegone (5.61%) with monoterpenes extracted from spearmint.", {"entities": [[64, 75, "Herb name"], [86, 97, "Herb name"], [108, 128, "Herb name"], [138, 149, "Herb name"], [163, 175, "Herb name"], [189, 215, "Herb name"], [219, 225, "Herb name"], [227, 244, "Herb name"], [284, 292, "Herb name"], [296, 304, "Herb name"], [319, 327, "Herb name"], [341, 353, "Herb name"], [369, 378, "Herb name"]]}], [4499, "A review of the literature indicated that sesquiterpene hydrocarbons and monoterpenes could be effective in various biological activities such as antioxidant effects [41,42].", {"entities": [[42, 68, "Herb name"], [73, 85, "Herb name"]]}], [4500, "Zhan et al.", {"entities": []}], [4501, "extracted \u03b1-zingiberene (22.29%), \u03b2-sesquiphellandrene (8.58%), \u03b1-farnesene (3.93%), \u03b2-bisabolene (3.87%), \u03b1-curcumene (2.63%) with sesquiterpene hydrocarbons from ginger volatile oil, which had antioxidant potency [43].", {"entities": [[10, 23, "Herb name"], [34, 54, "Herb name"], [64, 75, "Herb name"], [85, 97, "Herb name"], [107, 118, "Herb name"], [132, 158, "Herb name"], [164, 170, "Herb name"], [171, 183, "Extraction process"]]}], [4502, "In addition, it was shown in another study that the antioxidant effects of essential oils of cinnamon barks and ginger rhizomes could be ascribed to the presence of antioxidant constituents such as cinnamaldehyde, sesquiphellandrene, and zingiberene [44].", {"entities": [[75, 89, "Extraction process"], [93, 101, "Herb name"], [102, 107, "Herb part"], [112, 118, "Herb name"], [119, 127, "Herb part"], [198, 212, "Herb name"], [214, 232, "Herb name"], [238, 249, "Herb name"]]}], [4503, "Using the GC\u2013MS analysis, Telci et al.", {"entities": []}], [4504, "determined the main composition of spearmint as oxygenated monoterpenes including pulegone (26.71\u201329.56%) and piperitone (22.17\u201328.16%) as the major terpenoid group [45].", {"entities": [[35, 44, "Herb name"], [59, 71, "Herb name"], [82, 90, "Herb name"], [110, 120, "Herb name"], [149, 158, "Herb name"]]}], [4505, "Significant difference in the percentage of oil compositions in comparison to that of our study might depend on variation in environmental factors as well as difference in ecologies.", {"entities": [[44, 47, "Extraction process"]]}], [4506, "Regarding Table 4, our results clearly showed that after a 12-week intervention, levels of CAT, GPx, and SOD significantly increased in groups 2 and 3 compared to group 1.", {"entities": [[59, 66, "Duration"], [91, 94, "Parameter"], [96, 99, "Parameter"], [105, 108, "Parameter"]]}], [4507, "Although a significant decrease in case of MDA was seen in groups 2 and 3, there was no significant difference in comparison with group 1.", {"entities": [[43, 46, "Parameter"]]}], [4508, "Moreover, according to Table 5, levels of FBS in group 3, and insulin and HOMA-IR in group 2 significantly decreased compared to group 1.", {"entities": [[42, 45, "Parameter"], [62, 69, "Parameter"], [74, 81, "Parameter"]]}], [4509, "Many studies have indicated low serum antioxidant levels and insulin resistance in PCOS women [46,47,48].", {"entities": [[61, 79, "Pathology"], [83, 87, "Pathology"], [88, 93, "Sex"]]}], [4510, "In fact, hyperglycemia can enhance OS through numerous pathways.", {"entities": [[9, 22, "Pathology"]]}], [4511, "However, through a major non-enzymatic mechanism, it induces the intracellular ROS, generates electrochemical proton gradient produced by mitochondrial electron transport chain (mETC), and results in enhanced derivation of superoxide [49].", {"entities": [[65, 82, "Target"], [138, 183, "Target"], [223, 233, "Target"]]}], [4512, "In addition, reactive species by impairing glucose uptake in muscle and fat [50], and also by reducing insulin secretion from pancreatic \u03b2 cells play a crucial role in insulin resistance [7].", {"entities": [[13, 29, "Target"], [103, 110, "Target"], [168, 186, "Pathology"]]}], [4513, "On the other hand, an imbalance between oxidant-antioxidant is responsible for ovarian disturbance, insulin resistance, and chronic inflammation that is associated with pancreatic \u03b2 cell dysfunction in women with PCOS [10].", {"entities": [[79, 98, "Pathology"], [100, 118, "Pathology"], [124, 144, "Pathology"], [169, 198, "Pathology"], [202, 207, "Sex"], [213, 217, "Pathology"]]}], [4514, "Although ROS and RNS at low concentrations play physiological roles in cellular signaling pathways, in excess levels they may damage cellular functions [6].", {"entities": [[9, 12, "Target"], [17, 20, "Target"]]}], [4515, "Reactive oxygen species react with lipids, causing them to boost peroxidation products such as MDA [47].", {"entities": [[0, 23, "Target"], [35, 41, "Target"], [95, 98, "Target"]]}], [4516, "Cinnamon also reduces insulin resistance by enhancing phosphatidylinositol 3-kinase activity in the insulin signaling pathway [51].", {"entities": [[0, 8, "Herb name"], [22, 40, "Pathology"], [54, 83, "Target"]]}], [4517, "In several studies, the authors proved that cinnamon contained proanthocyanidins and phenolic compounds with antioxidant activities that not only neutralized free radicals, but also reduced blood glucose and insulin [52,53].", {"entities": [[44, 52, "Herb name"], [63, 80, "Herb name"], [85, 103, "Herb name"], [190, 203, "Parameter"], [208, 215, "Parameter"]]}], [4518, "Moselhy et al.", {"entities": []}], [4519, "indicated a strong hepatoprotective effect of cinnamon ethanolic extract against carbon tetrachloride (CCl4)-induced oxidative stress by increasing the SOD and CAT levels and decreasing the MDA level, the possible mechanism of which could be attributed to the free radical scavenging activity of polyphenol compounds [54].", {"entities": [[46, 54, "Herb name"], [55, 72, "Extraction process"], [152, 155, "Parameter"], [160, 163, "Parameter"], [190, 193, "Parameter"], [296, 316, "Herb name"]]}], [4520, "In a study examining the effect of ginger and onion (Allium cepa) on the levels of sexual hormones and OS, the reduction of MDA serum level was significant in the within-ginger group, but was not significant in comparison to the control group; this result was in line with ours [55].", {"entities": [[35, 41, "Herb name"], [46, 65, "Herb name"], [83, 98, "Target"], [103, 105, "Target"], [124, 139, "Parameter"], [170, 176, "Herb name"]]}], [4521, "A use of the combination of ginger and cinnamon in diabetic male rats in the study of Khaki et al.", {"entities": [[28, 34, "Herb name"], [39, 47, "Herb name"], [51, 59, "Pathology"], [60, 64, "Sex"]]}], [4522, "particularly illustrated an increase in the SOD, CAT, and GPx levels, while the MDA level more significantly decreased compared to other groups using only one herb [17].", {"entities": [[44, 47, "Parameter"], [49, 52, "Parameter"], [58, 61, "Parameter"], [80, 83, "Parameter"]]}], [4523, "In an animal study, Al-Amin et al.", {"entities": [[6, 18, "Study"]]}], [4524, "demonstrated that ginger could decrease the FBS level by the mechanism of serotonin receptors which activate pancreatic \u03b2 cells to release insulin [56].", {"entities": [[18, 24, "Herb name"], [44, 53, "Parameter"], [74, 93, "Target"], [109, 127, "Target"], [139, 146, "Target"]]}], [4525, "Additionally, Bayani et al.", {"entities": []}], [4526, "showed that phenolic phytochemicals of spearmint possessed hypoglycemic, and antioxidant attributes [57].", {"entities": [[12, 35, "Herb name"], [39, 48, "Herb name"]]}], [4527, "Deep et al.", {"entities": []}], [4528, "also revealed that methanolic extract of spearmint was a more potent antioxidant than ascorbic acid, which is recognized as the standard antioxidant.", {"entities": [[19, 37, "Extraction process"], [41, 50, "Herb name"]]}], [4529, "Furthermore, the levels of SOD, GPx, and CAT were duplicated, while MDA level fell by half [58].", {"entities": [[27, 30, "Parameter"], [32, 35, "Parameter"], [41, 44, "Parameter"], [68, 71, "Parameter"]]}], [4530, "In other research, Selmi et al.", {"entities": []}], [4531, "approved that hesperidin as one of the main flavonoids of C. sinensis reversed lipoperoxidation and hydrogen peroxide production, reduced MDA level, and increased antioxidant status (CAT, GPX, SOD levels) drastically [59].", {"entities": [[14, 24, "Herb name"], [44, 54, "Herb name"], [58, 69, "Herb name"], [79, 95, "Target"], [100, 117, "Target"], [138, 141, "Parameter"], [183, 186, "Parameter"], [188, 191, "Parameter"], [193, 196, "Parameter"]]}], [4532, "Volatile oil from C. sinensis peel contains naringin and naringenin as two kinds of flavonoids which have anti-diabetic and antioxidant properties [60].", {"entities": [[0, 12, "Extraction process"], [18, 29, "Herb name"], [30, 34, "Herb part"], [44, 52, "Herb name"], [57, 67, "Herb name"], [84, 94, "Herb name"]]}], [4533, "Polymethoxylated flavones (PMFs) of C. sinensis have hypolipidemic effects, resulting in a significant reduction of insulin tolerance and glucose levels [61].", {"entities": [[0, 32, "Herb name"], [36, 47, "Herb name"], [116, 123, "Target"]]}], [4535, "All of this research is consistent with our study.", {"entities": []}], [4536, "In this study, regular menstrual cycle, ovulation, and pregnancy occurred in all three groups.", {"entities": []}], [4537, "The main cause of this syndrome is the reduction in the sensitivity of pre-antral follicles to follicle stimulating hormone (FSH), and enhancement of follicular activity to luteinizing hormone (LH) leading to the inhibition of follicle maturation [63].", {"entities": [[95, 129, "Target"], [173, 197, "Target"]]}], [4538, "Similarly, excessive secretion of LH and gonadotropin-releasing hormone (GnRH) stimulate ovarian theca cells to produce androgens [64].", {"entities": [[34, 36, "Target"], [41, 78, "Target"], [120, 129, "Target"]]}], [4539, "As a consequence, hyperandrogenism not only arrests antral follicle growth, but also stimulates apoptosis of its granulose cells which convert androgen to estradiol employing aromatase enzyme [65].", {"entities": [[18, 34, "Pathology"], [143, 151, "Target"], [155, 164, "Target"], [175, 191, "Target"]]}], [4540, "The study of Khodaeifar et al.", {"entities": []}], [4541, "certified that cinnamon could improve ovulatory menstrual cycle by enhancing progesterone levels in the luteal phase of PCOS women [66].", {"entities": [[15, 23, "Herb name"], [77, 89, "Target"], [120, 124, "Pathology"], [125, 130, "Sex"]]}], [4542, "Similarly, Ataabadi et al.", {"entities": []}], [4543, "demonstrated that spearmint, through reducing body weight and level of testosterone and having antioxidant properties, matured follicles, and induced ovulation, led to higher number of Graafian follicles and corpus lutea and lower number of ovarian cysts and atretic follicles [24].", {"entities": [[18, 27, "Herb name"], [71, 83, "Target"]]}], [4544, "Ginger not only stimulated blood circulation for the treatment of inflammation and menstrual irregularities, but also enhanced AFC and ovarian reserve function [67].", {"entities": [[0, 6, "Herb name"], [66, 78, "Pathology"], [83, 107, "Pathology"]]}], [4545, "Clomiphene citrate stimulated ovulation and increased fertility rate via stimulating the secretion of gonadotropin-releasing hormone as well as anti-estrogenic effect [68].", {"entities": [[0, 18, "Drug"], [102, 132, "Target"]]}], [4546, "The results of the present study pointed out the fact that herbal mixture could increase the serum levels of CAT, GPx, SOD, and reduce the MDA level.", {"entities": [[109, 112, "Parameter"], [114, 117, "Parameter"], [119, 122, "Parameter"], [139, 142, "Parameter"]]}], [4547, "Likewise, CC along with herbal mixture could exert such effects.", {"entities": [[10, 12, "Drug"]]}], [4548, "This result may contribute to the point that although CC could not alter serum level of the antioxidant, it did not interfere in the activity of herbal supplement.", {"entities": [[54, 56, "Drug"]]}], [4549, "Although the FBS level did not reduce in the groups administered with CC and herbal mixture solely, their combination could decrease the FBS; this result might be ascribed to the synergistic effects of their combination.", {"entities": [[13, 16, "Parameter"], [70, 72, "Drug"], [137, 140, "Parameter"]]}], [4550, "Further studies are needed to prove these findings.", {"entities": []}], [4551, "One of the major strengths of this study was not only the analysis of essential pharmacophores, TPC, TFC, DPPH, and FRAP in a herbal mixture, but also the evaluation of its efficacy on serum antioxidant levels and glycemic biomarkers in infertile PCOS women.", {"entities": [[237, 251, "Pathology"], [252, 257, "Sex"]]}], [4552, "Furthermore, in previous studies, the effects of all aforementioned herbs were investigated separately, while we evaluated the effects of CC and herbal mixture as a new combination, which might have synergistic effects.", {"entities": [[138, 140, "Drug"]]}], [4553, "Nonetheless, the relatively small sample size, short-term follow-up, single-blind design, and using a fixed dose of herbal mixture in the clinical study were the limitations of this study.", {"entities": [[138, 152, "Study"]]}], [4554, "We recommend that further research should be undertaken regarding the effects of herbal mixtures on hormonal factors of PCOS women such as sexual hormones in both proliferative and secretory phases, and lipid profile in a longer follow-up.", {"entities": [[120, 124, "Pathology"], [125, 130, "Sex"], [139, 154, "Target"]]}], [4555, "In summary, the results indicated that phenolics and phyto-antioxidant constituents of the herbal mixture including zingiberene, \u03b1-curcumene, \u03b2-sesquiphellandrene, \u03b1-farnesene, \u03b2-bisabolene, cinnamic aldehyde, and pulegone could effectively improve antioxidant potential, and the levels of FBS, HOMA-IR, and insulin in the serum of PCOS patients.", {"entities": [[39, 48, "Herb name"], [53, 70, "Herb name"], [116, 127, "Herb name"], [129, 140, "Herb name"], [142, 162, "Herb name"], [164, 175, "Herb name"], [177, 189, "Herb name"], [191, 208, "Herb name"], [214, 222, "Herb name"], [290, 293, "Parameter"], [295, 302, "Parameter"], [308, 315, "Parameter"], [332, 336, "Pathology"]]}], [4556, "It can be concluded that consumption of a herbal mixture as a supplement alongside CC can improve the antioxidant activity, glycemic status, and pregnancy rate in PCOS patients.", {"entities": [[83, 85, "Drug"], [124, 139, "Parameter"], [163, 167, "Pathology"]]}], [4557, "Hence, it could be considered as a beneficial supplementary medicament for patients suffering from PCOS.", {"entities": [[99, 103, "Pathology"]]}], [4558, "We would like to thank the Pharmaceutical Aras Part Medicinal Herbs International Company for the preparing herbal mixture capsules, Women\u2019s Reproductive Health Research Center, Tabriz University of Medical Sciences, Tabriz, Iran for their infertility clinic, and Iran National Science Foundation (INSF) and Deputy of Research and Technology of Ministry of Health and Medical Education for the financial support.", {"entities": [[133, 138, "Sex"], [240, 251, "Pathology"]]}], [4559, "Our further appreciation goes to all of the investigators, coordinators, and patients who assisted or took part in this study.", {"entities": []}], [4560, "Conceptualization, N.A.", {"entities": []}], [4561, "and E.O.S.M.", {"entities": []}], [4562, "; Methodology, A.K.", {"entities": []}], [4563, "and E.O.S.M.", {"entities": []}], [4564, "; Statistical analysis, A.F.-K.; Managed patient recruitment and sample collection, N.A.", {"entities": []}], [4565, "; Laboratory analysis, N.A.", {"entities": []}], [4566, "and A.K.", {"entities": []}], [4567, "; Resources, A.K.", {"entities": []}], [4568, "and M.H.", {"entities": []}], [4569, "; Writing\u2014Original Draft Preparation, N.A.", {"entities": []}], [4570, "; Writing\u2014Review & Editing, A.K., E.O.S.M., A.F.-K. and M.H; Supervision, E.O.S.M.", {"entities": []}], [4571, "; Project Administration E.O.S.M; Funding Acquisition, E.O.S.M.", {"entities": []}], [4572, "; All authors read and approved the final manuscript.", {"entities": []}], [4573, "This research was funded by \u201cTabriz University of Medical Sciences, Tabriz, Iran (grant number: 5.4.9505)\u201d and \u201cIran National Science Foundation (INSF) and Deputy of Research and Technology of Ministry of Health and Medical Education (grant number: 96010160)\u201d.", {"entities": []}], [4574, "The authors declare no conflict of interests.", {"entities": []}], [4575, "Gas chomatography\u2013mass chromatogram (GC\u2013MS) of the essential oil of herbal mixture.", {"entities": [[51, 64, "Extraction process"]]}], [4576, "TIC*1.00: total ion current (1.0 std).", {"entities": []}], [4577, "Polycystic ovary syndrome (PCOS) patients\u2019 flow diagram.", {"entities": [[0, 32, "Pathology"]]}], [4578, "Group 1: Clomiphene citrate (CC), group 2: Herbal mixture, and group 3: CC along with herbal mixture.", {"entities": [[9, 32, "Drug"], [72, 74, "Drug"]]}], [4579, "IUI: intrauterine insemination, IVF: in vitro fertilization.", {"entities": []}], [4580, "DPPH, FRAP, TPC, and TFC of methanolic extract of herbal mixture.", {"entities": [[28, 46, "Extraction process"]]}], [4581, "DPPH (2,2-diphenyl-1-picrylhydrazyl) free radical scavenging activity, FRAP: ferric reducing antioxidant potential, TPC: total phenolic content, TFC: total flavonoid content.", {"entities": [[127, 135, "Herb name"], [156, 165, "Herb name"]]}], [4582, "Volatile compounds identified in the essential oil of herbal mixture.", {"entities": [[37, 50, "Extraction process"]]}], [4583, "Monoterpenes and derivatives: 15.45.", {"entities": [[0, 12, "Herb name"]]}], [4584, "Sesquiterpenes and derivatives: 55.49.", {"entities": [[0, 14, "Herb name"]]}], [4585, "Aldehydes: 19.38.", {"entities": [[0, 9, "Herb name"]]}], [4586, "Other compounds: 1.91.", {"entities": []}], [4587, "Total identified: 92.23.", {"entities": []}], [4588, "KI: Kovats index, Rt: retention time.", {"entities": []}], [4589, "General characteristics of the women with PCOS at baseline and after intervention.", {"entities": [[31, 36, "Sex"], [42, 46, "Pathology"]]}], [4590, "Comparison of mean \u00b1 SD serum levels of CAT, GPx, SOD, and MDA in participants receiving CC, herbal mixture, and CC along with herbal mixture.", {"entities": [[40, 43, "Parameter"], [45, 48, "Parameter"], [50, 53, "Parameter"], [59, 62, "Parameter"], [89, 91, "Drug"], [113, 115, "Drug"]]}], [4591, "CAT: Catalase, GPx: Glutathione peroxidase, SOD: Superoxide dismutase, MDA: Malondialdehyde.", {"entities": [[0, 13, "Parameter"], [15, 42, "Parameter"], [44, 69, "Parameter"], [71, 91, "Parameter"]]}], [4592, "p  Comparison of mean \u00b1 SD serum levels of FBS, insulin, and HOMA-IR in participants receiving CC, herbal mixture, CC along with herbal mixture.", {"entities": [[43, 46, "Parameter"], [48, 55, "Parameter"], [61, 68, "Parameter"], [95, 97, "Drug"], [115, 117, "Drug"]]}], [4593, "FBS: Fast blood sugar, HOMA-IR: Homeostatic model assessment for insulin resistance, p", {"entities": [[0, 21, "Parameter"], [23, 83, "Parameter"]]}], [4594, "The aim of this systematic review was to assess the published clinical evidence on interactions between herbal and conventional drugs.", {"entities": [[16, 33, "Study"]]}], [4595, "Four electronic databases were searched for case reports, case series or clinical trials of such interactions.", {"entities": [[44, 56, "Study"], [58, 69, "Study"], [73, 88, "Study"]]}], [4596, "The data were extracted and validated using a scoring system for interaction probability.", {"entities": []}], [4597, "One hundred and eight cases of suspected interactions were found.", {"entities": []}], [4598, "68.5% were classified as \u2018unable to be evaluated\u2019, 13% as \u2018well-documented\u2019 and 18.5% as \u2018possible\u2019 interactions.", {"entities": []}], [4599, "Warfarin was the most common drug (18 cases) and St John's wort the most common herb (54 cases) involved.", {"entities": [[0, 8, "Drug"], [49, 63, "Herb name"]]}], [4600, "Herb\u2013drug interactions undoubtedly do occur and may put individuals at risk.", {"entities": []}], [4601, "However our present knowledge is incomplete and more research is urgently needed.", {"entities": []}], [4602, "The PI is Professor Edmund J.D.", {"entities": []}], [4603, "Lee.", {"entities": []}], [4604, "This study evaluated the pharmacokinetics of gabapentin in Chinese subjects who received a diet rich in shiitake mushrooms.", {"entities": [[45, 55, "Drug"], [59, 66, "Ethnic group"], [104, 122, "Herb name"]]}], [4605, "Shiitake mushrooms have been shown to contain high amount of ergothioneine.", {"entities": [[0, 18, "Herb name"], [61, 74, "Herb name"]]}], [4606, "However, as it does not affect the AUC(0,t", {"entities": [[35, 38, "Parameter"]]}], [4607, "E. purpurea root extract capsules were added to the antiretroviral treatment (500 mg every 6 h) from days 1 to 14.", {"entities": [[0, 11, "Herb name"], [12, 16, "Herb part"], [78, 84, "Amount"], [85, 94, "Frequency"], [96, 114, "Duration"]]}], [4608, "Darunavir concentrations in plasma were determined by high-performance liquid chromatography immediately before and 1, 2, 4, 6, 8, 10, and 12 h after a morning dose of darunavir-ritonavir on days 0 (darunavir-ritonavir) and 14 (darunavir-ritonavir plus echinacea).", {"entities": [[0, 9, "Drug"], [168, 187, "Drug"], [199, 218, "Drug"], [228, 247, "Drug"], [253, 262, "Herb name"]]}], [4609, "Individual darunavir pharmacokinetic parameters were calculated by noncompartmental analysis and compared between days 0 and 14 with the geometric mean ratio (GMR) and its 90% confidence interval (CI).", {"entities": [[11, 20, "Drug"]]}], [4610, "The median age was 49 (range, 43 to 67) years, and the body mass index was 24.2 (range, 18.7 to 27.5) kg/m2.", {"entities": [[19, 21, "Age"], [55, 70, "Parameter"], [75, 79, "Amount"]]}], [4611, "Echinacea was well tolerated, and all participants completed the study.", {"entities": [[0, 9, "Herb name"]]}], [4612, "The GMR for darunavir coadministered with echinacea relative to that for darunavir alone was 0.84 (90% CI, 0.63-1.12) for the concentration at the end of the dosing interval, 0.90 (90% CI, 0.74-1.10) for the area under the concentration-time curve from 0 to 12 h, and 0.98 (90% CI, 0.82-1.16) for the maximum concentration.", {"entities": [[12, 21, "Drug"], [42, 51, "Herb name"], [73, 82, "Drug"], [208, 247, "Parameter"], [301, 322, "Parameter"]]}], [4613, "In summary, coadministration of E. purpurea with darunavir-ritonavir was safe and well tolerated.", {"entities": [[32, 43, "Herb name"], [49, 68, "Drug"]]}], [4614, "Individual patients did show a decrease in darunavir concentrations, although this did not affect the overall darunavir or ritonavir pharmacokinetics.", {"entities": [[11, 19, "Pathology"], [43, 52, "Drug"], [110, 119, "Drug"], [123, 132, "Drug"]]}], [4615, "Although no dose adjustment is required, monitoring darunavir concentrations on an individual basis may give reassurance in this setting.", {"entities": [[52, 61, "Drug"]]}], [4616, "Despite the widespread use and proven effectiveness of highly active antiretroviral therapy (HAART) for the management of HIV infection, the use of herbal remedies and other types of complementary and alternative medicine (CAM) is common among HIV-infected patients, who often do not report such use to their doctor (14; J. Molt\u00f3, C. Miranda, S. Malo, M. Valle, A. Andreu, X. Bonafont, and B. Clotet, presented at the 11th International Workshop in Clinical Pharmacology of HIV Therapy, 2010).", {"entities": [[55, 99, "Drug"], [122, 135, "Pathology"], [244, 266, "Pathology"]]}], [4617, "Many of these remedies are taken as complements rather than as substitutes for HAART.", {"entities": [[79, 84, "Drug"]]}], [4618, "This, together with limited evidence to support the safety of many of these combinations, makes it possible for potentially significant interactions between certain types of CAM and antiretroviral drugs to occur.", {"entities": [[182, 202, "Drug"]]}], [4619, "Herbal medicines are often perceived to be innocuous and healthier than manufactured medicines even though they can act on the metabolism of antiretroviral agents, decreasing or increasing drug concentrations through induction or inhibition of metabolic pathways (11, 13).", {"entities": [[141, 162, "Drug"]]}], [4620, "The most widely recognized botanical supplement associated with CYP450-mediated herb-drug interaction is St. John's wort (Hypericum perforatum).", {"entities": [[105, 144, "Herb name"]]}], [4621, "This herb may induce CYP3A4 activity, decreasing exposure to antiretroviral drugs such as indinavir or nevirapine (6, 18) and putting patients at risk of treatment failure and subsequent development of viral resistance to antiretroviral drugs.", {"entities": [[21, 37, "Target"], [90, 99, "Drug"], [103, 113, "Drug"], [134, 142, "Pathology"], [222, 242, "Drug"]]}], [4622, "Clinical pharmacokinetic interaction studies between antiretroviral agents and botanicals nonetheless remain scarce in the literature.", {"entities": [[0, 44, "Study"], [53, 74, "Drug"]]}], [4623, "Echinacea preparations rank among the top-selling botanical supplements worldwide (1, 4), and they are among the herbal medicines most commonly taken by HIV-infected patients (12), usually as a self-prescribed remedy and without medical supervision.", {"entities": [[0, 9, "Herb name"], [153, 174, "Pathology"]]}], [4624, "Although the exact mechanism of action of echinacea remains unknown (3, 17, 19, 22, 23), this substance has been reported to be an immunostimulant and its oral administration has been suggested to be beneficial in the early treatment of upper respiratory tract infections (3, 21, 24).", {"entities": [[42, 51, "Herb name"], [237, 271, "Pathology"]]}], [4625, "The main constituents of echinacea preparations are caffeic acid derivatives and alkamides, which have a potential to interact with cytochrome P450 (1).", {"entities": [[25, 34, "Herb name"], [52, 76, "Herb name"], [81, 91, "Herb name"], [132, 147, "Target"]]}], [4626, "Gorski et al.", {"entities": []}], [4627, "(10) investigated the in vivo effects of Echinacea purpurea on the activity of several CYP isozymes, including CYP3A4, after intravenous and oral midazolam administration.", {"entities": [[41, 59, "Herb name"], [87, 117, "Target"], [146, 155, "Drug"]]}], [4628, "In that study echinacea selectively modulated the catalytic activity of CYP3A4 at both hepatic and intestinal sites.", {"entities": [[14, 23, "Herb name"], [72, 78, "Target"]]}], [4629, "This differential effect on CYP3A4 activity at two sites makes it difficult to predict potential effects on the disposition of other CYP3A4 substrates such as HIV protease inhibitors.", {"entities": [[28, 34, "Target"], [133, 139, "Target"], [159, 162, "Pathology"]]}], [4630, "Similarly to other protease inhibitors, darunavir undergoes extensive metabolism by the CYP3A4 isoform of the cytochrome P450 enzyme family (20).", {"entities": [[40, 49, "Drug"]]}], [4631, "Therefore, in order to enhance its pharmacokinetic profile, darunavir must be coadministered with low doses of ritonavir, which acts as a potent CYP3A4 inhibitor, thereby boosting other CYP3A4 substrates.", {"entities": [[60, 69, "Drug"], [111, 120, "Drug"], [145, 151, "Target"], [186, 192, "Target"]]}], [4632, "Thus, at the approved dosage of darunavir-ritonavir, darunavir concentrations at the end of the dosing interval remain well above the concentration needed to inhibit replication of HIV strains (20; V. Sekar, S. Spinosa-Guzman, E. Lefebvre, and R. Hoetelmans, presented at the 16th International AIDS Conference, 2006).", {"entities": [[32, 51, "Drug"], [53, 62, "Drug"], [181, 184, "Pathology"], [295, 299, "Pathology"]]}], [4633, "However, induction or inhibition of CYP3A4 activity by other agents might result in inadequately low or excessively high darunavir concentrations, respectively, compromising antiretroviral treatment effectiveness.", {"entities": [[36, 42, "Target"], [121, 130, "Drug"], [174, 198, "Drug"]]}], [4634, "The aim of the present study was, therefore, to investigate the potential of this commonly used botanical supplement, E. purpurea, to interact with a protease inhibitor such as darunavir-ritonavir.", {"entities": [[118, 129, "Herb name"], [177, 196, "Drug"]]}], [4635, "Go to: MATERIALS AND METHODS  Study design.", {"entities": []}], [4637, "V05895B; Arkopharma, Madrid, Spain).", {"entities": []}], [4638, "Antiretroviral treatment remained unchanged.", {"entities": [[0, 24, "Drug"]]}], [4639, "Serial blood samples to determine darunavir and ritonavir concentrations in plasma were collected immediately before and 1, 2, 4, 6, 8, 10, and 12 h after a witnessed morning dose of darunavir-ritonavir on days 0 (darunavir-ritonavir) and 14 (darunavir-ritonavir plus echinacea).", {"entities": [[34, 43, "Drug"], [48, 57, "Drug"], [183, 202, "Drug"], [214, 233, "Drug"], [243, 262, "Drug"], [268, 277, "Herb name"]]}], [4640, "Demographic and clinical variables, including age, body weight and height, and use of concomitant drugs, including over-the-counter medications, were recorded.", {"entities": []}], [4641, "Safety was evaluated by clinical interview and physical examination and by laboratory assessment (blood counts, chemistry, CD4+ T-cell count, and HIV-1 RNA load) on days 0, 14, and 28.", {"entities": [[98, 110, "Parameter"], [123, 140, "Parameter"]]}], [4642, "To enhance adherence to scheduled clinical visits and the treatment protocol, patients were provided with a visit calendar.", {"entities": [[78, 86, "Pathology"]]}], [4643, "Apart from days 0 and 14, drug intake was not directly observed; adherence was assessed by means of a diary in which the patient recorded medication intake and by pill count on day 14.", {"entities": [[121, 128, "Pathology"]]}], [4644, "Analytical and pharmacokinetic analysis.", {"entities": []}], [4645, "Blood samples for darunavir and ritonavir determinations were collected into potassium- and EDTA-containing 10-ml tubes.", {"entities": [[18, 27, "Drug"], [32, 41, "Drug"]]}], [4646, "Plasma was isolated by centrifugation (3,200 \u00d7 g for 15 min), and stored at \u221220\u00b0C until analysis.", {"entities": []}], [4647, "Darunavir and ritonavir concentrations were determined by high-performance liquid chromatography with a photo diode array detector (HPLC-PDA 2996; Waters, Barcelona, Spain), according to a validated method.", {"entities": [[0, 9, "Drug"], [14, 23, "Drug"]]}], [4648, "The analytical column was a NovaPak C18 column (3.9 by 150 mm) with a NovaPak C18 guard column (Waters).", {"entities": []}], [4649, "The method involved liquid-liquid extraction of drug from plasma with methyl tert-butyl ether.", {"entities": []}], [4650, "The mobile phase consisted of a gradient elution with phosphate buffer in acetonitrile (pH 6.70).", {"entities": []}], [4651, "The method was linear over the range of 0.05 to 10.0 mg/liter for both drugs (the lower limit of quantification was 0.05 mg/liter, and intra- and interday variation was <10%).", {"entities": []}], [4652, "Our laboratory subscribes to the external quality assurance program organized by the Association for Quality Assessment in Therapeutic Drug Monitoring and Clinical Toxicology of Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands (7).", {"entities": []}], [4653, "Darunavir and ritonavir pharmacokinetic parameters were calculated for each individual using a noncompartmental approach by means of Winnonlin (Version 2.0; Pharsight, Mountain View, CA).", {"entities": [[0, 9, "Drug"], [14, 23, "Drug"]]}], [4655, "Maximum concentrations (Cmax) and the concentrations at the end of the dosing interval (C\u03c4) were obtained by inspection of the concentration data.", {"entities": [[0, 29, "Parameter"], [34, 91, "Parameter"]]}], [4656, "Statistical analysis.", {"entities": []}], [4657, "Data analysis was carried out using SPSS version 15.0 statistical software (Chicago, IL).", {"entities": []}], [4658, "Darunavir and ritonavir pharmacokinetic parameters were described by the geometric mean and compared between days 0 and 14 by the geometric mean ratio (GMR) and its 90% confidence interval (CI).", {"entities": [[0, 9, "Drug"], [14, 23, "Drug"]]}], [4659, "Pharmacokinetic parameters were natural log transformed before analysis, and confidence intervals for means (and for the difference between two means) were constructed on the natural log scale based on an analysis of variance model with treatment as a fixed effect.", {"entities": []}], [4660, "The results were exponentiated and reported with lower and upper limits of the 90% CIs.", {"entities": []}], [4661, "A power calculation indicated that 15 patients would provide an 80% chance of detecting a 40% difference in the AUC\u03c4 of darunavir at the P = 0.05 level of significance.", {"entities": [[112, 116, "Parameter"], [120, 129, "Drug"]]}], [4662, "One patient was a woman, and three patients were coinfected with hepatitis C virus.", {"entities": [[4, 11, "Pathology"], [18, 23, "Sex"], [35, 43, "Pathology"], [65, 82, "Pathology"]]}], [4663, "The median age was 49 (range, 43 to 67) years, and the body mass index was 24.2 (range, 18.7 to 27.5) kg/m2.", {"entities": [[19, 21, "Age"], [55, 70, "Parameter"], [75, 79, "Parameter"]]}], [4664, "In accordance with the inclusion criteria, all patients had an HIV-1 RNA load of <50 copies/ml.", {"entities": [[63, 77, "Parameter"], [81, 95, "Amount"]]}], [4665, "The median CD4+ T-cell count was 498 (range, 244 to 962) cells/mm3.", {"entities": [[11, 28, "Parameter"], [33, 36, "Amount"]]}], [4666, "Echinacea was well tolerated, and all participants completed the study.", {"entities": [[0, 9, "Herb name"]]}], [4667, "Reported adherence to echinacea and antiretroviral treatment was 100%.", {"entities": [[22, 31, "Herb name"], [36, 60, "Drug"]]}], [4668, "No patient reported adverse events during the study, and all maintained an HIV-1 RNA load of <50 copies/ml at the end of the study.", {"entities": [[3, 10, "Pathology"], [20, 34, "Pathology"], [75, 89, "Parameter"], [93, 106, "Amount"]]}], [4669, "Beside darunavir-ritonavir, antiretroviral treatment included lamivudine or emticitabine in 13 patients, raltegravir in 12, tenofovir in 11, and etravirine in 6 patients.", {"entities": [[7, 26, "Drug"], [28, 52, "Drug"], [62, 72, "Drug"], [76, 88, "Drug"], [105, 116, "Drug"], [124, 133, "Drug"], [145, 155, "Drug"], [161, 170, "Pathology"]]}], [4670, "Other antiretrovirals in use during the study included didanosine in three patients and abacavir and zidovudine in two patients and one patient, respectively.", {"entities": [[6, 21, "Drug"], [55, 65, "Drug"], [88, 96, "Drug"], [101, 111, "Drug"], [119, 127, "Pathology"], [136, 143, "Pathology"]]}], [4671, "Darunavir pharmacokinetics.", {"entities": [[0, 9, "Drug"]]}], [4672, "Darunavir plasma concentration-time profiles following administration of darunavir-ritonavir alone or in combination with multiple doses of E. purpurea are shown in Fig.", {"entities": [[0, 9, "Drug"], [73, 92, "Drug"], [140, 151, "Herb name"]]}], [4673, "\u200bFig.1.1.", {"entities": []}], [4674, "Table \u200bTable11 summarizes darunavir pharmacokinetic parameters with and without coadministration of echinacea.", {"entities": [[26, 35, "Drug"], [100, 109, "Herb name"]]}], [4675, "Coadministration of E. purpurea resulted in little change in darunavir pharmacokinetic parameters, with C\u03c4 and AUC\u03c4 decreasing by averages of 16% and 10%, respectively.", {"entities": [[20, 31, "Herb name"], [61, 70, "Drug"], [104, 106, "Parameter"], [111, 115, "Parameter"]]}], [4676, "However, looking at each participant individually, a decrease in darunavir C\u03c4 or AUC\u03c4 by as much as 40% and 30%, respectively, was observed in some patients (Table \u200b(Table11 and Fig.", {"entities": [[65, 74, "Drug"], [75, 77, "Parameter"], [81, 85, "Parameter"], [148, 156, "Pathology"]]}], [4677, "\u200bFig.2).2).", {"entities": []}], [4678, "There was no substantial effect on Cmax.", {"entities": [[35, 39, "Parameter"]]}], [4679, "An external file that holds a picture, illustration, etc.", {"entities": []}], [4680, "Object name is zac9991095660001.jpg FIG.", {"entities": []}], [4681, "1.", {"entities": []}], [4682, "Geometric mean darunavir (DRV) and ritonavir (RTV) plasma concentration profiles of darunavir-ritonavir (DRV/r) with or without coadministration of multiple doses of Echinacea purpurea.", {"entities": [[15, 30, "Drug"], [35, 50, "Drug"], [84, 111, "Drug"], [166, 184, "Herb name"]]}], [4683, "Error bars represent the 90% confidence interval.", {"entities": []}], [4684, "An external file that holds a picture, illustration, etc.", {"entities": []}], [4685, "Object name is zac9991095660002.jpg FIG.", {"entities": []}], [4686, "2.", {"entities": []}], [4687, "Darunavir (DRV) concentration at the end of the dosing interval (C\u03c4) and area under the time-concentration curve (AUC\u03c4) values after administration of darunavir-ritonavir with or without multiple doses of Echinacea purpurea.", {"entities": [[0, 15, "Drug"], [33, 68, "Parameter"], [73, 119, "Parameter"], [151, 170, "Drug"], [205, 223, "Herb name"]]}], [4688, "Gray lines represent individual values, and black lines represent the geometric mean.", {"entities": []}], [4689, "TABLE 1.", {"entities": []}], [4690, "bData are expressed as geometric mean (90% confidence interval).", {"entities": []}], [4691, "Ritonavir pharmacokinetics.", {"entities": [[0, 9, "Drug"]]}], [4692, "Figure \u200bFigure11 displays the ritonavir concentration-versus-time profile, and Table \u200bTable22 lists the pharmacokinetic parameters of ritonavir after multiple-dose administration of darunavir-ritonavir alone or in combination with E. purpurea.", {"entities": [[30, 39, "Drug"], [134, 143, "Drug"], [182, 201, "Drug"], [231, 242, "Herb name"]]}], [4693, "Mean ritonavir pharmacokinetic parameters were essentially unchanged by coadministration of echinacea (Table \u200b(Table22).", {"entities": [[5, 14, "Drug"], [92, 101, "Herb name"]]}], [4694, "TABLE 2.", {"entities": []}], [4695, "bData are expressed as geometric mean (90% confidence interval).", {"entities": []}], [4696, "Go to: DISCUSSION  There has been an upsurge in botanical supplement use in Western countries during the last decade, with 20% to 30% of prescription drug users taking concomitant herbal remedies (8, 25).", {"entities": []}], [4697, "The prevalence of herbal remedy intake is even higher among HIV-infected patients, and recent surveys indicate that more than one-third of HIV-infected patients may take herbal supplements along with antiretroviral therapy, often without notifying their physician (14; J. Molt\u00f3, C. Miranda, S. Malo, M. Valle, A. Andreu, X. Bonafont, and B. Clotet, presented at the 11th International Workshop in Clinical Pharmacology of HIV Therapy, 2010).", {"entities": [[60, 81, "Pathology"], [139, 160, "Pathology"], [200, 222, "Drug"]]}], [4698, "In spite of this, studies of clinical pharmacokinetic interactions between antiretroviral agents and botanicals are scarce in the literature.", {"entities": [[75, 96, "Drug"]]}], [4699, "The few pharmacokinetic studies that have been published have been conducted with healthy volunteers, and it has been noted that research has not kept pace with the standard of care for HIV management (13).", {"entities": [[4, 31, "Study"], [82, 89, "Pathology"], [186, 189, "Pathology"]]}], [4700, "As a result, it is difficult to extrapolate their results to HIV-infected patients receiving antiretroviral therapy with regimens commonly prescribed today, such as boosted protease inhibitors.", {"entities": [[61, 82, "Pathology"], [93, 115, "Drug"]]}], [4701, "In the present study we aimed to evaluate the potential interaction between one of the top-selling botanical supplements worldwide (1), E. purpurea, and darunavir-ritonavir as a model for boosted protease inhibitors.", {"entities": [[136, 148, "Herb name"], [153, 172, "Drug"]]}], [4702, "We hypothesized that there might be such an interaction based on previous in vivo data showing that E. purpurea influenced the activity of CYP3A4, the main enzyme involved in the metabolism of darunavir and other protease inhibitors, with opposite effects at the liver or at the intestinal sites (10).", {"entities": [[100, 111, "Herb name"], [139, 146, "Target"], [193, 202, "Drug"]]}], [4703, "However, the effect of echinacea on darunavir pharmacokinetics (C\u03c4, AUC\u03c4, and Cmax) was negligible in our study, as reflected in the close correspondence of the pharmacokinetic profiles in the presence or absence of coadministered echinacea across the entire 12-hour dosing interval.", {"entities": [[23, 32, "Herb name"], [36, 45, "Drug"], [64, 66, "Parameter"], [68, 72, "Parameter"], [78, 82, "Parameter"], [231, 240, "Herb name"]]}], [4704, "Nonetheless, although this result did not affect overall darunavir pharmacokinetics, individual patients did show a decrease in darunavir C\u03c4 and AUC\u03c4 by as much as by 40% and 30%, respectively, after coadministration of echinacea.", {"entities": [[57, 66, "Drug"], [128, 137, "Drug"], [138, 140, "Parameter"], [145, 149, "Parameter"], [220, 229, "Herb name"]]}], [4705, "This effect might be relevant in some clinical settings, such as in treatment-experienced patients with reduced viral susceptibility to darunavir.", {"entities": [[136, 145, "Drug"]]}], [4706, "The variability in the effect of echinacea on darunavir pharmacokinetics we observed in this cohort may imply some degree of uncertainty in the CYP3A4 inductive/inhibitory potential of this herbal remedy.", {"entities": [[33, 42, "Herb name"], [46, 55, "Drug"], [144, 150, "Target"]]}], [4707, "Considered together, these results support caution to be exercised and clinicians should be vigilant to the possibility of use of echinacea or other botanical supplements by their patients, monitoring plasma antiretroviral drug concentrations if possible.", {"entities": [[130, 139, "Herb name"], [180, 188, "Pathology"], [208, 227, "Drug"]]}], [4708, "The discrepancy between the lack of an interaction between echinacea and darunavir-ritonavir in our study and the increase in the oral bioavailability of the CYP3A4 substrate midazolam described by Gorski et al.", {"entities": [[59, 68, "Herb name"], [73, 92, "Drug"], [130, 150, "Parameter"], [175, 184, "Drug"]]}], [4709, "(10) may be explained because patients in the present study were also receiving low doses of ritonavir, which is a potent CYP3A4 inhibitor.", {"entities": [[93, 102, "Drug"], [122, 128, "Target"]]}], [4710, "This inhibition of CYP3A4 by ritonavir could mask the influence of echinacea on CYP3A4 activity.", {"entities": [[19, 25, "Target"], [29, 38, "Drug"], [67, 76, "Herb name"], [80, 86, "Target"]]}], [4711, "If so, a remaining question is whether the lack of a significant interaction between boosted darunavir and echinacea that we report here would be reproducible in patients receiving other antiretroviral agents which are CYP3A4 substrates but not necessarily coadministered with ritonavir, such as nonnucleoside reverse transcriptase inhibitors or maraviroc.", {"entities": [[93, 102, "Drug"], [107, 116, "Herb name"], [162, 170, "Pathology"], [187, 208, "Drug"], [277, 286, "Drug"], [296, 342, "Drug"], [346, 355, "Drug"]]}], [4712, "Although echinacea is considered one of the safest herbal medicines, there has been some concern about its use in HIV-infected patients (1, 2), in whom it has been thought to be potentially dangerous based on its T-cell-stimulating effect, which might cause a rise in viral load as a result of increasing replication of infected T cells (15).", {"entities": [[9, 18, "Herb name"], [114, 135, "Pathology"]]}], [4713, "In fact, some texts recommend that HIV-positive patients should avoid the use of echinacea.", {"entities": [[35, 56, "Pathology"], [81, 90, "Herb name"]]}], [4714, "We found, however, that E. purpurea was well tolerated, with no evident safety issue of concern.", {"entities": [[24, 35, "Herb name"]]}], [4715, "All participants completed the treatment period, and all of them maintained an undetectable viral load at the end of the study.", {"entities": []}], [4716, "One potential limitation of our study includes the fact that we did not perform independent phytochemical analyses for \u201cmarker compounds\u201d in the E. purpurea product used in this study.", {"entities": [[145, 156, "Herb name"]]}], [4717, "With the multitude of Echinacea brands available on the market, there may be great variability in product content, formulation, dissolution, and bioavailability.", {"entities": [[22, 31, "Herb name"], [145, 161, "Parameter"]]}], [4718, "Moreover, discrepancies between the labeled and the actual content of active constituents are possible, with commercial products not containing the labeled herb at all in some cases (9), thereby confounding the interpretation of pharmacokinetic drug interaction studies.", {"entities": [[229, 269, "Study"]]}], [4719, "To avoid this, a single lot of E. purpurea was purchased from a sole vendor.", {"entities": [[31, 42, "Herb name"]]}], [4720, "Arkopharma is a leader in the botanical supplement industry in Europe; it is externally controlled and has been granted the Good Manufacturing Practices certificate by the AFSSAPS (French Agency for the Sanitary Security for Health Products).", {"entities": []}], [4721, "In summary, the results of this study indicate that coadministration of E. purpurea root with darunavir-ritonavir is generally safe and well tolerated in HIV-infected patients.", {"entities": [[72, 83, "Herb name"], [94, 113, "Drug"], [154, 175, "Pathology"]]}], [4722, "Although the study did not show an effect on the overall darunavir or ritonavir pharmacokinetics, individual patients did show a decrease in darunavir concentrations.", {"entities": [[57, 66, "Drug"], [70, 79, "Drug"], [109, 117, "Pathology"], [141, 150, "Drug"]]}], [4723, "Although no dose adjustment is required, monitoring darunavir concentrations on an individual basis may give reassurance in this setting.", {"entities": [[52, 61, "Drug"]]}], [4724, "We assessed the human in vivo metabolic drug interaction profile of Ginkgo biloba extract EGb 761\u00ae with respect to the activities of major cytochrome P450 (CYP) enzymes.", {"entities": [[68, 98, "Herb name"], [133, 168, "Parameter"]]}], [4725, "A single-center, open-label, randomized, three-fold crossover, cocktail phenotyping design was applied.", {"entities": [[0, 90, "Study"]]}], [4726, "In the morning of day 8, administration was performed together with the orally administered phenotyping cocktail (enzyme, metric): 150\u00a0mg caffeine (CYP1A2, paraxanthine/caffeine plasma ratio 6-h postdose), 125\u00a0mg tolbutamide (CYP2C9, plasma concentration 24-h postdose), 20\u00a0mg omeprazole (CYP2C19, omeprazole/5-hydroxy omeprazole plasma ratio 3-h postdose), 30\u00a0mg dextromethorphan (CYP2D6, dextromethorphan/dextrorphan plasma ratio 3-h postdose), and 2\u00a0mg of midazolam (CYP3A, plasma concentration 6-h postdose).", {"entities": [[18, 23, "Duration"], [131, 137, "Amount"], [138, 146, "Herb name"], [148, 154, "Parameter"], [156, 177, "Herb name"], [191, 194, "Duration"], [206, 212, "Amount"], [213, 224, "Drug"], [226, 232, "Parameter"], [234, 254, "Parameter"], [255, 259, "Duration"], [271, 276, "Amount"], [277, 287, "Drug"], [289, 296, "Parameter"], [298, 329, "Drug"], [343, 346, "Duration"], [358, 363, "Amount"], [364, 380, "Drug"], [382, 388, "Parameter"], [390, 418, "Drug"], [432, 435, "Duration"], [451, 455, "Amount"], [459, 468, "Drug"], [470, 475, "Parameter"], [498, 501, "Duration"]]}], [4727, "Formally, absence of a relevant interaction was assumed if the 90% confidence intervals (CIs) for EGb 761\u00ae/placebo ratios of the metrics were within the 0.70\u20131.43 range.", {"entities": [[98, 106, "Herb name"]]}], [4728, "EGb 761\u00ae/placebo ratios for phenotyping metrics were close to unity for all CYPs.", {"entities": [[0, 8, "Herb name"], [76, 80, "Parameter"]]}], [4729, "Furthermore, respective CIs were within the specified margins for all ratios except CYP2C19 for EGb 761\u00ae 120\u00a0mg twice daily (90% CI 0.681\u20131.122) and for CYP2D6 for EGb 761\u00ae 240\u00a0mg once daily (90% CI 0.667\u20131.281).", {"entities": [[84, 91, "Parameter"], [96, 104, "Herb name"], [105, 111, "Amount"], [112, 123, "Frequency"], [153, 159, "Parameter"], [164, 172, "Herb name"], [173, 179, "Amount"], [180, 190, "Frequency"]]}], [4730, "These findings were attributed to the intraindividual variability of the metrics used.", {"entities": []}], [4731, "All treatments were well tolerated.", {"entities": []}], [4732, "EGb 761\u00ae has no relevant effect on the in vivo activity of the major CYP enzymes in humans and therefore has no relevant potential to cause respective metabolic drug\u2013drug interactions.", {"entities": [[0, 8, "Herb name"], [69, 80, "Parameter"]]}], [4733, "Ginkgo biloba extract is a popular herbal remedy used for a variety of disorders.", {"entities": [[0, 21, "Herb name"], [71, 80, "Pathology"]]}], [4734, "EGb 761\u00ae interferes with various pathomechanisms relevant to dementing disorders [2\u20134].", {"entities": [[0, 8, "Herb name"], [61, 80, "Pathology"]]}], [4735, "A large number of clinical trials suggest that Ginkgo biloba extract (GBE) has beneficial effects on memory, cognition, and the vascular system [5\u20139].", {"entities": [[18, 33, "Study"], [47, 74, "Herb name"]]}], [4736, "For a herbal drug to be taken by elderly people, who often have several chronic diseases, the ability of GBE to cause metabolic drug\u2013drug interactions should be known.", {"entities": [[6, 17, "Herb name"], [72, 88, "Pathology"], [105, 108, "Herb name"]]}], [4737, "In fact, available data for GBE effects on cytochrome P450 activity in vitro and in vivo from animal and human studies is inconsistent.", {"entities": [[28, 31, "Herb name"], [43, 67, "Parameter"], [94, 118, "Study"]]}], [4738, "In vitro studies in rat liver microsomes showed inhibitory effects of GBE on some CYPs [10\u201312], whereas both inhibition [13, 14] and induction [15\u201317] was reported for in vivo studies.", {"entities": [[0, 16, "Study"], [70, 73, "Herb name"], [82, 86, "Target"], [168, 183, "Study"]]}], [4739, "In vitro experiments carried out in human liver microsomes suggested that GBE weakly inhibits human CYP enzymes, e.g., CYP1A2 and CYP3A [18].", {"entities": [[0, 20, "Study"], [74, 77, "Herb name"], [94, 111, "Target"], [119, 135, "Target"]]}], [4740, "The effect of Ginkgo biloba was also assessed on a panel of recombinant human CYPs (CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP3A).", {"entities": [[14, 27, "Herb name"], [60, 123, "Parameter"]]}], [4741, "Constituents of Ginkgo biloba (ginkgolic acids I and II) significantly inhibited CYP1A2 (IC Whereas studies using enzymes from laboratory animals and in vitro studies with human material may provide some general information, especially with herbal drugs, it is difficult to predict drug\u2013drug interactions in patients in this way [22].", {"entities": [[16, 55, "Herb name"], [81, 87, "Target"], [100, 186, "Study"], [241, 253, "Herb name"]]}], [4742, "The interplay of multiple chemical moieties, each of these subject to its own pharmacokinetics, limits the applicability of mechanistic approaches for in vitro/in vivo extrapolations.", {"entities": []}], [4743, "Available in vivo studies in humans indicate that GBE has no effect on the hepatic microsomal drug oxidation system [23].", {"entities": [[10, 35, "Study"], [50, 53, "Herb name"], [71, 115, "Parameter"]]}], [4744, "No differences were observed between baseline and post-GBE treatment [25].", {"entities": [[55, 58, "Herb name"]]}], [4745, "A pharmacokinetic study in healthy volunteers conducted with diazepam as a substrate of CYP2C19 also did not provide evidence for a herb\u2013drug interaction [26].", {"entities": [[0, 23, "Study"], [27, 34, "Pathology"], [61, 69, "Drug"], [88, 95, "Parameter"]]}], [4746, "Izzo and Ernst [27] reviewed the literature (Medline, Cochrane Library and Embase) to determine the possible interactions between seven popular herbal medicines, including ginkgo.", {"entities": [[144, 160, "Herb name"], [172, 178, "Herb name"]]}], [4747, "They summarized from about 128 case reports and 80 clinical trials that an effect on CYP enzymes by ginkgo seems unlikely.", {"entities": [[31, 43, "Study"], [51, 66, "Study"], [85, 96, "Parameter"], [100, 106, "Herb name"]]}], [4748, "In summary, despite limited in vivo data supporting the absence of major effects, it cannot be excluded that EGb 761\u00ae may alter the activity of CYP enzymes in patients.", {"entities": [[109, 117, "Herb name"], [128, 155, "Parameter"]]}], [4749, "The objective of our study was to quantitatively assess the in vivo herbal drug\u2013drug interaction potential of EGb 761\u00ae with respect to the five major human drug-metabolizing CYP enzymes.", {"entities": [[110, 118, "Herb name"], [150, 185, "Parameter"]]}], [4750, "The study (EudraCT number 2008-005686-63) was approved by the Ethics Committee of the Chamber of Physicians of Northrhine and the pertinent regulatory authorities and conducted as defined in local regulations, International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH-GCP), Directive 2001/20/EC, and in accordance with the Declaration of Helsinki.", {"entities": []}], [4751, "Participants were considered to be in good health on the basis of medical history, physical examination, vital signs measurement, electrocardiogram (ECG), and clinical laboratory tests.", {"entities": [[38, 49, "Pathology"]]}], [4752, "Volunteers were required to be Caucasian, of either gender, aged between 18 and 55\u00a0years, to have a body mass index (BMI) between 19 and 29\u00a0kg/m The study had an open-label, single-center, randomized, threefold cross-over design.", {"entities": [[31, 40, "Ethnic group"], [65, 88, "Age"], [98, 121, "Parameter"], [122, 144, "Amount"], [145, 228, "Study"]]}], [4753, "The following treatments were administered for 8\u00a0days each: placebo twice daily (treatment A), EGb 761\u00ae 120\u00a0mg twice daily (treatment B), and EGb 761\u00ae 240\u00a0mg in the morning and placebo in the evening (treatment C).", {"entities": [[43, 53, "Duration"], [68, 79, "Frequency"], [95, 103, "Herb name"], [104, 110, "Amount"], [111, 122, "Frequency"], [142, 150, "Herb name"], [151, 157, "Amount"]]}], [4754, "Administration of 2\u00a0mg midazolam (MID) (Dormicum\u00ae V Injektionsl\u00f6sung, Roche Pharma AG, Germany) orally with 120\u00a0ml of water was administered 1 min thereafter.", {"entities": [[18, 22, "Amount"], [23, 68, "Drug"], [108, 114, "Amount"], [118, 123, "Extraction process"], [141, 146, "Duration"]]}], [4755, "The three study periods were separated by a washout phase of at least 14\u00a0days between cocktail administrations.", {"entities": [[61, 77, "Duration"]]}], [4757, "For an individual participant, the same time of study-drug administration was used for all periods.", {"entities": []}], [4758, "Participants fasted from 2 h before until 2 h after evening dose on day 7 and 8 and at least 9 h before until 6 h after administration in the morning of day 8 and from 2 h before until 2 h after evening dose on day 8.", {"entities": [[20, 51, "Duration"], [84, 96, "Duration"], [110, 113, "Duration"], [163, 194, "Duration"]]}], [4759, "Blood samples for phenotyping agents [to determine CAF, paraxanthine (PAX), TOL, OME, 5-hydroxy OME (5-OH-OME), DEX, dextrorphan (DOR), and MID] were collected via an indwelling catheter into 9-ml Li-Heparin Monovettes\u00ae (Sarstedt) on day 8 approximately 10 min prior to dosing of the cocktail and 3, 6, and 24 h thereafter.", {"entities": [[51, 54, "Herb name"], [56, 74, "Herb name"], [76, 79, "Drug"], [81, 84, "Drug"], [86, 110, "Drug"], [112, 134, "Drug"], [140, 143, "Drug"], [200, 207, "Parameter"], [254, 260, "Duration"], [297, 311, "Duration"]]}], [4760, "After thawing, plasma samples (200 \u03bcl) were precipitated with 400 \u03bcl acetonitrile (ACN) for the CAF, PAX, and TOL assays.", {"entities": [[62, 68, "Amount"], [69, 87, "Extraction process"], [96, 99, "Herb name"], [101, 104, "Herb name"], [110, 113, "Drug"]]}], [4761, "For this method, two internal standards [20 \u03bcl CAF-d3 (300\u00a0ng/ml) and 20 \u03bcl TOL-d9 (300\u00a0ng/ml) dissolved in ACN] were added.", {"entities": [[41, 46, "Amount"], [47, 50, "Herb name"], [55, 64, "Amount"], [70, 75, "Amount"], [76, 79, "Drug"], [84, 93, "Amount"], [108, 111, "Extraction process"]]}], [4762, "Precipitation was done the same way without an internal standard for OME, 5-OH-OME, DEX, DOR), and MID assays, respectively.", {"entities": [[69, 72, "Drug"], [74, 82, "Drug"], [84, 87, "Drug"], [89, 92, "Drug"], [99, 102, "Drug"]]}], [4764, "The effluent of LC system (300\u00a0ml/min; 1200 series; Agilent, Waldbronn, Germany) was delivered through a reversed-phase column (125 x 2\u00a0mm, 3 \u03bcm; Nucleodur C18 Isis, Macherey-Nagel, Dueren, Germany) eluted with a gradient solvent system consisting of water (A) and methanol (B) (0 \u2192 0.75 min A:B 80:20 \u2192 A:B 30:70, 0.75 \u2192 4.00 min A:B 30:70, 4.00 \u2192 5.00 min A:B 30:70 \u2192 A:B 80:20) to the mass spectrometer.", {"entities": [[27, 37, "Frequency"], [251, 256, "Extraction process"], [265, 273, "Extraction process"], [279, 291, "Duration"], [315, 330, "Duration"], [342, 357, "Duration"]]}], [4765, "The effluent (300\u00a0ml/min) was delivered through a different reversed-phase column (50 x 2.1\u00a0mm, 5 \u03bcm; Hypersil Gold, Thermo Electron, Runcorn, UK) eluted with a gradient solvent system consisting of 0.1% formic acid (A) and methanol (B) (0 \u2192 1.5 min A:B 95:5, 1.5 \u2192 1.51 min A:B 95:5 \u2192 A:B 10:90, 1.51 \u2192 6 min A:B 10:90 \u2192 6 \u2192 6.5 min A:B 10:90 \u2192 A:B 95:5, 6.5 \u2192 10 min A:B 95:5) to the mass spectrometer.", {"entities": [[14, 24, "Frequency"], [199, 203, "Amount"], [204, 215, "Extraction process"], [224, 232, "Extraction process"], [238, 249, "Duration"], [260, 274, "Duration"], [297, 309, "Duration"], [322, 333, "Duration"], [356, 368, "Duration"]]}], [4766, "Mobile phase was isocratic (0.9\u00a0ml/min) methanol/water/formic acid (500/500/0.25\u00a0v/v) on a reversed-phase column [250 x 4.6\u00a0mm, 5 \u03bcm; Luna C18(2), Phenomenex, Torrance, CA, USA] with postcolumn addition of methanol/ammonium hydroxide solution 30% (98/2\u00a0v/v) with 0.1\u00a0ml/min.", {"entities": [[28, 38, "Frequency"], [40, 66, "Extraction process"], [206, 242, "Extraction process"], [243, 246, "Amount"], [263, 273, "Frequency"]]}], [4767, "Bilobalide and ginkgolide A, B, and C were detected by negative ESI (ESI Estimation of individual CYP enzyme activity for each enzyme was based on established phenotyping metrics.", {"entities": [[0, 37, "Herb name"], [98, 117, "Parameter"]]}], [4768, "Evaluation of phenotyping metrics followed the standard bioequivalence approach, with adjusted margins.", {"entities": []}], [4769, "Between days 5 and 8, geometric mean plasma concentrations for the four terpene lactones showed only small variations: mean values (\u00b1 SD) varied for ginkgolide A between 2.78\u2009\u00b1\u20091.64\u00a0ng/ml (day 5) and 2.92\u2009\u00b1\u20091.78\u00a0ng/ml (day 7), ginkgolide B between 2.25\u2009\u00b1\u20090.90\u00a0ng/ml (day 5) and 2.34\u2009\u00b1\u20091.06\u00a0ng/ml (day 8), ginkgolide C between 0.75\u2009\u00b1\u20090.08\u20130.13\u00a0ng/ml (days 8 and 7) and 0.76\u2009\u00b1\u20090.14\u00a0ng/ml (day 5), and bilobalide between 1.87\u2009\u00b1\u20091.25\u00a0ng/ml (day 7) and 1.92\u2009\u00b1\u20091.37\u00a0ng/ml (day 5), indicating that steady state was reached.", {"entities": [[0, 20, "Duration"], [22, 58, "Parameter"], [72, 88, "Herb name"], [149, 161, "Herb name"], [170, 187, "Amount"], [200, 217, "Amount"], [227, 239, "Herb name"], [248, 265, "Amount"], [278, 295, "Amount"], [305, 317, "Herb name"], [326, 348, "Amount"], [368, 385, "Amount"], [399, 409, "Herb name"], [418, 435, "Amount"], [448, 465, "Amount"]]}], [4770, "Based on data from all 18 participants, the geometric mean ratios for the CYP1A2, CYP2C9, and CYP3A metric were similar for all three treatments (Table\u00a01), with 90% CIs for ratios of the respective metrics being within the predefined acceptance range (Table\u00a02).", {"entities": [[23, 38, "Cohort"], [74, 88, "Parameter"], [94, 99, "Parameter"]]}], [4771, "Thus, EGb 761\u00ae showed neither inhibition nor induction of these enzymes.", {"entities": [[6, 14, "Herb name"], [64, 71, "Parameter"]]}], [4772, "Overview of geometric means for the metrics of cytochrome P450s (CYPs) Test 1, 120\u00a0mg Ginkgo biloba special extract EGb 761\u00ae twice daily (b.i.d.)", {"entities": [[47, 70, "Parameter"], [79, 85, "Amount"], [86, 124, "Herb name"], [125, 136, "Frequency"]]}], [4773, "Test 2, 240\u00a0mg EGb 761\u00ae once daily (q.d.)", {"entities": [[8, 14, "Amount"], [15, 23, "Herb name"], [24, 34, "Frequency"]]}], [4774, "plus placebo once daily Placebo, placebo b.i.d.", {"entities": [[13, 23, "Frequency"]]}], [4775, "Summary of statistical analysis of cytochrome P450 (CYP) phenotyping metrics Log-transformed evaluation, results presented after back-transformation Ratios derived from least squares geometric means Test 1, 120\u00a0mg Gingko biloba special extract EGb 761\u00ae twice daily (b.i.d.)", {"entities": [[35, 56, "Parameter"], [207, 213, "Amount"], [214, 252, "Herb name"], [253, 264, "Frequency"]]}], [4776, "Test 2, 240\u00a0mg EGb 761\u00ae once daily (q.d.)", {"entities": [[8, 14, "Amount"], [15, 23, "Herb name"], [24, 34, "Frequency"]]}], [4777, "plus placebo once daily Placebo, placebo b.i.d.", {"entities": [[13, 23, "Frequency"]]}], [4778, "For CYP2C19, the lower limit of the 90% CI for its OME-based metric ratio exceeded the predefined range (0.681\u2009<\u20090.70, see Table\u00a02) in the 120-mg b.i.d.", {"entities": [[4, 11, "Parameter"], [51, 54, "Drug"], [139, 145, "Amount"]]}], [4779, "group.", {"entities": []}], [4780, "In contrast, the 90% CI for the other dosing schedule of 240\u00a0mg EGb 761\u00ae q.d.", {"entities": [[57, 63, "Amount"], [64, 72, "Herb name"]]}], [4781, "was completely within the predefined limits.", {"entities": []}], [4782, "Geometric mean ratios of CYP2D6 for all three treatments were similar (Table\u00a01) based on data from 14 of 18 participants (four were poor metabolizers).", {"entities": [[0, 31, "Parameter"], [105, 120, "Cohort"], [132, 149, "Parameter"]]}], [4783, "Although the point estimator (0.925) of the ratio for CYP2D6 in the 240-mg q.d.", {"entities": [[54, 60, "Parameter"], [68, 74, "Amount"]]}], [4784, "group was close to unity, the lower limit of the 90% CI exceeded the predefined range (0.667\u2009<\u20090.70, see Table\u00a02), whereas for the 120-mg EGb 761\u00ae b.i.d.", {"entities": [[131, 137, "Amount"], [138, 146, "Herb name"]]}], [4785, "group, the 90% CI for the ratios was within the limits.", {"entities": []}], [4786, "All 18 randomized participants received all three kinds of study medication and were included in the safety analysis set.", {"entities": [[4, 30, "Cohort"]]}], [4787, "Administration of EGb 761\u00ae 120\u00a0mg b.i.d.", {"entities": [[18, 26, "Herb name"], [27, 33, "Amount"]]}], [4788, "and EGb 761\u00ae 240\u00a0mg q.d.", {"entities": [[4, 12, "Herb name"], [13, 19, "Amount"]]}], [4789, "was well tolerated when given alone and together with the phenotyping cocktail.", {"entities": []}], [4790, "Overall, 19 adverse events (AE) occurred during the study, out of which 11 were considered as unlikely to be related to study medication, with headache being the most frequent event, for which a causal drug relationship could not be excluded.", {"entities": [[12, 31, "Pathology"], [143, 151, "Pathology"]]}], [4791, "Laboratory tests, 12-lead ECGs, physical examinations, and vital signs did not evince any risk of EGb 761\u00ae in any of the three treatment groups.", {"entities": [[59, 70, "Parameter"], [98, 106, "Herb name"]]}], [4792, "The aim of the study was to evaluate a possible effect of EGb 761\u00ae intake on the activity of five major human CYP enzymes using the cocktail-phenotyping approach.", {"entities": [[58, 66, "Herb name"], [104, 121, "Parameter"]]}], [4793, "We provide evidence that EGb 761\u00ae has no clinically relevant inhibitory or inducing effects toward the major human CYP enzymes when administered at chronic therapeutic doses in vivo.", {"entities": [[25, 33, "Herb name"], [109, 126, "Parameter"]]}], [4794, "Phenotyping for drug-metabolizing enzymes is defined as measuring its actual in vivo activity in an individual and is performed by administering a selective substrate for this enzyme and subsequently determining appropriate pharmacokinetic parameters closely reflecting enzyme activity [28].", {"entities": [[16, 41, "Parameter"], [270, 285, "Parameter"]]}], [4795, "Drugs within a cocktail should not interfere with metabolism of other drugs in the cocktail [29].", {"entities": []}], [4796, "Usually, a crossover design is used, with administration of the respective phenotyping agents in both periods, combined with coadministration of the drug to be tested on one period [28].", {"entities": [[9, 27, "Study"]]}], [4797, "This study was designed to combine a state-of-the-art drug\u2013drug-interaction cocktail [28, 30] with a minimal sampling strategy.", {"entities": []}], [4798, "Based on estimation of the samples size required, the number of participants was essentially sufficient, although intraindividual variability was higher than expected (Table\u00a02).", {"entities": []}], [4799, "As far as is known, the substrates are specific for individual CYPs, there are no interactions between these substrates, and the probe drugs in the coctail are among those that may be considered as best validated [31\u201334].", {"entities": [[63, 67, "Parameter"], [129, 140, "Drug"]]}], [4800, "A maximum exposure was realized with a 240-mg EGb 761\u00ae daily dose, and exposure duration was sufficient to eventually induce CYPs, as steady state for EGb 761\u00ae components was reached, and 1\u00a0week is typically sufficient to achieve full induction [35].", {"entities": [[39, 45, "Amount"], [46, 54, "Herb name"], [125, 129, "Target"], [151, 170, "Herb name"], [188, 194, "Duration"]]}], [4801, "As to whether phenotyping metrics used were optimal, the most recent European Medicines Agency draft guidelines on the investigation of drug interactions (CPMP/EWP/560/95/Rev.", {"entities": []}], [4802, "1 \u2013 Corr.", {"entities": []}], [4803, "), published after completion of this study, asks for determination of complete area under the concentration-time-curve (AUC) values of phenotyping substrates and discourages the use of single concentrations and metabolic ratios.", {"entities": [[80, 125, "Parameter"], [136, 158, "Parameter"], [186, 207, "Parameter"], [212, 228, "Parameter"]]}], [4804, "For simplicity, however, it is desirable to use metrics that need single samples [28], as done in our study.", {"entities": []}], [4805, "For either approach, it is decisive to what extent the metric indeed reflects enzyme activity.", {"entities": [[78, 93, "Parameter"]]}], [4806, "The metrics used for CYP1A2 and CYP2C9 may be considered as fully validated [28].", {"entities": [[21, 27, "Parameter"], [32, 38, "Parameter"]]}], [4807, "For CYPs1A2, 2C9, and 3A, 90% CIs were within the predefined acceptance range, indicating the absence of herbal drug\u2013drug interactions.", {"entities": [[4, 24, "Parameter"]]}], [4808, "This holds true for both dosing schedules.", {"entities": []}], [4809, "For CYP2C19, the lower limit of the 90% CI for its metric ratio was outside the predefined range (Table\u00a02) in the 120-mg group.", {"entities": [[4, 11, "Parameter"], [114, 120, "Amount"]]}], [4810, "Assuming this to be a real effect of EGb 761\u00ae on CYP2C19 activity would arouse suspicion that EGb 761\u00ae might induce CYP2C19 at the 120-mg b.i.d.", {"entities": [[37, 45, "Herb name"], [49, 65, "Parameter"], [94, 102, "Herb name"], [116, 123, "Target"], [131, 137, "Amount"]]}], [4811, "dose only.", {"entities": []}], [4812, "Conspicuously, data of this study obviously demonstrate that EGb 761\u00ae is free on any inhibitory effect directed toward CYP2C19, because the upper limit of the 90% CI for its metric ratio is clearly positioned within the predefined range (for both dosing schedules).", {"entities": [[61, 69, "Herb name"], [119, 126, "Parameter"]]}], [4813, "A pharmacokinetic study in healthy volunteers conducted with diazepam as a substrate of CYP2C19 presented no herb\u2013drug interaction between GBE and diazepam [26].", {"entities": [[0, 23, "Study"], [27, 34, "Pathology"], [61, 69, "Drug"], [88, 95, "Parameter"], [139, 142, "Herb name"], [147, 155, "Drug"]]}], [4814, "Also, another clinical study examined the possible effects of Ginkgo biloba on single-dose pharmacokinetics of voriconazole in healthy volunteers.", {"entities": [[14, 28, "Study"], [62, 75, "Herb name"], [79, 90, "Frequency"], [111, 123, "Drug"], [127, 134, "Pathology"]]}], [4815, "There was also no evidence of induction of CYP2C19 activity because of Ginkgo biloba treatment [38].", {"entities": [[43, 59, "Parameter"], [71, 84, "Herb name"]]}], [4816, "The study reported here suggests that the observed variability is the main reason for the lower CI range being outside the predefined limits, as the intraindividual CV of the CYP2C19 metric was the second highest of all CYPs considered (45.4%, Table\u00a02).", {"entities": [[175, 182, "Parameter"], [220, 224, "Parameter"]]}], [4817, "This is supported by the fact that the inability to formally exclude an interaction was observed for only one of the two dosing schedules.", {"entities": []}], [4818, "As a consequence, we concluded that there is no clinical relevance of CYP2C19-related findings of the cocktail study under consideration.", {"entities": [[70, 77, "Parameter"]]}], [4819, "A daily dose of 120\u00a0mg EGb 761\u00ae b.i.d.", {"entities": [[0, 12, "Frequency"], [16, 22, "Amount"], [23, 31, "Herb name"]]}], [4820, "does not affect CYP2C19 activity when administered over an 8-day period.", {"entities": [[16, 32, "Parameter"], [59, 71, "Duration"]]}], [4821, "Similar considerations also apply for CYP2D6, where the lower limit of the 90% CI for its metric ratio exceeded the predefined range (Table\u00a02), in this case only for the 240-mg q.d.", {"entities": [[38, 44, "Parameter"], [170, 176, "Amount"]]}], [4822, "group.", {"entities": []}], [4823, "Assuming this to be a real effect of EGb 761\u00ae would arouse suspicion that EGb 761\u00ae might affect CYP2D6 activity in the direction of induction, whereas there is clearly no inhibitory effect directed toward CYPD6.", {"entities": [[37, 45, "Herb name"], [74, 82, "Herb name"], [96, 111, "Parameter"], [205, 210, "Parameter"]]}], [4824, "Again, most probably, the variability observed is of key relevance for the inability to formally reject the possibility of an interaction, as the intraindividual CV of the CYP2D6 metric was the highest of all the CYPs considered (51.9%, Table\u00a02).", {"entities": [[172, 178, "Parameter"], [213, 217, "Parameter"]]}], [4825, "Published data regarding a potential induction of CYP2D6 by GBE has not been found.", {"entities": [[50, 56, "Target"], [60, 63, "Herb name"]]}], [4826, "In principle, CYP2D6 is not inducible in humans [39, 40].", {"entities": [[14, 20, "Parameter"]]}], [4827, "For probe substrates DEX (CYP2D6 activity) and alprazolam (CYP3A activity), no statistically significant differences were observed between baseline and post-GBE treatment, indicating a lack of effect on CYP2D6 and CYP3A [25].", {"entities": [[4, 24, "Drug"], [26, 41, "Parameter"], [47, 57, "Drug"], [59, 73, "Parameter"], [157, 160, "Herb name"], [203, 209, "Parameter"], [214, 219, "Parameter"]]}], [4828, "Taking these findings together, we conclude that there is no clinical relevance of CYP2D6-related findings of the drug-cocktail study under consideration.", {"entities": [[83, 89, "Parameter"]]}], [4829, "In general, in vitro and in vivo studies produced conflicting results [10\u201317].", {"entities": [[12, 40, "Study"]]}], [4830, "In vitro studies with human enzymes showed that Ginkgo biloba may inhibit CYPs [18\u201321].", {"entities": [[0, 16, "Study"], [22, 35, "Parameter"], [48, 61, "Herb name"], [74, 78, "Target"]]}], [4831, "Such inhibition has been associated with ginkgolic acids [20].", {"entities": [[41, 56, "Herb name"]]}], [4832, "Variability in ginkgolic acid content of tested extracts might therefore explain some of the observed variabilities.", {"entities": [[15, 29, "Herb name"]]}], [4833, "EGb 761\u00ae contains <5\u00a0ppm ginkgolic acids.", {"entities": [[0, 8, "Herb name"], [18, 24, "Amount"], [25, 40, "Herb name"]]}], [4834, "Taking all these contradictory data into account, however, in humans, we could not confirm any of these findings for the effect of EGb 761\u00ae on CYP activity following chronic administration, whereas results of the study reported are in accordance with published data from clinical studies assessed in human participants with this, and other, Ginkgo biloba preparation [23\u201326].", {"entities": [[131, 139, "Herb name"], [143, 155, "Parameter"], [271, 287, "Study"], [341, 366, "Herb name"]]}], [4835, "In summary, our data indicate that there is no inhibitory effect of EGb 761\u00ae on any of the five human CYPs.", {"entities": [[68, 76, "Herb name"], [102, 106, "Parameter"]]}], [4836, "Furthermore, our results suggest that EGb 761\u00ae does not induce CYP1A2, 2C9, and 3A activity.", {"entities": [[38, 46, "Herb name"], [63, 91, "Parameter"]]}], [4837, "For the noninducible CYP2D6, 90% CIs exceeding the acceptance range for one dosing schedule is meaningless.", {"entities": [[4, 27, "Parameter"], [72, 91, "Frequency"]]}], [4838, "For CYP2C19, 90% CIs exceeding the acceptance range toward an induction effect was not attended by corresponding results of clinical drug\u2013drug-interaction studies.", {"entities": [[4, 11, "Parameter"], [124, 162, "Study"]]}], [4839, "Thus, from a clinical point of view, a relevant effect on activity of the CYPs tested could be ruled out for both treatment regimens.", {"entities": [[58, 78, "Parameter"]]}], [4840, "Our results eliminate the need for further in vitro or in vivo evaluation of particular CYP-related drug\u2013drug interaction studies with EGb 761\u00ae.", {"entities": [[135, 143, "Herb name"]]}], [4841, "EGb 761\u00ae is the active substance of Tebonin\u00ae (Dr. Willmar Schwabe GmbH & Co. KG, Karlsruhe, Germany) In adherence to the guidelines of the International Committee of Medical Journal Editors, it is declared that this study is work for hire supported by Dr. Willmar Schwabe GmbH & Co. KG, Karlsruhe, Germany (sponsor).", {"entities": [[0, 8, "Herb name"], [36, 44, "Herb name"]]}], [4842, "SK, AD, and RH are employees of Dr. Willmar Schwabe GmbH & Co. KG, and TG received honoraria from Schwabe.", {"entities": []}], [4843, "No further conflict of interest is declared.", {"entities": []}], [4844, "This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.", {"entities": []}], [4845, "Competing Interests: The authors have declared that no competing interests exist.", {"entities": []}], [4846, "The aim of this study was to systematically review data regarding pharmacokinetic (PK)-pharmacodynamic (PD) parameters from randomized controlled trials relating to interactions between herbal medicines and warfarin.", {"entities": [[66, 118, "Parameter"], [124, 152, "Study"], [186, 202, "Herb name"], [207, 215, "Drug"]]}], [4847, "Three electronic databases were searched to identify relevant trials.", {"entities": [[62, 68, "Study"]]}], [4848, "Two reviewers independently performed the study selection and data extraction.", {"entities": []}], [4849, "The risk of bias and reporting quality were also assessed independently by two reviewers using the Cochrane risk of bias tool and the consolidated standards of reporting trials (CONSORT).", {"entities": [[170, 176, "Study"]]}], [4850, "Outcomes were measured for all reported PK-PD parameters and adverse events.", {"entities": [[40, 56, "Parameter"], [61, 75, "Pathology"]]}], [4851, "Nine randomized controlled trials met our inclusion criteria.", {"entities": [[5, 33, "Study"]]}], [4852, "Most of the included studies were unclear regarding the risk of bias and had a low quality of methodology.", {"entities": []}], [4853, "Using CONSORT, the reporting percentages for the articles ranged from 36.5% to 61.5% and the mean percentage for all articles was 45.6%.", {"entities": []}], [4854, "St John\u2019s wort and echinacea affected the PK parameters of warfarin.", {"entities": [[0, 14, "Herb name"], [19, 28, "Herb name"], [42, 55, "Parameter"], [59, 67, "Drug"]]}], [4855, "Ginseng, ginger, garlic, and cranberry had no significant effect on the PK parameters.", {"entities": [[0, 7, "Herb name"], [9, 15, "Herb name"], [17, 23, "Herb name"], [29, 38, "Herb name"], [68, 85, "Parameter"]]}], [4856, "St John\u2019s wort, ginseng, Korea red ginseng, ginkgo, ginger, garlic, aged garlic, and echincea did not significantly alter the PD parameters.", {"entities": [[0, 14, "Herb name"], [16, 23, "Herb name"], [25, 42, "Herb name"], [44, 50, "Herb name"], [52, 58, "Herb name"], [60, 66, "Herb name"], [68, 79, "Herb name"], [85, 93, "Herb name"], [122, 139, "Parameter"]]}], [4857, "Studies of ginkgo and cranberry showed conflicting results on the PK parameters and PD parameters, respectively.", {"entities": [[11, 17, "Herb name"], [22, 31, "Herb name"], [62, 79, "Parameter"], [84, 97, "Parameter"]]}], [4858, "The incidence of adverse events in all trials was low and no major adverse events were reported.", {"entities": [[17, 31, "Pathology"], [67, 81, "Pathology"]]}], [4859, "It was difficult to determine whether ten herbal medicines had significant effects on the PK-PD parameters of warfarin.", {"entities": [[86, 106, "Parameter"], [110, 118, "Drug"]]}], [4860, "Low quality of evidence, different compounds within and different compositions of the herbs, and methodological limitations of the crossover study, which is a clinical study in which subjects receive a sequence of different interventions, made it difficult to form conclusions.", {"entities": [[127, 237, "Study"]]}], [4861, "Additional studies that remedy these vulnerabilities are necessary to verify these results.", {"entities": []}], [4862, "All relevant data are within the paper and its Supporting Information files.", {"entities": []}], [4863, "Warfarin is the most common oral anticoagulant used for treating or preventing thromboembolic disorders.", {"entities": [[0, 8, "Drug"], [28, 46, "Drug"], [79, 103, "Pathology"]]}], [4864, "It has a narrow range between therapeutic and toxic doses, suggesting that warfarin should be administered after calculating the optimal dose.", {"entities": [[46, 51, "Pathology"], [75, 83, "Drug"]]}], [4865, "Patients taking warfarin should also be aware of its interaction with other drugs and foods, including herbal medicines, because the concomitant use of these agents might alter the metabolism and action of warfarin, necessitating an adjustment to the dose of warfarin for its safe and effective administration [1, 2].", {"entities": [[16, 24, "Drug"], [103, 119, "Herb name"], [206, 214, "Drug"], [259, 267, "Herb name"]]}], [4866, "Close monitoring of the anticoagulant effect of warfarin is recommended through the international normalized ratio (INR) in clinical practice [1\u20133].", {"entities": [[24, 44, "Pathology"], [48, 56, "Drug"], [80, 120, "Parameter"]]}], [4867, "Herbal medicines are often used by patients receiving anticoagulants.", {"entities": [[0, 16, "Herb name"], [54, 68, "Drug"]]}], [4868, "Nearly 40% of patients with cardiovascular disease have used complementary and alternative medicine, including herbal medicine, concomitantly with their prescribed medications [4].", {"entities": [[28, 50, "Pathology"], [111, 126, "Herb name"], [153, 175, "Drug"]]}], [4869, "Those who used herbal medicine for health management perceived herbal medicine to be helpful for their cardiac condition [5].", {"entities": [[15, 30, "Herb name"], [63, 78, "Herb name"], [103, 120, "Pathology"]]}], [4870, "In fact, some herbs, such as ginger, ginkgo, and garlic, have antiplatelet and anticoagulant activity [6\u201311].", {"entities": [[29, 35, "Herb name"], [49, 55, "Herb name"], [62, 101, "Pathology"]]}], [4871, "However, the mechanism of action of herbal medicines is difficult to study in vitro and in vivo because these medicines comprise complex mixtures of various compounds [12], which may simultaneously exhibit multiple physiological activities.", {"entities": []}], [4872, "Therefore, patients taking herbal medicine with warfarin are more likely to be exposed to potential herb-drug interactions [13].", {"entities": [[27, 42, "Herb name"], [48, 56, "Drug"]]}], [4873, "Previous studies have revealed some of the mechanisms of interaction of warfarin with herbal medicines via clinical reports [2, 14].", {"entities": [[72, 80, "Drug"], [86, 102, "Herb name"], [107, 123, "Study"]]}], [4874, "Each herb has a different chemical composition, hindering generalizations about herb-warfarin interactions.", {"entities": [[80, 84, "Herb name"], [85, 93, "Drug"]]}], [4875, "Although narrative reviews on herb-warfarin interactions are available [1, 5], no study has systematically reviewed them based on changes in pharmacokinetic (PK)-pharmacodynamic (PD) parameters.", {"entities": [[19, 26, "Study"], [30, 34, "Herb name"], [35, 43, "Drug"], [141, 193, "Parameter"]]}], [4876, "The aim of this article was to systematically review clinical data, including PK-PD parameters, from randomized controlled trials (RCTs) and to discuss interactions between herbal medicines and warfarin.", {"entities": [[78, 94, "Parameter"], [101, 136, "Study"], [173, 189, "Herb name"], [194, 202, "Drug"]]}], [4877, "Clinical trials were searched for and retrieved from core electronic databases, including PubMed, EMBASE, and CINAHL.", {"entities": [[0, 15, "Study"]]}], [4878, "The last search of the databases was performed in December 2015.", {"entities": []}], [4879, "Search terms consisted of text terms and controlled vocabulary, such as medical subject headings (MeSH).", {"entities": []}], [4880, "Three types of search terms were used: warfarin-related terms, herb-related terms, and interaction-related terms.", {"entities": [[39, 47, "Drug"], [63, 67, "Herb name"]]}], [4881, "Article type or study design-related terms were not included in the search terms.", {"entities": []}], [4882, "The search strategy for PubMed is stated below.", {"entities": []}], [4883, "The search terms for the two other databases were similar.", {"entities": []}], [4884, "#1 Warfarin [MeSH Terms] #2 Warfarin [Title/Abstract] #3 1\u20132 /or #4 Dietary supplementations [MeSH Terms] #5 Dietary supplement* [Title/Abstract] #6 Plant, medicinal [MeSH Terms] #7 Phytotherapy [MeSH Terms] #8 Medicine, traditional [MeSH Terms] #9 Pharmacognosy [MeSH Terms] #10 Plant extracts [MeSH Terms] #11 Ethnobotany [MeSH Terms] #12 Ethnopharmacology [MeSH Terms] #13 Diet, Food, and Nutrition [MeSH Terms] #14 Plant* [Title/Abstract] #15 Herb* [Title/Abstract] #16 4-15/or #17 Drug interactions [MeSH Terms] #18 Interaction* [Title/Abstract] #19 17-18/or #20 3 AND 16 AND 19 Two reviewers (SIC and UMJ) reviewed the titles and abstracts of the studies retrieved from the electronic searches to identify studies that met the inclusion criteria.", {"entities": [[3, 11, "Drug"], [28, 36, "Drug"], [149, 154, "Herb name"], [280, 294, "Herb name"], [419, 424, "Herb name"]]}], [4885, "Disagreements were resolved by discussion between the two reviewers or consultation with a third reviewer (DSO).", {"entities": []}], [4886, "No language restriction was applied.", {"entities": []}], [4887, "The inclusion criteria were as follows: Type of study.", {"entities": []}], [4888, "All relevant RCTs that reported interactions between herbal medicines and warfarin were included.", {"entities": [[13, 17, "Study"], [53, 69, "Herb name"], [74, 82, "Drug"]]}], [4889, "Type of participant.", {"entities": []}], [4890, "Studies that evaluated subjects who received herbal medicine concomitantly with warfarin were included.", {"entities": [[45, 60, "Herb name"], [80, 88, "Drug"]]}], [4891, "Type of intervention.", {"entities": []}], [4892, "Trials using warfarin alone or warfarin with placebo drug versus warfarin with herbal medicine were included.", {"entities": [[0, 6, "Study"], [13, 21, "Drug"], [65, 73, "Drug"], [79, 94, "Herb name"]]}], [4893, "An herb was defined as a product or an extract originating from a single botanical source.", {"entities": []}], [4894, "The definition of herb included raw or manufactured single or complex medicinal plants, plant extracts, and dietary supplements.", {"entities": [[70, 127, "Herb name"]]}], [4895, "However, single or synthesized substances from plant material were excluded.", {"entities": []}], [4896, "Type of outcome measures.", {"entities": []}], [4897, "Studies that measured more than one PK or PD parameter for herb-warfarin interactions were included.", {"entities": [[36, 54, "Parameter"], [59, 63, "Herb name"], [64, 72, "Drug"]]}], [4898, "The PK parameters included time to maximum plasma concentration (T Data were extracted from the titles and abstracts of the searched studies independently by two reviewers.", {"entities": [[0, 17, "Parameter"], [35, 63, "Parameter"]]}], [4899, "The study selection and data extraction used standard eligibility inclusion criteria as determined by two reviewers.", {"entities": []}], [4900, "The quality of methodology in all included studies was independently assessed according to the Cochrane Collaboration\u2019s seven criteria: 1) random sequence generation, 2) allocation concealment, 3) blinding of participants and personnel, 4) blinding of outcome assessment, 5) incomplete outcome data, 6) selective reporting, and 7) other bias (defined as baseline data comparability).", {"entities": []}], [4901, "For each domain, the evaluation was denoted as low risk, high risk, or unclear risk, according to the description of the methods used in each study.", {"entities": []}], [4902, "We also assessed the reporting quality of all included studies based on the Consolidated Standards of Reporting Trials (CONSORT) [17].", {"entities": [[112, 118, "Study"]]}], [4903, "We used the CONSORT 2010 checklist and the extension of the CONSORT statement simultaneously for trials of herbal medicinal interventions.", {"entities": [[97, 103, "Study"], [107, 123, "Herb name"]]}], [4904, "The Consort 2010 checklist is the latest version for assessing reporting quality.", {"entities": []}], [4905, "The elaborated CONSORT statements for trials of herbal interventions enhance the checklist items regarding the relevance to trials of herbal interventions [18, 19].", {"entities": [[38, 44, "Study"], [48, 68, "Herb name"], [124, 130, "Study"], [134, 154, "Herb name"]]}], [4906, "Study design and herbal medicines were analyzed among the included studies.", {"entities": [[17, 33, "Herb name"]]}], [4907, "Quantitative data synthesis was planned in a meta-analysis when the study design, type of herbal medicine, and outcomes of the included studies were homogeneous; otherwise, we suggested results in a narrative synthesis without meta-analysis [20].", {"entities": [[43, 58, "Study"], [90, 105, "Herb name"], [227, 240, "Study"]]}], [4908, "The search generated a total of 4437 potentially relevant studies; 295 duplicate and 4065 irrelevant studies were excluded by screening the titles and abstracts.", {"entities": []}], [4909, "Of the remaining studies, 77 full-text articles were reviewed and 9 studies [21\u201329] met our eligibility criteria.", {"entities": []}], [4910, "The PRISMA diagram of the search process and study selection is presented in Fig 1.", {"entities": []}], [4911, "Of these trials, three [23\u201325] were conducted in the United States, four [21, 22, 26, 28] were conducted in Australia, and one [27] was conducted in Korea.", {"entities": [[9, 15, "Study"]]}], [4912, "One trial [29] was conducted in China and published in Chinese.", {"entities": [[4, 9, "Study"], [55, 62, "Ethnic group"]]}], [4913, "Four studies [21, 22, 26, 28] had a three-way cross-over randomized design and compared two different herbal medicine plus warfarin groups with a warfarin alone group in healthy subjects.", {"entities": [[34, 74, "Study"], [102, 117, "Herb name"], [123, 131, "Drug"], [146, 154, "Drug"], [170, 177, "Pathology"]]}], [4914, "Three studies [23, 25, 29] used a placebo-controlled parallel design and compared the concomitant administration of herbal medicine and warfarin with the concomitant administration of placebo and warfarin.", {"entities": [[116, 131, "Herb name"], [136, 144, "Drug"], [196, 204, "Drug"]]}], [4915, "Two studies [24, 27] used a double-blind crossover design.", {"entities": [[26, 57, "Study"]]}], [4916, "The study sample sizes ranged from 7 to 48 and a total of 160 subjects were involved in the nine trials.", {"entities": [[97, 103, "Study"]]}], [4917, "Thirty participants were reported to have dropped out of the nine studies.", {"entities": []}], [4918, "The key data from the included RCTs are summarized in Table 1.", {"entities": [[31, 35, "Study"]]}], [4919, "Nine herbal medicines were identified in the included studies: Panax ginseng, Panax quinquefolius, Allium sativum, Gingko biloba, Vaccinium macrocarpon, Hypericum perforatum, Echinacea angustifolia, Echinacea purpurea, and Zingiber officinale.", {"entities": [[63, 76, "Herb name"], [78, 97, "Herb name"], [99, 113, "Herb name"], [115, 128, "Herb name"], [130, 151, "Herb name"], [153, 173, "Herb name"], [175, 197, "Herb name"], [199, 217, "Herb name"], [223, 242, "Herb name"]]}], [4921, "Gingko (Gingko biloba) [22, 29] and cranberry (Vaccinium macrocarpon) [24, 26] were used in two studies and St John\u2019s wort (Hypericum perforatum) [21], echinacea (Mixture of Echinacea angustifolia and Echinacea purpurea) [28], and ginger (Zingiber officinale) [22] were administered in one study.", {"entities": [[0, 22, "Herb name"], [36, 69, "Herb name"], [108, 145, "Herb name"], [152, 161, "Herb name"], [174, 196, "Herb name"], [201, 219, "Herb name"], [231, 259, "Herb name"]]}], [4922, "In addition, policosanol [28] was mentioned in one study.", {"entities": [[13, 24, "Herb name"]]}], [4923, "However, policosanol is a complex mixture of fatty alcohols derived from sugar cane wax and was not included in the inclusion criteria.", {"entities": [[9, 20, "Herb name"], [45, 87, "Herb name"]]}], [4924, "Extraction and formulation method, composition, and bioanalytical data regarding the herbal preparations from the included RCTs are summarized Table 2.", {"entities": [[85, 104, "Herb name"], [123, 127, "Study"]]}], [4925, "For random sequence generation, two [23] of the nine studies (22%) used a random table, whereas the other studies (78%) did not report a specific method of random sequence generation.", {"entities": []}], [4926, "For allocation concealment, one study [23, 24] (11%) used an opaque envelope method, whereas the other studies (89%) did not report any information about concealment.", {"entities": []}], [4927, "For blinding, four studies [23\u201325, 27] (44%) used a double-blinding method by blinding participants and researchers and four studies [21, 22, 26, 28] had an open-label design.", {"entities": [[52, 74, "Study"], [154, 174, "Study"]]}], [4928, "One study [29] did not provide information about blinding.", {"entities": []}], [4929, "For incomplete outcome data, seven trials [21\u201324, 26, 28, 29] reported detailed information regarding attrition by describing the number and reasons for withdrawal.", {"entities": [[35, 41, "Study"]]}], [4930, "For selective outcome reporting, only one study [26] presented the clinical trial identifier number, whereas the other trials did not report registration information.", {"entities": [[67, 81, "Study"], [119, 125, "Study"]]}], [4931, "Therefore, we could not compare the protocols and trial reports.", {"entities": [[50, 55, "Study"]]}], [4932, "Information for other risks of bias was not reported in the studies, except for one study [29] that was at high risk.", {"entities": []}], [4933, "The risk of bias assessment information is presented in Figs 2 and 3. Review of authors' judgments about each risk of bias item for all nine included studies.", {"entities": []}], [4934, "Plus (+) marked circle, Low risk of bias; Question (?)", {"entities": []}], [4935, "marked circle, Unclear risk of bias; Minus (-) marked circle, High risk of bias.", {"entities": []}], [4936, "Review of authors' judgments about each risk of bias item presented as percentages across all included studies.", {"entities": []}], [4937, "Based on the two CONSORT statements, the reporting percentage for each of the articles ranged from 36.5% to 61.5% and the mean percentage for all articles was 45.6%.", {"entities": []}], [4938, "All RCTs described the eligibility criteria, participant flow, and interpretation of the results.", {"entities": [[4, 8, "Study"]]}], [4939, "No trials provided information about the qualitative testing of interventions, periods of recruitment, or follow up.", {"entities": [[3, 9, "Study"]]}], [4940, "Detailed results are presented in the S1 Table.", {"entities": []}], [4941, "Because the two CONSORT statements were developed with the aim of evaluating and reporting quality for parallel design and two treatment groups, they may be insufficient to evaluate and reflect the characteristics of the crossover design.", {"entities": []}], [4942, "However, most of the items in the CONSORT checklist apply to all trial designs because they reflect the characteristics of RCTs rather than those of parallel design.", {"entities": [[65, 70, "Study"], [123, 127, "Study"]]}], [4943, "Therefore, the CONSORT statements were used to assess the reporting quality of all the included trials.", {"entities": [[96, 102, "Study"]]}], [4944, "There are many different methods of measuring outcome parameters.", {"entities": []}], [4945, "Because the aim of this review was to assess herb-warfarin interactions, various types of PK-PD parameters were evaluated (S2 Table).", {"entities": [[24, 30, "Study"], [45, 49, "Herb name"], [50, 58, "Drug"], [90, 106, "Parameter"]]}], [4946, "Five trials [21, 22, 26, 28, 29] reported PK data based on the absorption, distribution, metabolism, or elimination of warfarin when herbal medicine was co-administered with warfarin.", {"entities": [[5, 11, "Study"], [119, 127, "Drug"], [133, 148, "Herb name"], [174, 182, "Drug"]]}], [4947, "The AUC of INR for time to treatment was used in six studies [21\u201323, 26, 28, 29], INR max [26, 28] was evaluated in two studies, and INR change was reviewed in two studies [24, 27].", {"entities": [[4, 7, "Parameter"], [11, 14, "Parameter"], [82, 89, "Parameter"], [133, 143, "Parameter"]]}], [4948, "Five studies [21, 22, 26, 28, 29] used area under concentration-time curves until the last concentration observation (AUC All trials evaluated adverse events (AEs).", {"entities": [[39, 75, "Parameter"], [118, 121, "Parameter"], [126, 132, "Study"], [143, 163, "Pathology"]]}], [4949, "As shown in Table 1, AEs were reported for three studies and none of the events was major.", {"entities": [[21, 24, "Pathology"]]}], [4950, "Among these events, one study [22] reported that one subject experienced gastrointestinal side effects, including constipation, during the first two days of ginkgo pre-treatment and mild diarrhea during the first two days of ginger pre-treatment.", {"entities": [[73, 102, "Pathology"], [114, 127, "Pathology"], [157, 163, "Herb name"], [182, 195, "Pathology"], [225, 231, "Herb name"]]}], [4951, "One study [21] reported that three subjects experienced changes in sleeping habits during St John\u2019s wort treatment and one study [26] reported rashes in two subjects using cranberry-warfarin.", {"entities": [[90, 104, "Herb name"], [143, 149, "Pathology"], [172, 181, "Herb name"], [182, 190, "Drug"]]}], [4952, "In studies including garlic, one subject had evidence of nasal bleeding and one subject reported lip dryness.", {"entities": [[21, 27, "Pathology"], [57, 71, "Pathology"], [97, 108, "Pathology"]]}], [4953, "We assessed the methodological quality of RCTs using the Cochrane risk of bias tool and CONSORT and the results of quality assessments were reflected in the interpretation of this study.", {"entities": [[42, 46, "Study"]]}], [4954, "There was a low risk of AEs after co-administration of herbs and warfarin.", {"entities": [[24, 27, "Pathology"], [55, 60, "Herb name"], [65, 73, "Drug"]]}], [4955, "However, most of the included studies had low reporting quality and a crossover design that was unsuitable for meta-analysis.", {"entities": [[111, 124, "Study"]]}], [4956, "There were also inconsistent results from several studies that used the same herbal medicine.", {"entities": [[77, 92, "Herb name"]]}], [4957, "The use of herbal medicine is rapidly expanding and many reports have raised concerns about possible herb-drug interactions.", {"entities": [[11, 26, "Herb name"]]}], [4958, "Herb-drug interactions may be categorized as either PK or PD interactions.", {"entities": []}], [4959, "PK interactions include changes in absorption, distribution, metabolism, and elimination [30].", {"entities": []}], [4960, "PD interactions result from synergistic, additive, or antagonistic effects of herbs when co-administered with drugs.", {"entities": []}], [4961, "Well-aligned PK-PD data provides information regarding clinical efficacy and safety outcomes and guides the selection of doses and dosing schedules for clinical trials [31].", {"entities": [[152, 167, "Study"]]}], [4962, "All included studies investigated the PD interactions of warfarin with herbal medicines, but different parameters were used in each study.", {"entities": [[57, 65, "Drug"], [71, 87, "Herb name"]]}], [4963, "Only four studies reported PK interaction parameters between an herbal medicine and warfarin, whereas the five remaining studies did not measure PK parameters.", {"entities": [[64, 79, "Herb name"], [84, 92, "Drug"], [145, 158, "Parameter"]]}], [4964, "There were inconsistent results among those that used the same herbal medicine.", {"entities": [[63, 78, "Herb name"]]}], [4965, "Two studies that evaluated the interaction between cranberry and warfarin reported contradictory PD effects, possibly because one study [26] investigated healthy subjects and the other [24] included patients with atrial fibrillation.", {"entities": [[51, 60, "Herb name"], [65, 73, "Drug"], [97, 107, "Pathology"], [154, 161, "Pathology"], [213, 232, "Pathology"]]}], [4966, "The results of two studies that assessed the PK-PD interactions between warfarin and ginkgo also differed.", {"entities": [[72, 80, "Drug"], [85, 91, "Herb name"]]}], [4967, "One study [22] reported no significant differences in PK-PD parameters, whereas another [29] observed that ginkgo had limited effects on PK parameters.", {"entities": [[54, 70, "Parameter"], [107, 113, "Herb name"], [137, 150, "Parameter"]]}], [4968, "These studies used different types of clinical designs and subject conditions.", {"entities": [[38, 54, "Study"]]}], [4969, "The heterogeneous composition of compounds among the three types of ginseng might have led to different results.", {"entities": [[68, 75, "Herb name"]]}], [4970, "Several case reports have pointed to the risk associated with concomitant herb and warfarin use.", {"entities": [[8, 20, "Study"], [83, 91, "Drug"]]}], [4971, "There were two case reports of an increased INR after co-administration of warfarin with cranberry juice [34, 35].", {"entities": [[15, 27, "Study"], [44, 47, "Parameter"], [75, 83, "Drug"], [89, 104, "Herb name"]]}], [4972, "Interactions between ginseng and warfarin were also mentioned in one case report [36].", {"entities": [[21, 28, "Herb name"], [33, 41, "Drug"], [69, 80, "Frequency"]]}], [4973, "Two case reports suggested that a warfarin-St John\u2019s wort interaction was associated with a change in INR [37, 38].", {"entities": [[4, 16, "Study"], [34, 42, "Drug"], [43, 57, "Herb name"], [102, 105, "Parameter"]]}], [4974, "These relevant case reports indicated a potential herb-warfarin interaction, but it was difficult to identify a causal relationship.", {"entities": [[15, 27, "Study"], [50, 54, "Herb name"], [55, 63, "Drug"]]}], [4975, "Suspected herb-warfarin interactions are primarily limited to anecdotal case reports.", {"entities": [[10, 14, "Herb name"], [15, 23, "Drug"], [72, 84, "Study"]]}], [4976, "In addition, these case reports did not provide sufficient information about the patients\u2019 medical records and compounding factors may have existed, such as administration of other medications, dietary supplements, foods, or alcohol intake.", {"entities": [[19, 31, "Study"], [225, 239, "Parameter"]]}], [4977, "Some studies pointed out such limitations, that is, that case reports often result in misleading conclusions for multiple reasons [39, 40].", {"entities": [[57, 69, "Study"]]}], [4978, "There have been previous experiments and clinical studies of platelet aggregation caused by herbs.", {"entities": [[41, 57, "Study"], [61, 81, "Pathology"], [92, 97, "Herb name"]]}], [4979, "Several studies have suggested that herbal constituents may affect PK-PD and alter the anticoagulant and platelet aggregation effects of warfarin [41, 42].", {"entities": [[67, 72, "Parameter"], [83, 133, "Pathology"], [137, 145, "Drug"]]}], [4980, "Other studies have shown conflicting results as to whether herb-warfarin interactions were associated with increased risks.", {"entities": [[59, 63, "Herb name"], [64, 72, "Drug"]]}], [4981, "One review article reported that spontaneous bleeding occurred during the concurrent use of warfarin and these herbs.", {"entities": [[4, 10, "Study"], [33, 53, "Pathology"], [92, 100, "Drug"]]}], [4982, "Conversely, some cases did not indicate a significant inhibition of platelet function [44].", {"entities": [[68, 85, "Parameter"]]}], [4983, "One in vitro study suggested that gingko contributed to the altered platelet aggregation [45].", {"entities": [[4, 18, "Study"], [34, 40, "Herb name"], [60, 88, "Pathology"]]}], [4984, "In contrast, a clinical study confirmed that gingko did not change platelet aggregation.", {"entities": [[13, 29, "Study"], [45, 51, "Herb name"], [67, 87, "Pathology"]]}], [4985, "Furthermore, it was difficult to determine whether the combined use of warfarin and herbs led to increased platelet aggregation [46].", {"entities": [[71, 79, "Drug"], [84, 89, "Herb name"], [107, 127, "Pathology"]]}], [4986, "However, an in vivo study indicated that echinacea did not significantly affect the metabolism of drugs metabolized by CYP2C9 [47].", {"entities": [[12, 25, "Study"], [41, 50, "Herb name"], [119, 125, "Parameter"]]}], [4987, "Another in vivo study reported that gingko induced CYP enzyme activity in a dose-dependent manner, but did not cause hepatic damage [48].", {"entities": [[8, 21, "Study"], [36, 42, "Herb name"], [51, 70, "Parameter"]]}], [4988, "These results implied that concerns regarding increased hemorrhagic complications resulting from an herb-warfarin interaction were unfounded.", {"entities": [[100, 104, "Herb name"], [105, 113, "Drug"]]}], [4989, "Furthermore, herbal medicine did not significantly alter the anticoagulant effects of warfarin and no severe AEs were reported.", {"entities": [[13, 28, "Herb name"], [61, 82, "Pathology"], [86, 94, "Drug"], [109, 112, "Pathology"]]}], [4990, "There were four limitations of the current review.", {"entities": []}], [4991, "First, the rationale for determining the washout period in each study was lacking.", {"entities": []}], [4992, "Several studies adopted a crossover design, which has been used by many researchers to investigate potential drug-drug interactions.", {"entities": [[24, 42, "Study"]]}], [4993, "Because a crossover trial carries the risk of a carry-over effect, trials with a crossover design should use a sufficient washout period.", {"entities": [[8, 25, "Study"], [67, 73, "Study"]]}], [4994, "Otherwise, the effect of the first period treatment may persist into the subsequent period [49].", {"entities": []}], [4995, "The average washout period in seven studies was two weeks and one study did not mention the washout period.", {"entities": [[48, 57, "Duration"]]}], [4996, "To minimize the carry-over effect, the washout period in a crossover study should be at least five times the half-life of the drug [50].", {"entities": [[105, 130, "Parameter"]]}], [4997, "The mean range of T Second, clinical data are lacking in order to provide synthesized evidence for herb-drug interactions from crossover trials.", {"entities": [[127, 143, "Study"]]}], [4999, "A meta-analysis for crossover trials can be conducted if one of the following three measurements is available: 1) individual subject data, 2) the mean and standard deviation (or standard error) of the subject-specific differences between the experimental group and control group, 3) the mean difference and variables from a paired t-test (28).", {"entities": [[0, 36, "Study"]]}], [5000, "However, no studies were reported these data.", {"entities": []}], [5001, "Therefore, it was impossible to synthesize the data into a meta-analysis.", {"entities": [[59, 72, "Study"]]}], [5002, "Third, the reporting quality of the included studies was poor based on CONSORT 2010 and the extension of the CONSORT statement for trials of herbal medicine interventions.", {"entities": [[131, 137, "Study"], [141, 156, "Herb name"]]}], [5003, "This CONSORT extension enhances the checklist items regarding the relevance of herbal interventions to trials [19].", {"entities": [[79, 99, "Herb name"], [103, 109, "Study"]]}], [5004, "Several studies did not describe some of the items in this elaborated statement.", {"entities": []}], [5005, "For example, some studies autonomously prepared the intervention drug or herbal medicine without a quality control, making it difficult to report the characteristics of the herbal product, including the concentration of the extraction solvent, the method of the authentication of raw material, fingerprinting, and standardization.", {"entities": [[65, 69, "Drug"], [73, 88, "Herb part"], [169, 187, "Herb name"]]}], [5006, "The majority of studies also did not discuss randomization, including sequence generation, allocation, and concealment.", {"entities": []}], [5007, "The four crossover design studies did not report how the treatment group and control group were crossed.", {"entities": [[9, 33, "Study"]]}], [5008, "Therefore, the response rate for each article was less than 50%.", {"entities": []}], [5009, "Each single herb has a variety of biochemical compounds and the composition of components in the herb could vary upon cultivation, delivery, and product manufacturing conditions.", {"entities": []}], [5010, "These uncertainties and complexities make it difficult to determine standards for the PK-PD parameters of herbal medicines.", {"entities": [[86, 102, "Parameter"], [106, 122, "Herb name"]]}], [5011, "Therefore, this study could not include PK-PD evaluation of herbal medicines themselves and did not reflect the purpose of the administration and intention for use of the herbal medicine.", {"entities": [[40, 42, "Pathology"], [43, 45, "Parameter"], [60, 76, "Herb name"], [167, 186, "Herb name"]]}], [5012, "Further studies evaluating interactions between warfarin and herbal medicines should avoid the limitations mentioned in this study.", {"entities": [[48, 56, "Drug"], [61, 77, "Herb name"]]}], [5013, "The details of the information for a trial should be clearly described and fully reported.", {"entities": [[35, 42, "Study"]]}], [5015, "We recommend using high-quality RCTs to confirm herb-warfarin interactions.", {"entities": [[32, 36, "Study"], [48, 52, "Herb name"], [53, 61, "Drug"]]}], [5018, "We deliberately selected related studies after searching a wide range of databases and this analysis was based on available clinical trials that evaluated herb-warfarin interactions.", {"entities": [[124, 139, "Study"]]}], [5019, "Low quality of evidence, herbal uncertainties and complexities of different compounds and their compositions, and methodological limitations of the crossover study made it difficult to form conclusions.", {"entities": []}], [5020, "Further studies with an appropriate study design and reporting quality are necessary to verify herb-warfarin interactions.", {"entities": [[95, 99, "Herb name"], [100, 108, "Drug"]]}], [5021, "(DOCX) Click here for additional data file.", {"entities": []}], [5022, "(DOCX) Click here for additional data file.", {"entities": []}], [5023, "(DOC) Click here for additional data file.", {"entities": []}], [5024, "An increasing variety of alternative health care products and supplements known as over-the-counter (OTC) or non-prescription herbal medicines are taken by patients for different reasons.", {"entities": []}], [5025, "Unfortunately, these self-prescribed remedies have many food and drug interactions and unknown adverse effects and can lead to some important consequences.", {"entities": [[95, 110, "Pathology"]]}], [5026, "Here a case of bleeding disorder in a 28-year-old woman taking red clover is reported.", {"entities": [[5, 11, "Study"], [15, 32, "Pathology"], [38, 49, "Age"], [50, 55, "Sex"], [63, 73, "Herb name"]]}], [5027, "She had no history of warfarin use, but warfarin was detected in her blood serum analysis.", {"entities": [[22, 30, "Drug"], [40, 48, "Drug"]]}], [5028, "This agent is a source of natural coumarin and can cause an increase of international normalized ratio (INR) and bleeding.", {"entities": [[26, 42, "Herb name"], [72, 108, "Parameter"], [113, 121, "Pathology"]]}], [5029, "It is important that prescribers be alert to the possible disadvantage of herbal remedies and also probable herb-drug and herb-food interactions.", {"entities": []}], [5030, "Over-the-counter (OTC) herbal agents are classified as dietary supplements and are not rigorously regulated by the US Food and Drug Administration\u00a0(FDA).", {"entities": []}], [5031, "They are wrongly thought to have no complications, so herbal therapies are increasingly being used all around the world (1).", {"entities": []}], [5032, "Red clover (Trifolium pratense) is one of such herbs that has been used for various disorders such as skin ulcers, menopause syndrome, cough, sore throat, fever, pneumonia, meningitis, diarrhea, and hair loss (2-4).", {"entities": [[0, 31, "Herb name"], [102, 113, "Pathology"], [115, 133, "Pathology"], [135, 140, "Pathology"], [142, 153, "Pathology"], [155, 160, "Pathology"], [162, 171, "Pathology"], [173, 183, "Pathology"], [185, 193, "Pathology"], [199, 208, "Pathology"]]}], [5033, "Red clover is a legume whose flower top contains more than 100 chemical substances including tannins, isoflavone phytoestrogen, flavonoids, essential oil, polysaccharides, saponins, phaseolic acid, and salicylic acid (2, 3).", {"entities": [[0, 10, "Herb name"], [29, 39, "Herb part"], [93, 100, "Herb name"], [102, 112, "Herb name"], [113, 126, "Herb name"], [128, 138, "Herb name"], [155, 170, "Herb name"], [172, 180, "Herb name"], [182, 196, "Herb name"], [202, 216, "Herb name"]]}], [5034, "Red clover is also a source of natural coumarin and would be expected to enhance the effects of anticoagulants and antiplatelet agents (2, 5).", {"entities": [[0, 10, "Herb name"], [31, 47, "Herb name"], [96, 134, "Drug"]]}], [5035, "Clover is used in the form of herbal tea in Iran.", {"entities": [[0, 6, "Herb name"], [30, 40, "Extraction process"]]}], [5036, "There is a mixture of red clover and alfalfa in Iranian traditional medicine which is sold, presumably, as a platelet count enhancer.", {"entities": [[22, 32, "Herb name"], [37, 44, "Herb name"], [48, 55, "Ethnic group"]]}], [5037, "Although the product information warns of the theoretical bleeding risks with red clover, there are limited clinical case reports of bleeding attributed to it.", {"entities": [[58, 66, "Pathology"], [78, 88, "Herb name"], [108, 129, "Study"], [133, 141, "Pathology"]]}], [5038, "Here, we report a case with the clinical presentation of warfarin toxicity without warfarin ingestion.", {"entities": [[9, 22, "Study"], [57, 65, "Drug"], [66, 74, "Pathology"], [83, 91, "Drug"]]}], [5039, "A 28-year-old woman was admitted to the emergency department (ED) complaining of gross hematuria.", {"entities": [[2, 13, "Age"], [14, 19, "Sex"], [81, 96, "Pathology"]]}], [5040, "She arbitrarily used a herbal supplement that contained red clover and alfalfa.", {"entities": [[56, 66, "Herb name"], [71, 78, "Herb name"]]}], [5041, "The patient had been drinking this herbal tea a maximum of 5\u20136 cups every day for two consecutive weeks.", {"entities": [[35, 45, "Extraction process"], [59, 67, "Amount"], [68, 77, "Frequency"], [78, 103, "Duration"]]}], [5042, "After two weeks, few episodes of epistaxis occurred, and ecchymotic lesions developed on her limbs.", {"entities": [[33, 42, "Pathology"], [57, 75, "Pathology"]]}], [5043, "In the past medical history, she was diagnosed as a case of systemic lupus erythematosus (SLE) about five months back and had a history of idiopathic thrombocytopenic purpura (ITP) and low platelet count from that time.", {"entities": [[60, 94, "Pathology"], [139, 180, "Pathology"], [189, 203, "Parameter"]]}], [5044, "She was under treatment with prednisolone 1 mg/kg daily.", {"entities": [[29, 41, "Drug"], [42, 49, "Amount"], [50, 55, "Frequency"]]}], [5045, "There was no drug history of intake of anticoagulants.", {"entities": [[39, 53, "Drug"]]}], [5046, "She had several episodes of bleeding and epistaxis that had been treated with fresh frozen plasma (FFP) and Vitamin K.  On physical examination, the positive findings included diffuse ecchymosis in her limbs and mild bleeding from her lips.", {"entities": [[28, 36, "Pathology"], [41, 50, "Pathology"], [176, 194, "Pathology"], [212, 225, "Pathology"]]}], [5047, "At the time of admission to ED, she had a prothrombin time (PT) of more than 37 seconds, activated partial thromboplastin time (aPTT) more than 70 seconds, and international normalized ratio (INR) greater than seven.", {"entities": [[42, 63, "Parameter"], [67, 87, "Amount"], [89, 133, "Parameter"], [134, 154, "Amount"], [160, 196, "Parameter"], [197, 215, "Amount"]]}], [5048, "Other laboratory tests conducted at our hospital displayed the following results: white blood cell count 9.80 \u00d7 109/\u03bcl, hemoglobin 11.8g/dL, and platelet count 406\u00d7109/\u03bcl.", {"entities": [[82, 104, "Parameter"], [105, 118, "Amount"], [120, 130, "Parameter"], [131, 139, "Amount"], [145, 159, "Parameter"], [160, 170, "Amount"]]}], [5049, "The results of the liver and renal function tests were within the normal range.", {"entities": []}], [5050, "The level of coagulation factors were as follows: factor II 18% (normal range: 70\u2013120); factor \u2164 94% (normal range: 60\u2013130); factor III <1% (normal range: 55\u2013190); and factor X 7% (normal range: 70\u2013120).", {"entities": [[13, 32, "Parameter"], [50, 59, "Parameter"], [60, 63, "Amount"], [88, 96, "Parameter"], [97, 100, "Amount"], [125, 135, "Parameter"], [136, 139, "Amount"], [168, 176, "Parameter"], [177, 179, "Amount"]]}], [5051, "The fibrinogen level was 303 mg/dl (200\u2013400).", {"entities": [[4, 20, "Parameter"], [25, 34, "Amount"]]}], [5052, "A mixing test was performed that was normal.", {"entities": []}], [5053, "Therefore, the main clinical suspicion in this patient was poisoning by a vitamin K antagonist.", {"entities": []}], [5054, "This suggestion was confirmed by the detection of warfarin in the patient's blood sample; however, our patient did not have any history of warfarin or super-warfarin consumption.", {"entities": [[50, 58, "Drug"], [139, 147, "Drug"], [151, 165, "Drug"]]}], [5055, "The patient was treated empirically with 20 mg of intravenous vitamin K and four units of FFP within 10 days of hospitalization.", {"entities": [[41, 46, "Amount"], [76, 86, "Amount"], [90, 93, "Drug"], [94, 108, "Duration"]]}], [5056, "In that time, the bleeding stopped, and laboratory parameters returned to normal range (PT = 11.5 seconds and INR = 1).", {"entities": [[18, 26, "Pathology"], [88, 90, "Parameter"], [93, 105, "Amount"], [110, 113, "Parameter"], [116, 117, "Amount"]]}], [5057, "She was discharged and was advised not to use herbal supplements without a physician prescription.", {"entities": []}], [5058, "Identifying the cause in patients with coagulation disorders could be difficult.", {"entities": [[39, 60, "Pathology"]]}], [5059, "There may not always be a history of herbal exposure, and the initial clinical presentation is not always clear, which can affect the physician\u2019s ability to make the diagnosis.", {"entities": []}], [5060, "Other diagnostic considerations in a patient presenting with coagulopathy of unknown origin include warfarin or super-warfarin exposure, disseminated intravascular coagulation (DIC), vitamin K malabsorption, and pathologic inhibitors of coagulation (6).", {"entities": [[61, 73, "Pathology"], [100, 108, "Drug"], [112, 126, "Drug"], [137, 181, "Pathology"], [183, 206, "Pathology"], [212, 248, "Pathology"]]}], [5061, "Lupus anticoagulant factor as a cause of bleeding and increased PTT in this patient with a history of SLE was ruled out by the normal mixed test results and inactive SLE.", {"entities": [[0, 5, "Pathology"], [41, 49, "Pathology"], [64, 67, "Parameter"], [102, 105, "Pathology"], [166, 169, "Pathology"]]}], [5062, "Liver dysfunction as a major cause of increased PT and INR and decreased vitamin K dependent coagulation factors was ruled out in our patient by the normal liver enzyme levels, serum albumin concentration, and especially, normal serum factor V level which is another coagulation factor that is synthesized by the liver.", {"entities": [[0, 17, "Pathology"], [48, 50, "Parameter"], [55, 58, "Parameter"], [73, 112, "Target"], [177, 204, "Parameter"], [229, 249, "Parameter"]]}], [5063, "High consumption of coagulation factors seen in DIC was ruled out in our patient by the high concentration of serum factor VII (7).", {"entities": [[48, 51, "Pathology"], [110, 126, "Parameter"]]}], [5064, "Overall, when a patient presents with hemorrhagic coagulopathy and prolonged PT and aPTT values of unknown cause, testing for poisoning with warfarin-like compounds should be considered.", {"entities": [[38, 62, "Pathology"], [77, 79, "Parameter"], [84, 88, "Parameter"], [141, 149, "Drug"]]}], [5065, "On the other hand, it is important that prescribers be alert to the possible disadvantage of herbal remedies and also probable herb-drug and herb-food interactions.", {"entities": []}], [5066, "This case report showed the probability of toxicity of warfarin-like compounds causing significant coagulopathy following Red Clover misuse.", {"entities": [[5, 16, "Study"], [43, 51, "Pathology"], [55, 63, "Drug"], [99, 111, "Pathology"], [122, 132, "Herb name"]]}], [5067, "We express our thanks to the staff who were involved in management of this case.", {"entities": []}], [5068, "All the authors met the standards of authorship based on the recommendations of the International Committee of Medical Journal Editors.", {"entities": []}], [5069, "None declared.", {"entities": []}], [5070, "None declared.", {"entities": []}], [5071, "Quantitative prediction of herb\u2013drug interaction risk remains challenging.", {"entities": []}], [5072, "A quantitative framework to assess a potential interaction was used to evaluate a mechanism not previously tested in humans.", {"entities": []}], [5073, "\u2611 Herbal products may perpetrate untoward interactions with conventional drugs via numerous mechanisms.", {"entities": [[2, 17, "Herb name"], [60, 78, "Drug"]]}], [5074, "One potential mechanism, inhibition of intestinal glucuronidation, has been reported in preclinical models, but the clinical relevance of these observations is unexplored.", {"entities": [[39, 65, "Parameter"], [88, 106, "Study"]]}], [5075, "\u2022 WHAT QUESTION DID THIS STUDY ADDRESS?", {"entities": []}], [5076, "\u2611 This study addressed the application of a PBPK modeling approach to predict an herb\u2013drug interaction mediated via inhibition of intestinal glucuronidation, an uncharted mechanism in humans.", {"entities": [[130, 156, "Parameter"]]}], [5077, "The approach was evaluated via a proof\u2010of\u2010concept clinical study using silibinin as an exemplar herbal product perpetrator and raloxifene as an intestinal UGT probe victim.", {"entities": [[50, 64, "Study"], [71, 80, "Herb name"], [96, 110, "Herb name"], [127, 137, "Drug"], [144, 158, "Parameter"]]}], [5078, "\u2022 WHAT THIS STUDY ADDS TO OUR KNOWLEDGE \u2611 A mechanistic PBPK interaction model accurately predicted the minimal impact of the silibinin\u2013raloxifene interaction.", {"entities": [[126, 135, "Herb name"], [136, 146, "Drug"]]}], [5079, "This study demonstrates the utility of PBPK modeling and simulation to predict herb\u2013drug interactions mediated via alternate mechanisms.", {"entities": []}], [5080, "\u2022 HOW THIS MIGHT CHANGE CLINICAL PHARMACOLOGY AND THERAPEUTICS \u2611 These approaches can be used to establish paradigms for the prospective evaluation of herb\u2013drug interaction potential that will provide evidence\u2010based information about the risk or safety of herb\u2013drug combinations.", {"entities": []}], [5081, "Herbal product usage rates continue to climb, fueled in part by the common misperception that \u201cnatural\u201d is synonymous with \u201csafe.\u201d Consumers often turn to these products as a means to alleviate self\u2010diagnosed illnesses or supplement prescribed therapeutic regimens.", {"entities": [[0, 14, "Herb name"], [194, 218, "Pathology"]]}], [5082, "As a result, herbal products are frequently taken by patients in conjunction with prescribed and over\u2010the\u2010counter medications, triggering potential unwanted herb\u2013drug interactions.", {"entities": [[13, 28, "Herb name"]]}], [5083, "Drug interaction liability assessment of herbal products is inherently more complicated than for conventional drugs due to their complex composition and relatively scant knowledge of individual constituents that perpetrate these interactions.", {"entities": [[41, 56, "Herb name"], [97, 115, "Drug"]]}], [5084, "A robust approach that identifies causative constituents, characterizes the pharmacokinetics of those constituents, and describes herb\u2013drug interactions mechanistically is nonexistent.", {"entities": []}], [5085, "Consequently, in vitro\u2013in vivo disconnects are more the norm than the exception when translating herb\u2013drug interaction predictions to the clinic.", {"entities": []}], [5090, "The Berkeley Madonna base model structure was adapted from the literature,2 incorporating raloxifene and silibinin kinetic (K Physiologically based pharmacokinetic model input parameters See \u201cMethods\u201d for detailed information on model parameterization.", {"entities": [[90, 100, "Drug"], [105, 114, "Herb name"]]}], [5091, "Initial simulations used doses of raloxifene and silibinin products reported in previous studies.", {"entities": [[34, 44, "Drug"], [49, 58, "Herb name"]]}], [5092, "Observed concentration\u2013time profiles were extracted from the literature using GetData Graph Digitizer (v. 2.26).", {"entities": [[9, 36, "Parameter"]]}], [5093, "Solid lines denote physiologically based pharmacokinetic model simulations using Berkeley Madonna (a) or SimCYP (b).", {"entities": []}], [5094, "Dashed lines denote upper and lower 90% confidence intervals (b).", {"entities": []}], [5095, "Open symbols denote observed means and were obtained from ref.", {"entities": []}], [5096, "36.", {"entities": []}], [5097, "Siliphos capsules (n\u2009=\u200910) (Thorne Research, Dover, ID) were analyzed using previously described methods2 to ensure purity and content.", {"entities": [[0, 17, "Herb name"]]}], [5098, "In brief, the contents of each capsule were weighed and extracted twice with 2 mL acetone.", {"entities": [[77, 81, "Amount"], [82, 89, "Extraction process"]]}], [5099, "The extract was vortex\u2010mixed and centrifuged (13,000g \u00d7 2 minutes).", {"entities": []}], [5100, "The supernatant was transferred to a clean vial for analysis of milk thistle flavonolignans using an Acquity UPLC system with an HSS\u2010T3 (1.8 \u00b5m, 2.1 \u00d7 100 mm) column (Waters, Milford, MA).", {"entities": [[64, 91, "Herb name"]]}], [5101, "The WSU Institutional Review Board reviewed and approved the study protocol and consent form prior to subject enrollment.", {"entities": []}], [5102, "Eligibility to participate was based on screening evaluation and inclusion/exclusion criteria (Supplemental Table 1).", {"entities": []}], [5103, "Potential subjects provided written informed consent and Health Insurance Portability and Accountability Act authorization before undergoing screening, which consisted of the following: medical history, physical examination, liver function tests, complete blood count, and urinalysis.", {"entities": []}], [5104, "All women underwent a serum pregnancy test.", {"entities": [[4, 9, "Sex"], [28, 37, "Parameter"]]}], [5105, "Eligible participants were randomized to enter the control or treatment phase using a blocked design to ensure equal numbers of men and women in each sequence.", {"entities": [[128, 131, "Sex"], [136, 141, "Sex"]]}], [5106, "The randomization schedule was created using SAS PROC PLAN (v. 9.2; SAS Institute, Cary, NC).", {"entities": []}], [5107, "The control phase involved administration of 60 mg raloxifene (Teva Pharmaceuticals, Sellersville, PA) (Supplemental Figure 1).", {"entities": [[45, 50, "Amount"], [51, 61, "Drug"]]}], [5108, "Vital signs (blood pressure, pulse, oxygen saturation) were obtained on every study day.", {"entities": [[0, 54, "Parameter"], [72, 87, "Frequency"]]}], [5109, "Blood (7 mL) was collected in BD Vacutainer tubes containing EDTA (Becton, Dickinson, Franklin Lakes, NJ) through an intravenous line before and from 0.25\u201312 hours following drug administration.", {"entities": [[145, 163, "Duration"]]}], [5111, "Subjects returned to the CRU 24, 48, 72, and 96 hours postdrug administration for blood collection via venipuncture.", {"entities": [[29, 53, "Duration"]]}], [5112, "Plasma (\u223c3 mL) was harvested by centrifugation and collected in cryogenic vials (Corning, Tewksbury, MA) (\u223c1 mL each) for storage at \u221280\u00b0C pending analysis by UHPLC\u2010MS/MS.", {"entities": []}], [5113, "At least a seven\u2010day washout period separated each phase (Supplemental Figure 1).", {"entities": [[9, 35, "Duration"]]}], [5114, "The treatment phase involved administration of 60 mg raloxifene followed immediately by 480 mg Siliphos (based on labeled content) three times daily for the entire collection interval.", {"entities": [[47, 52, "Amount"], [53, 63, "Drug"], [88, 94, "Amount"], [95, 103, "Herb name"], [131, 148, "Frequency"]]}], [5115, "Each subject received his/her Siliphos in a blister pack and was asked to complete a pill diary documenting the time of administration, beverage, and approximate volume used to aid swallowing, and adverse events, if applicable.", {"entities": [[30, 38, "Herb name"], [150, 191, "Parameter"], [197, 211, "Pathology"]]}], [5116, "Subjects were instructed how to use the blister pack properly, and compliance was assessed at each study visit.", {"entities": []}], [5117, "Plasma collection times and procedures mirrored those outlined for the control phase.", {"entities": []}], [5118, "Plasma (100 \u00b5L) was treated with methanol (4 volumes with 0.1% formic acid) containing the internal standards raloxifene\u2010d Pharmacokinetic outcomes were recovered by noncompartmental analysis using Phoenix WinNonlin.", {"entities": [[33, 74, "Extraction process"], [110, 122, "Drug"]]}], [5119, "Concentrations below the limit of quantification for each analyte were excluded.", {"entities": [[0, 14, "Parameter"]]}], [5120, "The terminal elimination rate constant (\u03bb All statistical analyses were conducted using SAS (v. 9.2; SAS Institute).", {"entities": []}], [5121, "A single lot (#313823) of Siliphos capsules, labeled to contain 60 mg silibinin per capsule, was selected as the test herbal product.", {"entities": [[26, 43, "Herb name"], [64, 69, "Amount"], [70, 79, "Herb name"]]}], [5123, "The capsules also contained small amounts of the regioisomers isosilybin A (1.21\u2009\u00b1\u20090.03 mg) and isosilybin B (1.01\u2009\u00b1\u20090.06 mg).", {"entities": [[45, 74, "Herb name"], [76, 90, "Amount"], [96, 108, "Herb name"], [110, 124, "Amount"]]}], [5124, "Prior to the first study day, two participants (one man, one woman) withdrew consent due to unforeseen scheduling conflicts.", {"entities": [[52, 55, "Sex"], [61, 66, "Sex"]]}], [5125, "Two additional participants were screened, enrolled, and assigned to the randomization schedule of the participants they replaced.", {"entities": []}], [5126, "All participants who entered the study completed both phases (Supplemental Table 2).", {"entities": []}], [5127, "Raloxifene and Siliphos were well tolerated.", {"entities": [[0, 10, "Drug"], [15, 23, "Herb name"]]}], [5128, "One subject experienced nausea in response to venous catheter placement that was self\u2010limiting and not study drug\u2010related (occurred prior to administration).", {"entities": [[24, 30, "Pathology"], [46, 71, "Parameter"]]}], [5129, "The event did not limit the subject's continued participation.", {"entities": []}], [5130, "No other adverse events were reported.", {"entities": [[9, 23, "Pathology"]]}], [5131, "Symbols and error bars denote observed geometric means and upper limits of the 90% confidence interval, respectively.", {"entities": []}], [5132, "Effects of silibinin (480 mg three times daily for 4 days) on (a,c,e) C Pharmacokinetic outcomes for the raloxifene glucuronides were minimally altered by silibinin (<10%).", {"entities": [[11, 20, "Herb name"], [22, 28, "Amount"], [29, 46, "Frequency"], [47, 57, "Duration"], [101, 128, "Drug"], [155, 164, "Herb name"], [166, 170, "Amount"]]}], [5133, "Solid lines denote PBPK model simulations of mean concentration\u2013time profiles using Berkeley Madonna (a) or SimCYP (b).", {"entities": [[45, 77, "Parameter"]]}], [5134, "Dashed lines denote upper and lower 90% confidence intervals (b).", {"entities": []}], [5135, "Symbols and error bars denote observed geometric means and upper limits of the 90% confidence interval, respectively.", {"entities": []}], [5136, "Despite considerable investigation, quantitative prediction of herb\u2013drug interaction liability remains elusive.", {"entities": []}], [5137, "Regulatory guidelines in Western countries typically require premarket evaluation of drug\u2013drug interactions, but these guidelines generally do not apply to herb\u2013drug interactions.", {"entities": []}], [5138, "Approaches developed for the prediction of drug\u2013drug interactions are often inadequate to overcome the additional hurdles unique to the evaluation of herb\u2013drug interactions.1, 39, 40, 41 The complex composition of herbal products renders traditional static models of drug\u2013drug interaction potential generally less useful for the prediction of herb\u2013drug interactions.", {"entities": []}], [5139, "Highly variable and limited pharmacokinetic data available for herbal constituents, combined with a lack of herbal product standardization, continues to challenge the development of predictive herb\u2013drug interaction models.", {"entities": [[108, 122, "Herb name"]]}], [5140, "Consequently, approaches to assess herb\u2013drug interaction liability vary widely, yielding conflicting results, inconclusive translation to the clinical setting, and uncertain generalizability.", {"entities": []}], [5141, "The relative paucity of reliable pharmacokinetic data to describe herbal product constituents further complicates efforts to extrapolate preclinical data to predict clinical consequences.", {"entities": []}], [5143, "The intuitive user interface of SimCYP provides a means to populate built\u2010in model structures and generate simulated pharmacokinetic outcomes that can be output in a standard format.", {"entities": []}], [5144, "However, the built\u2010in model structures are limited in that a maximum of two perpetrators can be accommodated.", {"entities": []}], [5145, "This limitation applies particularly to the prediction of herb\u2013drug interactions, as herbal products are typically mixtures of multiple constituents that can alter ADME processes via multiple mechanisms.", {"entities": [[85, 100, "Herb name"], [164, 178, "Parameter"]]}], [5146, "In contrast, Berkeley Madonna is a general\u2010purpose differential equation solver that is limited in terms of model structures and perpetrator count only by the user's ability to adequately describe these processes mathematically.", {"entities": []}], [5147, "This flexibility, however, is accompanied by a lack of functionality to easily incorporate population and parameter variability and generate standardized outputs.", {"entities": []}], [5148, "These limitations may require additional software platforms to generate desired outcome measures and evaluate the impact of population and parameter uncertainty.", {"entities": []}], [5149, "Based on these advantages and disadvantages of SimCYP and Berkeley Madonna, both platforms were used and expanded with unique approaches to evaluate the consequences of an herb\u2013drug interaction mediated via inhibition of intestinal glucuronidation, a mechanism uncharted in humans.", {"entities": [[221, 247, "Parameter"]]}], [5150, "Silibinin was selected as a model herbal product perpetrator based on well\u2010characterized composition, availability of human pharmacokinetic data, and in vitro inhibitory potency (K Because standard approaches to evaluate herb\u2013drug interactions mediated via inhibition of intestinal glucuronidation in humans have not been described, two different modeling platforms were used to predict the likelihood and magnitude of the silibinin\u2013raloxifene interaction.", {"entities": [[0, 9, "Herb name"], [34, 48, "Herb name"], [271, 297, "Parameter"], [423, 432, "Herb name"], [433, 443, "Drug"]]}], [5151, "The Berkeley Madonna model incorporated data recovered from human microsomal systems,25 which contain the full complement of UGTs present in the intestine and liver.", {"entities": [[125, 129, "Parameter"]]}], [5152, "These data are consistent with the assertion that in vitro to in vivo extrapolation accuracy for UGT substrates is improved by incorporating parameters to describing drug disposition in multiple organs with metabolic capacity.20, 42 Raloxifene modulation of silibinin disposition via competitive inhibition was not incorporated into model predictions, as quantitative data (K The Berkeley Madonna interaction model overpredicted, whereas the SimCYP interaction model accurately predicted, the observed magnitude of interaction.", {"entities": [[97, 100, "Parameter"], [233, 243, "Drug"], [258, 267, "Herb name"]]}], [5153, "The discrepancy between the two models can be partially explained by the different in vitro parameters used to populate each model.", {"entities": []}], [5154, "The differing absorption models also may contribute.", {"entities": []}], [5155, "The Berkeley Madonna model used a relatively simple first\u2010order absorption model, whereas the SimCYP model used the advanced dissolution, absorption, and metabolism (ADAM) model.", {"entities": []}], [5156, "The ADAM model incorporates population variability of multiple component processes within a mechanistic framework to describe the passage of drug molecules along and through the gastrointestinal tract.30 The ADAM model divides the intestine into multiple transit compartments, effectively distributing any interactions between the herbal product perpetrator, silibinin, and the victim drug, raloxifene, along the entire length of the gastrointestinal tract.", {"entities": [[327, 368, "Herb name"], [374, 401, "Drug"]]}], [5157, "The net interaction potential reflects a summary of multiple processes governing the release, dissolution, permeability, metabolism, and transit of both the perpetrator and victim.", {"entities": [[81, 179, "Parameter"]]}], [5158, "In contrast, the Berkeley Madonna model assumes that the interaction occurs within a single, homogenous compartment.", {"entities": []}], [5159, "This assumption can result in overprediction of inhibitor concentration and residence time at the active site and may explain the overprediction of the interaction magnitude by the Berkeley Madonna model.", {"entities": [[48, 71, "Parameter"], [76, 109, "Parameter"]]}], [5160, "In general, the proof\u2010of\u2010concept clinical study suggested a low interaction risk of silibinin administered with raloxifene.", {"entities": [[12, 47, "Study"], [84, 93, "Herb name"], [112, 122, "Drug"]]}], [5161, "Alternate study designs, including silibinin predosing and multiple dosing of raloxifene, could provide further insight into interaction potential.", {"entities": [[35, 44, "Herb name"], [59, 74, "Frequency"], [78, 88, "Drug"]]}], [5162, "Design of drug molecules to avoid oxidative metabolism continues to emphasize the importance of conjugative metabolism in drug development.", {"entities": []}], [5163, "As a result, these modeling approaches may also be useful in the evaluation of drug\u2013drug interaction potential of new chemical entities cleared predominantly by glucuronidation.", {"entities": []}], [5164, "In summary, quantitative prediction of herb\u2013drug interactions remains challenging.", {"entities": []}], [5165, "This work evaluated the application of a quantitative framework to assess the risk of an herb\u2013drug interaction mediated via a mechanism not previously explored in humans.", {"entities": []}], [5166, "Model\u2010informed clinical evaluation of the silibinin\u2013raloxifene interaction indicated minimal clinical interaction liability, albeit some individuals may be more sensitive for as\u2010yet unknown reasons.", {"entities": [[42, 51, "Herb name"], [52, 62, "Drug"]]}], [5167, "Further development and validation of PBPK modeling and simulation approaches will enhance confidence in model predictions and facilitate generalizability to alternate combinations of herbal products and conventional drugs.", {"entities": [[184, 199, "Herb name"], [204, 222, "Drug"]]}], [5168, "Ultimately, these approaches can be used to establish paradigms for the prospective evaluation of herb\u2013drug interaction potential that will provide evidence\u2010based information about the risk or safety of herb\u2013drug combinations.", {"entities": []}], [5169, "The authors have no disclosures and declare no personal or financial conflicts of interest.", {"entities": []}], [5170, "B.T.G., J.R.W., J.T.B., N.H.O., and M.F.P.", {"entities": []}], [5171, "wrote the article.", {"entities": []}], [5172, "B.T.G.", {"entities": []}], [5173, "and M.F.P.", {"entities": []}], [5174, "designed research.", {"entities": []}], [5175, "B.T.G., J.T.B., V.G.P., J.R.W., and M.E.L.", {"entities": []}], [5176, "performed research.", {"entities": []}], [5177, "B.T.G., N.H.O., and M.F.P.", {"entities": []}], [5178, "analyzed data.", {"entities": []}], [5179, "N.H.O.", {"entities": []}], [5180, "contributed new reagents/analytical tools.", {"entities": []}], [5181, "Supporting Information Click here for additional data file.", {"entities": []}], [5182, "Supporting Information Click here for additional data file.", {"entities": []}], [5183, "Supporting Information Click here for additional data file.", {"entities": []}], [5184, "Supporting Information Click here for additional data file.", {"entities": []}], [5185, "Supporting Information Click here for additional data file.", {"entities": []}], [5186, "Supporting Information Click here for additional data file.", {"entities": []}], [5187, "The authors thank Judy Griffin and Yili Zhong (WSU) for their assistance in conducting the clinical study and Tyler Graf (UNCG) for verifying silibinin content in the test herbal product.", {"entities": [[91, 105, "Study"], [142, 151, "Herb name"], [172, 186, "Herb name"]]}], [5188, "The Health Sciences and Services Authority of Spokane provided financial support to purchase bioanalytical instrumentation.", {"entities": []}], [5189, "This work was supported by the National Institutes of Health National Institute of General Medical Sciences (Grant R01 GM077482\u2010S1).", {"entities": []}], [5190, "B.T.G.", {"entities": []}], [5191, "was supported by a fellowship awarded by the American Foundation for Pharmaceutical Education.", {"entities": []}], [5192, "B.T.G.", {"entities": []}], [5193, "is currently supported by the National Institute of General Medical Sciences (Grant T32 GM008425).", {"entities": []}], [5194, "M.F.P.", {"entities": []}], [5195, "dedicates this article to Dr. David P. Paine.", {"entities": []}], [5196, "Patients suffering from obesity-related diseases use multiple prescription drugs to control their condition, and it is therefore essential to determine the safety and efficacy of any combination.", {"entities": [[0, 8, "Pathology"], [24, 48, "Pathology"]]}], [5197, "Gliclazide is one of the most commonly used drug of choice for treatment of type 2 diabetes, and curcumin is a widely used herbal supplement to counter obesity condition.", {"entities": [[0, 10, "Drug"], [76, 91, "Pathology"], [97, 105, "Herb name"], [152, 159, "Pathology"]]}], [5198, "The objective of this study was to investigate the effect of oral administration of curcumin on pharmacodynamics and pharmacokinetics of gliclazide in rats and rabbits to further evaluate the safety and effectiveness of this combination.", {"entities": [[84, 92, "Herb name"], [137, 147, "Drug"]]}], [5199, "Influence of curcumin on the activity of gliclazide was determined by conducting single- and multiple-dose interaction studies in rats (normal and diabetic) and rabbits.", {"entities": [[13, 21, "Herb name"], [41, 51, "Drug"], [81, 134, "Study"]]}], [5200, "Blood samples collected at predetermined time intervals from experimental animals were used for the estimation of glucose and insulin levels by using automated clinical chemistry analyzer and radioimmunoassay method, respectively.", {"entities": []}], [5201, "The insulin resistance and \u03b2-cell function were determined by homeostasis model assessment.", {"entities": []}], [5202, "Additionally, serum gliclazide levels in rabbits were analyzed by high-performance liquid chromatography.", {"entities": [[20, 30, "Drug"]]}], [5203, "Gliclazide showed peak reduction in blood glucose levels at 2 and 8 hours in rats and at 3 hours in rabbits.", {"entities": [[0, 10, "Drug"], [36, 56, "Parameter"]]}], [5204, "This activity of gliclazide was not altered by single-dose treatment with curcumin.", {"entities": [[17, 27, "Drug"], [47, 58, "Frequency"], [74, 82, "Herb name"]]}], [5205, "However, in multiple-dose interaction studies, samples analyzed from all time points showed subtle but significantly greater reduction in percent blood glucose ranging from 23.38% to 42.36% in normal rats, 27.63% to 42.27% in diabetic rats, and 16.50% to 37.88% in rabbits.", {"entities": [[12, 45, "Study"], [146, 159, "Parameter"], [226, 234, "Pathology"]]}], [5206, "The pharmacokinetics of gliclazide was not altered by single- or multiple-dose curcumin treatments in rabbits.", {"entities": [[24, 34, "Drug"], [79, 87, "Herb name"]]}], [5207, "The interaction of curcumin with gliclazide up on multiple-dose treatment was pharmacodynamic in nature, indicating the need for periodic monitoring of glucose levels and dose adjustment as necessary when this combination is prescribed to obese patients.", {"entities": [[19, 27, "Herb name"], [33, 43, "Drug"], [239, 253, "Pathology"]]}], [5208, "Polypharmacy is the concurrent use of multiple medications.", {"entities": []}], [5209, "It can be associated with the prescription and/or use of unnecessary medications at dosages or frequencies higher than therapeutically essential.", {"entities": []}], [5210, "Polypharmacy is a common practice to treat single disorder or multiple disorders which occur simultaneously.", {"entities": []}], [5211, "In developing countries, where no strict control on over-the-counter drug distribution exists and lack of medical awareness in the consumer sector, polypharmacy is found to be more prevalent.", {"entities": []}], [5212, "Herbal medicines/supplements are widely used today either solely or in combination with modern pharmaceuticals.", {"entities": []}], [5213, "These therapeutic combinations may be toxic at the doses taken adding a new layer of complexity to patient care and thereby pose a significant public health problem.", {"entities": [[99, 106, "Pathology"]]}], [5214, "The possible adverse effects of herb\u2013drug interactions remain to be explained and poorly understood.", {"entities": [[13, 28, "Pathology"]]}], [5215, "Significant changes in the pharmacological or toxicological effects of either component may be seen when herbal active constituents and drugs are given in combination and therefore, it is important to study herb\u2013drug interactions.1 Obesity is recognized as a worldwide crisis and represents an area of increasing concern because of its predominant effects on mortality and economics.", {"entities": [[232, 239, "Pathology"]]}], [5217, "Patients with obesity are prone to develop diabetes, and maintenance of normal blood glucose level in these individuals is very critical for the prevention of undesirable complications associated with both hyperglycemia and hypoglycemia.", {"entities": [[0, 8, "Pathology"], [14, 21, "Pathology"], [43, 51, "Pathology"], [79, 98, "Parameter"], [206, 219, "Pathology"], [224, 236, "Pathology"]]}], [5218, "Oral hypoglycemic agents are used in the treatment of type 2 diabetes, of which gliclazide (second-generation sulfonylurea derivative) is the preferred choice of drug.", {"entities": [[0, 24, "Drug"], [59, 69, "Pathology"], [80, 90, "Drug"]]}], [5219, "It acts by selectively inhibiting pancreatic K Curcumin is the active ingredient present in medicinal plant Curcuma longa, also known as turmeric.", {"entities": [[47, 55, "Herb name"], [108, 121, "Herb name"], [137, 145, "Herb name"]]}], [5220, "From decades, it has been widely used in Ayurveda, Unani, and Siddha medicine to cure various diseases.", {"entities": []}], [5222, "Curcumin is readily available in market in various dose formulations and is consumed by people as herbal medicine/supplement/spice because of its known medicinal properties.", {"entities": [[0, 8, "Herb name"]]}], [5225, "To date, only little in vivo work is done to relate the interaction of curcumin on CYP enzymes.", {"entities": [[71, 79, "Herb name"]]}], [5226, "Based on the background information, the present study was designed and undertaken with the hypothesis that pretreatment of curcumin will influence the pharmacodynamics and pharmacokinetics of gliclazide in animal models.", {"entities": [[124, 132, "Herb name"], [193, 203, "Drug"]]}], [5227, "Gliclazide was obtained as a gift sample from Dr Reddy\u2019s Laboratories (Bachupally, Hyderabad, Telangana, India).", {"entities": [[0, 10, "Drug"]]}], [5228, "Curcumin commercially available as pure powder capsule (95%) was obtained from Quality Supplements and Vitamins (Fort Lauderdale, FL, USA).", {"entities": [[0, 8, "Herb name"]]}], [5229, "Alloxan monohydrate was purchased from Loba Chemie (Mumbai, Maharashtra, India).", {"entities": []}], [5230, "All reagents and chemicals used in the study were of analytical grade.", {"entities": []}], [5231, "Eight to 9-week-old male albino rats weighing between 170 and 250 g were procured from Vivo Biotech (Hyderabad, Telangana, India), and 3-month-old male albino rabbits weighing between 1 and 1.5 kg were procured from Rabiroof (Hyderabad, Telangana, India).", {"entities": [[0, 19, "Age"], [135, 146, "Age"]]}], [5232, "They were maintained under standard laboratory husbandry conditions at 25\u00b0C\u00b12\u00b0C and 50%\u00b115% relative humidity with a 12-hour light/dark cycle.", {"entities": []}], [5233, "Animals were fed with a commercially available pellet diet (Rayan\u2019s Boitechnologies Pvt Ltd, Hyderabad, Telangana, India) and water was provided ad libitum.", {"entities": []}], [5234, "Animals were fasted for 10 hours prior to the experiment, and during the experiment they were withdrawn from feed.", {"entities": []}], [5235, "The animal experiments were performed after prior approval of study protocol by the Institutional Animal Ethics Committee (Reg No DLL/IAEC/2013/02/04).", {"entities": []}], [5236, "The study was also conducted in accordance with the guidelines provided by the Committee for the Purpose of Control and Supervision of Experiments on Animals.", {"entities": []}], [5237, "Curcumin doses of 200 and 100 mg/kg were calculated from human oral therapeutic dose based on body surface area for rats and rabbits, respectively.15 From the results of gliclazide dose\u2013effect relationship study conducted in normal rats and rabbits, the doses of 2 and 4 mg/kg body weight were selected, respectively, for administration in animals.16 Oral dose formulation for curcumin was prepared by suspending in 0.5% carboxymethyl cellulose Na.", {"entities": [[0, 8, "Herb name"], [170, 180, "Drug"], [263, 276, "Amount"]]}], [5238, "Gliclazide solution was prepared by dissolving in few drops of 0.1 N NaOH and the final volume was made with water.17 The design of the study is as follows:  Stage 1: Pharmacodynamic interaction in normal rats.3 Stage 2: Pharmacodynamic interaction in diabetic rats.3 Stage 3: Pharmacodynamic and pharmacokinetic interaction in normal rabbits.18 Six rats were selected for stage 1 experiment.", {"entities": [[0, 10, "Drug"], [252, 260, "Pathology"]]}], [5239, "These rats were given gliclazide via the oral route at 2 mg/kg body weight, and their blood samples were collected at predetermined time points.", {"entities": [[22, 32, "Drug"], [55, 62, "Amount"]]}], [5240, "With a week washout period between each experiment, similar procedure was performed with either orally administered curcumin only or combination treatment with both curcumin and gliclazide at the previously mentioned doses.", {"entities": [[116, 124, "Herb name"], [165, 173, "Herb name"], [178, 188, "Drug"]]}], [5241, "After these single-dose interaction studies, the same group of animals were given daily treatments with curcumin for the next 20 days with regular feeding.", {"entities": [[12, 23, "Frequency"], [104, 112, "Herb name"]]}], [5242, "On day 21, animals were fasted for 10 hours before administering curcumin.", {"entities": [[65, 73, "Herb name"]]}], [5243, "After 30 minutes, the animals were given gliclazide at 2 mg/kg body weight.", {"entities": [[41, 51, "Drug"], [55, 62, "Amount"]]}], [5244, "Blood samples were collected at predetermined time intervals after each treatment with gliclazide alone, curcumin alone, or combination treatments (single and multiple).", {"entities": [[87, 97, "Drug"], [105, 113, "Herb name"]]}], [5245, "For stage 2 experiments, diabetes was induced in rats as previously described.19 Briefly, diabetes was induced in rats by the administration of alloxan monohydrate in two divided doses, that is, 100 and 50 mg/kg body weight intraperitoneally on 2 consecutive days.", {"entities": [[25, 33, "Pathology"], [90, 98, "Pathology"], [195, 211, "Amount"]]}], [5246, "After 72 hours, blood samples were collected from surviving rats by retro-orbital puncture, and blood glucose levels were measured using automated clinical chemistry analyzer.", {"entities": [[96, 116, "Parameter"]]}], [5247, "Six rats with blood glucose levels \u2265200 mg/dL were considered as diabetic and selected for the study.", {"entities": [[0, 8, "Cohort"], [14, 34, "Parameter"], [35, 45, "Amount"], [65, 73, "Pathology"]]}], [5248, "The same treatment protocols as described in stage 1 were tested in the diabetic rats.", {"entities": [[72, 80, "Pathology"]]}], [5249, "Six rabbits were selected for stage 3 experiment.", {"entities": [[0, 11, "Cohort"]]}], [5250, "These rabbits were given gliclazide via the oral route at 4 mg/kg body weight, and their blood was collected at predetermined time points.", {"entities": [[25, 35, "Drug"], [58, 65, "Amount"]]}], [5251, "With a week washout period between experiments, similar procedure was performed with either orally administered curcumin or combination treatment with both curcumin and gliclazide at the previously mentioned doses.", {"entities": [[7, 11, "Duration"], [112, 120, "Herb name"], [156, 164, "Herb name"], [169, 179, "Drug"]]}], [5252, "After this single-dose interaction study, the same animals received daily treatments with curcumin for the next 20 days with regular feeding.", {"entities": [[11, 22, "Frequency"], [68, 73, "Frequency"], [90, 98, "Herb name"], [112, 119, "Duration"]]}], [5253, "On day 21, the animals were fasted for 10 hours before administering curcumin.", {"entities": [[39, 47, "Duration"], [69, 77, "Herb name"]]}], [5254, "After 30 minutes, the animals received gliclazide at 4 mg/kg body weight.", {"entities": [[39, 49, "Drug"], [53, 60, "Amount"]]}], [5255, "Blood samples were collected at predetermined time intervals after each treatment of gliclazide, curcumin, or combination treatments (single and multiple).", {"entities": [[85, 95, "Drug"], [97, 105, "Herb name"]]}], [5256, "Blood samples were collected from retro-orbital plexus20 of each rat at 0, 1, 2, 3, 4, 6, 8, and 12 hours.", {"entities": []}], [5257, "Blood samples were withdrawn from the marginal ear vein of each rabbit at 0, 1, 2, 3, 4, 6, 8, 10, 12, 16, and 24 hours.", {"entities": []}], [5258, "The blood samples collected at all the intervals (except for 16 and 24 hours in rabbits) were tested for blood glucose by using automated clinical chemistry analyzer.", {"entities": []}], [5259, "Blood samples collected at 2- and 8-hour time intervals in normal, diabetic rats and at 3 hours from rabbits were also used for the estimation of serum insulin by radioimmunoassay method.17 These intervals were selected based on the peak percent blood glucose levels observed in rats and rabbits.17 Additionally, blood samples collected from rabbits were used for the estimation of gliclazide concentration in serum by high-performance liquid chromatography method.", {"entities": [[67, 75, "Pathology"], [246, 266, "Parameter"]]}], [5260, "The insulin resistance index and \u03b2-cell function were assessed by the Homeostatic Model Assessment protocol and was calculated as follows:17,21,22  Pharmacokinetic parameters of gliclazide in rabbit serum such as peak serum concentration (C Data are expressed as mean \u00b1 standard deviation values.", {"entities": [[178, 188, "Drug"]]}], [5261, "Student\u2019s paired t-test was used as statistical tool and p<0.05 is considered as statistically significant.", {"entities": []}], [5262, "Gliclazide produced hypoglycemic activity in normal rats with maximum biphasic reduction of 41.66%\u00b11.70% and 39.49%\u00b11.82% (Table 1) and antihyperglycemic activity in diabetic rats with peak biphasic reduction of 43.17%\u00b10.90 % and 40.91%\u00b11.56% at 2- and 8-hour time intervals, respectively (Table 2).", {"entities": [[0, 10, "Drug"], [166, 174, "Pathology"]]}], [5263, "Peak hypoglycemic activity was observed with maximum reduction of 34.10%\u00b11.90% at 3-hour time interval in rabbits (Table 3).", {"entities": []}], [5264, "Curcumin alone did not produce any significant change in the blood glucose level of both rats (normal and diabetic) and rabbits.", {"entities": [[0, 8, "Herb name"], [61, 80, "Parameter"], [106, 114, "Pathology"]]}], [5265, "Single-dose combination of curcumin with gliclazide did not induce any significant changes in percent blood glucose reduction, insulin levels, insulin resistance, and \u03b2-cell function in animal models.", {"entities": [[0, 11, "Frequency"], [27, 35, "Herb name"], [41, 51, "Drug"]]}], [5266, "However, multiple-dose combination of curcumin with gliclazide produced significantly greater reduction in percent blood glucose reduction at 3-, 4-, 6-, 8-, 10-, and 12-hour intervals after treatment in normal rats and rabbits when compared with gliclazide control.", {"entities": [[38, 46, "Herb name"], [52, 62, "Drug"], [247, 257, "Drug"]]}], [5267, "Similarly, greater significant increase in percent blood glucose reduction was observed in diabetic rats except at 8-hour interval.", {"entities": [[51, 64, "Parameter"], [91, 99, "Pathology"]]}], [5268, "No significant changes were observed in insulin levels, insulin resistance, and \u03b2-cell function (Tables 4\u20136) in both the animal models.", {"entities": []}], [5269, "The mean concentration versus time curve after oral administration of gliclazide in presence of curcumin is shown in Figure 1.", {"entities": [[70, 80, "Drug"], [96, 104, "Herb name"]]}], [5270, "The pharmacokinetic parameters of gliclazide alone and in the presence of curcumin following single- and multiple-dose administrations are given in Table 7.", {"entities": [[34, 44, "Drug"], [74, 82, "Herb name"]]}], [5271, "Curcumin in presence of gliclazide, both in single- and multiple-dose combinations, did not alter the pharmacokinetics of gliclazide in rabbits.", {"entities": [[0, 8, "Herb name"], [24, 34, "Drug"], [122, 132, "Drug"]]}], [5272, "Drug interactions studies are an important aspect of pharmacology research, and such interactions are usually evaluated in animal models.23 Although animal models can never replace the need for comprehensive studies in human subjects, their use can provide important information for understanding the mechanisms of drug interactions.", {"entities": [[0, 25, "Study"]]}], [5273, "The present study is designed to evaluate the influence of curcumin on the activity of gliclazide in animal models.", {"entities": [[59, 67, "Herb name"], [87, 97, "Drug"]]}], [5274, "Normal rats were used to identify the interaction and diabetic rats aided to validate the interaction in the actually used condition of the drug.", {"entities": [[54, 62, "Pathology"]]}], [5275, "Rabbit model was used further to validate the same in a dissimilar species.18 Consistent with previous reports showing that rats are more sensitive to gliclazide treatment,3 gliclazide produced a biphasic response at 2- and 8-hour intervals in rat model when administered alone, which might be due to biliary excretion and enterohepatic recycling.3,24,25 The biphasic effect was not seen in rabbit model and the maximum reduction in percent blood glucose was observed at 3-hour interval.", {"entities": [[151, 161, "Drug"], [174, 184, "Drug"], [441, 454, "Parameter"]]}], [5276, "This might due to the absence of enterohepatic recycling in rabbits.", {"entities": []}], [5277, "According to a recent clinical study, enterohepatic recirculation is also observed in humans and is therefore consistent with our data from the animal experiments substantiating the correlation between our preclinical data to human.26 Gliclazide is known for its hypoglycemic activity in rat mediated by blocking K Any drug/herbal active constituent, which is a potential inducer or inhibitor of drug-metabolizing enzymes, may alter the pharmacokinetics and pharmacodynamics activity of the substrate.", {"entities": [[22, 36, "Study"], [235, 245, "Drug"]]}], [5278, "Curcumin has the potential to cause herb\u2013drug interaction when administered with other drugs.29 This study revealed the influence of curcumin on the pharmacodynamic activity of gliclazide alone and in combination using single-and multiple-dose treatments in rats and rabbits.", {"entities": [[0, 8, "Herb name"], [133, 141, "Herb name"], [177, 187, "Drug"]]}], [5279, "The end points were evaluated in terms of glucose level (% reduction), insulin level, \u03b2-cell function, and insulin resistance using Homeostatic Model Assessment and pharmacokinetics of gliclazide in rabbits.", {"entities": [[185, 195, "Drug"]]}], [5280, "In the present study, no significant changes were observed in pharmacodynamics and pharmacokinetics of gliclazide following single-dose administration with curcumin.", {"entities": [[103, 113, "Drug"], [124, 135, "Frequency"], [156, 164, "Herb name"]]}], [5281, "Multiple-dose treatment of curcumin resulted in minor change to significant increase in percent blood glucose reduction in rats (normal and diabetic) and rabbits when compared with gliclazide control.", {"entities": [[27, 35, "Herb name"], [96, 109, "Parameter"], [140, 148, "Pathology"], [181, 191, "Drug"]]}], [5282, "The resulted changes in glucose levels might be due to additive effect of curcumin in presence of gliclazide.", {"entities": [[74, 82, "Herb name"], [98, 108, "Drug"]]}], [5283, "This effect of curcumin can be attributed due to one or more possible mechanisms as reported earlier.", {"entities": [[15, 23, "Herb name"]]}], [5284, "Curcumin is reported to exhibit hypoglycemic activity in rat by regulation of polyol pathway30 or by suppression of oxidative stress and inflammatory cytokines.31 Previous studies also indicate that the antihyperglycemic potential of curcumin in diabetic rats might be due to the regeneration of pancreatic \u03b2-cells, which were partially destroyed by alloxan thereby increasing insulin secretion.12 But the results obtained in the present study indicate that curcumin has no effect on insulin levels when taken in combination with gliclazide.", {"entities": [[0, 8, "Herb name"], [234, 242, "Herb name"], [246, 254, "Pathology"], [458, 466, "Herb name"], [530, 540, "Drug"]]}], [5285, "However, curcumin is also known for its extra pancreatic-related antihyperglycemic effect in diabetic rats by decreasing hepatic glucose level, attenuation of free fatty acids, and TNF-\u03b1 level as reported earlier.32 In the present study, the disposition of gliclazide after single oral dose was examined in rabbits with and without prior exposure to curcumin.", {"entities": [[9, 17, "Herb name"], [93, 101, "Pathology"], [121, 142, "Parameter"], [159, 175, "Parameter"], [181, 192, "Parameter"], [257, 267, "Drug"], [274, 290, "Frequency"], [350, 358, "Herb name"]]}], [5286, "Mean C Current work attempts to shed light on the practices of polypharmacy where combination of curcumin and gliclazide is used.", {"entities": [[97, 105, "Herb name"], [110, 120, "Drug"]]}], [5287, "The study confirms that the interaction of curcumin with gliclazide is pharmacodynamic in nature as the glucose levels in animal models are significantly altered and no change in pharmacokinetics of gliclazide is observed.", {"entities": [[43, 51, "Herb name"], [57, 67, "Drug"], [199, 209, "Drug"]]}], [5288, "Since the interaction is observed in two dissimilar species, it is also likely to occur in humans.", {"entities": []}], [5289, "Hence, this combination needs monitoring of glucose levels periodically when administered for their clinical benefits in obese patients.", {"entities": []}], [5290, "However, further studies are necessary to determine the possibility of these interactions in clinic and also to determine the exact mechanism of action of such interactions.", {"entities": []}], [5291, "The authors are thankful to Dr Reddy\u2019s Labs Ltd, Hyderabad, India, for providing gift sample of gliclazide for the research work.", {"entities": [[96, 106, "Drug"]]}], [5292, "The authors are grateful to the management of Delve labs Ltd, Hyderabad, India, for providing support in supplying and conducting of animal experiments.", {"entities": []}], [5293, "The authors are also thankful to Renuka Pillai, Aurigene Discovery Technologies Limited, Hyderabad, India, for reviewing and providing insights for the manuscript.", {"entities": []}], [5294, "Author contributions          KEK designed the research and interpreted the data; VLK designed the research, performed, analyzed, and drafted the manuscript.", {"entities": []}], [5295, "Both authors contributed toward data analysis, drafting and revising the paper and agree to be accountable for all aspects of the work.", {"entities": []}], [5296, "Disclosure          The authors report no conflicts of interest in this work.", {"entities": []}], [5297, "Mean gliclazide concentration in serum (ng/mL) before and after treatment with curcumin in rabbits (n=6).", {"entities": [[5, 15, "Drug"], [79, 87, "Herb name"]]}], [5298, "Abbreviations: MDT, multiple-dose treatment; SDT, single-dose treatment.", {"entities": [[45, 71, "Frequency"]]}], [5299, "Mean percent blood glucose reduction of gliclazide in presence and absence of curcumin in normal rats (n=6) Notes: Data expressed as mean \u00b1 standard deviation.", {"entities": [[13, 26, "Parameter"], [40, 50, "Drug"], [78, 86, "Herb name"]]}], [5300, "Statistically significant when compared with gliclazide control.", {"entities": [[45, 55, "Drug"]]}], [5301, "Abbreviations: MDT, multiple-dose treatment; SDT, single-dose treatment.", {"entities": [[45, 71, "Frequency"]]}], [5302, "Mean percent blood glucose reduction of gliclazide in presence and absence of curcumin in diabetic rats (n=6) Notes: Data expressed as mean \u00b1 standard deviation.", {"entities": [[40, 50, "Drug"], [78, 86, "Herb name"], [90, 98, "Pathology"]]}], [5303, "Statistically significant when compared with gliclazide control.", {"entities": [[45, 55, "Drug"]]}], [5304, "Abbreviations: MDT, multiple-dose treatment; SDT, single-dose treatment.", {"entities": [[45, 71, "Frequency"]]}], [5305, "Mean percent blood glucose reduction of gliclazide in presence and absence of curcumin in rabbits (n=6) Notes: Data expressed as mean \u00b1 standard deviation.", {"entities": [[13, 26, "Parameter"], [40, 50, "Drug"], [78, 86, "Herb name"]]}], [5306, "Statistically significant when compared with gliclazide control.", {"entities": [[45, 55, "Drug"]]}], [5307, "Abbreviations: MDT, multiple-dose treatment; SDT, single-dose treatment.", {"entities": [[45, 72, "Frequency"]]}], [5308, "Effect of curcumin on glucose insulin homeostasis of gliclazide in normal rats (n=6) Notes: Data expressed as mean \u00b1 standard deviation.", {"entities": [[10, 18, "Herb name"], [53, 63, "Drug"]]}], [5309, "Calculated by homeostasis model assessment.", {"entities": []}], [5310, "Abbreviations: MDT, multiple-dose treatment; SDT, single-dose treatment.", {"entities": [[45, 71, "Frequency"]]}], [5311, "Effect of curcumin on glucose insulin homeostasis of gliclazide in diabetic rats (n=6) Notes: Data expressed as mean \u00b1 SD.", {"entities": [[10, 18, "Herb name"], [53, 63, "Drug"]]}], [5312, "Calculated by homeostasis model assessment.", {"entities": []}], [5313, "Abbreviations: MDT, multiple-dose treatment; SD, standard deviation; SDT, single-dose treatment.", {"entities": [[69, 95, "Frequency"]]}], [5314, "Effect of curcumin on glucose insulin homeostasis of gliclazide in rabbits (n=6) Notes: Data expressed as mean \u00b1 standard deviation.", {"entities": [[10, 18, "Herb name"], [53, 63, "Drug"]]}], [5315, "Calculated by homeostasis model assessment.", {"entities": []}], [5316, "Abbreviations: MDT, multiple-dose treatment; SD, standard deviation; SDT, single-dose treatment.", {"entities": [[69, 96, "Frequency"]]}], [5317, "Mean pharmacokinetic parameters of gliclazide before and after administration of curcumin in rabbits (n=6) Note: Data expressed as mean \u00b1 standard deviation.", {"entities": [[35, 45, "Drug"], [81, 89, "Herb name"]]}], [5318, "Abbreviations: AUC, area under the concentration time curve; AUMC, area under first moment curve; CL, clearance; C", {"entities": [[15, 59, "Parameter"], [61, 96, "Parameter"], [98, 111, "Parameter"]]}], [5319, "Academic Editor: William C. S. Cho  Background.", {"entities": []}], [5320, "Carbamazepine (CBZ) is a first-line antiepileptic drug which may be prone to drug interactions.", {"entities": [[0, 19, "Drug"], [36, 54, "Drug"]]}], [5321, "Systematic review of herb- and food-drug interactions on CBZ is warranted to provide guidance for medical professionals when prescribing CBZ.", {"entities": []}], [5322, "Method.", {"entities": []}], [5323, "A systematic review was conducted on six English databases and four Chinese databases.", {"entities": [[68, 75, "Ethnic group"]]}], [5324, "Results.", {"entities": []}], [5325, "196 out of 3179 articles fulfilled inclusion criteria, of which 74 articles were reviewed and 33 herbal products/dietary supplement/food interacting with CBZ were identified.", {"entities": [[154, 157, "Drug"]]}], [5326, "No fatal or severe interactions were documented.", {"entities": []}], [5327, "The majority of the interactions were pharmacokinetic-based (80%).", {"entities": []}], [5328, "Traditional Chinese medicine accounted for most of the interactions (n = 17), followed by food (n = 10), dietary supplements (n = 3), and other herbs/botanicals (n = 3).", {"entities": [[12, 19, "Ethnic group"]]}], [5329, "Coadministration of 11 and 12 of the studied herbal products/dietary supplement/food significantly decreased or increased the plasma concentrations of CBZ.", {"entities": [[151, 154, "Drug"]]}], [5330, "Regarding pharmacodynamic interaction, Xiao-yao-san, melatonin, and alcohol increased the side effects of CBZ while caffeine lowered the antiepileptic efficacy of CBZ.", {"entities": [[39, 51, "Herb name"], [90, 102, "Pathology"], [106, 109, "Drug"], [116, 124, "Herb name"], [163, 166, "Drug"]]}], [5331, "Conclusion.", {"entities": []}], [5332, "This review provides a comprehensive summary of the documented interactions between CBZ and herbal products/food/dietary supplements which assists healthcare professionals to identify potential herb-drug and food-drug interactions, thereby preventing potential adverse events and improving patients' therapeutic outcomes when prescribing CBZ.", {"entities": [[84, 87, "Drug"], [261, 275, "Pathology"], [290, 298, "Pathology"], [338, 341, "Drug"]]}], [5333, "Introduced in 1960s, carbamazepine (CBZ) remains as one of the most commonly prescribed antiepileptic drugs worldwide and has established efficacy for the treatment of partial seizures, generalized tonic-clonic seizures, trigeminal neuralgia, and bipolar disorders [1\u20136].", {"entities": [[21, 40, "Drug"], [88, 107, "Drug"], [168, 184, "Pathology"], [186, 219, "Pathology"], [221, 241, "Pathology"], [247, 264, "Pathology"]]}], [5334, "Despite its clinical popularity, CBZ possesses several pharmacokinetic properties which make it prone to interaction with coadministered substances, including drugs, herbal products, and food [7].", {"entities": [[33, 36, "Drug"]]}], [5335, "CBZ is a potent inducer of CYP450 system and is subject to autoinduction.", {"entities": [[0, 3, "Drug"], [27, 33, "Target"]]}], [5336, "Its metabolism is exclusively hepatic and catalyzed by various enzymes including CYPs, UGTs, and SULTs [8].", {"entities": [[81, 86, "Target"], [87, 91, "Target"], [97, 102, "Target"]]}], [5337, "CYP3A4 is the most important enzyme involved in the metabolism of CBZ as it leads to the formation of the active metabolite CBZ 10,11-epoxide, which appears to contribute to the toxicity and efficacy of CBZ [9, 10].", {"entities": [[66, 69, "Drug"], [124, 141, "Drug"], [203, 206, "Drug"]]}], [5338, "Furthermore, CBZ has a considerably narrow therapeutic index of 2-3 while there is a wide interindividual variation in tolerable doses and blood levels, making therapeutic drug monitoring and slow titration necessary [11, 12].", {"entities": [[13, 16, "Drug"]]}], [5339, "Many side effects associated with CBZ are concentration-related.", {"entities": [[5, 17, "Pathology"], [34, 37, "Drug"]]}], [5340, "Nausea, vertigo, dizziness, and blurred vision are examples of CBZ adverse effects which mostly are mild, transient, and reversible if the dosage is reduced or if initiation of treatment is gradual [13].", {"entities": [[0, 6, "Pathology"], [8, 15, "Pathology"], [17, 26, "Pathology"], [32, 46, "Pathology"], [63, 66, "Drug"], [67, 82, "Pathology"]]}], [5341, "Signs of toxicity generally occur at plasma CBZ concentrations in excess of 10 to 12\u2009mg/L, with diplopia, nystagmus, and aplastic anemia being the most characteristic ones [11].", {"entities": [[44, 47, "Drug"], [76, 89, "Amount"], [96, 104, "Pathology"], [106, 115, "Pathology"], [121, 136, "Pathology"]]}], [5342, "Fatal cases of CBZ overdose were also recorded where patients were manifested with cardiac arrhythmias, abnormal movements, and seizures [14].", {"entities": [[15, 18, "Drug"], [53, 61, "Pathology"], [83, 102, "Pathology"], [104, 122, "Pathology"], [128, 136, "Pathology"]]}], [5343, "The occurrence of CBZ overdose is usually accidental, and in most times it is secondary to the coadministration of other substances [15\u201320].", {"entities": [[18, 21, "Drug"]]}], [5344, "Since antiepileptic regimens are normally given on a long-term basis, the opportunity of a clinical significant interaction between CBZ and coadministered substances is considerably high.", {"entities": [[132, 135, "Drug"]]}], [5345, "Herbal medicines, dietary supplements, and food may interact with CBZ pharmacokinetically and/or pharmacodynamically which leads to potential clinical consequences.", {"entities": [[66, 69, "Drug"]]}], [5346, "One of the contributing factors towards increasing incidence of herb-drug interaction is the increased popularity of herbal medicines [21].", {"entities": []}], [5348, "In China, integrated medicine is a common practice where Western and traditional Chinese medicines are prescribed concurrently for the treatment of epilepsy [28].", {"entities": []}], [5349, "Therefore, the opportunity of patients taking CBZ with herbal/dietary supplements is high, and it is necessary to address the safety issues of such combinational use.", {"entities": [[82, 89, "Ethnic group"]]}], [5350, "When making clinical decisions on the use of herbal or dietary supplements, the review article is one of the major information sources for healthcare professionals [29].", {"entities": []}], [5351, "In view of this, we tried to identify existing review articles that (1) summarized all the reports and studies on the pharmacokinetic and pharmacodynamic interactions of CBZ with herbs, dietary supplements, and food and (2) provided recommendations on their combinational use.", {"entities": [[170, 173, "Drug"]]}], [5352, "It was found that there is a lack of well-conducted systematic review on CBZ and its herb, food, and dietary supplement interactions.", {"entities": [[73, 76, "Drug"]]}], [5353, "The searching strategy adopted by these reviews is not comprehensive enough to identify all the relevant articles.", {"entities": []}], [5354, "Most of these reviews use general terms such as \u201cherb-drug interaction\u201d as searching keywords and do not focus on one particular drug (e.g., CBZ) [30\u201333].", {"entities": [[141, 144, "Drug"]]}], [5355, "This nondrug-specific searching method may result in missing CBZ-relevant papers if the paper does not contain the phrase of \u201cherb-drug interaction\u201d.", {"entities": [[61, 64, "Drug"]]}], [5356, "Besides, there is no single review that covers the interactions between CBZ and all the three aspects of herb, food, and dietary supplement.", {"entities": [[72, 75, "Drug"]]}], [5357, "A systematic review is warranted to provide guidance for healthcare professions when prescribing and monitoring patients taking CBZ.", {"entities": [[128, 131, "Drug"]]}], [5358, "From the review articles that report herb-drug interactions, we can see that herb-drug interactions are often less systematically documented and less familiar to medical practitioners compared to drug-drug interactions.", {"entities": []}], [5359, "The nonstandardized naming of herbals with several confusing generic names together with an unfamiliar Latin name may make it difficult for medical professionals to anticipate and monitor herb-drug interaction [34].", {"entities": []}], [5360, "Furthermore, most herbal formulas (especially traditional Chinese medicine, TCM) contain multiple herbs, making it often impossible to know which herbs and at what doses they are present.", {"entities": [[58, 65, "Ethnic group"]]}], [5361, "In view of all the constraints of the existing literature, a comprehensive systematic review focusing on CBZ and overcoming the mentioned hurdles is warranted for healthcare professionals to make proper decisions.", {"entities": [[105, 108, "Drug"]]}], [5362, "In this current report, we conducted a systematic review on interactions between CBZ and herbs, dietary supplements, and food, summarizing the scientific evidence for such interactions and providing recommendations for the combinational use.", {"entities": [[81, 84, "Drug"]]}], [5363, "In addition to the usual databases (e.g., Medline and Embase), we also included several Chinese databases to identify reports of interactions between CBZ and TCM which are written in Chinese.", {"entities": [[88, 95, "Ethnic group"], [150, 153, "Drug"]]}], [5364, "The aim of this review is to provide a clear and systematic presentation of herb and food interactions with CBZ to alert and provide guidance for medical professionals when prescribing CBZ.", {"entities": [[108, 111, "Drug"], [185, 188, "Drug"]]}], [5365, "A computer-based search of the following English databases was conducted: AMED (1985\u2013Oct.", {"entities": []}], [5366, "2012), CINAHL Plus (1937\u2013Oct.", {"entities": []}], [5367, "2012), Cochrane Database of Systematic Reviews (2005\u2013Dec.", {"entities": []}], [5368, "2011), CENTRAL (Oct. 2012), Embase (1947\u2013Oct.", {"entities": []}], [5369, "2012), Medline (1946\u2013Oct.", {"entities": []}], [5370, "2012), and SciFinder Scholar (1907\u2013Oct.", {"entities": []}], [5371, "2012).", {"entities": []}], [5372, "The keyword search terms for carbamazepine (\u201cCarbamazepine\u201d, \u201cTegretol\u201d, \u201cTegretol XR\u201d, \u201cG-32883\u201d, \u201c5H-Dibenz[b,f]azepine-5-carboxamide\u201d) were combined, using the combination term AND, with a comprehensive list of keywords and MeSH search terms for herbs, food, and dietary supplements (Table 1).", {"entities": [[29, 42, "Drug"], [45, 58, "Drug"], [62, 70, "Drug"], [74, 85, "Drug"], [112, 135, "Drug"]]}], [5373, "Such search list was refined to include most of the relevant articles.", {"entities": []}], [5374, "No language restriction was imposed during the search, but non-English articles were included only if they contained an English abstract with sufficient information.", {"entities": []}], [5375, "As defined by the Dietary Supplement Health and Education Act of 1994 (DSHEA), \u201cdietary supplement\u201d refers to any dietary products containing one or more of the following ingredients: vitamin, mineral, herb or other botanical, amino acid, and a dietary substance for use by man to supplement the diet by increasing the total dietary intake.", {"entities": []}], [5376, "In the current review, we separated \u201cherb or other botanical\u201d out and categorized this group as \u201cherbs\u201d while the remainings were referred to as \u201cdietary supplement\u201d.", {"entities": []}], [5377, "The third category is \u201cfood\u201d which includes any specific traditional food/fruit products or beverages.", {"entities": []}], [5378, "Paper containing only a general term of \u201cfood\u201d without specifying any particular food item will be excluded.", {"entities": []}], [5379, "In addition to the English databases, four Chinese databases had been searched, including Chinese BioMedical Literature Database (1978\u2013Oct.", {"entities": [[43, 50, "Ethnic group"], [90, 97, "Ethnic group"]]}], [5380, "2012), China Journal Net (1915\u2013Oct.", {"entities": []}], [5381, "2012), Traditional Chinese Medical Database System (1984\u2013Oct.", {"entities": [[19, 26, "Ethnic group"]]}], [5382, "2012), and Chinese Medical Academic Conference Database (1994\u2013Oct.", {"entities": [[11, 18, "Ethnic group"]]}], [5383, "2012).", {"entities": []}], [5384, "The MeSH headings and keywords used for the search were carbamazepine (Chinese name, Chinese common names, and chemical names) in combination with the Chinese equivalent terms of \u201cinteraction\u201d, \u201cChinese herbal medicines\u201d, and \u201cChinese and Western medicines\u201d (\u201cjie he\u201d, \u201cxiang hu zuo yong\u201d, and \u201czong yao\u201d, \u201czong cao yao\u201d, \u201czong xi yi\u201d).", {"entities": [[56, 69, "Drug"], [85, 92, "Ethnic group"], [151, 158, "Ethnic group"], [195, 202, "Ethnic group"], [227, 234, "Ethnic group"], [260, 266, "Herb name"], [270, 287, "Herb name"], [295, 303, "Herb name"], [307, 319, "Herb name"], [323, 333, "Herb name"]]}], [5385, "The bibliographies of every retrieved article were checked for any additional pertinent studies.", {"entities": []}], [5386, "The selection of relevant reports and evaluation of article eligibility was carried out by two reviewers independently (Fong and Gao).", {"entities": []}], [5387, "Articles were considered eligible for evaluation if they contained original data involving herb, food, or dietary supplement interactions with CBZ without restriction for in vitro studies, animal studies, clinical studies observational studies, or review articles.", {"entities": [[143, 146, "Drug"], [174, 187, "Study"], [189, 203, "Study"], [205, 243, "Study"]]}], [5388, "Any discrepancies were resolved by a third author (Zuo).", {"entities": []}], [5389, "All relevant literature fulfilling our inclusion criteria were extracted and complied, except for the interacting pairs that have beneficial effects.", {"entities": []}], [5390, "We grouped the natural products into four categories: TCM, other herb/botanical, vitamin/mineral/amino acid, and food.", {"entities": []}], [5391, "We categorized the mechanisms for pairs of interactions into three types: pharmacokinetics, pharmacodynamics, and both.", {"entities": []}], [5392, "In order to standardize the names of the included TCMs, the official compendium Pharmacopoeia of the People's Republic of China 2010 (Chinese Pharmacopoeia) was consulted and their Latin names (for herbs) or Chinese pinyin names (for herbal formulae) were presented.", {"entities": [[134, 141, "Ethnic group"], [208, 215, "Ethnic group"]]}], [5393, "A total of 3179 articles was initially found through database searches while an addition of 14 articles were obtained from scrutinizing the bibliographies of relevant literatures.", {"entities": []}], [5394, "196 articles fulfilling the inclusion criteria were selected for further evaluation with perfect agreement between the two authors.", {"entities": []}], [5395, "Finally, seventy-four articles with full text, including 40 original articles and 34 review articles, were qualified to undergo an in-depth review (Figure 1); a total of 33 unique herbal products/dietary supplement/food-CBZ interacting pairs were identified from these articles.", {"entities": [[220, 223, "Drug"]]}], [5396, "Summaries of the in vitro, animal, and clinical studies to retrieve information about interactions between CBZ and herbal products/dietary supplement/food for the original studies are listed in Tables 2 and 3, respectively.", {"entities": [[17, 55, "Study"], [107, 110, "Drug"]]}], [5397, "Among the original studies (n = 40), most are animal (n = 24) and human (n = 14) studies, with 2 mechanistic in vitro/ex vivo studies.", {"entities": [[46, 133, "Study"]]}], [5398, "Regarding the studied types of interaction, the majority (n = 32) are pharmacokinetic interactions followed by both pharmacokinetic and pharmacodynamic interactions (n = 6) and pharmacodynamic interactions (n = 2).", {"entities": []}], [5399, "Nineteen of the included original articles documented the interactions between 20 different herbal products and CBZ, where TCMs in the form of crude drug, extract, or single TCM compound were the major studied herbal products (n = 17).", {"entities": [[112, 115, "Drug"]]}], [5400, "Among the 17 documented pharmacokinetic interactions between CBZ and TCMs, Cassia auriculata Linn., piperine (an active compound in Piper longum Linn.", {"entities": [[61, 64, "Drug"], [75, 97, "Herb name"], [100, 108, "Herb name"], [132, 149, "Herb name"]]}], [5401, "), Platycodonis Radix, and Polygonum cuspidatum were demonstrated to increase the plasma level/oral bioavailability of CBZ through decreasing the metabolism of CBZ or improving gastric solubility of CBZ [37, 47\u201349].", {"entities": [[3, 21, "Herb name"], [27, 47, "Herb name"], [100, 115, "Parameter"], [119, 122, "Drug"], [160, 163, "Drug"], [199, 202, "Drug"]]}], [5402, "On the other hand, ginkgo biloba, Hu-gan-ning pian, Jia-wei-xiao-yao-san, and Xiao-yao-san decreased the plasma level/oral bioavailbaility of CBZ through increasing the metabolism of CBZ via CYP3A4 induction [40, 44, 53].", {"entities": [[19, 32, "Herb name"], [34, 50, "Herb name"], [52, 72, "Herb name"], [78, 90, "Herb name"], [123, 138, "Parameter"], [142, 145, "Drug"], [183, 186, "Drug"], [191, 197, "Target"]]}], [5403, "Ginsenoside (an active compound in ginseng) was also shown to activate CYP3A4 activity in vitro and thereby increased CBZ metabolism [39].", {"entities": [[0, 11, "Herb name"], [35, 42, "Herb name"], [71, 77, "Target"], [118, 121, "Drug"]]}], [5404, "Xiao-qing-long-tang and Xiao-cha-hu-tang delayed the time for CBZ to reach peak plasma concentration through decreasing gastric emptying rate [38, 50], whereas Paeoniae Radix decreased the T   A total of twenty-one original literatures covering 13 different dietary supplement/food-CBZ interaction studies were recorded in the current review.", {"entities": [[0, 19, "Herb name"], [24, 40, "Herb name"], [62, 65, "Drug"], [160, 174, "Herb name"], [282, 285, "Drug"]]}], [5405, "These included beverages (n = 7), food substances (n = 3), and dietary supplements (n = 3).", {"entities": []}], [5406, "Alcohol did not affect the pharmacokinetics of CBZ in healthy volunteers but increased the oral bioavailability and decreased the metabolism of CBZ in alcoholics [55].", {"entities": [[47, 50, "Drug"], [54, 61, "Pathology"], [91, 111, "Parameter"], [144, 147, "Drug"]]}], [5407, "Alcohol-CBZ combination also had an additive neurotoxicity in animals [54].", {"entities": [[8, 11, "Drug"], [45, 58, "Pathology"]]}], [5408, "Another beverage Coca-Cola increased the oral bioavailability of CBZ in a clinical study which may be due to the enhanced dissolution of CBZ by its acidity [60].", {"entities": [[41, 61, "Parameter"], [65, 68, "Drug"], [74, 88, "Study"], [137, 140, "Drug"]]}], [5409, "Caffeine decreased the oral bioavailability as well as the antiepileptic efficacy of CBZ in human and animal studies, respectively [57\u201359].", {"entities": [[0, 8, "Herb name"], [23, 43, "Parameter"], [85, 88, "Drug"], [92, 116, "Study"]]}], [5410, "Pharmacokinetic interactions between food substances and CBZ were recorded: butter increased while soy bean decreased the oral bioavailability of CBZ in animal study.", {"entities": [[57, 60, "Drug"], [99, 107, "Herb name"], [122, 142, "Parameter"], [146, 149, "Drug"], [153, 165, "Study"]]}], [5411, "The former might improve dissolution of CBZ while the later might decrease the gastric emptying and enhance the metabolism of CBZ [56, 73].", {"entities": [[40, 43, "Drug"], [79, 95, "Parameter"], [126, 129, "Drug"]]}], [5412, "Although honey was shown to decrease the oral bioavailability of CBZ in rabbits, it had no effect on the pharmacokinetic parameters of CBZ in human [63\u201365].", {"entities": [[41, 61, "Parameter"], [65, 68, "Drug"], [135, 138, "Drug"]]}], [5413, "As regards the dietary supplement-CBZ interactions, folinic acid did not alter the plasma level of CBZ in rats [61] while nicotinamide increased CBZ plasma level and decreased its clearance in two children with epilepsy [70].", {"entities": [[34, 37, "Drug"], [52, 64, "Drug"], [99, 102, "Drug"], [122, 134, "Drug"], [145, 148, "Drug"], [180, 189, "Parameter"], [193, 205, "Cohort"], [211, 219, "Pathology"]]}], [5414, "Melatonin did not interact with CBZ pharmacokinetically but potentiated the antiepileptic activity of CBZ in both animal and human studies [67\u201369].", {"entities": [[0, 9, "Herb name"], [32, 35, "Drug"], [102, 105, "Drug"], [114, 140, "Study"]]}], [5415, "Patients on antiepileptic therapy are usually on a long-term basis.", {"entities": [[0, 8, "Pathology"], [12, 33, "Drug"]]}], [5416, "Several antiepileptic drugs require therapeutic drug monitoring and are prone to drug interactions which may lead to serious consequences.", {"entities": [[8, 27, "Drug"], [117, 137, "Pathology"]]}], [5417, "CBZ is one of the antiepileptic drugs that are on the \u201cwatch-list\u201d.", {"entities": [[0, 3, "Drug"], [18, 37, "Drug"]]}], [5418, "With the increased popularity of herbal products as well as dietary supplement, prescribers may need to be aware of the potential herb-drug or food-drug interactions when prescribing and monitoring CBZ therapy.", {"entities": [[198, 201, "Drug"]]}], [5419, "In this study, we had conducted a systematic review and summarized the up-to-date evidence of the interactions between CBZ and herbal products/food/dietary supplements that have been reported in primary literature.", {"entities": [[119, 122, "Drug"]]}], [5420, "In order to achieve a comprehensive literature search, a total of eleven databases were searched.", {"entities": []}], [5421, "These included two conventional databases (EMBASE and MEDLINE), five other English databases (AMED, CINAHL Plus, Cochrane Database of Systematic Reviews, CENTRAL, and SciFinder Scholar) four Chinese databases.", {"entities": [[191, 198, "Ethnic group"]]}], [5422, "We had also consulted some relative tertiary literatures including Stockley's Herbal Medicines Interactions and Natural Medicines Comprehensive Database in case of any additional information.", {"entities": []}], [5423, "The keywords used for the search were optimized and refined in an attempt to include most of the relevant literatures (Table 1).", {"entities": []}], [5424, "We suggest that this search strategy could be applied on the search of other drugs\u2014herb/food/dietary supplement interactions by substituting the drug name.", {"entities": []}], [5425, "It is interesting to note that, although a total of 100 clinical trials or case reports involving the concurrent use of TCMs with CBZ were identified from the Chinese databases, more than 90 of them focus on the beneficial effects or the antagonism of the side effects of CBZ of such combinational use and fallout from our inclusion criteria.", {"entities": [[130, 133, "Drug"], [159, 166, "Ethnic group"], [256, 268, "Pathology"], [272, 275, "Drug"]]}], [5426, "There were altogether 33 different herbal products/food/dietary supplements identified from literature in which their effects on CBZ were studied.", {"entities": [[129, 132, "Drug"]]}], [5427, "These included 17 TCMs, 3 other herbs/botanicals, 10 foods, and 3 dietary supplements.", {"entities": []}], [5428, "The large number of studies involving TCM-drug interactions implies that TCM warrants special attention when coadministered with CBZ.", {"entities": [[129, 132, "Drug"]]}], [5429, "However, the nonstandardized naming and multiple constituents of TCMs often confuse prescribers when anticipating such interaction.", {"entities": []}], [5430, "After extracting the herbal names from the original articles, we standardized the herbal names in Latin according to the Chinese Pharmacopoeia 2010 (Table 2).", {"entities": []}], [5431, "In order to raise the prescribers' awareness to the different names of the TCM products, we also provide the synonyms of the included TCMs in Table 4.", {"entities": []}], [5432, "For herbal formulae, their composition and content were also listed (Table 5).", {"entities": []}], [5433, "No fatal or severe interactions between CBZ and herbal products/food/dietary supplement were found from the literature search.", {"entities": [[40, 43, "Drug"]]}], [5434, "Majority of the studied interactions were pharmacokinetic-based, where the oral bioavailability or plasma level of CBZ was significantly altered by the natural products (Table 6).", {"entities": [[75, 95, "Parameter"], [115, 118, "Drug"]]}], [5435, "In most cases the authors suggested that the increase in plasma CBZ concentrations was due to the inhibition of CYP3A4-mediated metabolism of CBZ by these natural products.", {"entities": [[64, 67, "Drug"], [112, 118, "Target"], [142, 145, "Drug"]]}], [5436, "Since CBZ has a narrow therapeutic index, and the side effects of CBZ are concentration-dependent, the increment of CBZ plasma level may result in serious adverse effects such as diplopia and nystagmus [75].", {"entities": [[6, 9, "Drug"], [50, 62, "Pathology"], [66, 69, "Drug"], [116, 119, "Drug"], [147, 162, "Pathology"], [179, 187, "Pathology"], [192, 201, "Pathology"]]}], [5437, "Therefore, it is advised to avoid the consumption of the food/herbal products which could elevate the CBZ plasma level as listed in Table 6.", {"entities": [[102, 105, "Drug"]]}], [5438, "On the other hand, nine natural products diminished the oral bioavailability/plasma level of CBZ significantly with four of them having clinical evidences: Ispaghula husk, Xiao-yao-san, Jia-wei-xiao-yao san, and caffeine (Table 4).", {"entities": [[56, 76, "Parameter"], [93, 96, "Drug"], [156, 170, "Herb name"], [172, 184, "Herb name"], [186, 206, "Herb name"], [212, 220, "Herb name"]]}], [5439, "Multiple mechanisms may contribute to the decrease of CBZ plasma level by these natural products, one of which is the increase in the metabolism of CBZ by induction of CYP3A4 (by Jia-wei-xiao-yao-san, ginkgo biloba, and soybean) and mixed function oxidase (by caffeine) activity.", {"entities": [[54, 57, "Drug"], [148, 151, "Drug"], [168, 174, "Target"], [179, 199, "Herb name"], [201, 214, "Herb name"], [220, 227, "Herb name"], [260, 268, "Herb name"]]}], [5440, "Ispaghula husk, septilin, soybean and Xiao-cha-hu-tang reduced the plasma level of CBZ by affecting its gastric absorption.", {"entities": [[0, 14, "Herb name"], [16, 24, "Herb name"], [26, 33, "Herb name"], [38, 54, "Herb name"], [83, 86, "Drug"]]}], [5441, "Coadministration of CBZ with herbal products/food which are enzyme inducers entails the possibility of a clinically significant drug interaction.", {"entities": [[20, 23, "Drug"]]}], [5442, "The reduction of CBZ plasma level may imply that less CBZ is present in the target site to assert its antiepileptic activity; a worsened seizure control may follow unless the dosage of CBZ is adjusted accordingly [76].", {"entities": [[17, 20, "Drug"], [54, 57, "Drug"], [185, 188, "Drug"]]}], [5443, "Since enzyme induction is a reversible phenomenon, particular caution is required when an enzyme-inducing agent is discontinued because the serum concentration of concurrently administered CBZ may rebound to potentially toxic levels.", {"entities": [[189, 192, "Drug"]]}], [5444, "Patients are therefore not recommended to take the food/herbal products which could decrease the CBZ plasma level listed in Table 6.", {"entities": [[0, 8, "Pathology"], [97, 100, "Drug"]]}], [5445, "Furthermore, CBZ has poor water solubility; consequently, its absorption time and extent are thus easily affected by coadministration of substances that may alter gastric conditions.", {"entities": [[13, 16, "Drug"]]}], [5446, "For example, Xiao-cha-hu-tang and Xiao-qing-long-tang delayed the time for CBZ to reach peak plasma concentration by decreasing the gastric emptying rate.", {"entities": [[13, 29, "Herb name"], [34, 53, "Herb name"], [75, 78, "Drug"]]}], [5447, "By improving the dissolution of CBZ, Paeoniae Radix allowed faster absorption while butter and Platycodonis Radix increased the extent absorption of CBZ.", {"entities": [[32, 35, "Drug"], [37, 51, "Herb name"], [95, 113, "Drug"], [149, 152, "Drug"]]}], [5454, "Compared to pharmacokinetic interactions, there were fewer studies reporting pharmacodynamic-based interactions between herbal products/food/dietary supplements and CBZ.", {"entities": [[165, 168, "Drug"]]}], [5455, "Pharmacodynamic interaction refers to the alteration of efficacy (antiepileptic activity) and/or the adverse effects of CBZ in the presence of natural products.", {"entities": [[101, 116, "Pathology"], [120, 123, "Drug"]]}], [5456, "Melatonin and Acorus calamus Linn.", {"entities": [[0, 9, "Herb name"], [14, 33, "Herb name"]]}], [5457, "potentiated the anticonvulsant activity of CBZ but had no effect on the plasma levels of CBZ in animal studies so such interactions are mainly pharmacodynamic-based.", {"entities": [[43, 46, "Drug"], [89, 92, "Drug"], [96, 110, "Study"]]}], [5458, "Despite the apparent efficacy-boosting effect, it is best to avoid the use of melatonin or Acorus calamus Linn.", {"entities": [[78, 87, "Herb name"]]}], [5459, "with CBZ until there further clinical evidence on the safe usage of such combination.", {"entities": [[5, 8, "Drug"]]}], [5460, "Caffeine, on the other hand, decreased the plasma level of CBZ in human while decreased the antiepileptic efficacy of CBZ in mouse.", {"entities": [[0, 8, "Herb name"], [59, 62, "Drug"], [118, 121, "Drug"]]}], [5461, "Although there are no clinical studies on whether the antiepileptic activity of CBZ is influenced by caffeine, advice should be given to patients on CBZ therapy not to take caffeine.", {"entities": [[22, 38, "Study"], [80, 83, "Drug"], [101, 109, "Herb name"], [137, 145, "Pathology"], [149, 152, "Drug"], [173, 181, "Herb name"]]}], [5462, "Caution should also be paid for beverage containing alcohol.", {"entities": []}], [5463, "Alcohol was demonstrated to have additive neurotoxicity with CBZ in mouse, including a potentiated motor incoordination and loss of righting reflex.", {"entities": [[42, 55, "Pathology"], [61, 64, "Drug"], [87, 147, "Pathology"]]}], [5464, "Together with the fact that alcohol caused an increase in the oral bioavailability of CBZ in alcoholics, it is advised not to consume any alcohol while patients take CBZ.", {"entities": [[62, 82, "Parameter"], [86, 89, "Drug"], [166, 169, "Drug"]]}], [5465, "In a randomized double-blinded control trial, Xiao-yao-san increased the incidence of CBZ-related side effects including dizziness, blurred vision, skin rash, and nausea in patients with major depression or bipolar disorder.", {"entities": [[3, 44, "Study"], [46, 58, "Herb name"], [86, 89, "Drug"], [121, 130, "Pathology"], [132, 146, "Pathology"], [148, 157, "Pathology"], [163, 169, "Pathology"], [187, 203, "Pathology"], [207, 223, "Pathology"]]}], [5466, "Though the mechanism is unknown, patients should be warned about the potential risks when taking this TCM with CBZ.", {"entities": [[111, 114, "Drug"]]}], [5467, "In this study, the documented evidence of interactions between CBZ and herbal products/food/dietary supplements was systematically reviewed from the published literature.", {"entities": [[63, 66, "Drug"]]}], [5468, "The intention of this review was to provide guidance to assist healthcare professionals in identifying patients taking CBZ that are more susceptible to these interactions and make proper actions.", {"entities": [[119, 122, "Drug"]]}], [5469, "A total of 33 unique herbal products/dietary supplement/food-CBZ interacting pairs were identified from this review.", {"entities": [[61, 64, "Drug"]]}], [5470, "Considering the popularity and frequent usage of both CBZ (as first-line epilepsy regimen) and herbal products/food/dietary supplements, the number of studied interactions is considerably small.", {"entities": [[54, 57, "Drug"]]}], [5471, "More evidence and reports are needed from research studies and, preferably, from adverse report system in clinical setting.", {"entities": []}], [5472, "Of course, the importance of therapeutic drug monitoring of CBZ is again emphasized while most pairs of natural products-CBZ interactions remained unknown.", {"entities": [[60, 63, "Drug"], [121, 124, "Drug"]]}], [5473, "On the other hand, the amount of documented CBZ-herbal products/food/dietary supplements interactions might be underreported in this review due to several limitations, including publication bias and language restrictions.", {"entities": [[44, 47, "Drug"]]}], [5474, "We had attempted to reduce language bias by including four evidence-based Chinese databases.", {"entities": [[74, 81, "Ethnic group"]]}], [5475, "However, the evidence regarding complementary alternative medicine or folk therapies, which were published in other languages (e.g., Japanese, Indian, and French), might be missing.", {"entities": [[133, 141, "Ethnic group"], [143, 149, "Ethnic group"], [155, 161, "Ethnic group"]]}], [5476, "Another limitation of this review was that it included all relevant information identified in the literature, regardless of the evidence types or quality of the studies.", {"entities": []}], [5477, "Such arrangement aimed to gather as much useful information regarding studies on interactions between CBZ and the natural products.", {"entities": [[102, 105, "Drug"]]}], [5478, "Although species differences existed, human pharmacokinetic parameters and pharmacodynamic behavior could be successfully extrapolated from animal studies [80, 81].", {"entities": [[140, 154, "Study"]]}], [5479, "Therefore, the data from animal studies are considered to be valuable, and hence the results should not be neglected.", {"entities": []}], [5480, "This review provides a structured summary of the evidence of the documented interactions between CBZ and herbal products/food/dietary supplements.", {"entities": [[97, 100, "Drug"]]}], [5481, "These findings should be helpful for healthcare professionals to identify potential herb-drug and food-drug interactions while prescribing CBZ and would also facilitate them to communicate these documented interactions to their patients, thus preventing potential adverse events and improving patients' therapeutic outcomes.", {"entities": [[139, 142, "Drug"]]}], [5482, "Grant from Hospital Authority of Hong Kong (Reference no.", {"entities": []}], [5483, "L/M (Q08-040) to HAHO(S)/P/45).", {"entities": []}], [5484, "Flow chart of literature search.", {"entities": []}], [5485, "Keyword and MeSH search terms for herbs, food, and dietary supplements.", {"entities": []}], [5486, "Summary of the included in vitro, animal, and clinical studies on interactions between carbamazepine and herbal products, dietary supplement, and food.", {"entities": [[24, 62, "Study"], [87, 100, "Drug"]]}], [5487, "*Types of herbal product: traditional Chinese medicines (TCM)/other herbal products (HP); N.D.: not determined by authors; N/A: not applicable.", {"entities": [[38, 45, "Ethnic group"]]}], [5488, "Summary of the included in vitro, animal and clinical studies on interactions between carbamazepine and dietary supplement/food.", {"entities": [[24, 61, "Study"], [86, 99, "Drug"]]}], [5489, "N.D.: not determined by authors.", {"entities": []}], [5490, "Synonyms of the included TCM products.", {"entities": []}], [5491, "Composition of individual herbs in the included herbal formulae.", {"entities": []}], [5492, "Pharmacokinetic and pharmacodynamic interactions of herbal products/food/dietary supplements with CBZ by direction of interactions.", {"entities": [[98, 101, "Drug"]]}], [5493, "(a) \u2009 \u2009*In alcoholics, not healthy volunteers; study type: human study (bold), animal study (regular).", {"entities": [[27, 34, "Pathology"], [59, 70, "Study"], [79, 91, "Study"]]}], [5494, "(b) \u2009 Study type: human study (bold), animal study (regular).", {"entities": [[18, 36, "Study"], [38, 60, "Study"]]}], [5495, "Edited by: Adolfo Andrade-Cetto, National Autonomous University of Mexico, Mexico Reviewed by: Thomas Efferth, University of Mainz, Germany; Daniel Shriner, National Human Genome Research Institute, USA This article was submitted to Ethnopharmacology, a section of the journal Frontiers in Pharmacology It is becoming increasingly evident that patients with diabetes do not rely only on prescription drugs for their disease management.", {"entities": []}], [5496, "The use of herbal medicines is one of the self-management practices adopted by these patients, often without the knowledge of their healthcare practitioners.", {"entities": []}], [5497, "This study assessed the potential for pharmacokinetic herb-drug interactions (HDIs) amongst Nigerian adult diabetic patients.", {"entities": [[92, 100, "Ethnic group"], [107, 115, "Pathology"]]}], [5498, "This was done through a literature analysis of the pharmacokinetic profile of their herbal medicines and prescription drugs, based on information obtained from 112 patients with type-2 diabetes attending two secondary health care facilities in Nigeria.", {"entities": [[160, 172, "Cohort"], [178, 193, "Pathology"]]}], [5499, "Fifty percent of the informants used herbal medicines alongside their prescription drugs.", {"entities": []}], [5500, "Worryingly, 60% of the patients taking herbal medicines did not know their identity, thus increasing the risk of unidentified HDIs.", {"entities": []}], [5501, "By comparing the pharmacokinetic profile of eight identified herbs taken by the patients for the management of diabetes against those of the prescription drugs, several scenarios of potential HDIs were identified and their clinical relevance is discussed.", {"entities": [[111, 119, "Pathology"]]}], [5502, "The lack of clinical predictors points toward cultural factors as the influence for herb use, making it more difficult to identify these patients and in turn monitor potential HDIs.", {"entities": []}], [5503, "In identifying these possible interactions, we have highlighted the need for healthcare professionals to promote a proactive monitoring of patients' use of herbal medicines.", {"entities": []}], [5504, "Herbal medicines are becoming an increasing component of Western pharmacotherapy mostly due to the perception that \u201cnatural\u201d means \u201csafe\u201d (Brantley et al., 2014).", {"entities": []}], [5505, "As a result, a large number of patients with diabetes use them alongside their prescription drugs in disease management (Arg\u00e1ez-L\u00f3pez et al., 2003; Kumar et al., 2006; Hasan et al., 2009); with evidence suggesting a higher use amongst those with more severe diabetic conditions (Nahin et al., 2012).", {"entities": [[45, 53, "Pathology"], [258, 266, "Pathology"]]}], [5506, "One reason for this might be because of the difficulty in attaining adequate glycaemic control in type-2 diabetic patients despite existing pharmacotherapy, due to the steady decline in beta cell function (Robertson et al., 2004).", {"entities": [[77, 86, "Parameter"], [98, 113, "Pathology"]]}], [5507, "Poor glycaemic control increases the risk of diabetic related complications ensuing in more complex treatment plans which the patients have to deal with for a long time.", {"entities": [[5, 14, "Parameter"], [45, 75, "Pathology"]]}], [5508, "This characteristic of the disease lends itself as a condition whose patients are likely to seek out alternative forms of treatment (Chang et al., 2007).", {"entities": []}], [5509, "Unfortunately, this high prevalence is accompanied by poor communication between patients and clinicians.", {"entities": []}], [5510, "In the US for instance, patients with diabetes were identified as the least likely to inform healthcare practitioners of their use of herbal medicines (Saydah and Eberhardt, 2006).", {"entities": [[38, 46, "Pathology"]]}], [5511, "With the use of herbal medicine becoming more widespread, a lot of focus has been given to evaluating them for possible herb-drug interactions (HDIs), particularly pharmacokinetic interactions since pharmacodynamic interactions are often easier to identify and monitor.", {"entities": []}], [5512, "Efforts have also been made to collate existing information about herbal medicines as a guide to healthcare practitioners, and as a means of forestalling potentially clinically relevant HDIs (Ulbricht et al., 2008; Williamson et al., 2013).", {"entities": []}], [5513, "These resources are however lacking in information about medicinal plants used in African countries, despite its proportionately high frequency of use.", {"entities": [[82, 89, "Ethnic group"]]}], [5514, "The implications of clinically relevant HDIs can have far-reaching effects for most African populations, such as Nigeria, with an inadequate healthcare system (Anyika, 2014).", {"entities": [[84, 91, "Ethnic group"]]}], [5515, "By anticipating potential toxicities or possible herb-drug interactions, clinically relevant HDIs with significant risks can be avoided.", {"entities": []}], [5516, "To address this issue, a fieldwork study to identify the herbal medicines used by diabetic patients in Nigeria in their disease management was carried out.", {"entities": [[25, 40, "Study"], [82, 90, "Pathology"]]}], [5517, "The objective of the study was to assess the potential for pharmacokinetic HDIs amongst this \u201cat risk\u201d group based on available information about herbal medicines and the pharmacokinetic profile of the prescribed drugs used by the patients.", {"entities": []}], [5518, "A fieldwork study was conducted in August and September 2012 in the Pharmacy departments of two secondary health care facilities\u2014the General hospital in Lagos Island and Central hospital in Benin City\u2014two urban cities in the southern part of Nigeria.", {"entities": [[2, 17, "Study"]]}], [5519, "The study-including the proposed questionnaire to be administered\u2014was approved by the ethics committee of UCL (Ethics Application 4124/001); and prior consent was also obtained from the ethics committee of both hospitals.", {"entities": []}], [5520, "During the study period, every prescription that was identified as having one or more oral hypoglycaemic drugs during the \u201cprescription assessment stage\u201d was assigned to the interviewer for drug dispensing and counseling and possible inclusion of the patient in the study.", {"entities": [[86, 110, "Drug"]]}], [5521, "Each patient was thereafter given a brief description of the study.", {"entities": []}], [5522, "However, only patients who gave their verbal consent to be asked additional questions relating to their use of herbal medicines, based on a semi-structured questionnaire were included.", {"entities": []}], [5523, "These questions were asked while drugs were being dispensed and medication counseling was given to the patients afterwards.", {"entities": []}], [5524, "Information obtained from the questionnaire include demographic background of respondents including age and sex, information on the identity of the herbs and prescription drugs used (where available) either for diabetes or other co-morbidities as well as the monthly cost of prescription.", {"entities": [[211, 219, "Pathology"]]}], [5525, "Herbal medicines as described in this study include the following: supplements containing extracts of medicinal plants, un-standardized herbal preparations from herbalists, herbal preparations made by the patients themselves using plant parts purchased in herbal markets or collected from their own gardens.", {"entities": []}], [5526, "No samples of herbal medicines were collected as part of the study.", {"entities": []}], [5527, "The identity of the herbal medicines used, were provided by the patients either as local names or its common name in English.", {"entities": []}], [5528, "Various literature sources were consulted to determine the botanical names of plants from their given local names.", {"entities": []}], [5529, "Verification of their local names were done by Mr. Ibrahim Muazzam, an ethnobotanist and staff of the department of medicinal plant research and traditional medicine, National Institute for Pharmaceutical Research and Development (NIPRD) and by staff of the Forestry Research Institute of Nigeria (FRIN) in Ibadan and assignment of the correct botanical names was done based on  Assessment of the potential HDIs was done by analysing the prescription drugs and herbal medicines used by the patients against published information about any known pharmacokinetic effects to identify possible overlapping effects that might pose a risk.", {"entities": []}], [5530, "The descriptive and inferential statistics to determine measures of frequency and relationship between variables were carried out using IBM SPSS statistical package (version 22, IBM U.S.A.).", {"entities": []}], [5531, "Chi square test was used to test the association of herb use with patients' background characteristics, such as gender, age groups, presence of co-morbidities, and cost of monthly prescription.", {"entities": []}], [5532, "A significant relationship between variables was identified if p < 0.05.", {"entities": []}], [5533, "A total number of 112 patients with type-2 diabetes, 37 from Central hospital Benin-city and 75 from General hospital Lagos gave their consent and were interviewed for the study.", {"entities": [[18, 30, "Cohort"], [36, 51, "Pathology"]]}], [5534, "A summary of the background characteristics of the interviewed patients is given in Table 1.", {"entities": []}], [5535, "Five age categories were created: < 30 years, 31\u201345 years, 46\u201360 years, 61\u201375 years, and >75 years.", {"entities": [[34, 44, "Age"], [46, 57, "Age"], [59, 70, "Age"], [72, 83, "Age"], [89, 98, "Age"]]}], [5536, "Most of the patients were aged between 61 and 75 years (50.9%), followed by those between 46 and 60 years (34.8%).", {"entities": [[26, 54, "Age"], [82, 105, "Age"]]}], [5537, "Tabular summary of data from patients with type-2 diabetes.", {"entities": [[43, 58, "Pathology"]]}], [5538, "Information about herb use in two patients was not given.", {"entities": []}], [5539, "Data on cost of prescription was not obtained from all the interviewed patients (\u00a31 \u2248 265 Naira, $1 \u2248 170 naira  More than 70% of the patients had one or more chronic co-morbidity alongside their diabetes, the most common of which was hypertension.", {"entities": [[196, 204, "Pathology"], [235, 247, "Pathology"]]}], [5540, "The other identified co-morbidities were arthritis, arteriosclerosis, hypercholesterolemia and neuropathy (Table 1).", {"entities": [[41, 50, "Pathology"], [52, 68, "Pathology"], [70, 90, "Pathology"], [95, 105, "Pathology"]]}], [5541, "Fifty percent of the patients took herbal medicines alongside their prescription drugs either for diabetes, for one of the co-morbidities or for the management of diabetes-related side effects, such as erectile dysfunction.", {"entities": [[98, 106, "Pathology"], [163, 192, "Pathology"], [202, 222, "Pathology"]]}], [5542, "Fourteen patients had recently discontinued their use of herbal medicines.", {"entities": []}], [5543, "For those who gave reasons, three said it was \u201cbased on advice by their doctor,\u201d two said it was \u201cdue to perceived side effects,\u201d and one patient was \u201cdisappointed at its lack of efficacy.\u201d Approximately 50% of all patients used herbal medicines alongside their prescription drugs, and this percentage was the same for both males and females.", {"entities": [[115, 127, "Pathology"], [324, 329, "Sex"], [334, 341, "Sex"]]}], [5544, "Almost 60% of those who used herbal medicines were older patients aged between 61 and 75 years (Table 1).", {"entities": [[66, 94, "Age"]]}], [5545, "This is possibly because the highest number of patients with type-2 diabetes fell within that age group.", {"entities": [[61, 76, "Pathology"]]}], [5546, "As such, there was no statistically significant association between age and herb use (x Given that the inherent characteristics of the individual (age and sex) were not a predictor of herb use, we hypothesized that the presence of one or more chronic co-morbidity as well as a high monthly prescription cost could be an incentive for patients to use herbal medicines as evidenced by the study carried out by Nahin et al.", {"entities": []}], [5547, "(2012).", {"entities": []}], [5548, "Although there were more herb users within the group of patients with two or more chronic co-morbid conditions than the group with only one or none at all, this relationship was not statistically significant (x In trying to understand the divergent relationship between number of co-morbidities and monthly cost of prescription with herb use, it was observed that the prescription cost was not necessarily dependent on the number of co-morbidities the patient was being treated for, but on the medications on the patient's prescription.", {"entities": []}], [5549, "For instance, a patient with only diabetes may have been prescribed gliclazide by his/her doctor, which is more expensive than other types of sulphonylureas.", {"entities": [[34, 42, "Pathology"], [68, 78, "Drug"], [142, 156, "Drug"]]}], [5550, "On the other hand, another patient having diabetes alongside other co-morbidities might be prescribed a cheaper sulphonylurea, such as glibenclamide as well as other non-expensive medications for their co-morbidities resulting in lower prescription costs.", {"entities": [[42, 50, "Pathology"], [112, 125, "Drug"], [135, 148, "Drug"]]}], [5551, "Thus, a patient with more co-morbidities may not necessarily have higher prescription costs.", {"entities": []}], [5552, "At the same time, based on the results of the study, patients with more drugs on their prescription due to co-morbidities or those with the need to spend more money on their prescription drugs were not more likely to use herbs than those without.", {"entities": []}], [5553, "As a result, the presence of diabetic complications wasn't identified as a predictor for herb use among patients with type-2 diabetes.", {"entities": [[29, 51, "Pathology"], [118, 133, "Pathology"]]}], [5554, "A summary of the drugs used in the pharmacological management of diabetes in the interviewed patients is given in Table 2.", {"entities": [[65, 73, "Pathology"]]}], [5555, "Eighty percent of the patients were prescribed more than one medication for their diabetes.", {"entities": [[82, 90, "Pathology"]]}], [5556, "This is in addition to the drugs prescribed for other existing co-morbidities.", {"entities": []}], [5557, "These results corroborate other studies that have shown inadequate blood glucose control with monotherapy in patients with type-2 diabetes.", {"entities": [[67, 80, "Parameter"], [123, 138, "Pathology"]]}], [5558, "Thus, despite the lack of an association between the presence of co-morbidities or number of medications and the use of herbal medicines as expected, diabetic patients could still be high risk candidates for HDIs since they are likely to be on a multiple drug regimen of orally administered drugs.", {"entities": [[150, 158, "Pathology"]]}], [5559, "Tabular summary of the pharmacological management of the patients' based on their prescribed hypoglycaemic agents.", {"entities": [[93, 113, "Drug"]]}], [5560, "The presence of co-morbidities indicates that there are other non-hypoglycaemic agents on the patient's prescription.", {"entities": []}], [5561, "Less than 10% of the patients interviewed used insulin either singly or in combination with an oral hypoglycaemic agent for their diabetes management.", {"entities": [[47, 54, "Drug"], [95, 119, "Drug"], [130, 138, "Pathology"]]}], [5562, "This isn't surprising as despite the proven efficacy of insulin in blood glucose control, its level of compliance and/or acceptance amongst patients with type-2 diabetes is still low due to its relatively higher cost compared to oral hypoglycaemic drugs and unpreferred mode of administration.", {"entities": [[56, 63, "Drug"], [67, 80, "Parameter"], [154, 169, "Pathology"], [229, 253, "Drug"]]}], [5563, "Additional factors which are unique to Nigeria and other developing countries include limited availability and unreliable storage facilities, given that constant power supply isn't guaranteed.", {"entities": []}], [5564, "Thus, despite the decreased risk of pharmacokinetic interactions with insulin, patients are still unlikely to use it as an alternative.", {"entities": [[70, 77, "Drug"]]}], [5565, "Out of the 56 patients who admitted to using herbal medicines alongside prescription drugs for their disease management, < 40% were aware of their identity.", {"entities": [[11, 22, "Cohort"]]}], [5566, "For these patients, they either grew the herbs themselves in their gardens or they purchased them from herbal markets.", {"entities": []}], [5567, "The remaining 60% were unaware of the identity of the herbal medicine used, primarily because these were unlabeled preparations (often multi-component) given to them by herbalists, whose constituents were not disclosed.", {"entities": []}], [5568, "A number of patients however said they were not very interested in finding out the identity as long as the preparation was effective.", {"entities": []}], [5569, "They considered herbal medicines to be relatively \u201csafe\u201d compared to conventional medicines.", {"entities": []}], [5570, "For this cohort of patients, the risk of HDIs would be greater as they wouldn't be able to provide any information to their physicians/healthcare practitioners that can enable them provide appropriate advice with regards to its efficacy and/or safety.", {"entities": [[9, 15, "Study"]]}], [5571, "Twelve medicinal plants were identified among the patients who knew the composition of the herbal medicines which they used for their disease management (Table 3).", {"entities": []}], [5572, "An extensive review of plants used in diabetes management in Nigeria, including information about their interactions with known pharmacokinetic parameters had previously been carried out by the authors (Ezuruike and Prieto, 2014); and this was used for the literature analysis.", {"entities": [[38, 46, "Pathology"]]}], [5573, "Camellia sinensis was the only plant mentioned by the patient which was not in the review.", {"entities": [[0, 17, "Herb name"]]}], [5574, "An independent literature search carried out for this did not however yield any published data on studies evaluating its possible interaction with known pharmacokinetic parameters.", {"entities": []}], [5575, "Tabular summary of the medicinal plants used by the patients and their pharmacokinetic profile.", {"entities": []}], [5576, "For all of the 12 identified plants, pharmacological evidence validating their traditional use in diabetes management have been published.", {"entities": [[98, 106, "Pathology"]]}], [5577, "As shown in Table 3, eight of the identified plants have also been shown to interact with known pharmacokinetic parameters, with a potential to cause HDIs when co-administered with prescription medicines.", {"entities": []}], [5578, "In addition, three of the plants\u2014Azadirachta indica A. Juss, Picralima nitida (Stapf) T. Durand and H. Durand, and Terminalia catappa L. have been known to cause specific organ toxicities in large doses (Table 3).", {"entities": [[33, 51, "Herb name"], [52, 59, "Herb name"], [61, 77, "Herb name"], [86, 95, "Herb name"], [100, 109, "Herb name"], [115, 133, "Herb name"], [171, 187, "Pathology"]]}], [5579, "Table 4 gives a summary of the pharmacokinetic effects of the different drugs prescribed to the interviewed patients.", {"entities": []}], [5580, "In particular, the table highlights overlapping effects with some of the identified herbal medicines on enzymes and/or proteins that are common targets for drug interactions.", {"entities": []}], [5581, "This assessment shows that based on available information, all of the prescribed drugs may interact with one or more of 7 out of the 12 identified herbs (Table 4).", {"entities": []}], [5582, "Map of the potential pharmacokinetic interaction between the prescribed drugs and the herbal medicines used by the patients.", {"entities": []}], [5583, "Key: For the prescription drugs, is an identified substrate of the enzyme/protein; inhibits enzyme/protein activity; enhances enzyme/protein activity; increases plasma levels of transaminases.", {"entities": [[161, 191, "Parameter"]]}], [5584, "The two letter codes denotes a herb which also affects the same PK target of the prescription drug: MI, Mangifera indica (Mango); VA, Vernonia amygdalina (Bitter leaf); OG, Ocimum gratissimum L. (Scent leaf); PN, Picralima nitida (Akuamma plant); AE, Abelmoschus esculentus (Okro); PA, Persea americana (Avocado pear); TC, Terminalia catappa (Tropical almond).", {"entities": [[100, 128, "Herb name"], [130, 167, "Herb name"], [169, 207, "Herb name"], [209, 245, "Herb name"], [247, 280, "Herb name"], [282, 317, "Herb name"], [319, 359, "Herb name"]]}], [5585, "Concurrent use of Albemoschus esculentus (okro) with metformin is a case to highlight, given that the potential HDI is based on in vivo experimental evidence and because of the extensive use of the drug by diabetic patients.", {"entities": [[18, 47, "Herb name"], [53, 62, "Drug"], [206, 214, "Pathology"]]}], [5586, "Although the experiment was carried out only with metformin, given that AE decreases intestinal absorption, it could also affect any other co-administered drug.", {"entities": [[50, 59, "Drug"], [72, 74, "Herb name"]]}], [5587, "Persea americana (Avocado) leaves, Vernonia amygdalina (bitter leaf), and Mangifera indica (mango) leaves interfere with the P-glycoprotein (P-gp) efflux pump and/or cytochromes 1A2 and 3A4 and could subsequently affect any drugs dependent on these enzymes and/or transporter.", {"entities": [[0, 26, "Herb name"], [27, 33, "Herb part"], [35, 68, "Herb name"], [74, 98, "Herb name"], [99, 105, "Herb part"], [125, 158, "Target"], [166, 189, "Target"]]}], [5588, "In addition, it can be seen from the table that mango leaves have the potential to interact with almost all the drugs in the table, since every drug is either metabolized by CYP 3A4 or is a substrate for P-gp.", {"entities": [[48, 53, "Herb name"], [54, 60, "Herb part"], [174, 181, "Target"], [204, 208, "Target"]]}], [5589, "Finally, ingestion of Ocimum gratissimum (scent) leaf, Picralima nitida (akuamma) plant, and/or Terminalia catappa (tropical almond) could enhance the adverse hepatic effects of pioglitazone and atorvastatin.", {"entities": [[22, 48, "Herb name"], [49, 53, "Herb part"], [55, 81, "Herb name"], [96, 132, "Herb name"], [151, 174, "Pathology"], [178, 190, "Drug"], [195, 207, "Drug"]]}], [5590, "With the above information, a practical assessment of potential HDI is herein carried out for one of the interviewed respondents \u201cX,\u201d a 41 year old lady who was taking the squeezed extract of Vernonia amygdalina (VA) regularly as well as an overnight decoction of Mangifera indica (MI) and had the following drugs on her prescription\u2014Metformin 1 g twice daily, Glimepiride 4 mg daily, Lisinopril 2.5 mg daily, Atorvastatin 20 mg daily, and Aspirin 75 mg daily.", {"entities": [[136, 147, "Age"], [148, 152, "Sex"], [172, 188, "Extraction process"], [192, 216, "Herb name"], [251, 260, "Extraction process"], [264, 285, "Herb name"], [334, 343, "Drug"], [344, 347, "Amount"], [348, 359, "Frequency"], [361, 372, "Drug"], [373, 377, "Amount"], [378, 383, "Frequency"], [385, 395, "Drug"], [396, 402, "Amount"], [403, 408, "Frequency"], [410, 422, "Drug"], [423, 428, "Amount"], [429, 434, "Frequency"], [440, 447, "Drug"], [448, 453, "Amount"], [454, 459, "Frequency"]]}], [5591, "A combination of the inhibitory effects of VA and MI on P-gp efflux activity as well as the ability of metformin to decrease P-gp expression (Kim et al., 2011), could bring about an overall increase in the plasma concentration of atorvastatin beyond the expected level, given that atorvastatin is a known P-gp substrate.", {"entities": [[43, 45, "Herb name"], [50, 52, "Herb name"], [56, 60, "Target"], [103, 112, "Drug"], [125, 129, "Target"], [230, 242, "Drug"], [281, 293, "Drug"], [305, 309, "Target"]]}], [5592, "Atorvastatin is however also dependent on CYP3A4 enzyme activity for metabolism to its active metabolite (Lennern\u00e4s, 2003).", {"entities": [[0, 12, "Drug"], [42, 48, "Target"]]}], [5593, "With significant CYP3A4 inhibition by MI, the clinical effect of atorvastatin would not be seen despite its high plasma concentration given that the metabolite is the pharmacologically active entity.", {"entities": [[17, 23, "Target"], [65, 77, "Drug"]]}], [5594, "With this knowledge of the pharmacokinetics of her herbal medicines as highlighted in Table 3; and based on the information provided in Table 4, a recommendation to discontinue the use of MI would be provided for this patient in this case so as not to affect the therapeutic benefits of atorvastatin given that its metabolism is absolutely essential to its effect.", {"entities": [[287, 299, "Drug"]]}], [5595, "On the other hand, there might not be a need to discontinue her use of VA unless its effect on P-gp is going to result in a significant increase in the plasma concentration of atorvastatin.", {"entities": [[71, 73, "Herb name"], [95, 99, "Target"], [176, 188, "Drug"]]}], [5596, "For this, a dosage adjustment may then be required particularly where clear evidence of the medicinal plant has been shown.", {"entities": []}], [5597, "The increased use of herbal medicines by patients alongside their prescription drugs has raised concerns for HDIs, which may be clinically relevant.", {"entities": []}], [5598, "By introducing a new and different approach to the results of our field study, we have carried out an investigation into the possible risks of pharmacokinetic HDIs amongst patients with diabetes in Nigeria; as well as a practical example with one patient of how such an assessment can be carried out given available information.", {"entities": [[66, 77, "Study"], [186, 194, "Pathology"]]}], [5599, "One of the key findings of our study was that over 50% of diabetic patients in Nigeria use herbal medicines alongside their conventional drugs for their disease management, which highlights the large number of patients at risk of HDI and the need for such assessments.", {"entities": [[58, 66, "Pathology"]]}], [5600, "More worrying is that of this high number, more than 60% are unaware of the identity of the herbal medicines being taken which in turn highlights a complete ignorance of the risks of HDIs.", {"entities": []}], [5601, "None of the observed variables\u2014age, gender, cost of disease management, and presence of co-morbidities was identified as a predictor of herbal medicine use; and therefore could not be used as a means of easily identifying patients at risk of HDIs.", {"entities": []}], [5602, "Based on the study carried out by Nahin et al.", {"entities": []}], [5603, "(2012), we had expected an association between the number of co-morbidities (which directly relates to disease severity in the patient) and the use of herbal medicine.", {"entities": []}], [5604, "The absence of this, even though our study identified more users of herbal medicine amongst patients with two or more co-morbidities, could therefore attribute non-clinical factors as predictors of herb use.", {"entities": []}], [5605, "Previous studies have indeed shown that the use of herbal medicines by an individual is very closely linked to his/her cultural health beliefs (van Andel and Westers, 2010).", {"entities": []}], [5606, "This is also directly related to one's perception about the health benefits of herbal medicines.", {"entities": []}], [5607, "A patient is therefore more likely to use herbal medicine if such practice is common in his/her family and if he/she is convinced of its efficacy.", {"entities": []}], [5608, "Thus, the sources of influence and people's personal opinion about herbal medicine could provide better prediction of herb use within a population.", {"entities": []}], [5609, "Given that these factors are not in themselves directly or clinically measurable, it further highlights the need for proactive approaches from healthcare practitioners to enhance increased communication with patients about their use of herbal medicines.", {"entities": []}], [5610, "One limitation to our study was the absence of information about non-clinical/cultural variables of the patients, such as educational background, demography, occupation and beliefs; as these would have enabled a better assessment of their influence on the use of herbal medicines.", {"entities": []}], [5611, "An analysis of the drugs commonly prescribed to patients with diabetes show that most of these are substrates or modulators of known pharmacokinetic parameters commonly implicated in drug interactions.", {"entities": [[62, 70, "Pathology"]]}], [5612, "Studies have shown that the risk of harmful drug interactions increases with the number of drugs given to a patient (Fakeye et al., 2008).", {"entities": []}], [5613, "Similarly, the risk of HDIs is greatly increased for those patients taking herbal medicines who are on more than one prescription drug (Patsalos et al., 2002).", {"entities": []}], [5614, "The analysis done in Table 4 was only carried out for the drugs used by the patients for diabetes and diabetic-related co-morbidities.", {"entities": [[89, 97, "Pathology"], [102, 133, "Pathology"]]}], [5615, "However, the complexities of potential drug interactions could increase further when one begins to consider medications for malaria or an antibiotic for an infection as well as multivitamins that diabetic patients may also be taking alongside.", {"entities": [[124, 131, "Pathology"], [138, 148, "Drug"], [156, 165, "Pathology"], [196, 204, "Pathology"]]}], [5616, "We recently conducted an extensive review of medicinal plants used in diabetes management in Nigeria.", {"entities": [[70, 78, "Pathology"]]}], [5617, "One of the findings of the study was the paucity of information on investigations into pharmacokinetic interactions of commonly administered herbal medicines, compared to experiments validating its pharmacological activity (Ezuruike and Prieto, 2014).", {"entities": []}], [5618, "Given the high percentage of use, the complex composition of most herbal medicines and the chronic nature of the disease, there is a high risk of unidentified HDIs amongst patients with diabetes.", {"entities": [[186, 194, "Pathology"]]}], [5619, "This makes a case for the need for researchers to re-direct their focus into evaluating commonly used medicinal plants for both their pharmacodynamic and pharmacokinetic effects.", {"entities": []}], [5620, "We have also shown how a true assessment of the risk of HDIs can be possible with the knowledge of a patient's herbal medicine.", {"entities": []}], [5621, "Healthcare practitioners who are aware of their patients' use of herbal medicines and its identity can more easily monitor them for any possible interactions using available information, such as that presented in Tables 3, 4.", {"entities": []}], [5622, "In addition to the expectation of an enhanced therapeutic effect for herbal medicines which are being taken for the same indication as the prescription drug (increased hypoglycaemia as in the case of diabetes); one should also be on the lookout for any associated pharmacokinetic interactions.", {"entities": [[168, 181, "Pathology"], [200, 208, "Pathology"]]}], [5623, "Such information could result in possible dose adjustments to accommodate the added benefit of the herbal medicine, or a complete withdrawal if harmful.", {"entities": []}], [5624, "This is even more important for HDIs involving the inhibition or induction of cytochrome enzymes which are required for drug conversions to the more active metabolites or the elimination of pharmacologically active compounds.", {"entities": [[78, 88, "Target"]]}], [5625, "Clinically relevant drug interactions have been identified between the anti-hypertensive drug losartan and grapefruit juice (GFJ), because of the inhibitory effects of GFJ on CYP 3A4 and the dependence of the former on CYP3A4 for conversion to its active metabolite E3174 (Zaidenstein et al., 2001).", {"entities": [[71, 102, "Drug"], [107, 129, "Extraction process"], [168, 171, "Extraction process"], [175, 182, "Target"], [219, 225, "Target"], [266, 271, "Drug"]]}], [5626, "It is important to mention here that the availability of reliable data is required to adequately determine the HDI liability of herbal medicines.", {"entities": []}], [5627, "As with the case of GFJ and losartan above, this was validated by evidence from the clinical study.", {"entities": [[20, 23, "Extraction process"], [28, 36, "Drug"]]}], [5628, "However, data obtained in vitro is very often required to plan and undertake a robust clinical assessment.", {"entities": []}], [5629, "In addition, it has now been shown that given the availability of in vitro data, physiologically based pharmacokinetic (PBPK) modeling and simulation tools can be used as an alternative means for the quantitative prediction of HDIs without the need for clinical studies (Brantley et al., 2014; Gufford et al., 2015).", {"entities": [[253, 269, "Study"]]}], [5630, "Unfortunately, the high percentage of users of unidentified herbal medicines due to non-disclosure by herbalists makes the task of therapeutic monitoring of herbal medicines difficult, an issue that is unlikely to be immediately tackled.", {"entities": []}], [5631, "This is because traditional medicine practitioners/herbalists who prepare the herbal preparations themselves insist that it is a \u201cfamily secret\u201d of which a disclosure will rob them of their business (Ogbera et al., 2010).", {"entities": []}], [5632, "They are therefore often rightly reticent to reveal all the ingredients of their remedies, because of the history of \u201cbio-piracy\u201d by companies seeking to patent and profit from their knowledge without sharing benefits (Willcox and Bodeker, 2010).", {"entities": []}], [5633, "This non-disclosure is a limitation to the integration of traditional medicine in conventional healthcare systems.", {"entities": []}], [5634, "For this reason, patients should be advised on the importance of knowing the identity of their herbal medicines especially as this would enable a proper identification of those with true therapeutic benefits.", {"entities": []}], [5635, "Given the increasing prevalence of herbal medicine use alongside prescription medicines for disease management, this is the first time a study has been carried out specifically looking to identify potential HDIs amongst diabetic patients in Nigeria.", {"entities": [[220, 228, "Pathology"]]}], [5636, "We identified a high percentage (50%) of patients who use herbal medicines, and by so doing are exposed to a number of pharmacokinetic interactions.", {"entities": []}], [5637, "The lack of clinical predictors point toward non-measurable cultural factors influencing the use of herbal medicines by Nigerian adult diabetic patients.", {"entities": [[120, 128, "Ethnic group"], [135, 143, "Pathology"]]}], [5638, "The identified pharmacokinetic HDIs are therefore highlighted here as a template for HDI assessment as well as to facilitate a more proactive monitoring by healthcare professionals.", {"entities": []}], [5639, "UE researched data and wrote the manuscript.", {"entities": []}], [5640, "JP contributed to the discussion and reviewed/edited the manuscript.", {"entities": []}], [5641, "The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.", {"entities": []}], [5642, "UE is grateful to the Commonwealth Scholarship Commission in the UK for the award of a DFID (Department for International Development) sponsored Award number NGCS-2010-306 and to the Rick Cannell trust for the award of a travel grant to carry out the study.", {"entities": []}], [5643, "The Supplementary Material for this article can be found online at:  Click here for additional data file.", {"entities": []}], [5644, "Alanine transaminase Aspartate transaminase Cytochrome P450 Glutathione Glutathione-S-transferases Herb-drug interactions P-glycoprotein.", {"entities": [[0, 20, "Parameter"], [21, 43, "Parameter"], [44, 59, "Target"], [60, 71, "Target"], [72, 98, "Target"], [122, 136, "Target"]]}], [5645, "Herb\u2013drug interactions strongly challenge the clinical combined application of herbs and drugs.", {"entities": []}], [5646, "Herbal products consist of complex pharmacological-active ingredients and perturb the activity of drug-metabolizing enzymes.", {"entities": [[0, 15, "Herb name"], [82, 123, "Parameter"]]}], [5648, "In the present study, a total of 22 components of PNS were separated and identified by UPLC-MS/MS.", {"entities": [[50, 53, "Herb name"]]}], [5649, "Using highly selective probe substrate analysis, PNS exerted robust inhibitory potency on human carboxylesterase 2 (hCE2), while had a minor influence on hCE1, butyrylcholinesterase (BChE) and paraoxonase (PON).", {"entities": [[49, 52, "Herb name"], [90, 121, "Target"], [154, 158, "Target"], [160, 188, "Target"], [193, 210, "Target"]]}], [5650, "These effects were also verified through molecular docking analysis.", {"entities": []}], [5651, "The protein level of hCE2 in HepaRG cells was suppressed after PNS treatment, while the level of BChE or PON1 in the extracellular matrix were elevated after PNS treatment.", {"entities": [[0, 25, "Parameter"], [63, 66, "Herb name"], [84, 109, "Parameter"], [158, 161, "Herb name"]]}], [5652, "Insignificant effect was observed on the mRNA expression of the esterases.", {"entities": [[37, 73, "Parameter"]]}], [5653, "These findings are important to understand the underlying efficacy and safety of co-administration of PNS and aspirin in clinical practice.", {"entities": [[102, 105, "Herb name"], [110, 117, "Drug"]]}], [5654, "Herbs have been used for primary health care for thousands of years before the advent of modern medicines.", {"entities": [[0, 5, "Herb name"], [45, 67, "Duration"]]}], [5655, "It is estimated that approximately 80% of the population in Asian countries currently uses herbs as complementary or alternative medicine [1].", {"entities": [[60, 65, "Ethnic group"], [91, 96, "Herb name"]]}], [5656, "Patients in these countries with complex diseases use herbs more frequently.", {"entities": [[33, 49, "Pathology"], [54, 59, "Herb name"]]}], [5657, "However, side effects of herb-drug interactions (HDI) might occur.", {"entities": []}], [5658, "Some research reported that herbs perturbed the activities of the metabolizing enzymes and/or transporters [2,3,4].", {"entities": [[28, 33, "Herb name"], [62, 106, "Parameter"]]}], [5659, "In the past decades, concerns about HDI have been raised.", {"entities": []}], [5660, "Liver is the primary drug metabolism site and entails a myriad of chemical reactions.", {"entities": []}], [5661, "HepaRG cell line, derived from a hepatocellular carcinoma, could express a large panel of liver-specific enzymes [5,6,7].", {"entities": [[48, 57, "Pathology"], [90, 112, "Parameter"]]}], [5662, "Due to the similarity with primary human hepatocytes, HepaRG cell line was found to be a valuable human-relevant in vitro model for testing drug interactions [8].", {"entities": []}], [5663, "Panax notoginseng saponins (PNS) are the main biologically active constituents in the roots of Panax notoginseng (family Araliaceae).", {"entities": [[0, 32, "Herb name"], [86, 91, "Herb part"], [95, 132, "Herb name"]]}], [5664, "In China, PNS-based drugs have been developed and widely used to treat cerebral infarction and ischemia [9], coronary heart disease and atherosclerosis [10].", {"entities": [[10, 13, "Herb name"], [71, 151, "Pathology"]]}], [5665, "Aspirin (acetylsalicylic acid) is an important member of the therapeutic arsenal for combating the vascular disease.", {"entities": [[0, 30, "Drug"], [95, 115, "Pathology"]]}], [5666, "After administration, aspirin is rapidly hydrolyzed in the body with an elimination half-life of approximatly 15 min [11,12].", {"entities": [[22, 29, "Drug"], [69, 93, "Parameter"], [110, 116, "Duration"]]}], [5667, "Aspirin and PNS-based drugs are often taken together to prevent thrombus and clinical benefits have been obtained.", {"entities": [[0, 7, "Drug"], [12, 15, "Herb name"], [64, 72, "Pathology"]]}], [5668, "On account of the presence of ester bond, aspirin could be catalyzed by esterases in the intestine, liver, and plasma [13], which mainly include human carboxylesterase 1 (hCE1) and hCE2 in the liver and intestine [14,15], and butyrylcholinesterase (BChE) [16], paraoxonase (PON) [17,18] in plasma.", {"entities": [[42, 49, "Drug"], [72, 81, "Parameter"], [145, 185, "Parameter"], [226, 254, "Parameter"], [261, 278, "Parameter"]]}], [5670, "The effects toward hCE2 were verified through molecular docking with PNS.", {"entities": [[19, 23, "Target"], [69, 72, "Herb name"]]}], [5671, "Further, we explored the possible HDI using the HepaRG cell line.", {"entities": []}], [5672, "The main chemical components of PNS were detected with UPLC/LTQ-Orbitrap MS/MS analysis.", {"entities": [[32, 35, "Herb name"]]}], [5673, "A total of 22 compounds were identified or tentatively identified (Figure 1).", {"entities": []}], [5674, "The retention time, m/z values of adduct ions and MS/MS fragment ions in negative ESI modes, mass error, and formula of all the identified compounds were listed in Table 1.", {"entities": [[0, 18, "Parameter"], [20, 69, "Parameter"]]}], [5675, "Compared with the positive inhibitors (bis-p-nitrophenyl phosphate, tetraisopropyl pyrophosphoramide and ethylenediaminetetracetic acid, which are abbreviated as BNPP, iso-OMPA and EDTA in order), PNS exhibited weak or negligible effects on hCE1 (Figure 2A), BChE (Figure 2B), and PON (Figure 2C).", {"entities": [[39, 66, "Parameter"], [68, 100, "Parameter"], [105, 135, "Parameter"], [162, 166, "Parameter"], [168, 176, "Parameter"], [181, 185, "Parameter"], [197, 200, "Herb name"], [241, 245, "Target"], [259, 263, "Target"], [281, 284, "Target"]]}], [5676, "Further, inhibition kinetic analysis was carried out to investigate the mechanism of PNS toward hCE2.", {"entities": [[85, 88, "Herb name"], [96, 100, "Target"]]}], [5677, "The half inhibition concentration (IC A clinical study reported that the integrated peak concentration (C Molecular docking programs use scoring functions to evaluate the binding energy of predicting ligand-receptor complex.", {"entities": [[0, 37, "Parameter"], [38, 54, "Study"], [69, 105, "Parameter"]]}], [5678, "The binding scores between PNS and hCE2 were shown in Table 2.", {"entities": [[27, 30, "Herb name"], [35, 39, "Parameter"]]}], [5679, "Among 22 compounds in PNS, the five main compounds (notoginsenoside R The effects of PNS exposure in HepaRG cells was conducted by an MTT assay to set the concentrations used in the following trials, using the medium-treated cells group as control.", {"entities": [[22, 25, "Herb name"], [52, 69, "Herb name"], [85, 88, "Herb name"], [151, 169, "Parameter"]]}], [5680, "The results were presented in Figure 7.", {"entities": []}], [5681, "There was no significant difference between BNPP (68 \u00b5g/mL) and PNS (150 \u00b5g/mL).", {"entities": [[44, 48, "Parameter"], [50, 58, "Amount"], [64, 67, "Herb name"], [69, 78, "Amount"]]}], [5682, "We further explored the role of PNS in the protein expression in HepaRG cells.", {"entities": [[32, 35, "Herb name"], [39, 61, "Parameter"]]}], [5683, "The results of the expression of hCE1, hCE2, BChE, and PON1 in HepaRG cells after PNS treatment were presented in Figure 8.", {"entities": [[33, 37, "Parameter"], [39, 43, "Parameter"], [45, 49, "Parameter"], [55, 59, "Parameter"], [82, 85, "Herb name"]]}], [5684, "There was no significant influence on hCE1 expression compared to the control (Figure 8A), while PNS (100 \u00b5g/mL) significantly reduced hCE2 protein level (p < 0.05) (Figure 8B).", {"entities": [[38, 53, "Parameter"], [97, 100, "Herb name"], [102, 111, "Amount"], [135, 153, "Parameter"]]}], [5685, "Though BChE levels intracelluar was not significantly changed compared to the control, PNS (100 \u00b5g/mL) led to the great rise in the extracelluler medium (Figure 8C,D).", {"entities": [[7, 31, "Parameter"], [87, 90, "Herb name"], [92, 101, "Amount"]]}], [5686, "The same situation was also seen in PON1 (Figure 8E,F).", {"entities": [[36, 40, "Parameter"]]}], [5687, "To elucidate the effect of PNS on the transcription factor contributed to the change of the protein level of esterases, we also explored mRNA expression in HepaRG cells with PNS treatment.", {"entities": [[27, 30, "Herb name"], [34, 58, "Parameter"], [88, 118, "Parameter"], [137, 152, "Parameter"], [174, 177, "Herb name"]]}], [5688, "Compared with the control, there was no significant difference on the mRNA expression of hCE1, hCE2, BChE, and PON1 (Figure 9).", {"entities": [[66, 115, "Parameter"]]}], [5689, "Multi-drug therapy is now a common therapeutic practice for patients due to their therapeutic benefits, in both developed and developing countries.", {"entities": []}], [5690, "As a consequence, drug interactions are sometimes unavoidable.", {"entities": []}], [5691, "Apart from cytochrome P450, esterases is an important class of phase I metabolic enzymes, and plays a vital role in the biotransformation of ester-linked compounds.", {"entities": [[11, 26, "Parameter"], [28, 37, "Parameter"]]}], [5692, "Except for synthetic compounds, many natural triterpenoids have been reported to exhibit the potent inhibitory effects on esterases in recent years [21,22,23].", {"entities": [[37, 58, "Herb name"], [122, 131, "Target"]]}], [5693, "Aspirin is one of the oldest antiplatelet agents used for antithrombotic therapy.", {"entities": [[0, 7, "Drug"], [58, 80, "Drug"]]}], [5694, "It is rapidly hydrolyzed to salicylic acid by esterases in the body.", {"entities": [[28, 42, "Drug"], [46, 55, "Parameter"]]}], [5695, "Compared with other esterases, it has been reported that aspirin was primarily hydrolyzed by hCE2 [15].", {"entities": [[20, 29, "Parameter"], [57, 64, "Drug"], [93, 97, "Parameter"]]}], [5696, "In China, aspirin and PNS-based drugs are often taken together under many conditions and produce enhanced therapeutic effects.", {"entities": [[10, 17, "Drug"], [22, 25, "Herb name"]]}], [5697, "Highly-selective probe substrate analysis is extensively used for determination of the inhibitory potential of a test compound.", {"entities": []}], [5698, "The basic premise of the methodology is that if test compounds cannot inhibit a particular metabolic enzyme, the probe substrate will be metabolized to its product (metabolite) which can then be measured.", {"entities": [[78, 107, "Parameter"]]}], [5699, "Conversely, if test compounds inhibit the enzyme, the substrate will not be metabolized or the rate of biotransformation and the formation of product declines [25].", {"entities": [[38, 48, "Target"]]}], [5700, "In the study, we used probe substrate analysis to explore the inhibitory effects of PNS toward esterases.", {"entities": [[84, 87, "Herb name"], [95, 104, "Target"]]}], [5701, "The results demonstrated that PNS exhibited strong inhibitory influence toward hCE2, whereas displayed weak inhibition toward hCE1, BChE, and PON with IC Theoretically, significant enzyme inhibition occurs when the concentration of the inhibitor at the metabolic site is not lower than the K Molecular docking is the widely used methods to investigate structure-activity relationships owing to the predictive ability of the conformation of small-molecule ligands within receptor binding sites [28].", {"entities": [[30, 33, "Herb name"], [79, 83, "Target"], [126, 130, "Target"], [132, 136, "Target"], [142, 145, "Target"], [211, 267, "Parameter"]]}], [5702, "By executing quantitative predictions of binding energetics, molecular docking provided rankings of docked compounds on the basis of the binding affinity of complexes [29,30].", {"entities": []}], [5703, "The main saponins presented in PNS include notoginsenoside R Almost all herbal drugs undergo phase I and/or phase II metabolism to yield inactive or active metabolites.", {"entities": [[9, 17, "Herb name"], [31, 34, "Herb name"], [43, 60, "Herb name"]]}], [5704, "Herbal drugs are made of a complex mixture of pharmacological active phytochemicals [32].", {"entities": [[0, 12, "Herb name"]]}], [5705, "This complexity may act as inhibitors or inducers of liver drug enzymes, thus altering the other drug\u2019s concentration in target sites and influencing therapeutic effects [2].", {"entities": [[53, 71, "Parameter"], [104, 117, "Parameter"]]}], [5706, "Liver drug enzymes are the common sites of drug interaction in human.", {"entities": [[0, 18, "Parameter"]]}], [5707, "The results further support our studies above and are consistent with our earlier finding that PNS is an effective inhibitor of esterases.", {"entities": [[95, 98, "Herb name"], [128, 137, "Target"]]}], [5708, "We further explored the potential effects of PNS on the major esterases expressed in the human liver.", {"entities": [[45, 48, "Herb name"], [62, 71, "Parameter"]]}], [5709, "PNS reduced the protein level of hCE2 in HepaRG cells, indicating together regulation of protein expression other than the catalytic activity.", {"entities": [[0, 3, "Herb name"], [12, 37, "Parameter"], [89, 107, "Parameter"]]}], [5710, "PON1 has been reported to be beneficial in preventing atherosclerosis, attributing to its ability to reduce lipid hydroperoxides [33].", {"entities": [[0, 4, "Parameter"], [54, 69, "Pathology"], [108, 128, "Parameter"]]}], [5711, "Blatter\u2013Garin et al.", {"entities": []}], [5712, "reported that aspirin application can increase the PON1 activity in plasma [34].", {"entities": [[14, 21, "Drug"], [51, 64, "Parameter"]]}], [5713, "In this study, PNS increased the release of PON1 out of the HepaRG cells.", {"entities": [[15, 18, "Herb name"], [44, 48, "Parameter"]]}], [5714, "Notably, PNS had insignificant effects on mRNA expression of four tested esterases.", {"entities": [[9, 12, "Herb name"], [42, 57, "Parameter"], [73, 82, "Parameter"]]}], [5715, "Taken together, it was conceived that the effects of PNS might be related to the translation, processing, and stability of the esterases.", {"entities": [[53, 56, "Herb name"], [123, 136, "Parameter"]]}], [5716, "The findings from our study clearly indicated that PNS possess high potency in the inhibition of esterases, in particular hCE2.", {"entities": [[51, 54, "Herb name"], [97, 106, "Target"], [122, 126, "Target"]]}], [5717, "It is likely that PNS could result in HDI in the clinical practice when combined with aspirin.", {"entities": [[18, 21, "Herb name"], [86, 93, "Drug"]]}], [5718, "In many case, however, the effects of some drug in vitro and in vivo have no inevitable correlation.", {"entities": []}], [5719, "A further study is warranted to investigate the HDI of PNS and aspirin in large test animals.", {"entities": [[55, 58, "Herb name"], [63, 70, "Drug"]]}], [5720, "Aspirin was obtained from the National Institute for the Control of Pharmaceutical and Biological Products (Beijing, China).", {"entities": [[0, 7, "Drug"]]}], [5721, "PNS was obtained from Yunnan Sanqi Technology Co., Ltd. (Wenshan, China).", {"entities": [[0, 3, "Herb name"]]}], [5722, "PNS contents were determined as: notoginsenoside R UPLC-MS/MS analysis was conducted on an Ultimate 3000 UPLC system (Thermo Fisher Scientific, Waltham, MA, USA) equipped with an LTQ-Orbitrap Elite mass spectrometer (Thermo Fisher Scientific, Waltham, MA, USA).", {"entities": [[0, 3, "Herb name"], [33, 50, "Herb name"]]}], [5723, "The chemical assays for hCE1 and hCE2 were performed according to the methods reported by Wang et al.", {"entities": [[24, 28, "Parameter"], [33, 37, "Parameter"]]}], [5724, "[35] and Wang et al.", {"entities": []}], [5725, "[36], respectively.", {"entities": []}], [5726, "The study on the effects of BChE was conducted using the method by Gulcin et al.", {"entities": [[28, 32, "Parameter"]]}], [5727, "[37].", {"entities": []}], [5728, "The influence test for PON was conducted by the method of Furlong et al.", {"entities": [[23, 26, "Parameter"]]}], [5729, "[38] with some modifications.", {"entities": []}], [5730, "Briefly, the reaction system contained fresh plasma and freshly prepared paraoxon substrate solution (1 mM) in a total of 200 \u00b5L of assay buffer (pH 8.0, 20 mM Tris-HCl, 1 mM CaCl Known inhibitors were run in triplicate as positive controls: BNPP for hCE1 or hCE2, iso-OMPA for BChE, and EDTA for PON.", {"entities": [[73, 100, "Parameter"], [102, 106, "Amount"], [122, 128, "Amount"], [146, 148, "Parameter"], [149, 152, "Amount"], [160, 168, "Extraction process"], [170, 174, "Amount"], [175, 179, "Parameter"], [242, 246, "Parameter"], [251, 255, "Parameter"], [259, 263, "Parameter"], [265, 273, "Parameter"], [278, 282, "Parameter"], [288, 292, "Parameter"], [297, 300, "Parameter"]]}], [5731, "The K The likelihood of HDI in vivo was predicted based on the [I] and K Molecular docking studies were performed to investigate the binding mode of PNS to hCE2 by using AutodockVina 1.1.2 ( HepaRG cells were generously provided by Du Yanan (Tsinghua University, Beijing, China).", {"entities": [[149, 152, "Herb name"], [156, 160, "Parameter"]]}], [5732, "Cells were cultured in growth medium composed of Williams\u2019 E medium supplemented with 12% fetal bovine serum (FBS), 100 U/mL penicillin, 100 \u00b5g/L streptomycin, 5 mg/mL insulin, 2 mM glutamax-I, and 50 \u00b5M hydrocortisone hemisuccinate under 5% CO The cell viability was examined by the methyl thiazolyl tetrazolium (MTT) assay.", {"entities": [[86, 89, "Amount"], [90, 114, "Parameter"], [116, 124, "Amount"], [125, 135, "Drug"], [137, 145, "Amount"], [146, 158, "Drug"], [160, 167, "Amount"], [168, 175, "Drug"], [177, 181, "Amount"], [182, 192, "Parameter"], [198, 203, "Amount"], [204, 232, "Drug"], [233, 241, "Amount"], [242, 244, "Parameter"], [245, 263, "Parameter"]]}], [5733, "The harvested cells were suspended in ice-cold buffer and then homogenized using an ultrasonic homogenizer under the ice-cold condition.", {"entities": []}], [5734, "The cell homogenate was diluted with HEPES buffer to the appropriate protein concentrations.", {"entities": [[69, 91, "Parameter"]]}], [5735, "PNS was added to the reaction solution and pre-incubated for 5 min.", {"entities": [[0, 3, "Herb name"], [57, 66, "Duration"]]}], [5736, "The reaction was then started by adding aspirin and terminated by adding ice-cold methanol.", {"entities": [[40, 47, "Drug"], [73, 90, "Extraction process"]]}], [5737, "After centrifugation, the supernatants containing acetic acid (final concentration of 2%) were determined using HPLC.", {"entities": [[50, 61, "Extraction process"], [69, 82, "Parameter"], [86, 88, "Amount"]]}], [5738, "The chromatographic separation was achieved using a C The expression level of hCE1, hCE2, PON1, and BChE in HepaRG cells treated by PNS was quantitatively measured using ELISA Kit according to the manufacturer\u2019s protocol.", {"entities": [[54, 104, "Parameter"], [132, 135, "Herb name"]]}], [5739, "Briefly, 2 \u00d7 10 Total RNA was extracted from the cells using the Trizol (CW0581, CWbio, Beijing, China).", {"entities": [[9, 15, "Amount"], [16, 25, "Parameter"]]}], [5740, "One microgram of RNA was used to synthesize cDNA using a reverse transcription reagents Kit (CW0744, CWbio, Beijing, China).", {"entities": [[0, 13, "Amount"], [17, 20, "Parameter"], [44, 48, "Parameter"]]}], [5741, "The qRT-PCR analysis was then carried out using UltraSYBR (with ROX) on Line Gene 9600 Plus qRT-PCR Detection system (Bioer Technology, Hangzhou, China) in the one-step protocol.", {"entities": []}], [5743, "The relative mRNA expressions of hCE1, hCE2, BChE, and PON1 mRNA were normalized to GAPDH and calculated using the 2 Statistical analysis was performed using Prism v5.0 (GraphPad Software Inc., San Diego, CA, USA).", {"entities": [[13, 59, "Parameter"], [84, 89, "Parameter"]]}], [5744, "Data were presented in the format of the mean \u00b1 SD from at least three independent measurements.", {"entities": []}], [5745, "ANOVA was run to determine significance between groups in the different experiments.", {"entities": []}], [5746, "A value of p < 0.05 was considered to be significant.", {"entities": []}], [5747, "In conclusion, we provided the comprehensive in vitro data that enable us to understand and predict HDI with PNS.", {"entities": [[109, 112, "Herb name"]]}], [5748, "PNS could directly affect the activity of esterases in vitro with varying potency with hCE2 being the most susceptible to inhibition.", {"entities": [[0, 3, "Herb name"], [26, 51, "Parameter"], [87, 91, "Parameter"]]}], [5749, "Molecular docking revealed that PNS targeted hCE2 thus leading to its inhibition.", {"entities": [[32, 35, "Herb name"], [45, 49, "Parameter"]]}], [5750, "We further confirmed the inhibitory potential at the cellular level.", {"entities": []}], [5751, "Our data also showed that PNS lead to the alteration of the esterase expression level, while exhibited insignificant effects on mRNA expression.", {"entities": [[26, 29, "Herb name"], [56, 85, "Parameter"], [128, 143, "Parameter"]]}], [5752, "The present work provides an insight into the mechanism exploration governing HDI between aspirin and PNS.", {"entities": [[90, 97, "Drug"], [102, 105, "Herb name"]]}], [5753, "We hope that the findings will urge us to pay more attention to the underlying safety and efficiency of combined drugs in the clinic.", {"entities": []}], [5754, "S.D.", {"entities": []}], [5755, "and P.L.", {"entities": []}], [5756, "conceived and designed the whole experiments.", {"entities": []}], [5757, "Z.S.", {"entities": []}], [5758, "and Y.W.", {"entities": []}], [5759, "performed the experiments; S.L.", {"entities": []}], [5760, "and S.H.", {"entities": []}], [5761, "analyzed the data; and B.Z.", {"entities": []}], [5762, "wrote the paper.", {"entities": []}], [5763, "This work was supported by the Fundamental Research Funds for the Central Universities (No.", {"entities": []}], [5764, "2017-JYB-XS-071).", {"entities": []}], [5765, "The authors declare no conflict of interest.", {"entities": []}], [5766, "The representative total ion current chromatogram of PNS in negative ESI modes.", {"entities": [[53, 56, "Herb name"]]}], [5767, "The corresponding compound names were given in Table 1 (varying from no.", {"entities": []}], [5768, "1 to 19).", {"entities": []}], [5769, "Inhibitory effects of PNS toward the esterases of hCE1, BChE, PON and hCE2 (A\u2013D in order) with BMBT (2-(2-benzoyloxy-3-methoxyphenyl)benzothiazole), FD (Fluorescein diacetate), BuSCh (S-Butyrylthiocholine chloride) and PA (phenyl acetate) as a highly selective substrate of each esterase.", {"entities": [[22, 25, "Herb name"], [33, 74, "Target"], [95, 147, "Parameter"], [149, 175, "Parameter"], [177, 214, "Parameter"], [219, 238, "Parameter"], [279, 287, "Parameter"]]}], [5770, "BNPP, iso-OMPA, and EDTA are well-known inhibitors for hCE1 (hCE2), BChE, and PON, respectively.", {"entities": [[0, 24, "Parameter"], [55, 81, "Target"]]}], [5771, "Data were presented as mean \u00b1 SD (n = 3).", {"entities": []}], [5772, "Various concentrations of PNS were used to measure the half inhibition concentration toward hCE2.", {"entities": [[26, 29, "Herb name"], [51, 96, "Parameter"]]}], [5773, "Each point represents the mean of three independent experiments.", {"entities": []}], [5774, "Inhibitory kinetics of PNS toward hCE2 using Lineweaver-Burk plots (A) and Dixon plots (B).", {"entities": [[23, 26, "Herb name"], [34, 38, "Target"]]}], [5775, "Data were presented as mean \u00b1 SD (n = 3).", {"entities": []}], [5776, "Molecular docking mode and interactions between hCE2 (shown in cartoon representation and colored structure) and notoginsenoside R Cytotoxicity tests of PNS on HepaRG cells.", {"entities": [[48, 52, "Parameter"], [113, 130, "Herb name"], [153, 156, "Herb name"]]}], [5777, "Data were presented as mean \u00b1 SD (n = 5).", {"entities": []}], [5778, "** and *** denoted result significantly different from that of the control group (p < 0.01 and p < 0.001, respectively).", {"entities": []}], [5779, "HepaRG cells homogenates were prepared and then diluted with 50 mM HEPES buffer (pH 7.4).", {"entities": [[61, 79, "Extraction process"], [81, 83, "Parameter"], [84, 87, "Amount"]]}], [5780, "No significance (ns) was detected between BNPP (68 \u00b5g/mL) and PNS (150 \u00b5g/mL) treated group.", {"entities": [[42, 46, "Parameter"], [48, 56, "Amount"], [62, 65, "Herb name"], [67, 76, "Amount"]]}], [5781, "Data were presented as mean \u00b1 SD (n = 3).", {"entities": []}], [5782, "*, and ** denoted results significantly different compared with the control group (p < 0.05, p < 0.01, respectively).", {"entities": []}], [5783, "Effects on human carboxylesterase 1 (hCE1) (A), hCE2 (B), BChE (C,D), and PON1 (E,F) protein level after PNS treatment.", {"entities": [[11, 98, "Parameter"], [105, 108, "Herb name"]]}], [5785, "Data were presented as mean \u00b1 SD (n = 3).", {"entities": []}], [5786, "* and ** denote results significantly different from those of the control group (p < 0.05, p < 0.01, respectively).", {"entities": []}], [5787, "Effects on mRNA expression of human carboxylesterase 1 (hCE1) (A), hCE2 (B), BChE (C), and PON1 (D) with PNS treatment.", {"entities": [[11, 26, "Parameter"], [30, 95, "Parameter"], [105, 108, "Herb name"]]}], [5789, "Data were presented as mean \u00b1 SD (n = 3).", {"entities": []}], [5790, "All the identified or tentatively identified components of PNS and their UPLC-MS/MS data.", {"entities": [[59, 62, "Herb name"]]}], [5791, "Docking scores between the compounds of PNS and hCE2.", {"entities": [[40, 43, "Herb name"], [48, 52, "Parameter"]]}], [5792, "Primer sequences for qRT-PCR.", {"entities": []}], [5793, "Samento (extract from Uncaria tomentosa) and Banderol (extract from Otoba parvifolia) have been demonstrated to have anti-inflammatory and antimicrobial properties, e.g., against different morphological forms of Borrelia burgdorferi.", {"entities": [[0, 7, "Herb name"], [22, 39, "Herb name"], [45, 53, "Herb name"], [68, 84, "Herb name"]]}], [5794, "However, there is hardly any data on the pharmacological safety of these two herbal medicines.", {"entities": []}], [5795, "This in vitro study aimed at scrutinizing their possible characteristics as perpetrators in pharmacokinetic herbal\u2013drug interactions.", {"entities": [[5, 19, "Study"]]}], [5796, "Inhibition of cytochrome P450 enzymes (CYPs) was quantified by commercial kits and inhibition of drug transporters by use of fluorescent probe substrates.", {"entities": [[14, 44, "Target"]]}], [5797, "Induction was quantified by real-time RT-PCR and activation of pregnane x receptor (PXR) and aryl hydrocarbon receptor (AhR) by reporter gene assays.", {"entities": [[63, 88, "Target"], [93, 124, "Target"]]}], [5798, "Organic anion transporting polypeptide 1B1 (OATP1B1) (IC Uncaria tomentosa (cat\u2019s claw), a Rubiacea found in Central and South America, represents an important medicinal plant especially in Peru, Brazil, and Central America [1,2,3,4].", {"entities": [[0, 52, "Target"], [57, 99, "Herb name"]]}], [5799, "The bioactivity is broad and there are numerous data demonstrating its anti-inflammatory, antioxidant, antimicrobial, antidiabetic, anticancer, and immunostimulant properties [4].", {"entities": []}], [5800, "Uncaria tomentosa exists in two chemical types, which contain either tetracyclic oxindole alkaloids (TOA) or pentacyclic oxindole alkaloids (POA) [5].", {"entities": [[0, 17, "Herb name"], [69, 105, "Herb name"], [109, 145, "Herb name"]]}], [5801, "In Western Europe, only the TOA-free form has been licensed for the treatment of rheumatoid arthritis (Krallendorn, Immodal Pharmaka, Volders, Austria), because data demonstrated that only POAs stimulate the immune system, whereas TOAs antagonize this effect [5].", {"entities": [[28, 31, "Herb name"], [81, 101, "Pathology"], [189, 193, "Herb name"], [231, 235, "Herb name"]]}], [5802, "Otoba parvifolia, a Myristicacea also growing in Central and South America, is traditionally used, e.g., by the Waorani Indians from Ecuador, to treat infections caused by mites and fungi [6].", {"entities": [[0, 32, "Herb name"], [112, 127, "Ethnic group"], [151, 187, "Pathology"]]}], [5803, "Moreover, antiprotozoal activity for extracts of this plant has been shown [7].", {"entities": []}], [5804, "Samento (a TOA-free extract from Uncaria tomentosa) and Banderol (an extract from Otoba parvifolia) have been demonstrated to be effective against different morphological forms (spirochetes, round bodies, and biofilm-like colonies) of Borrelia burgdorferi in vitro [8], one of the Borrelia species causing Lyme borreliosis [9].", {"entities": [[0, 51, "Herb name"], [56, 99, "Herb name"], [256, 264, "Study"], [306, 322, "Pathology"]]}], [5805, "Whereas doxycycline, one of the most commonly used antibiotics to treat Lyme borreliosis, was only efficient against the spirochetal form, both extracts and especially the combination of them were also effective against the round body forms and biofilms, which are considered to be the source of the persistent Lyme disease [10,11].", {"entities": [[8, 19, "Drug"], [51, 62, "Drug"], [72, 88, "Pathology"], [311, 323, "Pathology"]]}], [5806, "Although no clinical or prescription data have been published so far, Samento and Banderol represent herbal medicines often used by patients suffering from Lyme borreliosis.", {"entities": [[70, 77, "Herb name"], [82, 90, "Herb name"], [156, 172, "Pathology"]]}], [5807, "Moreover, its consumption is recommended, e.g., by the Borreliose and FSME Society Germany, as anti-inflammatory and antimicrobial concomitant therapy for borreliosis patients.", {"entities": [[55, 65, "Pathology"], [155, 166, "Pathology"]]}], [5808, "Concerning the safety of the clinical application of these two herbal medicines, there are only sparse data for Uncaria tomentosa, but no published data for Otoba parvifolia.", {"entities": [[112, 129, "Herb name"], [157, 173, "Herb name"]]}], [5809, "The use of the former is reported to be non-toxic [5].", {"entities": []}], [5810, "Irrespective of toxicity and adverse drug reactions, herb\u2013drug interactions are also of special importance for the safe administration of herbal drugs [12].", {"entities": [[29, 51, "Pathology"]]}], [5811, "Data indicate that extracts of Uncaria tomentosa inhibit the most important drug metabolizing enzyme cytochrome P450 3A4 (CYP3A4) [13], possibly explaining the published case report describing an interaction between this compound and the HIV protease inhibitors atazanavir, ritonavir, and saquinavir [14].", {"entities": [[31, 48, "Herb name"], [101, 129, "Target"], [170, 181, "Study"], [238, 261, "Drug"], [262, 272, "Drug"], [274, 283, "Drug"], [289, 299, "Drug"]]}], [5812, "Beyond this, no data exist on possible influences of Uncaria tomentosa and Otoba parvifolia on drug metabolizing enzymes or drug transporters being important for drug\u2013drug or herb\u2013drug interactions.", {"entities": [[53, 70, "Herb name"], [75, 91, "Herb name"]]}], [5813, "Thus, this in vitro study evaluated the effects of Samento and Banderol on the expression and activity of a broad set of drug transporting or metabolizing proteins.", {"entities": [[11, 25, "Study"], [51, 58, "Herb name"], [63, 71, "Herb name"]]}], [5814, "Neither Samento nor Banderol increased intracellular calcein fluorescence in L-MDR1 cells over-expressing human P-glycoprotein (P-gp), indicating lack of P-gp inhibition (data not shown).", {"entities": [[8, 15, "Herb name"], [20, 28, "Herb name"], [112, 133, "Target"], [154, 158, "Target"]]}], [5815, "Since P388/dx cells are more suitable to detect weak P-gp inhibitors, we also tested both compounds in these cells and the corresponding parental cell line.", {"entities": [[53, 57, "Target"]]}], [5816, "However, also in this cell system, no significant increase in intracellular calcein fluorescence by Samento or Banderol was observed, verifying the lack of P-gp inhibition by these extracts (data not shown).", {"entities": [[100, 107, "Herb name"], [111, 119, "Herb name"], [156, 160, "Target"]]}], [5817, "Banderol concentration-dependently decreased intracellular 8-FcA fluorescence in organic anion transporting polypeptide (OATP)1B1 and OATP1B3 over-expressing HEK293 cells, indicating OATP1B1 and OATP1B3 inhibition with IC CYP inhibition was tested with the respective P450-Glo\u2122 Screening Systems.", {"entities": [[0, 8, "Herb name"], [81, 129, "Target"], [134, 141, "Target"], [183, 190, "Target"], [195, 202, "Target"], [222, 225, "Target"]]}], [5818, "Up to the highest concentration tested, neither Banderol nor Samento profoundly inhibited CYP1A2, CYP2B6, CYP2C19, or CYP3A4 (Figure 2).", {"entities": [[48, 56, "Herb name"], [61, 68, "Herb name"], [90, 96, "Target"], [98, 104, "Target"], [106, 113, "Target"], [118, 124, "Target"]]}], [5819, "The highest inhibition was demonstrated for CYP3A4 by Samento (around 40% at a concentration of 1%) and Banderol (around 20% at a concentration of 1%) and for CYP2C19 by Banderol (about 20% at a concentration of 1%).", {"entities": [[44, 50, "Target"], [54, 61, "Herb name"], [104, 112, "Herb name"], [159, 166, "Target"], [170, 178, "Herb name"]]}], [5820, "Induction of several drug metabolizing enzymes and drug transporters was tested by incubation of LS180 cells with Samento, Banderol, or the positive controls for four days.", {"entities": [[114, 121, "Herb name"], [123, 131, "Herb name"], [158, 171, "Duration"]]}], [5821, "Figure 3 depicts the influence of Samento on the mRNA expression of several important drug metabolizing enzymes and drug transporters.", {"entities": [[34, 41, "Herb name"], [49, 53, "Target"]]}], [5822, "The highest concentration of Samento tested (1%) significantly induced the mRNA expression of CYP2J2, uridine diphosphate glucuronosyl transferase (UGT)1A3, UGT1A9, ABCB1, and SLCO1B1.", {"entities": [[29, 36, "Herb name"], [75, 79, "Target"], [94, 100, "Target"], [102, 155, "Target"], [157, 163, "Target"], [165, 170, "Target"], [176, 183, "Target"]]}], [5823, "The lowest concentration of Samento tested (0.033%) repressed mRNA expression of ABCG2 by 36%.", {"entities": [[28, 35, "Herb name"], [62, 66, "Target"], [81, 86, "Target"]]}], [5824, "No significant effects were observed on CYP1A1, CYP1A2, CYP3A4, and multidrug resistance-associated protein 2 (MRP2, ABCC2) expression.", {"entities": [[40, 46, "Target"], [48, 54, "Target"], [56, 62, "Target"], [68, 109, "Target"], [111, 115, "Target"], [117, 122, "Target"]]}], [5825, "In contrast, Banderol had no significant effect on the mRNA expression of any of the genes investigated (data not shown).", {"entities": [[13, 21, "Herb name"], [55, 59, "Target"]]}], [5826, "Samento significantly induced mRNA expression of genes that are regulated by the pregnane x receptor (PXR) (e.g., ABCB1, UGT1A3, UGT1A9, SLCO1B1).", {"entities": [[0, 7, "Herb name"], [30, 34, "Target"], [81, 106, "Target"], [114, 119, "Target"], [121, 127, "Target"], [129, 135, "Target"], [137, 144, "Target"]]}], [5827, "We therefore investigated by means of reporter gene assay, whether this extract can activate PXR.", {"entities": [[93, 96, "Target"]]}], [5828, "Indeed, Samento concentration-dependently increased PXR activity, whereas at the highest concentration tested (1%) the maximum effect was obviously not reached (Figure 4A).", {"entities": [[8, 15, "Herb name"], [52, 55, "Target"]]}], [5829, "To demonstrate possible influences on aryl hydrocarbon receptor (AhR), another important transcription factor regulating e.g., CYP1A, we also tested whether Samento can activate AhR and found only a minor effect compared to the positive control omeprazole (Figure 4B).", {"entities": [[38, 69, "Target"], [127, 132, "Target"], [157, 164, "Herb name"], [178, 181, "Target"], [245, 255, "Drug"]]}], [5830, "Induction of P-gp by 1% Samento was verified at the protein level (Figure 5).", {"entities": [[13, 17, "Target"], [24, 31, "Herb name"]]}], [5831, "In contrast, the small induction of CYP2J2 at the mRNA level (1.5-fold) was not observed at the protein level (data not shown).", {"entities": [[36, 42, "Target"], [50, 54, "Target"]]}], [5832, "Samento did not influence mRNA half-life of CYP2J2 (Figure 6) indicating that the increase in mRNA expression observed with 1% Samento (Figure 3) can be attributed to transcriptional regulation and not to posttranscriptional mechanisms.", {"entities": [[0, 7, "Herb name"], [26, 30, "Target"], [44, 50, "Target"], [94, 98, "Target"], [127, 134, "Herb name"]]}], [5833, "However, for safe application, it is crucial to know whether the pharmacokinetics of concomitantly used drugs can be altered by these herbal extracts.", {"entities": []}], [5834, "This study, therefore, scrutinized in vitro whether Samento and Banderol can inhibit the activity or induce the expression of important drug metabolizing enzymes and drug transporters.", {"entities": [[35, 43, "Study"], [52, 59, "Herb name"], [64, 72, "Herb name"]]}], [5835, "This data for the first time demonstrates that both extracts do not inhibit the drug efflux transporters P-gp and BCRP but inhibit the liver uptake transporters OATP1B1 and OATP1B3.", {"entities": [[105, 109, "Target"], [114, 118, "Target"], [161, 168, "Target"], [173, 180, "Target"]]}], [5836, "Inhibition of the OATPs was very weak by Samento but considerable by Banderol (Figure 1).", {"entities": [[18, 23, "Target"], [41, 48, "Herb name"], [69, 77, "Herb name"]]}], [5837, "Whether this inhibition is clinically relevant cannot be estimated, because it is completely unknown which ingredients at what concentrations reach the systemic circulation after ingestion of these herbal drugs.", {"entities": []}], [5838, "Inhibition of the CYPs tested was mostly weak or absent up to the maximum concentration tested (Figure 2).", {"entities": [[18, 22, "Target"]]}], [5839, "The most profound effect was observed for CYP3A4 inhibition by Samento, reaching about 40% at a concentration of 1%, roughly matching the data obtained earlier with another extract of Uncaria tomentosa (CYP3A4 inhibition IC Not only inhibition, but also induction of pharmacokinetically relevant enzymes and transporters can lead to drug\u2013drug or herb\u2013drug interactions [16].", {"entities": [[42, 48, "Target"], [63, 70, "Herb name"], [184, 201, "Herb name"], [203, 209, "Target"]]}], [5840, "PXR activating drugs (e.g., rifampicin) or herbal preparations (e.g., St. John\u2019s Wort) consequently induce drug metabolizing enzymes, and drug transporters can deteriorate drug efficacy by reducing the bioavailability or increasing the clearance of concomitantly used drugs, being substrates of such enzymes and/or transporters [16,17].", {"entities": [[0, 3, "Target"], [28, 38, "Drug"], [74, 85, "Herb name"], [202, 217, "Parameter"]]}], [5841, "Whereas Banderol had no effect on any gene expression investigated, Samento turned out to clearly activate PXR in a similar range as the positive control rifampicin.", {"entities": [[8, 16, "Herb name"], [68, 75, "Herb name"], [107, 110, "Target"], [154, 164, "Drug"]]}], [5842, "In contrast, AhR was not profoundly affected (Figure 4).", {"entities": [[13, 16, "Target"]]}], [5843, "This is in good agreement with the observed mRNA inductions of PXR-driven genes (e.g., ABCB1) (Figure 3).", {"entities": [[44, 48, "Target"], [63, 79, "Target"], [87, 92, "Target"]]}], [5845, "Possibly, induction provoked by one ingredient is superimposed by a repressive effect of another ingredient, leading to a net repressive effect at lower concentrations of Samento and a zero net effect at higher concentrations.", {"entities": [[171, 178, "Herb name"]]}], [5846, "Interestingly, CYP2J2 mRNA was also transcriptionally induced about 1.5-fold at the highest concentration of Samento tested.", {"entities": [[15, 26, "Target"], [109, 116, "Herb name"]]}], [5847, "This induction was not observed at the protein level.", {"entities": []}], [5848, "However, this might be attributed to the much lower sensitivity of western blot semi-quantification compared to quantitative RT-PCR.", {"entities": []}], [5849, "So far, only few data exist on the regulation of CYP2J2 expression.", {"entities": [[49, 55, "Target"]]}], [5850, "Our data indicate that a regulation via PXR seems unlikely, because the prototypical PXR activator rifampicin had no significant effect on CYP2J2 expression (Figure 3).", {"entities": [[40, 43, "Target"], [85, 88, "Target"], [99, 109, "Drug"], [139, 145, "Target"]]}], [5851, "Moreover, there are no characteristic response elements for PXR in the CYP2J2 upstream region [18], making it unlikely that PXR plays a major role in regulating CYP2J2 expression.", {"entities": [[60, 63, "Target"], [71, 77, "Target"], [124, 127, "Target"], [161, 167, "Target"]]}], [5852, "Other studies suggest that activator protein-1 (AP-1) and an AP-1-like element play a role in inducing CYP2J2 expression in human liver-derived cells [18], which might also be the case in our cell system.", {"entities": [[27, 53, "Target"], [103, 109, "Target"]]}], [5853, "CYP2J2 is mainly expressed in the heart and plays an important role in arachidonic acid metabolism and thus in cardiovascular physiology [18].", {"entities": [[0, 6, "Target"], [71, 98, "Target"]]}], [5854, "In contrast, its involvement in induction-mediated drug\u2013drug interactions is unknown so far, although several drug substrates have been described (e.g., ebastine, terfenadine, apixaban [18]), making this cytochrome another potential modulator of bioavailability.", {"entities": [[153, 161, "Drug"], [163, 174, "Drug"], [176, 184, "Drug"], [204, 214, "Target"], [246, 261, "Parameter"]]}], [5855, "Besides such drug-metabolizing enzymes, induction of ABCB1 by Samento could also lead to reduced bioavailability of some of the frequently used antibiotics in borreliosis therapy, which are P-gp substrates: tetracycline [19], minocycline [20], azithromycin [21], and clarithromycin [21].", {"entities": [[53, 58, "Target"], [62, 69, "Herb name"], [97, 112, "Parameter"], [144, 155, "Drug"], [159, 170, "Pathology"], [190, 194, "Target"], [207, 219, "Drug"], [226, 237, "Drug"], [244, 256, "Drug"], [267, 281, "Drug"]]}], [5856, "Unfortunately, it is unknown whether active compounds of Samento reach relevant systemic concentrations leading to hepatic induction of the genes investigated, but intestinal concentrations should be high enough to induce genes such as ABCB1, CYP2J2, UGT1A3, and UGT1A9.", {"entities": [[57, 64, "Herb name"], [236, 241, "Target"], [243, 249, "Target"], [251, 257, "Target"], [263, 269, "Target"]]}], [5857, "Phosphate buffered saline (PBS), cell culture media, supplements, fetal calf serum (FCS), omeprazole, the cytotoxicity detection kit (LDH), and the GenElute\u2122 Mammalian Total RNA Miniprep Kit were purchased from Sigma-Aldrich (Taufkirchen, Germany).", {"entities": [[90, 100, "Drug"]]}], [5858, "Rifampicin, dimethyl sulfoxide (DMSO), Tris-hydroxymethyl-aminomethane (TRIS), dithiothreitol (DTT), Tween Samento represents an extract from Uncaria tomentosa bark containing 22% ethanol.", {"entities": [[0, 10, "Drug"], [107, 114, "Herb name"], [142, 159, "Herb name"]]}], [5859, "Banderol is an extract from Otoba parvifolia bark containing 20\u201324% ethanol.", {"entities": [[0, 8, "Herb name"], [28, 49, "Herb name"]]}], [5860, "The maximum concentration used for both extracts was set to a dilution of 1:100 due to several reasons: (1) this dilution contains 0.2% ethanol, which does not influence the assays conducted; (2) dilutions of 1:400 showed best activity against the round-body forms of Borrelia burgdorferi in vitro, whereas higher concentrations were only effective against the spirochete form [8]; (3) the manufacturer of Samento and Banderol recommends to take a maximum of 30 drops (=1.5 mL) in about 100 mL water, which represents a dilution of 1:150 (=0.7%).", {"entities": [[289, 297, "Study"], [406, 413, "Herb name"], [418, 426, "Herb name"], [459, 477, "Amount"]]}], [5861, "Thus, it seemed unreasonable to test higher concentrations than a dilution of 1:100 (=1%).", {"entities": []}], [5862, "Toxic effects on cells can negatively influence transporter inhibition assays.", {"entities": [[0, 13, "Pathology"]]}], [5863, "Thus, prior to transporter inhibition assays, Samento and Banderol were investigated for their cell-toxic effects using the cytotoxicity detection kit (LDH) based on the release of lactate dehydrogenase according to the manufacturer\u2019s instruction.", {"entities": [[46, 53, "Herb name"], [58, 66, "Herb name"]]}], [5864, "Samento and Banderol were revealed to be non-toxic up to the maximum tested concentration (1%) in all cell lines used.", {"entities": [[0, 7, "Herb name"], [12, 20, "Herb name"]]}], [5865, "Possible P-gp inhibition by Samento and Banderol was assessed in a calcein assay using calcein acetoxymethylester as a fluorogenic substrate as validated and described previously [22,23].", {"entities": [[9, 13, "Target"], [28, 35, "Herb name"], [40, 48, "Herb name"]]}], [5866, "As cell models, we used L-MDR1 cells over-expressing human P-gp and its wild-type counterpart LLC-PK1 and P388/dx cells over-expressing murine P-gp and the corresponding parental cell line P388.", {"entities": [[59, 63, "Target"], [143, 147, "Target"]]}], [5867, "Cell lines were cultured and treated as published previously as were the results for the positive controls verapamil and quinidine [22,23], which are not depicted in this publication, because the potency of a small molecule (given in molar) cannot be compared to that of an extract (given as a dilution).", {"entities": [[107, 116, "Drug"], [121, 130, "Drug"]]}], [5868, "Each concentration of Samento and Banderol (0.001\u20131%) was tested in octuplet and each experiment was performed in triplicate.", {"entities": [[22, 29, "Herb name"], [34, 42, "Herb name"]]}], [5869, "BCRP inhibition was tested by flow cytometry using pheophorbide A as a specific BCRP substrate in MDCKII-BCRP cells compared to the parental cell line MDCKII as described previously [24].", {"entities": [[0, 4, "Target"], [80, 84, "Target"]]}], [5870, "Results for the positive controls were also published previously [24].", {"entities": []}], [5871, "Concentrations ranging from a dilution of 0.0033 to 1% were tested and the experiment was performed in triplicate.", {"entities": []}], [5872, "Inhibition of OATP1B1 and OATP1B3 was quantified by flow cytometry quantifying the uptake of 8-FcA into HEK293 cells over-expressing the respective transporter in comparison to HEK293 cells transfected with the empty control vector as published previously [25].", {"entities": [[14, 21, "Target"], [26, 33, "Target"]]}], [5873, "Concentrations ranging from a dilution of 0.0033 to 1% were tested and the experiment was performed in triplicate.", {"entities": []}], [5874, "Results for the positive controls rifampicin and cyclosporine A were published previously [25].", {"entities": [[34, 44, "Drug"], [49, 63, "Drug"]]}], [5875, "Inhibition of CYPs was assessed with the P450-Glo\u2122 Screening Systems according to the manufacturer\u2019s instructions.", {"entities": [[14, 18, "Target"]]}], [5876, "The kits contain a luminogenic substrate (luciferin-ME for CYP1A2, luciferin-2B6 for CYP2B6, luciferin-h EGE for CYP2C19, or luciferin-IPA for CYP3A4), which is converted by the respective enzyme into luciferin.", {"entities": [[59, 65, "Target"], [85, 91, "Target"], [113, 120, "Target"], [143, 149, "Target"]]}], [5877, "When incubated with the luciferin detection reagent, the luciferase generates light.", {"entities": []}], [5878, "Banderol and Samento were tested for their capacity to inhibit the production of the luminescent signal.", {"entities": [[0, 8, "Herb name"], [13, 20, "Herb name"]]}], [5879, "Positive controls used were ketoconazole for CYP3A4, omeprazole for CYP2C19, miconazole for CYP2B6, and \u03b2-naphthoflavone for CYP1A2.", {"entities": [[28, 40, "Drug"], [45, 51, "Target"], [53, 63, "Drug"], [68, 75, "Target"], [77, 87, "Drug"], [92, 98, "Target"], [125, 131, "Target"]]}], [5880, "Results are not depicted, because the potency (given in molar) of a small molecule cannot be compared to that of an extract (given as a dilution).", {"entities": []}], [5881, "Eight concentrations in triplicates ranging from 0.0033 to 1% were tested and each experiment was conducted 3\u20135 times.", {"entities": []}], [5882, "Prior to induction experiments, antiproliferative effects of Samento and Banderol were investigated in the cell lines used (LS180 cells) to exclude an influence on cell growth.", {"entities": [[61, 68, "Herb name"], [73, 81, "Herb name"]]}], [5883, "Proliferation was quantified by crystal violet staining and the assays were conducted as described previously [26].", {"entities": []}], [5884, "Each concentration (dilution 0.001\u20131%) was tested in octuplet and each experiment was performed in quadruplicate.", {"entities": []}], [5885, "Both extracts had no effects on cell proliferation up to the maximum concentration tested (1%).", {"entities": []}], [5886, "Therefore, Samento and Banderol were tested up to a dilution of 1% in the induction assay.", {"entities": [[11, 18, "Herb name"], [23, 31, "Herb name"]]}], [5887, "For induction experiments, the human colon adenocarcinoma cell line LS180 (available at ATCC, Manassas, VA, USA) was used.", {"entities": []}], [5888, "This cell line is a suitable surrogate for the intestine being a major site of drug interactions and it is ideal for investigating AhR and PXR mediated induction [27].", {"entities": [[131, 134, "Target"], [139, 142, "Target"]]}], [5889, "Cells were cultured under standard cell culture conditions as published previously [27].", {"entities": []}], [5890, "Three days before starting the assay, LS180 cells were seeded in culturing flasks.", {"entities": []}], [5891, "Medium was then changed to medium containing either Samento or Banderol (dilution 0.033%, 0.1%, 0.33%, 1%) and cells were incubated for four further days.", {"entities": [[52, 59, "Herb name"], [63, 71, "Herb name"]]}], [5892, "Rifampicin (20 \u00b5M) served as a positive control for PXR-driven genes, and the AhR ligand omeprazole (100 \u00b5M) for CYP1A1 and CYP1A2 induction, and compound-free medium as a negative control.", {"entities": [[0, 10, "Drug"], [52, 55, "Target"], [78, 81, "Target"], [89, 99, "Drug"], [113, 119, "Target"], [124, 130, "Target"]]}], [5893, "All media were adjusted to 0.03% DMSO.", {"entities": []}], [5894, "After harvesting, RNA was extracted immediately.", {"entities": []}], [5895, "Each experiment was conducted in quintuplicate.", {"entities": []}], [5896, "RNA was isolated using the GeneElute Mammalian Total RNA Miniprep Kit and cDNA was synthesized with the RevertAid\u2122 H Minus First Strand cDNA Synthesis Kit according to the manufacturers\u2019 instructions.", {"entities": []}], [5897, "Gene expression was quantified by real-time RT-PCR as described previously [28] for the following genes: CYP1A1, CYP1A2, CYP2J2, CYP3A4, UGT1A3, UGT1A9, ABCB1, ABCC2, ABCG2.", {"entities": [[105, 111, "Target"], [113, 119, "Target"], [121, 127, "Target"], [129, 135, "Target"], [137, 143, "Target"], [145, 151, "Target"], [153, 158, "Target"], [160, 165, "Target"], [167, 172, "Target"]]}], [5898, "For UGT1A3 a Quantitect Kit (Qiagen, Hilden, Germany) was used according to the manufacturer\u2019s instructions and primers for CYP2J2 were published by another group [29].", {"entities": [[4, 10, "Target"], [124, 130, "Target"]]}], [5899, "All other primer sequences and PCR conditions were published previously [27].", {"entities": []}], [5900, "The most stable housekeeping gene for normalization was identified using geNorm (version 3.4, Center for Medical Genetics, Ghent, Belgium), which determines most stable reference genes from a set of tested genes in a given cDNA sample panel [30].", {"entities": []}], [5901, "Among a panel of 7 housekeeping genes tested, glucuronidase \u03b2 (GU) was the most stable under the treatment with Samento, and glucose-6-phosphate dehydrogenase (G6PDH) under the treatment with Banderol and were thus used for normalization.", {"entities": [[46, 61, "Target"], [112, 119, "Herb name"], [125, 166, "Target"], [192, 200, "Herb name"]]}], [5902, "Primer sequences and conditions were published previously [31].", {"entities": []}], [5903, "Data were evaluated as described previously [28].", {"entities": []}], [5904, "All samples were amplified in duplicate and the mean of the technical duplicate was used for further calculation.", {"entities": []}], [5905, "To verify gene induction, one of the PXR-driven genes, P-gp, was also analyzed at the protein level.", {"entities": [[37, 53, "Target"], [55, 59, "Target"]]}], [5906, "Moreover, since the regulation of CYP2J2 is largely unknown, its up-regulation by Samento was also investigated at the protein level.", {"entities": [[34, 40, "Target"], [82, 89, "Herb name"]]}], [5907, "Protein expression was quantified by SDS-PAGE and western blotting according to standard protocols as published previously [25].", {"entities": []}], [5908, "Protein detection was carried out with a murine monoclonal antibody against human P-gp (clone C219, diluted 1:100 in TRIS-buffered saline containing 0.1% Tween To investigate whether inductions of typical PXR-driven genes, like ABCB1, by Samento truly originate from activation of PXR, a PXR reporter gene assay was conducted in LS180 cells using the Dual-Glo\u2122 Luciferase Assay System according to the manufacturer\u2019s instructions as published previously [25].", {"entities": [[82, 86, "Target"], [205, 221, "Target"], [228, 233, "Target"], [238, 245, "Herb name"], [281, 284, "Target"], [288, 291, "Target"]]}], [5909, "Increases of PXR activity after 24 h incubation with Samento or the control compound rifampicin were normalized to the transfection efficiency control (renilla luminescence) and to the PXR activity of non-treated controls set to 1 (=100%).", {"entities": [[13, 16, "Target"], [53, 60, "Herb name"], [85, 95, "Drug"], [185, 188, "Target"]]}], [5910, "The assay was conducted in triplicate.", {"entities": []}], [5911, "To investigate whether Samento can also activate AhR, a reporter gene assay for AhR in AZ-AhR cells stably transfected with a construct containing several AhR binding sites upstream of a luciferase reporter gene was conducted using the Steady-Glo\u2122 Luciferase Assay System according to the manufacturer\u2019s instructions as described previously [27].", {"entities": [[23, 30, "Herb name"], [49, 52, "Target"], [80, 83, "Target"], [155, 172, "Target"]]}], [5912, "Compound-induced increases of AhR activity were normalized to the activity of non-treated controls (set to 1 = 100%).", {"entities": [[30, 33, "Target"]]}], [5913, "The assay was conducted in triplicate and omeprazole was used as a positive control.", {"entities": [[42, 52, "Drug"]]}], [5914, "To investigate whether the increase of CYP2J2 mRNA under treatment with Samento can be attributed to posttranscriptional regulation, we determined whether Samento influences the mRNA decay of this gene.", {"entities": [[39, 50, "Target"], [72, 79, "Herb name"], [155, 162, "Herb name"], [178, 182, "Target"]]}], [5915, "LS180 cells were treated with Samento (0.033 or 1%) or medium only for 12 h. Afterwards, transcription was inhibited by addition of 5 \u00b5g/mL actinomycin D and cells were harvested and RNA extracted after 3, 6, 9, or 12 h of treatment.", {"entities": [[30, 37, "Herb name"], [140, 153, "Drug"]]}], [5916, "mRNA was quantified by qRT-PCR as described above.", {"entities": [[0, 4, "Target"]]}], [5917, "Since \u03b22-microglobulin (\u03b22mg) revealed to be most stable among a set of housekeeping genes tested under treatment with actinomycin D, it was used for normalization.", {"entities": [[6, 29, "Target"], [119, 132, "Drug"]]}], [5918, "Data were analyzed using GraphPad Prism Version 7.02 and InStat Version 3.06 (GraphPad Software, San Diego, USA).", {"entities": []}], [5919, "IC In conclusion, Samento and Banderol exhibit a completely different in vitro profile as perpetrators in herb\u2013drug interactions.", {"entities": [[18, 25, "Herb name"], [30, 38, "Herb name"], [70, 78, "Study"]]}], [5920, "Whereas Banderol crystallized as a potent inhibitor of the uptake transporters OATP1B1 and OATP1B3, Samento\u2019s inhibitory potential on CYP3A4 and its property as a PXR agonist and thus as a gene inducer warrant caution when using these herbal extracts concomitantly with other drugs.", {"entities": [[8, 16, "Herb name"], [79, 86, "Target"], [91, 98, "Target"], [100, 107, "Herb name"], [134, 140, "Target"], [163, 166, "Target"]]}], [5921, "Clinical studies are strongly recommended to clarify whether the effects observed in vitro translate into the clinical setting.", {"entities": [[0, 16, "Study"], [82, 90, "Study"]]}], [5922, "Thanks to J. Kocher, S. Rosenzweig, C. Mueller, A. Fautsch, and T. R\u00fctzert for excellent technical assistance, to D. Ballinari (Pharmacia & Upjohn, Milano, Italy) for providing P388 and P388/dx cells, to A. H. Schinkel (The Netherlands Cancer Institute, Amsterdam, The Netherlands) for providing MDCKII-BCRP cells, to D. Keppler (German Cancer Research Centre, Heidelberg, Germany) for providing HEK-OATP1B1 and HEK-OATP1B3 cell lines, to Z. Dvorak (Palyck\u00fd University, Olomouc, Czech Republic) for providing the AZ-AhR cells, and to D. Theile for careful proofreading of the manuscript.", {"entities": [[337, 343, "Pathology"]]}], [5923, "Sample Availability: Samples of the compounds Samento and Banderol are available from the authors.", {"entities": [[46, 53, "Herb name"], [58, 66, "Herb name"]]}], [5924, "This research received no external funding.", {"entities": []}], [5925, "The author declares no conflict of interest.", {"entities": []}], [5926, "Concentration-dependent effect of Samento and Banderol on intracellular 8-cAMP fluorescence in HEK293 cells over-expressing organic anion transporting polypeptide (OATP)1B1 and OATP1B3, respectively, normalized to the mock-transfected control cell line.", {"entities": [[34, 41, "Herb name"], [46, 54, "Herb name"], [124, 172, "Target"], [177, 184, "Target"]]}], [5927, "Data depict a biological triplicate \u00b1 S.E.M.", {"entities": []}], [5928, "with 30,000 cells measured by flow cytometry for each concentration in each experiment.", {"entities": []}], [5929, "(a) OATP inhibition by Banderol.", {"entities": [[4, 8, "Target"], [23, 31, "Herb name"]]}], [5930, "(b) OATP inhibition by Samento.", {"entities": [[4, 8, "Target"], [23, 30, "Herb name"]]}], [5931, "Concentration-dependent effect of Samento and Banderol on the activity of different cytochrome P450 enzymes (CYPs) quantified by P450-Glo\u2122 Screening Systems.", {"entities": [[34, 41, "Herb name"], [46, 54, "Herb name"], [84, 114, "Target"]]}], [5932, "Each curve depicts the results of 3\u20134 experiments with each concentration tested in octuplet.", {"entities": []}], [5933, "Data are expressed as mean \u00b1 S.E.M.", {"entities": []}], [5934, "Samento did not change the activity of CYP2B6 and CYP2C19 and data are therefore not shown.", {"entities": [[0, 7, "Herb name"], [39, 45, "Target"], [50, 57, "Target"]]}], [5935, "(a) Inhibition of CYP1A2 by Samento and Banderol.", {"entities": [[18, 24, "Target"], [28, 35, "Herb name"], [40, 48, "Herb name"]]}], [5936, "(b) Inhibition of CYP2B6 Banderol.", {"entities": [[18, 24, "Target"], [25, 33, "Herb name"]]}], [5937, "(c) Inhibition of CYP2C19 by Banderol.", {"entities": [[18, 25, "Target"], [29, 37, "Herb name"]]}], [5938, "(d) Inhibition of CYP3A4 by Samento and Banderol.", {"entities": [[18, 24, "Target"], [28, 35, "Herb name"], [40, 48, "Herb name"]]}], [5939, "Influence of Samento on the mRNA expression of several drug metabolizing enzymes and drug transporters in LS180 cells.", {"entities": [[13, 20, "Herb name"], [28, 32, "Target"]]}], [5940, "Cells were incubated for four days with different concentrations (0.033\u20131%) of Samento, or the positive controls rifampicin (20 \u00b5M) and omeprazole (100 \u00b5M), or medium alone (negative control).", {"entities": [[79, 86, "Herb name"], [113, 123, "Drug"], [136, 146, "Drug"]]}], [5941, "After harvesting, RNA extraction, and cDNA synthesis, mRNA was quantified by RT-PCR.", {"entities": [[54, 58, "Target"]]}], [5942, "Expression data were normalized to the housekeeping gene GU and to the negative control.", {"entities": []}], [5943, "Data are expressed as mean \u00b1 S.E.M.", {"entities": []}], [5944, "for n = 5 biological replicates.", {"entities": []}], [5945, "Data were analyzed using ANOVA with Dunnett\u2019s post hoc test compared to the medium control.", {"entities": []}], [5946, "* p < 0.05, ** p < 0.01.", {"entities": []}], [5947, "Results of the reporter gene assays.", {"entities": []}], [5948, "Each curve depicts the results of three experiments with each concentration tested in triplicate.", {"entities": []}], [5949, "(a) Concentration-dependent effect of Samento and the positive control rifampicin (insert) on pregnane x receptor (PXR) activity.", {"entities": [[38, 45, "Herb name"], [71, 81, "Drug"], [94, 119, "Target"]]}], [5950, "(b) Concentration-dependent effect of Samento and the positive control omeprazole (insert) on aryl hydrocarbon receptor (AhR) activity.", {"entities": [[38, 45, "Herb name"], [71, 81, "Drug"], [94, 125, "Target"]]}], [5951, "Effects of Samento (0.033\u20131%) and the positive control rifampicin (20 \u00b5M) on the protein expression of P-glycoprotein (P-gp) after four days of exposure.", {"entities": [[11, 18, "Herb name"], [55, 65, "Drug"], [103, 124, "Target"], [125, 140, "Duration"]]}], [5952, "\u03b2-actin was used as a loading control.", {"entities": [[0, 7, "Target"]]}], [5953, "Exemplarily, 1 blot of a series of 5 is depicted.", {"entities": []}], [5954, "Effect of Samento on CYP2J2 mRNA decay in LS180 cells.", {"entities": [[10, 17, "Herb name"], [21, 32, "Target"]]}], [5955, "Cells were pre-treated with Samento (0.033 or 1%) or medium only for 12 h. Transcription was then inhibited by addition of 5 \u00b5g/mL actinomycin D and cells were harvested and RNA extracted after 3, 6, 9, or 12 h of treatment.", {"entities": [[28, 35, "Herb name"], [131, 144, "Drug"]]}], [5956, "Expression of CYP2J2 mRNA was quantified by RT-PCR and results normalized to \u03b22mg and to t = 0.", {"entities": [[14, 25, "Target"], [77, 81, "Target"]]}], [5957, "Data are expressed as mean \u00b1 S.E.M.", {"entities": []}], [5958, "for n = 3 biological replicates.", {"entities": []}], [5959, "The aim of this open-label, fixed-sequence study was to investigate the potential of Echinacea purpurea, a commonly used botanical supplement, to interact with the boosted protease inhibitor darunavir-ritonavir.", {"entities": [[16, 48, "Study"], [85, 103, "Herb name"], [160, 210, "Drug"]]}], [5960, "Individual darunavir pharmacokinetic parameters were calculated by noncompartmental analysis and compared between days 0 and 14 with the geometric mean ratio (GMR) and its 90% confidence interval (CI).", {"entities": [[11, 20, "Drug"], [106, 127, "Duration"]]}], [5961, "The median age was 49 (range, 43 to 67) years, and the body mass index was 24.2 (range, 18.7 to 27.5) kg/m", {"entities": [[19, 45, "Age"], [51, 70, "Parameter"], [75, 106, "Amount"]]}], [5962, "Effects of woohwangcheongsimwon suspension on the pharmacokinetics of bupropion and its active metabolite, 4-hydroxybupropion, in healthy subjects Hyunmi Kim,1 Soo Kyung Bae,1,2 Soo-Jin Park,1 Eon-Jeong Shim,1 Ho-Sook Kim,1 Ji-Hong Shon,1,2 Kwang-Hyeon Liu,1 and Jae-Gook Shin1,2 Author information Article notes Copyright and License information PMC Disclaimer Go to: Abstract AIMS  To examine the effects of woohwangcheongsimwon suspension on the pharmacokinetics of bupropion and its active metabolite, 4-hydroxybupropion, formed via CYP2B6 in vivo.", {"entities": [[11, 42, "Herb name"], [70, 79, "Drug"], [107, 125, "Drug"], [130, 137, "Pathology"], [410, 441, "Herb name"], [469, 478, "Drug"], [506, 524, "Drug"], [537, 543, "Target"], [544, 551, "Study"]]}], [5963, "In phases I and II, subjects received 150 mg bupropion with or without woohwangcheongsimwon suspension four times (at \u22120.17, 3.5, 23.5 and 47.5 h, with the time of bupropion administration taken as 0 h) in a randomized balanced crossover order.", {"entities": [[38, 44, "Amount"], [45, 54, "Drug"], [71, 102, "Herb name"], [103, 113, "Frequency"], [164, 173, "Drug"]]}], [5964, "Bupropion and 4-hydroxybupropion plasma concentrations were measured for up to 72 h by LC-MS/MS.", {"entities": [[0, 9, "Drug"], [14, 32, "Drug"]]}], [5965, "Urine was collected up to 24 h to calculate the renal clearance.", {"entities": [[48, 63, "Parameter"]]}], [5966, "In addition, the CYP2B6*6 genotype was also analyzed.", {"entities": [[17, 25, "Target"]]}], [5968, "The corresponding values for 4-hydroxybupropion were 0.856 (0.802, 0.912) and 0.845 (0.782, 0.914), respectively.", {"entities": [[29, 47, "Drug"]]}], [5969, "The tmax values of bupropion and 4-hydroxybupropion were not significantly different between the two groups (P > 0.05).", {"entities": [[4, 8, "Parameter"], [19, 28, "Drug"], [33, 51, "Drug"]]}], [5970, "The pharmacokinetic parameters of bupropion and 4-hydroxybupropion were unaffected by woohwangcheongsimwon suspension.", {"entities": [[34, 43, "Drug"], [48, 66, "Drug"], [86, 117, "Herb name"]]}], [5971, "CONCLUSIONS  These results indicate that woohwangcheongsimwon suspension has a negligible effect on the disposition of a single dose of bupropion in vivo.", {"entities": [[41, 72, "Herb name"], [136, 145, "Drug"], [146, 153, "Study"]]}], [5972, "As a result, temporary co-administration with woohwangcheongsimwon suspension does not seem to require a dosage adjustment of bupropion.", {"entities": [[46, 77, "Herb name"], [126, 135, "Drug"]]}], [5973, "Keywords: 4-hydroxybupropion, bupropion, CYP2B6, drug interaction, woohwangcheongsimwon suspension WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT      Woohwangcheongsimwon suspension has traditionally been used for the treatment and prevention of stroke, hypertension, palpitations, convulsions and unconsciousness in various Asian countries.", {"entities": [[10, 28, "Drug"], [30, 39, "Drug"], [41, 47, "Target"], [67, 98, "Herb name"], [145, 176, "Herb name"], [241, 247, "Pathology"], [249, 261, "Pathology"], [263, 275, "Pathology"], [277, 288, "Pathology"], [293, 308, "Pathology"], [320, 325, "Ethnic group"]]}], [5974, "Woohwangcheongsimwon suspensions showed an inhibitory effect on CYP2B6 activity in vitro.", {"entities": [[0, 32, "Herb name"], [64, 70, "Target"], [80, 88, "Target"]]}], [5975, "Two terpenoids, borneol and isoborneol, are major constituents of woohwangcheongsimwon suspension, and show a competitive inhibition of CYP2B6 with Ki values of 9.5 and 5.9 \u00b5m, respectively.", {"entities": [[4, 14, "Herb name"], [16, 23, "Herb name"], [28, 38, "Herb name"], [66, 97, "Herb name"], [136, 142, "Target"]]}], [5976, "Bupropion undergoes metabolic transformation to the active metabolite, 4-hydroxybupropion, primarily via CYP2B6 both in vivo and in vitro.", {"entities": [[0, 9, "Drug"], [71, 89, "Drug"], [105, 111, "Target"], [117, 124, "Study"], [129, 137, "Study"]]}], [5977, "It is often used as a CYP2B6 substrate for clinical drug\u2013drug interaction studies.", {"entities": [[22, 28, "Target"], [43, 81, "Study"]]}], [5978, "Drug interactions may occur between woohwangcheongsimwon suspension and bupropion.", {"entities": [[36, 67, "Herb name"], [72, 81, "Drug"]]}], [5979, "WHAT THIS STUDY ADDS      Co-administration with woohwangcheongsimwon suspension did not alter the pharmacokinetics of bupropion or its metabolite, 4-hydroxybupropion.", {"entities": [[49, 80, "Herb name"], [119, 128, "Drug"], [148, 166, "Drug"]]}], [5980, "Dosage adjustment of bupropion is unnecessary in patients concomitantly administered the highest recommended daily dose of woohwangcheongsimwon suspension.", {"entities": [[21, 30, "Drug"], [123, 154, "Herb name"]]}], [5981, "Go to: Introduction  Woohwangcheongsimwon suspension (sometimes called \u2018uwhangchungsimwon\u2019), composed of 24 medicinal herbs (listed in Table 1), is a commonly used herbal medicine in Korea and other East Asian countries.", {"entities": [[21, 52, "Herb name"], [72, 89, "Herb name"], [204, 209, "Ethnic group"]]}], [5982, "Its original formulation was in a tablet form.", {"entities": []}], [5983, "It has been officially listed in the Korean Pharmaceutical Codex for a long time and an aqueous suspension has recently been developed for convenient administration [1].", {"entities": [[37, 43, "Ethnic group"], [88, 106, "Extraction process"]]}], [5984, "It has been widely used for treatment and prevention of stroke, hypertension, palpitations, convulsions and unconsciousness [2].", {"entities": [[56, 62, "Pathology"], [64, 76, "Pathology"], [78, 90, "Pathology"], [92, 103, "Pathology"], [108, 123, "Pathology"]]}], [5985, "In Korea, woohwangcheongsimwon suspension can easily be obtained over the counter in local pharmacies; nowadays, it is often preferred as a preventive medicine rather than a treatment.", {"entities": [[10, 41, "Herb name"]]}], [5986, "Table 1  The major ingredients of woohwangchengonsimwon suspension (Kwang-Dong Pharmaceutical Company, Seoul, Korea) Ingredients\tQuantity in 30 ml (mg) Bovis Calculus\t14 Dioscoreae Rhizoma\t282 Glycyrrhizae Radix et Rhizoma\t202 Ginseng Radix\t97 Typhae Pollen\t100 Massa Medicata Fermentata\t100 Glycine Semen Germinatum\t70 Cinnamomi cortex\t70 Paeoniae Radix\t60 Liriopis Tuber\t60 Scutellariae Radix\t60 Angelicae Gigantis Radix\t60 Saposhnikoviae Radix\t60 Atractylodis Rhizoma Alba\t60 Bupleuri Radix\t50 Platycodonis Radix\t50 Armeniacae Semen\t50 Poria Sclerotium\t50 Cnidii Rhizoma\t50 Civet\t15 Antelopis Cornu\t35 Borneolum*\t41 Ampelopsis Radis\t30 Zingiberis Rhizoma\t30 Open in a separate window *Borneolum included 38.58 mg of borneol and isoborneol.", {"entities": [[34, 66, "Herb name"], [170, 180, "Herb name"], [181, 188, "Herb part"], [193, 205, "Herb name"], [206, 211, "Herb part"], [215, 222, "Herb part"], [227, 234, "Herb name"], [235, 240, "Herb part"], [244, 250, "Herb name"], [251, 257, "Herb part"], [262, 287, "Herb name"], [320, 329, "Herb name"], [330, 336, "Herb part"], [340, 348, "Herb name"], [349, 354, "Herb part"], [358, 366, "Herb name"], [367, 372, "Herb part"], [376, 388, "Herb name"], [389, 394, "Herb part"], [398, 416, "Herb name"], [417, 422, "Herb part"], [426, 440, "Herb name"], [441, 446, "Herb part"], [450, 462, "Herb name"], [463, 470, "Herb part"], [479, 487, "Herb name"], [488, 493, "Herb part"], [497, 509, "Herb name"], [510, 515, "Herb part"], [519, 529, "Herb name"], [539, 555, "Herb name"], [559, 565, "Herb name"], [566, 573, "Herb part"], [577, 582, "Herb name"], [605, 614, "Herb name"], [619, 629, "Herb name"], [630, 635, "Herb part"], [639, 649, "Herb name"], [650, 657, "Herb part"], [688, 697, "Herb name"], [719, 726, "Herb name"], [731, 741, "Herb name"]]}], [5987, "Our previous studies have reported that woohwangcheongsimwon suspension inhibited CYP2B6 activity in vitro.", {"entities": [[40, 71, "Herb name"], [82, 88, "Target"], [98, 106, "Study"]]}], [5988, "Two terpenoids, borneol and isoborneol, are major constituents of woohwangcheongsimwon suspension, and show competitive inhibition of CYP2B6, with Ki values of 9.5 and 5.9 \u00b5m, respectively [2].", {"entities": [[4, 14, "Herb name"], [16, 23, "Herb name"], [28, 38, "Herb name"], [66, 97, "Herb name"], [134, 140, "Target"]]}], [5989, "Furthermore, we found that other monoterpenes, such as citral and geraniol, have inhibitory potency on CYP2B6-catalyzed bupropion 4-hydroxylation as well as isoborneol and borneol [3].", {"entities": [[33, 45, "Herb name"], [55, 61, "Herb name"], [66, 74, "Herb name"], [103, 109, "Target"], [120, 129, "Drug"], [157, 167, "Herb name"], [172, 179, "Herb name"]]}], [5990, "These findings suggested that a drug interaction study of woohwangcheongsimwon and CYP2B6 substrates in humans should be undertaken.", {"entities": [[58, 78, "Herb name"], [83, 89, "Target"]]}], [5991, "Bupropion is a monocyclic aminoketone that was first used as an antidepressant and subsequently found to be effective as an antismoking agent [4].", {"entities": [[0, 9, "Drug"]]}], [5992, "CYP2B6 is the major enzyme involved in biotransformation of bupropion to its active metabolite, 4-hydroxybupropion both in vivo and in vitro [5\u201310].", {"entities": [[0, 6, "Target"], [60, 69, "Drug"], [96, 114, "Drug"]]}], [5993, "Several studies have examined the interaction between bupropion as a probe substrate of CYP2B6 and other medications [7\u201310].", {"entities": [[54, 63, "Drug"], [88, 94, "Target"]]}], [5994, "Rifampicin treatment increases apparent clearance of bupropion by inducing CYP2B6 in vivo [7], whereas concomitant use of ticlopidine or clopidogrel significantly inhibits CYP2B6-catalyzed bupropion 4-hydroxylation [8].", {"entities": [[0, 10, "Drug"], [31, 49, "Parameter"], [53, 62, "Drug"], [75, 81, "Target"], [122, 133, "Drug"], [137, 148, "Drug"], [172, 178, "Target"], [189, 198, "Drug"]]}], [5995, "At high plasma concentrations, bupropion use increases the risk of seizure as a side-effect [11], which may be clinically important when bupropion is used with other drugs that affect its metabolism.", {"entities": [[31, 40, "Drug"], [67, 74, "Pathology"], [80, 91, "Pathology"], [137, 146, "Drug"]]}], [5996, "Although woohwangcheongsimwon is one of the most commonly used herbal medications in Korea, no clinical studies have been performed to determine the effect of woohwangcheongsimwon suspension on CYP2B6 activity or interactions with other drugs.", {"entities": [[9, 29, "Herb name"], [95, 111, "Study"], [159, 190, "Herb name"], [194, 200, "Target"]]}], [5997, "The purpose of this study was to investigate whether woohwangcheongsimwon suspension inhibits CYP2B6-catalyzed bupropion 4-hydroxylation in healthy male volunteers.", {"entities": [[53, 84, "Herb name"], [94, 100, "Target"], [111, 120, "Drug"], [140, 147, "Pathology"], [148, 152, "Sex"]]}], [5998, "All volunteers were determined healthy based on medical history, physical examination, vital signs and clinical laboratory tests performed 2 weeks or less before the start of the study.", {"entities": [[31, 38, "Pathology"]]}], [5999, "They were non-smokers, ate a normal diet, and none was a user of botanical supplements.", {"entities": []}], [6000, "Subjects were instructed to refrain from alcohol, caffeine, fruit juice and cruciferous vegetables throughout the study, and these limitations were further emphasized 1 week before probe drug administration.", {"entities": []}], [6001, "Subjects were also asked to abstain from taking prescription and over the counter medications for 2 weeks before and during the study period.", {"entities": []}], [6002, "The study protocol was approved by the Institutional Review Board of Inje University Busan Paik Hospital, Busan, Korea.", {"entities": []}], [6003, "In addition, all participants provided written informed consent prior to enrolment in this study.", {"entities": []}], [6004, "CYP2B6 genotyping  CYP2B6 genotyping was performed by pyrosequencing of polymerase chain reaction (PCR) products as described previously [13].", {"entities": [[0, 6, "Target"], [19, 25, "Target"]]}], [6005, "Commonly accepted CYP2B6 alleles consisting of a combination of the nucleotides at cDNA positions 516 and 785 were assessed; the wild-type allele CYP2B6*1 was defined as 516G/785A, while CYP2B6*6 was defined as 516T/785G.", {"entities": [[18, 32, "Target"], [129, 154, "Target"], [187, 195, "Target"]]}], [6006, "Study design  This study had an open-label, two-treatment crossover and randomized design with two phases.", {"entities": [[29, 105, "Study"]]}], [6007, "All doses of sustained-release bupropion 150 mg (Wellbutrin SR, GlaxoSmithKline, Research Triangle Park, NC) and each bottle (30 ml) of woohwangcheongsimwon suspension manufactured in compliance with the Korean Pharmaceutical Codex (Kwang-Dong Pharmaceutical Company, Seoul, Korea) were administered by study personnel with a standard low-fat meal.", {"entities": [[31, 40, "Drug"], [41, 47, "Amount"], [49, 62, "Amount"], [136, 167, "Herb name"], [204, 210, "Ethnic group"]]}], [6008, "In phases I and II, in randomized balanced crossover order, subjects received a dose of 150 mg bupropion alone as a control phase or 150 mg bupropion plus four doses of woohwangcheongsimwon suspension reflecting its maximal daily dosage at \u22120.17, 3.5, 23.5 and 47.5 h, with the time of bupropion administration taken as 0 h. In addition, a 2 week washout period was imposed between the two phases.", {"entities": [[88, 94, "Amount"], [95, 104, "Drug"], [133, 139, "Amount"], [140, 149, "Drug"], [155, 165, "Amount"], [169, 200, "Herb name"], [286, 295, "Drug"]]}], [6009, "Safety monitoring was performed throughout the study.", {"entities": []}], [6010, "Blood and urine sampling  Venous blood samples (5 ml each) were collected in lithium heparin tubes drawn from forearm venous catheters before drug administration on the first day of the study and following specified doses of bupropion alone and bupropion plus woohwangcheongsimwon suspension.", {"entities": [[225, 234, "Drug"], [245, 254, "Drug"], [260, 291, "Herb name"]]}], [6011, "Sampling for bupropion and its metabolite, 4-hydroxybupropion, was performed before and at 1, 2, 3, 4, 5, 6, 7, 8, 12, 24, 48 and 72 h after bupropion administration on study day 1 in each phase.", {"entities": [[13, 22, "Drug"], [43, 61, "Drug"], [141, 150, "Drug"]]}], [6012, "A spot of urine was collected as a blank sample before trial drug administration, and then urine was collected until 24 h after bupropion administration.", {"entities": [[128, 137, "Drug"]]}], [6013, "After collection, plasma was separated by centrifugation at 3000 rev min\u22121 for 10 min at 4\u00b0C.", {"entities": []}], [6014, "The plasma was transferred into cryovials and stored at \u201380\u00b0C until analysis.", {"entities": []}], [6015, "Urine was also stored at \u201380\u00b0C after measuring its volume.", {"entities": []}], [6016, "LC-MS/MS analysis of bupropion and 4-hydroxybupropion  Plasma or urine samples were analyzed for bupropion and 4-hydroxybupropion concentration using our LC-MS/MS method.", {"entities": [[21, 30, "Drug"], [35, 53, "Drug"], [97, 106, "Drug"], [111, 129, "Drug"]]}], [6017, "Briefly, samples were prepared by a simple deproteinization procedure involving the addition of 0.2 ml of acetonitrile containing 0.2 \u00b5m phenacetin as an internal standard to 0.1 ml of plasma sample.", {"entities": []}], [6018, "Chromatographic separation was carried on a reversed-phase column (Luna phenyl-hexyl 2.0 mm i.d.", {"entities": []}], [6019, "\u00d7 100 mm, 3 \u00b5m particle size; Phenomenex, Torrance, CA), with an isocratic mobile phase consisting of acetonitrile and distilled water containing 0.1% formic acid (60:40, v : v), a flow rate of 0.2 ml min\u22121 and a total run time of 3.0 min per sample.", {"entities": []}], [6020, "Detection and quantification were performed using a mass spectrometer in the selected reaction-monitoring mode with positive electrospray ionization at m/z 240 \u2192 184 for bupropion, m/z 256 \u2192 238 for 4-hydroxybupropion and m/z 180 \u2192 110 for phenacetin.", {"entities": [[170, 179, "Drug"], [199, 217, "Drug"]]}], [6021, "The TurboIonSpray interface was operated in positive ion mode at 5500 V and 500\u00b0C.", {"entities": []}], [6022, "The operating conditions were as follows: nebulizing gas flow, 8 l min\u22121; curtain gas flow, 10 l min\u22121; collision gas (nitrogen) pressure, medium; collision energy, 25 eV.", {"entities": []}], [6023, "Quadrupoles Q1 and Q3 were set on unity resolution.", {"entities": []}], [6024, "The analytical data were processed using Analyst software (version 1.4, Applied Biosystems, Foster City, CA).", {"entities": []}], [6025, "The assay was linear over a concentration range of 0.4\u2013200 ng ml\u22121 with a lower limit of quantification of 0.4 ng ml\u22121 for bupropion and 1\u2013500 ng ml\u22121 with a lower limit of quantification of 1 ng ml\u22121 for 4-hydroxybupropion, respectively, in human plasma.", {"entities": [[123, 132, "Drug"], [205, 223, "Drug"]]}], [6026, "Inter-day and intra-day coefficients of variation were less than 15% for both analytes.", {"entities": []}], [6027, "No relevant cross-talk or matrix effect was observed.", {"entities": []}], [6028, "Urine samples were diluted up to 50-fold with acetonitrile containing an internal standard following the same preparation.", {"entities": []}], [6029, "To determine total 4-hydroxybupropion, \u03b2-glucuronidase from Helix pomatia (2500 units ml\u22121 in 0.2 m acetate buffer, pH 5.0; Sigma-Aldrich, St Louis, MO) was added to a 10 \u00b5l aliquot of urine [14].", {"entities": [[19, 37, "Drug"]]}], [6030, "The mixture was manually mixed and incubated in a water-bath shaker kept at 37\u00b0C and at a rate of 50 oscillations min\u22121 for 2 h. Other procedures were similar to those of plasma samples.", {"entities": []}], [6031, "Pharmacokinetic analysis  The pharmacokinetic parameters of bupropion and 4-hydroxybupropion were calculated by noncompartmental analysis techniques using WinNonlin Professional software (version 5.2; Pharsight Corporation, Mountain View, CA).", {"entities": [[60, 69, "Drug"], [74, 92, "Drug"]]}], [6032, "The peak plasma concentration (Cmax) values and time to reach Cmax (tmax) were obtained directly from the observed plasma concentration\u2013time data.", {"entities": [[4, 36, "Parameter"], [48, 73, "Parameter"]]}], [6033, "The elimination rate constant (\u03bbz) was estimated from the least-squares regression slope of terminal plasma concentrations.", {"entities": [[0, 34, "Parameter"]]}], [6036, "The half-life (t1/2) of bupropion and 4-hydroxybupropion was calculated as 0.693/\u03bbz, the oral clearance of bupropion (CL/F) was calculated as dose/AUC(0,\u221e).", {"entities": [[4, 20, "Parameter"], [24, 33, "Drug"], [38, 56, "Drug"], [89, 103, "Parameter"], [107, 116, "Drug"], [117, 123, "Parameter"], [147, 155, "Parameter"]]}], [6037, "The renal clearance (CLR) was calculated as the ratio of Ae to AUC(0,\u221e), where Ae is the amount of bupropion excreted as unchanged drug into the urine within 24 h. Safety assessment  Safety was evaluated throughout the clinical study based on adverse event (AE) monitoring, clinical laboratory values, vital sign measurements and physical examination findings.", {"entities": [[0, 25, "Parameter"], [63, 71, "Parameter"], [99, 108, "Drug"], [219, 233, "Study"], [243, 261, "Pathology"]]}], [6038, "Statistical analysis  Study sample sizes were determined from variance estimates based on prior bupropion pharmacokinetic data.", {"entities": [[96, 105, "Drug"]]}], [6039, "To determine clinically relevant interactions, we used the bioequivalence approach [15].", {"entities": []}], [6040, "Geometric means were calculated for the AUC(0,\u221e), Cmax and so on of bupropion and 4-hydroxybupropion.", {"entities": [[40, 48, "Parameter"], [50, 54, "Parameter"], [68, 77, "Drug"], [82, 100, "Drug"]]}], [6041, "Geometric mean ratios (GMRs) with 90% confidence intervals (CIs) were calculated after log transformation of within-subject data.", {"entities": []}], [6042, "In addition, comparison of the tmax for the different treatment groups in vivo was performed using the Wilcoxon signed-rank test.", {"entities": [[31, 35, "Parameter"], [71, 78, "Study"]]}], [6043, "All statistical analyses were performed with the SAS software package (version 9.1.3; SAS Institute, Cary, NC) and P < 0.05 was considered statistically significant.", {"entities": []}], [6044, "The results are expressed as the means\u00b1standard deviation (SD), with the exception of tmax, which is expressed as the median (range).", {"entities": [[86, 90, "Parameter"]]}], [6045, "Go to: Results  All 14 subjects completed both phases according to the study protocol.", {"entities": [[20, 31, "Parameter"]]}], [6046, "None of the subjects reported any remarkable side-effects during the study period.", {"entities": [[45, 57, "Pathology"]]}], [6047, "No clinically significant alterations in blood pressure, heart rate or body temperature were observed.", {"entities": [[41, 55, "Parameter"], [57, 67, "Parameter"], [71, 87, "Parameter"]]}], [6048, "Mean plasma concentration\u2013time profiles of bupropion and 4-hydroxybupropion with or without woohwangcheongsimwon suspension were very similar, and some relevant pharmacokinetic parameters of bupropion and 4-hydroxybupropion are summarized in Table 2.", {"entities": [[43, 52, "Drug"], [57, 75, "Drug"], [92, 123, "Herb name"], [191, 200, "Drug"], [205, 223, "Drug"]]}], [6049, "As shown in Table 2, pharmacokinetic parameters of bupropion and 4-hydroxybupropion were comparable between the two groups.", {"entities": [[51, 60, "Drug"], [65, 83, "Drug"]]}], [6050, "The GMR and 90% CI of bupropion with woohwangcheonsimwon suspension relative to bupropion alone were 0.976 (0.917, 1.04) for AUC(0,\u221e) and 0.948 (0.830, 1.08) for Cmax, respectively.", {"entities": [[22, 31, "Drug"], [37, 67, "Herb name"], [80, 89, "Drug"], [125, 133, "Parameter"], [162, 166, "Parameter"]]}], [6051, "The corresponding values for 4-hydroxybupropion were 0.856 (0.802, 0.912) and 0.845 (0.782, 0.914), respectively.", {"entities": [[29, 47, "Drug"]]}], [6052, "The tmax of bupropion and 4-hydroxybupropion were not significantly different between the two groups (P > 0.05).", {"entities": [[4, 8, "Parameter"], [12, 21, "Drug"], [26, 44, "Drug"]]}], [6053, "Woohwangcheongsimwon suspension did not seem to affect the pharmacokinetic parameters of bupropion or 4-hydroxybupropion.", {"entities": [[0, 31, "Herb name"], [89, 98, "Drug"], [102, 120, "Drug"]]}], [6054, "In addition, the results of CYP2B6 genotyping indicated that our study population included two CYP2B6*1/*6 and 12 wild-type subjects, although this was insufficient to elucidate the interindividual differences in pharmacokinetic parameters (data are not shown).", {"entities": [[28, 34, "Target"], [95, 106, "Target"]]}], [6055, "The percentage of the oral dose of bupropion excreted in 24 h urine samples as intact drug was almost negligible in both groups.", {"entities": [[35, 44, "Drug"]]}], [6056, "The Ae values of both free (unconjugated) and total 4-hydroxybupropion were comparable between the two groups (Table 2).", {"entities": [[52, 70, "Drug"]]}], [6057, "The ratios of Aefree 4-hydroxybupropion : Aetotal 4-hydroxybupropion were 0.200 \u00b1 0.0567 and 0.201 \u00b1 0.0576 for bupropion alone and co-administration with woohwangcheongsimwon suspension, respectively, suggesting that glucuronidation activity was not changed by co-administration of woohwangcheongsimwon.", {"entities": [[21, 39, "Drug"], [50, 68, "Drug"], [112, 121, "Drug"], [155, 186, "Herb name"], [283, 303, "Herb name"]]}], [6059, "\u2020Not significant.", {"entities": []}], [6060, "\u2021Percentage of the bupropion dose excreted as free (unconjugated) form of 4-hydroxybupropion in the 24 h urine.", {"entities": [[19, 28, "Drug"], [74, 92, "Drug"]]}], [6061, "\u00a7Percentage of the bupropion dose excreted as total form of 4-hydroxybupropion in the 24-h urine.", {"entities": [[19, 28, "Drug"], [60, 78, "Drug"]]}], [6062, "Go to: Discussion  In this study, we examined the CYP2B6 inhibitory effects of woohwangcheongsimwon suspension on the pharmacokinetics of bupropion.", {"entities": [[50, 56, "Target"], [79, 110, "Herb name"], [138, 147, "Drug"]]}], [6063, "The maximum recommended daily dose (two bottles per day) of woohwangcheongsimwon suspension was assessed to maximize the CYP2B6 inhibitory potential of the woohwangcheongsimwon suspension.", {"entities": [[36, 47, "Amount"], [48, 55, "Frequency"], [60, 91, "Herb name"], [121, 127, "Target"], [156, 187, "Herb name"]]}], [6064, "To avoid confounding factors in this study, male, healthy, non-smoking subjects were selected, as oral contraceptives and smoking have been reported to affect CYP2B6 activity [9, 16].", {"entities": [[44, 48, "Sex"], [50, 57, "Pathology"], [159, 165, "Target"]]}], [6065, "In previous studies, only moderate changes in the AUC or Cmax of bupropion were observed with use of ticlopidine or clopidogrel, both of which are potent CYP2B6 inhibitors [8].", {"entities": [[50, 53, "Parameter"], [57, 61, "Parameter"], [65, 74, "Drug"], [101, 112, "Drug"], [116, 127, "Drug"], [154, 160, "Target"]]}], [6066, "In addition, the CYP2B6*6 allele, which is associated with reduced CYP2B6 activity, did not change the AUC or Cmax of bupropion compared with the wild type, although some alterations were observed in those of 4-hydroxybupropion [17].", {"entities": [[17, 32, "Target"], [67, 73, "Target"], [103, 106, "Parameter"], [110, 114, "Parameter"], [118, 127, "Drug"], [209, 227, "Drug"]]}], [6067, "As alternative metabolic pathways become progressively more important when the biotransformation to 4-hydroxybupropion is blocked, these alternative ketone-reduction pathways leading to the formation of the erythro-hyrdrobupropion and threo-hydrobupropion seem not to be mediated by CYP.", {"entities": [[100, 118, "Drug"], [207, 230, "Drug"], [235, 255, "Drug"], [283, 286, "Target"]]}], [6068, "Therefore, for CYP2B6 phenotyping purposes, quantification of the extent of 4-hydroxybupropion formation is necessary [8].", {"entities": [[15, 21, "Target"], [76, 94, "Drug"]]}], [6069, "Our results show that the maximum recommended daily dose of woohwangcheongsimwon suspension had no effect on the pharmacokinetics of bupropion or 4-hydroxybupropion.", {"entities": [[60, 91, "Herb name"], [133, 142, "Drug"], [146, 164, "Drug"]]}], [6070, "Co-administration with woohwangcheongsimwon did not result in clinically meaningful changes in exposure (AUC) of bupropion and 4-hydroxybupropion, as the 90% CIs for the ratio of geometric means were contained within the commonly applied no-effect bounds of 0.8, 1.25 (Table 2).", {"entities": [[23, 43, "Herb name"], [105, 108, "Parameter"], [113, 122, "Drug"], [127, 145, "Drug"]]}], [6071, "The metabolic ratios, calculated as the AUC ratio of 4-hydroxybupropion to bupropion, did not differ between the two groups: 15.8 \u00b1 4.62 and 13.8 \u00b1 4.12 in the absence and presence of woohwangcheongsimwon suspension, respectively.", {"entities": [[40, 43, "Parameter"], [53, 71, "Drug"], [75, 84, "Drug"], [184, 215, "Herb name"]]}], [6072, "This suggests that woohwangcheongsimwon suspension does not alter CYP2B6 activity determined by 4-hydroxylation of bupropion in vivo.", {"entities": [[19, 50, "Herb name"], [66, 72, "Target"], [115, 124, "Drug"]]}], [6073, "There is a limitation in explaining the dosing interval of woohwangcheongsimwon in the absence of available information on its pharmacokinetic properties.", {"entities": [[59, 79, "Herb name"]]}], [6074, "We designed the experiment to maximize the inhibitory effects of woohwangcheongsimwon as in other drug\u2013drug interaction studies, based on the maximum inhibitory dosage, within the recommended daily dosage.", {"entities": [[65, 85, "Herb name"]]}], [6075, "Considering the practical use of woohwangcheongsimwon for acute treatment, we applied the third and fourth dosages afterwards.", {"entities": [[33, 53, "Herb name"]]}], [6076, "A bottle of woohwangcheongsimwon suspension contains a total of 38.58 mg of borneol and isoborneol (Table 1).", {"entities": [[12, 43, "Herb name"], [64, 72, "Amount"], [76, 83, "Herb name"], [88, 98, "Herb name"]]}], [6077, "To our knowledge, no information is available regarding the bioavailability of either in humans.", {"entities": [[60, 75, "Parameter"]]}], [6078, "However, we postulated that their bioavailabilities would be low, based on the results of previous studies with other monoterpenes such as 1,8-cineole [18, 19].", {"entities": [[34, 51, "Parameter"], [118, 150, "Herb name"]]}], [6079, "We did not determine plasma concentrations of borneol and isoborneol after oral administration of woohwangcheongsimwon suspension.", {"entities": [[46, 53, "Herb name"], [58, 68, "Herb name"], [98, 129, "Herb name"]]}], [6080, "However, the plasma concentrations of borneol and isoborneol after administration of woohwangcheongsimwon suspension are likely lower than their Ki values, and therefore, do not have an effect in vivo.", {"entities": [[38, 45, "Herb name"], [50, 60, "Herb name"], [85, 116, "Herb name"]]}], [6081, "In summary, the results of the present study indicate that the maximum daily dose of woohwangcheongsimwon suspension has little inhibitory effect on CYP2B6-catalyzed 4-hydroxylation of bupropion in vivo.", {"entities": [[85, 116, "Herb name"], [149, 155, "Target"], [185, 194, "Drug"]]}], [6082, "For this systematic review, we explored 2183 published papers about herbal drugs interactions from November 1967 to August 2014, fulfilling eligibility criteria by searching in some databases such as Web of Science, Medline, Scopus, Embase, Cinahl, and the Cochrane database.", {"entities": [[9, 26, "Study"], [68, 80, "Herb name"], [94, 127, "Duration"]]}], [6083, "The main keywords used for searching included: herbal medicine, herbs, statin, lipid, and herb-drug interaction.", {"entities": [[47, 69, "Herb name"], [71, 77, "Drug"], [79, 84, "Parameter"]]}], [6084, "Among published articles about herb-drug interactions, 185 papers met the initial search criteria and among them, 92 papers were potentially retrievable including a description of 17 herbs and medicinal plants.", {"entities": [[183, 209, "Herb name"]]}], [6085, "In first step and by reviewing all published manuscripts on beneficial effects of herbs on serum lipids level, 17 herbs were described to be effective on lipid profile as lowering serum triglyceride, total cholesterol, low-density lipoprotein cholesterol as well as increasing serum high-density lipoprotein level.", {"entities": [[91, 109, "Parameter"], [154, 167, "Parameter"], [180, 198, "Parameter"], [200, 218, "Parameter"], [219, 254, "Parameter"], [277, 313, "Parameter"]]}], [6086, "Some herbs such as celery could even affect the hepatic triglyceride concentrations.", {"entities": [[19, 25, "Herb name"], [44, 83, "Parameter"]]}], [6087, "The herbal reaction toward different types of statins is varied so that grapefruit or pomegranate was interacted with only some types of statins, but not with all statin types.", {"entities": [[46, 53, "Drug"], [72, 82, "Herb name"], [86, 97, "Herb name"], [137, 144, "Drug"], [163, 169, "Drug"]]}], [6088, "Ischemic heart disease is one of the major causes of mortality and disabilities whole of the world, particularly in developing countries.", {"entities": [[0, 22, "Pathology"], [53, 79, "Pathology"]]}], [6089, "Because of its rapid progression in order to inappropriate lifestyle and nutritional modification, it has been produced as the greatest vulnerable event.1 The pattern of the spread of disease is highly associated with quality control of its major risk factors that among them, hyperlipidemia has the main staple role.2,3 Nowadays, tend to use synthetic drugs to lower serum lipid in patients with hyperlipidemia is gradually decreased because of their related side effects, as well as a progression of drug resistance.", {"entities": [[184, 191, "Pathology"], [277, 291, "Pathology"], [343, 358, "Drug"], [368, 379, "Parameter"], [397, 411, "Pathology"], [460, 472, "Pathology"], [502, 517, "Parameter"]]}], [6090, "In this regard, tend to use of medicinal plants has been doubled.4 However, in some cases, the multi-drug prescription such as using synthetic drugs and herbs become a necessary, leading herb-drug interaction that is a major concern of specialists in pharmacology.", {"entities": [[31, 47, "Herb name"], [133, 148, "Drug"]]}], [6091, "These interactions may also increase pharmacological therapeutic effect that is more important in drugs with low safety and narrow therapeutic indices.5 Unfortunately, the vast majority of these products are used unlicensed without the assessment of efficacy, safety, or quality.", {"entities": [[37, 71, "Parameter"]]}], [6093, "The present systematic review aimed to express the clinical anti-lipid effects of different types of herbs as well as described studied interactions between herbal remedies and prescribed drugs for hyperlipidemic patients which were based on in vitro experiments, animal studies, and empirical clinical experiences.", {"entities": [[12, 29, "Study"], [60, 78, "Parameter"], [157, 172, "Herb name"], [177, 193, "Drug"], [198, 212, "Pathology"], [242, 262, "Study"], [264, 278, "Study"], [284, 314, "Study"]]}], [6094, "For this systematic review, we explored 2183 published papers about herbal drugs interactions from November 1967 to August 2014, fulfilling eligibility criteria by searching in some databases such as Web of Science, Medline, Scopus, Embase, Cinahl and the Cochrane database.", {"entities": [[9, 26, "Study"], [68, 80, "Herb name"], [94, 127, "Duration"]]}], [6095, "Our research was restricted to English language studies.", {"entities": []}], [6096, "The main keywords used for searching included: herbal medicine, herbs, statin, lipid, and herb-drug interaction.", {"entities": [[47, 69, "Herb name"], [71, 77, "Drug"], [79, 84, "Parameter"]]}], [6097, "Studies were included, and eligible if evaluated herb-drug interactions in therapeutic regimens for treatment of hyperlipidemia.", {"entities": [[113, 127, "Pathology"]]}], [6098, "In this review, case reports were excluded.", {"entities": [[16, 28, "Study"]]}], [6099, "Papers matching inclusion criteria were reviewed in detail.", {"entities": []}], [6100, "Methodology of papers quality assessment was performed on the basis of some methodological elements that were previously described.10 These criteria were including: prospective data collection, method of sampling, age range specification, inclusion and exclusion items specification, study setting specification, measurement tools validation, definition of disease status, sex and age specific prevalence report, data collection description, study limitations and possible correlates of disease and complications.", {"entities": [[357, 364, "Pathology"], [487, 512, "Pathology"]]}], [6101, "Among 2183 published articles about herb-drug interactions, 185 papers met the initial search criteria and among them, 92 papers were potentially retrievable including a description of 17 herbs and medicinal plants.", {"entities": [[188, 214, "Herb name"]]}], [6102, "Anti-lipid effects of herbs and related mechanisms  Among all studies evaluating effects of herbs on lipid profile and also those who assessed interactions between these herbs and lipid-lowering drugs, especially statins (Table 1), a minority of the studies focused on herb-drug interactions.", {"entities": [[0, 18, "Pathology"], [101, 114, "Parameter"], [180, 200, "Drug"], [213, 220, "Drug"]]}], [6103, "Furthermore, with respect to the mechanisms of action as well as biological pathways involving drug interactions, these mechanisms have not been completely understood.", {"entities": []}], [6104, "It seems that the main enzymatic pathways involved in this mechanisms include displaying 1,1-diphenyl-2-picrylhydrasyl and superoxide radical scavenging activities and inhibited hemolysis induced by 2,2\u2019-azobis-2-amidinopropane dihydrochloride in a dose-dependent manner.42-45 The anti-lipid effects of the grape are mostly mediated by resveratrol component that can significantly lower oxidized LDL and elevate HDL-C level that can be beneficial in atherosclerosis prevention.", {"entities": [[89, 163, "Parameter"], [199, 243, "Parameter"], [281, 299, "Parameter"], [307, 312, "Herb name"], [336, 357, "Herb name"], [387, 399, "Parameter"], [412, 423, "Parameter"], [450, 465, "Pathology"]]}], [6105, "The alterations in the lipid metabolic pathways induced by GSPE were accompanied by lower free fatty acid levels in the plasma and decreased lipid and triglyceride accumulation.", {"entities": [[59, 63, "Herb name"], [90, 126, "Parameter"], [141, 176, "Parameter"]]}], [6108, "However, its physiological pathways have been already questioned.64,65 Among different types of herbs, the position of dill as an anti-lipid agent is highlighted.", {"entities": [[119, 123, "Herb name"], [130, 146, "Parameter"]]}], [6110, "Interaction between herbs and lipid lowering drugs  Regarding interaction between statin drugs and herbs which involved in lowering serum lipid profile, a few studies have been published.", {"entities": [[30, 50, "Drug"], [82, 94, "Drug"], [132, 151, "Parameter"]]}], [6111, "In a recent study by Rosenblat et al., although simvastatin with the dose 15 \u03bcg/ml could decrease macrophage cholesterol biosynthesis rate by 42% as compared to control cells, the combination of pomegranate and simvastatin resulted in an inhibitory effect up to 59% that was significant.", {"entities": [[48, 59, "Drug"], [74, 82, "Amount"], [98, 138, "Parameter"], [142, 145, "Amount"], [195, 206, "Herb name"], [211, 222, "Drug"], [262, 265, "Amount"]]}], [6112, "Although compounds isolated from herbs have been shown to have important pharmacologic activities, but in some observations, actions of the herbs have been overestimated or underestimated.", {"entities": [[73, 97, "Parameter"]]}], [6113, "Moreover, both administrators and costumers have little-evidenced information on safety, effectiveness, and adverse effects of these herbs.", {"entities": [[108, 123, "Pathology"]]}], [6114, "In this regard, the increasing number of foods containing herbs has raised concerns at the food and drug administration (FDA).", {"entities": []}], [6115, "Some herbs such as celery could even affect the hepatic triglyceride concentrations.", {"entities": [[19, 25, "Herb name"], [44, 83, "Parameter"]]}], [6116, "In fact, different parts of lipid metabolism pathways can be affected by various types of herbs.", {"entities": []}], [6117, "According to similar effects of chemical drugs on lipid metabolism process, interaction between these drugs and herbs is expectable.", {"entities": [[32, 46, "Drug"]]}], [6118, "However, few studies were implemented to clear these interactions.", {"entities": []}], [6119, "Regarding drug-herb interaction, the interaction between some types of herbs and statins that are commonly used for improving hyperlipidemia has been considered.", {"entities": [[81, 88, "Drug"], [126, 140, "Pathology"]]}], [6120, "As previously shown, the herbal reaction towards different types of statins is varied so that grapefruit or pomegranate were interacted with only some types of statins, but not with all statin types.", {"entities": [[68, 75, "Drug"], [94, 104, "Herb name"], [108, 119, "Herb name"], [160, 167, "Drug"], [186, 192, "Drug"]]}], [6122, "This article has been derived from the Ph.D. thesis of the first author and financially supported by the research deputy of Shahrekord University of Medical Sciences, Iran.", {"entities": []}], [6123, "Conflicts of Interest  Authors have no conflict of interests.", {"entities": []}], [6124, "Herbs with hypolipidemic effects LDL-C: Low-density lipoprotein cholesterol; HDL-C: High-density lipoprotein cholesterol", {"entities": [[11, 24, "Pathology"], [33, 75, "Parameter"], [77, 120, "Parameter"]]}], [6125, "Dasatinib (DAS), a narrow-therapeutic index drug, Bcr-Abl, and Src family kinases multitarget inhibitor have been approved for chronic myelogenous leukemia (CML) and Ph-positive acute lymphocytic leukemia (Ph+ ALL).", {"entities": [[0, 103, "Drug"], [127, 161, "Pathology"], [166, 214, "Pathology"]]}], [6126, "Apigenin (APG) has a long history of human usage in food, herbs, health supplements, and traditional medicine, and it poses low risk of damage.", {"entities": [[0, 14, "Herb name"]]}], [6127, "The concomitant use of APG containing herbs/foods and traditional medicine may alter the pharmacokinetics of DAS, that probably lead to possible herb\u2013drug interactions.", {"entities": [[23, 26, "Herb name"], [109, 112, "Drug"]]}], [6128, "The pharmacokinetic interaction of APG pretreatment with DAS in rat plasma following single and co-oral dosing was successfully deliberated using the UPLC\u2013MS/MS method.", {"entities": [[35, 38, "Herb name"], [57, 60, "Drug"]]}], [6129, "The in vivo pharmacokinetics and protein expression of CYP3A2, Pgp-MDR1, and BCPR/ABCG2 demonstrate that APG pretreatment has potential to drastically changed the DAS pharmacokinetics where escalation in the Cmax, AUC Traditional, time-limited, nonspecific cytotoxic chemotherapy regimens are being replaced by continuous oral treatment with particular protein-targeted medicines for a number of cancers [1].", {"entities": [[4, 11, "Study"], [55, 61, "Target"], [63, 71, "Target"], [77, 87, "Target"], [105, 108, "Herb name"], [163, 166, "Drug"], [208, 212, "Parameter"], [214, 217, "Parameter"], [396, 403, "Pathology"]]}], [6130, "Tyrosine kinases are vital for regulating the cell cycle, cell division, apoptosis, programmed cell death, growth, and metabolism [2].", {"entities": [[0, 16, "Target"]]}], [6131, "The overexpression or somatic mutations of tyrosine kinases are dysregulated in various malignancies [3].", {"entities": [[43, 59, "Target"]]}], [6132, "TKIs are commonly prescribed for the treatment in patients with leukemia for prolonged periods.", {"entities": [[0, 4, "Drug"], [64, 72, "Pathology"]]}], [6133, "They are therefore commonly given together with conventional therapies may cause harmful interactions [4].", {"entities": []}], [6134, "DAS is a narrow therapeutic index drug and a novel tyrosine kinase multitarget inhibitor of the BCR-ABL and Src family of kinases was permitted for the treatment of chronic myelogenous leukemia (CML) by the US FDA, as well as for Ph Apigenin (APG) (4\u2032,5,7-trihydroxyflavone) (Figure 1B) is a bioactive plant flavone present in wide variety of plants, such as celery, parsley, chamomile, and widely distributed in common food [14,15].", {"entities": [[0, 129, "Drug"], [165, 199, "Pathology"], [230, 274, "Herb name"], [308, 315, "Herb name"], [359, 365, "Herb name"], [367, 374, "Herb name"], [376, 385, "Herb name"]]}], [6135, "4\u2032,5,7-trihydroxyflavone (Apigenin) derivative of phenylpropanoid unit C6-C3 with glycosylated tricyclic core attached to sugar moieties through hydroxyl groups (O-glycosides) or carbon (C-glycosides).", {"entities": [[0, 35, "Herb name"]]}], [6136, "The known APG glycosides are apigenin-6-C-glucoside (isovitexin), apigenin-7-O-glucoside, pigenin 6-C-glucoside 8-C-arabinoside (schaftoside), apigenin-8-C-glucoside (vitexin), apigenin 7-O-neohesperidoside (rhoifolin), and apiin [16].", {"entities": [[10, 24, "Herb name"], [29, 64, "Herb name"], [66, 88, "Herb name"], [90, 141, "Herb name"], [143, 175, "Herb name"], [177, 218, "Herb name"], [224, 229, "Herb name"]]}], [6137, "APG is extensively used in food and traditional and modern herbal medicine owing to its therapeutic activity such as antioxidant, anti-inflammatory, hepatoprotective, antithrombotic, chemo-preventive, cardioprotective, antihypertensive, anticancer, antihyperlipidemic, antidepressant, and estrogenic effects [17].", {"entities": [[0, 3, "Herb name"]]}], [6138, "The widespread use of APG in food, herbs, health supplement, and in traditional medicine has a long human consumption history and poses little or no potential risk [18].", {"entities": [[22, 25, "Herb name"]]}], [6139, "Therefore, APG has ability to change the pharmacokinetic profile of several drugs absorption, distribution, metabolism and elimination (ADME) via the regulatory actions of the efflux pumps Pgp and BCPR and cytochrome P450 enzymes.", {"entities": [[11, 14, "Herb name"], [176, 192, "Target"], [197, 201, "Target"], [206, 229, "Target"]]}], [6140, "Dasatinib is a substrate of CYP3A, Pgp and BCRP and is subject to induction [19,20,21,22].", {"entities": [[0, 9, "Drug"], [28, 33, "Target"], [35, 38, "Target"], [43, 47, "Target"]]}], [6142, "Liu et al., 2013 previously reported the pharmacokinetic interaction of apigenin with imatinib and N-desmethyl imatinib in rats [23].", {"entities": [[72, 80, "Herb name"], [86, 94, "Drug"], [99, 119, "Drug"]]}], [6144, "Subsequently, the identification and comprehension of these APG\u2013DAS interactions remain important keys for risk assessment.", {"entities": [[60, 63, "Herb name"], [64, 67, "Drug"]]}], [6145, "There are no reports available on detailed mechanistic approach regarding the implication of drug metabolism (CYP3A and CYP2C11) and role of drug transporters (Pgp and BRCP) to resolve the possible interaction of APG with DAS.", {"entities": [[13, 20, "Study"], [110, 115, "Target"], [120, 127, "Target"], [160, 163, "Target"], [168, 172, "Target"], [213, 216, "Herb name"], [222, 225, "Drug"]]}], [6146, "This study has been designed to explore the effect of APG on pharmacokinetics of DAS in rats and to resolve the possible interaction mechanism.", {"entities": [[54, 57, "Herb name"], [81, 84, "Drug"]]}], [6147, "This study will further help to aid physicians and pharmacists in the clinical management of drug\u2013herb interactions.", {"entities": []}], [6148, "Careful consideration of DHI will help us create a treatment plan that is both effective and safe for the patient.", {"entities": []}], [6149, "The plasma concentration versus time profiles of the oral DAS 25 mg/kg alone and in combination with APG (40 mg/kg) pretreatment for seven days are represented in Figure 2.", {"entities": [[58, 61, "Drug"], [62, 70, "Amount"], [101, 104, "Herb name"], [106, 114, "Amount"], [129, 143, "Duration"]]}], [6150, "Pharmacokinetic parameters of DAS 25 mg/kg alone and with APG 40 mg/kg pretreatment for seven days are presented in Table 1.", {"entities": [[30, 33, "Drug"], [34, 42, "Amount"], [58, 61, "Herb name"], [62, 70, "Amount"], [84, 98, "Duration"]]}], [6151, "The pretreatment of oral APG 40 mg/kg and parallel use of DAS 25 mg/kg exhibits pharmacokinetic interaction.", {"entities": [[25, 28, "Herb name"], [29, 37, "Amount"], [58, 61, "Drug"], [62, 70, "Amount"]]}], [6152, "The DAS 25 mg/kg oral administration after APG 40 mg/kg seven days pretreatment significantly increased the plasma concentration of DAS as indicated by increased C As demonstrated in Figure 3A,B, the hepatic and intestinal CYP3A2 (p < 0.05) protein expression of the CYP3A2 was significantly increased 76.47%-fold and 79.13% in DAS administered rats as compared with normal control rats.", {"entities": [[4, 7, "Drug"], [8, 16, "Amount"], [43, 46, "Herb name"], [47, 55, "Amount"], [56, 79, "Duration"], [132, 135, "Drug"], [200, 229, "Target"], [267, 273, "Target"], [328, 331, "Drug"]]}], [6153, "Chronic administration of APG (40 mg/kg b.w.)", {"entities": [[26, 29, "Herb name"], [31, 39, "Amount"]]}], [6154, "pretreatment for seven days to DAS-administered rats significantly inhibits 50.92% and 49.22% hepatic and intestinal CYP3A2 protein expression as compared to DAS administered rats.", {"entities": [[13, 27, "Duration"], [31, 34, "Drug"], [94, 123, "Target"], [158, 161, "Drug"]]}], [6155, "APG (40 mg/kg) only pretreatment led to the inhibition of 87.24% and 90.97% of hepatic and intestinal CYP3A2 protein expression as compared to normal rats.", {"entities": [[0, 3, "Herb name"], [5, 13, "Amount"], [79, 108, "Target"]]}], [6156, "The inhibitory potential of APG on Pgp/MDR1 protein expression was investigated and shown in Figure 4A,B.", {"entities": [[28, 31, "Herb name"], [35, 38, "Target"], [39, 43, "Target"]]}], [6157, "hepatic and intestinal PGP/MDR1 protein expression was significantly decreased after APG pretreatment compared to that in normal rats.", {"entities": [[23, 26, "Target"], [27, 31, "Target"], [85, 88, "Herb name"]]}], [6158, "DAS peroral administration caused significant induction of (93.08% and 91.65%, respectively) (p < 0.05) hepatic and intestinal protein expression of Pgp/MDR1 compared to that in normal rats.", {"entities": [[0, 3, "Drug"], [149, 152, "Target"], [153, 157, "Target"]]}], [6159, "The APG-pretreated rats showed significant inhibition of the Pgp/MDR1 protein, that is 65.38% and 69.90% inhibition, respectively, as compared to DAS alone (p < 0.05).", {"entities": [[4, 7, "Herb name"], [61, 64, "Target"], [65, 69, "Target"], [146, 149, "Drug"]]}], [6160, "APG (40 mg/kg) only pretreatment led to the inhibition of 90.67% and 87.84% of hepatic and intestinal Pgp/MDR1 protein expression as compared to normal rats.", {"entities": [[0, 3, "Herb name"], [5, 13, "Amount"], [102, 105, "Target"], [106, 110, "Target"]]}], [6161, "The inhibitory potential of APG on BCRP/ABCG2 protein expression was investigated and shown in Figure 5A,B.", {"entities": [[28, 31, "Herb name"], [35, 39, "Target"], [40, 45, "Target"]]}], [6162, "hepatic and intestinal BCRP/ABCG2 protein expression was significantly reduced after APG pretreatment compared to that in normal rats.", {"entities": [[23, 27, "Target"], [28, 33, "Target"], [85, 88, "Herb name"]]}], [6163, "DAS peroral administration caused significant induction of 92.55% and 95.66%, respectively, (p < 0.05) hepatic and intestinal protein expression of BCPR/ABCG2 compared to that in normal rats.", {"entities": [[0, 3, "Drug"], [148, 152, "Target"], [153, 158, "Target"]]}], [6164, "The APG-pretreated rats showed significant inhibition of the BCPR/ABCG2 protein that is (66.77% and 41.06% inhibition, respectively) as compared to DAS only (p < 0.05).", {"entities": [[4, 7, "Herb name"], [61, 65, "Target"], [66, 71, "Target"], [148, 151, "Drug"]]}], [6165, "APG (40 mg/kg) only pretreatment led to the inhibition of 91.05% and 91.50% of hepatic and intestinal BCRP/ABCG2 protein expression as compared to normal rats.", {"entities": [[0, 3, "Herb name"], [5, 13, "Amount"], [102, 106, "Target"], [107, 112, "Target"]]}], [6166, "Chemotherapeutic drugs are extremely toxic and come with a wide variety of severe side effects.", {"entities": [[0, 22, "Drug"], [82, 94, "Pathology"]]}], [6167, "Cancer patients often use complementary therapies, such as herbal supplements, to lessen the unpleasant side effects of chemotherapy and improve their overall health [24].", {"entities": [[0, 6, "Pathology"], [104, 116, "Pathology"], [120, 132, "Drug"]]}], [6168, "The probable risk from HDI makes the benefits of using such herbs unwarranted.", {"entities": []}], [6169, "HDIs is undesirable in the management of cancer because of their swift dose effect relationship.", {"entities": [[41, 47, "Pathology"]]}], [6170, "Inhibition and/or induction of drug-metabolizing enzymes (DME) and or drug transporters mediated by herbs is the most typical mechanism of herb-drug interactions, which in turn alters the pharmacokinetic disposition of the drug [24,25].", {"entities": []}], [6171, "Chronic myelogenous leukemia (CML) and Philadelphia chromosome-positive acute lymphocytic leukemia patients who did not respond to first-line therapy are two of the cancer types for which DAS has been approved.", {"entities": [[0, 34, "Pathology"], [39, 98, "Pathology"], [165, 171, "Pathology"], [188, 191, "Drug"]]}], [6172, "BCR-ABL and Src family kinases are both inhibited by DAS, a new tyrosine kinase multitarget inhibitor [5].", {"entities": [[0, 7, "Target"], [12, 30, "Target"], [53, 101, "Drug"]]}], [6173, "DAS is broadly metabolized in the liver and intestine by the CYP3A4 [7].", {"entities": [[0, 3, "Drug"], [61, 67, "Target"]]}], [6174, "In addition, DAS is capable of induction, and is vulnerable to pharmacokinetic interaction.", {"entities": [[13, 16, "Drug"]]}], [6175, "Drug\u2013herb interaction (DHI) risks are possible with concomitant usage of APG along with DAS [8,9,10].", {"entities": [[73, 76, "Herb name"], [88, 91, "Drug"]]}], [6176, "The purpose of the current study was to determine whether or not APG has a pharmacokinetic interaction with DAS, and if so, how they would interact.", {"entities": [[65, 68, "Herb name"], [108, 111, "Drug"]]}], [6177, "The current study aims to study the probable interaction mechanism between APG pretreatment and DAS using pharmacokinetic analysis.", {"entities": [[75, 78, "Herb name"], [96, 99, "Drug"]]}], [6178, "The UPLC MS/MS technique was used to examine DAS levels in rat plasma.", {"entities": [[45, 48, "Drug"]]}], [6179, "The sensitivity and specificity of the analytes were enhanced by adjusting the mass spectrometer settings.", {"entities": []}], [6180, "Precision and accuracy were validated according to the \u201cUS Food and Drug Administration 2018 guideline for bioanalytical method validation\u201d.", {"entities": []}], [6181, "In both intraday and interday samples, differences in precision and accuracy were found to be well within the \u00b115% range which is considered acceptable.", {"entities": []}], [6182, "The concomitant use of supplements together with prescription medications, particularly those with a narrow therapeutic range, may lead to drug interactions.", {"entities": []}], [6183, "The wide spread use of herbs/herbal supplements/herbal medications with an estimated 40 to 60% of the US population with chronic disease and 20\u201325% patients with prescribed medication procuring herbal supplements [26,27].", {"entities": []}], [6184, "DAS has already been linked to a potentially harmful herb/drug interaction [11,28,29,30].", {"entities": [[0, 3, "Drug"]]}], [6185, "There is minimal risk associated with APG\u2019s long history of safe use in food, herbs, and herbal supplements.", {"entities": [[38, 43, "Herb name"]]}], [6186, "Pharmacokinetic interaction between herbs and pharmaceuticals is possible due to APG, a strong inhibitor of the CYPP450 enzyme system and the drug transporters Pgp and BCRP [19,20,21,22].", {"entities": [[81, 84, "Herb name"], [112, 119, "Target"], [142, 163, "Target"], [168, 172, "Target"]]}], [6187, "Therefore, APG has ability to change the pharmacokinetic profile of DAS absorption, distribution, metabolism, and elimination (ADME) via the regulatory actions of the efflux pumps PGP and BCPR and cytochrome P450 enzymes.", {"entities": [[11, 14, "Herb name"], [68, 71, "Drug"], [167, 183, "Target"], [188, 192, "Target"], [197, 220, "Target"]]}], [6188, "The probable pharmacokinetic interactions may take place with APG as a result, it is necessary to explore the safety concerns associated with such simultaneous or parallel usage.", {"entities": [[62, 65, "Herb name"]]}], [6189, "The radical alteration in the pharmacokinetic parameters of DAS 25 mg/kg P.O.", {"entities": [[60, 63, "Drug"], [64, 72, "Amount"]]}], [6190, "were examined with and without APG pretreatment in rats.", {"entities": [[31, 34, "Herb name"]]}], [6191, "Research on rats that were pretreated with APG revealed an increase in the plasma concentration of DAS.", {"entities": [[43, 46, "Herb name"], [99, 102, "Drug"]]}], [6192, "The rapid rate of absorption, as shown by the sharp increases in pharmacokinetic parameters such as Cmax, AUC DAS has been shown to increase the exposure of CYP3A4 substrates simvastatin and midazolam in humans and cyclosporine in rats in investigations [9,10,11].", {"entities": [[100, 104, "Parameter"], [106, 109, "Parameter"], [110, 113, "Drug"], [157, 163, "Target"], [175, 186, "Drug"], [191, 200, "Drug"], [215, 227, "Drug"]]}], [6193, "The outcomes of an immunoblot experiment executed on liver and intestinal tissues in all groups to explore for CYP3 A2, Pgp-MDR1, and BCPR/ABCG2 protein expression.", {"entities": [[111, 118, "Target"], [120, 128, "Target"], [134, 144, "Target"]]}], [6194, "In rats co-administered DAS/APG and APG alone, substantially suppressed the elevated CYP3A2, Pgp-MDR1, and BCPR/ABCG2 protein expression in the liver and gut compared to DAS alone.", {"entities": [[24, 27, "Drug"], [28, 31, "Herb name"], [36, 39, "Herb name"], [85, 91, "Target"], [93, 101, "Target"], [107, 111, "Target"], [112, 117, "Target"], [170, 173, "Drug"]]}], [6195, "APG is a bioactive polyphenol with the potential to influence CYP3A2/Pgp-MDR1/BCPR/ABCG2 in the liver and gut.", {"entities": [[0, 29, "Herb name"], [62, 68, "Target"], [69, 77, "Target"], [78, 82, "Target"], [83, 88, "Target"]]}], [6196, "APG pretreatment inhibits the expression of CYP3A2, Pgp-MDR1, and BCPR/ABCG2 proteins in the liver and gut of rats, according to our results.", {"entities": [[0, 3, "Herb name"], [44, 50, "Target"], [52, 60, "Target"], [66, 70, "Target"], [71, 76, "Target"]]}], [6197, "APG treatment substantially modulates the pharmacokinetics of DAS and pharmacokinetic parameters further validates these where Cmax), AUC APG has a minimal risk of harm to humans and has been used for centuries in food, herbs, health supplements, and traditional medicine.", {"entities": [[0, 3, "Herb name"], [62, 65, "Drug"], [127, 131, "Parameter"], [134, 137, "Parameter"], [138, 141, "Herb name"]]}], [6198, "It can be used at the same time as other medications if necessary.", {"entities": []}], [6199, "DAS ADME pharmacokinetics may be influenced by APG due to the regulatory actions of efflux pumps Pgp and BCPR and cytochrome P450 enzymes CYP3A2.", {"entities": [[0, 3, "Drug"], [47, 50, "Herb name"], [84, 100, "Target"], [105, 109, "Target"], [114, 144, "Target"]]}], [6200, "Consequentially, more systematic clinical study on herb\u2013drug interactions is essential, as is proper regulation in herbal safety and efficacy, as well as the avoidance of potentially fatal medication interactions when APG-containing foods or traditional herbs are used alongside DAS.", {"entities": [[33, 47, "Study"], [218, 221, "Herb name"], [279, 282, "Drug"]]}], [6201, "Dasatinib (DAS), apigenin (APG), and ibrutinib (IBR), were obtained from Sigma-Aldrich (St. Louis, MI, USA).", {"entities": [[0, 15, "Drug"], [17, 31, "Herb name"], [37, 52, "Drug"]]}], [6202, "Acetonitrile, formic acid, methanol, and ammonium acetate were purchased from BDH, Pool (UK) and antibodies anti-P-gp/MDR1/ABCB1, anti-BCRP/ABCG2, Anti-CYP3\u2009A2, and anti-\u03b2-actin antibodies were obtained from Santacruz (USA).", {"entities": [[113, 122, "Target"], [123, 128, "Target"], [135, 139, "Target"], [140, 145, "Target"], [152, 159, "Target"]]}], [6203, "The Central Animal House facility of College of Pharmacy, King Saud University\u2019s, Riyadh, Saudi Arabia, provided 24 healthy adult male Wistar rats (weighing 211\u2013223 g), and the experiment was authorized by the Animal Ethics Committee of the College of Pharmacy, King Saud University (KSU-SE-21-58).", {"entities": []}], [6204, "All animals were retained in polypropylene cages: 6 animals were caged (n = 6) per cage with a 12-h light/dark cycle, at 25 \u00b0C in humane conditions with free access to food and water and adapted to the living conditions one week prior to experiment The animals were categorized into four groups (n = 6) and fasted for 12 h before the experiment.", {"entities": [[283, 302, "Cohort"]]}], [6205, "Group I and II were orally administered with normal saline for 7 days and Group II was orally administered DAS (25 mg/kg) on the 7th day.", {"entities": [[59, 69, "Duration"], [107, 110, "Drug"], [112, 121, "Amount"]]}], [6206, "Group III was co-administered DAS with APG for 7 days and DAS (25 mg/kg p.o.)", {"entities": [[30, 33, "Drug"], [39, 42, "Herb name"], [43, 53, "Duration"], [58, 61, "Drug"], [63, 71, "Amount"]]}], [6207, "on the 7th day, 2\u2009h after APG 40 mg/kg administration, and Group IV was administered with APG 40 mg/kg for 7 days.", {"entities": [[26, 29, "Herb name"], [30, 38, "Amount"], [90, 93, "Herb name"], [94, 102, "Amount"], [103, 113, "Duration"]]}], [6208, "The blood was collected from the tail vein at various time points after DAS administration and subjected to centrifugation at 5000\u00d7 g for 10 min to obtain plasma for DAS quantification using ultra pressure liquid chromatography with mass.", {"entities": [[72, 75, "Drug"], [166, 169, "Drug"]]}], [6209, "At the end of the experiment, all animals were euthanized using carbon dioxide, and liver and intestine tissues were harvested and for Western blotting.", {"entities": []}], [6210, "Using UHPLC-MS/MS, DAS concentrations in rat plasma samples were determined.", {"entities": []}], [6211, "A mixture of DAS and IBR (internal standard) was separated on an Acquity BEH C18 column, and both compounds were eluted at a flow rate of 0.25 mL/min from a mobile phase consisting of acetonitrile, 0.1% formic acid, and 20mM ammonium acetate (95:5).", {"entities": [[13, 16, "Drug"], [21, 24, "Drug"]]}], [6212, "The entire duration of the study was about 2.5 min.", {"entities": []}], [6213, "The auto-sampler was kept at 10 \u00b0C, while the column oven was kept at a constant 40 \u00b0C.", {"entities": []}], [6214, "Electrospray ionization was used to ionize samples in a positive direction.", {"entities": []}], [6215, "In the concentration range examined (5\u20132500 ng/mL), the calibration curves displayed linearity over the concentration range.", {"entities": []}], [6216, "Multiple reaction monitoring (MRM) mode detection and quantitation of analyte (DAS) and IS (IBR) employed the precursor to product ion transition of 488.06 and gt; 401.1 and 441.16 and gt; 84.04, respectively.", {"entities": [[79, 82, "Drug"], [92, 95, "Drug"]]}], [6217, "Capillary voltage was 3.4 kV, source temperature was 150 \u00b0C, and desolvation temperature was 350 \u00b0C for optimum sample ionization using MS/MS.", {"entities": []}], [6218, "A flow rate of 600 L/h of nitrogen gas was utilized for the desolvation process, whereas a flow rate of 0.18 mL/min of argon gas was used for the collision process.", {"entities": []}], [6219, "The analyte and IS cone voltages were 46 V and 48 V, and the collision energy was 28 eV and 40 eV, respectively.", {"entities": []}], [6220, "Precision and accuracy were partially confirmed for the assay using the \u201cUS Food and Drug Administration 2018 guideline for bioanalytical technique validation,\u201d and found to be within acceptable ranges of 15% both intra- and inter-day.", {"entities": []}], [6221, "The samples were acquired using Masslynx 4.1 SCN 805, and then processed using TargetLynks.", {"entities": []}], [6222, "After making a few modifications to a previously reported study, it was put to use [38].", {"entities": []}], [6223, "A plasma sample of 150 \u00b5L was aliquoted into an Eppendorf tube, along with 20 \u00b5L of a spiked internal standard (250 ng/mL), and 1 mL of ethyl acetate was also added for the extraction phase.", {"entities": []}], [6224, "For 10 min at 4 \u00b0C and 10,500 rpm, centrifuged samples were shaken for 15 min after being vortexed.", {"entities": []}], [6225, "Finally, 800 \u00b5L of the organic upper layer were transferred to an Eppendorf tube and dried in a sample concentrator at room temperature.", {"entities": []}], [6226, "Following reconstitution with 150 \u00b5L of acetonitrile, the dried residue was transported to UHPLC-MS/MS for 5 \u00b5L of analysis.", {"entities": []}], [6227, "PK Solver software was employed to calculate the pharmacokinetic parameters using non-compartmental model.", {"entities": []}], [6228, "The calculated parameters were as follows: half-life (T A PierceTM BCA Protein Assay Kit (Thermo Fisher Scientific) was used to extract the total protein from the hepatic and intestinal tissues by bicinchoninic acid technique [39].", {"entities": [[43, 52, "Parameter"]]}], [6229, "Immunoblots were executed as per the methods of Towbin et al.", {"entities": []}], [6230, "(1979) with slight modification [40,41,42].", {"entities": []}], [6231, "Briefly, 10% SDS polyacrylamide gels were used to electrophorese 25 \u03bcg of hepatic and intestinal epithelial proteins.", {"entities": []}], [6232, "These proteins were then transferred to activated PVDF membranes and blocked with 4% skim milk and BSA in TBST.", {"entities": []}], [6233, "After that, membranes were treated with antibodies for CYP3A2 isozymes, active transporters P-glycoprotein/MDR1, BCRP/ABCG2, and \u03b2-actin protein expression for an overnight period (4 \u00b0C).", {"entities": [[55, 61, "Target"], [72, 106, "Target"], [107, 111, "Target"], [113, 117, "Target"], [118, 123, "Target"]]}], [6234, "The membrane strips were incubated with the suitable secondary antibodies for 2 h after repeated washing steps with 1% TBST and TBS (room temperature).", {"entities": []}], [6235, "The membrane strips were then washed four times with TBST for five minutes each time.", {"entities": []}], [6236, "Bands were developed using Luminata\u2122 Western Chemiluminescent HRP Substrates (Millipore), followed by densitometric evaluation of the immunoblots.", {"entities": []}], [6237, "The data were presented as a mean SE (SEM).", {"entities": []}], [6238, "Significance (p < 0.05) was determined using one-way analysis of variance followed by Dunnett\u2019s post hoc test (against respective controls).", {"entities": []}], [6239, "Using the UPLC-MS/MS technique, we effectively analyzed the pharmacokinetic interaction between APG and DAS in rat plasma after single and co-oral dosing.", {"entities": [[96, 99, "Herb name"], [104, 107, "Drug"]]}], [6240, "Consequentially, more systematic clinical study on herb\u2013drug interactions is recommended, as is proper regulation in herbal safety and efficacy, as well as the avoidance of potentially fatal medication interactions when APG-containing foods or traditional herbs are used alongside DAS.", {"entities": [[33, 47, "Study"], [220, 223, "Herb name"], [281, 284, "Drug"]]}], [6241, "Based on the findings of the present investigation, it was hypothesized that APG would influence the pharmacokinetics of CYP3A/Pgp substrate drugs in humans.", {"entities": [[77, 80, "Herb name"], [121, 126, "Target"], [127, 130, "Target"]]}], [6242, "However, quantitatively extrapolating these results to humans is challenging because the biotransformation rate of DAS in rats varies from that in humans.", {"entities": [[115, 118, "Drug"]]}], [6243, "This study\u2019s findings, however, were derived solely from studies conducted with rats.", {"entities": []}], [6244, "Further thorough in vivo studies of the APG\u2013DAS interaction in humans are warranted to support these findings.", {"entities": [[17, 32, "Study"], [40, 43, "Herb name"], [44, 47, "Drug"]]}], [6245, "Effective care requires health care providers to have an open discussion with patients about their use of herbal medications and to take careful notes.", {"entities": []}], [6246, "The possible benefits and risks of herbal products in cancer treatment should be made clear to patients.", {"entities": [[54, 60, "Pathology"]]}], [6247, "Patients should be aware of the risks of HDIs, including increased toxicity or ineffective treatment.", {"entities": []}], [6248, "Additionally, DAS drug monitoring is recommended when adverse events, such as toxicity or lack of clinical response, are suspected.", {"entities": [[14, 17, "Drug"], [54, 68, "Pathology"]]}], [6249, "Also, it is crucial to record any adverse events and share them with the pharmacovigilance network is of utmost importance.", {"entities": [[34, 48, "Pathology"]]}], [6250, "The authors extend their appreciation to the Deputyship for Research and Innovation, Ministry of Education in Saudi Arabia for funding this research work through the project no.", {"entities": []}], [6251, "(IFKSURG-2-233).", {"entities": []}], [6252, "Disclaimer/Publisher\u2019s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s).", {"entities": []}], [6253, "MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.", {"entities": []}], [6254, "Conceptualization, M.R.", {"entities": []}], [6255, "; data curation, M.A.A., K.M.A.", {"entities": []}], [6256, "and F.I.A.-J.", {"entities": []}], [6257, "; formal analysis, A.A. (Ajaz Ahmad), Y.A.B.J., A.A. (Abdul Ahad), M.A.K., M.I.", {"entities": []}], [6258, "and N.A.", {"entities": []}], [6259, "; funding acquisition, M.R.", {"entities": []}], [6260, "; investigation, M.R.", {"entities": []}], [6261, "and M.S.", {"entities": []}], [6262, "; methodology, A.A. (Ajaz Ahmad), M.S., A.A. (Abdul Ahad), M.A.K.", {"entities": []}], [6263, "and M.A.A.", {"entities": []}], [6264, "; project administration, M.R.", {"entities": []}], [6265, "and F.I.A.-J.", {"entities": []}], [6266, "; resources, Y.A.B.J., M.A.A.", {"entities": []}], [6267, "and M.I.", {"entities": []}], [6268, "; software, A.A. (Ajaz Ahmad), M.A.A.", {"entities": []}], [6269, "and M.I.", {"entities": []}], [6270, "; supervision, K.M.A.", {"entities": []}], [6271, "; validation, M.S., Y.A.B.J.", {"entities": []}], [6272, "and N.A.", {"entities": []}], [6273, "; visualization, A.A. (Ajaz Ahmad), A.A. (Abdul Ahad), M.A.K., N.A.", {"entities": []}], [6274, "and K.M.A.", {"entities": []}], [6275, "; writing\u2014original draft, M.R.", {"entities": []}], [6276, "and F.I.A.-J.", {"entities": []}], [6277, "; writing\u2014review and editing, M.R., A.A. (Ajaz Ahmad), A.A. (Abdul Ahad), K.M.A.", {"entities": []}], [6278, "and F.I.A.-J.", {"entities": []}], [6279, "All authors have read and agreed to the published version of the manuscript.", {"entities": []}], [6280, "The research was approved by the Research Ethics Committee of King Saud University College of Pharmacy Riyadh, Saudi Arabia (KSU-SE-21-58).", {"entities": []}], [6281, "Not applicable.", {"entities": []}], [6282, "All the data generated from the study are clearly presented in the manuscript.", {"entities": []}], [6283, "The authors declare no conflict of interest.", {"entities": []}], [6284, "Chemical structure of (A) dasatinib and (B) apigenin.", {"entities": [[26, 35, "Drug"], [44, 52, "Herb name"]]}], [6285, "Plasma concentration\u2013time curve of DAS and DAS along with APG (40 mg/kg p.o.", {"entities": [[35, 38, "Drug"], [43, 46, "Drug"], [58, 61, "Herb name"], [63, 71, "Target"]]}], [6286, "for 7 days) following an oral administration in rats (p < 0.05).", {"entities": [[0, 10, "Duration"]]}], [6287, "Hepatic (A) and intestinal (B) CYP3A2 protein expression in rats after DAS administration with or without APG pretreatment.", {"entities": [[31, 37, "Target"], [71, 74, "Drug"], [106, 109, "Herb name"]]}], [6288, "All results are presented as the average \u00b1 SD.", {"entities": []}], [6289, "* p < 0.05 (Normal control); # p < 0.05 (DAS).", {"entities": [[41, 44, "Drug"]]}], [6290, "Hepatic (A) and intestinal (B) PGP/MDR1 protein expression in rats after DAS administration with or without APG pretreatment.", {"entities": [[31, 34, "Target"], [35, 39, "Target"], [73, 76, "Drug"], [108, 111, "Herb name"]]}], [6291, "All results are presented as the average \u00b1 SD.", {"entities": []}], [6292, "* p < 0.05 (Normal control); # p < 0.05 (DAS).", {"entities": [[41, 44, "Drug"]]}], [6293, "Hepatic (A) and intestinal (B) BCRP/ABCG2 protein expression in rats after DAS administration with or without APG pretreatment.", {"entities": [[31, 35, "Target"], [36, 41, "Target"], [75, 78, "Drug"], [110, 113, "Herb name"]]}], [6294, "All results are presented as the average \u00b1 SD.", {"entities": []}], [6295, "* p < 0.05 (Normal control); # p < 0.05 (DAS).", {"entities": [[41, 44, "Drug"]]}], [6296, "Pharmacokinetic parameters (non-compartmental) of dasatinib along with apigenin following an oral administration in rats.", {"entities": [[50, 59, "Drug"], [71, 79, "Herb name"]]}], [6297, "Results are presented as the average \u00b1 SD.", {"entities": []}], [6298, "* p < 0.05 (DAS).", {"entities": [[12, 15, "Drug"]]}], [6299, "Elderly patients are more likely to ingest prescription medications concurrently with botanical supplements, therefore, they may be vulnerable to herb-drug interactions.", {"entities": []}], [6300, "Phytochemical-mediated modulation of cytochrome P-450 (CYP) activity may underlie many herb-drug interactions.", {"entities": []}], [6301, "Some evidence suggests that CYP activity may decrease in the elderly.", {"entities": []}], [6302, "If so, herb-mediated changes in CYP activity may take on greater clinical relevance in this population.", {"entities": []}], [6303, "Single time-point, phenotypic metabolic ratios were used to determine whether long-term supplementation of St. John\u2019s wort, garlic oil, Panax ginseng, and Ginkgo biloba affected CYP1A2, CYP2D6, CYP2E1, or CYP3A4 activity in elderly subjects.", {"entities": [[107, 122, "Herb name"], [124, 134, "Extraction process"], [136, 149, "Herb name"], [155, 168, "Herb name"], [178, 184, "Target"], [186, 192, "Target"], [194, 200, "Target"], [205, 211, "Target"]]}], [6305, "Probe drug cocktails of midazolam, caffeine, chlorzoxazone, and debrisoquine were administered before and at the end of supplementation.", {"entities": [[24, 33, "Drug"], [35, 43, "Drug"], [45, 58, "Drug"], [64, 76, "Drug"]]}], [6306, "Pre- and postsupplementation phenotypic ratios were determined for CYP3A4, CYP1A2, CYP2E1, and CYP2D6 using 1-hydroxymidazolam/midazolam serum ratios (1-hr), paraxanthine/caffeine serum ratios (6-hr), 6-hydroxychlorzoxazone/chlorzoxazone serum ratios (2-hr), and debrisoquine urinary recovery ratios (8-hr), respectively.", {"entities": [[108, 126, "Drug"], [127, 136, "Drug"], [158, 170, "Drug"], [171, 179, "Drug"], [201, 223, "Drug"], [224, 237, "Drug"], [263, 275, "Drug"]]}], [6307, "The content of purported \u201cactive\u201d phytochemicals was determined for each supplement.", {"entities": []}], [6308, "Comparisons of pre- and post-St. John\u2019s wort phenotypic ratios revealed significant induction of CYP3A4 (~140%) and CYP2E1 activity (~28%).", {"entities": [[28, 44, "Herb name"], [97, 103, "Target"], [116, 122, "Target"]]}], [6309, "Garlic oil inhibited CYP2E1 activity by approximately 22%.", {"entities": [[0, 10, "Extraction process"], [21, 27, "Target"]]}], [6310, "P. ginseng inhibition of CYP2D6 was statistically significant, but the magnitude of the effect (~7%) did not appear clinically relevant.", {"entities": [[0, 10, "Herb name"], [25, 31, "Target"]]}], [6311, "None of the supplements tested in this study appeared to affect CYP1A2 activity.", {"entities": [[64, 70, "Target"]]}], [6312, "Elderly subjects, like their younger counterparts, are susceptible to herb-mediated changes in CYP activity, especially those involving St. John\u2019s wort.", {"entities": [[95, 98, "Target"], [136, 151, "Herb name"]]}], [6313, "Pharmacokinetic herb-drug interactions stemming from alterations in CYP activity may adversely affect drug efficacy and/or toxicity.", {"entities": [[68, 71, "Target"]]}], [6314, "When compared to earlier studies that employed young subjects, the data suggest that some age-related changes in CYP responsivity to botanical supplementation may exist.", {"entities": []}], [6315, "Concomitant ingestion of botanical supplements with prescription medications, therefore, should be strongly discouraged in the elderly.", {"entities": []}], [6316, "Both authors contributed equally to this manuscript.", {"entities": []}], [6317, "The fruit of Schisandra chinensis (SC) is a well-known traditional herb used for pharmacological purposes in Asian countries (e.g., Korea, China, and Japan).", {"entities": [[4, 9, "Herb part"], [13, 38, "Herb name"], [109, 114, "Ethnic group"]]}], [6318, "In animal studies, SC extract supplementation had beneficial effects on muscle strength and lactate level.", {"entities": [[3, 17, "Study"], [19, 29, "Herb name"], [72, 87, "Parameter"], [92, 105, "Parameter"]]}], [6319, "However, the effect of SC extract supplementation on skeletal muscle strength and lactate at rest in humans remains unclear.", {"entities": [[23, 33, "Herb name"], [53, 77, "Parameter"], [82, 89, "Parameter"]]}], [6320, "The purpose of this study was to evaluate the effect of SC extract supplementation on quadriceps muscle strength (QMS) and lactate at rest in adult women.", {"entities": [[56, 66, "Herb name"], [86, 118, "Parameter"], [123, 130, "Parameter"], [148, 153, "Sex"]]}], [6321, "Forty five healthy post-menopausal middle-aged women (61.9 \u00b1 8.4 years) were randomly divided into the SC (n = 24) or the placebo group (n = 21).", {"entities": [[0, 10, "Cohort"], [11, 34, "Pathology"], [47, 52, "Sex"], [54, 70, "Age"], [103, 105, "Herb name"]]}], [6322, "The SC group consumed 1000 mg of SC extract per day, whereas the placebo group consumed 1000 mg of starch per day for 12 weeks.", {"entities": [[4, 6, "Herb name"], [22, 29, "Amount"], [33, 43, "Herb name"], [44, 51, "Frequency"], [88, 95, "Amount"], [99, 105, "Herb name"], [106, 113, "Frequency"], [114, 126, "Duration"]]}], [6323, "The difference in muscle mass, physical function, and biomarkers and the relative changes between baseline and 12 weeks were evaluated.", {"entities": [[18, 29, "Parameter"], [111, 119, "Duration"]]}], [6324, "We used two-factor repeated measures analysis of variance (ANOVA) to determine interaction (group \u00d7 time) effects for variables.", {"entities": []}], [6325, "Statistical significance was accepted at p < 0.05.", {"entities": []}], [6326, "In ANOVA results, QMS (p = 0.001) and lactate level (p = 0.038) showed significant interactions.", {"entities": [[38, 51, "Parameter"]]}], [6327, "With paired t-tests, QMS was significantly increased (p < 0.001) and lactate level at rest was significantly decreased (p < 0.05) after 12 weeks in the SC group.", {"entities": [[21, 24, "Parameter"], [69, 82, "Parameter"], [136, 144, "Duration"], [152, 154, "Target"]]}], [6328, "However, no interactions were found between the other variables.", {"entities": []}], [6329, "Supplementation of SC extract may help to improve QMS as well as decrease lactate level at rest in adult women.", {"entities": [[19, 29, "Herb name"], [50, 53, "Parameter"], [74, 87, "Parameter"], [105, 110, "Sex"]]}], [6330, "We believe that SC extract is a health supplement that can support healthy life in this population.", {"entities": [[16, 26, "Herb name"], [67, 74, "Pathology"]]}], [6331, "Schisandra chinensis (SC) extract has an extensive history as a medicinal herb in traditional Asian medicine for the treatment of diabetes mellitus, chronic cough, thirst, night sweating, hypertension, and obesity [1,2].", {"entities": [[0, 33, "Herb name"], [94, 99, "Ethnic group"], [130, 147, "Pathology"], [149, 162, "Pathology"], [164, 170, "Pathology"], [172, 186, "Pathology"], [188, 200, "Pathology"], [206, 213, "Pathology"]]}], [6332, "Several studies have reported that SC extract has effectively inhibited the damage of large arterial [3,4].", {"entities": [[35, 45, "Herb name"], [76, 100, "Pathology"]]}], [6333, "It has also been implicated in increasing endurance, accuracy of movement, and physical working capacity, as well as the control of arterial blood pressure [1] and the improvement of metabolic markers [2,5].", {"entities": [[132, 155, "Parameter"]]}], [6334, "Loss of muscle mass and strength are predictors of all-cause mortality, coronary heart disease (CHD), stroke, hospitalization, and disability in the middle-aged and elderly population [6,7].", {"entities": [[0, 32, "Pathology"], [72, 100, "Pathology"], [102, 108, "Pathology"], [131, 141, "Pathology"]]}], [6335, "Muscle strength and quantity can be used as markers of muscle quality; however, muscle strength is more important when estimating mortality risk [8,9].", {"entities": [[0, 28, "Parameter"], [80, 95, "Parameter"]]}], [6336, "For example, decreased muscle strength was strongly associated with aging, protein-energy wasting, and physical inactivity in the middle-aged and the elderly [10].", {"entities": [[23, 38, "Parameter"], [75, 97, "Pathology"]]}], [6337, "Furthermore, decreased leg muscle strength, specifically, was associated with an increased risk of mobility loss, physical disability within instrumental activities of daily living (IADLs), and functional limitation [11,12].", {"entities": [[23, 42, "Parameter"], [99, 112, "Pathology"], [114, 133, "Pathology"]]}], [6338, "Recent animal studies have reported beneficial effects of SC extract, for example, its supplementation appears to decrease protein degradation and increase protein synthesis, as well as display antioxidant and anti-inflammatory effects on skeletal muscle fibers [13,14].", {"entities": [[7, 21, "Study"], [58, 68, "Herb name"], [239, 261, "Target"]]}], [6339, "Additionally, SC extract was also found to improve mass and strength in skeletal muscle, as well as endurance in mice [13,14,15].", {"entities": [[14, 24, "Herb name"], [51, 87, "Parameter"]]}], [6340, "However, in humans, SC extract may not be as effective as in animals.", {"entities": [[20, 30, "Herb name"]]}], [6341, "Our first hypothesis is that the supplementation of SC extract in humans can increase muscle strength.", {"entities": [[52, 62, "Herb name"], [86, 101, "Parameter"]]}], [6342, "Blood lactate (BL) levels have been widely used as an indicator of muscle fatigue during the physical stress of the human body, such as acute exercise [16,17,18].", {"entities": [[0, 18, "Parameter"], [67, 81, "Pathology"]]}], [6343, "However, reliable cross-sectional and follow-up studies in adults have shown that high levels of resting BL are associated with a high risk of type 2 diabetes, CHD, and stroke [19,20].", {"entities": [[18, 55, "Study"], [105, 107, "Parameter"], [143, 158, "Pathology"], [160, 163, "Pathology"], [169, 175, "Pathology"]]}], [6344, "Meanwhile, a recent study by Cao et al.", {"entities": []}], [6345, "reported that long-term SC supplementation could prevent increased lactate after exercise [15].", {"entities": [[24, 26, "Herb name"], [67, 74, "Target"]]}], [6346, "However, it is still unclear the effect SC extract has on lactate level at rest and on skeletal muscle strength in humans.", {"entities": [[40, 50, "Herb name"], [58, 71, "Parameter"], [87, 111, "Parameter"]]}], [6347, "Our second hypothesis is that SC extract supplementation in humans reduces lactate at rest.", {"entities": [[30, 40, "Herb name"], [75, 82, "Parameter"]]}], [6348, "Thus, we aimed to investigate the effect of SC extract on quadriceps muscle strength (QMS) and lactate level at rest, in healthy post-menopausal middle-aged women.", {"entities": [[44, 54, "Herb name"], [58, 90, "Parameter"], [95, 102, "Parameter"], [121, 144, "Pathology"], [157, 162, "Sex"]]}], [6349, "This randomized, double-blind, placebo-controlled trial was performed in the Regional Clinical Trial Center, Dong-A University Hospital, Korea.", {"entities": [[5, 55, "Study"], [86, 100, "Study"]]}], [6350, "The 65 subjects were recruited by poster advertisements in the hospital or community welfare center.", {"entities": [[4, 15, "Cohort"]]}], [6351, "The inclusion criteria for this study were as follows: healthy post-menopausal middle-aged women, with a body mass index (BMI) of 18.5\u201330.0 kg/m Additionally, subjects were deemed unsuitable and also excluded if they possessed an aspartate aminotransferase and alanine aminotransferase > 60 IU/L, were hepatitis C positive, or participated in regular physical activity programs or other clinical studies within the last 3 months.", {"entities": [[55, 78, "Pathology"], [91, 96, "Sex"], [105, 126, "Parameter"], [130, 144, "Amount"], [230, 256, "Parameter"], [261, 285, "Parameter"], [286, 295, "Amount"], [302, 322, "Pathology"], [387, 403, "Study"]]}], [6352, "As a result of this, 13 subjects were excluded in this study.", {"entities": []}], [6353, "The 52 participants (55\u201378 yrs) were randomly divided into an SC group (n = 26) and a placebo group (n = 26), at a ratio of 1:1 by block randomization.", {"entities": [[4, 19, "Cohort"], [21, 30, "Age"], [62, 64, "Herb name"]]}], [6354, "During the 12-week period, 7 subjects dropped out due to the following: adherence rates of 2 subjects in the SC group were unclear, and 5 subjects in the placebo group withdrew consent (n = 3) or experienced symptoms of abdominal pain (n = 2).", {"entities": [[11, 18, "Duration"], [109, 111, "Herb name"], [220, 234, "Pathology"]]}], [6355, "The study was approved by the Institutional Review Board of Dong-A University Hospital (DAUHIRB-14-147) and was registered in the UMIN Clinical Trial Registry (UMIN 000024169;  The physical function test used the maximum value, after taking measurements of five different physical parameters twice, between 8:00\u201310:00 a.m.", {"entities": [[135, 149, "Study"]]}], [6356, "These measurement parameters and methods are as follows: grip strength was measured using an isometric dynamometer (TKK-5401, Tokyo, Japan) with the dominant arm.", {"entities": [[57, 70, "Parameter"]]}], [6357, "The measurement of one leg standing duration was terminated when the lifted lower limb touched the floor, or the position of the supporting lower limb shifted.", {"entities": []}], [6358, "The walking test measured the time taken to walk a 4 m straight distance while walking at a comfortable pace.", {"entities": []}], [6359, "The walking distance was designed to be a total of 7 m, by adding 1.5 m from the start and the finish line as acceleration and deceleration zones [22,23,24].", {"entities": []}], [6360, "The chair stand test involved measuring the time taken for the subject to rise 5 times, as fast as possible, from sitting in a chair to standing [25].", {"entities": []}], [6361, "Isokinetic muscle strength in the quadriceps was measured using an isokinetic dynamometer (Biodex Medical Systems 3, Inc., Shirley, NY, USA) in the dominant leg.", {"entities": [[11, 26, "Parameter"]]}], [6362, "Before testing, the subjects performed a warm-up exercise consisting of 5 submaximal knee extensions of the leg at 60 degrees/second.", {"entities": []}], [6363, "In the main test session, subjects performed 5 isokinetic knee extensions of the leg at an angular velocity of 60 degrees/second, and subjects recovered passively for 2 min between sets of measurements [26,27].", {"entities": []}], [6364, "The subject\u2019s knee joint center, measured using the femoral epicondyles as a joint center reference, was aligned with the axis of the isokinetic dynamometer.", {"entities": []}], [6365, "The leg was secured against the knee attachment pad, while the trunk, waist, and mid-thigh were secured with straps to the chair to reduce movement of these segments.", {"entities": []}], [6366, "SC in powdered form were provided by Bioport Korea Inc. (Gigang, Korea); the lot number (BPK-SC-001) was the same as that used in another animal study [28].", {"entities": [[0, 2, "Herb name"], [138, 150, "Study"]]}], [6367, "Simply, the collected SC (100 kg) was extracted in 20% ethanol at 90 \u00b0C for 4 h and filtered with an 80-mesh filter.", {"entities": [[22, 24, "Herb name"]]}], [6368, "The extract was lyophilised and yielded 23.2% reddish brown powders.", {"entities": []}], [6369, "The SC contained 4.92 \u00b1 0.06 mg/g of schizandrin as a specific ingredient by high-performance liquid chromatography analysis [28].", {"entities": [[4, 6, "Herb name"], [17, 33, "Amount"], [37, 48, "Herb name"]]}], [6370, "The SC provided by the company has been proven effective through animal studies [3,4,13,28], and the safety of the human body has been confirmed by the Regional Clinical Trials Center, Dong-A University, Busan, Korea.", {"entities": [[4, 6, "Herb name"], [65, 79, "Study"], [161, 176, "Study"]]}], [6371, "Previous animal studies showed that the optimal dose for the effects of SC extract on muscle strength was 250 mg/kg [13,28].", {"entities": [[9, 23, "Study"], [72, 82, "Herb name"], [86, 101, "Parameter"], [106, 115, "Amount"]]}], [6372, "In this study, participant weight ranged from 49.4\u201368.0 kg.", {"entities": []}], [6373, "SC intake was based on the lowest body weight, and the value was about 1000 mg per day.", {"entities": [[0, 2, "Herb name"], [71, 78, "Amount"], [79, 86, "Frequency"]]}], [6374, "The equation for human equivalent dose (HED) is as follows: HED (mg/kg) = Animal does mg/kg km ratio [29].", {"entities": []}], [6375, "All participants were randomized to receive placebo or SC pills containing 1000 mg of natural extract (twice per day, two pills per dose, each containing 250 mg).", {"entities": [[55, 57, "Herb name"], [75, 82, "Amount"], [103, 116, "Frequency"], [118, 160, "Amount"]]}], [6376, "Participants were instructed to take each treatment pill as prescribed after 30 min of breakfast and dinner for 12 weeks and to complete a daily diary of compliance.", {"entities": [[108, 120, "Duration"], [139, 144, "Frequency"]]}], [6377, "All participants were trained to maintain their daily physical activity and advised to not consume other dietary supplements during the intervention.", {"entities": [[48, 53, "Frequency"]]}], [6378, "Patients and clinical personnel were blinded to the treatment assigned until all data was collected at the 12-week visit.", {"entities": [[107, 114, "Duration"]]}], [6379, "Fasting venous blood samples were collected from all participants, at baseline and at 12 weeks.", {"entities": [[86, 94, "Duration"]]}], [6380, "Fasting was maintained for 12 h, and blood samples were collected between 8:00\u20139:00 a.m. on the following day.", {"entities": [[23, 31, "Duration"]]}], [6381, "Plasma samples were obtained by centrifugation and stored at \u221280 \u00b0C.", {"entities": []}], [6382, "Serum creatine kinase (CK) and lactate dehydrogenase (LDH) were measured from serum frozen with a commercial kit, according to the manufacturer\u2019s recommendations (Wiener Lab., Rosario, Argentina) [30].", {"entities": [[0, 26, "Parameter"], [31, 58, "Parameter"]]}], [6383, "Lactate and pyruvate concentration were determined by the fluorometric method of Maughan [31], which is based on the enzymatic reactions of NAD+ reduction (lactate) or NADH oxidation (pyruvate).", {"entities": [[0, 7, "Parameter"], [12, 20, "Parameter"], [156, 163, "Parameter"], [184, 192, "Parameter"]]}], [6384, "The SPSS statistical package version 23.0 for Windows (SPSS, Inc., Chicago, IL, USA) was used to perform all statistical evaluations.", {"entities": []}], [6385, "We used two-factor repeated measures ANOVA to determine interaction (group \u00d7 time) effects for all outcome variables.", {"entities": []}], [6386, "When significant group \u00d7 time interactions were identified, paired t-tests were performed to detect differences between time points.", {"entities": []}], [6387, "Statistical significance was accepted at the p < 0.05 level.", {"entities": []}], [6388, "All variables are presented as the mean \u00b1 standard deviation.", {"entities": []}], [6389, "The mean SC extract supplementation and placebo compliance were 97.3% (90.2\u2212100%) in the SC group and 95.8% (86.7\u2013100%) in the placebo group.", {"entities": [[9, 19, "Herb name"], [89, 91, "Herb name"]]}], [6390, "There were no significant differences between the groups for height, weight, or BMI at baseline (Table 1).", {"entities": [[80, 83, "Parameter"]]}], [6391, "ASM/height QMS is presented in Figure 1.", {"entities": [[0, 3, "Parameter"], [11, 14, "Parameter"]]}], [6392, "There was a significant interaction (p = 0.001) effect for group by time on QMS.", {"entities": [[76, 79, "Parameter"]]}], [6393, "While QMS significantly increased (p < 0.001) in the SC group from pre- to post-test, this value did not change in the placebo group.", {"entities": [[6, 9, "Parameter"], [53, 55, "Herb name"]]}], [6394, "Lactate level is presented in Figure 2.", {"entities": [[0, 13, "Parameter"]]}], [6395, "There was a significant interaction (p = 0.038) effect for group by time on lactate level.", {"entities": [[76, 89, "Parameter"]]}], [6396, "While lactate level significantly decreased (p = 0.045) in the SC group from pre- to post-test, this value did not change in the placebo group.", {"entities": [[6, 19, "Parameter"], [63, 65, "Herb name"]]}], [6397, "Maintaining a high level of muscle strength can be an important means of preventing frailty and hospitalization, as well as physical disability and function limitation in IADLs [11,12,32,33].", {"entities": [[28, 43, "Parameter"], [84, 91, "Pathology"], [124, 143, "Pathology"]]}], [6398, "Adequate nutritional supplementation is an important element of any strategy for the preservation of skeletal muscle mass, muscle strength, and muscle protein synthesis during aging [34,35,36].", {"entities": [[101, 121, "Parameter"], [123, 138, "Parameter"]]}], [6399, "SC is one of the most well-known herbal medicines and has been extensively used in Asia, including Japan, China, and Korea [37].", {"entities": [[0, 2, "Herb name"]]}], [6400, "Nevertheless, human studies on the use of SC extract are limited.", {"entities": [[14, 27, "Study"], [42, 52, "Herb name"]]}], [6401, "A randomized, double-blind, placebo-controlled study by Kim et al.", {"entities": [[0, 52, "Study"]]}], [6402, "reported that SC extract supplementation for 12 weeks was effective against menopausal symptoms, especially hot flushes, sweating, and heart palpitations [38].", {"entities": [[14, 24, "Herb name"], [41, 53, "Duration"], [76, 95, "Pathology"], [108, 119, "Pathology"], [121, 129, "Pathology"], [135, 153, "Pathology"]]}], [6403, "However, another randomized, double-blind, placebo-controlled study of obese women by Song et al.", {"entities": [[17, 67, "Study"], [71, 76, "Pathology"], [77, 82, "Sex"]]}], [6404, "reported that SC extract supplementation for 12 weeks had no effect on significant obesity-related parameters [2].", {"entities": [[14, 24, "Herb name"], [41, 53, "Duration"], [83, 90, "Pathology"]]}], [6405, "Therefore, the effect of SC extract on humans is not yet clear.", {"entities": [[25, 35, "Herb name"]]}], [6406, "Recently, two studies have shown that SC supplementation increased calf muscle strength as well as muscle mass in mice [13,28].", {"entities": [[38, 40, "Herb name"], [72, 87, "Parameter"]]}], [6407, "Our study, however, is the first to investigate the association between muscle strength and SC extract in humans.", {"entities": [[72, 87, "Parameter"], [92, 102, "Herb name"]]}], [6408, "In addition, the results of our study showed that supplementation of SC extract for 12 weeks in humans improved muscle strength (mean 7.7% for QMS).", {"entities": [[69, 79, "Herb name"], [80, 92, "Duration"], [112, 127, "Parameter"]]}], [6409, "Trapani et al.", {"entities": []}], [6410, "reported that the contractive strength of muscles is determined by the activity of adenosine triphosphatase (ATPase) [39].", {"entities": [[83, 116, "Target"]]}], [6411, "In addition, SC extract supplementation has been shown to increase ATPase activity in gastrocnemius and soleus muscles in mice [13].", {"entities": [[13, 23, "Herb name"], [67, 73, "Target"]]}], [6412, "This may be the theoretical basis for the mechanism of increase in muscle strength by SC extract supplementation.", {"entities": [[67, 82, "Parameter"], [86, 96, "Herb name"]]}], [6413, "However, our study did not investigate the activity of ATPase.", {"entities": [[55, 61, "Target"]]}], [6414, "This needs to be established through further study.", {"entities": []}], [6415, "Skeletal muscle mass tended to increase in this study, but it was not statistically significant.", {"entities": [[0, 20, "Parameter"]]}], [6416, "A change in muscle strength is known to have a positive relationship with changes in muscle mass [40,41,42].", {"entities": [[12, 27, "Parameter"], [85, 96, "Parameter"]]}], [6417, "However, it is not a strong relationship, and individual differences may be present in adults [40,42].", {"entities": []}], [6418, "In our study, the SC extract supplement was 1000 mg per day.", {"entities": [[18, 28, "Herb name"], [44, 51, "Amount"], [52, 59, "Frequency"]]}], [6419, "The SC extract we provided may not be sufficient enough to induce a positive effect on skeletal muscle metabolism [13].", {"entities": [[4, 14, "Herb name"], [87, 113, "Target"]]}], [6420, "In our study, ASM and other physical performance variables did not change after 12 weeks.", {"entities": [[14, 17, "Parameter"], [80, 88, "Duration"]]}], [6421, "A few studies reported that leg muscle strength is related to hand grip strength, gait speed, chair stand, and balance in adults [43,44,45].", {"entities": [[28, 47, "Parameter"], [62, 80, "Parameter"]]}], [6422, "In spite of this, our SC group had no changes in other physical performance variables, except leg muscle strength.", {"entities": [[22, 24, "Herb name"], [94, 113, "Parameter"]]}], [6423, "This result differs from the increase in skeletal muscle found in mice after SC extract supplementation.", {"entities": [[41, 56, "Target"], [77, 87, "Herb name"]]}], [6424, "Therefore, a clear relationship between physical performance variables and SC extract supplementation should be demonstrated through further studies.", {"entities": [[75, 85, "Herb name"]]}], [6425, "Resting lactate level was measured at baseline and after 12 weeks, and results are presented in Figure 2.", {"entities": [[8, 21, "Parameter"], [57, 65, "Duration"]]}], [6426, "There was a significant interaction (p = 0.038) effect for group by time on resting lactate level.", {"entities": [[84, 97, "Parameter"]]}], [6427, "In the SC group, the lactate level at rest was significantly decreased (p < 0.05), but had no change in the placebo group after 12 weeks.", {"entities": [[7, 9, "Herb name"], [21, 34, "Parameter"], [128, 136, "Duration"]]}], [6428, "A follow-up study by Matsushita et al.", {"entities": [[2, 17, "Study"]]}], [6429, "reported that resting lactate levels were associated with body fat, blood pressure, serum lipids, insulin, and high sensitivity C-reactive protein in adults [20].", {"entities": [[22, 36, "Parameter"], [58, 66, "Parameter"], [68, 82, "Parameter"], [84, 96, "Parameter"], [98, 105, "Parameter"], [128, 146, "Parameter"]]}], [6430, "In other cross-sectional and follow-up studies, a high lactate level at rest was associated with chronic diseases such as type 2 diabetes and hypertension [19,46].", {"entities": [[9, 46, "Study"], [55, 68, "Parameter"], [122, 137, "Pathology"], [142, 154, "Pathology"]]}], [6431, "It was associated with a high risk of coronary heart disease (CHD), stroke, and all-cause mortality [20].", {"entities": [[38, 66, "Pathology"], [68, 74, "Pathology"]]}], [6432, "The normal range of lactic acid at rest is not yet clear.", {"entities": [[20, 31, "Parameter"]]}], [6433, "The normal range for lactate in the study of Matsushita et al.", {"entities": [[21, 28, "Parameter"]]}], [6434, "was 2.3\u20135.3 mg/dL [20], which was also similar in Juraschek et al.\u2019s study [46].", {"entities": [[4, 17, "Amount"]]}], [6436, "Recently, animal study suggests that SC intake could lower the lactate level caused by exercise [15].", {"entities": [[10, 22, "Study"], [37, 39, "Herb name"], [63, 76, "Parameter"]]}], [6437, "SC was also effective for menopausal symptoms in middle-aged women [38].", {"entities": [[0, 2, "Herb name"], [26, 45, "Pathology"], [61, 66, "Sex"]]}], [6438, "However, the effect of SC on lactic acid at rest was still unclear.", {"entities": [[23, 25, "Herb name"], [29, 40, "Parameter"]]}], [6439, "Our study is the first to demonstrate the effect of SC supplementation on resting lactate.", {"entities": [[52, 54, "Herb name"], [82, 89, "Parameter"]]}], [6440, "The exact mechanism to explain the effect of SC extract supplementation on the lactate level is not yet known.", {"entities": [[45, 55, "Herb name"], [79, 92, "Parameter"]]}], [6441, "The results of Zagari et al.", {"entities": []}], [6442, "have shown the association between high lactate production and reduced oxidative metabolism [47].", {"entities": [[40, 47, "Parameter"]]}], [6443, "They also reported that mitochondria play a central role in lactate metabolism [47].", {"entities": [[60, 67, "Parameter"]]}], [6444, "An animal study by Chiu et al.", {"entities": [[3, 15, "Study"]]}], [6445, "reported that long-term SC treatment could enhance the renal mitochondrial antioxidant status, as well as improve mitochondrial function [48].", {"entities": [[24, 26, "Herb name"], [55, 93, "Target"]]}], [6446, "We thought of the possibility that the improvement of lactate metabolism may be due to the improvement of mitochondrial function by SC extract supplementation.", {"entities": [[54, 72, "Target"], [132, 142, "Herb name"]]}], [6447, "Nevertheless, further studies are needed to clarify the association between SC supplementation and lactate concentration.", {"entities": [[76, 94, "Herb name"], [99, 120, "Parameter"]]}], [6448, "CK catalyzes ATP dependent phosphorylation of creatine, and LDH is involved in the metabolism of pyruvate in skeletal muscle [49,50].", {"entities": [[0, 2, "Parameter"], [13, 54, "Target"], [60, 63, "Parameter"], [97, 124, "Target"]]}], [6449, "CK and LDH are reported to serve as markers of acute or chronic muscular damage and cell necrosis [51,52].", {"entities": [[0, 2, "Parameter"], [7, 10, "Parameter"], [47, 79, "Pathology"], [84, 97, "Pathology"]]}], [6450, "Additionally, activation of CK and LDH may increase symptoms such as pain, fatigue, and a decline in muscular strength during high-intensity, long-distance exercise due to damaged skeletal muscles [51,52].", {"entities": [[28, 30, "Parameter"], [35, 38, "Parameter"], [69, 73, "Pathology"], [75, 82, "Pathology"], [101, 118, "Parameter"], [172, 196, "Pathology"]]}], [6451, "Recently, in an animal study, SC was shown to effectively delay CK and LDH increases after acute exercise [13], but another animal study did not shown in this effect [53].", {"entities": [[16, 28, "Study"], [30, 32, "Herb name"], [64, 66, "Parameter"], [71, 74, "Parameter"], [124, 136, "Study"]]}], [6452, "In our study, SC extract supplementation did not alter CK, LDH, or pyruvate at rest in humans.", {"entities": [[14, 24, "Herb name"], [55, 57, "Parameter"], [59, 62, "Parameter"], [67, 75, "Parameter"]]}], [6453, "Our research has some limitations.", {"entities": []}], [6454, "Firstly, participants\u2019 physical activity and diet were not examined during the intervention period.", {"entities": []}], [6455, "We trained subjects to not to alter lifestyles (participation in physical activity programs, or intake of other healthy supplementation) that could affect the study during the intervention.", {"entities": []}], [6456, "Secondly, the subjects did not include men, so the effects of SC on muscle strength and resting lactic acid could not be seen in both men and women.", {"entities": [[39, 42, "Sex"], [62, 64, "Sex"], [68, 83, "Parameter"], [96, 107, "Parameter"], [134, 137, "Sex"], [142, 147, "Sex"]]}], [6457, "Thirdly, the sample size was relatively small.", {"entities": []}], [6458, "In conclusion, SC extract supplementation increased QMS and decreased lactate level at rest in adult women.", {"entities": [[15, 41, "Herb name"], [52, 55, "Parameter"], [70, 83, "Parameter"], [101, 106, "Sex"]]}], [6459, "SC extract is thought to be a health food that supports the healthy life of post-menopausal middle-aged women.", {"entities": [[0, 10, "Herb name"], [76, 91, "Pathology"], [104, 109, "Sex"]]}], [6460, "Our results illustrate the potential of SC extract supplementation in the prevention of declining muscle strength.", {"entities": [[40, 50, "Herb name"], [88, 113, "Pathology"]]}], [6461, "Further studies are required to cement this link and investigate whether this influences physical performance.", {"entities": []}], [6462, "We are grateful to all study participants and for the technical support of Dong-A University, Dong-A Hospital, and Dong Ju College research staff.", {"entities": []}], [6463, "Conceptualization, H.P.", {"entities": []}], [6464, "and S.H.", {"entities": []}], [6465, "; methodology, H.P.", {"entities": []}], [6466, "; software, J.P.; validation, J.P., S.H., and H.P.", {"entities": []}], [6467, "; formal analysis, J.P. and S.H.", {"entities": []}], [6468, "; investigation, J.P.; resources, S.H.", {"entities": []}], [6469, "; data curation, J.P.; writing\u2014original draft preparation, J.P., S.H., and H.P.", {"entities": []}], [6470, "; writing\u2014review and editing, H.P and S.H.", {"entities": []}], [6471, "; visualization, J.P.; project administration, H.P.", {"entities": []}], [6472, "; funding acquisition, S.H.", {"entities": []}], [6473, "All authors have read and agreed to the published version of the manuscript.", {"entities": []}], [6474, "This work was supported by the Dong-A University research fund.", {"entities": []}], [6475, "The authors declare no conflict of interest.", {"entities": []}], [6476, "Comparisons of quadriceps muscles strength at baseline and 12 weeks after age adjustment.", {"entities": [[15, 42, "Parameter"], [59, 67, "Duration"]]}], [6477, "SC: Schisandra chinensis; ES: effect size; *** p < 0.001 versus baseline interventions.", {"entities": [[0, 24, "Herb name"]]}], [6478, "Comparisons of lactate concentration at baseline and 12 weeks after age adjustment.", {"entities": [[15, 36, "Parameter"], [53, 61, "Duration"]]}], [6479, "SC: Schisandra chinensis; ES: effect size; * p < 0.05 versus between baseline and after intervention.", {"entities": [[0, 24, "Herb name"]]}], [6480, "The characteristics of the subjects.", {"entities": []}], [6481, "Values are means \u00b1 SD; SC: Schisandra chinesis.", {"entities": [[23, 46, "Herb name"]]}], [6482, "Comparisons of appendicular skeletal mass and physical performance variables at baseline and at 12 weeks, after age adjustement.", {"entities": [[15, 41, "Parameter"], [96, 104, "Duration"]]}], [6483, "Values are means \u00b1 SD; SC: Schisandra chinesis; ASM: appendicular skeletal mass.", {"entities": [[23, 46, "Herb name"], [48, 79, "Parameter"]]}], [6484, "Comparisons of blood variables at baseline and 12 weeks, after age adjustment.", {"entities": [[47, 55, "Duration"]]}], [6485, "Values are means \u00b1 SD; SC: Schisandra chinesis.", {"entities": [[23, 46, "Herb name"]]}], [6486, "The first clinically relevant reports of preparations of St. John's wort (SJW), a herbal medicine with anti\u2010depressant effects, interacting with other drugs, altering their bioavailability and efficacy, were published about 20 years ago.", {"entities": [[30, 37, "Study"], [57, 78, "Herb name"], [173, 188, "Parameter"]]}], [6487, "In 2000, a pharmacokinetic interaction between SJW and cyclosporine caused acute rejection in two heart transplant patients.", {"entities": [[47, 50, "Herb name"], [55, 67, "Drug"], [75, 123, "Pathology"]]}], [6488, "Since then, subsequent research has shown that SJW altered the pharmacokinetics of drugs such as digoxin, tacrolimus, indinavir, warfarin, alprazolam, simvastatin, or oral contraceptives.", {"entities": [[47, 50, "Herb name"], [97, 104, "Drug"], [106, 116, "Drug"], [118, 127, "Drug"], [129, 137, "Drug"], [139, 149, "Drug"], [151, 162, "Drug"], [167, 186, "Drug"]]}], [6489, "These interactions were caused by pregnane\u2010X\u2010receptor (PXR) activation.", {"entities": [[34, 59, "Target"]]}], [6490, "Preparations of SJW are potent activators of PXR and hence inducers of cytochrome P450 enzymes (most importantly CYP3A4) and P\u2010glycoprotein.", {"entities": [[16, 19, "Herb name"], [45, 48, "Target"], [71, 94, "Target"], [113, 119, "Target"], [125, 139, "Target"]]}], [6491, "The degree of CYP3A4 induction correlates significantly with the hyperforin content in the preparation.", {"entities": [[14, 20, "Target"], [65, 75, "Herb name"]]}], [6492, "Twenty years after the first occurrence of clinically relevant pharmacokinetic drug interactions with SJW, this review revisits the current knowledge of the mechanisms of action and on how pharmacokinetic drug interactions with SJW could be avoided.", {"entities": [[102, 105, "Herb name"], [112, 118, "Study"], [228, 231, "Herb name"]]}], [6493, "This article is part of a themed section on The Pharmacology of Nutraceuticals.", {"entities": [[5, 12, "Study"]]}], [6494, "To view the other articles in this section visit    [Correction added on 27 January 2020, after first online publication: Title has been amended ATP\u2010binding cassette subfamily B member 1 cytochrome P450 enzyme diagnostic and statistical manual of mental disorders European Medicines Agency European Scientific Cooperative on Phytotherapy Hamilton rating scale for depression Committee on Herbal Medicinal Products of the EMA multidrug resistance multidrug resistance\u2010related protein organic\u2010anion\u2010transporting polypetide organic cation transporter pregnenolone 16\u03b1\u2010carbonitrile P\u2010glycoprotein (MDR1) pregnane X response element St. John's wort ( solute carrier uridine 5\u2032\u2010diphospho\u2010glucuronosyltransferase Preparations of St. John's wort (SJW;  SJW extracts contain numerous constituents belonging to at least 10 biologically active chemical classes (Nahrstedt & Butterweck, 2010).", {"entities": [[18, 26, "Study"], [187, 209, "Target"], [247, 263, "Pathology"], [364, 374, "Pathology"], [483, 547, "Target"], [578, 599, "Target"], [600, 619, "Target"], [628, 643, "Herb name"], [722, 737, "Herb name"], [739, 742, "Herb name"], [745, 757, "Herb name"]]}], [6495, "Major compounds are naphthodianthrones (such as hypericin), phloroglucinol derivatives (such as  Chemical structures of major compounds found in  The general public perception that herbal\u2010based medicinal products are safe was reinforced by studies showing fewer adverse events occurring with SJW preparations, being possibly even safer than conventional antidepressants (Beaubrun & Gray, 2000; Gaster, 2000; Linde, Berner, & Kriston, 2008; McIntyre, 2000).", {"entities": [[20, 38, "Herb name"], [48, 57, "Herb name"], [60, 74, "Drug"], [262, 276, "Pathology"], [292, 295, "Herb name"], [341, 369, "Drug"]]}], [6496, "However, the mood enhancement effect was similar to synthetic antidepressants (Philipp et al., 1999; Schrader, 2000; Schwarz & Cupp, 2000; Woelk, 2000).", {"entities": [[52, 77, "Drug"]]}], [6497, "Undesirable effects that were most commonly reported were gastrointestinal irritations (0.6%), allergic reactions (0.5%), fatigue (0.4%), and restlessness (0.3%).", {"entities": [[0, 19, "Pathology"], [58, 86, "Pathology"], [95, 113, "Pathology"], [122, 129, "Pathology"], [142, 154, "Pathology"]]}], [6498, "A meta\u2010analysis based on traditional SJW preparations revealed that when adverse reactions occur, they are generally mild, transient, and similar to placebo (Linde et al., 1996).", {"entities": [[2, 15, "Study"], [37, 40, "Herb name"], [73, 90, "Pathology"]]}], [6499, "In a review of SJW preparations and their adverse drug reactions (ADR), the author noted that this incidence was some 10 times less than that for synthetic antidepressants (Schulz, 2002).", {"entities": [[15, 18, "Herb name"], [146, 171, "Drug"]]}], [6500, "The most common adverse events (one per 300,000 treated cases) among the spontaneous reports in a German ADR recording system between October 1991 and December 1999 involved reactions of the skin exposed to light (27 incidents) that was followed by increased bleeding time with coumarin\u2010type oral anticoagulants (16 reports), eight incidents of breakthrough bleeding with oral contraceptives, and seven reported decreases in  Since then, several case studies addressed the clinical significance of interactions between cyclosporine and SJW.", {"entities": [[16, 30, "Pathology"], [174, 212, "Pathology"], [259, 272, "Parameter"], [278, 311, "Drug"], [316, 323, "Study"], [345, 366, "Pathology"], [372, 391, "Drug"], [446, 458, "Study"], [519, 531, "Drug"], [536, 539, "Herb name"]]}], [6501, "Awareness of the clinical relevance of this interaction was raised after a liver allograft transplantation in a 63\u2010year\u2010old patient.", {"entities": [[112, 123, "Age"]]}], [6502, "Fourteen months after transplantation, this patient developed severe acute rejection, which was related with an unexpected decrease in cyclosporine levels.", {"entities": [[62, 84, "Pathology"], [135, 147, "Drug"]]}], [6506, "CYP 2D6 CYP 3A4 Desogestrel Ethinylestradiol 0.65 CYP 3A4 No significant change in C No clinically relevant interaction.", {"entities": [[0, 7, "Target"], [8, 15, "Target"], [16, 27, "Drug"], [28, 44, "Drug"], [50, 57, "Target"]]}], [6507, "CYP 3A4 CYP 1A2 CYP 3A4 P\u2010gp CYP 2C9 Caffeine Alprazolam Digoxin Tolbutamide CYP 3A4 P\u2010gp No significant interaction in AUC  Note.", {"entities": [[0, 7, "Target"], [8, 15, "Target"], [16, 23, "Target"], [24, 28, "Target"], [29, 36, "Target"], [37, 45, "Herb name"], [46, 56, "Drug"], [57, 64, "Drug"], [65, 76, "Drug"], [77, 84, "Target"], [85, 89, "Target"], [120, 123, "Parameter"]]}], [6508, "No clinically relevant interactions could be found at indicated low daily doses of hyperforin.", {"entities": [[83, 93, "Herb name"]]}], [6509, "Abbreviations: C  While the use of SJW products in Switzerland, Germany, Austria, and some other European countries is controlled because they are regulated as drugs, SJW preparations are available as dietary supplements in the United States with little regulation and low regulatory hurdles to pass.", {"entities": [[35, 38, "Herb name"], [167, 170, "Herb name"]]}], [6510, "Based on the Dietary Supplement Health and Education Act of 1994, the U.S. Food and Drug Administration is not authorized to review dietary supplements for safety and effectiveness prior to marketing.", {"entities": []}], [6511, "While very different with respect to regulatory definition, the terms \u201cdietary supplements\u201d and \u201cherbal supplements\u201d are often used synonymously in the literature.", {"entities": []}], [6512, "It is beyond the scope of this review to discuss regulatory issues in detail, however, the interested reader is referred to Data S1 of this article where a brief definition of these terms, in view of the associated regulations in various countries is provided.", {"entities": [[31, 37, "Study"]]}], [6513, "Twenty years after the appearance of the first reports of clinically relevant drug interactions with SJW, this herbal medicine still attracts significant attention in the matter of safety, efficacy, and mechanism of action.", {"entities": [[47, 54, "Study"], [101, 104, "Herb name"]]}], [6514, "The most important information has been comprehensively summarized (Borrelli & Izzo, 2009; Chrubasik\u2010Hausmann, Vlachojannis, & McLachlan, 2019; Gurley, Fifer, & Gardner, 2012; Izzo, 2004; Soleymani, Bahramsoltani, Rahimi, & Abdollahi, 2017; Whitten, Myers, Hawrelak, & Wohlmuth, 2006).", {"entities": []}], [6516, "Up to now, it is impossible to attribute the various pharmacological effects of SJW to the action of single constituents.", {"entities": [[80, 83, "Herb name"]]}], [6517, "Therefore, the single compounds of the extract may be regarded to act synergistically (Schmidt & Butterweck, 2015).", {"entities": []}], [6518, "The extract is considered to be the pharmacological principle, and thus, SJW extracts are classified as quantified extracts (Pharm Eur, 01/2017:1874; see also Data S1) by the European regulatory authorities (European Medicines Agency [EMA]/Committee on Herbal Medicinal Products of the EMA [HMPC], 2009).", {"entities": [[73, 85, "Herb name"]]}], [6519, "SJW extracts as well as isolated constituents (hyperforin, hypericin, or flavonoids) have been investigated in vitro and in vivo for their interactions with a variety of potentially relevant targets for depression.", {"entities": [[0, 12, "Herb name"], [47, 57, "Herb name"], [59, 68, "Herb name"], [73, 83, "Herb name"], [108, 116, "Study"], [121, 128, "Study"], [203, 213, "Pathology"]]}], [6520, "However, the current review briefly summarizes only data that were reported for SJW extracts:  Receptor\u2010binding studies motivated by the monoamine neurotransmitter hypothesis suggested an interaction with  The effect of SJW extract on \u03b2\u2010adrenoceptors was first studied by the group of M\u00fcller, Rolli, Sch\u00e4fer, and Hafner (1997) who showed that the number of rat cortical \u03b2\u2010adrenoceptors was down\u2010regulated after treatment with an SJW extract, while no change in receptor affinity was observed.", {"entities": [[21, 27, "Study"], [80, 92, "Herb name"], [220, 231, "Herb name"], [235, 250, "Target"], [357, 385, "Target"], [429, 440, "Herb name"]]}], [6521, "Kientsch et al.", {"entities": []}], [6522, "(2001) demonstrated that chronic exposure of an extract, devoid of hyperforin, dose\u2010dependently down\u2010regulated the number of \u03b2\u2010adrenoceptors in C6 cells, comparable to desipramine.", {"entities": [[67, 77, "Herb name"], [125, 140, "Target"], [168, 179, "Drug"]]}], [6523, "In vivo, a SJW extract reduced the number of \u03b2\u2010adrenoceptors in rat frontal cortex (Simbrey, Winterhoff, & Butterweck, 2004).", {"entities": [[0, 7, "Study"], [11, 22, "Herb name"], [45, 82, "Target"]]}], [6524, "As observed for  Acute immobilization stress following 8 weeks of SJW extract administration decreased mRNA levels of  In several neuropsychiatric diseases, including major depression, elevated inflammatory cytokine levels were observed (Miller, Maletic, & Raison, 2009), where microglia seem to be a primary source of brain cytokines.", {"entities": [[55, 62, "Duration"], [66, 77, "Herb name"], [130, 155, "Pathology"], [167, 183, "Pathology"], [194, 222, "Parameter"]]}], [6525, "in vitro inhibition of cytokine release was inhibited in PHA/LPS\u2010stimulated hippocampal HT22 cells (Bonaterra et al., 2018; Thiele, Brink, & Ploch, 1994).", {"entities": [[0, 8, "Study"]]}], [6526, "An SJW extract also protected rat and human pancreatic islets against cytokine toxicity (Novelli et al., 2014).", {"entities": [[3, 14, "Herb name"]]}], [6528, "As a hyperactivity of the hypothalamic\u2013pituitary\u2013adrenal axis appears to be involved in depression (Arborelius, Owens, Plotsky, & Nemeroff, 1999), several investigations showed modulating effects of SJW extracts on this axis (Butterweck, Winterhoff, & Herkenham, 2003; Butterweck et al., 2001).", {"entities": [[88, 98, "Pathology"], [199, 211, "Herb name"]]}], [6529, "Short\u2010 and long\u2010term administration of an SJW extract to rats reduced the expression of genes that are involved in the regulation of the hypothalamic\u2013pituitary\u2013adrenal axis and lowered plasma  Verjee, Weston, Kolb, Kalbhenn\u2010Aziz, and Butterweck (2018) showed in recent in vitro experiments that the SSRI citalopram as well as a commercial SJW extract could antagonize the dexamethasone stress\u2010induced increase in expression of the mRNA for FK506\u2010binding protein 51 ( Recently, an SJW extract containing low amounts of hyperforin was investigated for its effect on plasma membrane fluidity in rat C6 glioblastoma cells (Keksel et al., 2019).", {"entities": [[42, 53, "Herb name"], [269, 289, "Study"], [299, 314, "Drug"], [339, 350, "Herb name"], [372, 385, "Drug"], [480, 491, "Herb name"], [518, 528, "Herb name"], [599, 611, "Pathology"]]}], [6530, "The antidepressant effects of SJW extracts have been tested and confirmed in several animal models of depression: Of particular interest is the forced swimming test, in which a good correlation between the decrease of immobility observed and the corresponding clinical potency has been demonstrated (Porsolt, Le Pichon, & Jalfre, 1977).", {"entities": [[30, 42, "Herb name"], [102, 112, "Pathology"]]}], [6531, "Several studies demonstrated that SJW extracts dose\u2010dependently decreased immobility time in this model, an effect which was comparable to synthetic antidepressants (Bano & Dawood, 2008; Butterweck, Jurgenliemk, Nahrstedt, & Winterhoff, 2000; Butterweck, Petereit, Winterhoff, & Nahrstedt, 1998; Butterweck, Wall, Lieflander\u2010Wulf, Winterhoff, & Nahrstedt, 1997; De Vry, Maurel, Schreiber, de Beun, & Jentzsch, 1999; Lozano\u2010Hernandez et al., 2010; Paulke, N\u00f6ldner, Schubert\u2010Zsilavecz, & Wurglics, 2008; Tian et al., 2014).", {"entities": [[34, 46, "Herb name"], [139, 164, "Drug"]]}], [6532, "The tail suspension test, which also measures changes in immobility in rodents after antidepressant treatment, was applied by several investigators (Butterweck, Christoffel, et al., 2003; Machado et al., 2008; Tian et al., 2014) and SJW extracts significantly reduced the time of immobility in this test.", {"entities": [[85, 110, "Drug"], [233, 245, "Herb name"]]}], [6533, "Several studies also demonstrated that various SJW extracts could reduce stress\u2010induced behavioural deficits in the learned helplessness test (Bhattacharya, Chakrabarti, & Chatterjee, 1998; Chatterjee et al., 1998; Gambarana et al., 1999; Scheggi et al., 2016).", {"entities": [[47, 59, "Herb name"], [73, 108, "Pathology"]]}], [6534, "The effect on cognition ability was tested in Barnes maze or Morris water maze.", {"entities": []}], [6535, "SJW alleviated stress and corticosterone related memory impairments (Trofimiuk & Braszko, 2008; Trofimiuk, Holownia, & Braszko, 2011).", {"entities": [[0, 3, "Herb name"], [15, 21, "Pathology"], [26, 67, "Pathology"]]}], [6536, "In conclusion, a variety of behavioural studies have been performed in animal models and have independently confirmed the antidepressant effects of SJW extracts.", {"entities": [[148, 160, "Herb name"]]}], [6537, "Comparing the scientific evidence of clinical efficacy of SJW with the available data on its mechanism of action, it is still unknown how exactly SJW causes its antidepressive effects.", {"entities": [[58, 61, "Herb name"], [146, 149, "Herb name"]]}], [6538, "A complex multicomponent mixture such as an extract of a medicinal plant does not exert its effects based on one single component.", {"entities": []}], [6539, "Therefore, over the years, several potential pharmacological targets have been investigated not only with SJW extracts but also with single constituents.", {"entities": [[106, 118, "Herb name"]]}], [6540, "Noteworthy, none of the identified single components of SJW extracts has been shown to fully explain the clinical efficacy in the treatment of symptoms of major depressive disorders.", {"entities": [[56, 68, "Herb name"], [155, 181, "Pathology"]]}], [6541, "Therefore, SJW is a prime example of the entire extract being defined as the active constituent.", {"entities": [[11, 14, "Herb name"]]}], [6542, "The contribution of hyperforin to the clinical efficacy of SJW extracts has been a matter for considerable debate.", {"entities": [[20, 30, "Herb name"], [59, 71, "Herb name"]]}], [6543, "Initially, the component was suggested as the major active principle of SJW leading to antidepressant effects (Chatterjee et al., 1998).", {"entities": [[72, 75, "Herb name"]]}], [6547, "Data are from 30 dose regimens from 28 clinical trials with patients with major depressive disorder.", {"entities": [[39, 54, "Study"], [74, 99, "Pathology"]]}], [6548, "Each data point represents one treatment result at the indicated dosage.", {"entities": []}], [6549, "No dose\u2010dependency was found in daily doses \u2265180 mg (linear regression slope b = 0.003 \u00b1 0.0042 is not significantly different from 0, P = .475, R  It was shortly after the first reports on single cases of SJW being associated with significant changes in pharmacokinetics of the concomitantly used  Commercial preparations differ significantly in their content of hyperforin, hypericin, and flavonoids.", {"entities": [[32, 37, "Frequency"], [44, 51, "Amount"], [197, 202, "Study"], [206, 209, "Herb name"], [364, 374, "Herb name"], [376, 385, "Herb name"], [391, 401, "Herb name"]]}], [6550, "Importantly, the induction of CYP3A4 in intestinal cells correlates with the content of hyperforin, as reported by G\u00f6dtel\u2010Armbrust et al.", {"entities": [[30, 36, "Target"], [88, 98, "Herb name"]]}], [6551, "(2007).", {"entities": []}], [6552, "Similar results have been recently shown for PXR transactivation, using hepatoma cells for heterologous expression (Sch\u00e4fer et al., 2019).", {"entities": [[45, 48, "Target"]]}], [6553, "The PXR is a member of the family of nuclear receptors and is involved in the regulation of metabolic processes in response to xenobiotics (Pascussi, Gerbal\u2010Chaloin, Drocourt, Maurel, & Vilarem, 2003).", {"entities": [[4, 7, "Target"]]}], [6554, "It exhibits a ligand\u2010binding domain and a DNA\u2010binding domain and acts as a ligand\u2010activated transcription factor after heterodimerizing with the  Based on a PXR pharmacophore model developed by Ekins and Erickson (2002), hypericin, the second presumably active ingredient of SJW, would be classified as potential, but non\u2010potent, activator of the human PXR.", {"entities": [[157, 160, "Target"], [221, 230, "Herb name"], [275, 278, "Herb name"], [353, 356, "Target"]]}], [6555, "However, experimental data show that there is no significant transactivation in cells exposed to hypericin (Moore et al., 2000).", {"entities": [[97, 106, "Herb name"]]}], [6556, "So far, the PXR has evolved into a central regulator of drug metabolism, which not only modulates the activity of CYP3A4, but also of other phase I or phase II metabolizing enzymes, and drug transporters (Tolson & Wang, 2010; Waxman, 1999).", {"entities": [[12, 15, "Target"], [114, 120, "Target"]]}], [6557, "In the network of genes involved in drug metabolism, the PXR functions as a xenobiotic receptor or \u201cxenosensor,\u201d which, after ligand binding, translocates to the nucleus, where it binds to specific PXR response elements (PXRRE) in the promotor of various genes, modulating their transcription.", {"entities": [[57, 60, "Target"], [198, 227, "Target"]]}], [6558, "Accordingly, this nuclear receptor balances cellular exposure and the activity of the gene network.", {"entities": []}], [6559, "The function of the gene network is biotransformation and excretion of potentially harmful xenobiotics.", {"entities": []}], [6560, "The regulation of cytochrome P450 enzymes by PXR is assumed to be one of the mechanisms contributing to the interindividual variability in phase I biotransformation as summarized by Zanger and Schwab (2013).", {"entities": [[18, 41, "Target"], [45, 48, "Target"]]}], [6561, "However, considering that drug elimination is based on an interplay of multiple mechanisms, increased clearance can only be achieved if phase I and phase II biotransformation and cellular efflux are modulated at the same time (Figure 3).", {"entities": []}], [6564, "In the context of the SJW constituents, OATP1B3 is inhibited by hyperforin, suggesting interaction of the compound with this transporter (Smith, Acharya, Desai, Figg, & Sparreboom, 2005).", {"entities": [[22, 25, "Herb name"], [40, 47, "Target"], [64, 74, "Herb name"]]}], [6565, "For OATP2B1, we have recently shown that this transporter is not only inhibited by hyperforin but also transports this constituent of SJW (Sch\u00e4fer, Bock, & Meyer Zu Schwabedissen, 2018), thus influencing the intracellular transactivation of PXR by hyperforin (Sch\u00e4fer et al., 2019).", {"entities": [[4, 11, "Target"], [83, 93, "Herb name"], [134, 137, "Herb name"], [241, 244, "Target"], [248, 258, "Herb name"]]}], [6566, "Importantly, OATP2B1 is expressed not only in human hepatocytes but also in enterocytes (Kobayashi et al., 2003), and cells of the renal tubule (Ferreira et al., 2018), where it is assumed to influence oral drug absorption and renal elimination.", {"entities": [[13, 20, "Target"]]}], [6567, "Interaction with hyperforin may therefore be not only limited to metabolized substrates but may even be extended.", {"entities": [[17, 27, "Herb name"]]}], [6568, "For the efflux transporters, and especially for ABCB1 (P\u2010glycoprotein) and  It is assumed that modulation of ABCB1 by PXR is tissue specific, with pronounced changes in enterocytes, but only limited effects in liver in vivo.", {"entities": [[48, 53, "Target"], [55, 69, "Target"], [109, 114, "Target"], [118, 121, "Target"]]}], [6569, "In detail, Haslam, Jones, Coleman, and Simmons (2008) reported induction of ABCB1 (MDR1) in human intestinal epithelial cells (T84 cells) upon treatment with hyperforin, resulting in significant changes in transepithelial transport of digoxin.", {"entities": [[76, 81, "Target"], [83, 87, "Target"], [158, 168, "Herb name"], [235, 242, "Drug"]]}], [6570, "In their study, treatment with hyperforin reduced the apical to basal, while enhancing the basal to apical transport of the substrate of ABCB1.", {"entities": [[31, 41, "Herb name"], [137, 142, "Target"]]}], [6571, "In the human colon carcinoma cell line LS147T, Geick et al.", {"entities": [[19, 28, "Pathology"]]}], [6572, "(2001) showed a similar effect on ABCB1 expression for rifampicin.", {"entities": [[34, 39, "Target"], [55, 65, "Drug"]]}], [6574, "(1999).", {"entities": []}], [6575, "However, even if ABCB1 is regulated in human hepatocytes or hepatoma cell lines treated with PXR ligands, there are data suggesting a limited effect on hepatic expression of ABCB1 in patients treated with carbamazepine, suggesting that response to this PXR inducer is tissue specific (D\u00fcrr et al., 2000; Oscarson et al., 2006).", {"entities": [[17, 22, "Target"], [93, 96, "Target"], [174, 179, "Target"], [205, 218, "Drug"], [253, 256, "Target"]]}], [6576, "A similar compartmentalization of the transcriptional response has been observed for the  ABCB1 is a determinant in the protection of the brain, as it functions as a potent efflux pump in the brain capillary endothelial cells, which form the blood\u2013brain barrier.", {"entities": [[90, 95, "Target"]]}], [6577, "Administration of SJW extract significantly increased the expression of the rodent ABCB1 isoform Mdr1a in the rat hippocampus after 21 days of treatment (Mrozikiewicz et al., 2014), suggesting that there may even be an influence on the functionality of the blood\u2013brain barrier.", {"entities": [[18, 29, "Herb name"], [83, 102, "Target"], [132, 139, "Duration"]]}], [6578, "Bauer et al.", {"entities": []}], [6579, "also reported induction of P\u2010glycoprotein expression and function in the blood\u2013brain barrier.", {"entities": [[27, 41, "Target"]]}], [6580, "Exposing isolated capillaries to PCN (a potent activator of murine PXR) resulted in enhanced expression and function, as shown for the fluorescent cyclosporine derivative (Bauer, Hartz, Fricker, & Miller, 2004).", {"entities": [[67, 70, "Target"], [147, 159, "Drug"]]}], [6581, "An increase in ABCB1 expression in brain capillaries has also been shown in mice (transgenic for Alzheimer's disease) after 120 days exposure to SJW extracts (Brenn et al., 2014).", {"entities": [[15, 20, "Target"], [97, 116, "Pathology"], [124, 132, "Duration"], [145, 157, "Herb name"]]}], [6582, "It is important to mention, in this context, that there is only limited transactivation of the rat PXR by hyperforin, which is significantly enhanced after exchanging the amino acid F305 for leucine (Tirona, Leake, Podust, & Kim, 2004).", {"entities": [[99, 102, "Target"], [106, 116, "Herb name"]]}], [6583, "Accordingly, data reporting on hyperforin effects in rodent models have to be carefully evaluated before being translated.", {"entities": [[31, 41, "Herb name"]]}], [6584, "No such species difference has been observed for transactivation of Pxr in cynomolgus monkeys.", {"entities": [[68, 71, "Target"]]}], [6585, "Indeed, Kim et al.", {"entities": []}], [6590, "This statement was provided even before another comprehensive pharmacokinetic interaction study was published, where no clinically relevant interactions were found for seven test drugs in concomitant application with a low\u2010hyperforin SJW extract (Zahner et al., 2019).", {"entities": [[219, 245, "Herb name"]]}], [6592, "Taken together, data on the pharmacokinetic interactions with SJW preparations correlate directly with the daily dose of hyperforin (M\u00fcller et al., 2006).", {"entities": [[62, 65, "Herb name"], [107, 112, "Frequency"], [121, 131, "Herb name"]]}], [6594, "To avoid pharmacokinetic interactions and to contribute to SJW product safety, low\u2010hyperforin SJW extracts should be recommended for therapeutic use.", {"entities": [[59, 62, "Herb name"], [79, 106, "Herb name"]]}], [6595, "At daily dosages of maximum 1\u2010mg hyperforin, no clinically relevant pharmacokinetic interactions are to be expected (EMA/HMPC, 2018; ESCOP, 2018; Zahner et al., 2019).", {"entities": [[3, 8, "Frequency"], [20, 32, "Amount"], [33, 43, "Herb name"]]}], [6597, "Up to a maximum daily dose of 1\u2010mg hyperforin, no clinically relevant interactions are to be expected.", {"entities": [[16, 21, "Frequency"], [30, 34, "Amount"], [35, 45, "Herb name"]]}], [6599, "This could either be for clinical purposes such as treatment of Crigler\u2010Najjar\u2010Syndrome type II or in pharmacokinetic interaction studies as inducer of CYP3A4, P\u2010gp, or UGTs.", {"entities": [[64, 95, "Pathology"], [152, 158, "Target"], [160, 164, "Target"], [169, 173, "Target"]]}], [6600, "Importantly, as recommended by the EMA in 2009, the amount of hyperforin should be declared for medicinal products containing SJW.", {"entities": [[62, 72, "Herb name"], [126, 129, "Herb name"]]}], [6601, "Unfortunately, even for herbal medicinal products, this safety\u2010relevant recommendation is rarely followed and is completely neglected in botanicals and food/dietary supplements.", {"entities": []}], [6602, "Also, in clinical pharmacokinetic studies and case reports, the administered SJW products were often lacking sufficient specifications (herbal drug substance or extract, drug\u2010extract ratio, solvent), especially regarding the hyperforin content.", {"entities": [[9, 41, "Study"], [46, 58, "Study"], [77, 80, "Herb name"], [225, 235, "Herb name"]]}], [6603, "The ongoing use of high\u2010hyperforin SJW products among botanicals and food/dietary supplements explains why an unnecessary safety risk for pharmacokinetic drug interactions persists in the public, despite labelling and warnings.", {"entities": [[19, 47, "Herb name"]]}], [6604, "This fact highlights also the importance of clinical and analytical comparison studies among different SJW preparations to provide information on hyperforin content of considerably safer products.", {"entities": [[44, 86, "Study"], [103, 106, "Herb name"], [146, 156, "Herb name"]]}], [6605, "Therefore, to avoid unnecessary drug safety risks in co\u2010medication therapy, low\u2010hyperforin SJW extracts should be prescribed to patients suffering from depressive episodes.", {"entities": [[76, 103, "Herb name"], [152, 171, "Pathology"]]}], [6606, "Currently, the recommended daily intake of SJW varies between 180 and 1800 mg. As higher doses of SJW do not lead to a more pronounced decrease of depressive symptoms, SJW products with lower extract doses should be preferentially recommended to avoid further safety risks.", {"entities": [[27, 32, "Frequency"], [43, 46, "Herb name"], [62, 77, "Amount"], [98, 101, "Herb name"], [147, 166, "Pathology"], [168, 171, "Herb name"]]}], [6607, "In countries with regulations of SJW status other than a registered drug, herbal medicinal product or traditional herbal medicinal product, awareness should increase among physicians regarding hyperforin as dose\u2010dependent inducer of cytochrome P450 enzymes (e.g., CYP3A4), transporters (e.g., P\u2010gp, OATP1A2), and other PXR\u2010related targets.", {"entities": [[33, 36, "Herb name"], [193, 203, "Herb name"], [233, 256, "Target"], [264, 270, "Target"], [293, 297, "Target"], [299, 306, "Target"], [319, 338, "Target"]]}], [6608, "To avoid the risk of unnecessary pharmacokinetic interactions with SJW, a safety threshold of maximum 1\u2010mg hyperforin per day is recommended.", {"entities": [[67, 70, "Herb name"], [94, 106, "Amount"], [107, 117, "Herb name"], [118, 125, "Frequency"]]}], [6609, "Key protein targets and ligands in this article are hyperlinked to corresponding entries in  S.N., J.D., and V.B.", {"entities": []}], [6610, "are employees of a manufacturer of an SJW herbal medicinal product.", {"entities": [[38, 41, "Herb name"]]}], [6611, "H.M. has no conflict of interest to declare.", {"entities": []}], [6612, "Data S1.", {"entities": []}], [6613, "Supporting Information Click here for additional data file.", {"entities": []}], [6614, "Lingzhi and Yunzhi are medicinal mushrooms commonly used with cytotoxic chemotherapy in cancer patients in Asian countries.", {"entities": [[0, 7, "Herb name"], [12, 18, "Herb name"], [88, 94, "Pathology"], [107, 112, "Ethnic group"]]}], [6615, "The current systematic review aims to identify potential pharmacokinetic or pharmacodynamic interactions from the existing literature to ensure their effective and safe combination usage in cancer patients.", {"entities": [[190, 196, "Pathology"]]}], [6616, "A systematic search was conducted on nine major Chinese and English databases, including China Journal Net, Allied and Complementary Medicine Database, and Ovid MEDLINE This search identified 213 studies, including 77 clinical studies that reported on the combined use of cytotoxic drugs with Yunzhi (n\u2009=\u200956) or Lingzhi (n\u2009=\u200921).", {"entities": [[48, 55, "Ethnic group"], [60, 67, "Ethnic group"], [218, 234, "Cohort"], [293, 299, "Herb name"], [312, 319, "Herb name"]]}], [6617, "Majority of these clinical studies demonstrated modest methodological quality.", {"entities": [[18, 34, "Study"]]}], [6618, "In clinical practice, the most commonly used cytotoxic drugs with Lingzhi were cisplatin, 5-fluorouracil (5-FU) and paclitaxel, whereas Tegafur/uracil (UFT)/Tegafur, 5-FU, and mitomycin were the ones used more often with Yunzhi.", {"entities": [[66, 73, "Herb name"], [79, 88, "Drug"], [90, 111, "Drug"], [116, 126, "Drug"], [136, 165, "Drug"], [166, 170, "Drug"], [176, 185, "Drug"], [221, 227, "Herb name"]]}], [6619, "Only two clinical pharmacokinetic studies were available showing no significant interactions between Polysaccharide K (PSK) and Tegafur.", {"entities": [[9, 41, "Study"], [101, 123, "Herb name"], [128, 135, "Drug"]]}], [6620, "From the pharmacodynamic interactions perspective, combination uses of Yunzhi/Lingzhi with cytotoxic drugs in clinical practice could lead to improvement in survival (n\u2009=\u200931) and quality of life (n\u2009=\u200917), reduction in tumor lesions (n\u2009=\u200922), immune modulation (n\u2009=\u200938), and alleviation of chemotherapy-related side effects (n\u2009=\u200914) with no reported adverse effects.", {"entities": [[71, 77, "Herb name"], [78, 85, "Herb name"], [218, 231, "Pathology"], [310, 322, "Pathology"], [349, 364, "Pathology"]]}], [6621, "Our findings suggest that the clinical combination use of Lingzhi or Yunzhi with cytotoxic drugs could enhance the efficacy and ameliorate the adverse effects of cytotoxic drugs, leading to improved quality of life in cancer patients.", {"entities": [[58, 65, "Herb name"], [69, 75, "Herb name"], [143, 158, "Pathology"], [218, 224, "Pathology"]]}], [6622, "More high quality clinical studies including pharmacokinetic herb-drug interactions studies are warranted to verify these observations and mechanisms involved.", {"entities": [[18, 34, "Study"]]}], [6623, "Based on the high quality clinical data, pharmacoepidemiology methods and bioinformatics or data mining could be adopt for further identification of clinical meaningful herb-drug interactions in cancer therapies.", {"entities": [[195, 201, "Pathology"]]}], [6624, "Although chemotherapy and radiotherapy remain the mainstay of cancer treatment in developed countries, an increasing number of cancer patients are seeking benefits from complementary and alternative medicine.", {"entities": [[9, 21, "Drug"], [26, 38, "Drug"], [62, 68, "Pathology"], [127, 133, "Pathology"]]}], [6625, "Surveys in the United States, Canada and Europe revealed that an average rate of 35% of cancer patients have utilized Chinese herbal medicine during their treatment [1].", {"entities": [[88, 94, "Pathology"], [118, 125, "Ethnic group"]]}], [6626, "Such prevalence of Chinese herbal medicine use in cancer patients from Asian countries is expected to be even higher [2, 3].", {"entities": [[19, 26, "Ethnic group"], [50, 56, "Pathology"], [71, 76, "Ethnic group"]]}], [6627, "It is well-known that the concurrent use of Chinese and Western medicines can cause herb-drug interactions that lead to both beneficial and harmful health outcomes.", {"entities": [[44, 51, "Ethnic group"], [56, 63, "Ethnic group"]]}], [6628, "To highlight, herb\u2013drug interactions are not uncommon in cancer treatment and may affect the clinical efficacy or safety of the treatment.", {"entities": [[57, 63, "Pathology"]]}], [6629, "One study demonstrated that over half of the patients undergoing chemotherapy took herbal products, of whom 27% were found to be at risk of clinically significant interactions between chemotherapy drug and herbs.", {"entities": [[65, 77, "Drug"], [184, 196, "Drug"]]}], [6630, "In another study, authors detected 120 possible herb\u2013drug interactions in 149 patients who reported concurrent use of Chinese herbs with conventional anti-cancer drugs [4, 5].", {"entities": [[74, 77, "Cohort"], [118, 125, "Ethnic group"], [150, 167, "Drug"]]}], [6631, "As most chemotherapy drugs have a narrow therapeutic index, there is an urging need for clinicians and scientists to address the potential herb-drug interactions in oncology practice.", {"entities": [[8, 20, "Drug"]]}], [6632, "Among Chinese herbs, medicinal mushrooms have been used for a long time during the cancer treatment.", {"entities": [[6, 13, "Ethnic group"], [83, 89, "Pathology"]]}], [6633, "Lingzhi (Reishi or Mannentake in Japanese) and Yunzhi (commonly known as Turkey tail) are common medicinal mushrooms that are readily available in Asian countries.", {"entities": [[0, 7, "Herb name"], [9, 15, "Herb name"], [19, 29, "Herb name"], [47, 53, "Herb name"], [73, 84, "Herb name"]]}], [6634, "They are believed to possess medicinal properties to treat cancers or relieve cancer-related symptoms [6].", {"entities": [[59, 66, "Pathology"], [78, 84, "Pathology"]]}], [6635, "The two mushrooms both belong to the Polyporaceae family and have similar characteristics based on Traditional Chinese Medicine theory including flavour and nature [7].", {"entities": [[111, 118, "Ethnic group"]]}], [6636, "Despite their popular use in cancer patients, there are limited reports on the clinical outcomes from their herb-drug interactions during anti-cancer treatment.", {"entities": [[29, 35, "Pathology"], [138, 149, "Drug"]]}], [6637, "Although systematic reviews and meta-analysis of Lingzhi and Yunzhi as an adjunct for cancer treatment have been performed [8\u201310], these reviews mostly focused on clinical outcomes with no mechanistic explanations for the potential beneficial or harmful interactions.", {"entities": [[49, 56, "Herb name"], [61, 67, "Herb name"], [86, 92, "Pathology"]]}], [6638, "By gathering both clinical and preclinical studies of this subject matter, the current systematic review aimed to evaluate the effects of the co-administration of cytotoxic drugs with the medicinal mushrooms, Lingzhi and Yunzhi.", {"entities": []}], [6639, "Specifically, we will identify potential pharmacokinetic and pharmacodynamic interactions between these medicinal mushrooms and chemotherapy drugs and discuss the implications of these interactions on the efficacy and safety of cancer treatment.", {"entities": [[128, 140, "Drug"], [228, 234, "Pathology"]]}], [6640, "A comprehensive search was conducted on the following databases: China Journal Net (1915 to June 2020), Wanfang Database (1990 to June 2020), and Chinese Biomedical Literature Database (1878 to June 2020).", {"entities": [[146, 153, "Ethnic group"]]}], [6641, "English databases included Allied and Complementary Medicine (1985 to June 2020), Embase (1910 to June 2020), Ovid MEDLINE The combination of search terms included keywords for cytotoxic anticancer drugs and medicinal mushrooms as shown in Additional file 1: Table S1.", {"entities": [[0, 7, "Ethnic group"], [177, 197, "Drug"]]}], [6642, "The keywords used for cytotoxic drugs were based on the Hong Kong Hospital Authority Drug Formulary with no targeted therapy drugs included in the current review.", {"entities": []}], [6643, "In addition, chemoprotectants such as leucovorin and mesna were included in the current search.", {"entities": [[38, 48, "Drug"], [53, 58, "Drug"]]}], [6644, "Besides the specific names of the cytotoxic drugs, general terms such as \u201ccytotoxic drug\u201d and \u201cantineoplastic drug\u201d were also included in the search to increase the coverage.", {"entities": [[74, 88, "Drug"], [95, 114, "Drug"]]}], [6645, "For the two medicinal mushrooms, Chinese name, English name, Pinyin and Latin name of them together with the names of their active ingredients were incorporated in the search.", {"entities": []}], [6646, "For Lingzhi, keywords for search included Reishi, Mannentake, Lingzhi, Ganoderma lucidum, Ganoderma sinense, Ganoderic acid, Polysaccharide, \u9748\u829d, \u9748\u829d\u9178, and \u591a\u7cd6.", {"entities": [[4, 11, "Herb name"], [42, 48, "Herb name"], [50, 60, "Herb name"], [62, 69, "Herb name"], [71, 88, "Herb name"], [90, 107, "Herb name"], [109, 123, "Herb name"], [125, 139, "Herb name"], [141, 148, "Herb name"], [154, 156, "Herb name"]]}], [6647, "For Yunzhi, Turkey Tail, Yunzhi, Coriolus versicolor, Trametes versicolor, Polyporus versicolor, Krestin (PSK), Polysaccharide, Polysaccharide peptide (PSP), \u96f2\u829d and \u591a\u7cd6\u80bd.", {"entities": [[4, 10, "Herb name"], [12, 23, "Herb name"], [25, 31, "Herb name"], [33, 52, "Herb name"], [54, 73, "Herb name"], [75, 95, "Herb name"], [97, 110, "Herb name"], [112, 126, "Herb name"], [128, 156, "Herb name"], [158, 160, "Herb name"], [165, 168, "Herb name"]]}], [6648, "General terms including \u201cmedicinal mushroom\u201d was also utilized in the search for more comprehensive coverage.", {"entities": []}], [6649, "This review included clinical, animal and in-vitro studies that reported the concurrent use of any cytotoxic drug with the two medicinal mushroom(s).", {"entities": [[21, 58, "Study"]]}], [6650, "The name of drug used, dosage form and administration route should be specified.", {"entities": []}], [6651, "The mushroom(s) could exist in any formulation containing a raw or processed form of the mushroom(s) that included the extract of its (their) active phytochemical components.", {"entities": []}], [6652, "They could be used alone or with other herbs or ingredients in a composite formula.", {"entities": []}], [6653, "Clinical studies had to involve two groups of patients, a control group that received only the cytotoxic drug or the medicinal mushroom(s) (or the mushroom-containing herbal formula) and a co-administration group that received the cytotoxic drug together with the medicinal mushroom(s).", {"entities": [[0, 16, "Study"]]}], [6654, "If the control group also received medicinal mushrooms, there should be significant dosage differences of the mushrooms in the treatment group.", {"entities": []}], [6655, "The languages of the included articles were restricted to English, Chinese and Japanese.", {"entities": []}], [6656, "The Jadad scale was used to assess the quality of the clinical studies.", {"entities": [[54, 70, "Study"]]}], [6657, "This is a 5-point scale evaluating randomization, blinding, and withdrawals or dropouts of the clinical trials [11].", {"entities": [[95, 110, "Study"]]}], [6658, "Figure\u00a01 summarizes the process of database searching and literature selection.", {"entities": []}], [6659, "The initial search identified 9712 studies.", {"entities": []}], [6660, "After screening their titles and abstracts, about 455 studies were included and subjected to further full-text inspection and verifications based on the inclusion criteria.", {"entities": []}], [6661, "In total, 213 studies were included in this review with 119 of them focused on Lingzhi, 93 of them on Yunzhi, and 1 on the combination of Lingzhi and Yunzhi.", {"entities": []}], [6662, "Other characteristics of the included studies including languages used, type of studies, type of the mushroom preparations, and country of the origin, type of cancer together with Jadad score of the included clinical studies were summarized in Additional file 1: Table S2 and distributions of the included cytotoxic drugs were shown Additional file 1: Figure S1.", {"entities": [[208, 224, "Study"]]}], [6663, "The detailed information on the 77 clinical studies and 137 preclinical studies were listed in Additional file 1: Tables S3, S4, respectively.", {"entities": [[35, 51, "Study"], [60, 79, "Study"]]}], [6664, "PRISMA flow chart of current database search and literature selection In general, evidence on the pharmacokinetic interactions between Lingzhi or Yunzhi and cytotoxic drugs was scarce, except for the clinical pharmacokinetics interaction investigations between PSK and Tegafur as illustrated below.", {"entities": [[135, 142, "Herb name"], [146, 152, "Herb name"], [261, 264, "Herb name"], [269, 276, "Drug"]]}], [6665, "Of all the 213 studies included in this review, only two studies evaluated the clinical pharmacokinetic interactions between cytotoxic drugs and medicinal mushrooms.", {"entities": []}], [6666, "Both studies evaluated the interactions between PSK (Yunzhi) and Tegafur (tetrahydrofuryl-5-fluorouracil), the prodrug of cytotoxic drug 5-FU.", {"entities": [[48, 60, "Herb name"], [65, 105, "Drug"], [137, 141, "Drug"]]}], [6667, "The conversion of Tegafur to 5-FU is mediated primarily by the CYP2A6 enzyme.", {"entities": [[18, 25, "Drug"], [29, 33, "Drug"]]}], [6668, "Only small or non-significant changes in the blood level of 5-FU and Tegafur was observed in most patients with up to 8\u201314\u00a0months PSK co-administration [12, 13].", {"entities": [[60, 64, "Drug"], [69, 76, "Drug"], [130, 133, "Herb name"]]}], [6669, "Only two in-vitro studies included in the review evaluated the pharmacokinetic interactions between Lingzhi and cytotoxic drugs.", {"entities": [[9, 25, "Study"], [100, 107, "Herb name"]]}], [6670, "Ganoderic polysaccharides were shown to increase the distribution of doxorubicin in drug-resistant cancer cell lines, while Ganoderic acid B was shown to reverse the resistance of hepatocellular carcinoma toward doxorubicin, paclitaxel, and vincristine but not cisplatin [14, 15].", {"entities": [[0, 25, "Herb name"], [69, 80, "Drug"], [99, 105, "Pathology"], [124, 140, "Herb name"], [180, 204, "Pathology"], [212, 223, "Drug"], [225, 235, "Drug"], [241, 252, "Drug"], [261, 270, "Drug"]]}], [6671, "Since doxorubicin, paclitaxel, and vincristine are substrates of P-glycoprotein, Lingzhi or its components were expected to modulate the P-gp mediated efflux of these cytotoxic drugs to increase their cell accumulation and reverse their resistance in the tumor cells [16].", {"entities": [[6, 17, "Drug"], [19, 29, "Drug"], [35, 46, "Drug"], [81, 88, "Herb name"]]}], [6672, "For Yunzhi, consistent with clinical findings, an animal study showed that regardless of the administration route, PSK had no effect on the tissue level of 5-FU or its prodrug Tegafur in tumor-bearing mice [17].", {"entities": [[4, 10, "Herb name"], [115, 118, "Herb name"], [156, 160, "Drug"], [176, 183, "Drug"]]}], [6673, "In addition, another animal study showed that PSP could decrease cyclophosphamide clearance and increase the plasma half-life without affecting its distribution or protein binding.", {"entities": [[21, 33, "Study"], [46, 49, "Herb name"], [65, 81, "Drug"]]}], [6674, "It was also found that a dose-dependent relationship existed between the systemic exposure of cyclophosphamide and acute rather than sub-chronic treatment with PSP [18].", {"entities": [[94, 110, "Drug"], [160, 163, "Herb name"]]}], [6675, "Tables\u00a01 and 2 summarized the clinical and preclinical pharmacodynamic interactions between Lingzhi/Yunzhi and cytotoxic drugs, respectively.", {"entities": [[92, 99, "Herb name"], [100, 106, "Herb name"]]}], [6676, "Outcomes on survival and quality of life, tumor inhibition and disease control rate, immune system and alleviation of the other adverse effects of cytotoxic drugs were further illustrated as follows.", {"entities": []}], [6679, "Reduction in CD57+ T cell [39].", {"entities": [[13, 25, "Parameter"]]}], [6680, "Reduce T cell apoptosis and caspase 3 activity through downregulating Bax expression in T cells [170] Increase in efficacy and survival [20], better symptomatic relief [20] increase in T cells count (CD4, CD4/CD8) [20] Better symptomatic relief [141] and increase appetite [144] Less reduction in WBC (CD3+, CD4+ T cells, NK cells) [141, 144], platelets [144] Pharmacodynamic interactions between medicinal mushrooms and cytotoxic drugs in preclinical studies Increase in tumor inhibition effect [83, 84, 98] and survival time [63] Less decrease in WBC [83, 84, 145], platelets [83] and other bone marrow cells [84] Greater recovery rate from intestinal damage caused by 5-FU [173] Increase in survival [67], cytotoxicity and inhibit metastasis [111] Reduce immunosuppression (reduce the decrease in phagocytic activity, antibody production [111], delayed hypersensitivity [111, 112]) Increase in tumor inhibition and apoptotic rate (dose-related or time-dependent) [98\u2013103], similar effect at lower dose of 5-FU [105] Induce cell cycle arrest at different phases [99, 101], increase caspase 3 and 8 expression and activity [100].", {"entities": [[7, 23, "Parameter"], [28, 46, "Parameter"], [70, 84, "Parameter"], [187, 198, "Parameter"], [200, 203, "Parameter"], [205, 208, "Parameter"], [209, 212, "Parameter"], [297, 300, "Parameter"], [302, 306, "Parameter"], [308, 320, "Parameter"], [322, 330, "Parameter"], [344, 353, "Parameter"], [440, 459, "Study"], [549, 552, "Parameter"], [568, 577, "Parameter"], [593, 610, "Parameter"], [643, 660, "Pathology"], [671, 675, "Drug"], [734, 744, "Pathology"], [800, 819, "Parameter"], [821, 840, "Parameter"], [1008, 1012, "Drug"], [1084, 1093, "Parameter"]]}], [6681, "Reverse resistance [106, 109] Modulate Fas/FasL-mediated apoptosis [107] Induce cell cycle arrest by interfering with HER2/PI3K/Akt pathway [108].", {"entities": [[39, 66, "Target"], [118, 139, "Target"]]}], [6682, "Inhibit expression of cIAP-1, enhance caspase-3 activation [120] Prolong survival in additive function [63] Less decrease in WBC and platelet [157] Relieve myocardial and hepatocellular injury through modulation of enzymes (ALT, AST, LDH, CK) and oxidative stress biomarkers (GST, GPx, SOD, CAT) [157, 181, 182] Less decrease in CD3+, CD4+ T cells, IL-2 and IL-2R expression [129, 130] Increase Bax, decrease Bcl-2 and CDK4 [129, 130] Synergistic [15, 124] or no effects [14] on tumor inhibition, reverse resistance [14, 15] Increase apoptosis, decrease Ku80 and enhance reactive oxygen species production [124] Enhance apoptotic effect [128] Increase expression of\u00a0Bax, decrease Bcl-xL, Bcl-xL/Bax ratio [128] Enhance apoptotic effect [128] Increase Bid, decrease Bcl-xL expression and Bcl-xL/Bax ratio [128] Prolong survival in additive function [66] Reduce induced small intestinal damage [162] Dose-related increase in immunoglobulin A and modulate change in oxidative stress marker such as SOD and MDA induced by methotrexate [162] Increase in survival rate or time [72\u201374], tumor growth inhibition [73] Dose-related decrease in frequency of sister chromatid exchanges [188] Recover antibody production and delayed-type hypersensitivity [73, 112] Decrease incidence of high mobility cells, increase low mobility cells [72] Increase in cytotoxicity to tumor cells [103] Protection against mutation damage [185] Increase in tumor inhibition [95\u201397] and efficacy of paclitaxel [95] Increase let-7 expression [95] Restore antitumorigenic immune cells via inhibiting immune checkpoints [97] Down-regulation of Warburg effect-related proteins to inhibit tumor metabolism [97] Restore gut dysbiosis induced by paclitaxel [97] Enhance tumor growth inhibition [96, 108, 110] and apoptosis [96], reverse resistance [14] Induce cell cycle arrest by interfering with HER2/PI3K/Akt pathway [108], inhibition of HER2 signaling pathway and downregulate expression of HER2 related proteins [96, 108] No significant increase in efficacy [147] Reduce damage to intestine [173] and less reduction in WBC, but not platelet [147] Increase in cytotoxicity and inhibit metastasis [111] Reduce immunosuppression (phagocytic activity, antibody production) [111]                a.", {"entities": [[22, 28, "Target"], [38, 47, "Target"], [125, 128, "Parameter"], [133, 141, "Parameter"], [224, 227, "Parameter"], [229, 232, "Parameter"], [234, 237, "Parameter"], [239, 241, "Parameter"], [247, 295, "Parameter"], [329, 333, "Parameter"], [335, 347, "Parameter"], [349, 353, "Parameter"], [358, 363, "Target"], [395, 398, "Target"], [409, 414, "Target"], [419, 423, "Parameter"], [479, 484, "Pathology"], [554, 558, "Parameter"], [666, 669, "Target"], [680, 686, "Target"], [688, 704, "Parameter"], [751, 754, "Target"], [765, 771, "Target"], [787, 803, "Parameter"], [923, 939, "Parameter"], [995, 998, "Parameter"], [1003, 1006, "Parameter"], [1018, 1030, "Drug"], [1080, 1085, "Pathology"], [1356, 1361, "Pathology"], [1427, 1432, "Pathology"], [1468, 1478, "Drug"], [1653, 1658, "Pathology"], [1683, 1696, "Pathology"], [1708, 1718, "Drug"], [1732, 1737, "Pathology"], [1860, 1881, "Target"], [1903, 1925, "Target"], [1957, 1961, "Target"], [2086, 2089, "Parameter"], [2099, 2107, "Parameter"], [2151, 2161, "Pathology"], [2194, 2213, "Parameter"], [2215, 2235, "Parameter"]]}], [6684, "In this review, Yunzhi showed more clinical evidence than Lingzhi on increase in the survival rate and prolongation of the survival time.", {"entities": [[16, 22, "Herb name"], [58, 65, "Herb name"]]}], [6685, "Among the 21 clinical studies on Lingzhi, only three studies measured survival outcomes with two of them reported increase in survival rate [19\u201321].", {"entities": [[13, 29, "Study"], [33, 40, "Herb name"]]}], [6686, "The survival rate increased when herbal formulae containing Lingzhi were used together with chemotherapy regimens (including 5-FU, cisplatin, doxorubicin, mitomycin, or vincristine).", {"entities": [[60, 67, "Herb name"], [125, 129, "Drug"], [131, 140, "Drug"], [142, 153, "Drug"], [155, 164, "Drug"], [169, 180, "Drug"]]}], [6687, "Notably, 37 of the 56 clinical studies on Yunzhi evaluated survival outcomes, 36 of which used PSK and one used Yunzhi-containing herbal formula.", {"entities": [[22, 38, "Study"], [42, 48, "Herb name"], [95, 98, "Herb name"], [112, 118, "Herb name"]]}], [6688, "Twenty-nine of the 37 studies showed survival benefits of Yunzhi when co-administered with cytotoxic drugs.", {"entities": [[58, 64, "Herb name"]]}], [6689, "Among these Yunzhi\u2013drug combinations, more evidence of survival benefits was reported for combinations with 5-FU, mitomycin, and UFT or Tegafur [22\u201350], whereas no survival benefits were reported for the combination with leucovorin [51].", {"entities": [[12, 18, "Herb name"], [108, 112, "Drug"], [114, 123, "Drug"], [129, 132, "Drug"], [136, 143, "Drug"], [221, 231, "Drug"]]}], [6690, "Most of the Japanese studies on Yunzhi showed survival benefits of 3 or 5\u00a0years in gastric and colorectal cancers, leading to the approval of PSK approved as an adjunct in cancer treatment in Japan.", {"entities": [[12, 20, "Ethnic group"], [32, 38, "Herb name"], [83, 113, "Pathology"], [142, 145, "Herb name"], [172, 178, "Pathology"]]}], [6691, "In terms of quality of life, Lingzhi co-administration with cytotoxic drugs has more clinical evidence than that for Yunzhi.", {"entities": [[29, 36, "Herb name"], [117, 123, "Herb name"]]}], [6692, "Among the 21 included studies for Lingzhi, 12 of them measured the quality of life of cancer patients, and all of them observed an improvement by the co-administration of Lingzhi with 5-FU, capecitabine, cisplatin, gemcitabine, leucovorin, oxaliplatin, paclitaxel, and vinorelbine.", {"entities": [[34, 41, "Herb name"], [86, 92, "Pathology"], [171, 178, "Herb name"], [184, 188, "Drug"], [190, 202, "Drug"], [204, 213, "Drug"], [215, 226, "Drug"], [228, 238, "Drug"], [240, 251, "Drug"], [253, 263, "Drug"], [269, 280, "Drug"]]}], [6693, "The improvement in the quality of life was mostly observed in lung cancer patients (8 of the 12 studies) [21, 52\u201359].", {"entities": [[62, 73, "Pathology"]]}], [6694, "Among the included studies, only 5 of the 56 clinical studies on Yunzhi measured the quality of life of cancer patients after the co-administration of Yunzhi with various cytotoxic drugs (5-FU, cisplatin, carboplatin, capecitabine, cyclophosphamide, doxorubicin, etoposide, mitomycin, oxaliplatin, paclitaxel and UFT) and all of them showed improvement [48, 49, 60\u201362].", {"entities": [[45, 61, "Study"], [65, 71, "Herb name"], [104, 110, "Pathology"], [151, 157, "Herb name"], [188, 192, "Drug"], [194, 203, "Drug"], [205, 216, "Drug"], [218, 230, "Drug"], [232, 248, "Drug"], [250, 261, "Drug"], [263, 272, "Drug"], [274, 283, "Drug"], [285, 296, "Drug"], [298, 308, "Drug"], [313, 316, "Drug"]]}], [6695, "Overall, more clinical evidence was reported on the survival benefits for the co-administration of chemotherapy with Yunzhi specifically PSK especially in gastric and colorectal cancer, whereas more evidence was reported on the improvement in the quality of life for the co-administration of chemotherapy with Lingzhi, especially in lung cancer patients.", {"entities": [[99, 111, "Drug"], [117, 123, "Herb name"], [137, 140, "Herb name"], [155, 184, "Pathology"], [292, 304, "Drug"], [310, 317, "Herb name"], [333, 344, "Pathology"]]}], [6696, "b. Preclinical evidence              Animal studies on the concurrent use of Lingzhi or Yunzhi with cytotoxic drugs also measured the survival outcomes and substantiated the findings of the above-mentioned clinical studies.", {"entities": [[37, 51, "Study"], [77, 84, "Herb name"], [88, 94, "Herb name"], [206, 222, "Study"]]}], [6697, "With regard to Lingzhi, its survival benefits were also observed in animal studies when co-administered with 5-FU, carboplatin, cisplatin, and doxorubicin which also shown benefits in clinical studies [63\u201366].", {"entities": [[15, 22, "Herb name"], [68, 82, "Study"], [109, 113, "Drug"], [115, 126, "Drug"], [128, 137, "Drug"], [143, 154, "Drug"], [184, 200, "Study"]]}], [6698, "With regard to Yunzhi, the survival rate or time of animals increased when it was co-administered with 5-FU, cyclophosphamide, etoposide, and mitomycin, which were consistent with the findings from clinical studies [67\u201374].", {"entities": [[15, 21, "Herb name"], [103, 107, "Drug"], [109, 125, "Drug"], [127, 136, "Drug"], [142, 151, "Drug"], [198, 214, "Study"]]}], [6699, "a.", {"entities": []}], [6700, "Clinical evidence              Most of the clinical studies identified in our review measured efficacy based on World Health Organization or the Response Evaluation Criteria in Solid Tumor (RECIST) [75].", {"entities": [[43, 59, "Study"]]}], [6702, "In addition, co-administration of Lingzhi with 5-FU and cisplatin could further reduce the expressions of microRNA-21 (miR-21), endoglin, transforming growth factor (TGF)-\u03b2, and vascular endothelial growth factor (VEGF) [76].", {"entities": [[34, 41, "Herb name"], [47, 51, "Drug"], [56, 65, "Drug"], [106, 126, "Parameter"], [128, 172, "Parameter"], [178, 219, "Parameter"]]}], [6703, "The co-administration of Yunzhi with several cytotoxic drugs (carboplatin, capecitabine, cisplatin, cyclophosphamide, doxorubicin, etoposide, mercaptopurine, oxaliplatin and paclitaxel) showed increase in clinical efficacy [49, 62, 79, 80] and improvements in disease progression or control [48, 50].", {"entities": [[25, 31, "Herb name"], [62, 73, "Drug"], [75, 87, "Drug"], [89, 98, "Drug"], [100, 116, "Drug"], [118, 129, "Drug"], [131, 140, "Drug"], [142, 156, "Drug"], [158, 169, "Drug"], [174, 184, "Drug"]]}], [6704, "Some Yunzhi\u2013drug combinations (5-FU, carboplatin, cisplatin, cyclophosphamide, doxorubicin, etoposide and UFT) also reduced tumor recurrence [25, 38, 42, 44] and metastasis [49].", {"entities": [[5, 11, "Herb name"], [31, 35, "Drug"], [37, 48, "Drug"], [50, 59, "Drug"], [61, 77, "Drug"], [79, 90, "Drug"], [92, 101, "Drug"], [106, 109, "Drug"], [124, 129, "Pathology"], [162, 172, "Pathology"]]}], [6705, "Lower level of markers for tumor cell division, proliferation and invasion were found when paclitaxel and carboplatin were used with PSP [62].", {"entities": [[91, 101, "Drug"], [106, 117, "Drug"], [133, 136, "Herb name"]]}], [6706, "Notably, most studies showed an enhancement in the cytotoxicity toward tumor cells when cytotoxic drug were used with these two medicinal mushrooms, suggesting no disadvantage for the addition of mushrooms in chemotherapy regimens.", {"entities": [[209, 221, "Drug"]]}], [6707, "b. Preclinical and mechanistic evidence              Our review revealed that the mechanisms of interactions between Lingzhi or Yunzhi and cytotoxic drugs involve multiple targets, including genes, proteins, and signaling pathways, to synergistically increase the tumor-inhibitory effect.", {"entities": [[117, 124, "Herb name"], [128, 134, "Herb name"], [191, 196, "Target"], [198, 206, "Target"], [212, 230, "Target"]]}], [6708, "Most animal studies support the clinical findings above.", {"entities": [[5, 19, "Study"]]}], [6709, "For Lingzhi, increase in the tumor inhibition rate was also demonstrated in animal studies [81\u201398] and in-vitro studies [96\u2013110].", {"entities": [[4, 11, "Herb name"], [76, 90, "Study"], [103, 119, "Study"]]}], [6710, "Some animal studies also observed suppression of metastasis by the co-administration of Lingzhi with cyclophosphamide [90, 91].", {"entities": [[5, 19, "Study"], [49, 59, "Pathology"], [88, 95, "Herb name"], [101, 117, "Drug"]]}], [6711, "Regarding Yunzhi, enhancement of the antitumor effects of cytotoxic drugs and reduction in metastasis by Yunzhi have also been demonstrated in animal studies [68\u201371, 73, 111\u2013117] and in-vitro studies [18, 115, 117\u2013121].", {"entities": [[10, 16, "Herb name"], [91, 101, "Pathology"], [105, 111, "Herb name"], [143, 159, "Study"], [183, 199, "Study"]]}], [6712, "The effects of Lingzhi co-administered with cytotoxic drugs on tumor inhibition were multifaceted in both animal and in-vitro studies.", {"entities": [[15, 22, "Herb name"], [63, 68, "Pathology"], [106, 134, "Study"]]}], [6713, "Some combinations exert synergistic effect through induction of cell cycle arrest at different stages or increase the apoptotic rate [81, 89, 91, 96, 99\u2013102, 122\u2013124].", {"entities": []}], [6714, "In addition, the enhancement of the antitumor effect was shown to be achieved via the inhibition of tumor cell angiogenesis [104] or increase in the reactive oxygen species production [124].", {"entities": []}], [6715, "Various in-vitro studies have shown that Lingzhi could enhance the tumor-inhibitory effect by reversing resistance to cytotoxic drugs [14\u201316] Lingzhi co-administration with cytotoxic drugs affects different pathways and cancer targets.", {"entities": [[8, 24, "Study"], [41, 48, "Herb name"], [142, 149, "Herb name"], [220, 226, "Pathology"]]}], [6716, "In animal and in-vitro studies, various pathways related to cell cycle arrest, apoptosis, and angiogenesis were affected, including the Janus kinase/signal transducer and activator of transcription 3 (JAK\u2013STAT3), the protein kinase B (Akt) [106, 123] and the Human epidermal growth factor receptor 2 (HER2) signaling pathway [96, 108], eventually affecting the apoptotic molecules, for example, by altering B-cell lymphoma (Bcl) and Bcl-2-associated X (Bax) [66, 81, 125], caspase 3 and 8 activation [81, 100, 107, 125], and Fas and Fas Ligand (Fasl) [104].", {"entities": [[3, 30, "Study"], [184, 211, "Parameter"], [217, 239, "Parameter"], [259, 306, "Parameter"], [407, 428, "Parameter"], [433, 457, "Parameter"], [473, 482, "Parameter"], [525, 550, "Parameter"]]}], [6717, "The expression of other target genes or proteins was also affected, such as aquaporin [125, 126], VEGF and basic fibroblast growth factor (bFGF) [104, 127], and tumor metastasis suppressor gene 1 (TMSG-1) protein [91], all of which increased tumor inhibition.", {"entities": [[76, 85, "Target"], [98, 102, "Target"], [107, 144, "Target"], [161, 212, "Target"]]}], [6718, "Notably, a recent study found that such synergistic effect may be due to the inhibition of tumor metabolism via down-regulating Warburg-related proteins and restoration of the gut dysbiosis induced by paclitaxel [97].", {"entities": [[176, 189, "Pathology"], [201, 211, "Drug"]]}], [6719, "Regarding the increasing evidence of microbiota involvement in chemotherapy outcomes, it is worth looking into interactions with other cytotoxic drugs on gut microbiome level.", {"entities": [[63, 75, "Drug"]]}], [6720, "For Yunzhi, both PSK and PSP were reported to further enhance the apoptotic activity when co-administered with docetaxel, doxorubicin and etoposide [114, 115, 120, 128].", {"entities": [[4, 10, "Herb name"], [17, 20, "Herb name"], [25, 28, "Herb name"], [111, 121, "Drug"], [122, 133, "Drug"], [138, 147, "Drug"]]}], [6721, "Similar to cytotoxic drugs, Yunzhi and its components could also act on the (a) expression of cell cycle arrest and apoptosis related genes and proteins, including Fas and Fasl [113]; Bax, Bcl-2, and BH3 interacting-domain death agonist (Bid) [128\u2013130]; nuclear factor-\u03baB (NF-kB) [115, 117, 120]; cellular inhibitor of apoptosis protein 1 (cIAP-1) [120] and caspase-3 [113, 120] and (b) targets related to angiogenesis and cell invasion, including matrix metallopeptidase 9 (MMP-9) [115], leading to synergistic effect when they are used together.", {"entities": [[28, 34, "Herb name"], [164, 176, "Target"], [184, 187, "Target"], [189, 194, "Target"], [200, 242, "Target"], [254, 278, "Target"], [297, 347, "Target"], [358, 367, "Target"], [448, 481, "Target"]]}], [6722, "Yunzhi could also enhance the cytotoxicity of anticancer drugs via other mechanisms, such as direct increase in the activity of cytotoxic and tumor-infiltrating lymphocytes, decrease in the activity of suppressor T cells [38, 70], and decrease and increase in superoxide dismutase (SOD) and lipid peroxide levels, respectively, in cancer cells [131].", {"entities": [[0, 6, "Herb name"], [46, 62, "Drug"], [202, 220, "Parameter"], [260, 286, "Parameter"], [291, 312, "Parameter"], [331, 337, "Pathology"]]}], [6723, "In addition, PSK was shown to enhance the antitumor effect of 5-FU and Tegafur by downregulating the expression of dihydropyrimidine dehydrogenase messenger RNA (mRNA) [118], as well as docetaxel via the suppression of survivin expression activated by docetaxel [117].", {"entities": [[13, 16, "Herb name"], [62, 66, "Drug"], [71, 78, "Drug"], [115, 167, "Parameter"], [186, 195, "Drug"], [252, 261, "Drug"]]}], [6724, "a.", {"entities": []}], [6725, "Clinical evidence              In clinical studies, Lingzhi co-administration with cytotoxic drugs generally relieved bone marrow suppression.", {"entities": [[34, 50, "Study"], [52, 59, "Herb name"]]}], [6726, "The combinations alleviated the decrease in white blood cells (WBCs), including lymphocytes and neutrophils, caused by chemotherapy alone (5-FU, capecitabine, cisplatin, doxorubicin, gemcitabine, leucovorin, mitomycin, oxaliplatin, paclitaxel, and vinorelbine).", {"entities": [[44, 68, "Parameter"], [80, 91, "Parameter"], [96, 107, "Parameter"], [119, 131, "Drug"], [139, 143, "Drug"], [145, 157, "Drug"], [159, 168, "Drug"], [170, 181, "Drug"], [183, 194, "Drug"], [196, 206, "Drug"], [208, 217, "Drug"], [219, 230, "Drug"], [232, 242, "Drug"], [248, 259, "Drug"]]}], [6727, "The number of other blood cells, including red blood cells (RBCs), hemoglobin, and platelets was also increased by the combinations compared with chemotherapy alone [19\u201321, 52\u201357, 59, 77, 78, 132\u2013134].", {"entities": [[43, 65, "Parameter"], [67, 77, "Parameter"], [83, 92, "Parameter"], [146, 158, "Drug"]]}], [6729, "Co-administrations of Yunzhi with various cytotoxic drugs (capecitabine, mercaptopurine, oxaliplatin, and Tegafur) were also shown to reduce immunosuppression in clinical studies [47, 48, 50, 135].", {"entities": [[22, 28, "Parameter"], [59, 71, "Drug"], [73, 87, "Drug"], [89, 100, "Drug"], [106, 113, "Drug"], [162, 178, "Study"]]}], [6730, "Studies have shown a reversal of the decrease in WBCs, in particular, improvement of the increase in or alleviation of the decrease in T cells (CD3+, CD4+, CD8+), increase in the CD4+/CD8+ ratio, NK cell activity, and subsequent the production of immunoglobulins and interleukins (IL) [23, 38, 49, 60, 62, 68, 79, 80, 136\u2013144].", {"entities": [[49, 53, "Parameter"], [135, 161, "Parameter"], [179, 194, "Parameter"], [196, 212, "Parameter"], [247, 262, "Parameter"], [267, 284, "Parameter"]]}], [6731, "Inhibition on other blood cells, such as platelets and hemoglobin by cytotoxic drugs were also alleviated by the co-administered Yunzhi [80, 136\u2013140, 144].", {"entities": [[20, 31, "Parameter"], [55, 65, "Parameter"], [129, 135, "Herb name"]]}], [6732, "b. Preclinical and mechanistic studies              Animal studies also showed alleviation in the WBCs decrease with the co-administration of Lingzhi and different cytotoxic drugs, particularly in T cells and NK cells [65, 66, 81, 83\u201385, 87, 89, 90, 125\u2013127, 145\u2013158, 163].", {"entities": [[3, 38, "Study"], [52, 66, "Study"], [98, 102, "Parameter"], [142, 149, "Herb name"], [197, 204, "Parameter"], [209, 217, "Parameter"]]}], [6733, "In addition, phagocytic activity and production of cytokines, including immunoglobulins, interferons (IFN), IL, and TGF, were shown to be restored [64, 81, 85, 88\u201390, 127, 146, 149\u2013151, 153, 155, 156, 158\u2013162, 165].", {"entities": [[89, 106, "Parameter"], [108, 111, "Parameter"], [116, 120, "Parameter"]]}], [6734, "Suppression in the number of RBCs, platelets, and in hemoglobin was also found to be alleviated in animal studies [83, 84, 87, 150, 153, 156, 157, 163\u2013165].", {"entities": [[29, 33, "Parameter"], [53, 63, "Parameter"], [99, 113, "Study"]]}], [6735, "The co-administration of Yunzhi with cytotoxic drugs showed similar effects on immune function in animal studies as those observed in clinical studies.", {"entities": [[25, 31, "Herb name"], [98, 112, "Study"], [134, 150, "Study"]]}], [6736, "Immunosuppression was reduced, including alleviation of the decrease in WBCs, particularly B cell and T cells (CD3+ and CD4+); increase in the CD4+/CD8+ ratio, NK cells and phagocytic activity; and subsequent production of interleukins, immunoglobulins, and antibodies [69, 73, 111\u2013114, 129, 130, 148, 166\u2013168].", {"entities": [[72, 76, "Parameter"], [91, 97, "Parameter"], [102, 126, "Parameter"], [143, 158, "Parameter"], [160, 168, "Parameter"], [173, 192, "Parameter"], [223, 235, "Parameter"], [237, 253, "Parameter"], [258, 268, "Parameter"]]}], [6737, "Inhibition on other blood cells, including hemoglobin, also was alleviated [69].", {"entities": [[43, 53, "Parameter"]]}], [6738, "A complete understanding of the mechanisms and factors underlying the effects of the interaction of Lingzhi or Yunzhi with cytotoxic drugs on the immune system is still obscure.", {"entities": [[100, 107, "Herb name"], [111, 117, "Herb name"]]}], [6739, "Multiple mechanisms may be involved, including upregulation of transcription factors such as T-box protein expressed in T cells (T-bet) and GATA-3, which modulate the T helper cell balance [169]; downregulation of Bax expression to reduce caspase 3 activity and T cell apoptosis [170]; and reduction of the expression of negative regulators/transcription factors of immune responses, including Forkhead box protein 3 (Foxp3) and programmed death 1 (PD-1) [171].", {"entities": [[93, 135, "Target"], [140, 146, "Target"], [239, 248, "Target"], [262, 268, "Target"], [394, 424, "Target"], [429, 454, "Target"]]}], [6740, "a.", {"entities": []}], [6741, "Clinical evidence              The co-administration of Lingzhi with some cytotoxic drugs (5-FU, capecitabine, cisplatin, doxorubicin, gemcitabine, leucovorin, mitomycin, oxaliplatin, and paclitaxel) was shown to reduce common adverse effects, such as reduction of gastrointestinal discomfort (nausea, vomiting, constipation, and diarrhea) and stomatitis [19, 53, 56, 59, 77, 78].", {"entities": [[56, 63, "Herb name"], [91, 95, "Drug"], [97, 109, "Drug"], [111, 120, "Drug"], [122, 133, "Drug"], [135, 146, "Drug"], [148, 158, "Drug"], [160, 169, "Drug"], [171, 182, "Drug"], [188, 198, "Drug"], [227, 242, "Pathology"], [294, 300, "Pathology"], [302, 310, "Pathology"], [312, 324, "Pathology"], [330, 338, "Pathology"], [344, 354, "Pathology"]]}], [6742, "Specific adverse effect, such as nephrotoxicity [56] was also shown to be ameliorated.", {"entities": [[9, 23, "Pathology"], [33, 47, "Pathology"]]}], [6743, "In clinical studies on Yunzhi, the use of PSK and PSP with cytotoxic drugs (5-FU, capecitabine, mitomycin, oxaliplatin, and UFT) ameliorated the general adverse effects, such as gastrointestinal discomfort (nausea and vomiting, diarrhea, and constipation) [48, 61, 136], mucositis [48], and fatigue [136].", {"entities": [[3, 19, "Study"], [23, 29, "Herb name"], [42, 45, "Herb name"], [50, 53, "Herb name"], [76, 80, "Drug"], [82, 94, "Drug"], [96, 105, "Drug"], [107, 118, "Drug"], [124, 127, "Drug"], [153, 168, "Drug"], [207, 213, "Pathology"], [218, 226, "Pathology"], [228, 236, "Pathology"], [242, 255, "Pathology"], [271, 280, "Pathology"], [291, 298, "Pathology"]]}], [6744, "Specific adverse effects of cytotoxic drugs, including peripheral neuropathy [143], mutations [172], and hand-foot syndrome [48], were also reduced.", {"entities": [[9, 24, "Pathology"], [55, 76, "Pathology"], [84, 93, "Pathology"], [105, 123, "Pathology"]]}], [6745, "b. Preclinical and mechanistic evidence              The Lingzhi and cytotoxic drug combinations were also found to relieve some adverse effects in animal studies; for example, they reduced damage to different organs, including the intestine [162, 173], the kidney [64\u201366, 174\u2013180], the liver [66, 86, 157, 164, 165], and the heart [157, 181, 182]; and their adverse effects, such as nausea and vomiting [147, 183, 184], mutation [185], and neural tube defects [186].", {"entities": [[57, 64, "Herb name"], [148, 162, "Study"], [359, 374, "Pathology"], [384, 390, "Pathology"], [395, 403, "Pathology"], [421, 429, "Pathology"], [441, 460, "Pathology"]]}], [6746, "Some studies have evaluated the mechanism underlying the protective effects of the mushroom\u2013drug combinations against chemotherapy-induced side effects.", {"entities": [[139, 151, "Pathology"]]}], [6747, "For example, the mechanism underlying the reduction of doxorubicin-induced myocardial damage was found to be via the modulation of cardiac enzymes and reduction of the oxidative stress (such as increase in glutathione S-transferase (GST) and glutathione peroxidase (GPx) levels) in myocardial cells by Lingzhi or Ganoderma polysaccharides [181, 182].", {"entities": [[55, 66, "Drug"], [75, 92, "Pathology"], [206, 237, "Target"], [242, 270, "Target"], [302, 309, "Herb name"], [313, 338, "Herb name"]]}], [6748, "Similarly, Lingzhi and its polysaccharides likely increased renocortical antioxidant levels and relieved the oxidative stress, thereby ameliorating cisplatin-induced renal damage.", {"entities": [[11, 18, "Herb name"], [27, 42, "Herb name"], [148, 157, "Drug"], [166, 178, "Pathology"]]}], [6749, "Furthermore, Lingzhi reduced the occurrence of neural tube defects caused by retinoic acid by upregulating the transcription of cyclin-dependent kinase 4 (CDK4) mRNA and the expression of CDK4 and nestin in neural epithelia [186].", {"entities": [[13, 20, "Herb name"], [47, 66, "Pathology"], [128, 165, "Target"], [188, 192, "Target"], [197, 223, "Target"]]}], [6750, "For Yunzhi animal studies, cisplatin-induced renal damage was reduced by decreasing blood urea nitrogen (BUN) and serum creatinine (Scr) levels [166].", {"entities": [[4, 10, "Herb name"], [11, 25, "Study"], [27, 36, "Drug"], [84, 109, "Parameter"], [114, 136, "Parameter"]]}], [6751, "In both animal and in-vitro studies, PSK reduced the mutagenicity of mitomycin by decreasing the frequency of sister chromatid exchange and micronuclei formation [187, 188].", {"entities": [[8, 35, "Study"], [37, 40, "Herb name"], [69, 78, "Drug"]]}], [6752, "In summary, the aforementioned outcomes suggest that medicinal mushrooms have great potential to ameliorate the adverse effects of chemotherapeutic drugs in clinical settings.", {"entities": [[112, 127, "Pathology"]]}], [6753, "Several chemotherapy drugs are known to cause oxidative stress which damage tumor cells but concomitantly damage normal cells and produce adverse effects [189].", {"entities": [[8, 20, "Drug"], [138, 153, "Pathology"]]}], [6754, "The co-administration of Lingzhi with cytotoxic drugs, including cisplatin, cyclophosphamide, doxorubicin, and methotrexate increased the total antioxidant capacity and levels of different antioxidant enzymes, including superoxide dismutase (SOD), glutathione, GPx, and catalase, and decreased malondialdehyde levels, thereby reducing the oxidative stress [64, 81, 150, 157, 162, 175\u2013182, 190\u2013192].", {"entities": [[25, 32, "Herb name"], [65, 74, "Drug"], [76, 92, "Drug"], [94, 105, "Drug"], [111, 123, "Drug"], [220, 246, "Target"], [248, 264, "Target"], [270, 278, "Target"], [294, 309, "Target"]]}], [6755, "In an in-vitro study, the co-administration of Yunzhi with cisplatin prevented the decrease in SOD activity by mimicking it to protect normal healthy cells while selectively promoting the decrease in SOD activity and increase in lipid peroxide levels in cancer cells, both of which synergistically increased tumor inhibition while leaving normal cells unaffected [131].", {"entities": [[6, 20, "Study"], [47, 53, "Herb name"], [59, 68, "Drug"], [200, 212, "Target"], [229, 243, "Target"], [254, 260, "Pathology"], [308, 313, "Pathology"]]}], [6756, "However, these findings have not yet been substantiated in clinical settings.", {"entities": []}], [6757, "Overall, there is no reported undesirable herb-drug interaction between Lingzhi or Yunzhi and cytotoxic drugs in our included studies.", {"entities": [[72, 79, "Herb name"], [83, 89, "Herb name"]]}], [6758, "Although interaction between PSP and cyclophosphamide may potentially increase the systemic exposure of cyclophosphamide, it is not known whether it could lead to significant changes in clinical outcomes [193].", {"entities": [[29, 32, "Herb name"], [37, 53, "Drug"], [104, 120, "Drug"]]}], [6759, "Since our findings indicated that Lingzhi/Yunzhi and their components may potentially affect pharmacokinetics of anticancer drug, further clinical pharmacokinetic studies are warranted to investigate the necessity for dose adjustment of anticancer drug in clinical practice.", {"entities": [[34, 41, "Herb name"], [42, 48, "Herb name"], [138, 170, "Study"], [237, 247, "Drug"]]}], [6760, "The clinical studies on the concurrent use of Lingzhi or Yunzhi with cytotoxic drugs were rated using the Jadad scale.", {"entities": [[4, 20, "Study"], [46, 53, "Herb name"], [57, 63, "Herb name"]]}], [6761, "Overall, most of the clinical studies on the combined use of mushrooms and cytotoxic drugs were not of high quality, scoring mostly 0\u20133 points.", {"entities": [[21, 37, "Study"]]}], [6762, "Most of them did not adopt blinding measures, probably because it is not feasible to blind chemotherapy regimens and complex herbal therapies.", {"entities": [[91, 103, "Drug"]]}], [6763, "In addition, many studies lacked comprehensive description of withdrawal and dropouts.", {"entities": []}], [6764, "Only half of the randomized studies provided details on their randomization methods.", {"entities": [[17, 35, "Study"]]}], [6765, "Similar to the findings from others on clinical trials with Chinese medicine [194], the trials involved in the current review were also with poor clinical trial design and insufficient reporting of studies.", {"entities": [[60, 67, "Ethnic group"]]}], [6766, "Although the SPIRIT 2013 and CONSORT 2010 guideline have been published with intent to improve the design and reporting of randomized controlled trials, they may not be completely applied to the trials of Chinese medicine formulas.", {"entities": [[205, 212, "Ethnic group"]]}], [6768, "The combination of Lingzhi and Yunzhi with cytotoxic anti-cancer drugs showed great potential in offering beneficial effects in clinical settings with no undesirable interactions reported so far.", {"entities": [[19, 26, "Herb name"], [31, 37, "Herb name"]]}], [6769, "The survival benefits can be increased, especially for Lingzhi and the quality of life of cancer patients can be enhanced especially for Yunzhi.", {"entities": [[55, 62, "Herb name"], [137, 143, "Herb name"]]}], [6770, "Both Lingzhi and Yunzhi showed synergistic effect on tumor inhibition with chemotherapy, reducing immunosuppression and alleviating general and specific chemotherapy related side effects.", {"entities": [[5, 12, "Herb name"], [17, 23, "Herb name"], [75, 87, "Drug"], [153, 165, "Drug"], [174, 186, "Pathology"]]}], [6771, "Despite a relatively large number of clinical studies conducted, the quality of clinical studies included in this review remained not high, especially with lack of blinding and description of all withdrawals and dropouts.", {"entities": [[37, 53, "Study"], [80, 96, "Study"]]}], [6772, "Trials based on guidance from CONSORT 2010 extension and SPIRIT-TCM extension are highly recommended in the future to ensure the higher quality of clinical trial on Chinese medicines.", {"entities": [[165, 172, "Ethnic group"]]}], [6773, "Pharmacokinetic effects of Lingzhi or Yunzhi on cytotoxic drugs were inconclusive.", {"entities": [[27, 34, "Herb name"], [38, 44, "Herb name"]]}], [6774, "There was currently significantly lack of studies on pharmacokinetic herb-drug interactions as revealed above.", {"entities": []}], [6775, "Considering the narrow therapeutic index of many cytotoxic drugs, more clinical pharmacokinetic studies are warranted for their safe and effective use.", {"entities": [[71, 103, "Study"]]}], [6776, "In recent years, there are revolutionary advancements in the oncology world that sees many new breakthrough treatments, including targeted therapies, immunotherapy as well as gene therapy.", {"entities": [[150, 163, "Drug"], [175, 187, "Drug"]]}], [6777, "Future studies should identify potential synergistic and harmful interaction between Chinese Medicine and these advanced cancer therapies.", {"entities": [[85, 92, "Ethnic group"], [121, 127, "Pathology"]]}], [6778, "With increasing number of studies on combined usage of Chinese and western medicine, future studies can harness modern techniques such as bioinformatics and data mining to identify patterns of herb\u2013herb and drug-herb combinations, especially those show the strongest evidence for tumor inhibition.", {"entities": [[55, 62, "Ethnic group"]]}], [6779, "Moreover, considering the large population utilizing Chinese Medicine in Asian countries and increasing prevalence in Europe and US, future pharmacoepidemiology studies can be conducted to observe the clinical impact of integrative medicine among cancer patients in a real word setting, in particular long-term and delayed effect that cannot be revealed in ordinary clinical trial settings.", {"entities": [[53, 60, "Ethnic group"], [140, 168, "Study"], [247, 253, "Pathology"]]}], [6780, "Additional file 1.", {"entities": []}], [6781, "Table S1.", {"entities": []}], [6782, "Keywords for cytotoxic drugs in the current database search.", {"entities": []}], [6783, "Table S2.", {"entities": []}], [6784, "Characteristics of included studies.", {"entities": []}], [6785, "Table S3.", {"entities": []}], [6786, "Detailed information of the included clinical studies.", {"entities": [[37, 53, "Study"]]}], [6787, "Table S4.", {"entities": []}], [6788, "Detailed information of the included pre-clinical studies.", {"entities": [[37, 58, "Study"]]}], [6789, "Figure S1.", {"entities": []}], [6790, "Distribution of pre-clinical and clinical studies for combination use of cytotoxic drugs with Lingzhi and Yunzhi.", {"entities": [[16, 49, "Study"], [94, 101, "Herb name"], [106, 112, "Herb name"]]}], [6792, "Supplementary information accompanies this paper at 10.1186/s13020-020-00356-4.", {"entities": []}], [6793, "Not applicable.", {"entities": []}], [6794, "Conception or design of the work: All authors.", {"entities": []}], [6795, "Data acquisition from literature search: CSL and LPC.", {"entities": []}], [6796, "Analysis and interpretation of data: All.", {"entities": []}], [6797, "Drafting the work: CSL.", {"entities": []}], [6798, "Revising it critically for important intellectual content: All.", {"entities": []}], [6799, "Final approval of the version to be published: All.", {"entities": []}], [6800, "Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved: All.", {"entities": []}], [6801, "All authors read and approved the final manuscript.", {"entities": []}], [6802, "Not applicable.", {"entities": []}], [6803, "Not applicable.", {"entities": []}], [6804, "Not applicable.", {"entities": []}], [6805, "Not applicable.", {"entities": []}], [6806, "The authors declare that they have no competing interests.", {"entities": []}], [6807, "Women diagnosed with breast cancer frequently seek complementary and alternative (CAM) treatment options that can help to cope with their disease and the side effects of conventional cancer therapy.", {"entities": [[21, 34, "Pathology"], [154, 166, "Pathology"], [183, 189, "Pathology"]]}], [6808, "Especially in Europe, breast cancer patients use herbal products containing mistletoe (Viscum album L.).", {"entities": [[22, 35, "Pathology"], [76, 103, "Herb name"]]}], [6809, "Aside from positive clinical experience with the combination of tamoxifen and mistletoe, little is known about possible herb-drug interactions (HDIs) between the two products.", {"entities": [[20, 39, "Study"], [64, 73, "Drug"], [78, 87, "Herb name"]]}], [6810, "In the present in vitro study, we investigated the effect of standardized commercial mistletoe preparations on the activity of endoxifen, the major active metabolite of tamoxifen.", {"entities": [[15, 29, "Study"], [85, 94, "Herb name"], [127, 136, "Drug"], [169, 178, "Drug"]]}], [6811, "Each concentration of the drug was combined with fermented Viscum album L. extracts (VAE) at clinically relevant doses, and proliferation, apoptosis and cell cycle were analyzed.", {"entities": [[49, 58, "Extraction process"], [59, 89, "Herb name"]]}], [6812, "In parallel, possible inhibition of CYP3A4/5 and CYP2D6 was investigated using 50-donor mixed gender pooled human liver microsomes (HLMs).", {"entities": [[36, 44, "Target"], [49, 55, "Target"]]}], [6813, "VAE did not inhibit endoxifen induced cytostasis and cytotoxicity.", {"entities": [[0, 3, "Herb name"], [20, 29, "Drug"], [38, 48, "Pathology"], [53, 65, "Pathology"]]}], [6814, "At higher concentrations, VAE showed an additive inhibitory effect.", {"entities": [[26, 29, "Herb name"]]}], [6815, "VAE preparations did not cause inhibition of CYP3A4/5 and CYP2D6 catalyzed tamoxifen metabolism.", {"entities": [[0, 3, "Herb name"], [45, 53, "Target"], [58, 64, "Target"], [75, 84, "Drug"]]}], [6816, "The in vitro results suggest that mistletoe preparations can be used in combination with tamoxifen without the risk of HDIs.", {"entities": [[4, 12, "Study"], [34, 43, "Herb name"], [89, 98, "Drug"]]}], [6817, "The online version of this article (10.1186/s12906-019-2439-2) contains supplementary material, which is available to authorized users.", {"entities": []}], [6818, "Breast cancer accounts for nearly a quarter of all cancers in females and affects about 12% of all women during their lifetime [1].", {"entities": [[0, 13, "Pathology"], [51, 58, "Pathology"], [62, 69, "Sex"], [99, 104, "Sex"]]}], [6819, "Approximately 70\u201380% of all breast tumors are estrogen receptor (ER) positive [2], and hormonal therapy plays therefore an important role in the therapy of early stage and metastatic ER-positive breast cancer.", {"entities": [[28, 41, "Pathology"], [46, 68, "Target"], [87, 103, "Drug"], [183, 208, "Pathology"]]}], [6820, "The non-steroidal selective estrogen receptor modulator (SERM) tamoxifen is the oldest and most commonly used endocrine drug for the treatment of hormone-dependent breast cancer [3, 4].", {"entities": [[0, 72, "Drug"], [110, 124, "Drug"], [146, 177, "Pathology"]]}], [6821, "Tamoxifen is a prodrug with a relatively low affinity for estrogen receptors.", {"entities": [[0, 9, "Drug"], [58, 76, "Target"]]}], [6822, "The compound is metabolized in the liver by cytochrome P450 isoforms CYP2D6 and CYP3A4/5 to active metabolites such as endoxifen (4-hydroxy-N-desmethyl-tamoxifen).", {"entities": [[44, 68, "Target"], [69, 75, "Target"], [80, 88, "Target"], [119, 162, "Drug"]]}], [6823, "Endoxifen competes with estrogen and binds to ERs with an almost 100-fold higher affinity than tamoxifen [5].", {"entities": [[0, 9, "Drug"], [24, 32, "Target"], [46, 49, "Target"], [95, 104, "Drug"]]}], [6824, "It shows pro- and anti-estrogenic activity by its binding to ER\u03b1 and/or ER\u03b2, which are ligand-activated intracellular transcription factors.", {"entities": [[61, 64, "Target"], [72, 75, "Target"], [87, 139, "Target"]]}], [6825, "The resulting nuclear complexes change the transcription of estrogen-responsive genes responsible for the generation of multiple growth-promoting signals [6].", {"entities": [[60, 85, "Target"]]}], [6826, "Cancer patients, especially women with breast cancer, often use complementary and alternative therapies (CAM), as they conceive them as an important part of their coping with the disease [7, 8].", {"entities": [[0, 6, "Pathology"], [28, 33, "Sex"], [39, 52, "Pathology"]]}], [6827, "In Europe, pharmaceutical preparations derived from mistletoe (Viscum album L.) are widely used and registered as drugs in many countries [9].", {"entities": [[52, 79, "Herb name"]]}], [6828, "Cancer patients use them frequently, mostly in addition to conventional therapies, with the aim to cope better with the side effects of conventional cancer treatment, to boost the immune system, to reduce symptoms, and to increase the quality of life.", {"entities": [[0, 6, "Pathology"], [120, 132, "Pathology"], [149, 155, "Pathology"]]}], [6829, "Clinical studies have reported on the benefits of Viscum album extracts (VAE) not only in breast cancer patients but also for other types of cancer [10\u201313].", {"entities": [[0, 16, "Study"], [50, 77, "Herb name"], [90, 103, "Pathology"], [141, 147, "Pathology"]]}], [6830, "As the prevalence of CAM use has increased, so have concerns about potential interactions with standard oncological drugs [14].", {"entities": [[104, 121, "Drug"]]}], [6831, "Therefore, it is important to provide information about the efficacy, safety and interactions of complementary mistletoe therapy.", {"entities": [[111, 120, "Herb name"]]}], [6832, "Earlier in vitro studies proved that mistletoe extracts had no negative effects on the cytostatic and cytotoxic activity of several common conventional chemotherapeutic drugs and the therapeutic antibody Herceptin (trastuzumab) when used at concentrations that are typical for clinical use [15, 16].", {"entities": [[8, 24, "Study"], [37, 46, "Herb name"], [87, 97, "Pathology"], [102, 111, "Pathology"], [152, 174, "Drug"], [183, 227, "Drug"]]}], [6833, "The present study aimed at investigating possible effects of clinically relevant doses of a standardized fermented Viscum album extract (VAE) on the in vitro activity of endoxifen in the ER-positive breast carcinoma cell line MCF-7.", {"entities": [[105, 114, "Extraction process"], [115, 141, "Herb name"], [149, 157, "Study"], [170, 179, "Drug"], [187, 215, "Pathology"]]}], [6834, "As the growth of MCF-7 cells is concentration-dependently influenced by estradiol, the experiments were carried out in the absence and presence of a defined estradiol concentration.", {"entities": [[72, 81, "Target"], [157, 166, "Target"]]}], [6835, "In parallel, possible CYP3A4/5 and CYP2D6 inhibitions by VAE using pooled HLMs (human liver microsomes) from 50 donors and tamoxifen, dextromethorphan, and testosterone as substrates were investigated.", {"entities": [[22, 30, "Target"], [35, 41, "Target"], [57, 60, "Herb name"], [123, 132, "Drug"], [134, 150, "Drug"], [156, 168, "Target"]]}], [6836, "The aqueous, fermented mistletoe preparation Iscador M spec.", {"entities": [[4, 22, "Extraction process"], [23, 32, "Herb name"], [45, 54, "Herb name"]]}], [6837, "5\u2009mg (VAEM, host tree Malus domestica, Lot 1404/4159/1, total mistletoe lectin concentration 309\u2009ng/mL), mistletoe preparations Iscador P 10\u2009mg (VAEP, host tree Pinus sylvestris, Lot 6187/02), Iscador M spec.", {"entities": [[0, 4, "Amount"], [6, 10, "Herb name"], [22, 37, "Herb name"], [62, 78, "Herb name"], [105, 114, "Herb name"], [128, 137, "Herb name"], [138, 143, "Amount"], [145, 149, "Herb name"], [161, 177, "Herb name"], [193, 202, "Herb name"]]}], [6838, "5\u2009mg (VAEM, host tree Malus domestica, Lot 7054/0, total mistletoe lectin concentration 306\u2009ng/mL), and Iscador Qu spec.", {"entities": [[0, 4, "Amount"], [6, 10, "Herb name"], [22, 37, "Herb name"], [57, 73, "Herb name"], [104, 114, "Herb name"]]}], [6839, "5\u2009mg (VAEQu, host tree Quercus robur/petraea, Lot 7026/02, total mistletoe lectin concentration 444\u2009ng/mL) were provided by Iscador AG (Arlesheim, Switzerland).", {"entities": [[0, 4, "Amount"], [6, 11, "Herb name"], [23, 44, "Herb name"], [65, 81, "Herb name"], [124, 134, "Herb name"]]}], [6840, "(E/Z)-endoxifen hydrochloride (4-hydroxy-N-desmethyltamoxifen hydrochloride), \u03b2-estradiol (E2) and dextrorphan-d Pooled human liver microsomes (HLMs, 50 donors, mixed gender) were purchased from Bioreclamation IVT (Baltimore, USA).", {"entities": [[0, 76, "Drug"], [78, 94, "Target"], [99, 112, "Drug"]]}], [6841, "NADPH regenerating system containing solution A (26\u2009mM NADP The human breast carcinoma cell line MCF-7 was obtained from DSMZ (German Collection of Microorganisms and Cell Cultures, Braunschweig, Germany).", {"entities": [[0, 5, "Target"], [55, 59, "Target"], [64, 86, "Pathology"]]}], [6842, "MCF-7 cells were kept growing in log phase in phenol red-free Eagle\u2019s MEM (Sigma-Aldrich) supplemented with 10% FCS, 2\u2009mM\u2009L-glutamine and 1% Penicillin-Streptomycin (Sigma-Aldrich) at 37\u2009\u00b0C in an atmosphere of 5% CO The median endoxifen serum levels measurable in tamoxifen-treated early-stage breast cancer patients are between about 9\u2009nM (poor metabolizers) and 67\u2009nM (ultrarapid metabolizers) [18, 19].", {"entities": [[141, 151, "Drug"], [152, 164, "Drug"], [227, 236, "Drug"], [264, 273, "Drug"], [294, 307, "Pathology"]]}], [6843, "Iscador concentrations representative for a subcutaneous application are 0.1 and 1\u2009\u03bcg/mL.", {"entities": [[0, 7, "Herb name"]]}], [6844, "These concentrations are nearly equivalent to an injection of 5\u2009mg Iscador when referring to the body weight or the circulating blood volume.", {"entities": [[62, 66, "Amount"], [67, 74, "Herb name"]]}], [6845, "Concentrations of about 10\u2009\u03bcg/mL correspond to doses used for intravenous Iscador applications.", {"entities": [[74, 81, "Herb name"]]}], [6846, "In preliminary experiments the optimal concentration range and incubation time regarding in vitro activity was determined for (E/Z)-endoxifen hydrochloride and VAEM.", {"entities": [[89, 97, "Study"], [126, 155, "Drug"], [160, 164, "Herb name"]]}], [6847, "In the main experiments, (E/Z)-endoxifen hydrochloride was applied at concentrations between 0.1\u2009nM (10 Steroid depleted cells (4\u2009\u00d7\u200910 Cells were cultured for 7\u2009days under standard culture conditions, and each experiment was performed in triplicate in the absence or presence of 0.5\u2009\u03bcM estradiol.", {"entities": [[25, 54, "Drug"], [93, 99, "Amount"], [155, 165, "Duration"], [279, 285, "Amount"], [286, 295, "Target"]]}], [6848, "The proliferation rate was measured 4\u2009h after incubation with WST-1 reagent (Roche, Mannheim, Germany) using a Labsystems multiscan RC microplate reader.", {"entities": []}], [6849, "The upper limit of absorbance was 2.0\u20132.1.", {"entities": []}], [6850, "All values were expressed as percent inhibition of proliferation relative to cells cultured without estradiol (untreated control).", {"entities": [[100, 109, "Target"]]}], [6851, "Steroid depleted cells (2\u2009\u00d7\u200910 To detect apoptotic cell death, 2\u2009\u00d7\u200910 Steroid depleted cells (3\u2009\u00d7\u200910 The CycleTest\u2122 Plus DNA Kit (BD Biosciences, San Jose, CA) was used according to manufacturer\u2019s instructions for cell cycle analysis and DNA QC particles for quality control.", {"entities": []}], [6852, "Data were acquired with a FACS Calibur flow cytometer (BD Biosciences, San Jose, CA) and analyzed using the FlowJo 7.6.1 software (Ashland, OR, USA).", {"entities": []}], [6853, "Daily working solutions of substrates (tamoxifen, testosterone, dextromethorphan) were prepared in sample dilution buffer (5\u2009\u03bcM EDTA in 100\u2009mM potassium phosphate buffer PPB) from the DMSO stock solutions, with a final DMSO concentration of 0.1% (v/v) in the incubation mixture.", {"entities": [[39, 48, "Drug"], [50, 62, "Target"], [64, 80, "Drug"]]}], [6854, "The incubation mixture (total volume of 500\u2009\u03bcL) was initially constituted of 100\u2009mM PPB pH\u20097.4, 50-donor pooled HLMs (0.5\u2009mg protein/ml), a NADPH regenerating system to initiate the reaction, and the potential inhibitors ketoconazole (0.1; 1; 2; 5; 10; 100\u2009\u03bcM) as specific inhibitor of CYP3A4/5, quinidine (0.1; 1; 2; 5; 10; 100\u2009\u03bcM) as specific inhibitor of CYP2D6, or test concentrations (0.1; 1; 5; 10; 100; 500\u2009\u03bcg/mL) of the mistletoe preparations.", {"entities": [[140, 145, "Target"], [221, 233, "Drug"], [286, 294, "Target"], [296, 305, "Drug"], [358, 364, "Target"], [428, 437, "Herb name"]]}], [6855, "The mixture was pre-incubated for 15\u2009min at 37\u2009\u00b0C with gentle stirring (300\u2009rpm) using a BioShake iQ (Quantifoil Instruments GmbH, Jena, Germany).", {"entities": []}], [6856, "The reaction was then started by adding the corresponding substrates at 5\u2009\u03bcM for each CYP450 (testosterone for CYP3A4/5, dextromethorphan for CYP2D6, and tamoxifen for both CYP3A4/5 and CYP2D6).", {"entities": [[86, 92, "Target"], [94, 106, "Target"], [111, 119, "Target"], [121, 137, "Drug"], [142, 148, "Target"], [154, 163, "Drug"], [173, 181, "Target"], [186, 192, "Target"]]}], [6857, "Reactions were quenched after 30\u2009min by adding 500\u2009\u03bcL of ice-cold acetonitrile with the corresponding internal standard (IS), namely testosterone-d3 (200\u2009ng/mL) for 6\u03b2-hydroxytestosterone, dextrorphan-d3 (200\u2009ng/mL) for dextrorphan and endoxifen-d5 (200\u2009ng/mL) for endoxifen).", {"entities": [[133, 145, "Target"], [165, 187, "Target"], [189, 200, "Drug"], [220, 231, "Drug"], [236, 245, "Drug"], [265, 274, "Drug"]]}], [6858, "To detect possible chemical instability of compounds three negative control incubations were performed, namely without inhibitors, without inhibitors and microsomes, and without inhibitors, microsomes and NADPH.", {"entities": [[205, 210, "Target"]]}], [6859, "Positive control incubations were performed with specific inhibitors of each CYP.", {"entities": [[77, 80, "Target"]]}], [6860, "After incubation, samples were centrifuged (11,688\u2009g, 4\u2009\u00b0C) for 10\u2009min, and 900\u2009\u03bcL of supernatant were collected and dried under nitrogen flow (Evaporex EVX-96, Apricots Designs Inc., USA).", {"entities": []}], [6861, "Dried residues were redissolved in 200\u2009\u03bcL of DMSO by shaking on a BioShake iQ (Quantifoil Instruments GmbH, Jena, Germany) at 1500\u2009rpm for 30\u2009min prior to UHPLC-MS/MS analysis of the corresponding metabolites, namely endoxifen for tamoxifen, 6-\u03b2-hydroxytestosterone for testosterone, and dextrorphan for dextromethorphan.", {"entities": [[217, 226, "Drug"], [231, 240, "Drug"], [242, 265, "Target"], [270, 282, "Target"], [288, 299, "Drug"], [304, 320, "Drug"]]}], [6862, "All CYP450 inhibition assays were analyzed using an UHPLC 1290 system coupled to a 6460 tandem mass spectrometer with an Agilent Jet Stream electrospray ionization source in positive mode (all Agilent Technologies, Waldbronn, Germany).", {"entities": [[4, 10, "Target"]]}], [6863, "All compounds were separated with a flow rate of 0.4\u2009mL/min on a Phenomenex Kinetex XBC18 column (1.7\u2009\u03bcm, 2.1\u2009\u00d7\u200950\u2009mm; Phenomenex, Torrance, CA, USA) heated at 55\u2009\u00b0C and the mobile phases were: 10\u2009mM ammonium formate with 0.05% formic acid as eluent A and acetonitrile with 0.05% formic acid as eluent B.", {"entities": []}], [6864, "Five \u03bcL injected were used for the multiple reaction mode (MRM) quantitation.", {"entities": []}], [6865, "The source was operated with these optimized settings: nebulizer pressure at 30\u2009psi, nozzle voltage at 0\u2009V, sheath gas flow at 11\u2009L/min, sheath gas temperature at 300\u2009\u00b0C, drying gas flow at 10\u2009L/min, drying gas temperature at 320\u2009\u00b0C and capillary voltage at 3500\u2009V. MRM transitions, fragmentor voltage and collision energy for each substrate, metabolite and corresponding IS are provided in supporting information Additional file 1: Table S1.", {"entities": []}], [6866, "All CYP450 inhibition assays were performed in triplicate, and the results were expressed as % metabolite vs control (mean\u2009\u00b1\u2009S.D.).", {"entities": [[4, 10, "Target"]]}], [6867, "For each combination of endoxifen and mistletoe extract, three to five independent experiments were performed.", {"entities": [[24, 33, "Drug"], [38, 47, "Herb name"]]}], [6868, "Data were analyzed with 2-way analysis of variance (ANOVA, Type 6 decomposition) using Statistica 6.0 (Statsoft Inc., Tulsa, USA).", {"entities": []}], [6869, "The protected Fisher LSD-test was used for pairwise comparisons.", {"entities": []}], [6870, "This procedure gives a good safeguard against false-positive as well as false-negative errors [20].", {"entities": []}], [6871, "Limit of significance was defined as p\u2009\u2264\u20090.05.", {"entities": []}], [6873, "Given that estradiol has a mitogenic effect on hormone receptor positive tumor cells and therefore may interfere with the effects of the investigated drugs, we performed the experiments in both estrogen-depleted conditions and in the presence of a defined estradiol concentration.", {"entities": [[11, 20, "Target"], [47, 78, "Pathology"], [194, 202, "Target"], [256, 265, "Target"]]}], [6874, "ER-positive breast cancer cells MCF-7 require estradiol for maximum growth in vitro.", {"entities": [[0, 25, "Pathology"], [46, 55, "Target"], [75, 83, "Study"]]}], [6875, "The proliferation rate of untreated cells grown in estradiol supplemented medium was about 90% higher compared to cells grown in steroid-depleted medium (Fig.\u00a01).", {"entities": [[51, 60, "Target"]]}], [6877, "Cell growth kinetics was assessed with the WST-1 assay.", {"entities": []}], [6878, "Results are presented as % relative to untreated control (mean\u2009\u00b1\u2009SE from three independent experiments).", {"entities": []}], [6879, "Significances are given relative to the VAEM untreated values (*p\u00a0<\u20090.05, **p\u00a0<\u20090.01, ***p\u00a0<\u20090.001) VAEM, as well as endoxifen, showed a concentration-dependent inhibition of proliferation (Fig.", {"entities": [[40, 44, "Herb name"], [100, 104, "Herb name"], [117, 126, "Drug"]]}], [6880, "1a, b).", {"entities": []}], [6881, "In cells cultured in the presence or absence of estradiol, proliferation was significantly inhibited by VAEM concentrations \u226510\u2009\u03bcg/mL (p\u2009<\u20090.05).", {"entities": [[48, 57, "Target"], [104, 108, "Herb name"]]}], [6882, "100\u2009\u03bcg/mL VAEM reduced the proliferation of cells cultured in presence of estradiol to 20% and in cells cultured without estradiol to 15% (p\u2009<\u20090.001) (Fig.", {"entities": [[10, 14, "Herb name"], [74, 83, "Target"], [121, 130, "Target"]]}], [6883, "1a).", {"entities": []}], [6884, "In cells grown without estradiol, proliferation was significantly inhibited by endoxifen concentrations \u22650.01\u2009\u03bcM (p\u2009<\u20090.001).", {"entities": [[23, 32, "Target"], [79, 88, "Drug"]]}], [6885, "The anti-proliferative effect of 0.01\u2009\u03bcM endoxifen was prevented by 0.5\u2009\u03bcM estradiol.", {"entities": [[33, 40, "Amount"], [41, 50, "Drug"], [68, 74, "Amount"], [75, 84, "Target"]]}], [6886, "1\u2009\u03bcM Endoxifen significantly inhibited proliferation in cells cultured with or without estradiol (p\u2009<\u20090.01), and complete cell death was achieved at a concentration of 100\u2009\u03bcM endoxifen under both conditions (Fig.", {"entities": [[0, 4, "Amount"], [5, 14, "Drug"], [87, 96, "Target"], [168, 174, "Amount"], [175, 184, "Drug"]]}], [6887, "1b).", {"entities": []}], [6888, "Mean proliferation values of MCF-7 cells after simultaneous application of VAEM and endoxifen with and without estradiol are shown in Fig.", {"entities": [[75, 79, "Herb name"], [84, 93, "Drug"], [111, 120, "Target"]]}], [6889, "1c, d. Concentrations of 0.1 and 1\u2009\u03bcg/mL VAEM did not alter the cytostatic activity of endoxifen.", {"entities": [[41, 45, "Herb name"], [87, 96, "Drug"]]}], [6890, "At a concentration of 10\u2009\u03bcg/mL VAEM distinctly inhibited the proliferation and significantly enhanced the anti-proliferative effect of 10 Annexin V/7-AAD dual staining was used to evaluate the type of cell death induced by treatment with VAEM, endoxifen and their combinations in MCF-7 cells cultured in the presence or absence of estradiol (Fig.\u00a02).", {"entities": [[22, 30, "Amount"], [31, 35, "Herb name"], [238, 242, "Herb name"], [244, 253, "Drug"], [331, 340, "Target"]]}], [6891, "Apoptosis induction in MCF-7 cells by treatment with endoxifen or VAEM for 5\u2009days.", {"entities": [[53, 62, "Drug"], [66, 70, "Herb name"], [71, 81, "Duration"]]}], [6892, "Flow cytometric analysis of apoptotic death in MCF-7 cells labeled with annexin-V FITC and 7-AAD in the presence (top) and absence (bottom) of 0.5\u2009\u03bcM \u03b2-estradiol (E2).", {"entities": [[143, 149, "Amount"], [150, 166, "Target"]]}], [6893, "This figure is representative of three independent experiments.", {"entities": []}], [6894, "The percentages in the graphs represent the percentage of cell numbers in each quadrant.", {"entities": []}], [6895, "Q1 and Q2: late apoptotic/necrotic cells, Q3: early apoptotic cells, Q4: viable cells VAEM concentrations between 0.1 and 10\u2009\u03bcg/mL had no effect on the viability of MCF-7 cells cultured with or without estradiol.", {"entities": [[86, 90, "Target"], [202, 211, "Target"]]}], [6896, "Under both treatment conditions, VAEM at 100\u2009\u03bcg/mL significantly reduced the number of viable and increased the amount of late apoptotic/necrotic cells (p\u2009<\u20090.001) (Fig.", {"entities": [[33, 37, "Herb name"], [41, 50, "Amount"]]}], [6897, "3a, c).", {"entities": []}], [6898, "Apoptosis induction (%) in MCF-7 cells by endoxifen and VAEM, respectively.", {"entities": [[42, 51, "Drug"], [56, 60, "Herb name"]]}], [6899, "Mean values (\u00b1SE) of early apoptosis, late apoptosis/necrosis and viable cells after 5\u2009days treatment with (a) VAEM in the presence of 0.5\u2009\u03bcM \u03b2-estradiol (E2), (b) endoxifen in the presence of 0.5\u2009\u03bcM \u03b2-estradiol, (c) VAEM in the absence of 0.5\u2009\u03bcM \u03b2-estradiol and (d) endoxifen in the absence of 0.5\u2009\u03bcM \u03b2-estradiol are presented.", {"entities": [[85, 91, "Duration"], [111, 115, "Herb name"], [135, 141, "Amount"], [142, 158, "Target"], [164, 173, "Drug"], [193, 199, "Amount"], [200, 211, "Target"], [217, 221, "Herb name"], [240, 246, "Amount"], [247, 258, "Target"], [267, 276, "Drug"], [295, 301, "Amount"], [302, 313, "Target"]]}], [6900, "Significance values are given relative to the untreated control (*p\u2009<\u20090.05, **p\u2009<\u20090.01, ***p\u2009<\u20090.001) Endoxifen at a concentration of 10\u2009\u03bcM was highly cytotoxic.", {"entities": [[102, 111, "Target"], [134, 139, "Amount"], [151, 160, "Pathology"]]}], [6901, "A small but significant increase in early apoptosis (p\u2009<\u20090.05) in the presence of estradiol, and a massive increase of the amount of late apoptotic/necrotic cells was detected after treatment with 10\u2009\u03bcM endoxifen in cells cultured in the presence or absence of estradiol (p\u2009<\u20090.001).", {"entities": [[82, 91, "Target"], [197, 202, "Amount"], [203, 212, "Drug"], [261, 270, "Target"]]}], [6902, "Lower endoxifen concentrations did not significantly affect cell viability (Fig.", {"entities": [[6, 15, "Drug"]]}], [6903, "3b, d).", {"entities": []}], [6904, "Figure\u00a04 shows the mean values of early apoptosis and late apoptosis/necrosis of MCF-7 breast carcinoma cells treated with different concentrations of endoxifen in combination with different concentrations of VAEM.", {"entities": [[87, 103, "Pathology"], [151, 160, "Drug"], [209, 213, "Herb name"]]}], [6905, "In cells cultured either in the presence of estradiol or under steroid depleted conditions, only the highest VAEM concentration of 100\u2009\u03bcg/mL significantly increased the cytotoxic effect of 0.1\u201310\u2009\u03bcM endoxifen.", {"entities": [[44, 53, "Target"], [63, 70, "Target"], [109, 113, "Herb name"], [131, 140, "Amount"], [189, 198, "Amount"], [199, 208, "Herb name"]]}], [6906, "Due to the high cytotoxicity of 10\u2009\u03bcM endoxifen combined with 100\u2009\u03bcg/mL VAEM, the number of early apoptotic cells was significantly reduced.", {"entities": [[32, 37, "Amount"], [38, 47, "Drug"], [62, 71, "Amount"], [72, 76, "Herb name"]]}], [6907, "Apoptosis induction (%) in MCF-7 cells after 5\u2009days treatment with endoxifen in combination with VAEM.", {"entities": [[45, 51, "Duration"], [67, 76, "Drug"], [97, 101, "Herb name"]]}], [6908, "Mean values (\u00b1SE) of (a) early apoptosis in the presence of 0.5\u2009\u03bcM \u03b2-estradiol (E2) (b) late apoptosis/necrosis in the presence of 0.5\u2009\u03bcM \u03b2-estradiol, (c) early apoptosis in the absence of 0.5\u2009\u03bcM \u03b2-estradiol and (d) late apoptosis/necrosis in the absence of 0.5\u2009\u03bcM \u03b2-estradiol are presented (*p\u2009<\u20090.05, **p\u2009<\u20090.01, ***p\u2009<\u20090.001) VAEM affected the cell cycle kinetics at 10\u2009\u03bcg/mL in MCF-7 cells grown in the presence of estrogen, and at 100\u2009\u03bcg/mL under estrogen depleted conditions by inducing a significant G2/M accumulation of 11% vs. about 9% in the appropriate control (p\u2009<\u20090.05 and p\u2009<\u20090.01, respectively) (Fig.\u00a05a).", {"entities": [[60, 66, "Amount"], [67, 78, "Target"], [131, 137, "Amount"], [138, 149, "Target"], [189, 195, "Amount"], [196, 207, "Target"], [258, 264, "Amount"], [265, 276, "Target"], [329, 333, "Herb name"], [419, 427, "Target"], [436, 445, "Amount"], [452, 460, "Target"]]}], [6909, "In cells grown in the presence of estradiol, no significant effect of endoxifen on the cell cycle was observed (Fig.", {"entities": [[34, 43, "Target"], [70, 79, "Drug"]]}], [6910, "5b).", {"entities": []}], [6911, "Under steroid depleted conditions, 1\u2009\u03bcM endoxifen induced a significant accumulation of MCF-7 cells in the G0/G1 cell cycle phase (p\u2009<\u20090.01).", {"entities": [[6, 13, "Target"], [35, 39, "Amount"], [40, 49, "Drug"]]}], [6912, "The percentage of cells in G0/G1 phase was 83.6% after treatment with 1\u2009\u03bcM endoxifen, compared to 74.8% in the control.", {"entities": [[70, 74, "Amount"], [75, 84, "Drug"]]}], [6913, "The treatment with endoxifen also led to a significant decrease in the S (p\u2009<\u20090.05) and G2/M phase (p\u2009<\u20090.001).", {"entities": [[19, 28, "Drug"]]}], [6914, "MCF-7 cell cycle analysis of cells treated with (a) VAEM (b) endoxifen and (c) 1\u2009\u03bcM endoxifen and VAEM, both in presence or absence of \u03b2-estradiol (E2), respectively.", {"entities": [[52, 56, "Herb name"], [61, 70, "Drug"], [79, 83, "Amount"], [84, 93, "Drug"], [98, 102, "Herb name"], [135, 151, "Target"]]}], [6915, "Cells were harvested after 3d, fixed, stained and analyzed for DNA content by flow cytometry.", {"entities": []}], [6916, "The distribution and percentage of cells in G0/G1, S and G2/M phase of the cell cycle are indicated.", {"entities": []}], [6917, "Results are presented as mean values from six independent experiments.", {"entities": []}], [6918, "(SE values are omitted for clarity).", {"entities": []}], [6919, "Significance values are given relative to the VAEM and endoxifen untreated controls (*p\u2009<\u20090.05, **p\u2009<\u20090.01, ***p\u2009<\u20090.001).", {"entities": [[46, 50, "Herb name"], [55, 64, "Drug"]]}], [6920, "Discrepancies from 100% can be attributed to slight gating differences and the display of mean values In the presence of estradiol and endoxifen, VAEM showed no effect on the cell cycle.", {"entities": [[121, 130, "Target"], [135, 144, "Drug"], [146, 150, "Herb name"]]}], [6921, "In estradiol-free MCF-7 cells simultaneously treated with endoxifen and VAEM, the G2/M arrest promoting effect of 100\u2009\u03bcg/mL VAEM antagonized the induction of the G0/G1 arrest by endoxifen significantly (p\u2009<\u20090.01) but, as shown earlier, in combination with a profound growth reducing activity (Fig.", {"entities": [[3, 12, "Target"], [58, 67, "Drug"], [72, 76, "Herb name"], [124, 128, "Herb name"], [178, 187, "Drug"]]}], [6922, "5c).", {"entities": []}], [6923, "A decrease in the formation of the metabolite (dextrorphan or endoxifen) compared to vehicle control is commonly used to determine the CYP inhibition profiles.", {"entities": [[47, 58, "Drug"], [62, 71, "Drug"], [135, 138, "Target"]]}], [6924, "The three mistletoe preparations (VAEP, VAEQu and VAEM) were incubated separately with the CYP2D6 industry accepted probe substrate dextromethorphan (Additional file 4: Figure S1) and with the drug test substrate tamoxifen (Fig.\u00a06a).", {"entities": [[10, 19, "Herb name"], [34, 38, "Herb name"], [40, 45, "Herb name"], [50, 54, "Herb name"], [91, 97, "Target"], [132, 148, "Drug"], [213, 222, "Drug"]]}], [6925, "In vitro effects of mistletoe preparations (VAEP, VAEQu and VAEM) on (a) CYP2D6 and (b) CYP3A4/5 catalyzed metabolism of tamoxifen.", {"entities": [[0, 8, "Study"], [20, 29, "Herb name"], [44, 48, "Herb name"], [50, 55, "Herb name"], [60, 64, "Herb name"], [73, 79, "Target"], [88, 96, "Target"], [121, 130, "Drug"]]}], [6926, "Results are presented as mean rate values \u00b1 SE (from three independent experiments) of (E/Z)-endoxifen formation in vitro expressed as a percent of the control without inhibitor.", {"entities": [[87, 102, "Drug"], [113, 121, "Study"]]}], [6927, "Significance values are given relative to the negative controls without inhibitors (*p\u00a0<\u20090.05, **p\u2009<\u20090.01, ***p\u2009<\u20090.001) In contrast to quinidine, none of the VAE preparations showed a significant inhibition of CYP2D6 for both substrates: tamoxifen (Fig.", {"entities": [[136, 145, "Drug"], [159, 162, "Herb name"], [211, 217, "Target"], [239, 248, "Drug"]]}], [6928, "6a) and dextromethorphan (Additional file 4: Figure S1).", {"entities": [[8, 24, "Drug"]]}], [6929, "A decrease in the formation of the metabolite (6\u03b2-hydroxytestosterone or endoxifen) compared to vehicle control is used to display the CYP inhibition profiles.", {"entities": [[47, 69, "Target"], [73, 82, "Drug"], [135, 138, "Target"]]}], [6930, "The three mistletoe preparations (VAEP, VAEQu and VAEM) were incubated separately with the CYP3A4/5 industry accepted probe substrate testosterone (Additional file 7: Figure S4) and with the drug test substrate tamoxifen (Fig.", {"entities": [[10, 19, "Herb name"], [34, 38, "Herb name"], [40, 45, "Herb name"], [50, 54, "Herb name"], [91, 99, "Target"], [134, 146, "Target"], [211, 220, "Drug"]]}], [6931, "6b).", {"entities": []}], [6932, "In contrast to ketoconazole, VAEM and VAEQu showed no significant inhibition of CYP3A4/5 for tamoxifen (Fig.", {"entities": [[15, 27, "Drug"], [29, 33, "Herb name"], [38, 43, "Herb name"], [80, 88, "Target"], [93, 102, "Drug"]]}], [6933, "6b).", {"entities": []}], [6934, "Only VAEP at 500\u2009\u03bcg/mL showed a statistically highly significant inhibition (p\u2009\u2264\u20090.001) of the formation of endoxifen.", {"entities": [[5, 9, "Herb name"], [13, 22, "Amount"], [108, 117, "Drug"]]}], [6935, "At last, all VAE preparations at 100 and 500\u2009\u03bcg/mL showed a statistically highly significant inhibition of CYP3A4/5 for testosterone as isoform-specific substrate (Additional file 7: Figure S4).", {"entities": [[13, 16, "Herb name"], [33, 50, "Amount"], [107, 115, "Target"], [120, 132, "Target"]]}], [6936, "Our in vitro study showed that the combined treatment of MCF-7 breast cancer cells with endoxifen and VAEM did not inhibit the antiproliferative effect of the major active metabolite of tamoxifen.", {"entities": [[4, 18, "Study"], [63, 76, "Pathology"], [88, 97, "Drug"], [102, 106, "Herb name"], [186, 195, "Drug"]]}], [6937, "This finding is in line with our earlier interaction studies on VAE with several chemotherapeutic drugs and with trastuzumab, where we did not find any adverse effects of VAE [15, 16].", {"entities": [[41, 60, "Study"], [64, 67, "Herb name"], [113, 124, "Drug"], [152, 167, "Pathology"], [171, 174, "Herb name"]]}], [6939, "Endoxifen concentrations \u226510\u2009\u03bcM led to cell death.", {"entities": [[0, 9, "Drug"], [25, 31, "Amount"]]}], [6940, "These findings correspond with reports showing that 10\u20131000\u2009nM endoxifen leads to an enhancement of ER\u03b1 protein degradation by the proteasome in MCF-7 and other breast cancer cell lines.", {"entities": [[52, 62, "Amount"], [63, 72, "Drug"], [100, 111, "Target"], [161, 174, "Pathology"]]}], [6941, "In the presence of estradiol, the transcriptional activation of an estrogen response element and the activation of estrogen-responsive endogenous genes was reduced or blocked [21].", {"entities": [[19, 28, "Target"], [67, 75, "Target"], [115, 123, "Target"]]}], [6942, "Saji et al.", {"entities": []}], [6943, "reported IC The proliferation of MCF-7 cells was significantly inhibited at VAEM concentrations \u2265\u200910\u2009\u03bcg/mL, but at 100\u2009\u03bcg/mL, no complete inhibition of cell growth was achieved.", {"entities": [[76, 80, "Herb name"], [96, 106, "Amount"], [115, 124, "Amount"]]}], [6944, "In cells treated simultaneously with endoxifen, VAEM concentrations \u226510\u2009\u03bcg/mL led to an additive inhibitory effect at all endoxifen concentrations.", {"entities": [[37, 46, "Drug"], [48, 52, "Herb name"], [68, 77, "Amount"], [122, 131, "Drug"]]}], [6945, "Although MCF-7 cells lack the expression of caspase 3, it has been shown that they are able to respond by apoptosis via sequential activation of caspases 9, 7 and 6 and P21 accumulation [23].", {"entities": [[44, 53, "Target"], [145, 164, "Target"], [169, 172, "Target"]]}], [6946, "Our apoptosis experiments revealed a strong cytotoxic effect of 10\u2009\u03bcM endoxifen.", {"entities": [[44, 60, "Pathology"], [64, 69, "Amount"], [70, 79, "Drug"]]}], [6947, "VAEM contains mistletoe lectins (ML) known to possess ribosome inactivating properties leading to the induction of apoptosis via the intrinsic pathway [24].", {"entities": [[0, 4, "Herb name"], [14, 36, "Herb name"], [54, 62, "Target"]]}], [6948, "However, our results did not show an increased proportion of early apoptotic cells following treatment with VAEM with and without estradiol.", {"entities": [[108, 112, "Herb name"], [130, 139, "Target"]]}], [6949, "Only 100\u2009\u03bcg/mL VAEM significantly induced cell death.", {"entities": [[15, 19, "Herb name"]]}], [6950, "In all treatment variants, the proportion of early apoptotic cells compared to dead cells was low.", {"entities": []}], [6951, "We observed this also at a shorter treatment time (3\u2009days, Additional file 10: Figure S7).", {"entities": [[51, 57, "Duration"]]}], [6952, "The induction of the intrinsic apoptosis pathway by MLs seems to be impossible in MCF-7 cells probably due to the lack of caspase 3.", {"entities": [[52, 55, "Herb name"], [122, 131, "Target"]]}], [6953, "Necroptosis [25], an alternative type of programmed cell death triggered through the same signals that induce apoptosis might be responsible for the cytotoxic effect of MLs.", {"entities": [[149, 165, "Pathology"], [169, 172, "Herb name"]]}], [6954, "For several RIPs II the induction of caspase-independent cell death pathways, proven e.g.", {"entities": []}], [6955, "by using necrostatin-1, an inhibitor of necroptosis have been described [26\u201328].", {"entities": []}], [6956, "That MCF-7 cells are able to conduct necroptosis was shown by Han et al.", {"entities": []}], [6957, "[29].", {"entities": []}], [6958, "Whether necroptosis or another type of cell death, such as autophagic lytic cell death, as described for tamoxifen, 4-hydroxy-tamoxifen or ICI 164384 [30] is responsible for the cytotoxic effect of VAEM on MCF-7 cells remains to be investigated in further experiments.", {"entities": [[105, 114, "Drug"], [116, 135, "Drug"], [178, 194, "Pathology"], [198, 202, "Herb name"]]}], [6959, "The cell cycle analysis revealed the induction of a significant G0/G1 arrest by 1\u2009\u03bcM endoxifen in estrogen-depleted cells but not in the presence of estrogen.", {"entities": [[80, 84, "Amount"], [85, 94, "Amount"], [98, 106, "Target"], [149, 157, "Target"]]}], [6960, "Treatment of cells with VAEM alone at \u226510\u2009\u03bcg/mL led to a small but significant G2/M arrest under both cell culture conditions.", {"entities": [[24, 28, "Herb name"], [38, 47, "Amount"]]}], [6961, "100\u2009\u03bcg/mL VAEM alone or in combination with all endoxifen concentrations dramatically lowered cell proliferation.", {"entities": [[0, 9, "Amount"], [10, 14, "Herb name"], [48, 57, "Drug"]]}], [6962, "We think that the cytostatic and cytotoxic activity together with a likely S/G2M blockade prevented the development of a G0/G1 arrest induced by endoxifen.", {"entities": [[145, 154, "Drug"]]}], [6963, "We already observed the induction of a G2/M arrest by VAEM in an earlier in vitro study with trastuzumab [16].", {"entities": [[54, 58, "Herb name"], [73, 87, "Study"], [93, 104, "Drug"]]}], [6964, "In humans, tamoxifen is metabolized in the liver by members of the cytochrome P450 enzyme family.", {"entities": [[11, 20, "Drug"], [67, 82, "Target"]]}], [6965, "The primary metabolic route leads from tamoxifen via CYP3A catalyzed N-demethylation to N-desmethyl tamoxifen and via CYP2D6 mediated hydroxylation to endoxifen [31].", {"entities": [[39, 48, "Drug"], [53, 58, "Target"], [88, 109, "Drug"], [118, 124, "Target"], [151, 160, "Drug"]]}], [6966, "The CYP2D6 gene is highly polymorphic.", {"entities": [[4, 10, "Target"]]}], [6967, "Based on genotype combinations encoding for varying enzyme phenotypes, patients have been classified as poor, intermediate, extensive, or ultra-rapid metabolizers [32, 33].", {"entities": []}], [6968, "The plasma concentration of the most potent tamoxifen metabolite endoxifen depends, among others, on the CYP2D6 metabolizer phenotype [34].", {"entities": [[44, 53, "Drug"], [65, 74, "Drug"], [105, 111, "Target"]]}], [6969, "The metabolic activity of CYP2D6 was suggested to be associated with the long-term outcomes in breast cancer, although the studies are inconsistent [35].", {"entities": [[26, 32, "Target"], [95, 108, "Pathology"]]}], [6970, "Given that cytochrome P450 enzymes are critical for phase I drug metabolism, other medications might interfere with tamoxifen metabolism and thereby increase the risk of cancer recurrence.", {"entities": [[11, 26, "Target"], [116, 125, "Drug"], [170, 176, "Pathology"]]}], [6971, "This is assumed for several antidepressants, especially some selective serotonin reuptake inhibitors (SSRIs) prescribed to alleviate disease-related problems and side effects of the anti-hormonal treatment like anxiety, depression or hot flashes [36, 37].", {"entities": [[28, 43, "Drug"], [61, 108, "Drug"], [162, 174, "Pathology"], [182, 205, "Drug"], [211, 218, "Pathology"], [220, 230, "Pathology"], [234, 245, "Pathology"]]}], [6972, "Recommendations exist to avoid the prescription of antidepressants most likely to inhibit CYP2D6 [36, 38, 39].", {"entities": [[51, 66, "Drug"], [90, 96, "Target"]]}], [6973, "For the CYP3A4/5 and CYP2D6 inhibition assays in this study, we used 50-donor mixed gender pooled human liver microsomes rather than recombinant isoenzymes, given that microsomes contain the full set of CYP450 enzymes and thus are closer to the in vivo situation [40].", {"entities": [[8, 16, "Target"], [21, 27, "Target"], [203, 217, "Target"]]}], [6974, "The significant inter-individual variability of CYP2D6 activity due to genetic polymorphisms was mitigated by the use of pooled microsomes from 50 donors [41].", {"entities": [[48, 54, "Target"]]}], [6975, "With exception of a significant inhibition of CYP3A4/5 by 500\u2009\u03bcg/mL of VAEP, all other VAE preparations showed no significant inhibition of CYP3A4/5 and CYP2D6 at all test concentrations (Fig.", {"entities": [[46, 54, "Target"], [58, 67, "Amount"], [71, 75, "Herb name"], [87, 90, "Herb name"], [140, 148, "Target"], [153, 159, "Target"]]}], [6976, "6).", {"entities": []}], [6977, "Thus, we conclude that mistletoe extracts do not interfere with CYP450 (3A4/5 and 2D6) in their ability to metabolize tamoxifen.", {"entities": [[23, 32, "Herb name"], [64, 86, "Target"], [118, 127, "Drug"]]}], [6978, "A possible inhibition of CYP3A4 by mistletoe preparations has been investigated in an in vitro study earlier [42].", {"entities": [[25, 31, "Target"], [35, 44, "Herb name"], [86, 100, "Study"]]}], [6979, "Our data confirm these findings and suggest that clinically relevant systemic interactions with CYP3A4 and CYP2D6 are unlikely.", {"entities": [[96, 102, "Target"], [107, 113, "Target"]]}], [6980, "The positive effects of an adjuvant treatment with mistletoe preparations on the quality of life and cancer-related fatigue have been reported in several clinical studies [11, 43].", {"entities": [[51, 60, "Herb name"], [101, 123, "Pathology"], [154, 170, "Study"]]}], [6981, "Our investigations of mistletoe interactions with CYP3A4/5 and CYP2D6, secure recommendations for the use of mistletoe extracts to treat cancer related-fatigue in breast cancer patients receiving tamoxifen.", {"entities": [[22, 31, "Herb name"], [50, 58, "Target"], [63, 69, "Target"], [109, 118, "Herb name"], [137, 159, "Pathology"], [163, 176, "Pathology"], [196, 205, "Drug"]]}], [6982, "Given the prevalent use of CAM by cancer patients, there is an increasing need to assess the risk of combining CAM with conventional medications.", {"entities": [[34, 40, "Pathology"]]}], [6983, "Mistletoe belongs to the medicinal herbs that are widely used as supportive care during standard anticancer therapy.", {"entities": [[0, 9, "Herb name"], [97, 115, "Drug"]]}], [6984, "The present in vitro study contributes to the knowledge of possible herb-drug interactions and supports the assessment of breast cancer patient\u2019s safety hazard by potential adverse reactions from the combination of Viscum album preparations and tamoxifen.", {"entities": [[12, 26, "Study"], [122, 135, "Pathology"], [173, 190, "Pathology"], [215, 227, "Herb name"], [245, 254, "Drug"]]}], [6985, "We could demonstrate in vitro that clinically relevant doses of an aqueous, fermented mistletoe preparation did not inhibit the cytostatic and cytotoxic activity of (E/Z)-endoxifen, an active metabolite of tamoxifen.", {"entities": [[21, 29, "Study"], [64, 85, "Extraction process"], [86, 95, "Herb name"], [165, 180, "Drug"], [206, 215, "Drug"]]}], [6986, "Higher doses showed additive effects.", {"entities": []}], [6987, "VAE preparations did not show inhibition of CYP3A4/5 and CYP2D6.", {"entities": [[0, 3, "Herb name"], [44, 52, "Target"], [57, 63, "Target"]]}], [6988, "These findings further substantiate the knowledge on the safety of breast cancer patients receiving tamoxifen concomitantly with mistletoe preparations.", {"entities": [[67, 80, "Pathology"], [100, 109, "Drug"], [129, 138, "Herb name"]]}], [6989, "Table S1.", {"entities": []}], [6990, "Optimized MS/MS parameters in ESI positive mode for analytes (S: substrate and M: metabolite) and corresponding IS.", {"entities": []}], [6991, "(PDF 14 kb) Data_proliferation_apoptosis_cell_cycle.", {"entities": []}], [6993, "(PDF 105 kb) Figure S1.", {"entities": []}], [6994, "Dextromethorphan in vitro inhibition profiles of CYP2D6 by mistletoe preparations (VAEP, VAEQu, and VAEM).", {"entities": [[0, 16, "Drug"], [17, 25, "Study"], [49, 55, "Target"], [59, 68, "Herb name"], [83, 87, "Herb name"], [89, 94, "Herb name"], [100, 104, "Herb name"]]}], [6995, "Results are presented as mean rate values \u00b1 SE (from three independent experiments) of dextrorphan formation in vitro expressed as a percent of the control without inhibitor.", {"entities": [[87, 98, "Drug"], [109, 117, "Study"]]}], [6996, "Significance values are given relative to the negative controls without inhibitors (*p<0.05, **p < 0.01, ***p < 0.001).", {"entities": []}], [6997, "(PDF 36 kb) Figure S2.", {"entities": []}], [6998, "Tamoxifen in vitro inhibition profiles of CYP2D6 by reference inhibitor: Quinidine (0.1-1-2-5-10-100 \u03bcM).", {"entities": [[0, 9, "Drug"], [10, 18, "Study"], [42, 48, "Target"], [73, 82, "Drug"]]}], [6999, "Results are presented as mean rate values \u00b1 SE (from three independent experiments) of (E/Z)-endoxifen formation in vitro expressed as a percent of the control without inhibitor.", {"entities": [[87, 102, "Drug"], [113, 121, "Study"]]}], [7000, "(PDF 27 kb) Figure S3.", {"entities": []}], [7001, "Dextromethorphan in vitro inhibition profiles of CYP2D6 by reference inhibitor: Quinidine (0.1-1-2-5-10-100 \u03bcM).", {"entities": [[0, 16, "Drug"], [17, 25, "Study"], [49, 55, "Target"], [80, 89, "Drug"]]}], [7002, "Results are presented as mean rate values \u00b1 SE (from three independent experiments) of dextrorphan formation in vitro expressed as a percent of the control without inhibitor.", {"entities": [[87, 98, "Drug"], [109, 117, "Study"]]}], [7003, "(PDF 26 kb) Figure S4.", {"entities": []}], [7004, "Testosterone in vitro inhibition profiles of CYP3A4/5 (VAEP, VAEQu, VAEM).", {"entities": [[0, 12, "Target"], [13, 21, "Study"], [45, 53, "Target"], [55, 59, "Herb name"], [61, 66, "Herb name"], [68, 72, "Herb name"]]}], [7005, "Results are presented as mean rate values \u00b1 SE (from three independent experiments) of 6\u03b2-hydroxytestosterone formation in vitro expressed as a percent of the control without inhibitor.", {"entities": [[87, 109, "Target"], [120, 128, "Study"]]}], [7006, "(PDF 40 kb) Figure S5.", {"entities": []}], [7007, "Tamoxifen in vitro inhibition profile of CYP3A4/5 by reference inhibitor: Ketoconazole (0.1-1-2-5-10-100 \u03bcM).", {"entities": [[0, 9, "Drug"], [10, 18, "Study"], [41, 49, "Target"], [74, 86, "Drug"]]}], [7008, "Results are presented as mean rate values \u00b1 SE (from three independent experiments) of (E/Z)-endoxifen formation in vitro expressed as a percent of the control without inhibitor.", {"entities": [[87, 102, "Drug"], [113, 121, "Study"]]}], [7009, "(PDF 27 kb) Figure S6.", {"entities": []}], [7010, "Testosterone in vitro inhibition profile of CYP3A4/5 by reference inhibitor: Ketoconazole (0.1-1-2-5-10-100 \u03bcM).", {"entities": [[0, 12, "Target"], [13, 21, "Study"], [44, 52, "Target"], [77, 89, "Drug"]]}], [7011, "Results are presented as mean rate values \u00b1 SE (from three independent experiments) of 6\u03b2-hydroxytestosterone formation in vitro expressed as a percent of the control without inhibitor.", {"entities": [[87, 109, "Target"], [120, 128, "Study"]]}], [7012, "(PDF 31 kb) Figure S7.", {"entities": []}], [7013, "Apoptosis induction (%) in MCF-7 cells after 3d treatment with endoxifen in combination with VAEM.", {"entities": [[63, 72, "Drug"], [93, 97, "Herb name"]]}], [7014, "Mean values (\u00b1SE) of (A) early apoptosis in the presence of 0.5\u00a0\u03bcM \u03b2-estradiol (E2) (B) late apoptosis/necrosis in the presence of 0.5 \u03bcM \u03b2-estradiol, (C) early apoptosis in the absence of 0.5 \u03bcM \u03b2-estradiol and (D) late apoptosis/necrosis in the absence of 0.5 \u03bcM \u03b2-estradiol are presented (*p < 0.05, **p\u2009<\u20090.01, ***p < 0.001).", {"entities": [[60, 66, "Amount"], [67, 83, "Target"], [131, 137, "Amount"], [138, 149, "Target"], [189, 195, "Amount"], [196, 207, "Target"], [258, 264, "Amount"], [265, 276, "Target"]]}], [7015, "(PDF 53 kb) Complementary and Alternative Medicine Cytochrome P450 2D6 Cytochrome P450 3A4/5 \u03b2-estradiol Estrogen receptor Fetal calf serum Herb-drug interactions Human liver microsomes Internal standard Mistletoe lectin Viscum album extracts VAE from host tree Malus domestic VAE from host tree Pinus sylvestris VAE from host tree Quercus robur petraea Not applicable.", {"entities": [[51, 70, "Target"], [71, 92, "Target"], [93, 122, "Target"], [204, 246, "Herb name"], [262, 280, "Herb name"], [296, 316, "Herb name"], [332, 353, "Herb name"]]}], [7016, "Not applicable.", {"entities": []}], [7017, "All data generated or analyzed during this study are included in this published article and its supplementary information files.", {"entities": []}], [7018, "UW and MK conceived and designed the study, MK, UW, MO, JTW and UR performed analyses, MO and SB performed statistical analysis.", {"entities": []}], [7019, "UW and MO prepared a manuscript draft, which was critically revised by KU, MH, and SB.", {"entities": []}], [7020, "All authors read and approved the final manuscript.", {"entities": []}], [7021, "Not applicable.", {"entities": []}], [7022, "This study did not involve the use of animal or human subjects.", {"entities": []}], [7023, "Not applicable.", {"entities": []}], [7024, "The Society for Cancer Research holds a minority share in stocks of the manufacturer (Iscador AG, Arlesheim, Switzerland) of the mistletoe extracts investigated.", {"entities": [[16, 22, "Pathology"], [129, 138, "Herb name"]]}], [7025, "SB, MK, and UR are part-time employees of Iscador AG.", {"entities": [[42, 52, "Herb name"]]}], [7026, "Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.", {"entities": []}], [7027, "Academic Editor: Evan P. Cherniack  Hibiscus sabdariffa L. (Malvaceae) is a traditional medicinal herb widely consumed as a beverage (\u201chibiscus tea\u201d), and its global popularity is expanding due to health benefits such as blood pressure and cholesterol control.", {"entities": [[36, 70, "Herb name"], [135, 147, "Herb name"], [221, 235, "Parameter"], [240, 251, "Parameter"]]}], [7028, "Previous studies showed that Hibiscus sabdariffa is coadministered with antihypertensives and antihyperlipidemics, thus predisposing herb-drug interactions.", {"entities": [[29, 48, "Herb name"], [72, 89, "Drug"], [94, 113, "Drug"]]}], [7029, "We investigated the pharmacokinetic interaction between H. sabdariffa L. aqueous extract and captopril, a frequently prescribed antihypertensive.", {"entities": [[56, 72, "Herb name"], [73, 88, "Extraction process"], [93, 102, "Drug"], [128, 144, "Drug"]]}], [7031, "The male Sprague Dawley rats were divided into two groups of six rats.", {"entities": [[4, 8, "Sex"], [47, 69, "Study"]]}], [7032, "Group I received a single dose of captopril suspension (4.5\u2009mg/200\u2009g body weight (BW) orally (p.o.))", {"entities": [[34, 43, "Drug"], [56, 85, "Amount"]]}], [7033, "while group II received H. sabdariffa L. aqueous extract (60\u2009mg/200\u2009g BW; p.o.)", {"entities": [[24, 40, "Herb name"], [41, 56, "Extraction process"], [58, 72, "Amount"]]}], [7034, "daily for two weeks prior to the same captopril dose.", {"entities": [[0, 5, "Frequency"], [6, 19, "Duration"], [38, 47, "Drug"]]}], [7035, "Multiple blood samples were collected at predetermined times after captopril administration and the plasma concentration was analyzed using ultrahigh-pressure liquid chromatography-tandem mass spectrometry.", {"entities": [[67, 76, "Drug"]]}], [7036, "Chemical profiling of the H. sabdariffa L. aqueous extract showed that the extract contains chlorogenic acid, myricetin 3-arabinogalactoside, 5-O-caffeoylshikimic acid, quercetin 3-rutinoside, delphinidin 3-sambubioside, and cyanidin 3-sambubioside.", {"entities": [[26, 42, "Herb name"], [43, 58, "Extraction process"], [92, 108, "Herb name"], [110, 140, "Herb name"], [142, 167, "Herb name"], [169, 191, "Herb name"], [193, 219, "Herb name"], [225, 248, "Herb name"]]}], [7037, "Ingestion of the extract significantly reduced the captopril area under the curve (AUC)  Hibiscus sabdariffa L. (Malvaceae) is an herbaceous shrub grown in tropical areas such as India, Malaysia, Africa, Australia, Florida, the Philippines, and Indonesia [1].", {"entities": [[51, 60, "Drug"], [61, 87, "Parameter"], [89, 123, "Herb name"]]}], [7038, "Beverages made from H. sabdariffa L. (variously referred to as \u201csour tea\u201d or \u201chibiscus tea\u201d) are consumed in many regions of the world and extracts have been used as traditional medicines in numerous cultures [2\u20134].", {"entities": [[20, 36, "Herb name"], [64, 72, "Herb name"], [78, 90, "Herb name"]]}], [7039, "The consumption of hibiscus tea is growing in popularity owing to accumulating evidence that it can safely reduce blood pressure and serum cholesterol, two major risk factors for cardiovascular disease [3].", {"entities": [[19, 31, "Herb name"], [114, 128, "Parameter"], [133, 150, "Parameter"], [179, 201, "Pathology"]]}], [7040, "Furthermore, benefits against cancer, excess weight, liver disease, infertility, and diabetes have been proposed [1, 4].", {"entities": [[30, 36, "Pathology"], [38, 51, "Pathology"], [53, 66, "Pathology"], [68, 79, "Pathology"], [85, 93, "Pathology"]]}], [7041, "A survey by Showande et al.", {"entities": []}], [7042, "[5] on staff and students at the University of Ibadan in Africa found that some respondents often consume sour tea with pharmaceuticals such as antibiotics, antihypertensives, antipsychotics, antihyperlipidemics, and antiretrovirals.", {"entities": [[106, 114, "Herb name"], [144, 155, "Drug"], [157, 174, "Drug"], [176, 190, "Drug"], [192, 211, "Drug"], [217, 232, "Drug"]]}], [7043, "It is therefore important to determine whether there are herb-drug interactions that may interfere with the primary drug activity.", {"entities": []}], [7044, "Indeed, previous preclinical and clinical studies showed that ingestion of H. sabdariffa L. extract with conventional pharmaceuticals such as acetaminophen, chloroquine, hydrochlorothiazide, and simvastatin can change the pharmacokinetics profile of the primary drug, potentially affecting the treatment efficacy [5\u20139].", {"entities": [[17, 49, "Study"], [75, 99, "Herb name"], [142, 155, "Drug"], [157, 168, "Drug"], [170, 189, "Drug"], [195, 206, "Drug"]]}], [7045, "Animal models, particularly rodents, are widely used in preclinical studies and have become a valuable tool for providing information on the efficacy, safety, and mechanism of action of various drugs and compounds used in treatment [10, 11].", {"entities": [[56, 75, "Study"]]}], [7046, "The findings of animal research could traditionally be projected to humans [10].", {"entities": [[16, 31, "Study"]]}], [7047, "One of the reasons of using animals in biomedical research is due to its similarities to human, particularly its similarity in anatomical basis and physiological functions with humans [11].", {"entities": []}], [7048, "In Indonesia, H. sabdariffa L. is often consumed with angiotensin-converting enzyme inhibitor captopril, a frequently prescribed antihypertensive [12]; however, a previous study showed that coadministration of H. sabdariffa does not influence the antihypertensive potency of captopril in a 2K1C rat hypertension model [13].", {"entities": [[14, 30, "Herb name"], [54, 103, "Drug"], [129, 145, "Drug"], [210, 223, "Herb name"], [275, 284, "Drug"], [299, 311, "Pathology"]]}], [7049, "To our knowledge, there is no available information regarding pharmacokinetic interactions between captopril and H. sabdariffa.", {"entities": [[99, 108, "Drug"], [113, 126, "Herb name"]]}], [7050, "Therefore, this study examined changes in the captopril pharmacokinetic characteristics in rats following prolonged administration of H. sabdariffa L. aqueous extract.", {"entities": [[46, 55, "Drug"], [134, 150, "Herb name"], [151, 167, "Extraction process"]]}], [7051, "Reference standard captopril, propranolol hydrochloride (used as the internal standard (IS)), and the derivatization reagent 2-4-dibromoacetophenone were purchased from Sigma-Aldrich (Singapore).", {"entities": [[19, 28, "Drug"], [30, 55, "Drug"]]}], [7052, "HPLC grade acetonitrile (ACN) and formic acid were purchased from Merck Chemicals (Germany).", {"entities": []}], [7053, "The calyces of H. sabdariffa L were procured from the Research Institute for Medicinal and Aromatic Plants (Bogor, Indonesia) and identified by the Indonesian Institute of Sciences Center for Plant Conservation Botanic Garden (Bogor, Indonesia; reference number B-2306/IPH.3/KS/VII/2018).", {"entities": [[15, 30, "Herb name"], [148, 158, "Ethnic group"]]}], [7054, "Extraction was performed by maceration at 50\u00b0C for 6-7 hours (ratio between simplicia and water was 1\u2009:\u20096).", {"entities": [[28, 38, "Extraction process"]]}], [7055, "The aqueous extract was evaporated until it forms the honey-like form and then stored at 4\u00b0C\u201310\u00b0C.", {"entities": [[4, 19, "Extraction process"]]}], [7056, "The yield of extract was 35.4%.", {"entities": []}], [7057, "This procedure was performed at the Research Institute for Medicinal and Aromatic Plants.", {"entities": []}], [7058, "The captopril sample used for pharmacokinetic measurements was obtained from 25\u2009mg generic tablets which were marketed in Indonesia.", {"entities": [[4, 13, "Drug"], [77, 82, "Amount"]]}], [7059, "Chemical profile of H. sabdariffa L. aqueous extract was identified using a high-pressure performance chromatography (HPLC) system (Agilent Technologies 1200 Series HPLC-0053, Germany) equipped with a diode-array detector (DAD; serial no.", {"entities": [[20, 36, "Herb name"], [37, 52, "Extraction process"]]}], [7060, "DE60555816).", {"entities": []}], [7061, "Compounds separation was performed using a reversed phase C18 column (Inertsil ODS-3; 5.0\u2009\u00b5m, 4.6\u2009\u00d7\u2009150\u2009mm; Japan) as the stationary phase and two gradient programs of the mobile phase running at a flow rate of 0.5\u2009mL/min [14].", {"entities": []}], [7062, "Gradient program 1 contained a mixture of solution A (1% formic acid\u2009:\u2009ACN (10\u2009:\u200990)) and solution B (ACN) while gradient program 2 contained a mixture of solution A (10% formic acid in water) and solution B (ACN).", {"entities": []}], [7063, "Detections were performed at 360\u2009nm for gradient program 1 and 520\u2009nm for gradient program 2.", {"entities": []}], [7064, "The injection volume for the sample was 20\u2009\u00b5L.", {"entities": []}], [7065, "Twelve adult male Sprague Dawley rats (approximately 3 months old) weighing 150\u2013250\u2009g were obtained from Bogor Agricultural University (IPB; Bogor, Indonesia).", {"entities": [[0, 12, "Cohort"], [13, 17, "Sex"], [53, 65, "Age"]]}], [7066, "The rats were housed under a controlled ambient temperature (25\u2009\u00b1\u20095 \u00b0C) and a 12\u2009h\u2009:\u200912\u2009h light\u2009:\u2009dark cycle with free access to food and water.", {"entities": []}], [7067, "The bedding for each cage was replaced thrice a week.", {"entities": [[39, 52, "Frequency"]]}], [7068, "All animal care and experimental procedures were prepared according to Animal (Scientific Procedures) Act 1986 and were reviewed as well as approved by the Ethics Committee of the Faculty of Medicine, Universitas Indonesia (Jakarta, Indonesia) under the reference number 0646/UN2.F1.ETIK/2018.", {"entities": []}], [7069, "Captopril was measured in the plasma using a modified ultrahigh-pressure liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) method [15\u201318].", {"entities": [[0, 9, "Drug"]]}], [7070, "Chromatography was performed using a reversed phase C18 column (Acquity UPLC BEH Shield RP; 1.7\u2009\u00b5m, 2.1\u2009\u00d7\u2009100\u2009mm; Waters, Milford, CT, USA) at a column temperature of 40\u00b0C.", {"entities": []}], [7071, "A mixture of 0.1% formic acid and ACN was used as the mobile phase with the gradient elution profile shown in Table 1.", {"entities": []}], [7072, "Captopril was detected using a Xevo TQD mass spectrometer (Waters, USA) equipped with a positive electrospray ionization ion source in multiple reaction monitoring modes.", {"entities": [[0, 9, "Drug"]]}], [7073, "The operational parameters for mass detection are presented in Table 2.", {"entities": []}], [7074, "Acquisition and integration of data were performed using MassLynx 4.1 SCN805 Software solution.", {"entities": []}], [7075, "The stock solution of the reference standard captopril (1000\u2009mg/L) was prepared by dissolving 10\u2009mg of the reference standard in 10\u2009mL aquadest.", {"entities": [[45, 54, "Drug"]]}], [7076, "The stock solution of propranolol (1000\u2009mg/L, IS) was prepared by dissolving 10\u2009mg of the reference standard in 10\u2009mL methanol\u2009:\u2009aquadest (50\u2009:\u200950).", {"entities": [[22, 33, "Drug"]]}], [7077, "The stock solution of 2-4-dibromoacethophenone (520\u2009mg/L) was prepared by dissolving 5.2\u2009mg in 10\u2009mL methanol.", {"entities": []}], [7078, "Quality control samples and calibration standards were prepared by diluting standard stock solutions with rat plasma.", {"entities": []}], [7079, "The captopril quality control samples were prepared at concentrations of 9, 40, and 80\u2009ng/mL, while the calibration standards were prepared at concentrations of 3, 9, 12, 25, 50, 80, and 100\u2009ng/mL.", {"entities": [[4, 13, "Drug"]]}], [7080, "The validation method in analysis of captopril was performed by examining the accuracy, precision, sensitivity, selectivity, matrix effect, carry over, and stability profiles of captopril according to EMA guidelines.", {"entities": [[37, 46, "Drug"], [178, 187, "Drug"]]}], [7081, "Blood samples were collected in EDTA tubes and centrifuged at 5,000\u2009rpm for 10\u2009min to obtain plasma.", {"entities": []}], [7082, "For derivatization of plasma captopril, a plasma sample (180\u2009\u00b5L) was first mixed with 20\u2009\u00b5L of 520\u2009ppm 2-4-dibromoacetophenone stock solution and 20\u2009\u00b5L of 5% ammonia solution, vortexed for 30 seconds, and incubated at room temperature for 30\u2009min.", {"entities": [[29, 38, "Drug"]]}], [7083, "The derivatization reaction was stopped by adding 20\u2009\u00b5L of 15% formic acid.", {"entities": []}], [7084, "Then, 20\u2009\u00b5L of 1\u2009mg/L propranolol (IS) was added to the mixture and vortexed for 30\u2009s [17, 18].", {"entities": [[22, 33, "Drug"]]}], [7085, "Plasma proteins were precipitated by adding 600\u2009\u00b5L ice-cold ACN, vortexing for 30\u2009s, and centrifuging at 12,000\u2009rpm for 5\u2009min.", {"entities": []}], [7086, "Supernatant samples (600\u2009\u00b5L) were evaporated by nitrogen gas flowing at 60\u00b0C for 15\u2009min.", {"entities": []}], [7087, "The residue was dissolved in 300\u2009\u00b5L of the mobile phase and transferred to an autosampler vial.", {"entities": []}], [7088, "The injection volume for UPLC-MS/MS was 5\u2009\u00b5L.", {"entities": []}], [7089, "The experimental animals were divided randomly and blindly into two groups (n\u2009=\u20096/group).", {"entities": [[4, 74, "Study"]]}], [7090, "Group I received single dose captopril suspension (4.5\u2009mg/200\u2009g BW; p.o.)", {"entities": [[29, 38, "Drug"], [51, 66, "Amount"]]}], [7091, "while group II received H. sabdariffa L. aqueous extract (60\u2009mg/200\u2009g BW; p.o.)", {"entities": [[24, 40, "Herb name"], [41, 56, "Extraction process"], [58, 72, "Amount"]]}], [7092, "daily for two weeks at morning and a single captopril dose (4.5\u2009mg/200\u2009g BW; p.o.)", {"entities": [[0, 5, "Frequency"], [6, 19, "Duration"], [44, 53, "Drug"], [60, 75, "Amount"]]}], [7093, "immediately after the last extract administration.", {"entities": []}], [7094, "The animals were anaesthetized before blood collection process.", {"entities": []}], [7095, "Blood samples (approximately 0.36\u2009mL per sample) were obtained before captopril administration and 5, 15, 30, 45, 60, 120, 180, 300, 420, and 600\u2009min after administration.", {"entities": [[70, 79, "Drug"]]}], [7096, "The loss of body fluid was compensated by administrating 1.0\u2009mL saline solution (p.o.)", {"entities": []}], [7097, "every 30\u2009min.", {"entities": [[0, 12, "Frequency"]]}], [7098, "Plasma was then isolated from blood samples as described.", {"entities": []}], [7099, "The captopril pharmacokinetic parameters area under curve (AUC Separation and identification of polyphenols, HCA, and lactone were performed using gradient program 1 at 360\u2009nm, while anthocyanins were detected using gradient program 2 at 520\u2009nm [13].", {"entities": [[4, 13, "Drug"], [41, 57, "Parameter"], [59, 62, "Parameter"], [96, 107, "Herb name"], [109, 112, "Herb name"], [118, 125, "Herb name"], [183, 195, "Herb name"]]}], [7100, "The chemical profile (Figure 1) showed that H. sabdariffa aqueous extracts contained chlorogenic acid (1), myricetin 3-arabinogalactoside (2), 5-O-caffeoylshikimic acid (3), quercetin 3-rutinoside (4), delphinidin 3-sambubioside (5), and cyanidin 3-sambubioside (6).", {"entities": [[44, 57, "Herb name"], [58, 74, "Extraction process"], [85, 101, "Herb name"], [107, 137, "Herb name"], [143, 168, "Herb name"], [174, 196, "Herb name"], [202, 228, "Herb name"], [238, 261, "Herb name"]]}], [7101, "Anthocyanins were detected using a gradient elution with 10% formic acid and detection at 520\u2009nm since the acid-base equilibrium state of this class is stable at acidic pH [14].", {"entities": [[0, 12, "Herb name"]]}], [7102, "Among the compounds identified, delphinidin 3-sambubioside and cyanidin 3-sambubioside have been shown to inhibit angiotensin-converting enzyme while quercetin has been shown the vasodilator activity [19, 20].", {"entities": [[32, 58, "Herb name"], [63, 86, "Herb name"], [114, 143, "Target"], [150, 159, "Herb name"]]}], [7103, "All rats used in this experiment were weighted prior to treatment procedure.", {"entities": []}], [7104, "The weights of rats were in the range of 150\u2013250\u2009g (172.92\u2009\u00b1\u200921.90).", {"entities": []}], [7105, "The rats were also in good health condition, which was shown by clear eyes, normal behaviour, and motoric movement.", {"entities": [[19, 33, "Pathology"]]}], [7106, "The chromatography system yielded shape peaks for propranolol and captopril derivatives, with retention times of 1.73 and 3.22\u2009min, respectively (Figure 2).", {"entities": [[50, 61, "Drug"], [66, 75, "Drug"]]}], [7107, "The captopril calibration curve was linear over the range 3\u2013100\u2009ng/mL (r\u2009=\u20090.9998).", {"entities": [[4, 13, "Drug"], [58, 69, "Amount"]]}], [7108, "The LLOQ was 3\u2009ng/mL with a coefficient of variation (%CV) of 14.38% and a % Diff between \u221216.39% and 16.07%.", {"entities": []}], [7109, "The within-run accuracy and precision of captopril analysis ranged from 1.56% to 14.38% (Table 3).", {"entities": [[41, 50, "Drug"]]}], [7110, "In selectivity testing, six rats plasma was used.", {"entities": []}], [7111, "Selectivity testing was performed on LLOQ concentration and the interference value was compared to blank plasma solution.", {"entities": []}], [7112, "The results showed that the interference values of endogenous substances were within limit.", {"entities": []}], [7113, "The maximum of carry over value is 1.16% for captopril and 3.22% for propranolol.", {"entities": [[45, 54, "Drug"], [69, 80, "Drug"]]}], [7114, "Those values were within the acceptance criteria for the analyte (<20%) and the internal standard (<5%).", {"entities": []}], [7115, "Ion suppression was observed during matrix effect testing (0.97); however, the value is still within the acceptance criteria (0.80\u20131.20).", {"entities": []}], [7116, "The stability profiles of captopril were assessed in different storage conditions.", {"entities": [[26, 35, "Drug"]]}], [7117, "Based on our study, the QCH and QCL solutions were stabile when stored in room temperature for 24\u2009hrs, in autosamples for 24\u2009hrs, and in freezer (\u221225\u00b0C) for 7 days.", {"entities": []}], [7118, "The QCL and QCH solutions were also stabile after 3 cycles of freeze-thaw.", {"entities": []}], [7119, "The mean captopril plasma concentration versus time curve is shown in Figure 3 and the pharmacokinetic parameters are listed in Table 4.", {"entities": [[9, 18, "Drug"]]}], [7120, "Consumption of H. sabdariffa L. aqueous extract for two weeks reduced the captopril AUC  H. sabdariffa L. aqueous extract or sour tea is growing in popularity due to a variety of purposed health benefits, but several studies have reported that its consumption can alter the pharmacokinetic profiles and potential efficacies of prescribed medications [5\u20139].", {"entities": [[15, 31, "Herb name"], [32, 47, "Extraction process"], [48, 61, "Duration"], [74, 83, "Drug"], [84, 87, "Parameter"], [89, 105, "Herb name"], [106, 121, "Extraction process"], [125, 133, "Herb name"]]}], [7121, "Among the best described health benefits of H. sabdariffa L. is blood pressure control for hypertension, suggesting that many patients on conventional antihypertensives may also consume H. sabdariffa L. extract [3, 5, 12].", {"entities": [[44, 60, "Herb name"], [64, 78, "Parameter"], [91, 103, "Pathology"], [138, 168, "Drug"], [186, 210, "Herb name"]]}], [7122, "Administration of the extract was given two weeks prior to the administration of captopril since the extracts need time to induce the enzyme metabolizing captopril.", {"entities": [[81, 90, "Drug"], [154, 163, "Drug"]]}], [7123, "Moreover, the study literature showed that two-week period of H. sabdariffa extract administration could produce the antihypertensive activity.", {"entities": [[43, 58, "Duration"], [62, 83, "Herb name"]]}], [7124, "In this study, we would like to determine whether coadministration of H. sabdariffa extract with captopril which is given in the same manner in a pharmacodynamics study could produce pharmacokinetic herb-drug interaction.", {"entities": [[70, 91, "Herb name"], [97, 106, "Drug"], [146, 168, "Study"]]}], [7125, "Captopril is an unstable and photolabile compound with a sulfhydryl group prone to dimerization and binding to various endogenous plasma molecules with sulfhydryl groups such as cysteine and glutathione [21, 22].", {"entities": [[0, 9, "Drug"], [191, 202, "Target"]]}], [7126, "In this experiment, we used 2-4-dibromoacetophenone as a derivatization agent to prevent the sulfhydryl group in captopril from binding to plasma sulfhydryl groups.", {"entities": [[113, 122, "Drug"]]}], [7127, "Ammonia was used during derivatization since the reaction is optimal at basic pH.", {"entities": []}], [7128, "The reaction was then stopped by adding formic acid [17].", {"entities": []}], [7129, "The chromatography system yielded sharp chromatograms for both derivate captopril and propranolol (the IS) within 5\u2009min and a captopril LLOQ of 3\u2009ng/mL.", {"entities": [[72, 81, "Drug"], [86, 97, "Drug"], [126, 135, "Drug"]]}], [7130, "The accuracy and precision of the captopril measurements were determined by five replicates of each quality control sample (3, 9, 40, and 80\u2009ng/mL), which yielded %CV values of 1.56%\u201314.38% and % Diff values of less than 15%.", {"entities": [[34, 43, "Drug"]]}], [7131, "Thus, the chromatographic method was of sufficient reliability and reproducibility for captopril measurement within the analytical range [23].", {"entities": [[87, 96, "Drug"]]}], [7132, "The selectivity, carry over, and matrix effect tests also showed that the chromatographic method fulfills the acceptance criteria.", {"entities": []}], [7133, "Therefore, the developed method could be concluded as a valid method.", {"entities": []}], [7134, "It is known that captopril absorption by the gut is influenced by the presence of food [21, 22].", {"entities": [[17, 26, "Drug"]]}], [7135, "Therefore, captopril was administered one hour after the final oral administration of H. sabdariffa L. However, the present study showed that two weeks of regular H. sabdariffa L. aqueous extract consumption reduced the AUC and peak plasma concentration of captopril suggesting reduced efficacy (Tables 4 and 5) and the geometric mean ratios were falling outside the bioequivalent range.", {"entities": [[11, 20, "Drug"], [86, 102, "Herb name"], [142, 151, "Duration"], [163, 179, "Herb name"], [180, 195, "Extraction process"], [220, 223, "Parameter"], [228, 253, "Parameter"], [257, 266, "Drug"]]}], [7136, "There is no side effect observed after the treatment of captopril and Hibiscus sabdariffa aqueous extract.", {"entities": [[12, 23, "Pathology"], [56, 65, "Drug"], [70, 89, "Herb name"], [90, 105, "Extraction process"]]}], [7137, "Previous herb-drug pharmacokinetic interaction studies on Hibiscus sabdariffa aqueous extract showed similar observation.", {"entities": [[9, 54, "Study"], [58, 77, "Herb name"], [78, 93, "Extraction process"]]}], [7138, "Coadministration of the extract could increase the clearance of acetaminophen, reduce the AUC and Cmax of chloroquine, and increase the clearance as well as reduce the AUC of simvastatin [4, 7, 8].", {"entities": [[64, 77, "Drug"], [90, 93, "Parameter"], [98, 102, "Parameter"], [106, 117, "Drug"], [168, 171, "Parameter"], [175, 186, "Drug"]]}], [7139, "However, the coadministration of Hibiscus sabdariffa aqueous extract with captopril does not influence the antihypertensive potency of captopril or its effects on biomarkers of the renin-angiotensin-aldosterone system (RAAS).", {"entities": [[33, 52, "Herb name"], [53, 68, "Extraction process"], [74, 83, "Drug"], [135, 144, "Drug"], [181, 224, "Target"]]}], [7140, "The coadministration also does not negatively influence captopril action [13].", {"entities": [[56, 65, "Drug"]]}], [7141, "Comparing the results of this study and our previous study [13], we could not determine the exact mechanism of this herb-drug interaction.", {"entities": []}], [7142, "However, there are some hypotheses which could explain the interaction as follows: H. sabdariffa L. extract has well documented antioxidant activity, which could increase the plasma concentration of GSH [24].", {"entities": [[83, 99, "Herb name"], [199, 202, "Target"]]}], [7143, "This could in turn increase the formation of a mixed disulfide captopril complex and lower the concentration of free captopril in plasma [25].", {"entities": [[63, 72, "Drug"], [117, 126, "Drug"]]}], [7144, "Quercetin contained in Hibiscus sabdariffa aqueous extract could reduce the expression of the PEPT1 transporter.", {"entities": [[0, 9, "Herb name"], [23, 42, "Herb name"], [43, 58, "Extraction process"], [94, 111, "Target"]]}], [7145, "The transporter plays an important role in absorption of ACE inhibitor drugs, such as captopril.", {"entities": [[57, 76, "Drug"], [86, 95, "Drug"]]}], [7146, "It therefore could reduce the concentration of captopril absorbed into blood circulation and finally reduce the concentration of free captopril in plasma [26, 27].", {"entities": [[47, 56, "Drug"], [134, 143, "Drug"]]}], [7147, "Two weeks of coadministration of H. sabdariffa extract is sufficient enough to affect the GSH level or the expression of the PEPT1 transporter.", {"entities": [[0, 9, "Duration"], [33, 46, "Herb name"], [90, 93, "Target"], [125, 142, "Target"]]}], [7148, "The total number of samples used in this study is limited; therefore, there is a possibility that the effect shown in humans especially when performed in large population will be different.", {"entities": []}], [7149, "In order to minimize the differences possibility, the doses used in this study were extrapolated from the usual doses given to humans.", {"entities": []}], [7150, "The researcher also applied the refinement procedure during housing and blood collection as explained in the Materials and Methods section to minimize any bias during the study.", {"entities": []}], [7151, "Two weeks of coadministration of H. sabdariffa L. extract prior to administration of captopril could affect the pharmacokinetic profile of captopril significantly Therefore, regular consumption of H. sabdariffa L. aqueous extracts such as tea should be avoided when taking captopril.", {"entities": [[0, 9, "Duration"], [33, 49, "Herb name"], [85, 94, "Drug"], [139, 148, "Drug"], [197, 213, "Herb name"], [214, 230, "Extraction process"], [239, 242, "Extraction process"], [273, 282, "Drug"]]}], [7152, "The authors have much appreciated the financial support from Directorate of Research and Community Engagement, Universitas Indonesia (QQ 2019 grant).", {"entities": []}], [7153, "Angiotensin converting enzyme Acetonitril Analysis of variance Area under curve Ethylene bridged hybrid Body weight Th apparent total body clearance Maximum concentration Coefficient of variation Diode-array detector Ethylenediaminetetraacetic acid Reduced glutathione  Hibiscus sabdariffa  Hidroxycitric acid High-pressure performance chromatography Internal standard The values of elimination constant Lower limit of quantification Peptide transporter 1 Per-oral administration Quality control sample low concentration Quality control sample medium concentration Quality control sample high concentration Standard deviation Maximum time Half-life; Ultrahigh-pressure liquid chromatography-tandem mass spectrometry Triple quadrupole detector The apparent volume of distribution.", {"entities": [[0, 29, "Target"], [63, 79, "Parameter"], [128, 148, "Parameter"], [149, 170, "Parameter"], [257, 268, "Target"], [270, 289, "Herb name"], [634, 648, "Parameter"]]}], [7154, "The data used to support the findings of this study are available from the corresponding author upon request.", {"entities": []}], [7155, "The funding sponsors had no intervention in the design of the study; collection, analyses, and interpretation of data; writing the manuscript; and also the decision to publish the experiment results.", {"entities": []}], [7156, "The authors declare that there are no conflicts of interest.", {"entities": []}], [7157, "Chromatographic profile of Hibiscus sabdariffa L aqueous extract using the gradient programs described in methods.", {"entities": [[27, 48, "Herb name"], [49, 64, "Extraction process"]]}], [7158, "(a) UV chromatogram at 360\u2009nm using gradient program 1.", {"entities": []}], [7159, "(b) UV chromatogram at 520\u2009nm using gradient program 2.", {"entities": []}], [7160, "Chromatogram of derivate captopril and propranolol.", {"entities": [[25, 34, "Drug"], [39, 50, "Drug"]]}], [7161, "Mean plasma concentration vs. time curves of the captopril group and on coadministration with Hibiscus sabdariffa aqueous extract in rats.", {"entities": [[49, 58, "Drug"], [94, 113, "Herb name"], [114, 129, "Extraction process"]]}], [7162, "Gradient profile of the mobile phase used to analyze plasma captopril.", {"entities": [[60, 69, "Drug"]]}], [7163, "Operational parameters for mass spectrometry detection of captopril and propranolol.", {"entities": [[58, 67, "Drug"], [72, 83, "Drug"]]}], [7164, "Accuracy and precision of plasma captopril detection.", {"entities": [[33, 42, "Drug"]]}], [7165, "Plasma pharmacokinetic profile of captopril and its coadministration with Hibiscus sabdariffa aqueous extract in rats.", {"entities": [[34, 43, "Drug"], [74, 93, "Herb name"], [94, 109, "Extraction process"]]}], [7166, "Group I, captopril alone; group II, coadministration with Hibiscus sabdariffa extract; AUC, area under the curve; Cmax, maximum concentration; Cl/F, apparent total body clearance; Vd/F, apparent volume of distribution.", {"entities": [[9, 18, "Drug"], [58, 85, "Herb name"], [87, 112, "Herb part"], [114, 141, "Herb part"], [143, 178, "Herb part"], [180, 217, "Herb part"]]}], [7167, "90% CI for geometric mean ratios of AUC Group I, captopril alone; group II, coadministration with Hibiscus sabdariffa extract; AUC, area under the curve; Cmax, maximum concentration;", {"entities": [[4, 6, "Parameter"], [36, 39, "Parameter"], [49, 58, "Drug"], [98, 125, "Herb name"], [127, 152, "Parameter"], [154, 181, "Parameter"]]}], [7168, "So these results showed that the herb-drug interaction between GLT and AC might occur, and the clinical efficacy could increase when they were co-administered.", {"entities": [[63, 66, "Herb name"], [71, 73, "Drug"]]}], [7169, "Therefore, the clinical dose of AC should be decreased when GLT and AC are co-administered.", {"entities": [[32, 34, "Drug"], [60, 63, "Herb name"], [68, 70, "Drug"]]}], [7170, "2016; Eng et\u00a0al.", {"entities": []}], [7171, "2016; Cruz-Correa et\u00a0al.", {"entities": []}], [7172, "2017; Dennison et\u00a0al.", {"entities": []}], [7173, "2017).", {"entities": []}], [7174, "Atorvastatin is commonly prescribed for the treatment of hypercholesterolaemia and for the prevention of coronary heart disease (Kadam et\u00a0al.", {"entities": [[0, 12, "Drug"], [57, 78, "Pathology"], [105, 127, "Pathology"]]}], [7175, "2016; Liu et\u00a0al.", {"entities": []}], [7176, "2016; Bautista et\u00a0al.", {"entities": []}], [7177, "2017; Kasabri et\u00a0al.", {"entities": []}], [7178, "2017; Kashihara et\u00a0al.", {"entities": []}], [7179, "2017).", {"entities": []}], [7181, "2016; Shu et\u00a0al.", {"entities": []}], [7182, "2016; Wang et\u00a0al.", {"entities": []}], [7183, "2016).", {"entities": []}], [7184, "Most of the statins except pravastatin are metabolized by the cytochrome P450 (CYP) enzymes (Wei & Zhang 2015; Hsiao et\u00a0al.", {"entities": [[12, 19, "Drug"], [27, 38, "Drug"], [58, 91, "Parameter"]]}], [7185, "2016).", {"entities": []}], [7186, "Interactions involving CYP are, therefore, possible.", {"entities": [[23, 26, "Parameter"]]}], [7187, "2014; Dybro et\u00a0al.", {"entities": []}], [7188, "2016).", {"entities": []}], [7189, "2003; Chung et\u00a0al.", {"entities": []}], [7190, "2006; Yang et\u00a0al.", {"entities": []}], [7191, "2017).", {"entities": []}], [7192, "The main components of GLT are Ginkgo flavone glycosides, ginkgolides, and bilobalides (Liu et\u00a0al.", {"entities": [[23, 26, "Herb name"], [31, 86, "Herb name"]]}], [7193, "2009; Guan et\u00a0al.", {"entities": []}], [7194, "2014; Rao et\u00a0al.", {"entities": []}], [7195, "2014).", {"entities": []}], [7196, "Atorvastatin calcium (AC) and GLT are often simultaneously used for the treatment of coronary heart disease in China clinics.", {"entities": [[0, 25, "Drug"], [30, 33, "Herb name"], [85, 107, "Pathology"]]}], [7197, "However, the herb-drug interaction between GLT and AC are still unknown.", {"entities": [[43, 46, "Herb name"], [51, 53, "Drug"]]}], [7198, "In this study, the potential herb-drug interactions of between GLT and AC were systematically investigated.", {"entities": [[63, 66, "Herb name"], [71, 73, "Drug"]]}], [7199, "The effects of GLT on the metabolic stability of AC were also studied using rat liver microsome incubation systems.", {"entities": [[15, 18, "Herb name"], [22, 51, "Parameter"]]}], [7200, "Standards of AC (purity >98%) were purchased from the National Institute for the Control of Pharmaceutical and Biological Products (Beijing, China).", {"entities": [[13, 15, "Drug"]]}], [7201, "2016).", {"entities": []}], [7202, "Pooled rat liver microsomes were purchased from BD Biosciences Discovery Labware (Woburn, MA, USA).", {"entities": []}], [7203, "Acetonitrile was purchased from Fisher Scientific (Fair Lawn, NJ, USA).", {"entities": [[0, 12, "Extraction process"]]}], [7204, "Formic acid was purchased from Anaqua Chemicals Supply Inc. Limited (Houston, TX, USA).", {"entities": [[0, 11, "Extraction process"]]}], [7205, "All other reagents and solvents were of analytical reagent grade.", {"entities": []}], [7206, "This animal experimental protocol was approved by the Animal Ethics Committee of the Weifang Medical University (Weifang, China).", {"entities": []}], [7207, "Male Sprague\u2013Dawley rats weighing 220\u2013250\u2009g were supplied by Sino-British Sippr/BK Lab Animal Ltd. (Shanghai, China).", {"entities": [[0, 4, "Sex"], [34, 43, "Amount"]]}], [7208, "The rats were maintained in an air-conditioned animal quarters at 22\u2009\u00b1\u20092\u2009\u00b0C and 50\u2009\u00b1\u200910% relative humidity.", {"entities": [[66, 72, "Amount"], [73, 75, "Parameter"], [80, 88, "Amount"], [89, 107, "Parameter"]]}], [7209, "Water and food (laboratory rodent chow, Shanghai, China) were allowed ad libitum.", {"entities": []}], [7210, "The animals were acclimatized to the facilities for 5\u2009days, and then fasted with free access to water for 12\u2009h prior to each experiment.", {"entities": [[48, 58, "Duration"], [102, 110, "Duration"]]}], [7211, "The determination of AC was performed as previously reported by Sun et\u00a0al.", {"entities": [[21, 23, "Drug"]]}], [7212, "(2018).", {"entities": []}], [7213, "The analysis was performed on an Agilent 1290 series liquid chromatography system (Agilent Technologies, Palo Alto, CA, USA).", {"entities": []}], [7214, "The chromatographic analysis of AC was performed on a Waters X-Bridge C18 column (3.0\u2009\u00d7\u2009100\u2009mm, i.d.", {"entities": [[32, 34, "Drug"]]}], [7215, "; 3.5\u2009\u03bcm, USA) at room temperature.", {"entities": [[18, 34, "Parameter"]]}], [7216, "The mobile phase was water (containing 0.1% formic acid) and acetonitrile (30:70, v:v) at a flow rate of 0.4\u2009mL/min.", {"entities": [[39, 43, "Amount"], [44, 55, "Extraction process"], [61, 73, "Extraction process"], [105, 115, "Frequency"]]}], [7217, "The mass scan mode was the positive MRM mode.", {"entities": []}], [7218, "The precursor ion and product ion were m/z 559.2 \u2192 440.2 for AC and m/z 419.9 \u2192 199.4 for the simvastatin, respectively.", {"entities": [[61, 63, "Drug"], [94, 105, "Drug"]]}], [7219, "The collision energy for AC and simvastatin were 30 and 25\u2009eV, respectively.", {"entities": [[0, 20, "Parameter"], [25, 27, "Drug"], [32, 43, "Drug"], [49, 51, "Amount"], [56, 61, "Amount"]]}], [7220, "2016; Sun et\u00a0al.", {"entities": []}], [7221, "2018).", {"entities": []}], [7222, "Blood samples (0.25\u2009mL) were collected into a heparinized tube via the oculi chorioideae vein before drug administration and at 0.083, 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, and 24\u2009h after drug administration.", {"entities": []}], [7223, "After centrifuge at 3500\u2009rpm for 5\u2009min, the supernatant was obtained and frozen at \u221280\u2009\u00b0C until analysis.", {"entities": [[83, 86, "Amount"], [87, 89, "Parameter"]]}], [7224, "Rat liver microsomes were used to determine the metabolic rate of AC.", {"entities": [[66, 68, "Drug"]]}], [7225, "The assay conditions and reaction mixtures were similar as reported previously (Qi et\u00a0al.", {"entities": []}], [7226, "2013; Qin et\u00a0al.", {"entities": []}], [7227, "2014).", {"entities": []}], [7228, "Aliquots of 30\u2009\u03bcL were collected from reaction volumes at 0, 1, 3, 5, 15, 30, and 60\u2009min and 60\u2009\u03bcL ice-cold acetonitrile was added to terminate the reaction, and then the sample preparation method was the same as the plasma sample preparation method and determined by LC-MS/MS.", {"entities": [[93, 98, "Amount"], [99, 120, "Extraction process"]]}], [7229, "The half-life (t Experimental values are expressed as mean\u2009\u00b1\u2009SD.", {"entities": [[0, 16, "Parameter"]]}], [7230, "Statistical analysis of results obtained from clinical study was performed using Student\u2019s paired t-test.", {"entities": [[46, 60, "Study"]]}], [7231, "Differences were considered statistically significant when p values were <0.05.", {"entities": []}], [7232, "Statistical analysis was conducted using Graph-Pad Prism version 3.0 for Windows (San Diego, CA, USA).", {"entities": []}], [7233, "Pharmacokinetic parameters of AC in rats after oral administration of AC (1\u2009mg/kg; n\u2009=\u20096, Mean\u2009\u00b1\u2009S.D.)", {"entities": [[30, 32, "Drug"], [70, 72, "Drug"], [74, 81, "Amount"]]}], [7234, "*p\u2009<\u20090.05 indicate significant differences from the control.", {"entities": []}], [7235, "As we know, the metabolism of AC was mainly modulated by CYP3A4 enzymes, and therefore, in this research, the effects of GLT on the metabolic stability of AC were further investigated in rat liver microsomes in vitro.", {"entities": [[30, 32, "Drug"], [57, 71, "Parameter"], [121, 124, "Herb name"], [155, 157, "Drug"]]}], [7236, "The pharmacokinetic experiments showed that GLT could increase the system exposure of AC in rats when they are co-administered.", {"entities": [[44, 47, "Herb name"], [86, 88, "Drug"]]}], [7237, "2016; Wang et\u00a0al.", {"entities": []}], [7238, "2016; Turkanovic et\u00a0al.", {"entities": []}], [7239, "2017).", {"entities": []}], [7240, "2007; Zadoyan et\u00a0al.", {"entities": []}], [7241, "2012; Palle & Neerati 2017).", {"entities": []}], [7242, "To investigate its potential mechanism, the metabolism clearance was also investigated using rat liver microsome incubation systems, and the results revealed that GLT could inhibit its metabolism clearance in rat liver microsomes.", {"entities": [[40, 64, "Parameter"], [163, 166, "Herb name"]]}], [7243, "Previous studies (Sun et\u00a0al.", {"entities": []}], [7244, "The results suggest that the herb-drug interaction between GLT and AC might occur when they were co-administered.", {"entities": [[59, 62, "Herb name"], [67, 69, "Drug"]]}], [7245, "These changes could increase AC efficacy, so it was suggested that the dosage should be adjusted when GLT and AC are co-administered in the clinics.", {"entities": [[29, 31, "Drug"], [102, 105, "Herb name"], [110, 112, "Drug"]]}], [7246, "Therefore, GLT could increase its clinical efficacy of AC when they are co-administered.", {"entities": [[11, 14, "Herb name"], [55, 57, "Drug"]]}], [7247, "The authors of this manuscript declare no conflict of interest.", {"entities": []}], [7248, "All data generated or analyzed during this study are included in this published article.", {"entities": []}], [7249, "Green tea (GT) alters the disposition of a number of drugs, such as nadolol and lisinopril.", {"entities": [[0, 14, "Herb name"], [68, 75, "Drug"], [80, 90, "Drug"]]}], [7250, "However, it is unknown whether GT affects disposition of hydrophilic anti\u2010allergic drugs.", {"entities": [[31, 33, "Herb name"], [69, 88, "Drug"]]}], [7251, "In the GTE phase, the area under the plasma concentration\u2010time curve and the amount excreted unchanged into urine for 24\u2009hours of fexofenadine were significantly decreased by 70% (P\u2009<\u20090.001) and 67% (P\u2009<\u20090.001), respectively, compared with control.", {"entities": [[7, 10, "Herb name"], [18, 68, "Parameter"], [73, 113, "Parameter"], [114, 126, "Duration"], [130, 142, "Drug"], [175, 178, "Amount"], [195, 198, "Amount"]]}], [7252, "There were no differences in time to maximum plasma concentration and the elimination half\u2010life of fexofenadine between phases.", {"entities": [[37, 65, "Parameter"], [70, 95, "Parameter"], [99, 111, "Drug"]]}], [7253, "On the contrary, the concomitant administration of GTE did not influence the pharmacokinetics of pseudoephedrine.", {"entities": [[51, 54, "Herb name"], [97, 112, "Drug"]]}], [7254, "WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC?", {"entities": []}], [7255, "\u2611 Green tea (GT) and its catechin components interact with hydrophilic drugs, such as nadolol and lisinopril.", {"entities": [[2, 16, "Herb name"], [25, 33, "Herb name"], [86, 93, "Drug"], [98, 108, "Drug"]]}], [7256, "A combination of fexofenadine and pseudoephedrine is clinically available for treatment of allergic rhinitis.", {"entities": [[17, 29, "Drug"], [34, 49, "Drug"], [91, 108, "Pathology"]]}], [7257, "WHAT QUESTION DID THIS STUDY ADDRESS?", {"entities": []}], [7258, "WHAT DOES THIS STUDY ADD TO OUR KNOWLEDGE?", {"entities": []}], [7259, "\u2611 Plasma concentrations and urinary excretions of fexofenadine were markedly decreased when coadministered with GTE, containing ~\u2009300\u2009mg of (\u2212)\u2010epigallocatechin gallate.", {"entities": [[2, 23, "Parameter"], [28, 46, "Parameter"], [50, 62, "Drug"], [112, 115, "Herb name"], [128, 136, "Amount"], [140, 168, "Herb name"]]}], [7260, "No differences were observed in the pharmacokinetics of pseudoephedrine between water and GTE.", {"entities": [[56, 71, "Drug"], [90, 93, "Herb name"]]}], [7261, "HOW MIGHT THIS CHANGE CLINICAL PHARMACOLOGY OR TRANSLATIONAL SCIENCE?", {"entities": []}], [7262, "The inhibition of intestinal OATP1A2 by (\u2212)\u2010epigallocatechin gallate is a likely mechanism underlying this interaction.", {"entities": [[18, 36, "Target"], [40, 68, "Herb name"]]}], [7263, "Green tea (GT; Camellia sinensis) and its main components, catechins, are perpetrators of clinically relevant food\u2010drug interactions with hydrophilic and nonmetabolized drugs, such as nadolol and lisinopril.", {"entities": [[0, 33, "Herb name"], [59, 68, "Herb name"], [184, 191, "Drug"], [196, 206, "Drug"]]}], [7264, "The H At present, a combined tablet of fexofenadine and pseudoephedrine, a nasal decongestant, is available for the treatment of allergic rhinitis in several countries, such as the United States (Allegra\u2010D) and Japan (Dellegra).", {"entities": [[39, 51, "Drug"], [56, 71, "Drug"], [129, 146, "Pathology"], [196, 205, "Drug"], [218, 226, "Drug"]]}], [7265, "The study was conducted in compliance with the principles of the Declaration of Helsinki.", {"entities": []}], [7266, "The GTE contained 92.5% (w/w) of EGCG, and 325\u2009mg of which was dissolved in water with stirring.", {"entities": [[4, 7, "Herb name"], [18, 29, "Amount"], [33, 37, "Herb name"], [43, 49, "Amount"]]}], [7267, "Subjects had a snack at 1\u2009hour and a standardized meal at 4\u2009hours after administration.", {"entities": [[24, 30, "Duration"], [58, 65, "Duration"]]}], [7268, "In each study period, 5\u2009mL venous blood samples were collected from an indwelling catheter placed in an antecubital vein or by direct venipuncture into EDTA\u2010treated tubes at 0, 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 24\u2009hours after administration.", {"entities": [[22, 26, "Amount"], [209, 217, "Duration"]]}], [7269, "Blood samples were immediately centrifuged at 2,000\u2009g for 10\u2009minutes at 4\u00b0C.", {"entities": [[46, 53, "Amount"], [58, 68, "Duration"], [72, 75, "Parameter"]]}], [7270, "Urine was collected during periods of 0\u20134, 4\u20138, and 8\u201324\u2009hours after administration.", {"entities": [[38, 41, "Duration"], [43, 46, "Duration"], [52, 62, "Duration"]]}], [7271, "Plasma and urine samples were stored at \u221280\u00b0C until analysis.", {"entities": [[40, 45, "Parameter"]]}], [7272, "The concentrations of fexofenadine and pseudoephedrine in plasma and urine were determined using ultra\u2010performance liquid chromatography (UPLC) with fluorescence detection (UPLC, Waters, Milford, MA), as summarized in  Methods S1 .", {"entities": [[22, 34, "Drug"], [39, 54, "Drug"]]}], [7273, "Diphenhydramine and phenylephrine were used as internal standards for fexofenadine and pseudoephedrine, respectively.", {"entities": [[0, 15, "Drug"], [20, 33, "Drug"], [70, 82, "Drug"], [87, 102, "Drug"]]}], [7275, "The inter\u2010day coefficients of variation of fexofenadine and pseudoephedrine were 9.9% and 7.3%, respectively.", {"entities": [[43, 55, "Drug"], [60, 75, "Drug"], [81, 85, "Amount"], [90, 94, "Amount"]]}], [7276, "Sulfobromophthalein (BSP) was used as a typical substrate for OATP2B1.", {"entities": [[0, 25, "Drug"], [62, 69, "Target"]]}], [7277, "The transporter\u2010expressing cells and the respective vector control cells were cultured according to previous studies.", {"entities": []}], [7278, "To examine the possibility of direct chemical binding between fexofenadine and EGCG in the gastrointestinal tract, fexofenadine (400\u2009\u03bcg/mL, based on the maximum concentration when a 60\u2010mg dose was dissolved in 150\u2009mL) was incubated in the presence or absence of EGCG (1\u2009mg/mL) in saline at 37\u00b0C for 1, 2, and 24\u2009hours.", {"entities": [[62, 74, "Drug"], [79, 83, "Herb name"], [115, 127, "Drug"], [129, 138, "Amount"], [182, 187, "Amount"], [210, 216, "Amount"], [262, 266, "Herb name"], [268, 275, "Amount"], [290, 294, "Parameter"], [299, 300, "Duration"], [302, 303, "Duration"], [309, 317, "Duration"]]}], [7279, "Bortezomib (20\u2009\u03bcg/mL) was used as a positive control for the chemical interaction with EGCG.", {"entities": [[0, 10, "Drug"], [12, 20, "Amount"], [87, 91, "Herb name"]]}], [7280, "The chromatographic separation of the samples was achieved by UPLC (Waters) system, as stated in detail in  Methods S1 .", {"entities": []}], [7281, "The peak plasma concentration (C   In vitro data are expressed as mean\u2009\u00b1\u2009standard error mean.", {"entities": [[0, 32, "Parameter"]]}], [7282, "Clinical pharmacokinetic data are expressed as geometric means and coefficient of variation (geoCV, %) unless otherwise noted.", {"entities": []}], [7283, "The number of subjects was deemed to be sufficient to detect a potentially clinically meaningful effect size of 35% difference in AUC All participants completed the study.", {"entities": [[112, 115, "Amount"], [130, 133, "Parameter"]]}], [7284, "None of the subjects experienced any adverse events related to the drugs.", {"entities": [[37, 51, "Pathology"]]}], [7285, "Three individuals were genotyped as SLCO2B1 c.1457CC (*1/*1) carriers, 5 individuals as SLCO2B1 c.1457CT (*1/*3) carriers, and 2 individuals as SLCO2B1 c.1457TT (*3/*3) carriers.", {"entities": []}], [7286, "Plasma concentration\u2010time profiles and pharmacokinetic parameters of fexofenadine are shown in Figure  1  and Table  1 .", {"entities": [[0, 34, "Parameter"], [69, 81, "Drug"]]}], [7287, "There were no apparent differences in pharmacokinetic parameters of fexofenadine stratified for SLCO2B1 *3 SNV in water (control) phase (data not shown).", {"entities": [[68, 80, "Drug"]]}], [7288, "Data are expressed as the arithmetic mean\u2009\u00b1\u2009SD.", {"entities": []}], [7289, "The inset is the log\u2010concentration vs. time profile.", {"entities": []}], [7290, "Data are expressed as the arithmetic mean\u2009\u00b1\u2009SD.", {"entities": []}], [7291, "The inset is the log\u2010concentration vs. time profile.", {"entities": []}], [7292, "In vitro uptake assays of fexofenadine in HEK\u2010OATP1A2 cells or sulfobromophthalein (BSP) in HEK\u2010OATP2B1 cells (black bars), and in the respective HEK control cells (PQX) for OATP1A2 or (VC) for OATP2B1 (white bars).", {"entities": [[26, 38, "Drug"], [63, 88, "Drug"]]}], [7293, "Data are presented as mean\u2009\u00b1\u2009SEM.", {"entities": []}], [7294, "(n\u00a0=\u00a06).", {"entities": [[5, 6, "Amount"]]}], [7295, "**P\u2009<\u20090.01, vs. uptake into HEK293 control cells (PQX or VC);  It has been reported that GT catechins chemically interacted with various kinds of drugs including bortezomib, a proteasome inhibitor (Figure  S4  a).", {"entities": [[89, 101, "Herb name"], [162, 196, "Drug"]]}], [7296, "In contrast, no substantial differences were observed in the pharmacokinetics of pseudoephedrine between GTE and control phases (Figures 3, 4).", {"entities": [[81, 96, "Drug"], [105, 108, "Herb name"]]}], [7297, "A second possible mechanism is a direct chemical interaction between fexofenadine and EGCG.", {"entities": [[69, 81, "Drug"], [86, 90, "Herb name"]]}], [7298, "Indeed, various drugs, including aripiprazole, bortezomib, cetirizine, and sunitinib, has been reported to interact with EGCG.", {"entities": [[33, 45, "Drug"], [47, 57, "Drug"], [59, 69, "Drug"], [75, 84, "Drug"], [121, 125, "Herb name"]]}], [7299, "Due to high solubility and low permeability, pseudoephedrine was provisionally classified as BCS class 3 drug.", {"entities": [[45, 60, "Drug"]]}], [7300, "A limitation of this study is that all volunteers were Japanese, so it remains unclear whether ethnic differences effect pharmacokinetic interactions between GT and fexofenadine.", {"entities": [[55, 63, "Ethnic group"], [158, 160, "Herb name"], [165, 177, "Drug"]]}], [7301, "In relation to ethnicity, there was no influence of the SLCO2B1*3 SNV on fexofenadine pharmacokinetics, although we confirmed that this polymorphism is common in Japanese population.", {"entities": [[73, 85, "Drug"], [162, 170, "Ethnic group"]]}], [7302, "Considering that brewed GT contains more catechins and flavonoids in addition to EGCG, we propose that GT should not be taken during anti\u2010allergic therapy using, at least, fexofenadine.", {"entities": [[24, 26, "Herb name"], [41, 50, "Herb name"], [55, 65, "Herb name"], [81, 85, "Herb name"], [103, 105, "Herb name"], [133, 154, "Drug"], [172, 184, "Drug"]]}], [7303, "This study was partly supported by JSPS KAKENHI Grant Number 17K17983 and 17K08949.", {"entities": []}], [7304, "The authors declared no competing interests for this work.", {"entities": []}], [7305, "S.M., Y.O., R.T., J.K., H.W., M.F., and K.S.", {"entities": []}], [7306, "wrote the manuscript.", {"entities": []}], [7307, "S.M., J.K., H.W., M.F., and K.S.", {"entities": []}], [7308, "designed the research.", {"entities": []}], [7309, "S.M., Y.O., R.T., E.H., T.O., H.O., and K.S.", {"entities": []}], [7310, "performed the research.", {"entities": []}], [7311, "S.M., Y.O., R.T., J.K., H.W., M.F., and K.S.", {"entities": []}], [7312, "analyzed the data.", {"entities": []}], [7313, "Figure S1  Click here for additional data file.", {"entities": []}], [7314, "Figure S2  Click here for additional data file.", {"entities": []}], [7315, "Figure S3  Click here for additional data file.", {"entities": []}], [7316, "Figure S4  Click here for additional data file.", {"entities": []}], [7317, "Appendix S1  Click here for additional data file.", {"entities": []}], [7318, "The authors thank Dr. Kazuo Minamikawa, Dr. Akihiro Inano, Ms. Hazuki Ito, and Ms. Momoka Ito for support on conducting the clinical trial.", {"entities": [[124, 138, "Study"]]}], [7319, "Eugenia jambolana (EJ) is an Indian traditional herb widely used for the treatment of diabetes mellitus.", {"entities": [[0, 22, "Herb name"], [29, 35, "Ethnic group"], [86, 103, "Pathology"]]}], [7320, "This herb is globally marketed as single or multi herb formulations.", {"entities": []}], [7321, "Many diabetes patients consume EJ extract oral hypoglycemic drugs together.", {"entities": [[5, 13, "Pathology"], [31, 33, "Herb name"], [42, 65, "Drug"]]}], [7322, "This calls for a need to assess risks versus benefit of this co-administration.", {"entities": []}], [7323, "In present investigation, pharmacodynamic and pharmacokinetic interactions of aqueous extract of EJ seeds at the dose of 400\u202fmg/kg are studied with 10 mg/kg of oral hypoglycaemic drug sitagliptin (SITA) by co-administrating them for 28 days in streptozotocin (STZ) induced diabetic rats.", {"entities": [[78, 93, "Extraction process"], [97, 99, "Herb name"], [100, 105, "Herb part"], [121, 130, "Amount"], [148, 156, "Amount"], [160, 202, "Drug"], [229, 240, "Duration"], [244, 263, "Drug"], [273, 281, "Pathology"]]}], [7324, "The pharmacokinetic parameters of SITA were determined using HPLC-ESI-MS/MS and it was found that the combination treatment reduces the systemic exposure of SITA by showing 38.70% reduction in concentration maximum (Cmax) and 22.40% reduction in area under curve (AUC).", {"entities": [[34, 38, "Drug"], [157, 161, "Drug"], [193, 221, "Parameter"], [246, 268, "Parameter"]]}], [7325, "Despite low levels of SITA, the combination demonstrated a significant reduction in blood glucose level when compared with individual drug and individual extract administered groups during pharmacodynamic study.", {"entities": [[22, 26, "Drug"], [84, 103, "Parameter"], [189, 210, "Study"]]}], [7326, "In addition, the liver function, the kidney function and the lipid parameters were found to be significantly improved and beneficial effects were found with respect to food intake and water intake and urine output in case of combination treatment groups when compared with individual treatment groups.", {"entities": []}], [7327, "Histopathological examination of pancreatic tissue suggests its significant recovery of having normal acinus with better cell protection in combination treatment.", {"entities": []}], [7328, "In conclusion, the combination treatment demonstrated reduced systemic exposure of SITA without compromising on its antihyperglycemic activity and improvement in conditions associated with diabetes.", {"entities": [[83, 87, "Drug"], [189, 197, "Pathology"]]}], [7329, "Jamuns (Eugenia jambolana Lam.)", {"entities": [[0, 31, "Herb name"]]}], [7330, "(EJ) are considered to be functional foods owing to their anti-diabetic Several research groups studying the protective and therapeutic effect of EJE and have identified presence of various classes of bioactive constituents like anthocyanins, flavonoids Gliptins are a class of oral anti-diabetic agents which act by competitively antagonizing the enzyme dipeptidyl peptidase-4 (DDP-4).", {"entities": [[1, 3, "Herb name"], [146, 149, "Herb name"], [229, 241, "Herb name"], [243, 253, "Herb name"], [254, 262, "Drug"], [278, 303, "Drug"], [348, 385, "Target"]]}], [7331, "The first agent of this class is Sitagliptin (SITA), approved by FDA in 2006.", {"entities": [[33, 51, "Drug"]]}], [7332, "It is known to be transported by human organic anion transporter (hOAT3), organic anion transporting polypeptide (OATP4C1) and multidrug resistance (MDR) P-glycoprotein (P-gp).", {"entities": [[33, 72, "Target"], [74, 122, "Target"], [154, 175, "Target"]]}], [7333, "Various herb drug interaction studies have been carried out in past with respect to antidiabetic activity and Gupta et\u00a0al.", {"entities": [[8, 37, "Study"]]}], [7334, "(2017) have published a complied review of the same.", {"entities": []}], [7335, "The present work was carried out to check the safety and efficacy of one of the probable concomitant treatments that a diabetic patient is likely to undertake during the course of his treatment.", {"entities": [[119, 127, "Pathology"]]}], [7336, "It evaluates the effect of sub-chronic (28 days) administration of EJE on the pharmacokinetic (PK) and pharmacodynamic (PD) activity of one of the widely used oral hypoglycemic, sitagliptin (SITA) in streptozotocin induced diabetic rats.", {"entities": [[40, 47, "Duration"], [67, 70, "Herb name"], [159, 196, "Drug"], [200, 214, "Drug"], [223, 231, "Pathology"]]}], [7337, "SITA was a gift from by U.S Vitamins, Mumbai, India and STZ was purchased from Sigma Chemical Co, St Louis, MO, USA., Erba Diagnostic kits like Glucose oxidase peroxidase (GOD-POD), Aspartate aminotransferase (AST), Alanine aminotransferase (ALT), Total cholesterol (TC), Triglyceride (TG), Blood urea nitrogen (BUN) were purchased from Nobel Diagnostics, Mumbai, India.", {"entities": [[0, 4, "Drug"], [56, 59, "Drug"], [144, 180, "Parameter"], [182, 214, "Parameter"], [216, 246, "Parameter"], [248, 270, "Parameter"], [272, 289, "Parameter"], [291, 316, "Parameter"]]}], [7338, "Ammonium acetate, ammonium formate, citric acid, tri-sodium citrate and EDTA were purchased from Qualigens fine chemicals, Mumbai, India.", {"entities": []}], [7339, "LC-MS grade solvents methanol, acetonitrile and formic acid were procured from Merck Fresh EJ seeds were ordered and procured from Borivali National Park, Mumbai, India.", {"entities": [[91, 93, "Herb name"], [94, 99, "Herb part"]]}], [7340, "Taxonomical identification and authentication of specimen was done at Agharkar Research Institute, Pune, India and a voucher specimen no.15\u2013237 was deposited.", {"entities": []}], [7341, "Dried seed of Eugenia jambolana were powdered and used for preparation of aqueous extract by using the double maceration technique.", {"entities": [[6, 10, "Herb part"], [14, 31, "Herb name"], [74, 89, "Extraction process"], [103, 130, "Extraction process"]]}], [7342, "Powdered seed (500\u202fg) were macerated with 5L of distilled water for seven days.", {"entities": [[9, 13, "Herb part"], [27, 36, "Extraction process"]]}], [7343, "After seven days, the extract was filtered and the filtrate was stored in refrigerator until next processing.", {"entities": []}], [7344, "The marc was further macerated with fresh distilled water for additional seven days.", {"entities": [[21, 30, "Extraction process"]]}], [7345, "It was filtered and the filtrate obtained in this step was mixed with the previous filtrate.", {"entities": []}], [7346, "The combined filtrates were concentrated by spray drying at 75\u00b0 C to yield the dry powder extract.", {"entities": [[79, 97, "Extraction process"]]}], [7347, "EJ extract was standardised for the content of ellagic acid using previously reported high performance liquid chromatography method Farrukh A and co-worker Male Sprague Dawley rats, weighing 180\u2013220\u202fg were maintained at animal facility of Shri Vile Parle Kelvani Mandal's, Narsee Monjee Institute of Management Study (SVKM\u2019S NMIMS), Mumbai, India.", {"entities": [[0, 2, "Herb name"], [47, 59, "Herb name"]]}], [7348, "The animals were housed in clean polypropylene cages under standard conditions of humidity (50\u202f\u00b1\u202f5%), temperature (25\u202f\u00b1\u202f2\u202f\u00b0C) and light (12\u202fh light/12\u202fh dark cycle) and fed with a standard pellet diet and water ad libitum.", {"entities": []}], [7349, "All animals were handled with human care and all the procedures were performed as per the guidelines of the Committee for the Purpose of Control and Supervision of Experiments on Animals (CPCSEA), Ministry of Animal Welfare Division, Government of India, New Delhi, and protocol was approved by Institutional Animal Ethical Committee Animal House (Registration No.", {"entities": []}], [7350, "1830/PO/Re/S/15/CPCSEA).", {"entities": []}], [7351, "Diabetes mellitus was induced by single intraperitoneal injection of freshly prepared STZ (55\u202fmg/kg b.w) in 0.1\u202fM citrate buffer (pH 4.5) at a volume of 1\u202fmL/kg bw.", {"entities": [[0, 17, "Pathology"], [86, 89, "Drug"], [91, 99, "Amount"]]}], [7352, "After 72\u202fh, blood was collected from each rat from retro orbital plexus, plasma was separated by centrifugation at 4000\u0261.", {"entities": []}], [7353, "Glucose level was determined using GOD-POD Erba diagnostic kits.", {"entities": [[0, 13, "Parameter"]]}], [7354, "Rats with fasting blood glucose level above 250\u202fmg/dL were considered to be diabetic and selected for the further study.", {"entities": [[10, 37, "Parameter"], [38, 53, "Amount"], [76, 84, "Pathology"]]}], [7355, "The diabetic rats were randomly divided into five groups of six animals each.", {"entities": [[4, 12, "Pathology"]]}], [7356, "Group I consisted of non-diabetic rats, (Normal Control- NC) administered with distilled water (1\u202fml/kg, p.o) daily for 28 days.", {"entities": [[25, 33, "Pathology"], [96, 103, "Amount"], [110, 115, "Frequency"], [116, 127, "Duration"]]}], [7357, "Group II consisted of 55\u202fmg/kg STZ induced diabetic rats (Diabetic control- DC).", {"entities": [[22, 30, "Amount"], [31, 34, "Drug"], [43, 51, "Pathology"], [58, 66, "Pathology"]]}], [7358, "Group III diabetic animals were treated with SITA alone for 28 days at dose of 10\u202fmg/kg p.o and Group IV diabetic animal were administered with EJE for 28 days at dose 400\u202fmg/kg, p.o.", {"entities": [[10, 18, "Pathology"], [45, 49, "Drug"], [56, 67, "Duration"], [79, 87, "Amount"], [105, 113, "Pathology"], [144, 147, "Herb name"], [148, 159, "Duration"], [168, 177, "Amount"]]}], [7359, "Group V diabetic animals received EJE (400\u202fmg/kg) and SITA (10\u202fmg/kg) for 28 days.", {"entities": [[8, 16, "Pathology"], [34, 37, "Herb name"], [39, 48, "Amount"], [54, 58, "Drug"], [60, 68, "Amount"], [70, 81, "Duration"]]}], [7360, "The solutions of SITA and EJE were freshly prepared in distilled water and administered via oral route using an oral gavage needle.", {"entities": [[17, 21, "Drug"], [26, 29, "Target"]]}], [7361, "In Group V animals, SITA was administered first, followed by EJE.", {"entities": [[20, 24, "Drug"], [61, 64, "Herb name"]]}], [7362, "LD On the 28th day, after the treatment, blood was collected in heparinised tubes from retro-orbital plexus (0.4\u20130.5\u202fmL) from group III and V at predetermined time interval 0, 0.083, 0.25, 0.5, 1, 2, 4, 6, 8 and 24\u202fh. The animals were anaesthetized using isoflurane during blood withdrawal.", {"entities": []}], [7363, "The time intervals were selected with commonly used strategies for pharmacokinetic studies i.e.", {"entities": [[67, 90, "Study"]]}], [7364, "the total blood withdrawal should not be over 20% of the total blood volume.", {"entities": []}], [7365, "Blood samples were centrifuged at 4000\u0261 for 10\u202fmin\u202fat 4\u202f\u00b0C to obtain the plasma which was stored at\u00a0\u221280\u202f\u00b0C until analysis using HPLC-ESI-MS/MS method.", {"entities": []}], [7366, "The pharmacokinetic parameters such as concentration maximum (C HPLC-ESI-MS/MS method was developed for quantification of SITA in rat plasma using pramipexole (PRM) as an internal standard (IS).", {"entities": [[39, 60, "Parameter"], [122, 126, "Drug"], [147, 164, "Drug"]]}], [7367, "The liquid chromatography system (Shimadzu, 8040) consisted of a binary LC-20AD prominence pump, an autosampler (SIL\u201320 AC The standard stock solutions of SITA and the PRM were prepared by dissolving their accurately weighted amounts in methanol to get a final concentration of 1000\u202f\u03bcg/mL.", {"entities": [[155, 159, "Drug"], [168, 171, "Drug"]]}], [7368, "This was further diluted to prepare the working solution of SITA in the concentration range of 0.025\u201325\u202f\u03bcg/mL and for PRM at the concentration of 10\u202f\u03bcg/ml using methanol as diluent.", {"entities": [[60, 64, "Drug"], [118, 121, "Drug"]]}], [7369, "The solutions were stored at 2\u20138\u202f\u00b0C and were brought to room temperature before use.", {"entities": []}], [7370, "The calibration standards were prepared by spiking 90\u202f\u03bcL of blank rat plasma with 10\u202f\u03bcL respective working solutions to produce the final concentrations of 25, 50, 100, 250, 500, 1000, 2500, 5000, 10000, 25000\u202fng/mL for SITA.", {"entities": [[220, 224, "Drug"]]}], [7371, "The quality controls standards were prepared at 25\u202fng/mL (low limit of quality control, LLOQ, 100\u202fng/mL (low quality control, LQC), 1000\u202fng/mL (middle quality control, MQC) and 10000\u202fng/mL (high quality control, HQC).", {"entities": []}], [7372, "10\u202f\u03bcL PRM was added as an internal standard final concentration of 1000\u202fng/mL to each of the samples.", {"entities": [[6, 9, "Drug"]]}], [7373, "1000\u202f\u03bcL of ethyl acetate was added as an extraction solvent to each of the samples.", {"entities": []}], [7374, "After vortexing for 10\u202fmin and centrifuging the samples at 4000\u0261 for 10\u202fmin, 900\u202f\u03bcL of the supernatant was withdrawn, evaporated to dryness at 40\u202f\u00b0C under nitrogen gas and reconstituted with 100\u202f\u03bcL of mobile phase.", {"entities": []}], [7375, "8\u202f\u03bcL of the samples were injected into the HPLC-ESI-MS/MS.", {"entities": []}], [7376, "For determination of pharmacodynamic parameters, blood was withdrawn from animals of each group after the last treatment dose on the 28th day and various biochemical parameters were analyzed.", {"entities": []}], [7377, "FBG and biochemical parameters like Alanine transaminase (ALT), Aspartate transaminase (AST), total cholesterol (TC), triglyceride (TG), and blood urea nitrogen (BUN) were estimated using ERBA diagnostic kits as per manufacturer's protocol.", {"entities": [[36, 62, "Parameter"], [64, 92, "Parameter"], [94, 116, "Parameter"], [118, 135, "Parameter"], [141, 166, "Parameter"]]}], [7378, "Food intake, water intake and urine output were determined using metabolic cages.", {"entities": []}], [7379, "At the end of 28 days, rats from each treatment group were sacrificed, the pancreas were isolated and rinsed with ice cold saline.", {"entities": [[14, 21, "Duration"]]}], [7380, "Then the tissues were fixed with 10% formaldehyde.", {"entities": []}], [7381, "The tissue histopathology was carried out at Chaitanya pathology laboratory, Pune, India.", {"entities": []}], [7382, "The sections were stained with hematoxylin and eosin (H & E) and were examined at least at three different sites under a light microscope for histo-architectural changes.", {"entities": []}], [7383, "The pathological grading was done on the basis of the extent of necrosis of islet cells.", {"entities": [[64, 72, "Pathology"]]}], [7384, "The result of pharmacodynamic study was expressed as mean\u202f\u00b1\u202fstandard error of mean (SEM) of six animals from each group.", {"entities": [[14, 35, "Study"]]}], [7385, "Graph Pad prism Version 6.00 of Graph Pad Software Inc., San Diego, USA, software was used for statistical analysis and the results were analyzed using one-way ANOVA followed by the Tukey\u2013Kramer post test; p\u202f<\u202f0.001 was considered as level of significance for pharmacodynamic parameter.", {"entities": []}], [7386, "Pharmacokinetic parameters were analyzed using two-way ANOVA followed by the Tukey\u2013Kramer post test; C The content of ellagic acid in the aqueous extract of EJ seeds by HPLC was found to be 0.37%w/w.", {"entities": [[118, 130, "Herb name"], [138, 153, "Extraction process"], [157, 159, "Herb name"], [160, 165, "Herb part"]]}], [7387, "Ellagic acid is a known polyphenolic antioxidant and is reported to reduce blood sugar in diabetic rats.", {"entities": [[0, 12, "Herb name"], [24, 48, "Herb name"], [75, 86, "Parameter"], [90, 98, "Pathology"]]}], [7388, "HPLC-ESI MS/MS method was developed and validated for determination of SITA in rat plasma samples.", {"entities": [[71, 75, "Drug"]]}], [7389, "The retention time for SITA and PRM were found to be 0.642 and 0.483\u202fmin respectively (Fig.", {"entities": [[23, 27, "Drug"], [32, 35, "Drug"]]}], [7390, "1a) and their masses was confirmed at m/z 408.04 and 212.20 (Fig.", {"entities": []}], [7391, "2a and b).", {"entities": []}], [7392, "Further collision induced fragmentation of SITA led to product ions of m/z 193.0, 174.0, 154.0 and that of PRM led to product ions of m/z 111.0, 67.10 (Fig.", {"entities": [[43, 47, "Drug"], [107, 110, "Drug"]]}], [7393, "3a and b).", {"entities": []}], [7394, "These were used to set MRM transitions at m/z 408.04\u202f\u2192\u202f193.0, 174.0, 154.0 for SITA and m/z 212.20\u202f\u2192\u202f111.0, 67.10 for PRM for the purpose of their quantification in rat plasma.", {"entities": [[79, 83, "Drug"], [118, 121, "Drug"]]}], [7395, "Mass chromatograms of SITA and PRM (Peak for SITA at 0.642min, PRM at 0.482\u202fmin).", {"entities": [[22, 26, "Drug"], [31, 34, "Drug"], [45, 49, "Drug"], [63, 66, "Drug"]]}], [7396, "a) Mass spectra of SITA at m/z 408.04, b) PRM at m/z 212.10. a) Productions of SITA at m/z 198, 174, 154\u202fb) PRM at m/z 111, 67.10.", {"entities": [[19, 23, "Drug"], [42, 45, "Drug"], [79, 83, "Drug"], [108, 111, "Drug"]]}], [7397, "Ethyl acetate was used as extraction solvent to recover SITA and PRM from plasma.", {"entities": [[56, 60, "Drug"], [65, 68, "Drug"]]}], [7398, "The extraction efficiency with ethyl acetate was found to be 72.46%.", {"entities": []}], [7399, "The method was validated for linearity, accuracy and precision.", {"entities": []}], [7400, "The calibration curves showed good linear correlation in the concentration range of 25\u201325000\u202fng/mL with r The effects of EJ extracts at a dose of 400\u202fmg/kg on pharmacokinetics (PK) of SITA (10\u202fmg/kg) were studied in STZ induced diabetic rats.", {"entities": [[121, 123, "Herb name"], [146, 155, "Amount"], [184, 188, "Drug"], [190, 198, "Amount"], [216, 219, "Drug"], [228, 236, "Pathology"]]}], [7401, "Though PK interaction studies can be carried out in normal rats, we carried it out in diabetic rats to relate it with the real-life condition.", {"entities": [[7, 29, "Study"], [86, 94, "Pathology"]]}], [7402, "Various recent researches have proposed the disease system approach as various diseases and pathological conditions associated with disease can modify the drug disposition.", {"entities": []}], [7404, "Values expressed as mean\u00a0\u00b1\u00a0SEM of six rats.", {"entities": []}], [7405, "*significantly different from SITA treated group at p\u00a0<\u00a00.05.", {"entities": [[30, 34, "Drug"]]}], [7406, "Main Pharmacokinetic parameters of SITA in diabetic rats (n\u202f=\u202f6) treated with SITA (100\u202fmg/kg) and SITA\u00a0+\u00a0EJE (400\u202fmg/kg).", {"entities": [[35, 39, "Drug"], [43, 51, "Pathology"], [78, 82, "Drug"], [84, 93, "Amount"], [99, 103, "Drug"], [106, 109, "Herb name"], [111, 120, "Amount"]]}], [7407, "Data expressed as mean\u00a0+\u00a0SD.", {"entities": []}], [7408, "**significant with respect to SITA alone treated group.", {"entities": [[30, 34, "Drug"]]}], [7409, "The fasting blood glucose levels were significantly increased (p\u202f<\u202f0.001) in diabetic rats as compared to normal control rats.", {"entities": [[4, 32, "Parameter"], [77, 85, "Pathology"]]}], [7410, "Oral administration of SITA (10\u202fmg/kg), aqueous extract of EJ seeds (400\u202fmg/kg) and their combinations at respective doses for 28 days decreased the FBG significantly (p\u202f<\u202f0.001) to 333, 321.86 and 298.74\u202fmg/dL respectively as compared to diabetic control having fasting blood glucose 577.2\u202fmg/dL (Fig.\u00a05).", {"entities": [[23, 27, "Drug"], [29, 37, "Amount"], [40, 55, "Extraction process"], [59, 61, "Herb name"], [62, 67, "Herb part"], [69, 78, "Amount"], [123, 134, "Duration"], [149, 152, "Parameter"], [182, 210, "Amount"], [239, 247, "Pathology"], [263, 284, "Parameter"], [285, 296, "Amount"]]}], [7411, "It can be seen that despite low levels of SITA during pharmacokinetic interaction study, reduction in FBG levels was more significant with combination treatment as compared to SITA alone or EJE alone.", {"entities": [[42, 46, "Drug"], [54, 87, "Study"], [102, 105, "Parameter"], [176, 180, "Drug"], [190, 193, "Herb name"]]}], [7412, "Effect of SITA, EJE and SITA\u00a0+\u00a0EJE on Fasting blood glucose (FBG).", {"entities": [[10, 14, "Drug"], [16, 19, "Herb name"], [24, 28, "Drug"], [31, 34, "Herb name"], [38, 65, "Parameter"]]}], [7413, "Results expressed as mean\u00a0\u00b1\u00a0SEM of six rats.", {"entities": []}], [7414, "*significantly different from normal group, # significantly different from diabetic control group at p\u00a0<\u00a00.001.", {"entities": [[75, 83, "Pathology"]]}], [7415, "Plasma levels of the enzymes ALT and AST are used biomarkers for liver damage.", {"entities": [[29, 32, "Parameter"], [37, 40, "Parameter"], [65, 77, "Pathology"]]}], [7416, "Diabetes mellitus is associated with elevated levels of AST and ALT.", {"entities": [[0, 17, "Pathology"], [56, 59, "Parameter"], [64, 67, "Parameter"]]}], [7417, "The underlying mechanism of diabetes that contributes to liver damage is the combination of increased oxidative stress and an aberrant inflammatory response.", {"entities": [[28, 36, "Pathology"], [57, 69, "Pathology"], [102, 118, "Pathology"], [126, 156, "Pathology"]]}], [7418, "Effect of SITA, EJE and SITA\u00a0+\u00a0EJE on Alanine transaminase (ALT) and Aspartate transaminase.", {"entities": [[10, 14, "Drug"], [16, 19, "Herb name"], [24, 28, "Drug"], [31, 34, "Herb name"], [38, 64, "Parameter"], [69, 91, "Parameter"]]}], [7419, "(AST).", {"entities": [[1, 4, "Parameter"]]}], [7420, "Values expressed as mean\u00a0\u00b1\u00a0SEM of six rats.", {"entities": []}], [7421, "*significantly different from normal group, # significantly different from diabetic control group at p\u00a0<\u00a00.001.", {"entities": [[75, 83, "Pathology"]]}], [7422, "Levels of ALT, AST, TC, TG, BUN, water intake, food intake and urine output in rats treated with SITA (100\u00a0mg/kg), EJE (400\u00a0mg/kg) and SITA\u00a0+\u00a0EJE (100\u00a0+\u00a0400\u00a0mg/kg).", {"entities": [[10, 13, "Parameter"], [15, 18, "Parameter"], [20, 22, "Parameter"], [24, 26, "Parameter"], [28, 31, "Parameter"], [97, 101, "Drug"], [103, 112, "Amount"], [115, 118, "Drug"], [120, 129, "Amount"], [135, 139, "Drug"], [142, 145, "Drug"], [147, 162, "Amount"]]}], [7423, "Data expressed as mean\u202f\u00b1\u202fSEM.", {"entities": []}], [7424, "*Significant with respect to NC, #- Significant with respect to DC (p\u00a0<\u00a00.001).", {"entities": []}], [7425, "Diabetes is known to be associated with dyslipidemia and patients suffering from diabetic dyslipidemia are considered to be at 2\u20134 times higher risk of cardiovascular complications.", {"entities": [[0, 8, "Pathology"], [40, 52, "Pathology"], [81, 102, "Pathology"], [152, 180, "Pathology"]]}], [7426, "Diabetic dyslipidemia is characterised by elevated TC and TG.", {"entities": [[0, 21, "Pathology"], [51, 53, "Parameter"], [58, 60, "Parameter"]]}], [7427, "Reaching adequate blood glucose control is important in decreasing microvascular complications associated with diabetes; however, good lipid management is vital for reducing the incidence of cardiovascular events in patients with diabetes.", {"entities": [[18, 31, "Parameter"], [67, 94, "Pathology"], [111, 119, "Pathology"], [191, 212, "Pathology"], [230, 238, "Pathology"]]}], [7428, "The present study showed significantly increased level of total cholesterol in plasma of STZ induced diabetic group.", {"entities": [[58, 85, "Parameter"], [89, 92, "Drug"], [101, 109, "Pathology"]]}], [7429, "Though SITA reduced TC and TG significantly, reduction with EJE and SITA\u00a0+\u00a0EJE was more significant (p\u202f<\u202f0.001) bringing them down almost to normal in STZ induced diabetic rats (Fig.", {"entities": [[7, 11, "Drug"], [20, 22, "Parameter"], [27, 29, "Parameter"], [60, 63, "Herb name"], [68, 72, "Drug"], [75, 78, "Herb name"], [151, 154, "Drug"], [163, 171, "Pathology"]]}], [7430, "7, Table\u00a02).", {"entities": []}], [7431, "Effect of SITA, EJE and SITA\u00a0+\u00a0EJE on total cholesterol and triglyceride.", {"entities": [[10, 14, "Drug"], [16, 19, "Herb name"], [24, 28, "Drug"], [31, 34, "Herb name"], [38, 55, "Parameter"], [60, 72, "Parameter"]]}], [7432, "Values expressed as mean\u00a0\u00b1\u00a0SEM of six rats.", {"entities": []}], [7433, "*significantly different from normal group, # significantly different from diabetic control group at p\u00a0<\u00a00.001.", {"entities": [[75, 83, "Pathology"]]}], [7434, "BUN is a reliable marker for kidney function.", {"entities": [[0, 3, "Parameter"]]}], [7435, "The levels of BUN were significantly elevated to 38.76\u202f\u00b1\u202f2.3 IU/dL) in DC animals.", {"entities": [[14, 17, "Parameter"], [49, 66, "Amount"], [71, 73, "Pathology"]]}], [7436, "Treatment with EJE and EJE\u202f+\u202fSITA significantly (p\u202f<\u202f0.001) reduced the elevated levels of BUN (Fig.", {"entities": [[15, 18, "Herb name"], [23, 27, "Herb name"], [28, 33, "Drug"], [91, 94, "Parameter"]]}], [7437, "8, Table\u00a02).", {"entities": []}], [7438, "Effect of SITA, EJE and SITA\u00a0+\u00a0EJE on Blood urea nitrogen (BUN).", {"entities": [[10, 14, "Drug"], [16, 19, "Herb name"], [24, 28, "Drug"], [31, 34, "Herb name"], [38, 63, "Parameter"]]}], [7439, "Values expressed as mean\u00a0\u00b1\u00a0SEM of six rats.", {"entities": []}], [7440, "*significantly different from normal group, # significantly different from diabetic control group at p\u00a0<\u00a00.001.", {"entities": [[75, 83, "Pathology"]]}], [7441, "Polyuria, polydipsia, polyphagia are the three major symptoms of diabetes.", {"entities": [[0, 8, "Pathology"], [10, 20, "Pathology"], [22, 32, "Pathology"], [65, 73, "Pathology"]]}], [7442, "STZ induced diabetic rats showed significant (p\u202f<\u202f0.001) increased levels of food intake, water intake and urine output.", {"entities": [[0, 3, "Drug"], [12, 20, "Pathology"]]}], [7443, "Treatment with SITA reduced the elevated levels, however the effect was more significant (p\u202f<\u202f0.001) in case of EJE as well as the combination treatment (Fig.", {"entities": [[15, 19, "Drug"], [112, 115, "Herb name"]]}], [7444, "9, Table\u00a02).", {"entities": []}], [7445, "Effect of SITA, EJE, SITA\u00a0+\u00a0EJE on food intake, water intake and urine output, Values expressed as mean\u00a0\u00b1\u00a0SEM of six rats.", {"entities": [[10, 14, "Drug"], [16, 19, "Herb name"], [21, 25, "Drug"], [28, 31, "Herb name"]]}], [7446, "*significantly different from normal group, # significantly different from diabetic control group at p\u00a0<\u00a00.001.", {"entities": [[75, 83, "Pathology"]]}], [7447, "The histopathological study of normal control group reveals normal histology of the pancreatic tissue (Grade 0).", {"entities": [[4, 27, "Study"]]}], [7448, "Pancreatic tissue of DC group animals elicited severe injury showing necrosis of adipose tissues, macrophage infiltration with cytoplasmic vacuolation at endocrine pancreas (Grade\u00a0++++) with decrease in the number of islet cells.", {"entities": [[21, 23, "Pathology"], [69, 96, "Pathology"], [98, 121, "Pathology"], [127, 172, "Pathology"]]}], [7449, "Treatment with SITA alone (10\u00a0mg/kg) for 28 days reduced the damage to a moderate level (Grade\u00a0++), whereas treatment with EJ alone for 28 days elicited recovery of pancreatic tissue as compared to SITA alone (Grade\u00a0+++).", {"entities": [[15, 19, "Drug"], [27, 35, "Amount"], [37, 48, "Duration"], [123, 125, "Herb name"], [132, 143, "Duration"], [198, 202, "Drug"]]}], [7450, "Interestingly treatment with concomitant administration of SITA and EJ for 28 days elicited the significant recovery of pancreatic tissue (Grade\u00a0+) having normal acinus with better cell protection than other treatment group (Fig.\u00a010).", {"entities": [[59, 63, "Drug"], [68, 70, "Herb name"], [71, 82, "Duration"]]}], [7451, "Histopathology of pancreatic tissue.", {"entities": []}], [7452, "NC:Showing normal acinus (arrowhead), normal interlobular duct (large arrow), and normal Islet of Langerhans (star).", {"entities": []}], [7453, "DC: Showing necrosis of adipose tissues (small arrow), macrophage infiltration (arrow head) with cytoplasmic vacuolation at endocrine pancreas (arrow).", {"entities": [[0, 2, "Pathology"], [12, 39, "Pathology"], [55, 78, "Pathology"], [97, 142, "Pathology"]]}], [7454, "SITA: Focal minimal lymphocytic infiltration, Focal mild necrosis peri parenchymal adipose tissue (arrow head).", {"entities": [[0, 4, "Drug"], [20, 44, "Pathology"], [57, 97, "Pathology"]]}], [7455, "EJE: Focal minimal lymphocytic infiltration (small arrow).", {"entities": [[0, 3, "Herb name"], [19, 43, "Pathology"]]}], [7456, "SITA\u00a0+\u00a0EJE: Focal minimal lymphocytic infiltration (small arrow), normal acinus.", {"entities": [[0, 4, "Drug"], [7, 10, "Herb name"], [26, 50, "Pathology"]]}], [7458, "Study of pharmacokinetic parameters indicated significantly reduced systemic exposure of SITA when given in combination with EJE as compared to SITA alone.", {"entities": [[89, 93, "Drug"], [125, 128, "Herb name"], [144, 148, "Drug"]]}], [7459, "Despite this, the therapeutic response in terms of FBG levels was not significantly affected.", {"entities": [[51, 61, "Parameter"]]}], [7460, "This effect can be ascribed to two different mechanisms through which SITA and EJE act.", {"entities": [[70, 74, "Drug"], [79, 82, "Herb name"]]}], [7461, "The reduced systemic exposure of SITA can be beneficial in reducing its side effects without lowering its therapeutic efficacy when given concomitantly with EJE.", {"entities": [[33, 37, "Drug"], [72, 84, "Pathology"], [157, 160, "Herb name"]]}], [7462, "Moreover, liver, kidney damage biomarkers, lipid profile, food and water intake, urine output and pancreatic cells damage showed prominent improvement in case of combination treatment when compared with SITA alone.", {"entities": [[10, 30, "Pathology"], [98, 121, "Pathology"], [203, 207, "Drug"]]}], [7463, "Additionally, there were no incidences of hypoglycaemia involved in the combination treatment.", {"entities": [[42, 55, "Pathology"]]}], [7464, "The combination SITA\u202f+\u202fEJ did not show any adverse herb drug interaction and is safe to be explored in a clinical set up.", {"entities": [[16, 21, "Drug"], [22, 25, "Herb name"]]}], [7465, "The benefit of the SITA\u00a0+\u00a0EJE combination lies in significant improvement in co-morbidities associated with diabetes mellitus when compared with SITA alone treatment.", {"entities": [[19, 23, "Drug"], [26, 29, "Herb name"], [108, 125, "Pathology"], [145, 149, "Drug"]]}], [7466, "None.", {"entities": []}], [7467, "We are thankful to  Peer review under responsibility of The Center for Food and Biomolecules, National Taiwan University.", {"entities": []}], [7468, "The aim of this open-label, fixed-sequence study was to investigate the potential of the botanical supplement", {"entities": [[16, 48, "Study"], [89, 109, "Herb name"]]}], [7469, "These authors contributed equally to this work.", {"entities": []}], [7470, "Alpinia officinarum Hance of the Chinese traditional herb for the treatment of emesis, abdominal pain and diarrhea has been used to counteract gastric disease induced by indomethacin in rats without obvious side effects.", {"entities": [[0, 25, "Herb name"], [33, 40, "Ethnic group"], [79, 85, "Pathology"], [87, 101, "Pathology"], [106, 114, "Pathology"], [143, 158, "Pathology"], [170, 182, "Drug"], [207, 219, "Pathology"]]}], [7471, "However, the role of herb-drug interaction between indomethacin and A.\u00a0officinarum based on pharmacokinetic, tissue distribution and excretion still remains unknown.", {"entities": [[51, 63, "Drug"], [68, 82, "Herb name"]]}], [7472, "Our results clarified that oral administration of A.\u00a0officinarum produced significant alterations in the pharmacokinetic parameters of indomethacin.", {"entities": [[50, 64, "Herb name"], [135, 147, "Drug"]]}], [7473, "And the pharmacokinetic interaction between indomethacin and A.\u00a0officinarum reduced the systemic exposure of indomethacin and increased its elimination.", {"entities": [[44, 56, "Drug"], [61, 75, "Herb name"], [109, 121, "Drug"]]}], [7474, "Tissue distribution results demonstrated that co-administration of A.\u00a0Officinarum could not reduce the accumulation of indomethacin in the target tissue of the stomach, but could accelerate the excretions of indomethacin and its three metabolites including ODI, NDI and IDA\u03b2G in the bile and feces of rats in the excretion study.", {"entities": [[67, 81, "Herb name"], [119, 131, "Drug"], [208, 220, "Drug"]]}], [7475, "Therefore, A.\u00a0Officinarum might have a gastrointestinal protective effect through the interaction role with indomethacin based on the pharmacokinetics and excretion in rats.", {"entities": [[11, 25, "Herb name"]]}], [7476, "An UFLC-MS/MS method was developed for simultaneous determination of indomethacin and its metabolites by oral administration of indomethacin with and without A.\u00a0officinarum Hance and applied to comparative pharmacokinetic, tissue distribution and excretion studies.", {"entities": [[69, 81, "Drug"], [128, 140, "Drug"], [158, 178, "Herb name"]]}], [7477, "Our results first clarified that oral administration of A.\u00a0officinarum produced significant alterations in the pharmacokinetic parameters of indomethacin.", {"entities": [[56, 70, "Herb name"], [141, 153, "Drug"]]}], [7478, "And the pharmacokinetic interaction between indomethacin and A.\u00a0officinarum leaded to reduce the systemic exposure of indomethacin and increase its elimination.", {"entities": [[44, 56, "Drug"], [61, 75, "Herb name"], [118, 130, "Drug"]]}], [7479, "A.\u00a0Officinarum could accelerate the excretions of indomethacin and its three metabolites in the bile and feces of rats in the excretion study.", {"entities": [[0, 14, "Herb name"], [50, 62, "Drug"]]}], [7480, "Therefore, A.\u00a0Officinarum might be of the gastrointestinal protective effect through the interaction role with indomethacin based on the pharmacokinetics and excretion in rats.", {"entities": [[11, 25, "Herb name"], [111, 123, "Drug"]]}], [7481, "Non-steroidal anti-inflammatory drugs (NSAIDs) are widely applied worldwide and used by more than 30 million people every day, accounting for about 60% of OTC market shares of the painkiller in the United States [1].", {"entities": [[0, 46, "Drug"]]}], [7482, "However, adverse reactions in the upper digestive tract, such as gastric ulcer, are always accompanied by therapeutic effects with markedly health risks, and thus the use of NSAIDs is frequently curtailed [[2], [3], [4]].", {"entities": [[9, 26, "Pathology"], [174, 180, "Drug"]]}], [7483, "Indomethacin, one of the most effective NSAIDs, is applied to the treatment of reducing fever, pain and swelling but is also harmful to the gastrointestinal tract [[5], [6], [7]].", {"entities": [[0, 12, "Drug"], [40, 46, "Drug"], [88, 93, "Pathology"], [95, 99, "Pathology"], [104, 112, "Pathology"]]}], [7484, "Its plasma drug concentration and bioavailability are high and oral absorption is fast; however, cumulative medicinal doses and high plasma drug concentrations would also boost the gastrointestinal side effects of NSAIDs [[8], [9], [10]].", {"entities": [[34, 49, "Parameter"], [198, 210, "Pathology"], [214, 220, "Drug"]]}], [7485, "Therefore, how to alleviate or eliminate the gastric injury caused by NSAIDs is a huge challenge we are facing.", {"entities": [[45, 59, "Pathology"], [70, 76, "Drug"]]}], [7486, "So far, concomitant use of synthetic drugs, such as H2 receptor antagonists, mucosal protective agents and proton pump inhibitors, has been widely employed for relieving side effects of gastrointestinal injuries induced by NSAIDs, thereby reducing mortality and morbidity rates [[11], [12], [13]].", {"entities": [[52, 75, "Drug"], [77, 102, "Drug"], [107, 129, "Drug"], [170, 182, "Pathology"], [186, 211, "Pathology"], [223, 229, "Drug"]]}], [7487, "However, they are not completely effective and these allopathic medicines may cause undesirable side effects.", {"entities": [[96, 108, "Pathology"]]}], [7488, "It has been reported that these agents may exacerbate NSAID-induced small intestine injury by dysbiosis and further research is needed to prove their safety and effectiveness [14,15].", {"entities": [[54, 59, "Drug"], [74, 90, "Pathology"], [94, 103, "Pathology"]]}], [7489, "Safety and effectiveness concerns related to NSAIDs have prompted the development of plant-derived drugs.", {"entities": [[45, 51, "Drug"]]}], [7490, "Traditional Chinese medicine from natural products of botanic origin is a promising therapeutic resource with fewer adverse effects in the treatment of the gastrointestinal damage [[16], [17], [18]].", {"entities": [[12, 19, "Ethnic group"], [116, 131, "Pathology"]]}], [7491, "Alpinia officinarum Hance of the Zingiberaceae family is a Chinese traditional herb that mainly grows in the south of China.", {"entities": []}], [7492, "There is a long history of its use for counteracting emesis, abdominal pain and diarrhea without obvious side effects in Asia.", {"entities": [[53, 59, "Pathology"], [61, 75, "Pathology"], [80, 88, "Pathology"], [105, 117, "Pathology"]]}], [7493, "Therefore, A.\u00a0officinarum has been considered for the treatment of NSAIDs-induced gastric diseases [[19], [20], [21], [22]].", {"entities": [[11, 25, "Herb name"], [67, 73, "Drug"]]}], [7494, "Furthermore, our previous studies have preliminarily demonstrated the antiulcer effect of A.\u00a0officinarum extract in an ethanol-induced gastrointestinal injury rat model and pharmacological mechanisms in treating indomethacin-induced gastric injury through cyclooxygenase and non-cyclooxygenase pathways [23,24].", {"entities": [[90, 104, "Herb name"], [135, 158, "Pathology"], [212, 224, "Drug"], [233, 247, "Pathology"], [256, 302, "Target"]]}], [7495, "However, it is also plausible that the effect of reducing the gastric injury could be due to decreasing system exposure of indomethacin and increasing the excretion of indomethacin and its metabolites after oral administration of A.\u00a0officinarum extract to rats.", {"entities": [[62, 76, "Pathology"], [123, 135, "Drug"], [168, 180, "Drug"], [230, 244, "Herb name"]]}], [7496, "Researches on antiulcer effects and action mechanisms of A.\u00a0officinarum induced by indomethacin in rats were previously conducted using molecular biology methods, and further research in terms of pharmacokinetics is necessary to understand the efficacy and safety of A.\u00a0officinarum.", {"entities": [[57, 71, "Herb name"], [83, 95, "Drug"], [267, 282, "Herb name"]]}], [7497, "A.\u00a0officinarum Hance was collected from Xuwen County, Guangdong Province of China, in August 2016 and identified by Prof. Jianping Tian of Hainan Medical University, China.", {"entities": [[0, 14, "Herb name"]]}], [7498, "The plant was deposited at the School of Pharmacy of Hainan Medical University (No.", {"entities": []}], [7499, "20160716).", {"entities": []}], [7500, "The pulverised rhizomes of A.\u00a0officinarum (1\u00a0kg) were weighed precisely and extracted 3 times under reflux with 8-fold 80% ethanol for 1\u00a0h. The combined ethanol extracts were concentrated to 40% and purified with AB-8 macroporous resin by 80% ethanol.", {"entities": [[15, 23, "Herb part"], [27, 41, "Herb name"]]}], [7501, "Then, polysaccharides, monosaccharides, and phenolic acids were removed.", {"entities": []}], [7502, "Indomethacin (purity 99%, CAS 53-86-1) was purchased from Dalian Meilun Biotechnology Co., Ltd (China).", {"entities": [[0, 12, "Drug"]]}], [7503, "The indomethacin metabolites of O-desmethyl indomethacin (ODI; purity 99%, CAS 2504-32-7) and N-deschlorodenzoyl indomethacin (NDI; purity 99%, CAS 2882-15-7), indomethacin acyl-\u03b2-D-glucuronide (IDA\u03b2G; purity 99%, CAS 75523-11-4) and internal standard (IS) of indobufen (purity 99%, CAS  Male Sprague-Dawley (SD) rats (Tianqin Biotechnology, Changsha, China), weighing 220\u2013250\u00a0g, were housed under a 12\u00a0h light/dark cycle at 25\u00a0\u00b0C and allowed ad libitum access to water and food.", {"entities": [[4, 16, "Drug"]]}], [7504, "All rat experiments were performed and approved by per International Guidelines for Care and Use of Laboratory Animals and the Animal Ethics Committee of Hainan Medical University (reg.", {"entities": []}], [7505, "no.", {"entities": []}], [7506, "201506017/HMU).", {"entities": []}], [7507, "All biological samples were analyzed using a Shimadzu LC-20 AD UFLC system (Shimadzu Corp., Tokyo, Japan) coupled to an AB-SCIEX API 4000 plus mass spectrometer (Toronto, Canada) with an electrospray ionization (ESI) source.", {"entities": []}], [7508, "The ultra-fast liquid-tandem mass spectrometry (UFLC-MS/MS) system and data processing were controlled by AB-SCIEX Analyst software.", {"entities": []}], [7509, "Prepared biological samples were separated on a Kinetex XB-C All analytes were measured with optimized multiple reaction monitoring (MRM) in the negative ion mode.", {"entities": []}], [7510, "The parameters of the ESI (\u2212) mode were selected: curtain gas (CUR) at 50 psi; ion spray voltage at\u00a0\u22124.5\u00a0kV; nebulizer N Standard stock solutions of indomethacin, ODI, NDI and IDA\u03b2G were prepared in methanol at 1.2\u00a0mg/mL.", {"entities": [[149, 161, "Drug"]]}], [7511, "The four stock solutions were pooled with the same volume to produce combined standard working solutions at concentrations of 0.3\u00a0mg/mL for every standard.", {"entities": []}], [7512, "IS working solution was diluted with methanol to 4\u00a0\u03bcg/mL.", {"entities": []}], [7513, "All prepared stock and working solutions were stored at\u00a0\u221220\u00a0\u00b0C prior to use.", {"entities": []}], [7514, "Calibration samples were freshly prepared by spiking the appropriate working solutions into the blank matrices (plasma/tissue homogenates/bile/urine/feces homogenates) to achieve the appropriate final concentrations for indomethacin and its three metabolites in different biological matrices.", {"entities": [[220, 232, "Drug"]]}], [7515, "The QC sample concentrations were also prepared using the same method and stored at\u00a0\u221220\u00a0\u00b0C for whole analysis.", {"entities": []}], [7516, "A protein precipitation process was followed for extraction of indomethacin and its metabolites from rat samples (plasma/tissues/bile/urine/feces).", {"entities": [[63, 75, "Drug"]]}], [7517, "An aliquot of 50\u00a0\u03bcL plasma diluted 6- and 30-fold step by step using blank rat plasma, respectively, was precipitated with 290\u00a0\u03bcL methanol-acetonitrile solution (1:1, V/V) after the addition of 10\u00a0\u03bcL IS (indobufen, 4\u00a0\u03bcg/mL).", {"entities": []}], [7518, "The plasma diluted 6-fold was used to analyze the ODI and NDI, and 30-fold diluted plasma was analyzed for indomethacin.", {"entities": [[107, 119, "Drug"]]}], [7519, "Then, the mixtures were vortex-mixed for 10\u00a0min\u00a0at 2000\u00a0rpm and centrifuged at 13,000\u00a0rpm for 10\u00a0min.", {"entities": []}], [7520, "Finally, 5\u00a0\u03bcL of the resultant mixtures were applied for UFLC-MS/MS analysis.", {"entities": []}], [7521, "Tissue samples were homogenized in four parts of ice-cold 0.9% saline solution and then centrifuged at 13000\u00a0rpm for 10\u00a0min to obtain tissue homogenates.", {"entities": []}], [7522, "Tissue homogenates were treated by the same method as plasma sample preparation except dilution process.", {"entities": []}], [7523, "And an aliquot of 10 \u03bcL urine was precipitated with 70\u00a0\u03bcL methanol-acetonitrile solution (1:1, V/V, including 5% formic acid and 80\u00a0ng/mL IS).", {"entities": []}], [7524, "After urine sample extraction, it was vortex-mixed for 10\u00a0min\u00a0at 2000\u00a0rpm and centrifuged at 13,000\u00a0rpm for 10\u00a0min.", {"entities": []}], [7525, "And then 5\u00a0\u03bcL supernatants were injected into the UFLC-MS/MS system to analyze.", {"entities": []}], [7526, "Besides, 10\u00a0\u03bcL of bile samples were mixed with the same volume of 0.5% formic-aqueous solution and then were precipitated with 60\u00a0\u03bcL methanol-acetonitrile solution (1:1, V/V, including 0.5% formic acid and 40\u00a0ng/mL IS).", {"entities": []}], [7527, "After bile samples were extracted, the same treatment methods with urine samples were conducted and used for the bile analysis.", {"entities": []}], [7528, "Feces samples were homogenized in 0.9% saline and then centrifuged at 13,000\u00a0rpm for 15\u00a0min to gather the feces homogenates (4\u00a0\u00b0C).", {"entities": []}], [7529, "The protein precipitation and subsequent experimental methods of feces homogenates were in the same way as those of urine and applied for the feces analysis.", {"entities": []}], [7530, "Seventy-two SD rats were applied to 4 experiments by collecting plasma, tissues, bile, urine and feces, respectively, to investigate the effects of A.\u00a0Officinarum on systemic exposure, tissue distribution and excretion of indomethacin.", {"entities": [[0, 19, "Cohort"], [148, 162, "Herb name"], [222, 234, "Drug"]]}], [7531, "Of them, eighteen rats were randomly divided into 3 groups (model, single- and multiple-dose groups of A.\u00a0officinarum) with six rats in each group and applied to plasma experiment.", {"entities": [[103, 117, "Herb name"]]}], [7532, "The rat gastric ulcer model was induced by indomethacin as described preciously [25].", {"entities": [[8, 21, "Pathology"], [43, 55, "Drug"]]}], [7533, "Briefly, indomethacin (20\u00a0mg/kg of body weight) was orally administered to rats in the model group after 12\u00a0h of fasting.", {"entities": [[9, 21, "Drug"], [23, 31, "Amount"]]}], [7534, "The single-dose group of A.\u00a0officinarum (S-AOE) was pretreated by oral administration of A.\u00a0officinarum ethanol extract (0.18\u00a0g/kg) once 30\u00a0min before receiving indomethacin (20\u00a0mg/kg).", {"entities": [[25, 39, "Herb name"], [89, 103, "Herb name"], [161, 173, "Drug"], [174, 183, "Amount"]]}], [7535, "The multiple-dose group of A.\u00a0officinarum (M-AOE) was pretreated once daily with A.\u00a0officinarum extract (0.18\u00a0g/kg) for 15 days and then indomethacin at an oral dosage of 20\u00a0mg/kg body weight was given to rats 30\u00a0min after the end of the experimental period (15 days).", {"entities": [[27, 41, "Herb name"], [65, 75, "Frequency"], [81, 95, "Herb name"], [104, 114, "Amount"], [120, 127, "Duration"], [137, 149, "Drug"], [171, 179, "Amount"], [259, 266, "Duration"]]}], [7536, "And other experiments were divided into 2 groups: model group and M-AOE group, with six rats in each group.", {"entities": []}], [7537, "Serial blood samples were withdrawn from the orbital sinus into heparin-treated tubes under ether anaesthesia before dosing (0\u00a0min) and 0.167, 0.5, 1, 1.5, 2, 3, 5, 7, 9, 11 and 24\u00a0h after dosing.", {"entities": []}], [7538, "Next, heparinized blood samples were centrifuged at 3000\u00a0rpm for 10\u00a0min\u00a0at room temperature to obtain the plasma fractions.", {"entities": []}], [7539, "Tissue experiment was performed by collecting the kidney, stomach, small intestine, large intestine, liver and spleen at 0.5, 1, 2, 4 and 6\u00a0h after administration.", {"entities": []}], [7540, "These tissues were washed by cold 0.9% physiological saline (4\u00a0\u00b0C) and excess water was drained with filter paper.", {"entities": []}], [7541, "Then tissue samples were accurately weighed and subjected to the processing described in the sample preparation section.", {"entities": []}], [7542, "The whole procedures for treating rat tissues were carried out on the ice surface.", {"entities": []}], [7543, "The rats in bile experiment were fixed on wooden plates and anesthetized with 3% pentobarbital sodium (0.15 mL/100\u00a0g, i.p.).", {"entities": []}], [7544, "Then rats\u2019 abdomen was incised, and the common bile duct was cannulated with polyethylene tubing to collect the bile.", {"entities": []}], [7545, "The bile was collected during 0\u20131\u00a0h, 1\u20132\u00a0h, 2\u20133\u00a0h, 3\u20134\u00a0h, 4\u20135\u00a0h, 5\u20136\u00a0h and 6\u20137\u00a0h after dosing.", {"entities": []}], [7546, "In the course of bile collection, 1\u00a0mL of water was administered via the tail vein to the rats every 2\u00a0h. The rats in urine and feces experiment were kept separate in stainless steel metabolic cages.", {"entities": []}], [7547, "Urine and feces were collected 0\u20136\u00a0h, 6\u201318\u00a0h and 18\u201328\u00a0h after administration.", {"entities": []}], [7548, "Urine at each time point was centrifuged at 3000\u00a0rpm for 10\u00a0min and the supernatant was transferred into clean tubes.", {"entities": []}], [7549, "All biological samples were frozen at\u00a0\u221280\u00a0\u00b0C until assayed.", {"entities": []}], [7550, "The method was fully validated in compliance with the U.S. Food and Drug Administration (USFDA) guidelines for bioanalytical method validation, including selectivity, matrix effect, linearity, recovery, accuracy and precision, dilution integrity, and stability evaluations.", {"entities": []}], [7551, "Non-compartmental pharmacokinetic parameters of all the analytes in rat biological samples were calculated by DAS 3.0 software package (BioGuider Co., Shanghai, China).", {"entities": []}], [7552, "All data obtained from this study were assumed to describe a normal standard distribution and are expressed as the mean\u00a0\u00b1\u00a0standard deviation (SD), along with relative standard deviation (RSD).", {"entities": []}], [7553, "Statistical analysis was performed using a one-way analysis of variance.", {"entities": []}], [7554, "A value of P\u00a0\u2264\u00a00.05 was deemed to be statistically significant.", {"entities": []}], [7555, "The cumulative excretion rates of indomethacin in bile and urine were calculated according to the following formula: cumulative excretion rate (%)\u00a0=\u00a0cumulative excretion/administered dose\u00a0\u00d7\u00a0100%.", {"entities": [[4, 30, "Parameter"], [34, 46, "Drug"]]}], [7556, "All tested analytes and IS were well separated with no significant endogenous or other interfering substances under the established UFLC-MS/MS conditions.", {"entities": []}], [7557, "Typical MS/MS ion spectra of the protonated molecules ([M\u00a0\u2212\u00a0H] Typical MS/MS ion spectra of the protonated molecules ([M\u00a0\u2212\u00a0H] Representative MRM chromatograms of indomethacin, NDI, ODI, IDA\u03b2G and IS in rat liver.", {"entities": [[162, 174, "Drug"]]}], [7558, "(A) Blank liver samples, (B) blank liver samples spiked with four analytes and IS, and (C) liver samples at 30\u00a0min after oral administration of indomethacin solution (20\u00a0mg/kg).", {"entities": [[144, 156, "Drug"], [167, 175, "Amount"]]}], [7559, "Calibration curves and LLOQs of indomethacin and its three metabolites in rat biological samples.", {"entities": []}], [7560, "Pharmacokinetic (PK) parameters of indomethacin and its two metabolites in the model, S-AOE and M-AOE groups in rat plasma.", {"entities": [[35, 47, "Drug"]]}], [7561, "Mean \u00b1 SD, n = 6.", {"entities": []}], [7562, "\u2217P < 0.05 and \u2217\u2217P < 0.01 versus mode group.", {"entities": []}], [7563, "Plasma samples were diluted 6-fold for analysis of ODI and NDI and 30-fold for analysis of indomethacin by reason of the high exposure concentration of indomethacin and its metabolites in rat plasma.", {"entities": [[91, 103, "Drug"], [152, 164, "Drug"]]}], [7564, "The plasma concentration-time curves of three analytes in model, S-AOE and M-AOE groups are presented in Fig.", {"entities": []}], [7565, "3, and main pharmacokinetic parameters are summarized in Table\u00a02.", {"entities": []}], [7566, "Mean (\u00b1SD, n\u00a0=\u00a06) plasma concentration-time profiles of (A) indomethacin, (B)\u00a0ODI and (C)\u00a0NDI in the model, S-AOE and M-AOE groups in rat plasma.", {"entities": []}], [7567, "Numerous studies have demonstrated that pharmacokinetic parameters, tissue distributions, and excretion could be altered by drug-drug, herb-drug or herb-herb interactions [8,9,[26], [27], [28], [29]].", {"entities": []}], [7568, "Therefore, the protective effect of A.\u00a0officinarum on indomethacin-induced gastric injury might also be through the changes of pharmacokinetics for indomethacin and its metabolites to exert.", {"entities": [[36, 50, "Herb name"], [54, 66, "Drug"], [75, 89, "Pathology"]]}], [7569, "In our study, the changing trends in the plasma concentration-time curves of indomethacin in S-AOE and M-AOE groups were similar to those in model group shown in Fig.", {"entities": []}], [7570, "3, but significant differences between AOE groups and model group in the pharmacokinetic parameters of indomethacin can be observed in Table\u00a02.", {"entities": [[103, 115, "Drug"]]}], [7571, "Pharmacokinetic parameters including maximum plasma concentration (C Since pharmacokinetic study results indicated that the method of multiple dosing was more effective, the tissue distribution and excretion experiments were not performed in a single-dose group.", {"entities": [[37, 65, "Parameter"], [174, 207, "Parameter"]]}], [7572, "Tissue distribution profiles of indomethacin and its three metabolites in the model and M-AOE groups are depicted in Fig.\u00a04.", {"entities": [[0, 19, "Parameter"], [32, 44, "Drug"]]}], [7573, "Tissue distribution profiles of indomethacin and its three metabolites in the model and M-AOE groups.", {"entities": [[32, 44, "Drug"]]}], [7574, "Tissue distribution results suggested that indomethacin was rapidly distributed into various tissues, including the kidney, stomach, small intestine, large intestine, liver and spleen, and mainly metabolized as the conjugated form, IDA\u03b2G, which principally existed in the small intestine following in the stomach, liver, kidney, spleen and large intestine in the model group.", {"entities": [[43, 55, "Drug"]]}], [7575, "Interestingly, the concentration of indomethacin was almost unchanged in the small intestine in M-AOE group versus model group but the concentration of IDA\u03b2G was significantly decreased, which might be the cause that A.\u00a0Officinarum promoted IDA\u03b2G metabolized into low molecular weight components by the gut flora or excreted in the bile.", {"entities": [[36, 48, "Drug"]]}], [7576, "And A.\u00a0Officinarum promoted the accumulation of indomethacin in the liver tissue 2\u00a0h after administration in the M-AOE group; thereby it benefited the metabolism of indomethacin by various metabolic enzymes.", {"entities": [[4, 18, "Herb name"], [48, 60, "Drug"], [165, 177, "Drug"]]}], [7577, "However, the concentration of indomethacin in the stomach tissue was not reduced in M-AOE group compared with model group but its metabolites of ODI and IDA\u03b2G were significantly inhibited, indicating that indomethacin was metabolized less in the stomach and A.\u00a0Officinarum was not by means of reducing the accumulation of indomethacin in stomach to exert gastrointestinal protection.", {"entities": [[30, 42, "Drug"], [205, 217, "Drug"], [258, 272, "Herb name"], [322, 334, "Drug"]]}], [7578, "Meanwhile, the concentration of indomethacin in the kindney tissue was decreased after A.\u00a0officinarum treatment, suggesting that A.\u00a0Officinarum did not act by promoting the excretion pathway of indomethacin in the urine.", {"entities": [[32, 44, "Drug"], [87, 101, "Herb name"], [129, 143, "Herb name"], [194, 206, "Drug"]]}], [7579, "In addition, the distributions of indomethacin and its metabolites in the large intestine tissue were all very little, and ODI in M-AOE group was significantly decreased, which might be also the effect of degradation of intestinal flora.", {"entities": [[34, 46, "Drug"], [205, 236, "Pathology"]]}], [7580, "The data in the spleen tissue were not changed statistically and the concentrations of all the analytes were very low.", {"entities": []}], [7581, "Therefore, the protective effect of A.\u00a0Officinarum on the gastrointestinal tract induced by indomethacin did not occur by reducing the accumulation of indomethacin in the target tissue, but might be through the degradation of the gut flora in the small intestine.", {"entities": [[36, 50, "Herb name"], [92, 104, "Drug"], [151, 163, "Drug"], [211, 239, "Pathology"]]}], [7582, "The cumulative excretion profiles of indomethacin and its three metabolites in bile, urine and feces of rats after oral administration in the model and M-AOE groups are presented in Fig.\u00a05.", {"entities": [[4, 24, "Parameter"], [37, 49, "Drug"]]}], [7583, "(A) Biliary, (B)\u00a0urinary and (C)\u00a0fecal cumulative excretion profiles of indomethacin and its three metabolites after oral administration of 20\u00a0mg/kg to rats in the model and M-AOE groups (n\u00a0=\u00a06).", {"entities": [[0, 59, "Parameter"], [72, 84, "Drug"], [140, 148, "Amount"]]}], [7584, "Obviously, all analytes were excreted in the bile after 4\u00a0h of oral dosing in two experimental groups shown in Fig.", {"entities": []}], [7585, "5A and the biliary cumulative excretion of IDA\u03b2G was highest compared with the excretions of all the analytes in the bile, urine and feces (52.82% in model group and 75.86% in M-AOE group within 7\u00a0h), indicating that parent drug indomethacin was mainly metabolized to the phase \u2161 metabolite of IDA\u03b2G in the liver and excreted in the bile.", {"entities": [[11, 39, "Parameter"], [229, 241, "Drug"]]}], [7586, "Furthermore, we found that biliary excretions of indomethacin and its three metabolites in the M-AOE group were significantly more than that in model group, which suggested that co-administration of A.\u00a0Officinarum contributed to increasing the excretions of indomethacin and its metabolites in the bile.", {"entities": [[27, 45, "Parameter"], [49, 61, "Drug"], [258, 270, "Drug"]]}], [7587, "Moreover, the consistent results in Figs.", {"entities": []}], [7588, "5B and C showed that urinary and fecal cumulative excretions of indomethacin and its three metabolites in M-AOE group were all larger than those in the model group except the excretion of indomethacin and ODI in the urine, which were coincident with tissue distribution results that indomethacin was less distributed in the kidney in M-AOE group versus model group.", {"entities": [[21, 60, "Parameter"], [64, 76, "Drug"]]}], [7589, "However, the urinary excretions of indomethacin and its metabolites in both experimental groups were very little (<2%), so that indomethacin was not primarily excreted in the urine.", {"entities": [[13, 31, "Parameter"], [35, 47, "Drug"], [128, 140, "Drug"]]}], [7590, "From the above, the excretion study results indicated that indomethacin was principally excreted in the bile in the form of phase \u2161 metabolite of IDA\u03b2G, and co-administration of A.\u00a0Officinarum could facilitate the excretions of indomethacin and its three metabolites in the bile and feces of rats.", {"entities": [[59, 71, "Drug"], [178, 192, "Herb name"], [228, 240, "Drug"]]}], [7591, "Therefore, one of the reasons for the gastrointestinal protection of A.\u00a0Officinarum might promote excretion effects of indomethacin and its metabolites in the excretory system of rats.", {"entities": [[69, 83, "Herb name"], [119, 131, "Drug"]]}], [7592, "In summary, this study developed and validated a UFLC-MS/MS method for simultaneous determination of indomethacin and its three metabolites and successfully applied it to comparative pharmacokinetic, tissue distribution and excretion studies to expound protective effect of A.\u00a0officinarum against gastric injury induced by indomethacin in rats.", {"entities": [[101, 113, "Drug"], [274, 288, "Herb name"], [297, 311, "Pathology"], [323, 335, "Drug"]]}], [7593, "The results showed that co-administration of A.\u00a0Officinarum produced significant alterations in the pharmacokinetic parameters of indomethacin and reduced the systemic exposure and the retention time of indomethacin, and increased its elimination.", {"entities": [[45, 59, "Herb name"], [130, 142, "Drug"], [203, 215, "Drug"]]}], [7594, "However, A.\u00a0Officinarum did not act by reducing the accumulation of indomethacin in the target tissue of the stomach to exert gastrointestinal protection, but by promoting the excretions of indomethacin and its three metabolites including ODI, NDI and IDA\u03b2G in the bile and feces of rats, and thereby played a significant role in the gastroprotective effect.", {"entities": [[9, 23, "Herb name"], [68, 80, "Drug"], [190, 202, "Drug"]]}], [7595, "The authors declare that there are no conflicts of interest.", {"entities": []}], [7596, "The following is the Supplementary data to this article: This work was financially supported by the  Peer review under responsibility of Xi\u2019an Jiaotong University.", {"entities": []}], [7597, "Supplementary data to this article can be found online at", {"entities": []}], [7598, "Bleeding due to a probable interaction between warfarin and Gouqizi (Lycium Barbarum L.) Jinhua Zhang,a,\u204e Lihong Tian,a and Bixiang Xieb Author information Article notes Copyright and License information PMC Disclaimer Go to: Abstract  Unlike what is widely anticipated by the public, herbal medicines are not always safe despite being natural.", {"entities": [[0, 8, "Pathology"], [47, 55, "Drug"], [60, 88, "Herb name"]]}], [7599, "We describe a 65-year-old Chinese man taking a prolonged maintenance dose of warfarin who experienced an elevated international normalized ratio (INR) with associated bleeding after drinking Gouqizi (goji berry) wine.", {"entities": [[14, 25, "Age"], [26, 33, "Ethnic group"], [34, 37, "Sex"], [77, 85, "Drug"], [114, 150, "Parameter"], [167, 175, "Pathology"], [191, 211, "Herb name"], [212, 216, "Extraction process"]]}], [7600, "This report illustrates that large doses (more than 6\u201312 g) of Gouqizi can significantly enhance the anticoagulant action of warfarin and may cause similar adverse effects in keeping with three previous reports.", {"entities": [[5, 11, "Study"], [42, 58, "Amount"], [63, 70, "Herb name"], [125, 133, "Drug"], [156, 171, "Pathology"], [203, 210, "Study"]]}], [7601, "Therefore, the use of herbal medicines must adhere to pharmacopoeia-recommended guidelines, including dosage regimes.", {"entities": []}], [7602, "Doctors should advise patients regarding possible interactions between herbs and warfarin when prescribing and should increase the frequency of INR monitoring for those patients concurrently receiving warfarin and medicinal herbs.", {"entities": [[81, 89, "Drug"], [144, 147, "Parameter"], [201, 209, "Drug"]]}], [7603, "Further study is needed to do for the mechanism of interaction between Gouqizi and warfarin.", {"entities": [[71, 78, "Herb name"], [83, 91, "Drug"]]}], [7605, "The use of warfarin introduces challenges not only because it is known to have a narrow therapeutic range and risk of bleeding, but also because there are patient variables and potential drug\u2013drug, drug\u2013food and drug\u2013herb interactions that can complicate its management [16].", {"entities": [[11, 19, "Drug"], [118, 126, "Pathology"]]}], [7606, "The dosage of warfarin must be adjusted according to the international normalized ratio (INR) and patients are treated to obtain certain target INR ranges [5].", {"entities": [[14, 22, "Drug"], [57, 93, "Parameter"], [144, 147, "Parameter"]]}], [7607, "If the INR is lower than the target INR, there is the risk of thrombosis; however, if the INR is higher than the target INR, there is a high risk of bleeding.", {"entities": [[7, 10, "Parameter"], [36, 39, "Parameter"], [62, 72, "Pathology"], [90, 93, "Parameter"], [120, 123, "Parameter"], [149, 157, "Pathology"]]}], [7608, "Consequently, in hospital patients are closely monitored and the risk of bleeding and thrombosis are considered, allowing the dose of warfarin to be adjusted as necessary.", {"entities": [[73, 81, "Pathology"], [86, 96, "Pathology"], [134, 142, "Drug"]]}], [7609, "However, when patients are discharged from hospital, there is an increased risk that they may take other medicines and/or herbs, possibly prescribed by another doctor, and that their diet may change, resulting in an increased risk of bleeding or thrombosis due to interactions between warfarin and herbs or foodstuffs.", {"entities": [[234, 242, "Pathology"], [246, 256, "Pathology"], [285, 293, "Drug"]]}], [7610, "In China, traditional Chinese medicine (TCM) is popular for the treatment of minor ailments, such as colds or fevers, and herbs are often prescribed to patients by TCM practitioners.", {"entities": [[22, 29, "Ethnic group"], [101, 106, "Pathology"], [110, 116, "Pathology"]]}], [7611, "In the case of more serious conditions, patients generally combine TCM with Western medicine.", {"entities": [[7, 11, "Study"]]}], [7612, "In addition, culinary herbs are typically consumed seasonally in order to maintain good health.", {"entities": []}], [7613, "Taking into account all of the above, it may be considered that there is an increased risk of drug\u2013herb interactions in patients consuming culinary herbs for medicinal purposes or those taking TCMs, which may lead to the enhanced or reduced effect of warfarin, possibly leading to bleeding or thrombosis.", {"entities": [[251, 259, "Drug"], [281, 289, "Pathology"], [293, 303, "Pathology"]]}], [7614, "TCMs, such as Danshen [3], Ginkgo biloba and Dong quai [4] have been reported to enhance the anticoagulation activity of warfarin, while Panax ginseng [4] has been reported to impede its action.", {"entities": [[14, 21, "Herb name"], [27, 40, "Herb name"], [45, 54, "Herb name"], [121, 129, "Drug"], [137, 150, "Herb name"]]}], [7616, "It belongs to the Solanaceae family and, typically, the dried ripe fruit of Lycium barbarum L. (Ningxia gouqi) are harvested from summer to autumn (Chinese Pharmacopoeia, Fig.", {"entities": [[18, 28, "Herb name"], [56, 72, "Herb part"], [76, 110, "Herb name"]]}], [7617, "1).", {"entities": []}], [7618, "Polysaccharides represent quantitatively the most important group of substances in Lycium barbarum L. [12].", {"entities": [[0, 15, "Herb name"], [83, 101, "Herb name"]]}], [7619, "An external file that holds a picture, illustration, etc.", {"entities": []}], [7620, "Object name is gr1.jpg Fig.", {"entities": []}], [7621, "1  Lycium barbarum L., also known as goji berry and widely used in food and herbal medicine, is defined in the Chinese Pharmacopoeia as Gouqizi.", {"entities": [[3, 21, "Herb name"], [37, 47, "Herb name"], [111, 118, "Ethnic group"], [136, 143, "Herb name"]]}], [7622, "Gouqizi is used in TCM as a mild Yin tonic, enriching Yin in the liver and kidneys whilst moistening lung Yin.", {"entities": [[0, 7, "Herb name"]]}], [7623, "Clinical manifestations derived from Yin deficiencies include blurred vision and diminished visual perception, infertility, abdominal pain, dry cough, fatigue and headaches [12].", {"entities": [[62, 76, "Pathology"], [81, 109, "Pathology"], [111, 122, "Pathology"], [124, 138, "Pathology"], [140, 150, "Pathology"], [151, 158, "Pathology"], [163, 172, "Pathology"]]}], [7624, "Gouqizi is also a popular ingredient in Chinese herbal cuisine and is consumed in soups and porridge, as well as with seafood, meat and vegetables.", {"entities": [[0, 7, "Herb name"], [40, 47, "Ethnic group"]]}], [7625, "For its health benefits, Gouqizi is traditionally consumed in the form of tea, juice or wine in China.", {"entities": [[25, 32, "Herb name"], [74, 77, "Extraction process"], [79, 84, "Extraction process"], [88, 92, "Extraction process"]]}], [7626, "To date, three articles focused on the interaction between Gouqizi and warfarin have been published: two case reports from America [13], [8] and one case from Hong Kong [9].", {"entities": [[59, 66, "Herb name"], [71, 79, "Drug"], [105, 117, "Study"], [149, 153, "Study"]]}], [7627, "In these three cases, Gouqizi was ingested as a form of juice or tea.", {"entities": [[15, 20, "Study"], [22, 29, "Herb name"], [56, 61, "Extraction process"], [65, 68, "Extraction process"]]}], [7628, "In both cases, patient's INR increased after consuming the juice or tea.", {"entities": [[8, 13, "Study"], [25, 28, "Parameter"], [59, 64, "Extraction process"], [68, 71, "Extraction process"]]}], [7629, "In this case report, we provide additional evidence for the interaction between warfarin and Gouqizi contained in a wine product commonly sold in China.", {"entities": [[8, 19, "Study"], [80, 88, "Drug"], [93, 100, "Herb name"]]}], [7630, "Go to: 1.", {"entities": []}], [7631, "Case report  A 65-year-old Chinese man with a history of prosthetic heart valve replacement had been stabilized on warfarin anticoagulation therapy for two years.", {"entities": [[0, 11, "Study"], [15, 26, "Age"], [27, 34, "Sex"], [35, 38, "Sex"], [57, 91, "Pathology"], [115, 147, "Drug"], [152, 161, "Duration"]]}], [7632, "He has no other medical conditions and his only medication was warfarin.", {"entities": [[63, 71, "Drug"]]}], [7633, "The patient was compliant regarding the attendance of appointments and in taking the medication, and maintained a therapeutic INR (1.7\u20132.5) on a maintenance daily dose of 1.875 mg warfarin with monthly INR monitoring.", {"entities": [[126, 129, "Parameter"], [131, 138, "Amount"], [157, 162, "Frequency"], [171, 179, "Amount"], [180, 188, "Drug"], [206, 216, "Parameter"]]}], [7634, "The patient did not exhibit symptoms of ecchymosis, nosebleeds, bleeding gums or blood clots and denied drinking and smoking.", {"entities": [[40, 50, "Pathology"], [52, 62, "Pathology"], [64, 77, "Pathology"], [81, 92, "Pathology"]]}], [7635, "On the morning of November 10, 2013, the patient developed macroscopic hematuria and consequently attended hospital.", {"entities": [[59, 80, "Pathology"]]}], [7636, "The urine test results confirmed hematuria with an abnormal urinary red blood cell count of 33201.5/\u03bcl (the normal range is 0\u201323/\u03bcl) and an INR of 3.84.", {"entities": [[33, 42, "Pathology"], [60, 88, "Parameter"], [92, 102, "Amount"], [140, 143, "Parameter"], [147, 151, "Amount"]]}], [7637, "The patient did not report any change in the state of his condition and denied taking any additional medication or a change in diet or lifestyle; however, he indicated that he had consumed 20 ml of Gouqizi wine in the evening on November 9 on the advice of a friend as he was suffering from blurred vision.", {"entities": [[189, 194, "Amount"], [198, 205, "Herb name"], [206, 210, "Extraction process"], [291, 305, "Pathology"]]}], [7638, "Although the patient was aware that the wine could influence the therapeutic effect of warfarin, he had previously consumed 60 ml of wine (not containing Gouqizi) and not experienced any negative effects.", {"entities": [[40, 44, "Extraction process"], [87, 95, "Drug"], [154, 161, "Herb name"]]}], [7639, "Application of the Naranjo Adverse Drug Reaction (ADR) Scale [11] indicated a probable relationship (score of 6) between the elevated INR with hematuria and the patient\u2019s concomitant use of warfarin and Gouqizi.", {"entities": [[19, 26, "Herb name"], [134, 137, "Parameter"], [143, 152, "Pathology"], [190, 198, "Drug"], [203, 210, "Herb name"]]}], [7640, "The patient was advised to discontinue the use of Gouqizi wine and to abstain from warfarin for 2 days.", {"entities": [[50, 57, "Herb name"], [58, 62, "Extraction process"], [83, 91, "Drug"], [92, 102, "Duration"]]}], [7641, "On the morning of November 11, the patient continued to see blood in the urine, with diminished color intensity; by the evening, the hematuria had resolved.", {"entities": [[60, 78, "Pathology"], [133, 142, "Pathology"]]}], [7642, "On November 12, the patient's INR was 2.12 and urine test results were normal with a urinary red blood cell count of 11/\u03bcl.", {"entities": [[30, 33, "Parameter"], [38, 42, "Amount"], [85, 113, "Parameter"], [117, 122, "Amount"]]}], [7643, "He continued warfarin at a daily dose of 1.875 mg and the INR was found to be 2.0 after 1 week (Table 2).", {"entities": [[13, 21, "Drug"], [27, 32, "Frequency"], [41, 49, "Amount"], [58, 61, "Parameter"], [78, 81, "Amount"]]}], [7644, "Table 2  INR vs warfarin dose (mg) before and after consumption of Gouqizi wine.", {"entities": [[9, 12, "Parameter"], [16, 24, "Drug"], [67, 74, "Herb name"], [75, 79, "Extraction process"]]}], [7645, "16-Jul-2013\t19-Aug-2013\t17-Sept-2013\t16-Oct-2013\t10-Nov-2013\t11-Nov-2013\t12-Nov-2013\t19-Nov- 2013 INR\t2.11\t2.1\t1.91\t2.46\t3.84\t\u2013\t2.12\t2.0 Warfarin (mg)\t1.875\t1.875\t1.875\t1.875\t\u2013\t\u2013\t1.875\t1.875 Open in a separate window Go to: 2.", {"entities": [[137, 145, "Drug"]]}], [7646, "Discussion  Gouqizi is a highly nutritional fruit, which has been used for more than 2000 years in China for the prevention and treatment of disease as part of TCM with early records dating back to the Tang Dynasty (1000\u20131400 AD) [2].", {"entities": [[12, 19, "Herb name"], [44, 49, "Herb part"]]}], [7647, "TCM uses both the fruit and root bark of Lycium barbarum L., where the fruit (Gouqizi) is used to tonify Yin, while the root bark (Digupi) is used to \u201cclean\u201d the heart.", {"entities": [[18, 23, "Herb part"], [28, 37, "Herb part"], [41, 59, "Herb name"], [71, 76, "Herb part"], [78, 85, "Herb name"], [120, 138, "Herb part"]]}], [7648, "Nowadays, Gouqizi is widely used for its anti-aging properties and as a health food worldwide.", {"entities": [[10, 17, "Herb name"]]}], [7649, "Previously, Amagase et al.", {"entities": []}], [7650, "[1] showed that Gouqizi has a high nutrient value and contains high levels of antioxidants, with 68% carbohydrate, 12% protein, 10% fiber and 10% fat.", {"entities": [[16, 23, "Herb name"]]}], [7651, "In this case report, the Naranjo ADR score of 6 showed that the patient's elevated INR and related bleeding may be due to an interaction between warfarin and Gouqizi wine.", {"entities": [[8, 19, "Study"], [25, 32, "Herb name"], [83, 86, "Parameter"], [99, 107, "Pathology"], [145, 153, "Drug"], [158, 165, "Herb name"], [166, 170, "Extraction process"]]}], [7652, "Karlson et al.", {"entities": []}], [7653, "[7] previously showed that administration of 375 ml wine did not result in thrombin times (TTs) outside the therapeutic range, which suggested that a moderate intake of alcohol occasionally may be acceptable during anticoagulant therapy.", {"entities": [[45, 51, "Amount"], [52, 56, "Extraction process"], [75, 95, "Parameter"], [215, 236, "Drug"]]}], [7654, "In this case, the patient had previously consumed 60 ml of wine without a negative effect, suggesting that the reported hematuria was not due to the alcohol content of the herbal wine.", {"entities": [[8, 12, "Study"], [50, 55, "Amount"], [59, 63, "Extraction process"], [120, 129, "Pathology"], [179, 183, "Extraction process"]]}], [7655, "Furthermore, we eliminated the influence of another disease (such as fever, diarrhea, thyroid hyperfunction, etc.", {"entities": [[69, 74, "Pathology"], [76, 84, "Pathology"], [86, 107, "Pathology"]]}], [7656, "), other drugs (antibiotics, statins, amiodarone, etc.)", {"entities": [[16, 27, "Drug"], [29, 36, "Drug"], [38, 48, "Drug"]]}], [7657, "or other herbs (Danshen, Ginkgo biloba, Dong quai, etc.).", {"entities": [[16, 23, "Herb name"], [25, 38, "Herb name"], [40, 49, "Herb name"]]}], [7658, "The patient did not report any changes to his lifestyle or diet.", {"entities": []}], [7659, "As such, we considered that Gouqizi may have enhanced the effect of warfarin, thus leading to the occurrence of hematuria.", {"entities": [[28, 35, "Herb name"], [68, 76, "Drug"], [112, 121, "Pathology"]]}], [7660, "In China, Gouqizi is a popular component of the daily diet, making the prohibition of its consumption in patients taking warfarin difficult to implement.", {"entities": [[10, 17, "Herb name"], [121, 129, "Drug"]]}], [7662, "Furthermore, symptoms induced by the interaction between Gouqizi and warfarin can be managed by withholding warfarin or the use of vitamin K (Table 1).", {"entities": [[57, 64, "Herb name"], [69, 77, "Drug"], [108, 116, "Drug"], [131, 140, "Drug"]]}], [7663, "However, it is important to establish the dosage of Gouqizi that can enhance the effect of warfarin.", {"entities": [[52, 59, "Herb name"], [91, 99, "Drug"]]}], [7664, "The little study in Appendix A showed that 6 g of Gouqizi daily is a safe dose for patients taking warfarin.", {"entities": [[43, 46, "Amount"], [50, 57, "Herb name"], [58, 63, "Frequency"], [99, 107, "Drug"]]}], [7665, "Table 1  Case reports describing interactions between warfarin and Gouqizi.", {"entities": [[9, 21, "Study"], [54, 62, "Drug"], [67, 74, "Herb name"]]}], [7666, "Case\tLocation\tIndication\tGouqizi form\tGouqizi dose\tINR before Gouqizi\tINR after Gouqizic\tTreatment Lam and Elmer [8]\tSeattle, WA, USA\tAFa\tTea\t72\u223c96 oz\t2.5\t4.1\tWarfarin withheld for 1 day Leung et al.", {"entities": [[25, 32, "Herb name"], [38, 45, "Herb name"], [51, 54, "Parameter"], [62, 69, "Herb name"], [70, 73, "Parameter"], [80, 88, "Herb name"], [138, 141, "Extraction process"], [159, 167, "Drug"], [177, 182, "Duration"]]}], [7667, "[9]\tHong Kong, China\tAFa\tTea\t50 g\t3.0\t4.97\tWarfarin withheld for 2 days 40 g\t2.75\t3.86\tWarfarin withheld for 2 days Rivera et al.", {"entities": [[25, 28, "Extraction process"], [29, 33, "Amount"], [43, 51, "Drug"], [61, 71, "Duration"], [72, 76, "Amount"], [105, 115, "Duration"]]}], [7669, "bPHV: prosthetic heart valve.", {"entities": [[1, 28, "Pathology"]]}], [7671, "In China it is common to use Western medicine alongside TCM to treat disease and this may explain the increased risk of warfarin-induced bleeding in China compared to other countries [10].", {"entities": [[120, 128, "Drug"], [137, 145, "Pathology"]]}], [7672, "Due to public concern regarding the risk of bleeding during treatment with warfarin, as well as the uneasy relationship between allopathic doctors and their patients, no more than 10% of patients with atrial fibrillation take warfarin in China [5].", {"entities": [[44, 52, "Pathology"], [75, 83, "Drug"], [201, 220, "Pathology"], [226, 234, "Drug"]]}], [7673, "Thus, we encourage the collection and publication of data focused on the interactions between TCMs and warfarin, as well as the consequential risk of bleeding or thrombosis, to promote the use of warfarin in Chinese patients and to better prevent thrombi.", {"entities": [[103, 111, "Drug"], [150, 158, "Pathology"], [162, 172, "Pathology"], [196, 204, "Drug"], [247, 254, "Pathology"]]}], [7674, "Such data may also alert doctors from all countries to the risk of warfarin-induced bleeding due to the effects of TCMs.", {"entities": [[67, 75, "Drug"], [84, 92, "Pathology"]]}], [7675, "Go to: 3.", {"entities": []}], [7676, "Conclusion  This case revealed that Gouqizi can enhance the anticoagulant effect of warfarin and may consequently cause bleeding.", {"entities": [[17, 21, "Study"], [36, 43, "Herb name"], [84, 92, "Drug"], [120, 128, "Pathology"]]}], [7677, "However, a daily Gouqizi dose of 6 g (dosing recommended by Chinese Pharmacopoeia) for 3 days did not enhance the effects of warfarin in three patients with prosthetic heart values who were concomitantly taking warfarin.", {"entities": [[11, 16, "Frequency"], [17, 24, "Herb name"], [33, 36, "Amount"], [60, 67, "Ethnic group"], [83, 93, "Duration"], [125, 133, "Drug"], [157, 173, "Pathology"], [211, 219, "Drug"]]}], [7678, "Further study is needed to establish the dose of Gouqizi that can have an additive effect on the anticoagulant activity of warfarin.", {"entities": [[49, 56, "Herb name"], [123, 131, "Drug"]]}], [7679, "Pharmacists and doctors who manage anticoagulation clinics should pay particular attention to patients who take warfarin concomitantly with TCMs and INR monitoring should be increased in such patients.", {"entities": [[112, 120, "Drug"], [149, 152, "Parameter"]]}], [7680, "Furthermore, patients should be better educated with regards to the possible interactions between warfarin and herbal medicines.", {"entities": [[98, 106, "Drug"]]}], [7681, "Go to: Conflict of interests  There is no conflict of interests.", {"entities": []}], [7682, "Go to: Acknowledgements  This work was supported by grants from the Scientific Research Foundation for the Returned Overseas Chinese Scholars, State Education Ministry (No.", {"entities": [[125, 132, "Ethnic group"]]}], [7683, "2015B001) and the Fujian Medical Innovation Project (No.", {"entities": []}], [7684, "2014-CX-18).", {"entities": []}], [7685, "Go to: Appendix A.", {"entities": []}], [7686, "The interaction study of warfarin and Lycium barbarum L.  Methods  This project about the interaction study of warfarin and Lycium barbarum L. is approved by Fujian Medical University Union Hospital ethics committee (NO: 2015KY002).", {"entities": [[25, 33, "Drug"], [38, 56, "Herb name"], [111, 119, "Drug"], [124, 142, "Herb name"]]}], [7687, "This study required patients who had taken warfarin for at least three monthes.", {"entities": [[43, 51, "Drug"], [52, 78, "Duration"]]}], [7688, "Three patients with prosthetic heart valves were included in this study.", {"entities": [[0, 14, "Cohort"], [20, 43, "Pathology"]]}], [7689, "A starting INR was taken before taking Gouqizi, and then Gouqizi (6 g) was administered as a tea for three consecutive days, then the INR was taken in the fourth day.", {"entities": [[11, 14, "Parameter"], [39, 46, "Herb name"], [57, 64, "Herb name"], [66, 69, "Amount"], [93, 96, "Extraction process"], [97, 123, "Duration"], [134, 137, "Parameter"]]}], [7690, "Results and discussion  The results showed that, during the 3-day study period when the patients concurrently took warfarin (no other medication), a daily dose of 6 g (dosing recommended by Chinese Pharmacopoeia is 6\u201312 g daily) Gouqizi (total dose: 18 g) did not affect the INR, which remained within the target range (1.7\u20132.5) for all three patients (Fig.", {"entities": [[60, 65, "Duration"], [115, 123, "Drug"], [149, 154, "Frequency"], [163, 166, "Amount"], [190, 197, "Ethnic group"], [215, 221, "Amount"], [222, 227, "Frequency"], [229, 236, "Herb name"], [250, 254, "Amount"], [275, 278, "Parameter"], [320, 327, "Amount"], [337, 351, "Cohort"]]}], [7691, "2), suggesting that this may represent a safe dose.", {"entities": []}], [7692, "In these four cases in Table 1, the dosing of Gouqizi is larger (case 1 is 72\u201396 OZ; case 2 is 50 g and 40 g; case 3 is 240 ml; case 4 is 20 ml).", {"entities": [[14, 19, "Study"], [46, 53, "Herb name"], [65, 69, "Study"], [85, 89, "Study"], [95, 99, "Amount"], [104, 108, "Amount"], [110, 114, "Study"], [120, 126, "Amount"], [128, 132, "Study"], [138, 143, "Amount"]]}], [7693, "So maybe it is safe for patients who take warfarin concomitantly with Gouqizi 6 g daily, and it is unsafe for patients who take warfarin concomitantly with Gouqizi more than 6 g daily.", {"entities": [[42, 50, "Drug"], [70, 77, "Herb name"], [78, 81, "Amount"], [82, 87, "Frequency"], [128, 136, "Drug"], [156, 163, "Herb name"], [174, 177, "Amount"], [178, 183, "Frequency"]]}], [7694, "However, the limitations of this small study should be considered in the interpretation of these results as it was not convenient to collect the patients' blood samples for further determination of drug concentrations in the blood because the patients lived in various regions of the Fujian province.", {"entities": []}], [7695, "Thus, further research is needed to establish a safe dose of Gouqizi to use alongside warfarin treatment and to study the possible mechanism of interaction between Gouqizi and warfarin.", {"entities": [[61, 68, "Herb name"], [86, 94, "Drug"], [164, 171, "Herb name"], [176, 184, "Drug"]]}], [7696, "Hibiscus sabdariffa L. in the treatment of hypertension and hyperlipidemia: a comprehensive review of animal and human studies Allison L. Hopkins, PhD,a,* Marnie G. Lamm, MD,a Janet Funk, MD,b and Cheryl Ritenbaugh, PHD, MPHa Author information Copyright and License information PMC Disclaimer The publisher's final edited version of this article is available at Fitoterapia Go to: Abstract  The effectiveness of Hibiscus sabdariffa L. (HS) in the treatment of risk factors associated with cardiovascular disease is assessed in this review by taking a comprehensive approach to interpreting the randomized clinical trial (RCT) results in the context of the available ethnomedical, phytochemical, pharmacological, and safety and toxicity information.", {"entities": [[0, 22, "Herb name"], [43, 55, "Pathology"], [60, 74, "Pathology"], [76, 126, "Study"], [413, 440, "Herb name"], [490, 512, "Pathology"], [533, 539, "Study"], [591, 626, "Study"]]}], [7697, "HS extracts have a low degree of toxicity with a LD50 ranging from 2,000 to over 5,000 mg/kg/day.", {"entities": [[0, 11, "Herb name"], [33, 41, "Pathology"], [49, 53, "Parameter"], [62, 96, "Amount"]]}], [7698, "There is no evidence of hepatic or renal toxicity as the result of HS extract consumption, except for possible adverse hepatic effects at high doses.", {"entities": [[24, 49, "Pathology"], [67, 77, "Herb name"], [111, 134, "Pathology"]]}], [7699, "There is evidence that HS acts as a diuretic, however in most cases the extract did not significantly influence electrolyte levels.", {"entities": [[23, 25, "Herb name"], [36, 44, "Pathology"], [112, 130, "Parameter"]]}], [7700, "Animal studies have consistently shown that consumption of HS extract reduces blood pressure in a dose dependent manner.", {"entities": [[0, 14, "Study"], [59, 69, "Herb name"], [78, 92, "Parameter"]]}], [7701, "Total cholesterol, low-density lipoprotein cholesterol (LDL-C), and triglycerides were lowered in the majority of normolipidemic, hypolipidemic, and diabetic animal models, whereas high-density lipoprotein cholesterol (HDL-C) was generally not affected by the consumption of HS extract.", {"entities": [[0, 17, "Parameter"], [19, 62, "Parameter"], [68, 81, "Parameter"], [114, 128, "Pathology"], [130, 143, "Pathology"], [149, 157, "Pathology"], [181, 225, "Parameter"], [275, 285, "Herb name"]]}], [7702, "Keywords: Hibiscus sabdariffa L., Roselle, hypertension, cholesterol, randomized clinical trials, ethnopharmacology Go to: 1.", {"entities": [[10, 32, "Herb name"], [34, 41, "Herb name"], [43, 55, "Pathology"], [57, 68, "Parameter"], [70, 96, "Study"]]}], [7703, "Two systematic reviews have been published on the effectiveness of HS for the treatment of hypertension [1, 2].", {"entities": [[4, 22, "Study"], [67, 69, "Herb name"], [91, 103, "Pathology"]]}], [7704, "However Ngamjarus and colleagues [2] excluded all randomized clinical trials (RCTs) as being of too low quality, and Wahabi and colleagues [1] established the quality of studies using the Jadad scale, a scale which focuses exclusively on randomization, blinding and participant withdrawals [3\u20136].", {"entities": [[50, 83, "Study"]]}], [7705, "Both reviews determined that the evidence available at the time of review was inconclusive.", {"entities": [[5, 12, "Study"]]}], [7706, "However, subsequent to the publication of these two previous reviews, expanded criteria allowing for a more comprehensive evaluation of the totality of evidence related to the medicinal use of botanicals have been proposed by Fonnebo and colleagues [7].", {"entities": [[61, 68, "Study"]]}], [7707, "This review applies these updated and expanded criteria to assess data related to the use of HS for hypertension, including data from a high quality study published subsequent to earlier reviews [8].", {"entities": [[5, 11, "Study"], [93, 95, "Herb name"], [100, 112, "Pathology"], [187, 194, "Study"]]}], [7708, "Furthermore, to obtain a more complete view of potential protective effects of HS as relates to cardiovascular disease, evidence related to HS effects on cholesterol metabolism are also reviewed.", {"entities": [[79, 81, "Herb name"], [96, 118, "Pathology"], [140, 142, "Herb name"], [154, 165, "Parameter"]]}], [7709, "These data are reviewed in the context of ethnomedicinal information on HS use, preparation, and dosage and updated phytochemical, pharmacological, and toxicological information on HS, which was last reviewed by Ali and colleagues in 2005 [9].", {"entities": [[72, 74, "Herb name"], [181, 183, "Herb name"]]}], [7710, "The objective of this review is to:      Examine the evidence of the effectiveness of HS on cardiovascular risk factors based on ethnomedicinal, safety and toxicity, pharmacological, phytochemical information  Go to: 2.", {"entities": [[22, 28, "Study"], [86, 88, "Herb name"], [92, 119, "Pathology"]]}], [7711, "Methods 2.1.", {"entities": []}], [7712, "Information Sources  The following databases were searched from commencement to November 14, 2012: AGRICOLA, AMED, BIOSIS Previews, Cochrane Library, International Pharmaceutical Abstracts, ISI Web of Knowledge, MEDLINE, Pubmed, Natural Medicines Comprehensive Database.", {"entities": []}], [7714, "Additionally, original articles were retrieved from existing reviews [1, 2, 9] and re-reviewed.", {"entities": [[61, 68, "Study"]]}], [7715, "2.2.", {"entities": []}], [7716, "Search  We used the search terms of Hibiscus or Hibiscus sabdariffa and hypertension or cholesterol.", {"entities": [[36, 44, "Herb name"], [48, 67, "Herb name"], [72, 84, "Pathology"], [88, 99, "Parameter"]]}], [7717, "Using the additional search terms of the common names for HS, including Sour Tea, Roselle, Red Sorrel, Karkade, Jamaica, or Flor de Jamaica, or herbal tea or herbal medicine in combination with high blood pressure, elevated blood pressure, hypertension, pre-hypertension, mild hypertension, or dyslipidemia, hypercholesterolemia, lipid profiles, hypolipidemic effect, hyperlipidemic, or atherosclerosis did not yield any further results.", {"entities": [[58, 60, "Herb name"], [72, 80, "Herb name"], [82, 173, "Herb name"], [199, 213, "Parameter"], [224, 238, "Parameter"], [240, 402, "Pathology"]]}], [7718, "The literature search using keywords \u201chypertension\u201d and \u201chibiscus\u201d resulted in the retrieval of 154 titles, 70 of which were duplicates and 28 were regarding species or conditions not focused on in this review.", {"entities": [[38, 50, "Pathology"], [57, 65, "Herb name"], [203, 209, "Study"]]}], [7719, "After removing irrelevant articles, 77 articles remained for review, of which 5 were RCTs [8, 10\u201313].", {"entities": [[61, 67, "Study"], [85, 89, "Study"]]}], [7720, "In the second literature search \u201chibiscus\u201d was kept as a keyword and \u201chypertension\u201d was replaced with \u201ccholesterol\u201d.", {"entities": [[33, 41, "Herb name"], [70, 82, "Pathology"], [103, 114, "Parameter"]]}], [7721, "The search yielded 167 total titles, of which 58 duplicates and 30 articles were removed because they focused on irrelevant species or conditions.", {"entities": []}], [7722, "The remaining 79 articles were reviewed, 5 of which were RCTs [14\u201318].", {"entities": [[57, 61, "Study"]]}], [7723, "2.3.", {"entities": []}], [7724, "Data Collection Process and Data Items  The articles identified using the aforementioned search strategy were sorted into the following categories: ethnobotany, safety and toxicity, pharmacology, with animal and human studies in separate categories, and phytochemistry.", {"entities": [[201, 225, "Study"]]}], [7725, "The data from the RCT studies were extracted and categorized by two authors (AH and ML) and presented in appropriate sections.", {"entities": [[18, 29, "Study"]]}], [7726, "The quality of trial and herbal intervention reporting in the RCTs was assessed by the same authors through determining the percentage of items reported from herbal interventions elaboration of the 2001 Consolidated Standards of Reporting Trials (CONSORT) statement, as these reflect the industry standard for the minimum information necessary for reporting RCTs at the time most of the trials in this review were carried out [4, 19, 20].", {"entities": [[15, 20, "Study"], [62, 66, "Study"], [239, 245, "Study"], [358, 362, "Study"], [387, 393, "Study"], [402, 408, "Study"]]}], [7727, "Go to: 3.", {"entities": []}], [7728, "Ethnomedicinal Uses and Preparation  HS is consumed as a beverage in the United States [8], Mexico [11, 13, 16], Nigeria and other West African countries [21\u201325], Egypt [26], Iran [10, 14, 18], India [17, 27, 28], Thailand [29], and Tawian [15, 30, 31], among other countries.", {"entities": [[37, 39, "Herb name"]]}], [7729, "Ethnomedicinal studies have reported the use of HS for the treatment of various cardiovascular risk factors including hypertension in Egypt, Jordan, and Trinidad and Tobago [32\u201335], hypotension in Jordan and Iraq [34, 36], hyperlipidemia in Jordan, Greece, Brazil, and Trinidad and Tobago [33, 35, 37, 38], and obesity in Iraq, Greece, and Brazil [36\u201338].", {"entities": [[48, 50, "Herb name"], [80, 107, "Pathology"], [118, 130, "Pathology"], [182, 193, "Pathology"], [223, 237, "Pathology"], [311, 318, "Pathology"]]}], [7730, "The flowers, or more specifically the calyxes, are typically prepared using an aqueous decoction or infusion [32, 33, 36, 38].", {"entities": [[0, 11, "Herb part"], [34, 45, "Herb part"], [76, 108, "Extraction process"]]}], [7731, "However, the Bedouins in the North Badia region of Jordan use the leaves, as well as the flowers, and they drink the infusions hot when treating high blood pressure and cold when treating low blood pressure [34].", {"entities": [[9, 21, "Ethnic group"], [62, 72, "Herb part"], [85, 96, "Herb part"], [113, 126, "Extraction process"], [150, 164, "Parameter"], [192, 206, "Parameter"]]}], [7732, "In Trinidad and Tobago only the leaves are used to treat high blood pressure and the flower and seeds are used to treat high cholesterol [35].", {"entities": [[28, 38, "Herb part"], [62, 76, "Parameter"], [81, 101, "Herb part"], [125, 136, "Parameter"]]}], [7733, "Dosing was only described in 1 [36] of the 7 ethnobotancial studies reviewed.", {"entities": []}], [7734, "Go to: 4.", {"entities": []}], [7735, "Phytochemical Properties  The main compounds found in HS flowers are organic acids, mainly citric and malic acids, anthocyanins, a myriad of flavonoids and glycosides, and fiber [9, 39\u201341].", {"entities": [[54, 56, "Herb name"], [57, 64, "Herb part"], [69, 177, "Herb name"]]}], [7736, "The calyxes have the same organic acid and anthocyanin constituents, but the presence of flavonoids and glycosides is minimal [9].", {"entities": [[0, 11, "Herb part"], [26, 67, "Herb name"], [89, 114, "Herb name"]]}], [7737, "Anthocyanins, particularly delphinidin-3-sambubioside and cyanidin-3-sambubioside, are generally believed to be the active constituents responsible for the antihypertensive, antioxidant, and hypocholesterolemic effects of HS, possibly because they are found in high relative quantities in aqueous extracts [8, 11, 13, 16].", {"entities": [[0, 81, "Herb name"], [156, 210, "Pathology"], [222, 224, "Herb name"], [289, 305, "Extraction process"]]}], [7738, "Hibiscus acid may also be playing a role in lower blood pressure and cholesterol [43].", {"entities": [[0, 13, "Herb name"], [50, 64, "Parameter"], [69, 80, "Parameter"]]}], [7739, "The plant parts used, the color of the parts, the harvesting practices and the preparation method greatly influence the volatile composition of the extract and influence dosing [9].", {"entities": []}], [7740, "The HS varieties with deeper red calyxes exhibited greater antioxidant activity as compared to lighter red or white varieties [44, 45].", {"entities": [[4, 6, "Herb name"], [33, 40, "Herb part"], [59, 79, "Pathology"]]}], [7741, "Greater antioxidant activity was found in flowers that were harvested at 35 days after flowering as compared to less mature flowers [45].", {"entities": [[8, 28, "Pathology"], [42, 49, "Herb part"]]}], [7742, "However, aqueous extractions are appropriate for studies interested in testing the effectiveness of traditional preparation practices and capturing the broad public health implications of this herbal treatment.", {"entities": [[9, 28, "Extraction process"]]}], [7743, "Very little research has been done on the bioavailability of HS extract.", {"entities": [[61, 71, "Herb name"]]}], [7744, "McKay and colleagues [8] provide the only exception in their clinical trial where they brewed HS tea by steeping 1,250 mg of dried HS in 240 mL of boiled water, administering one such serving three times a day.", {"entities": [[61, 75, "Study"], [94, 96, "Herb name"], [97, 100, "Extraction process"], [113, 121, "Amount"], [125, 133, "Herb name"], [137, 143, "Amount"], [147, 159, "Extraction process"], [192, 209, "Frequency"]]}], [7745, "No anthocyanins were detected in the urine within one hour of consumption of this HS tea, which contained 22 mg gallic acid equivalents (GAE) total phenols, 7 mg cyanidin glucoside equivalents (CGE) total anthocyanins, 4 mg CGE delphinidin-3-sambubioside, 0.02 mg CGE cyanidin-3-sambubioside, and 1950 \u00b5mol trolox equivalents/g oxygen radical absorbance capacity (ORAC).", {"entities": [[3, 15, "Herb name"], [82, 84, "Herb name"], [85, 88, "Extraction process"], [106, 111, "Amount"], [112, 155, "Herb name"], [157, 161, "Amount"], [162, 217, "Herb name"], [219, 223, "Amount"], [224, 254, "Herb name"], [256, 263, "Amount"], [264, 291, "Herb name"], [297, 306, "Amount"], [307, 369, "Parameter"]]}], [7746, "Go to: 5.", {"entities": []}], [7747, "Safety and Toxicity  Studies carried out in animals and humans have primarily demonstrated either no change or decreases in measures related to function of the liver (AST and ALT liver enzymes [16, 46, 47]) or kidney (creatinine [16, 18, 22, 23, 31, 46, 48], blood urea nitrogen [18, 31], and urea [16]) function (Table 1).", {"entities": [[167, 192, "Parameter"], [218, 228, "Parameter"], [259, 278, "Parameter"], [293, 297, "Parameter"]]}], [7748, "However, at doses of 300 mg/kg/day of HS over a 3 month period, an adverse effect on liver enzymes was observed, suggesting that at very high doses the extract could be hepatotoxic [46].", {"entities": [[21, 24, "Amount"], [25, 34, "Frequency"], [38, 40, "Herb name"], [48, 62, "Duration"], [67, 81, "Pathology"], [148, 159, "Herb name"], [169, 180, "Pathology"]]}], [7749, "Uric acid levels were reported to be elevated in rodents given extremely high doses of HS, a potential adverse effect that could exacerbate or contribute to the development of gout [23].", {"entities": [[0, 16, "Parameter"], [87, 89, "Herb name"], [103, 117, "Pathology"], [176, 180, "Pathology"]]}], [7750, "Table 1  Effect of administration of HS extracts on creatinine, urea, AST, ALT, and electrolyte levels in rodents and humans.", {"entities": [[37, 48, "Herb name"], [52, 102, "Parameter"]]}], [7751, "HS consumption in most cases had no significant effect on electrolytes, including magnesium, sodium, potassium, and/or chlorine/chloride [11, 13, 18, 22, 49], although sodium [13] and chlorine levels [11] in humans increased statistically significantly from baseline to final measurement at 30 days of receiving HS extract.", {"entities": [[0, 2, "Herb name"], [58, 136, "Parameter"], [168, 174, "Parameter"], [184, 199, "Parameter"], [312, 322, "Herb name"]]}], [7752, "The diuretic behavior of HS extract in these two studies has been compared to the potassium sparing group of diuretic pharmaceuticals, such as Spironolactone or aldosterone antagonists [11, 13].", {"entities": [[4, 12, "Pathology"], [25, 35, "Herb name"], [109, 117, "Pathology"], [143, 157, "Drug"], [161, 184, "Drug"]]}], [7753, "A few other studies among animals suggest that HS extracts have a low degree of acute toxicity with the median lethal dose (LD50) ranging from 2,000 to over 5,000 mg/kg [23, 46, 49].", {"entities": [[47, 58, "Herb name"], [80, 94, "Pathology"], [100, 129, "Parameter"], [138, 168, "Amount"]]}], [7754, "In contrast, one studied showed that doses as high as 4,600 mg/kg can be administered for several months in an animal model with no report of mortality, although negative effects on testes and sperm count were found [50].", {"entities": [[54, 65, "Amount"], [86, 104, "Duration"]]}], [7755, "The variation in these findings may be due to the type of solvents used for extraction, the method and length of administration and the variety of HS used [46].", {"entities": [[147, 149, "Herb name"]]}], [7756, "Herb-drug interactions between HS and hydrochlorothiazide (HCTZ) [49], a commonly prescribed diuretic medication, and acetaminophen [51], an antipyretic-analgesic over-the-counter medication, were examined.", {"entities": [[31, 33, "Herb name"], [38, 112, "Drug"], [118, 162, "Drug"]]}], [7757, "Co-administration of HS extract (40 mg/kg) and HCTZ (10 mg/kg) in rats caused a significant increase in the volume of urine excreted, but electrolyte levels were more similar to controls than HCTZ alone [49].", {"entities": [[21, 31, "Herb name"], [33, 41, "Amount"], [47, 51, "Drug"], [53, 61, "Amount"], [104, 132, "Parameter"], [138, 156, "Parameter"], [192, 196, "Drug"]]}], [7758, "These results suggest a possible herb-drug interaction and HS should not be used in conjunction with HCTZ.", {"entities": [[59, 61, "Herb name"], [101, 105, "Drug"]]}], [7759, "Based on these findings, acetaminophen should be taken 3\u20134 hours before drinking HS to avoid shorten its therapeutic effect.", {"entities": [[25, 38, "Drug"], [81, 83, "Herb name"]]}], [7760, "Go to: 6.", {"entities": []}], [7761, "HS in the Treatment of High Blood Pressure 6.1.", {"entities": [[0, 2, "Herb name"], [28, 42, "Parameter"]]}], [7762, "Animal Studies  The results from animal studies presented in table 2 consistently show the beneficial effects of HS extracts on lowering blood pressure [21\u201323, 52].", {"entities": [[0, 14, "Study"], [33, 47, "Study"], [113, 124, "Herb name"], [137, 151, "Parameter"]]}], [7763, "Although the same effects on blood pressure occur in normotensive animal models, the positive effects are greater in hypertensive animals [21, 23].", {"entities": [[29, 43, "Parameter"], [117, 129, "Pathology"]]}], [7764, "There is evidence that the positive effects are dose dependent at lower doses [21], but not at extremely high doses [23].", {"entities": []}], [7765, "Table 2  Effect of administration of HS extract on rodent systolic and diastolic blood pressure.", {"entities": [[37, 47, "Herb name"], [58, 95, "Parameter"]]}], [7766, "Primary author, year\tCondition\tSample size\tPlant Part\tExtract mode\tDose\tEnd time point\tWithin group SBP\tBetween group SBP\tWithin group DBP\tBetween group DBP Mojiminiyi, 2007\tNormo\t6 rats\tC\tW\t1a\t1\tRed\t\tRed\t Mojiminiyi, 2007\tNormo\t6 rats\tC\tW\t5a\t1\tRed\t\tRed\t Mojiminiyi, 2007\tNormo\t6 rats\tC\tW\t25a\t1\tRed\t\tRed\t Mojiminiyi, 2007\tNormo\t6 rats\tC\tW\t125a\t1\tRed\t\tRed\t Onyenekwe, 1999\tNormo\t5 rats\tP\tW\t500a\t21\tRed\tN/A\tRed\tN/A Onyenekwe, 1999\tNormo\t5 rats\tP\tW\t1000a\t21\tRed\tN/A\tRed\tN/A Mojiminiyi, 2007\tHypera\t6 rats\tC\tW\t1a\t1\tNS\t\tNS\t Mojiminiyi, 2007\tHyperb\t6 rats\tC\tW\t1a\t1\tRed\t\tRed\t Mojiminiyi, 2007\tHypera\t6 rats\tC\tW\t5a\t1\tRed\t\tRed\t Mojiminiyi, 2007\tHyperb\t6 rats\tC\tW\t5a\t1\tRed\t\tRed\t Mojiminiyi, 2007\tHypera\t6 rats\tC\tW\t25a\t1\tRed\t\tRed\t Mojiminiyi, 2007\tHyperb\t6 rats\tC\tW\t25a\t1\tRed\t\tRed\t Mojiminiyi, 2007\tHypera\t6 rats\tC\tW\t125a\t1\tRed\t\tRed\t Mojiminiyi, 2007\tHyperb\t6 rats\tC\tW\t125a\t1\tRed\t\tRed\t Odigie, 2003\tHyper\t5 rats\tP\tW\t250a\t56\tRed\tDep\tN/A\tDep Onyenekwe, 1999\tHyper\t5 mice\tP\tW\t500a\t21\tRed\tDep\tRed\tDep Onyenekwe, 1999\tHyper\t5 mice\tP\tW\t1000a\t21\tN/A\tN/A\tN/A\tN/A Inuwa, 2012\tHyper\t8 rats\tC\tW\t10b\t70\tRed\tDep\tRed\tDep Inuwa, 2012\tHyper\t8 rats\tC\tW\t15b\t70\tRed\tDep\tRed\tDep Inuwa, 2012\tHyper\t8 rats\tC\tW\t20b\t70\tRed\tDep\tRed\tDep Inuwa, 2012\tHyper\t6 rats\tF\tA\t50a\t5\tNS\t\tNS\t Inuwa, 2012\tHyper\t6 rats\tF\tA\t100a\t5\tNS\t\tNS\t Inuwa, 2012\tHyper\t6 rats\tF\tA\t200a\t5\tNS\t\tNS\t Open in a separate window  Notes: Condition: Normo=normotension, Hyper=hypertension, asalt loaded induced, bchronic oxide synthase inhibition induced; Plant part used in extract=F=flower, C=calyx, P=petal L=leaf; Extract mode: W=water, A=alcohol;  Dose: a=mg of HS extract/kg weight of animal/day, b%; End time point: number of days after start of treatment when measurement was taken; SBP=Systolic blood pressure; DBP=Diastolic blood pressure; Results: N/A=not available, NS=not significant, Dep=depressed, Ele=elevated, Red=reduced, Inc=increased, depressed or elevated used accordingly when values compared with appropriate control, increased or reduced used when values compared between baseline and end of treatment within the same group 6.2.", {"entities": [[1376, 1394, "Pathology"], [1396, 1414, "Pathology"], [1509, 1517, "Herb part"], [1519, 1526, "Herb part"], [1528, 1535, "Herb part"], [1536, 1542, "Herb part"], [1558, 1565, "Extraction process"], [1567, 1576, "Extraction process"], [1593, 1603, "Herb name"], [1607, 1623, "Parameter"], [1717, 1744, "Parameter"], [1746, 1774, "Parameter"]]}], [7767, "Human Study  The clinical study populations ranged from pre and mildly hypertensive [8, 10] to stage 1 or 2 hypertensive [11, 12] (Table 3; Table 6 quality of reporting).", {"entities": [[0, 11, "Study"], [13, 31, "Study"], [71, 83, "Pathology"], [108, 120, "Pathology"]]}], [7768, "Only one study chose to recruit people with the additional condition of type 2 diabetes [10].", {"entities": [[72, 87, "Pathology"]]}], [7769, "The study designs included comparing HS to black tea [10], blood pressure medication [11, 13], or a placebo beverage [8].", {"entities": [[37, 39, "Herb name"], [43, 52, "Extraction process"], [59, 73, "Parameter"]]}], [7770, "HS was generally prepared as a tea, but Herrera-Arellano and colleagues [11] prepared it as a standardized aqueous extract.", {"entities": [[0, 2, "Herb name"], [31, 34, "Extraction process"], [94, 122, "Extraction process"]]}], [7772, "The duration of most of the studies was 4 weeks [10, 11, 13], although one study only lasted 12 days [12] and another was 6 weeks long [8].", {"entities": [[40, 47, "Duration"], [93, 100, "Duration"], [122, 134, "Duration"]]}], [7773, "Table 3  Hypertension RCT interventions and effects on systolic blood pressure and diastolic blood pressure.", {"entities": [[9, 21, "Pathology"], [22, 25, "Study"], [55, 78, "Parameter"], [83, 107, "Parameter"]]}], [7775, "Primary author, year\tCONSORT 2001\tCONSORT Herbal Interventions Elaboration McKay, 2010\t95.45\t66.67 Haji, 1999\t81.82\t27.78 Mozaffari-Khosravi, 2009\t81.82\t50.00 Herrera-Arellano, 2004\t81.82\t60.00 Herrera-Arellano, 2007\t68.18\t55.00 Mohagheghi, 2011\t63.64\t33.33 Gurrola-Diaz, 2010\t63.64\t65.00 Kuriyan, 2010\t72.73\t50.00 Mozaffari-Khosravi, 2009\t81.82\t38.89 Lin, 2007\t59.09\t65.00 Open in a separate window  Systolic blood pressure (SBP) and diastolic blood pressure (DBP) declined with HS treatment in all but one study where DBP did not achieve statistical significance relative to pre-treatment levels [10].", {"entities": [[401, 430, "Parameter"], [435, 465, "Parameter"], [480, 482, "Herb name"], [520, 523, "Parameter"]]}], [7776, "When comparing the results of the HS experimental groups with the placebo and black tea groups, the decline in SBP and DBP was significantly greater in the HS experimental groups [8, 10, 12].", {"entities": [[34, 36, "Herb name"], [78, 87, "Herb name"], [111, 114, "Parameter"], [119, 122, "Parameter"], [156, 158, "Herb name"]]}], [7777, "When comparing effects of HS to those of two commonly used ACE-inhibitors, HS was as effective as Captopril in lowering SBP and DSP in one study [13], but less effective than Lisinopril in another [11].", {"entities": [[26, 28, "Herb name"], [59, 73, "Drug"], [75, 77, "Herb name"], [98, 107, "Drug"], [120, 123, "Parameter"], [128, 131, "Parameter"], [175, 185, "Drug"]]}], [7778, "Go to: 7.", {"entities": []}], [7779, "HS in the Treatment of Elevated Cholesterol 7.1.", {"entities": [[0, 2, "Herb name"], [32, 43, "Parameter"]]}], [7780, "Animal Studies  The data presented in table 4 indicates that results from studies of the effect of HS extract on animal cholesterol metabolism are varied.", {"entities": [[0, 14, "Study"], [99, 109, "Herb name"], [120, 131, "Parameter"]]}], [7781, "High-density lipoprotein cholesterol (HDL-C) was not statistically significantly impacted by HS extract consumption [24, 25, 30] and low-density lipoproteins (LDL-C) was reduced at lower doses [24], but no data was available at higher doses [25, 30].", {"entities": [[0, 44, "Parameter"], [93, 103, "Herb name"], [133, 165, "Herb name"]]}], [7782, "Table 4  Effect of administration of HS extract on animal total cholesterol, HDL-C, LDL-C and triglycerides.", {"entities": [[37, 47, "Herb name"], [58, 75, "Parameter"], [77, 82, "Parameter"], [84, 89, "Parameter"], [94, 107, "Parameter"]]}], [7783, "HDL-C was not significantly changed by HS extract consumption in diabetic animals [25, 31].", {"entities": [[0, 5, "Parameter"], [39, 49, "Herb name"], [65, 73, "Pathology"]]}], [7784, "7.2.", {"entities": []}], [7785, "Human Studies  The clinical study populations were diverse and included healthy people as well as those with metabolic syndrome [16], hyperlipidemia [15, 17], hypertension [18], or type 2 diabetes [14] (Table 5; Table 6 quality of reporting).", {"entities": [[0, 13, "Study"], [15, 33, "Study"], [72, 79, "Pathology"], [109, 127, "Pathology"], [134, 148, "Pathology"], [159, 171, "Pathology"], [181, 196, "Pathology"]]}], [7786, "The study designs compared different doses of HS [15] or compared HS to black tea [14, 18], diet and a combination of HS and diet [16], or a placebo [17].", {"entities": [[46, 48, "Herb name"], [66, 68, "Herb name"], [72, 81, "Herb name"], [118, 120, "Herb name"]]}], [7787, "Alcohol extractions formulated with 500 g of fresh calyxes were administered once daily [16] and alcohol extracts made from 60,000 g of fresh leaves were administered twice daily [17].", {"entities": [[0, 19, "Extraction process"], [36, 41, "Amount"], [45, 58, "Herb part"], [77, 87, "Frequency"], [97, 113, "Extraction process"], [124, 132, "Amount"], [136, 148, "Herb part"], [167, 178, "Frequency"]]}], [7788, "The duration of the studies ranged from 15 days [18] to 90 days [17] with most lasting one month [14\u201316].", {"entities": [[40, 47, "Duration"], [56, 63, "Duration"], [87, 96, "Duration"]]}], [7789, "Table 5  Cholesterol RCT interventions and effects of cholesterol RCT interventions on total cholesterol, HDL-C, LDL-C, and triglycerides.", {"entities": [[9, 20, "Parameter"], [21, 24, "Study"], [54, 65, "Parameter"], [66, 69, "Study"], [87, 104, "Parameter"], [106, 111, "Parameter"], [113, 118, "Parameter"], [124, 137, "Parameter"]]}], [7791, "One brief 15 day study reported a significant increase in total cholesterol among hypertensive patients administered HS [18].", {"entities": [[10, 16, "Duration"], [58, 75, "Parameter"], [82, 94, "Pathology"], [117, 119, "Herb name"]]}], [7792, "In this same study, HDL-C increased and triglyceride and LDL-C values remained unchanged.", {"entities": [[20, 25, "Parameter"], [40, 52, "Parameter"], [57, 62, "Parameter"]]}], [7793, "Of the remaining 4 studies, one showed no significant change in total cholesterol and the month long studies showed significant decreases in total cholesterol among participants with hypertension, metabolic syndrome and those receiving the two lower doses of HS [14\u201316].", {"entities": [[64, 81, "Parameter"], [90, 95, "Duration"], [141, 158, "Parameter"], [183, 195, "Pathology"], [197, 215, "Pathology"], [259, 261, "Herb name"]]}], [7794, "HS significantly increased beneficial HDL-C levels in participants with and without metabolic syndrome [16] and hypertension [14].", {"entities": [[0, 2, "Herb name"], [38, 50, "Parameter"], [84, 102, "Pathology"], [112, 124, "Pathology"]]}], [7795, "LDL-C was significantly decreased as a result of the consumption of HS in participants with metabolic syndrome [16], hyperlipidemia [17], and type 2 diabetes [14].", {"entities": [[0, 5, "Parameter"], [68, 70, "Herb name"], [92, 110, "Pathology"], [117, 131, "Pathology"], [142, 157, "Pathology"]]}], [7796, "Triglyceride levels were significantly decreased by HS in participants with hyperlipidemia [17], type 2 diabetes [14], and without metabolic syndrome [16].", {"entities": [[0, 19, "Parameter"], [52, 54, "Herb name"], [76, 90, "Pathology"], [97, 112, "Pathology"], [131, 149, "Pathology"]]}], [7797, "Go to: 8.", {"entities": []}], [7798, "Quality of RCT Reporting  The studies consistently reported the CONSORT items relevant to all RCTs with scores ranging from 59% [15] of the items reported to 96% [8] (Table 6).", {"entities": [[11, 14, "Study"], [94, 98, "Study"]]}], [7799, "The items 1\u20136 and 12 were reported by most RCTs and included information on eligibility criteria for participants, a description of the intervention, outcome measurements and statistical methods (item 12).", {"entities": [[43, 47, "Study"]]}], [7800, "Items from the results section including participant flow (item 13), baseline data (item 15), and results from analyses (items 17 and 18) were also generally included.", {"entities": []}], [7801, "In addition all discussion items, including interpretation of results (item 20) within the context of current evidence (item 22) and external validity (item 21).", {"entities": []}], [7802, "However, there were several areas where reporting could be improved, including sample size (item 7), randomization sequence allocation (item 8), allocation concealment (item 9), and implementation (item 10), blinding (item 11), recruitment (item 14), numbers analyzed (item 16), and adverse events (item 19).", {"entities": [[283, 297, "Pathology"]]}], [7803, "More specifically, most studies did not make clear the type of RCT being conducted and in many cases there were study design problems.", {"entities": [[63, 66, "Study"]]}], [7804, "In several RCTs black tea was used as the comparator, as opposed to a placebo, making the results difficult to interpret because of the active pharmacological properties of black tea [10, 12, 14, 18].", {"entities": [[11, 15, "Study"], [16, 25, "Herb name"], [173, 182, "Herb name"]]}], [7805, "In some comparative effectiveness trials it was difficult to compare effectiveness between treatments because the medication was not administered as directed by doctors [11], whereas other trials provided realistic comparators [13, 16].", {"entities": [[8, 40, "Study"], [189, 195, "Study"]]}], [7806, "The results from the study on dose response are difficult to interpret because the baseline values for total cholesterol differed substantially between groups [15].", {"entities": [[103, 120, "Parameter"]]}], [7807, "Additionally, there were several problems specific to the cholesterol RCTs.", {"entities": [[54, 69, "Parameter"], [70, 74, "Study"]]}], [7808, "Differences between groups were impossible to assess because none of the studies included effect sizes or statistical analyses of the between-group differences [14\u201318].", {"entities": []}], [7809, "Another problem with most of the cholesterol trials was short study duration with 4 trials lasting 15 days [18] to 30 days [14\u201316] and only one trial of a longer 90 day duration [17].", {"entities": [[29, 44, "Parameter"], [45, 51, "Study"], [84, 90, "Study"], [99, 106, "Duration"], [115, 122, "Duration"], [162, 168, "Duration"]]}], [7810, "In general, lipid profiles can take up to 2 months to reflect meaningful change in patients given statin medication or modifications to their diet and lifestyle [55, 56].", {"entities": [[12, 26, "Parameter"], [42, 50, "Duration"], [98, 115, "Drug"]]}], [7811, "The hypertension trials selected patient populations with mild to moderate hypertension [8, 11\u201313] with only one study providing the additional condition of diabetes [10], whereas the patient populations in the cholesterol trials had an array of conditions, many of which did not include elevated cholesterol [14, 16, 18], making it difficult to assess the effectiveness of HS in treating hyperlipidemia.", {"entities": [[4, 16, "Pathology"], [17, 23, "Study"], [58, 87, "Pathology"], [157, 165, "Pathology"], [211, 222, "Parameter"], [223, 229, "Study"], [297, 308, "Parameter"], [374, 376, "Herb name"], [389, 403, "Pathology"]]}], [7812, "Reporting was particularly lacking in the herbal description in the title or abstract (item 1), description of how traditional theories and concepts were maintained, including traditional preparation and dosing practices (item 3), all aspects of the intervention (items 4a, 4c\u20134f), except characteristics of the herbal product (item 4b), concomitant medications (item 15), interpretation in the light of the product and dosage regimen used (item 20) and how the herbal product and dosage regimen used relates to self-care (item 21).", {"entities": []}], [7813, "There were also several problems with the preparation of HS.", {"entities": [[57, 59, "Herb name"]]}], [7814, "Many of the studies did not report the part of the plant that was used in the preparation.", {"entities": []}], [7815, "Kuriyan and colleagues [17] used the leaves in their extract without explanation, whereas the calyxes are most commonly used in HS preparations.", {"entities": [[33, 43, "Herb part"], [90, 101, "Herb part"], [128, 144, "Herb name"]]}], [7816, "In addition, the amount of HS used in preparations and the dose administered varied greatly with Mohagheghi and colleagues [18] choosing to use an extremely small amount of HS calyxes in the preparation per dose and many of the studies failing to include any measure of marker constituents.", {"entities": [[27, 29, "Herb name"], [173, 175, "Herb name"], [176, 183, "Herb part"]]}], [7817, "The absence of information related to product content and the method of preparation and the lack of uniformity of extracts made it difficult to compare findings between studies.", {"entities": []}], [7818, "In addition, the lack of information regarding ethnobotanical use made it difficult to determine the relationship between the studies and traditional therapeutic use.", {"entities": []}], [7819, "Go to: 9.", {"entities": []}], [7820, "Biological Mechanisms  In vitro and in vivo studies focused on mechanism of action have determined several potential mechanisms of the HS extracts that may explain the hypotensive activity, including (1) vasodilation mediated through endothelium-derived relaxant pathways and inhibition of calcium influx [9, 57], (2) ACE inhibition [9] by the stimulation of new vessel formation and a reduction of myocardial mass [52] or anthocyanins competing with the substrate for the active site [58], (3) decrease in blood viscosity through cyclooxygenase inhibitory activity [44], and (4) inhibition of adipocyte differentiation through the modulation of PI3-K/Akt and ERK pathway [59].", {"entities": [[23, 51, "Study"], [135, 146, "Herb name"], [168, 189, "Pathology"], [204, 216, "Pathology"], [290, 304, "Parameter"], [318, 321, "Target"], [399, 414, "Parameter"], [423, 435, "Herb name"], [507, 522, "Parameter"], [531, 565, "Parameter"], [594, 619, "Parameter"], [646, 655, "Parameter"], [660, 663, "Parameter"]]}], [7821, "Other potential mechanisms have been tested to explain the positive impact of HS extract on cholesterol metabolism.", {"entities": [[78, 88, "Herb name"], [92, 103, "Parameter"]]}], [7822, "For example, cholesterol biosynthesis may be reduced by inhibiting HMG-CoA reductase [42, 60].", {"entities": [[13, 24, "Parameter"], [67, 84, "Target"]]}], [7823, "The positive effects of the extract in diabetic animal models may be partially the result of the reduction in the expression of CTGF and RAGE [30].", {"entities": [[39, 47, "Pathology"], [128, 132, "Parameter"], [137, 141, "Parameter"]]}], [7824, "Go to: 10.", {"entities": []}], [7825, "Conclusions  There are many strengths and limitations to the array of evidence considered in this review.", {"entities": [[98, 104, "Study"]]}], [7826, "Ethnomedicinal studies provide evidence for the widespread use of a tea made with HS calyxes to treat hypertension and hyperlipidemia, but these studies provide little guidance for animal and human studies through their lack of attention to cultivation, preparation, and consumption patterns.", {"entities": [[0, 22, "Study"], [66, 71, "Extraction process"], [82, 84, "Herb name"], [85, 92, "Herb part"], [102, 114, "Pathology"], [119, 133, "Pathology"], [181, 205, "Study"]]}], [7827, "HS extracts are generally considered to have a low degree of toxicity.", {"entities": [[0, 11, "Herb name"], [61, 69, "Pathology"]]}], [7828, "Studies demonstrate that HS consumption does not adversely effect liver and kidney function at lower doses, but may be hepatotoxic at extremely high doses.", {"entities": [[25, 27, "Herb name"], [119, 130, "Pathology"]]}], [7829, "In addition, electrolyte levels generally are not effected by ingesting HS extracts despite its diuretic effects.", {"entities": [[13, 31, "Parameter"], [72, 83, "Herb name"], [96, 112, "Pathology"]]}], [7830, "Animal studies have consistently shown that consumption of HS extract reduces blood pressure in a dose dependent manner.", {"entities": [[0, 14, "Study"], [59, 69, "Herb name"], [78, 92, "Parameter"]]}], [7831, "They have also shown that total cholesterol, LDL-C, and triglycerides were lowered in the majority of normolipidemic, hyperlipidemic, and diabetic animal models, whereas HDL-C was generally not affected by the consumption of HS extract.", {"entities": [[26, 43, "Parameter"], [45, 50, "Parameter"], [56, 69, "Parameter"], [102, 116, "Pathology"], [118, 132, "Pathology"], [138, 146, "Pathology"], [170, 175, "Parameter"], [225, 235, "Herb name"]]}], [7832, "McKay and colleagues [8] provide a notable exception with their high quality placebo-controlled trial.", {"entities": [[77, 101, "Study"]]}], [7833, "As the findings related to the effects of HS on blood pressure from lower quality studies are consistent with those of this high quality study, the totality of evidence suggests that HS consumption may have a public health benefit due to its anti-hypertensive effects.", {"entities": [[42, 44, "Herb name"], [48, 62, "Parameter"], [183, 185, "Herb name"], [242, 267, "Pathology"]]}], [7834, "Anthocyanins found in abundance in HS calyxes are generally considered the phytochemicals responsible for the antihypertensive and hypocholesterolemic effects, however evidence has also been provided for the role of polyphenols and hibiscus acid.", {"entities": [[0, 12, "Herb name"], [35, 37, "Herb name"], [38, 45, "Herb part"], [75, 89, "Herb name"], [110, 126, "Pathology"], [131, 158, "Pathology"], [216, 245, "Herb name"]]}], [7835, "Research on active compounds in HS and the mechanisms of action are still fairly nascent making it difficult to justify carrying out RCTs using anything other than the whole plant parts used in general practice.", {"entities": [[32, 34, "Herb name"], [133, 137, "Study"]]}], [7836, "This body of evidence interpreted together suggests that HS has great potential to reduce risk factors associated with cardiovascular disease and merits further study.", {"entities": [[57, 59, "Herb name"], [119, 141, "Pathology"]]}], [7837, "Go to: Acknowledgements  This research was funded by the National Center for Complementary and Alternative Medicine at the National Institutes of Health grant (T32AT001287).", {"entities": []}], [7838, "The funders had no involvement in the preparation or writing up of this research.", {"entities": []}], [7839, "Go to: Footnotes  Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication.", {"entities": []}], [7840, "As a service to our customers we are providing this early version of the manuscript.", {"entities": []}], [7841, "The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form.", {"entities": []}], [7842, "Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.", {"entities": []}], [7844, "Potential for pharmacokinetic interactions between Schisandra sphenanthera and bosutinib, but not imatinib: in vitro metabolism study combined with a physiologically\u2010based pharmacokinetic modelling approach Jeffry Adiwidjaja, 1 Alan V. Boddy, 2 , 3 and Andrew J. McLachlancorresponding author 1 Author information Article notes Copyright and License information PMC Disclaimer Associated Data  Supplementary Materials  Data Availability Statement  Go to: Abstract Aims  This study aimed to investigate the potential interaction between Schisandra sphenanthera, imatinib and bosutinib combining in vitro and in silico methods.", {"entities": [[51, 74, "Herb name"], [79, 88, "Drug"], [98, 106, "Drug"], [108, 206, "Study"], [536, 559, "Herb name"], [561, 569, "Drug"], [574, 583, "Drug"]]}], [7845, "Methods  In vitro metabolism of imatinib and bosutinib using recombinant enzymes and human liver microsomes were investigated in the presence and absence of Schisandra lignans.", {"entities": [[32, 40, "Drug"], [45, 54, "Drug"], [157, 175, "Herb name"]]}], [7846, "Physiologically\u2010based pharmacokinetic (PBPK) models for the lignans accounting for reversible and mechanism\u2010based inhibitions and induction of CYP3A enzymes were built in the Simcyp Simulator (version 17) and evaluated for their capability to predict interactions with midazolam and tacrolimus.", {"entities": [[143, 156, "Parameter"], [269, 278, "Drug"], [283, 293, "Drug"]]}], [7847, "Their potential effect on systemic exposures of imatinib and bosutinib were predicted using PBPK in silico simulations.", {"entities": [[48, 56, "Drug"], [61, 70, "Drug"]]}], [7848, "All three compounds showed a strong reversible inhibition on CYP2C8 enzyme with k i of less than 0.5 \u03bcmol L\u22121.", {"entities": [[61, 74, "Target"], [80, 83, "Parameter"], [97, 109, "Amount"]]}], [7849, "The verified PBPK models were able to describe the increase in systemic exposure of midazolam and tacrolimus due to co\u2010administration of S. sphenanthera, consistent with the reported changes in the corresponding clinical interaction study (AUC ratio of 2.0 vs 2.1 and 2.4 vs 2.1, respectively).", {"entities": [[84, 93, "Drug"], [98, 108, "Drug"], [137, 152, "Herb name"], [212, 238, "Study"], [240, 249, "Parameter"], [253, 256, "Amount"], [260, 263, "Amount"], [268, 271, "Amount"], [275, 278, "Amount"]]}], [7850, "The PBPK simulation predicted that at recommended dosing regimens of S. sphenanthera, co\u2010administration would result in an increase in bosutinib exposure (AUC ratio 3.0) but not in imatinib exposure.", {"entities": [[69, 84, "Herb name"], [135, 144, "Drug"], [155, 164, "Parameter"], [165, 168, "Amount"], [181, 189, "Drug"]]}], [7851, "Conclusion  PBPK models for Schisandra lignans were successfully developed.", {"entities": [[28, 46, "Herb name"]]}], [7852, "Interaction between imatinib and Schisandra lignans was unlikely to be of clinical importance.", {"entities": [[20, 28, "Drug"], [33, 51, "Herb name"]]}], [7853, "Conversely, S. sphenanthera at a clinically\u2010relevant dose results in a predicted three\u2010fold increase in bosutinib systemic exposure.", {"entities": [[12, 27, "Herb name"], [104, 113, "Drug"]]}], [7854, "Keywords: drug metabolism, herb\u2013drug interactions, modelling and simulation, physiologically\u2010based pharmacokinetic (PBPK) What is already known about this subject      Physiologically\u2010based pharmacokinetic (PBPK) modelling approaches combined with in vitro to in vivo extrapolation techniques have been extensively used for predicting clinically meaningful pharmacokinetic drug interactions.", {"entities": [[213, 292, "Study"]]}], [7855, "Schisandrin A, schisantherin A and schisandrol B, the major bioactive lignans in Schisandra sphenanthera are potent CYP3A modulators with evidence for clinically\u2010significant drug interactions.", {"entities": [[0, 13, "Herb name"], [15, 30, "Herb name"], [35, 48, "Herb name"], [70, 77, "Herb name"], [81, 104, "Herb name"], [116, 121, "Parameter"]]}], [7856, "What this study adds      PBPK models for the perpetrator compounds in S. sphenanthera were developed with a capability to predict the interactions of Schisandra constituents with midazolam and tacrolimus.", {"entities": [[71, 86, "Herb name"], [151, 174, "Herb name"], [180, 189, "Drug"], [194, 205, "Drug"]]}], [7857, "Go to: 1.", {"entities": []}], [7858, "INTRODUCTION  Schisandra sphenanthera has long been an integral part of traditional Chinese medicine, while other closely\u2010related species, Schisandra chinensis can be found in many Western countries.", {"entities": [[14, 37, "Herb name"], [84, 91, "Ethnic group"], [139, 159, "Herb name"]]}], [7859, "1 These natural products (typically administered as dried ethanol extracts) are used mainly for their putative hepatoprotective effect 2 , 3 , 4 and have been explored for anti\u2010cancer properties.", {"entities": [[52, 74, "Extraction process"], [111, 134, "Pathology"], [172, 183, "Pathology"]]}], [7861, "4 Several biologically\u2010active dibenzocyclooctadiene lignans, namely schisantherin A, schisandrin A and schisandrol B (Table 1) have been identified in S. sphenanthera extract with evidence for cytochrome P450 (CYP)3A modulations.", {"entities": [[30, 59, "Herb name"], [68, 83, "Herb name"], [85, 98, "Herb name"], [103, 116, "Herb name"], [151, 174, "Herb name"], [204, 216, "Parameter"]]}], [7863, "aRetrieved from ChemSpider (www.chemspider.com).", {"entities": []}], [7864, "bAccessed from PubChem (pubchem.ncbi.nlm.gov) and ChEMBL (ebi.ac.uk/chembl).", {"entities": []}], [7865, "cExperimental data from Zhang et al.", {"entities": []}], [7866, "9 dPredicted in the Simcyp Simulator.", {"entities": []}], [7867, "eOptimised through a sensitivity analysis.", {"entities": []}], [7868, "fAssumed equal to 1.", {"entities": []}], [7870, "9 and f m , CYP3A4 was estimated based on the extent of inhibition by ketoconazole.", {"entities": [[12, 18, "Parameter"], [70, 82, "Drug"]]}], [7872, "11 i In vitro metabolism data in recombinant CYP3A4 and CYP3A5.", {"entities": [[45, 51, "Parameter"], [56, 62, "Parameter"]]}], [7873, "12 jReversible inhibition towards CYP3A enzymes using erythromycin as a probe substrate.", {"entities": [[34, 47, "Target"]]}], [7874, "13 k K i was derived from IC50 towards metabolism of midazolam in recombinant CYP3A4, assuming a competitive inhibition.", {"entities": [[26, 30, "Parameter"], [53, 62, "Drug"], [66, 84, "Parameter"]]}], [7875, "12 l In vitro inhibition data obtained from this study.", {"entities": []}], [7876, "mInhibition of transport of rhodamine 123 in Caco\u20102 cell line.", {"entities": [[15, 37, "Parameter"]]}], [7877, "14 oParameters related to CYP3A induction were estimated from the increase of CYP3A4 mRNA in hepatocytes as a result of exposure to S. sphenanthera extract (see Section 2 for more details).", {"entities": [[26, 31, "Parameter"], [78, 84, "Parameter"], [132, 155, "Herb name"]]}], [7878, "15  Clinically\u2010important herb\u2013drug interactions with Schisandra lignans as the perpetrators have been reported for midazolam, 16 sirolimus 17 and tacrolimus.", {"entities": [[53, 71, "Herb name"], [115, 124, "Drug"], [129, 138, "Drug"], [146, 156, "Drug"]]}], [7879, "4 , 18 , 19 Administration of S. sphenanthera extract (equivalent to 14, 19 and 1 mg day\u22121 of schisandrin A, schisantherin A and schisandrol B, respectively) in Chinese transplant recipients expressing CYP3A5 enzyme reduced by 40% the tacrolimus dose required to achieve the predefined target of trough blood concentrations 19 and thus was more cost\u2010effective.", {"entities": [[30, 53, "Herb name"], [69, 84, "Amount"], [94, 142, "Herb name"], [161, 168, "Ethnic group"], [202, 215, "Parameter"], [227, 230, "Amount"], [235, 245, "Drug"], [303, 323, "Parameter"], [324, 326, "Amount"]]}], [7880, "20 This has led to the investigation of S. sphenanthera as a promising pharmacokinetic enhancer (booster) to increase the bioavailability of CYP3A substrates.", {"entities": [[40, 55, "Herb name"], [118, 157, "Parameter"]]}], [7881, "19 Conversely, there is also a potential for unwanted herb\u2013drug interactions with S. sphenanthera, e.g.", {"entities": [[82, 97, "Herb name"]]}], [7882, "a higher risk for exposure\u2010related adverse events of the victim drugs.", {"entities": [[35, 49, "Pathology"]]}], [7883, "However, it is not possible to cover all the various permutations of combinations between natural products and conventional medicines by conducting dedicated clinical interaction studies.", {"entities": [[158, 186, "Study"]]}], [7884, "21 Clearly, a reliable and systematic approach to predict these herb\u2013drug interactions is needed.", {"entities": []}], [7885, "As for drug\u2013drug interactions, physiologically\u2010based pharmacokinetic (PBPK) modelling and simulation has been advocated for quantitative prediction of drug interactions with natural products.", {"entities": []}], [7886, "22 Nevertheless, PBPK prediction of herb\u2013drug interactions is more challenging than that with conventional perpetrator drugs.", {"entities": []}], [7887, "23 Prior knowledge of perpetrator compounds in a complex mixture (extract) and their typical maintenance dosing regimens are necessary for an accurate in vitro to in vivo extrapolation of herb\u2013drug interactions or lack thereof.", {"entities": []}], [7888, "There is also a possibility for interactions among compounds in the extract which may alter their systemic exposure.", {"entities": []}], [7889, "Hence, well\u2010characterised natural products are essential for implementing this quantitative framework.", {"entities": []}], [7890, "26  Imatinib and bosutinib are both approved as the first\u2010line treatments for Philadelphia chromosome\u2010positive (Ph+) chronic myeloid leukaemia (CML).", {"entities": [[4, 12, "Drug"], [17, 26, "Drug"], [78, 148, "Pathology"]]}], [7891, "diarrhoea, 28 , 31 while elevation of alanine transaminase is more frequent for bosutinib.", {"entities": [[0, 9, "Pathology"], [38, 58, "Parameter"], [80, 89, "Drug"]]}], [7892, "28 S. sphenanthera may be beneficial for ameliorating these adverse events, 3 , 4 in addition to its potential anti\u2010cancer activity.", {"entities": [[3, 18, "Herb name"], [60, 74, "Pathology"], [111, 131, "Pathology"]]}], [7893, "5 , 6 Imatinib and bosutinib have distinct pharmacokinetic characteristics.", {"entities": [[6, 14, "Drug"], [19, 28, "Drug"]]}], [7894, "Imatinib is a substrate for both CYP3A4 and CYP2C8 enzymes and has a low hepatic extraction ratio (EH), 32 while bosutinib is a high EH drug almost exclusively metabolised by CYP3A4.", {"entities": [[0, 8, "Drug"], [33, 39, "Parameter"], [44, 58, "Parameter"], [73, 102, "Parameter"], [113, 122, "Drug"], [133, 135, "Parameter"], [175, 181, "Parameter"]]}], [7895, "33 Therefore, both medicines are prone to CYP3A modulation by S. sphenanthera.", {"entities": [[42, 47, "Parameter"], [62, 77, "Herb name"]]}], [7896, "The development and evaluation of PBPK models for the Schisandra lignans will provide a greater understanding and allow the prediction of interactions with both drugs.", {"entities": [[54, 72, "Herb name"]]}], [7897, "The aim of this study was to build, evaluate and implement PBPK models of key perpetrator compounds found in S. sphenanthera extract for investigating the potential herb\u2013drug interactions with imatinib and bosutinib.", {"entities": [[109, 132, "Herb name"], [193, 201, "Drug"], [206, 215, "Drug"]]}], [7898, "Go to: 2.", {"entities": []}], [7899, "METHODS 2.1.", {"entities": []}], [7900, "Inhibition of in vitro metabolism of imatinib and bosutinib by Schisandra lignans 2.1.1.", {"entities": [[37, 45, "Drug"], [50, 59, "Drug"], [63, 81, "Herb name"]]}], [7901, "Materials  Imatinib (mesylate salt), bosutinib, schisandrin A, schisantherin A, schisandrol B, \u03b2\u2010nicotinamide adenine dinucleotide 2\u2032\u2010phosphate reduced (NADPH) tetrasodium salt, azamulin, dipotassium hydrogen phosphate trihydrate, potassium dihydrogen phosphate, dimethyl sulfoxide (DMSO) and pooled human liver microsomes (M0317) were purchased from Sigma\u2010Aldrich (Castle Hill, NSW, Australia).", {"entities": [[11, 35, "Drug"], [37, 46, "Drug"], [48, 61, "Herb name"], [63, 78, "Herb name"], [80, 93, "Herb name"], [95, 176, "Parameter"], [178, 186, "Drug"], [188, 229, "Parameter"], [231, 261, "Parameter"], [263, 288, "Extraction process"]]}], [7902, "N\u2010desmethyl imatinib was obtained from Toronto Research Chemicals (North York, ON, Canada).", {"entities": [[0, 20, "Drug"]]}], [7903, "Recombinant CYP3A4 enzyme were procured from Corning (Woburn, MA; distributed by In Vitro Technologies, Noble Park, VIC, Australia).", {"entities": [[0, 25, "Parameter"]]}], [7904, "2.1.2.", {"entities": []}], [7905, "In vitro inhibition study on metabolism of imatinib and bosutinib  The rate of formation of N\u2010desmethyl imatinib (NDMI) from imatinib was evaluated in recombinant CYP3A4 (rCYP3A4) and human liver microsomes (HLM) at a concentration of 12.5 pmol CYP mL\u22121 and 0.25 mg microsomal protein mL\u22121, respectively.", {"entities": [[0, 25, "Study"], [43, 51, "Drug"], [56, 65, "Drug"], [92, 119, "Drug"], [125, 133, "Drug"], [151, 179, "Parameter"], [184, 212, "Parameter"], [218, 231, "Parameter"], [235, 253, "Amount"], [258, 289, "Amount"]]}], [7906, "Azamulin (5 \u03bcmol L\u22121) was added to the latter to specifically inactivate CYP3A4 enzyme (mechanism\u2010based inhibition, MBI).", {"entities": [[0, 8, "Drug"], [10, 20, "Amount"], [73, 86, "Target"]]}], [7907, "34 This system was assumed to represent a CYP2C8 pathway since CYP enzymes other than CYP3A4 and CYP2C8 had a very minor contribution (3%) to imatinib metabolism.", {"entities": [[42, 48, "Parameter"], [63, 74, "Parameter"], [86, 92, "Parameter"], [97, 103, "Parameter"], [142, 150, "Drug"]]}], [7909, "DMSO was used at a concentration that has a minimum impact on imatinib N\u2010demethylation (data not shown).", {"entities": [[0, 4, "Extraction process"], [62, 70, "Drug"]]}], [7910, "An extensive in vitro study showed that recombinant CYP2C8 enzyme (supersomes) was less sensitive than human liver microsomes (HLM) to identify potential mechanism\u2010based inhibitors and was characterised by a high lot\u2010to\u2010lot variability.", {"entities": [[13, 27, "Study"], [40, 78, "Parameter"], [103, 131, "Parameter"]]}], [7911, "Conversely, HLM are more reliable sources of CYP2C8 enzyme to evaluate mechanism\u2010based inhibition of the enzyme.", {"entities": [[12, 15, "Parameter"], [45, 58, "Parameter"]]}], [7912, "36 This is also likely to be the case for reversible inhibition of CYP2C8 enzyme.", {"entities": [[67, 80, "Parameter"]]}], [7914, "This was due to the lack of inhibitors capable of completely inhibiting CYP2C8 enzyme in HLM (gemfibrozil glucuronide inhibited the enzyme by up to 85%).", {"entities": [[72, 85, "Target"], [94, 117, "Drug"], [128, 138, "Target"], [148, 151, "Amount"]]}], [7915, "37 An overlap between CYP3A4 and CYP3A5 substrates has been recognised.", {"entities": [[22, 28, "Parameter"], [33, 39, "Parameter"]]}], [7916, "However, the contribution of CYP3A5 for imatinib metabolism has been ruled out from thorough in vitro work 35 and clinical studies, including in a large number of patients genotyped for the CYP3A5 gene.", {"entities": [[29, 35, "Parameter"], [40, 48, "Drug"], [114, 130, "Study"], [190, 196, "Parameter"]]}], [7917, "38 , 39  Although bosutinib has a high in vivo extraction ratio (EH), its intrinsic clearance in HLM was low (<20% reduction after a 60\u2010min incubation).", {"entities": [[18, 27, "Drug"], [39, 68, "Parameter"], [74, 93, "Parameter"], [110, 114, "Amount"], [133, 139, "Duration"]]}], [7919, "Incubation medium for this reaction was as described for NDMI formation, except that HLM (0.5 mg protein mL\u22121) in a final volume of 100 \u03bcL was used.", {"entities": [[57, 61, "Drug"], [85, 88, "Parameter"], [90, 109, "Amount"], [132, 138, "Amount"]]}], [7920, "The formation rates of NDMI and M5 were determined over the concentration range of 5\u2013100 \u03bcmol L\u22121 for the respective parent compounds in the absence and presence of schisantherin A (0.1\u201325 \u03bcmol L\u22121), schisandrin A and schisandrol B (0.5\u201325 \u03bcmol L\u22121) without pre\u2010incubation to evaluate their potential for reversible inhibition.", {"entities": [[23, 27, "Drug"], [32, 34, "Drug"], [83, 97, "Amount"], [165, 180, "Herb name"], [182, 197, "Amount"], [200, 231, "Herb name"], [233, 248, "Amount"]]}], [7921, "The temperature of incubation mixtures was equilibrated by placing the tubes in the water bath for 5 min.", {"entities": [[0, 38, "Parameter"], [95, 104, "Duration"]]}], [7922, "The reaction was initiated by the addition of NADPH and terminated by placing the tubes on a cooling block (Selleckchem, Houston, TX, USA).", {"entities": [[46, 51, "Parameter"]]}], [7923, "Sample preparation and analytical methods for NDMI and M5 are described in the supplementary materials.", {"entities": [[46, 50, "Drug"], [55, 57, "Drug"]]}], [7924, "The inhibitory constants (k i) for a selective inhibitor of CYP enzymes are expected to be similar across different substrates of the enzyme only for purely competitive inhibitions.", {"entities": [[0, 30, "Parameter"], [60, 71, "Parameter"]]}], [7925, "40 This is, however, not generally the case due to the possibility of non\u2010competitive and mixed inhibition.", {"entities": []}], [7927, "The k i values were estimated using a nonlinear regression implemented in GraphPad Prism version 7.02 (GraphPad Software, La Jolla, CA, USA).", {"entities": [[0, 14, "Parameter"]]}], [7928, "The competitive, noncompetitive and mixed\u2010inhibition models (Equations 1\u20133, respectively) were considered.", {"entities": []}], [7929, "The best\u2010fit equations for each of the ki estimations were selected based on visual inspections of model predictions versus experimental data and Akaike information criterion (AIC).", {"entities": [[39, 41, "Parameter"]]}], [7930, "\ud835\udc63=\ud835\udc49\ud835\udc5a\ud835\udc4e\ud835\udc65.", {"entities": [[0, 11, "Parameter"]]}], [7931, "It is noteworthy that the reversible enzyme inactivation in the Simcyp Simulator is modelled solely by competitive inhibition.", {"entities": []}], [7932, "Theoretically, the discrimination between competitive and noncompetitive inhibitions is not critical when concentrations of substrates are much lower than their K m values, which is often the case in the clinical setting.", {"entities": [[106, 134, "Parameter"], [161, 171, "Parameter"]]}], [7934, "43 Thus, the k i values for Schisandra lignans were corrected for nonspecific binding during incubation (fu inc) based on their partition coefficients (log P) and protein concentrations ([P]) in incubation mixtures (Equation 4).", {"entities": [[9, 23, "Parameter"], [28, 46, "Herb name"], [128, 158, "Parameter"], [163, 191, "Parameter"]]}], [7936, "Evaluations with a more intensive sampling time were performed for those showing significant depletion compared to control (one\u2010way analysis of variance with Tukey post\u2010hoc test, GraphPad Prism version 7.02).", {"entities": []}], [7937, "Potential depletion of the inhibitors was modelled by first\u2010order kinetics as reported previously.", {"entities": []}], [7938, "45 Corrections for k i values accounting for the concentrations of inhibitor at the end 45 , 46 and mid\u2010time of incubation 46 have been proposed, the latter of which was adopted for this study.", {"entities": [[19, 29, "Parameter"], [45, 76, "Parameter"]]}], [7939, "2.2.", {"entities": []}], [7940, "PBPK models for Schisandra lignans  All population\u2010based PBPK modelling and simulations were conducted using the Simcyp Simulator (version 17 release 1, Certara UK Limited, Simcyp Division, Sheffield, UK) using the \u2018healthy Chinese\u2019 and \u2018general North European Caucasian\u2019 population library data, which represent typical healthy adult people from the respective ancestry.", {"entities": [[16, 34, "Herb name"], [216, 223, "Pathology"], [224, 231, "Ethnic group"], [246, 270, "Ethnic group"], [321, 328, "Pathology"]]}], [7941, "The description of Simcyp Simulator workflow, basic algorithm and ordinary differential equations have been detailed previously.", {"entities": []}], [7942, "47 , 48  The drug\u2010related input parameters for Schisandra lignans are summarised in Table 1.", {"entities": [[47, 65, "Herb name"]]}], [7944, "A whole\u2010body PBPK model was used to describe the distribution of the three lignans.", {"entities": [[75, 82, "Herb name"]]}], [7945, "Drug partitioning to each of the tissue compartments was predicted in silico using the algorithms by Poulin and Theil (for schisandrin A and schisantherin A) 7 or Rodgers and Rowland (schisandrol B).", {"entities": []}], [7946, "8 Partition coefficients (log P) of neutral compounds are generally the most influential parameter dictating the extent of distribution to different tissues.", {"entities": [[2, 32, "Parameter"]]}], [7947, "8 , 49 A global sensitivity analysis suggested that uncertainties in tissue composition (that is concentrations of neutral lipids, neutral phospholipids, albumin and intracellular and extracellular water), but not tissue volumes may affect the in silico predictions of V ss of neutral compounds.", {"entities": [[97, 203, "Parameter"], [214, 228, "Parameter"], [269, 294, "Parameter"]]}], [7948, "Inter\u2010correlation between tissue composition and log P also had a significant impact on the estimation of K p (tissue\u2010to\u2010plasma partition coefficients).", {"entities": [[49, 54, "Parameter"], [106, 151, "Parameter"]]}], [7949, "49 For neutral compounds with a relatively small log P, e.g.", {"entities": [[49, 54, "Parameter"]]}], [7950, "schisantherin A, both prediction methods by Rodgers and Rowland 8 and Poulin and Theil 7 performed similarly.", {"entities": [[0, 15, "Herb name"]]}], [7951, "Therefore, the latter was selected for schisantherin A due to its simplicity.", {"entities": [[39, 54, "Herb name"]]}], [7952, "Interestingly, the Rodgers and Rowland algorithm provided a better estimate of K p of schisandrol B to different tissues, reflected by a better predictive performance of its pharmacokinetic profile compared to that of Poulin and Theil despite similar overall extent of distributions (V ss).", {"entities": [[79, 82, "Parameter"], [86, 99, "Herb name"], [284, 288, "Parameter"]]}], [7953, "However, the Rodgers and Rowland method tends to overestimate V ss and K p for highly lipophilic neutral compound, e.g.", {"entities": [[62, 66, "Parameter"], [71, 74, "Parameter"]]}], [7954, "schisandrin A and thus the algorithm by Poulin and Theil is preferable for this lignan.", {"entities": [[0, 13, "Herb name"], [80, 86, "Herb name"]]}], [7955, "11 The mechanism\u2010based inhibition and induction of CYP3A4 following the chronic exposure to S. sphenanthera extract were modelled by an enzyme turnover model, depicted by an increase in degradation and synthesis of the active enzyme, respectively.", {"entities": [[51, 57, "Parameter"], [92, 115, "Herb name"]]}], [7957, "This was further corrected for the nonspecific binding during incubation (estimated fu inc of 0.4, Equation 4) assuming that 0.32 mg protein was present per million of hepatocytes (according to the hepatocellularity and content of microsomal protein per gram of liver 51 ).", {"entities": [[74, 90, "Parameter"], [94, 97, "Amount"], [125, 132, "Amount"], [133, 140, "Parameter"]]}], [7959, "Induction of CYP3A4 enzyme is not analogous to a reversible inhibition due to a possibility for different binding sites on the enzyme (that is competitive, noncompetitive and mixed\u2010inhibition) in the latter.", {"entities": [[13, 26, "Target"]]}], [7960, "This results in a high variability of inhibitory constants (k i) across different substrates, even for a selective CYP inhibitor, as has been observed with ketoconazole.", {"entities": [[38, 64, "Parameter"], [115, 118, "Target"], [156, 168, "Drug"]]}], [7961, "40 Conversely, induction of CYP3A4 enzyme involves binding and stimulation of pregnane X receptor (PXR), a nuclear receptor that regulates the expression of CYP3A genes.", {"entities": [[28, 41, "Target"], [78, 168, "Parameter"]]}], [7962, "53 This receptor binds to a variety of compounds (ligands) in a relatively nonspecific manner 54 and thus, the variability of in vitro induction parameters of CYP3A4 enzyme between structurally similar compounds is expected to be lower than that of reversible enzyme inhibition.", {"entities": [[159, 172, "Parameter"]]}], [7963, "PBPK simulations for Schisandra lignans were performed (10 virtual trials each) with trial designs (number of people, ethnicity, age range, proportion of male to female and dosing regimens) matched to the corresponding clinical studies (Table 2).", {"entities": [[21, 39, "Herb name"], [154, 158, "Sex"], [162, 168, "Sex"], [219, 235, "Study"]]}], [7964, "Clinically\u2010observed concentrations were superimposed to simulated profiles to allow visual inspection of the predictive performance.", {"entities": [[0, 34, "Parameter"]]}], [7965, "Prediction differences of pharmacokinetic parameters for the three lignans, expressed as the ratio of PBPK model prediction to clinically\u2010reported parameter values were also evaluated.", {"entities": [[67, 74, "Herb name"]]}], [7966, "PBPK simulations were also carried out to evaluate the capability of PBPK models of Schisandra lignans in predicting the extent of interactions with midazolam and tacrolimus with trial designs as detailed in Table 3.", {"entities": [[84, 102, "Herb name"], [149, 158, "Drug"], [163, 173, "Drug"], [179, 192, "Study"]]}], [7967, "PBPK models for perpetrator and victim compounds were linked through competitive inhibition, MBI and induction of hepatic and intestinal CYP3A enzymes as described previously.", {"entities": [[126, 150, "Parameter"]]}], [7968, "48 The PBPK model of tacrolimus based on clinical pharmacokinetic data in people from European ancestry 57 was utilised (Table S1).", {"entities": [[21, 31, "Drug"], [86, 94, "Ethnic group"]]}], [7969, "The default PBPK model of midazolam within the Simcyp Simulator was initially used for PBPK prediction of the interaction with S. sphenanthera.", {"entities": [[26, 35, "Drug"], [127, 142, "Herb name"]]}], [7970, "58 The reason for a far lower clearance in this cohort is not yet clear.", {"entities": [[30, 39, "Parameter"]]}], [7972, "aGiven as Schisandra sphenanthera extract.", {"entities": [[10, 41, "Herb name"]]}], [7973, "bReported as geometric mean values of PBPK model prediction.", {"entities": []}], [7974, "cPopulation data for people from Chinese ancestry within the Simcyp Simulator were used for the PBPK simulation.", {"entities": [[33, 40, "Ethnic group"]]}], [7975, "TABLE 3  PBPK model predictions and clinically\u2010reported pharmacokinetic parameters of midazolam and tacrolimus in the presence and absence of S. sphenanthera extract in healthy people \tC max (ng mL\u22121) a \tAUC0\u201324h (ng h\u22121 mL \u22121)\tCL/F (L h\u22121) Victim drug alone\tAlong with S. sphenantera \tRatio\tVictim drug alone\tAlong with S. sphenantera \tRatio\tVictim drug alone\tAlong with S. sphenantera \tRatio> Interaction with a single dose of midazolam (15 mg) based on the study by Xin et al.", {"entities": [[86, 95, "Drug"], [100, 110, "Drug"], [142, 165, "Herb name"], [169, 176, "Pathology"], [185, 200, "Parameter"], [204, 227, "Parameter"], [228, 240, "Parameter"], [270, 284, "Herb name"], [321, 335, "Herb name"], [372, 386, "Herb name"], [412, 425, "Frequency"], [429, 438, "Drug"], [440, 445, "Amount"]]}], [7976, "16 , b PBPK prediction\t138.2\t217.1\t1.57\t551.2\t1,117.5\t2.03\t27.2\t13.4\t0.49 Clinically\u2010reported values\t171.4 \u00b1 69.8\t282.3 \u00b1 152.2\t1.65\t577.7 \u00b1 226.8\t1,185.6 \u00b1 319.8\t2.05\t30.9 \u00b1 16.7\t13.8 \u00b1 5.8\t0.45 Prediction fold\u2010difference c \t0.81\t0.77\t0.95\t0.95\t0.94\t0.99\t0.88\t0.97\t1.09 Interaction with a single dose of tacrolimus (2 mg) based on the study by Xin et al.", {"entities": [[288, 301, "Frequency"], [305, 315, "Drug"], [317, 321, "Amount"]]}], [7977, "18 , d PBPK prediction\t21.5\t60.5\t2.81\t125.2\t305.1\t2.44\t16.0\t6.6\t0.41 Clinically\u2010reported values\t22.2 \u00b1 10.6\t66.4 \u00b1 12.3\t2.99\t129.5 \u00b1 65.1\t274.8 \u00b1 64.9\t2.12\t17.7 \u00b1 12.6\t6.5 \u00b1 1.5\t0.37 Prediction fold\u2010difference \t0.97\t0.91\t0.94\t0.97\t1.11\t1.15\t0.90\t1.02\t1.11 Open in a separate window  AUC0\u201324h, area under the plasma concentration\u2010time curve during 24 h after dose; CL/F, apparent clearance; C max, peak concentration.", {"entities": [[283, 291, "Parameter"], [293, 362, "Parameter"], [364, 388, "Parameter"], [390, 415, "Parameter"]]}], [7978, "A single oral dose of midazolam (15 mg) was given with and without S. sphenanthera extract containing schisandrin A (7.25 mg), schisantherin A (7.33 mg) and schisandrol B (0.12 mg) twice daily for 7 days prior to midazolam administration.", {"entities": [[0, 18, "Frequency"], [22, 31, "Drug"], [33, 38, "Amount"], [67, 90, "Herb name"], [102, 115, "Herb name"], [117, 124, "Amount"], [127, 142, "Herb name"], [144, 151, "Amount"], [157, 170, "Herb name"], [172, 179, "Amount"], [181, 192, "Frequency"], [193, 203, "Duration"], [213, 222, "Drug"]]}], [7979, "cPrediction\u2010fold differences were expressed as the ratio of PBPK prediction to clinically\u2010observed values.", {"entities": []}], [7980, "A single oral dose of tacrolimus (2 mg) was given in the presence and absence of S. sphenanthera extract containing schisandrin A (7.25 mg), schisantherin A (7.33 mg) and schisandrol B (0.12 mg) twice daily for 13 days prior to tacrolimus administration.", {"entities": [[0, 18, "Frequency"], [22, 32, "Drug"], [34, 38, "Amount"], [81, 104, "Herb name"], [116, 129, "Herb name"], [131, 138, "Amount"], [141, 156, "Herb name"], [158, 165, "Amount"], [171, 184, "Herb name"], [185, 193, "Amount"], [195, 206, "Frequency"], [207, 218, "Frequency"], [228, 238, "Drug"]]}], [7981, "2.3.", {"entities": []}], [7982, "PBPK prediction of interactions with imatinib and bosutinib  Input parameters for the PBPK model of imatinib and bosutinib 59 are summarised in Table S1.", {"entities": [[37, 45, "Drug"], [50, 59, "Drug"], [100, 108, "Drug"], [113, 122, "Drug"]]}], [7983, "Development and verification of the PBPK model of imatinib in adults from European ancestry at both single\u2010dose administration and steady\u2010state have been detailed elsewhere.", {"entities": [[50, 58, "Drug"], [74, 82, "Ethnic group"], [100, 111, "Frequency"]]}], [7984, "60 The PBPK model was also verified against clinical pharmacokinetic data in people from Chinese ancestry (unpublished).", {"entities": [[89, 96, "Ethnic group"]]}], [7985, "Imatinib was given at hypothetical single\u2010 and multiple\u2010dose of 400 mg, while bosutinib was administered at a single oral dose of 400 mg.", {"entities": [[0, 8, "Drug"], [35, 60, "Frequency"], [64, 70, "Amount"], [78, 87, "Drug"], [108, 126, "Frequency"], [130, 136, "Amount"]]}], [7986, "The typical maintenance dosing regimens were assigned for each Schisandra lignan based on their contents in commercial product 61 and recommended dose of S. sphenanthera extract.", {"entities": [[63, 80, "Herb name"], [154, 177, "Herb name"]]}], [7987, "Schisantherin A (9.4 mg), schisandrin A (6.8 mg) and schisandrol B (0.5 mg) were administered every 8 h for 14 days (steady\u2010state concentrations were assumed to be achieved within this timeframe).", {"entities": [[0, 15, "Herb name"], [17, 23, "Amount"], [26, 39, "Herb name"], [41, 47, "Amount"], [53, 66, "Herb name"], [68, 74, "Amount"], [94, 103, "Frequency"], [104, 115, "Duration"], [117, 144, "Parameter"]]}], [7988, "2.4.", {"entities": []}], [7989, "Nomenclature of targets and ligands  Key protein targets and ligands in this article are hyperlinked to corresponding entries in http://www.guidetopharmacology.org, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY, 62 and are permanently archived in the Concise Guide to PHARMACOLOGY 2017/18.", {"entities": []}], [7990, "63 , 64 Go to: 3.", {"entities": []}], [7991, "RESULTS 3.1.", {"entities": []}], [7992, "Inhibition of in vitro metabolism of imatinib and bosutinib by Schisandra lignans  Inhibitions of metabolite formation from imatinib and bosutinib by Schisandra lignans mainly followed a competitive inhibition model as depicted in Figure 1.", {"entities": [[37, 45, "Drug"], [50, 59, "Drug"], [63, 81, "Herb name"], [124, 132, "Drug"], [137, 146, "Drug"], [150, 168, "Herb name"]]}], [7993, "For model selection, the proposed models (competitive, noncompetitive and mixed\u2010inhibitions) were fitted to the experimental data, and their goodness\u2010of\u2010fit based on AIC is summarised in Table S2.", {"entities": []}], [7994, "Overall, k i,u values for bosutinib were substantially lower than those for imatinib.", {"entities": [[9, 14, "Parameter"], [26, 35, "Drug"], [76, 84, "Drug"]]}], [7995, "All the lignans exerted potent inhibitory activities towards the CYP2C8 enzyme, with k i,u of less than 0.5 \u03bcmol L\u22121 (Figure 1D\u2013F).", {"entities": [[8, 15, "Herb name"], [65, 78, "Target"], [85, 90, "Parameter"], [104, 116, "Amount"]]}], [7997, "The associated k i,u values were corrected for this depletion over the course of incubation (Figure 1).", {"entities": [[15, 20, "Parameter"]]}], [7998, "An external file that holds a picture, illustration, etc.", {"entities": []}], [7999, "Formation rates of N\u2010desmethyl bosutinib were expressed as peak ratios to the internal standard due to the absence of an authentic standard.", {"entities": [[19, 40, "Drug"]]}], [8000, "Inhibition models that fitted best to each set of experimental data and their associated k i,u values are summarised.", {"entities": [[89, 94, "Parameter"]]}], [8001, "Experimental data are depicted as the mean values and standard deviations (n = 3) An external file that holds a picture, illustration, etc.", {"entities": []}], [8002, "PBPK model prediction of interactions between Schisandra lignans and midazolam (D) and tacrolimus (E).", {"entities": [[46, 64, "Herb name"], [69, 78, "Drug"], [87, 97, "Drug"]]}], [8003, "Clinically\u2010observed data (mean concentrations with associated standard deviations) are overlaid on simulated pharmacokinetic profiles shown in linear scales with the corresponding semi\u2010logarithmic plots as insets.", {"entities": [[31, 45, "Parameter"]]}], [8004, "All clinical pharmacokinetic data were from studies in healthy Chinese people, except for schisandrol B which were from people of Korean ancestry An external file that holds a picture, illustration, etc.", {"entities": [[55, 62, "Pathology"], [63, 70, "Ethnic group"], [90, 103, "Herb name"], [130, 136, "Ethnic group"]]}], [8005, "Object name is BCP-86-2080-g006.jpg FIGURE 3  Evaluation of stability of Schisandra lignans during incubations with human liver microsomes (HLM, in the presence and absence of azamulin) and recombinant CYP3A4 (rCYP3A4) compared to control (A).", {"entities": [[73, 91, "Herb name"], [176, 184, "Drug"], [190, 218, "Parameter"]]}], [8006, "Conversely, schisandrin A was relatively stable in HLM in the presence of azamulin (C).", {"entities": [[12, 25, "Herb name"], [74, 82, "Drug"]]}], [8007, "* means significantly different to control (P < .01; one\u2010way analysis of variance) 3.2.", {"entities": []}], [8008, "PBPK models for Schisandra lignans  PBPK predictions of pharmacokinetics of schisandrin A, schisantherin A and schisandrol B following a single\u2010dose administration of S. sphenanthera extract were similar to the clinically\u2010observed values (Figure 2, Table 2).", {"entities": [[16, 34, "Herb name"], [76, 89, "Herb name"], [91, 106, "Herb name"], [111, 124, "Herb name"], [135, 148, "Frequency"], [167, 190, "Herb name"]]}], [8009, "There was good agreement between PBPK model predictions and clinical pharmacokinetic data of midazolam and tacrolimus with and without concomitant administration of S. sphenanthera extract.", {"entities": [[93, 102, "Drug"], [107, 117, "Drug"], [165, 188, "Herb name"]]}], [8010, "The clinically\u2010observed concentrations of both victim drugs all lay within the 5th to 95th percentiles of PBPK prediction (Figure 2).", {"entities": [[24, 38, "Parameter"]]}], [8012, "3.3.", {"entities": []}], [8013, "PBPK prediction of interactions with imatinib and bosutinib  Schisandra lignans at their recommended dose were predicted to increase systemic exposure (AUC) of a single dose of imatinib in people from Chinese or European ancestry by 40% and 33%, respectively (Figure 4A, D).", {"entities": [[37, 45, "Drug"], [50, 59, "Drug"], [61, 79, "Herb name"], [133, 156, "Parameter"], [160, 173, "Frequency"], [177, 185, "Drug"], [201, 208, "Ethnic group"], [212, 220, "Ethnic group"], [233, 236, "Amount"], [241, 244, "Amount"]]}], [8014, "Conversely, interactions with imatinib at steady\u2010state were predicted to be of no clinical importance in either population (less than 5% increase in AUC0\u201324h,ss and C min,ss of imatinib).", {"entities": [[30, 38, "Drug"], [134, 136, "Amount"], [149, 160, "Parameter"], [165, 173, "Parameter"], [177, 185, "Drug"]]}], [8015, "PBPK simulations enable prediction and interpretation of clinical consequences from different mechanism of interactions in isolation.", {"entities": []}], [8016, "An external file that holds a picture, illustration, etc.", {"entities": []}], [8017, "Object name is BCP-86-2080-g007.jpg FIGURE 4  PBPK model prediction of the interactions between Schisandra sphenanthera extract and imatinib (400 mg) at single\u2010 (A, D) and multiple\u2010dosing regimens (B, E) and single 400 mg of bosutinib (C, F).", {"entities": [[96, 127, "Herb name"], [132, 140, "Drug"], [142, 148, "Amount"], [153, 187, "Frequency"], [208, 214, "Frequency"], [215, 221, "Amount"], [225, 234, "Drug"]]}], [8018, "PBPK simulations were performed in both European and Chinese populations and depicted as mean predicted concentrations in the presence and absence of co\u2010administration with S. sphenanthera.", {"entities": [[40, 48, "Ethnic group"], [53, 60, "Ethnic group"], [104, 118, "Parameter"], [173, 188, "Herb name"]]}], [8019, "Schisantherin A (9.4 mg), schisandrin A (6.8 mg) and schisandrol B (0.5 mg) were given every 8 h as recommended in the product information.", {"entities": [[0, 15, "Herb name"], [17, 23, "Amount"], [26, 39, "Herb name"], [41, 47, "Amount"], [53, 66, "Herb name"], [68, 74, "Amount"], [87, 96, "Frequency"]]}], [8020, "MBI, mechanism\u2010based inhibition Go to: 4.", {"entities": []}], [8021, "DISCUSSION  PBPK models of the three lignans in S. sphenanthera responsible for interactions with CYP3A substrates were successfully developed in this study.", {"entities": [[37, 63, "Herb name"], [98, 103, "Parameter"]]}], [8022, "The PBPK models have an excellent performance in predicting the interactions with midazolam 16 and tacrolimus 18 with Schisandra lignans as observed in the corresponding clinical studies.", {"entities": [[82, 91, "Drug"], [99, 109, "Drug"], [118, 136, "Herb name"], [170, 186, "Study"]]}], [8023, "The verified models were then implemented to predict (a priori) the extent of interactions with imatinib and bosutinib.", {"entities": [[96, 104, "Drug"], [109, 118, "Drug"]]}], [8024, "It is noteworthy that S. sphenanthera is less commonly used in Western countries compared to Schisandra chinensis.", {"entities": [[22, 37, "Herb name"], [93, 113, "Herb name"]]}], [8025, "1 However, there is a paucity of clinical pharmacokinetic data for the latter.", {"entities": []}], [8026, "Despite a substantial difference in major constituents for both Schisandra species, 52 the trend and extent of interactions with midazolam, a probe drug for CYP3A enzymes at an equivalent dose of the respective extracts, are likely to be similar.", {"entities": [[64, 82, "Herb name"], [129, 138, "Drug"], [157, 170, "Parameter"]]}], [8027, "15  Although the PBPK models for schisandrin A and schisantherin A have been described before, 9 , 66 the evaluation of their capabilities in describing the clinically\u2010observed interactions with victim drugs is lacking.", {"entities": [[33, 46, "Herb name"], [51, 66, "Herb name"]]}], [8029, "Inhibition of tacrolimus metabolism by the combination of schisandrin A and schisantherin A was considerably overestimated using the previously reported models.", {"entities": [[14, 24, "Drug"], [58, 71, "Herb name"], [76, 91, "Herb name"]]}], [8030, "9 This limitation was inherently circumvented by the incorporation of CYP3A induction 15 to the models as described in this study (Table 1).", {"entities": [[70, 75, "Target"]]}], [8031, "16 , 17 , 18 , 19 In this complex interaction scenario (simultaneous reversible and mechanism\u2010based inhibitions and induction of CYP3A enzymes by multiple modulators), a PBPK modelling approach is best positioned to provide a more mechanistic prediction of the extent of interaction.", {"entities": [[129, 142, "Target"]]}], [8032, "48 A comprehensive characterisation of metabolic pathways for each of the perpetrator compounds in S. sphenanthera extract 11 , 12 also enables auto\u2010inhibition and potential interactions among Schisandra lignans to be accounted for in the PBPK models.", {"entities": [[99, 122, "Herb name"], [193, 211, "Herb name"]]}], [8033, "However, a lack of clinical pharmacokinetic data following multiple\u2010dosing regimens of S. sphenanthera extract limited further verification of the models at steady state.", {"entities": [[87, 110, "Herb name"]]}], [8034, "It is noteworthy that while clinical pharmacokinetic data for schisandrin A and schisantherin A were extracted from a study by Wei et al.", {"entities": [[62, 75, "Herb name"], [80, 95, "Herb name"]]}], [8035, "55 clinical data of schisandrol B were taken from another study.", {"entities": [[20, 33, "Herb name"]]}], [8037, "Unfortunately, clinical data of both schisandrin A and schisantherin A were not reported in this study.", {"entities": [[37, 50, "Herb name"], [55, 70, "Herb name"]]}], [8038, "The interactions between Schisandra lignans and both midazolam and tacrolimus in Chinese people were predicted with excellent accuracy (Figure 2, Table 3).", {"entities": [[25, 43, "Herb name"], [53, 62, "Drug"], [67, 77, "Drug"], [81, 88, "Ethnic group"]]}], [8039, "The simulation results implied that the PBPK model for tacrolimus, which was originally developed in European people, 57 could seamlessly be extrapolated to a Chinese population relying on the differences in body size, amount of CYP3A enzymes and frequency of CYP3A5 expression in the populations.", {"entities": [[55, 65, "Drug"], [101, 109, "Ethnic group"], [159, 166, "Ethnic group"], [229, 242, "Parameter"], [260, 277, "Parameter"]]}], [8040, "58 Despite this modification, the overall trend of interaction between Schisandra lignans and midazolam was well captured by the PBPK simulation, shown by similar ratios of AUC and C max compared to the clinically\u2010reported parameter values (Table 3).", {"entities": [[71, 89, "Herb name"], [94, 103, "Drug"], [173, 176, "Parameter"], [181, 186, "Parameter"]]}], [8041, "S. sphenanthera was predicted to affect midazolam given intravenously to a lesser extent than that by oral administration (AUC ratios of 1.4 vs 2.0, respectively; simulations not shown), suggesting a more extensive inhibition of intestinal CYP3A compared to the corresponding enzymes in hepatocytes.", {"entities": [[0, 15, "Herb name"], [40, 49, "Drug"], [123, 133, "Parameter"], [137, 140, "Amount"], [144, 147, "Amount"], [229, 245, "Target"], [276, 298, "Parameter"]]}], [8042, "This disparity was attributed to the mechanism\u2010based inactivation of CYP3A4 69 by a reactive metabolite of imatinib.", {"entities": [[69, 75, "Target"], [107, 115, "Drug"]]}], [8043, "70 This leads to a lower sensitivity towards CYP3A inhibition at steady\u2010state, as demonstrated by a lack of clinically\u2010significant interaction between imatinib and ritonavir.", {"entities": [[45, 50, "Target"], [151, 159, "Drug"], [164, 173, "Drug"]]}], [8044, "by carbamazepine and phenytoin, 72 the predominant outcome from a chronic exposure to Schisandra lignans is a CYP3A inhibition and not induction.", {"entities": [[3, 16, "Drug"], [21, 30, "Drug"], [86, 104, "Herb name"], [110, 115, "Target"]]}], [8045, "To our knowledge, this is the first study to highlight a reversible CYP2C8 inhibition by Schisandra lignans which may have clinical implications for other CYP2C8 substrates.", {"entities": [[68, 74, "Target"], [89, 107, "Herb name"], [155, 161, "Parameter"]]}], [8046, "The extent of interactions between imatinib and S. sphenanthera extract in Chinese and European people were predicted to be similar.", {"entities": [[35, 43, "Drug"], [48, 71, "Herb name"], [75, 82, "Ethnic group"], [87, 95, "Ethnic group"]]}], [8047, "It is worth mentioning that the PBPK models of Schisandra lignans have not been verified in European people due to the lack of clinical pharmacokinetic data in this population.", {"entities": [[47, 65, "Herb name"], [92, 100, "Ethnic group"]]}], [8048, "75 This was in concordance with in vitro metabolic phenotyping which hinted at a significant role of CYP3A4 enzyme (but not CYP3A5) in bosutinib metabolism with minor contribution from flavin\u2010containing monooxygenase (FMO) and uridine 5\u2032\u2010diphospho\u2010glucuronosyltransferase (UGT) enzymes.", {"entities": [[101, 114, "Parameter"], [124, 130, "Parameter"], [135, 144, "Drug"], [185, 222, "Parameter"], [227, 285, "Parameter"]]}], [8049, "77 N\u2010desmethyl bosutinib (M5) and oxydechlorinated bosutinib (M2) are the main circulating metabolites in plasma with systemic exposures (AUC) of approximately 25 and 20% of the parent drug, respectively.", {"entities": [[3, 29, "Drug"], [34, 65, "Drug"], [118, 142, "Parameter"], [160, 162, "Amount"], [167, 170, "Amount"]]}], [8051, "Unlike imatinib, bosutinib has a high hepatic extraction ratio and its metabolism relies heavily on CYP3A4 enzyme.", {"entities": [[7, 15, "Drug"], [17, 26, "Drug"], [100, 113, "Parameter"]]}], [8052, "33 Therefore, it was unsurprising that bosutinib was predicted to be more affected by Schisandra lignans compared to imatinib (Figure 4).", {"entities": [[39, 48, "Drug"], [86, 104, "Herb name"], [117, 125, "Drug"]]}], [8053, "PBPK simulation indicated a more important role of reversible compared to mechanism\u2010based inactivation of CYP3A enzymes to the overall interaction between Schisandra lignans and bosutinib.", {"entities": [[106, 119, "Target"], [155, 173, "Herb name"], [178, 187, "Drug"]]}], [8054, "However, given a long turnover half\u2010life for CYP3A4 (approximately 1.5 days 79 ), the effect of MBI towards this enzyme may persist beyond cessation of S. sphenanthera consumption.", {"entities": [[31, 51, "Parameter"], [67, 75, "Amount"], [152, 167, "Herb name"]]}], [8055, "The target AUC0\u201324h for bosutinib is likely to be around 2.5\u20133 \u03bcg h\u22121 mL \u22121, above which the probability of developing diarrhoea and rash reaches a maximum without significant improvement in clinical responses.", {"entities": [[11, 19, "Parameter"], [24, 33, "Drug"], [57, 75, "Amount"], [119, 128, "Pathology"], [133, 137, "Pathology"]]}], [8056, "80 Based on this apparent threshold for target AUC, the PBPK simulations suggested that daily dose of bosutinib should be reduced from 400 to 150\u2013200 mg in the presence of interaction with Schisandra lignans at clinically\u2010relevant concentrations.", {"entities": [[47, 51, "Parameter"], [102, 111, "Drug"], [135, 138, "Amount"], [142, 152, "Amount"], [189, 207, "Herb name"], [231, 245, "Parameter"]]}], [8057, "One of the limitations of the current work is that the MBI 81 and induction of CYP3A enzymes by schisandrol B 82 were not included in the PBPK model.", {"entities": [[79, 92, "Target"], [96, 109, "Herb name"]]}], [8058, "The available data for a key related parameter, that is the ratio of K inact to K I of schisandrol B 81 is unrealistically higher than that of schisandrin A and schisantherin A 9 (336 vs 1 and 2 L \u03bcmol\u22121 h\u22121, respectively).", {"entities": [[69, 76, "Parameter"], [80, 83, "Parameter"], [87, 100, "Herb name"], [143, 156, "Herb name"], [161, 176, "Herb name"], [180, 183, "Amount"], [187, 207, "Amount"]]}], [8059, "Another limitation of the current study is the reliance on the assumption that Schisandra lignans are solely responsible for the interactions with CYP substrates.", {"entities": [[79, 97, "Herb name"], [147, 150, "Parameter"]]}], [8060, "However, this is reasonable as other constituents of S. sphenanthera extract are either unlikely to interact with CYP3A4 and CYP2C8 enzymes (e.g.", {"entities": [[53, 76, "Herb name"], [114, 120, "Parameter"], [125, 139, "Parameter"]]}], [8061, "lipids or triacylglycerols and essential oils) or are present at very low concentrations, e.g.", {"entities": [[0, 6, "Parameter"], [10, 26, "Parameter"], [31, 45, "Parameter"]]}], [8062, "\u03b2\u2010sitosterol (0.5%).", {"entities": [[0, 12, "Herb name"], [14, 18, "Amount"]]}], [8063, "83 Although \u03b2\u2010sitosterol has been reported as a CYP3A inhibitor (IC50 = 421 \u03bcmol L\u22121), 84 the steady\u2010state concentrations that may be attained from a standard clinical dose of S. sphenanthera extract is lower than its IC50 by five orders of magnitude.", {"entities": [[12, 24, "Herb name"], [48, 53, "Target"], [65, 69, "Parameter"], [72, 84, "Amount"], [90, 121, "Parameter"], [176, 191, "Herb name"], [218, 222, "Parameter"]]}], [8064, "85 A further limitation to this study is a lack of consideration for pharmacodynamic\u2010based interactions with both imatinib and bosutinib.", {"entities": [[114, 122, "Drug"], [127, 136, "Drug"]]}], [8065, "A clinical study in Chinese liver transplant recipients suggested that S. sphenanthera extract may alleviate diarrhoea associated with treatment with tacrolimus.", {"entities": [[0, 16, "Study"], [20, 27, "Ethnic group"], [71, 86, "Herb name"], [109, 118, "Pathology"], [150, 160, "Drug"]]}], [8066, "4 Given diarrhoea is also common in patients receiving imatinib or bosutinib, 28 , 31 , 80 Schisandra lignans may help ameliorate this adverse event.", {"entities": [[8, 17, "Pathology"], [55, 63, "Drug"], [67, 76, "Drug"], [91, 109, "Herb name"], [135, 148, "Pathology"]]}], [8067, "Constituents of S. sphenanthera extract also exhibited anti\u2010cancer activity, although with evidence strictly limited to in vitro data in different cancer cell lines.", {"entities": [[16, 39, "Herb name"], [55, 75, "Pathology"]]}], [8068, "5 , 6 Potential clinical benefits for patients with CML remain to be investigated.", {"entities": [[52, 55, "Pathology"]]}], [8069, "Go to: 5.", {"entities": []}], [8070, "CONCLUSIONS  PBPK models for the constituents of S. sphenanthera extract responsible for interactions were successfully developed and verified using existing clinical pharmacokinetic and herb\u2013drug interaction data with midazolam and tacrolimus.", {"entities": [[49, 72, "Herb name"], [219, 228, "Drug"], [233, 243, "Drug"]]}], [8071, "Further clinical studies to confirm the extent of interaction with bosutinib and implications for the clinical outcomes are warranted.", {"entities": [[8, 24, "Study"], [67, 76, "Drug"]]}], [8072, "Ginkgo biloba is available as an over-the-counter drug and reported to cause haemorrhage when coadministered with other antiplatelet agents.", {"entities": [[0, 13, "Herb name"], [77, 88, "Pathology"], [120, 139, "Drug"]]}], [8073, "We set out to study the interactions of G. biloba with cilostazol and clopidogrel.", {"entities": [[40, 49, "Herb name"], [55, 65, "Drug"], [70, 81, "Drug"]]}], [8075, "Platelet aggregation, platelet count, bleeding time and clotting time were measured 0 and 6 h after drug administration.", {"entities": [[0, 20, "Parameter"], [22, 36, "Parameter"], [38, 51, "Parameter"], [56, 69, "Parameter"]]}], [8076, "Platelet aggregation was performed using a dual channel aggregometer, by the turbimetric technique using adenosine diphosphate 5 \u00b5mol and 10 \u00b5mol, and collagen 1 \u00b5g ml Platelet inhibition with the combination of G. biloba and clopidogrel or cilostazol was not statistically significant compared with individual doses of drugs, with all the three aggregants.", {"entities": [[0, 20, "Parameter"], [212, 221, "Herb name"], [226, 237, "Drug"], [241, 251, "Drug"]]}], [8077, "There was significant (P< 0.05) potentiation of prolongation of bleeding time with the combination of cilostazol and G. biloba compared with individual doses of both the drugs.", {"entities": [[64, 77, "Parameter"], [102, 112, "Drug"], [117, 126, "Herb name"]]}], [8078, "There was no significant change in clotting time and platelet count.", {"entities": [[35, 48, "Parameter"], [53, 67, "Parameter"]]}], [8079, "Coadministration of G. biloba either with cilostazol or clopidogrel did not enhance antiplatelet activity compared with individual agents.", {"entities": [[20, 29, "Herb name"], [42, 52, "Drug"], [56, 67, "Drug"]]}], [8080, "Ginkgo biloba potentiated the bleeding time prolongation effect of cilostazol.", {"entities": [[0, 13, "Herb name"], [30, 43, "Parameter"], [67, 77, "Drug"]]}], [8081, "There was no significant correlation between prolongation of bleeding time and inhibition of platelet aggregation.", {"entities": [[61, 74, "Parameter"], [93, 113, "Parameter"]]}], [8083, "Conflict of Interest/Disclosure The authors have no conflicts of interest to disclose.\nBotanical dietary supplements produced from hops (Humulus lupulus) containing the chemopreventive compound xanthohumol and phytoestrogen 8-prenylnaringenin are used by women to manage menopausal symptoms.\nDue to the long half-lives of prenylated hop phenols and reports that they inhibit certain cytochrome P450 enzymes, a botanically authenticated and chemically standardized hop extract was tested for Phase I pharmacokinetic drug interactions.\nSixteen peri- and post-menopausal women consumed the hop extract twice daily for 2 weeks, and the pharmacokinetics of tolbutamide, caffeine, dextromethorphan, and alprazolam were evaluated before and after supplementation as probe substrates for the enzymes CYP2C9, CYP1A2, CYP2D6, and CYP3A4/5, respectively.\nThe observed area under the time-concentration curves were unaffected, except for alprazolam which decreased 7.6% (564.6 \u00b1 46.1 h*\u03bcg/L pre-hop and 521.9 \u00b1 36.1 h*\u03bcg/L post-hop; p-value 0.047), suggesting minor induction of CYP3A4/5.\nNo enzyme inhibition was detected.\nAccording to FDA guidelines, this hop dietary supplement caused no clinically relevant pharmacokinetic interactions with respect to CYP2C9, CYP1A2 , CYP2D6, or CYP3A4/5.\nSerum obtained after consumption of the hop extract was analyzed using UHPLC-MS/MS to confirm compliance.\nAbundant Phase II conjugates of the hop prenylated phenols were observed including monoglucuronides and monosulfates as well as previously unreported diglucuronides and sulfate-glucuronic acid diconjugates.\n", {"entities": [[131, 135, "Herb name"], [137, 152, "Herb name"], [194, 205, "Herb name"], [210, 242, "Herb name"], [255, 260, "Sex"], [322, 344, "Herb name"], [383, 398, "Target"], [534, 567, "Cohort"], [568, 573, "Sex"], [599, 610, "Frequency"], [615, 622, "Duration"], [652, 663, "Drug"], [665, 673, "Drug"], [675, 691, "Drug"], [697, 707, "Drug"], [857, 897, "Parameter"], [926, 936, "Drug"], [959, 978, "Amount"], [991, 1010, "Amount"], [1067, 1075, "Target"], [1146, 1149, "Herb name"], [1424, 1446, "Herb name"], [1471, 1487, "Herb name"], [1492, 1504, "Herb name"], [1538, 1552, "Herb name"], [1557, 1593, "Herb name"]]}], [8084, "Radix Salvia miltiorrhiza (Danshen) and Radix Puerariae lobatae (Gegen) are used in Traditional Chinese Medicine to treat cardiovascular diseases.", {"entities": [[0, 35, "Herb name"], [40, 71, "Herb name"], [96, 103, "Ethnic group"], [122, 145, "Pathology"]]}], [8085, "However, adverse herb-drug interactions were observed between warfarin and herbal remedies containing Danshen and Gegen.", {"entities": [[62, 70, "Drug"], [102, 109, "Herb name"], [114, 119, "Herb name"]]}], [8086, "This study aims to investigate the pharmacokinetic and pharmacodynamic interactions between warfarin and the different components found in Danshen and Gegen.", {"entities": [[92, 100, "Drug"], [139, 146, "Herb name"], [151, 156, "Herb name"]]}], [8087, "Sixty Sprague\u2013Dawley rats were used to investigate the effects of warfarin (0.2\u00a0mg/kg), Danshen (240 or 480\u00a0mg/kg) and Gegen (240 or 480\u00a0mg/kg) both in isolation and combination.", {"entities": [[66, 74, "Drug"], [76, 85, "Amount"], [88, 95, "Herb name"], [97, 113, "Amount"], [119, 124, "Herb name"], [126, 142, "Amount"]]}], [8088, "The rats in the warfarin and Danshen/Gegen combination groups were given an oral dose of Danshen or Gegen 2\u00a0h after being given an oral dose of warfarin.", {"entities": [[16, 24, "Drug"], [29, 36, "Herb name"], [37, 42, "Herb name"], [89, 96, "Herb name"], [100, 105, "Herb name"], [144, 152, "Drug"]]}], [8089, "After five consecutive days of treatment, the pharmacokinetic interactions between Danshen/Gegen and warfarin were investigated by simultaneously monitoring and comparing the cytochrome P450 (CYP) activities, mRNA and protein expression levels in the livers of the rats from the different treatment groups.", {"entities": [[6, 27, "Duration"], [83, 90, "Herb name"], [91, 96, "Herb name"], [101, 109, "Drug"], [175, 196, "Target"]]}], [8090, "The pharmacodynamic interactions were evaluated by monitoring and comparing the vitamin K epoxide reductase (VKOR) activities, mRNA and protein expression levels in the livers of rats from the different groups, as well as the thrombomodulin (TM) activities, mRNA and protein in the lungs of these animals.", {"entities": [[80, 114, "Target"], [226, 245, "Target"]]}], [8091, "Microsomes incubation, Real Time-Polymerase Chain Reaction and Western blot was applied respectively to study the activity, mRNA expression and protein expression of CYP, VKOR and TM.", {"entities": [[166, 169, "Target"], [171, 175, "Target"], [180, 182, "Target"]]}], [8092, "The activities and expression levels of the CYP and VKOR enzymes in the warfarin-Gegen combination groups increased by nearly 30\u00a0% (P\u00a0=\u00a00.02) compared with the warfarin-alone group, whereas those of TM decreased by almost 25\u00a0% (P\u00a0=\u00a00.02).", {"entities": [[44, 47, "Target"], [52, 56, "Target"], [72, 80, "Drug"], [81, 86, "Herb name"], [160, 168, "Drug"], [199, 201, "Target"]]}], [8093, "The administration of Danshen did not lead to any changes in the activities or the expression levels of the CYP, VKOR or TM enzymes compared with those of the control group.", {"entities": [[22, 29, "Herb name"], [108, 111, "Target"], [113, 117, "Target"], [121, 123, "Target"]]}], [8094, "Gegen induced several warfarin-metabolizing CYP enzymes and neutralized the effects of warfarin towards VKOR and TM.", {"entities": [[0, 5, "Herb name"], [22, 30, "Drug"], [44, 55, "Target"], [87, 95, "Drug"], [104, 108, "Target"], [113, 115, "Target"]]}], [8095, "Gegen, rather than Danshen at the same tested dosage, offsets the anticoagulant effects of warfarin by accelerating the phase I liver metabolism of warfarin, as well as increasing the activity, mRNA and protein expression of VKOR while decreasing those of TM.", {"entities": [[0, 5, "Herb name"], [19, 26, "Herb name"], [91, 99, "Drug"], [148, 156, "Drug"], [225, 229, "Target"], [256, 258, "Target"]]}], [8096, "The online version of this article (doi:10.1186/s13020-016-0078-9) contains supplementary material, which is available to authorized users.", {"entities": []}], [8097, "The use of the anticoagulant warfarin in combination with herbal remedies has caused several safety concerns because of the narrow therapeutic window of warfarin [1].", {"entities": [[11, 37, "Drug"], [153, 161, "Drug"]]}], [8098, "According to reports from pharmacists in the United Kingdom, about 58\u00a0% of patients prescribed warfarin also regularly consumed herbal medicines to manage their conditions [2, 3].", {"entities": [[95, 103, "Drug"]]}], [8099, "A racemic mixture of warfarin consists of a 1:1 mixture of its R- and S-enantiomers, which differ considerably in terms of their potency and the rate at which they are metabolized [4].", {"entities": [[21, 29, "Drug"]]}], [8100, "Both of the enantiomers of warfarin are metabolized by cytochrome P450 (CYP) enzymes in a region- and stereo-selective manner, to afford the corresponding 6-, 7-, 8-, 10- and 4\u2032-hydroxywarfarin compounds as the major metabolites [5].", {"entities": [[27, 35, "Drug"], [55, 84, "Target"], [155, 193, "Drug"]]}], [8101, "The ingestion of certain plant materials such as grapefruit [6] and garlic [7, 8] can have a pronounced effect on the activity and/or expression of the CYP enzymes, which could have serious consequences for the metabolism of warfarin.", {"entities": [[49, 59, "Herb name"], [68, 74, "Herb name"], [152, 163, "Target"], [225, 233, "Drug"]]}], [8102, "The co-administration of herbs and drugs can also affect the activity and expression of vitamin K epoxide reductase (VKOR), which is the target protein of warfarin in terms of its anticoagulant effects.", {"entities": [[88, 122, "Target"], [155, 163, "Drug"]]}], [8103, "Although there were two separate studies pertaining to the inhibitory activities of the drug-warfarin interactions of paracetamol and sodium dehydroacetate (DHA-S) towards VKOR [9, 10], there were studies concerning the impact of herbs on the activity or expression of VKOR.", {"entities": [[93, 101, "Drug"], [118, 129, "Drug"], [172, 176, "Target"], [269, 273, "Target"]]}], [8104, "In addition to VKOR, plasma-soluble thrombomodulin TM (sTM), which is the cleavage product of cellular TM [11], could be used as a potential biomarker for identifying patients at high risk of bleeding during warfarin treatment [12\u201314].", {"entities": [[15, 19, "Target"], [21, 59, "Target"], [192, 200, "Pathology"], [208, 216, "Drug"]]}], [8105, "Notably, Salvianolic acid B led to an increase in the activity and expression of TM in vitro [15].", {"entities": [[81, 83, "Target"], [84, 92, "Study"]]}], [8106, "Danshen-Gegen formula (DGF), which is a herbal medicine containing Radix Salvia miltiorrhiza (Danshen) and Radix Puerariae lobatae (Gegen), led to a 5.36-fold increase in the mRNA expression of TM [16].", {"entities": [[0, 27, "Herb name"], [67, 102, "Herb name"], [107, 139, "Herb name"]]}], [8107, "DGF, which is the aqueous extract derived of a 7:3 (w/w) mixture of Danshen and Gegen, was recently developed in Hong Kong [17].", {"entities": [[0, 3, "Herb name"], [18, 33, "Extraction process"], [68, 75, "Herb name"], [80, 85, "Herb name"]]}], [8108, "DGF contains a variety of active components, including danshensu, salvianolic acid B (SAB), protocatechuic aldehyde (PCA), puerarin, daidzin and daidzein [18], and was reported to be an effective agent for the treatment of cardiovascular diseases [19\u201321].", {"entities": [[0, 3, "Herb name"], [55, 64, "Herb name"], [66, 90, "Herb name"], [92, 121, "Herb name"], [123, 131, "Herb name"], [133, 140, "Herb name"], [145, 153, "Herb name"], [223, 246, "Pathology"]]}], [8109, "The results of our previous in vivo study in rats demonstrated that the co-administration of DGF with warfarin led to pronounced herb-drug interactions [22], including a significant decrease in the C Danshen was reported to improve microcirculation, cause coronary vasodilation, suppress the formation of the thromboxane and inhibit the adhesion and aggregation of platelets.", {"entities": [[28, 41, "Study"], [93, 96, "Herb name"], [102, 110, "Drug"], [198, 207, "Herb name"], [256, 277, "Pathology"]]}], [8110, "Based on its many interesting biological properties, Danshen has been widely used to treat coronary artery disease and numerous other cardiovascular diseases in China, Korea and Japan, as well as several other Asian countries [23\u201325].", {"entities": [[53, 60, "Herb name"], [91, 114, "Pathology"], [134, 157, "Pathology"], [210, 215, "Ethnic group"]]}], [8111, "Although the results of several previous studies suggested that Danshen interacts with warfarin by changing its pharmacokinetic and pharmacodynamic parameters [26\u201329], these studies generally fail to provide dosage information for Danshen.", {"entities": [[64, 71, "Herb name"], [87, 95, "Drug"], [231, 238, "Herb name"]]}], [8112, "Furthermore, there are several inconsistencies in the findings of these studies.", {"entities": []}], [8113, "Preclinical studies in this area not reached an agreement on the effects of Danshen on the PT time of warfarin after the co-administration of these agents [30, 31].", {"entities": [[0, 19, "Study"], [76, 83, "Herb name"], [91, 98, "Parameter"], [102, 110, "Drug"]]}], [8114, "The discrepancies observed in these pre-clinical and clinical research data could be explained in terms of the differences in the administration routes, dosages and Danshen preparations used in the different studies.", {"entities": [[36, 70, "Study"], [165, 172, "Herb name"]]}], [8115, "In this study, we used an ex vivo approach to mimic the clinical behaviors of warfarin and Danshen and investigate the underlying mechanism of interaction between these two agents.", {"entities": [[26, 42, "Study"], [78, 86, "Drug"], [91, 98, "Herb name"]]}], [8116, "Compared with Danshen, there were very few reports pertaining to the herb-drug interactions of Gegen, which is another major component of DGF.", {"entities": [[14, 21, "Herb name"], [95, 100, "Herb name"], [138, 141, "Herb name"]]}], [8117, "In a similar manner to Danshen, Gegen was reported to improve micro-circulation, increasing blood flow and preventing coronary artery disease [32].", {"entities": [[23, 30, "Herb name"], [32, 37, "Herb name"], [118, 141, "Pathology"]]}], [8118, "Puerarin and Gegen extract were reported to regulate the activity of certain CYP enzymes in rats [33].", {"entities": [[0, 8, "Herb name"], [13, 18, "Herb name"], [77, 88, "Target"]]}], [8119, "Furthermore, the results of a recent clinical study showed that puerarin induced the activity of CYP1A2 and inhibited the activity of CYP2D6 [34], which indicated that there could be potential interactions between warfarin and Gegen.", {"entities": [[37, 51, "Study"], [64, 72, "Herb name"], [97, 103, "Target"], [134, 140, "Target"], [214, 222, "Drug"], [227, 232, "Herb name"]]}], [8120, "Existing mechanistic studies mainly focused on the impact of changes in the pharmacokinetics of warfarin rather than its pharmacodynamics, despite the fact that changes in the latter account for 79.9\u00a0% of all the identifiable herb-drug interaction mechanisms [35].", {"entities": [[9, 28, "Study"], [96, 104, "Drug"]]}], [8121, "This study aims to investigate the pharmacokinetic and pharmacodynamic interactions between warfarin and Danshen/Gegen.", {"entities": [[92, 100, "Drug"], [105, 112, "Herb name"], [113, 118, "Herb name"]]}], [8122, "To achieve these goals, we applied an ex vivo approach to investigate the effects of Danshen/Gegen on the different CYP enzymes involved in the metabolism of warfarin (for pharmacokinetic analysis).", {"entities": [[38, 54, "Study"], [85, 92, "Herb name"], [93, 98, "Herb name"], [116, 127, "Target"], [158, 166, "Drug"]]}], [8123, "We also monitored the effects of Danshen/Gegen on the activities and mRNA and protein expression levels of VKOR and TM (for pharmacodynamic analysis).", {"entities": [[33, 40, "Herb name"], [41, 46, "Herb name"], [107, 111, "Target"], [116, 118, "Target"]]}], [8124, "The concentrated Chinese medicine granules of Danshen (Batch No.", {"entities": [[17, 24, "Ethnic group"], [46, 53, "Herb name"]]}], [8125, "1007) and Gegen (Batch No.", {"entities": [[10, 15, "Herb name"]]}], [8126, "1027) with the extraction ratio of 1:5 were purchased from Nong\u2019s Company Limited (Hong Kong).", {"entities": []}], [8127, "The raw herbs were morphologically authenticated by an in-house herbalist and chemically by the thin layer chromatography in accordance with the Chinese Pharmacopoeia 2005 [36].", {"entities": [[145, 152, "Ethnic group"]]}], [8128, "The plant names in current study were used according to the latest revision in \u201cThe Plant List\u201d ( Racemic warfarin, diclofenac sodium and naringin (internal standards) were purchased from Sigma-Aldrich (St. Louis, MO, USA).", {"entities": [[106, 114, "Drug"], [116, 133, "Drug"], [138, 146, "Herb name"]]}], [8130, "Phenobarbital (PB), beta-naphthoflavone (BNF), cyclophosphamide monohydrate (CPA), bovine serum albumin, S-2238 and human thrombin were purchased from Sigma-Aldrich (St. Louis, MO, USA).", {"entities": [[0, 18, "Drug"], [47, 81, "Drug"]]}], [8131, "Vitamin K Healthy male SD rats (220\u2013250\u00a0g) were supplied by the Animal Service Center at the Chinese University of Hong Kong and fasted overnight before use.", {"entities": [[0, 9, "Target"], [10, 17, "Pathology"], [18, 22, "Sex"], [93, 100, "Ethnic group"]]}], [8132, "The experiments were carried out under the approval by the Animal Ethics Committee of the Chinese University of Hong Kong with an approval number of (12-538) in DH/HA&P/8/2/1 Pt.26 (Additional file 1).", {"entities": [[90, 97, "Ethnic group"]]}], [8133, "The LC/MS/MS system, used for sample analyses of warfarin and its monohydroxylated metabolites, were performed with an ABI 2000 tandem triple quadruple LC/MS spectrometer equipped with an electrospray ionization source (ESI), two Perkin-Elmer PE-200 series micro-pumps and auto-sampler (Perkin-Elmer, Norwalk, CT, USA).", {"entities": [[49, 57, "Drug"]]}], [8134, "The liquid chromatographic sample analyses instrument for detecting VK and VKO was a Waters HPLC system (Waters, Milford, MA,USA) equipped with 996 photodiode-array detector and 2695 separation module (pump and auto sampler).", {"entities": [[68, 70, "Target"], [75, 78, "Target"]]}], [8135, "The chromatographic separation was performed at ambient temperature by X-Bridge\u2122 C Identification and quantification of the major components in Danshen and Gegen granules were performed by Waters HPLC according to our previous study with modifications [22].", {"entities": [[144, 151, "Herb name"], [156, 161, "Herb name"]]}], [8136, "The chromatographic separation of the analytes was achieved by an Agilent Eclipse XDB-C18 column (250\u00a0\u00d7\u00a04.6\u00a0mm i.d., 5\u00a0\u03bcm particle size).", {"entities": []}], [8137, "The mobile phase consisting of 0.5\u00a0% acetic acid in acetonitrile (solvent A) and 0.5\u00a0% acetic acid in water (solvent B) was run with gradient elution at a flow rate of 1\u00a0mL/min.", {"entities": []}], [8138, "The linear gradient elution was carried out as follows with a total running time of 90\u00a0min: solvent A was kept at 5\u00a0% for the first 5\u00a0min, and then increased to 10, 17, 35 and 90\u00a0% in the next 13, 12, 10 and 30\u00a0min, respectively, then returned to 5\u00a0% in 5\u00a0min and equilibrated for 15\u00a0min before the next injection.", {"entities": []}], [8139, "HPLC analyses indicated that the marker compounds (\u00b5g/100\u00a0mg granules, mean\u00a0\u00b1\u00a0SD, n\u00a0=\u00a03) for Danshen granules were danshensu (1140.3\u00a0\u00b1\u00a024.6), SAB (821.3\u00a0\u00b1\u00a033.1), PCA (82.2\u00a0\u00b1\u00a04.6), and that for Gegen granules were puerarin (1314.9\u00a0\u00b1\u00a044.1), daidzein (74.4\u00a0\u00b1\u00a09.4) and daidzin (89.2\u00a0\u00b1\u00a07.2), respectively.", {"entities": [[93, 100, "Herb name"], [115, 124, "Herb name"], [162, 165, "Herb name"], [193, 198, "Herb name"], [213, 221, "Herb name"], [239, 247, "Herb name"], [265, 272, "Herb name"]]}], [8140, "The dosage of Danshen and Gegen for rats were both 240\u00a0mg/kg/day (twice a day), which were calculated from its respective clinical therapeutic dose recommended by Chinese Pharmacopeia [36].", {"entities": [[14, 21, "Herb name"], [26, 31, "Herb name"], [51, 64, "Amount"], [66, 77, "Frequency"], [163, 170, "Ethnic group"]]}], [8141, "Since the clinical therapeutic dosage of warfarin in common use was 1\u20132\u00a0mg/day for a person, the equivalent rats dosage was calculated to be 0.2\u00a0mg/kg (human equivalent dosage in rat\u00a0=\u00a0human dosage/60\u00a0kg\u00a0\u00d7\u00a06.2), once daily [38].", {"entities": [[41, 49, "Drug"], [68, 78, "Amount"], [141, 150, "Amount"], [212, 222, "Frequency"]]}], [8142, "Danshen/Gegen was given to rats twice daily.", {"entities": [[0, 7, "Herb name"], [8, 13, "Herb name"], [32, 43, "Frequency"]]}], [8143, "In the combination groups, Danshen/Gegen was given to rats 2\u00a0h after the oral dosing of warfarin.", {"entities": [[27, 34, "Herb name"], [35, 40, "Herb name"], [88, 96, "Drug"]]}], [8144, "In addition to the drug-treated groups, H The rat livers were perfused by saline before being excided surgically on ice and cut into pieces for storage at \u221280\u00a0\u00b0C.", {"entities": []}], [8145, "The liver microsomes were prepared by series centrifugation as described previously [39].", {"entities": []}], [8146, "Briefly, liver samples were thawed and weighed before homogenization medium were added.", {"entities": []}], [8147, "The tissue was chopped using scissors and homogenized with an automatic homogenizer at 500\u00a0rpm (IKA Labortechnik, Staufen, Germany).", {"entities": []}], [8148, "The resultant homogenates were transferred to clean centrifuge tubes, and centrifuged (Beckman Colter, Inc, Fullerton, CA, USA) at 20,000\u00d7g for 20\u00a0min at 4\u00a0\u00b0C.", {"entities": []}], [8149, "The supernatant was collected and further centrifuged at 100,000\u00d7g for 1\u00a0h under 4\u00a0\u00b0C by the L8-70 Beckman ultracentrifuge.", {"entities": []}], [8150, "The obtained microsomal pellet was re-suspended with homogenization medium and stored at \u221280\u00a0\u00b0C.", {"entities": []}], [8151, "Protein concentrations of the prepared liver microsomes were determined by the Bio-Rad protein assay kit (Bio-Rad Pacific Ltd, Hong Kong) and analyzed by the micro-plate reader (Benchmark, Japan) [40].", {"entities": []}], [8152, "Rat lungs were perfused by saline before being excided surgically on ice and cut into pieces for storage at \u221280\u00a0\u00b0C.", {"entities": []}], [8153, "Pieces of lung were then homogenized in a glass tissue grinder of 50\u00a0mL at 4\u00a0\u00b0C.", {"entities": []}], [8154, "Centrifuge was performed at 30,000\u00d7g for 40\u00a0min at 4\u00a0\u00b0C to get the pellet, which was re-suspended in 250\u00a0mL buffer (0.25\u00a0M sucrose, 0.02\u00a0M Tris\u2013HCl and 1\u00a0mM benzamidine-HCl, pH 7.5), homogenized, and centrifuged again as described above.", {"entities": []}], [8155, "The TM was finally extracted from the pellet by homogenization in 0.25\u00a0M sucrose, 0.02\u00a0M Tris\u2013HCl, 1\u00a0mM benzamidine-HCl, and 0.5\u00a0% (v/v) Triton X-100, pH 7.5.", {"entities": [[4, 6, "Target"]]}], [8156, "This process was repeated three times and TM activity was assessed in the resulting extract [41].", {"entities": []}], [8157, "The protein concentration of the extract was measured with Bio-Rad protein assay kit and adjusted to 100\u00a0ng/mL.", {"entities": []}], [8158, "The activities of rat liver microsomes for metabolizing warfarin were detected according to methods from our previous study [22].", {"entities": [[56, 64, "Drug"]]}], [8159, "A typical incubation (100\u00a0\u03bcL) contained 50\u00a0mM Tris\u2013HCl buffer (pH 7.4), 10\u00a0mM MgCl Approximately 30\u00a0mg of rat livers were homogenized, and RNA was isolated with the Qiagen RNA extraction kit (Valencia, CA, USA).", {"entities": []}], [8160, "The quality of RNA was evaluated by measuring the 260/280 ratio (\u02c31.9) with an ultraviolet light spectrophotometer (Shimadzu, Japan).", {"entities": []}], [8161, "The sequence of the sense and antisense primers for rat CYP1A1 (FP: CCAAACGAGTTCCGGCCT; RP: TGCCCAAACCAAAGAGAATGA) [42], CYP2B1 (FP:AACCCTTGATGACCGCAGTAAA; RP: TGTGGTACTCCAATAGGGACAAGATC) [42], CYP2C6 (FP: ATAAGACGCTTTACCCTCAC; RP: GATTTTCCTGCTTCCACTTA) [43], CYP2C11 (FP: TGCCCCCTTTTTACGAGGCT; RP: GGAACAGATGACTCTGAATTCT) [44] and GAPDH (FP: CAAGGTCATCCATGACAACTTTG; RP: GGGCCATCCACAGTCTTCTG) [42] gene were designed as described previously.", {"entities": [[56, 62, "Target"], [121, 127, "Target"], [194, 200, "Target"], [260, 267, "Target"], [332, 337, "Target"]]}], [8162, "The reaction mixture system (final volume 20\u00a0\u00b5L) was prepared as follow: 4 units multiscribe reverse transcriptase, 1\u00d7RT buffer, 1\u00a0mM random hexamer primers, 0.5\u00a0mM each of dATP, dGTP, dCTP and dTTP, and 10\u00a0mL total mRNA extract.", {"entities": []}], [8163, "The PCR involved an initiating heating for 10\u00a0min at 95\u00a0\u00b0C, 40 cycles consisting of 10\u00a0s at 95\u00a0\u00b0C, 20\u00a0s at 60\u00a0\u00b0C, and a final extension step of 30\u00a0s at 72\u00a0\u00b0C.", {"entities": []}], [8164, "The fold change of target gene expression level in different drug treatment groups (after correction with the level of GAPDH) was determined by the following equation: Fold change\u00a0=\u00a02 The levels of CYP1A1, 2B1/2, 2C6, 2C11 and GAPDH proteins in rat liver microsomes obtained from different treatment groups were determined by Western blotting.", {"entities": [[119, 124, "Target"], [198, 222, "Target"], [227, 232, "Target"]]}], [8165, "Sodium dodecyl sulfate (SDS)\u2013PAGE was performed by a Mini-Protean II system (Bio-Rad) as described previously [45].", {"entities": []}], [8166, "After denaturing with sample buffer, rat liver microsomal proteins were separated in a 10\u00a0% (w/v) SDS\u2013polyacrylamide gel and blotted onto a PVDF membrane (Immobilon transfer membrane, Millipore, Billerica, MA, USA).", {"entities": []}], [8167, "The membrane was blocked in 5\u00a0% defatted milk which was then incubated with the primary and secondary antibodies (horseradish peroxidase labeled anti-mouse or anti-rabbit IgG).", {"entities": []}], [8168, "The membrane was then immersed in the enhanced chemiluminescence solution (Millipore, Billerica, MA, USA) for 60\u00a0s. Digital chemiluminescence images were captured and analyzed by FluorChem Q Imaging System (Alpha Innotech Corporation, Santa Clara, CA, USA).", {"entities": []}], [8169, "Rat liver microsomes of different treatment groups were rinsed and re-suspended in the 0.02\u00a0M Tris\u2013HCl buffer (pH 7.4) to obtain a microsomal protein concentration of 5\u00a0mg/mL 0.02\u00a0mL of this microsomal suspension was mixed with 0.071\u00a0mL of the 0.02\u00a0M Tris\u2013HCl buffered solution (pH 7.4).", {"entities": []}], [8170, "The mixture was pre-incubated for 3\u00a0min at 30\u00a0\u00b0C.", {"entities": []}], [8171, "Tris\u2013HCl buffered solution (pH 7.4, 2\u00a0\u00b5L 0.02\u00a0M) containing 0.1\u00a0M DTT (Sigma-Aldrich, St. Louis, MO, USA) were added, mixed and incubated for 5\u00a0min at 30\u00a0\u00b0C.", {"entities": []}], [8172, "Synthesized VKO (10\u00a0nM) in 2\u00a0\u00b5L of isopropanol was also added and subsequently incubated for 60\u00a0min at 30\u00a0\u00b0C.", {"entities": []}], [8173, "The reaction was stopped by the addition of 0.1\u00a0mL of ice-chilled isopropanol.", {"entities": []}], [8174, "Tocopheryl acetate (2.5\u00a0\u00b5g; Sigma-Aldrich, St. Louis, MO, USA) in 0.2\u00a0mL of hexane was added as the internal standard.", {"entities": []}], [8175, "After vortex for 1\u00a0min, the mixture was centrifuged at 15,000\u00d7g for 5\u00a0min.", {"entities": []}], [8176, "The hexane phase was evaporated to dryness with nitrogen [39].", {"entities": []}], [8177, "The residue was dissolved in 150\u00a0\u00b5L mixed buffer containing acetonitrile/isopropanol/water (100/8/2: v/v/v), and 10\u00a0\u00b5L was analyzed by HPLC.", {"entities": []}], [8178, "The amount of vitamin K The sequence of the sense and antisense primers for rat VKOR gene (VKORC1) used in RT-PCR was designed as described previously [46].", {"entities": [[14, 23, "Target"], [80, 98, "Target"]]}], [8179, "RT-PCR procedures for detecting mRNA expression of VKORC1 were same as that described for CYP mRNA expression.", {"entities": [[51, 57, "Target"], [90, 93, "Target"]]}], [8180, "VKOR protein expression detection was conducted with the same operations for CYP protein expression.", {"entities": [[0, 4, "Target"], [77, 80, "Target"]]}], [8181, "The ability of TM to accelerate protein C activation by thrombin was tested by a chromogenic assay as follow: 0.5\u00a0M of purified protein C (Stago) in 100\u00a0\u00b5L of buffer was activated by 10\u00a0nM (1 NIH unit) of human thrombin (Sigma-Aldrich, St. Louis, MO, USA) in 10\u00a0\u00b5L of buffer in the presence of 5\u00a0mM calcium, 3\u00a0mg/mL of bovine serum albumin and of 50\u00a0\u00b5L of lung extracts from different substance treated groups.", {"entities": [[15, 17, "Target"], [32, 41, "Target"], [56, 64, "Target"], [211, 219, "Target"]]}], [8182, "The final volume was 200\u00a0\u00b5L.", {"entities": []}], [8183, "Incubation of the mixture lasted 30\u00a0min at 37\u00a0\u00b0C.", {"entities": []}], [8184, "The activation phase was stopped by adding 2 units of hirudin.", {"entities": [[54, 61, "Drug"]]}], [8185, "The hydrolytic activity of the activated protein C (APC) thus generated was assessed by spectrophotometric measurement at 405\u00a0nm of the rate of hydrolysis of D-Phe-Pip-Arg-pNA\u00b72HCl, that is, S-2238.", {"entities": [[31, 56, "Target"]]}], [8186, "For this purpose, 800\u00a0\u00b5L of Tris\u2013HCl buffer, pH 7.5, containing 0.1\u00a0mM of S-2238 was added to the mixture (final volume: 1\u00a0mL).", {"entities": []}], [8187, "The changes in optical density per minute were converted into units of APC formed by referring to a standard curve constructed with concentrations of 20, 40, 80, 160 and 320 n of standard APC (Stago).", {"entities": [[71, 74, "Target"], [188, 191, "Target"]]}], [8188, "The activity of TM could be expressed as the amount of APC formed during incubation [47].", {"entities": [[16, 18, "Target"], [55, 58, "Target"]]}], [8189, "TM mRNA and protein (extracted from rat lung) expression were detected as that described for CYP.", {"entities": [[0, 2, "Target"], [93, 96, "Target"]]}], [8190, "The sequence of the sense and antisense primers for rat TM used in RT-PCR was designed as described previously [48].", {"entities": [[56, 58, "Target"]]}], [8191, "After the animal treatment described previously, blood was collected using 3.8\u00a0% sodium citrate (sodium citrate: blood\u00a0=\u00a01:9) as an anticoagulant.", {"entities": []}], [8192, "Plasma was obtained by centrifuging the blood at 15,000\u00d7g for 3\u00a0min.", {"entities": []}], [8193, "The plasma samples were frozen and stored at \u221280\u00a0\u00b0C until the assay.", {"entities": []}], [8194, "An enzyme-linked immunosorbent assay (ELISA) was used to measure the plasma concentration of sTM.", {"entities": [[93, 96, "Target"]]}], [8195, "Standard sTM was series diluted to make a calibration curve.", {"entities": [[9, 12, "Target"]]}], [8196, "The concentration of sTM was determined from the optical density of each sample at 450\u00a0nm against a calibration graph.", {"entities": [[21, 24, "Target"]]}], [8197, "Data were expressed as the mean\u00a0\u00b1\u00a0SD.", {"entities": []}], [8198, "Differences between two groups were analyzed by an unpaired student\u2019s t test.", {"entities": []}], [8199, "Differences between groups for continuous variables were evaluated by one way ANOVA with post hoc Tukey (when variances were equal according to Levene\u2019s test) or Games-Howell test (when variances were not equal according to Levene\u2019s test) [49].", {"entities": []}], [8200, "P value less than 0.05 was considered as statistically significant.", {"entities": []}], [8203, "No significant differences were observed in the amounts of the mono-hydroxylated metabolites formed between the vehicle control and Danshen groups.", {"entities": [[63, 92, "Drug"], [132, 139, "Herb name"]]}], [8204, "In the positive control groups, the formation of 7- and 8-hydroxylated warfarin increased by 281\u00a0% (P\u00a0<\u00a00.001) and 242\u00a0% (P\u00a0<\u00a00.001) when the animals were treated with PB and BNF (positive controls for the activities of rat CYP2C6 and CYP1A1, respectively, contributing to the formation of 7- and 8-hydroxylated warfarin) [22], respectively, compared with the results of the vehicle control group (Fig.\u00a01).", {"entities": [[49, 79, "Drug"], [224, 230, "Target"], [235, 241, "Target"], [290, 320, "Drug"]]}], [8205, "Relative amount of formed monohydroxywarfarin (% of control) from different treatment groups.", {"entities": [[26, 45, "Drug"]]}], [8206, "Using R-warfarin as substrate.", {"entities": [[6, 16, "Drug"]]}], [8207, "*P\u00a0<\u00a00.05; **P\u00a0<\u00a00.01; ***P\u00a0<\u00a00.001, compared with the vehicle control group.", {"entities": []}], [8210, "No inductive effects were observed in the Danshen-treated groups based on a comparison of the warfarin metabolites formed in this group with those in the vehicle control group.", {"entities": [[42, 49, "Herb name"], [94, 102, "Drug"]]}], [8211, "In the positive control groups, the formation of 7-hydroxywarfarin increased by 237\u00a0% (P\u00a0<\u00a00.001) when the rats were treated with PB (positive controls for rat CYP2C6, contributing to the formation of 7-hydroxywarfarin) compared with the vehicle control group (Fig.\u00a02).", {"entities": [[49, 66, "Drug"], [160, 166, "Target"], [201, 218, "Drug"]]}], [8212, "Relative amount of formed monohydroxywarfarin (% of control) from different treatment groups.", {"entities": [[26, 45, "Drug"]]}], [8213, "Using S-warfarin as substrate.", {"entities": [[6, 16, "Drug"]]}], [8214, "*P\u00a0<\u00a00.05; **P\u00a0<\u00a00.01; ***P\u00a0<\u00a00.001, compared with the vehicle control group.", {"entities": []}], [8217, "No inductive effect was observed when for the warfarin metabolites formed in the Danshen-treated groups based on a comparison of these results with those of the vehicle control group.", {"entities": [[46, 66, "Drug"], [81, 88, "Herb name"]]}], [8218, "In the positive control groups, the formation of the 7- and 8-hydroxywarfarin metabolites increased by 251\u00a0% (P\u00a0<\u00a00.001) and 209\u00a0% (P\u00a0<\u00a00.001) when the rats were treated with PB and BNF, respectively, compared with the vehicle control group (Fig.\u00a03).", {"entities": [[53, 89, "Drug"]]}], [8219, "Relative amount of formed monohydroxywarfarin (% of control) from different treatment groups.", {"entities": [[26, 45, "Drug"]]}], [8220, "Using racemic warfarin as substrate.", {"entities": [[6, 22, "Drug"]]}], [8221, "*P\u00a0<\u00a00.05; **P\u00a0<\u00a00.01; ***P\u00a0<\u00a00.001, compared with the vehicle control group.", {"entities": []}], [8224, "However, these increases were small in size compared with those of the positive control groups.", {"entities": []}], [8225, "For example, BNF afforded a 8761-fold increase, whereas PB gave a 2812-fold increase.", {"entities": []}], [8228, "No inductive effects were observed in the mRNA expression levels of CYP1A1 and CYP2B1 when the Danshen-treated group was compared with the vehicle control group.", {"entities": [[68, 74, "Target"], [79, 85, "Target"], [95, 102, "Herb name"]]}], [8229, "Rat liver mRNA expression (Fold of Control) for target CYP isoforms from different treatment groups.", {"entities": [[55, 67, "Target"]]}], [8230, "*P\u00a0<\u00a00.05; **P\u00a0<\u00a00.01; ***P\u00a0<\u00a00.001, compared with the vehicle control group.", {"entities": []}], [8231, "PB was used as a positive control to detect the mRNA expression of CYP2C6.", {"entities": [[67, 73, "Target"]]}], [8232, "Compared with the vehicle control group, there was a significant increase of 420\u00a0% (P\u00a0<\u00a00.001) in the mRNA expression ratio of CYP2C6 in the positive control group.", {"entities": [[127, 133, "Target"]]}], [8236, "Furthermore, no inductive effects were observed in the mRNA expression level of CYP2C6 for both doses of Danshen compared with the vehicle control group.", {"entities": [[80, 86, "Target"], [105, 112, "Herb name"]]}], [8239, "Changes in the protein expression levels of the target CYP isozymes were determined to be minor compared with those observed for the metabolic activity and mRNA expression levels (Fig.\u00a05).", {"entities": [[55, 67, "Target"]]}], [8241, "No inductive effects were observed in the expression levels of any of the target CYP proteins in the Danshen-treated groups compared with the vehicle control group.", {"entities": [[81, 84, "Target"], [101, 108, "Herb name"]]}], [8242, "In the positive control groups, the expression levels of the CYP1A1, CYP2B1/2B2 and CYP2C6 proteins increased significantly by 6.1- (P\u00a0<\u00a00.001), 5.6- (P\u00a0<\u00a00.001) and 1.7-fold (P\u00a0=\u00a00.003), respectively, compared with the vehicle control group.", {"entities": [[61, 67, "Target"], [69, 79, "Target"], [84, 90, "Target"]]}], [8243, "Protein level (Fold of Control) for target rat liver CYP isoforms from different treatment groups.", {"entities": [[53, 65, "Target"]]}], [8244, "*P\u00a0<\u00a00.05; **P\u00a0<\u00a00.01; ***P\u00a0<\u00a00.001, compared with the vehicle control group.", {"entities": []}], [8247, "Warfarin reduced the activity of VKOR by 52.4\u00a0\u00b1\u00a05.1\u00a0% (P\u00a0<\u00a00.001) compared with the vehicle control group, which was consistent with its therapeutic effect.", {"entities": [[0, 8, "Drug"], [33, 37, "Target"]]}], [8250, "However, it was not possible to completely offset the inhibitory activity of warfarin towards VKOR using Gegen (Fig.\u00a06).", {"entities": [[77, 85, "Drug"], [94, 98, "Target"], [105, 110, "Herb name"]]}], [8251, "Fold of change in VKOR activity from different treatment groups.", {"entities": [[18, 22, "Target"]]}], [8252, "*P\u00a0<\u00a00.05; **P\u00a0<\u00a00.01; ***P\u00a0<\u00a00.001, compared with the vehicle control group.", {"entities": []}], [8256, "Warfarin led to significant reductions of 43.7\u00a0\u00b1\u00a013.9\u00a0% (P\u00a0<\u00a00.001) and 71.6\u00a0\u00b1\u00a011.4\u00a0% (P\u00a0=\u00a00.004) in the mRNA and protein expression levels of VKOR, respectively compared with the vehicle control group.", {"entities": [[0, 8, "Drug"], [143, 147, "Target"]]}], [8257, "Compared with the mRNA and protein expression levels of VKOR in the warfarin-alone group, there were significant increases (P\u00a0<\u00a00.001) of 27\u00a0% (mRNA expression) and 25\u00a0% (protein expression) in the corresponding Gegen combination groups, respectively.", {"entities": [[56, 60, "Target"], [68, 76, "Drug"], [212, 217, "Herb name"]]}], [8258, "However, the co-administration of Danshen with warfarin had no discernible impact of the mRNA or protein expression of VKOR (Fig.\u00a07).", {"entities": [[34, 41, "Herb name"], [47, 55, "Drug"], [119, 123, "Target"]]}], [8259, "Fold of change in VKOR mRNA (left) and protein (right) expression from different treatment groups.", {"entities": [[18, 22, "Target"]]}], [8260, "*P\u00a0<\u00a00.05; **P\u00a0<\u00a00.01; ***P\u00a0<\u00a00.001, compared with the vehicle control group.", {"entities": []}], [8262, "Warfarin led to a significant increase of 125.7\u00a0\u00b1\u00a04.2\u00a0% (P\u00a0<\u00a00.001) in the TM activity compared with the vehicle control group.", {"entities": [[0, 8, "Drug"], [75, 77, "Target"]]}], [8265, "Gegen could therefore be used to offset the induction effect of warfarin towards TM activity (Fig.\u00a08).", {"entities": [[0, 5, "Herb name"], [64, 72, "Drug"], [81, 83, "Target"]]}], [8266, "Fold of change in TM activity from different treatment groups.", {"entities": [[18, 20, "Target"]]}], [8267, "*P\u00a0<\u00a00.05; **P\u00a0<\u00a00.01; ***P\u00a0<\u00a00.001, compared with the vehicle control group.", {"entities": []}], [8268, "Compared with the vehicle control group, no significant change was observed in the expression of the TM protein in the Danshen group, but we did observe an increase of almost 125\u00a0% (P\u00a0=\u00a00.02) in the mRNA expression of TM.", {"entities": [[101, 103, "Target"], [119, 126, "Herb name"], [218, 220, "Target"]]}], [8271, "Significant increases of 141.9\u00a0\u00b1\u00a017.8\u00a0% (P\u00a0=\u00a00.003) and 158.6\u00a0\u00b1\u00a08.2\u00a0% (P\u00a0=\u00a00.002) were observed in the mRNA and protein expression levels of TM in the warfarin-alone group compared with the vehicle control group.", {"entities": [[141, 143, "Target"], [151, 159, "Drug"]]}], [8272, "Compared with the mRNA and protein expression levels of TM in the warfarin-alone group, we observed decreases of nearly 25\u00a0% (P\u00a0=\u00a00.03, mRNA expression) and 12\u00a0% (P\u00a0=\u00a00.04, protein expression), respectively, in the Gegen combination groups.", {"entities": [[56, 58, "Target"], [66, 74, "Drug"], [215, 220, "Herb name"]]}], [8273, "Notably, the co-administration of Danshen with warfarin had no discernible impact on the mRNA or protein expression levels of TM compared with the warfarin-alone group (Fig.\u00a09).", {"entities": [[34, 41, "Herb name"], [47, 55, "Drug"], [126, 128, "Target"], [147, 155, "Drug"]]}], [8274, "Fold of change in TM mRNA (left) and protein (right) expression from different treatment groups.", {"entities": [[18, 20, "Target"]]}], [8277, "Warfarin led to an increase in the plasma concentration of sTM to 112.0\u00a0\u00b1\u00a03.2\u00a0% (P\u00a0=\u00a00.03) compared with the vehicle control group.", {"entities": [[0, 8, "Drug"], [59, 62, "Target"]]}], [8280, "Fold of change in sTM plasma concentration from different treatment groups.", {"entities": [[18, 21, "Target"]]}], [8281, "Danshen and Gegen elicit their effects by improving microcirculation and inhibiting platelet aggregation [24, 32], whereas warfarin exerts its anticoagulant effect by inhibiting the activity of VKOR and inducing TM.", {"entities": [[0, 7, "Herb name"], [12, 17, "Herb name"], [123, 131, "Drug"], [194, 198, "Target"], [212, 214, "Target"]]}], [8282, "In the healthy Sprague\u2013Dawley rats used in the current study, Gegen rather than Danshen interacted with warfarin to offset its anticoagulant effects.", {"entities": [[7, 14, "Pathology"], [62, 67, "Herb name"], [80, 87, "Herb name"], [104, 112, "Drug"]]}], [8283, "In the Gegen-warfarin interaction, Gegen could induce the phase I metabolism of warfarin in the liver by increasing the activities and mRNA expression levels of the different CYP isozymes, as well as inducing the activity and expression levels of VKOR and inhibiting those of TM.", {"entities": [[7, 12, "Herb name"], [13, 21, "Drug"], [35, 40, "Herb name"], [80, 88, "Drug"], [175, 188, "Target"], [247, 251, "Target"], [276, 278, "Target"]]}], [8284, "The results of our previous study showed that the administration of a DFG-warfarin combination led to a reduction in the warfarin plasma concentration and PT time of rats [23, 32].", {"entities": [[70, 73, "Herb name"], [74, 82, "Drug"], [121, 129, "Drug"], [155, 162, "Parameter"]]}], [8285, "Taken together with the results of the current study, it seems clear that these effects could be attributed to the Gegen present in DFG.", {"entities": [[115, 120, "Herb name"], [132, 135, "Herb name"]]}], [8286, "Although there were no clinical reports in the literature pertaining to the interactions between Gegen and warfarin, the results of several case reports indicated that Danshen can interact with warfarin in humans [20\u201322].", {"entities": [[23, 39, "Study"], [97, 102, "Herb name"], [107, 115, "Drug"], [140, 152, "Study"], [168, 175, "Herb name"], [194, 202, "Drug"]]}], [8287, "However, these reports are inconsistent with our current findings.", {"entities": [[15, 22, "Study"]]}], [8288, "This discrepancy could be caused by several different factors, including (1) the use of different sources and preparations of Danshen (e.g., differences in the quality of the herbal medicines/contamination profiles); (2) a lack of adequate information in the documented case report (e.g., only one case report failed to infer a causal relationship); and (3) differences in the nature of the animals used in the different studies (e.g., rats versus humans).", {"entities": [[126, 133, "Herb name"], [270, 281, "Study"], [298, 309, "Study"]]}], [8289, "CYP enzymes represent some of the most highly conserved entities among different species, with relatively small differences in the primary amino acid sequences of the CYP enzymes across different species [50, 51].", {"entities": [[0, 11, "Target"], [167, 178, "Target"]]}], [8290, "Human CYP2C9, CYP2C19, CYP1A1 and CYP1A2 play important roles in warfarin metabolism, especially CYP2C9 [5], whereas the corresponding enzymes in rats are CYP2C11, CYP2C6, CYP1A1 and CYP2B1 (Fig.", {"entities": [[6, 12, "Target"], [14, 21, "Target"], [23, 29, "Target"], [34, 40, "Target"], [65, 73, "Drug"], [97, 103, "Target"], [155, 162, "Target"], [164, 170, "Target"], [172, 178, "Target"], [183, 189, "Target"]]}], [8291, "11) [52].", {"entities": []}], [8292, "Rat CYP1A1 shows a high level of conservation among species with greater than 80\u00a0% sequence identity compared with the corresponding enzyme in humans [50, 51].", {"entities": [[4, 10, "Target"]]}], [8293, "The 6-, 7- and 8-mono-hydroxylated warfarin metabolites are formed by the CYP1A1 enzymes in rats and humans [50, 51].", {"entities": [[4, 55, "Drug"], [74, 80, "Target"]]}], [8294, "Furthermore, gene sequence similarities of 74\u201380\u00a0% were reported for the CYP2C11 and CYP2C6 enzymes in rats compared with the human enzymes belonging to the CYP2C subfamily (mainly CYP2C9 and 2C19) [50, 51].", {"entities": [[73, 80, "Target"], [85, 91, "Target"], [157, 197, "Target"]]}], [8295, "The 4\u2032-, 6- and 7-mono-hydroxylated warfarin metabolites are mainly formed by CYP2C11 and CYP2C6 in rats.", {"entities": [[4, 56, "Drug"], [78, 85, "Target"], [90, 96, "Target"]]}], [8296, "In humans, however, these metabolites are formed by CYP2C9, CYP2C19 and CYP2C18.", {"entities": [[52, 58, "Target"], [60, 67, "Target"], [72, 79, "Target"]]}], [8297, "Notably, a genetic similarity of 78\u00a0% was reported between the rat and human CYP2B1 enzymes, which are responsible for the formation of 4\u2032-mono-hydroxylated warfarin [50, 51].", {"entities": [[77, 83, "Target"], [136, 165, "Drug"]]}], [8298, "Based on the details provided above, CYP2C11, CYP2C6, CYP1A1 and CYP2B1 were selected in the current study to investigate warfarin-related interactions in a rat model.", {"entities": [[37, 44, "Target"], [46, 52, "Target"], [54, 60, "Target"], [65, 71, "Target"], [122, 130, "Drug"]]}], [8299, "Although these isoforms are expressed in several different species, a high degree of similarity in their gene sequences between rats and human may not automatically result in similar levels of catalytic specificity and activity.", {"entities": []}], [8300, "CYPs involved in warfarin metabolism in human and rat As well as assessing the impact of warfarin on the activities of CYPs, we also investigated the variability in the effects of warfarin in humans caused by polymorphisms in the CYP2C9 and VKORC1 genes [53].", {"entities": [[0, 4, "Target"], [17, 25, "Drug"], [89, 97, "Drug"], [119, 123, "Target"], [180, 188, "Drug"], [230, 236, "Target"], [241, 247, "Target"]]}], [8301, "Algorithms that integrate the relevant genetic and physical factors into comprehensive, individualized predictive models were used to predict warfarin dose [54].", {"entities": [[142, 150, "Drug"]]}], [8302, "Furthermore, physiological-based pharmacokinetic (PBPK) modeling and simulation software, including Simcyp, PK-Sim, GastroPlus and MATLAB Sim-Biology, were recently made available to quantitatively predict the drug/herb-drug interactions of warfarin in humans based on rat data [54].", {"entities": [[241, 249, "Drug"]]}], [8303, "The results of an in vitro study using HepG2 cells indicated that tanshinones could be used to induce the expression of CYP1A1 and CYP1A2 [55].", {"entities": [[18, 32, "Study"], [66, 77, "Herb name"], [120, 126, "Target"], [131, 137, "Target"]]}], [8304, "The treatment of rats with Danshen, which mainly consists of danshensu, SAB and tanshinones, led to an increase in the activity and protein expression of CYP1A2.", {"entities": [[27, 34, "Herb name"], [61, 70, "Herb name"], [72, 75, "Herb name"], [80, 91, "Herb name"], [154, 160, "Target"]]}], [8305, "However, the activity of CYP1A2 did no change when rat hepatocytes were treated with danshensu or SAB in isolation [56].", {"entities": [[25, 31, "Target"], [85, 94, "Herb name"], [98, 101, "Herb name"]]}], [8306, "Furthermore, CYP1A-, CYP2C- and CYP3A-inducing agents were found in the ethyl acetate extract, but not in the aqueous extract of Danshen [57].", {"entities": [[13, 19, "Target"], [21, 27, "Target"], [32, 38, "Target"], [72, 93, "Extraction process"], [110, 125, "Extraction process"], [129, 136, "Herb name"]]}], [8307, "Taken together, the results of these previous studies indicate that the lipophilic tanshinones in Danshen, rather than the hydrophilic components, were responsible for inducing the activity and enhancing expression of the different CYP isozymes.", {"entities": [[72, 94, "Herb name"], [98, 105, "Herb name"], [232, 244, "Target"]]}], [8308, "We found that the major components in Danshen granules were hydrophilic compounds, including danshensu (1140.3\u00a0\u00b1\u00a024.6\u00a0\u00b5g/100\u00a0mg granules), SAB (821.3\u00a0\u00b1\u00a033.1\u00a0\u00b5g/100\u00a0mg granules) and PCA (82.2\u00a0\u00b1\u00a04.6\u00a0\u00b5g/100\u00a0mg granules), which might explain why Danshen showed no effect on the CYP activities or expression levels.", {"entities": [[38, 45, "Herb name"], [93, 102, "Herb name"], [104, 127, "Amount"], [139, 142, "Herb name"], [144, 166, "Amount"], [181, 184, "Herb name"], [186, 206, "Amount"], [242, 249, "Herb name"], [274, 277, "Target"]]}], [8309, "This finding is also supported by Yueng\u2019s study, where the major tanshinone components rather than the aqueous extract of Danshen showed effects on warfarin hydroxylation in vitro and in vivo [58].", {"entities": [[65, 75, "Herb name"], [103, 118, "Extraction process"], [122, 129, "Herb name"], [148, 156, "Drug"], [171, 191, "Study"]]}], [8310, "Although paracetamol and sodium dehydroacetate (DHA-S) were reported to interact with warfarin by inhibiting VKOR activity, leading to hemorrhage in Sprague\u2013Dawley rats, similar studies pertaining to the VKOR activity have never been conducted in context of herb-warfarin interactions [9, 10].", {"entities": [[9, 20, "Drug"], [86, 94, "Drug"], [109, 113, "Target"], [135, 145, "Pathology"], [204, 208, "Target"], [263, 271, "Drug"]]}], [8311, "Regarding the results of previous studies on TM, the treatment of H9c2 cells with DFG led to a 5.36-fold up-regulation in the mRNA expression of TM compared with a control system [16].", {"entities": [[45, 47, "Target"], [82, 85, "Herb name"], [145, 147, "Target"]]}], [8312, "Furthermore, SAB led to an 1.25- and 1.8-fold increases in the activity and mRNA expression of TM, respectively, over the control levels in human umbilical vein endothelial cells [15].", {"entities": [[13, 16, "Herb name"], [95, 97, "Target"]]}], [8313, "In our study, the mRNA expression of TM in the Danshen-treated group was slightly higher than that of the vehicle control group.", {"entities": [[37, 39, "Target"], [47, 54, "Herb name"]]}], [8314, "However, there were no significant differences in the activity and protein expression levels of TM between these two groups.", {"entities": [[96, 98, "Target"]]}], [8315, "The inconsistencies observed between our own findings and those reported by other researchers could be attributed to differences in the nature of the experiments.", {"entities": []}], [8316, "For example, SAB was directly loaded onto the cells used in Shi\u2019s study at a high concentration (0.0125\u20130.5\u00a0mg/mL) [15].", {"entities": [[13, 16, "Herb name"], [97, 113, "Amount"]]}], [8317, "However, SAB was reported to be poorly absorbed in animal studies and has an extremely low systemic bioavailability [59].", {"entities": [[9, 12, "Herb name"], [51, 65, "Study"], [100, 115, "Parameter"]]}], [8318, "In our study, although SAB was used as a major component of the Danshen granules, the in vivo effects were very different to those observed in cells because of the poor absorption and bioavailability of SAB.", {"entities": [[23, 26, "Herb name"], [64, 71, "Herb name"], [86, 101, "Study"], [184, 199, "Parameter"], [203, 206, "Herb name"]]}], [8319, "Moreover, the other components in the herbs could also act on the CYP, VKOR and TM enzymes.", {"entities": [[66, 69, "Target"], [71, 75, "Target"], [80, 82, "Target"]]}], [8320, "All of these factors could therefore be considered as potential explanations for the discrepancies observed between the in vitro and in vivo results.", {"entities": [[120, 128, "Study"], [133, 140, "Study"]]}], [8321, "Gegen, rather than Danshen at the same tested dosage, offsets the anticoagulant effects of warfarin by accelerating the phase I liver metabolism of warfarin, as well as increasing the activity, mRNA and protein expression of VKOR while decreasing those of TM.", {"entities": [[0, 5, "Herb name"], [19, 26, "Herb name"], [91, 99, "Drug"], [148, 156, "Drug"], [225, 229, "Target"], [256, 258, "Target"]]}], [8322, "10.1186/s13020-016-0078-9 Animal liscence.", {"entities": []}], [8323, "liver cytochrome P450 vitamin K epoxide reductase vitamin K vitamin K thrombomodulin Danshen\u2013Gegen Formula salvianolic acid B phenobarbital beta-naphthoflavone cyclophosphamide enzyme-linked immunosorbent assay Beikang Ge and Zhen Zhang contributed equally to this work BKG, ZZh and ZZu conceived and designed the study.", {"entities": [[0, 21, "Target"], [22, 49, "Target"], [50, 59, "Target"], [60, 69, "Target"], [70, 84, "Target"], [85, 92, "Herb name"], [93, 98, "Herb name"], [107, 125, "Herb name"], [126, 139, "Drug"], [160, 176, "Drug"]]}], [8324, "BKG and ZZh performed the experiments.", {"entities": []}], [8325, "BKG, ZZh and ZZu analyzed the data.", {"entities": []}], [8326, "BKG, ZZh and.", {"entities": []}], [8327, "ZZu wrote the manuscript.", {"entities": []}], [8328, "All authors read and approved the final manuscript.", {"entities": []}], [8329, "This work was supported by the Health and Medical Research Fund 6903483 from the Food and Health Bureau, Hong Kong SAR, China.", {"entities": []}], [8330, "The authors declare that they have no competing interests.", {"entities": []}], [8331, "Women receiving treatment for breast cancer commonly ingest herbal medicines.", {"entities": [[0, 5, "Sex"], [30, 43, "Pathology"]]}], [8332, "Little is known about the potential for herb-drug interactions in this population.", {"entities": []}], [8333, "The aim of this study is to investigate the effect of ginkgo biloba co-administration on the pharmacokinetics of tamoxifen, anastrozole and letrozole.", {"entities": [[54, 67, "Herb name"], [113, 122, "Drug"], [124, 135, "Drug"], [140, 149, "Drug"]]}], [8334, "This was a prospective open-label cross-over study in 60 women with early stage breast cancer taking either tamoxifen, anastrozole or letrozole (n=20/group).", {"entities": [[11, 50, "Study"], [54, 62, "Cohort"], [68, 93, "Pathology"], [108, 117, "Drug"], [119, 130, "Drug"], [134, 143, "Drug"]]}], [8335, "Participants received ginkgo biloba (EGb 761) for 3 weeks (120 mg twice daily).", {"entities": [[22, 45, "Herb name"], [50, 57, "Duration"], [59, 65, "Amount"], [66, 77, "Frequency"]]}], [8336, "Trough concentrations of drugs were measured before and after ginkgo biloba treatment using LC-MS/MS.", {"entities": [[62, 75, "Herb name"]]}], [8337, "Toxicities were graded according to National Cancer Institute Common Terminology Criteria for Adverse Events.", {"entities": [[94, 108, "Pathology"]]}], [8338, "Trough concentrations before and after treatment with ginkgo biloba were not significantly different for tamoxifen (93.5 \u00b1 29.0, 86.5 \u00b1 25.3 ng/mL; p=0.16), letrozole (91.1 \u00b1 50.4, 89.6 \u00b1 52.14 ng/mL; p=0.60) or anastrozole (29.1 \u00b1 8.6, 29.1 \u00b1 7.6 ng/mL; p=0.97).", {"entities": [[54, 67, "Herb part"], [105, 114, "Drug"], [157, 166, "Drug"], [212, 223, "Drug"]]}], [8339, "Ginkgo biloba was well tolerated, with no difference in toxicity during ginkgo biloba.", {"entities": [[0, 13, "Herb name"], [72, 85, "Herb name"]]}], [8340, "Co-administration of ginkgo biloba does not significantly affect the pharmacokinetics of tamoxifen, anastrozole or letrozole.", {"entities": [[21, 34, "Herb name"], [89, 98, "Drug"], [100, 111, "Drug"], [115, 124, "Drug"]]}], [8341, "There was no difference in the toxicity profile of hormone therapy with ginkgo biloba use in women with early stage breast cancer.", {"entities": [[51, 66, "Drug"], [72, 85, "Herb name"], [93, 98, "Sex"], [104, 129, "Pathology"]]}], [8342, "Complementary and alternative medicines (CAM) are widely used by a large proportion of cancer patients (mean 36%, range up to 80%) (Sparreboom et al.", {"entities": [[87, 93, "Pathology"]]}], [8343, "The herbal medicine ginkgo biloba is commonly used in the community (Sparreboom et al.", {"entities": [[11, 26, "Herb name"]]}], [8344, "No published RCT have assessed the effects of ginkgo biloba on anti-cancer hormone pharmacokinetics (Sparreboom et al.", {"entities": [[13, 16, "Study"], [46, 59, "Herb name"]]}], [8345, "The aim of this study is to investigate the effect of ginkgo biloba co-administration on the pharmacokinetics of tamoxifen, anastrozole and letrozole in women with early stage breast cancer.", {"entities": [[54, 67, "Herb name"], [113, 122, "Drug"], [124, 135, "Drug"], [140, 149, "Drug"], [153, 158, "Sex"], [164, 189, "Pathology"]]}], [8346, "Anastrozole, D12-anastrozole, letrozole, D4-letrozole, tamoxifen and D5-tamoxifen were purchased from Research Chemical North York (Ontario, Canada).", {"entities": [[0, 11, "Drug"], [13, 28, "Drug"], [30, 39, "Drug"], [41, 53, "Drug"], [55, 64, "Drug"], [69, 81, "Drug"]]}], [8347, "Methanol was purchased from Fisher Scientific (New Jersey USA).", {"entities": []}], [8348, "Orthophosphoric Acid (85%), hydrochloric acid (AnalaR) and ammonia (AR) were purchased from BDH, Biolab (Scoresby, VIC, Australia).", {"entities": []}], [8349, "Formic Acid (AR grade) was purchased from Merck (Kilsyth, VIC, Australia).", {"entities": []}], [8350, "Strata-X-C 33Hm Cation Mixed-Mode Polymeric Sorbent solid phase extraction cartridges (200\u2009mg /3\u2009mL) were obtained from Phenomenex (Torrana, CA, USA).", {"entities": []}], [8351, "This was a prospective open-label cross-over study in 60 women with early stage breast cancer taking tamoxifen, anastrozole or letrozole (n=20/group).", {"entities": [[11, 50, "Study"], [54, 62, "Cohort"], [68, 93, "Pathology"], [101, 110, "Drug"], [112, 123, "Drug"], [127, 136, "Drug"]]}], [8352, "Women were being treated at Concord Repatriation General Hospital, Royal Prince Alfred Hospital and Strathfield Breast Centre in Sydney, Australia.", {"entities": [[0, 5, "Sex"]]}], [8353, "All women had previously completed surgery \u00b1 adjuvant chemotherapy for localised breast cancer, and had no evidence of a recurrence of their cancer.", {"entities": [[4, 9, "Sex"], [45, 66, "Drug"], [71, 94, "Pathology"], [141, 147, "Pathology"]]}], [8354, "They had to have been on a stable dose of the hormone for a minimum of two months, to ensure steady-state had been achieved.", {"entities": [[54, 81, "Duration"]]}], [8355, "The study exclusion criteria included: use of trazodone, monoamine oxidase inhibitors, thiazide diuretics, anticoagulation, or anti-platelet medications other than low-dose aspirin or coumarin/heparin flushes associated with use of a portacath, and ingestion of ginkgo biloba within 4\u2009weeks of the study commencement.", {"entities": [[46, 85, "Drug"], [87, 105, "Drug"], [107, 122, "Drug"], [127, 140, "Drug"], [173, 180, "Drug"], [184, 192, "Drug"], [193, 200, "Drug"], [262, 275, "Herb name"], [276, 290, "Duration"]]}], [8356, "At baseline, toxicity data for hormone treatment and ginkgo biloba were collected.", {"entities": [[31, 48, "Drug"], [53, 66, "Herb name"]]}], [8357, "Women then commenced an open label standardised extract of ginkgo biloba (EGb 761, 120\u2009mg bd) for a three week period.", {"entities": [[0, 5, "Sex"], [24, 55, "Extraction process"], [59, 81, "Herb name"], [83, 89, "Amount"], [94, 117, "Duration"]]}], [8358, "Toxicity data were collected at the end of the dosing interval.", {"entities": []}], [8359, "Plasma samples to measure the concentration of the anastrozole, letrozole or tamoxifen were taken to assess trough concentrations of each drug.", {"entities": [[51, 62, "Drug"], [64, 73, "Drug"], [77, 86, "Drug"]]}], [8360, "The study was approved by the Human Research Ethics Committee of all participating institutions and written informed consent was obtained from all participants.", {"entities": []}], [8361, "Blood samples were collected into heparinised collecting tubes by venepuncture.", {"entities": []}], [8362, "Samples were centrifuged for 10\u2009min at 4\u00b0C and plasma transferred into vials, which were stored at -70\u00b0C until analysed.", {"entities": []}], [8363, "Sample preparation was based on the publication by (Beer et al.", {"entities": []}], [8364, "The chromatographic system consisted of a Waters Acquity\u00ae UPLC solvent delivery system and autosampler (Milford MA, USA) and an AB Sciex QTrap 4000 linear quadrupole mass spectrometer (Concord, ON, Canada) equipped with a turbo ion spray (ESI) source.", {"entities": []}], [8365, "The mass spectrometer was operated in positive ion mode.", {"entities": []}], [8366, "Multiple reaction monitoring (MRM) was performed using specific precursor-to-product ion transitions m/z.", {"entities": []}], [8367, "Chromatographic separation was accomplished on a Restek PFP C The calibration curves for each analyte were linear over the concentration range of 2.5 to 750\u2009ng/mL.", {"entities": []}], [8368, "The lower limit of quantitation for anastrozole and letrozole was 2.5\u2009ng/mL and 10\u2009ng/mL for tamoxifen.", {"entities": [[36, 47, "Drug"], [52, 61, "Drug"], [93, 102, "Drug"]]}], [8369, "The extraction recovery from human plasma was considered acceptable with a mean recovery of greater than 88% for each analyte.", {"entities": []}], [8370, "Minimal ionization suppression was observed in both the low concentration and high concentration spiked plasma samples and the variation in matrix effects between the five different sources of plasma was minimal for all analytes over a range of concentrations.", {"entities": []}], [8371, "No endogenous peaks were identified in the extracted ion chromatograms that would cause interference with drug quantitation.", {"entities": []}], [8372, "The assay performance was assessed over 3\u2009days (4 replicates) at 3 concentration levels.", {"entities": []}], [8373, "The relative error for each analyte was less than 9% and the intra-day and inter-day precision (%RSD) was less than 7% for anastrozole, letrozole and tamoxifen.", {"entities": [[123, 134, "Drug"], [136, 145, "Drug"], [150, 159, "Drug"]]}], [8374, "Steady-state trough concentrations of each drug were compared before and during treatment with ginkgo biloba extract.", {"entities": [[95, 116, "Extraction process"]]}], [8375, "Comparisons were made using a paired t-test.", {"entities": []}], [8376, "Toxicities are graded according to National Cancer Institute Common Terminology Criteria for Adverse Events Version 3.0 (NCI CTCAE).", {"entities": [[93, 107, "Pathology"]]}], [8377, "Sixty women with early stage breast cancer participated; 20 were using tamoxifen, letrozole and anastrozole respectively.", {"entities": [[0, 11, "Cohort"], [17, 42, "Pathology"], [71, 80, "Drug"], [82, 91, "Drug"], [96, 107, "Drug"]]}], [8378, "The 48 (80%) women who had received adjuvant chemotherapy were a mean of 37\u2009months (range 4\u2013113) from completion of chemotherapy.", {"entities": [[36, 57, "Drug"]]}], [8379, "Twenty four (40%) had received a taxane-containing regimen and 24 (40%) an anthracycline regimen, with 6 (10%) women also being treated with adjuvant Trastuzumab.", {"entities": [[33, 39, "Drug"], [75, 88, "Drug"], [111, 116, "Sex"], [150, 161, "Drug"]]}], [8380, "Twelve (20%) women had not required adjuvant chemotherapy.", {"entities": [[13, 18, "Sex"], [36, 57, "Drug"]]}], [8381, "The median age of participants was 57\u2009years (range: 33\u2013 86\u2009years).", {"entities": [[4, 65, "Age"]]}], [8383, "A) Tamoxifen.", {"entities": [[3, 12, "Drug"]]}], [8384, "B) Letrozole.", {"entities": [[3, 12, "Drug"]]}], [8385, "C) Anastrazole.", {"entities": [[3, 14, "Drug"]]}], [8386, "Pharmacokinetics of tamoxifen, letrozole and anastrozole before and after treatment with                            ginkgo biloba (GB)                         *paired test; data presented as mean \u00b1 standard deviation.", {"entities": [[20, 29, "Drug"], [31, 40, "Drug"], [45, 56, "Drug"], [116, 134, "Herb name"]]}], [8387, "Thirty-one of the 60 women reported no side effects.", {"entities": [[18, 26, "Cohort"], [39, 51, "Pathology"]]}], [8388, "There were no grade 3 toxicities but two women reported grade 2 toxicities (1 headache, 1 flu-like symptoms).", {"entities": [[78, 86, "Pathology"], [90, 107, "Pathology"]]}], [8389, "The most common side effects were headache (n=8), flatulence (n=6), hot flushes (n=5), nausea (n=2) and diarrhoea (n=2).", {"entities": [[16, 28, "Pathology"], [34, 42, "Pathology"], [50, 60, "Pathology"], [68, 79, "Pathology"], [87, 93, "Pathology"], [104, 113, "Pathology"]]}], [8390, "One woman each complained of appetite loss, dizziness, disturbed dreams, dry skin, flu-like symptoms, pain in extremities and a metallic taste.", {"entities": [[4, 9, "Sex"], [29, 42, "Pathology"], [44, 53, "Pathology"], [55, 71, "Pathology"], [73, 81, "Pathology"], [83, 100, "Pathology"], [102, 121, "Pathology"], [128, 142, "Pathology"]]}], [8391, "Although ginkgo biloba is a CAM that is commonly used by cancer patients, there is a lack of information about the impact of ginkgo biloba administration on cancer treatments such as chemotherapy and hormonal treatment.", {"entities": [[9, 22, "Herb name"], [57, 63, "Pathology"], [125, 138, "Herb name"], [157, 163, "Pathology"], [183, 195, "Drug"], [200, 218, "Drug"]]}], [8392, "This study investigated the interaction between the anti-cancer hormonal agents tamoxifen, anastrozole and letrozole, and a standardised extract of ginkgo biloba (EGb761) in women with breast cancer.", {"entities": [[52, 79, "Drug"], [80, 89, "Drug"], [91, 102, "Drug"], [107, 116, "Drug"], [148, 170, "Herb name"], [174, 179, "Sex"], [185, 198, "Pathology"]]}], [8393, "This patient population was selected as women with breast cancer are reported to use more CAM than other cancer patients, and the majority take tamoxifen, anastrozole or letrozole for a period of 5\u2009years.", {"entities": [[40, 45, "Sex"], [51, 64, "Pathology"], [105, 111, "Pathology"], [144, 153, "Drug"], [155, 166, "Drug"], [170, 179, "Drug"], [186, 203, "Duration"]]}], [8394, "It is therefore critical to know if there is a pharmacokinetic interaction between ginkgo biloba and common anti-cancer hormonal treatment.", {"entities": [[83, 96, "Herb name"], [108, 138, "Drug"]]}], [8395, "There are no published controlled trials that have assessed the effects of ginkgo biloba on chemotherapy pharmacokinetics (Sparreboom et al.", {"entities": [[23, 40, "Study"], [75, 88, "Herb name"]]}], [8396, "Zadoyan et al.", {"entities": []}], [8397, "recently reported a cocktail drug interaction study exploring potential interaction with the ginkgo biloba standardised extract EGb 761 (Zadoyan et al.", {"entities": [[93, 135, "Extraction process"]]}], [8398, "Several large placebo-controlled RCT have found ginkgo biloba to be extremely well tolerated, with no differences in side effects between those receiving ginkgo biloba and those receiving placebo.", {"entities": [[48, 61, "Herb name"], [117, 129, "Pathology"], [154, 167, "Herb name"]]}], [8399, "In our study the majority of participants reported either no side effects or minor side effects such as headache, flatulence and hot flushes - some of which are likely to have been due to the hormonal treatment rather than the ginkgo biloba.", {"entities": [[61, 73, "Pathology"], [83, 95, "Pathology"], [104, 112, "Pathology"], [114, 124, "Pathology"], [129, 140, "Pathology"], [192, 210, "Drug"], [227, 240, "Herb name"]]}], [8400, "In conclusion, ginkgo biloba (EGb761) co-administration did not significantly affect the pharmacokinetics of tamoxifen, anastrozole or letrozole, and was well tolerated with minimal side effects.", {"entities": [[15, 37, "Herb name"], [109, 118, "Drug"], [120, 131, "Drug"], [135, 144, "Drug"], [182, 194, "Pathology"]]}], [8401, "Our results suggest that the co-administration of EGb761 is unlikely to lead to clinically significant interactions for women who are receiving hormonal treatment for breast cancer.", {"entities": [[50, 56, "Extraction process"], [120, 125, "Sex"], [144, 162, "Drug"], [167, 180, "Pathology"]]}], [8402, "A study is in progress evaluating the pharmacokinetic impact of ginkgo biloba on common chemotherapy agents in women receiving adjuvant chemotherapy for early stage breast cancer.", {"entities": [[64, 77, "Herb name"], [88, 107, "Drug"], [111, 116, "Sex"], [153, 178, "Pathology"]]}], [8403, "Competing interests          The authors have declared no conflicts of interests.", {"entities": []}], [8404, "Authors\u2019 contributions          JV, AM, HD and SC conceived and designed the study and JV, AM and HD wrote the protocol.", {"entities": []}], [8405, "IO, FL, AW, HD, JB, AS, AH, PB recruited patients and IO, FL, AW and HD supervised blood sample collection and data collection.", {"entities": []}], [8406, "AR and AM supervised the pharmacokinetic analyses.", {"entities": []}], [8407, "AM analysed the pharmacokinetic data.", {"entities": []}], [8408, "JV, HD and AM wrote the manuscript.", {"entities": []}], [8409, "All authors read and approved the final manuscript.", {"entities": []}], [8410, "This work was supported by an American Society of Clinical Oncology (ASCO) Career Development Award awarded to A/Prof.", {"entities": [[30, 38, "Ethnic group"]]}], [8411, "Vardy and a National Institute of Complementary Medicine project grant.", {"entities": []}], [8412, "A/Prof.", {"entities": []}], [8413, "Vardy is supported by a Cancer Institute NSW Clinical Research Fellowship and Dr Olesen was supported by an National Health and Medical Research Council PhD Scholarship.", {"entities": []}], [8414, "The authors acknowledge Stacey Richards and John Keledjian from the Australian Racing Forensic Laboratory (Randwick, Australia) who conducted the sample analysis.", {"entities": [[68, 78, "Ethnic group"]]}], [8415, "Increasing use of medicinal herbs as nutritional supplements and traditional medicines for the treatment of diabetes, hypertension, hyperlipidemia, and malaria fever with conventional drugs poses possibilities of herb\u2013drug interactions ( In vitro inhibition of eight major   Mangifera indica moderately inhibited  Potential for clinically important     Funding information  This research did not receive any specific grant from funding agencies in the public, commercial, or not\u2010for\u2010profit sectors Management of chronic diseases is burdensome to patients (Eton et\u00a0al., 2013; \u00d8rtenblad, Meillier, & J\u00f8nsson, 2017) who tend to seek alternative remedies to conventional medications that may supposedly provide cure or offer safe use (Yarney et\u00a0al., 2013; Joeliantina, Agil, Qomaruddin, Jonosewojo, & Kusnanto, 2016) This self\u2010medication practice is common among chronically ill patients or patients with terminal diseases (Bodenheimer, Lorig, Holman, & Grumbach, 2002; Hasan, Ahmed, Bukhari, & Loon, 2009), and the major culprit in this group of patients are dietary supplements and herbal medicines (Gardiner, Graham, Legedza, Eisenberg, & Phillips, 2006; Gardiner, Phillips, & Shaughnessy, 2008).", {"entities": [[108, 116, "Pathology"], [118, 130, "Pathology"], [132, 146, "Pathology"], [152, 165, "Pathology"], [238, 246, "Study"], [275, 291, "Herb name"]]}], [8416, "The perceived believe of cure and safety of these agents makes ambulatory patients take them without due recourse to their physician (Mehta, Gardiner, Phillips, & McCarthy, 2008; Zhang, Onakpoya, Posadzki, & Eddouks, 2015).", {"entities": []}], [8417, "In various settings, about 40%\u201357% of patients fail to disclose herbs used concomitantly with their medications to the physician (Robinson & McGrail, 2004; Fakeye, Tijani, & Adebisi, 2008; Kennedy, Wang, & Wu, 2008).", {"entities": []}], [8418, "Some of these herbs especially in sub\u2010Saharan Africa, India, and in some other parts of the world are consumed as seasoning agents (garlic\u2014Allium sativum), vegetables (Gongronema latifolium and Moringa oleifera), and as edible fruits and seeds (Musa sapientum, Mangifera indica, and Tetracarpidium conophorum).", {"entities": [[132, 153, "Herb name"], [168, 189, "Herb name"], [194, 210, "Herb name"], [227, 233, "Herb part"], [238, 243, "Herb part"], [245, 259, "Herb name"], [261, 277, "Herb name"], [283, 308, "Herb name"]]}], [8419, "Patients who are on medications and consumes these medicinal herbs may not be aware of potential herb\u2013drug interactions (HDIs) that may occur.", {"entities": []}], [8420, "Others such as Alstonia boonei, Bauhinia monandra, and Picralima nitida are frequently used in sub\u2010Saharan Africa and India in the management of chronic diseases such as hypertension, diabetes, asthma, peptic ulcer, and cancer, as antimalarials and antimicrobials and other minor ailments (Mahomoodally, 2013; Ezuruike & Prieto, 2014; Iwu, 2014).", {"entities": [[15, 30, "Herb name"], [32, 49, "Herb name"], [55, 71, "Herb name"], [170, 182, "Pathology"], [184, 192, "Pathology"], [194, 200, "Pathology"], [202, 214, "Pathology"], [220, 226, "Pathology"]]}], [8421, "Sometimes, in the treatment of these diseases, herbs may be used singly or in combination and prepared as dried powder or decoction.", {"entities": [[106, 118, "Extraction process"], [122, 131, "Extraction process"]]}], [8422, "There are many examples of such practice.", {"entities": []}], [8423, "For example, for rheumatism, bark of Picralima nitida, leaves of Allium ascalonicum, Calliandra portoricensis, and Xylopia aethiopica are grounded, cooked, and 15\u00a0ml of the mixture is mixed with corn pap and taken once daily (Olorunnisola, Adetutu, & Afolayan, 2015).", {"entities": [[17, 27, "Pathology"], [29, 33, "Herb part"], [37, 53, "Herb name"], [55, 61, "Herb part"], [65, 83, "Herb name"], [85, 109, "Herb name"], [115, 133, "Herb name"], [195, 199, "Herb name"], [200, 203, "Extraction process"]]}], [8424, "For anemia, a mixture of the bark of Mangifera indica and fruits of Aframomum melequeta is dried and powdered with one tablespoonful administered daily (Gbadamosi, Moody, & OYekini, 2012).", {"entities": [[4, 10, "Pathology"], [29, 33, "Herb part"], [37, 53, "Herb name"], [58, 64, "Herb part"], [68, 87, "Herb name"], [91, 109, "Extraction process"], [146, 151, "Frequency"]]}], [8425, "A decoction of dried bark of Alstonia boonei is also taken two\u2010 to three times daily by diabetic patients to lower blood glucose (Adotey, Adukpo, Opoku Boahen, & Armah, 2012).", {"entities": [[2, 20, "Extraction process"], [21, 25, "Herb part"], [29, 44, "Herb name"], [59, 84, "Frequency"], [88, 96, "Pathology"], [115, 128, "Parameter"]]}], [8426, "Many diseases are usually managed or treated with conventional medicines which are mostly metabolized by cytochrome P450 (CYP) isoenzymes (Rendic & Guengerich, 2014).", {"entities": [[105, 137, "Target"]]}], [8427, "These isoenzymes are responsible for the metabolism of over 70% of prescription and over\u2010the\u2010counter medications (Rendic & Guengerich, 2014).", {"entities": []}], [8428, "Concomitantly administered drug may modulate these CYP isoenzymes activities leading to clinically significant drug\u2013drug interactions.", {"entities": [[51, 65, "Target"]]}], [8429, "Such interaction may result in serious adverse drug reactions requiring hospitalization, especially drugs with narrow therapeutic index such as carbamazepine, theophylline, digoxin warfarin, and phenytoin (Greenblatt & von Moltke, 2005; Perucca, 2006; de Leon, 2007; Patel, Rana, Suthar, Malhotra, & Patel, 2014).", {"entities": [[39, 61, "Pathology"], [144, 157, "Drug"], [159, 171, "Drug"], [173, 180, "Drug"], [181, 189, "Drug"], [195, 204, "Drug"]]}], [8430, "It is thus rational to expect herbs to also elicit similar HDIs via modulation of cytochrome P450 isoenzymes when concomitantly administered with conventional drugs.", {"entities": [[82, 108, "Target"]]}], [8431, "Herbs contain bioactive secondary metabolites such as anthocyanins, flavonoid, tannins, saponins, alkaloids, and cardenolides, some of which have been shown to inhibit the activity of CYP isoenzymes (Henderson, Miranda, Stevens, Deinzer, & Buhler, 2000; Dreiseitel et\u00a0al., 2008; Kimura, Ito, Ohnishi, & Hatano, 2010; Sand et\u00a0al., 2010).", {"entities": [[54, 66, "Herb name"], [68, 77, "Herb name"], [79, 86, "Herb name"], [88, 96, "Herb name"], [98, 107, "Herb name"], [113, 125, "Herb name"], [184, 198, "Target"]]}], [8432, "Several studies have documented the occurrence of serious adverse events as a result of concurrent administration of herbs and drugs.", {"entities": [[58, 72, "Pathology"]]}], [8433, "Such interactions included bleeding experienced with coadministration of Allium sativum and nonsteroidal anti\u2010inflammatory drugs (Fugh\u2010Berman, 2000), manic episode with Panax ginseng and phenelzine (Fugh\u2010Berman, 2000), and fatal seizure with concomitant administration of Ginkgo biloba and valproate (Kupiec & Raj, 2005).", {"entities": [[27, 35, "Pathology"], [73, 87, "Herb name"], [92, 128, "Drug"], [150, 163, "Pathology"], [169, 182, "Herb name"], [187, 197, "Drug"], [229, 236, "Pathology"], [272, 285, "Herb name"], [290, 299, "Drug"]]}], [8434, "Little is known of the effect of most tropical medicinal herbs on the metabolic capacity of CYP isoenzymes.", {"entities": [[92, 106, "Target"]]}], [8435, "The possibility of occurrence of HDIs when herbs are consumed as seasoning agents, vegetables, fruits and as herbal medicines with conventional drugs informed this study.", {"entities": []}], [8437, "Some of the herbs considered in this study have also been shown to inhibit CYP isoenzymes.", {"entities": [[75, 89, "Target"]]}], [8438, "Allium sativum inhibits CYP 2C9, 2C19, 2D6, 3A4/5, and 3A7 (Foster et\u00a0al., 2001; Greenblatt, Leigh\u2010Pemberton, & von Moltke, 2006; Engdal & Nilsen, 2009); Moringa oleifera\u2014CYP 1A2, 3A4, and 2D6 (Monera, Wolfe, Maponga, Benet, & Guglielmo, 2008; Taesotikul, Navinpipatana, & Tassaneeyakul, 2010; Ahmmed et\u00a0al., 2015; Awortwe, 2015); Musa sapientum\u2014CYP 1A2 and 3A11 (Chatuphonprasert & Jarukamjorn, 2012) while Mangifera indica has been shown to inhibit CYP 1A2, 2C9, 2C19, 2D6, 3A4, and 3A11 (Chatuphonprasert & Jarukamjorn, 2012).", {"entities": [[0, 14, "Herb name"], [24, 58, "Target"], [154, 170, "Herb name"], [171, 192, "Target"], [331, 345, "Herb name"], [346, 362, "Target"], [408, 424, "Herb name"], [451, 489, "Target"]]}], [8439, "In the above studies, different enzyme sources, probe substrates, and extraction methods were employed in evaluating one to five CYP isoenzyme inhibition profiles of the stated herbs which do not represent the full complement of major human CYP isoenzymes.", {"entities": [[129, 142, "Target"], [241, 255, "Target"]]}], [8440, "The present study improved on this by mimicking local methods of preparation of plant extracts, used pooled human liver microsomes containing eight major CYP isoenzymes responsible for over 70% metabolism of drugs (Rendic & Guengerich, 2014), and nine probe substrates with N\u2010in\u2010one cocktail method to profile the inhibitory potentials of the herbs on CYP isoenzymes.", {"entities": [[154, 168, "Target"], [352, 366, "Target"]]}], [8441, "Nine medicinal herbs widely used in the tropics for the management of chronic diseases such as hypertension, diabetes, dyslipidemia, chronic kidney disease were selected for this study with the plant parts used and listed in Table\u00a01.", {"entities": [[95, 107, "Pathology"], [109, 117, "Pathology"], [119, 131, "Pathology"], [133, 155, "Pathology"]]}], [8442, "Plant parts used were sourced from open market and herb vendors.", {"entities": []}], [8443, "Some were identified and authenticated at the Department of Pharmacognosy, University of Ibadan with voucher numbers DPHUI 1385, DPHUI 1386, DPHUI 1387, DPHUI 1388, and DPHUI 1624 for Alstonia boonei, Mangifera indica, Musa sapientum, Bauhinia monandra, and Moringa oleifera leaves, respectively.", {"entities": [[184, 199, "Herb name"], [201, 217, "Herb name"], [219, 233, "Herb name"], [235, 252, "Herb name"], [258, 274, "Herb name"], [275, 281, "Herb part"]]}], [8444, "Other plants parts such as Tetracarpidium conophorum seeds, Picralima nitida seed, Allium sativum bulb, and Gongronema latifolium leaves were collected and identified at Forestery Research Institute of Nigeria with voucher numbers No.", {"entities": [[27, 52, "Herb name"], [53, 58, "Herb part"], [60, 76, "Herb name"], [77, 81, "Herb part"], [83, 97, "Herb name"], [98, 102, "Herb part"], [108, 129, "Herb name"], [130, 136, "Herb part"]]}], [8445, "FHI110276, FHI210232, FHI210233, and FHI210234, respectively.", {"entities": []}], [8446, "Plant parts were chopped into smaller bits and dried in the oven (Gallenhamp oven, Cat number GVH 500.010\u00a0G. Germany) separately at 40\u00b0C for 24\u201348\u00a0hr until a constant weight was obtained.", {"entities": []}], [8447, "Thereafter, each plant part was blended with Kenwood blender (model number: OWBL436003, China) for 3\u00a0min.", {"entities": []}], [8448, "Detail of medicinal herbs used in the screening of potential inhibition of cytochrome P450 isoenzymes I, Igbo; Y, Yoruba; H, Hausa.", {"entities": [[75, 101, "Target"]]}], [8449, "Three hundred gram each of dried and powdered Alstonia boonei stem bark, Mangifera indica stem bark, Musa sapientum unriped fruits, Bauhinia monandra leaves, Tetracarpidium conophorum seeds, Allium sativum bulb, and Gongronema latifolium leaves were macerated in 1.5\u00a0L of distilled water for 24\u00a0hr according to extraction procedure practiced locally by users of these herbs.", {"entities": [[27, 45, "Extraction process"], [46, 61, "Herb name"], [62, 71, "Herb part"], [73, 89, "Herb name"], [90, 99, "Herb part"], [101, 115, "Herb name"], [116, 130, "Herb part"], [132, 149, "Herb name"], [150, 156, "Herb part"], [158, 183, "Herb name"], [184, 189, "Herb part"], [191, 205, "Herb name"], [206, 210, "Herb part"], [216, 237, "Herb name"], [238, 244, "Herb part"]]}], [8450, "Dry powdered Moringa oleifera leaves (50\u00a0g) and powdered dry Picralima nitida seeds (70\u00a0g) were each macerated in 300\u00a0ml of distilled water.", {"entities": [[0, 12, "Extraction process"], [13, 29, "Herb name"], [30, 36, "Herb part"], [48, 60, "Extraction process"], [61, 77, "Herb name"], [78, 83, "Herb part"], [101, 110, "Extraction process"]]}], [8451, "Each mixture was filtered, concentrated, and freeze\u2010dried.", {"entities": []}], [8452, "The freeze\u2010dried extracts were stored at \u221220\u00b0C until needed for in vitro analysis.", {"entities": [[4, 25, "Extraction process"], [64, 81, "Study"]]}], [8453, "Acetic acid and HPLC\u2010grade acetonitrile were purchased from Merck (LiChrosolv GG, Darmstadt, Germany).", {"entities": []}], [8454, "Hydroxydiclofenac, desmethylomeprazole, 3\u2010hydroxyomeprazole, and hydroxycoumarin were obtained from Sigma\u2010Aldrich, St Louis, USA; 6\u2010hydroxytestosterone, dextrorphan, and desethylamodiaquine form BD Biosciences Discovery Labware, Bedford, USA; 5\u2010hydroxyomeprazole and omeprazole sulfone from Astra Zeneca, M\u00a8olndal, Sweden; 1\u2010hydroxymidazolam from F. Hoffmann\u2010La Roche, Basel, Switzerland; phenacetin from ICN Biomedicals, Costa Mesa, USA.", {"entities": [[0, 17, "Drug"], [19, 38, "Drug"], [40, 59, "Drug"], [65, 80, "Drug"], [130, 151, "Drug"], [153, 164, "Drug"], [170, 189, "Drug"], [243, 262, "Drug"], [267, 277, "Drug"], [323, 341, "Drug"], [389, 399, "Drug"]]}], [8455, "Hydroxybupropion was a free gift from Glaxo SmithKline Research Triangle, NC.", {"entities": [[0, 16, "Drug"]]}], [8456, "Water used was purified by Simplicity 185 water purifier (Millipore, Molsheim, France).", {"entities": []}], [8457, "All other chemicals and reagents were of analytical grade.", {"entities": []}], [8459, "Briefly, the incubation mixture was made up of 0.3\u00a0mg microsomal protein/ml, 0.1\u00a0M phosphate buffer (pH 7.4), 1\u00a0mM NADPH, and nine probe substrates representing the major drug\u2010metabolizing CYPs.", {"entities": [[115, 120, "Target"], [189, 193, "Target"]]}], [8460, "The specific probe substrate used for each CYP isoenzymes studied and the respective final concentration in the incubation mixture were as follows: acetaminophen (CYP1A2, 10\u00a0\u03bcM), coumarin (CYP2A6, 2\u00a0\u03bcM), bupropion (CYP2B6, 2\u00a0\u03bcM), repaglinide (CYP2C8, 5\u00a0\u03bcM), diclofenac (CYP2C9, 5\u00a0\u03bcM), omeprazole (CYP2C19 and CYP3A4, 5\u00a0\u03bcM), dextromethorphan (CYP2D6, 1\u00a0\u03bcM), midazolam (CYP3A4, 1\u00a0\u03bcM), and testosterone (CYP3A4, 5\u00a0\u03bcM).", {"entities": [[43, 65, "Study"], [148, 161, "Drug"], [163, 169, "Target"], [179, 187, "Drug"], [189, 195, "Target"], [204, 213, "Drug"], [215, 221, "Target"], [230, 241, "Drug"], [243, 249, "Target"], [258, 268, "Drug"], [270, 276, "Target"], [285, 295, "Drug"], [297, 304, "Target"], [309, 315, "Target"], [324, 340, "Drug"], [342, 348, "Target"], [357, 366, "Drug"], [368, 374, "Target"], [387, 399, "Target"], [401, 407, "Target"]]}], [8461, "Each freeze\u2010dried aqueous herb extract was dissolved into methanol and added to the incubation mixture to obtain final concentrations of 0.001, 0.01, 0.1, 1, 10, 100, and 1000\u00a0\u03bcg/ml.", {"entities": [[5, 38, "Extraction process"]]}], [8462, "The resulting reaction mixture (200\u00a0\u03bcl) contains 1% (v/v) methanol.", {"entities": []}], [8463, "This was preincubated in a shaking incubator block (Eppendorf Thermomixer 5436, Hamburg, Germany) for 6\u00a0min at 37\u00b0C prior to the initiation of the reaction with the addition of NADPH.", {"entities": [[177, 182, "Target"]]}], [8464, "Each reaction mixture containing different herb extracts or solvent control and other components was stopped after a period of 15\u00a0min by adding 200\u00a0\u03bcl of ice\u2010cold acetonitrile.", {"entities": []}], [8465, "Proteins were precipitated from the sample by cooling it in an ice bath.", {"entities": []}], [8466, "Supernatants collected from the samples were then stored at \u221220\u00b0C until analyzed.", {"entities": []}], [8467, "Prior to analysis, all incubation samples were thawed at room temperature, votex\u2010mixed, and centrifuged for 10\u00a0min at 10000\u00a0g. The experiments were performed in duplicate.", {"entities": []}], [8468, "The validated parameters for the methods were adequate for quantification ranges\u00a0<\u00a01%\u2013300% of the forming metabolite concentrations with LOD 0.2\u201310\u00a0nM, accuracies 85%\u2013115%, and precisions <15% at all concentrations, and with good autosampler stability (>95%) up to 48\u00a0hr.", {"entities": []}], [8469, "Positive controls (see Supporting Information data, Table S1), CYP isoenzymes inhibited, and concentration used in the N\u2010in\u2010one assay are as reported in the validated methods (Turpeinen et\u00a0al., 2005; Tolonen et\u00a0al., 2007; Showande et\u00a0al., 2013).", {"entities": [[63, 77, "Target"]]}], [8470, "Spiked standard samples were not used for quantification of probe metabolites, but quantification based on relative peak areas was used (solvent control\u00a0=\u00a0100%).", {"entities": []}], [8472, "Briefly, a Waters Acquity UPLC system (Waters Corp., Milford, MA) was used together with a Waters HSS C18 column (2.1\u00a0mm \u00d7 50\u00a0mm; 1.8\u00a0\u03bcm particle size) and an online filter at 35\u00b0C.", {"entities": []}], [8473, "The injection volume was 4\u00a0\u03bcl, and UPLC eluents were aqueous 0.1% acetic acid (pH 3.2, A) and acetonitrile (B).", {"entities": []}], [8474, "The gradient elution from 2%\u201365%\u201395% B was applied in 0\u20132.5\u20133.5\u00a0min, followed by column equilibration, giving a total time of 4.5\u00a0min/injection.", {"entities": []}], [8475, "The eluent flow rate was 0.5\u00a0ml/min.", {"entities": []}], [8476, "Data were acquired using a Thermo TSQ Endura triple quadrupole MS.", {"entities": []}], [8477, "Multiple reaction monitoring (MRM) mode using positive ion mode.", {"entities": []}], [8478, "For all compounds, the spray voltage was 4500\u00a0V, vaporizer temperature and transfer tube temperature were 400\u00b0C and 350\u00b0C, respectively.", {"entities": []}], [8479, "The CID argon pressure was set to 2.0 mTorr.", {"entities": []}], [8480, "The MRM transitions were as previously described (Tolonen et\u00a0al., 2007; Turpeinen et\u00a0al., 2005).", {"entities": []}], [8481, "For acetaminophen, hydroxyrepaglinide and 4\u2010hydroxydiclofenac MRM's were m/z 152\u00a0>\u00a0 m/z 110, m/z 469\u00a0>\u00a0 m/z 246, m/z 312\u00a0>\u00a0 m/z 231, respectively.", {"entities": [[4, 17, "Drug"], [19, 37, "Drug"], [42, 61, "Drug"]]}], [8482, "The instruments were controlled using Thermo Xcalibur 3.0.63 software.", {"entities": []}], [8483, "Fifty percent inhibitory concentration (IC   where A\u00a0=\u00a0log of concentration of aqueous extract of herb in the incubations.", {"entities": [[0, 38, "Parameter"], [79, 94, "Extraction process"]]}], [8484, "The herb extracts were classified as potent, moderate, or weak inhibitor depending on the IC Determination of molar IC   Aqueous extracts of Musa sapientum unripe fruits, Tetracarpidium conophorum seeds, and Allium sativum bulbs did not produce significant inhibition of the CYP isoenzymes investigated at any of the concentrations used, IC Estimated in vitro IC IC Percentage inhibition of the control by herbs with IC Aqueous extract of Mangifera indica stem bark showed weak inhibitory activities on CYP2A6, CYP2C19 and CYP3A4 but exhibited moderate inhibition of CYP1A2, CYP2B6, CYP2C8, CYP2C9, and CYP2D6 (Table\u00a02).", {"entities": [[90, 92, "Parameter"], [116, 118, "Parameter"], [121, 137, "Extraction process"], [141, 155, "Herb name"], [163, 169, "Herb part"], [171, 196, "Herb name"], [197, 202, "Herb part"], [208, 222, "Herb name"], [223, 228, "Herb part"], [275, 289, "Target"], [338, 340, "Parameter"], [351, 359, "Study"], [360, 362, "Parameter"], [363, 365, "Parameter"], [417, 419, "Parameter"], [420, 435, "Extraction process"], [439, 455, "Herb name"], [456, 465, "Herb part"], [503, 509, "Target"], [511, 518, "Target"], [523, 529, "Target"], [567, 573, "Target"], [575, 581, "Target"], [583, 589, "Target"], [591, 597, "Target"], [603, 609, "Target"]]}], [8485, "The plant extract displayed 100% inhibition of all the CYP isoenzymes investigated at a dose of 1000\u00a0\u03bcg/ml (Figure\u00a01b).", {"entities": [[55, 69, "Target"]]}], [8486, "Picralima nitida seeds aqueous extract demonstrated potent inhibitory activity on CYP2D6, with IC In order to estimate the possibility of in vivo inhibitory potential from the in vitro data, IC Inhibition of cytochrome P450 isoezymes by herbs with IC Drug\u2013drug interaction or herb\u2013drug interaction studies could be conducted as in vitro or in vivo studies, case reports, and human studies using human subjects.", {"entities": [[0, 16, "Herb name"], [17, 22, "Herb part"], [23, 38, "Extraction process"], [82, 88, "Target"], [95, 97, "Parameter"], [176, 184, "Study"], [191, 193, "Parameter"], [208, 223, "Target"], [248, 250, "Parameter"], [276, 305, "Study"], [328, 336, "Study"], [340, 355, "Study"], [357, 369, "Study"], [375, 388, "Study"]]}], [8487, "In vitro herb\u2013drug interactions studies are mostly conducted for commonly used herbs to evaluate and predict potentially significant in vivo herb\u2013drug interactions and to help design appropriate in vivo herb\u2013drug interaction studies (Fasinu, Bouic, & Rosenkranz, 2012; Awortwe, Bouic, Masimirembwa, & Rosenkranz, 2013).", {"entities": [[0, 39, "Study"], [195, 232, "Study"]]}], [8488, "According to Food and Drug Administration, 2017, in vitro drug\u2013drug interaction (DDI) studies are designed to determine if a drug is a substrate, inhibitor, or inducer of metabolizing enzymes (Phase I or Phase II enzymes), transporter proteins (P\u2010gp, BCRP, OATP1B1, OATP1B3, OAT, OCT, and MATE) and also to evaluate whether the metabolite of a drug is a substrate or inhibitor of metabolizing enzymes or transporter proteins.", {"entities": [[49, 93, "Study"], [245, 249, "Target"], [251, 255, "Target"], [257, 264, "Target"], [266, 273, "Target"], [275, 278, "Target"], [280, 283, "Target"], [289, 293, "Target"]]}], [8489, "These are referred to as metabolism\u2010based or transporter\u2010based drug interaction studies.", {"entities": [[25, 87, "Study"]]}], [8490, "Preclinical methods for predicting drug interactions use enzyme sources such as purified CYP450 isoenzymes, immortalized cell lines, recombinant P450 isoenzymes, liver slices, human microsomes, and hepatocyte cultures.", {"entities": [[0, 19, "Study"], [89, 106, "Target"]]}], [8491, "Microsomes isolated from human hepatocytes have become the \u201cgold standard\u201d of in vitro experimentation for drug interactions and contain the CYPs in proportion to their in vivo representation.", {"entities": [[78, 102, "Study"], [141, 145, "Target"]]}], [8492, "Pooled human liver microsomes were employed in this study to circumvent the large interindividual variability in CYP expression when microsomes from a single individual are used which may produce biased results.", {"entities": [[113, 116, "Target"]]}], [8493, "The N\u2010in\u2010one assay method employed in this study allows for rapid screening of many herbs or herbal products for inhibitory potential of major human CYP isoenzymes.", {"entities": [[149, 152, "Target"]]}], [8494, "This may help clinicians and patients to avoid concomitant use of herbs and drugs that may lead to potential or actual HDIs.", {"entities": []}], [8495, "Three of the plants studied did not exhibit inhibitory potential on any of the eight major human CYP isoenzymes used even at the highest dose of the extract, that is, aqueous extracts of Musa sapientum unripe fruits, Tetracarpidium conophorum seeds, and Allium sativum bulbs.", {"entities": [[97, 111, "Target"], [167, 183, "Extraction process"], [187, 201, "Herb name"], [202, 215, "Herb part"], [217, 242, "Herb name"], [243, 248, "Herb part"], [254, 268, "Herb name"], [269, 274, "Herb part"]]}], [8496, "There are conflicting reports on the inhibitory potential of Allium sativum extracts on CYP isoenzymes.", {"entities": [[61, 75, "Herb name"], [88, 102, "Target"]]}], [8497, "This herb was classified by Engdal and Nilsen (2009) as a noninhibitor of CYP3A4 using human c\u2010DNA baculovirus expressed CYP3A4.", {"entities": [[74, 80, "Target"], [121, 127, "Target"]]}], [8498, "Using similar methods, Foster et\u00a0al.", {"entities": []}], [8499, "(2001) reported in vitro inhibition of CYP 2C9, 2C19, 2D6, 3A4/5, and 3A7 by different types of Allium sativum.", {"entities": [[16, 24, "Study"], [39, 73, "Target"], [96, 110, "Herb name"]]}], [8500, "In another study, only two water\u2010soluble components of aged garlic were able to moderately inhibit CYP3A4 (Greenblatt et\u00a0al., 2006).", {"entities": [[60, 66, "Herb name"], [99, 105, "Target"]]}], [8501, "Also, aged garlic extract produced no significant inhibition of CYP isoenzymes in humans (Markowitz, 2003).", {"entities": [[11, 17, "Herb name"], [64, 78, "Target"]]}], [8502, "Though we did not report any inhibition of CYP isoenzymes by Allium sativum, the discrepancies in these reports and ours may be due to the extraction procedure, assay method, concentration and type of the extract used and enzyme sources.", {"entities": [[43, 57, "Target"], [61, 75, "Herb name"]]}], [8503, "In this study, aqueous extract of oven\u2010dried Allium sativum bulbs was used.", {"entities": [[15, 44, "Extraction process"], [45, 59, "Herb name"], [60, 65, "Herb part"]]}], [8504, "There is no conclusive report of a significant in vitro inhibition of CYP isoforms by Allium sativum both from this study and others.", {"entities": [[47, 55, "Study"], [70, 82, "Target"], [86, 100, "Herb name"]]}], [8505, "Thus, the possibility of Allium sativum aqueous extract in vivo HDIs mediated by CYP isoenzymes may be remote as supported by our study and that of Markowitz (2003).", {"entities": [[25, 39, "Herb name"], [40, 55, "Extraction process"], [81, 95, "Target"]]}], [8506, "Aqueous extract of Moringa oleifera leaves showed weak inhibition of CYP1A2 and CYP2C9.", {"entities": [[0, 15, "Extraction process"], [19, 35, "Herb name"], [36, 42, "Herb part"], [69, 75, "Target"], [80, 86, "Target"]]}], [8507, "This result is similar to the inhibition of CYP1A2 by ethanolic and aqueous extracts of Moringa oleifera leaves reported earlier (Taesotikul et\u00a0al., 2010).", {"entities": [[44, 50, "Target"], [54, 84, "Extraction process"], [88, 104, "Herb name"], [105, 111, "Herb part"]]}], [8508, "Other studies reported inhibition of CYP3A4 (Ahmmed et\u00a0al., 2015; Awortwe, 2015; Monera et\u00a0al., 2008) and CYP2D6 by aqueous and/or ethanolic extract(s) of M. oleifera leaves (Ahmmed et\u00a0al., 2015) which were not observed in this study.", {"entities": [[37, 43, "Target"], [106, 112, "Target"], [116, 151, "Extraction process"], [155, 166, "Herb name"], [167, 173, "Herb part"]]}], [8509, "The possibility of in vivo inhibition of CYPs 1A2 and 2C9 by aqueous extract of M. oleifera is likely since the IC Stem bark aqueous extract of Mangifera indica moderately inhibited CYP1A2, CYP2B6, CYP2C8, CYP2C9, and CYP2D6 (IC The potential for Mangifera indica stem bark aqueous extract to cause in vivo HDIs specifically with drugs with narrow therapeutic index is supported by the estimated IC Several studies have used Strandell et\u00a0al.", {"entities": [[41, 57, "Target"], [61, 76, "Extraction process"], [80, 91, "Herb name"], [112, 114, "Parameter"], [115, 124, "Herb part"], [125, 140, "Extraction process"], [144, 160, "Herb name"], [182, 188, "Target"], [190, 196, "Target"], [198, 204, "Target"], [206, 212, "Target"], [218, 224, "Target"], [226, 228, "Parameter"], [247, 263, "Herb name"], [264, 273, "Herb part"], [274, 289, "Extraction process"], [396, 398, "Parameter"]]}], [8510, "(2004) methods to predict possibilities of in vivo inhibition of CYP isoenzymes from in vitro data.", {"entities": [[65, 79, "Target"], [85, 98, "Study"]]}], [8511, "For example, in vitro study by Sevior et\u00a0al.", {"entities": [[13, 27, "Study"]]}], [8512, "(2010) predicted the possible absence of in vivo inhibition of CYP 2D6 and 3A4 by black cohosh and aqueous extract of valerian and inhibition of CYP2D6 by goldenseal.", {"entities": [[63, 78, "Target"], [82, 94, "Herb name"], [99, 114, "Extraction process"], [118, 126, "Herb name"], [145, 151, "Target"], [155, 165, "Herb name"]]}], [8513, "Earlier studies by Gurley et\u00a0al.", {"entities": []}], [8514, "(2005, 2006, 2008) confirmed these predictions.", {"entities": []}], [8515, "Strandell et\u00a0al.", {"entities": []}], [8516, "(2004) predicted the likelihood of potent in vivo inhibition of CYP3A4 by hypericum (St John's Wort) preparations; this also confirmed the report of Markowitz et\u00a0al.", {"entities": [[64, 70, "Target"], [74, 100, "Herb name"]]}], [8517, "(2000).", {"entities": []}], [8518, "Currently, no study seems to be available on the in vitro or in vivo inhibitory activity of six of the herbs studied\u2014aqueous extracts of Picralima nitida seeds, Gongronema latifolium leaves, Tetracarpidium conophorum seeds, Musa sapientum unripe fruits, Bauhinia monandra leaves, and Alstonia boonei stem bark.", {"entities": [[117, 133, "Extraction process"], [137, 153, "Herb name"], [154, 159, "Herb part"], [161, 182, "Herb name"], [183, 189, "Herb part"], [191, 216, "Herb name"], [217, 222, "Herb part"], [224, 238, "Herb name"], [239, 252, "Herb part"], [254, 271, "Herb name"], [272, 278, "Herb part"], [284, 299, "Herb name"], [300, 309, "Herb part"]]}], [8519, "Our study may be the first report of the in vitro inhibitory potential of these herb extracts.", {"entities": [[41, 49, "Study"]]}], [8520, "Gongronema latifolium and Alstonia boonei may produce in vivo inhibitory activity on CYP1A2, CYP2C19 and CYP3A4 since the converted in vitro IC One of the problems of studying herb\u2013drug interactions is the difficulty in identifying or quantifying the inhibiting components of the complex mixtures of phytochemicals in the herb.", {"entities": [[0, 21, "Herb name"], [26, 41, "Herb name"], [85, 91, "Target"], [93, 100, "Target"], [105, 111, "Target"], [132, 140, "Study"], [141, 143, "Parameter"]]}], [8521, "Because of this, it is difficult to quantify the molar IC  Picralima nitida seem to be the most potent of the nine herbs studied with IC It should be borne in mind that the IC Of the nine aqueous herb extracts evaluated in this study, Picralima nitida, Alstonia boonei, and Mangifera indica showed significant in vitro inhibition of several cytochrome P450 isoenzymes including CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 with potential for significant clinical herb\u2013drug interactions.", {"entities": [[55, 57, "Parameter"], [59, 75, "Herb name"], [134, 136, "Parameter"], [173, 175, "Parameter"], [188, 209, "Extraction process"], [235, 251, "Herb name"], [253, 268, "Herb name"], [274, 290, "Herb name"], [310, 318, "Study"], [341, 367, "Target"], [378, 384, "Target"], [386, 392, "Target"], [394, 400, "Target"], [402, 408, "Target"], [410, 417, "Target"], [419, 425, "Target"], [431, 437, "Target"]]}], [8522, "The potent in vitro inhibitory effect of aqueous extract of Picralima nitida on CYP2D6 makes it a candidate for immediate further clinical investigations.", {"entities": [[11, 19, "Study"], [41, 56, "Extraction process"], [60, 76, "Herb name"], [80, 86, "Target"], [130, 153, "Study"]]}], [8523, "However, before this is done, caution should be exercised by clinician and patients alike in recommending or coadministering aqueous extracts of Picralima nitida seeds with substrates of CYP2D6.", {"entities": [[125, 141, "Extraction process"], [145, 161, "Herb name"], [162, 167, "Herb part"], [187, 193, "Target"]]}], [8524, "Authors have no conflict of interest to declare.", {"entities": []}], [8525, "This study does not involve any human or animal testing.", {"entities": []}], [8526, "Click here for additional data file.", {"entities": []}], [8527, "Authors would like to appreciate the kind gift of Picralima nitida seeds by Dr James Adetunji Bello, The Chief Medical Director, Oyo state Hospital, Ogbomoso.", {"entities": [[50, 66, "Herb name"], [67, 72, "Herb part"]]}], [8528, "The herbal medicine Echinacea purpurea (E. purpurea) has been shown to induce cytochrome P450 3A4 (CYP3A4) both in vitro and in humans.", {"entities": [[0, 52, "Herb name"], [78, 106, "Target"]]}], [8529, "In both cycles, pharmacokinetic parameters of docetaxel were determined.", {"entities": [[16, 42, "Parameter"], [46, 55, "Drug"]]}], [8530, "The applied E. purpurea product at the recommended dose may be combined safely with docetaxel in cancer patients.", {"entities": [[12, 23, "Herb name"], [84, 93, "Drug"], [97, 103, "Pathology"]]}], [8531, "            The percentage inhibition of MenoAct851 on CYP450 showed a statistically significant difference when compared to Ketoconazole in ethanol Concentration-dependent CYP450 inhibition was found in fluorescence screening assay by the MenoAct851 MenoAct851 showed a weaker inhibitory potential on CYP3A4 and CYP2D6 when compared to Ketoconazole and Quinidine respectively.", {"entities": [[41, 51, "Herb name"], [55, 61, "Target"], [125, 137, "Drug"], [173, 179, "Target"], [240, 250, "Herb name"], [251, 261, "Herb name"], [302, 308, "Target"], [313, 319, "Target"], [337, 349, "Drug"], [354, 363, "Drug"]]}], [8532, "MenoAct851 is likely to affect the exposure of Simvastatin when co-administered MenoAct851 (Varanasi BioResearch Pvt.", {"entities": [[0, 10, "Herb name"], [47, 58, "Drug"], [80, 90, "Herb name"]]}], [8533, "Ltd., Varanasi, India) is a patented polyherbal formulation developed to manage menopause symptoms that can be taken along with other allopathic medicines.", {"entities": [[80, 98, "Pathology"]]}], [8534, "The present study aims to evaluate the drug interaction potential of MenoAct851 to inhibit cytochrome (CY) P450 in vitro in rats, and to measure its effects on simvastatin pharmacokinetic parameters in healthy human volunteers.", {"entities": [[69, 79, "Herb name"], [91, 111, "Study"], [160, 171, "Drug"], [202, 209, "Pathology"]]}], [8535, "CYP450-carbon monoxide assay of MenoAct851 was performed in rat liver microsomes to calculate the percentage inhibition.", {"entities": [[32, 42, "Herb name"]]}], [8536, "Fluorometric assays of CYP3A4 and CYP2D6 determined half maximal inhibitory concentration value.", {"entities": []}], [8537, "The selected volunteers were randomized to receive placebo or MenoAct851 500 mg BID PO for 14 days.", {"entities": [[51, 58, "Drug"], [62, 72, "Herb name"], [73, 79, "Amount"], [91, 98, "Duration"]]}], [8538, "On the 15th day, each group received 40 mg single-dose simvastatin.", {"entities": [[37, 42, "Amount"], [43, 54, "Frequency"], [55, 66, "Drug"]]}], [8539, "Blood samples were drawn at different intervals to measure simvastatin pharmacokinetic parameters.", {"entities": [[59, 70, "Drug"]]}], [8540, "The mean (SD) CYP450 concentration of the diluted microsome sample was calculated and found to be 0.405 (0.12) nmol/mg.", {"entities": [[14, 34, "Parameter"], [98, 118, "Amount"]]}], [8541, "The inhibitory potential of MenoAct851 (41.16% [1.24%]) was found to be less than ketoconazole.", {"entities": [[28, 38, "Herb name"], [82, 94, "Drug"]]}], [8542, "Half maximal inhibitory concentration values of MenoAct851 on CYP3A4 and CYP2D6 were 11.96 (1.04) \u00b5g/mL and 15.24 (0.58) \u00b5g/mL, respectively, but they were higher than respective positive controls.", {"entities": [[48, 58, "Herb name"], [62, 68, "Target"], [73, 79, "Target"], [85, 103, "Amount"], [108, 126, "Amount"]]}], [8543, "There was no statistically significant difference between MenoAct851 and placebo groups concerning the pharmacokinetic parameters such as C MenoAct851 produced weaker interaction potential with CYP3A4 and CYP2D6 substrates based on in vitro assays, but the findings of clinical pharmacokinetic analysis indicate that MenoAct851 increased the AUC of simvastatin and simvastatin hydroxy acid.", {"entities": [[58, 68, "Herb name"], [73, 80, "Drug"], [140, 150, "Herb name"], [194, 200, "Target"], [205, 211, "Target"], [317, 327, "Herb name"], [342, 345, "Parameter"], [349, 360, "Drug"], [365, 389, "Drug"]]}], [8544, "Therefore, coadministration of MenoAct851 might lead to drug-herb interaction, thereby affecting the therapeutic effect of CYP3A4 substrates.", {"entities": [[31, 41, "Herb name"], [123, 129, "Target"]]}], [8545, "(Curr Ther Res Clin Exp.", {"entities": []}], [8546, "2020; 81:XXX\u2013XXX) Transition to menopause is associated with a period of increased risk for problematic symptoms, including hot flashes, night sweats, sleep disturbances, sexual dysfunction, mood disorders, weight gain, and cognitive declines.", {"entities": [[32, 41, "Pathology"], [124, 135, "Pathology"], [137, 149, "Pathology"], [151, 169, "Pathology"], [171, 189, "Pathology"], [191, 205, "Pathology"], [207, 218, "Pathology"], [224, 242, "Pathology"]]}], [8547, "PHFs use is more common in developing countries because of easy accessibility, availability, affordability, and societal acceptability  The MenoAct851 formulation could increase the potential for an herb-drug interaction when it is coadministered with an allopathic medication if the herbal product affects the allopathic drug's metabolism.", {"entities": [[140, 150, "Herb name"]]}], [8548, "CYP450 enzymes play a significant role in the Phase I oxidative metabolism of a wide variety of exogenous chemicals, including drugs; carcinogens; toxins; and endogenous compounds such as steroids, fatty acids, and prostaglandins.", {"entities": [[0, 6, "Target"], [134, 145, "Drug"], [147, 153, "Drug"], [159, 229, "Drug"]]}], [8549, "Isoforms of CYP450 such as CYP3A4, CYP2D6, CYP2C9, CYP2C19, and CYP1A2 are primarily responsible for metabolizing a majority of the drugs used to treat human beings.", {"entities": [[12, 18, "Target"], [27, 33, "Target"], [35, 41, "Target"], [43, 49, "Target"], [51, 58, "Target"], [64, 70, "Target"]]}], [8551, "All of the chemicals and solvents for the preparation of rat liver microsomes and CYP450-carbon monoxide complex assay were of analytical grade (potassium chloride [catalog No.", {"entities": []}], [8552, "P9333], and sodium hydrosulfite [catalog No.", {"entities": []}], [8553, "71699]), and purchased from Sigma-Aldrich, Mumbai, India.", {"entities": []}], [8554, "Vivid CYP450 Screening Kit and Vivid Substrates were purchased from Invitrogen Drug Discovery Solutions (Waltham, Massachusetts).", {"entities": []}], [8555, "Vivid CYP3A4 Red (catalog No.", {"entities": []}], [8556, "P2856) and Vivid CYP2D6 Blue (catalog No.", {"entities": []}], [8557, "P2972) screening kits included baculosome respective isozymes and nicotinamide adenine dinucleotide phosphate-P450 reductase; regeneration system glucose-6-phosphate; glucose-6-phosphate dehydrogenase and nicotinamide adenine dinucleotide phosphate were used for the study.", {"entities": []}], [8558, "Ninety-six well black, flat-bottom, polystyrene, untreated microplate were obtained from Corning (Corning, New York).", {"entities": []}], [8559, "Ketoconazole was obtained as a gift sample from M/s Micro Labs Pvt Ltd, Hosur, Tamil Nadu, India, and quinidine was obtained as a gift sample from M/s Trigenesis Life Sciences Pvt Ltd, Bangalore, Karnataka, India.", {"entities": [[0, 12, "Drug"], [102, 111, "Drug"]]}], [8560, "LC-MS grade methanol (catalog No.", {"entities": []}], [8561, "34860-2.5L-R) and ammonium acetate (catalog No.", {"entities": []}], [8562, "V800034) were used for the pharmacokinetic parameters study.", {"entities": [[27, 59, "Study"]]}], [8563, "The probe drug, simvastatin, and the internal standard, lovastatin, were obtained from Mankind Pharmaceuticals Pvt Ltd, Bangalore, India.", {"entities": [[16, 27, "Drug"], [56, 66, "Drug"]]}], [8564, "Liver microsomes were isolated from male Wistar rats weighing 200 to 250 g, based on the method described by Pandit et al  High throughput screening assays were performed in black 96-well microplates.", {"entities": []}], [8565, "Fluorescence readings were obtained on BioTekFLx 800 fluorescence microplate reader (BioTek, Winooski, Vermont) using appropriate excitation/emission wavelength (\u03bb).", {"entities": []}], [8566, "The assay was performed according to a protocol provided by Invitrogen Drug Discovery Solutions.", {"entities": []}], [8567, "All measurements were performed in triplicate.", {"entities": []}], [8568, "Product formation from the fluorogenic probes was determined from the fluorescence data at 7 different concentrations of the inhibitors and tests.", {"entities": []}], [8569, "The following formula determines the half-maximal inhibitory concentration (IC SRM Medical College Hospital and Research Centre and SRM Institute of Science and Technology, Kattankulathur ethics committees approved the protocol (approval No.", {"entities": []}], [8570, "476/IEC/2013) and the study was conducted in accordance with the Declaration of Helsinki in its revised edition, the Guidelines of Good Clinical Practice (CPMP/ICH/135/95), and directives 2001/20/EC and 2005/28/EC and with international and local regulatory requirements.", {"entities": []}], [8571, "Following a full explanation of the study, volunteers provided written consent to participate.", {"entities": []}], [8572, "Volunteers were compensated per Institutional Ethics Committee (IEC) guidelines.", {"entities": []}], [8573, "Volunteers were excluded if they had any clinically significant history or presence of a cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, or neurologic disease/disorder.", {"entities": [[89, 231, "Pathology"]]}], [8575, "Female volunteers were excluded if they were pregnant (positive test for serum human chorionic gonadotropin at screening or check-in), breastfeeding, or planning to conceive a child within 30 days of treatment cessation.", {"entities": [[0, 6, "Sex"], [73, 107, "Parameter"], [189, 196, "Duration"]]}], [8576, "The volunteers were forbidden from using any medications or herbal products for 15 days before and during the study.", {"entities": [[80, 87, "Duration"]]}], [8577, "Drugs that are known to cause enzyme induction or inhibition and grapefruit juice were not allowed for the 30 days leading up to the study.", {"entities": [[107, 114, "Duration"]]}], [8578, "Consuming coffee, tea, alcohol, and cola drinks were not allowed during the study.", {"entities": []}], [8579, "Nicotine use was assessed by the Fagerstrom test for nicotine dependence.", {"entities": []}], [8580, "The study was a double-blind, randomized, placebo-controlled, single-dose simvastatin and multiple-dose MenoAct851 drug-herb interaction study.", {"entities": [[16, 60, "Study"], [62, 73, "Frequency"], [74, 85, "Drug"], [104, 114, "Herb name"]]}], [8581, "The selected volunteers were randomized to placebo (inert substitute for a treatment or intervention) or MenoAct851 formulation (500 mg BID for 14 days in double-blind fashion) groups.", {"entities": [[43, 50, "Drug"], [105, 115, "Herb name"], [129, 135, "Amount"], [144, 151, "Duration"]]}], [8582, "Double-blinded treatments were allocated using sequentially numbered drug containers.", {"entities": []}], [8583, "The randomization code was concealed to avoid selection bias, which secured the trial's blinding codes.", {"entities": []}], [8584, "On day 15 of the trial, each group was received a 40 mg single-dose simvastatin.", {"entities": [[50, 55, "Amount"], [56, 67, "Frequency"], [68, 79, "Drug"]]}], [8585, "Per the schedule, the selected volunteers fasted overnight on those days.", {"entities": []}], [8586, "As soon as the volunteers assembled, Venflon Paul Medical Systems, Chennai, India was inserted by vein puncture into each volunteer's forearm vein before the drug administration, and 5 mL blood was drawn at T Following the administered dose of simvastatin, blood samples were taken at the following intervals: 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours after the administration of the drug, including predose (total of 13 samples, each 3 mL).", {"entities": [[244, 255, "Drug"]]}], [8587, "All of the samples were collected by trained personnel using an intravenous cannula placed in a forearm/arm vein using prelabeled vacutainers containing K Simvastatin and simvastatin hydroxy acid with lovastatin as an internal standard were determined in plasma by validated LC-MS method.", {"entities": [[155, 166, "Drug"], [171, 195, "Drug"], [201, 211, "Drug"]]}], [8588, "An amount of 50 \u00b5L internal standard lovastatin was added to tubes containing 200 \u00b5L plasma.", {"entities": [[13, 18, "Amount"], [37, 47, "Drug"]]}], [8589, "After a thorough vortex mixing for 30 seconds, mixtures were extracted with 2 mL acetonitrile, vortex-mixed for 3 minutes, and centrifuged at 4000 rpm for 10 minutes.", {"entities": []}], [8590, "An amount of 1.5 mL of the organic layer was removed to another centrifuge tube and evaporated under a stream of nitrogen gas in the thermostatically controlled water-bath maintained at 40\u00b0C until completely dry.", {"entities": [[13, 19, "Amount"]]}], [8591, "The dried residue obtained was dissolved in 100 \u00b5L methanol, vortex-mixed for 2 minutes, centrifuged at 4000 rpm for 10 minutes, and 20 \u00b5L of the supernatant liquid was injected into the LC-MS system.", {"entities": []}], [8592, "The created strategy was linear in the fixation scope of 0.100 to 74.626 ng/mL for simvastatin and 0.100 to 48.971 ng/mL for simvastatin hydroxy acid, with connection coefficient more prominent than 0.99 for both analytes.", {"entities": [[83, 94, "Drug"], [125, 149, "Drug"]]}], [8593, "The approach demonstrated considerable reproducibility for all analytes, with intra- and interday precision with <5.6%, and intra- and interday precision of \u00b110.1% of nominal values.", {"entities": []}], [8594, "Quantitation was performed by multiple reaction monitoring mode of precursor\u2013production transitions at m/z 435.2\u202f\u2192\u202f281.2 for simvastatin, m/z 412.3\u202f\u2192\u202f286.3 for simvastatin hydroxy acid at 150 ms per transition.", {"entities": [[125, 136, "Drug"], [160, 184, "Drug"]]}], [8595, "Limit of quantitation was 0.24 ng/mL and 0.22 ng/mL for simvastatin and simvastatin hydroxy acid, respectively.", {"entities": [[56, 67, "Drug"], [72, 96, "Drug"]]}], [8596, "Simvastatin and simvastatin hydroxy acid concentrations were calculated for each volunteer when simvastatin was dosed with the placebo, and in combination with MenoAct851 formulation, a noncompartmental method was applied using WinNonlin professional version 5.0.1 (Pharsight Corp, Mountain View, California).", {"entities": [[0, 11, "Drug"], [16, 40, "Drug"], [96, 107, "Drug"], [127, 134, "Drug"], [160, 170, "Herb name"]]}], [8597, "The key pharmacokinetic parameters calculated for simvastatin and simvastatin hydroxy acid included C The results are presented as the mean (standard deviation).", {"entities": [[50, 61, "Drug"], [66, 90, "Drug"]]}], [8598, "IC The mean (SD) concentration of protein in isolated rat liver microsome was 6.2 (0.81) mg/mL (n\u202f=\u202f3).", {"entities": []}], [8599, "CYP450-carbon monoxide complex assay was used to assess the inhibitory potential of MenoAct851.", {"entities": [[84, 94, "Herb name"]]}], [8600, "The mean (SD) CYP450 concentration of the diluted microsome sample was calculated and was found to be 0.405 (0.12) nmol/mg protein (n\u202f=\u202f3).", {"entities": [[14, 34, "Parameter"], [102, 122, "Amount"]]}], [8601, "Two different solvents ethanol and dimethyl sulfoxide were used for CYP450 inhibition assay to confirm the solvent effect.", {"entities": [[68, 74, "Target"]]}], [8602, "Percentage inhibition of MenoAct851 versus positive controls (n\u202f=\u202f3).", {"entities": [[25, 35, "Herb name"]]}], [8603, "Values are expressed in mean (SD).", {"entities": []}], [8604, "ANOVA followed by Dunnett's multiple comparison test.", {"entities": []}], [8605, "DMSO\u202f=\u202fdimethyl sulfoxide.", {"entities": []}], [8606, "*Level of significance at P < 0.05.", {"entities": []}], [8607, "MenoAct851 and positive controls were assayed between concentrations ranging from 1.5 to 25 \u03bcg/mL.", {"entities": [[0, 10, "Herb name"], [82, 98, "Amount"]]}], [8608, "All samples were assayed in triplicate, the end point mode was selected, and IC Half maximal inhibitory concentration (IC Values are expressed as mean (SD).", {"entities": []}], [8609, "Concentration dependent inhibitory effect of MenoAct851 and positive controls dimethyl sulfoxided (DMSO).", {"entities": [[45, 55, "Herb name"]]}], [8610, "(A) cytochrome (CY) P3A4.", {"entities": [[4, 25, "Target"]]}], [8611, "(B) CYP2D6.", {"entities": [[4, 10, "Target"]]}], [8612, "Values are expressed as mean (SD) (n\u202f=\u202f3).", {"entities": []}], [8613, "LC-MS chromatograms of standard simvastatin, plasma-spiked simvastatin, and the volunteers\u2019 plasma samples are shown in Figure 3.", {"entities": [[32, 43, "Drug"], [59, 70, "Drug"]]}], [8614, "The mean (SD) for each parameter was given for the 2 groups in which simvastatin was administered.", {"entities": [[69, 80, "Drug"]]}], [8615, "The mean (SD) plasma concentrations of simvastatin, its metabolite simvastatin hydroxy acid, and internal standard lovastatin are shown in Figure\u00a04.", {"entities": [[39, 50, "Drug"], [67, 91, "Drug"], [115, 125, "Drug"]]}], [8616, "Maximal simvastatin levels were observed in the placebo group after 1.32 (0.44) hours and 1.92 (0.26) hours in MenoAct851 group (Figure 5).", {"entities": [[8, 19, "Drug"], [48, 55, "Drug"], [111, 121, "Herb name"]]}], [8617, "Maximal simvastatin hydroxy acid levels were observed in placebo group after 1.28 (0.66) hours and 1.51 (0.24) hours in MenoAct851 group (Figure 6).", {"entities": [[8, 32, "Drug"], [57, 64, "Drug"], [120, 130, "Herb name"]]}], [8618, "The peak plasma concentration of simvastatin 18.44 (1.56) ng/mL and simvastatin hydroxy acid 14.11 (2.12) ng/mL in MenoAct851 group was slightly higher than the placebo group.", {"entities": [[4, 29, "Parameter"], [33, 44, "Drug"], [45, 63, "Amount"], [68, 92, "Drug"], [93, 111, "Amount"], [115, 125, "Herb name"], [161, 168, "Drug"]]}], [8619, "Chromatogram.", {"entities": []}], [8620, "(A) Standard simvastatin.", {"entities": [[13, 24, "Drug"]]}], [8621, "(B) Blank plasma spiked with simvastatin.", {"entities": [[29, 40, "Drug"]]}], [8622, "x-axis\u202f=\u202fruntime; y-axis\u202f=\u202fmV.", {"entities": []}], [8623, "Pharmacokinetic parameters of simvastatin with placebo and in combination with MenoAct851 (Varanasi BioResearch Pvt.", {"entities": [[30, 41, "Drug"], [47, 54, "Drug"], [79, 89, "Herb name"]]}], [8624, "Ltd., Varanasi, India) formulation.", {"entities": []}], [8625, "Values are expressed as mean (SD).", {"entities": []}], [8626, "A difference was considered significant at P < 0.05.", {"entities": []}], [8627, "Pharmacokinetic parameters of simvastatin hydroxy acid with placebo and in combination with MenoAct851 (Varanasi BioResearch Pvt.", {"entities": [[30, 54, "Drug"], [60, 67, "Drug"], [92, 102, "Herb name"]]}], [8628, "Ltd., Varanasi, India) formulation.", {"entities": []}], [8629, "Values are expressed as mean (SD).", {"entities": []}], [8630, "A difference was considered significant at P < 0.05.", {"entities": []}], [8631, "Chromatogram.", {"entities": []}], [8632, "(A) Internal standard lovastatin.", {"entities": [[22, 32, "Drug"]]}], [8633, "(B) Plasma obtained from the volunteer received single oral dose of 40 mg simvastatin.", {"entities": [[48, 64, "Frequency"], [68, 73, "Amount"], [74, 85, "Drug"]]}], [8634, "x-axis\u202f=\u202fruntime; y-axis\u202f=\u202fmV.", {"entities": []}], [8635, "Mean plasma concentration time-profiles of simvastatin after a single oral dose of 40 mg simvastatin with placebo and after pretreatment with 500 mg MenoAct851 BID PO for 14 days.", {"entities": [[0, 39, "Parameter"], [43, 54, "Drug"], [63, 79, "Frequency"], [83, 88, "Amount"], [89, 100, "Drug"], [106, 113, "Drug"], [142, 148, "Amount"], [149, 159, "Herb name"], [171, 178, "Duration"]]}], [8636, "Mean plasma concentration time-profiles of simvastatin hydroxy acid after a single oral dose of 40 mg simvastatin with placebo and after pretreatment with 500 mg MenoAct851 BID PO for 14 days.", {"entities": [[0, 39, "Parameter"], [43, 67, "Drug"], [76, 92, "Frequency"], [96, 101, "Amount"], [102, 113, "Drug"], [119, 126, "Drug"], [155, 161, "Amount"], [162, 172, "Herb name"], [184, 191, "Duration"]]}], [8637, "MenoAct851 was well tolerated throughout the study and also when coadministered with simvastatin.", {"entities": [[0, 10, "Herb name"], [85, 96, "Drug"]]}], [8638, "No serious adverse events occurred.", {"entities": [[3, 25, "Pathology"]]}], [8639, "The only adverse events reported by more than 1 volunteer during MenoAct851 or placebo treatment period were nausea and abdominal discomfort.", {"entities": [[9, 23, "Pathology"], [65, 75, "Herb name"], [79, 86, "Drug"], [109, 115, "Pathology"], [120, 140, "Pathology"]]}], [8640, "All mean laboratory parameters for serum chemistry, hematology, and urinalysis remained within reference range during their discharge.", {"entities": []}], [8641, "There were no remarkable findings in the vital signs, echocardiograms, physical examinations, visual acuity tests, and slit-lamp examinations in this study.", {"entities": []}], [8642, "None of the adverse events resulted in discontinuation from the study.", {"entities": []}], [8643, "Herb-drug interactions incidence was predicted to increase due to herbal medicines' worldwide popularity with the development of several herbal formulations with improved bioavailability.", {"entities": [[171, 186, "Parameter"]]}], [8644, "Numerous case studies have described harmful herb-drug interactions that could lead to morbidity or mortality.", {"entities": []}], [8645, "In the present study, an approach is made to evaluate the interaction potential of MenoAct851 on CYP450, through rat liver microsomes and high throughput fluorescence screening assays.", {"entities": [[83, 93, "Herb name"], [97, 103, "Target"]]}], [8646, "Orally administered medicinal products were mostly metabolized by gut flora before being absorbed into the systematic circulation.", {"entities": []}], [8647, "There was no statistically significant difference between the MenoAct851 and the placebo groups with respect to the mean pharmacokinetic parameters like C Lack of nicotine estimation in the volunteers was the limitation of the clinical pharmacokinetic parameters study.", {"entities": [[62, 72, "Herb name"], [81, 88, "Drug"]]}], [8648, "This study reports only the effects of MenoAct851 on CYP3A4 and CYP2D6 isoforms, the effects on other isoforms remains unknown.", {"entities": [[39, 49, "Herb name"], [53, 59, "Target"], [64, 70, "Target"]]}], [8649, "Further tests on other CY isoforms and transporters should be conducted to determine whether MenoAct851 has any additional effects on allopathic medicines\u2019 metabolism and pharmacokinetic parameters.", {"entities": [[93, 103, "Herb name"]]}], [8650, "Thus, MenoAct851 is likely to affect the exposure of CYP3A4 substrates following coadministration.", {"entities": [[6, 16, "Herb name"], [53, 59, "Target"]]}], [8651, "Accordingly, caution should be taken when MenoAct851 formulations are used in combination with allopathic drugs metabolized by CYP3A4.", {"entities": [[42, 52, "Herb name"], [127, 133, "Target"]]}], [8652, "Dr Govind Prasad Dubey holds the patent for MenoAct851.", {"entities": [[44, 54, "Herb name"]]}], [8653, "The authors have indicated that they have no other conflicts of interest regarding the content of this article.", {"entities": []}], [8654, "All the authors contributed equally.", {"entities": []}], [8655, "The authors thank the Department of Science and Technology, Government of India (grant No.", {"entities": []}], [8656, ": VI-D&P/372/10-11/TDT) for their financial assistance and support.", {"entities": []}], [8657, "The authors also thank Dr K. Ananth Kumar, Dr I. Jyothi, and Dr K. Vasanth from Interdisciplinary Institute of Indian System of Medicine Department for their support throughout the study.", {"entities": []}], [8658, "In addition, the authors thank Dr S. Sheller-Miller, Department of Obstetrics and Gynecology, The University of Texas Medical Branch, Galveston, Texas, for assisting with the English in the manuscript as well as Editing Press for final English language copyediting.", {"entities": []}], [8659, "Case Report: Fatigue and Bleeding in a Polymedicated Patient Using Several Herbal Supplementations, Detected with g-Nomic\u00ae Software Abel Saldarreaga Marin, 1 Marc Cendros, 2 Carlos J Ciudad, 3 and Ana Sabater 2 Author information Article notes Copyright and License information PMC Disclaimer Go to: Abstract  This was a case report of severe fatigue and bleeding in a 65-year-old man with ischemic heart disease who was wearing a stent and taking multiple medications for hypertension and diabetes.", {"entities": [[0, 11, "Study"], [13, 20, "Pathology"], [25, 33, "Pathology"], [75, 98, "Herb name"], [321, 332, "Study"], [336, 350, "Pathology"], [355, 363, "Pathology"], [369, 380, "Age"], [381, 384, "Sex"], [390, 412, "Pathology"], [473, 485, "Pathology"], [490, 498, "Pathology"]]}], [8660, "Correction of these interactions resulted in complete remission of the reported side effects.", {"entities": [[80, 92, "Pathology"]]}], [8661, "This supports the idea that non-pharmaceuticals potentiated the effects of acetylsalicylic acid on haemostasis, producing the bleeding that would have caused fatigue.", {"entities": [[75, 95, "Pathology"], [126, 134, "Pathology"], [158, 165, "Pathology"]]}], [8662, "It is important to use appropriate tools to detect drug interactions that also take into account commonly used non-pharmaceutical products.", {"entities": []}], [8663, "Drug interactions can be considered illnesses by themselves.", {"entities": [[36, 45, "Pathology"]]}], [8664, "Keywords: pharmacogenetics, SNP, drug-drug interaction, drug-lifestyle interactions, drug-herb, software, bleeding, fatigue, polymedication, medication risk, pharmacogenetics software, personalized prescription Go to: Introduction  Drug treatment can be affected by significant variability in the degree of response and the occurrence of side effects.", {"entities": [[106, 114, "Pathology"], [116, 123, "Pathology"], [338, 350, "Pathology"]]}], [8665, "Adverse drug reactions are responsible for considerable morbidity and mortality.", {"entities": [[43, 79, "Pathology"]]}], [8666, "Sometimes these undesirable effects are intrinsic to the drug, but in many cases they are due to drug-drug interactions.1,2 It is known that drug-drug interactions can trigger adverse effects of medicines that would have been safe if they had not been used in combination.", {"entities": [[16, 35, "Pathology"], [176, 191, "Pathology"]]}], [8667, "In addition, other substances that are not usually considered pharmaceuticals, like herbal products, may also cause drug-lifestyle interactions.", {"entities": []}], [8668, "Recognising and managing these interactions can be an invaluable process in achieving safer therapy.", {"entities": []}], [8669, "We present a case of a polymedicated patient who was taking apparently harmless substances and dietary supplements and who presented with bleeding and fatigue.", {"entities": [[138, 146, "Pathology"], [151, 158, "Pathology"]]}], [8670, "This situation was resolved by identifying and managing drug interactions using g-Nomic\u00ae personalised prescription software.", {"entities": []}], [8671, "Go to: Case Presentation  A 65-year-old Caucasian man with hypertension, type 2 diabetes, elevated LDL-cholesterol and ischemic cardiomyopathy, wearing a stent, presented unexplained fatigue with physical activity and coagulation defects consisting of gingival bleeding and frequent bruising.", {"entities": [[28, 39, "Age"], [40, 49, "Ethnic group"], [50, 53, "Sex"], [59, 71, "Pathology"], [73, 88, "Pathology"], [99, 114, "Parameter"], [119, 142, "Pathology"], [183, 190, "Pathology"], [218, 237, "Pathology"], [252, 269, "Pathology"], [274, 291, "Pathology"]]}], [8672, "Analytical Explorations  All biochemical parameters were within the normality except for elevated LDL-c levels.", {"entities": [[98, 110, "Parameter"]]}], [8673, "Hepatic and renal functions were normal (Alanine transaminase -ALT 17 U/L, aspartate transaminase AST 21 u/L, gamma-glutamyltransferase 24 U/L, creatinine 0.94 mg/dL, blood urea 35 mg/dL, glucose 95 mg/dL, glycosylated haemoglobin 6.1%).", {"entities": [[41, 66, "Parameter"], [67, 73, "Amount"], [75, 101, "Parameter"], [102, 108, "Amount"], [110, 135, "Parameter"], [136, 142, "Amount"], [144, 154, "Parameter"], [155, 165, "Amount"], [167, 177, "Parameter"], [178, 186, "Amount"], [188, 195, "Parameter"], [196, 204, "Amount"], [206, 230, "Parameter"], [231, 235, "Amount"]]}], [8674, "Prothrombin time (seconds): 10.2\u201c (8.9\u201313.3).", {"entities": [[0, 26, "Parameter"], [28, 44, "Amount"]]}], [8676, "Examination  Except for fatigue and bleeding, the patient showed good general condition; he was conscious, oriented and collaborative, eupnoeic at rest and afebrile.", {"entities": [[24, 31, "Pathology"], [36, 44, "Pathology"], [96, 105, "Pathology"], [135, 143, "Pathology"], [156, 164, "Pathology"]]}], [8677, "Cardiopulmonary auscultation and abdominal examination did not result in pathological findings.", {"entities": []}], [8678, "Basal oxygen saturation: 98%.", {"entities": [[0, 23, "Parameter"], [25, 28, "Amount"]]}], [8679, "Blood pressure: 138 mm Hg (systolic)/76 mm Hg (diastolic).", {"entities": [[0, 14, "Parameter"], [16, 57, "Amount"]]}], [8680, "Heart rate; 85 bpm.", {"entities": [[0, 10, "Parameter"], [12, 18, "Amount"]]}], [8681, "Respiratory rate at rest: 14 bpm.", {"entities": [[0, 24, "Parameter"], [26, 32, "Amount"]]}], [8682, "Temperature: 35.8 \u00b0C.", {"entities": [[0, 11, "Parameter"], [13, 20, "Amount"]]}], [8683, "The patient\u2019s medication regime was evaluated using g-Nomic\u00ae software3 to check for interactions and possible genetic effects.", {"entities": [[110, 125, "Pathology"]]}], [8684, "In Figure 1 it is shown all the initial drugs entered in the personalized prescription software.", {"entities": []}], [8685, "An external file that holds a picture, illustration, etc.", {"entities": []}], [8686, "Object name is PGPM-14-963-g0001.jpg Figure 1  All initial drugs entered in the personalized prescription software.", {"entities": []}], [8687, "In addition, the same personalized prescription software was used to check for possible substances that could contribute to interactions even if they are not considered drugs per se, referred to in the software as lifestyle habits.", {"entities": []}], [8688, "In addition, the patient quit smoking nine years ago, and since then has been consuming liquorice ever since to support abstinence.", {"entities": [[30, 37, "Parameter"]]}], [8689, "Figure 2 shows the list of lifestyle habits that may interact negatively with the patient\u2019s prescription entered into the personalized prescription software.", {"entities": []}], [8690, "The physician should ask the patient if he/she takes any of these substances on a regular basis in his/her daily life.", {"entities": []}], [8691, "If so, the doctor should click on the hyperlink to make this lifestyle habits part of the prescription as a whole.", {"entities": []}], [8692, "An external file that holds a picture, illustration, etc.", {"entities": []}], [8693, "Object name is PGPM-14-963-g0002.jpg Figure 2  Shows the list of all lifestyle habits that could interact with patient's medication, reported by the personalized prescription software.", {"entities": []}], [8694, "Actions and Outcome  After evaluating the possible interactions between medication and lifestyle, some measures were taken to avoid those interactions.", {"entities": []}], [8695, "Figure 3 shows drug-drug interactions as well as drug- lifestyle interactions.", {"entities": []}], [8696, "Figure 4 shows the possible interactions due to inhibitions and inductions caused by patient\u2019s polymedication.", {"entities": []}], [8697, "It is known that substances with inhibitory capacity can also impair enzyme activity even in the absence of loss-of-function variants.", {"entities": [[69, 84, "Parameter"]]}], [8698, "Therefore, a person who would be classified as a normal metaboliser based on a genetic test alone would experience a phenoconversion to a poor metaboliser when exposed to a strong inhibitor.", {"entities": [[47, 67, "Parameter"], [136, 154, "Parameter"]]}], [8699, "Similarly, enzyme inducers can increase enzyme activity beyond what a genetic test might indicate.", {"entities": [[40, 55, "Parameter"]]}], [8700, "This reasoning can be extended to drug-herb and drug-lifestyle interactions as potential modulators of drug metabolism and thus drug response.", {"entities": []}], [8701, "An external file that holds a picture, illustration, etc.", {"entities": []}], [8702, "Object name is PGPM-14-963-g0003.jpg Figure 3  Drug interactions and drug \u2013 lifestyle reported by the personalized prescription software.", {"entities": []}], [8703, "An external file that holds a picture, illustration, etc.", {"entities": []}], [8704, "Object name is PGPM-14-963-g0004.jpg Figure 4  Pharmacogenetics interactions described by the personalized prescription software.", {"entities": []}], [8705, "Liquorice was maintained, but the patient was told to minimize its use.", {"entities": []}], [8706, "As the patient was already being treated with a beta-blocker to control blood pressure, telmisartan was temporarily discontinued to minimise the side effects of the combination of two antihypertensive drugs.", {"entities": [[46, 60, "Drug"], [72, 86, "Parameter"], [88, 99, "Drug"], [145, 157, "Pathology"], [184, 206, "Drug"]]}], [8707, "Figure 5 shows the primary genes to be considered when checking the specific medication for to this clinical case.", {"entities": [[100, 113, "Study"]]}], [8708, "After assessing all drug interactions, no genetic testing of the patient was considered necessary.", {"entities": []}], [8709, "An external file that holds a picture, illustration, etc.", {"entities": []}], [8710, "Object name is PGPM-14-963-g0005.jpg Figure 5  Pharmacogenetics markers described by the personalized prescription software.", {"entities": []}], [8711, "The patient was scheduled for a follow-up evaluation two months later.", {"entities": []}], [8712, "At the next visit, there was a clear improvement in both his clinical condition and general wellbeing.", {"entities": []}], [8713, "The coagulation defects had disappeared with no further gingival bleeding or skin bruising.", {"entities": [[0, 23, "Pathology"], [56, 73, "Pathology"], [77, 90, "Pathology"]]}], [8714, "Blood pressure was normal (BP: 134/68 mmHg) despite the discontinuation of telmisartan, and it was considered that reinstating the antihypertensive was not justified.", {"entities": [[0, 14, "Parameter"], [27, 29, "Parameter"], [31, 42, "Amount"], [75, 86, "Drug"], [127, 147, "Drug"]]}], [8715, "Furthermore, glycaemia was also correct (HbA1c: 5.4%) and it was decided to discontinue metformin leaving only Empagliflozin to manage the patient\u2019s diabetes.", {"entities": [[13, 22, "Parameter"], [41, 46, "Parameter"], [48, 52, "Amount"], [88, 97, "Drug"], [111, 124, "Drug"], [149, 157, "Pathology"]]}], [8716, "The patient\u2019s general condition and well-being had also increased enormously: he did not complain of fatigue and had started exercising outdoors and working out at the gym three times a week.", {"entities": [[101, 108, "Pathology"], [172, 190, "Frequency"]]}], [8717, "Go to: Discussion  Drug interactions seem to have been the cause of the patient\u2019s worsening condition, as the improvement was remarkable after addressing the detected potential risks of interactions.", {"entities": []}], [8718, "The main concern in this patient was the excessive bleeding.", {"entities": [[41, 59, "Pathology"]]}], [8720, "All of this would contribute to increase the effects of salicylates on both platelet aggregation and blood pressure.", {"entities": [[56, 67, "Herb name"], [76, 96, "Parameter"], [101, 115, "Parameter"]]}], [8722, "They would have been overlooked unless the personalised prescribing software had reported them as potential risks of interaction with the patients\u2019 medication.", {"entities": []}], [8723, "The proactive warning prompted the physician to ask the patient about the consumption of these products.", {"entities": []}], [8724, "No specific cause of the fatigue was identified with certainty, but it was likely to be a side effect of the blood loss.", {"entities": [[25, 32, "Pathology"], [90, 101, "Pathology"], [109, 119, "Pathology"]]}], [8726, "Caution is recommended whenever natural products are used in combination with drugs affecting haemostasis.", {"entities": []}], [8727, "The patient\u2019s condition improved as the drug regimen was reduced and simplified, meaning that some drugs may have been unnecessary in the first place.", {"entities": []}], [8728, "For example, the hypertension could have been secondary to the use of liquorice and salicylate potentiation, and in this case, discontinuation of these substances would have been more helpful in controlling blood pressure than starting telmisartan.", {"entities": [[17, 29, "Pathology"], [84, 94, "Herb name"], [207, 221, "Parameter"], [236, 247, "Drug"]]}], [8729, "Go to: Conclusion  This case report serves to illustrate two concepts: I) the importance of recognizing the interactions of existing compounds in commonly consumed products, in this particular case with anticoagulants.", {"entities": [[24, 35, "Study"], [203, 217, "Drug"]]}], [8730, "It is therefore advisable to use drug interaction software that take into account lifestyle habits.", {"entities": []}], [8731, "II) Be aware of the increased risk of drug-drug interactions in patients consuming multiple natural products not considered drugs, which may be the cause of many drug-drug interactions.", {"entities": []}], [8732, "While being aware of the dangers of polymedication with multiple therapeutic drugs, other substances such as herbal products and dietary supplements, should not be disregarded.", {"entities": []}], [8733, "Reducing the drug regimen may occasionally lower the amount and severity of drug interactions, provided that the remaining drugs are enough to control the pathology.", {"entities": [[151, 164, "Pathology"]]}], [8734, "This work emphasizes the need for personalized approaches for patient empowerment in both clinical settings and home health care.", {"entities": []}], [8735, "PMCID: PMC2856051 PMID: 20573086 Pharmacokinetic and pharmacodynamic interactions of echinacea and policosanol with warfarin in healthy subjects Mohi Iqbal Mohammed Abdul,1 Xuemin Jiang,1,* Kenneth M Williams,2 Richard O Day,3,4 Basil D Roufogalis,1 Winston S Liauw,2 Hongmei Xu,1 Anita Matthias,5 Reginald P Lehmann,5 and Andrew J McLachlan1,6 Author information Article notes Copyright and License information PMC Disclaimer Go to: Abstract AIMS  This study investigated the pharmacokinetic and pharmacodynamic interactions of echinacea and policosanol with warfarin in healthy subjects.", {"entities": [[85, 94, "Herb name"], [99, 110, "Herb name"], [116, 124, "Drug"], [128, 135, "Pathology"], [529, 538, "Herb name"], [543, 554, "Herb name"], [560, 568, "Drug"], [572, 579, "Pathology"]]}], [8736, "METHODS  This was an open-label, randomized, three-treatment, cross-over, clinical trial in healthy male subjects (n= 12) of known CYP2C9 and VKORC1 genotype who received a single oral dose of warfarin alone or after 2 weeks of pre-treatment with each herbal medicine at recommended doses.", {"entities": [[21, 88, "Study"], [92, 99, "Pathology"], [100, 104, "Sex"], [115, 120, "Cohort"], [131, 137, "Target"], [142, 148, "Target"], [193, 201, "Drug"], [217, 224, "Duration"]]}], [8737, "RESULTS  The apparent clearance of (S)-warfarin (90% CI of ratio; 1.01, 1.18) was significantly higher during concomitant treatment with echinacea but this did not lead to a clinically significant change in INR (90% CI of AUC of INR; 0.91, 1.31).", {"entities": [[9, 31, "Parameter"], [35, 47, "Drug"], [137, 146, "Herb name"], [207, 210, "Parameter"], [222, 225, "Parameter"], [229, 232, "Parameter"]]}], [8738, "Policosanol did not significantly affect warfarin enantiomer pharmacokinetics or warfarin response.", {"entities": [[0, 11, "Herb name"], [41, 49, "Drug"], [81, 89, "Drug"]]}], [8739, "Neither echinacea nor policosanol had a significant effect on platelet aggregation after 2 weeks of pre-treatment with the respective herbal medicines.", {"entities": [[8, 17, "Herb name"], [22, 33, "Herb name"], [62, 82, "Parameter"], [89, 96, "Duration"]]}], [8740, "CONCLUSION  Echinacea significantly reduced plasma concentrations of S-warfarin.", {"entities": [[12, 21, "Herb name"], [69, 79, "Drug"]]}], [8741, "However, neither echinacea nor policosanol significantly affected warfarin pharmacodynamics, platelet aggregation or baseline clotting status in healthy subjects.", {"entities": [[17, 26, "Herb name"], [31, 42, "Herb name"], [66, 74, "Drug"], [93, 113, "Parameter"], [126, 141, "Parameter"], [145, 152, "Pathology"]]}], [8742, "Keywords: echinacea, herb-drug interaction, pharmacodynamic, pharmacokinetic, policosanol, warfarin WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT      Echinacea and policosanol are commonly used herbal medicines which may be ingested by patients receiving warfarin.", {"entities": [[10, 19, "Herb name"], [78, 89, "Herb name"], [91, 99, "Drug"], [146, 155, "Herb name"], [160, 171, "Herb name"], [251, 259, "Drug"]]}], [8743, "Echinacea has been implicated in interacting with drug metabolizing enzymes and policosanol has been shown to decrease platelet aggregation.", {"entities": [[0, 9, "Herb name"], [80, 91, "Herb name"], [119, 139, "Parameter"]]}], [8744, "The potential interaction of echinacea and policosanol with warfarin has not previously been investigated.", {"entities": [[29, 38, "Herb name"], [43, 54, "Herb name"], [60, 68, "Drug"]]}], [8745, "WHAT THIS STUDY ADDS      Concomitant treatments with echinacea increased the apparent clearance of S-warfarin but did not have a clinically significant effect on warfarin pharmacodynamics in healthy subjects.", {"entities": [[54, 63, "Herb name"], [78, 96, "Parameter"], [100, 110, "Drug"], [163, 171, "Drug"], [192, 199, "Pathology"]]}], [8746, "Policosanol did not significantly affect warfarin pharmacokinetics or pharmacodynamics.", {"entities": [[0, 11, "Herb name"], [41, 49, "Drug"]]}], [8747, "Go to: Introduction  Warfarin is widely used in cardiovascular medicine to prevent thromboembolic complications.", {"entities": [[21, 29, "Drug"], [83, 111, "Pathology"]]}], [8748, "Warfarin exhibits wide inter-subject variability in its response which has been partly attributed to genetic factors, age, hepatic function, diet and drug interactions [1, 2].", {"entities": [[0, 8, "Drug"]]}], [8749, "The rise in the use of herbal medicines in the community increases the likelihood that herbal and conventional medicines will be administered concomitantly despite the limited evidence to support the safe use of many of these combinations.", {"entities": []}], [8750, "Therefore, two commonly used herbal medicines, echinacea and policosanol were investigated for their potential to interact with warfarin.", {"entities": [[47, 56, "Herb name"], [61, 72, "Herb name"], [128, 136, "Drug"]]}], [8751, "Echinacea is a popular herbal medicine reported to be an immunostimulant [3].", {"entities": [[0, 9, "Herb name"]]}], [8752, "Of the different species used medicinally, Echinacea purpurea and Echinacea angustifolia are more commonly used in the community [3].", {"entities": [[43, 61, "Herb name"], [66, 88, "Herb name"]]}], [8753, "The main constituents in preparations of these two species are caffeic acid derivatives and alkamides (alkylamides) [3].", {"entities": [[63, 87, "Herb name"], [92, 115, "Herb name"]]}], [8754, "Alkamides have been shown to achieve systemic concentrations after administration of echinacea tablets [4\u20136].", {"entities": [[0, 9, "Herb name"], [85, 94, "Herb name"]]}], [8755, "In vitro and in vivo evidence indicates that constituents of echinacea have the potential to interact with cytochrome P450 enzymes [7, 8].", {"entities": [[0, 8, "Study"], [13, 20, "Study"], [61, 70, "Study"], [107, 130, "Target"]]}], [8756, "Gorski et al.", {"entities": []}], [8757, "[9] investigated the in vivo effects of Echinacea purpurea administration on the activity of different CYP enzymes, including those enzymes involved in the metabolism of the enantiomers of warfarin.", {"entities": [[21, 28, "Study"], [40, 58, "Herb name"], [103, 114, "Target"], [189, 197, "Drug"]]}], [8758, "This study indicated that echinacea significantly decreased CYP1A2 activity, significantly increased hepatic CYP3A4 activity and there was a trend towards decreased CYP2C9 activity.", {"entities": [[26, 35, "Herb name"], [60, 66, "Target"], [109, 115, "Target"], [165, 171, "Target"]]}], [8759, "The possible interaction between echinacea and warfarin is difficult to predict due to the lack of a controlled clinical study investigating this potential herb-drug interaction but is of particular relevance given the narrow therapeutic index of warfarin.", {"entities": [[33, 42, "Herb name"], [47, 55, "Drug"], [101, 126, "Study"], [247, 255, "Drug"]]}], [8760, "Policosanol is a complex mixture of alcohols which are mostly extracted from sugar cane wax (Saccharum officinarum) but may also be obtained from wheat, rice and beeswax [10].", {"entities": [[0, 11, "Herb name"], [77, 115, "Herb name"], [146, 151, "Herb name"], [153, 157, "Herb name"]]}], [8761, "Policosanol contains a mixture of long chain (20\u201336 carbons) higher aliphatic primary alcohols [10] consisting of approximately 66% octacosanol (C28), 12% triacontanol (C30), 7% hexacosanol (C26) and lower proportions of other alcohols including docosanol (C22) and tetracosanol (C24) [10].", {"entities": [[0, 11, "Herb name"], [132, 149, "Herb name"], [155, 173, "Herb name"], [178, 195, "Herb name"], [246, 261, "Herb name"], [266, 284, "Herb name"]]}], [8762, "Policosanol has been investigated and promoted for its cholesterol lowering effects [11] and hence may be used concomitantly by patients with cardiovascular disease receiving warfarin.", {"entities": [[0, 11, "Herb name"], [142, 164, "Pathology"], [175, 183, "Drug"]]}], [8763, "There are no clinical studies investigating the potential policosanol-warfarin interaction, although controlled studies have shown that policosanol can decrease platelet aggregation, suggesting there may be an aspirin-like interaction with warfarin [12].", {"entities": [[13, 29, "Study"], [58, 69, "Herb name"], [70, 78, "Drug"], [101, 119, "Study"], [136, 147, "Herb name"], [161, 181, "Parameter"], [210, 217, "Drug"], [240, 248, "Drug"]]}], [8764, "Hepatic CYP2C9 is the enzyme responsible for (S)-warfarin metabolism and the impact of genetic variation in CYP2C9 genotype on warfarin effects is well documented [13].", {"entities": [[8, 14, "Target"], [45, 57, "Drug"], [108, 123, "Target"], [127, 135, "Drug"]]}], [8765, "Variation in the vitamin K epoxide reductase complex subunit 1 (VKORC1) gene has been found to contribute to clinically meaningful variations in warfarin response [14].", {"entities": [[17, 76, "Target"], [145, 153, "Drug"]]}], [8766, "The impact of genetic variation on the significance of herb-drug interactions with warfarin remains unclear.", {"entities": [[83, 91, "Drug"]]}], [8767, "The aim of this study was to investigative the possible pharmacokinetic or pharmacodynamic interaction of echinacea and policosanol with warfarin in healthy male subjects of known CYP2C9 and VKORC1 genotype.", {"entities": [[106, 115, "Herb name"], [120, 131, "Herb name"], [137, 145, "Drug"], [149, 156, "Pathology"], [157, 161, "Sex"], [180, 186, "Target"], [191, 197, "Target"]]}], [8768, "This study also examined the steady-state concentration-time profiles of echinacea alkamides in healthy subjects after 2 weeks of regular dosing with echinacea.", {"entities": [[73, 92, "Herb name"], [96, 103, "Pathology"], [119, 126, "Duration"], [150, 159, "Herb name"]]}], [8769, "Go to: Materials and methods Study design  This study was approved by the St Vincent's Hospital Human Research Ethics Committee, Darlinghurst, Australia and the Human Ethics Committee of the University of Sydney, Australia.", {"entities": []}], [8770, "Healthy male subjects (n= 12), aged between 18 and 34 years, who were non-smokers and not taking any medication including any herbal medicines or dietary supplements (for at least 2 weeks), were recruited into the trial.", {"entities": [[0, 7, "Pathology"], [8, 12, "Sex"], [23, 28, "Cohort"], [31, 59, "Age"]]}], [8771, "Subjects who gave written consent to participate in the study were selected after a full medical history, physical examination and clinical laboratory evaluation.", {"entities": []}], [8772, "Subjects with any medical condition that could alter warfarin effects, including any clotting disorders, hepatic dysfunction or platelet dysfunction were excluded from the study.", {"entities": [[53, 61, "Drug"], [85, 103, "Pathology"], [105, 124, "Pathology"], [128, 148, "Pathology"]]}], [8773, "Subjects were randomly allocated to three treatment groups to receive a single dose of warfarin (25 mg, Coumadin 5 \u00d7 5 mg tablets; Boots HealthCare Australia Pty Ltd, North Ryde, NSW, Australia) alone or after 2 weeks pre-treatment with multiple doses of either echinacea (1275 mg four times daily containing a mixture of 600 mg of E. angustifolia roots and 675 mg of E. purpurea root; standardized to contain 5.75 mg of total alkamides per tablet; MediHerb Premium Echinacea\u2122 tablets, MediHerb Pty.", {"entities": [[87, 95, "Drug"], [97, 102, "Amount"], [104, 112, "Drug"], [113, 121, "Amount"], [210, 217, "Duration"], [262, 271, "Herb name"], [273, 280, "Amount"], [281, 297, "Frequency"], [322, 328, "Amount"], [332, 347, "Herb name"], [348, 353, "Herb part"], [358, 364, "Amount"], [368, 379, "Herb name"], [380, 384, "Herb part"], [410, 417, "Amount"], [427, 436, "Herb name"], [449, 475, "Herb name"]]}], [8774, "Ltd, Warwick, QLD, Australia) or policosanol (10 mg tablet twice daily; Policosanol derived from sugar cane wax; Blackmores, Balgowlah, NSW, Australia).", {"entities": [[33, 44, "Herb name"], [46, 51, "Amount"], [59, 70, "Frequency"], [72, 83, "Herb name"], [97, 111, "Herb name"]]}], [8775, "Dosing with herbal medicines continued throughout the 7 days after warfarin administration, i.e.", {"entities": [[54, 60, "Duration"], [67, 75, "Drug"]]}], [8776, "until the last blood sample was drawn.", {"entities": []}], [8777, "Subjects were subsequently crossed over to the other treatments following a wash-out period of 2 weeks.", {"entities": [[95, 102, "Duration"]]}], [8778, "To enhance adherence to clinical visits and the treatment protocol subjects were provided with a visit calendar and a diary to record medication intake.", {"entities": []}], [8779, "Herbal medicine ingestion was not directly supervised.", {"entities": []}], [8780, "Adherence to medicines, general well-being and signs of possible adverse events were also assessed using regular mobile phone calls/text messages and e-mail contact.", {"entities": [[65, 79, "Pathology"]]}], [8781, "Blood samples were collected into sodium citrate (for INR measurement) and EDTA (for warfarin enantiomer measurement and genotyping) vacutainer tubes before (\u221248, \u221224, 0 h) and after (1, 2, 4, 8, 12, 24, 48, 72, 96, 120, 144 and 168 h) warfarin dosing.", {"entities": [[54, 57, "Parameter"], [85, 104, "Drug"], [236, 244, "Drug"]]}], [8782, "Plasma was harvested by centrifugation at 1500 g for 15 min.", {"entities": []}], [8783, "Platelet aggregation was assessed in whole blood samples (collected in sodium citrate tubes) taken before warfarin administration in all three treatment arms.", {"entities": [[0, 20, "Parameter"], [106, 114, "Drug"]]}], [8784, "CYP2C9 and VKORC1 genotyping  The CYP2C9*1,*2 and *3 polymorphisms of CYP2C9 were detected by polymerase chain reaction-based restriction fragment length polymorphism (PCR-RFLP) analysis.", {"entities": [[0, 6, "Target"], [11, 17, "Target"], [34, 76, "Target"]]}], [8785, "The primers and restriction sites for the CYP2C9*2 and CYP2C9*3 alleles used in this study were as described by Xu et al.", {"entities": [[42, 50, "Target"], [55, 63, "Target"]]}], [8786, "[15].", {"entities": []}], [8787, "The VKORC11173 T > C polymorphism was detected using allelic discrimination real-time PCR as described by Li et al.", {"entities": [[4, 14, "Target"]]}], [8788, "[16] with minor modifications.", {"entities": []}], [8789, "Plasma warfarin enantiomers concentrations  Plasma samples were analyzed using a validated, chiral, HPLC assay [17].", {"entities": [[7, 27, "Drug"]]}], [8790, "Precision of the assay (expressed as coefficient of variation) was less than 15% for both warfarin enantiomers.", {"entities": [[90, 110, "Drug"]]}], [8791, "Inter- and intra-day accuracy of the assay was within 15% of the nominal warfarin enantiomer concentration.", {"entities": [[73, 92, "Drug"]]}], [8792, "The extraction recovery of both (S)- and (R)-warfarin was within the range of 86\u201393%.", {"entities": [[32, 53, "Drug"]]}], [8793, "The fraction unbound of (S)-warfarin and (R)-warfarin in plasma samples was investigated using a validated ultra- filtration method [17] based upon the assumption that warfarin fraction unbound is independent of concentration up to 25 \u00b5g ml\u22121 of rac-warfarin as demonstrated by Banfield et al.", {"entities": [[24, 36, "Drug"], [41, 53, "Drug"], [168, 176, "Drug"], [246, 258, "Drug"]]}], [8794, "[18].", {"entities": []}], [8795, "In brief, rac-warfarin (15 \u00b5g) was added to plasma samples (1 ml) from each subject obtained by pooling samples collected between 1\u20138 h, 12\u201372 h and 96\u2013168 h after the warfarin dose.", {"entities": [[10, 22, "Drug"], [168, 176, "Drug"]]}], [8796, "Unbound warfarin enantiomers were separated by ultrafiltration (Centrifree\u2122 YM-30, Millipore, Australia Pty Ltd, North Ryde, NSW, Australia) with centrifugation at 1500 g for 20 min.", {"entities": [[8, 28, "Drug"]]}], [8797, "Ultrafiltrate was assayed using the validated chiral HPLC assay described above [17].", {"entities": []}], [8798, "The unbound fraction was calculated as the ratio of ultrafiltrate to plasma warfarin enantiomer concentrations.", {"entities": [[76, 95, "Drug"]]}], [8799, "Platelet aggregation and International Normalised Ratio (INR) measurement  Platelet aggregation was measured within 3 h of blood collection using a whole blood aggregometer (Chrono-par; Chrono-log Corp., USA, Edward Keller Australia Pty Ltd, Hallam, VIC, Australia) [17] by addition of adesonine diphosphate (ADP, 10 \u00b5m), arachidonic acid (0.5 mm), or collagen (2 \u00b5g ml\u22121).", {"entities": [[0, 20, "Parameter"], [25, 61, "Parameter"], [75, 95, "Parameter"]]}], [8800, "INR was measured using a BFT II analyzer\u2122 (Dade Behring Diagnostics Pty Ltd, Lane Cove, NSW, Australia) as previously reported [17].", {"entities": [[0, 3, "Parameter"]]}], [8801, "Determination of echinacea alkamides in tablets and in plasma  Echinacea alkamide content in the echinacea tablets used in this study and in the plasma of subjects after oral administration of multiple doses of echinacea tablets were determined using a previously reported and validated LCMS method [5].", {"entities": [[17, 36, "Herb name"], [63, 81, "Herb name"], [97, 106, "Herb name"], [211, 220, "Herb name"]]}], [8802, "Echinacea alkamide content in plasma was determined from blood samples collected over a dosing interval after 2 weeks of regular echinacea intake.", {"entities": [[0, 18, "Herb name"], [110, 117, "Duration"], [129, 138, "Herb name"]]}], [8803, "Data analysis  The pharmacodynamic response of warfarin was assessed by measuring the area under the curve of the International Normalised Ratio vs. time (AUCINR) profile estimated using the linear trapezoidal rule.", {"entities": [[47, 55, "Drug"], [82, 162, "Parameter"]]}], [8804, "INR at baseline (INR0) prior to warfarin administration and the maximum observed INR (INRmax) were also recorded.", {"entities": [[0, 22, "Parameter"], [32, 40, "Drug"], [60, 93, "Parameter"]]}], [8805, "The elimination rate constant (\u03bbz) was calculated from the slope of the terminal portion of the natural logarithmic concentration\u2013time curve for (S)- and (R)-warfarin.", {"entities": [[145, 166, "Drug"]]}], [8806, "Area under the concentration\u2013time curve (AUC) to the last quantifiable concentration (AUC(0,t)) was determined using the trapezoidal rule and extrapolated to infinity (AUC(0,\u221e)) by adding Ct/\u03bbz, where Ct is the observed warfarin enantiomer concentration in the last quantifiable sample.", {"entities": [[0, 45, "Parameter"], [86, 94, "Parameter"], [168, 176, "Parameter"], [220, 228, "Drug"]]}], [8808, "The maximum concentration (Cmax) and the time it occurred (tmax) were determined by observation.", {"entities": [[0, 32, "Parameter"], [59, 63, "Parameter"]]}], [8809, "Statistical analysis  A power calculation indicated that 12 subjects in a crossover study design would provide an 80% chance of detecting a 20% difference in the AUC(0,\u221e) of (S)-warfarin at the P= 0.05 level of significance.", {"entities": [[57, 68, "Cohort"], [72, 89, "Study"], [162, 170, "Parameter"], [174, 186, "Drug"]]}], [8810, "This study design has been used successfully in our previous herb\u2013drug interaction studies with warfarin [17].", {"entities": [[96, 104, "Drug"]]}], [8811, "Pharmacokinetic and pharmacodynamic parameters after treatment with warfarin alone (control) and in warfarin with herbal medicine treatment arm (intervention) were logarithmically transformed and reported as the geometric mean ratios (intervention to control) and 90% confidence intervals (CI) of the ratio.", {"entities": [[68, 76, "Drug"], [100, 108, "Drug"]]}], [8812, "If the 90% CI of the ratios included the value of 1.0 then the difference between parameters was considered as being not significantly different.", {"entities": []}], [8813, "Residual mean square error (RMSE) for each logarithmically transformed parameter for each treatment was obtained using anova with nested parameters in treatment and sequence order.", {"entities": []}], [8814, "Statistical analyses were conducted using Stata\u00ae 5.0 (Stata Corp., TX, USA).", {"entities": []}], [8815, "Go to: Results  The mean (and range) age, weight and height of the 12 subjects in the study were 24 years (20\u201335 years), 68 kg (57\u201384 kg) and 177 cm (171\u2013184 cm), respectively.", {"entities": [[67, 78, "Cohort"], [97, 119, "Age"]]}], [8816, "Six subjects were of European ancestry and six subjects were of Asian ancestry (four of whom were of South Asian origin).", {"entities": [[0, 12, "Cohort"], [21, 29, "Ethnic group"], [43, 55, "Cohort"], [64, 69, "Ethnic group"], [101, 112, "Ethnic group"]]}], [8817, "Nine subjects had the CYP2C9*1/*1 genotype and one subject each carried the CYP2C9*1/*2, CYP2C9*1/*3 and CYP2C9*2/*2 variant.", {"entities": [[0, 13, "Cohort"], [22, 33, "Target"], [47, 58, "Cohort"], [76, 87, "Target"], [89, 100, "Target"], [105, 116, "Target"]]}], [8818, "Four subjects carried the VKORC1 wild-type (CC) and eight subjects carried variant VKORC1 alleles including six with heterozygous (CT) and two with homozygous (TT) alleles.", {"entities": [[0, 13, "Cohort"], [26, 47, "Target"], [52, 66, "Cohort"], [83, 171, "Target"]]}], [8819, "All subjects completed the study and no adverse events related to either of the herbal medicines or warfarin were reported.", {"entities": [[40, 54, "Pathology"], [100, 108, "Drug"]]}], [8820, "One subject received a dose of 20 mg (rather than 25 mg) in the warfarin only treatment arm.", {"entities": [[0, 11, "Cohort"], [31, 36, "Amount"], [64, 72, "Drug"]]}], [8821, "The pharmacokinetic data for this subject were included after dose normalization but the pharmacodynamic data (AUCINR, INRmax) were excluded from the final analysis.", {"entities": [[111, 117, "Parameter"], [119, 125, "Parameter"]]}], [8822, "Pharmacokinetics of warfarin  Figures 1 and \u200band22 present the concentration\u2013time profiles of (S)- and (R)-warfarin, respectively, in the different treatments arms of this study.", {"entities": [[20, 28, "Drug"], [94, 115, "Drug"]]}], [8823, "Co-administration of echinacea with warfarin led to a significant decreased in the AUC of (S)-warfarin (Table 1), although the magnitude of the mean change was small (8%).", {"entities": [[21, 30, "Herb name"], [36, 44, "Drug"], [83, 86, "Parameter"], [90, 102, "Drug"]]}], [8824, "Moreover, for the majority of subjects (n= 10), the apparent total clearance of (S)-warfarin in the warfarin and echinacea treatment arm tended to be higher when compared with the warfarin only treatment arm.", {"entities": [[52, 76, "Parameter"], [80, 92, "Drug"], [100, 108, "Drug"], [113, 122, "Herb name"], [180, 188, "Drug"]]}], [8825, "However, the pharmacokinetics of (R)-warfarin (Table 1) were not affected by co-administration with echinacea, nor did echinacea significantly affect the unbound plasma concentrations of either (S)- or (R)-warfarin (Table 1).", {"entities": [[33, 45, "Drug"], [100, 109, "Herb name"], [119, 128, "Herb name"], [194, 214, "Drug"]]}], [8827, "Object name is bcp0069-0508-f1.jpg Figure 1  Plasma concentration\u2013time profile of (S)-warfarin after a single oral dose of warfarin either alone (solid squares) or after multiple doses of echinacea tablets (open squares) or policosanol tablets (open triangles).", {"entities": [[82, 94, "Drug"], [123, 131, "Drug"], [188, 205, "Herb name"], [224, 235, "Herb name"]]}], [8828, "Values are presented as means \u00b1 SD An external file that holds a picture, illustration, etc.", {"entities": []}], [8829, "Object name is bcp0069-0508-f2.jpg Figure 2  Plasma concentration\u2013time profile of (R)-warfarin after a single oral dose of warfarin alone (solid squares) or after multiple doses of echinacea tablets (open squares) or policosanol tablets (open triangles).", {"entities": [[82, 94, "Drug"], [123, 131, "Drug"], [181, 190, "Herb name"], [217, 228, "Herb name"]]}], [8830, "Values are presented as mean \u00b1 SD  Co-administration of policosanol did not affect the pharmacokinetics of either (S)- or (R)-warfarin (Figures 1 and \u200band2;2; Table 1).", {"entities": [[56, 67, "Herb name"], [114, 134, "Drug"]]}], [8831, "Pharmacodynamic end points  Co-administration of either echinacea or policosanol did not significantly affect warfarin pharmacodynamics (Table 2).", {"entities": [[56, 65, "Herb name"], [69, 80, "Herb name"], [110, 118, "Drug"]]}], [8832, "This analysis included pharmacodynamic data for 11 of the 12 subjects as one subject received a lower dose of warfarin and was therefore excluded.", {"entities": [[58, 69, "Cohort"], [110, 118, "Drug"]]}], [8833, "Neither echinacea nor policosanol altered the platelet aggregation induced by the three different platelet agonists (ADP, arachidonic acid and collagen) (Table 3).", {"entities": [[8, 17, "Herb name"], [22, 33, "Herb name"], [46, 66, "Parameter"]]}], [8834, "Table 3  Platelet aggregation (Ohms) after 2 weeks of echinacea and policosanol pre-treatment (n= 12) \tControl\tPolicosanol treatment\tEchinacea treatment Agonist\tMean (95% CI)\tMean (95% CI)\tGeometric mean ratio to control (90% CI)\tMean (95% CI)\tGeometric mean ratio to control (90% CI) ADP*\t7.8 (5.5, 10.0)\t6.8 (4.9, 8.8)\t0.92 (0.64, 1.30)\t7.5 (4.1, 10.8)\t0.84 (0.59, 1.19) Arachidonic acid\t11.0 (9.6, 12.5)\t11.2 (9.4, 12.9)\t1.00 (0.82, 1.23)\t12.1 (9.3, 15.0)\t1.06 (0.86, 1.30) Collagen\t13.0 (11.5, 14.6)\t14.9 (12.6, 17.2)\t1.13 (0.93, 1.37)\t15.8 (12.2, 19.5)\t1.17 (0.97, 1.42) Open in a separate window *Adenosine diphosphate.", {"entities": [[9, 29, "Parameter"], [54, 63, "Herb name"], [68, 79, "Herb name"], [111, 122, "Herb name"], [133, 142, "Herb name"]]}], [8835, "Table 2  Warfarin pharmacodynamics during treatment with herbal medicines (n= 11) \tMean (95 % CI)\tGeometric mean ratio (90% CI) Parameter\tWarfarin\tWarfarin and policosanol\tWarfarin and echinacea\tWarfarin and policosanol to warfarin only\tWarfarin and echinacea to warfarin only INR0\t1.0 (1.0, 1.0)\t1.0 (1.0, 1.1)\t1.0 (1.0, 1.1)\t1.04 (1.01, 1.07)\t1.01 (0.98, 1.04) INRmax\t1.7 (1.5, 1.9)\t1.9 (1.7, 2.1)\t1.8 (1.6, 2.0)\t1.08 (0.99, 1.18)\t1.04 (0.95, 1.13) AUCINR\t52.7 (38.3, 67.2)\t55.2 (41.2, 69.2)\t55.2 (42.8, 67.6)\t1.11 (0.92, 1.33)\t1.09 (0.91, 1.31) Open in a separate window CYP2C9 and VKORC1 genotype (S)-warfarin pharmacokinetics and interaction with herbal medicines  The apparent clearance of (S)-warfarin was CYP2C9 genotype dependent in the order of CYP2C9*1/*1 > CYP2C9*1/*2 > CYP2C9*1/*3 > CYP2C9*2/*2 in all the treatment arms (data not shown).", {"entities": [[9, 17, "Drug"], [138, 146, "Drug"], [147, 155, "Drug"], [160, 171, "Herb name"], [172, 180, "Drug"], [185, 194, "Herb name"], [195, 203, "Drug"], [208, 219, "Herb name"], [223, 231, "Drug"], [237, 245, "Drug"], [250, 259, "Herb name"], [263, 271, "Drug"], [277, 281, "Parameter"], [363, 369, "Parameter"], [451, 457, "Parameter"], [574, 580, "Target"], [585, 591, "Target"], [601, 613, "Drug"], [670, 692, "Parameter"], [696, 708, "Drug"], [713, 719, "Target"], [755, 766, "Target"], [769, 780, "Target"], [783, 794, "Target"], [797, 808, "Target"]]}], [8836, "This study found no evidence of any apparent effect of CYP2C9 or VKORC1 genotype on the interaction with neither policosanol or echinacea and warfarin.", {"entities": [[55, 61, "Target"], [65, 71, "Target"], [113, 124, "Herb name"], [128, 137, "Herb name"], [142, 150, "Drug"]]}], [8837, "Pharmacokinetics of echinacea alkamides  The echinacea herbal medicine product used in the study was found to contain the following major echinacea alkamides; 2,4-dienes, 0.88 mg/tablet; 2-ene, 0.66 mg/tablet and tetraene, 0.93 mg/tablet.", {"entities": [[20, 39, "Herb name"], [45, 54, "Herb name"], [138, 157, "Herb name"]]}], [8838, "Trough plasma concentrations of the major echinacea alkamide tetraene ranged from 1 to 23 ng ml\u22121, and the Cmax was found to range from 13 to 65 ng ml\u22121.", {"entities": [[42, 69, "Herb name"], [107, 111, "Parameter"]]}], [8839, "These data supported the quality of the echinacea tablets used in this investigation and confirm that subjects were taking the echinacea herbal medicine product.", {"entities": [[40, 49, "Herb name"], [127, 136, "Herb name"]]}], [8840, "Go to: Discussion  Warfarin exhibits stereo- and regio-selective metabolism [19], with the more potent (S)-warfarin being metabolized by CYP2C9 and CYP3A4 [19] and the less active (R)-enantiomer being metabolized by CYP3A4 and CYP1A2 [19].", {"entities": [[19, 27, "Drug"], [103, 115, "Drug"], [137, 143, "Target"], [148, 154, "Target"], [216, 222, "Target"], [227, 233, "Target"]]}], [8841, "This metabolic profile, together with the well-recognised narrow therapeutic index of warfarin, and the likelihood that herbal medicines will be ingested concomitantly with warfarin, provided the rationale for investigating the possible interaction between echinacea and warfarin, and policosanol and warfarin.", {"entities": [[86, 94, "Drug"], [173, 181, "Drug"], [257, 266, "Herb name"], [271, 279, "Drug"], [285, 296, "Herb name"], [301, 309, "Drug"]]}], [8842, "However, this study found that echinacea treatment only slightly increased the apparent total clearance of the more potent (S)-warfarin and did not affect the pharmacokinetics of the (R)-enantiomer.", {"entities": [[31, 40, "Herb name"], [79, 103, "Parameter"], [123, 135, "Drug"]]}], [8843, "Interestingly, this effect on the pharmacokinetics of (S)-warfarin was not associated with a significant effect on warfarin pharmacodynamics.", {"entities": [[54, 66, "Drug"], [115, 123, "Drug"]]}], [8844, "Policosanol had no effect on either the pharmacokinetics or pharmacodynamics of warfarin.", {"entities": [[0, 11, "Herb name"], [80, 88, "Drug"]]}], [8845, "Neither herbal medicine altered platelet aggregation.", {"entities": [[32, 52, "Parameter"]]}], [8846, "Gorski et al.", {"entities": []}], [8847, "[9] have reported that, in vivo, echinacea inhibited hepatic CYP1A2 enzymes (27% decrease in caffeine clearance) and to a lesser extent, hepatic CYP2C9 (12% decrease in tolbutamide clearance).", {"entities": [[24, 31, "Study"], [33, 42, "Herb name"], [53, 75, "Target"], [137, 151, "Target"], [169, 180, "Drug"]]}], [8848, "Echinacea has also been reported to induce hepatic CYP3A4 enzyme activity (a 42% increase in the systematic clearance of midazolam) [9].", {"entities": [[0, 9, "Herb name"], [43, 64, "Target"], [121, 130, "Drug"]]}], [8850, "However, the lack of effect of echinacea on the pharmacodynamics of warfarin is reported here despite using a herbal medicine product of known quality that was demonstrated to yield quantifiable concentrations of echinacea constituents in the plasma of all subjects.", {"entities": [[31, 40, "Herb name"], [68, 76, "Drug"], [213, 222, "Herb name"]]}], [8851, "The study by Gorski et al.", {"entities": []}], [8852, "[9] employed echinacea tablets containing Echinacea purpurea root that contained greater than 1% phenols (caftaric acid, chlorogenic acid, echinacoside and cichoric acid) and also alkamides (2-ene and 2,4-dienes).", {"entities": [[13, 22, "Herb name"], [42, 60, "Herb name"], [61, 65, "Herb part"], [97, 104, "Herb name"], [106, 119, "Herb name"], [121, 137, "Herb name"], [139, 151, "Herb name"], [156, 169, "Herb name"], [180, 212, "Herb name"]]}], [8853, "This study and that by Matthias et al.", {"entities": []}], [8854, "[5] reported that alkamides from echinacea are orally available.", {"entities": [[18, 27, "Herb name"], [33, 42, "Herb name"]]}], [8855, "By contrast, Matthias et al.", {"entities": []}], [8857, "In this study we were also able to quantitate the alkamide constituents of echinacea (prepared from roots of E. angustifolia and E. purpurea) during multiple dosing.", {"entities": [[50, 58, "Herb name"], [75, 84, "Herb name"], [100, 105, "Herb part"], [109, 124, "Herb name"], [129, 140, "Herb name"]]}], [8858, "The echinacea product used in this study contained similar constituents to the echinacea formulation used by Gorski et al.", {"entities": [[4, 13, "Herb name"], [79, 88, "Herb name"]]}], [8859, "[9] which in addition also contained constituents from E. angustifolia roots.", {"entities": [[55, 70, "Herb name"], [71, 76, "Herb part"]]}], [8860, "Similarities between the E. purpurea root and E. angustifolia root in terms of alkylamide content were reported.", {"entities": [[25, 36, "Herb name"], [37, 41, "Herb part"], [46, 61, "Herb name"], [62, 66, "Herb part"], [79, 89, "Herb name"]]}], [8861, "Furthermore pharmacokinetic parameters of alkamides of combination product of E. purpurea and E. angustifolia root and of E. angustifolia root alone were reported to be similar [5, 6, 21] and hence the results from the study Gorski et al.", {"entities": [[42, 51, "Herb name"], [78, 89, "Herb name"], [94, 109, "Herb name"], [110, 114, "Herb part"], [122, 137, "Herb name"], [138, 142, "Herb part"]]}], [8862, "[9] can be compared with the present study with respect to alkylamide pharmacokinetics.", {"entities": [[59, 69, "Herb name"]]}], [8863, "Policosanol has been reported to be effective in lowering serum cholesterol concentrations in both healthy subjects and in patients [22, 23].", {"entities": [[0, 11, "Herb name"], [58, 90, "Parameter"], [99, 115, "Pathology"]]}], [8864, "However, recent studies provide conflicting data [24].", {"entities": []}], [8865, "The optimal cholesterol lowering dose of policosanol is reported to be 20 mg daily [25] and dose-dependent effects have been reported with respect to platelet aggregation [26].", {"entities": [[41, 52, "Herb name"], [71, 76, "Amount"], [77, 82, "Frequency"], [150, 170, "Parameter"]]}], [8866, "In the present study the possibility of a policosanol-warfarin interaction was investigated at a policosanol dose of 20 mg day\u22121.", {"entities": [[42, 53, "Herb name"], [54, 62, "Drug"], [97, 108, "Herb name"], [117, 122, "Amount"]]}], [8867, "Previous studies have reported that policosanol up to this dose inhibited platelet aggregation induced by ADP and collagen by more than 20% [27].", {"entities": [[36, 47, "Herb name"], [74, 94, "Parameter"]]}], [8868, "Interestingly, the present study showed no significant alteration in platelet aggregation after 2 weeks of treatment with 20 mg daily policosanol.", {"entities": [[69, 89, "Parameter"], [96, 103, "Duration"], [122, 127, "Amount"], [128, 133, "Frequency"], [134, 145, "Herb name"]]}], [8869, "The reason for the discrepancy with previous studies remains unclear.", {"entities": []}], [8870, "The sample size of this study is comparable with the previous studies in terms of the subjects who received the intervention.", {"entities": []}], [8871, "One possibility is that the observed differences may be attributable to variations in the constituents in policosanol used in each study.", {"entities": [[106, 117, "Herb name"]]}], [8872, "Typically, policosanol is standardized for octacosanol content, which is expected to contribute to its cholesterol lowering effects, and it is possible that other constituents are responsible for platelet effects.", {"entities": [[11, 22, "Herb name"], [43, 54, "Herb name"]]}], [8873, "Reiner et al.", {"entities": []}], [8874, "[28] reported no change in blood coagulation factors after 8 weeks pre-treatment with rice policosanol 10 mg daily in hypercholesterolaemic patients from a randomized, double-blind, placebo-controlled, crossover trial which is in agreement with the findings from the present study.", {"entities": [[27, 52, "Target"], [59, 66, "Duration"], [86, 102, "Herb name"], [103, 108, "Amount"], [109, 114, "Frequency"], [118, 139, "Pathology"], [154, 217, "Study"]]}], [8875, "This study found no significant relationship between CYP2C9 or VKORC1 genotype and interactions with these herbal medicines, although genotype-dependent interactions have been previously reported [29, 30].", {"entities": [[53, 59, "Target"], [63, 69, "Target"]]}], [8876, "However, the relatively small sample size for each genotype in the present study limits further interpretation of these findings.", {"entities": []}], [8877, "In conclusion, this study found no clinically significant pharmacokinetic or pharmacodynamic interaction between echinacea or policosanol and warfarin in healthy male subjects.", {"entities": [[113, 122, "Herb name"], [126, 137, "Herb name"], [142, 150, "Drug"], [154, 161, "Pathology"], [162, 166, "Sex"]]}], [8878, "While treatment with echinacea tended to increase the apparent clearance of (S)-warfarin, this did not alter the pharmacodynamic response to warfarin.", {"entities": [[21, 30, "Herb name"], [50, 72, "Parameter"], [76, 88, "Drug"], [141, 149, "Drug"]]}], [8879, "The results of the present study cannot unequivocally exclude the possibility of a herb-drug interaction in patients receiving warfarin as this study did not include subjects with possible contributing factors (such as older age, concomitant medicines, co-existing medical conditions and organ dysfunction).", {"entities": [[127, 135, "Drug"]]}], [8880, "Go to: Competing interests  K.M.W and R.O.D have received research funds from Blackmores, B.D.R has acted as a paid consultant for various manufacturers of herbal medicine products and A.M. and R.P.L.", {"entities": []}], [8881, "are employees of MediHerb Research Laboratories.", {"entities": []}], [8882, "The authors acknowledge the financial support of a Project grant from the Australian National Health and Medical Research Council and the clinical support from the staff at the St Vincent's Clinical Trial Centre (Darlinghurst, NSW, Australia).", {"entities": [[74, 84, "Ethnic group"]]}], [8883, "The authors also acknowledge Dr Heather James (Institute of Medical and Veterinary Science, Adelaide, Australia) for the VKORC1 genotyping.", {"entities": [[121, 127, "Target"]]}], [8884, "Policosanol tablets were a generous gift from Blackmores, Australia, and echinacea was purchased from MediHerb Pty.", {"entities": [[0, 11, "Herb name"], [73, 82, "Herb name"]]}], [8885, "Understanding the potential for adverse drug reactions (ADRs), from herb-drug interactions, is a key aspect of medicinal plant safety, with particular relevance for public health in countries where medicinal plant use is highly prevalent.", {"entities": [[32, 61, "Pathology"]]}], [8887, "Further analysis of other crude extracts demonstrated potent inhibition of CYP1A2 activity for a dried plant ethanol extract (1.5 \u00b5g/mL), fresh plant ethanol extract (3.9 \u00b5g/mL), and moderate activity for a fresh plant aqueous extract (27.8 \u00b5g/mL).", {"entities": [[26, 40, "Extraction process"], [75, 81, "Target"], [97, 124, "Extraction process"], [138, 165, "Extraction process"], [207, 234, "Extraction process"]]}], [8888, "All four extracts demonstrated strong antioxidant activity, compared to the positive control (ascorbic acid, 1.3 \u00b5g/mL), with the dried plant ethanol extract being the most potent (1.6 \u00b5g/mL).", {"entities": [[130, 157, "Extraction process"]]}], [8889, "Analysis of the dried plant aqueous extract confirmed the identity of seven phytochemicals, five lignans and two triterpenes.", {"entities": [[16, 43, "Extraction process"], [97, 104, "Herb name"], [113, 124, "Herb name"]]}], [8890, "Individual screening of these phytochemicals against the activity of CYP1A2 identified yatein as a moderate inhibitor (71.9 \u03bcM), likely to contribute to the plant extract\u2019s potent bioactivity.", {"entities": [[69, 75, "Target"]]}], [8891, "Further analysis on the impact of this plant on key drug metabolizing enzymes in vivo appears warranted for likely ADRs, as well as furthering development as a potential chemopreventive agent.", {"entities": [[115, 119, "Pathology"]]}], [8892, "The use of medicinal plants continues to be high, with the World Health Organisation (WHO) estimating 80% prevalence in developing countries [1], and many people continuing to rely on them as their main or only type of primary healthcare [2].", {"entities": []}], [8893, "We previously reported that 73% of Jamaican adults use medicinal plants to treat illness and maintain health [3].", {"entities": [[35, 43, "Ethnic group"]]}], [8894, "From the same research, we also reported that 27% of Jamaican medicinal plant users take pharmaceutical drugs concomitantly.", {"entities": [[53, 61, "Ethnic group"]]}], [8895, "A survey of cancer patients attending the oncology and urology clinics at the University Hospital of the West Indies in Kingston, and two earlier surveys of Jamaican prescription drug users identified high levels of herb-drug use (80% [4] 80% [5] and 81% [6], respectively), while awareness of such herb-drug use amongst health care professionals was low across all four surveys (13% [5], 15% [4], 18% [6] and 19% [3], respectively).", {"entities": [[12, 18, "Pathology"], [157, 165, "Ethnic group"]]}], [8896, "High levels of concomitant herb-drug use and low physician awareness are reported elsewhere.", {"entities": []}], [8897, "For example, a survey of 381 patients in Norwegian general practice reported 44% prevalence for medicinal plant use, 45% concomitant use with pharmaceutical drugs, and 25% awareness amongst attending physicians [7].", {"entities": [[15, 21, "Study"], [25, 37, "Cohort"], [41, 50, "Ethnic group"]]}], [8898, "Adverse drug reactions (ADRs) resulting from the altered metabolism of one drug caused by the interaction of a second drug are well researched and documented [8].", {"entities": [[0, 29, "Pathology"]]}], [8899, "Herb-drug interactions, however, are far less researched, particularly in developing countries, where medicinal plant use is most prevalent [1,3].", {"entities": []}], [8900, "Understanding the clinical impact and potential risk of ADRs, resulting from herb-drug interactions, is a critical public health issue, and a key aspect of medicinal plant safety.", {"entities": [[56, 60, "Pathology"]]}], [8901, "However, most of the plant-based research, to date, has been completed in developed countries, predominantly using in vitro studies, but, also with increasing numbers of clinical studies.", {"entities": [[115, 131, "Study"], [170, 186, "Study"]]}], [8902, "Clinical studies of some of the most commonly researched plants include garlic (Allium sativum), St. John\u2019s wort (Hypericum perforatum), Panax ginseng, and Ginkgo biloba [9].", {"entities": [[0, 16, "Study"], [72, 95, "Herb name"], [97, 135, "Herb name"], [137, 150, "Herb name"], [156, 169, "Herb name"]]}], [8903, "Our laboratory has been working to address both the imbalance in research output from the Caribbean, and the potential public health risk, by testing medicinal plants, commonly used in Jamaica, for their impact on key drug metabolizing enzymes [10,11,12].", {"entities": [[90, 99, "Ethnic group"]]}], [8904, "Plants tested include Artocarpus altilis [13], Peperomia pellucida [14], Petiveria alliacea [15] and Picrasma excelsa [16].", {"entities": [[22, 40, "Herb name"], [47, 66, "Herb name"], [73, 91, "Herb name"], [101, 117, "Herb name"]]}], [8905, "This latest study set out to investigate the inhibitory impact of various extracts of H. verticillata on a number of key drug metabolizing CYP450 enzymes, its characterisation and further impact on CYP1A2, representing the first such in vitro evaluation for this plant, and to add to the growing list of screened Caribbean medicinal plants.", {"entities": [[74, 82, "Extraction process"], [86, 101, "Herb name"], [139, 153, "Target"], [198, 204, "Target"], [234, 253, "Study"], [313, 322, "Ethnic group"]]}], [8906, "CYP1 inhibitions and associated antioxidant activities have also been linked with chemopreventive potential and thus we also carried out an in vitro antioxidant screen [8].", {"entities": [[0, 4, "Target"], [140, 167, "Study"]]}], [8907, "H. verticillata was previously identified as one of the top 25 medicinal plants used by Jamaicans in a TRAMIL survey [3,17].", {"entities": [[0, 15, "Herb name"], [88, 97, "Ethnic group"]]}], [8908, "TRAMIL, a Caribbean-wide applied research programme, scientifically evaluates and documents the efficacy and safety of medicinal plant remedies used for primary healthcare [18].", {"entities": [[10, 19, "Ethnic group"]]}], [8909, "An earlier comprehensive review of this plant details its extensive traditional uses, phytochemistry pharmacology and toxicology [19].", {"entities": []}], [8910, "For example, traditional uses documented in Jamaica include, bronchitis, cold, colic, fever, indigestion, itchy skin, mucous congestion, arthritis, tonsillitis, and fibroids [19].", {"entities": [[61, 71, "Pathology"], [73, 77, "Pathology"], [79, 84, "Pathology"], [86, 91, "Pathology"], [93, 104, "Pathology"], [106, 116, "Pathology"], [118, 135, "Pathology"], [137, 146, "Pathology"], [148, 159, "Pathology"], [165, 173, "Pathology"]]}], [8911, "In our earlier survey, documenting concomitant use, respondents identified their use of H. verticillata in combination with a number of pharmaceutical drugs, including aspirin, hydralazine, hydrochlorothiazide, and metformin.", {"entities": [[88, 103, "Herb name"], [168, 175, "Drug"], [177, 188, "Drug"], [190, 209, "Drug"], [215, 224, "Drug"]]}], [8912, "Respondents identified using H. verticillata for different health conditions to those for which they were prescribed a pharmaceutical drug(s) [3].", {"entities": [[29, 44, "Herb name"]]}], [8913, "Best-fit non-linear plots were fitted to the data points using the 4-parameter logistic (4PL) non-linear regression model (SigmaPlot) and IC Best-fit non-linear plots were fitted to the data points using the 4-parameter logistic (4PL) non-linear regression model (SigmaPlot) and IC The 1,1-diphenyl-2-picrylhydrazyl (DPPH) assay was used to measure the antioxidant capacity of four different extracts of the aerial parts of H. verticillata (Figure 2).", {"entities": [[408, 420, "Herb part"], [424, 439, "Herb name"]]}], [8914, "The reduction of DPPH to hydrazine produces a colour change from purple to yellow, which is measured spectrophotometrically and compared with the known antioxidant, ascorbic acid, as described in the Materials and Methods section.", {"entities": []}], [8915, "All four extracts demonstrated strong antioxidant activity in comparison to the positive control, with the ethanol dried plant extract showing the most potent activity, almost directly comparable to that of ascorbic acid (Figure 2).", {"entities": [[107, 134, "Extraction process"]]}], [8916, "An initial separation of the aqueous extract of H. verticillata (dried aerial material) was undertaken using RP-HPLC, through which fractions were collected using a Gilson FC 203B fraction collector and concentrated on a Savant SpeedVac concentrator (Appendix A, Figure A1), and subsequent analysis undertaken using LC-MS (Appendix B, Table A1), as described in the Materials and Methods section.", {"entities": [[29, 44, "Extraction process"], [48, 63, "Herb name"], [65, 86, "Herb part"]]}], [8917, "The exact mass to charge ratio (m/z) values of all ion species detected by a high resolution LC-MS were recorded, interpreted, and compared with the molecular weights of all known metabolites that have been identified to date for the aerial parts of H. verticillata [19,20,21] and fifteen potentially positive spectral results were identified (Table 1) (Appendix B, Table A1).", {"entities": [[234, 246, "Herb part"], [250, 265, "Herb name"]]}], [8918, "In each case, mass differences between calculated and measured were within calibrant tolerance.", {"entities": []}], [8919, "The use of exact mass and adduct measurement confirms in most cases the identity of the compounds.", {"entities": []}], [8920, "The fifteen LC-MS spectral results cross-referenced with data from the RP-HPLC analysis using standards (Table 1) (Appendix A, Figure A1 and Figure A2 & Appendix B, Table A1) confirmed the presence of five lignans, deoxydehydropodophyllotoxin, 4\u2032-demethylpodophyllotoxin, (-)-yatein, dehydropodophyllotoxin and podophyllotoxin (Table 1, Figure 3).", {"entities": [[206, 213, "Herb name"], [215, 242, "Herb name"], [244, 270, "Herb name"], [272, 282, "Herb name"], [284, 306, "Herb name"], [311, 326, "Herb name"]]}], [8921, "RP-HPLC analysis with standards alone, confirmed the presence of one further phytochemical, the triterpene oleanolic acid (Table 1, Figure 3) (Appendix A, Figure A2 and Appendix B, Table A1).", {"entities": [[96, 121, "Herb name"]]}], [8922, "Key phytochemicals were individually assessed for their impact on CYP1A2 activity.", {"entities": [[66, 72, "Target"]]}], [8923, "Best-fit non-linear plots were fitted to the data points using the 4-parameter logistic (4PL) non-linear regression model (SigmaPlot) and IC The mix of five lignans demonstrated moderate inhibition against the activity of CYP1A2 (61.8 \u00b5g/mL).", {"entities": [[222, 228, "Target"]]}], [8925, "The IC It was not possible to determine the IC In vitro CYP assays offer an accurate, and relatively inexpensive, first stage assessment tool for gauging the potential for herb-drug interactions.", {"entities": [[47, 66, "Study"]]}], [8926, "They are useful for initial risk assessment of medicinal plants capable of causing adverse drug reactions (ADRs) when taken concomitantly with pharmaceutical drugs metabolised by the same enzyme [22].", {"entities": [[83, 112, "Pathology"]]}], [8927, "CYPs 1A2, 2D6, and 3A4 are three of the key enzymes involved in drug metabolism, and together, are responsible for the CYP mediated metabolism of approximately 83% of marketed pharmaceuticals.", {"entities": [[0, 22, "Target"]]}], [8928, "Broken down, the figures are 50% for CYP3A4, 25% for CYP2D6, and 8% for CYP1A2 [23].", {"entities": [[37, 43, "Target"], [53, 59, "Target"], [72, 78, "Target"]]}], [8929, "CYP3A4 is the enzyme most implicated in drug interactions, while CYP2D6 is important, firstly because of the high percentage of drugs metabolized and secondly, because the enzyme is associated with high levels of polymorphism [8,24].", {"entities": [[0, 6, "Target"], [65, 71, "Target"]]}], [8930, "CYP1A2 is important, as it metabolizes many commonly prescribed drugs including the bronchodilator theophylline, the tricyclic antidepressant imipramine, the beta blocker propranolol and the antipsychotic clozapine [24].", {"entities": [[0, 6, "Target"], [80, 111, "Drug"], [113, 152, "Drug"], [154, 182, "Drug"], [187, 214, "Drug"]]}], [8931, "Published results, including those previously reported from our laboratory, point to a general consensus on the levels of inhibition that constitute potent, moderate, and weak inhibition in relation to the in vitro inhibition of crude extracts of medicinal plants on human CYP enzymes [15,16,25]: Potent: \u22649.9 \u00b5g/mL; Moderate (mild): 10\u201399.9 \u00b5g/mL; Weak: \u2265100 \u00b5g/mL.", {"entities": [[206, 214, "Study"], [229, 243, "Extraction process"]]}], [8932, "Such potent inhibition against recombinant CYP enzymes points to the potential for metabolism-based drug interactions in vivo and requires further investigation for confirmation of clinical relevance.", {"entities": []}], [8933, "In vitro indications are accepted as a useful initial screen for selecting potential candidates worthy of in vivo evaluations.", {"entities": [[0, 8, "Study"], [106, 125, "Study"]]}], [8934, "Additional research, undertaken to assess the bioactivity of other traditionally prepared extracts, aqueous (fresh) and ethanol (dry and fresh), against the activity of the CYP enzyme most potently inhibited, in this case CYP1A2, demonstrated similar results to those originally obtained with the aqueous extract (dry plant material).", {"entities": [[90, 143, "Extraction process"], [222, 228, "Target"], [297, 333, "Extraction process"]]}], [8935, "The exception was the moderate level of inhibition seen for the aqueous extract of the fresh plant material (27.8 \u00b5g/mL).", {"entities": [[60, 107, "Extraction process"]]}], [8936, "This is most likely due to the lower concentration of plant material on a weight by volume basis in the aqueous extract prepared with fresh plant material.", {"entities": [[100, 154, "Extraction process"]]}], [8937, "Fresh plant material has a higher water content, and as a result approximately 3\u20134 g of fresh plant material is required to provide the equivalent weight of 1 g of dried material [26].", {"entities": []}], [8938, "CYP1A2 is an important enzyme, because it is responsible for metabolizing a number of commonly prescribed drugs, several of which are used in psychiatric medicine\u2014drugs such as fluvoxamine, amitriptyline, clomipramine and clozapine.", {"entities": [[0, 6, "Target"], [142, 168, "Drug"], [177, 188, "Drug"], [190, 203, "Drug"], [205, 217, "Drug"], [222, 231, "Drug"]]}], [8939, "Several of these drugs have narrow therapeutic ranges, which consequently increases the risk of serious ADRs when interactions occur [23].", {"entities": [[104, 108, "Pathology"]]}], [8940, "The potent inhibition of this important drug metabolizing enzyme by the aqueous (dried aerial material) and ethanol (fresh and dried aerial material) extracts of H. verticillata indicate the potential for pharmacokinetic metabolism-based drug interactions and warrants further in vivo investigations [8,27].", {"entities": [[68, 158, "Extraction process"], [162, 177, "Herb name"], [277, 299, "Study"]]}], [8941, "In addition, certain CYP enzymes, particularly the CYP1 family, play a role as potential cancer promoting agents.", {"entities": [[47, 62, "Target"], [89, 95, "Pathology"]]}], [8942, "Potent inhibitors of these enzymes, in vitro, have chemopreventive potential in vivo, and warrant further investigation [28,29,30,31].", {"entities": [[36, 44, "Study"], [77, 84, "Study"]]}], [8943, "CYP1A1 is particularly implicated in lung, colorectal, breast, and prostate cancers, CYP1B1 in hormone dependent cancers of the prostate, breast, and endometrium, and CYP1A2 in colorectal, lung, and breast cancers [29,31,32].", {"entities": [[0, 6, "Target"], [37, 83, "Pathology"], [85, 91, "Target"], [95, 161, "Pathology"], [167, 173, "Target"], [177, 213, "Pathology"]]}], [8944, "Selectivity is an important criterion in short-listing plants for further assessment.", {"entities": []}], [8945, "It is notable that natural products successfully patented for their potential therapeutic value tend to demonstrate high selectivity in their inhibition of specific CYP activities [33].", {"entities": []}], [8946, "Such likely chemopreventive properties are often corroborated by the antioxidant activities displayed by extracts.", {"entities": []}], [8947, "The four tested extracts demonstrated strong DPPH scavenging activity with IC Similar antioxidant research on a number of other plants from the Lamiaceae family, reported IC The antioxidant activity of H. verticillata was previously reported by Williams et al.", {"entities": [[144, 160, "Herb name"], [202, 217, "Herb name"]]}], [8948, "On this occasion, the researchers reported antioxidant activity as percentage activity relative to control with reported results ranging from 0% to 96%.", {"entities": []}], [8949, "Of the plants screened, seven were from the Lamiaceae family and their reported antioxidant activities ranged from 17% to 55% with H. verticillata and Rosmarinus officinalis both reporting antioxidant activities of 55%.", {"entities": [[44, 60, "Herb name"], [131, 146, "Herb name"], [151, 173, "Herb name"]]}], [8950, "The combined use of RP-HPLC and LC-MS confirmed the presence of five phytochemicals.", {"entities": []}], [8951, "These were the five lignans, podophyllotoxin, 4\u2032-demethylpodophyllotoxin, (-)-yatein, dehydropodophyllotoxin and deoxydehydropodophyllotoxin, the latter two being part of the five-lignan mixture (Table 1, Figure 3).", {"entities": [[20, 27, "Herb name"], [29, 44, "Herb name"], [46, 72, "Herb name"], [74, 84, "Herb name"], [86, 108, "Herb name"], [113, 140, "Herb name"], [180, 186, "Herb name"]]}], [8952, "The presence of the triterpene, oleanolic acid was confirmed by RP-HPLC alone (Table 1, Figure 3).", {"entities": [[20, 30, "Herb name"], [32, 46, "Herb name"]]}], [8953, "The two triterpenes, oleanolic acid and ursolic acid exist as regioisomers, with the only difference between them being the position of one methyl group.", {"entities": [[8, 19, "Herb name"], [21, 35, "Herb name"], [40, 52, "Herb name"]]}], [8954, "Whilst ursolic acid was not directly analysed to confirm its presence, based on the reports that both triterpenes exist together in plants simultaneously, it is highly likely that ursolic acid is also present [36,37].", {"entities": [[7, 19, "Herb name"], [102, 113, "Herb name"], [180, 192, "Herb name"]]}], [8955, "Five individual phytochemicals, together with the mixture of five lignans were tested for their impact on the activity of CYP1A2.", {"entities": [[66, 73, "Herb name"], [122, 128, "Target"]]}], [8956, "The lignan mix and one individual phytochemical, (-)-yatein, demonstrated moderate/weak inhibition, with IC Two further phytochemicals, cadina-4,10(15)-dien-3-one and \u00df\u2013sitosterol were found to be weak inhibitors of CYP1A2 (Table 2).", {"entities": [[4, 10, "Herb name"], [49, 59, "Herb name"], [136, 179, "Herb name"], [216, 222, "Target"]]}], [8957, "Their presence was ruled out through RP-HPLC screening with standards, however if they had been found to be present, their weak inhibition would indicate that they would not have contributed to the potent inhibition seen with the aqueous extract of H. verticillata (dried aerial plant).", {"entities": [[230, 245, "Extraction process"], [249, 264, "Herb name"], [266, 284, "Herb part"]]}], [8958, "By way of comparison, an assay with a known CYP1A2 inhibitor, furafylline, was tested against the activity of CYP1A2, and an IC Table 3 summarises the impact of a number of the key phytochemicals, identified in the aqueous extract of H. verticillata (dried aerial material), on CYP enzyme activity where this has been independently reported in the literature.", {"entities": [[44, 50, "Target"], [110, 116, "Target"], [215, 230, "Extraction process"], [234, 249, "Herb name"], [251, 272, "Herb part"]]}], [8959, "Only two of the phytochemicals, oleanolic and ursolic acid, appear to have been previously screened against the activity of CYP1A2 [38].", {"entities": [[32, 58, "Herb name"], [124, 130, "Target"]]}], [8960, "In both cases, the reported inhibition was weak, >100 \u03bcM, in line with the results now being reported in our laboratory.", {"entities": []}], [8961, "Podophyllotoxin and (-)-yatein are reported as potent inhibitors of CYP3A4 [39,40] and (-)-yatein is reported as a moderate/weak inhibitor against the activity of CYP2D6 [39] (Table 3).", {"entities": [[0, 15, "Herb name"], [20, 30, "Herb name"], [68, 74, "Target"], [87, 97, "Herb name"], [163, 169, "Target"]]}], [8962, "Our results, reporting no inhibition by podophyllotoxin and moderate/weak inhibition by (-)-yatein against the activity of CYP1A2 for the first time, further strengthens the earlier reports of selectively potent inhibition of CYP3A4 by these two phytochemicals (Table 2).", {"entities": [[40, 55, "Herb name"], [88, 98, "Herb name"], [123, 129, "Target"], [226, 232, "Target"]]}], [8963, "Having confirmed the identity of seven phytochemicals in the aqueous extract of H. verticillata (dried aerial material), and screened them for their impact on the activity of CYP1A2, it appears that the bioactivity displayed by the crude aqueous extract of the plant (dried aerial material) can be attributed in part to yatein and two of the phytochemicals identified from the mixture of lignans, which displayed moderate/weak and moderate inhibition, respectively, of the same enzyme.", {"entities": [[61, 76, "Extraction process"], [80, 95, "Herb name"], [97, 118, "Herb part"], [175, 181, "Target"], [228, 266, "Extraction process"], [268, 289, "Herb part"], [320, 326, "Herb name"], [388, 395, "Herb name"]]}], [8964, "The potential also remains for other unidentified contributors, along with synergistic activities.", {"entities": []}], [8965, "Whilst research on many medicinal plants has been able to identify and link one key phytochemical, or class of phytochemicals, to the bioactivity of a plant, an alternative explanation is that of a synergistic effect.", {"entities": []}], [8966, "This is where a number of phytochemicals act together synergistically to contribute to the observed bioactivity, a fact previously noted and attributed to a number of the documented pharmacological effects and traditional uses of H. verticillata [41].", {"entities": [[230, 245, "Herb name"]]}], [8967, "Initial attempts made to quantify synergy using isobolograms proved inconclusive at this stage, however the investigations would benefit with an extension using a wider cocktail of phytochemicals.", {"entities": []}], [8968, "A growing body of research into synergistic effects is reported in the literature [42,43,44].", {"entities": []}], [8969, "Research, and the understanding of synergistic effects, is not limited solely to natural products, but is also gaining recognition in the emerging fields of network pharmacology and compound synergy [45,46,47,48].", {"entities": []}], [8970, "In conclusion, this research presents the results of an in-depth assessment of the medicinal plant H. verticillata, its impact on a number of key CYP450 enzymes, antioxidant properties, and its characterisation and further impact on CYP1A2.", {"entities": [[99, 114, "Herb name"], [146, 152, "Target"], [233, 239, "Target"]]}], [8971, "Four traditional preparations of the aerial plant material demonstrated strong antioxidant activity, which, together with the plant extracts potent inhibition of known carcinogen activators, CYPs 1A1 and 1B1, and previously reported anti-inflammatory and anticancer properties [19] warrants further research into the potential chemopreventive properties of this interesting plant, bearing in mind the knowledge of its inhibitory impact on drug metabolizing CYP enzymes.", {"entities": [[37, 58, "Herb part"], [191, 207, "Target"]]}], [8972, "Screening phytochemicals against the activity of CYP1A2 identified yatein as a moderate-weak contributor to the plant\u2019s potent bioactivity, with potential for synergistic activity among other constituents.", {"entities": [[49, 55, "Target"], [67, 73, "Herb name"]]}], [8974, "CYP substrates and metabolites were purchased from BD Gentest Corporation (Woburn, MA, USA).", {"entities": []}], [8975, "All other chemicals were purchased from Sigma Aldrich (St. Louis, MO, USA), unless otherwise stated.", {"entities": []}], [8976, "\u03b2-Sitosterol, cadina-4,10(15)-dien-3-one and a mix of five lignans comprised of dehydropodophyllotoxin, deoxydehydropodophyllotoxin, 4\u2032-demethyldesoxypodophyllotoxin, 5\u2032-methoxydehydropodophyllotoxin, and dehydro-b-peltatin methyl ether were supplied by the Department of Chemistry, University of the West Indies, Mona Campus, Jamaica.", {"entities": [[0, 12, "Herb name"], [14, 40, "Herb name"], [59, 66, "Herb name"], [80, 102, "Herb name"], [104, 131, "Herb name"], [133, 165, "Herb name"], [167, 199, "Herb name"], [205, 236, "Herb name"]]}], [8977, "4\u2032-Demethyl-podophyllotoxin and (-)-yatein were purchased from BOC Sciences (New York, NY, USA), oleanolic acid, ursolic acid, and rosmarinic acid were purchased from Cayman Chemical (Ann Arbor, MI, USA) and podophyllotoxin was purchased from Sigma Aldrich.", {"entities": [[0, 27, "Herb name"], [32, 42, "Herb name"], [97, 111, "Herb name"], [113, 125, "Herb name"], [131, 146, "Herb name"], [208, 223, "Herb name"]]}], [8978, "LC-MS grade high purity water and LC-MS grade high purity methanol were purchased from Sigma Aldrich (Gillingham, UK).", {"entities": []}], [8979, "2,2-diphenyl-1-picrylhydrazyl (DPPH) was purchased from Sigma Aldrich (St. Louis, MO, USA).", {"entities": []}], [8980, "Escherichia coli membranes expressing human CYP1A1, CYP1A2, CYP1B1, CYP3A4, and CYP2D6, co-expressed with CYP reductase, were purchased from Cypex Ltd. (Dundee, UK).", {"entities": [[44, 50, "Target"], [52, 58, "Target"], [60, 66, "Target"], [68, 74, "Target"], [80, 86, "Target"], [106, 119, "Target"]]}], [8981, "Samples of the plant material were collected, and voucher specimens prepared (voucher number 35473) and deposited with the Herbarium at the University of the West Indies, Mona, Jamaica, where the identity of the plant was confirmed by Mr. Patrick Lewis, botanist and Herbarium Curator.", {"entities": []}], [8982, "The following method of preparation was previously developed and refined in our laboratory [10,16].", {"entities": []}], [8983, "Collected leaf and stem plant material was bench-dried in our laboratory and then finely crushed using a coffee grinder.", {"entities": [[10, 14, "Herb part"], [19, 23, "Herb part"]]}], [8984, "The ground plant material was prepared as an infusion following traditional Jamaican practices [17,19] using 100 mL of boiled deionized water per 1 g of dried plant material and infused for fifteen to twenty minutes.", {"entities": [[45, 53, "Extraction process"], [76, 84, "Ethnic group"], [109, 115, "Amount"], [146, 149, "Amount"], [178, 185, "Extraction process"], [186, 215, "Duration"]]}], [8985, "The resulting liquor was suction filtered through type 1 Whatman filter paper and centrifuged (MSE Micro Centaur, Sanyo, Osaka, Japan) at 13,000 g for five minutes to remove suspended solids.", {"entities": [[14, 20, "Extraction process"]]}], [8986, "The samples were frozen at \u221220 \u00b0C in round bottom flasks and lyophilised using a freeze drier (Labconco, Kansas City, MO, USA).", {"entities": []}], [8987, "The resulting solids were placed in vials and kept at \u221220 \u00b0C until required, and not subjected to more than two freeze-thaw cycles.", {"entities": []}], [8988, "The fresh aerial parts (leaf and stem) of H. verticillata were roughly cut and prepared as infusions without drying.", {"entities": [[0, 38, "Herb part"], [42, 57, "Herb name"], [91, 100, "Extraction process"]]}], [8989, "All other details of the methodology employed were the same as those detailed above.", {"entities": []}], [8990, "Ethanol extracts (tinctures) were prepared from fresh and dried plant material (leaf and stem) using documented traditional methods [17,19].", {"entities": [[0, 28, "Extraction process"], [80, 84, "Herb part"], [89, 93, "Herb part"]]}], [8991, "Dried plant material was bench-dried in the laboratory, finely chopped in a coffee grinder and placed into a sealable, darkened glass container.", {"entities": []}], [8992, "The tincture was prepared by maceration at room temperature using 10 mL of 75% ethanol (Sigma Aldrich, USA) per gram of dried plant material.", {"entities": [[4, 12, "Extraction process"], [29, 39, "Extraction process"]]}], [8993, "The sealed container was shaken and turned daily for a period of two weeks at room temperature.", {"entities": [[43, 48, "Frequency"], [49, 74, "Duration"]]}], [8994, "The resulting liquor was suction-filtered through type 1 Whatman filter paper and stored in a sealed darkened glass container.", {"entities": [[14, 20, "Extraction process"]]}], [8995, "The resulting extract was a 1:10 (w/v) (75% EtOH) standard tincture, in which 10 mL of the final preparation is equivalent to 1 g of the dried plant from which the preparation was made.", {"entities": [[59, 67, "Extraction process"]]}], [8996, "Fresh plant material (leaf and stem) was roughly cut and placed into a darkened sealable glass container.", {"entities": [[22, 26, "Herb part"], [31, 35, "Herb part"]]}], [8997, "The tincture was prepared as above.", {"entities": [[4, 12, "Extraction process"]]}], [8998, "The resulting extract was a 1:10 (w/v) (75% EtOH) specific tincture (fresh plant material).", {"entities": [[59, 67, "Extraction process"]]}], [8999, "The following chromatographic methods were employed.", {"entities": []}], [9000, "RP-HPLC analysis was carried out on a Series 200 instrument (Perkin Elmer, Waltham, MA, USA) equipped with a quaternary pump, thermostatted autosampler, column oven, and diode array detector.", {"entities": []}], [9001, "The column used was an RP-18 reversed phase ChromoSep HPLC SS (250 \u00d7 4.6 mm, 5 \u03bcm) (Varian, Palo Alto, CA, USA) including s holder with an Intersil ODS-2 ChromoSep guard column.", {"entities": []}], [9002, "Appropriate methodologies were developed based on previous analysis of the plant in the Department of Chemistry, UWI, [20] and on published methodologies for key phytochemicals previously identified in the aerial parts of H. verticillata [36,53].", {"entities": [[202, 218, "Herb part"], [222, 237, "Herb name"]]}], [9003, "The LC\u2013MS system used comprised a 1260 Infinity LC system (Agilent Technologies, Craven Arms, UK) coupled to a 6430 triple quadrupole mass spectrometer (Agilent Technologies).", {"entities": []}], [9004, "The LC system consisted of a 1290 infinity thermostatted autosampler, degasser, binary pumps, and column heater.", {"entities": []}], [9005, "An electrospray ionisation (ESI) source was used for sample analysis.", {"entities": []}], [9006, "The sample was injected through a Zorbax Eclipse plus C18 (2.1 \u00d7 100 mm, 1.8 \u03bcm) column.", {"entities": []}], [9007, "The column was heated to 50 \u00b0C for good reproducibility.", {"entities": []}], [9008, "The analytical column was connected in tandem with a 0.2 \u03bcm inline filter to prevent it from blocking.", {"entities": []}], [9009, "The mobile phase consisted of solvent A, LC-MS grade high purity water and solvent B, LC-MS grade high purity methanol.", {"entities": []}], [9010, "A gradient elution was used for analysis whereby 20% methanol was run for 2 min and then increased to 60% methanol linearly over 4 min and held for 2 min.", {"entities": []}], [9011, "Methanol was further increased to 80% linearly over 9 min and held for 7 min.", {"entities": []}], [9012, "The column was washed by running 100% methanol for 8 min then decreased to 20% methanol for 2 min to equilibrate the column for the next injection.", {"entities": []}], [9013, "The flow rate through the column was set at 0.4 mL/min.", {"entities": []}], [9014, "The total run time was thirty-four minutes.", {"entities": []}], [9015, "A sample (20 \u00b5L) was injected on to the LC-MS system.", {"entities": []}], [9016, "Auto needle wash was set up to remove any carryover effects in the LC analysis.", {"entities": []}], [9017, "The bypass configurations were set up for the mixer and damper with Agilent HPLC 1260 binary pump.", {"entities": []}], [9018, "This was to convert the pump to low delay volume mode and better reproducibility.", {"entities": []}], [9019, "Both positive and negative ESI were utilised in Full Scan mode.", {"entities": []}], [9020, "Positive ESI was selected for further analysis because it gave more prominent ion peaks in the full scan mode.", {"entities": []}], [9021, "The mass spectrometer was operated in the positive ionization polarity made at a spray capillary voltage of 3000 V. Sheath gas temperature and flow were 350 \u00b0C &12 L/min resp., nozzle voltage was 450 V, drying gas temperature and flow 300 \u00b0C & 8 L/min resp., nebulizer gas pressure was 25 psi.", {"entities": []}], [9022, "High resolution LC-MS was conducted using a Waters LCT Time of Flight Mass Spectrometer (Waters Micromass Ltd., Wilmslow, UK), with a Waters Alliance 2690 HPLC and Mass Lynx V4.1 software using similar HPLC conditions to those described above.", {"entities": []}], [9023, "The following methodology was developed by Crespi et al.", {"entities": []}], [9024, "[54] and adapted by Shields et al.", {"entities": []}], [9025, "[16] and Murray et al.", {"entities": []}], [9026, "[15] to screen natural products for cytochrome P450 inhibition potential with a particular emphasis on the P450 enzymes, CYPs 1A1, 1A2, 1B1, 3A4 and 2D6.", {"entities": [[36, 51, "Target"], [107, 119, "Target"], [121, 152, "Target"]]}], [9027, "Plant extracts and various phytochemicals were evaluated for their ability to inhibit the catalytic activity of human cytochrome P450 enzymes by means of high throughput fluorometric inhibition assays conducted in 96 well microtitre plates as described by Crespi et al., BD Gentest [54] and Murray et al.", {"entities": [[118, 141, "Target"]]}], [9028, "[15].", {"entities": []}], [9029, "7-Ethoxy-3-cyanocoumarin (CEC) was used as a substrate for detecting the activities of CYPs 1A1, and 1A2, 7-ethoxyresorufin (ERes) for CYP1B1, 7-benzyloxy-4-trifluoromethylcoumarin (BFC) for CYP3A4, and 3-[2-(N,N-diethyl-N-methylammonium)-ethyl]-7-methoxy-4-methylcoumarin (AMMC) for CYP2D6.", {"entities": [[87, 104, "Target"], [135, 141, "Target"], [191, 197, "Target"], [284, 290, "Target"]]}], [9030, "The reactions were monitored fluorometrically at 37 \u00b0C, using an Eclipse Fluorescence Spectrophotometer (Varian Cary, Palo Alto, CA, USA).", {"entities": []}], [9032, "In assaying the inhibitory effect of materials on CYP activity, the choice of solvent systems is important.", {"entities": []}], [9033, "The activity of CYP enzymes is known to be significantly inhibited or induced by certain non-aqueous solvents at higher concentrations [55,56].", {"entities": []}], [9034, "Dimethylformamide (DMF) has been identified as one of the least inhibitory solvents towards CYP1A2 [55].", {"entities": [[92, 98, "Target"]]}], [9035, "Control assays run with DMF confirmed that no inhibition against CYP1A2 occurred at concentrations levels below 3%, demonstrating the least impact with no significant levels of inhibition or potentiation of fluorescence across the range of concentrations tested.", {"entities": [[65, 71, "Target"]]}], [9036, "Each of the various crude extracts, shortlisted phytochemicals and solvents (DMSO, DMF and ethanol) were assessed for intrinsic or natural fluorescence to ensure no interference with known metabolite fluorescence at each of the relevant excitation and emission wavelengths.", {"entities": [[20, 34, "Extraction process"]]}], [9037, "Each of the various crude extracts, shortlisted phytochemicals and solvents (DMSO, DMF and ethanol) were investigated for their potential levels of quenching against the fluorescence of each known metabolite.", {"entities": [[20, 34, "Extraction process"]]}], [9038, "Concentrations that resulted in quenching were avoided in subsequent screenings.", {"entities": []}], [9039, "The DPPH radical scavenging capacity of extracts of H. verticillata were evaluated by the method described by Williams et al.", {"entities": [[52, 67, "Herb name"]]}], [9040, "[35].", {"entities": []}], [9041, "The electron-donating ability of each extract, at varying concentrations, was measured colourimetrically through the bleaching of purple-coloured MeOH solution of DPPH.", {"entities": []}], [9042, "The known antioxidant, ascorbic acid, was used as a positive control.", {"entities": []}], [9043, "Each test extract, as well as the ascorbic acid control, was made up in methanol to a starting concentration of 50 \u00b5g/mL and serially diluted in ninety-six well microtitre plates.", {"entities": []}], [9044, "100 \u00b5L of various concentrations of the extracts, and the ascorbic acid control, in methanol, were added to 100 \u00b5L of a 0.02% (w/v) stock solution of the free radical 2,2-diphenyl-1-picrylhydrazyl (DPPH) in methanol.", {"entities": []}], [9045, "After a thirty-minute incubation period at room temperature, the absorbance was read against a blank, comprising methanol, at 517 nm.", {"entities": []}], [9046, "All tests were carried out in duplicate for at least two independent experiments.", {"entities": []}], [9047, "IC The level of DPPH inhibition was calculated according to the formula:  IC We thank the Commonwealth Scholarship Commission, the University of the West Indies Postgraduate Research Fund, Forest Conservation Fund and the National Health Fund for funding support and Paul Reese, Sylvia Mitchell, Patrick Lewis and JeAnn Murray for their support.", {"entities": []}], [9048, "Sample Availability: Not available.", {"entities": []}], [9049, "David Picking conducted all laboratory assays, evaluated results and wrote the paper; Bentley Chambers conducted HPLC separations and interpreted data; James Barker and Iltaf Shah conducted and interpreted all HPLC-MS data; Roy Porter aided in isolating active ingredients and methods development; Declan Naughton helped in the evaluation and interpretation of results; Rupika Delgoda conceptualized and coordinated the study.", {"entities": []}], [9050, "All authors contributed to the writing of the paper.", {"entities": []}], [9051, "The authors declare no conflict of interest.", {"entities": []}], [9052, "RP-HPLC analysis of reconstituted aqueous extract of H. verticillata (I) with comparison to standards: 5 lignan mix (II) [6 mg/mL]; podophyllotoxin (III) [7.8 mM]; (-)-yatein [10 mM] (IV) and 4\u2032-demethylpodophyllotoxin [2 mM] (V).", {"entities": [[34, 49, "Extraction process"], [53, 68, "Herb name"], [105, 111, "Herb name"], [132, 147, "Herb name"], [164, 174, "Herb name"], [192, 218, "Herb name"]]}], [9053, "Separations were achieved using a Perkin-Elmer Series 200 chromatograph, Waltham, MA, USA fitted with a Chromsep C18, 250 \u00d7 4.6 mm, 5 \u00b5m column and C18 guard column.", {"entities": []}], [9054, "An injection volume of 20 uL was independently run for H. verticillata (I) and each of the standards (II, III, IV and V) for 34 min at a flow rate of 1 mL/min.", {"entities": [[55, 70, "Herb name"]]}], [9055, "at wavelength 290 nm at an ambient temperature of 18 \u00b0C.", {"entities": []}], [9056, "The mobile phase consisted of methanol and water using gradient elution: 20% methanol for 2 min increased to 60% linearly over 4 min and held for 2 min.", {"entities": []}], [9057, "Methanol was further increased to 80% linearly over 9 min and held for 7 min.", {"entities": []}], [9058, "The column was washed by running 100% methanol for 8 min then decreased to 20% to equilibrate the column for the next injection.", {"entities": []}], [9059, "RP-HPLC analysis of reconstituted aqueous extract of H. verticillata (I) with comparison to standard: oleanolic acid (VI) [7.8 mM].", {"entities": [[34, 49, "Extraction process"], [53, 68, "Herb name"], [102, 116, "Herb name"]]}], [9060, "Separations were achieved using a Perkin-Elmer Series 200 chromatograph, Waltham, MA (USA) fitted with a Chromsep C18, 250 \u00d7 4.6 mm, 5 \u00b5m column and C18 guard column.", {"entities": []}], [9061, "An injection volume of 20 uL was independently run for H. verticillata (I) and the standard (VI) for 34 min at a flow rate of 1 mL/min.", {"entities": [[55, 70, "Herb name"]]}], [9062, "at wavelength 290 nm at an ambient temperature of 18 \u00b0C.", {"entities": []}], [9063, "The mobile phase consisted of methanol and water using gradient elution: 20% methanol for 2 min increased to 60% linearly over 4 min and held for 2 min.", {"entities": []}], [9064, "Methanol was further increased to 80% linearly over 9 min and held for 7 min.", {"entities": []}], [9065, "The column was washed by running 100% methanol for 8 min then decreased to 20% to equilibrate the column for the next injection.", {"entities": []}], [9066, "LC-MS and HPLC analysis and summary.", {"entities": []}], [9067, "(A) Impact of H. verticillata aqueous extract on CYP activities.", {"entities": [[14, 29, "Herb name"], [30, 45, "Extraction process"]]}], [9068, "Human CYPs 1A1, 1A2 catalyzed 7-ethoxy-3-cyanocoumarin (CEC) (0.5, 5.0 \u03bcM respectively) metabolism, CYP1B1 catalyzed 7-ethoxyresorufin (ERes) (0.37 \u03bcM) metabolism and CYP3A4 catalyzed 7-benzyloxy-4-trifluoromethylcoumarin (BFC) (50 \u03bcM) metabolism were determined in the presence of varying concentrations of reconstituted freeze-dried aqueous extract of H. verticillata ranging from 0.02 to 575 \u00b5g/mL, as described in the Materials and Methods section.", {"entities": [[0, 19, "Target"], [100, 106, "Target"], [167, 173, "Target"], [322, 350, "Extraction process"], [354, 369, "Herb name"]]}], [9069, "Control enzyme activity (mean \u00b1 SEM) for CYPs 1A1, 1A2, 1B1 and 3A4 was 1.43 \u00b1 0.2, 1.49 \u00b1 0.001, 0.95 \u00b1 0.001 and 0.86 \u00b1 0.000 (\u00b5M/min/pmol) of CYP, respectively.", {"entities": [[41, 67, "Target"]]}], [9070, "Data are expressed as mean percentage of enzyme activity for experiments carried out in triplicate; (B) Summary of results.", {"entities": []}], [9071, "(A) DPPH antioxidant assay for H. verticillata extracts.", {"entities": [[31, 46, "Herb name"]]}], [9072, "Antioxidant capacity was determined in the presence of varying concentrations of reconstituted freeze-dried aqueous extracts and ethanol extracts of H. verticillata from both fresh and dry aerial plant material ranging from 0.097 to 50 \u00b5g/mL, as described in the Materials and Methods section.", {"entities": [[95, 124, "Extraction process"], [129, 145, "Extraction process"], [149, 164, "Herb name"], [189, 210, "Herb part"]]}], [9073, "Positive control activity was determined in the presence of varying concentrations of known antioxidant, ascorbic acid, ranging from 0.097 to 50 \u00b5g/mL.", {"entities": []}], [9074, "Data are expressed as Mean Percentage Antioxidant Activity (% Inhibition of DPPH) for duplicate assays for at least two independent experiments.", {"entities": [[27, 81, "Parameter"]]}], [9075, "(B) Summary of results.", {"entities": []}], [9076, "Structures of phytochemicals identified in the aqueous extract of H. verticillata (aerial, dried).", {"entities": [[43, 62, "Extraction process"], [66, 81, "Herb name"], [83, 89, "Herb part"]]}], [9077, "LC-MS * and RP-HPLC analysis and summary.", {"entities": []}], [9078, "IC Review of published CYP inhibition research for key phytochemicals.", {"entities": []}], [9079, "Investigation was carried out in adult New Zealand white rabbits to study the influence of curcumin pre-treatment on pharmacokinetic disposition of norfloxacin following single oral administration.", {"entities": [[91, 99, "Herb name"], [148, 159, "Drug"], [170, 196, "Frequency"]]}], [9080, "Sixteen rabbits were divided into two groups of eight each consisting of either sex.", {"entities": [[0, 15, "Cohort"]]}], [9081, "Blood samples were drawn from the marginal ear vein into heparin-coated vials at 0 (zero time), 5, 10, 15, 30 min and 1, 2, 4, 6, 12 and 24 h post-treatment.", {"entities": [[57, 64, "Parameter"], [81, 156, "Duration"]]}], [9082, "The plasma concentration-time profile of norfloxacin was adequately described by a one-compartment open model.", {"entities": [[4, 24, "Parameter"], [41, 52, "Drug"]]}], [9083, "The pharmacokinetic data revealed that curcumin-treated animals had significantly (p \u2264 0.05) higher area under the plasma concentration-time curve and area under the first moment of plasma drug concentration-time curve.", {"entities": [[39, 47, "Herb name"], [100, 146, "Parameter"], [151, 218, "Parameter"]]}], [9084, "Prior treatment of curcumin significantly (p \u2264 0.05) increased elimination half-life and volume of distribution of norfloxacin.", {"entities": [[19, 27, "Herb name"], [63, 84, "Parameter"], [89, 111, "Parameter"], [115, 126, "Drug"]]}], [9085, "Further treatment with curcumin reduced loading and maintenance doses by 26% and 24% respectively.", {"entities": [[23, 31, "Herb name"], [73, 76, "Amount"], [81, 84, "Amount"]]}], [9086, "Norfloxacin is a member of the fluoroquinolone group of antimicrobial agents.", {"entities": [[0, 11, "Drug"], [27, 76, "Drug"]]}], [9087, "It has a wide spectrum of activity, excellent tissue penetration and is rapidly bactericidal at low concentrations.", {"entities": [[46, 64, "Parameter"], [100, 114, "Parameter"]]}], [9088, "Norfloxacin has a minimum inhibitory concentration (MIC Turmeric (Curcuma longa) is a medicinal plant extensively used in Ayurveda, Unani and Siddha medicine as a home remedy for various diseases.", {"entities": [[0, 11, "Drug"], [18, 55, "Parameter"], [56, 80, "Herb name"], [187, 195, "Pathology"]]}], [9089, "Curcumin, which is the active component of Curcuma longa, improves the per-os bioavailability of the immunosuppressive agent mylophenolic acid by inhibiting non-specific drug metabolizing enzymes [4].", {"entities": [[0, 8, "Herb name"], [43, 56, "Herb name"], [71, 93, "Parameter"], [97, 142, "Drug"], [157, 195, "Target"]]}], [9090, "Similarly, curcumin suppresses drug metabolizing enzymes (CYP3A4) in the liver [23] as well as inducing changes in the drug transporter P-glycoprotein, hence increasing the maximum absorption concentration (C The study was conducted in New Zealand white rabbits weighing 1.65 \u00b1 0.22 kg, divided into two groups with eight rabbits in each group.", {"entities": [[11, 19, "Herb name"], [31, 65, "Target"], [115, 150, "Target"], [169, 208, "Parameter"], [271, 285, "Amount"]]}], [9091, "The rabbits were acclimatized for three weeks to laboratory conditions before initiating the experiment.", {"entities": [[30, 45, "Duration"]]}], [9092, "They were housed in individual cages and fed with antibiotic free diet.", {"entities": [[50, 60, "Drug"]]}], [9093, "Feed and water were provided ad libitum.", {"entities": []}], [9094, "Feed was withheld for at least 6-8 h before and until 4 h after drug administration.", {"entities": [[18, 36, "Duration"], [54, 57, "Duration"]]}], [9095, "Necessary approval from the Institutional Animal Ethics Committee was obtained to carry out the investigation.", {"entities": []}], [9096, "Norfloxacin (Aravind Pharma, India) was dissolved in 0.1 N HCl to obtain a 3.33% solution (50 mg of norfloxacin in 1.5 mL 0.1 N HCl).", {"entities": [[0, 11, "Drug"], [53, 58, "Amount"], [75, 80, "Amount"], [91, 96, "Amount"], [100, 111, "Drug"], [115, 121, "Amount"], [122, 127, "Amount"], [128, 131, "Extraction process"]]}], [9098, "Group-I rabbits (control) received norfloxacin at the rate of 100 mg/kg body weight as a single oral dose.", {"entities": [[35, 46, "Drug"], [62, 71, "Amount"], [72, 83, "Parameter"], [89, 105, "Frequency"]]}], [9100, "Dilutions of norfloxacin (E. Merck, India) ranging from 0.01-4 mg/mL were carried out with the mobile phase to obtain a standard curve.", {"entities": [[13, 24, "Drug"], [56, 68, "Amount"]]}], [9101, "The HPLC system consisted of double pump (LC-20AT), rheodyne manual injector with 20 \u00b5L loop, dual wavelength ultraviolet detector (SPD-20A) and LC Solution software for data analysis.", {"entities": []}], [9102, "Chromatography was carried out using a reverse phase C The plasma concentration-time profile of norfloxacin of each experimental animal was used to determine its pharmacokinetics.", {"entities": [[59, 79, "Parameter"], [96, 107, "Drug"]]}], [9103, "The pharmacokinetic data of norfloxacin was analyzed using the 'method of least square' and 'method of residual yields' [8].", {"entities": [[28, 39, "Drug"]]}], [9104, "The compartmental analysis of the data was undertaken using the mono-exponential equation: C where, C The total AUC and area under the first moment of plasma drug concentration-time curve (AUMC) were calculated as described previously [18].", {"entities": [[102, 115, "Parameter"], [120, 194, "Parameter"]]}], [9105, "The volume of distribution (V The loading and maintenance dosage schedules were selected to maintain a MIC of 0.1, 0.5 and 1.0 \u00b5g/mL in plasma [12].", {"entities": [[0, 29, "Parameter"], [103, 106, "Parameter"], [110, 113, "Amount"], [115, 118, "Amount"], [123, 132, "Amount"]]}], [9106, "The difference between the means of the two treatments was determined by student's t-test [21] and the data were analyzed using GraphPad Instant software (GraphPad Software, USA).", {"entities": []}], [9107, "1).", {"entities": []}], [9108, "The absorption rate constant and absorption half-life revealed a significant (p \u2264 0.05) change (Table 2).", {"entities": [[0, 28, "Parameter"], [33, 53, "Parameter"]]}], [9109, "Prior administration of curcumin modified the kinetic profile of norfloxacin as evidenced by the higher AUC, AUMC and mean resident time.", {"entities": [[24, 32, "Herb name"], [65, 76, "Drug"], [104, 107, "Parameter"], [109, 113, "Parameter"], [118, 136, "Parameter"]]}], [9110, "Similarly, there was a significant increase in V Norfloxacin has antimicrobial activity against a wide range of bacteria and is being effectively used to treat respiratory, urinary and gastro-intestinal tract infections in man and animals.", {"entities": [[47, 48, "Parameter"], [49, 60, "Drug"], [160, 219, "Pathology"]]}], [9111, "Pharmacokinetic studies on norfloxacin in rabbits are limited [14,19].", {"entities": [[27, 38, "Drug"]]}], [9112, "Curcumin, a flavonoid isolated from Curcuma longa, improves the therapeutic concentrations of co-administered drugs [4,24].", {"entities": [[0, 49, "Herb name"], [60, 90, "Parameter"]]}], [9113, "With this background, the present study was undertaken to examine the influence of curcumin on the disposition profile of norfloxacin in rabbits after oral administration.", {"entities": [[83, 91, "Herb name"], [122, 133, "Drug"]]}], [9114, "The disposition of norfloxacin after a single oral dose (100 mg/kg body weight) was examined in rabbits with or without prior exposure to curcumin.", {"entities": [[19, 30, "Drug"], [37, 55, "Frequency"], [57, 66, "Amount"], [67, 78, "Parameter"], [138, 146, "Herb name"]]}], [9115, "The observed plasma concentration-time profile of norfloxacin was best described by the one compartment open model.", {"entities": [[13, 33, "Parameter"], [50, 61, "Drug"]]}], [9116, "It is more likely that the increased absorption observed in the present study may have been due to the ability of curcumin to influence drug transporter protein (P-gp) in the intestine, as occurs with celiprolol [24].", {"entities": [[37, 47, "Parameter"], [114, 122, "Herb name"], [136, 167, "Parameter"], [201, 211, "Drug"]]}], [9117, "Furthermore, in contrast to the fact that curcumin can induce hepatic glucuronyltransferase, its suppression at a higher dose cannot be ruled out.", {"entities": [[42, 50, "Herb name"], [62, 91, "Target"]]}], [9118, "The higher plasma elimination half life (t From a practical point of view, a dosage regimen of 80 and 77 mg/kg of norfloxacin alone or 60 and 55 mg/kg of norfloxacin after curcumin pre-treatment as the loading and maintenance dose, respectively, at a 12 h interval adequately maintains optimal therapeutic concentration of 0.5 \u00b5g/mL plasma against resistant pathogens infecting rabbits.", {"entities": [[11, 39, "Parameter"], [95, 97, "Amount"], [102, 110, "Amount"], [114, 125, "Drug"], [135, 137, "Amount"], [142, 150, "Amount"], [154, 165, "Drug"], [172, 180, "Herb name"], [251, 264, "Duration"], [294, 319, "Parameter"], [323, 339, "Amount"]]}], [9119, "The reduction in the loading and maintenance doses indicates that prior administration of curcumin is of economic significance as well as being capable of reducing side effects, as a lesser amount of drug would be required.", {"entities": [[90, 98, "Herb name"], [164, 176, "Pathology"]]}], [9120, "The bioenhancer nature of curcumin is comparable to piperine [20], an alkaloid obtained from Piper longum.", {"entities": [[26, 34, "Herb name"], [52, 105, "Herb name"]]}], [9121, "Thus, bioenhancer properties of curcumin can be clinically exploited after appropriate dose titration studies.", {"entities": [[32, 40, "Herb name"]]}], [9122, "The authors are thankful to the Dean of the Veterinary College, Karnataka Animal, Veterinary and Fishery Sciences University, Bidar, for providing the necessary facilities to carry out the investigation.", {"entities": []}], [9123, "Semilogarithmic plot of plasma concentration-time profile of norfloxacin in control (Group-I) and curcumin treated (Group-II) rabbits following single oral dose administration.", {"entities": [[24, 44, "Parameter"], [61, 72, "Drug"], [98, 106, "Herb name"], [144, 160, "Frequency"]]}], [9124, "Worse than the Disease?", {"entities": [[11, 22, "Pathology"]]}], [9125, "The Rash of Lomatium Dissectum Kenneth D. Marshall, MD, MA, FACEP and Stephen L. Thornton, MD Author information Article notes Copyright and License information PMC Disclaimer Go to: Introduction  Influenza is a respiratory illness responsible for epidemic outbreaks of disease, and accounts for 500,000 to 1,000,000 emergency department (ED) visits in the United States each year.1 Because of the high prevalence of disease and its potential morbidity, emergency physicians must be facile in its diagnosis and treatment.", {"entities": [[0, 8, "Pathology"], [12, 30, "Herb name"], [197, 231, "Pathology"], [270, 277, "Pathology"], [417, 424, "Pathology"]]}], [9126, "In addition, some treatments for influenza, such as neuraminidase inhibitors, are associated with a higher risk of symptoms, such as gastrointestinal and central nervous system effects, which themselves can prompt ED visits.2 While front-line physicians have become adept at recognizing and managing both the symptoms of influenza and side effects of well-studied medical treatments, a further diagnostic challenge includes side effects of compounds or therapies recommended for influenza that are not well studied in Western medicine.", {"entities": [[33, 42, "Pathology"], [52, 76, "Drug"], [133, 184, "Pathology"], [305, 330, "Pathology"], [335, 347, "Pathology"], [364, 382, "Drug"], [424, 436, "Pathology"], [479, 488, "Pathology"], [518, 525, "Ethnic group"]]}], [9127, "Here, we present a report novel to the peer-reviewed medical literature of an adverse event due to the use of an herbal remedy for influenza.", {"entities": [[17, 31, "Study"], [75, 91, "Pathology"], [131, 140, "Pathology"]]}], [9128, "Go to: Case Report  A 74-year-old woman with a history of hypertension and coronary artery disease presented to the ED with a diffuse, intensely pruritic maculopapular rash of four days\u2019 duration (Figures 1\u200b1\u200b - \u200b-4).4).", {"entities": [[7, 18, "Study"], [22, 33, "Age"], [34, 39, "Sex"], [58, 70, "Pathology"], [75, 98, "Pathology"], [124, 172, "Pathology"], [176, 195, "Duration"]]}], [9129, "She visited her primary care physician three days prior to her ED visit, where she denied any medication changes, reporting only her longstanding use of hydrochlorothiazide, lisinopril, and clopidogrel, of which she had been on stable doses for a year.", {"entities": [[153, 172, "Drug"], [174, 184, "Drug"], [190, 201, "Drug"], [241, 251, "Duration"]]}], [9130, "She also denied environmental or occupational exposures.", {"entities": []}], [9131, "Her primary care physician (PCP) prescribed a course of glucocorticoids, and when the rash continued to progress despite therapy, she was instructed to go to the ED.", {"entities": [[56, 71, "Drug"], [82, 90, "Pathology"]]}], [9132, "While the patient had denied new medications or exposures to her PCP, in the ED, it occurred to her that she had been exposed to an herbal supplement that she had not mentioned during her clinic visit.", {"entities": [[129, 149, "Herb name"]]}], [9133, "She recalled that the week previous to the development of her rash, she had experienced chills and cough, and had been diagnosed by a naturalist with influenza and advised to take an extract marketed as \u201cLDM-100,\u201d an extract of Lomatium dissectum, a plant used as an herbal remedy for viral illnesses.", {"entities": [[62, 66, "Pathology"], [88, 104, "Pathology"], [150, 159, "Pathology"], [204, 211, "Herb name"], [228, 246, "Herb name"], [285, 300, "Pathology"]]}], [9134, "She had taken this extract for two days as directed (six drops orally five times daily) when the rash erupted and continued taking it after the rash was present, but had stopped taking the extract the day before presentation to the ED because her cough and fever had resolved.", {"entities": [[19, 26, "Herb name"], [27, 39, "Duration"], [53, 62, "Amount"], [70, 86, "Frequency"], [93, 101, "Pathology"], [140, 148, "Pathology"], [185, 196, "Herb name"], [247, 262, "Pathology"]]}], [9135, "An external file that holds a picture, illustration, etc.", {"entities": []}], [9136, "Object name is kjm-11-2-54f1.jpg Figure 1  Facial rash.", {"entities": [[43, 54, "Pathology"]]}], [9137, "An external file that holds a picture, illustration, etc.", {"entities": []}], [9138, "Object name is kjm-11-2-54f2.jpg Figure 2  Abdominal rash.", {"entities": [[43, 57, "Pathology"]]}], [9139, "An external file that holds a picture, illustration, etc.", {"entities": []}], [9140, "Object name is kjm-11-2-54f3.jpg Figure 3  Rash of the leg.", {"entities": [[43, 58, "Pathology"]]}], [9141, "An external file that holds a picture, illustration, etc.", {"entities": []}], [9142, "Object name is kjm-11-2-54f4.jpg Figure 4  Rash of the arm.", {"entities": [[43, 58, "Pathology"]]}], [9143, "In the ED, a complete blood count, complete metabolic panel and inflammatory markers were unremarkable.", {"entities": [[22, 33, "Parameter"], [64, 84, "Parameter"]]}], [9144, "It was deduced the Lomatium dissectum was the likely source of the rash, the patient was discharged home, and she elected to discontinue steroids.", {"entities": [[19, 37, "Herb name"], [63, 71, "Pathology"], [137, 145, "Drug"]]}], [9145, "Five days after presentation, her symptoms had completely resolved.", {"entities": []}], [9149, "In addition to the preparation used by our patient, Lomatium can also be ingested as the unprocessed plant, used in teas, and also prepared in \u201cisolate\u201d form with the resins removed, which is a form alleged in some sources (without clear evidence) to be less likely to cause rash.", {"entities": [[52, 60, "Herb name"], [116, 120, "Extraction process"], [143, 181, "Extraction process"], [275, 279, "Pathology"]]}], [9150, "The naturopathic literature from which most information about rashes caused by Lomatium is drawn do not indicate a well-studied treatment of the rash aside from supportive care and cessation of Lomatium ingestion.", {"entities": [[62, 68, "Pathology"], [79, 87, "Herb name"], [141, 149, "Pathology"], [194, 202, "Herb name"]]}], [9151, "In our patient, the rash was refractory to glucocorticoids and only resolved once her exposure to the extract ceased, although antihistamines were helpful to reduce pruritis.", {"entities": [[16, 24, "Pathology"], [43, 58, "Drug"], [127, 141, "Drug"], [165, 173, "Pathology"]]}], [9152, "A strategy of withholding Lomatium and focusing on symptom relief would seem to be a reasonable approach in similar cases.", {"entities": [[26, 34, "Herb name"]]}], [9153, "Prior to this case report, there were no reports of this reaction to Lomatium dissectum in the peer-reviewed medical literature.", {"entities": [[14, 25, "Study"], [41, 48, "Study"], [69, 87, "Herb name"]]}], [9154, "Considering the likely continued use of Lomatium for influenza and other viral illnesses and the dramatic nature of the rash, physicians should be aware of this side effect.", {"entities": [[40, 48, "Herb name"], [53, 62, "Pathology"], [73, 88, "Pathology"], [116, 124, "Pathology"], [161, 172, "Pathology"]]}], [9155, "According to Traditional Chinese Medicine theory, influenza is categorized as a warm disease or Wen Bing.", {"entities": [[25, 32, "Ethnic group"], [50, 92, "Pathology"]]}], [9156, "The Wen Bing formulas, such as Yin-Qiao-San and Sang-Ju-Yin, are still first-line herbal therapies in combating variant influenza virus.", {"entities": [[4, 21, "Herb name"], [31, 43, "Herb name"], [48, 59, "Herb name"], [120, 135, "Pathology"]]}], [9157, "To continue our study on the pharmacokinetic and pharmacodynamic interactions between Wen Bing formulas and oseltamivir (OS), the first-line western drug for the treatment of influenza, further interactions between OS and the eight single herbs and their relevant marker components from Wen Bing formulas were investigated in the current study.", {"entities": [[86, 103, "Herb name"], [108, 124, "Drug"], [175, 184, "Pathology"], [215, 217, "Drug"], [287, 304, "Herb name"]]}], [9158, "To establish an in-vitro screening platform for investigation of the potential anti-influenza herbs/herbal components that may have pharmacokinetic and pharmacodynamic interactions with OS.", {"entities": [[16, 34, "Study"], [84, 93, "Pathology"], [186, 188, "Drug"]]}], [9159, "To screen potential inhibition on OS hydrolysis, 1\u202f\u03bcg/mL of OS is incubated with herbs/herbal components in diluted rat plasma, microsomes and human recombinant carboxylesterase 1(hCE1) under optimized conditions.", {"entities": [[34, 36, "Drug"], [60, 62, "Drug"], [143, 185, "Target"]]}], [9160, "MDCK-WT and MDCK-MDR1 cell lines are utilized to identify potential modification on P-gp mediated transport of OS by herbs/herbal components.", {"entities": [[84, 107, "Target"], [111, 113, "Drug"]]}], [9161, "Caco-2\u202fcells with and without Gly-Sar inhibition are performed to study the uptake of OS via PEPT1 transporters.", {"entities": [[86, 88, "Drug"], [93, 111, "Target"]]}], [9162, "Modification on OAT3 mediated transport is verified by the uptake of OS on HEK293-MOCK/HEK293-OAT3 cells.", {"entities": [[16, 20, "Target"], [69, 71, "Drug"], [94, 98, "Target"]]}], [9163, "Anti-virus effects were evaluated using plaque reduction assay on H1N1 and H3N2 viruses.", {"entities": []}], [9164, "Potential pharmacokinetic and pharmacodynamic interaction between OS (30\u202fmg/kg) and the selected herb, Radix Scutellariae (RS), at 300\u2013600\u202fmg/kg were carried out on rats.", {"entities": [[66, 68, "Drug"], [70, 78, "Amount"], [103, 126, "Herb name"], [131, 144, "Amount"]]}], [9165, "All samples are analyzed by an LC/MS/MS method for the contents of OS and OSA.", {"entities": [[67, 69, "Drug"], [74, 77, "Drug"]]}], [9166, "A mechanistic PK model was developed to interpret the HDI between OS and RS in rats.", {"entities": [[66, 68, "Drug"], [73, 75, "Herb name"]]}], [9167, "Our developed platform was successfully applied to screen the eight herbal extracts and their ten marker components on metabolic inhibition of OS and modification of OS transport mediated by P-gp, OAT3 and PEPT1.", {"entities": [[143, 145, "Drug"], [166, 168, "Drug"], [191, 195, "Target"], [197, 201, "Target"], [206, 211, "Target"]]}], [9168, "Results from six in-vitro experiments were analyzed after converting raw data from each experiment to corresponding fold-change (FC) values, based on which Radix Scutellariae (RS) were selected to have the most HDI potential with OS.", {"entities": [[17, 37, "Study"], [156, 179, "Herb name"], [230, 232, "Drug"]]}], [9169, "By analyzing the plasma and urine pharmacokinetic data after co-administration of OS with a standardized RS extract in rats using an integrated population pharmacokinetics model, it is suggested that RS could inhibit OS hydrolysis during absorption and increase the absorbed fraction of OS, which leads to the increased ratio of OS concentration versus that of OSA in both rat plasma and urine.", {"entities": [[82, 84, "Drug"], [105, 107, "Herb name"], [200, 202, "Herb name"], [217, 219, "Drug"], [287, 289, "Drug"], [329, 331, "Drug"], [361, 364, "Drug"]]}], [9170, "Never the less, the anti-virus effects of 2.5\u202fh post-dose rat plasma were not influenced by co-administration of OS with RS.", {"entities": [[113, 115, "Drug"], [121, 123, "Herb name"]]}], [9171, "A six-dimension in-vitro screening platform has been developed and successfully applied to find RS as a potential herb that would influence the co-administrated OS in rats.", {"entities": [[16, 34, "Study"], [96, 98, "Herb name"], [161, 163, "Drug"]]}], [9172, "Although co-administered RS could inhibit OS hydrolysis during absorption and increase the absorbed fraction of OS, which lead to the increased ratio of OS concentration versus that of OSA in both rat plasma and urine, the anti-virus effect of OS was not influenced by co-administered RS.", {"entities": [[25, 27, "Herb name"], [42, 44, "Drug"], [112, 114, "Drug"], [153, 155, "Drug"], [185, 188, "Drug"], [244, 246, "Drug"], [285, 287, "Herb name"]]}], [9174, "Wen Bing formulas have been used for more than 200 years since their publication in Wen Bing Tiao Bian by Wu Jutong in 1798.", {"entities": [[0, 17, "Herb name"], [84, 92, "Pathology"]]}], [9175, "These formulas include Yin-Qiao-San (a formula made up by Fructus Forsythiae, Flos Lonicerae Japonicae, Platycodonis Radix, Menthae Haplocalycis Herba, Radix et Rhizoma Glycyrrhizae, Herba Schizonepetae, Sojae Semen Praeparatum, Fructus Arctii and Reed Rhizome) and Sang-Ju-Yin (a formula made up by Armeniacae Semen Amarum, Fructus Forsythiae, Menthae Haplocalycis Herba, Folium Mori, Chrysanthemi Flos, Platycodonis Radix, Radix et Rhizoma Glycyrrhizae and Reed Rhizome).", {"entities": [[23, 35, "Herb name"], [58, 76, "Herb name"], [78, 103, "Herb name"], [104, 122, "Herb name"], [124, 150, "Herb name"], [152, 181, "Herb name"], [183, 202, "Herb name"], [204, 227, "Herb name"], [229, 243, "Herb name"], [248, 260, "Herb name"], [266, 277, "Herb name"], [300, 323, "Herb name"], [325, 343, "Herb name"], [345, 371, "Herb name"], [373, 384, "Herb name"], [386, 403, "Herb name"], [405, 423, "Herb name"], [425, 454, "Herb name"], [459, 471, "Herb name"]]}], [9176, "Up to now, these two formulas are still the first line herb therapies for treatment and prevention of early-stage influenza in China as recommended by National Health Commission, PRC (National Health Commission, 2018).", {"entities": [[102, 123, "Pathology"]]}], [9177, "As for middle-stage influenza, the recommended formula is Ma-Xing-Shi-Gan-Tang, which is adapted from Shanghan Lun compiled by Zhang Zhongjing before year 220, at the end of the Han dynasty.", {"entities": [[7, 29, "Pathology"], [58, 78, "Herb name"]]}], [9178, "This formula is made up by Ephedrae Herba, Armeniacae Semen Amarum, Gypsum Fibrosum, Anemarrhenae Rhizoma, Fritillariae Thunbergii Bulbus, Platycodonis Radix, Radix Scutellariae, Bupleuri Radix and Radix et Rhizoma Glycyrrhizae.", {"entities": [[27, 41, "Herb name"], [43, 66, "Herb name"], [68, 84, "Herb name"], [85, 105, "Herb name"], [107, 137, "Herb name"], [139, 157, "Herb name"], [159, 177, "Herb name"], [179, 193, "Herb name"], [198, 227, "Herb name"]]}], [9179, "Per the pattern differentiation of TCM, more herbs could be added to the original formulas for specific disease presentations.", {"entities": []}], [9180, "The TCM formula commonly used during the Severe Acute Respiratory Syndrome (SARS) epidemic of 2003 in China is the Sang-Ju-Yin formula adjusted by adding Radix Isatidis, Radix Scutellariae and Radix Astragali (Fratkin, 2010).", {"entities": [[41, 81, "Pathology"], [154, 168, "Herb name"], [170, 188, "Herb name"], [193, 208, "Herb name"]]}], [9181, "These Wen Bing formulas were also recommended by TCM experts from Healthy Authority (HA) of Hong Kong for the prophylaxis and treatment of influenza with Oseltamivir (OS).", {"entities": [[6, 23, "Herb name"], [139, 148, "Pathology"], [154, 170, "Drug"]]}], [9182, "In collaboration with the HA, investigations of the pharmacokinetic and pharmacodynamic interactions between OS and HA recommended Chinese formula, namely CMF1 (a combined formula of Yin-Qiao-San and Sang-Ju-Yin) in both animal and human subjects were performed by our group since 2008 (Chang et al., 2014).", {"entities": [[109, 111, "Drug"], [131, 138, "Ethnic group"], [155, 212, "Herb name"], [216, 246, "Study"]]}], [9183, "To explore more, we would like to investigate the interactions between OS and selected single herbs from these Wen Bing formulas.", {"entities": [[71, 73, "Drug"], [111, 128, "Herb name"]]}], [9185, "In addtion, ten relevant marker components in these eight herbs were also selected to help understand the interaction between OS and herbs: epigoitrin from Radix Isatidis; glycyrrhizic acid, liquirtin from Radix et Rhizoma Glycyrrhizae; baicalein, baicalein, wogonin from Radix Scutellariae; phillyrin from Fructus Forsythiae; chlorogenic acid from Flos Lonicerae Japonicae; rutin from Folium Mori and arctiin from Fructus Arctii.", {"entities": [[126, 128, "Drug"], [140, 150, "Herb name"], [156, 170, "Herb name"], [172, 189, "Herb name"], [191, 200, "Herb name"], [206, 235, "Herb name"], [237, 246, "Herb name"], [248, 257, "Herb name"], [259, 266, "Herb name"], [272, 290, "Herb name"], [292, 301, "Herb name"], [307, 325, "Herb name"], [327, 343, "Herb name"], [349, 373, "Herb name"], [375, 380, "Herb name"], [386, 397, "Herb name"], [402, 409, "Herb name"], [415, 429, "Herb name"]]}], [9186, "OS is the ethyl ester prodrug of oseltamivir acid (OSA, Ro 64\u20130802), a potent and selective inhibitor of the neuraminidases glycoprotein essential for replication of influenza A and B viruses (He et al., 1999).", {"entities": [[0, 49, "Drug"], [51, 54, "Drug"], [109, 136, "Target"], [166, 191, "Pathology"]]}], [9187, "It is currently marketed under the trade name Tamiflu OS has limited potential for clinically relevant pharmacokinetics interactions with commonly co-administered drugs, such as paracetamol, cimetidine, amoxicllin, aspirin or antacids (Dutkowski et al., 2003).", {"entities": [[46, 56, "Drug"], [178, 189, "Drug"], [191, 201, "Drug"], [203, 213, "Drug"], [215, 222, "Drug"], [226, 234, "Drug"]]}], [9188, "Comparing with drug-drug interactions of OS, reports on its herb-drug interactions are even fewer.", {"entities": [[41, 43, "Drug"], [45, 52, "Study"]]}], [9189, "Effects of herbal supplement and traditional medicines (including extracts from six traditional Cree botanicals, a commercially available Echinacea product, Goldenseal and a traditional Chinese medicine) on the in-vitro activity of human hepatic microsomal-mediated metabolism of OS have been evaluated by Liu et al.", {"entities": [[138, 147, "Herb name"], [157, 167, "Herb name"], [186, 193, "Ethnic group"], [211, 219, "Study"], [280, 282, "Drug"]]}], [9190, "(2010).", {"entities": []}], [9191, "The findings suggested that there is a potential for health/herbal supplement used by patients in response to pandemic A/H1N1 to reduce efficacy of OS, however the potential clinical significance of such interaction was not studied.", {"entities": [[119, 125, "Pathology"], [148, 150, "Drug"]]}], [9192, "In addition to limited reports on the herb-drug interactions of OS at pharmacokinetics levels, it was found that the potential interaction could also be at the pharmacodynamics level.", {"entities": [[23, 30, "Study"], [64, 66, "Drug"]]}], [9193, "Pomegranate polyphenol extract has not only demonstrated its in-vitro inhibition on the replication of human influenza A/Hong Kong (H3N2), but has also shown a synergistic effect with OS (Haidari et al., 2009).", {"entities": [[0, 30, "Herb name"], [61, 69, "Study"], [109, 137, "Pathology"], [184, 186, "Drug"]]}], [9194, "Therefore, we propose to establish an in-vitro screening platform for investigation of the potential herbs/herbal components that may have pharmacokinetic and pharmacodynamic interactions with OS.", {"entities": [[38, 56, "Study"], [193, 195, "Drug"]]}], [9195, "Such screening platform will be based on available knowledge of absorption, disposition and antiviral activities of OS, and built with our existing models of in-vitro enzymatic reactions of liver microsomes, in-vitro transport using cell lines that over-expressed with P-gp, PEPT1 or OAT, and in-vitro plaque-reduction assay.", {"entities": [[116, 118, "Drug"], [158, 166, "Study"], [208, 216, "Study"], [269, 273, "Target"], [275, 280, "Target"], [284, 287, "Target"], [293, 301, "Study"]]}], [9196, "Raw herbs, namely Radix Isatidis (H1), Radix et Rhizoma Glycyrrhizae (H2), Radix Scutellariae (H3), Fructus Forsythiae (H4), Flos Lonicerae Japonicae (H5), Folium Mori (H6), Herba Schizonepetae (H7) and Fructus Arctii (H8), were purchased from Hong Wang Herbal Drug Store in Hong Kong.", {"entities": [[18, 37, "Herb name"], [39, 73, "Herb name"], [75, 98, "Herb name"], [100, 123, "Herb name"], [125, 154, "Herb name"], [156, 172, "Herb name"], [174, 198, "Herb name"], [203, 222, "Herb name"]]}], [9197, "Authentic compounds, epigoitrin (C1), glycyrrhizic acid (C2), liquirtin (C3), baicalein (C4), baicalin (C5), wogonin (C6), phillyrin (C7), chlorogenic acid (C8), rutin (C9) and arctiin (C10), were purchased from Chengdu Must Bio-technology Co. LTD (Chengdu, China).", {"entities": [[21, 36, "Herb name"], [38, 60, "Herb name"], [62, 76, "Herb name"], [78, 92, "Herb name"], [94, 107, "Herb name"], [109, 121, "Herb name"], [123, 137, "Herb name"], [139, 160, "Herb name"], [162, 172, "Herb name"], [177, 190, "Herb name"]]}], [9198, "Content of authentic compounds in the studied herbs were determined using a LC-MS/MS method which employed an Agilent 6430 triple quadruple mass spectrometer (Agilent Technologies) coupled with electrospray ionization (ESI) source.", {"entities": []}], [9199, "MS parameters and separation conditions were optimized for each herb as shown in Table S1.", {"entities": []}], [9200, "Contents of C1\u2013C10 in herbs were determined using an external calibration method.", {"entities": [[12, 18, "Herb name"]]}], [9201, "Triplicate samples were prepared for each herb and analyzed.", {"entities": []}], [9202, "Finally, the concentrations of C1\u2013C10 in each gram of herbal extracts were summarized in Table S2.", {"entities": [[31, 37, "Herb name"]]}], [9203, "A commercially available, standardized and purified Radix Scutellariae extract (RS) was obtained from Shanghai U-sea Biotech Co., Ltd. (Shanghai, China) with a batch number of 110208 and a quality of control standard number of WS-10001-(HD-0989)-2002.", {"entities": [[52, 83, "Herb name"]]}], [9204, "The content (w/w) of C4, C5 and C6 in RS were 2.0%, 48.0% and 0.4%, respectively, as quantified by our LC\u2013MS/MS method.", {"entities": [[21, 23, "Herb name"], [25, 27, "Herb name"], [32, 34, "Herb name"], [38, 40, "Herb name"]]}], [9205, "Oseltamivir (OS) and oseltamivir acid (OSA) (both purity \u226599%) were kindly provided by Roche Company (St. Louis, MO, USA).", {"entities": [[0, 16, "Drug"], [21, 43, "Drug"]]}], [9206, "Albuterol (as internal standard) was purchased from Sigma-Aldrich Chem.", {"entities": []}], [9207, "Hygromycin B, glycyl-sarcosine (Gly-Sar) and thiazolyl blue tetrazolium bromide (MTT) were purchased from Sigma-Aldrich Chem.", {"entities": []}], [9208, "Co. (Milwaukee, WI, USA).", {"entities": []}], [9209, "For cell culture, Dulbecco\u2019s modified Eagle\u2019s medium, 0.25% trypsin-EDTA, fetal bovine serum, penicillin-streptomycin, hank\u2019s balanced salt solution (HBSS), sodium butyrate and non-essential amino acids were purchased from Gibco BRL Co. Ltd (Carlsbad, CA, USA) and lifer Technologies (Grand Island, NY, USA).", {"entities": []}], [9210, "Six-well plates with Transwell MDCK-WT and MDCK-MDR1 cells were generously provided by Prof. P. Borst (The Netherlands Cancer Institute).", {"entities": []}], [9211, "For cell culture, MDCK-WT and MDCK-MDR1 cells were cultured in Dulbecco\u2019s modified Eagle\u2019s medium at 37\u202f\u00b0C, supplemented with 10% fetal bovine serum, 1% nonessential amino acids, in an atmosphere of 5% CO Caco-2\u202fcells were purchased from American Type Culture Collection.", {"entities": []}], [9212, "For cell culture, Caco-2\u202fcells were cultured in Dulbecco\u2019s modified Eagle\u2019s medium at 37\u202f\u00b0C, supplemented with 10% fetal bovine serum, 1% nonessential amino acids, 100 U/mL of penicillin, and 100 U/mL of streptomycin in an atmosphere of 5% CO Empty vector (mock) transfected and human organic anion transporter 3 (OAT3) transfected HEK293\u202fcells were generously provided by Prof. Dafang Zhong (Shanghai Institute of Materia Medica).", {"entities": [[285, 319, "Target"]]}], [9213, "For cell culture, HEK293-MOCK and HEK293-OAT3 were cultured in flasks with Dulbecco\u2019s modified Eagle\u2019s medium at 37\u202f\u00b0C, supplemented with 10% fetal bovine serum, 1% nonessential amino acids, 100 U/mL of penicillin, 100 U/mL of streptomycin, and 100\u202f\u03bcg/mL of hygromycin B in an atmosphere of 5% CO Diluted rat plasma (10%) of 400\u202f\u03bcL was spiked with 4\u202f\u03bcL herb/herbal components (H1\u2013H8: 50\u202fmg/mL; C1\u2013C10: 10\u202fmg/mL), which were dissolved in DMSO (control group was spiked with only DMSO).", {"entities": []}], [9214, "These reaction mixtures were pre-incubated for 5\u202fmin in a 37\u202f\u00b0C water bash.", {"entities": []}], [9215, "Then, 40\u202f\u03bcL of 10\u202f\u03bcg/mL OS was added to initialize the reaction.", {"entities": [[24, 26, "Drug"]]}], [9216, "The final mixture was incubated for 30\u202fmin and terminated by adding 400\u202f\u03bcL ice-cold acetonitrile and 200\u202f\u03bcL internal standard (100\u202fng/mL of albuterol in water).", {"entities": []}], [9217, "After vertex and centrifugation at 13,000\u202frpm for 10\u202fmin, 2\u202f\u03bcL of the supernatant was injected for LC/MS/MS analysis.", {"entities": []}], [9218, "Thaw rat liver microsome (RLM) slowly on ice and adjust concentration to 10\u202fmg/mL.", {"entities": []}], [9219, "The incubation system was composed of: (1) 176\u202f\u03bcL of 50\u202fmM PBS; (2) 2\u202f\u03bcL of 100\u202f\u03bcg/mL OS and 2\u202f\u03bcL of 100\u202f\u03bcg/mL herb components (C1 to C10); (3) 10\u202f\u03bcL of 10\u202fmg/mL RLM.", {"entities": [[86, 88, "Drug"], [128, 137, "Herb name"]]}], [9220, "Pre-incubate the above mixture in water bath for 5\u202fmin.", {"entities": []}], [9221, "Initiate the reactions with the addition of 10\u202f\u03bcL of 20\u202fmM NADPH regenerating system (NADP Thaw hCE1 slowly on ice and diluted to 40\u202f\u03bcg/mL with 50\u202fmM PBS (pH 7.4).", {"entities": [[96, 100, "Target"]]}], [9222, "Pre-incubate hCE1 in 37\u202f\u00b0C water bath for 5min.", {"entities": [[13, 17, "Target"]]}], [9223, "The hydrolysis reaction was initiated by the addition of OS and herbal components (200\u202f\u03bcL, final concentration 10\u202f\u03bcM) for 60\u202fmin.", {"entities": [[57, 59, "Drug"]]}], [9224, "The reaction was terminated by adding 5\u202f\u03bcL of 8\u202fmg/mL dichlorvos and then mixed with 600\u202f\u03bcL PBS.", {"entities": []}], [9225, "Vortex the samples, and centrifuge at 13, 000\u202frpm for 10\u202fmin.", {"entities": []}], [9226, "Pipette 100\u202f\u03bcL supernatant into 50\u202f\u03bcL internal standard (100\u202fng/mL albuterol in water) and 100\u202f\u03bcL water.", {"entities": []}], [9227, "After vortex and centrifugation, 10\u202f\u03bcL of supernatant were injected for LC/MS/MS analysis.", {"entities": []}], [9228, "The cytotoxicity of OS combined with selective herbs/herbal components to interfere with the growth of MDCK-WT, MDCK-MDR1, Caco-2, HEK293-MOCK and HEK293-OAT3 cells were determined by MTT assay.", {"entities": [[20, 22, "Drug"], [117, 121, "Target"], [154, 158, "Target"]]}], [9229, "The cells were seeded onto a 96-well plate at a density of 5\u202f\u00d7\u202f10 To identify potential modification on P-gp mediated transport of OS by herbs/herbal components, the A to B transport study of OS with or without herbs/herbal components was carried out in MDCK-WT and MDCK-MDR1 cell lines.", {"entities": [[104, 108, "Target"], [131, 133, "Drug"], [192, 194, "Drug"]]}], [9230, "Cells were rinsed twice and equilibrated with HBSS at 37\u202f\u00b0C before experiment.", {"entities": []}], [9231, "Test solutions (30\u202f\u03bcg/mL OS dissolved in HBSS with or without herbs/herbal components) were loaded into the apical side of chamber (AP, 1.5\u202fmL volume).", {"entities": [[25, 27, "Drug"]]}], [9232, "400\u202f\u03bcL of solution was collected from basolateral side (BL, 2.6\u202fmL in volume) at 30\u202fmin, 60\u202fmin, 90\u202fmin, and 120\u202fmin, followed by replacing with equal volume of blank HBSS to the receiver chamber, and finally subjected to analysis for OS by LC/MS/MS.", {"entities": [[235, 237, "Drug"]]}], [9233, "Caco-2\u202fcells were used for the screening of herbs/herbal components to determine their effect on the uptake of OS via PEPT1.", {"entities": [[111, 113, "Drug"], [118, 123, "Target"]]}], [9234, "Caco-2\u202fcells grown on the 6-well plates for 7 days were rinsed with HBSS containing 10\u202fmM Gly-Sar twice and pre-incubated for 20\u202fmin before uptake study.", {"entities": []}], [9235, "After pre-incubation, test solutions (30\u202f\u03bcg/mL OS dissolved in HBSS with or without herbs/herbal components) were added to initiate uptake.", {"entities": [[47, 49, "Drug"]]}], [9236, "The uptake of OS increased linearly up to 1\u202fmin.", {"entities": [[14, 16, "Drug"]]}], [9237, "Thus, the Caco-2\u202fcells were incubated at 37\u202f\u00b0C for 1\u202fmin and then washed 5 times with 2\u202fmL of ice-cold blank HBSS to terminate the uptake of OS.", {"entities": [[141, 143, "Drug"]]}], [9238, "The cells were lysed by the multigelation method and the content of OS in cells was then analyzed by LC/MS/MS.", {"entities": [[68, 70, "Drug"]]}], [9239, "HEK293-MOCK and HEK293-OAT3 cells were used to illustrate the effect of the herbs/herbal components on the modification of OS via OAT3.", {"entities": [[23, 27, "Target"], [123, 125, "Drug"], [130, 134, "Target"]]}], [9240, "Cells were washed twice with HBSS on day 3 or 4 and pre-incubated at 37\u202f\u00b0C for 20\u202fmin.", {"entities": []}], [9241, "Experiments were initiated by the addition of HBSS containing OS with or without herbs/herbal components and terminated by removing the solutions and washed 3 times carefully with ice-cold HBSS.", {"entities": [[62, 64, "Drug"]]}], [9242, "Subsequently, the cells were lysed by the multigelation method and the supernatant after processing was injected to LC/MS/MS for analysis of OS.", {"entities": [[141, 143, "Drug"]]}], [9243, "The experiments were carried out after approval by the Animal Ethics Committee of The Chinese University of Hong Kong (Ref No.", {"entities": [[86, 93, "Ethnic group"]]}], [9244, "14-171-MIS).", {"entities": []}], [9245, "Male Sprague-Dawley (SD) rats (weighting ~250\u202fg) used in the experiment were provided by Laboratory Animal Services Center of The Chinese University of Hong Kong (Hong Kong SAR, People\u2019s Republic of China).", {"entities": [[0, 4, "Sex"], [130, 137, "Ethnic group"]]}], [9246, "Solutions of oseltamivir (OS, 7.5\u202fmg/mL) were freshly prepared before each experiment by dissolving OS in deionized water.", {"entities": [[13, 24, "Drug"], [26, 28, "Drug"], [30, 39, "Amount"], [100, 102, "Drug"]]}], [9247, "RS extract was prepared as a suspension (Low dose: 75\u202fmg/g; High dose: 150\u202fmg/g) in water containing 5% (w/w) PEG400.", {"entities": [[0, 10, "Herb name"], [51, 58, "Amount"], [71, 79, "Amount"]]}], [9248, "A total of 60 rats were randomly divided into 6 groups (G1 to G6), with 10 rats in each group, to receive various oral drug treatments for 5 days.", {"entities": [[11, 18, "Cohort"], [24, 93, "Study"], [135, 145, "Duration"]]}], [9249, "On 9AM and 6PM of each day, rats in G1 to G3 received a dose of 30\u202fmg/kg OS and rats in G4 to G6 were given water only at the same time.", {"entities": [[64, 72, "Amount"], [73, 75, "Drug"]]}], [9250, "On 11AM and 8PM of each day, the doses administered to rats were water for G1 and G6, 300\u202fmg/kg RS for G2 and G4, and 600\u202fmg/kg RS for G3 and G5, respectively.", {"entities": [[86, 95, "Amount"], [96, 98, "Herb name"], [118, 127, "Amount"], [128, 130, "Herb name"]]}], [9251, "On Day 4, 1\u202fh after receiving the 11AM-dose, a jugular vein cannulation surgery was performed on rats under light anesthesia.", {"entities": []}], [9252, "After surgery, the rats were placed individually into metabolic cages and allowed to recover, with overnight fasting but free access to water.", {"entities": []}], [9253, "After the 9AM dosing on Day 5, 10 blood samples (0.2\u202fmL each) were obtained via the catheter at 0, 15, 30, 60, 90, 120, 180, 240, 360 and 480\u202fmin post dose.", {"entities": []}], [9254, "After each blood sampling, 0.2\u202fmL of normal saline containing 20 units/mL of heparin were immediately injected into the catheter to flush the catheter.", {"entities": []}], [9255, "The urine samples were collected over 8\u202fh post-dose and combined with the volume of water used for rinsing the metabolic cage.", {"entities": []}], [9256, "The collected urine samples were stored at \u221280\u202f\u00b0C until analysis.", {"entities": []}], [9257, "At 30\u202fmin following the 8PM dose on Day 5, the rats were anesthetized and about 10\u202fmL of blood were collected from rats\u2019 inferior vena for determination of antiviral activity.", {"entities": []}], [9258, "The blood samples collected in G6 (group with no treatment) served as control.", {"entities": []}], [9259, "Rat plasma or diluted urine samples were purified with a Waters Oasis MCX extraction cartridge (1\u202fcc, 30\u202fmg) per the following procedure: 1) Equilibrate the cartridge with 1\u202fmL methanol and 1\u202fmL H An Agilent 6430 triple quadruple mass spectrometer (Agilent Technologies) coupled with electrospray ionization (ESI) source was employed for detecting OS and OSA in the above-mentioned bio-samples.", {"entities": [[348, 350, "Drug"], [355, 358, "Drug"]]}], [9260, "MS parameters and separation conditions were optimized for each kind of bio-samples.", {"entities": []}], [9261, "Generally, nitrogen was used as the de-solvation (10\u00a0L/min) and nebulizer gas (50 psi) and the source parameters were: ESI (+), temperature 350\u00a0\u00b0C, source voltage 4000\u00a0V and delta EMV 400\u00a0V. Chromatographic separations were achieved by a SunFire C The MDCK SIAT-1\u202fcell line was grown in DMEM, high glucose, pyruvate supplemented with 10% fetal bovine serum, 2\u202fmM L-glutamine (all from Thermo Fisher Scientific, Massachusetts, USA) at 37\u202f\u00b0C in 5% CO MDCK SIAT-1\u202fcells were seeded at 6.25\u202f\u00d7\u202f10 For inhibition of OS hydrolysis, OSA formation rate were calculated by the molar amount of OSA divided by reaction time and volume of rat plasma (or protein amount of RLM and hCE1).", {"entities": [[510, 512, "Drug"], [525, 528, "Drug"], [583, 586, "Drug"]]}], [9262, "For P-gp transport study, apparent permeability coefficient (P Selection of herb for verification of the potential herb-drug interaction (HDI) in rats.", {"entities": [[4, 8, "Target"]]}], [9263, "To comprehensively compare the influential of herbs/herbal components on the inhibition of OS hydrolysis and the transport/uptake of OS, the results from each experiment were expressed as a fold change (FC) by the following equation: Nonlinear mixed-effects modeling was performed with NONMEM (version 7.4; ICON Development Solutions, Ellicott City, Maryland, USA) and Perl-speaks-NONMEM (version 4.8.1; Uppsala University, Uppsala, Sweden).", {"entities": [[91, 93, "Drug"], [133, 135, "Drug"]]}], [9264, "The structural model building was performed under ADVAN 6 with the first order conditional method with interaction (FOCE\u00a0+\u00a0I), and the variance\u2013covariance matrix was calculated using the default method to estimate the relative standard error (RSE) of each parameter.", {"entities": []}], [9265, "The final model was established in a stepwise manner per the following criteria: (1) minimum of objective function value (OFV); (2) successful both for minimization and covariance calculation; (3) RSE\u00a0<\u00a050%; (4) only accepting additional parameter when the dropped OFV>3.84 (p\u202f<\u202f0.05); (5) shrinkage\u202f<\u202f50% for accepting the addition of an inter-individual variability (IIV) of one parameter.", {"entities": []}], [9266, "All models were also visually qualified based on goodness-of-fit of plasma concentration\u2013time profiles and accumulative urine amount of OS and OSA on an individual and population level.", {"entities": [[136, 138, "Drug"], [143, 146, "Drug"]]}], [9267, "A visual predictive check (VPC) and bootstrap procedure (n\u202f=\u202f1000) were used as internal validation tools to ensure the ruggedness and predictability of the final model.", {"entities": []}], [9268, "From the bootstrap estimation, the median and 2.5th and 97.5th percentiles were obtained to represent the non-parametric 95% confidence intervals (CI).", {"entities": []}], [9269, "Inhibition effects of the eight herb extracts (H1 to H8) and their ten marker components (C1 to C10) on the hydrolysis of OS were evaluated in rat plasma, RLM and hCE1 by incubating OS in presence and absence of studied herb/herbal components.", {"entities": [[90, 92, "Herb name"], [96, 99, "Herb name"], [122, 124, "Drug"], [182, 184, "Drug"]]}], [9270, "The incubation system for rat plasma contains 1\u202f\u03bcg/mL of OS and 10% rat plasma since the super-fast reaction rate of 100% rat plasma resulted in no discrimination for nearly all the studied herb/herbal components.", {"entities": []}], [9271, "The results were demonstrated in Fig.", {"entities": []}], [9272, "S1.", {"entities": []}], [9273, "The formation rate of OSA could be significantly suppressed by all the herb/herbal components.", {"entities": [[22, 25, "Drug"]]}], [9274, "Among all the selected herbs, H4 (Fructus Forsythiae) and H8 (Fructus Arctii) can almost completely inhibit the hydrolysis of OS (>97% OS remained after 60\u202fmin incubation).", {"entities": [[34, 52, "Herb name"], [62, 76, "Herb name"], [126, 128, "Drug"], [135, 137, "Drug"]]}], [9275, "For the herbal components, C4 and C6, which are the marker compounds from Radix Scutellariae, could inhibit more than 50% of OS hydrolysis.", {"entities": [[27, 29, "Herb name"], [34, 36, "Herb name"], [74, 92, "Herb name"], [125, 127, "Drug"]]}], [9276, "Results from RLM and hCE1 showed a similar trend for the ten marker components (Figs.", {"entities": []}], [9277, "S2 and S3), in which both C1 and C2 significantly suppressed the OS hydrolysis.", {"entities": [[26, 28, "Herb name"], [33, 35, "Herb name"], [65, 67, "Drug"]]}], [9278, "This suggests the hydrolysis of OS in RLM are mainly mediated by an analogue of hCE1.", {"entities": [[32, 34, "Drug"]]}], [9281, "The viability of all cells was more than 80% in presence of both oseltamivir (30\u202f\u03bcg/mL) and herbs/herbal components at the studied highest concentrations.", {"entities": [[65, 76, "Drug"], [78, 86, "Amount"]]}], [9282, "The maximum concentrations of herbs and herbal components for transport and uptake studies were therefore set at 1\u202fmg/mL and 100\u202f\u03bcg/mL, respectively, for MDCK-WT, MDCK-MDR1, HEK29-MOCK and HEK293-OAT3 cells.", {"entities": [[113, 120, "Amount"], [125, 134, "Amount"]]}], [9283, "As shown in Fig.", {"entities": []}], [9284, "S4, the P The above in-vitro experiments suggested that there should be some potential HDI between OS and these anti-influenza herbs/herbal components during absorption and metabolism.", {"entities": [[20, 40, "Study"], [99, 101, "Drug"]]}], [9285, "Since testing HDI in rat models is expensive and time-consuming, we prefer to select one herb, having the most possibility of HDI, to perform in-vivo experiments.", {"entities": [[142, 161, "Study"]]}], [9286, "To make it comparable for the results from the six in-vitro experiments, original values were converted to fold-change (FC) of the control group (no herb/herbal component interference) and then, the FC values in each experiment were converted into z-scores using z-transform.", {"entities": [[51, 71, "Study"]]}], [9287, "After z-transform, results from different experiments would be comparable since the mean and standard deviation of z-scores is always zero and one, respectively.", {"entities": []}], [9288, "The z-scores of each experiment were given in Fig.", {"entities": []}], [9289, "1 .", {"entities": []}], [9290, "The sum values of absolute z-scores of each herb/herbal component were given on the top of Fig.", {"entities": []}], [9291, "1, right above each sample\u2019s results.", {"entities": []}], [9292, "Based on the sum values of absolute z-scores, H3 (Radix Scutellariae), having a highest score (14.6) among all the studied herbs, was selected for further in-vivo experiments.", {"entities": [[46, 69, "Herb name"], [155, 174, "Study"]]}], [9293, "Heat map of z-transformed fold-change results (z-scores) for (1) in-vitro inhibition of OS hydrolysis in rat plasma (RP), rat liver microsomes (RLM) and human recombinant carboxylesterase 1 (hCE1); (2) modification on P-gp, PEPT1, OAT3 mediated transport by herbs (H1 to H8) and herbal components (C01 to C10).", {"entities": [[65, 73, "Study"], [88, 90, "Drug"], [171, 196, "Target"], [218, 222, "Target"], [224, 229, "Target"], [231, 235, "Target"], [265, 267, "Herb name"], [271, 273, "Herb name"], [298, 301, "Herb name"], [305, 308, "Herb name"]]}], [9294, "Per the above in-vitro screening in cells and enzymes, we found that H3 (Radix Scutellariae) and its marker components (C4\u2013C6) have a clear hint to interact with OS during the absorption, transportation and metabolism processes.", {"entities": [[14, 32, "Study"], [69, 92, "Herb name"], [120, 122, "Herb name"], [123, 125, "Herb name"], [162, 164, "Drug"]]}], [9295, "Thus, a standardized herbal extract of Radix Scutellariae (RS) was utilized to perform an herb-drug interaction study with OS in rats.", {"entities": [[39, 62, "Herb name"], [123, 125, "Drug"]]}], [9297, "2 , right) and their corresponding 8-h accumulated amount in urine were obtained.", {"entities": []}], [9298, "These data were analyzed using non-compartmental analysis (Table S3).", {"entities": []}], [9299, "The results suggested that co-administration with RS could significantly increase the systemic exposure of OS and decrease that of OSA (Fig.", {"entities": [[50, 52, "Herb name"], [107, 109, "Drug"], [131, 134, "Drug"]]}], [9300, "S7).", {"entities": []}], [9301, "This can further be verified by the lowered OSA/OS ratio in rat urine samples after co-administration with RS (Fig.", {"entities": [[44, 47, "Drug"], [48, 50, "Drug"], [107, 109, "Herb name"]]}], [9302, "S8).", {"entities": []}], [9304, "Concentrations were given as mean\u00a0\u00b1\u00a0SD.", {"entities": []}], [9306, "As shown in Fig.", {"entities": []}], [9307, "2 (left), the final model was a four compartmental PK model (two compartments for OS and OSA distribution, and another two to represent the reservoirs of OS and OSA in urine) with two absorption compartments (one for directly absorbed amount of OS and one for first-pass eliminated amount of OS).", {"entities": [[82, 84, "Drug"], [89, 92, "Drug"], [154, 156, "Drug"], [161, 164, "Drug"], [245, 247, "Drug"], [292, 294, "Drug"]]}], [9309, "k Goodness-of-fit plots showed good agreement between predicted and observed concentrations/amounts with no apparent bias in residual (Figs.", {"entities": []}], [9310, "S9 and S10).", {"entities": []}], [9311, "The VPC result for the final model is presented in Fig.", {"entities": []}], [9312, "3 .", {"entities": []}], [9313, "Overall, the 2.5th, 50th and 97.5th percentiles of observed concentrations were within the predicted 95% confidence interval (CI) of these percentiles, suggesting accurate model fitting across different interference groups.", {"entities": []}], [9314, "Bootstrapping resulted in median parameter estimates and 95% CIs like the estimates from the original dataset, indicating that the final model provided good precision for parameter estimation (Table 1).", {"entities": []}], [9315, "Visual predictive check of the final population pharmacokinetics model developed from 1000 simulations.", {"entities": []}], [9316, "The solid line is the median of the observed data and the dotted lines are the 5th and 95th percentiles of the observed data.", {"entities": []}], [9317, "The shaded areas are the 95% confidence intervals for the median, 5th percentile and 95th percentiles of the simulated data.", {"entities": []}], [9318, "Observed concentrations are displayed as open circles.", {"entities": []}], [9319, "OS: oseltamivir; OSA: oseltamivir acid.", {"entities": [[0, 15, "Drug"], [17, 38, "Drug"]]}], [9320, "By observing the microscopic morphological changes of MDCK SAIT-1\u202fcells after incubating with serial dilutions of diluted rat plasma for 48\u202fh, it showed that the maximum concentration of plasma preparation could be used for plaque reduction assay was 1:80.", {"entities": []}], [9321, "This plasma dilution was used for plaque reduction assay.", {"entities": []}], [9322, "The virus plaque reduction results of groups 1\u20136 (G1 to G6) are shown in Table 2 .", {"entities": []}], [9323, "Results were mean values from 3 rats with each plasma sample tested in triplicate.", {"entities": []}], [9324, "The no.", {"entities": []}], [9325, "of plaque obtained from the G6 (no herb and no oseltamivir administration) was used as reference.", {"entities": [[47, 58, "Drug"]]}], [9326, "The herb only groups (G4 and G5) did not show significant reduction in virus plaque of either H1N1 or H3N2.", {"entities": [[71, 106, "Target"]]}], [9327, "A significant reduction in the number of virus plaque (both H1N1 and H3N2) was observed for oseltamivir treated groups (G1, G2 and G3) and co-administration of one/two times HED of RS extracts with OS did not increase the total antivirus effect.", {"entities": [[41, 74, "Target"], [92, 103, "Drug"], [160, 173, "Frequency"], [181, 192, "Herb name"], [198, 200, "Drug"]]}], [9328, "Effect of plasma samples obtained from different treatment groups on influenza A H1N1 and H3N2 virus plaque formation (n\u202f=\u202f3).", {"entities": [[69, 85, "Pathology"], [90, 100, "Pathology"]]}], [9329, "Note: OS: oseltamivir, W: water, 1H: 300\u00a0mg/kg of Radix Scutellariae, 2H: 600\u00a0mg/kg of Radix Scutellariae.", {"entities": [[6, 21, "Drug"], [33, 35, "Herb name"], [37, 46, "Amount"], [50, 68, "Herb name"], [70, 72, "Herb name"], [74, 83, "Amount"], [87, 105, "Herb name"]]}], [9330, "Student t-test were calculated between W\u00a0+\u00a0W (control group) and other groups (**p\u202f<\u202f0.01).", {"entities": []}], [9331, "\u2014 not applicable.", {"entities": []}], [9332, "In our current study, a screening platform based on microsomes, enzymes, cells and influenza viruses have for the first time been developed and utilized to screen potential interaction between OS and anti-influenza herb/herbal components.", {"entities": [[193, 195, "Drug"]]}], [9333, "Plentiful and meaningful information was obtained in different levels and varied degrees.", {"entities": []}], [9334, "The metabolic inhibition studies performed in rat plasma suggested that all the herbal extracts (500\u202f\u03bcg/mL) and all the herbal components (100\u202f\u03bcg/mL) could inhibit the hydrolysis of OS in rat plasma, but the % inhibition rate varied between herbs/herbal components.", {"entities": [[97, 106, "Amount"], [139, 148, "Amount"], [182, 184, "Drug"]]}], [9335, "Unexpectedly, we noticed different inhibition trends for C4 and C1 in microsomes and purified enzymes (hCE1) incubation studies.", {"entities": [[57, 59, "Herb name"], [64, 66, "Herb name"], [103, 107, "Target"]]}], [9336, "C4 showed the strongest inhibition of OS hydrolysis in rat plasma, but no inhibition in microsomes and hCE1 systems.", {"entities": [[0, 2, "Herb name"], [38, 40, "Drug"], [103, 107, "Target"]]}], [9337, "Among the herbal components, herbal component C1 was the strongest inhibitor for OS hydrolysis in microsomes and hCE1 while in rat plasma it ranked behind C4, C6 and C10.", {"entities": [[46, 48, "Herb name"], [81, 83, "Drug"], [113, 117, "Target"], [155, 157, "Herb name"], [159, 161, "Herb name"], [166, 169, "Herb name"]]}], [9338, "The composition and enzymes in rat plasma are much more complex than those in microsomes and hCE1.", {"entities": [[93, 97, "Target"]]}], [9339, "Major esterases in plasma are butyrylcholinesterase (BChE), paraoxonase (PON), and carboxylesterase (CES) (Bahar et al., 2012).", {"entities": [[6, 15, "Target"], [30, 58, "Target"], [60, 77, "Target"], [83, 105, "Target"]]}], [9340, "The most abundant plasma protein is albumin, which occasionally shows hydrolyzing activity.", {"entities": [[36, 43, "Target"]]}], [9341, "Esterified compounds are hydrolyzed by these major plasma proteins via different catalytic mechanisms.", {"entities": []}], [9342, "The hydrolase activities in rat plasma may be originated from more than one kind of enzymes (not only hCE1) and the inhibition activities of these herbal components to each kind of hydrolysis enzymes are different.", {"entities": [[102, 106, "Target"]]}], [9343, "More work will be performed to clarify the inhibition mechanism of each herbal component.", {"entities": []}], [9344, "Since the data from the six in-vitro experiments have different units and intensity ranges, they cannot be compared directly.", {"entities": [[28, 48, "Study"]]}], [9345, "Our current proposed method is to first convert the raw values of each experiment to fold change (FC) of their control groups and then normalize the FC values of each experiment with z-transformation to make the results with different nature comparable between experiments.", {"entities": []}], [9346, "Fold change is a measure describing how much a quantity changes going from an initial (control) to a final value and is often used in analysis of gene expression data in microarray and RNA-Seq experiments, for measuring change in the expression level of a gene (Tusher et al., 2001).", {"entities": []}], [9347, "In our experiments, FC could be considered as the contribution of herbs/herbal components in each experiment.", {"entities": []}], [9348, "The more FC is far from one (bigger or less than 1), the more likely the studied herbs/herbal components have an HDI with OS.", {"entities": [[122, 124, "Drug"]]}], [9349, "However, FC still could not be compared between experiments due to varied FC ranges in each experiment.", {"entities": []}], [9350, "Inspired by multivariate statistical methods (Varmuza and Filzmoser, 2009), we chose z-transformation, a common normalization method, to normalize the FC values in each experiment to make them having the same distribution of N(0,1).", {"entities": []}], [9351, "After such a normalization, the absolute z-score of an herb/herbal component effect on OS would be proportional to its level of HDI relevancy with OS.", {"entities": [[87, 89, "Drug"], [147, 149, "Drug"]]}], [9352, "Thus, the sum of all the absolute z-scores for each herb/herbal component in the six in-vitro experiments would be an indicator for their HDI potential.", {"entities": [[85, 93, "Study"]]}], [9353, "Based on the in-vitro screening results, RS extract was co-administrated with OS for five days with 6 kinds of combinations.", {"entities": [[13, 31, "Study"], [41, 51, "Herb name"], [78, 80, "Drug"], [85, 94, "Duration"]]}], [9354, "It indicated that co-administration of RS extract with OS could significantly increase the systemic exposure of OS and decrease the systemic exposure of OSA, which is consisted with those observed when co-administration of CMF1 (herbal formula containing RS) with OS (Zuo et al., 2009).", {"entities": [[39, 49, "Herb name"], [55, 57, "Drug"], [112, 114, "Drug"], [153, 156, "Drug"], [223, 258, "Herb name"], [264, 266, "Drug"]]}], [9355, "The plasma samples from G1 to G6 were further evaluated on influenza virus H1N1 and H3N2.", {"entities": [[59, 88, "Target"]]}], [9356, "The herb-only groups (G4 and G5) showed no virus plaque reduction effect.", {"entities": [[43, 55, "Target"]]}], [9357, "All oseltamivir groups (G1, G2 and G3) could significantly reduce the number of plaques for virus H1N1 and H3N2, but no addition effects were observed when co-administration of OS with RS extracts.", {"entities": [[4, 15, "Drug"], [80, 111, "Target"], [177, 179, "Drug"], [185, 196, "Herb name"]]}], [9358, "The reason that interactions between OS and RS were only observed in pharmacokinetics not pharmacodynamics could be due to different time-points in our current PK and PD evaluations.", {"entities": [[37, 39, "Drug"], [44, 46, "Herb name"]]}], [9359, "For PK studies, plasma concentration data from 10 time-points were used, while only one time-point at 2.5\u202fh after oseltamivir administration were used for the PD study.", {"entities": [[114, 125, "Drug"]]}], [9360, "According to the PK profiles for G1, G2 and G3, the concentration of OSA around 2.5\u202fh were approximately calculated using the mean values of those at 2\u202fh and 3\u202fh. The calculated OSA concentrations at 2.5\u202fh for G1, G2 and G3 are 719.4\u202f\u00b1\u202f416.8, 502.8\u202f\u00b1\u202f83.7 and 460.4\u202f\u00b1\u202f143.5\u202fng/mL, respectively.", {"entities": [[69, 72, "Drug"], [178, 181, "Drug"]]}], [9361, "It showed no significant difference between any two groups for these calculated OSA concentrations in these three groups after performing a two-tailed t-test.", {"entities": [[80, 83, "Drug"]]}], [9362, "Since there was no difference on the OSA concentrations in oseltamivir treated groups and the antivirus effect mainly origins from OSA, it could be deduced that no anti-virus effects difference should be observed for these three groups.", {"entities": [[37, 40, "Drug"], [59, 70, "Drug"], [131, 134, "Drug"]]}], [9363, "We developed a model to simultaneously fit all the PK and accumulative urine concentration data from groups G1, G2 and G3 which provides several mechanistic and quantitative insights on the interaction between OS and RS as follows: PK of OS exhibited a flip-flop kinetics after oral administration as evidenced by a much slower k  BIO (absorbed fraction) and FP (fraction that escaped first-pass metabolism) were successfully estimated with the urine PK data when the intravenous PK of OS for OS only (G1) and co-administration groups (G2 and G3) are not available.", {"entities": [[210, 212, "Drug"], [217, 219, "Herb name"], [238, 240, "Drug"], [331, 354, "Parameter"], [359, 407, "Parameter"], [486, 488, "Drug"], [493, 495, "Drug"]]}], [9364, "The assumption to use urine PK to estimate BIO is that all (or majority) of the absorbed OS would be collected in urine in the form of OS or its metabolite (OSA), which has already been verified in rats and human studies (He et al., 1999).", {"entities": [[43, 46, "Parameter"], [89, 91, "Drug"], [135, 137, "Drug"], [157, 160, "Drug"], [198, 220, "Study"]]}], [9365, "The estimated BIO of OS after 5-days administration of OS in G1 is 23.6%, slightly lower than its reported oral bioavailability (35%) in rats after single dose of 10\u202fmg/kg of OS (Li et al., 1998).", {"entities": [[14, 17, "Parameter"], [21, 23, "Drug"], [24, 51, "Duration"], [55, 57, "Drug"], [107, 127, "Parameter"], [163, 171, "Amount"], [175, 177, "Drug"]]}], [9366, "Moreover, our current modeling method of integrating plasma and urine PK has an advantage of using less rats (no IV groups needed).", {"entities": []}], [9367, "As shown in Table 1, after co-administration with RS, BIO of OS increased by 62% without change in its absorption rate (k  The developed pop-PK model lets us have an interpretation on the contradictory phenomena that co-administration of RS would increase both the elimination rate and systemic exposure (AUC The pop-PK model could separately estimate the metabolic clearance (CL  A platform including a six-dimension in-vitro screening, an in-vivo pharmacokinetics in rats and an ex-vivo pharmacodynamic evaluation, has been developed and successfully applied to find RS as a potential herb that would influence the co-administrated OS in rats.", {"entities": [[50, 52, "Herb name"], [54, 57, "Parameter"], [61, 63, "Drug"], [238, 240, "Herb name"], [305, 308, "Parameter"], [418, 436, "Study"], [441, 448, "Study"], [481, 488, "Study"], [569, 571, "Herb name"], [634, 636, "Drug"]]}], [9368, "Our work sets a good example to demonstrate the feasibility and advantage of using multidisciplinary techniques including experimental science, informatics and pharmacometrics on the investigation of herb-drug interactions.", {"entities": []}], [9369, "Potential herb-drug interaction (HDI) between OS and herb/herbal components observed in the current project serve as a good platform to identify the potential interacted herbs and related mechanism for future clinical monitoring of OS during its integrative medicine practice in human subjects.", {"entities": [[46, 48, "Drug"], [232, 234, "Drug"]]}], [9370, "Our six-dimension in-vitro screening identified RS as the herb to have the most HDI potential with OS.", {"entities": [[18, 36, "Study"], [48, 50, "Herb name"], [99, 101, "Drug"]]}], [9371, "Co-administered RS could inhibit OS hydrolysis during absorption and increase the absorbed fraction of OS, which lead to the increased ratio of OS concentration versus that of OSA in both rat plasma and urine.", {"entities": [[16, 18, "Herb name"], [33, 35, "Drug"], [103, 105, "Drug"], [144, 146, "Drug"], [176, 179, "Drug"]]}], [9372, "Never the less, the anti-virus effects of OS were not influenced by co-administered RS.", {"entities": [[42, 44, "Drug"], [84, 86, "Herb name"]]}], [9373, "Radix Scutellariae (Root of Scutellaria baicalensis Georgi, Huangqin).", {"entities": [[0, 18, "Herb name"], [20, 24, "Herb part"], [28, 58, "Herb name"]]}], [9374, "Radix Isatidis (Root of Isatis indigotica Fort., Banlangen).", {"entities": [[0, 14, "Herb name"], [16, 20, "Herb part"], [24, 46, "Herb name"]]}], [9375, "Radix et Rhizoma Glycyrrhizae (Rhizome of Glycyrrhiza uralensis Fisch., Gancao).", {"entities": [[0, 29, "Herb name"], [31, 38, "Herb part"], [42, 63, "Herb name"]]}], [9376, "Fructus Forsythiae (Fruit of Forsythia suspensa (Thunb.)", {"entities": [[0, 18, "Herb name"], [20, 25, "Herb part"], [29, 47, "Herb name"]]}], [9377, "Vahl, Lianqiao).", {"entities": []}], [9378, "Flos Lonicerae Japonicae (Flower of Lonicera japonica Thunb., Jinyinhua).", {"entities": [[0, 24, "Herb name"], [26, 32, "Herb part"], [36, 53, "Herb name"]]}], [9379, "Folium Mori (Leaf of Morus alba L., Sangye).", {"entities": [[0, 11, "Herb name"], [13, 17, "Herb part"], [21, 34, "Herb name"]]}], [9380, "Herba Schizonepetae (Aerial part of Schizonepeta tenuifolia (Benth.)", {"entities": [[0, 19, "Herb name"], [21, 32, "Herb part"], [36, 59, "Herb name"]]}], [9381, "Briq., Jingjie).", {"entities": []}], [9382, "Fructus Arctii (Fruit of Arctium lappa L., Niubangzi).", {"entities": [[0, 14, "Herb name"], [16, 21, "Herb part"], [25, 41, "Herb name"]]}], [9383, "There are no conflicts of interest among the authors.", {"entities": []}], [9384, "Yufeng Zhang, Rat PK, modeling and Manuscript drafting; Chunming Lyu, In-vitro metabolic inhibition and transporter study; Sophia Fong, Transporter study; Qian Wang, Rat PK; Chenrui Li, Rat PK; Nicolas James Ho, Manuscript proof reading; Kay Sheung Chan, Experimental design and plaque reduction assays; Xiaoyu Yan, PK modeling; Zhong Zuo, Experimental design, data analyses and manuscript drafting The following are the Supplementary data to this article: This work is supported by  Supplementary data to this article can be found online at", {"entities": [[70, 121, "Study"]]}], [9385, "30%\u201370% of clinical breast cancer patients use natural products, which may increase the likelihood of drug interactions.", {"entities": [[20, 33, "Pathology"]]}], [9386, "Objective: To evaluate the evidence for the interactions between natural products and TAM in breast cancer.", {"entities": [[86, 89, "Drug"], [93, 106, "Pathology"]]}], [9387, "Methods: Electronic databases, including PubMed, CINAHL Plus (via EbscoHost), European PMC, Medline, and Google Scholar, were searched for relevant publications.", {"entities": []}], [9388, "The search terms include complementary and alternative medicine, natural products, plant products, herbs, interactions, tamoxifen, breast cancer, and their combinations.", {"entities": [[120, 129, "Drug"], [131, 144, "Pathology"]]}], [9389, "In contrast, some natural products, including Angelica sinensis (Oliv.)", {"entities": [[46, 71, "Herb name"]]}], [9390, "Diels [Apiaceae], Paeonia lactiflora Pall., Rehmannia glutinosa (Gaertn.)", {"entities": [[0, 16, "Herb name"], [18, 42, "Herb name"], [44, 73, "Herb name"]]}], [9391, "DC., Astragalus mongholicus Bunge, and Glycyrrhiza glabra L. [Fabaceae], showed estrogen-like activity, which may reduce the anti-cancer effect of TAM.", {"entities": [[0, 3, "Herb name"], [5, 33, "Herb name"], [39, 71, "Herb name"], [80, 88, "Parameter"], [125, 143, "Pathology"], [147, 150, "Drug"]]}], [9392, "However, three are limited clinical studies on the combination of natural products and TAM.", {"entities": [[27, 43, "Study"], [87, 90, "Drug"]]}], [9393, "Conclusion: There is evidence for potential interactions of various natural products with TAM in pre-clinical studies, although the relevant clinical evidence is still lacking.", {"entities": [[68, 84, "Herb name"], [90, 93, "Drug"], [97, 117, "Study"]]}], [9394, "Further studies are warranted to evaluate the potential interactions of natural products with TAM in clinical settings.", {"entities": [[72, 88, "Herb name"], [94, 97, "Drug"]]}], [9395, "Breast cancer is one of the more frequently diagnosed cancers and the leading cause of cancer deaths in women worldwide (Jemal et al., 2011).", {"entities": [[0, 13, "Pathology"], [54, 61, "Pathology"], [87, 100, "Pathology"], [104, 109, "Sex"]]}], [9396, "The latest cancer statistics in 2019 show that breast cancer accounts for around 30% of all the new cancer diagnoses in women in the United States, of which approximately 1 in 6.5 (15.5%) will die of cancer (Siegel et al., 2019).", {"entities": [[11, 17, "Pathology"], [47, 60, "Pathology"], [100, 106, "Pathology"], [120, 125, "Sex"], [200, 206, "Pathology"]]}], [9397, "According to the presence of immunohistochemistry markers, such as estrogen receptor (ER), progesterone receptor (PR), or human epidermal growth factor 2 (HER2) molecular markers, breast cancer can be classified into three main subtypes: hormone receptor-positive (ER+, PR+, HER2\u2212), HER2 positive (ER\u2212, PR\u2212, HER2+), and triple-negative breast cancer TNBC (ER\u2212, PR\u2212, HER2\u2212).", {"entities": [[29, 57, "Parameter"], [67, 89, "Parameter"], [91, 117, "Parameter"], [122, 178, "Parameter"], [180, 193, "Pathology"], [238, 372, "Pathology"]]}], [9398, "Among them, estrogen receptor-positive (ER+) breast cancer accounts for approximately 60%\u201375% of all breast cancer patients.", {"entities": [[12, 58, "Pathology"], [101, 114, "Pathology"]]}], [9399, "Adjuvant endocrine therapy is an established effective systemic treatment for most ER+ breast cancers and has become the most widely employed therapy to treat hormone receptor-positive breast cancers.", {"entities": [[0, 26, "Drug"], [83, 101, "Pathology"], [159, 199, "Pathology"]]}], [9400, "Tamoxifen (TAM) is a selective estrogen receptor modulator, acting as an estrogen antagonist in the breast while acting as an estrogen agonist in the uterus.", {"entities": [[0, 15, "Drug"], [31, 39, "Parameter"], [73, 81, "Parameter"], [126, 134, "Parameter"]]}], [9401, "TAM demonstrated clinically significant effects of reducing breast cancer recurrence rate by 40%\u201350% and could reduce the mortality and temporary remission rate after treatment and may reduce mortality and increase remission rate (Karn et al., 2010).", {"entities": [[0, 3, "Drug"], [60, 73, "Pathology"], [122, 131, "Pathology"], [192, 201, "Pathology"]]}], [9402, "However, on top of the concern for survival and growth of TAM-tolerant cells, there are adverse events (AE) associated with TAM therapy, including hot flashes, increased risk of endometrial cancer, and, in rare instances, liver abnormalities (Viedma-Rodr\u00edguez et al., 2014).", {"entities": [[58, 61, "Drug"], [88, 107, "Pathology"], [124, 135, "Drug"], [147, 196, "Pathology"], [222, 241, "Pathology"]]}], [9403, "Recently there has been an increase in studies on the anti-cancer properties of natural products (Wu et al., 2017; Lichota and Gwozdzinski, 2018) and increasing use of various natural products by cancer patients (Chen XW et al., 2011).", {"entities": [[54, 76, "Pathology"], [80, 96, "Herb name"], [176, 192, "Herb name"], [196, 202, "Pathology"]]}], [9404, "Of all the cancer patients, breast cancer patients, in particular, are more likely to turn to complementary and alternative medicine (CAM) treatment (Wanchai et al., 2010).", {"entities": [[11, 17, "Pathology"], [28, 41, "Pathology"]]}], [9405, "An Australian study found that 55% of patients using biological-based CAM and 80% of patients using nonbiological-based CAM did not discuss their use of CAM with their oncologist (Kremser et al., 2008).", {"entities": [[3, 13, "Ethnic group"]]}], [9406, "Many studies report that herbal or dietary supplements can affect various molecular targets and signaling pathways, leading to the possible use of breast cancer combination therapy (Chen et al., 2011a; Mansour et al., 2012; Oleaga et al., 2012; Pawlik et al., 2016).", {"entities": [[147, 160, "Pathology"]]}], [9407, "However, there is still a lack of evidence-based information or guidance for clinicians and consumers on the interaction between herbs and drugs used to treat and prevent cancer (Sparreboom et al., 2004).", {"entities": [[171, 177, "Pathology"]]}], [9408, "This review aimed to evaluate the evidence available from the literature on the combined use of natural or plant products and TAM in breast cancer studies and identify the current gaps and possible future studies for improving treatment strategies for breast cancer.", {"entities": [[5, 11, "Study"], [126, 129, "Drug"], [133, 146, "Pathology"], [252, 265, "Pathology"]]}], [9409, "Electronic databases, including PubMed, CINAHL Plus (via EbscoHost), European PMC, Medline, and Google Scholar, were searched for relevant publications.", {"entities": []}], [9410, "The search terms include \u201ccomplementary and alternative medicine,\u201d \u201cnatural product*,\u201d \u201cplant product*,\u201d \u201cherb*,\u201d \u201cinteraction*,\u201d \u201ctamoxifen,\u201d \u201cbreast cancer,\u201d and \u201cendoxifen\u201d and their combinations.", {"entities": [[131, 140, "Drug"], [144, 158, "Pathology"], [165, 174, "Drug"]]}], [9411, "The search results include publications from their inceptions to 2021 on the single herbs or a combination of herbs or natural products except for unpublished studies or abstracts that do not have sufficient data for analysis.", {"entities": []}], [9412, "The exclusion criteria are as follows: articles that did not analyze herb and TAM in combination or separately or comment on herb-TAM interactions; articles that included a cocktail of endocrine agents; non-English publications (not including articles with English abstracts, tables, or figures); and contribution articles such as letters, editorials, commentaries, or letters to the editor.", {"entities": [[69, 73, "Herb name"], [78, 81, "Drug"], [125, 129, "Herb name"], [130, 133, "Drug"]]}], [9413, "A total of 100 relevant articles were identified among 1,518 entries found in the literature search, including 24 pharmacokinetic studies on herbal medicines and 76 on pharmacodynamics studies.", {"entities": [[114, 137, "Study"], [168, 192, "Study"]]}], [9414, "A summary of the findings is shown in Tables 1\u20136, with Table 1 on pharmacokinetics interactions, Table 2, 3 on synergetic anti-effects, Table 4 on sensitization, Table 5 on side effects or toxicity of combined use, and Table 6 on antagonizing effects.", {"entities": [[111, 134, "Pathology"], [173, 185, "Pathology"], [189, 197, "Pathology"]]}], [9415, "Reported pharmacokinetics interactions of natural products and tamoxifen.", {"entities": [[42, 58, "Herb name"], [63, 72, "Drug"]]}], [9416, "AUC: area under the plasma concentration-time curve.", {"entities": [[0, 51, "Parameter"]]}], [9417, "C CL/F: systemic clearance.", {"entities": [[0, 27, "Parameter"]]}], [9418, "AB (%): absolute bioavailability.", {"entities": [[0, 32, "Parameter"]]}], [9419, "MR (%): metabolite-parent ratio.", {"entities": [[0, 31, "Parameter"]]}], [9420, "ECGC: epigallocatechin gallate.", {"entities": [[0, 30, "Herb name"]]}], [9421, "Reported synergetic effects of a combination of inhibiting tumor growth, inhibiting proliferation, or inducing apoptosis.", {"entities": [[59, 64, "Pathology"]]}], [9422, "JEKHT: composed of Paeonia (Paeonia lactiflora Pall.", {"entities": [[0, 52, "Herb name"]]}], [9423, "Merr.", {"entities": [[0, 5, "Herb name"]]}], [9424, "), White atractylis (Atractylodes lancea (Thunb.)", {"entities": [[3, 49, "Herb name"]]}], [9425, "DC.", {"entities": [[0, 3, "Herb name"]]}], [9426, "), R. glutinosa (Rehmannia glutinosa (Gaertn.)", {"entities": [[3, 46, "Herb name"]]}], [9427, "DC.", {"entities": [[0, 3, "Herb name"]]}], [9428, "), Dried orange peel (Citrus aurantium L.), Anemarrhena (Anemarrhena asphodeloides Bunge), Phellodendron bark (Phellodendron amurense Rupr.", {"entities": [[3, 42, "Herb name"], [44, 89, "Herb name"], [91, 139, "Herb name"]]}], [9429, "), Licorice (Glycyrrhiza glabra L.), Ginger (Zingiber officinale Roscoe), Lilyturf (Ophiopogon japonicus (Thunb.)", {"entities": [[3, 35, "Herb name"], [37, 72, "Herb name"], [74, 113, "Herb name"]]}], [9430, "Ker Gawl.", {"entities": [[0, 9, "Herb name"]]}], [9431, "), Jujube (Ziziphus jujuba Mill.)", {"entities": [[3, 33, "Herb name"]]}], [9432, "Reported evidence of reducing toxic and side effects of tamoxifen.", {"entities": [[30, 52, "Pathology"], [56, 65, "Drug"]]}], [9433, "JEKHT: composed Paeonia (Paeonia lactiflora Pall.", {"entities": [[0, 49, "Herb name"]]}], [9434, "), Korean angelica root (Angelica gigas Nakai), Asparagi Tuber (Asparagus cochinchinensis (Lour.)", {"entities": [[3, 46, "Herb name"], [48, 97, "Herb name"]]}], [9435, "Merr.", {"entities": [[0, 5, "Herb name"]]}], [9436, "), White atractylis (Atractylodes lancea (Thunb.)", {"entities": [[3, 49, "Herb name"]]}], [9437, "DC.", {"entities": [[0, 2, "Herb name"]]}], [9438, "), R. glutinosa (Rehmannia glutinosa (Gaertn.)", {"entities": [[3, 46, "Herb name"]]}], [9439, "DC.", {"entities": [[0, 2, "Herb name"]]}], [9440, "), dried orange peel (Citrus aurantium L.), Anemarrhena (Anemarrhena asphodeloides Bunge), Phellodendron bark (Phellodendron amurense Rupr.", {"entities": [[3, 42, "Herb name"], [44, 89, "Herb name"], [91, 139, "Herb name"]]}], [9441, "), Licorice (Glycyrrhiza glabra L.), Ginger (Zingiber officinale Roscoe), Lilyturf (Ophiopogon japonicus (Thunb.)", {"entities": [[3, 35, "Herb name"], [37, 72, "Herb name"], [74, 113, "Herb name"]]}], [9442, "Ker Gawl.", {"entities": [[0, 9, "Herb name"]]}], [9443, "), Jujube (Ziziphus jujuba Mill.)", {"entities": [[3, 33, "Herb name"]]}], [9444, "Reported evidence of reducing anti-cancer effects.", {"entities": [[30, 49, "Pathology"]]}], [9445, "SWT: composed of Angelica sinensis (Oliv.)", {"entities": [[0, 3, "Herb name"], [17, 42, "Herb name"]]}], [9446, "Diels [Apiaceae], Ligusticum chuanxiong Hort., Paeonia lactiflora Pall., and Radix Rehmanniae Preparata (Rehmannia glutinosa (Gaertn.)", {"entities": [[0, 16, "Herb name"], [18, 45, "Herb name"], [47, 71, "Herb name"], [77, 134, "Herb name"]]}], [9447, "DC.).", {"entities": [[0, 4, "Herb name"]]}], [9448, "BZT: consisting of Lilium brownii var.", {"entities": [[0, 3, "Herb name"], [19, 38, "Herb name"]]}], [9449, "viridulum Baker (L. brownii) and Anemarrhena asphodeloides Bunge.", {"entities": [[0, 28, "Herb name"], [33, 64, "Herb name"]]}], [9450, "TAM has a relatively lower affinity for the estrogen receptor (Brauch et al., 2009; Kim et al., 2021).", {"entities": [[0, 3, "Drug"], [44, 52, "Parameter"]]}], [9451, "After a single oral administration, the maximum plasma concentration of the parent drug and demethylated metabolites can be reached within a few hours.", {"entities": [[6, 14, "Frequency"], [36, 68, "Parameter"]]}], [9452, "Within the therapeutic margin, it is highly bound to serum proteins, which will then undergo extensive liver metabolism.", {"entities": [[53, 67, "Parameter"]]}], [9453, "Metabolism of TAM takes place mainly through two main pathways, 4-hydroxylation and N-demethylation, from which TAM is converted to primary metabolites 4-hydroxy-tamoxifen and N-desmethyl-tamoxifen (Klein et al., 2013).", {"entities": [[14, 17, "Drug"], [112, 115, "Drug"], [152, 171, "Drug"], [176, 197, "Drug"]]}], [9454, "Both primary metabolites are further converted to secondary metabolite endoxifen, catalyzed by CYP3A4/5 and CYP2D6 (Desta et al., 2004).", {"entities": [[71, 80, "Drug"], [95, 103, "Parameter"], [108, 114, "Parameter"]]}], [9455, "Endoxifen competes with estrogen and binds to ER with nearly 100 times higher affinity than TAM (Brauch et al., 2009).", {"entities": [[0, 9, "Drug"], [24, 32, "Parameter"], [46, 48, "Parameter"], [92, 95, "Drug"]]}], [9456, "It exhibits estrogenic activity by binding to ligand-regulated transcription factors ER\u03b1/ER\u03b2.", {"entities": [[12, 31, "Parameter"], [46, 92, "Parameter"]]}], [9457, "The resulting nuclear complex affects the transcription of estrogen-responsive genes, which is responsible for the production of various growth-promoting signals (Riggs and Hartmann, 2003).", {"entities": [[59, 67, "Parameter"]]}], [9458, "However, silybin, EGCG, myricetin, baicalein, curcumin, and quercetin significantly changed AUC On the contrary, studies found no interactions between certain natural products and TAM.", {"entities": [[9, 16, "Herb name"], [18, 22, "Herb name"], [24, 33, "Herb name"], [35, 44, "Herb name"], [46, 54, "Herb name"], [60, 69, "Herb name"], [92, 95, "Parameter"], [180, 183, "Drug"]]}], [9459, "For example, Ginkgo biloba L. extract is an effective herb widely used in diseases including breast cancer (Jacobs and Browner, 2000).", {"entities": [[13, 37, "Herb name"], [93, 106, "Pathology"]]}], [9460, "Fucoidan is a polysaccharide compound naturally occurring in brown algae.", {"entities": [[0, 8, "Herb name"], [14, 28, "Herb name"], [61, 72, "Herb name"]]}], [9461, "In vivo and in vitro studies have shown that fucoidan can prevent and treat breast cancer, promyelocytic leukemia, colon cancer, breast cancer, liver cancer, and melanoma (Atashrazm et al., 2015).", {"entities": [[0, 28, "Study"], [45, 53, "Herb name"], [76, 89, "Pathology"], [91, 113, "Pathology"], [115, 127, "Pathology"], [129, 142, "Pathology"], [144, 156, "Pathology"], [162, 170, "Pathology"]]}], [9462, "These results indicate that, at research, fucoidan does not interact with letrozole and TAM (Tocaciu et al., 2018).", {"entities": [[42, 50, "Herb name"], [74, 83, "Drug"], [88, 91, "Drug"]]}], [9463, "The key mechanisms of action of anti-cancer drugs involve apoptosis, autophagy, and cell cycle arrest (Chen and Karantza-Wadsworth, 2009; Wang et el., 2011; Kon et al., 2013).", {"entities": [[32, 43, "Pathology"], [58, 101, "Pathology"]]}], [9464, "In the normal state, apoptosis is a highly specific and carefully controlled programmed cell death.", {"entities": [[21, 30, "Pathology"], [88, 98, "Pathology"]]}], [9465, "Under pathological conditions, especially in cancer, cells lose their ability to induce apoptosis and proliferate uncontrollably.", {"entities": [[45, 51, "Pathology"], [88, 97, "Pathology"]]}], [9466, "In the catalytic activation of the apoptotic cascade, caspase family proteases and BCL-2 family proteins such as Bcl-2-associated X (BAX) and B-cell lymphoma 2 (Bcl-2) play an important role (Pistritto et al., 2016).", {"entities": [[31, 52, "Pathology"], [54, 78, "Parameter"], [83, 137, "Parameter"], [142, 167, "Parameter"]]}], [9467, "Programmed cell death (PCD) is not limited to apoptosis (type I) PCD but also autophagic (type II) PCD (Bursch et al., 2000).", {"entities": [[0, 27, "Pathology"], [46, 68, "Pathology"], [78, 102, "Pathology"]]}], [9468, "Regulating autophagy can also improve anti-cancer treatment (Moretti et al., 2007).", {"entities": [[11, 20, "Pathology"], [38, 49, "Pathology"]]}], [9469, "It is an important process in programmed cell death and the phagocytosis and degradation of non-essential or abnormal organelles and proteins (Denton et al., 2012).", {"entities": [[30, 51, "Pathology"], [92, 141, "Parameter"]]}], [9470, "As deregulation of the cell cycle is one of the main characteristics of cancer cells, cell cycle arrest may be an effective strategy to control the abnormal proliferation of cancer cells (Nov\u00e1k and Tyson, 2003).", {"entities": [[72, 78, "Pathology"], [174, 180, "Pathology"]]}], [9471, "Genome replication and cell division are regulated by cell cycle progression (Malumbres and Barbacid, 2009).", {"entities": []}], [9472, "The control and coordination of cell cycle progression involve cyclin-dependent kinases (CDK) and cyclins, including p53, p21, p16, and cdc25 (Malumbres and Barbacid, 2009).", {"entities": [[63, 93, "Parameter"], [98, 105, "Parameter"], [117, 141, "Parameter"]]}], [9473, "Current evidence, summarized in Tables 2, 3, reports that natural or plant products and TAM can target the physiological characteristics of cancer cells, inhibit cell proliferation, and exert anti-cancer effects via participation in the aforementioned cellular mechanisms such as apoptosis, autophagy, and cell cycle.", {"entities": [[53, 83, "Herb name"], [88, 91, "Drug"], [140, 146, "Pathology"], [192, 203, "Pathology"], [280, 289, "Pathology"], [291, 300, "Pathology"]]}], [9474, "There is also evidence of the combined use of some natural or plant products combined with TAM, in which the natural or plant products can significantly increase the sensitivity of drug-resistant cells to TAM in vitro (Table 4).", {"entities": [[51, 76, "Herb name"], [91, 94, "Drug"], [105, 134, "Herb name"], [205, 208, "Drug"]]}], [9475, "The plant flavonoid hesperidin (HES) is a natural product with obvious anti-tumor effects and is widely present in citrus fruits, piperine (PIP), and bee venom (BV) extracted from black pepper (Piper nigrum L.) and long pepper (Piper longum L.) (Park et al., 2011; Palit et al., 2015; Deng et al., 2016).", {"entities": [[0, 35, "Herb name"], [71, 89, "Pathology"], [115, 128, "Herb name"], [130, 144, "Herb name"], [150, 244, "Herb name"]]}], [9476, "A recent study has shown that the combined use of HES, PIP, and BV with TAM showed an enhanced anti-proliferative effect on MCF7 and T47D and can significantly increase cell apoptosis (Khamis et al., 2018).", {"entities": [[50, 53, "Herb name"], [55, 58, "Herb name"], [64, 66, "Herb name"], [72, 75, "Drug"], [95, 120, "Pathology"], [174, 183, "Pathology"]]}], [9477, "Furthermore, this study reports that the mRNA level of the pro-apoptotic factor BAX is upregulated, whereas the mRNA level of the anti-apoptotic protein Bcl-2 is downregulated (Khamis et al., 2018).", {"entities": [[37, 83, "Parameter"], [108, 158, "Parameter"]]}], [9478, "The combined use of tangerine with TAM exhibited a synergistic inhibitory effect on the growth of MCF-7/6 cells (Bracke et al., 1999).", {"entities": [[20, 29, "Herb name"], [35, 38, "Drug"], [84, 111, "Parameter"]]}], [9479, "Isoflavone genistein is one of the most important phytoestrogens.", {"entities": [[0, 20, "Herb name"], [50, 64, "Herb name"]]}], [9480, "When combined with TAM, it can further inhibit the proliferation of MCF-7, MDA-231, and MDA-435 cells (Tanos et al., 2002).", {"entities": [[19, 22, "Drug"], [47, 101, "Parameter"]]}], [9481, "Another study showed that the combination of genistein and TAM could further inhibit the proliferation of BT-474 cells, increase apoptosis, arrest the cell cycle in the G1 phase, and be involved in the synergistic downregulation of the expression of survivin (Mai et al., 2007).", {"entities": [[45, 54, "Herb name"], [59, 62, "Drug"], [232, 258, "Parameter"]]}], [9482, "Persin is a novel phytotoxin, which, combined with 4-hydroxytamoxifen on MCF-7 and T-47D cells, increases the sensitivity of cells to TAM, increases cell apoptosis, reduces ER\u03b1mRNA expression, and increases B-cell lymphoma 2 interacting mediator of cell death (BIM) mRNA expression (Roberts et al., 2007).", {"entities": [[0, 6, "Herb name"], [18, 28, "Herb name"], [51, 69, "Drug"], [134, 137, "Drug"], [154, 163, "Pathology"], [173, 191, "Parameter"], [207, 281, "Parameter"]]}], [9483, "When combined with TAM, it exhibits a significant synergistic inhibitory effect on MCF-7 and T-47D cell growth (Cho et al., 2010).", {"entities": [[19, 22, "Drug"], [83, 110, "Parameter"]]}], [9484, "Z-Ligustilide, a phthalate compound, is the primary active ingredient of the Chinese herbal medicine Angelica sinensis (Oliv.)", {"entities": [[0, 35, "Herb name"], [77, 84, "Ethnic group"], [101, 126, "Herb name"]]}], [9485, "Diels.", {"entities": []}], [9486, "When used in combination with TAM, it has been found to increase the growth inhibitory effect in ER\u03b1-breast cancer cells MDA-MB-231 and induce cell apoptosis and cell cycle arrest in S and G2/M phases (Ma et al., 2017).", {"entities": [[30, 33, "Drug"], [97, 100, "Parameter"], [101, 114, "Pathology"], [148, 157, "Pathology"]]}], [9487, "A combination of Z-ligustilide with TAM is also found to activate the expression and transcriptional activity of ER\u03b1 of MDA-MB-231 cells and reduce the expression of metastasis-associated protein 1 (MTA1) (Yaacob et al., 2015).", {"entities": [[17, 30, "Herb name"], [36, 39, "Drug"], [66, 116, "Parameter"], [148, 204, "Parameter"]]}], [9488, "The study also reports that the anti-cancer effect of SRS involves the downregulation of ER\u03b1 protein; however, it is independent of ER-mediated mechanism in MDA-MB-231 cells (Yaacob et al., 2014).", {"entities": [[32, 50, "Pathology"], [54, 57, "Herb name"], [89, 100, "Parameter"], [132, 135, "Parameter"]]}], [9489, "In addition to water, green tea (Camellia sinensis (L.) Kuntze [Theaceae]) is the most widely consumed beverage in the world; current studies have reported that drinking green tea can improve the prognosis of breast cancer (Nagata et al., 1998; Fujiki et al., 1999).", {"entities": [[22, 74, "Herb name"], [170, 179, "Herb name"], [209, 222, "Pathology"]]}], [9490, "The combination of the main active ingredient of green tea epigallocatechin-3-gallate (EGCG) and TAM also exhibited significant inhibition of MCF-7 cell proliferation (Sakata et al., 2011).", {"entities": [[49, 58, "Herb name"], [59, 92, "Herb name"], [97, 100, "Drug"]]}], [9491, "Mistletoe (Viscum album L.) derived medicinal preparations are widely used and registered as medicines in many European countries.", {"entities": [[0, 27, "Herb name"], [111, 119, "Ethnic group"]]}], [9492, "A clinical study on the combined use of mistletoe with the active metabolite of TAM (E/Z) endoxifen reports that clinically relevant doses of VAE did not affect the growth inhibition and cytotoxicity effect of (E/Z) endoxifen on tumor cells and could significantly induce cell cycle in the G0/G1 phase (Weissenstein et al., 2019).", {"entities": [[0, 16, "Study"], [40, 49, "Herb name"], [80, 99, "Drug"], [142, 145, "Herb name"], [187, 199, "Pathology"], [210, 225, "Drug"], [229, 234, "Pathology"]]}], [9493, "Fucoidan extract (FE) in combination with TAM has been reported with significant induction of cell growth inhibition, apoptosis, and cell cycle modification in MDA-MB-231 and MCF-7 cells (Zhang et al., 2013).", {"entities": [[0, 21, "Herb name"], [42, 45, "Drug"]]}], [9494, "Huaier, also known as Trametes robiniophila Murr., has been used as a traditional Chinese medicine in China for about 1,600\u00a0years, with its extracts documented for anti-tumor effects, including inhibition of cell proliferation, anti-metastasis, interference with tumor angiogenesis, induction of autophagic cell death, and tumor-specific immune regulation (Pan et al., 2019).", {"entities": [[0, 6, "Herb name"], [22, 49, "Herb name"], [82, 89, "Ethnic group"], [108, 129, "Duration"], [164, 182, "Pathology"], [263, 268, "Pathology"], [312, 317, "Pathology"], [323, 328, "Pathology"]]}], [9495, "Red clover, Trifolium pratense L., is a member of the legume family, used as a health food for humans, and has been extracted for various isoflavone preparations used in nutritional supplements (Vlaisavljevic et al., 2014).", {"entities": [[0, 33, "Herb name"], [50, 67, "Herb name"], [138, 161, "Herb name"]]}], [9496, "The combination of hydroethanolic extract of red clover and TAM can significantly reduce the survival of MCF-7 and MDA-MB-231 cells.", {"entities": [[19, 41, "Extraction process"], [45, 55, "Herb name"], [60, 63, "Drug"]]}], [9497, "The CI values across different dose combinations on the two cell lines were less than 1, implying that all combinations exhibited a synergistic effect (Khazaei and Pazhouhi, 2019).", {"entities": [[4, 6, "Parameter"]]}], [9498, "At the same time, the DRI value of TAM > 1 indicates that the TAM dose can be reduced under a given therapeutic effect (Khazaei and Pazhouhi, 2019).", {"entities": [[35, 38, "Drug"], [62, 65, "Drug"]]}], [9499, "HPC 03 herbal formula contains extracts of Angelica gigas Nakai, Ligusticum officinale (Makino) Kitag, and Cinnamomum cassia (L.) J. Presl.", {"entities": [[0, 21, "Herb name"], [31, 139, "Herb name"]]}], [9500, "BreastDefend Ginkgo leaf extract (GbE) is an effective herbal medicine widely used as a CAM for diseases including breast cancer (Jacobs and Browner, 2000).", {"entities": [[0, 38, "Herb name"], [96, 104, "Pathology"], [115, 128, "Pathology"]]}], [9501, "In a study adopting 7,12-dimethyl-benz(a)anthracene- (DMBA-) induced breast cancer animal model, the combined use of GbE and TAM was demonstrated to a significant reduction in the tumor area, increase in the tumor necrosis area, and reduction in the number of proliferating cell nuclear antigen- (PCNA-) positive cells (Dias et al., 2013).", {"entities": [[20, 60, "Parameter"], [69, 82, "Pathology"], [117, 120, "Herb name"], [125, 128, "Drug"], [180, 185, "Pathology"], [208, 222, "Pathology"], [260, 303, "Parameter"]]}], [9502, "In a study involving an MCF-7 cell xenograft mouse model, it was reported that the combination of green tea extract (GTE) and TAM significantly inhibit the growth and angiogenesis of tumor tissues (Sartippour et al., 2006).", {"entities": [[98, 121, "Herb name"], [126, 129, "Drug"], [183, 188, "Pathology"]]}], [9503, "Another study on the combined GTE and TAM reports a significant reduction in the number of hyperplastic alveolar nodules (HAN) and the number of argyrophilic nucleolar organization areas (AgNOR) (Sakata et al., 2011).", {"entities": [[30, 33, "Herb name"], [38, 41, "Drug"], [77, 126, "Parameter"], [131, 194, "Parameter"]]}], [9504, "BD alone can inhibit the growth and infiltration of highly metastatic triple-negative human breast cancer cells in vitro and in vivo (Jiang et al., 2011; Jiang et al., 2012).", {"entities": [[0, 2, "Herb name"], [92, 105, "Pathology"]]}], [9505, "Among all CAM products used by breast cancer patients, flaxseed (FS) is the third most commonly used (Boon et al., 2007).", {"entities": [[31, 44, "Pathology"], [55, 68, "Herb name"]]}], [9506, "When used in combination with TAM, it can effectively reduce the growth of MCF-7 breast tumors in ovariectomized (OVX) athymic mice at low circulating estrogen levels (Saggar et al., 2010).", {"entities": [[30, 33, "Drug"], [81, 94, "Pathology"], [151, 166, "Parameter"]]}], [9507, "The underlying mechanism includes ER and growth factor-signaling pathways and involves proteins such as phosphorylated mitogen-activated protein kinase, PAKT, BCL2, and angiogenesis and vascular endothelial growth factor (Saggar et al., 2010).", {"entities": [[34, 36, "Parameter"], [41, 54, "Parameter"], [104, 157, "Parameter"], [159, 164, "Parameter"], [186, 220, "Parameter"]]}], [9508, "TAM is an endocrine drug that is most commonly used to block the effects of estrogen at all stages of breast cancer, especially in postmenopausal patients.", {"entities": [[0, 3, "Drug"], [76, 84, "Parameter"], [102, 115, "Pathology"], [131, 145, "Pathology"]]}], [9509, "Therefore, in the experimental studies, many TAM-resistant cell lines were derived.", {"entities": [[14, 38, "Study"], [45, 48, "Drug"]]}], [9510, "At present, the mechanism of TAM resistance mainly includes the alteration or loss of ER expression; the activation or inactivation of various signal pathways involved in cellular processes, such as survival, proliferation, stress response, cell cycle, apoptosis inhibition regulated by the BCL-2 family, autophagy, and changes in mRNA expression (Rond\u00f3n-Lagos et al., 2016).", {"entities": [[29, 32, "Drug"], [86, 99, "Parameter"], [287, 303, "Parameter"], [331, 346, "Parameter"]]}], [9511, "A study involving the TAM-resistant cells named MCF-7 Curcumin is a bioactive compound of the Chinese medicine turmeric that exhibits effective anti-cancer activity.", {"entities": [[22, 25, "Drug"], [54, 62, "Herb name"], [94, 101, "Ethnic group"], [144, 155, "Pathology"]]}], [9512, "Curcumin and its analogs also exhibit multi-target biological effects and have been used to enhance targeted therapy to assist breast cancer chemotherapy treatment (Nagaraju et al., 2012).", {"entities": [[0, 8, "Herb name"], [100, 116, "Drug"], [127, 140, "Pathology"], [141, 163, "Drug"]]}], [9513, "A study involving the TAM-resistant cell lines named MCF-7/LCC2 and MCF-7/LCC9 reported that the combined use of curcumin and TAM resulted in synergistic growth inhibition, an increase in the sensitivity of MCF-7/LCC2 and MCF-7/LCC9 cells to TAM, and a reduction in IC  Antrodia cinnamomea (AC) is a medical mushroom that could have a novel role in breast cancer management (Lin et al., 2018).", {"entities": [[22, 25, "Drug"], [113, 121, "Herb name"], [126, 129, "Drug"], [242, 245, "Drug"], [266, 268, "Parameter"], [270, 294, "Herb name"], [349, 362, "Pathology"]]}], [9514, "In a study involving TAM-resistant cell line MCF-7 tam-R, while 10 Evn-50 is an ethyl acetate extract of Vitex negundo L. When used in combination with TAM to treat TAM-resistant MCF-7/TAM-R cells, it significantly reduces cell viability, inhibits cell growth, induces apoptosis, and reverses TAM resistance of MCF-7/TAM-R cells (Hu et al., 2012).", {"entities": [[21, 24, "Drug"], [64, 73, "Herb name"], [80, 101, "Extraction process"], [105, 121, "Herb name"], [152, 155, "Drug"], [165, 168, "Drug"], [223, 237, "Parameter"], [248, 259, "Parameter"], [293, 296, "Drug"]]}], [9515, "The study reports a decrease in phosphorylated AKT and p-MAPK44/42 levels, while total AKT and MAPK44/42 expressions were stable.", {"entities": [[32, 73, "Parameter"], [81, 116, "Parameter"]]}], [9516, "This highlights that the underlying mechanism may be related to the downregulation of AKT and MAPK signaling pathways (Hu et al., 2012).", {"entities": [[86, 89, "Parameter"], [94, 98, "Parameter"]]}], [9517, "The combined use of persin and 4-OHT on TAM-R cells showed a synergistic induction of drug-resistant cell apoptosis pre-dominantly mediated by the CHOP-dependent endoplasmic reticulum stress (ERS) signaling cascades (McCloy et al., 2013).", {"entities": [[20, 26, "Herb name"], [31, 36, "Drug"], [40, 43, "Drug"], [147, 151, "Parameter"]]}], [9518, "Jaeumkanghwa soup (JEKHT) is a compound composed of 12 traditional herbs (Jung et al., 2010).", {"entities": [[0, 25, "Herb name"]]}], [9519, "All the above evidence shows that natural or plant products can increase the sensitivity of drug-resistant cell lines to TAM.", {"entities": [[73, 88, "Parameter"], [121, 124, "Drug"]]}], [9520, "On the contrary, some studies showed no significant interactions between TAM and certain natural products.", {"entities": [[73, 76, "Drug"]]}], [9521, "In ovariectomized athymic mice with established MCF-7 that had only TAM implanted, increased biomechanical bone strength and bone mineral content (BMC) and density (BMD) in the femur and lumbar spine were reported (Chen et al., 2011b).", {"entities": [[68, 71, "Drug"], [93, 120, "Parameter"], [125, 151, "Parameter"], [156, 169, "Parameter"]]}], [9522, "In the mice group receiving a combination of SDG and FO diet with TAM therapy, no effects on the BMC and BMD of the femur or vertebrae were reported, indicating that the combined use of FS and TAM exhibited no obvious effect on bone health (Chen et al., 2011b).", {"entities": [[45, 48, "Herb name"], [66, 69, "Drug"], [93, 100, "Parameter"], [105, 108, "Parameter"], [186, 188, "Herb name"], [193, 196, "Drug"]]}], [9523, "Jiawei Xiaoyao San (JWXYS) is a very common Chinese herbal formula used by the Chinese for thousands of years (Chen et al., 2014).", {"entities": [[0, 26, "Herb name"], [44, 51, "Ethnic group"], [79, 86, "Ethnic group"], [87, 109, "Duration"]]}], [9524, "In MCF-7 cells, a study reports no statistically significant difference between TAM only and combined JWXYS with TAM groups in terms of cell number, cell cycle progression, and cell proliferation signal proteins such as AKT, ERK, P38, p27 (Kip1), and light chain (LC3) I, II (Chen et al., 2014).", {"entities": [[80, 83, "Drug"], [102, 107, "Herb name"], [113, 116, "Drug"], [177, 245, "Parameter"]]}], [9525, "A study utilizing uterotrophic assay in 21-day immature female SD rats reports that the combined use of EGb 761 and TAM showed no significant effect on absolute or relative uterine weight, luminal epithelial cell height (LECH), and luminal circumference (LCO), indicating that EGB761 has no agonism nor antagonism on utero (Moon et al., 2018).", {"entities": [[40, 46, "Age"], [56, 62, "Sex"], [104, 111, "Herb name"], [116, 119, "Drug"], [173, 187, "Parameter"], [189, 226, "Parameter"], [232, 259, "Parameter"], [277, 283, "Herb name"]]}], [9526, "Although the use of TAM as an adjuvant endocrine therapy has effectively reduced the recurrence of ER+ breast patients and improved their survival rate, more and more studies have reported a series of side effects related to TAM that include hot flashes, night sweats, vaginal dryness, sleep, and emotional problems (Lorizio et al., 2012).", {"entities": [[20, 23, "Drug"], [27, 56, "Drug"], [99, 109, "Pathology"], [201, 213, "Pathology"], [225, 228, "Drug"], [242, 315, "Pathology"]]}], [9527, "Occasionally, more severe adverse events may occur, including endometrial cancer (Fisher et al., 1994; Kloos et al., 2002) and abnormal liver function (Yang et al., 2013).", {"entities": [[26, 40, "Pathology"], [62, 80, "Pathology"], [127, 150, "Pathology"]]}], [9528, "However, some natural or plant products can reduce the side effects of TAM, as shown in Table 5.", {"entities": [[55, 67, "Pathology"], [71, 74, "Drug"]]}], [9529, "A clinical observation study assessing the effect of Actaea racemosa L. [Ranunculaceae] (CR BNO 1055) and TAM combination on the number and intensity of hot flashes found that the number and severity of hot flashes decreased in patients after 12 months of combined use (Hern\u00e1ndez Mu\u00f1oz & Pluchino, 2003).", {"entities": [[0, 28, "Study"], [53, 101, "Herb name"], [106, 109, "Drug"], [153, 164, "Pathology"], [203, 214, "Pathology"]]}], [9530, "Only 24.4% of the patients in the group receiving combined therapy reported severe hot flashes, while 73.9% of the patients in the control group reported severe hot flashes, showing that the combination of TAM and CR BNO 1055 for 12 months can provide a satisfactory reduction of the number and severity of hot flashes (Hern\u00e1ndez Mu\u00f1oz & Pluchino, 2003).", {"entities": [[76, 94, "Pathology"], [154, 172, "Pathology"], [206, 209, "Drug"], [214, 225, "Herb name"], [226, 239, "Duration"], [307, 318, "Pathology"]]}], [9531, "In retrospective study of all breast cancer patients who received TAM treatment in the Taiwan Health Insurance Research Database between 1 January 1998 and 31 December 2008, it was found that among breast cancer survivors aged 20\u201379, the risk of endometrial cancer in patients treated with Angelica sinensis (Oliv.)", {"entities": [[30, 43, "Pathology"], [66, 69, "Drug"], [129, 172, "Duration"], [198, 211, "Pathology"], [227, 232, "Age"], [246, 264, "Pathology"], [290, 314, "Herb name"]]}], [9532, "Diels is lower when compared with patients who have never used Angelica sinensis (Oliv.)", {"entities": [[0, 5, "Herb name"], [63, 88, "Herb name"]]}], [9533, "Diels (HR: 0.61, 95% CI: 0.44\u20130.84) (Wu et al., 2014).", {"entities": [[0, 5, "Herb name"], [7, 9, "Parameter"], [11, 20, "Amount"], [21, 23, "Parameter"], [25, 34, "Amount"]]}], [9534, "Two of the most commonly used CHPs are Jiawei Xiaoyao San and Shujing Huoxue Decoction (Tsai et al., 2014).", {"entities": [[30, 34, "Herb name"], [39, 57, "Herb name"], [62, 86, "Herb name"]]}], [9535, "Compared with non-CHP users, the risk ratio for the development of endometrial cancer among CHP users was 0.50 (95% CI = 0.38\u20130.64) (Tsai et al., 2014).", {"entities": [[18, 21, "Herb name"], [67, 85, "Pathology"], [92, 95, "Herb name"]]}], [9536, "The above results indicate that the combination of natural or plant products with TAM may reduce the risk of endometrial cancer after breast cancer.", {"entities": [[51, 76, "Herb name"], [82, 85, "Drug"], [109, 127, "Pathology"], [134, 147, "Pathology"]]}], [9537, "JEKHT is a compound consisting of 12 traditional herbs (Jung et al., 2010).", {"entities": [[0, 5, "Herb name"]]}], [9538, "In a study adopting DMBA-induced ER+ breast cancer rat model, it was reported that the combined treatment of JEKHT with TAM can reduce risk of recurrence and developing TAM resistance, prevent the development of precancerous endometrial lesions, and prevent the immunosuppressive effects of TAM (De Oliveira Andrade et al., 2019).", {"entities": [[20, 24, "Parameter"], [33, 50, "Pathology"], [109, 114, "Herb name"], [120, 123, "Drug"], [169, 172, "Drug"], [212, 244, "Pathology"], [262, 287, "Pathology"], [291, 294, "Drug"]]}], [9539, "When compared with the TAM-only group, the combination of JEKHT and TAM significantly downregulated Il-6, Foxp3/T regulatory cell (Treg) markers, and Tgf\u03b21 that activate Treg (De Oliveira Andrade et al., 2019).", {"entities": [[23, 26, "Drug"], [58, 63, "Herb name"], [68, 71, "Drug"], [100, 104, "Parameter"], [106, 111, "Parameter"], [112, 144, "Parameter"], [150, 155, "Parameter"], [170, 174, "Target"]]}], [9540, "In TAM-intoxicated rats, a study found significantly increased levels of serum glutamic-oxaloacetic transaminase (sGOT), serum glutamic-pyruvic transaminase (sGPT), alkaline phosphatase (ALP), triglycerides (TG), cholesterol, urea, uric acid, bilirubin, and creatinine.", {"entities": [[3, 6, "Drug"], [73, 119, "Parameter"], [121, 163, "Parameter"], [165, 191, "Parameter"], [193, 211, "Parameter"], [213, 224, "Parameter"], [226, 230, "Parameter"], [232, 241, "Parameter"], [243, 252, "Parameter"], [258, 268, "Parameter"]]}], [9541, "The study proposed that the change in parameters may be related to extensive liver damage during TAM treatment (Rahate and Rajasekaran, 2015).", {"entities": [[67, 89, "Pathology"], [97, 100, "Drug"]]}], [9542, "Desmostachya bipinnata (L.) Stapf (PFDB) is used in Indian traditional medicine and is commonly called \u201csacrificial grass\u201d in English (Rahate and Rajasekaran, 2015).", {"entities": [[0, 40, "Herb name"], [52, 58, "Ethnic group"], [104, 121, "Herb name"]]}], [9543, "The study reported that rats pre-treated with PFDB were effectively protected from TAM-induced hepatotoxicity.", {"entities": [[46, 50, "Herb name"], [83, 86, "Drug"], [95, 109, "Pathology"]]}], [9544, "Reduced levels of the liver function test parameters, as discussed above, in serum were detected in these rats.", {"entities": [[8, 52, "Parameter"]]}], [9545, "Degree of liver cell necrosis was observed in these rats in histopathological studies (Rahate and Rajasekaran, 2015).", {"entities": [[0, 29, "Parameter"], [60, 85, "Study"]]}], [9546, "The protective effect is dose-dependent (Rahate and Rajasekaran, 2015).", {"entities": [[4, 21, "Pathology"]]}], [9547, "GTE also show hepatoprotective effect against TAM-induced liver injury in rats.", {"entities": [[0, 3, "Herb name"], [14, 37, "Pathology"], [46, 49, "Drug"], [58, 70, "Pathology"]]}], [9549, "Rats treated with TAM showed elevated aminotransaminase, carbonyl groups (CGs), and 8-hydroxydeoxyguanosine (8OHdG) (Codo\u00f1er-Franch et al., 2013).", {"entities": [[18, 21, "Drug"], [38, 55, "Parameter"], [57, 78, "Parameter"], [84, 115, "Parameter"]]}], [9550, "Baill.", {"entities": [[0, 6, "Herb name"]]}], [9551, "(Kim et al., 1999).", {"entities": []}], [9552, "Oxidative stress status of TAM-intoxicated liver injury in rats is determined by the change in levels of antioxidant enzymes (glutathione-S-transferase, glutathione peroxidase, and catalase), glutathione, TBARS, liver transaminase, sGPT, and sGOT (El-Beshbishy, 2005a).", {"entities": [[0, 16, "Pathology"], [27, 30, "Drug"], [43, 55, "Pathology"], [95, 246, "Parameter"]]}], [9553, "DDB is found to alleviate the oxidative stress status of TAM-intoxicated liver injury in rats, with the study reporting a significant increase in antioxidant enzymes, a significant decrease in the activity of sGPT and sGOT, reduction of glutathione concomitant, and a significant reduction of TBARS and liver transaminases (El-Beshbishy, 2005b).", {"entities": [[0, 3, "Herb name"], [26, 46, "Pathology"], [57, 60, "Drug"], [73, 85, "Pathology"], [146, 165, "Parameter"], [193, 222, "Parameter"], [237, 260, "Parameter"], [293, 298, "Parameter"], [303, 322, "Parameter"]]}], [9554, "There is growing evidence on the potential benefits of complementary and alternative medicine usage in treatment of cancer (Horneber et al., 2012).", {"entities": [[116, 122, "Pathology"]]}], [9555, "Prevalence rate of CAM usage among breast cancer survivor was reported to fall within 60-70%; with herbal preparations, vitamin and diet supplements being the more common CAM products used (Matthews et al., 2007).", {"entities": [[35, 48, "Pathology"], [99, 148, "Herb name"]]}], [9556, "In vivo Xanthorrhizol is a sesquiterpene compound isolated from turmeric and has been reported to have antimicrobial, antibacterial, anti-metastatic, and anti-inflammatory effects (Oon et al., 2015).", {"entities": [[8, 72, "Herb name"], [103, 179, "Pathology"]]}], [9557, "Si-Wu-Tang (SWT) is a Chinese herbal medicine composition consisting of Angelica sinensis (Oliv.)", {"entities": [[0, 16, "Herb name"], [22, 29, "Ethnic group"], [72, 97, "Herb name"]]}], [9558, "Diels, Paeonia lactiflora Pall., Ligusticum striatum DC., and Rehmannia glutinosa (Gaertn.)", {"entities": [[0, 91, "Herb name"]]}], [9559, "DC.", {"entities": [[0, 2, "Herb name"]]}], [9560, "(Chen et al., 2013).", {"entities": []}], [9561, "The combination of SWT and TAM also increased protein expressions of ERK, AKT, P38, and p27 (Kip1), which could indicate the phytoestrogenic effect of SWT that could contribute to adverse effects when SWT interacts with TAM in the body (Chen et al., 2013) Baihe Zhimu Tang (BZ) is a traditional Chinese medicine formula that consists of Lilium brownii var.", {"entities": [[19, 22, "Herb name"], [27, 30, "Drug"], [46, 98, "Parameter"], [121, 147, "Pathology"], [151, 154, "Herb name"], [180, 195, "Pathology"], [201, 204, "Herb name"], [220, 223, "Drug"], [256, 276, "Herb name"], [295, 302, "Ethnic group"], [337, 356, "Herb name"]]}], [9562, "viridulum Baker and Anemarrhena asphodeloides Bunge, often used to treat depression (Li et al., 2019).", {"entities": [[0, 15, "Herb name"], [20, 51, "Herb name"], [73, 83, "Pathology"]]}], [9563, "This evidence reports adverse effects that occur between the interaction of certain herbal or plant products with TAM that doctors and patients should pay attention to during treatment of ER+ breast cancer.", {"entities": [[22, 37, "Pathology"], [114, 117, "Drug"], [188, 205, "Pathology"]]}], [9564, "This review has covered the potential interactions of TAM with 33 commonly used natural or plant products and 5 commonly used herbal formulas.", {"entities": [[5, 11, "Study"], [54, 57, "Drug"], [91, 105, "Herb name"], [126, 141, "Herb name"]]}], [9565, "However, there are also studies that report no effect or adverse effects when certain natural or plant products are combined with TAM.", {"entities": [[57, 72, "Pathology"], [97, 111, "Herb name"], [130, 133, "Drug"]]}], [9566, "While there are significant discoveries and advancements in the study of drug combinations, there are still limitations in the experimental design of some studies.", {"entities": []}], [9567, "Firstly, while most in vitro studies adopted single cell line models, in vitro tumor environments tend to be vastly different, limiting the relevance of the research evidence.", {"entities": [[20, 36, "Study"], [79, 84, "Pathology"]]}], [9568, "Secondly, studies on the mechanism of synergistic anti-tumor effect need to be further elucidated, particularly on contributions by different signaling pathways.", {"entities": [[50, 67, "Pathology"]]}], [9569, "Table 7 includes some of the phytochemicals that have been investigated in the selected reviewed studies.", {"entities": [[29, 43, "Herb name"]]}], [9570, "Studies have shown that just the monitoring of protein expression levels is insufficient in understanding transcription activity in vitro (Gord\u00e2n et al., 2009).", {"entities": [[47, 72, "Parameter"]]}], [9571, "Chemical structures of TAM, phytochemicals mentioned in the review.", {"entities": [[23, 26, "Drug"], [28, 42, "Herb name"], [56, 66, "Study"]]}], [9572, "IUPAC, name, and chemical structures are retrieved from National Center for Biotechnology Information (2022).", {"entities": []}], [9573, "Additionally, there are still issues relating to herbal formulations and their composition that is often unaddressed, such as the clarification of herbal formula composition and quality control of herbal products.", {"entities": []}], [9574, "Moreover, in studies that investigate herbal formulations or plant extracts, there is increased complexity in the determination of which combinations of compounds are producing the observed additive, synergistic, or antagonistic effects.", {"entities": []}], [9575, "Natural or plant products have been used in clinical practice for thousands of years, with numerous modern-day studies reporting the anti-cancer effects of such herbal medicines and compounds.", {"entities": [[62, 84, "Duration"], [129, 152, "Pathology"]]}], [9576, "While continuous efforts in scientific and laboratory investigations of individual herbal and herbal compositions in breast cancer treatment have given rise to various evidence from the derivation of major anti-cancer components and especially evaluation of effects from combination with conventional breast cancer treatment drugs, it is necessary to conduct further research and review them systematically, in particular, clinical studies to verify the herb\u2013drug interactions.", {"entities": [[117, 130, "Pathology"], [206, 217, "Pathology"], [301, 314, "Pathology"], [423, 439, "Study"]]}], [9577, "In this regard, cooperation between medical doctors, traditional Chinese medicine practitioners, and allied health practitioners that use herbal products to monitor and evaluate the use of natural or plant products in patients receiving TAM endocrine treatment for breast cancer is important to ensure the effectiveness of the treatments and the safety of patients.", {"entities": [[65, 72, "Ethnic group"], [237, 240, "Drug"], [265, 278, "Pathology"]]}], [9578, "Such efforts, including further research, are critical for the integration of the scientific evidence into clinical practice to guide the use of natural or plant products and anti-cancer drugs such as TAM for better care of breast cancer patients.", {"entities": [[175, 186, "Pathology"], [201, 204, "Drug"], [224, 237, "Pathology"]]}], [9579, "CY and FZ wrote the draft manuscript.", {"entities": []}], [9580, "FZ, CY, ZY, and XZ searched the related literature.", {"entities": []}], [9581, "CL guided the writing and critically revised the manuscript.", {"entities": []}], [9582, "All authors have read and approved the manuscript.", {"entities": []}], [9583, "The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.", {"entities": []}], [9584, "All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations or those of the publisher, the editors, and the reviewers.", {"entities": []}], [9585, "Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.", {"entities": []}], [9586, " Edited by:   Reviewed by:    This article was submitted to Drug Metabolism and Transport, a section of the journal Frontiers in Pharmacology  Background: Combination of Polygonum capitatum Buch.-Ham.", {"entities": []}], [9587, "ex D. Don extract (PCE) and ciprofloxacin (CIP) was commonly prescribed in the treatment of urinary tract infections.", {"entities": [[3, 23, "Herb name"], [28, 47, "Drug"], [92, 116, "Pathology"]]}], [9588, "Their pharmacokinetic herb-drug interactions (HDIs) were focused in this study to assess potential impact on the safety and effectiveness.", {"entities": []}], [9589, "Methods: A randomized, three-period, crossover trial was designed to study the pharmacokinetic HDI between PCE and CIP in healthy humans.", {"entities": [[9, 52, "Study"], [107, 110, "Herb name"], [115, 118, "Drug"]]}], [9590, "Their pharmacokinetic- and tissue distribution-based HDIs were also evaluated in rats.", {"entities": []}], [9591, "Gallic acid (GA) and protocatechuic acid (PCA) were chosen as PK-markers of PCE in humans and rats.", {"entities": [[0, 16, "Herb name"], [21, 46, "Herb name"], [76, 79, "Herb name"]]}], [9592, "Potential drug interaction mechanisms were revealed by assessing the effects of PCE on the activity and expression of multiple transporters, including OAT1/3, OCT2, MDR1, and BCRP.", {"entities": [[80, 83, "Herb name"], [151, 157, "Target"], [159, 163, "Target"], [165, 169, "Target"], [175, 179, "Target"]]}], [9593, "Results: Concurrent use of PCE substantially reduced circulating CIP (approximately 40%\u201350%) in humans and rats, while CIP hardly changed circulating GA and PCA.", {"entities": [[27, 30, "Herb name"], [65, 68, "Drug"], [119, 122, "Drug"], [150, 152, "Herb name"], [157, 160, "Herb name"]]}], [9594, "PCE significantly increased the tissue distribution of CIP in the prostate and testis of rats, but decreased in liver and lungs.", {"entities": [[0, 3, "Herb name"], [55, 58, "Drug"]]}], [9595, "Meanwhile, CIP significantly increased the tissue distribution of GA or PCA in the prostate and testis of rats, but decreased in kidney and heart.", {"entities": [[11, 14, "Drug"], [66, 68, "Herb name"], [72, 75, "Herb name"]]}], [9596, "In the transporter-mediated in vitro HDI, GA and PCA presented inhibitory effects on OAT1/3 and inductive effects on MDR1 and BCRP.", {"entities": [[42, 44, "Herb name"], [49, 52, "Herb name"], [85, 91, "Target"], [117, 121, "Target"], [126, 130, "Target"]]}], [9597, "Conclusion: Multiple transporter-mediated HDI contributes to effects of PCE on the reduced systemic exposure and altered tissue distribution of CIP.", {"entities": [[72, 75, "Herb name"], [144, 147, "Drug"]]}], [9598, "More attention should be paid on the potential for PCE-perpetrated interactions.", {"entities": [[51, 54, "Herb name"]]}], [9599, "Communicable diseases are still leading causes of death and disability globally, according to WHO\u2019s Global Health Estimates 2000\u20132019 (GBD Diseases and Injuries, 2020).", {"entities": [[0, 21, "Pathology"]]}], [9600, "Antibiotics present a vital role in universal health insurance and global health protection.", {"entities": [[0, 11, "Drug"]]}], [9601, "However, the clinical pipeline and recently approved antibiotics are insufficient to tackle the challenge of increasing emergence and spread of antimicrobial resistance.", {"entities": [[53, 64, "Drug"]]}], [9602, "In recent years, traditional Chinese medicine (TCM)-based herbal therapies have been widely used to treat infectious diseases and solve the problem of microbial resistance.", {"entities": [[29, 36, "Ethnic group"], [106, 125, "Pathology"]]}], [9603, "In particular, since the outbreak of COVID-19, TCM has fully participated in the prevention, control and treatment of the epidemic and made important contributions (Huang et al., 2021).", {"entities": [[37, 45, "Pathology"]]}], [9604, "According to the WHO Expert Meeting on Evaluation of TCM in the Treatment of COVID-19, WHO encouraged Member States to consider the integrated traditional Chinese and Western medicine model (WHO, 2022).", {"entities": [[77, 85, "Pathology"]]}], [9605, "Polygonum capitatum Buch.-Ham.", {"entities": [[0, 29, "Herb name"]]}], [9606, "ex D. Don (P. capitatum), a Chinese herbal plant, is often used alone or in combination with antibacterial agents to treat urinary tract infections, pyelonephritis, and prostatitis in China (Chinese Pharmacopoeia Commission, 2010; Liao et al., 2011).", {"entities": [[0, 24, "Herb name"], [28, 35, "Ethnic group"], [93, 113, "Drug"], [123, 147, "Pathology"], [149, 163, "Pathology"], [169, 180, "Pathology"], [191, 198, "Ethnic group"]]}], [9607, "Relinqing Gallic acid (GA) and protocatechuic acid (PCA) were identified as appropriate pharmacokinetic markers (PK-markers) of P. capitatum because of their extensive pharmacological activities, high systemic exposures, and acceptable pharmacokinetic properties.", {"entities": [[0, 26, "Herb name"], [31, 56, "Herb name"], [128, 140, "Herb name"]]}], [9608, "Specifically, they are the two most abundant phenolic acids in P. capitatum (Liao et al., 2013; Zhang et al., 2013a; Zhang et al., 2013b; Li et al., 2021b), and their anti-microbial, anti-inflammatory, anti-oxidant, and analgesic activities associated with P. capitatum efficacy (Liao et al., 2011; Khan et al., 2015; Choubey et al., 2018; Song et al., 2020; Bai et al., 2021).", {"entities": [[63, 75, "Herb name"], [257, 269, "Herb name"]]}], [9609, "The qualitative and quantitative analysis of PCE systemic exposure showed that GA and PCA possess a relatively high exposure in rats (Ma et al., 2015, 2016; Huang et al., 2019; Guan et al., 2022) and humans (Li et al., 2021b).", {"entities": [[45, 48, "Herb name"], [79, 81, "Herb name"], [86, 89, "Herb name"]]}], [9610, "After oral administration of PCE, GA and PCA underwent a rapid absorption (Ma et al., 2015; Li et al., 2021b), a dose-dependent profile (Ma et al., 2015), and a relatively targeted distribution in kidney tissue (Ma et al., 2016).", {"entities": [[29, 32, "Herb name"], [34, 36, "Herb name"], [41, 44, "Herb name"]]}], [9611, "Consequently, GA and PCA were chosen as PCE tracer components in the pharmacokinetic- and tissue distribution-based HDIs studies.", {"entities": [[14, 16, "Herb name"], [21, 24, "Herb name"], [40, 43, "Herb name"]]}], [9612, "Ciprofloxacin (CIP) was selected as a representative fluoroquinolone agent in this study because 1) it is a commonly used antibiotic in the treatment of urinary system diseases alone or in combination (Bonkat et al., 2022), and 2) it is cleared by active tubular secretion and intestinal excretion (H\u00f6ffken et al., 1985; Rohwedder et al., 1990; Vance-Bryan et al., 1990).", {"entities": [[0, 19, "Drug"], [53, 68, "Drug"], [122, 132, "Drug"]]}], [9613, "CIP\u2019s absolute bioavailability is approximately 70%, with no substantial loss by first pass metabolism, and its metabolites together account for approximately 10% of an oral dose (Vance-Bryan et al., 1990).", {"entities": [[0, 3, "Drug"], [15, 30, "Parameter"]]}], [9614, "Renal clearance of CIP accounts for 2/3 of its total clearance and exceeds the normal glomerular filtration rate, suggesting that active tubular secretion may play a role (H\u00f6ffken et al., 1985; Mulgaonkar et al., 2012).", {"entities": [[0, 15, "Parameter"], [19, 22, "Drug"], [86, 112, "Parameter"]]}], [9615, "Approximately 20% of an intravenous dose of CIP is eliminated into the intestine (Rohwedder et al., 1990; Haslam et al., 2011).", {"entities": [[44, 47, "Drug"]]}], [9616, "Approximately 60% of CIP is excreted in unchanged form into the urine (Vance-Bryan et al., 1990).", {"entities": [[21, 24, "Drug"]]}], [9617, "At physiological pH = 7.4, CIP predominantly exists as a zwitterion indicating that both anion and cation transporters may contribute to its excretion (Vanwert et al., 2008; Haslam et al., 2011; Arakawa et al., 2012; Mulgaonkar et al., 2012).", {"entities": [[27, 30, "Drug"]]}], [9618, "Stably expressing cell lines of hOAT1-MDCK, hOAT3-MDCK, hOCT2-S2, hMDR1-MDCK, hBCRP-MDCK, and their mock cells were obtained from Japan Fuji Biomedical Co., Ltd.", {"entities": []}], [9619, "The cells were maintained in DMEM (Sigma) supplemented with 10% FCS, 1% non-essential amino acids (Sigma), and 2% L-glutamine.", {"entities": []}], [9620, "The medium for the Transwell Briefly, the hOAT1-MDCK, hOAT3-MDCK, and hOCT2-S2 cells were trypsinized and suspended in the culture medium to provide a density of 1.5 \u00d7 10 A bidirectional assay in Caco-2 cells is a preferred method to determine whether an investigational drug is a substrate for P-gp/BCRP or whether an investigational drug is an inhibitor of P-gp/BCRP (US FDA, 2020).", {"entities": []}], [9621, "CIP is a known substrate of the ATP-binding cassette transporters, which have been implicated in its intestinal secretion, biliary excretion and secretion into breast milk (Vance-Bryan et al., 1990; Merino et al., 2006; Ando et al., 2007; Mulgaonkar et al., 2012).", {"entities": [[0, 3, "Drug"]]}], [9622, "Overall, drug transporter-mediated HDIs were assessed to reveal the altered systemic exposure and tissue distribution of CIP after combined treatment with PCE in this study.", {"entities": [[76, 93, "Parameter"], [121, 124, "Drug"], [155, 158, "Herb name"]]}], [9623, "Male Sprague-Dawley rats weighing 200\u2013220\u00a0g were purchased from HFK Bioscience Co., Ltd. (SCXK 2019\u20130008, Beijing, China).", {"entities": []}], [9624, "All of the experimental procedures were carried out according to the Guidance for Ethical Treatment of Laboratory Animals.", {"entities": []}], [9625, "Approval for this study was granted by the Institutional Animal Care and Use Committee of Tianjin University of Traditional Chinese Medicine.", {"entities": [[124, 131, "Ethnic group"]]}], [9626, "All animals were housed at the individually ventilated cages (three rats per cage) in a temperature-controlled room under a 12-h light/dark cycle.", {"entities": []}], [9627, "Water and food were supplied ad libitum and the rats were fasted only with free access to water for 12\u00a0h prior to experiment.", {"entities": []}], [9628, "In the pharmacokinetic-HDI study, eighteen rats were randomly assigned to three experimental groups (n = 6 per group).", {"entities": [[7, 32, "Study"]]}], [9629, "Rats in the PCE, CIP, and PCE + CIP groups were orally given a single dose of PCE (0.72\u00a0g/kg, comparable to a clinical dose of 8\u00a0g Relinqing In the tissue distribution-HDI study, thirty-six rats were randomly assigned to three experimental groups (n = 12 per group).", {"entities": [[12, 15, "Herb name"], [17, 20, "Drug"], [26, 29, "Herb name"], [32, 35, "Drug"], [61, 74, "Frequency"], [78, 81, "Herb name"], [83, 92, "Amount"], [148, 177, "Study"]]}], [9630, "Rats in the PCE, CIP, and PCE + CIP groups were given a single dose of PCE (0.72\u00a0g/kg, comparable to a clinical dose of 8\u00a0g Relinqing Considering the relative exposure characteristics, GA and PCA were selected as PK-marker and Q-marker components of PCE in previous studies (Ma et al., 2015; Ma et al., 2016; Li et al., 2021b).", {"entities": [[12, 15, "Herb name"], [17, 20, "Drug"], [26, 29, "Herb name"], [32, 35, "Drug"], [56, 67, "Frequency"], [76, 85, "Amount"], [120, 123, "Amount"], [185, 187, "Herb name"], [192, 195, "Herb name"], [250, 253, "Herb name"]]}], [9631, "In this study, we investigated the concentration-dependent inhibitions of GA and PCA on multiple transporters, including OAT1, OAT3, OCT2, MDR1, and BCRP.", {"entities": [[74, 76, "Herb name"], [81, 84, "Herb name"], [121, 125, "Target"], [127, 131, "Target"], [133, 137, "Target"], [139, 143, "Target"], [149, 153, "Target"]]}], [9632, "The Caco-2 cell lines were obtained from the National Collection of Authenticated Cell Cultures (NCACC, Shanghai, China).", {"entities": []}], [9633, "The bi-directional transport assay was performed on 12-mm Transwell Permeable Supports with 0.4\u00a0mm-pore polycarbonate membrane insert and 1.12\u00a0cm Caco-2 cells induced with the positive control or tested drugs were then incubated in a 37\u00b0C incubator with 5% CO The tissue samples were homogenized using a tissue homogenizer (JXFSTPRP-24, Shanghaijingxin Experimental Technology, Shanghai, China) in physiological saline solution (1:4, w/v).", {"entities": []}], [9634, "The analytes and internal standards were extracted from tissue homogenates and plasma samples by a simple protein precipitation method.", {"entities": []}], [9635, "Briefly, an aliquot of 100\u00a0\u03bcl biological samples, 5\u00a0\u03bcl internal standard solutions, and 300\u00a0\u03bcl acetonitrile were vortex-mixed for 3\u00a0min and then centrifuged at 14,000\u00a0rpm for 10\u00a0min.", {"entities": []}], [9636, "The residues were reconstituted with 100\u00a0\u03bcl of 20% acetonitrile solution, vortex-mixed for 1\u00a0min, and centrifugated at 14,000\u00a0rpm for 10\u00a0min.", {"entities": []}], [9637, "Samples were analyzed using a Waters ACQUITY\u2122 ultra performance liquid chromatography system (Waters Corp., Milford, MA, United States) equipped with an QTRAP5500 triple-quadrupole mass spectrometer (SCIEX, Framingham, MA, United States) and an electrospray source.", {"entities": []}], [9638, "Data acquisition was controlled by Analyst 1.7.2 software (SCIEX, Concord, ON, Canada).", {"entities": []}], [9639, "Chromatographic separation of GA and PCA was achieved on an ACQUITY UPLC BEH C18 (2.1\u00a0mm \u00d7 100\u00a0mm, 1.7\u00a0\u00b5m; Waters Corp., Milford, MA, United States) with a mobile phase of (A) 0.1% formic acid aqueous solution and (B) 0.1% formic acid acetonitrile at a flow rate of 0.3\u00a0ml/min.", {"entities": [[30, 32, "Herb name"], [37, 40, "Herb name"]]}], [9640, "The gradient elution program was as follows: 0\u20138.5\u00a0min, 97% A; 8.7\u201311\u00a0min, 60% A; 11.5\u201313.5\u00a0min, 10% A; 14\u201315\u00a0min, 97% A.", {"entities": []}], [9641, "The quantitation of GA and PCA was performed using multiple reaction monitoring (MRM) mode with an electron spray ionization (ESI) source in negative-ionization mode.", {"entities": [[20, 22, "Herb name"], [27, 30, "Herb name"]]}], [9642, "The precursor-product ion transitions of GA, PCA, and chloramphenicol (internal standard) were 169.0\u2192125.1, 153.1\u2192109.0, and 321.1\u2192152.1, respectively.", {"entities": [[41, 43, "Herb name"], [45, 48, "Herb name"], [54, 69, "Drug"]]}], [9643, "The supernatant was transferred and dried using a gentle stream of nitrogen at 35\u00b0C.", {"entities": []}], [9644, "The supernate was utilized for the quantification of GA, PCA, and CIP.", {"entities": [[53, 55, "Herb name"], [57, 60, "Herb name"], [66, 69, "Drug"]]}], [9645, "The source operation parameters were optimized as follows: ion spray voltage, \u22124,500\u00a0V; source temperature, 550\u00b0C; ion source gas1, 55\u00a0psi; ion source gas2, 60\u00a0psi; curtain gas, 35\u00a0psi.", {"entities": []}], [9646, "The separation of CIP was performed on the same column and mobile phase as GA and PCA.", {"entities": [[18, 21, "Drug"], [75, 77, "Herb name"], [82, 85, "Herb name"]]}], [9647, "The gradient elution program was as follows: 0\u20132.5\u00a0min, 85% A; 3\u20134\u00a0min, 10% A; 4.5\u20136\u00a0min, 85% A; 14\u201315\u00a0min, 97% A.", {"entities": []}], [9648, "The quantitation of CIP was performed using MRM mode with an ESI source in positive-ionization mode.", {"entities": [[20, 23, "Drug"]]}], [9649, "The source parameters were chosen as follows: ion spray voltage, 5,500\u00a0V; source temperature, 450\u00b0C; ion source gas1, 50\u00a0psi; ion source gas2, 50\u00a0psi; curtain gas, 35\u00a0psi.", {"entities": []}], [9650, "The precursor-product ion transitions of CIP and ofloxacin (internal standard) were 332.1\u2192288.1 and 362.2\u2192318.1, respectively.", {"entities": [[41, 44, "Drug"], [49, 58, "Drug"]]}], [9651, "PK parameters were estimated with noncompartmental methods using WinNonlin version 6.4 (Certara, Princeton, NJ).", {"entities": []}], [9652, "The peak plasma concentration (C  All data were summarized as mean \u00b1 standard deviation (SD).", {"entities": []}], [9653, "All statistical analyses were performed using SPSS software (Chicago, IL, United States).", {"entities": []}], [9654, "Comparisons between groups were performed using unpaired Student\u2019s t-test.", {"entities": []}], [9655, "A p-value of less than 0.05 was considered statistically significant.", {"entities": []}], [9656, "Pharmacokinetic interactions were reported as 90% confidence intervals (CI) for the geometric mean ratios (GMR) of the observed pharmacokinetic measures in the presence and absence of the interacting drug.", {"entities": []}], [9657, "If the 90% CI for systemic exposure ratios was entirely encompassed within the equivalence range of 0.80\u20131.25, we concluded that clinically significant difference was not present.", {"entities": []}], [9658, "All recruited subjects were healthy Chinese natives.", {"entities": [[28, 35, "Pathology"], [36, 43, "Ethnic group"]]}], [9659, "All enrolled subjects completed the study protocol as planned.", {"entities": []}], [9660, "Their age, height, weight, and body mass index were summarized in Supplementary Table S1.", {"entities": [[11, 17, "Parameter"], [19, 25, "Parameter"], [31, 46, "Parameter"]]}], [9661, "No major protocol deviations were identified, and no serious adverse reactions were observed throughout the study.", {"entities": [[61, 78, "Pathology"]]}], [9662, "The effects of PCE on CIP plasma concentrations were investigated by comparing alterations in PK exposure measures between control and treatment groups.", {"entities": [[15, 18, "Herb name"], [22, 25, "Drug"]]}], [9663, "The CIP concentration-time profiles and PK parameters are shown in Figure 2A and Table 1, respectively.", {"entities": [[4, 7, "Drug"]]}], [9664, "Median (range).", {"entities": []}], [9665, "PCE Multiple doses of PCE (8\u00a0g, TID) for seven consecutive days.", {"entities": [[0, 3, "Herb name"], [22, 25, "Herb name"], [27, 30, "Amount"], [41, 63, "Duration"]]}], [9666, "The plasma ciprofloxacin AUC  Plasma ciprofloxacin (CIP) concentration-time profiles (A), the systemic exposure parameters including AUC  Pharmacokinetic parameters of ciprofloxacin after the oral administration of ciprofloxacin hydrochloride tablets (CIP, 0.5\u00a0g) with and without PCE (8\u00a0g) to human subjects (mean \u00b1 SD, n = 12).", {"entities": [[11, 24, "Drug"], [25, 28, "Parameter"], [37, 56, "Drug"], [133, 136, "Parameter"], [168, 181, "Drug"], [215, 228, "Drug"], [252, 256, "Drug"], [257, 262, "Amount"], [281, 284, "Herb name"], [286, 289, "Amount"]]}], [9667, "*p< 0.05, significant differences were observed when compared with the CIP, group.", {"entities": [[71, 74, "Drug"]]}], [9668, "GA and PCA were identified as PK-markers of PCE to present the effects of CIP on PCE systemic exposures.", {"entities": [[0, 2, "Herb name"], [7, 10, "Herb name"], [44, 47, "Herb name"], [74, 77, "Drug"], [81, 84, "Herb name"]]}], [9669, "After co-administration of CIP and PCE, the PK changes of GA and PCA are displayed in Figures 3, 4, respectively.", {"entities": [[27, 30, "Drug"], [35, 38, "Herb name"], [58, 60, "Herb name"], [65, 68, "Herb name"]]}], [9670, "Their PK parameters (Table 2) were calculated from the plasma concentration-time curves (Figures 3A, 4A).", {"entities": []}], [9671, "No significant differences between control and combination treatment groups were observed on the systemic exposure parameters of GA (Figures 3B,C) and PCA (Figures 4B,C).", {"entities": [[129, 131, "Herb name"]]}], [9672, "Following co-treatment with CIP and a single dose of PCE, the GMRs \u00b190% CI of GA AUC  Plasma gallic acid (GA) concentration-time profiles (A), the systemic exposure parameters of GA including AUC  Plasma protocatechuic acid (PCA) concentration-time profiles (A), the systemic exposure parameters of PCA including AUC  Pharmacokinetic parameters of gallic acid (GA) and protocatechuic acid (PCA) after the oral administration of PCE (8\u00a0g) with and without ciprofloxacin hydrochloride tablets (CIP, 0.5\u00a0g) to human subjects (mean \u00b1 SD, n = 12).", {"entities": [[28, 31, "Drug"], [53, 56, "Herb name"], [78, 80, "Herb name"], [81, 92, "Parameter"], [93, 109, "Herb name"], [179, 181, "Herb name"], [192, 203, "Parameter"], [204, 229, "Herb name"], [299, 302, "Herb name"], [313, 316, "Parameter"], [348, 364, "Herb name"], [369, 394, "Herb name"], [428, 431, "Herb name"], [433, 436, "Amount"], [455, 468, "Drug"], [492, 495, "Drug"], [497, 502, "Amount"]]}], [9673, "Median (range).", {"entities": []}], [9674, "No significant differences were observed when compared with the PCE The effects of PCE on circulating CIP concentrations were observed by comparing changes in PK exposure measures between CIP and CIP + PCE groups.", {"entities": [[64, 67, "Herb name"], [83, 86, "Herb name"], [102, 105, "Drug"], [188, 191, "Drug"], [196, 199, "Drug"], [202, 205, "Herb name"]]}], [9675, "The CIP concentration-time profiles and PK parameters are presented in Figure 5A and Table 3, respectively.", {"entities": [[4, 7, "Drug"]]}], [9676, "The AUC  Circulating ciprofloxacin (CIP) concentration-time profiles (A) and the 90% confidence intervals (CI) for the geometric mean ratios [GMR, (B)] of C  Pharmacokinetic parameters of ciprofloxacin after intragastric administration of ciprofloxacin (CIP, 0.045\u00a0g/kg) with and without PCE (0.72\u00a0g/kg) to rats (mean \u00b1 SD, n = 6).", {"entities": [[4, 7, "Parameter"], [21, 40, "Drug"], [188, 201, "Drug"], [239, 252, "Drug"], [254, 257, "Drug"], [259, 269, "Amount"], [288, 291, "Herb name"], [293, 302, "Amount"]]}], [9677, "Median (range).", {"entities": []}], [9678, "*p< 0.05, significant differences were observed when compared with the CIP, group.", {"entities": [[71, 74, "Drug"]]}], [9679, "After combination therapy, the altered circulating exposures of PCE PK-markers (GA and PCA) are shown in Figures 5C\u2013F.", {"entities": [[64, 67, "Herb name"], [80, 82, "Herb name"], [87, 90, "Herb name"]]}], [9680, "The PK parameters of GA and PCA are summarized in Table 4.", {"entities": [[21, 23, "Herb name"], [28, 31, "Herb name"]]}], [9681, "PCE Multiple doses of PCE (8\u00a0g, TID) for seven consecutive days.", {"entities": [[0, 3, "Herb name"], [22, 25, "Herb name"], [27, 30, "Amount"], [41, 63, "Duration"]]}], [9682, "No significant differences between PCE and PCE + CIP groups were observed on the main PK parameters of GA and PCA.", {"entities": [[35, 38, "Herb name"], [43, 46, "Herb name"], [49, 52, "Drug"], [103, 105, "Herb name"], [110, 113, "Herb name"]]}], [9683, "After co-treatment with CIP and PCE, the GMRs \u00b190% CI of GA AUC  Pharmacokinetic parameters of gallic acid and protocatechuic acid after intragastric administration of PCE (0.72\u00a0g/kg) with and without ciprofloxacin (CIP, 0.045\u00a0g/kg) to rats (mean \u00b1 SD, n = 6).", {"entities": [[24, 27, "Drug"], [32, 35, "Herb name"], [57, 59, "Herb name"], [60, 63, "Parameter"], [95, 106, "Herb name"], [111, 130, "Herb name"], [168, 171, "Herb name"], [173, 182, "Amount"], [201, 214, "Drug"], [216, 219, "Drug"], [221, 231, "Amount"]]}], [9684, "Median (range).", {"entities": []}], [9685, "No significant differences were observed when compared with the PCE, group (p > 0.05).", {"entities": [[64, 67, "Herb name"]]}], [9686, "PCE had little effect on plasma CIP after intravenous injection using rats (Supplementary Figure S1; Supplementary Table S2).", {"entities": [[0, 3, "Herb name"], [32, 35, "Drug"]]}], [9687, "The tissue distribution profiles of CIP in normal rats after intravenous administration of CIP in the absence and presence of PCE are charted in Figures 6A,B, respectively.", {"entities": [[36, 39, "Drug"], [91, 94, "Drug"], [126, 129, "Herb name"]]}], [9688, "PCE significantly increased the tissue to plasma distribution coefficients (K  Tissue distribution profiles of ciprofloxacin (CIP) after intravenous administration of CIP in the absence (A) and presence (B) of PCE to rats, as well as the tissue to plasma distribution coefficients [K  The tissue distribution curves of GA in normal rats after intragastric administration of PCE in the absence and presence of CIP are displayed in Figures 7A,B, respectively.", {"entities": [[0, 3, "Herb name"], [111, 130, "Drug"], [167, 170, "Drug"], [210, 213, "Herb name"], [319, 321, "Herb name"], [374, 377, "Herb name"], [409, 412, "Drug"]]}], [9689, "CIP significantly increased the K  Tissue distribution profiles of gallic acid (GA) after oral administration of PCE in the absence (A) and presence (B) of ciprofloxacin, as well as the tissue to plasma distribution coefficients [K  The tissue distribution curves of PCA in the absence and| presence of CIP are shown in Figures 8A,B, respectively.", {"entities": [[0, 3, "Drug"], [67, 83, "Herb name"], [113, 116, "Herb name"], [156, 169, "Drug"], [267, 270, "Herb name"], [303, 306, "Drug"]]}], [9690, "CIP did not significantly alter the K  Tissue distribution profiles of protocatechuic acid (PCA) after oral administration of PCE in the absence (A) and presence (B) of ciprofloxacin, as well as the tissue to plasma distribution coefficients [K  Significant inhibitory effects of the positive inhibitors of probenecid, cimetidine, rifampicin, verapamil, and cyclosporine were presented on the transporters hOAT1, hOAT3, hOCT2, hMDR1, and hBCRP, respectively (Supplementary Figure S2).", {"entities": [[0, 3, "Drug"], [71, 96, "Herb name"], [126, 129, "Herb name"], [169, 182, "Drug"], [307, 317, "Drug"], [319, 329, "Drug"], [331, 341, "Drug"], [343, 352, "Drug"], [358, 370, "Drug"], [406, 411, "Target"], [413, 418, "Target"], [420, 425, "Target"], [427, 432, "Target"], [438, 443, "Target"]]}], [9691, "A concentration-dependent inhibition type was observed on the transporters hOAT1 and hOAT3 for GA, as well as the transporters hOAT1, hOAT3 and hOCT2 for PCA (Figures 9A\u2013C).", {"entities": [[75, 80, "Target"], [85, 90, "Target"], [95, 97, "Herb name"], [127, 132, "Target"], [134, 139, "Target"], [144, 149, "Target"], [154, 157, "Herb name"]]}], [9692, "GA and PCA presented significant inhibitory effects on the hOAT1-mediated uptake of  Inhibitory effects of GA and PCA on the activity of multiple transporters, including human organic anion transporter 1 [hOAT1, (A)], [hOAT3 (B)], human organic cation transporter 2 [hOCT2, (C)], human multidrug resistance protein 1 [hMDR1, (D)], and human breast cancer resistance protein [hBCRP, (E)] (mean \u00b1 SD, n = 3).", {"entities": [[0, 2, "Herb name"], [7, 10, "Herb name"], [59, 64, "Target"], [107, 109, "Herb name"], [114, 117, "Herb name"], [170, 210, "Target"], [219, 224, "Target"], [231, 273, "Target"], [280, 324, "Target"], [335, 381, "Target"]]}], [9693, "In the bidirectional transport assay with Caco-2 cells, the net flux ratio of CIP after 0.5 and 1\u00a0h were 4.13 \u00b1 0.76 and 3.48 \u00b1 0.10, respectively.", {"entities": [[78, 81, "Drug"]]}], [9694, "After co-incubation with GA, PCA and PCE, the net flux ratio of CIP showed varying degrees of enlargement (Figures 10A,B).", {"entities": [[25, 27, "Herb name"], [29, 32, "Herb name"], [37, 40, "Herb name"], [64, 67, "Drug"]]}], [9695, "A significant improvement was observed in the net efflux ratios after co-treatment with GA (50\u00a0\u03bcM), PCA (50\u00a0\u03bcM), and PCE (100\u00a0mg/ml) (p < 0.05).", {"entities": [[88, 90, "Herb name"], [100, 103, "Herb name"], [117, 120, "Herb name"]]}], [9696, "The increased net flux ratio facilitates the flow of CIP from the blood to the intestinal lumen, renal tubules or bile ducts, which may be related to the reduction of CIP systemic exposure.", {"entities": [[53, 56, "Drug"], [167, 170, "Drug"]]}], [9697, "The effect of PCE on the expression of MDR1 and BCRP mRNAs are shown in Figures 10C,D, respectively.", {"entities": [[14, 17, "Herb name"], [39, 43, "Target"], [48, 52, "Target"]]}], [9698, "After pretreatment with bosentan, the expression of P-gp and BCRP mRNAs in Caco-2 cells were increased by 7.36- and 4.31-fold, respectively.", {"entities": [[24, 33, "Drug"], [52, 56, "Target"], [61, 71, "Target"]]}], [9699, "After pretreatment with the investigated drugs, the expression of MDR1 and BCRP mRNAs increased 6.02- and 6.00-fold in cells treated with GA, 3.56- and 3.33-fold in cells treated with PCA, and 4.04- and 3.95-fold in cells treated with PCE, respectively.", {"entities": [[66, 70, "Target"], [75, 85, "Target"], [138, 140, "Herb name"], [184, 187, "Herb name"], [235, 238, "Herb name"]]}], [9700, "The increased MDR1 and BCRP mRNA expressions may contribute to CIP efflux from the blood circulatory system.", {"entities": [[14, 18, "Target"], [23, 32, "Target"], [63, 66, "Drug"]]}], [9701, "Thereafter, due to the pharmacokinetic- and pharmacodynamic-based HDIs, the concurrent use of herbal medicinal products may mimic, magnify, or oppose the effects of medicinal products (Fugh-Berman, 2000).", {"entities": []}], [9702, "Pharmacokinetic HDIs may increase or decrease the systemic exposures of either component through multiple mechanisms, including drug-metabolizing enzymes (e.g., CYP450s and UGTs), drug transporters (e.g., P-gp and BCRP) and plasma protein (e.g., albumin and globulin), which is basically similar to pharmacokinetic DDIs (Li et al., 2019).", {"entities": []}], [9703, "Effects of gallic acid (GA), protocatechuic acid (PCA) and PCE on the change of ciprofloxacin efflux ratios at 0.5\u00a0h (A) and 1\u00a0h (B), and the mRNA expressions of MDR1 (C) and BCRP (D) in Caco-2 cells (mean \u00b1 SD, n = 3).", {"entities": [[11, 27, "Herb name"], [29, 54, "Herb name"], [59, 62, "Herb name"], [80, 93, "Drug"], [162, 166, "Target"], [175, 179, "Target"]]}], [9704, "Herbal medicinal products are commonly used as a complementary or alternative treatment for a variety of diseases, rehabilitation and health care (Meng and Liu, 2014).", {"entities": []}], [9705, "Nevertheless, the research of pharmacokinetic HDIs is generally more challenging than that of DDIs, given the complicated herbal components and the batch-to-batch variation of herbal medicines (Meng and Liu, 2014).", {"entities": []}], [9706, "This has led to a phenomenon that most of the current studies pay more attention to the unidirectional effect (herbs\u2192drugs) than the bidirectional effect (herbs\u2194drugs).", {"entities": []}], [9708, "GA and PCA were identified as appropriate PK-marker components of P. capitatum because of 1) their extensive pharmacological activities consistent with P. capitatum (Liao et al., 2011; Khan et al., 2015; Choubey et al., 2018; Song et al., 2020; Bai et al., 2021), 2) their rich in vitro (Liao et al., 2013; Zhang et al., 2013a; Zhang et al., 2013b; Li et al., 2021b) and in vivo exposures (Ma et al., 2015, 2016; Huang et al., 2019; Li et al., 2021b; Guan et al., 2022), and 3) their acceptable pharmacokinetic properties (Ma et al., 2015; Li et al., 2021b) and targeted distribution in kidney tissue (Ma et al., 2016).", {"entities": [[0, 2, "Herb name"], [7, 10, "Herb name"], [66, 78, "Herb name"], [152, 164, "Herb name"]]}], [9709, "However, there is a risk that the two compounds were possibly not the most critical compounds responsible for PCE\u2019s effect, and the use of any single compound of the two compounds in the study could not reflect the overall effect of PCE.", {"entities": [[110, 115, "Herb name"], [233, 236, "Herb name"]]}], [9710, "Although herbal crude extract has been used as perpetrator in some cell experiments, false positive or false negative results will inevitably occur (Ge et al., 2010).", {"entities": []}], [9711, "The main reasons include but are not limited to the following aspects.", {"entities": []}], [9712, "PCE addition can alter some extracellular characteristics, such as pH value and ionic strength.", {"entities": [[0, 3, "Herb name"]]}], [9713, "PCE contains some components that are not absorbed into blood when administered orally, which may interfere with cultured cells.", {"entities": [[0, 3, "Herb name"]]}], [9714, "Despite serum pharmacological method can solve the above problems, preparation of test serum for cell experiment is a complicated process: Besides chemicals or heat pretreatment, it involves the proteolytic cascades of coagulation along with complement, fibrinolysis and kinin systems, as well as leukocyte and platelet activation resulting in release reactions (Ge et al., 2010).", {"entities": []}], [9715, "The pretreatment deviates serum sample elements away from the original in vivo state.", {"entities": []}], [9716, "The shortcomings of using these two compounds are the same as those of using PK-markers.", {"entities": []}], [9717, "Clinical evidence showed that combination of PCE and CIP could produce a better effect for the treatment of chronic prostatitis (Zhou et al., 2016) and urinary tract infections (Pu et al., 2016).", {"entities": [[45, 48, "Herb name"], [53, 56, "Drug"], [108, 127, "Pathology"], [152, 176, "Pathology"]]}], [9718, "However, since co-administration of PCE significantly reduces plasma CIP in human (Figure 2), the results seemed not to support such an effect.", {"entities": [[36, 39, "Herb name"], [69, 72, "Drug"]]}], [9719, "Since CIP is a substrate of multiple transporters, the drug-transporter mediated inhibition test was performed to study the responsibilities for the reduced CIP exposure.", {"entities": [[6, 9, "Drug"], [157, 160, "Drug"]]}], [9720, "The results obtained from the drug-containing serum are at least partially uncertain in its validity.", {"entities": []}], [9721, "Interestingly, we found that the combined therapy significantly increased the exposure of CIP in the prostate (Figure 6), which may be the target tissue for the treatment of chronic prostatitis (Lipsky et al., 2010).", {"entities": [[90, 93, "Drug"], [174, 193, "Pathology"]]}], [9722, "In addition to CIP, GA and PCA (PCE PK-markers) presented high exposure in the urogenital system, such as prostate, kidney, and seminal vesicle gland (Figures 7, 8).", {"entities": [[15, 18, "Drug"], [20, 22, "Herb name"], [27, 30, "Herb name"], [32, 35, "Herb name"]]}], [9723, "The antibacterial, anti-inflammatory, antioxidant and analgesic activities of PCE, GA and PCA are helpful to improve the efficacy of CIP in the treatment of infectious diseases of urogenital system (Liao et al., 2011; Khan et al., 2015; Choubey et al., 2018; Song et al., 2020; Bai et al., 2021).", {"entities": [[78, 81, "Herb name"], [83, 85, "Herb name"], [90, 93, "Herb name"], [133, 136, "Drug"], [157, 197, "Pathology"]]}], [9724, "The in vitro study proves that PCA increased up to 50% of the antibacterial activity, especially that of levofloxacin against Staphylococcus aureus and Escherichia coli (Fifere et al., 2022).", {"entities": [[31, 34, "Herb name"], [105, 117, "Drug"]]}], [9725, "Considering the manner in which the drug is removed from the body, CIP is primarily cleared by active tubular secretion (up to 2/3 of the total clearance, H\u00f6ffken et al., 1985; Mulgaonkar et al., 2012) and intestinal excretion (approximately 18%, Rohwedder et al., 1990).", {"entities": [[67, 70, "Drug"]]}], [9726, "Since the liver metabolism (approximately 10%) and biliary excretion (approximately 1%) of the drug is relatively low (Vance-Bryan et al., 1990), the reduced circulating CIP in humans was mainly attributed to the change of CIP across the renal and intestinal epithelia.", {"entities": [[170, 173, "Drug"], [223, 226, "Drug"]]}], [9727, "CIP is a known substrate of the ATP-binding cassette transporters BCRP (Alvarez et al., 2008; Haslam et al., 2011) and MDR1 (Brillault et al., 2010; Arakawa et al., 2012; Zhang et al., 2019; Zimmermann et al., 2019), both of which are located in the apical (luminal) membrane of kidney proximal tubules and intestinal epithelia (International Transporter Consortium, 2010).", {"entities": [[0, 3, "Drug"], [66, 70, "Target"], [119, 123, "Target"]]}], [9728, "Due to the zwitterionic nature, CIP is likely to interact with organic anion and cation transporters, such as OAT1, OAT3, and OCT2 (Dautrey et al., 1999; Vanwert et al., 2008; Arakawa et al., 2012; Mulgaonkar et al., 2012; Ong et al., 2013).", {"entities": [[32, 35, "Drug"], [110, 114, "Target"], [116, 120, "Target"], [126, 130, "Target"]]}], [9729, "That is, the decrease of CIP systematic exposure in the combined group was caused by the integrated effect of synergy/antagonism among multiple transporters.", {"entities": [[25, 28, "Drug"]]}], [9730, "Additionally, the reduced circulating CIP may also come from other transporter-mediated interactions (eg., OATPs, MRPs, Wu et al., 2012; Marquez et al., 2009), drug metabolizing enzyme-mediated interactions (eg., CYP450, Zheng et al., 2014), and other PCE composition-perpetrated interactions (eg., flavonoids, An et al., 2014).", {"entities": [[38, 41, "Drug"], [107, 112, "Target"], [114, 118, "Target"], [252, 255, "Herb name"]]}], [9731, "Tissue distribution-based HDI studies were also implemented to assess the effects of combination therapy on the altered distribution kinetics of CIP, GA, and PCA, which may directly or indirectly lead to changes in their therapeutic effect.", {"entities": [[145, 148, "Drug"], [150, 152, "Herb name"], [158, 161, "Herb name"]]}], [9732, "The combined administration increased CIP exposure in the prostate, testis, and seminal vesicle gland, which may help to treat infectious diseases of the male reproductive system.", {"entities": [[38, 41, "Drug"], [127, 146, "Drug"]]}], [9733, "As summarized by Obligacion et al.", {"entities": []}], [9734, "Concurrent use of PCE significantly reduced circulating CIP in humans and rats, consistent with previous reports (Lu et al., 2016).", {"entities": [[18, 21, "Herb name"], [56, 59, "Drug"]]}], [9735, "(2006), the human prostate tissue contains the multidrug resistance protein (MRP) transporters MRP1, MRP2, MRP3, and MRP4, and MDR1.", {"entities": []}], [9736, "Thus, the increased distribution of CIP in the prostate gland may be attributed to the activation of MRPs and MDR1 after treated with GA and PCA.", {"entities": [[36, 39, "Drug"], [101, 105, "Target"], [110, 114, "Target"], [134, 136, "Herb name"], [141, 144, "Herb name"]]}], [9737, "Although no significant alteration in the circulating GA and PCA after combination therapy, there were some elevated distribution kinetics and tissue exposures in the prostate and lung.", {"entities": [[54, 56, "Herb name"], [61, 64, "Herb name"]]}], [9738, "Interestingly, the exposures of CIP, GA, and PCA all showed an increase in the prostate tissue after combined administration, which will contribute to the treatment of chronic prostatitis.", {"entities": [[32, 35, "Drug"], [37, 39, "Herb name"], [45, 48, "Herb name"], [168, 187, "Pathology"]]}], [9739, "A meta-analysis of randomized controlled trials of combination therapy indicated that PCE-based products (Relinqing In summary, we focused on the pharmacokinetic herb-drug interactions between PCE and CIP in humans, rats and cells.", {"entities": [[0, 47, "Study"], [86, 89, "Herb name"], [193, 196, "Herb name"], [201, 204, "Drug"]]}], [9741, "The reduced plasma CIP may be attributed to integrated routes mediated by multiple transporters, including BCRP, MDR1, and OAT1/3.", {"entities": [[19, 22, "Drug"], [107, 111, "Target"], [113, 117, "Target"], [123, 129, "Target"]]}], [9742, "GA and PCA were highly exposed to urogenital tissues after intragastric administration of PCE with or without CIP to rats.", {"entities": [[0, 2, "Herb name"], [7, 10, "Herb name"], [90, 93, "Herb name"], [110, 113, "Drug"]]}], [9743, "Although the decreased circulating CIP seemed not to support the clinical synergism of CIP and PCE, the combined therapy increased the exposure of CIP, GA and PCA in the prostate gland.", {"entities": [[35, 38, "Drug"], [87, 90, "Drug"], [95, 98, "Herb name"], [147, 150, "Drug"], [152, 154, "Herb name"], [159, 162, "Herb name"]]}], [9744, "The enrichment of these drugs in prostate will be helpful to the treatment of chronic bacterial prostatitis.", {"entities": [[78, 107, "Pathology"]]}], [9745, "Additionally, the effect of combination therapy should pay attention to both the pharmacokinetic- and pharmacodynamic-based interactions, rather than unilaterally.", {"entities": []}], [9746, "Further in-depth research should be carried out in the future.", {"entities": []}], [9747, "The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author.", {"entities": []}], [9748, "The studies involving human participants were reviewed and approved by the Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine.", {"entities": []}], [9749, "The patients/participants provided their written informed consent to participate in this study.", {"entities": []}], [9750, "The animal study was reviewed and approved by the Institutional Animal Care and Use Committee of Tianjin University of Traditional Chinese Medicine.", {"entities": [[0, 16, "Study"], [131, 138, "Ethnic group"]]}], [9751, "Conceptualization: ZL, BW, and YH.", {"entities": []}], [9752, "Methodology: ZL, XZ, SF, ST, and XD.", {"entities": []}], [9753, "Software: ZL and XD.", {"entities": []}], [9754, "Validation: ZL and XD.", {"entities": []}], [9755, "Formal analysis: ZL and ST. Investigation: ZL, XZ, SF, ST, XD, RW, and YL.", {"entities": []}], [9756, "Data curation: ZL, XZ, and SF.", {"entities": []}], [9757, "Writing\u2014original draft preparation: ZL and ST. Writing\u2014review and editing: YH.", {"entities": []}], [9758, "Visualization: ZL and ST.", {"entities": []}], [9759, "Supervision: YL, RW, and BW.", {"entities": []}], [9760, "Project administration: YH.", {"entities": []}], [9761, "Funding acquisition: ZL, YH, and BW.", {"entities": []}], [9762, "All authors have read and agreed to the published version of the manuscript.", {"entities": []}], [9763, "The study was funded by the Scientific Research Project of Tianjin Municipal Education Commission (2021ZD017 and 2021ZD030), and the National Science and Technology Major Project of China under Grant number (2018ZX09734-002), Youth Qihuang Scholars Support Project of the National Administration of Traditional Chinese Medicine.", {"entities": [[311, 318, "Ethnic group"]]}], [9764, "The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.", {"entities": []}], [9765, "All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers.", {"entities": []}], [9766, "Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.", {"entities": []}], [9767, "The Supplementary Material for this article can be found online at:  Click here for additional data file.", {"entities": []}], [9768, "Click here for additional data file.", {"entities": []}], [9769, "Click here for additional data file.", {"entities": []}], [9770, "Click here for additional data file.", {"entities": []}], [9771, " Edited by:   Reviewed by:    This article was submitted to Drug Metabolism and Transport, a section of the journal Frontiers in Pharmacology  Background: Combination of Polygonum capitatum Buch.-Ham.", {"entities": [[170, 200, "Herb name"]]}], [9772, "Yerba Mat\u00e9 (YM), has become a popular herb ingested for enhancing metabolic health and weight-loss outcomes.", {"entities": [[0, 15, "Herb name"]]}], [9773, "No studies have tested the combined metabolic, satiety, and psychomotor effects of YM during exercise.", {"entities": [[83, 85, "Herb name"]]}], [9774, "We tested whether YM ingestion affects fatty acid oxidation (FAO), profile of mood state score (POMS), and subjective appetite scale (VAS), during prolonged moderate exercise.", {"entities": [[18, 20, "Herb name"], [39, 65, "Parameter"], [107, 138, "Parameter"]]}], [9775, "Participants rested for 120 min before performing a 30-min cycling exercise corresponding to individuals\u2019 crossover point intensity (COP).", {"entities": [[24, 31, "Duration"]]}], [9776, "FAO, determined using indirect calorimetry, was significantly higher during the 30-min exercise in YM vs. PLC (0.21 \u00b1 0.07 vs. 0.17 \u00b1 0.06 g/min, p < 0.05).", {"entities": [[0, 3, "Parameter"], [99, 101, "Herb name"]]}], [9777, "VAS scores for hunger, prospective eating, and desire to eat were all reduced (p < 0.05).", {"entities": [[0, 10, "Parameter"]]}], [9778, "Whereas, POMS measures of focus, energy, and concentration were all increased (p < 0.05).", {"entities": []}], [9779, "There was no significant time-effect for any of the measured variables, nor was there any interaction effects between YM treatment and time.", {"entities": [[118, 120, "Herb name"]]}], [9780, "Combining YM intake with prolonged exercise at targeted \u201dfat-loss\u201d\u2019 intensities augments FAO and improves measures of satiety and mood state.", {"entities": [[10, 12, "Herb name"], [89, 92, "Parameter"]]}], [9781, "Such positive combined metabolic, satiety, and psychomotor effects may provide an important role for designing future fat and weight-loss lifestyle interventions.", {"entities": []}], [9782, "Nutritional and exercise lifestyle strategies are primary tools for weight and fat loss to prevent major health risks and lifestyle diseases such as obesity, diabetes, and cardiovascular disease.", {"entities": [[149, 156, "Pathology"], [158, 166, "Pathology"], [172, 194, "Pathology"]]}], [9783, "The effectiveness of healthy lifestyle strategies can be maximized with a variety of nutritional aids in the form of functional foods and naturally available herbal ingredients [1,2].", {"entities": []}], [9784, "Yerba Mat\u00e9 (YM), the plant Ilex paraguariensis, is traditionally consumed in many South American regions, but its popularity is increasing in North America, Europe, and other regions worldwide [3].", {"entities": [[0, 15, "Herb name"], [27, 46, "Herb name"]]}], [9785, "Several anti-atherogenic and weight-loss properties have been associated with the regular consumption of YM [4], including anti-oxidation, vasodilation, reduction in blood lipids, and other anti-mutagenic and anti-glycation benefits [5,6,7,8,9].", {"entities": [[105, 107, "Herb name"]]}], [9786, "These health properties have been attributed to several naturally-present bioactive ingredients, which have been detected in YM including polyphenols and caffeoyl derivatives (caffeic acid, chlorogenic acid, 3,4-Dicaffeoylquinic acid, 4,5-Dicaffeoylquinic acid and 3,5-Dicaffeoylquinic acid), phytosterols, saponins, some amino acids, vitamins, and minerals [4,5].", {"entities": [[125, 127, "Herb name"], [138, 149, "Herb name"], [154, 162, "Herb name"], [176, 188, "Herb name"], [190, 206, "Herb name"], [208, 233, "Herb name"], [235, 260, "Herb name"], [265, 290, "Herb name"], [293, 305, "Herb name"], [307, 315, "Herb name"]]}], [9787, "Metabolic functions of YM components are thought to be responsible for reductions in serum cholesterol, serum triglycerides, and glucose concentrations; and an improved glycemic control and lipid profile in in high-fat fed mice [7], reduced body fat mass, and distribution and reduced waist to hip ratio in humans, all shown following YM ingestion [10,11].", {"entities": [[23, 25, "Herb name"], [85, 103, "Parameter"], [104, 123, "Parameter"], [129, 151, "Parameter"], [190, 203, "Parameter"], [335, 337, "Herb name"]]}], [9788, "Recent findings have also indicated that YM metabolic properties may be combined with positive psychomotor and appetite control effects, which complement the YM fat-loss promoting properties.", {"entities": [[41, 43, "Herb name"], [158, 160, "Herb name"]]}], [9789, "Such effects include suppressed appetite through an increased expression of glucagon-like peptide-1 (GLP-1) and delayed gastric emptying, as seen in mice studies [12,13], and increased ghrelin up to 4.2-fold in rat models following YM ingestion [14].", {"entities": [[76, 107, "Target"], [120, 136, "Parameter"], [149, 161, "Study"], [185, 192, "Target"], [232, 234, "Herb name"]]}], [9790, "A trend towards increased satiety, reduced hunger, and improved mood state has also been found using visual analogue scale in human participants who ingested YM combined with other fat-loss ingredients [15,16].", {"entities": [[158, 160, "Herb name"]]}], [9791, "The reported psychomotor effects include improved total mood disturbance score [15], increased focus, alertness and energy, and decreased fatigue in habitual caffeine consumers [16].", {"entities": [[158, 166, "Herb name"]]}], [9792, "Modifying behavioral factors of mood state and appetite control is considered essential for effective weight-loss lifestyle interventions [17,18,19].", {"entities": []}], [9793, "Consequently, indications of the positive YM effects combined with exercise on those outcomes should be further investigated, especially given the known positive effects of exercise on mood state and mental health [20].", {"entities": [[42, 44, "Herb name"]]}], [9794, "Along with the nutritional metabolic weight and fat-loss benefits, exercise is known to stimulate fat metabolism, and reverse associated metabolic health risks.", {"entities": []}], [9795, "YM effects on thermogenesis has been suggested to promote fat-loss by influencing indirect calorimetry measures such as energy expenditure (EE), fatty acid oxidation (FAO), and respiratory exchange ratio (RER) in resting healthy obese participants [21].", {"entities": [[0, 2, "Herb name"], [120, 143, "Parameter"], [145, 171, "Parameter"], [177, 209, "Parameter"], [221, 228, "Pathology"]]}], [9796, "However, little is known about such YM metabolic effects during exercise.", {"entities": [[36, 38, "Herb name"]]}], [9797, "Our recent work has shown that YM favors FAO as a fuel source during exercise, when either ingested as a single ingredient [22] or combined with other fat-loss compounds in a multi-ingredient supplement [15].", {"entities": [[31, 33, "Herb name"], [41, 44, "Parameter"]]}], [9798, "In Alkhatib, 2014 it was found that 1 g of YM can induce an over 20% increase in FAO at the exercise intensity range of 40\u201370% of peak oxygen uptake ( Given our recent promising findings of YM acute effects on FAO during exercise intensities in the COP range [15,22], and the YM weight-loss postulated effects on satiety and mood state [13,22], our study is important to test whether and how YM affects FAO, satiety, and mood state during prolonged exercise at individuals\u2019 COP intensities.", {"entities": [[36, 39, "Amount"], [43, 45, "Herb name"], [81, 84, "Parameter"], [190, 192, "Herb name"], [210, 213, "Parameter"], [276, 278, "Herb name"], [392, 394, "Herb name"], [403, 406, "Herb name"]]}], [9799, "This study aims to test the hypothesis that YM ingestion combined with steady state exercise at the COP intensities augments FAO, and improves the measures of satiety and mood state.", {"entities": [[44, 46, "Herb name"], [125, 128, "Parameter"]]}], [9800, "The study followed a double-blind repeated-measures crossover placebo-controlled design.", {"entities": [[4, 88, "Study"]]}], [9801, "All tests were performed at similar laboratory environmental conditions controlling for air temperature, barometric pressure, and relative humidity.", {"entities": []}], [9802, "The study was approved by the institution\u2019s ethical committee.", {"entities": []}], [9803, "All experimental procedures were carried out in accordance with the ethical guidelines of the World Medical Association Declaration of Helsinki.", {"entities": []}], [9804, "All study participants provided their informed written consent and were given an explanation of the purpose of the research and experimental procedures.", {"entities": []}], [9805, "Exclusion criteria were as follows.", {"entities": []}], [9806, "(1) History of any cardiovascular or respiratory disease, hypertension, liver or kidney disease, musculoskeletal or neuromuscular or neurological disease, autoimmune disease, cancer, peptic ulcers or anemia; (2) Taking medications, including those for heart, pulmonary, thyroid, anti-hyperlipidemic, hypoglycemic, anti-hypertensive, endocrinologic, psychotropic, neuromuscular, neurological, or androgenic conditions, as well as a family history of heart problems, high blood pressure, and/or stroke, and being pregnant or breastfeeding.", {"entities": [[19, 56, "Pathology"], [58, 70, "Pathology"], [72, 95, "Pathology"], [97, 153, "Pathology"], [155, 173, "Pathology"], [175, 181, "Pathology"], [183, 196, "Pathology"], [200, 206, "Pathology"], [279, 298, "Drug"], [314, 331, "Drug"], [465, 484, "Pathology"], [493, 499, "Pathology"]]}], [9809, "Each testing session (between 09:30 and 11:30 a.m.) was separated by at least three days within a two-week period.", {"entities": [[78, 88, "Duration"], [98, 106, "Duration"]]}], [9810, "Session one involved the participants being assessed for their body composition and exercise performance variables for all participants, including  Body composition was assessed using bioelectrical impedance scale, which also provides body weight, assessed to the nearest 0.1 kg (InBody version 720, Biospace, Seoul, Korea).", {"entities": []}], [9811, "Height was assessed to the nearest 0.5 cm using a Stadiometer (Seca scales, Hamburg, Germany).", {"entities": []}], [9812, "The baseline exercise protocol involved the participants completing an incremental exercise test using an electronically braked cycle ergometer (Lode, Excalibur Sport, Groningen, The Netherlands).", {"entities": []}], [9813, "The saddle height and distance from the handlebar were recorded at the initial visit and re-applied in all subsequent visits.", {"entities": []}], [9814, "Participants began cycling at 25 watts for three minutes and work rate increased by 25 watts every three minutes until volitional exhaustion.", {"entities": []}], [9815, "The breath-by breath cardiorespiratory data of  Participants received the supplement immediately before resting for 120 min in a semi-recumbent position during which they remained awake, while not talking and limited their movement.", {"entities": [[116, 123, "Duration"]]}], [9816, "At the end of the resting period, participants were transitioned to a cycle ergometer where they cycled continuously for 30 min at a workload pre-determined from their COP calculated during the baseline visit.", {"entities": [[121, 127, "Duration"]]}], [9817, "The cadence for the exercise protocol was self-selected to fall within a range of 60\u201380 RPM for the two supplementation trials.", {"entities": []}], [9818, "Appetite and satiety were measured using a visual analogue 100 mm scale (VAS), which recorded perceived hunger, fullness, desire to eat, and prospective food consumption [30].", {"entities": [[59, 65, "Amount"], [73, 76, "Parameter"]]}], [9819, "The scale was anchored at each end with the labels \u201cnot at all\u201d (0 mm) and \u201cextremely\u201d (100 mm).", {"entities": []}], [9820, "Subjects marked a line through the scale between the two extremes of the symptoms being rated which they considered to indicate the degree of the subjective feeling being rated.", {"entities": []}], [9821, "VAS was completed prior to supplementation, every 30 min during the 120-min resting period, immediately post exercise (0 min), and 30 min post exercise.", {"entities": [[0, 3, "Parameter"], [68, 75, "Duration"]]}], [9822, "Profile of mood state (POMS) questionnaire [31] was used to assess participants\u2019 mood state (perceived alertness, focus, energy, fatigue, and concentration).", {"entities": []}], [9823, "Participants were asked to rate their perceived mood on a scale ranging between one and five for all five categories.", {"entities": []}], [9824, "POMS questionnaires were completed prior to supplementation, every 30-min during the 120-min resting period, immediately post exercise, and 30-min post exercise.", {"entities": [[85, 92, "Duration"]]}], [9825, "All data are presented as means and standard deviations.", {"entities": []}], [9826, "FAO, CHO, EE, HR, POMS, and VAS were analyzed using two-way repeated measures ANOVA (YM \u00d7 Time), with YM supplement as within factors, and six time points during 30-min for the exercise metabolic data (FAO, CHO, EE, HR) as between factors.", {"entities": [[0, 3, "Parameter"], [5, 8, "Parameter"], [10, 12, "Parameter"], [14, 16, "Parameter"], [28, 31, "Parameter"], [102, 104, "Herb name"], [162, 168, "Duration"], [202, 205, "Herb name"], [207, 210, "Herb name"], [212, 214, "Herb name"], [216, 218, "Herb name"]]}], [9827, "Bonferroni post hoc test was applied to analyze the differences at each time point.", {"entities": []}], [9828, "For VAS and POMS the measured time points were analyzed using two-way ANOVA (Treatment \u00d7 Time) for both rest condition at time points (0, 30, 60, 90, and 120 min), and exercise condition immediately before supplementation (0-min), immediately before exercise (120-min), immediately after exercise (150-min), and post 30-min recovery following exercise (180-min).", {"entities": [[4, 7, "Parameter"], [12, 16, "Parameter"], [260, 267, "Duration"], [298, 305, "Duration"], [353, 360, "Duration"]]}], [9829, "The area under the curve (AUC) was calculated using trapezoidal method, and was compared between the treatments using a paired t-test.", {"entities": [[4, 30, "Parameter"]]}], [9830, "For all statistics SPSS IBM statistics V24 was used and the significance level was set at p < 0.05.", {"entities": []}], [9831, "The exercise power output at the cross-over point (COP) determined during the baseline assessment was 50.8 \u00b1 22.3 W corresponding to a relative exercise intensity of 37.5 \u00b1 8.0%  The YM treatment elicited significantly higher FAO compared with PLC during the 30-min steady-state exercise (ANOVA treatment effects, p = 0.037), (Figure 1).", {"entities": [[183, 185, "Herb name"], [226, 229, "Parameter"]]}], [9832, "The difference was also affected by the time of exercise (ANOVA time effect p < 0.001).", {"entities": []}], [9833, "The highest FAO difference was after 20 min (0.21 \u00b1 0.07 vs. 0.17 \u00b1 0.05 g/min, p = 0.039), and 25 of exercise (0.22 \u00b1 0.07 vs. 0.17 \u00b1 0.06 g/min, p = 0.015) for YM compared with PLC (Figure 1).", {"entities": [[12, 15, "Herb name"], [162, 164, "Herb name"]]}], [9834, "Calculating AUC showed a higher total AUC for FAO in YM than PLC (5.22 vs. 4.20, p < 0.001).", {"entities": [[12, 15, "Parameter"], [38, 41, "Parameter"], [46, 49, "Parameter"], [53, 55, "Herb name"]]}], [9835, "However, there was no significant interaction between YM treatment and exercise time.", {"entities": [[54, 56, "Herb name"]]}], [9836, "CHO was not significantly different between the treatments, but there was a time effect (ANOVA time effects, p < 0.001) with the CHO initially increased and then decreased over exercise time in both treatments (Figure 2).", {"entities": [[0, 3, "Parameter"], [129, 132, "Parameter"]]}], [9837, "No interaction for CHO between treatment and time was found.", {"entities": [[19, 22, "Parameter"]]}], [9838, "However, the total AUC for CHO was lower in YM than PLC (13.3 vs. 15.00, p < 0.001).", {"entities": [[19, 22, "Parameter"], [27, 30, "Parameter"], [44, 46, "Herb name"]]}], [9839, "Total Energy Expenditure (TEE) was neither significantly affected by the treatment (YM vs. PLC) nor the exercise time (Figure 3).", {"entities": [[0, 30, "Parameter"], [84, 86, "Herb name"], [91, 94, "Drug"]]}], [9840, "However, the total AUC for TEE was higher (85.60 vs. 82.13, p < 0.001) in YM than PLC.", {"entities": [[19, 22, "Parameter"], [27, 30, "Parameter"], [74, 76, "Herb name"]]}], [9841, "HR was not different between the treatments, but the time had significant effects (p < 0.001), (Figure 4).", {"entities": []}], [9842, "No interaction effects were found.", {"entities": []}], [9843, "RPE, measured at three exercise time points, was also not affected between the treatments (YM vs. PLC) or exercise duration, nor was there any interaction effect between YM and exercise time (Figure 5).", {"entities": [[91, 93, "Herb name"], [170, 172, "Herb name"]]}], [9844, "There were significant treatment effects (YM vs. PLC) on VAS measures of Hunger (p = 0.019), Prospective eating (p = 0.022), and a trend towards a reduced desire to eat (p = 0.079) for exercise (Pre, immediately before, after, and 30 min post exercise).", {"entities": [[42, 44, "Herb name"], [57, 60, "Parameter"]]}], [9845, "There was no YM effect on fullness score.", {"entities": [[13, 15, "Herb name"]]}], [9846, "The time effect was not significant for all VAS satiety measures, and there was no interaction between time and YM treatment (Table 1).", {"entities": [[44, 47, "Parameter"], [112, 114, "Herb name"]]}], [9847, "When analyzing the resting data only (immediately pre-ingestion 0 to 120 min rest duration), only prospective eating score was slightly reduced (p = 0.046) at YM treatment compared with PLC, but there were no significant YM treatment or rest time effects in any of the remaining VAS measures, nor were there any interaction effects (Table 1).", {"entities": [[69, 76, "Duration"], [159, 161, "Herb name"], [221, 223, "Herb name"]]}], [9848, "YM significantly affected POMS measures following exercise by an increased focus (p = 0.022), energy (p = 0.008) and concentration (p = 0.003), and a trend towards an increased alertness (p = 0.066) in the YM treatment compared with PLC (Table 2).", {"entities": [[0, 2, "Herb name"], [206, 208, "Herb name"], [233, 236, "Drug"]]}], [9849, "No effects were found for fatigue scores.", {"entities": [[26, 33, "Pathology"]]}], [9850, "Targeting such intensities with exercise training enhances fat metabolism, and associated \u201cfat-loss\u201d metabolic health outcomes including increased insulin sensitivity [25], enhanced lipolysis and ability to oxidize lipids [32,33], and microvascular activity [26].", {"entities": [[147, 166, "Parameter"], [235, 257, "Parameter"]]}], [9851, "Exercise time had no effect on any of the POMS measures nor was there any interaction between treatment and time (Table 2).", {"entities": []}], [9852, "When analyzing the resting data only (immediately pre-ingestion 0 to 120 min rest duration) no significant effects were found for YM treatment, rest duration, nor were there any interaction effects (Table 2).", {"entities": [[69, 76, "Duration"], [130, 132, "Herb name"]]}], [9853, "In this experiment, YM increased FAO during prolonged steady-state exercise and induced positive psychomotor mood state and satiety during and after exercise without affecting the exercise RPE.", {"entities": [[20, 22, "Herb name"], [33, 36, "Parameter"]]}], [9854, "Augmented FAO was approximately 23% higher in YM compared with PLC during 30 min of steady-state low-to-moderate intensity exercise corresponding to individuals\u2019 COP intensity (Figure 1).", {"entities": [[10, 13, "Parameter"], [46, 48, "Herb name"], [63, 66, "Drug"]]}], [9855, "This increase is comparable with 24% increase found during low to moderate exercise intensities determined using an incremental protocol in our previous study [22].", {"entities": []}], [9856, "The present study extended previous findings by determining COP individually, and demonstrated that YM ingestion is effective in enhancing the impact of FAO at the targeted COP exercise intensities.", {"entities": [[100, 102, "Herb name"], [153, 156, "Parameter"]]}], [9857, "Therefore, YM augments such metabolic outcomes when combined with prolonged exercise at such given fat-loss intensities.", {"entities": [[11, 13, "Herb name"]]}], [9858, "Previous studies in human participants have shown promising effects of YM ingestion on metabolic rate and RER acutely [21], and after 12 weeks of ingestion, on blood lipid metabolites in healthy obese participants [11,21].", {"entities": [[71, 73, "Herb name"], [134, 142, "Duration"], [187, 194, "Pathology"]]}], [9859, "However, these metabolic effects were only tested at rest.", {"entities": []}], [9861, "In two separate studies conducted previously, we tested the exercise-dependent effects on FAO at various intensities with 1 g YM [22] or when YM combined with a proprietary thermogenic blend of 1.5 g dose [15].", {"entities": [[90, 93, "Parameter"], [122, 125, "Amount"], [126, 128, "Herb name"], [142, 144, "Herb name"], [194, 199, "Amount"]]}], [9862, "Both studies used mixed gender samples and showed an augmented FAO during low-to-moderate intensity exercise of 24% and 26% in YM compared with PLC.", {"entities": [[63, 66, "Parameter"], [127, 129, "Herb name"], [144, 147, "Drug"]]}], [9863, "This is close to the 23% found for FAO in this cohort of female participants, using a higher ingestion dose of 2 g (Figure 1).", {"entities": [[35, 38, "Parameter"], [57, 63, "Sex"], [111, 114, "Amount"]]}], [9864, "The 38%  It is likely that active YM thermogenic ingredients work in synergy to promote lipolysis and augment FAO during exercise.", {"entities": [[34, 36, "Herb name"], [110, 113, "Parameter"]]}], [9865, "The metabolic effects include adrengenic effects and stimulated central nervous system associated with caffeine, anti-lipolytic, and hypocholesterolemic properties in chlorogenic acids (mono- and di-caffeolquinic acids) hydroxycinnamic acids (caffeic acid, quinic acid) and triterpenic saponins, and other minerals and vitamins [5].", {"entities": [[103, 111, "Herb name"]]}], [9866, "Anti-oxidant compounds in YM such as flavonoids and polypheonols are common in other herbal teas and may affect nitric oxide levels, which have been shown to be effective in inducing vasodialatory effects [37] when combined with exercise [27,38].", {"entities": [[26, 28, "Herb name"], [37, 47, "Herb name"], [52, 64, "Herb name"]]}], [9867, "Anti-oxidant compounds of YM have been recently attributed to accelerating muscle strength recovery 24 h after exercise, suggesting that YM favored the concentration of blood antioxidant compounds [39].", {"entities": [[26, 28, "Herb name"], [100, 104, "Duration"], [137, 139, "Herb name"]]}], [9868, "Therefore, YM active ingredients may have played a synergetic role in the metabolic effects found during exercise.", {"entities": [[11, 13, "Herb name"]]}], [9869, "However, further research is required to assess active ingredients of YM capsules and analyze their bioavailability following ingestion.", {"entities": [[70, 72, "Herb name"], [100, 115, "Parameter"]]}], [9870, "Favorable psychomotor effects on mood state and satiety are often expected outcomes of fat and weight-loss supplementation protocols.", {"entities": []}], [9871, "However, several negative side effects were reported for common thermogenic supplements containing caffeine including jitteriness, mood swings, and headache [40].", {"entities": [[26, 38, "Pathology"], [99, 107, "Herb name"], [118, 129, "Pathology"], [131, 142, "Pathology"], [148, 156, "Pathology"]]}], [9872, "It is suggested that these effects can be reduced with YM ingested with other ingredients compared with caffeine [22,40].", {"entities": [[55, 57, "Herb name"], [104, 112, "Herb name"]]}], [9873, "The present study found an improvement in almost all measures of POMS and VAS (Table 1).", {"entities": [[74, 77, "Parameter"]]}], [9874, "In particular, there was an increased focus (p = 0.022), energy (p = 0.008) and concentration (p = 0.003) in the YM treatment compared with PLC, which was combined with no effects on fatigue scores.", {"entities": [[113, 115, "Herb name"], [140, 143, "Drug"]]}], [9875, "Interestingly, the RPE score was not different (Figure 5), suggesting that the positive psychomotor YM effects had no negative effects on the perception of effort and fatigue during exercise, which is important when considering adherence to prescribed exercise for weight loss and sport performance outcomes.", {"entities": [[100, 102, "Herb name"]]}], [9876, "There was also a reduction in appetite VAS measures, especially for hunger (p = 0.019) and prospective eating (p = 0.022), (Table 1) following the YM ingestion compared with PLC.", {"entities": [[39, 42, "Parameter"], [147, 149, "Herb name"], [174, 177, "Drug"]]}], [9877, "These YM appetite control effects are reported in humans for the first time, considering previous positive effects reported in animal models [13,14], and the recent report of appetite suppression following exercise in trained female participants [41].", {"entities": [[6, 8, "Herb name"], [226, 232, "Sex"]]}], [9878, "The reduced VAS appetite scores are also in line with previous results found when YM was combined with other multi-ingredients before and after moderate exercise at Fatmax intensities at 43%  HR response is a standard measurement for exercise intensity and training cardiovascular adaptations, but it was not significantly affected by YM ingestion (Figure 5).", {"entities": [[12, 31, "Parameter"], [82, 84, "Herb name"], [335, 337, "Herb name"]]}], [9879, "Cardiovascular benefits for YM consumption have been reported using more sensitive biomarkers such as detecting an increase in vascular endothelium-dependent vasorelaxing activity in rats [43,44].", {"entities": [[28, 30, "Herb name"], [127, 179, "Target"]]}], [9880, "Such microvascular measurements have been shown to be sensitive to the exercise-dependent effects in human lifestyle interventions [26].", {"entities": []}], [9881, "Perhaps HR monitoring is insufficient to detect vascular responses associated with combining YM ingestion with exercise, and future research could determine more sensitive macro- and microvascular health effects associated with YM ingestion during exercise, especially when combined with detecting YM metabolic effects found in the present study.", {"entities": [[93, 95, "Herb name"], [228, 230, "Herb name"], [298, 300, "Herb name"]]}], [9882, "Although there was not significance for all variables, the significant increase in FAO is mathematically accounted for by combined non-significant reductions in glucose oxidation and non-significant elevated TEE for YM (Figure 3).", {"entities": [[83, 86, "Parameter"], [161, 178, "Parameter"], [208, 211, "Parameter"], [216, 218, "Herb name"]]}], [9883, "The estimates are approximately 0.35 kcal/min greater FAO, and 0.23 reduced CHO with 0.14 kcal/min greater TEE, and with a corresponding significant YM on the calculated total AUC for FAO, CHO, and TEE (p < 0.001).", {"entities": [[32, 45, "Amount"], [54, 57, "Parameter"], [76, 79, "Parameter"], [85, 98, "Amount"], [107, 110, "Parameter"], [149, 151, "Herb name"], [176, 179, "Parameter"], [184, 187, "Parameter"], [189, 192, "Parameter"], [198, 201, "Parameter"]]}], [9884, "It is unclear whether there are additional YM effects on glucose and adipose tissue levels not determined in this study [45].", {"entities": [[43, 45, "Herb name"]]}], [9885, "We used indirect calorimetry methodology to estimate metabolic variables, so perhaps future studies could use different techniques to estimate YM effects on different body compartments, tissues, and metabolites by including in vitro and muscle biopsy methods.", {"entities": [[143, 145, "Herb name"]]}], [9886, "With respect to the gender-specific effects on metabolism, females\u2019 FAO during exercise is known to be higher compared to men [46], possibly due to higher total body fat percentage, fitness level, and exercise modality [47].", {"entities": [[68, 71, "Parameter"]]}], [9887, "The BF% data indicated all females who took part were at the lower BF% percentile, indicating that they were physically active, with higher  Although the positive effects of YM on fat-loss outcomes during exercise are found only in single trials, future research could test the longitudinal YM effectiveness, especially when combining regular exercise training with YM treatment.", {"entities": [[27, 34, "Sex"], [174, 176, "Herb name"], [291, 293, "Herb name"], [366, 368, "Herb name"]]}], [9888, "This is important for lifestyle disease prevention, given the effectiveness found for YM alone as treatment for human obesity, found in recent randomized controlled trials [10,11].", {"entities": [[86, 88, "Herb name"], [143, 171, "Study"]]}], [9889, "The present study used COP as an effective and a well-established \u201cfat burning\u201d exercise training intensity [24,32,33], but other established concepts in a similar domain, such as Fatmax intensity, can also be effective as we previously demonstrated [15].", {"entities": []}], [9890, "The debate concerning a relevant exercise training intensity to maximize \u201cfat-loss\u201d is beyond the scope of this study, and has been sufficiently discussed elsewhere [23,24,28,32,33].", {"entities": []}], [9891, "Most of the studies cited within the present study have attributed their YM ingestion effects to the several bioactive ingredients and only some of those studies have analyzed YM supplement (e.g., total phenolic compounds, caffeine, and saponins) for such ingredients as part of their protocol [39].", {"entities": [[73, 75, "Herb name"], [176, 178, "Herb name"], [203, 221, "Herb name"], [223, 231, "Herb name"], [237, 245, "Herb name"]]}], [9892, "However, methodological differences in terms of YM supplement preparations and methods used should be considered for such comparisons.", {"entities": [[48, 50, "Herb name"]]}], [9893, "For example, the encapsulated ground green YM leaves used in this study is different from lyophilized YM extracts brewed and used elsewhere [39].", {"entities": [[46, 45, "Herb name"], [102, 104, "Herb name"]]}], [9894, "Also, the study did not specifically analyze the polyphenolic content of YM, and only relied on the supplier\u2019s certificate of analysis for YM content, which makes it difficult to attribute findings to a single YM ingredient.", {"entities": [[73, 75, "Herb name"], [139, 141, "Herb name"], [210, 212, "Herb name"]]}], [9895, "Nonetheless, it is reasonable to infer synergetic effects of naturally-occurring YM ingredients but, from a biochemical point of view, performing phytochemical analysis on the supplement is important for future research.", {"entities": [[81, 83, "Herb name"]]}], [9896, "It would be also interesting to follow up with testing the YM active ingredients\u2019 bioavailability post ingestion.", {"entities": [[59, 61, "Herb name"], [82, 97, "Parameter"]]}], [9897, "Limited research has been conducted in humans prior to this study [10,11,22], which makes it difficult to confirm some parallels made with animal models when explaining YM mechanisms.", {"entities": [[169, 171, "Herb name"]]}], [9898, "Nonetheless, our findings in human participants extend previous knowledge and demonstrate novel applications of YM for human metabolic health.", {"entities": [[112, 114, "Herb name"]]}], [9899, "Combining YM ingestion with exercise prescription at COP training intensities improves FAO, measures of satiety and mood state compared with exercise alone.", {"entities": [[10, 12, "Herb name"], [87, 90, "Parameter"]]}], [9900, "The underlying mechanisms of such effects require further investigation.", {"entities": []}], [9901, "The combined exercise and YM effects on metabolic, psychomotor, and appetite control outcomes are essential for designing an optimized lifestyle prevention for metabolic health and exercise fat-loss outcomes.", {"entities": [[26, 28, "Herb name"]]}], [9902, "Future research should test the longitudinal effectiveness of YM and exercise for metabolic health outcomes.", {"entities": [[62, 64, "Herb name"]]}], [9903, "The authors would like to thank the volunteer participants and the laboratory technicians at Sheffield Hallam University for their help during data collection phase.", {"entities": []}], [9904, "A.A. conceived the idea, designed the study, supervised data collection, analyzed the data, and wrote the full manuscript.", {"entities": []}], [9905, "R.A. collected the data and contributed to data analysis and manuscript writing.", {"entities": []}], [9906, "Both authors approved the final manuscript version.", {"entities": []}], [9907, "The authors declare no conflict of interest.", {"entities": []}], [9908, "Fatty Acid Oxidation (FAO) during exercise in Yerba Mate (YM) vs. placebo (PLC).", {"entities": [[0, 26, "Parameter"], [46, 61, "Herb name"], [66, 79, "Drug"]]}], [9909, "ANOVA treatment effect (p < 0.05).", {"entities": []}], [9910, "* Significantly higher in YM compared with PLC.", {"entities": [[26, 28, "Herb name"], [43, 46, "Drug"]]}], [9911, "Carbohydrate oxidation during exercise in Yerba Mate (YM) vs. placebo (PLC), (p > 0.05).", {"entities": [[0, 22, "Parameter"], [42, 57, "Herb name"], [62, 75, "Drug"]]}], [9912, "Total Energy expenditure during exercise in Yerba Mate (YM) vs. placebo (PLC).", {"entities": [[44, 59, "Herb name"], [64, 77, "Drug"]]}], [9913, "Heart rate response during exercise in Yerba Mate (YM) vs. placebo (PLC).", {"entities": [[39, 54, "Herb name"], [59, 72, "Drug"]]}], [9914, "Rate of perceived exertion during exercise in Yerba Mate (YM) vs. placebo (PLC).", {"entities": [[46, 61, "Herb name"], [66, 80, "Drug"]]}], [9916, "Results displayed as Mean \u00b1 SD.", {"entities": []}], [9918, "Results displayed as Mean \u00b1 SD.", {"entities": []}], [9919, "Drug transporters play important roles in the absorption, distribution, and elimination of drugs and thereby, modulate drug efficacy and toxicity.", {"entities": [[0, 17, "Parameter"], [46, 96, "Parameter"], [137, 145, "Pathology"]]}], [9920, "With a growing use of poly pharmacy, concurrent administration of herbal extracts that modulate transporter activities with drugs can cause serious adverse reactions.", {"entities": [[66, 81, "Herb name"], [96, 118, "Parameter"], [148, 165, "Pathology"]]}], [9921, "Therefore, prediction and evaluation of drug-drug interaction potential is important in the clinic and in the drug development process.", {"entities": []}], [9922, "DA-9801, comprising a mixed extract of Dioscoreae rhizoma and Dioscorea nipponica Makino, is a new standardized extract currently being evaluated for diabetic peripheral neuropathy in a phase II clinical study.", {"entities": [[0, 88, "Herb name"], [99, 119, "Extraction process"], [150, 180, "Pathology"], [184, 209, "Study"]]}], [9923, "The effects of DA-9801 on the pharmacokinetics of relevant substrate drugs of these transporters were also examined in vivo in rats.", {"entities": [[15, 22, "Herb name"], [26, 96, "Parameter"]]}], [9924, "Diabetic peripheral neuropathy is one of the most debilitating complications of type 1 and type 2 diabetes and its histopathology is characterized by axonal degeneration, demyelination, and atrophy [1,2].", {"entities": [[0, 30, "Pathology"], [80, 106, "Pathology"], [150, 197, "Pathology"]]}], [9925, "Approximately 50% of diabetes patients have symptoms of diabetic peripheral neuropathy [3].", {"entities": [[21, 29, "Pathology"], [44, 86, "Pathology"]]}], [9926, "DA-9801 may improve diabetic neuropathy-induced tissue damage by increasing nerve growth factor levels in target tissues, improving nerve conduction velocity, and promoting recovery from neuronal degeneration [4,5].", {"entities": [[0, 7, "Herb name"], [20, 61, "Pathology"], [76, 102, "Parameter"], [132, 157, "Parameter"], [187, 208, "Pathology"]]}], [9927, "It also showed neuroprotective effects on peripheral nerves in streptozotocin-induced diabetic rats [6,7].", {"entities": [[63, 77, "Drug"], [86, 94, "Pathology"]]}], [9928, "Herb-drug interactions, resulting from concurrent use of herbal drugs may cause adverse reactions such as toxicity and treatment failure [8].", {"entities": [[57, 69, "Herb name"], [80, 97, "Pathology"], [106, 114, "Pathology"]]}], [9929, "The mechanisms underlying herb-drug interactions involve inhibition or induction of cytochrome P450 (CYP) enzymes, UDP-glucuronosyltransferase (UGT) enzymes, and drug transporters [9,10].", {"entities": [[84, 179, "Target"]]}], [9930, "St. John\u2019s wort (Hypericum perforatum), ginkgo (Ginko biloba), ginseng (Panax ginseng), milk thistle (Silybum marianum), and licorice (Glycyrrhiza glabra) have been reported to cause drug interactions with anticoagulants, antiretroviral drugs, anticancer drugs, immunosuppressants, or antidepressants [11-15].", {"entities": [[0, 154, "Herb name"], [206, 300, "Drug"]]}], [9931, "Therefore, it is necessary to evaluate herb-drug interactions in order to prevent potentially dangerous clinical outcomes.", {"entities": [[94, 121, "Pathology"]]}], [9932, "DA-9801 did not potently inhibit CYP 1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, or 3A4 and UGT 1A1, 1A4, 1A9, or 2B7 in human liver microsomes, indicating that DA-9801 may not inhibit the metabolism of CYP- and UGT-catalyzed drugs in humans [8].", {"entities": [[0, 7, "Herb name"], [33, 109, "Target"], [153, 160, "Herb name"], [177, 223, "Parameter"]]}], [9933, "We also investigated the effects of DA-9801 on the pharmacokinetics of substrates for the effected transporters in vivo in rats.", {"entities": [[36, 43, "Herb name"], [47, 111, "Parameter"]]}], [9934, "Co., Seoul, Korea) and their identity was kindly confirmed by Prof. Yeong Bae Seo (a specialist in plant classification, Natural Products Research Institute, Seoul National University, Seoul, Korea).", {"entities": []}], [9935, "DA-9801 was prepared as previously reported [5].", {"entities": [[0, 7, "Herb name"]]}], [9936, "The levels of two marker components - dioscin (1.37%) and allantoin (3.29%) - in DA-9801 were determined using high performance liquid chromatography [5].", {"entities": [[38, 75, "Herb name"], [81, 88, "Herb name"]]}], [9937, "[ HEK293 cells transiently overexpressing OAT1, OAT3, OCT1, OCT2, OATP1B1, and OATP1B3 transporters were purchased from Corning-Gentest (Tewksbury, MA, USA).", {"entities": [[42, 99, "Parameter"]]}], [9938, "Animals were acclimated for 1\u00a0week in a temperature controlled room (23\u2009\u00b1\u20092\u00b0C), with a relative humidity of 55\u2009\u00b1\u200910%, an illumination intensity of 150\u2013300 lux, a frequency of air ventilation of 15\u201320 times/h, and a 12\u00a0h illumination (07:00\u201319:00).", {"entities": [[24, 34, "Duration"], [40, 51, "Parameter"], [69, 77, "Amount"], [96, 104, "Parameter"], [108, 116, "Amount"], [121, 143, "Parameter"], [147, 158, "Amount"], [160, 207, "Frequency"], [215, 245, "Duration"]]}], [9939, "Food and water were supplied ad libitum.", {"entities": []}], [9940, "All animal procedures were approved by the Animal Care and Use Committee in The Catholic University of Korea.", {"entities": []}], [9941, "Rats were cannulated with polyethylene tubing (PE-50, Natsume Co, Tokyo, Japan) in the jugular vein for sampling under anesthesia with isoflurane.", {"entities": [[119, 129, "Parameter"], [135, 145, "Drug"]]}], [9942, "Each rat was housed individually in a rat metabolic cage and allowed to recover from anesthesia.", {"entities": [[85, 95, "Parameter"]]}], [9943, "The rats were not restrained at any time during the study.", {"entities": []}], [9944, "Heparinized isotonic saline (10 U/mL) was used to flush the catheters to prevent blood clotting.", {"entities": [[0, 27, "Extraction process"], [29, 36, "Amount"], [81, 95, "Pathology"]]}], [9945, "The rats were fasted for more than 12\u00a0h before oral administration of drugs.", {"entities": [[14, 20, "Parameter"], [35, 39, "Duration"]]}], [9946, "DA-9801 was dissolved in DMSO/propylene glycol/deionized water (2:6:2, v/v), and a 1,000\u00a0mg/kg dose was administered to the rats by oral gavages (vehicle dosing volume, 3\u00a0mL/kg) at 5\u00a0min and 2\u00a0h prior to the oral administration of cimetidine at a dose of 10\u00a0mg/kg [18] and furosemide at a dose of 10\u00a0mg/kg [19] (vehicle dosing volume, 2\u00a0mL/kg).", {"entities": [[0, 7, "Herb name"], [25, 75, "Extraction process"], [83, 94, "Amount"], [181, 186, "Duration"], [191, 194, "Duration"], [231, 241, "Drug"], [255, 263, "Amount"], [273, 283, "Drug"], [297, 305, "Amount"]]}], [9947, "Cimetidine and furosemide were dissolved in deionized water and DMSO/propylene glycol/deionized water (2:4:4, v/v/v), respectively.", {"entities": [[0, 10, "Drug"], [15, 25, "Drug"], [44, 116, "Extraction process"]]}], [9948, "Blood samples were collected prior to cimetidine and furosemide administration (to serve as a control), 5, 15, 30, 45\u00a0min, and 1, 1.5, 2, 3, 4, 6, 8\u00a0h after oral administration of cimetidine and furosemide.", {"entities": [[38, 48, "Drug"], [53, 63, "Drug"], [104, 156, "Duration"], [180, 190, "Drug"], [195, 205, "Drug"]]}], [9949, "[20].", {"entities": []}], [9950, "Thirty \u03bcL of rat plasma samples, calibration standards, and quality control (QC) samples were vortex-mixed with 100\u00a0\u03bcL of tiapride in methanol (5\u00a0ng/mL, internal standard, IS) for 3\u00a0min at a high speed.", {"entities": [[112, 118, "Amount"], [122, 130, "Drug"], [134, 142, "Extraction process"], [144, 151, "Amount"], [176, 185, "Duration"]]}], [9951, "An aliquot (3\u00a0\u03bcL) was injected into the LC-MS/MS system.", {"entities": []}], [9952, "Ten \u03bcL of rat urine samples, urine calibration standards, and QC samples were vortex-mixed with 1,000\u00a0\u03bcL of tiapride in methanol (5\u00a0\u03bcg/mL) for 3\u00a0min at high speed.", {"entities": [[96, 104, "Amount"], [108, 116, "Drug"], [120, 128, "Extraction process"], [130, 137, "Amount"], [139, 148, "Duration"]]}], [9954, "The LC-MS/MS system consisted of an Agilent 1200 series (Agilent Technologies, Wilmington, DE, USA) and a 6460 triple quadrupole mass spectrometer (Agilent Technologies).", {"entities": []}], [9955, "Mass Hunter software (Agilent Technologies) was used for LC-MS/MS system control and data processing.", {"entities": []}], [9956, "Separation was performed on a Luna phenyl-hexyl column (5\u00a0\u03bcm, 2.1\u00a0mm i.d.", {"entities": []}], [9957, "\u00d7\u2009100\u00a0mm, Phenomenex, Torrance, CA, USA) with a gradient elution of 5% methanol with 10\u00a0mM ammonium formate (mobile phase A) and 95% methanol with 10\u00a0mM ammonium formate (mobile phase B) at a flow rate of 0.4\u00a0mL/min: 30% mobile phase B for 0.5\u00a0min, 30% to 85% mobile phase B for 0.5\u00a0min, 85% mobile phase B for 3.0\u00a0min, 85% to 30% mobile phase B for 0.1\u00a0min, 30% mobile phase B for 4\u00a0min.", {"entities": [[68, 70, "Amount"], [71, 79, "Extraction process"], [85, 90, "Amount"], [91, 107, "Extraction process"], [129, 132, "Amount"], [133, 141, "Extraction process"], [147, 152, "Amount"], [153, 169, "Extraction process"], [205, 215, "Frequency"], [236, 247, "Duration"], [275, 286, "Duration"], [307, 318, "Duration"], [346, 357, "Duration"], [378, 387, "Duration"]]}], [9958, "Selected reaction monitoring (SRM) mode was used for quantification: m/z 253.1\u2009\u2192\u2009159.1 for cimetidine and m/z 329.1\u2009\u2192\u2009256 for tiapride.", {"entities": [[91, 101, "Drug"], [126, 134, "Drug"]]}], [9959, "[21].", {"entities": []}], [9960, "Thirty \u03bcL of rat plasma samples, calibration standards, and QC samples were vortex-mixed with 100\u00a0\u03bcL of 4-hydroxydiclofenac-d In the inhibition studies, the percentages of inhibition were calculated using the ratio of the transport rate of probe substrates with or without DA-9801 and the relevant data were fitted to an inhibitory effect model [i.e.", {"entities": [[94, 100, "Amount"], [104, 125, "Drug"], [240, 256, "Parameter"], [273, 280, "Herb name"]]}], [9961, "In the in vivo rat studies, non-compartmental pharmacokinetic analysis was also performed using the WinNonlin software.", {"entities": [[7, 26, "Study"]]}], [9963, "The area from the last datum point to time infinity (AUC Statistical significance was analyzed using the Mann\u2013Whitney U test, and values of p\u2009<\u20090.05 were considered statistically significant.", {"entities": [[0, 56, "Parameter"]]}], [9964, "The SPSS software package (ver.", {"entities": []}], [9965, "19.0, SPSS, Chicago, IL) was used for statistical analysis.", {"entities": []}], [9966, "To characterize the inhibitory effect of DA-9801 on the uptake transporters, we measured the uptake of representative substrates for each transporter in HEK293 cells overexpressing OAT1, OAT3, OCT1, OCT2, OATP1B1, and OATP1B3 in the presence of DA-9801 (1\u2013300\u00a0\u03bcg/mL).", {"entities": [[41, 48, "Herb name"], [52, 75, "Target"], [89, 149, "Parameter"], [181, 225, "Parameter"], [245, 252, "Herb name"]]}], [9967, "**p <0.01, for the comparison with control group.", {"entities": []}], [9968, "Each data point represents the mean\u2009\u00b1\u2009S.D.", {"entities": []}], [9969, "of five rats.", {"entities": []}], [9970, "Each data point represents the mean\u2009\u00b1\u2009S.D.", {"entities": []}], [9971, "of five rats.", {"entities": []}], [9972, "The recent trend toward the use of poly pharmacy, which comprises drugs with different mechanisms of action, necessitates careful consideration of the potential drug-drug interactions (DDI) between the combined medicines.", {"entities": []}], [9973, "DDIs between inhibitors and substrates of metabolizing enzymes or transporters can cause serious adverse reactions.", {"entities": [[13, 78, "Parameter"], [97, 114, "Pathology"]]}], [9974, "Therefore, prediction and evaluation of DDI potential is important in the clinic and in the drug development process.", {"entities": []}], [9975, "It is increasingly recognized that drug transporters have a significant impact on DDIs by modulating the absorption, distribution, and excretion of drugs, alone or in interaction with drug-metabolizing enzymes [16,25,26].", {"entities": [[35, 52, "Parameter"], [101, 153, "Parameter"]]}], [9976, "In particular, screening of clinically important drug transporters such as OCT1, OCT2, OAT1, OAT3, OATP1B1, OATP1B3, P-gp, and BCRP in the drug development stage is recommended [16].", {"entities": [[49, 131, "Parameter"]]}], [9977, "In this study, we investigated the inhibitory effects of DA-9801 on these transporters.", {"entities": [[57, 64, "Herb name"]]}], [9978, "IC It is important to note that in vivo human studies investigating the interactions between DA-9801 and substrates for the affected transporters such as OCT1, OCT2, and OAT3 are necessary to determine whether the in vitro inhibition of these transporters by DA-9801 is relevant or not.", {"entities": [[32, 53, "Study"], [93, 100, "Herb name"], [105, 174, "Parameter"], [259, 266, "Herb name"]]}], [9979, "Therefore, we treated DA-9801 at a dose of 1,000\u00a0mg/kg in this study since the inhibitor has been treated at a maximum effective dose to investigate the highest possibility of in vivo herb-drug interaction.", {"entities": [[22, 29, "Herb name"], [43, 54, "Amount"], [109, 133, "Parameter"]]}], [9980, "Then, although the experimental systems and species were not perfectly matched, after determining the IC Cimetidine is a H2 receptor antagonist used for the treatment of peptic ulcers and related disorders.", {"entities": [[105, 143, "Drug"], [170, 205, "Pathology"]]}], [9981, "It is eliminated mainly by renal excretion in rats, with 70% eliminated by 72\u00a0h after oral ingestion without significant metabolism [29].", {"entities": [[27, 42, "Parameter"], [57, 60, "Amount"], [75, 79, "Duration"]]}], [9982, "Cimetidine undergoes extensive tubular secretion in which Oct1/2 and Oat3 play major roles [23].", {"entities": [[0, 10, "Drug"], [31, 48, "Parameter"], [58, 73, "Parameter"]]}], [9983, "While DA-9801 pre-dose (5\u00a0min or 2\u00a0h) did not change the pharmacokinetics of furosemide, it decreased the C The authors have declared that no competing interests exist.", {"entities": [[6, 13, "Herb name"], [24, 36, "Duration"], [77, 87, "Drug"]]}], [9984, "Conceived and designed the experiments: ISS, HEK, SZC, MS, HSL.", {"entities": []}], [9985, "Performed the experiments: ISS, TYK, HYJ, ENK, SSK.", {"entities": []}], [9986, "Analyzed the data: ISS, TYK, HUJ, ENK, SSK, HEK, SZC, MS, HSL.", {"entities": []}], [9987, "Wrote the paper: ISS, TYK, HUJ, ENK, SSK, HEK, SZC, MS, HSL.", {"entities": []}], [9988, "All authors read and approved the final manuscript.", {"entities": []}], [9989, "The pre-publication history for this paper can be accessed here:           This work was supported by the Global Leading Technology Program of the Office of Strategic R&D Planning (OSP), funded by the Ministry of Knowledge Economy (MKE), Republic of Korea (10039303) and The Catholic University of Korea, 2011 (M-2011-B0002-00046).", {"entities": []}], [9990, "The management of neuropsychiatric disorders relies heavily on pharmacotherapy.", {"entities": [[18, 44, "Pathology"]]}], [9991, "The use of herbal products as complimentary medicine, often concomitantly, is common among patients taking prescription neuropsychiatric drugs.", {"entities": [[120, 142, "Drug"]]}], [9992, "Herb-drug interaction, a clinical consequence of this practice, may jeopardize the success of pharmacotherapy in neuropsychiatry.", {"entities": []}], [9993, "This study reviewed the relevant literature and identified 13 commonly used herbal products - celery, echinacea, ginkgo, ginseng, hydroxycut, kava, kratom, moringa, piperine, rhodiola, St. John\u2019s wort, terminalia/commiphora ayurvedic mixture and valerian - which have shown clinically relevant interactions with prescription drugs used in the management of neuropsychiatric disorders.", {"entities": [[94, 100, "Herb name"], [102, 111, "Herb name"], [113, 119, "Herb name"], [121, 128, "Herb name"], [130, 140, "Herb name"], [142, 146, "Herb name"], [148, 154, "Herb name"], [156, 163, "Herb name"], [165, 173, "Herb name"], [175, 183, "Herb name"], [185, 200, "Herb name"], [202, 233, "Herb name"], [246, 254, "Herb name"], [357, 383, "Pathology"]]}], [9994, "This underscores the importance of caution in herb-drug co-medication.", {"entities": []}], [9995, "Herbal products are globally popular as complementary and/or alternative medicine [1].", {"entities": []}], [9996, "The 2019 Herb Market Report estimates that $9.6 billion was spent on herbal supplements in the United States alone, showing an increase of 8.6% in sales over the previous year [2].", {"entities": []}], [9997, "Furthermore, the global financial investment in herbal medicine is expected to reach $129 billion by the year 2023 [3].", {"entities": []}], [9998, "Among several reasons, including culture and accessibility, the general perception of safety and absence of adverse effects with the use of herbal medicines is considered the overbearing factor responsible for the popularity of herbal medicine [4, 5].", {"entities": [[108, 123, "Pathology"]]}], [9999, "However, like conventional drugs, the phytochemical constituents of herbs are capable of exerting pharmacological changes in the human body.", {"entities": []}], [10000, "Data on the prevalence of herb-drug combination use may vary based on such factors as age, disease, health education, culture and geography.", {"entities": []}], [10001, "The data from the 2015 National Consumer Survey on the Medication Experience and Pharmacists' Roles, as analyzed by Rashrash et al.", {"entities": []}], [10002, "showed that the practice of herbal co-medication with prescription drugs cut across various patient demographics, with 38% of respondents reporting concomitant herbal use [6].", {"entities": []}], [10003, "Thus, a toxic response to herbal ingestion is not uncommon.", {"entities": []}], [10004, "Besides the well-known ability of phytochemicals to inhibit and/or induce drug-metabolizing enzymes and transport proteins, several phytoconstituents are capable of exerting pharmacological effects on the central nervous system.", {"entities": []}], [10005, "The consequent pharmacokinetic and pharmacodynamic interactions with orthodox medications often result in deleterious clinical consequences.", {"entities": []}], [10006, "A study reported 36.4% prevalence of concomitant Chinese medicine/antipsychotic drug use [7], while a similar survey found a 33.6% prevalence among British community-dwelling older adults [8].", {"entities": [[66, 84, "Drug"]]}], [10007, "Depending on other factors, these figures have been reported to be as high as 80% [9, 10].", {"entities": []}], [10008, "Thus, it can be conservatively estimated that one in three patients taking prescription medicine also consumes herbal supplements concurrently.", {"entities": []}], [10009, "Like drug-drug interactions, HDIs occur when the expected systemic disposition and/or effect of an administered drug is altered by, or due to, the presence/action of a concomitantly administered herbal product.", {"entities": []}], [10010, "Since the accidental discovery of the ability of grapefruit juice to alter the pharmacokinetic profiles of felodipine through the inhibition of cytochrome P450 (CYP) and P-glycoprotein (P-gp), more studies have elucidated various mechanisms of HDI [11].", {"entities": [[49, 65, "Herb name"], [107, 117, "Drug"], [144, 165, "Target"], [170, 191, "Target"]]}], [10011, "Besides the inhibitory and inductive effects of phytochemicals on drug-metabolizing enzymes (DMEs) and transport proteins, the intrinsic ability of phytoconstituents to interact with physiologic receptors can precipitate antagonistic, additive, or synergistic pharmacodynamic responses in the presence of prescription drugs.", {"entities": []}], [10012, "While most HDIs might be clinically inconsequential, many others are deleterious and lead to therapy failure and/or toxic manifestations [12, 13].", {"entities": []}], [10013, "Achieving stable control of symptoms with pharmacotherapy in neuropsychiatry takes time and requires professional skills in dose titration and maximization while avoiding toxicity.", {"entities": []}], [10014, "The potential of herbal products to disrupt this careful balance could be dangerous to patients and complicate management strategies.", {"entities": []}], [10015, "Several drugs used in neuropsychiatry are substrates of CYPs, making them potential victims of HDIs.", {"entities": []}], [10016, "Herbal products with claimed beneficial effects in mental health may elicit pharmacodynamic changes via similar mechanisms to prescription medicines.", {"entities": []}], [10017, "The purpose of this paper is to provide a review of the current evidence for HDIs in the pharmacotherapy of neuropsychiatric disorders.", {"entities": [[108, 135, "Pathology"]]}], [10018, "It is aimed that the review, with a focus on clinically relevant interactions, will be of interest to the health-consuming public, researchers, and healthcare professionals, particularly those who manage neuropsychiatric disorders.", {"entities": [[204, 230, "Pathology"]]}], [10019, "A systematic review of the literature was conducted to identify and provide an overview of individual herbal products that have shown clinically relevant HDIs.", {"entities": []}], [10020, "While herbal medicine is generally not replacing prescription medicine, the practice of concurrent use of herbal and prescription medicines raises concerns of herb-drug interactions (HDIs).", {"entities": []}], [10021, "The potential for synergy or antagonism is, therefore, a cause for clinical concern in herb-drug combination therapies.", {"entities": []}], [10022, "The following search terms and the combinations thereof were used: herbal medicine, herbal products, herbal interactions, psychiatry, neuropsychiatry, pharmacotherapy.", {"entities": []}], [10023, "Further searches were conducted with combinations of identified individual herbal products commonly used in neuropsychiatry and individual neuropsychiatric drugs.", {"entities": [[139, 161, "Drug"]]}], [10024, "Retrieved studies were screened for inclusion which was based on the availability of the publications in the English language and the performance of the studies in human subjects.", {"entities": []}], [10025, "Studies included for extensive reviews were not limited by the time or place of study/publication.", {"entities": []}], [10026, "A total of 525 publications were retrieved from the searches, with only 32 found to meet inclusion criteria for extensive review (Fig.", {"entities": []}], [10027, "1).", {"entities": []}], [10028, "Overall, 13 herbal products were identified to have shown clinically relevant HDIs in neuropsychiatry.", {"entities": []}], [10029, "These are celery, echinacea, ginkgo, ginseng, hydroxycut, kava, kratom, moringa, piperine, rhodiola, St. John\u2019s wort, terminalia/commiphora ayurvedic mixture and valerian.", {"entities": [[10, 16, "Herb name"], [18, 27, "Herb name"], [29, 35, "Herb name"], [37, 44, "Herb name"], [46, 56, "Herb name"], [58, 62, "Herb name"], [64, 70, "Herb name"], [72, 79, "Herb name"], [81, 89, "Herb name"], [91, 99, "Herb name"], [101, 116, "Herb name"], [118, 149, "Herb name"], [162, 170, "Herb name"]]}], [10030, "A summary of the reviewed studies is presented in Table 1.", {"entities": []}], [10031, "Celery (Apium graveolens) is an aromatic plant whose fresh herbs are commonly used in salad preparations and extracted into juices.", {"entities": [[0, 25, "Herb name"], [109, 130, "Extraction process"]]}], [10032, "Celery root and leaf extracts are consumed as medicinal supplements in capsule, tablet, and liquid formulations.", {"entities": [[0, 6, "Herb name"], [7, 11, "Herb part"], [16, 20, "Herb part"]]}], [10033, "The plant is a member of the umbelliferous family of herbs which contains phytoestrogens, the natural estrogen-like phytochemicals capable of directly binding and activating estrogen receptors.", {"entities": [[174, 192, "Target"]]}], [10034, "Potent inhibition of the several isoforms of CYP by celery extracts, including active components like methoxsalen, has been reported [48-50].", {"entities": [[33, 48, "Target"], [52, 58, "Herb name"], [102, 113, "Herb name"]]}], [10035, "Searches were conducted using the PubMed, Medline, and Google Scholar databases for original clinical studies, including case reports and case series, where the focus is on HDIs.", {"entities": []}], [10036, "Thus, celery supplements are popular for the management of low estrogen states, such as menopause.", {"entities": [[6, 12, "Herb name"], [88, 97, "Pathology"]]}], [10037, "Phytoestrogens and other bioactive components of celery can interact with the DMEs, including those in the CYP450 family.", {"entities": [[49, 55, "Herb name"], [78, 82, "Target"], [107, 120, "Target"]]}], [10038, "In animal studies, celery extracts inhibit the metabolism and prolong the effects of CYP substrates [51, 52].", {"entities": [[3, 17, "Study"], [19, 25, "Herb name"], [85, 88, "Target"]]}], [10039, "There are currently no randomized controlled clinical trials to highlight the celery-mediated HDIs in humans.", {"entities": []}], [10040, "However, a published case report highlights a pharmacokinetic interaction between celery and venlafaxine.", {"entities": [[82, 88, "Herb name"], [93, 104, "Drug"]]}], [10041, "A 52-year-old patient with a medical history of major depressive disorder, stabilized with venlafaxine and SJW, developed mania and hallucinations within 48 hours after initiating celery supplementation for menopausal issues.", {"entities": [[2, 13, "Age"], [48, 73, "Pathology"], [91, 102, "Drug"], [107, 110, "Drug"], [122, 127, "Pathology"], [132, 146, "Pathology"], [154, 162, "Duration"], [180, 186, "Herb name"], [207, 224, "Pathology"]]}], [10042, "The presentations were associated with a higher-than-expected plasma level of venlafaxine.", {"entities": [[78, 89, "Drug"]]}], [10043, "The discontinuation of celery resolved the patient\u2019s symptoms.", {"entities": [[23, 29, "Herb name"]]}], [10044, "Anecdotal pieces of evidence like this not only highlight the reality and severity of the consequences of HDIs, they underscore the importance of further studies to guide clinical decisions.", {"entities": []}], [10045, "Echinacea is a commonly used herbal preparation as complementary treatment for respiratory infections and common cold.", {"entities": [[0, 9, "Herb name"], [79, 101, "Pathology"], [106, 117, "Pathology"]]}], [10046, "Although there are nine common species of Echinacea, most commercial preparations of echinacea in the United States are made from Echinacea purpurea.", {"entities": [[42, 51, "Herb name"], [85, 94, "Herb name"], [130, 148, "Herb name"]]}], [10047, "Preclinical studies have suggested echinacea as a modulator of CYP enzymes and P-gp [53, 54].", {"entities": [[0, 19, "Study"], [35, 44, "Herb name"]]}], [10048, "The result suggests that the in vitro inhibition of CYP3A4 by echinacea is potent enough to translate to HDI with drugs that are primarily eliminated by CYP3A4-dependent metabolism.", {"entities": [[52, 58, "Target"], [62, 71, "Herb name"]]}], [10049, "The commercial ginkgo products currently on the market are prepared mainly by leaf extraction, standardized to contain specified levels of flavones, glycosides, and terpenoids [57].", {"entities": [[15, 21, "Herb name"], [139, 147, "Herb name"], [149, 159, "Herb name"], [165, 175, "Herb name"]]}], [10050, "Several controlled clinical studies, as shown by review and meta-analysis of published data, suggest that the use of ginkgo is associated with clinically significant improvement in symptoms of cognition decline and memory loss, anxiety and mood disorders, fatigue and general well-being, as well as cardiovascular disorders [59-61].", {"entities": [[0, 35, "Study"], [117, 123, "Herb name"], [193, 210, "Pathology"], [215, 226, "Pathology"], [228, 235, "Pathology"], [240, 254, "Pathology"], [256, 263, "Pathology"], [299, 323, "Pathology"]]}], [10051, "Historically associated with traditional Chinese medicines, ginkgo (Ginkgo biloba) is now globally popular and has been a top-seller in the US as a dietary supplement for several health conditions, including anxiety, Alzheimer\u2019s dementia, peripheral artery disease, and tinnitus [55, 56].", {"entities": [[41, 48, "Ethnic group"], [60, 82, "Herb name"], [208, 215, "Pathology"], [217, 237, "Pathology"], [239, 264, "Pathology"], [270, 278, "Pathology"]]}], [10052, "In an open-label, crossover study, extracts of echinacea increased the systemic clearance of midazolam by 34%, while decreasing the AUC by 23% [17].", {"entities": [[0, 33, "Study"], [47, 56, "Herb name"], [71, 89, "Parameter"], [93, 102, "Drug"], [132, 135, "Parameter"]]}], [10053, "The study analyzed the PK of midazolam, a probe substrate of CYP3A4, before and after an 8-day course of echinacea treatment in 12 healthy volunteers.", {"entities": [[23, 25, "Parameter"], [29, 38, "Drug"], [61, 67, "Target"], [89, 94, "Duration"], [105, 114, "Herb name"], [128, 149, "Cohort"]]}], [10054, "The flavonoids have been shown to have antioxidant activity, while the ginkgolides have demonstrated an inhibitory effect on the platelet-activating factor with potential cardiovascular benefits [58].", {"entities": [[4, 14, "Herb name"], [71, 82, "Herb name"], [129, 155, "Target"]]}], [10055, "The popularity of ginkgo supplements raises concern for concurrent use with prescription medications and the risk for HDIs.", {"entities": [[18, 24, "Herb name"]]}], [10056, "Preclinical studies have shown that the phytochemical constituents of ginkgo significantly inhibit/induce DMEs enzymes and transport proteins, including CYPs, UGTs, P-gp, and OATPs [62-69].", {"entities": [[0, 19, "Study"], [70, 76, "Herb name"], [153, 157, "Target"], [159, 163, "Target"], [165, 169, "Target"], [175, 180, "Target"]]}], [10057, "Nine clinically relevant HDI reports (5 clinical study, 3 case reports, and 1 case series) were identified with regard to ginkgo biloba extracts (GBE) and neuropsychiatric drugs.", {"entities": [[38, 55, "Study"], [56, 70, "Study"], [76, 89, "Study"], [122, 150, "Herb name"]]}], [10058, "Two open-label-crossover studies evaluated the clinical significance of reported in vitro CYP3A4 inhibitory activity of GBE using midazolam as probe substrate.", {"entities": [[0, 32, "Study"], [90, 96, "Target"], [120, 123, "Herb name"], [130, 139, "Drug"]]}], [10059, "In both studies, the concomitant use of GBE was associated with the significant reduction (up to 34%) in the AUC of midazolam in the healthy volunteers [24, 25].", {"entities": [[40, 43, "Herb name"], [109, 112, "Parameter"], [116, 125, "Drug"], [133, 140, "Pathology"]]}], [10060, "Three other studies evaluated GBE interaction with specific neuropsychiatric drugs.", {"entities": [[30, 33, "Herb name"]]}], [10061, "Lei et al., whose study analyzed bupropion in 14 healthy volunteers before and after a 14-day pretreatment with GBE, did not find clinically significant HDIs between GBE and bupropion [18].", {"entities": [[33, 42, "Drug"], [46, 67, "Cohort"], [87, 93, "Duration"], [112, 115, "Drug"], [166, 169, "Herb name"], [174, 183, "Drug"]]}], [10062, "Although no significant change was observed in the total bupropion exposure (AUC) in the absence/presence of GBE, the combination was associated with significantly reduced t In the study by Yasui\u2010Furukori et al., the steady-state pharmacokinetics of donepezil in 14 in-patients with Alzheimer's disease was analyzed before and after 30-day ginkgo supplementation with no significant difference observed [23].", {"entities": [[57, 66, "Drug"], [76, 81, "Parameter"], [109, 112, "Herb name"], [250, 259, "Drug"], [263, 277, "Cohort"], [283, 302, "Drug"], [333, 339, "Duration"], [340, 346, "Herb name"]]}], [10064, "These mixed results suggest that the modulatory effect of GBE on CYPs may not affect all CYP-substrates equally.", {"entities": [[58, 61, "Herb name"], [65, 69, "Target"], [89, 103, "Target"]]}], [10065, "The duration of supplementation may also be an important factor for consideration.", {"entities": []}], [10066, "A case report of ginkgo-induced HDI involved a patient with a history of schizophrenia who was stable with risperidone treatment for over three years.", {"entities": [[0, 13, "Study"], [17, 23, "Herb name"], [73, 86, "Pathology"], [107, 118, "Drug"], [133, 149, "Duration"]]}], [10067, "The patient developed priapism within 2 weeks of initiating GBE for occasional tinnitus.", {"entities": [[22, 30, "Pathology"], [38, 45, "Duration"], [60, 63, "Herb name"], [79, 87, "Pathology"]]}], [10068, "The concurrent use of GBE and risperidone was believed to have increased the serum risperidone concentrations due to CYP inhibition, leading to priapism, a known dose-dependent adverse effect of risperidone.", {"entities": [[22, 25, "Herb name"], [30, 41, "Drug"], [117, 120, "Target"], [144, 152, "Pathology"], [177, 191, "Pathology"], [195, 206, "Drug"]]}], [10069, "This interaction was further supported by the absence of reoccurrence when the patient discontinued GBE upon treatment and discharge [19].", {"entities": [[100, 103, "Herb name"]]}], [10070, "Another case report involved GBE and trazodone in a patient who had a history of cognitive impairment that was refractory to donepezil and vitamin E therapy.", {"entities": [[29, 32, "Herb name"], [37, 46, "Drug"], [81, 101, "Pathology"], [125, 134, "Drug"], [139, 156, "Drug"]]}], [10071, "The patient fell into coma (reversible with flumazenil) within three days of initiating concomitant therapy with trazodone and GBE.", {"entities": [[22, 26, "Pathology"], [44, 54, "Drug"], [113, 122, "Drug"], [127, 130, "Herb name"]]}], [10072, "Multiple plausible explanations for this obvious HDI include GBE-mediated CYP3A4 inhibition with consequent accumulation of trazodone, induction of CYP3A4 enzymes and enhanced production of active GABAnergic metabolites from trazodone, and/or additive GABAnergic effects of GBE [20].", {"entities": [[61, 64, "Herb name"], [74, 80, "Target"], [124, 133, "Drug"], [148, 162, "Target"], [197, 219, "Target"], [225, 234, "Drug"], [274, 277, "Herb name"]]}], [10073, "The third case involved a report of fatal seizures due to probable HDIs involving ginkgo [21].", {"entities": [[36, 50, "Pathology"], [82, 88, "Herb name"]]}], [10074, "The 55-year-old patient with a history of epilepsy had been managed and stabilized with sodium valproate and phenytoin.", {"entities": [[4, 15, "Age"], [42, 50, "Pathology"], [88, 104, "Drug"], [109, 118, "Drug"]]}], [10075, "He was reported to have experienced a seizure before his death, and the toxicological autopsy results revealed subtherapeutic serum levels for both drugs.", {"entities": [[38, 45, "Pathology"]]}], [10076, "The patient had recently initiated ginkgo supplementation, and the apparent HDI was believed to be due to CYP induction by ginkgo resulting in enhanced systemic clearance of the anticonvulsant drugs.", {"entities": [[35, 41, "Herb name"], [106, 109, "Target"], [123, 129, "Herb name"], [178, 198, "Drug"]]}], [10077, "Similarly, two patients who were stably managed with valproate and who had been seizure-free for years prior to starting ginkgo supplementation experienced recurrent seizures which ceased upon the discontinuation of ginkgo [22].", {"entities": [[11, 23, "Cohort"], [53, 62, "Drug"], [80, 87, "Pathology"], [121, 127, "Herb name"], [166, 174, "Pathology"], [216, 222, "Herb name"]]}], [10078, "Despite the limited reports of clinical HDIs with GBE and neuropsychiatric drugs, it is essential to note that the well-reported CNS effects of GBE make it a potential agent to mediate both pharmacokinetic and pharmacodynamic HDIs with CNS drugs.", {"entities": [[50, 53, "Herb name"], [58, 80, "Drug"], [129, 140, "Pathology"], [144, 147, "Herb name"], [236, 245, "Drug"]]}], [10079, "Now popular in Western countries, the use of ginseng for medicinal purposes dates back over 5,000 years in traditional Chinese medicine.", {"entities": [[45, 52, "Herb name"], [119, 126, "Ethnic group"]]}], [10080, "Used as a complimentary medicine to enhance cognitive function, concentration, and physical endurance, ginseng has also been used as a supplement in the management of depression, fatigue, diabetes, and cancer [70].", {"entities": [[103, 110, "Herb name"], [167, 177, "Pathology"], [179, 186, "Pathology"], [188, 196, "Pathology"], [202, 208, "Pathology"]]}], [10081, "While several ginseng species have been identified, the most commonly marketed formulations of ginseng in the US are made from the root extracts of Panax ginseng (Korean ginseng) and Panax quinquefolius (American ginseng).", {"entities": [[14, 21, "Herb name"], [95, 102, "Herb name"], [131, 135, "Herb part"], [148, 161, "Herb name"], [163, 169, "Ethnic group"], [170, 177, "Herb name"], [183, 202, "Herb name"], [204, 212, "Ethnic group"], [213, 220, "Herb name"]]}], [10082, "Extracts of ginseng have also been shown to interact with multiple DMEs and transport proteins via conflicting mechanisms [80-85].", {"entities": [[12, 19, "Herb name"]]}], [10083, "Additionally, an epileptogenic neurotoxin has been identified in ginkgo nuts, which may play pharmacodynamic and antagonistic roles in the interactions.", {"entities": [[17, 41, "Herb name"], [65, 71, "Herb name"], [72, 76, "Herb part"]]}], [10084, "Caution is generally advised with GBE in patients who are taking prescription medications, especially for CNS disorders.", {"entities": [[34, 37, "Herb name"], [106, 119, "Drug"]]}], [10085, "Ginsenosides, the main active components of ginseng, have demonstrated anti-inflammatory, antioxidant, and cytotoxic effects in laboratory studies [79].", {"entities": [[0, 12, "Herb name"], [44, 51, "Herb name"], [128, 146, "Study"]]}], [10086, "Published studies have reported clinically significant interactions between ginseng and warfarin [86], and imatinib [87].", {"entities": [[76, 83, "Herb name"], [88, 96, "Drug"], [107, 115, "Drug"]]}], [10087, "Minimal interactions between ginseng and neuro- psychiatric drugs have been reported in the literature.", {"entities": [[29, 36, "Herb name"], [41, 65, "Drug"]]}], [10088, "A common finding is an interaction between ginseng and midazolam, although midazolam is used in these studies as a probe substrate for CYP3A4.", {"entities": [[43, 50, "Herb name"], [55, 64, "Drug"], [75, 84, "Drug"], [135, 141, "Target"]]}], [10089, "The inhibitory and inductive effect of the different phytochemicals in ginseng on CYP3A4 is demonstrated through the observed changes in the AUC and other pharmacokinetic parameters of midazolam in these human studies [27, 88].", {"entities": [[71, 78, "Herb name"], [82, 88, "Target"], [141, 144, "Parameter"], [185, 194, "Drug"], [204, 217, "Study"]]}], [10090, "A case report documents a patient with chronic depression who was started on phenelzine while taking ginseng.", {"entities": [[39, 57, "Pathology"], [77, 87, "Drug"], [101, 108, "Herb name"]]}], [10091, "The patient became active and extremely optimistic while experiencing insomnia, tension headaches, and visual hallucinations.", {"entities": [[70, 78, "Pathology"], [80, 97, "Pathology"], [103, 124, "Pathology"]]}], [10092, "Once the patient discontinued phenelzine, depression returned with no other signs and symptoms.", {"entities": [[30, 40, "Drug"], [42, 52, "Pathology"]]}], [10093, "It was suggested that the patient experienced a pharmacodynamic interaction occasioned by additive stimulant activities of phenelzine and ginseng.", {"entities": [[123, 133, "Drug"], [138, 145, "Herb name"]]}], [10094, "Extracts of P. ginseng inhibits cyclic AMP phosphodiesterase enhancing psychoactive effect in combination with monoamine oxidase inhibitors such as phenelzine [28, 89].", {"entities": [[12, 22, "Herb name"], [32, 60, "Target"], [148, 158, "Drug"]]}], [10095, "Chronic use of ginseng on its own has been associated with manic psychosis [90].", {"entities": [[15, 22, "Herb name"], [59, 74, "Pathology"]]}], [10096, "Thus, the potential of ginseng for additive CNS effect, in addition to its metabolism-linked interaction with neuropsychiatric drugs, necessitates extreme caution in its use among patients on prescription CNS drugs.", {"entities": [[23, 30, "Herb name"], [44, 54, "Pathology"], [110, 132, "Drug"], [205, 214, "Drug"]]}], [10097, "Hydroxycut is a popular herbal formulation marketed for weight loss.", {"entities": [[0, 10, "Herb name"]]}], [10098, "Initially introduced in 2002, hydroxycut formulations have undergone changes.", {"entities": [[30, 40, "Herb name"]]}], [10099, "Earlier reported CNS and cardiovascular adverse effects were attributed to the ephedra components which the FDA banned in 2004 [91].", {"entities": [[17, 55, "Pathology"], [79, 86, "Herb name"]]}], [10100, "Modified ephedra-free formulation was later popularized but hampered by reports of hepatotoxicity that prompted the issuance of a safety warning by the FDA, and subsequent withdrawal in 2009 of the product from the market by the manufacturer [92, 93].", {"entities": [[9, 16, "Herb name"]]}], [10101, "There has been a newer formulation of hydroxycut on the market for the same indication for which adverse effects have also been reported [94, 95].", {"entities": [[38, 48, "Herb name"], [97, 112, "Pathology"]]}], [10102, "In a published report highlighting an apparent HDI with this newer hydroxycut formulaion, Cvetanovich et al.", {"entities": [[67, 77, "Herb name"]]}], [10103, "reported the case of a patient being treated for depression with citalopram, who developed reversible cerebral vasoconstriction syndrome (RCVS) during concurrent supplementation with hydroxycut for weight loss [29].", {"entities": [[49, 59, "Pathology"], [65, 75, "Drug"], [102, 143, "Pathology"], [183, 193, "Herb name"]]}], [10104, "The herbal product was believed to have exerted an additive or synergistic sympathomimetic effect through some of its components, including caffeine (the daily dose of the hydroxycut formulation includes 400 mg of caffeine).", {"entities": [[140, 148, "Herb name"], [172, 182, "Herb name"], [204, 210, "Amount"], [214, 222, "Herb name"]]}], [10105, "More clinical data is required to ascertain the safety of hydroxycut used alone or with other drugs.", {"entities": [[58, 68, "Herb name"]]}], [10106, "Commercial kava formulations are made from the extracts of the rhizome of the kava plant (Piper methysticum).", {"entities": [[11, 15, "Herb name"], [63, 70, "Herb part"], [78, 82, "Herb name"], [90, 107, "Herb name"]]}], [10107, "The pharmacological activities of kava have been attributed to kavalactones, which are concentrated in the rhizomes [96].", {"entities": [[34, 38, "Herb name"], [63, 75, "Herb name"], [107, 115, "Herb part"]]}], [10108, "Originally used among the pacific islanders for cultural and medicinal purposes, kava has gained popularity in Western countries for its anxiolytic and sedative effects [97].", {"entities": [[26, 43, "Ethnic group"], [81, 85, "Herb name"]]}], [10109, "While several studies have failed to demonstrate any significant clinical benefits of kava, others have shown that kava can be beneficial in anxiety disorders [98-101].", {"entities": [[86, 90, "Herb name"], [115, 119, "Herb name"], [141, 158, "Pathology"]]}], [10110, "A recent review of several clinical studies suggests that kava is superior to placebo in reducing anxiety symptoms [102].", {"entities": [[27, 43, "Study"], [58, 62, "Herb name"], [98, 105, "Pathology"]]}], [10111, "As the use and popularity of kava grew, there were reports of kava-associated hepatotoxicity, leading to initial restrictions in its use in some countries [103, 104].", {"entities": [[29, 38, "Herb name"], [62, 66, "Herb name"], [78, 92, "Pathology"]]}], [10112, "Despite the general concern about its safety, kava is still popularly consumed for CNS benefits.", {"entities": [[46, 50, "Herb name"]]}], [10113, "There is, therefore, concern for HDIs among those who consume it concurrently with their prescribed medications.", {"entities": []}], [10114, "Extracts of kava have shown strong inhibitory activities against multiple isoforms of CYP [81, 105, 106].", {"entities": [[12, 16, "Herb name"], [86, 89, "Target"]]}], [10115, "Interactions of kava with CNS drugs have also been demonstrated in animal studies [107, 108].", {"entities": [[16, 20, "Herb name"], [26, 35, "Drug"], [67, 81, "Study"]]}], [10116, "These non-clinical interactions have not always translated into clinical HDIs.", {"entities": []}], [10117, "A study in 18 health volunteers did not show any clinically relevant interaction between kava and bromazepam [104].", {"entities": [[11, 31, "Cohort"], [89, 93, "Herb name"], [98, 108, "Drug"]]}], [10118, "A patient who was on pharmacotherapy with alprazolam went into a coma after kava consumption in an apparent HDI involving kava-mediated CYP inhibition leading to increased alprazolam activity [30].", {"entities": [[2, 9, "Pathology"], [42, 52, "Drug"], [65, 69, "Pathology"], [76, 80, "Herb name"], [122, 126, "Herb name"], [136, 139, "Target"], [172, 182, "Drug"]]}], [10119, "The second case report was about a patient who had been stabilized on levodopa, but suddenly developed movement disorders following a concurrent intake of kava [31].", {"entities": [[35, 42, "Pathology"], [70, 78, "Drug"], [103, 121, "Pathology"], [155, 159, "Herb name"]]}], [10120, "The apparent reduction in the effectiveness of levodopa could be explained by the known inhibitory effects of the kavalactones on dopaminergic transmission [109, 110].", {"entities": [[47, 55, "Drug"], [114, 126, "Herb name"], [130, 155, "Target"]]}], [10121, "Due to the effects of kava on the drug-metabolizing enzymes, potential hepatotoxicity, and CNS effects, it may be clinically prudent to avoid kava-drug combination, even in the absence of sufficient clinically relevant HDI studies.", {"entities": [[22, 26, "Herb name"], [142, 146, "Herb name"]]}], [10122, "Originating from Southeast Asia, the plant Mitragyna speciosa is an herb traditionally used for its analgesic effect.", {"entities": [[43, 61, "Herb name"]]}], [10123, "Mitragynine, the active constituent, is a mu-opioid receptor agonist, thus, exhibiting opioid-like pain relief and has made kratom a popular product among patients with opioid use disorder.", {"entities": [[0, 11, "Herb name"], [42, 60, "Target"], [124, 130, "Herb name"]]}], [10124, "Kratom is also used as complementary medicine to manage diabetes, diarrhea, improve circulation, enhance alertness and concentration, and increase libido [111-114].", {"entities": [[0, 6, "Herb name"], [56, 64, "Pathology"], [66, 74, "Pathology"]]}], [10125, "While crude extracts of kratom have shown inhibitory and inductive activity against multiple CYP isozymes, mitragynine itself is a substrate and inhibitor of CYPs [115\u2013117].", {"entities": [[6, 20, "Extraction process"], [24, 30, "Herb name"], [93, 105, "Target"], [107, 118, "Herb name"], [158, 162, "Target"]]}], [10126, "One case report of an HDI with mitragynine involved a concurrent use with quetiapine, a CYP3A4 substrate.", {"entities": [[31, 42, "Herb name"], [74, 84, "Drug"]]}], [10127, "The 27-year-old man with a history of Asperger Syndrome, bipolar disorder, and substance use disorder was found deceased in his residence with a lethal blood concentration of quetiapine (12 mg/mL) in conjunction with a qualitative presence of mitragynine [32].", {"entities": [[4, 15, "Age"], [16, 19, "Sex"], [38, 55, "Pathology"], [57, 73, "Pathology"], [175, 185, "Drug"], [243, 254, "Herb name"]]}], [10128, "The fatality was attributed to quetiapine accumulation as a result of mitragynine-mediated inhibition of CYP and P-gp.", {"entities": [[31, 41, "Drug"], [70, 81, "Herb name"], [105, 108, "Target"], [113, 117, "Target"]]}], [10129, "CYP inhibition reduces the systemic clearance of quetiapine, while the inhibition of intestinal P-gp enhances the absorption and bioavailability of quetiapine.", {"entities": [[0, 3, "Target"], [49, 59, "Drug"], [96, 100, "Target"], [148, 158, "Drug"]]}], [10130, "The potential for deleterious HDIs with kratom is very significant considering its use among patients with CNS disorders, its tendency to be abused, and its effects on DMEs.", {"entities": [[40, 46, "Herb name"], [107, 120, "Pathology"]]}], [10131, "It is advisable to avoid concurrent use of kratom and CNS drugs.", {"entities": [[43, 49, "Herb name"], [54, 63, "Drug"]]}], [10132, "Two case reports, however, suggested that kava use with prescription neuropsychiatric medications may not always be safe.", {"entities": [[42, 46, "Herb name"], [69, 97, "Drug"]]}], [10133, "Extracts and formulations of Morinda citrifolia have been used as nutritional and medicinal supplements for over 2000 years [118].", {"entities": [[29, 47, "Herb name"]]}], [10134, "It has been reported to contain several phytochemicals including scopoletin, octoanoic acid, terpenoids, alkaloids, and anthraquinones.", {"entities": [[65, 75, "Herb name"], [77, 91, "Herb name"], [93, 103, "Herb name"], [105, 114, "Herb name"], [120, 134, "Herb name"]]}], [10135, "Its extracts are traditionally used for the treatment of, among others, infections, cardiovascular and neuropsychiatric disorders [119].", {"entities": [[72, 82, "Pathology"], [84, 129, "Pathology"]]}], [10136, "Noni juice, made from fruits, is one of the most popular products of M. citrifolia.", {"entities": [[0, 10, "Extraction process"], [69, 82, "Herb name"]]}], [10137, "Extracts of noni have been shown to modulate the metabolic activities of multiple CYP isoforms.", {"entities": [[82, 94, "Target"]]}], [10138, "[120, 121].", {"entities": []}], [10139, "reported the case of a patient whose epilepsy has been managed with phenytoin for over 10 years without major side effects [33].", {"entities": [[37, 45, "Pathology"], [68, 77, "Drug"], [82, 95, "Duration"], [110, 122, "Pathology"]]}], [10140, "Noni juice had been earlier reported to reduce the AUC of phenytoin in rats through apparent induction of the CYP2C9-mediated phenytoin metabolism [122].", {"entities": [[0, 10, "Extraction process"], [51, 54, "Parameter"], [58, 67, "Drug"], [110, 116, "Target"], [126, 135, "Drug"]]}], [10141, "Thus, in the current patient, the concomitant use of noni juice resulted in the subtherapeutic exposure to phenytoin resulting in seizure.", {"entities": [[53, 63, "Extraction process"], [107, 116, "Drug"], [130, 137, "Pathology"]]}], [10142, "This represents a typical PK HDI that should be avoided in patients taking drugs that are metabolized by CYPs.", {"entities": [[26, 28, "Parameter"]]}], [10143, "Piperine-rich extracts are often marketed as medicinal supplements for use in enhancing attention and cognition.", {"entities": [[0, 8, "Herb name"]]}], [10144, "Some studies have suggested beneficial effects in vitiligo and cardiovascular diseases [123, 124].", {"entities": [[63, 86, "Pathology"]]}], [10145, "Preclinical studies have shown the inhibitory effect of piperine on metabolic enzymes and transport proteins [125].", {"entities": [[0, 19, "Study"], [56, 64, "Herb name"], [68, 85, "Target"], [90, 108, "Target"]]}], [10146, "As such, it has been touted as a potential pharmacokinetic enhancer capable of influencing the oral bioavailability of neuropsychiatric drugs.", {"entities": [[100, 115, "Parameter"], [119, 141, "Drug"]]}], [10147, "In a published report, Kang et al.", {"entities": []}], [10148, "The patient developed poor seizure control after repeated consumption of noni juice.", {"entities": [[27, 34, "Pathology"], [73, 83, "Extraction process"]]}], [10149, "Piperine is the major bioactive phytochemical in black pepper (Piper nigrum) and other Piper species.", {"entities": [[0, 8, "Herb name"], [49, 76, "Herb name"], [87, 92, "Herb name"]]}], [10150, "In a placebo-controlled clinical study conducted in 24 healthy individuals, pretreatment with piperine caused a statistically significant increase in the half-life and decrease in the clearance of midazolam [34].", {"entities": [[24, 38, "Study"], [52, 74, "Cohort"], [94, 102, "Herb name"], [197, 206, "Drug"]]}], [10151, "However, no significant difference was observed in the AUC In two studies in patients with epilepsy, authors compared the steady-state PK of phenytoin and carbamazepine before and after a single piperine dose administration [35, 36].", {"entities": [[55, 58, "Parameter"], [91, 99, "Pathology"], [135, 137, "Parameter"], [141, 150, "Drug"], [155, 168, "Drug"], [195, 203, "Herb name"]]}], [10152, "In both cases, piperine increased the AUC and the steady-state concentration of the drugs while decreasing their clearance.", {"entities": [[15, 23, "Herb name"], [38, 41, "Parameter"]]}], [10153, "For supplements like piperine, concurrent use with drugs like phenytoin and carbamazepine, which have a narrow margin of safety, should be discouraged.", {"entities": [[21, 29, "Herb name"], [62, 71, "Drug"], [76, 89, "Drug"]]}], [10154, "The use to enhance oral bioavailability has not been validated.", {"entities": [[24, 39, "Parameter"]]}], [10155, "However, when such use is employed, deliberate efforts for therapeutic drug monitoring should be utilized to established optimal dosing parameters.", {"entities": []}], [10156, "Rhodiola rosea, also known as roseroot or golden root, and originally found within the provinces of Iceland, Norway, Sweden, and Russia, is a herbal product used as complementary medicine for increasing endurance and work performance and to manage fatigue, impotence, fatigue, anxiety, stress, mood disorders, cancer, and tuberculosis [126, 127].", {"entities": [[0, 14, "Herb name"], [30, 38, "Herb name"], [42, 53, "Herb name"], [248, 255, "Pathology"], [257, 266, "Pathology"], [268, 275, "Pathology"], [277, 284, "Pathology"]]}], [10157, "Laboratory studies have shown that roseroot is capable of neuronal stimulation to enhance the activity of neurotransmitters - noradrenaline, dopamine, serotonin, and acetylcholine, resulting in pronounced psychotropic effects [128-131].", {"entities": [[0, 18, "Study"], [35, 43, "Herb name"], [126, 139, "Target"], [141, 149, "Target"], [151, 160, "Target"], [166, 179, "Target"]]}], [10158, "It has been investigated in human clinical studies showing promising results in generalized anxiety disorders, depression, stress, fatigue, and exercise endurance [132-136].", {"entities": [[28, 50, "Study"], [92, 109, "Pathology"], [111, 121, "Pathology"], [123, 129, "Pathology"], [131, 138, "Pathology"]]}], [10159, "Extracts of roseroot have been found to potently inhibit CYP3A4, CYP2D6, and P-gp, which is significant for CNS drugs [137, 138].", {"entities": [[12, 20, "Herb name"], [57, 63, "Target"], [65, 71, "Target"], [77, 81, "Target"], [108, 117, "Drug"]]}], [10160, "Extracts of rosewood also inhibited the CYP2C9-dependent metabolic pathway in a clinical study, which may be significant for neuropsychiatric drugs that are CYP2C9 substrates [139].", {"entities": [[12, 20, "Herb name"], [40, 46, "Target"], [80, 94, "Study"], [125, 147, "Drug"]]}], [10161, "In a published case report, a patient with recurrent depression treated with paroxetine developed serotonergic syndrome after self-medicating with rhodiola [37].", {"entities": [[53, 63, "Pathology"], [77, 87, "Drug"], [98, 119, "Pathology"], [147, 155, "Herb name"]]}], [10162, "The 68-year-old had been stable on paroxetine before initiating supplementation with roseroot to \u2018strengthen nerves\u2019.", {"entities": [[4, 15, "Age"], [35, 45, "Drug"], [85, 93, "Herb name"]]}], [10163, "The development of symptoms consistent with serotonin syndrome - reduced concentration, irritability, restlessness, excessive sweating, loss of appetite and insomnia - was thought to be induced by multiple mechanisms, including the serotonergic effect of roseroot and the potentiation of paroxetine effect by roseroot-mediated CYP2D6 inhibition and reduced paroxetine clearance.", {"entities": [[44, 62, "Pathology"], [88, 100, "Pathology"], [102, 114, "Pathology"], [116, 134, "Pathology"], [136, 152, "Pathology"], [157, 165, "Pathology"], [255, 263, "Herb name"], [288, 298, "Drug"], [309, 317, "Herb name"], [327, 333, "Target"], [357, 367, "Drug"]]}], [10164, "Thus, the intrinsic CNS effects of roseroot and its inhibitory effect on CYPs make it an herbal candidate to induce pharmacodynamic and pharmacokinetic interactions with neuropsychiatric drugs.", {"entities": [[35, 43, "Herb name"], [73, 77, "Target"], [170, 192, "Drug"]]}], [10165, "SJW (Hypericum perforatum) is a well-known herbal product used for the management of mild to moderate depression, an indication for which it has been widely investigated with positive clinical benefits [140].", {"entities": [[0, 26, "Herb name"], [102, 112, "Pathology"]]}], [10166, "The global popularity of SJW was likely enhanced by its inclusion in official recommendations for the treatment of depression [141].", {"entities": [[25, 28, "Herb name"], [115, 125, "Pathology"]]}], [10167, "Other traditional indications for SJW include somatoform disorders, premenstrual syndrome, and alcohol withdrawal [142-144].", {"entities": [[34, 37, "Herb name"], [46, 66, "Pathology"], [68, 89, "Pathology"], [95, 113, "Pathology"]]}], [10168, "SJW is notorious for its inductive effect on CYPs and P-gp, with consequential HDI with several drugs, including immunosuppressants, protease inhibitors, tricyclic antidepres- sants, antihistamines, and hormonal contraceptives [38, 39, 146-148].", {"entities": [[0, 3, "Herb name"], [45, 49, "Target"], [54, 58, "Target"], [113, 131, "Drug"], [133, 152, "Drug"], [154, 181, "Drug"], [183, 197, "Drug"], [203, 226, "Drug"]]}], [10169, "Apart from CYP/P-gp induction, SJW mediates interactions through its serotonergic effects.", {"entities": [[31, 34, "Herb name"]]}], [10170, "Three clinical studies, three case ports, and one case series highlight the evidence of clinical interactions between SJW and neuropsychiatric drugs (Table 1).", {"entities": [[6, 22, "Study"], [118, 121, "Herb name"], [126, 148, "Drug"]]}], [10171, "Following well established in vitro results, Dresser et al.", {"entities": []}], [10172, "investigated the ability of SJW to interact with CYP3A4 in a 2-way, open-label crossover study of 21 healthy subjects using midazolam as the probe substrate.", {"entities": [[28, 31, "Herb name"], [49, 55, "Target"], [68, 94, "Study"], [98, 117, "Cohort"], [124, 133, "Drug"]]}], [10173, "Pretreatment with SJW was associated with a 2.7-fold increase in the oral clearance, 50% reduction in C The other two clinical studies were performed in an open-label crossover design where the steady state pharmacokinetics of amitriptyline and alprazolam were compared pre- and post-SJW treatment.", {"entities": [[18, 21, "Herb name"], [118, 134, "Study"], [156, 176, "Study"], [227, 240, "Drug"], [245, 255, "Drug"], [284, 287, "Herb name"]]}], [10174, "Pretreatment with SJW caused a statistically significant increase in the clearance and decrease in the AUC and half-life of both alprazolam and amitryptyline (Table 1) [38, 39].", {"entities": [[18, 21, "Herb name"], [103, 106, "Parameter"], [129, 139, "Drug"], [144, 157, "Drug"]]}], [10175, "These findings were anticipated because alprazolam, like most other benzodiazepines, and amitriptyline are substrates of CYPs, which are potently induced by SJW.", {"entities": [[40, 50, "Drug"], [68, 83, "Drug"], [89, 102, "Drug"], [121, 125, "Target"], [157, 160, "Herb name"]]}], [10176, "In what may likely be due to induction of clozapine clearance by SJW, a published case report documented a patient with a history of schizophrenia stably managed by clozapine and who began to experience symptoms after initiating SJW supplements [41].", {"entities": [[42, 51, "Drug"], [65, 68, "Herb name"], [133, 146, "Pathology"], [165, 174, "Drug"], [229, 232, "Herb name"]]}], [10177, "The discontinuation of SJW resulted in normalized clozapine levels and controlled symptoms.", {"entities": [[23, 26, "Herb name"], [50, 59, "Drug"]]}], [10178, "A typical pharmacodynamic interaction with SJW was also reported in a patient who had been on SJW for several years and then developed orofacial dystonia following the concurrent use of bupropion [40].", {"entities": [[43, 46, "Herb name"], [94, 97, "Herb name"], [135, 153, "Pathology"], [186, 197, "Drug"]]}], [10179, "The combination was believed to exert additive inhibition of serotonin reuptake, with additional enhanced dopaminergic effects such as dystonia.", {"entities": [[135, 143, "Pathology"]]}], [10180, "A similar effect has been reported in a patient with chronic depression whose concurrent use of paroxetine and SJW resulted in symptoms consistent with serotonin syndrome - incoherence, nausea, weakness, fatigue, and limp muscle tone [43].", {"entities": [[53, 71, "Pathology"], [96, 106, "Drug"], [111, 114, "Herb name"], [152, 184, "Pathology"], [186, 192, "Pathology"], [194, 202, "Pathology"], [204, 211, "Pathology"], [217, 233, "Pathology"]]}], [10181, "Several constituents have been isolated and characterized from SJW, with hyperforin identified as the antidepressant entity capable of centrally inhibiting the synaptic reuptake of serotonin, dopamine, and norepinephrine [145].", {"entities": [[63, 66, "Herb name"], [73, 83, "Herb name"], [181, 190, "Target"], [192, 200, "Target"], [206, 220, "Target"]]}], [10182, "There is an abundance of clinical evidence in the literature to show clinically significant HDIs between SJW and most CYP/ P-gp substrates.", {"entities": [[105, 108, "Herb name"]]}], [10183, "Lastly, Lantz et al.", {"entities": []}], [10184, "reported 5 patient cases with depression/anxiety treated with sertraline or nefazodone [44].", {"entities": [[30, 40, "Pathology"], [41, 48, "Pathology"], [62, 72, "Drug"], [76, 86, "Drug"]]}], [10185, "After initiating supplementation with SJW, each patient experienced signs and symptoms of serotonin syndrome within 2-4 days.", {"entities": [[38, 41, "Herb name"], [90, 108, "Pathology"]]}], [10186, "Discontinuation of the combination resolved the symptoms in all the patients.", {"entities": []}], [10187, "The interactions are mechanistically predictable and dangerous.", {"entities": []}], [10188, "On the other hand, additive or synergistic effects of SJW on the central neurotransmitters have consequential psychotropic effects.", {"entities": [[54, 57, "Herb name"]]}], [10189, "Concomitant administration should be avoided in patients taking prescription drugs for neuropsychiatric disorders.", {"entities": [[87, 113, "Pathology"]]}], [10191, "T. chebula is a well-known herbal product in India and Middle Eastern countries for the treatment of dementia, diabetes, digestive and urinary tract diseases [149].", {"entities": [[0, 10, "Herb name"], [101, 109, "Pathology"], [111, 119, "Pathology"], [121, 157, "Pathology"]]}], [10192, "It is claimed to help improve memory retention and cognition, making it a commonly used herbal supplement in patients with psychological and psychiatric disorders, including confusion, depression, Alzheimer\u2019s disease, general apathy, and misanthropy [150].", {"entities": [[141, 162, "Pathology"], [174, 183, "Pathology"], [185, 195, "Pathology"], [197, 216, "Pathology"], [218, 232, "Pathology"], [238, 249, "Pathology"]]}], [10193, "The pharmacologically active compounds of T. chebula are polyphenols (tannins) which are expressed in the sour but edible fruits [151].", {"entities": [[42, 52, "Herb name"], [57, 78, "Herb name"]]}], [10194, "Herbal products from the Commiphora species are commonly used in Asia to treat inflammatory diseases, cardiovascular disorders, trauma, arthritis, and obesity [152].", {"entities": [[25, 35, "Herb name"], [79, 100, "Pathology"], [102, 126, "Pathology"], [128, 134, "Pathology"], [136, 145, "Pathology"], [151, 158, "Pathology"]]}], [10195, "Phytosteroidal compounds found in the resinous exudates are believed to be responsible for the pharmacological effects of Commiphora [153, 154].", {"entities": [[0, 14, "Herb name"], [38, 55, "Herb part"], [122, 132, "Herb name"]]}], [10196, "HDIs with SJW can be one of the most significant in neuropsychiatry due to the popularity of SJW among patients with depression and other CNS disorders.", {"entities": [[10, 13, "Herb name"], [93, 96, "Herb name"], [117, 127, "Pathology"], [138, 151, "Pathology"]]}], [10197, "On one hand, there is risk of therapeutic failure due to SJW-mediated enhanced clearance of neuropsychiatric drugs.", {"entities": [[57, 60, "Herb name"], [92, 114, "Drug"]]}], [10198, "Extracts of T. chebula and C. wightii have demonstrated inhibitory activity against CYP enzymes [155, 156].", {"entities": [[12, 22, "Herb name"], [27, 37, "Herb name"], [84, 95, "Target"]]}], [10199, "The interaction was understood to result from increased clearance of sertraline due to CYP induction.", {"entities": [[69, 79, "Drug"], [87, 90, "Target"]]}], [10200, "Since Ayurvedic preparations are often made with multiple herbal components, the potential for deleterious HDIs is high with drug substrates of CYP.", {"entities": []}], [10201, "Valerian (Valeriana officinalis) from the honeysuckle family Caprifoliaceae, is the most popular herbal supplement to enhance sleep and decrease restlessness.", {"entities": [[0, 32, "Herb name"], [145, 157, "Pathology"]]}], [10202, "Valerian extracts contain several phytoconstituents, but the pharmacological property of the herb is attributed to valerenic acid and its derivatives.", {"entities": [[0, 8, "Herb name"], [115, 129, "Herb name"]]}], [10203, "Valerenic acid is a partial agonist of the 5-HT receptor in vitro [157].", {"entities": [[0, 14, "Herb name"], [43, 56, "Target"]]}], [10204, "Thus, it potentially alters a variety of physiological and behavioral processes with synergic activity with other components.", {"entities": []}], [10205, "In a clinical trial with twelve healthy volunteers, alprazolam and dextromethorphan (probe substrates of CYP3A4 and CYP2D6, respectively) were administered to the volunteers before and after a 14-day pretreatment with valerian.", {"entities": [[5, 19, "Study"], [25, 51, "Cohort"], [52, 62, "Drug"], [67, 83, "Drug"], [193, 199, "Duration"], [218, 226, "Herb name"]]}], [10206, "The C Also, the pharmacodynamic actions of valerian in the CNS may be antagonistic or additive to the effect of prescribed neuropsychiatric drugs.", {"entities": [[123, 145, "Drug"]]}], [10207, "In a case report of a patient who has been taking lorazepam for generalized anxiety disorder, the concomitant use of valerian/passiflora herbal preparations for 4 days resulted in the development of movement disorders [48].", {"entities": [[50, 59, "Drug"], [76, 92, "Pathology"], [117, 125, "Herb name"], [126, 136, "Herb name"], [161, 167, "Duration"], [199, 217, "Pathology"]]}], [10208, "This observation was attributed to the additive or synergistic CNS effect of lorazepam and valerian/passiflora, a pharmacodynamic HDI.", {"entities": [[77, 86, "Drug"], [91, 99, "Herb name"], [100, 110, "Herb name"]]}], [10209, "In general, herbal products with CNS effect may not only elicit PK HDI but sometimes can precipitate antagonistic, additive, or synergistic central drug effects.", {"entities": [[64, 66, "Parameter"]]}], [10210, "Some of the top-selling herbal products, including SJW, kava, ginkgo, and valerian, are traditionally used for the prevention and treatment of neuropsychiatric disorders.", {"entities": [[51, 54, "Herb name"], [56, 60, "Herb name"], [62, 68, "Herb name"], [74, 82, "Herb name"], [143, 169, "Pathology"]]}], [10211, "The lone published clinical report regarding these two herbal products involved a patient with chronic depression who had combined sertraline and Ayurvedic preparations [46].", {"entities": [[95, 113, "Pathology"], [131, 141, "Drug"]]}], [10212, "The patient soon developed acute symptoms of depression which were resolved by discontinuing the herbal remedy.", {"entities": [[45, 55, "Pathology"]]}], [10213, "Therefore, it is safer to discourage the combination of such herbal products and neuropsychiatric products.", {"entities": []}], [10214, "Valerian extracts reduce CYP3A4 and P-gp activity in both in vitro and animal studies [158, 159].", {"entities": [[0, 8, "Herb name"], [25, 31, "Target"], [36, 40, "Target"], [71, 85, "Study"]]}], [10215, "Due to the laxed regulatory requirement for marketing herbal products, not much premarketing information regarding efficacy and safety is available for these herbs.", {"entities": []}], [10216, "This has placed the responsibility of identifying and managing safety-related concerns of herbal medicines on clinicians, most of whose training did not involve herbal medicine.", {"entities": []}], [10217, "Unprompted, most patients do not disclose their use of herbal medicines to their health professionals.", {"entities": []}], [10218, "This often complicates therapy and delays the identification and treatment of herbal-related side effects or HDIs.", {"entities": [[93, 105, "Pathology"]]}], [10219, "Although controlled clinical studies on HDIs are very sparse in literature, there is a preponderance of information on the ability of herbal products to cause pharmacokinetic and/or pharmacodynamic drug interactions.", {"entities": [[20, 36, "Study"]]}], [10220, "Pharmacokinetic interactions can be gastrointestinal, in which case the presence of the herbal product influences the absorption or action of the drug within the gastrointestinal tract.", {"entities": []}], [10221, "This is important because the vast majority of herbal products are orally administered.", {"entities": []}], [10222, "The modulatory activities of herbal products on these enzymes and transporters are known to alter the oral bioavailability of their substrates.", {"entities": [[102, 122, "Parameter"]]}], [10223, "Absorbed herbal products can elicit further pharmacokinetic interactions through the modulatory actions on the hepatic enzymes, other tissues enzymes, transport proteins (including the efflux and uptake proteins), plasma/tissue binding proteins, as well as renal excretory pathways [160].", {"entities": []}], [10224, "The inhibition of DMEs and transport proteins often leads to delayed and/decreased systemic clearance of drugs.", {"entities": []}], [10225, "When DMEs are induced, metabolism is enhanced with the risk of subtherapeutic exposure to the prescribed drugs.", {"entities": []}], [10226, "Drug transporters, including P-gp, are part of the physiologic blood-brain barrier regulating CNS exposure to drugs.", {"entities": []}], [10227, "Therefore, alterations in the functions of the transport proteins present a real risk to central functions due to enhanced/reduced drug access.", {"entities": []}], [10228, "Ascertaining the specific mechanism or the actual interacting phytochemical in a herbal product is challenging.", {"entities": []}], [10229, "This is because many marketed herbal products are made of mixtures of different herbal species and/or dietary supplements whose biological disposition in humans is poorly understood.", {"entities": []}], [10230, "CYP3A4 and P-gp are richly expressed in the human small intestinal enterocytes.", {"entities": []}], [10231, "The resulting drug accumulation from DME inhibition can precipitate toxic manifestations.", {"entities": []}], [10232, "Several neuropsy- chiatric drugs, including tricyclic antidepressants, anti-epileptic drugs, antipsychotics, benzodiazepines, and narcotic analgesic agents, are substrates of CYPs and P-gp (Table 2).", {"entities": [[44, 69, "Drug"], [71, 91, "Drug"], [93, 107, "Drug"], [109, 124, "Drug"], [130, 155, "Drug"]]}], [10233, "Pharmacokinetic HDIs can also occur through the influence of herbal products on the glomerular filtration or tubular reabsorption in the kidneys.", {"entities": []}], [10234, "This mechanism should be of concern with herbal products with known nephrotoxicity.", {"entities": [[68, 82, "Pathology"]]}], [10235, "Of particular importance is pharmacodynamic HDIs in neuropsychiatry.", {"entities": []}], [10236, "The beneficial effects of most herbal medicines in mental health have been attributed to central receptor activity and/or interactions with central neuro- transmitters.", {"entities": []}], [10237, "This review identified 13 herbal products - celery, echinacea, ginkgo, ginseng, hydroxycut, kava, kratom, moringa, piperine, rhodiola, St. John\u2019s wort, terminalia/commiphora ayurvedic mixture and valerian \u2013 all of which have shown interactions with specific neuropsychiatric drugs.", {"entities": [[44, 50, "Herb name"], [52, 61, "Herb name"], [63, 69, "Herb name"], [71, 78, "Herb name"], [80, 90, "Herb part"], [92, 96, "Herb name"], [98, 104, "Herb name"], [106, 113, "Herb name"], [115, 123, "Herb name"], [125, 133, "Herb name"], [135, 150, "Herb name"], [152, 191, "Herb name"], [196, 204, "Herb name"], [258, 280, "Drug"]]}], [10238, "While the extracts of celery, ginkgo, kava, SJW, and valerian modulate the activity of DMEs, products of ginkgo, ginseng, kava, kratom, rhodiola, and SJW have direct pharmacodynamic effects on the CNS, affecting GABAnergic and/or serotonergic transmission.", {"entities": [[22, 28, "Herb name"], [30, 36, "Herb name"], [38, 42, "Herb name"], [44, 47, "Herb name"], [53, 61, "Herb name"], [105, 111, "Herb name"], [113, 120, "Herb name"], [122, 126, "Herb name"], [128, 134, "Herb name"], [136, 144, "Herb name"], [150, 153, "Herb name"], [212, 255, "Target"]]}], [10239, "Some other commonly used herbal products in neuropsychiatric conditions include Black cohosh, German chamomile, evening primrose, hops, lemon balm, passion flowers, and skullcap.", {"entities": [[80, 92, "Herb name"], [94, 110, "Herb name"], [112, 128, "Herb name"], [130, 134, "Herb name"], [136, 147, "Herb name"], [148, 163, "Herb name"], [169, 177, "Herb name"]]}], [10240, "The majority of the evidence of clinically relevant HDI presented in this review is based on case reports and case series.", {"entities": []}], [10241, "This type of clinical evidence is inferior to randomized controlled trials and other clinical studies that include larger number of human subjects.", {"entities": [[46, 74, "Study"], [85, 101, "Study"]]}], [10242, "Thus, the data presented should be understood within the context and limitations of case studies/series.", {"entities": []}], [10243, "Inter-individual variations in pharmacokinetics and pharmacodynamics, individual-specific factors, and misdiagnosis (wrong herbal association) by clinicians are some of the limitations of HDI case studies/series.", {"entities": []}], [10244, "It is vital, however, for both patients and providers alike to be educated on the potential interactions between herbal products and prescription medicines.", {"entities": []}], [10245, "Healthcare providers can thus be proactive in the anticipatory prevention of HDIs with these drugs.", {"entities": []}], [10246, "The mu receptor-stimulating effect of kratom or the serotonin reuptake inhibitory activity of hyperforin in SJW are examples of mechanistic pathways through which herbal products can exert additive/antagonistic pharmacodyna- mic HDIs.", {"entities": [[38, 44, "Herb name"], [94, 104, "Herb name"], [108, 111, "Herb name"]]}], [10247, "While there are no reported clinical interactions with these herbs, some of them have shown inhibitory/inductive effects on hepatic enzymes based on in vitro studies [161, 162].", {"entities": [[152, 167, "Study"]]}], [10248, "Informed use of an herbal product can be beneficial in therapy.", {"entities": []}], [10249, "Neuropsychiatric drugs that are substrates to cytochrome P450 enzymes and P-glycoprotein.", {"entities": [[0, 22, "Drug"]]}], [10250, "One of the best ways to avoid dangerous HDIs, if herbal use is necessary, is to avoid same-time coadministration, which minimizes absorption-related interaction and may also reduce the pharmacokinetic interactivity.", {"entities": []}], [10251, "Overall, HDIs could be serious and affect therapy outcomes in the pharmacotherapy of neuropsychiatric disorders.", {"entities": [[85, 111, "Pathology"]]}], [10252, "In order to prevent or mitigate the effect of HDI in neuropsychiatry, clinicians should actively seek information on herb-drug combination use among their patients and apply appropriate clinical judgement as necessary.", {"entities": []}], [10253, "It is strongly suggested that continuing professional education for healthcare providers should include periodic updates on clinically relevant HDIs to make up for the current gap on this subject in most health-related curricula.", {"entities": []}], [10254, "With only limited data available on clinical HDIs, healthcare professionals should continue to use their clinical judgment to create appropriate treatment and monitoring plans in patients with habitual and concomitant herbal intake.", {"entities": []}], [10255, "Not applicable.", {"entities": []}], [10256, "None.", {"entities": []}], [10257, "The authors declare no conflict of interest, financial or otherwise.", {"entities": []}], [10258, "Clinically relevant herbal interactions with neuropsychiatric drugs.", {"entities": [[45, 67, "Drug"]]}], [10259, "Healthcare professionals need to be aware of their patients\u2019 habitual/occasional use of herbal products for a myriad of indications.", {"entities": []}], [10260, "Declared none.", {"entities": []}], [10261, "Search strategy and search results for herbal interactions in neuropsychiatry.", {"entities": []}], [10262, "Abbreviations: GBE \u2013 Ginkgo biloba extract; SJW \u2013 St. John\u2019s wort.", {"entities": [[15, 18, "Herb name"], [21, 34, "Herb name"], [44, 47, "Herb name"], [50, 65, "Herb name"]]}], [10263, "Herbal products are not entirely free of adverse effects and can alter therapeutic outcomes when co-administered with prescription drugs.", {"entities": [[41, 56, "Pathology"]]}], [10264, "Sirolimus is an immunosuppressive drug used to prevent graft rejection.", {"entities": [[0, 9, "Drug"]]}], [10265, "Therapeutic drug monitoring is required as with other immunosuppressive drugs.", {"entities": []}], [10266, "Previous studies have shown the interactions between sirolimus and drugs that affect the activity of cytochrome P450 3A4 and P-glycoprotein.", {"entities": [[53, 62, "Drug"]]}], [10267, "There is an increasing tendency for the use of herbal remedies in many countries.", {"entities": []}], [10268, "Medicinal herbs are rich sources of natural bioactive compounds that could interact with drugs.", {"entities": []}], [10269, "Parsley, Petroselinum crispum, is a food, spice, and also a medicinal herb.", {"entities": [[0, 7, "Herb name"], [9, 29, "Herb name"]]}], [10270, "We report a case of a renal transplant recipient who had a supratherapeutic blood level of sirolimus due to consuming excessive parsley to highlight a possible herb\u2013drug interaction.", {"entities": [[91, 100, "Drug"]]}], [10271, "This is the first case report describing sirolimus\u2013parsley interaction.", {"entities": [[41, 50, "Drug"], [51, 58, "Herb name"]]}], [10272, "Herb\u2013drug interactions are especially important for drugs with a narrow therapeutic window.", {"entities": []}], [10273, "For this reason, healthcare professionals should question all patients, especially transplant patients, about the use of herbs or herbal products and report interactions.", {"entities": []}], [10274, "Parsley, a commonly consumed food, affects the level of an important drug in a renal transplant recipient: A case report  Sirolimus is a drug that suppresses the immune response used to prevent organ rejection in people who have had kidney transplants.", {"entities": [[0, 7, "Herb name"], [122, 131, "Drug"]]}], [10275, "In order to reach the optimum balance between therapeutic efficacy and adverse effects, sirolimus blood levels should be closely monitored.", {"entities": [[71, 86, "Pathology"], [88, 97, "Drug"]]}], [10276, "Previous studies have shown the interactions between sirolimus and drugs that affect the activities of metabolizing enzymes and transporter proteins.", {"entities": [[53, 62, "Drug"]]}], [10277, "Parsley is a food, spice, and also a medicinal herb.", {"entities": [[0, 7, "Herb name"]]}], [10278, "Medicinal herbs are rich sources of natural bioactive compounds that could interact with a prescription drug.", {"entities": []}], [10279, "We report a case of a renal transplant recipient who had a rise in the blood level of sirolimus due to the ingestion of an excessive amount of parsley to highlight possible herb\u2013drug interaction.", {"entities": [[86, 95, "Drug"], [143, 150, "Herb name"]]}], [10280, "Sirolimus, a macrolide compound isolated from Streptomyces hygroscopicus, was introduced in the late 1990s.", {"entities": [[0, 9, "Drug"]]}], [10281, "The demonstration of the potent immunosuppressive activity of sirolimus has led to its usage for the prevention of graft rejection in kidney transplantation.", {"entities": [[62, 71, "Drug"], [115, 130, "Pathology"]]}], [10282, "Sirolimus binds to a protein (FK binding protein-12) and this complex inhibits the activation of the mammalian target of rapamycin, which is a key regulatory kinase for cell cycle progression, thus suppressing cytokine-driven T-cell proliferation.", {"entities": [[0, 9, "Drug"]]}], [10283, "Sirolimus displays a synergistic action with calcineurin inhibitors and a distinctive mechanism of action from calcineurin inhibitors, which are indispensable immunosuppressive agents in kidney transplantation.", {"entities": [[0, 9, "Drug"], [45, 67, "Drug"], [111, 133, "Drug"]]}], [10284, "In addition, sirolimus has some advantages compared with calcineurin inhibitors: sirolimus causes less nephrotoxicity, has anticancer effects, and allows once-daily administration.", {"entities": [[13, 22, "Drug"], [57, 79, "Drug"], [81, 90, "Drug"], [103, 117, "Pathology"]]}], [10285, "In recent years, the increasing use of herbs and herbal medicines for primary healthcare and chronic diseases has been widely reported in many countries.", {"entities": []}], [10286, "One of the important safety concerns with the widespread herbal remedy use is the potential interactions of herbal medicines with prescription drugs that may augment or inhibit the effect of the drugs.", {"entities": []}], [10287, "This is especially important for drugs with a narrow therapeutic window.", {"entities": []}], [10288, "Parsley, Petroselinum crispum, is commonly consumed as part of the diet.", {"entities": [[0, 7, "Herb name"], [9, 29, "Herb name"]]}], [10289, "Parsley, which is also a medicinal herb, is stated to have carminative, antispasmodic, diuretic, emmenagogue, expectorant, antirheumatic, and antimicrobial properties.", {"entities": [[0, 7, "Herb name"]]}], [10290, "The drug interaction probability scale (DIPS) is a tool to assess the causal relationship between interactions and adverse events.", {"entities": []}], [10291, "DIPS consists of 10 questions each with three response options to which a score is assigned.", {"entities": []}], [10292, "PubMed database and Google Scholar were searched using the key terms \u2018parsley\u2019, \u2018sirolimus\u2019, and \u2018herb\u2013drug interaction\u2019 up to 15 October 2020.", {"entities": [[70, 77, "Herb name"], [80, 90, "Drug"]]}], [10293, "Articles published in the English language were reviewed.", {"entities": []}], [10294, "Herein, we report a possible interaction between parsley and sirolimus in a kidney transplant patient leading to supratherapeutic blood concentrations of sirolimus.", {"entities": [[49, 56, "Herb name"], [61, 70, "Drug"], [154, 163, "Drug"]]}], [10295, "A 19-year-old woman was diagnosed with chronic kidney disease secondary to juvenile nephronophthisis.", {"entities": [[2, 13, "Age"], [14, 19, "Sex"], [39, 100, "Pathology"]]}], [10296, "In 2013, the patient underwent renal transplantation from her mother.", {"entities": []}], [10297, "Postrenal transplantation immunosuppressive therapy of the patient comprised a triple drug combination of prednisolone, tacrolimus, and mycophenolate mofetil.", {"entities": [[106, 118, "Drug"], [120, 130, "Drug"], [136, 157, "Drug"]]}], [10298, "The patient\u2019s medical history included pseudotumor cerebri and hypophosphatemic rickets.", {"entities": []}], [10299, "Her other significant medications included enalapril 10\u2009mg once daily, calcitriol 0.5\u2009\u00b5g once daily, and 1000\u2009mg elemental phosphorus containing effervescent tablet twice daily.", {"entities": [[43, 52, "Drug"], [53, 58, "Amount"], [59, 69, "Frequency"], [71, 81, "Drug"], [82, 88, "Amount"], [89, 99, "Frequency"], [105, 112, "Amount"], [165, 176, "Frequency"]]}], [10300, "The patient received tacrolimus-based immunosuppression until April 2016, and then the treatment was switched from tacrolimus to sirolimus due to evident tremors.", {"entities": [[21, 31, "Drug"], [115, 125, "Drug"], [129, 138, "Drug"], [154, 161, "Pathology"]]}], [10302, "In July 2020 at an out-patient follow-up visit, the patient\u2019s blood level of sirolimus (14.8\u2009ng/ml) was seen to be high.", {"entities": [[77, 86, "Drug"], [88, 99, "Amount"]]}], [10303, "Previous blood sirolimus levels ranged from 2\u2009ng/ml to 4\u2009ng/ml.", {"entities": [[15, 24, "Drug"], [44, 51, "Amount"], [55, 62, "Amount"]]}], [10304, "The concentration\u2013time profile is shown in Figure 1.", {"entities": []}], [10305, "At that time the serum creatinine level was 74.27\u2009\u00b5mol/L and was stable.", {"entities": [[17, 39, "Parameter"], [44, 56, "Amount"]]}], [10306, "Other factors that could increase the sirolimus level were questioned and ruled out.", {"entities": [[38, 47, "Drug"]]}], [10307, "No new drug that could influence the sirolimus levels had been administered.", {"entities": [[37, 46, "Drug"]]}], [10308, "The next day testing of the blood sirolimus level (14.6\u2009ng/ml) confirmed that there was no laboratory mistake.", {"entities": [[34, 43, "Drug"], [50, 61, "Amount"]]}], [10309, "A more detailed history was taken from the patient.", {"entities": []}], [10310, "It was learned that she regularly made a juice of parsley and consumed the parsley juice daily to lose weight and promote her health.", {"entities": [[41, 57, "Extraction process"], [75, 88, "Extraction process"], [89, 94, "Frequency"]]}], [10311, "The juice, which contained about 30\u2009g of parsley, was consumed by the patient for 7\u2009days.", {"entities": [[33, 37, "Amount"], [41, 48, "Herb name"], [82, 88, "Duration"]]}], [10312, "Sirolimus blood concentration versus time.", {"entities": [[0, 9, "Drug"]]}], [10313, "She was asked to pay attention to a balanced diet and avoid consuming excessive amounts of a single vegetable, fruit, and herb for a week.", {"entities": []}], [10314, "A week later, the patient\u2019s sirolimus level (4.6\u2009ng/ml) was seen in the normal range.", {"entities": [[28, 37, "Drug"], [44, 55, "Amount"]]}], [10315, "No alternative causes for the rise in sirolimus exposure were found.", {"entities": [[38, 47, "Drug"]]}], [10316, "Assessment with DIPS was found to be five, which showed this interaction to be probable.", {"entities": []}], [10317, "In addition, the patient\u2019s low-density lipoprotein and triglyceride levels showed a spontaneous decline by 6% and 17%, respectively, 3\u2009months after the peak level of sirolimus, which implied that sirolimus levels were associated with an elevation in cholesterol and triglyceride.", {"entities": [[27, 74, "Parameter"], [166, 175, "Drug"], [196, 205, "Drug"], [250, 261, "Parameter"], [266, 278, "Parameter"]]}], [10318, "The probability of this reaction to sirolimus is \u2018probable\u2019 based on Liverpool Adverse Drug Reaction Causality Assessment Tool.", {"entities": [[36, 45, "Drug"]]}], [10319, "In this patient, we reported the possible effect of parsley juice on the level of sirolimus.", {"entities": [[52, 59, "Herb name"], [82, 91, "Drug"]]}], [10320, "We propose that in this patient blood concentration of sirolimus increased because of the parsley juice she had used intensively to lose weight.", {"entities": [[55, 64, "Drug"], [90, 103, "Extraction process"]]}], [10321, "The normalization of the drug level when parsley juice was stopped also supports this consideration.", {"entities": [[41, 54, "Extraction process"]]}], [10322, "In addition, DIPS was performed and expert opinions were received.", {"entities": []}], [10323, "According to these data the probability of herb\u2013drug interaction is reasonable.", {"entities": []}], [10324, "Experimental animal and clinical data have shown that sirolimus is a critical-dose drug requiring therapeutic drug monitoring to minimize drug-related toxicities and maximize efficacy.", {"entities": [[54, 63, "Drug"]]}], [10325, "For this reason, close therapeutic drug monitoring is recommended for sirolimus, which has a narrow therapeutic window similar to other immunosuppressive drugs.", {"entities": [[70, 79, "Drug"]]}], [10326, "Some known inhibitors of CYP3A4 and P-gp, such as voriconazole, Due to being natural, herbs and herbal products are thought safer and more efficacious than pharmaceutically derived medications.", {"entities": [[25, 31, "Target"], [36, 40, "Target"], [50, 62, "Drug"]]}], [10327, "Contrary to this safety perception, herb\u2013drug interactions could lead to serious adverse effects.", {"entities": [[81, 96, "Pathology"]]}], [10328, "There are a few studies that state interactions between sirolimus and herbs.", {"entities": [[56, 65, "Drug"]]}], [10329, "A phase I study reported grapefruit juice increased sirolimus AUC approximately 350%.", {"entities": [[25, 41, "Extraction process"], [52, 61, "Drug"], [62, 65, "Parameter"]]}], [10330, "The pharmacological and toxicological properties of parsley are primarily associated with the volatile oil (apiole, myristicin), flavonoid, and furanocoumarin constituents.", {"entities": [[52, 59, "Herb name"], [94, 127, "Herb name"], [129, 138, "Herb name"], [144, 158, "Herb name"]]}], [10331, "Herb\u2013drug interactions could represent a serious clinical problem during the management of patients treated with some drugs.", {"entities": []}], [10332, "These interactions, which could lead to drug toxicity or graft function loss, are especially important for some special patient populations like transplant patients.", {"entities": []}], [10333, "There is a lack of clinical research assessing the efficacy and safety of medicinal herbs including parsley.", {"entities": [[100, 107, "Herb name"]]}], [10334, "Parsley should not be consumed in a quantity that markedly exceeds the amounts used in a regular diet, as excessive ingestion may result in drug interactions and toxicity.", {"entities": [[0, 7, "Herb name"]]}], [10335, "There is little known about herb\u2013drug interactions so it is logical to be alert about medicinal herbs and herbal supplementations that may have pharmacological effects.", {"entities": []}], [10336, "Further researches, including prospective studies on medicinal herbs, are needed to investigate interactions with drugs.", {"entities": []}], [10337, "Author contributions: MK drafted the initial and final versions of the manuscript.", {"entities": []}], [10338, "MSA drafted the initial version of the manuscript.", {"entities": []}], [10339, "NSK provided intellectual review of the manuscript as well as involvement in the care of this patient.", {"entities": []}], [10340, "TY, SRY, and YE were involved in patient care as nephrologists and contributed towards the intellectual review of the manuscript.", {"entities": []}], [10341, "Conflict of interest statement: The authors declare that there is no conflict of interest.", {"entities": []}], [10342, "Funding: The authors received no financial support for the research, authorship, and/or publication of this article.", {"entities": []}], [10343, "Informed consent: Written informed consent for patient information was provided by the patient.", {"entities": []}], [10344, "ORCID iD: Melek Kurtaran", {"entities": []}], [10345, "Sirolimus is an immunosuppressive drug used to prevent graft rejection.", {"entities": [[0, 9, "Drug"], [55, 70, "Pathology"]]}], [10346, "Therapeutic drug monitoring is required as with other immunosuppressive drugs.", {"entities": []}], [10347, "Previous studies have shown the interactions between sirolimus and drugs that affect the activity of cytochrome P450 3A4 and P-glycoprotein.", {"entities": [[53, 62, "Drug"], [101, 120, "Target"], [125, 139, "Target"]]}], [10348, "There is an increasing tendency for the use of herbal remedies in many countries.", {"entities": []}], [10349, "Medicinal herbs are rich sources of natural bioactive compounds that could interact with drugs.", {"entities": []}], [10350, "Parsley, Petroselinum crispum, is a food, spice, and also a medicinal herb.", {"entities": [[0, 7, "Herb name"], [9, 29, "Herb name"]]}], [10351, "We report a case of a renal transplant recipient who had a supratherapeutic blood level of sirolimus due to consuming excessive parsley to highlight a possible herb\u2013drug interaction.", {"entities": [[91, 100, "Drug"], [128, 135, "Herb name"]]}], [10352, "This is the first case report describing sirolimus\u2013parsley interaction.", {"entities": [[41, 50, "Drug"], [51, 58, "Herb name"]]}], [10353, "Herb\u2013drug interactions are especially important for drugs with a narrow therapeutic window.", {"entities": []}], [10354, "For this reason, healthcare professionals should question all patients, especially transplant patients, about the use of herbs or herbal products and report interactions.", {"entities": []}], [10355, "Parsley, a commonly consumed food, affects the level of an important drug in a renal transplant recipient: A case report  Sirolimus is a drug that suppresses the immune response used to prevent organ rejection in people who have had kidney transplants.", {"entities": [[0, 7, "Herb name"], [122, 131, "Drug"], [194, 209, "Pathology"]]}], [10356, "In order to reach the optimum balance between therapeutic efficacy and adverse effects, sirolimus blood levels should be closely monitored.", {"entities": [[88, 97, "Drug"]]}], [10357, "Previous studies have shown the interactions between sirolimus and drugs that affect the activities of metabolizing enzymes and transporter proteins.", {"entities": [[53, 62, "Drug"]]}], [10358, "Parsley is a food, spice, and also a medicinal herb.", {"entities": [[0, 7, "Herb name"]]}], [10359, "Medicinal herbs are rich sources of natural bioactive compounds that could interact with a prescription drug.", {"entities": []}], [10360, "We report a case of a renal transplant recipient who had a rise in the blood level of sirolimus due to the ingestion of an excessive amount of parsley to highlight possible herb\u2013drug interaction.", {"entities": [[86, 95, "Drug"], [143, 150, "Herb name"]]}], [10361, "Sirolimus, a macrolide compound isolated from Streptomyces hygroscopicus, was introduced in the late 1990s.", {"entities": [[0, 9, "Drug"]]}], [10362, "The demonstration of the potent immunosuppressive activity of sirolimus has led to its usage for the prevention of graft rejection in kidney transplantation.", {"entities": [[115, 130, "Pathology"]]}], [10363, "Sirolimus binds to a protein (FK binding protein-12) and this complex inhibits the activation of the mammalian target of rapamycin, which is a key regulatory kinase for cell cycle progression, thus suppressing cytokine-driven T-cell proliferation.", {"entities": [[0, 9, "Drug"], [101, 110, "Target"]]}], [10364, "Sirolimus displays a synergistic action with calcineurin inhibitors and a distinctive mechanism of action from calcineurin inhibitors, which are indispensable immunosuppressive agents in kidney transplantation.", {"entities": [[0, 9, "Drug"], [45, 67, "Drug"], [111, 133, "Drug"]]}], [10365, "In addition, sirolimus has some advantages compared with calcineurin inhibitors: sirolimus causes less nephrotoxicity, has anticancer effects, and allows once-daily administration.", {"entities": [[13, 22, "Drug"], [57, 79, "Drug"], [81, 90, "Drug"], [103, 117, "Pathology"]]}], [10366, "In recent years, the increasing use of herbs and herbal medicines for primary healthcare and chronic diseases has been widely reported in many countries.", {"entities": []}], [10367, "One of the important safety concerns with the widespread herbal remedy use is the potential interactions of herbal medicines with prescription drugs that may augment or inhibit the effect of the drugs.", {"entities": []}], [10368, "This is especially important for drugs with a narrow therapeutic window.", {"entities": []}], [10369, "Parsley, Petroselinum crispum, is commonly consumed as part of the diet.", {"entities": [[0, 8, "Herb name"], [9, 29, "Herb name"]]}], [10370, "Parsley, which is also a medicinal herb, is stated to have carminative, antispasmodic, diuretic, emmenagogue, expectorant, antirheumatic, and antimicrobial properties.", {"entities": [[0, 7, "Herb name"]]}], [10371, "The drug interaction probability scale (DIPS) is a tool to assess the causal relationship between interactions and adverse events.", {"entities": []}], [10372, "DIPS consists of 10 questions each with three response options to which a score is assigned.", {"entities": []}], [10373, "PubMed database and Google Scholar were searched using the key terms \u2018parsley\u2019, \u2018sirolimus\u2019, and \u2018herb\u2013drug interaction\u2019 up to 15 October 2020.", {"entities": [[70, 77, "Herb name"], [80, 90, "Drug"]]}], [10374, "Articles published in the English language were reviewed.", {"entities": []}], [10375, "Herein, we report a possible interaction between parsley and sirolimus in a kidney transplant patient leading to supratherapeutic blood concentrations of sirolimus.", {"entities": [[49, 56, "Herb name"], [61, 70, "Drug"], [154, 163, "Drug"]]}], [10376, "A 19-year-old woman was diagnosed with chronic kidney disease secondary to juvenile nephronophthisis.", {"entities": [[2, 13, "Age"], [14, 19, "Sex"], [39, 100, "Pathology"]]}], [10377, "In 2013, the patient underwent renal transplantation from her mother.", {"entities": []}], [10378, "Postrenal transplantation immunosuppressive therapy of the patient comprised a triple drug combination of prednisolone, tacrolimus, and mycophenolate mofetil.", {"entities": [[106, 118, "Drug"], [120, 130, "Drug"], [136, 157, "Drug"]]}], [10379, "The patient\u2019s medical history included pseudotumor cerebri and hypophosphatemic rickets.", {"entities": []}], [10380, "Her other significant medications included enalapril 10\u2009mg once daily, calcitriol 0.5\u2009\u00b5g once daily, and 1000\u2009mg elemental phosphorus containing effervescent tablet twice daily.", {"entities": [[43, 52, "Drug"], [53, 58, "Amount"], [59, 69, "Frequency"], [71, 81, "Drug"], [82, 88, "Amount"], [89, 99, "Frequency"], [105, 112, "Amount"], [165, 176, "Frequency"]]}], [10381, "The patient received tacrolimus-based immunosuppression until April 2016, and then the treatment was switched from tacrolimus to sirolimus due to evident tremors.", {"entities": [[21, 31, "Drug"], [115, 125, "Drug"], [154, 161, "Pathology"]]}], [10383, "In July 2020 at an out-patient follow-up visit, the patient\u2019s blood level of sirolimus (14.8\u2009ng/ml) was seen to be high.", {"entities": [[77, 86, "Drug"], [88, 98, "Amount"]]}], [10384, "Previous blood sirolimus levels ranged from 2\u2009ng/ml to 4\u2009ng/ml.", {"entities": [[15, 24, "Drug"], [44, 51, "Amount"], [55, 62, "Amount"]]}], [10385, "The concentration\u2013time profile is shown in Figure 1.", {"entities": []}], [10386, "At that time the serum creatinine level was 74.27\u2009\u00b5mol/L and was stable.", {"entities": [[17, 39, "Parameter"], [44, 56, "Amount"]]}], [10387, "Other factors that could increase the sirolimus level were questioned and ruled out.", {"entities": [[38, 47, "Drug"]]}], [10388, "No new drug that could influence the sirolimus levels had been administered.", {"entities": [[37, 46, "Drug"]]}], [10389, "The next day testing of the blood sirolimus level (14.6\u2009ng/ml) confirmed that there was no laboratory mistake.", {"entities": [[34, 43, "Drug"], [51, 61, "Amount"]]}], [10390, "A more detailed history was taken from the patient.", {"entities": []}], [10391, "It was learned that she regularly made a juice of parsley and consumed the parsley juice daily to lose weight and promote her health.", {"entities": [[41, 57, "Extraction process"], [75, 88, "Extraction process"], [89, 94, "Frequency"]]}], [10392, "The juice, which contained about 30\u2009g of parsley, was consumed by the patient for 7\u2009days.", {"entities": [[33, 37, "Amount"], [82, 88, "Duration"]]}], [10393, "Sirolimus blood concentration versus time.", {"entities": [[0, 9, "Drug"]]}], [10394, "She was asked to pay attention to a balanced diet and avoid consuming excessive amounts of a single vegetable, fruit, and herb for a week.", {"entities": [[133, 137, "Duration"]]}], [10395, "A week later, the patient\u2019s sirolimus level (4.6\u2009ng/ml) was seen in the normal range.", {"entities": [[28, 37, "Drug"], [45, 55, "Amount"]]}], [10396, "No alternative causes for the rise in sirolimus exposure were found.", {"entities": []}], [10397, "Assessment with DIPS was found to be five, which showed this interaction to be probable.", {"entities": []}], [10398, "In addition, the patient\u2019s low-density lipoprotein and triglyceride levels showed a spontaneous decline by 6% and 17%, respectively, 3\u2009months after the peak level of sirolimus, which implied that sirolimus levels were associated with an elevation in cholesterol and triglyceride.", {"entities": [[27, 74, "Parameter"], [166, 175, "Drug"], [196, 205, "Drug"], [250, 261, "Parameter"], [266, 278, "Parameter"]]}], [10399, "The probability of this reaction to sirolimus is \u2018probable\u2019 based on Liverpool Adverse Drug Reaction Causality Assessment Tool.", {"entities": [[36, 45, "Drug"]]}], [10400, "In this patient, we reported the possible effect of parsley juice on the level of sirolimus.", {"entities": [[82, 91, "Drug"]]}], [10401, "We propose that in this patient blood concentration of sirolimus increased because of the parsley juice she had used intensively to lose weight.", {"entities": [[55, 64, "Drug"], [90, 103, "Extraction process"]]}], [10402, "The normalization of the drug level when parsley juice was stopped also supports this consideration.", {"entities": [[41, 54, "Extraction process"]]}], [10403, "In addition, DIPS was performed and expert opinions were received.", {"entities": []}], [10404, "According to these data the probability of herb\u2013drug interaction is reasonable.", {"entities": []}], [10405, "Experimental animal and clinical data have shown that sirolimus is a critical-dose drug requiring therapeutic drug monitoring to minimize drug-related toxicities and maximize efficacy.", {"entities": [[54, 63, "Drug"]]}], [10406, "For this reason, close therapeutic drug monitoring is recommended for sirolimus, which has a narrow therapeutic window similar to other immunosuppressive drugs.", {"entities": [[70, 79, "Drug"]]}], [10407, "Some known inhibitors of CYP3A4 and P-gp, such as voriconazole, Due to being natural, herbs and herbal products are thought safer and more efficacious than pharmaceutically derived medications.", {"entities": [[25, 31, "Target"], [36, 40, "Target"], [50, 62, "Drug"]]}], [10408, "Contrary to this safety perception, herb\u2013drug interactions could lead to serious adverse effects.", {"entities": [[81, 96, "Pathology"]]}], [10409, "There are a few studies that state interactions between sirolimus and herbs.", {"entities": [[56, 65, "Drug"]]}], [10410, "A phase I study reported grapefruit juice increased sirolimus AUC approximately 350%.", {"entities": [[25, 41, "Extraction process"], [52, 61, "Drug"], [62, 65, "Parameter"]]}], [10411, "The pharmacological and toxicological properties of parsley are primarily associated with the volatile oil (apiole, myristicin), flavonoid, and furanocoumarin constituents.", {"entities": [[52, 59, "Herb name"], [94, 127, "Herb name"], [129, 138, "Herb name"], [144, 158, "Herb name"]]}], [10412, "Herb\u2013drug interactions could represent a serious clinical problem during the management of patients treated with some drugs.", {"entities": []}], [10413, "These interactions, which could lead to drug toxicity or graft function loss, are especially important for some special patient populations like transplant patients.", {"entities": []}], [10414, "There is a lack of clinical research assessing the efficacy and safety of medicinal herbs including parsley.", {"entities": [[100, 107, "Herb name"]]}], [10415, "Parsley should not be consumed in a quantity that markedly exceeds the amounts used in a regular diet, as excessive ingestion may result in drug interactions and toxicity.", {"entities": [[0, 7, "Herb name"]]}], [10416, "There is little known about herb\u2013drug interactions so it is logical to be alert about medicinal herbs and herbal supplementations that may have pharmacological effects.", {"entities": []}], [10417, "Further researches, including prospective studies on medicinal herbs, are needed to investigate interactions with drugs.", {"entities": []}], [10418, "Author contributions: MK drafted the initial and final versions of the manuscript.", {"entities": []}], [10419, "MSA drafted the initial version of the manuscript.", {"entities": []}], [10420, "NSK provided intellectual review of the manuscript as well as involvement in the care of this patient.", {"entities": []}], [10421, "TY, SRY, and YE were involved in patient care as nephrologists and contributed towards the intellectual review of the manuscript.", {"entities": []}], [10422, "Conflict of interest statement: The authors declare that there is no conflict of interest.", {"entities": []}], [10423, "Funding: The authors received no financial support for the research, authorship, and/or publication of this article.", {"entities": []}], [10424, "Informed consent: Written informed consent for patient information was provided by the patient.", {"entities": []}], [10425, "ORCID iD: Melek Kurtaran", {"entities": []}], [10427, "Epimedium sagittatum (Sieb.", {"entities": [[0, 20, "Herb name"]]}], [10428, "et Zucc.)", {"entities": []}], [10429, "Maxim is one of the herbs used to treat erectile dysfunction in Traditional Chinese Medicine.", {"entities": [[0, 5, "Herb name"], [40, 60, "Pathology"], [76, 83, "Ethnic group"]]}], [10430, "Sildenafil is a phosphodiesterase 5 inhibitor used to treat erectile dysfunction in Western Medicine.", {"entities": [[0, 45, "Drug"], [60, 80, "Pathology"]]}], [10431, "This study evaluates the herbal-drug interaction of Epimedium sagittatum extract on the pharmacokinetics of sildenafil in rats by ultra-performance liquid chromatography.", {"entities": [[52, 72, "Herb name"], [73, 80, "Extraction process"], [108, 118, "Drug"]]}], [10432, "The pharmacokinetic data demonstrate that the area under the concentration-time curve (AUC) of sildenafil (10 mg/kg) was significantly decreased in groups that received a high dose of Epimedium sagittatum extract.", {"entities": [[46, 91, "Parameter"], [95, 105, "Drug"], [107, 115, "Amount"], [184, 204, "Herb name"], [205, 212, "Extraction process"]]}], [10433, "In conclusion, the study demonstrates that there was significant herb-drug interaction of Epimedium sagittatum extract on the pharmacokinetics of sildenafil at low and high daily doses, suggesting co-administration use of Epimedium sagittatum extract and sildenafil in clinical practice should be prevented due to possible herb-drug interactions.", {"entities": [[90, 110, "Herb name"], [111, 118, "Extraction process"], [146, 156, "Drug"], [173, 178, "Frequency"], [222, 242, "Herb name"], [243, 250, "Extraction process"], [255, 265, "Drug"]]}], [10434, "Erectile dysfunction is an age-related problem with a prevalence rate of 17.7% in men older than 40, and it increases with age and number of comorbidities [1].", {"entities": [[0, 20, "Pathology"], [82, 85, "Sex"]]}], [10435, "The inability to maintain erectile function results in anxiety, loss of self-esteem and relationship strains [2,3].", {"entities": [[55, 62, "Pathology"]]}], [10436, "It is not surprising erectile dysfunction affects interpersonal relationships between partners, resulting in diminished psychosocial functioning in men with erectile dysfunction.", {"entities": [[21, 41, "Pathology"], [157, 177, "Pathology"]]}], [10437, "Treatment of erectile dysfunction leads to improved quality of life in both the sexual and emotional aspects [4,5,6].", {"entities": [[13, 33, "Pathology"]]}], [10438, "Since 1998, sildenafil, one of the phosphodiesterase-5 inhibitors, which acts by regulating the blood flow of penis via inhibition of cGMP specific phosphodiesterase 5 in the corpus cavernosum, was considered the treatment of choice for erectile dysfunction, with a response rate ranging from 68\u201369% [7].", {"entities": [[12, 22, "Drug"], [35, 65, "Drug"], [134, 167, "Target"], [237, 257, "Pathology"]]}], [10439, "Sildenafil was absorbed and acted within 30 min to 150 min while a mean half-life of approximately 240 min over the dose range of 25 mg to 200 mg.", {"entities": [[0, 10, "Drug"], [72, 81, "Parameter"], [99, 106, "Amount"], [130, 145, "Amount"]]}], [10440, "The mean absolute oral bioavailability is 41% after single oral intake of sildenafil and food imposes a small reduction in the rate and extent of systemic exposure [8].", {"entities": [[23, 38, "Parameter"], [74, 84, "Drug"]]}], [10441, "Sildenafil is metabolized by liver microsomes and CYP3A4 and excreted through either the urinary tract or gastrointestinal tract [9,10].", {"entities": [[0, 10, "Drug"], [50, 56, "Target"]]}], [10442, "There are some possible side effects mentioned in the literature, such as hot flushes, blue tinged vision, headache, and dizziness.", {"entities": [[24, 36, "Pathology"], [74, 85, "Pathology"], [87, 105, "Pathology"], [107, 115, "Pathology"], [121, 130, "Pathology"]]}], [10443, "Despite this, it remains the treatment of choice for men with mild to moderate erectile dysfunction [11].", {"entities": [[62, 99, "Pathology"]]}], [10444, "Epimedium sagittatum is one of the Herba Epimedii species and is distributed from middle Asia to southeast China [11].", {"entities": [[0, 20, "Herb name"], [35, 57, "Herb name"]]}], [10446, "It is also reported to have potential effects on the management of erectile dysfunction [15,16,17].", {"entities": [[67, 87, "Pathology"]]}], [10447, "Epimedium sagittatum has been used to treat male erectile dysfunction in Traditional Chinese Medicine for many centuries.", {"entities": [[0, 20, "Herb name"], [44, 48, "Sex"], [49, 69, "Pathology"], [85, 92, "Ethnic group"]]}], [10448, "The main functions of Epimedium sagittatum in ancient Chinese books focused on the nourishment of kidney viscera and reinforcement of \u2018yang\u2019, resulting in the restoration of erectile function in males [18].", {"entities": [[22, 42, "Herb name"], [195, 200, "Sex"]]}], [10449, "Although Epimedium sagittatum is reported to have multiple treatment effects in Traditional Chinese Medicine, the pharmacokinetic profile data in the literature is limited, and is mainly focused on icariin, the major purified product from the Epimedium sagittatum species [19,20].", {"entities": [[9, 29, "Herb name"], [92, 99, "Ethnic group"], [198, 205, "Herb name"], [243, 271, "Herb name"]]}], [10450, "Previous studies have indicated epimedii herba extract modulates liver metabolic enzyme activities, such as CYP1A2, CYP3A4 and CYP2E1, which are the main isoforms of cytochrome P450, and total flavonoids may be responsible for the inhibition the metabolism of sildenafil [13,21].", {"entities": [[32, 46, "Herb name"], [47, 54, "Extraction process"], [108, 114, "Target"], [116, 122, "Target"], [127, 133, "Target"], [166, 181, "Target"], [193, 203, "Herb name"], [260, 270, "Drug"]]}], [10451, "Our recent work has demonstrated biliary excretion is the major elimination pathway for icariin, while P-glycoprotein might play a role in the metabolism of icariin in rats [22].", {"entities": [[88, 95, "Herb name"], [103, 117, "Target"], [157, 164, "Herb name"]]}], [10452, "The cultural differences of Asian and Western countries result in different attitudes and willingness to receive treatment for erectile dysfunction.", {"entities": [[127, 147, "Pathology"]]}], [10453, "In Asian countries, men with erectile dysfunction are primarily seeking alternative/Traditional Chinese Medicine instead of/along with Western Medicine [23].", {"entities": [[20, 23, "Sex"], [29, 49, "Pathology"], [96, 103, "Ethnic group"]]}], [10454, "Hence, the combination use of Western Medicine and Traditional Chinese Medicine is a common phenomenon for Asian [24].", {"entities": [[63, 70, "Ethnic group"], [107, 112, "Ethnic group"]]}], [10455, "Since Epimedium sagittatum has been used to treat erectile dysfunction in Traditional Chinese Medicine for a long time, the use of oral phosphodiesterase 5 inhibitors and Epimedium sagittatum for managing erectile dysfunction has probably been in practice since the initial use of phosphodiesterase 5 inhibitors for Asians.", {"entities": [[6, 26, "Herb name"], [50, 70, "Pathology"], [86, 93, "Ethnic group"], [136, 166, "Drug"], [171, 191, "Herb name"], [205, 225, "Pathology"], [281, 311, "Drug"], [316, 322, "Ethnic group"]]}], [10456, "In 2007, Zhang reported the switching phenomenon between Traditional Chinese Medicine and sildenafil among impotence patients became common after the application of sildenafil in China [24].", {"entities": [[69, 76, "Ethnic group"], [90, 100, "Drug"], [165, 175, "Drug"]]}], [10457, "They reported that switching back and forth between sildenafil and Traditional Chinese Medicine (mainly herba epimedii) represents not only two types of medications, but also revolves around the sexual desire and the cultivation of life in China.", {"entities": [[52, 62, "Drug"], [79, 86, "Ethnic group"], [104, 118, "Herb name"]]}], [10458, "Hence, the investigation of herbal drug effect between sildenafil and herba epimedii deserves further investigation so as to understand the possible safety issues regarding the combination use of sildenafil and herba epimedii.", {"entities": [[55, 65, "Drug"], [70, 84, "Herb name"], [196, 206, "Drug"], [211, 225, "Herb name"]]}], [10459, "According to a survey of the PubMed database, the pharmacokinetic interactions for the combined use of Epimedium sagittatum and sildenafil have not been reported in the literature.", {"entities": [[103, 123, "Herb name"], [128, 138, "Drug"]]}], [10460, "To understand the possible herbal drug interaction between Epimedium sagittatum and phosphodiesterase 5 inhibitors, the pharmacokinetic interaction of the Epimedium sagittatum species and sildenafil should be understood.", {"entities": [[59, 79, "Herb name"], [84, 114, "Drug"], [155, 183, "Herb name"], [188, 198, "Drug"]]}], [10461, "The aim of this study is to investigate the herbal drug pharmacokinetic interaction of Epimedium sagittatum extract and sildenafil in rats.", {"entities": [[87, 107, "Herb name"], [108, 115, "Extraction process"], [120, 130, "Drug"]]}], [10462, "The retention time for the internal standard (p-hydrobenzoate) and sildenafil were 3.7 min and 8 min, respectively.", {"entities": [[67, 77, "Drug"]]}], [10463, "There was no interference during the retention time of 6\u201310 min in the blank plasma dialysate.", {"entities": []}], [10464, "The accuracy was calculated by the nominal concentration (Cnom) and the mean value of the observed concentrations (Cobs) as follows: accuracy (%) = (Cobs/Cnom) \u00d7 100.", {"entities": []}], [10465, "The precision, relative standard deviation (RSD), was estimated from the observed concentrations as follows: RSD (%) = (standard deviation (SD)/Cobs) \u00d7 100.", {"entities": []}], [10466, "Table 1 showed the analytical precision and accuracy of sildenafil in rat plasma.", {"entities": [[56, 66, "Drug"]]}], [10467, "The calibration curve for sildenafil had good linearity (R HPLC chromatograms of intravenous sildenafil after oral administration of the Epimedium sagittatum extract.", {"entities": [[26, 36, "Drug"], [93, 103, "Drug"], [137, 157, "Herb name"], [158, 165, "Extraction process"]]}], [10468, "(A) blank plasma, (B) blank plasma spiked with sildenafil (1 \u00b5g/mL), (C) plasma sample collected at 15 min after treatment of epimedii extract 2 h before sildenafil administration (10 mg/kg).", {"entities": [[47, 57, "Drug"], [126, 134, "Herb name"], [135, 142, "Extraction process"], [154, 164, "Drug"], [181, 189, "Amount"]]}], [10469, "1: Internal Standard (p-hydrobenzoate), 2: sildenafil.", {"entities": [[43, 53, "Drug"]]}], [10470, "Inter-day and intra-day assay of sildenafil in rat plasma.", {"entities": [[33, 43, "Drug"]]}], [10471, "Data are expressed as mean \u00b1 S. D. (n = 6).", {"entities": []}], [10472, "* The relative standard deviation (RSD) was estimated from the observed concentrations as follows: RSD (%) = (standard deviation (SD)/Cobs) \u00d7 100.", {"entities": []}], [10473, "** The accuracy was calculated by the nominal concentration (Cnom) and the mean value of the observed concentrations (Cobs) : accuracy (%) = (Cobs/Cnom) \u00d7 100.", {"entities": []}], [10474, "The dosage regimens of Epimedium sagittatum extract and sildenafil are listed in Table 2.", {"entities": [[23, 43, "Herb name"], [44, 51, "Extraction process"], [56, 66, "Drug"]]}], [10475, "Figure 2 showed the concentration-time profiles in the groups received the 1 g/kg Epimedium sagittatum extract pretreatment (groups 1\u20134).", {"entities": [[75, 81, "Amount"], [82, 102, "Herb name"], [103, 110, "Extraction process"]]}], [10476, "The dosage regimens of Epimedium sagittatum (Sieb.", {"entities": [[23, 43, "Herb name"]]}], [10477, "et Zucc.)", {"entities": []}], [10479, "et Zucc.)", {"entities": []}], [10480, "Maxim extract (1 g/kg) 2 h pretreated + sildenafil (10 mg/kg), group 3: low dose Epimedium sagittatum (Sieb.", {"entities": [[0, 5, "Herb name"], [6, 13, "Extraction process"], [15, 21, "Amount"], [40, 50, "Drug"], [52, 60, "Amount"], [81, 101, "Herb name"]]}], [10481, "et Zucc.)", {"entities": []}], [10482, "et Zucc.)", {"entities": []}], [10483, "Data are presented as expressed as mean \u00b1 standard error of the mean (S.E.", {"entities": []}], [10484, "), n = 6 for each group.", {"entities": []}], [10485, "The half-life (t The AUC data showed statistically significant differences between groups 1 and 4 (348 versus 536, p < 0.001) and between groups 1 and 2 (348 versus 183, p = 0.001), while similar results were found between groups 3 and 4 (296 versus 536, p < 0.001) and between groups 2 and 3 (183 versus 296, p = 0.034).", {"entities": [[4, 13, "Parameter"], [21, 24, "Parameter"]]}], [10486, "The AUC data showed statistically significant differences between group 1 and 2 and between groups 2 and 3 possibly suggest the herb-drug interaction between Epimedium sagittatum extract and sildenafil.", {"entities": [[4, 7, "Parameter"], [158, 178, "Herb name"], [179, 186, "Extraction process"], [191, 201, "Drug"]]}], [10487, "The volume of distribution at steady state (V Pharmacokinetic parameters of sildenafil in various groups.", {"entities": [[0, 26, "Parameter"], [76, 86, "Drug"]]}], [10488, "The half-life (t Plasma concentration-time profile of sildenafil in the blood of group 5: high dose Epimedium sagittatum (Sieb.", {"entities": [[0, 13, "Parameter"], [54, 64, "Drug"], [100, 120, "Herb name"]]}], [10489, "et Zucc.)", {"entities": []}], [10490, "et Zucc.)", {"entities": []}], [10491, "Data are presented as expressed as mean \u00b1 standard error of the mean (S.E.", {"entities": []}], [10492, "), n = 6 for each group.", {"entities": []}], [10493, "Pharmacokinetic parameters of sildenafil in group 5 and 6.", {"entities": [[30, 40, "Drug"]]}], [10494, "For example, the dose-normalized (based on 10 mg/kg sildenafil) C Pharmacokinetic parameters of dose-normalized sildenafil in various groups.", {"entities": [[43, 51, "Amount"], [52, 62, "Drug"], [112, 122, "Drug"]]}], [10495, "For groups that received 3 days Epimedium sagittatum extract (group 3, 4, 5, 6), dose-normalized AUC values showed statistically significant differences between group 3 and other groups, and between group 4 and 5, which indicated further support to the dose-dependent herbal drug interaction between Epimedium sagittatum extract and sildenafil.", {"entities": [[25, 31, "Duration"], [32, 52, "Herb name"], [53, 60, "Extraction process"], [97, 100, "Parameter"], [300, 320, "Herb name"], [321, 328, "Extraction process"], [333, 343, "Drug"]]}], [10496, "The Cl showed statistically significant differences between group 1 and group 5 (27 versus 111, p = 0.003) and between group 3 and group 5 (33 versus 111, p = 0.007).", {"entities": []}], [10497, "The V Phosphodiesterase 5 inhibitors are common medications for managing erectile dysfunction and Epimedium sagittatum is one of the common herbs used in Traditional Chinese Medicine for this purpose.", {"entities": [[6, 36, "Drug"], [73, 93, "Pathology"], [98, 118, "Herb name"], [166, 173, "Ethnic group"]]}], [10498, "We choose sildenafil and Epimedium sagittatum as our study targets to investigate the herb-drug interaction between Western and Traditional Chinese Medicines.", {"entities": [[10, 20, "Drug"], [25, 45, "Herb name"], [140, 147, "Ethnic group"]]}], [10499, "To our knowledge, this is the first pharmacokinetic study of phosphodiesterase 5 inhibitors and the Epimedium sagittatum species.", {"entities": [[36, 57, "Study"], [61, 91, "Drug"], [100, 128, "Herb name"]]}], [10500, "In this study, dose-normalized C There were some limitations to this study.", {"entities": []}], [10501, "First, we used Epimedium sagittatum extract rather than isolated herbal ingredients from Epimedium sagittatum.", {"entities": [[15, 35, "Herb name"], [36, 43, "Extraction process"], [89, 109, "Herb name"]]}], [10502, "In fact, we tried to demonstrate the actual clinical scenario regarding the daily life of Chinese culture in this study.", {"entities": [[90, 97, "Ethnic group"]]}], [10504, "Second, the pretreatment period of Epimedium sagittatum extract might have been too short to identify the possible herbal drug effect.", {"entities": [[35, 55, "Herb name"], [56, 63, "Extraction process"]]}], [10505, "In 2010, Shindel et al.", {"entities": []}], [10506, "reported the use of icariin, the main components of Epimedium sagittatum, could induce erectogenic and neurotrophic effects in castrated rats [28].", {"entities": [[20, 27, "Herb name"], [52, 72, "Herb name"]]}], [10507, "They indicated that continuous use low dose icariin for 28 days might significantly affect neurite growth of pelvic ganglion and increase intracavernous pressure in the penile tissues.", {"entities": [[44, 51, "Herb name"], [52, 63, "Duration"]]}], [10508, "However, the use of icariin differs from Epimedium sagittatum extract in our study, meaning the comparison between these two studies requires further investigation.", {"entities": [[20, 27, "Herb name"], [41, 61, "Herb name"], [62, 69, "Extraction process"]]}], [10509, "Besides, the different pretreatment period (3 days versus 28 days) is another consideration in comparing the different data from these studies.", {"entities": [[44, 50, "Duration"], [58, 65, "Duration"]]}], [10510, "Hence, the necessity to prolong the pretreatment period of Epimedium sagittatum extract deserves further investigation and will be conducted in upcoming research projects.", {"entities": [[59, 79, "Herb name"], [80, 87, "Extraction process"]]}], [10511, "Third, the dosage of Epimedium sagittatum extract treatment for rats in this study was high, and it is expected Epimedium sagittatum extract may have no significant effect on the pharmacokinetics of sildenafil at a normal daily ingested dose.", {"entities": [[21, 41, "Herb name"], [42, 49, "Extraction process"], [112, 132, "Herb name"], [133, 140, "Extraction process"], [199, 209, "Drug"], [222, 227, "Frequency"]]}], [10512, "Sildenafil was obtained from Pfizer Pharmaceuticals (New York, NY, USA).", {"entities": [[0, 10, "Drug"]]}], [10513, "Liquid chromatographic grade solvent and reagents were purchased from E. Merck (Darmstadt, Germany).", {"entities": []}], [10514, "Triplied deionized water was prepared by the Milli-Q system (Millipore, Bedford, MA, USA) and used for all preparations.", {"entities": []}], [10515, "Epimedium sagittatum (Sieb.", {"entities": [[0, 20, "Herb name"]]}], [10516, "et Zucc.)", {"entities": []}], [10517, "Maxim was purchased from a local traditional Chinese medicine distributor (Taipei, Taiwan) and was verified by Ching-Song Shyu, director of Chia Huei Co., Inc., Taipei, Taiwan, based on comparisons of the external appearance of the leaves with the figures drawn in the literature [29].", {"entities": [[0, 5, "Herb name"], [45, 52, "Ethnic group"], [232, 238, "Herb part"]]}], [10518, "A voucher specimen was deposited in the National Research Institute of Chinese Medicine, Taipei, Taiwan.", {"entities": [[71, 78, "Ethnic group"]]}], [10519, "Epimedium sagittatum (10 kg) was immersed in 160 liters of ethanol and extracted two times.", {"entities": [[0, 20, "Herb name"]]}], [10520, "A total of 320 liters Epimedium sagittatum extract were collected and filtered through layers of gauze.", {"entities": [[22, 42, "Herb name"], [43, 50, "Extraction process"]]}], [10521, "The residues were discarded and the filtrates were kept at \u221220 \u00b0C and frozen.", {"entities": []}], [10522, "The final weight of the Epimedium sagittatum extract was 1,076 g. HPLC-UV instrumentation was performed with a Shimadzu chromatographic pump (LC-20AT), a DGU-20A5 degasser, an autosampler (SIL-20AC) and a photo-diode array detector (SPD-M20A) (Shimadzu, Kyoto, Japan).", {"entities": [[24, 44, "Herb name"], [45, 52, "Extraction process"]]}], [10523, "Epimedium sagittatum extract and sildenafil were separated using a Phenomenex Kinetex C Plasma (100 \u03bcL) was alkalized with NaOH (1 mM, 20 \u03bcL) and extracted with ethyl acetate (500 \u03bcL) for liquid-liquid extraction.", {"entities": [[0, 20, "Herb name"], [21, 28, "Extraction process"], [33, 43, "Drug"], [188, 212, "Extraction process"]]}], [10524, "The samples were vortex-mixed for 5 min and centrifuged at 6000 \u00d7 g for 10 min, and this process was repeated three times.", {"entities": []}], [10525, "The combined extraction solution was then evaporated to dryness.", {"entities": []}], [10526, "The residues were reconstituted in 100 \u03bcL mobile phase.", {"entities": []}], [10527, "The samples were vortex-mixed and centrifuged at 3200 \u00d7 g for 10 min.", {"entities": []}], [10528, "The supernatants were filtered through 0.22 \u03bcm membrane filter prior to HPLC analysis.", {"entities": []}], [10529, "Calibration standards of plasma samples were prepared by adding known amounts of sildenafil into blank rat plasma to give a range of 0.05 to 10 \u03bcg/mL.", {"entities": [[81, 91, "Drug"]]}], [10530, "The inter-day and intra-day assays of sildenafil in rat plasma were determined by quantitating six replicates using the HPLC method.", {"entities": [[38, 48, "Drug"]]}], [10531, "The study protocol has been reviewed and approved by the Institutional Animal Care and Use Committee (IACUC, approval number 1010911) by the Institutional Animal Experimentation Committee of National Yang-Ming University, Taipei, Taiwan.", {"entities": []}], [10532, "Male Sprague-Dawley rats (6 weeks, 250 \u00b1 20 g body weight) were purchased from the laboratory animal center of National Yang-Ming University.", {"entities": []}], [10533, "All experimental animals were housed in standard rat cages on a 12-hour light/dark cycle under institutional guidelines and had free access to food and water throughout the entire experiment until 12 hours before the intravenous sildenafil administration.", {"entities": [[229, 239, "Drug"]]}], [10534, "One 0.8 cm incision was made at left femoral canal and dissected layer by layer till identification of left femoral vein.", {"entities": []}], [10535, "Vascular cannulation was performed for intravenous sildenafil injection.", {"entities": [[51, 61, "Drug"]]}], [10536, "Another 0.8 cm incision was made at right neck and dissected layer by layer till identification of right external jugular vein.", {"entities": []}], [10537, "Vascular cannulation was performed for sequential blood sampling.", {"entities": []}], [10538, "The WinNonlin Standard Edition (Version 1.1, Scientific Consulting Inc., Apex, NC, USA) was used to calculate pharmacokinetic data.", {"entities": []}], [10539, "An IV-bolus input non-compartmental model was used to find the blood pharmacokinetic parameters, including elimination half life (t Based on a pharmacokinetics perspective, there was a significant herb-drug interaction between Epimedium sagittatum extract and sildenafil.", {"entities": [[227, 247, "Herb name"], [248, 255, "Extraction process"], [260, 270, "Drug"]]}], [10540, "Patients who considered integrated use of Epimedium sagittatum extract and sildenafil might be advised to prevent possible therapeutic failure due to enhanced elimination of sildenafil.", {"entities": [[42, 62, "Herb name"], [63, 70, "Extraction process"], [75, 85, "Drug"], [174, 184, "Drug"]]}], [10541, "From this study, we hope to provide more information on integrating eastern herbal medicine and western medications for managing erectile dysfunction in clinical practice.", {"entities": [[129, 149, "Pathology"]]}], [10542, "Funding for this study was provided in part by research grants from the National Research Institute of Chinese Medicine, Taipei, Taiwan; the National Science Council (NSC99-2113-M-010-001-MY3, NSC99-2628-B-010-008-MY3) Taiwan; TCH 96001-62-014, 10001-62-007 from Taipei City Hospital, Taipei, Taiwan.", {"entities": [[103, 110, "Ethnic group"]]}], [10543, "Sample Availability: Samples of the compounds Epimedium sagittatum (Sieb.", {"entities": [[46, 66, "Herb name"]]}], [10544, "et Zucc.)", {"entities": []}], [10545, "Maxim extract are available from the authors.", {"entities": [[0, 5, "Herb name"], [6, 13, "Extraction process"]]}], [10546, "The authors declare no conflict of interest.", {"entities": []}], [10547, "Many people worldwide use plant preparations for medicinal purposes.", {"entities": [[26, 44, "Herb name"]]}], [10548, "Even in industrialized regions, such as Europe, where conventional therapies are accessible for the majority of patients, there is a growing interest in and usage of phytomedicine.", {"entities": []}], [10549, "Plant preparations are not only used as alternative treatment, but also combined with conventional drugs.", {"entities": [[0, 18, "Herb name"], [86, 105, "Drug"]]}], [10550, "These combinations deserve careful contemplation, as the complex mixtures of bioactive substances in plants show a potential for interactions.", {"entities": []}], [10551, "Induction of CYP enzymes and pGP by St John\u2019s wort may be the most famous example, but there is much more to consider.", {"entities": [[13, 24, "Target"], [29, 32, "Target"], [36, 50, "Herb name"]]}], [10552, "In this review, we shed light on what is known about the interactions between botanicals and drugs, in order to make practitioners aware of potential drug-related problems.", {"entities": [[8, 14, "Study"]]}], [10553, "The main focus of the article is the treatment of inflammatory diseases, accompanied by plant preparations used in Europe.", {"entities": [[50, 71, "Pathology"]]}], [10554, "Despite the dominance of medicinal products, with one, or few, chemically-defined active substance(s), in industrialized countries, herbal medicinal products remain popular, and their relevance even grows [1].", {"entities": []}], [10555, "Surveys among pediatric, adult, and elderly patients in several countries reveal that between 15 and 45% of patients use herbal products for healthcare purposes, besides prescribed medicine [2,3,4,5,6].", {"entities": []}], [10556, "The use of complementary herbal medicines and food supplements is particularly frequent among women and older people [7,8,9].", {"entities": [[94, 99, "Sex"]]}], [10557, "Surveys indicate that patients with chronic diseases use more supplements [8].", {"entities": [[36, 52, "Pathology"]]}], [10558, "Many patients consider them \u201cnatural\u201d and, thus, \u201cless harmful\u201d and having no, or fewer, side effects [6,10].", {"entities": [[89, 101, "Pathology"]]}], [10559, "That may result in not considering them as medicine or medicinal products and missing to report them to health professionals, if not explicitly asked [5,6,10,11].", {"entities": []}], [10560, "When patients use herbal medicinal products (HMP) or herbal supplements conjointly with conventional drugs, this bears the risk of unrecognized potential interactions.", {"entities": [[18, 71, "Herb name"], [88, 106, "Drug"]]}], [10561, "The legal background of plant products for health purposes in the European Union is complex.", {"entities": [[66, 74, "Ethnic group"]]}], [10562, "The status ranks from herbal dietary supplements fall under food legislation and cosmetics to HMPs, with different kinds of market authorization.", {"entities": []}], [10563, "There are three kinds of HMPs in the European Union (regulated in Directive 2001/83/EC and its amendment, Directive 2004/24/EC [12]): (i) products based on \u201ctraditional use\u201d with at least 30 years of documented usage and without known safety concerns, (ii) \u201cwell-established use\u201d, and (iii) HMPs with a regular approval, based on preclinical and clinical data.", {"entities": [[25, 29, "Herb name"], [37, 45, "Ethnic group"], [188, 196, "Duration"], [291, 295, "Herb name"]]}], [10564, "The Committee on Herbal Medicinal Products (HMPC), which belongs to the European Medicines Agency (EMA), develops monographs on herbal drugs and plant products, collecting evidence for \u201ctraditional\u201d and \u201cwell-established\u201d use, the latter requiring scientific evidence for beneficial effects, at least ten years of experience, and publications indicating safety.", {"entities": [[72, 103, "Ethnic group"], [301, 310, "Duration"]]}], [10565, "These monographs are considered when evaluating applications for market authorization.", {"entities": []}], [10566, "Products with documented \u201ctraditional use\u201d or \u201cwell-established use\u201d status gain market authorization through a facilitated process.", {"entities": []}], [10567, "A more detailed description of the regulatory environment in Europe, as well as its practical effects, can be found in the Bilia and C\u00e9u Costas review [13].", {"entities": []}], [10568, "The complex regulation of HMPs and other botanicals reflects different levels of evidence, but products with less evidence cannot be regarded as generally inactive.", {"entities": [[26, 30, "Herb name"]]}], [10569, "It most often means that we have less knowledge of benefits, as well as risks.", {"entities": []}], [10570, "Food supplements are usually restricted to lower daily doses than medicinal products and, thus, considered safe.", {"entities": []}], [10571, "However, depending on individual susceptibility, with conditions such as age or renal impairment, medication, and consumer-driven dose changes, there still remains a risk for adverse effects and/or interactions.", {"entities": [[80, 96, "Pathology"], [175, 190, "Pathology"]]}], [10572, "That means, for the purpose of risk assessment, all herbal products impartial of their legal status should be considered.", {"entities": []}], [10573, "This review aims to include plant derived products (extracts, powdered plant, and teas) used systemically for health improvement or treatment of disease, regardless of their legal status.", {"entities": [[145, 152, "Pathology"]]}], [10574, "Products for topical use are not in the focus of this review because of their lower potential for systemic drug interactions.", {"entities": []}], [10575, "Adverse effects, such as allergies, are more relevant for topic herbal products.", {"entities": [[0, 15, "Pathology"], [25, 34, "Pathology"]]}], [10576, "Caution is advised for patients receiving phototoxic medication, as many plants, such as citrus species or chamomile, have phototoxic potential (reviewed in [14]).", {"entities": [[42, 52, "Pathology"], [89, 103, "Herb name"], [107, 116, "Herb name"], [123, 133, "Pathology"]]}], [10577, "Classical homeopathic products are diluted and thus can usually be regarded as safe, in terms of interactions.", {"entities": []}], [10578, "However, practitioners should be aware of products with low potency (D6 and smaller) dilutions and undiluted original tinctures (often marked with \u00d8 in the declaration).", {"entities": []}], [10579, "They can deliver plant metabolites in relevant amounts.", {"entities": []}], [10580, "The interaction potential of vitamins, minerals, or animal-originated products (such as glucosamine) is not part of this article.", {"entities": [[29, 37, "Herb name"], [39, 47, "Herb name"], [88, 99, "Herb name"]]}], [10581, "An overview can be found in [15,16,17,18].", {"entities": []}], [10582, "There is extensive regional variation in the extent of herbal medicine usage and, more so, the preferred species based on tradition and availability.", {"entities": []}], [10583, "The interest in medical systems, such as Traditional Chinese Medicine or Ayurveda, is growing, but most of the plants used in these systems are still not common in western countries.", {"entities": [[53, 60, "Ethnic group"], [164, 181, "Ethnic group"]]}], [10584, "It would go beyond the scope of this review to discuss popular medicinal plants of all world regions.", {"entities": []}], [10585, "Main focus of this article are plants originated from Europe or whose medicinal use is established in Europe and western countries.", {"entities": [[113, 130, "Ethnic group"]]}], [10586, "Chronic inflammatory diseases, such as rheumatoid arthritis (RA) or chronic inflammatory bowel diseases (IBD), are characterized by complex immune mediated processes which maintain inflammation and destroy physical structures.", {"entities": [[0, 29, "Pathology"], [39, 64, "Pathology"], [68, 109, "Pathology"], [181, 193, "Pathology"]]}], [10587, "Despite progress during the last decades, the pathophysiology is not completely understood and treatment is not always effective.", {"entities": [[17, 40, "Duration"]]}], [10588, "Therapy regimens usually include long-term use of cytostatic-like or immune modulating drugs, often with small therapeutic windows and a high potential for adverse effects.", {"entities": [[50, 65, "Drug"], [69, 92, "Drug"], [156, 171, "Pathology"]]}], [10590, "Though non-pharmacological treatments are the main therapy for these patients, application of analgetic drugs is common, often over years.", {"entities": [[94, 109, "Drug"]]}], [10591, "Many patients try to improve their condition using food supplements and/or complementary medicine [19].", {"entities": []}], [10592, "This is more common for those with insufficient symptom control [19,20].", {"entities": [[35, 63, "Pathology"]]}], [10593, "Herbs can change pharmacokinetic parameters by affecting absorption, distribution, metabolism, or elimination (ADME) or cause pharmacodynamic interactions.", {"entities": [[57, 116, "Parameter"]]}], [10594, "Most studies on herb\u2013drug interactions focus on CYP enzymes or transporter molecules.", {"entities": [[48, 59, "Parameter"], [63, 84, "Parameter"]]}], [10595, "Beyond that, additional toxic effects may occur.", {"entities": [[24, 37, "Pathology"]]}], [10596, "Several plants have been connected to drug-induced liver injury (DILI) or herb-induced liver injury (HILI).", {"entities": [[38, 70, "Pathology"], [74, 106, "Pathology"]]}], [10597, "Women are more often severely affected by DILI than men [22].", {"entities": [[0, 5, "Sex"], [42, 46, "Pathology"], [52, 55, "Sex"]]}], [10598, "This review aims to give an actual compilation of plants that are commonly popular among patients or could be used to treat inflammatory diseases and their interaction potential with important conventional drugs in this field.", {"entities": [[5, 11, "Study"], [124, 145, "Pathology"]]}], [10599, "In an attempt for width, rheumatoid arthritis, chronic inflammatory bowel diseases, and osteoarthritis are used as examples to determine conventional medication and botanicals that could be used by patients.", {"entities": [[25, 102, "Pathology"]]}], [10600, "To determine the plant species most commonly used for medicinal purposes in Europe, PubMed, and Web of Science were searched for surveys on HMP and herbal food supplement consumption.", {"entities": [[140, 170, "Herb name"]]}], [10601, "Papers published before 2000 were excluded to focus on more recent patient behavior.", {"entities": []}], [10602, "From the combined literature, a list of the most frequently occurring species was established.", {"entities": []}], [10603, "Species that are used specifically to treat inflammatory diseases were determined from surveys among patients, preferably from European countries.", {"entities": [[44, 65, "Pathology"], [127, 145, "Ethnic group"]]}], [10604, "Additionally, in an attempt to include the plants possibly used by patients, which do not appear in the scarce survey data, additional sources were used.", {"entities": []}], [10605, "That includes HMPC-monographs, treatment guidelines [23,24,25], and database searches (PubMed and Web of Science, search terms: herbal medicine, herbal supplement, rheumatoid arthritis, osteoarthritis, and chronic inflammatory bowel disease).", {"entities": [[164, 240, "Pathology"]]}], [10606, "For the combined list of plant species, PubMed was searched for herb\u2013drug interactions, without restrictions regarding the year of publication (search terms: scientific and English plant name, interaction).", {"entities": []}], [10607, "In vitro- and in vivo studies, case reports and meta-analyses were included.", {"entities": [[0, 29, "Study"], [31, 43, "Study"], [48, 61, "Study"]]}], [10608, "Review articles were searched for additional references.", {"entities": [[0, 15, "Cohort"]]}], [10609, "HMPC monographs, if existing, and their corresponding reference lists were consulted.", {"entities": []}], [10610, "Additionally, interaction checks were run on UpToDate ( Most surveys on complementary medicine use or food supplement consumption ask for the use of botanicals, but not for the species used.", {"entities": []}], [10611, "Six general surveys, supplying data on plant species used for health improvement/medicinal purposes, conducted in European countries, were identified: a questionnaire completed by 271 outpatient clinic patients in the United Kingdom (UK) found 87 different species used in herbal supplements [27].", {"entities": [[114, 132, "Ethnic group"], [180, 210, "Cohort"]]}], [10612, "Garlic (taken by 31.9%), ginkgo (28.1%), echinacea (22.6%), evening primrose oil (17%), St. Johns wort (10.4%), ginseng (7%; without differentiation between Korean, American, and Siberian ginseng), Aloe barbadensis (7%), devils claw (5.6%), cranberry (4.8%), and saw palmetto (4.4%) were the ten plants most frequently reported.", {"entities": [[0, 6, "Herb name"], [25, 31, "Herb name"], [41, 50, "Herb name"], [60, 80, "Herb name"], [88, 102, "Herb name"], [112, 119, "Herb name"], [157, 163, "Ethnic group"], [165, 173, "Ethnic group"], [179, 187, "Ethnic group"], [188, 195, "Herb name"], [198, 214, "Herb name"], [221, 232, "Herb name"], [241, 250, "Herb name"], [263, 275, "Herb name"]]}], [10613, "Djuv et al.", {"entities": []}], [10615, "Of 381 persons who completed the questionnaire, 44% used herbal products.", {"entities": [[3, 14, "Cohort"]]}], [10616, "Sixteen plant species were reported, of which bilberry, green tea, garlic, aloe vera, echinacea, cranberry, and ginger were taken by at least 10% of users.", {"entities": [[46, 118, "Herb name"]]}], [10617, "A survey with 8081 participants in Ireland asking for dietary supplements and prescribed medication listed evening primrose oil, garlic, and ginseng [8].", {"entities": [[14, 31, "Cohort"], [107, 148, "Herb name"]]}], [10618, "The study focused on supplements that caused interactions with prescribed drugs.", {"entities": []}], [10619, "Species not involved in potential interactions in the study population were not reported in the paper.", {"entities": []}], [10620, "Garcia-Alvarez et al.", {"entities": []}], [10621, "conducted a retrospective consumer survey in six European countries (Finland, Germany, Italy, Romania, Spain, and UK), asking for use of plant dietary supplements [7].", {"entities": [[49, 67, "Ethnic group"], [137, 162, "Herb name"]]}], [10622, "Herbal medicinal products were excluded.", {"entities": [[0, 25, "Herb name"]]}], [10623, "In this study, 2874 respondents reported to have administered at least one herbal product during the past 12 months.", {"entities": [[15, 31, "Cohort"], [90, 115, "Duration"]]}], [10624, "Due to differences in consumer preference and the legal status of the products in different countries, the authors found a huge number of species that were each taken by a small proportion of participants.", {"entities": []}], [10625, "The ten species mentioned most often (by at least 102 participants or 3.5%) were ginkgo, evening primrose, artichoke, ginseng, aloe vera, fennel, valerian, soybean, lemon balm, and echinacea.", {"entities": [[81, 190, "Herb name"]]}], [10626, "A more recent survey of plant food supplement use (excluding herbal medicines), among 1230 participants, was published by Jeurissen et al.", {"entities": [[86, 103, "Cohort"]]}], [10627, "[9].", {"entities": []}], [10628, "They found that products of a great variety of species (>100) were used with echinacea (14.2%), ginkgo, cranberry, ginseng, algae (such as spirulina and chlorella), citrus bioflavonoids, grape seeds, valerian, rose hip, and garlic (4.7%) being the ten most frequently reported.", {"entities": [[77, 86, "Herb name"], [96, 102, "Herb name"], [104, 113, "Herb name"], [115, 122, "Herb name"], [124, 129, "Herb name"], [139, 148, "Herb name"], [153, 162, "Herb name"], [165, 185, "Herb name"], [187, 192, "Herb name"], [193, 198, "Herb part"], [200, 208, "Herb name"], [210, 218, "Herb name"], [224, 230, "Herb name"]]}], [10629, "As \u201calgae\u201d and \u201ccitrus bioflavonoids\u201d are poorly defined, they were not included in the list.", {"entities": [[4, 9, "Herb name"], [16, 36, "Herb name"]]}], [10630, "Knotek et al.", {"entities": []}], [10631, "published data on herbal product use by Czech adults, obtained in 1000 face-to-face interviews [28].", {"entities": [[40, 45, "Ethnic group"], [66, 70, "Cohort"]]}], [10632, "They found a prevalence of 56.6%.", {"entities": []}], [10633, "The most frequently used plants were Mentha x piperita (18.4%), Melissa officinalis (12.4%), Plantgo lanceolata (12.2%), Tilia cordata (11.8%), and Matricaria recutita (10.7%).", {"entities": [[37, 54, "Herb name"], [64, 83, "Herb name"], [93, 111, "Herb name"], [121, 134, "Herb name"], [148, 167, "Herb name"]]}], [10634, "Information about specific HMPs and herbal supplements used by patients with rheumatoid arthritis (RA), chronic inflammatory bowel diseases (IBD), or osteoarthritis are scarce.", {"entities": [[27, 54, "Herb name"], [77, 164, "Pathology"]]}], [10635, "Most surveys on complementary and alternative therapy or supplement use by those patients did not ask for the species used [4,19,29] or were conducted outside of the geographical area of this review [30,31,32], or both [33,34].", {"entities": []}], [10636, "Among surveys on supplement use by arthritis patients from the last 20 years, no survey from Europe that revealed actual plant species could be found.", {"entities": [[35, 44, "Pathology"], [68, 76, "Duration"]]}], [10637, "Thus, two studies from Canada and the USA were screened to find plants that patients might use.", {"entities": []}], [10638, "The only plant listed as a joint-specific product was turmeric.", {"entities": [[54, 62, "Herb name"]]}], [10639, "It was used by 12 patients, or 3.1% of supplement users [32].", {"entities": []}], [10640, "Skiba et al.", {"entities": []}], [10641, "conducted a survey in southern Arizona (USA) that was completed by 696 adult patients diagnosed with rheumatoid arthritis [30].", {"entities": [[67, 85, "Cohort"], [101, 121, "Pathology"]]}], [10642, "The most popular plants used concomitantly with prescribed therapy were turmeric (43.5% ever usage, 30.3% current usage), ginger (25.5%/13.3%), and flaxseed (25%/9%).", {"entities": [[72, 80, "Herb name"], [122, 128, "Herb name"], [148, 156, "Herb name"]]}], [10643, "About 10% reported experience with boswellia or milk thistle, respectively.", {"entities": [[35, 44, "Herb name"], [48, 60, "Herb name"]]}], [10644, "Usage of complementary therapies, including herbal products by patients with IBD (Crohn\u2019s disease, ulcerative colitis), is widespread in Europe [4,19,29,35].", {"entities": [[77, 118, "Pathology"]]}], [10645, "However, most surveys did not ask for the plant species used.", {"entities": []}], [10646, "A study among children <18 years and their guardians in Scotland, with 86 patients who completed the survey, reported aloe vera, garlic, echinacea, and evening primrose [36].", {"entities": [[23, 32, "Age"], [71, 82, "Cohort"], [118, 127, "Herb name"], [129, 135, "Herb name"], [137, 146, "Herb name"], [152, 168, "Herb name"]]}], [10647, "Garlic and echinacea are probably taken for other purposes.", {"entities": [[0, 6, "Herb name"], [11, 20, "Herb name"]]}], [10648, "Boswellia serrata was mentioned in two surveys among adults in Germany, which do not specify other herbal products [19,35].", {"entities": [[0, 17, "Herb name"]]}], [10649, "A Spanish study reports Aloe vera [37].", {"entities": [[2, 9, "Ethnic group"], [24, 33, "Herb name"]]}], [10650, "The only indication to be found in HMPC monographs that fits the diseases used as example, while being of acceptable specificity, is \u201crelief of minor articular pain\u201d.", {"entities": [[144, 164, "Pathology"]]}], [10651, "Herbal drugs that can claim traditional use against this symptom are meadowsweet (herb and flowers), ash leaf, devil\u2019s claw root, bogbean leaf, blackcurrant leaf, willow bark, and nettle herb.", {"entities": [[69, 80, "Herb name"], [82, 98, "Herb part"], [101, 104, "Herb name"], [105, 109, "Herb part"], [111, 123, "Herb name"], [124, 128, "Herb part"], [130, 137, "Herb name"], [138, 142, "Herb part"], [144, 156, "Herb name"], [157, 161, "Herb part"], [163, 169, "Herb name"], [170, 174, "Herb part"], [180, 186, "Herb name"], [187, 191, "Herb part"]]}], [10652, "Patients with osteoarthritis or rheumatoid arthritis could decide to try products based on these herbal drugs.", {"entities": [[14, 28, "Pathology"], [32, 52, "Pathology"]]}], [10653, "There are positive clinical data for the complementary use of Plantago ovata [38], curcumin [39], and a combination of myrrh, chamomile, and coffee charcoal [40] by patients with ulcerative colitis, preferably as approved herbal medicinal product.", {"entities": [[62, 76, "Herb name"], [83, 91, "Herb name"], [119, 124, "Herb name"], [126, 135, "Herb name"], [141, 156, "Herb name"], [179, 197, "Pathology"]]}], [10654, "Wormwood extract can reduce the amount of steroids needed by Crohn\u2019s disease patients [41,42].", {"entities": [[0, 8, "Herb name"], [42, 50, "Parameter"], [61, 76, "Pathology"]]}], [10655, "The extract is not marketed, but patients might try to use tea or tinctures.", {"entities": [[59, 62, "Extraction process"], [66, 75, "Extraction process"]]}], [10656, "Cannabis flowers have been used by patients with various diseases to treat pain, appetite loss, and muscle spasms.", {"entities": [[0, 8, "Herb name"], [9, 16, "Herb part"], [75, 113, "Pathology"]]}], [10657, "The drug and preparations of it (e.g., oil extracts) gain popularity among RA [43], osteoarthritis [44], and IBD [45] patients.", {"entities": [[39, 51, "Extraction process"], [75, 77, "Pathology"], [84, 98, "Pathology"], [109, 112, "Pathology"]]}], [10658, "Animal studies and in vitro experiments suggest immune modulatory and anti-inflammatory properties of cannabinoids, which makes them possible candidates for therapy of autoimmune diseases (reviewed in [46]).", {"entities": [[0, 14, "Study"], [19, 39, "Study"], [48, 65, "Pathology"], [70, 87, "Pathology"], [102, 114, "Herb name"], [168, 187, "Pathology"]]}], [10659, "All plants considered in this review are summarized in Table 1.", {"entities": []}], [10660, "Common drugs for the treatment of rheumatoid arthritis, IBD and osteoarthritis were taken from surveys [30,36] and treatment guidelines [23,24,25,47,48,49].", {"entities": [[34, 78, "Pathology"]]}], [10661, "Table 2 shows the drugs considered with their indications and interaction potential.", {"entities": []}], [10662, "For RA, also hydroxychloroquine, chloroquine, and leflunomid are used.", {"entities": [[4, 6, "Pathology"], [13, 31, "Drug"], [33, 44, "Drug"], [50, 60, "Drug"]]}], [10663, "In both RA and IBD, cyclosporine is an option if first line therapies fail.", {"entities": [[8, 10, "Pathology"], [15, 18, "Pathology"], [20, 32, "Drug"]]}], [10664, "During therapy establishment (RA) or acute episodes, glucocorticoids are applied to quell inflammation.", {"entities": [[30, 32, "Pathology"], [37, 51, "Pathology"], [53, 68, "Drug"], [90, 102, "Pathology"]]}], [10665, "RA patients use cyclooxygenase inhibitors (non-steroidal antirheumatic drugs, NSAIDs) episodically to treat articular pain, until their newly started or disease modifying therapy reaches full potency.", {"entities": [[0, 2, "Pathology"], [16, 85, "Drug"], [108, 122, "Pathology"], [153, 160, "Pathology"]]}], [10666, "Acetaminophen is less effective than NSAIDs and can be considered for patients with contraindications.", {"entities": [[0, 13, "Drug"], [37, 43, "Drug"]]}], [10667, "In rare cases, when no other options for symptomatic pain therapy are left, opioids may be used.", {"entities": [[41, 57, "Pathology"], [76, 83, "Drug"]]}], [10668, "Pharmacokinetic interactions with mAbs and other therapeutic proteins are rare [50].", {"entities": [[34, 38, "Drug"]]}], [10669, "Exceptions among therapeutic proteins are alterations of CYP expression, as a side effect of signaling modification.", {"entities": [[57, 71, "Parameter"], [78, 89, "Pathology"]]}], [10670, "More important, biologicals carry the risk of immune reactions, from mild skin reactions to anaphylaxis.", {"entities": [[46, 62, "Pathology"], [69, 88, "Pathology"], [92, 103, "Pathology"]]}], [10671, "Another problem is loss of function, due to anti-mAb-antibodies.", {"entities": [[44, 63, "Parameter"]]}], [10672, "Additionally, there are target-specific risks, the most important for the immune modulating biologicals used in therapy of chronic inflammatory diseases being elevated infection risk and reactivation of inapparent infections [51].", {"entities": [[74, 103, "Drug"], [123, 152, "Pathology"], [159, 182, "Pathology"], [187, 224, "Pathology"]]}], [10673, "Liver injury is more common with TNF\u03b1-inhibitors, such as infliximab [26].", {"entities": [[0, 12, "Pathology"], [33, 48, "Drug"], [58, 68, "Drug"]]}], [10674, "Methotrexate, leflunomide, and acetaminophen pose a risk of hepatotoxicity, as well [52].", {"entities": [[0, 12, "Drug"], [14, 25, "Drug"], [31, 44, "Drug"], [60, 74, "Pathology"]]}], [10675, "Combination of these drugs with liver toxic herbs should be avoided.", {"entities": [[32, 43, "Pathology"]]}], [10676, "Many potentially hepatotoxic herbs are not studied extensively enough to determine a safe daily dose.", {"entities": [[17, 28, "Pathology"], [90, 95, "Frequency"]]}], [10677, "Patients suffering from osteoarthritis are mainly treated non-pharmacologically, but episodic or long-term use of pain medication is widespread, with NSAIDs as the most common group.", {"entities": [[24, 38, "Pathology"], [114, 118, "Pathology"], [150, 156, "Drug"]]}], [10678, "They can be combined with proton pump inhibitors (PPI) to protect against gastrointestinal ulceration and bleeding.", {"entities": [[26, 54, "Drug"], [74, 101, "Pathology"], [106, 114, "Pathology"]]}], [10679, "Chronic pain can also be treated with selective serotonin and noradrenaline reuptake inhibitors (SSNRI), such as duloxetine.", {"entities": [[0, 12, "Pathology"], [38, 103, "Drug"], [113, 123, "Drug"]]}], [10680, "Short-term use of opioids for patients who cannot reach pain relief otherwise may occur, e.g., to bridge the time until surgical intervention.", {"entities": [[18, 25, "Drug"], [56, 60, "Pathology"]]}], [10681, "For many herbal drugs, no interactions are known, or there are only scarce or contradicting in vitro data.", {"entities": []}], [10682, "This is indicated in Table 3 that summarizes the interaction potential of all plants considered in this review, with emphasis on the chosen plants and patient population.", {"entities": [[104, 110, "Study"]]}], [10683, "Selected herbals are discussed below.", {"entities": []}], [10684, "Aloe barbadensis leaves contain a gel rich in mono- and polysaccharides that is used in cosmetics and as food flavor.", {"entities": [[0, 16, "Herb name"], [17, 23, "Herb part"], [46, 71, "Herb name"]]}], [10685, "It is suspected to have anti-inflammatory properties.", {"entities": [[24, 41, "Pathology"]]}], [10686, "For alopolysaccharide, a polymer from aloe gel, JAK2 inhibition was confirmed in vitro and in a rat model [111].", {"entities": [[4, 21, "Herb name"], [38, 42, "Herb name"], [43, 46, "Extraction process"], [48, 52, "Target"]]}], [10687, "However, clinical data supporting oral use to treat diseases (e.g., ulcerative colitis) are scarce.", {"entities": [[52, 60, "Pathology"], [68, 86, "Pathology"]]}], [10688, "No clinical relevant interactions have been reported for aloe vera gel.", {"entities": [[57, 66, "Herb name"], [67, 70, "Extraction process"]]}], [10689, "Yet, the leaf rind latex (aloe juice) contains anthraquinones (aloin and derivatives), which are considered potential carcinogens [112].", {"entities": [[5, 24, "Herb part"], [26, 30, "Herb name"], [31, 36, "Extraction process"], [47, 85, "Herb name"], [118, 129, "Pathology"]]}], [10690, "They act as laxatives and thus can induce hypokalemia with chronic use.", {"entities": [[42, 53, "Pathology"], [59, 70, "Frequency"]]}], [10691, "To avoid anthraquionone-associated risks, product quality is of great importance if patients wish to try aloe vera gel.", {"entities": [[9, 23, "Herb name"], [105, 114, "Herb name"], [115, 118, "Extraction process"]]}], [10692, "There are case reports of liver injury caused by aloe vera.", {"entities": [[26, 38, "Pathology"], [49, 58, "Herb name"]]}], [10693, "One patient took 420 mg extract per day over three months [115].", {"entities": [[17, 23, "Amount"], [32, 39, "Frequency"], [40, 57, "Duration"]]}], [10694, "Another patient experienced liver injury after taking 500 mg leaf powder every 2\u20133 days as a laxative [117].", {"entities": [[28, 40, "Pathology"], [54, 60, "Amount"], [61, 65, "Herb part"], [66, 72, "Extraction process"], [73, 87, "Frequency"]]}], [10695, "In relation to other plants, such as green tea, HILI seems to be rare with aloe vera [118].", {"entities": [[37, 46, "Herb name"], [48, 52, "Pathology"], [75, 84, "Herb name"]]}], [10696, "A cell culture study suggests that aloe vera gel can open tight junctions between intestinal epithel cells and, thus, enhance drug absorption [119], but clinical data are missing.", {"entities": [[0, 20, "Study"], [35, 44, "Herb name"], [45, 48, "Extraction process"], [126, 141, "Parameter"]]}], [10697, "Aloe vera gel has a very low potential for interactions.", {"entities": [[0, 9, "Herb name"], [10, 13, "Extraction process"]]}], [10698, "Patients taking prescription drugs that are potentially hepatotoxic, such as methotrexate or leflonomid, should be careful or avoid aloe products.", {"entities": [[56, 67, "Pathology"], [77, 89, "Drug"], [93, 103, "Drug"], [132, 136, "Herb name"]]}], [10699, "It is to be considered that there is no sufficient clinical evidence for the benefits of oral use of aloe vera gel to treat inflammatory diseases.", {"entities": [[101, 110, "Herb name"], [111, 114, "Extraction process"], [124, 145, "Pathology"]]}], [10700, "There are only food supplements available, with insufficiently defined product quality.", {"entities": []}], [10701, "With the legalization of medical cannabis products in a growing number of countries, the use of this plant and its extracts to treat symptoms of chronic diseases increases.", {"entities": [[33, 41, "Herb name"], [133, 161, "Pathology"]]}], [10702, "Still, a significant proportion of patients obtains the marijuana they intend to use medically from illegal sources with unknown quality (e.g., 52.9% of cannabis users among IBD patients in a survey conducted 2019 in Germany [45]).", {"entities": [[56, 65, "Herb name"], [153, 161, "Herb name"], [174, 177, "Pathology"]]}], [10703, "Besides, cannabidiol (CBD), a non-psychotropic cannabinoid, gained popularity and is used as an ingredient in cosmetics and marketed as a food supplement.", {"entities": [[9, 58, "Herb name"]]}], [10704, "This is not yet covered by European legislation, as these products would have to be approved as \u201cnovel food\u201d, with proof of safety.", {"entities": [[27, 35, "Ethnic group"]]}], [10705, "There are several chemotypes with great variation in cannabinoid content and composition.", {"entities": [[53, 64, "Herb name"]]}], [10706, "Additionally, cannabinoids bind, to different extents, to several other receptors, including 5-HT2 and 3, M1, M4, glutamate receptors, and vanilloid-1 receptor, which is present in nociceptive neurons [46].", {"entities": [[14, 26, "Herb name"], [93, 104, "Target"], [106, 108, "Target"], [110, 112, "Target"], [114, 133, "Target"], [139, 159, "Target"]]}], [10707, "Cannabinoids affect T- and B-cells via CB2R and, thus, act immune modulatory.", {"entities": [[0, 12, "Herb name"], [20, 34, "Parameter"], [39, 43, "Target"], [59, 76, "Pathology"]]}], [10708, "They lower IL-17 and \u03b3-IFN secretion and increase IL-10 secretion, among further effects on immune cells and their behavior [46].", {"entities": [[11, 36, "Parameter"], [50, 65, "Parameter"]]}], [10709, "Animal model experiments, surveys, and small pilot studies show potential benefits in IBD treatment over short periods (8 weeks), while longer use (6 months) is associated with a higher rate of surgery (reviewed in [123]).", {"entities": [[86, 89, "Pathology"], [120, 127, "Duration"], [148, 156, "Duration"]]}], [10710, "Cannabis, and its extracts, show a high potential for interactions.", {"entities": [[0, 26, "Herb name"]]}], [10711, "Common side effects are drowsiness, somnolence, and euphoria [60], which are intensified in combination with other CNS depressant drugs.", {"entities": [[7, 19, "Pathology"], [24, 60, "Pathology"], [115, 135, "Drug"]]}], [10712, "The combination of cannabinoids and opioids should be avoided.", {"entities": [[19, 31, "Herb name"], [36, 43, "Drug"]]}], [10713, "Antagonism at muscarinic receptors may cause tachycardia, when combined with other anticholinergic drugs.", {"entities": [[14, 34, "Target"], [45, 56, "Pathology"], [83, 104, "Drug"]]}], [10714, "Cannabinoids are substrates of CYP3A4 and 2C9.", {"entities": [[0, 12, "Herb name"], [31, 45, "Parameter"]]}], [10715, "In vitro data suggest the influence of cannabinoids and their metabolites on several CYP 450 enzymes [62,124].", {"entities": [[39, 51, "Herb name"], [85, 100, "Target"]]}], [10716, "The strongest effects were CYP2C9, 2B6, and 2D6 inhibition, but CYP 1A2, 2C19, and 3A4 might be affected as well.", {"entities": [[27, 47, "Target"], [64, 86, "Target"]]}], [10717, "Clinical outcomes of such opposing effects are difficult to estimate, and in vitro data concerning CYP 3A4, 1A2, and 2C19 are contradictory.", {"entities": [[99, 121, "Parameter"]]}], [10718, "Patients receiving medication affected by the mentioned enzymes should be monitored, especially in case of drugs with a small therapeutic window, such as cyclosporine and tacrolimus.", {"entities": [[154, 166, "Drug"], [171, 181, "Drug"]]}], [10719, "Cannabinoids inhibit UDP-glucuronosyltransferase (UGT) 1A6, 1A9, 2B4, and 2B7 [125].", {"entities": [[0, 12, "Herb name"], [21, 77, "Target"]]}], [10720, "This can affect drugs, such as propofol, morphine, acetaminophen, and ibuprofen.", {"entities": [[31, 39, "Drug"], [41, 49, "Drug"], [51, 64, "Drug"], [70, 79, "Drug"]]}], [10721, "Cannabis preparations are emerging as a promising option for co-treatment of inflammatory diseases.", {"entities": [[0, 8, "Herb name"], [77, 98, "Pathology"]]}], [10722, "There is much research needed to determine which patients benefit and the optimal dose and composition, as well as treatment time.", {"entities": []}], [10723, "Treatment with cannabinoids has to be carefully considered because of the high interaction potential.", {"entities": [[15, 27, "Herb name"]]}], [10724, "For many potential interactions, the clinical relevance is unknown, and differences between extracts and chemotypes are possible.", {"entities": []}], [10725, "Patients should be educated and carefully monitored.", {"entities": []}], [10726, "A special problem is that patients may try to self-medicate with illegally obtained cannabis flowers, which brings quality issues and makes it even more likely that they will not reveal that treatment to their health professional.", {"entities": [[84, 92, "Herb name"], [93, 100, "Herb part"]]}], [10727, "The roots of this plant, originating from southern Africa, are traditionally used to treat digestive disorders and mild articular pain [126].", {"entities": [[4, 9, "Herb part"], [91, 110, "Pathology"], [115, 134, "Pathology"]]}], [10728, "Aqueous extracts have been shown to have anti-inflammatory and antioxidant effects.", {"entities": [[0, 16, "Extraction process"], [41, 58, "Pathology"], [63, 82, "Pathology"]]}], [10729, "There are promising clinical data for the use in treatment of osteoarthritis.", {"entities": [[62, 76, "Pathology"]]}], [10730, "For the treatment of IBD, there have been ex vivo experiments showing positive results, but no clinical studies, so far (effects reviewed by Menghini et al.", {"entities": [[21, 24, "Pathology"], [95, 111, "Study"]]}], [10731, "[127]).", {"entities": []}], [10732, "Inhibition of cyclooxygenase 2 seems to contribute to the anti-inflammatory effect [128].", {"entities": [[14, 30, "Target"], [58, 75, "Pathology"]]}], [10733, "Adverse effects in clinical studies are rare and mostly restricted to digestive complaints and allergies [129].", {"entities": [[0, 15, "Pathology"], [19, 35, "Study"], [70, 104, "Pathology"]]}], [10734, "There are only in vitro data concerning possible pharmacokinetic interactions.", {"entities": []}], [10735, "Romiti et al.", {"entities": []}], [10736, "The extent was different for the three commercial products.", {"entities": []}], [10737, "Harpagosid did not inhibit the transport protein.", {"entities": [[0, 10, "Herb name"]]}], [10738, "Elevated gene expression may balance protein inhibition to a certain degree, but might result in higher clearance after stopping Harpagophytum.", {"entities": [[9, 24, "Parameter"], [129, 142, "Herb name"]]}], [10739, "The clinical significance of these in vitro findings is unclear.", {"entities": []}], [10740, "Several in vitro studies found weak inhibition of CYP enzymes, especially CYP3A4 [96,97,132].", {"entities": [[8, 24, "Study"], [50, 80, "Target"]]}], [10741, "Interestingly, Modarai et al.", {"entities": []}], [10742, "found CYP3A4 inhibition by five out of ten commercial products, but not by harpagoside and harpagid [132].", {"entities": [[6, 12, "Target"], [75, 86, "Herb name"], [91, 99, "Herb name"]]}], [10743, "There were different results for different batches of the same product.", {"entities": []}], [10744, "It seems that unidentified and, thus, unquantified substances are responsible for this effect.", {"entities": []}], [10745, "Overall, the potential for clinical relevant interactions with devil\u2019s claw seems to be low.", {"entities": [[63, 75, "Herb name"]]}], [10746, "Patients taking cyclosporine should be monitored when starting or discontinuing Harpagophytum preparates.", {"entities": [[16, 28, "Drug"], [80, 93, "Herb name"]]}], [10747, "Patients with stomach or duodenal ulcers should avoid Devil\u2019s claw because of the COX-1 inhibition and content of bittering agents [126,128,133].", {"entities": [[14, 40, "Pathology"], [54, 66, "Herb name"], [82, 87, "Target"]]}], [10748, "Herb and roots of several Echinacea species are common for prevention and treatment of common cold.", {"entities": [[0, 4, "Herb part"], [9, 14, "Herb part"], [26, 35, "Herb name"], [87, 98, "Pathology"]]}], [10749, "Patients also take the plant for general strengthening of the immune system.", {"entities": []}], [10750, "This is debated, and there are hints to possible beneficial effects [135].", {"entities": []}], [10751, "There are conflicting data regarding possible pharmacokinetic interactions.", {"entities": []}], [10752, "Gorski et al.", {"entities": []}], [10753, "found opposite effects on intestinal and hepatic CYP 3A4 in a small clinical repeated measures design study (12 volunteers, 8 days, application of probe drugs, before and after echinacea), possibly because of differences in expression induction [139].", {"entities": [[49, 56, "Parameter"], [68, 107, "Study"], [109, 122, "Cohort"], [124, 130, "Duration"], [147, 158, "Drug"], [177, 186, "Herb name"]]}], [10754, "There are also in vitro [140,141] and open label repeated measure designed clinical studies [142,143] that find no effects.", {"entities": [[15, 91, "Study"]]}], [10755, "Considering their wide use, standardized Echinacea root extracts are considered safe, regarding pharmacokinetic interactions [104,135,144].", {"entities": [[41, 50, "Herb name"], [51, 55, "Herb part"]]}], [10756, "Still, possible effects, due to individual susceptibility, should be taken into account for patients receiving drugs with highly CYP 3A4-dependent metabolism.", {"entities": [[129, 136, "Parameter"]]}], [10757, "Evening primrose oil is used to treat systemic inflammatory diseases and promote women\u2019s health [145], but clinical evidence is scarce.", {"entities": [[0, 16, "Herb name"], [17, 20, "Extraction process"], [38, 68, "Pathology"], [81, 86, "Sex"]]}], [10758, "The popular oral use against eczema has been proven ineffective in a meta-analysis [146].", {"entities": [[29, 35, "Pathology"], [69, 82, "Study"]]}], [10759, "There have been case reports of seizures with evening primrose oil [147] and animal studies suggesting platelet inhibition [148,149].", {"entities": [[16, 28, "Study"], [32, 40, "Pathology"], [46, 62, "Herb name"], [63, 66, "Extraction process"], [77, 91, "Study"], [103, 111, "Target"]]}], [10760, "The doses applied in the rabbit study were relatively high (90, 180, and 360 microl/kg/d, corresponding to 5.4/10.8/21.6 mL/d or 5.0/10.0/20 g/d for 60 kg humans) [149].", {"entities": [[25, 37, "Study"], [60, 88, "Amount"], [107, 125, "Amount"], [129, 144, "Amount"], [149, 154, "Amount"]]}], [10761, "A small randomized clinical trial with RA patients did not find differences in platelet activity between evening primrose oil, omega-3 oil, and fish oil supplementation [150], but these oils\u2019 effects on platelet aggregation are debated, as well.", {"entities": [[8, 33, "Study"], [39, 41, "Pathology"], [79, 96, "Parameter"], [105, 121, "Herb name"], [122, 125, "Extraction process"], [127, 134, "Herb name"], [135, 138, "Extraction process"], [203, 223, "Parameter"]]}], [10762, "Recently, thrombocytopenia, after hysterectomy in a patient chronically taking evening primrose oil and black seed oil (Nigella sativa), was reported [151].", {"entities": [[10, 26, "Pathology"], [60, 71, "Frequency"], [79, 95, "Herb name"], [96, 99, "Extraction process"], [104, 114, "Herb name"], [115, 118, "Extraction process"], [120, 134, "Herb name"]]}], [10763, "Nigella sativa oil contains thymoquionone, which can lead to thrombocytopenia.", {"entities": [[0, 14, "Herb name"], [15, 18, "Extraction process"], [28, 41, "Herb name"], [61, 77, "Pathology"]]}], [10764, "The authors discuss the case as multifactorial, with the surgery and both herbal oils contributing to the development of thrombocytopenia [151].", {"entities": [[57, 64, "Parameter"], [74, 85, "Extraction process"], [121, 137, "Pathology"]]}], [10765, "Overall, the clinical risk of evening primrose oil seems to be low, but cumulative thrombocyte inhibitory effects of prescription drugs and combined herbal treatments should be taken into regard.", {"entities": [[30, 46, "Herb name"], [47, 50, "Extraction process"], [83, 94, "Target"], [117, 135, "Drug"], [149, 166, "Herb name"]]}], [10766, "An herbal drug widely used to prevent atherosclerosis and treat common cold is garlic [152,153].", {"entities": [[38, 53, "Pathology"], [64, 75, "Pathology"], [79, 85, "Herb name"]]}], [10767, "The European pharmacopoeia monographs pulverized dried bulbs of Allium sativum containing at least 0.45% allicin [154].", {"entities": [[4, 12, "Cohort"], [55, 60, "Herb part"], [64, 78, "Herb name"], [99, 104, "Amount"], [105, 112, "Herb name"]]}], [10768, "Clinical data suggest favorable influence of garlic on risk factors for atherosclerosis, such as blood pressure and hypercholesterolemia (reviewed in [152]).", {"entities": [[45, 51, "Herb name"], [72, 87, "Pathology"], [97, 111, "Parameter"], [116, 136, "Pathology"]]}], [10769, "Garlic also shows possible antimicrobial properties (reviewed in [155]).", {"entities": [[0, 6, "Herb name"]]}], [10770, "Active constituents are organic sulfur components, the best studied of which are alliin and allicin, which are derived from alliin by the enzyme alliinase [156].", {"entities": [[24, 49, "Herb name"], [81, 99, "Herb name"], [124, 130, "Herb name"], [134, 154, "Herb name"]]}], [10771, "Garlic is available in a great variety of preparations.", {"entities": [[0, 6, "Herb name"]]}], [10772, "The latter contains numerous volatile allyl sulfides, but not alliin or allicin [157].", {"entities": [[29, 52, "Herb name"], [62, 79, "Herb name"]]}], [10773, "Allicin has been suspected to be the main active compound; due to its instability, enteric coated products containing alliin and alliinase were used to enable allicin formation in the intestine, but bioavailability varies between products and study data were contradictory [158].", {"entities": [[0, 7, "Herb name"], [118, 124, "Herb name"], [129, 138, "Herb name"], [159, 166, "Herb name"], [199, 214, "Parameter"]]}], [10774, "There have been small open label clinical studies to determine possible influences on metabolizing enzymes and pGP, usually via probe drugs.", {"entities": [[22, 49, "Study"], [86, 106, "Target"], [111, 114, "Target"], [128, 139, "Drug"]]}], [10775, "Markowitz et al.", {"entities": []}], [10776, "supplemented 14 volunteers, for 14 days, with 1800 mg dry extract, containing alliin equivalent to 1800 \u00b5g allicin twice daily.", {"entities": [[13, 26, "Cohort"], [28, 39, "Duration"], [46, 53, "Amount"], [54, 65, "Extraction process"], [78, 84, "Herb name"], [99, 106, "Amount"], [107, 114, "Herb name"], [115, 126, "Frequency"]]}], [10777, "They did not observe changes in CYP 2D6 or 3A4 activity [71].", {"entities": [[32, 55, "Parameter"]]}], [10778, "Gurley et al.", {"entities": []}], [10779, "Hajda et al.", {"entities": []}], [10780, "Based on this limited evidence, garlic preparations seem to be safe concerning CYP metabolism, but caution is recommended with pGP substrates.", {"entities": [[32, 38, "Herb name"], [79, 93, "Parameter"], [127, 141, "Parameter"]]}], [10781, "Case reports of bleeding complications after excessive garlic ingestion raised concerns regarding the bleeding risk of patients taking garlic preparations [160,161].", {"entities": [[16, 38, "Pathology"], [55, 61, "Herb name"], [102, 115, "Pathology"], [135, 141, "Herb name"]]}], [10782, "Beckert et al.", {"entities": []}], [10783, "No significant difference to the baseline measurement was observed.", {"entities": []}], [10784, "After a washout period, ASA was tested as a positive control [73].", {"entities": [[24, 27, "Drug"]]}], [10785, "Mohammed et al.", {"entities": []}], [10786, "They received a single dose of 5 mg, with or without two weeks pretreatment with a commercial product containing 2000 mg fresh garlic bulb, equivalent to 3.71 mg allicin, which was continued one week after warfarin application.", {"entities": [[31, 35, "Amount"], [53, 62, "Duration"], [113, 120, "Amount"], [127, 133, "Herb name"], [134, 138, "Herb part"], [154, 161, "Amount"], [162, 169, "Herb name"], [191, 199, "Duration"], [206, 214, "Drug"]]}], [10787, "No difference was observed between garlic treatment and control periods [74].", {"entities": [[35, 41, "Herb name"]]}], [10788, "Macan et al.", {"entities": []}], [10789, "compared 5 mL aged garlic extract (standardized to S-allylcysteine) against the placebo in parallel design in 48 participants on warfarin treatment for 12 weeks.", {"entities": [[9, 13, "Amount"], [19, 25, "Herb name"], [51, 66, "Herb name"], [110, 125, "Cohort"], [129, 137, "Drug"], [148, 160, "Duration"]]}], [10790, "No INR change or bleeding events were observed [162].", {"entities": [[3, 6, "Parameter"], [17, 32, "Parameter"]]}], [10791, "Clinical data on possible interactions of garlic products are limited due to the wide variety of tested products that makes studies difficult to compare.", {"entities": [[42, 48, "Herb name"]]}], [10792, "Considering the mostly negative results and the widespread use of garlic as medicinal plant, as well as food with few reports of potentially dangerous incidents, garlic bears a low-risk for interactions.", {"entities": [[66, 72, "Herb name"], [162, 168, "Herb name"]]}], [10793, "Patients taking cyclosporine should be monitored when starting or ending garlic supplementation because of the possible induction of intestinal pGP.", {"entities": [[16, 28, "Drug"], [73, 79, "Herb name"], [133, 147, "Target"]]}], [10794, "Medicinal products based on ginkgo are used to treat (vascular) dementia, vertigo, and peripheral arterial disease.", {"entities": [[28, 34, "Herb name"], [53, 114, "Pathology"]]}], [10795, "The HMPC-monograph classifies this extract as \u201cwell established use\u201d for \u201cthe improvement of (age-associated) cognitive impairment and of quality of life in mild dementia\u201d.", {"entities": [[93, 130, "Pathology"], [157, 170, "Pathology"]]}], [10796, "The latter may contain elevated amounts of ginkgolic acids, which are potent allergens and possibly express cytotoxic, genotoxic and carcinogenic properties [164].", {"entities": [[43, 58, "Herb name"], [108, 145, "Pathology"]]}], [10797, "For the refined quantified dry extract, the ginkgolic acid content is limited to 5 ppm [154].", {"entities": [[8, 38, "Extraction process"], [44, 58, "Herb name"], [81, 86, "Amount"]]}], [10798, "A recent meta-analysis found no effect of ginkgo on CYP3A4 [168].", {"entities": [[9, 22, "Study"], [42, 48, "Herb name"], [52, 58, "Parameter"]]}], [10799, "Based on cases of severe bleeding events associated with ginkgo [169,170], the plant has been suspected to increase bleeding risk of patients with anticoagulant or platelet inhibiting co-medication.", {"entities": [[18, 40, "Pathology"], [57, 63, "Herb name"], [116, 129, "Pathology"], [147, 197, "Drug"]]}], [10800, "Inhibition of platelet aggregation factor (PAF) by ginkgo leaf ingredients has been discussed controversially [171].", {"entities": [[14, 47, "Target"], [51, 57, "Herb name"], [58, 62, "Herb part"]]}], [10801, "There are in vitro experiments confirming thrombin inhibition [172].", {"entities": [[10, 30, "Study"], [42, 50, "Target"]]}], [10802, "Yet clinical studies [81,173] and a meta-analysis [174] could not find an elevated bleeding risk or influence on coagulation parameters.", {"entities": [[4, 20, "Study"], [36, 49, "Study"], [83, 96, "Pathology"], [113, 135, "Parameter"]]}], [10803, "A small randomized, double-blind, placebo-controlled clinical study, with patients taking 325 mg/d ASA plus EGb 761 or placebo, found no difference in platelet function or bleeding/ bruising reports [175].", {"entities": [[8, 67, "Study"], [90, 98, "Amount"], [99, 102, "Drug"], [108, 115, "Herb name"], [151, 168, "Parameter"], [172, 190, "Pathology"]]}], [10804, "In a study analyzing a medical database that included several thousand patients using warfarin, with or without ginkgo, an elevated bleeding risk was found for concomitant use.", {"entities": [[86, 94, "Drug"], [112, 118, "Herb name"], [132, 145, "Pathology"]]}], [10805, "Despite excluding patients whose ginkgo use was recorded at the same time as the bleeding event, there still may be a reporting bias.", {"entities": [[33, 39, "Herb name"], [81, 95, "Pathology"]]}], [10806, "No information was provided about dosage and other medication [176].", {"entities": []}], [10807, "In conclusion, a possible elevation of bleeding risk by ginkgo seems to be small.", {"entities": [[39, 52, "Pathology"], [56, 62, "Herb name"]]}], [10808, "Therapy monitoring is advisable for high-risk patients, as well as discontinuing ginkgo before planned surgery.", {"entities": [[81, 87, "Herb name"]]}], [10809, "Ginseng is among the most popular herbs and applied by healthy, mostly elder persons, as well as patients with chronical diseases (3.1., Table 1).", {"entities": [[0, 7, "Herb name"], [55, 62, "Pathology"], [111, 129, "Pathology"]]}], [10810, "The drug has a long tradition as \u201ctonic\u201d or adaptogen, a substance that is meant to enhance physical and mental performance or help regain strength, in East Asia [177] and has been adopted into western herbal medicine.", {"entities": []}], [10811, "The term \u201cginseng\u201d can be used for several drugs.", {"entities": [[10, 17, "Herb name"]]}], [10812, "They can be differentiated into dried (white ginseng) and steamed (red ginseng), but this distinction is not always made.", {"entities": [[32, 37, "Extraction process"], [39, 52, "Herb name"], [58, 65, "Extraction process"], [67, 78, "Herb name"]]}], [10813, "The monograph \u201cginseng radix\u201d in the European Pharmacopoeia names only P. ginseng and defines a minimum content of 4.0% ginsenosides (triterpene saponins) [154].", {"entities": [[15, 28, "Herb name"], [37, 45, "Ethnic group"], [71, 81, "Herb name"], [115, 119, "Amount"], [120, 154, "Herb name"]]}], [10814, "It is sometimes mixed up with Panax-species, but has its own PhEur monograph (\u201cEleutherococci radix\u201d).", {"entities": [[30, 35, "Herb name"], [79, 99, "Herb name"]]}], [10815, "It is used in Europe, but less popular than P. ginseng [7,9].", {"entities": [[44, 54, "Herb name"]]}], [10816, "There have been plenty of in vitro, in vivo and mostly small clinical studies regarding the effects of ginseng extracts or ginsenosides on CYP enzymes and transport proteins.", {"entities": [[26, 77, "Study"], [103, 119, "Herb name"], [123, 135, "Herb name"], [139, 150, "Parameter"], [155, 173, "Parameter"]]}], [10817, "Results are contradictory.", {"entities": []}], [10818, "Gurley et al.", {"entities": []}], [10819, "found no influence on CYP3A4, 1A2, and 2E1 and a slight (7%) inhibition of CYP2D6 in healthy volunteers [70].", {"entities": [[22, 42, "Parameter"], [57, 59, "Amount"], [75, 81, "Target"], [85, 92, "Pathology"]]}], [10820, "Other clinical studies found induction (1000 mg extract/d) [178] or weak inhibition (2.1 g dried root/d) [179] of CYP3A4.", {"entities": [[6, 22, "Study"], [40, 47, "Amount"], [85, 90, "Amount"], [91, 96, "Extraction process"], [97, 101, "Herb part"], [114, 120, "Target"]]}], [10821, "A case report of imatinib-induced liver toxicity promoted by ginseng in energy drinks speculates about CYP3A4 inhibition as potential interaction mechanism [180].", {"entities": [[0, 13, "Study"], [17, 25, "Drug"], [34, 48, "Pathology"], [61, 68, "Herb name"], [103, 109, "Target"]]}], [10822, "Seong et al.", {"entities": []}], [10823, "There may be inter-individual differences in susceptibility.", {"entities": []}], [10824, "Hao et al.", {"entities": []}], [10825, "showed in cell culture experiments that ginsenosides and their deglucosylated metabolites show different effects on CYP1A1, 1A2, and 3A4 [182].", {"entities": [[40, 52, "Herb name"], [116, 136, "Parameter"]]}], [10826, "If that is the case in vivo, interindividual differences in enzyme activity could contribute to the interaction potential.", {"entities": [[60, 75, "Parameter"]]}], [10827, "Ginseng has been discussed as to promote bleeding.", {"entities": [[0, 7, "Herb name"], [41, 49, "Pathology"]]}], [10828, "A small double-blind, randomized study with patients with cardiac valve replacement found no difference of INR between warfarin + ginseng and warfarin + placebo [184].", {"entities": [[8, 38, "Study"], [58, 83, "Pathology"], [107, 110, "Parameter"], [119, 127, "Drug"], [130, 137, "Herb name"], [142, 150, "Drug"]]}], [10829, "In a randomized, assessor-blinded study with 42 participants Wang et al.", {"entities": [[5, 39, "Study"], [45, 60, "Cohort"]]}], [10830, "found that ASA + P. notoginseng extract results in stronger platelet inhibition than ASA + placebo, but reduced gastric mucosa injury [185].", {"entities": [[11, 14, "Drug"], [17, 39, "Herb name"], [60, 68, "Target"], [85, 88, "Drug"], [112, 133, "Pathology"]]}], [10831, "Lau et al.", {"entities": []}], [10832, "compared the influence of extracts of the three Panax-species on in vitro platelet aggregation and rat bleeding time and found the effect strongest in P. notoginseng and weakest in P. quinquefolium [186].", {"entities": [[48, 53, "Herb name"], [74, 94, "Parameter"], [103, 116, "Parameter"], [151, 165, "Herb name"], [181, 197, "Herb name"]]}], [10833, "Kwon et al.", {"entities": []}], [10834, "stated, based on in vitro experiments, that the composition of ginsenosides seems to be more important for the effect on platelet inhibition than the total content [187].", {"entities": [[17, 37, "Study"], [63, 75, "Herb name"], [121, 129, "Target"]]}], [10835, "Ginsenosides and ASA mutually enhance their absorption in Caco-2 cells and rats [188,189], but there are no clinical data regarding this phenomenon.", {"entities": [[0, 12, "Herb name"], [17, 20, "Drug"]]}], [10837, "For P. quinquefolium, a small study with healthy volunteers showed a reduced anticoagulant effect of warfarin and lower plasma concentrations [191].", {"entities": [[4, 20, "Herb name"], [41, 48, "Pathology"], [77, 97, "Parameter"], [101, 109, "Drug"], [120, 141, "Parameter"]]}], [10838, "The mechanism is unknown.", {"entities": []}], [10839, "As ginseng may lower blood glucose and is studied as potential antidiabetic [192], it might increase the hypoglycemia risk by chloroquine or hydroxychloroquine.", {"entities": [[3, 10, "Herb name"], [21, 34, "Parameter"], [63, 75, "Pathology"], [105, 122, "Pathology"], [126, 137, "Drug"], [141, 159, "Drug"]]}], [10840, "The clinical relevance is probably low [193].", {"entities": []}], [10841, "Patients should know and pay attention to the symptoms.", {"entities": []}], [10842, "Overall, the potential of ginseng for herb\u2013drug interactions is low.", {"entities": [[26, 33, "Herb name"]]}], [10843, "The intake of beverages prepared from green tea (unfermented leaves of Camellia sinensis), has been part of food culture in East Asia for centuries.", {"entities": [[38, 47, "Herb name"], [49, 67, "Herb part"], [71, 88, "Herb name"]]}], [10844, "In modern times, it has gained popularity worldwide.", {"entities": []}], [10845, "Tea has been suggested to have health benefits in prevention of cardiovascular disease, cancer and neurodegenerative diseases (reviewed in [194]) and is part of supplements advertised for weight control.", {"entities": [[0, 3, "Herb name"], [64, 125, "Pathology"], [188, 194, "Parameter"]]}], [10846, "Clinical evidence is still sketchy.", {"entities": []}], [10847, "The leaves contain flavonoids and catechins, the most active and most abundant of which is (-)-epigallocatechin-3-gallate (EGCG).", {"entities": [[4, 10, "Herb part"], [19, 29, "Herb name"], [34, 43, "Herb name"], [91, 128, "Herb name"]]}], [10848, "Dey et al.", {"entities": []}], [10849, "recommend in their review on beverages and nutrition of RA patients moderate tea consumption because of antiinflammatory effects of catechins and caffeine [195].", {"entities": [[56, 58, "Pathology"], [77, 80, "Herb name"], [104, 120, "Pathology"], [132, 141, "Herb name"], [146, 154, "Herb name"]]}], [10850, "Green Tea has been associated with HILI.", {"entities": [[0, 9, "Herb name"], [35, 39, "Pathology"]]}], [10851, "A scientific opinion of EFSA [196] from 2018 states that the common food consumption is safe, as there are only few cases of HILI associated with tea consumption despite the widespread use.", {"entities": [[125, 129, "Pathology"], [146, 149, "Herb name"]]}], [10852, "However, the regular application of green tea extracts as food supplements, with doses above 800 mg EGCG per day, is associated with an increase of serum transaminases that can indicate liver injury.", {"entities": [[36, 54, "Herb name"], [93, 99, "Amount"], [100, 104, "Herb name"], [105, 112, "Frequency"], [148, 167, "Parameter"], [186, 198, "Pathology"]]}], [10853, "The risk is higher when the supplement is taken under fasting conditions and/or as single bolus instead of split doses due to higher EGCG bioavailability.", {"entities": [[54, 72, "Parameter"], [133, 137, "Herb name"], [138, 153, "Parameter"]]}], [10854, "In this randomized, double-blind study, 513 participants were treated with GTE (mean daily dose 1315 mg total catechins, 843 mg EGCG, split into two doses) and 508 with placebo.", {"entities": [[8, 38, "Study"], [75, 78, "Herb name"], [85, 95, "Frequency"], [96, 103, "Amount"], [110, 119, "Herb name"], [121, 127, "Amount"], [128, 132, "Herb name"]]}], [10855, "In the verum arm, 5.1% of participants developed moderate to severe liver function abnormalities.", {"entities": [[49, 96, "Pathology"]]}], [10856, "Serum ALT returned to normal when GTE was discontinued and raised again upon rechallenge [198].", {"entities": [[0, 9, "Parameter"], [34, 37, "Herb name"]]}], [10857, "HILI could occur more frequently in these groups because of the combination of risk factors.", {"entities": [[0, 4, "Pathology"]]}], [10858, "In conclusion, GTE supplementation, especially with high doses, should be avoided by patients with elevated risk of liver injury or hepatotoxic medication, such as methotrexate or azathioprine.", {"entities": [[15, 18, "Herb name"], [116, 128, "Pathology"], [132, 143, "Pathology"], [164, 176, "Drug"], [180, 192, "Drug"]]}], [10859, "Moderate tea consumption is less problematic regarding HILI.", {"entities": [[9, 12, "Herb name"], [55, 59, "Pathology"]]}], [10860, "It still may cause liver injury in rare cases due to individual susceptibility and should be assessed in unclear cases of liver impairment.", {"entities": [[19, 31, "Pathology"], [53, 78, "Parameter"], [122, 138, "Pathology"]]}], [10861, "Green tea has been suspected to antagonize Warfarin, but evidence is scarce and contradicting [201,202].", {"entities": [[0, 9, "Herb name"], [43, 51, "Drug"]]}], [10862, "Patients taking coumarin derivatives should be monitored when changing GTE supplementation or pronounced tea drinking habits.", {"entities": [[16, 36, "Herb name"], [71, 74, "Herb name"], [105, 108, "Herb name"]]}], [10863, "The effect of GTE and EGCG on various cytochrome P 450 enzymes has been studied in vitro and in vivo.", {"entities": [[14, 17, "Herb name"], [22, 26, "Herb name"], [38, 62, "Parameter"]]}], [10864, "Green tea extract and EGCG inhibited CYP2B6, 2C8 and 3A4 in pooled liver and intestine microsomes.", {"entities": [[0, 17, "Herb name"], [22, 26, "Herb name"], [37, 56, "Target"]]}], [10865, "The isoenzymes 2C19 and 2D6 were inhibited, as well, but with IC50 48.7 and 25.1 \u00b5g/mL, which the authors argue is above what can be expected in vivo [203].", {"entities": [[0, 27, "Target"], [62, 66, "Parameter"], [67, 71, "Amount"], [76, 86, "Amount"]]}], [10866, "Yao et al.", {"entities": []}], [10867, "applied atorvastatin in rats after 3 weeks of drinking green tea or water.", {"entities": [[8, 20, "Drug"], [29, 42, "Duration"], [55, 64, "Herb name"]]}], [10868, "Clinical studies showed no [205] or minor [206] effects on CYP3A4 activity and no effect on CYP1A2, 2D6 and 2C9.", {"entities": [[0, 16, "Study"], [59, 74, "Parameter"], [92, 111, "Parameter"]]}], [10869, "The concentration returned to normal with GT abstinence.", {"entities": [[0, 17, "Parameter"], [42, 44, "Herb name"]]}], [10870, "Genotyping revealed the patient as \u201cpoor metabolizer\u201d with alleles CYP3A4*1B and CYP3A4*10.", {"entities": [[59, 90, "Parameter"]]}], [10871, "The authors state that CYP3A4 inhibition or pGP inhibition could have caused the interaction.", {"entities": [[23, 29, "Target"], [44, 47, "Target"]]}], [10872, "They favor CYP, as the patient could be unusually susceptible due to the individual genotype [207].", {"entities": [[11, 14, "Parameter"]]}], [10873, "A bigger issue than CYP interactions is the inhibition of several transport proteins by green tea catechins.", {"entities": [[20, 23, "Parameter"], [66, 84, "Target"], [88, 107, "Herb name"]]}], [10874, "GT catechins inhibit pGP in vitro [208,209] and in vivo.", {"entities": [[0, 12, "Herb name"], [21, 24, "Target"]]}], [10875, "A small clinical repeated measures design study (n = 15) was done with digoxin as probe drug.", {"entities": [[8, 56, "Study"], [71, 92, "Drug"]]}], [10877, "Cmax was reduced by 39.2% (0.4 mg) and 27.4% (5 mg), AUC was reduced by 26.6% and 39.9%.", {"entities": [[0, 4, "Parameter"], [20, 25, "Amount"], [27, 33, "Amount"], [39, 44, "Amount"], [46, 50, "Amount"], [53, 56, "Parameter"], [72, 77, "Amount"], [82, 87, "Amount"]]}], [10878, "Test subjects took 250 mL GT or water three times daily two days before the test day and five times during the test day (30 min before, with and until 2 h after folic acid).", {"entities": [[19, 25, "Amount"], [26, 28, "Herb name"], [38, 55, "Frequency"], [56, 64, "Duration"], [89, 99, "Amount"], [121, 134, "Duration"], [151, 160, "Duration"], [161, 171, "Drug"]]}], [10879, "Augustin et al.", {"entities": []}], [10880, "Green tea inhibits OATP1A2 (organic anion transporting polypeptide), as has been demonstrated in vitro [209] and in small clinical crossover studies [217,218].", {"entities": [[0, 9, "Herb name"], [19, 67, "Target"], [122, 148, "Study"]]}], [10881, "The inhibition of uptake transporters persists at least one hour after green tea consumption [219].", {"entities": [[18, 37, "Target"], [47, 64, "Duration"], [71, 80, "Herb name"]]}], [10882, "Additionally, in vitro studies show inhibition of OATP1B1, 2B1, and 1B3 [209,220].", {"entities": [[14, 30, "Study"], [50, 71, "Target"]]}], [10883, "Main concern regarding herb\u2013drug interactions with green tea is the inhibition of OATPs, especially OATP1A2, which can affect absorption, liver-uptake (1B, 2B) or renal excretion (1A2) [221].", {"entities": [[51, 60, "Herb name"], [82, 87, "Target"], [100, 107, "Target"], [126, 136, "Parameter"], [138, 150, "Parameter"], [163, 178, "Parameter"]]}], [10884, "The inhibition of pGP or CYP3A4 could be relevant in susceptible individuals, especially when combined with substrate drugs with small therapeutic index.", {"entities": [[18, 21, "Target"], [25, 31, "Target"]]}], [10885, "Methotrexate, leflunomide, azathioprine, cyclosporine and tacrolimus should not be combined with green tea extracts or high amounts of green tea.", {"entities": [[0, 12, "Drug"], [14, 25, "Drug"], [27, 39, "Drug"], [41, 53, "Drug"], [58, 68, "Drug"], [97, 115, "Herb name"], [135, 144, "Herb name"]]}], [10886, "Dietary supplements with their often insufficient specification and declaration should generally be avoided.", {"entities": []}], [10887, "Regarding the possible absorption inhibition and liver toxicity risk of high amounts of EGCG, coffee or black tea would be better nutritional caffeine sources for patients taking MTX than green tea.", {"entities": [[23, 33, "Parameter"], [49, 68, "Pathology"], [88, 92, "Herb name"], [94, 100, "Herb name"], [104, 113, "Herb name"], [142, 150, "Herb name"], [179, 182, "Drug"], [188, 197, "Herb name"]]}], [10888, "Tumeric (Curcuma longa) and its main active substance curcumin show anti-inflammatory activity addressing multiple targets [223,224] and there is a growing body of evidence for benefits in inflammatory diseases [225,226] Still, there is a need for more high quality clinical studies and addressing the poor bioavailability [227,228].", {"entities": [[0, 23, "Herb name"], [54, 62, "Herb name"], [68, 85, "Pathology"], [189, 210, "Pathology"], [266, 282, "Study"], [307, 322, "Parameter"]]}], [10889, "Contribution of modulating effects on the gut microbiome is also discussed [229].", {"entities": []}], [10890, "Curcuminoids have been shown to inhibit CY3A4 and 2C9 in vitro [230].", {"entities": [[0, 12, "Herb name"], [40, 53, "Target"]]}], [10891, "A small (n = 6) repeated measures design study with dextromethorphan as probe drug showed inhibition of CYP2D6 and minor inhibition of CYP3A4 by 2 \u00d7 1.5 g/d [231].", {"entities": [[16, 46, "Study"], [52, 82, "Drug"], [104, 110, "Target"], [135, 141, "Target"], [145, 156, "Amount"]]}], [10892, "This could have been caused by CYP2C9 inhibition.", {"entities": [[31, 37, "Target"]]}], [10893, "The clinical relevance of these data is unclear.", {"entities": []}], [10894, "Both drugs contain flavonoids and salicylates and are traditionally used to treat fever and pain.", {"entities": [[19, 29, "Herb name"], [34, 45, "Herb name"], [82, 87, "Pathology"], [92, 96, "Pathology"]]}], [10895, "Salicylates might increase the effects of NSAIDs on coagulation as well as their gastro- and nephrotoxicity.", {"entities": [[0, 11, "Herb name"], [42, 48, "Drug"], [81, 107, "Pathology"]]}], [10896, "Willow bark extract showed a smaller effect on platelet aggregation in humans than ASA [234].", {"entities": [[0, 19, "Herb name"], [47, 67, "Parameter"], [83, 86, "Drug"]]}], [10897, "If this interaction occurs as well with salicylic acid derivatives in plant extracts is not known.", {"entities": [[40, 66, "Herb name"]]}], [10898, "Extract doses applied in clinical studies contain low amounts of salicin (240 mg/d).", {"entities": [[25, 41, "Study"], [65, 72, "Herb name"], [74, 82, "Amount"]]}], [10899, "Other substances, especially flavonoids, are suspected to be relevant for the effect [236].", {"entities": [[29, 39, "Herb name"]]}], [10900, "Willow bark extract is effective in treatment of lower back pain (low to moderate evidence) [237], but a study with OA and RA patients was negative [238].", {"entities": [[0, 19, "Herb name"], [49, 64, "Pathology"], [116, 118, "Pathology"], [123, 125, "Pathology"]]}], [10901, "The authors state that the reason could be a different composition of the extract compared with the previous pilot study due to a switch from Salix purpurea x daphnoides to the more commonly used S. daphnoides.", {"entities": [[109, 120, "Study"], [142, 169, "Herb name"], [196, 209, "Herb name"]]}], [10902, "They found differences in the content of other substances aside of salicin, which was standardized.", {"entities": [[67, 74, "Herb name"]]}], [10903, "With MTX doses between 7.5 and 15 mg weekly, this effect is moderate (AUC +28% with ASA, less for the others), and there is inter-individual variability.", {"entities": [[5, 8, "Drug"], [15, 36, "Amount"], [37, 43, "Frequency"], [70, 73, "Parameter"], [74, 78, "Amount"], [84, 87, "Drug"]]}], [10904, "Salicylates from herbal drugs might show similar effects.", {"entities": [[0, 11, "Herb name"]]}], [10905, "The clinical significance of this phenomenon depends on individual susceptibility.", {"entities": [[56, 81, "Parameter"]]}], [10906, "The combination of herbal drugs that contain salicylates with NSAIDs, in doses used for pain treatment, should be avoided.", {"entities": [[19, 56, "Herb name"], [62, 68, "Drug"], [88, 92, "Pathology"]]}], [10907, "Patients taking methotrexate should be cautious and discontinue the herbal product if adverse effects increase.", {"entities": [[16, 28, "Drug"], [64, 82, "Herb name"], [86, 101, "Pathology"]]}], [10908, "Medicinal plants and plant extracts are complex mixtures of chemical substances and, as such, can address multiple targets.", {"entities": [[0, 35, "Herb name"]]}], [10909, "Metabolite contents vary depending on plant species, chemotype, growth conditions, harvest, and processing, as well as the extraction process.", {"entities": []}], [10910, "Availability and use of differently prepared extracts results in barely comparable products and data.", {"entities": []}], [10911, "The predictability of HMP efficacy and possible adverse effects is constrained for many herbal drugs by the lack of knowledge, concerning their targets and active substances, as well as in the effective dose.", {"entities": [[48, 63, "Pathology"], [193, 207, "Parameter"]]}], [10912, "Synergistic effects between several metabolites in plant extracts are suspected [241,242,243], but good clinical evidence is missing.", {"entities": []}], [10913, "Besides, the metabolites responsible for herb\u2013drug interactions or adverse drug reactions need not be the same that produce the desirable effects.", {"entities": [[67, 89, "Pathology"]]}], [10914, "If available, standardized or quantified extracts should be preferred.", {"entities": []}], [10915, "According the HMPC, standardized herbal substances are adjusted to a given content of constituents with known therapeutic activity, whereas quantified herbal substances are adjusted to a given content range of active markers (substances that are generally accepted to contribute to the therapeutic activity).", {"entities": []}], [10916, "Herbal products with unknown active principles are defined solely by the production process.", {"entities": []}], [10917, "Analytical markers can be specified, but are not part of the declaration [244].", {"entities": []}], [10918, "For plant derived products that are marketed as food supplements, quality requirements and declaration rules are less extensive.", {"entities": []}], [10919, "Manufacturers may prefer marketing their products as food supplements, instead of medicinal products, for safe development and production costs.", {"entities": []}], [10920, "However, these products are less reliable and cannot be recommended for the (adjuvant) treatment of diseases or non-desirable health conditions.", {"entities": [[100, 143, "Pathology"]]}], [10921, "Important contributions of unknown substances to effect or interaction mechanisms can lead to fluctuations in effect strength between similar products or even batches of the same product, as mentioned for ginseng, willow bark, and devil\u2019s claw.", {"entities": [[205, 212, "Herb name"], [214, 225, "Herb name"], [231, 243, "Herb name"]]}], [10922, "Considering the wide use of herbal products, these fluctuations are usually beneath clinical relevance.", {"entities": [[28, 43, "Herb name"]]}], [10923, "Still, caution should be taken in susceptible individuals (e.g., taking interaction sensitive prescription drugs, known CYP mutations).", {"entities": [[94, 112, "Drug"], [120, 133, "Parameter"]]}], [10924, "Much work remains in order to better understand mechanisms of desired and adverse effects of most medical herbs and the responsible constituents.", {"entities": [[74, 89, "Pathology"]]}], [10925, "The interpretation of in vitro data regarding the influence of plant extracts on metabolizing enzymes or transporters is challenging, more so if single constituents are tested.", {"entities": [[81, 117, "Parameter"]]}], [10926, "Not all activity changes that can be measured in vitro need to be clinically relevant.", {"entities": []}], [10927, "It is common that findings from in vitro studies, which seem alarming at first, cannot be confirmed in humans, sometimes documented in the same publication [202,245].", {"entities": [[32, 48, "Study"]]}], [10928, "Possible reasons for this phenomenon can be found in the complex nature of plant extracts and are reviewed in [246].", {"entities": []}], [10929, "In brief, it is difficult to estimate relevant test concentrations that reflect in vivo conditions, as knowledge on absorption (pre-absorption), metabolism, and the eventual active metabolite and plasma binding rates of the multiple substances is usually scarce.", {"entities": [[47, 66, "Parameter"], [196, 216, "Parameter"]]}], [10930, "The extract constituents may influence each other, which makes studies with purified substances less representative and can cause reproducibility problems, due to natural variability, as seen in [132].", {"entities": []}], [10931, "Nevertheless, in vitro studies are a fast way to discover potential concerns for further investigation and a necessary means to elucidate the underlying mechanisms and responsible constituents [246].", {"entities": [[14, 30, "Study"]]}], [10932, "A potential risk of using herbal products from \u201cunofficial\u201d sources is adulteration with prescription drugs [247].", {"entities": []}], [10933, "This has been reported most often for products advertised for weight loss, sexual performance, and sports performance enhancement and can be assumed to be less frequent in other products.", {"entities": [[62, 68, "Parameter"]]}], [10934, "It is still worth considering, should unusual effects occur.", {"entities": []}], [10935, "Patient\u2019s reasons to use plant products of various qualities for medical purposes are diverse.", {"entities": []}], [10936, "They include short-term treatment of mild to moderate acute symptoms with HMPs or herbal teas and long-term intake of supplements or HMPs for specific conditions or general well-being.", {"entities": [[74, 93, "Herb name"], [133, 137, "Herb name"]]}], [10937, "Patients with chronic diseases, who use complementary therapies, including herbal products, hope to optimize their therapy, reduce conventional drugs (especially steroids), or mitigate adverse effects of their prescribed therapy.", {"entities": [[14, 30, "Pathology"], [131, 149, "Drug"], [162, 170, "Drug"], [185, 200, "Pathology"]]}], [10938, "Besides that, emotional well-being, taking responsibility for their therapy, and the wish for a holistic approach are frequent motivations [10,19,248].", {"entities": []}], [10939, "In this setting, it can be reasonable for a patient to take a product with insufficient evidence of efficacy, as a means of self-empowerment, sufficient quality, and safety, in combination with the prescribed therapy provided.", {"entities": []}], [10940, "It is important to make patients aware of the fact that plants can cause adverse effects and are not safe in every situation by being \u201cnatural\u201d.", {"entities": [[73, 88, "Pathology"]]}], [10941, "Many patients talk about complementary therapies, including herbal products, only if asked directly, often because they think the products are harmless and information not important for their health professional [5,249,250,251,252].", {"entities": []}], [10942, "Another reason is fear of a negative reaction [5,251].", {"entities": []}], [10943, "This puts emphasis on an open and trustful practitioner\u2013patient relationship.", {"entities": []}], [10944, "A majority of patients wish to be informed about complementary therapies by their physician [251]; however, in real life, the most important sources for information are friends, family, and media [28,248].", {"entities": []}], [10945, "Respondents in Knotek et al.\u2019s survey also frequently named pharmacists as source of information.", {"entities": []}], [10946, "This survey asks not only for dietary supplements or complementary therapies, in general, but for medicinal herbs, in general, and the most important health issues were cold and digestion problems [28].", {"entities": [[169, 173, "Pathology"], [178, 196, "Pathology"]]}], [10947, "There may be a difference in patient behavior, depending on the reason for using herbal products.", {"entities": [[81, 96, "Herb name"]]}], [10948, "Still, this stresses the responsibility of pharmacists, who are a possible source of herbal medicinal products, to raise awareness for possible risks and educate the patients.", {"entities": []}], [10949, "Pharmaceutical care programs that include medication assessments pose another opportunity to obtain a full account of the patient\u2019s medication and supplementation and discover problematic combinations.", {"entities": []}], [10950, "Practitioners should be aware that patients might use herbal products intermittently.", {"entities": []}], [10951, "In Garcia-Alvarez et al.\u2019s consumer survey, 37.3% of respondents reported that they take their supplements \u201cperiodically\u201d [7].", {"entities": []}], [10952, "While regular, long-term use of herbals with kinetic interaction potential may contribute to titration or dose finding of newly started drugs and, thus, not affect the outcome, regular discontinuing and restarting of the plant product would be more likely to cause problems.", {"entities": []}], [10953, "Hence, it is reasonable to ask not only for current use of herbal products but for temporary, repeated use, as well.", {"entities": []}], [10954, "Most of the surveys used to determinate frequently used plants focused on dietary supplements and excluded herbal medical products.", {"entities": []}], [10955, "This excludes plants represented exclusively or predominantly as HMPs in the respective countries, as well as herbal teas.", {"entities": [[110, 121, "Extraction process"]]}], [10956, "The legal status of products with the same plant may differ largely between countries.", {"entities": []}], [10957, "Valerian, for example, is marketed in Germany, mainly as HMP, and, thus, possibly a great proportion of consumption was not included in the survey by Garcia-Alvarez [7].", {"entities": [[57, 60, "Herb name"]]}], [10958, "In many countries, food supplements and HMPs can be found of popular plants.", {"entities": [[40, 44, "Herb name"]]}], [10959, "Elsewhere, the same plant can be found only as a supplement or HMP.", {"entities": [[63, 66, "Herb name"]]}], [10960, "Detailed information about the legal status of valerian, St. John\u2019s wort, ginseng, green tea, and ginkgo in European countries are provided in [13].", {"entities": [[47, 55, "Herb name"], [57, 72, "Herb name"], [74, 81, "Herb name"], [83, 92, "Herb name"], [98, 104, "Herb name"], [108, 116, "Ethnic group"]]}], [10961, "Especially plants commonly used to treat symptoms of common cold are likely underrepresented (such as thyme, primrose, ivy, licorice, and yellow gentian).", {"entities": [[53, 64, "Pathology"], [102, 107, "Herb name"], [109, 117, "Herb name"], [119, 122, "Herb name"], [124, 132, "Herb name"], [138, 152, "Herb name"]]}], [10962, "Likewise, the list of frequently used plants in this article misses some plants for the treatment of digestive disorders (caraway, rosemary, anise, and cinnamon), possibly because they are rarely marketed as dietary supplements.", {"entities": [[101, 120, "Pathology"], [122, 129, "Herb name"], [131, 139, "Herb name"], [141, 146, "Herb name"], [152, 160, "Herb name"]]}], [10963, "Digestive problems occur widespread and are often treated without consulting a physician.", {"entities": [[0, 18, "Pathology"]]}], [10964, "Patients suffering from inflammatory bowel disease may try herbs in search for relief if they cannot achieve sufficient symptom control with their prescribed drugs.", {"entities": [[24, 50, "Pathology"], [147, 163, "Drug"]]}], [10965, "Several countries, mainly in Middle and Eastern Europe, are not represented in the survey data that the plant selection was based on.", {"entities": []}], [10966, "Plants are known by numerous common names in different countries, and sometimes the same name is used for more than one species.", {"entities": []}], [10967, "This may result in translation errors or assigning mentions to the wrong species, in some cases.", {"entities": []}], [10968, "The majority of clinical studies on herb\u2013drug interactions are conducted on small groups of healthy and younger volunteers.", {"entities": [[16, 32, "Study"], [92, 99, "Pathology"]]}], [10969, "They are likely to miss interactions that depend on individual condition or susceptibility (e.g., gene variants and liver or renal impairment).", {"entities": [[76, 90, "Parameter"], [98, 111, "Parameter"], [116, 141, "Pathology"]]}], [10970, "This can explain contradictions between clinical trials and case reports (as for CYP2C9 inhibition by ginger or milk thistle, see Table 3).", {"entities": [[40, 55, "Study"], [60, 72, "Study"], [81, 87, "Target"], [102, 108, "Herb name"], [112, 124, "Herb name"]]}], [10971, "Gauging the risks for patients with complex diseases, based on such data, is challenging.", {"entities": [[36, 52, "Pathology"]]}], [10972, "The focus of this survey lies on RA, IBD, and osteoarthritis, as well as the medication that patients are usually treated with.", {"entities": [[33, 35, "Pathology"], [37, 40, "Pathology"], [46, 60, "Pathology"]]}], [10973, "Interactions with drugs beyond this topic are sometimes mentioned (especially anticoagulants), but incomplete.", {"entities": [[78, 92, "Drug"]]}], [10974, "The use of herbal products for health improvement is common among patients.", {"entities": [[11, 26, "Herb name"]]}], [10975, "It is more frequent among women and elderly people.", {"entities": [[26, 31, "Sex"]]}], [10976, "Among patients with chronic diseases, those with poor symptom control are more likely to try complementary/alternative medicines, including herbal products.", {"entities": [[20, 36, "Pathology"]]}], [10977, "Concomitant use with prescription medicine bears the risk of interactions.", {"entities": []}], [10978, "For many potential herb\u2013drug interactions, the clinical significance is still discussed and high-quality data are rare.", {"entities": []}], [10979, "Reasons for individual susceptibility are often unknown.", {"entities": [[12, 37, "Parameter"]]}], [10980, "The following points should be considered to handle the matter: The basis is a trusting and respectful relationship between patient and health professional.", {"entities": []}], [10981, "Patients should not be afraid to admit interest in, or use of, alternative therapies, food supplements, or self-acquired medical products.", {"entities": []}], [10982, "Health professionals should explicitly ask about use of herbal products, sensitize patients for the importance of such information, and encourage them to seek advice for risk assessment before they try self-acquired medical products or supplements.", {"entities": [[56, 71, "Herb name"]]}], [10983, "Herbal medicinal products, preferably with standardized or quantified extracts, should be preferred over food supplements, as quality and declaration requirements are more extensive for medicinal products.", {"entities": [[0, 78, "Herb name"]]}], [10984, "Food supplements should not be actively recommended.", {"entities": []}], [10985, "A brief list of high- and low-risk plants can be found in Table 4.", {"entities": []}], [10986, "It is important to report suspected herb\u2013drug interactions, in order to collect data.", {"entities": []}], [10987, "Information on patient, medication, the suspected product, and the course of treatment should be collected as complete as possible.", {"entities": []}], [10988, "Publisher\u2019s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.", {"entities": []}], [10989, "Conceptualization, A.L.", {"entities": []}], [10990, "and B.R.", {"entities": []}], [10991, "; methodology, A.L.", {"entities": []}], [10992, "and B.R.", {"entities": []}], [10993, "; writing\u2014original draft preparation, A.L.", {"entities": []}], [10994, "; writing\u2014review and editing, A.L.", {"entities": []}], [10995, "and B.R.", {"entities": []}], [10996, "; supervision B.R.", {"entities": []}], [10997, "All authors have read and agreed to the published version of the manuscript.", {"entities": []}], [10998, "This research received no external funding.", {"entities": []}], [10999, "Not applicable.", {"entities": []}], [11000, "Not applicable.", {"entities": []}], [11001, "Not applicable.", {"entities": []}], [11002, "The authors declare no conflict of interest.", {"entities": []}], [11003, "This table lists the plants considered for possible interactions, with both their English and botanical names.", {"entities": []}], [11004, "It indicates if they were reported in general surveys or by patients with rheumatoid arthritis/inflammatory bowel disease, if they could be considered useful for treatment of these conditions, and the references.", {"entities": [[74, 94, "Pathology"], [95, 121, "Pathology"]]}], [11005, "Conventional drugs in therapy of RA, IBD, or osteoarthritis and their interaction potential (focus on mechanisms that can influence the effect of the drug or elevate its risks, not on their potential to influence others).", {"entities": [[33, 35, "Pathology"], [37, 40, "Pathology"], [45, 59, "Pathology"]]}], [11006, "This table shows the plants/herbal combination products included in this review, in alphabetic order, and possible herb\u2013drug interaction mechanisms and risks that could cumulate.", {"entities": [[73, 79, "Study"]]}], [11007, "The right column lists drugs applied in RA/osteoarthritis/IBD treatment that are, or could, be affected.", {"entities": [[40, 42, "Pathology"], [43, 57, "Pathology"], [58, 61, "Pathology"]]}], [11008, "Short summary of the interaction risk of the reviewed plants in RA, IBD, and osteoarthritis treatment.", {"entities": [[64, 66, "Pathology"], [68, 71, "Pathology"], [77, 91, "Pathology"]]}], [11009, "Details can be found in Table 3 and Section 3.2.", {"entities": []}], [11010, "Diabetes is a complex condition with a variety of causes and pathophysiologies.", {"entities": [[0, 8, "Pathology"]]}], [11011, "The current single target approach has not provided ideal clinical outcomes for the treatment of the disease and its complications.", {"entities": []}], [11012, "Herbal medicine has been used for the management of various diseases such as diabetes over centuries.", {"entities": [[77, 85, "Pathology"]]}], [11013, "Many diabetic patients are known to use herbal medicines with antidiabetic properties in addition to their mainstream treatments, which may present both a benefit as well as potential risk to effective management of their disease.", {"entities": [[5, 13, "Pathology"]]}], [11014, "In this review we evaluate the clinical and experimental literature on herb\u2013drug interactions in the treatment of diabetes.", {"entities": [[114, 122, "Pathology"]]}], [11015, "Pharmacokinetic and pharmacodynamic interactions between drugs and herbs are discussed, and some commonly used herbs which can interact with antidiabetic drugs summarised.", {"entities": [[141, 159, "Drug"]]}], [11016, "Herb\u2013drug interactions can be a double-edged sword presenting both risks (adverse drug events) and benefits (through enhancement).", {"entities": [[74, 93, "Pathology"]]}], [11017, "There is a general lack of data on herb\u2013drug interactions.", {"entities": []}], [11018, "As such, more rigorous scientific research is urgently needed to guide clinical practice as well as to safeguard the wellbeing of diabetes patients.", {"entities": [[130, 138, "Pathology"]]}], [11019, "Diabetes mellitus refers to a group of chronic metabolic diseases which are generally characterised by hyperglycaemia, which eventually leads to damage of multiple body systems.", {"entities": [[0, 17, "Pathology"], [39, 65, "Pathology"], [103, 117, "Pathology"]]}], [11020, "There are two types of diabetes, type 1 (T1DM) and type 2 (T2DM) diabetes mellitus.", {"entities": [[10, 82, "Pathology"]]}], [11021, "T1DM is referred as insulin-dependent diabetes mellitus (IDDM) and is caused by the impaired production of insulin.", {"entities": [[0, 4, "Pathology"], [20, 62, "Pathology"]]}], [11022, "T2DM, however, is commonly associated with the inability of cells to respond to insulin (insulin resistance) and hence referred as non-insulin dependent diabetes mellitus (NIDDM).", {"entities": [[0, 4, "Pathology"], [89, 107, "Pathology"], [131, 178, "Pathology"]]}], [11023, "The prevalence of diabetes has been increasing globally.", {"entities": [[18, 26, "Pathology"]]}], [11024, "In 2015, an estimated 415 million adults were living with diabetes, and this number is projected to increase to 642 million by 2040 [1].", {"entities": [[58, 66, "Pathology"]]}], [11025, "Over 70% of those with T2DM live in developing countries, and this proportion is increasing annually [2].", {"entities": [[23, 27, "Pathology"]]}], [11026, "In Australia, diabetes is among the top 10 leading causes of death and was responsible for 3% of all Australian deaths in 2011, whereby the most common cause of diabetes related death was coronary heart disease, accounting for 64% of deaths from diabetes [3].", {"entities": [[14, 22, "Pathology"], [101, 111, "Ethnic group"], [161, 169, "Pathology"], [197, 210, "Pathology"], [246, 254, "Pathology"]]}], [11027, "Evidence suggests that lifestyle changes such as exercise, diet and other nonpharmacological interventions can delay and even prevent the development of T2DM.", {"entities": [[153, 157, "Pathology"]]}], [11028, "However, compliance to these interventions is low; with only about 50% of those with chronic illnesses have been shown to adhere to recommended lifestyle interventions [4].", {"entities": []}], [11029, "Many antidiabetic pharmaceutical drugs are available, but the increase in the incidence of T2DM, especially in developing countries, together with adverse events associated with these drugs, has highlighted the need for more effective, safer and less costly management approaches.", {"entities": [[5, 38, "Drug"], [91, 95, "Pathology"], [147, 161, "Pathology"]]}], [11030, "The global use of complementary and alternative medicine (CAM) for the management of diseases such as diabetes has rapidly increased over the last decade.", {"entities": [[102, 110, "Pathology"]]}], [11031, "It is reported that up to 72.8% of people with diabetes used herbal medicine, dietary supplements and other CAM therapies [5].", {"entities": [[47, 55, "Pathology"]]}], [11032, "Furthermore, research indicates that most people who use CAM therapies do so in addition to, rather than in place of, conventional medicine [6].", {"entities": []}], [11033, "A large number of medicinal plants are believed to possess antidiabetic properties and have been utilised to manage diabetes [7\u20139].", {"entities": [[116, 124, "Pathology"]]}], [11034, "However the concurrent use of antidiabetic herbs and pharmaceutical medicines has raised safety concerns.", {"entities": []}], [11035, "Unlike pharmaceutical medicines, where the ingredients are well defined and characterised, herbal medicine contains multiple bioactive components for which there is a lack of understanding of how these components interact with each other and with pharmaceutical medicines when taken in combination.", {"entities": []}], [11036, "Although many studies regarding herb\u2013drug interactions emphasise the potential harmful effects of such interactions, the possibility of herbal components beneficially enhancing or facilitating the action of antidiabetic pharmaceutical agents (or vice versa) may also exist.", {"entities": [[207, 241, "Drug"]]}], [11037, "Positive interactions between herbs and drugs may lead to enhanced effectiveness of the antidiabetic agents through additive or synergistic actions.", {"entities": [[88, 107, "Drug"]]}], [11038, "This review aims to provide an overview of the studies investigating interactions between antidiabetic herbs and conventional medicine, identifying of both negative and positive aspects of these interactions.", {"entities": []}], [11039, "Two (or more) drugs when administered together have the potential to cause chemical or pharmacological interactions.", {"entities": []}], [11040, "Such interactions may alter the effect of either agent, leading to decreased or increased effectiveness or severity of adverse effects.", {"entities": [[119, 134, "Pathology"]]}], [11041, "The outcomes are dependent on many chemical and pharmacological factors, such as the physicochemical nature of the drugs in use and how they affect each other pharmacokinetically and pharmacodynamically (Fig.\u00a01).", {"entities": []}], [11042, "Although, the mechanisms of interactions between herbs and drugs are similar, they are more complex in nature when several compounds are involved.", {"entities": []}], [11043, "Herb\u2013drug interactions (HDI) may affect clinical safety and efficacy via additive/synergistic or antagonistic interactions among the herbal components and drug molecules.", {"entities": []}], [11044, "Whilst negative or harmful interactions tend to receive more attention due to safety considerations, additive/synergistic effects induced by HDIs may result in an enhancement of desired pharmacological effects.", {"entities": []}], [11045, "For example, the blood glucose lowering effect of antidiabetic drugs has been shown to be increased by agrimony [10].", {"entities": [[17, 30, "Parameter"], [50, 68, "Drug"]]}], [11046, "Mechanisms of action of herb\u2013drug interactions A number of mechanisms may be associated with pharmacokinetic HDIs including quantitative alterations in renal clearance [11, 12], bioavailability [13], drug distribution [14, 15], absorption [16\u201318], and elimination processes [19].", {"entities": [[152, 167, "Parameter"], [178, 193, "Parameter"]]}], [11047, "Hepatic metabolic enzyme systems, particularly the cytochrome P450 (CYP450) isoenzyme family, remain a common pathway for pharmacokinetic HDIs.", {"entities": [[51, 92, "Target"]]}], [11048, "Many anti-diabetic drugs are substrates of CYP450 isoenzymes, e.g.", {"entities": [[5, 24, "Drug"], [43, 60, "Target"]]}], [11049, "pioglitazone, repaglinide and rosiglitazone for CYP2C8, glibenclamide, glimepiride, glipizide, nateglinide and rosiglitazone for CYP2C9, proguanil for CYP2C19, and pioglitazone and repaginate for CYP3A4 [20\u201322].", {"entities": [[0, 12, "Drug"], [14, 25, "Drug"], [30, 43, "Drug"], [48, 54, "Target"], [56, 69, "Drug"], [71, 82, "Drug"], [84, 93, "Drug"], [95, 106, "Drug"], [111, 124, "Drug"], [129, 135, "Target"], [137, 146, "Drug"], [151, 158, "Target"], [164, 176, "Drug"], [181, 191, "Drug"], [196, 202, "Target"]]}], [11050, "A large number of herbs have also been suggested to affect the CYP450 system.", {"entities": [[63, 76, "Target"]]}], [11051, "For example, St John\u2019s wort inhibits CYP2C and CYP3A and ginkgo inhibits CYP3A4, CYP2C9 and CYP2C19 [23].", {"entities": [[13, 27, "Herb name"], [37, 42, "Target"], [47, 52, "Target"], [57, 63, "Herb name"], [73, 79, "Target"], [81, 87, "Target"], [92, 99, "Target"]]}], [11052, "Pharmacodynamic HDIs can modify the drug/herb actions in a qualitative manner through effects on various organs, receptor sites or enzymes.", {"entities": []}], [11053, "Such interactions can result in antagonistic, additive or synergistic effects.", {"entities": []}], [11054, "For example, many herbal medicines possess antioxidant properties which could be beneficial for reducing oxidative stress, a key pathogenic factor of diabetes [24\u201326].", {"entities": [[150, 158, "Pathology"]]}], [11055, "Several pharmaceutical agents effective in reducing diabetic mortalities (e.g., 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors) have also been shown to have antioxidant activities [24].", {"entities": [[52, 72, "Pathology"], [80, 138, "Drug"]]}], [11056, "When these herbs and drugs are used together, pharmacodynamic HDI (either additive/synergistic) may occur.", {"entities": []}], [11057, "Some of the known interactions between selected antidiabetic drug and antidiabetic herbs are discussed in \u201cCommon herb\u2013drug interactions in diabetes\u201d [24\u201326].", {"entities": [[48, 65, "Drug"], [140, 148, "Pathology"]]}], [11058, "Several groups of pharmaceutical agents are currently used for the treatment of diabetes via different mechanisms, such as stimulation of the release of insulin (e.g., sulfonylureas), reduction of hepatic glucose output and enhancement of the peripheral uptake of glucose (e.g.", {"entities": [[80, 88, "Pathology"], [153, 160, "Target"], [168, 181, "Drug"]]}], [11059, "biguanidines) [27\u201329].", {"entities": [[0, 12, "Drug"]]}], [11060, "Some of the commonly used antidiabetic drugs include biguanides, e.g., metformin (via acting directly to influence insulin resistance), peroxisome proliferator activated receptor (PPAR) activators, e.g., thiazolidindiones (via improving insulin resistance), vidagliptin and other related \u201cgliptins\u201d (via blocking DPP-4, an enzyme that degrades the incretin GLP-1) and \u03b1-glucosidase inhibitors, e.g.", {"entities": [[26, 44, "Drug"], [53, 63, "Drug"], [71, 80, "Drug"], [115, 122, "Target"], [136, 196, "Drug"], [204, 221, "Drug"], [237, 244, "Target"], [258, 269, "Drug"], [289, 297, "Drug"], [313, 319, "Target"], [348, 362, "Target"], [368, 392, "Drug"]]}], [11061, "acarbose and miglitol (via delaying the digestion of complex carbohydrates).", {"entities": [[0, 8, "Drug"], [13, 21, "Drug"]]}], [11062, "Other diabetic agents target pancreatic beta-cell receptors by binding to the sulfonylurea receptor subunit, blocking the K An increasing number of medicinal plants are being used to treat diabetes and its related conditions.", {"entities": [[6, 21, "Drug"], [29, 59, "Target"], [78, 99, "Target"], [189, 197, "Pathology"]]}], [11063, "The current NAPRALERT database lists over 1300 species of plants representing more than 750 genera within 190 families, covering lower plants such as algae and fungi to almost all types of higher plants.", {"entities": [[150, 155, "Herb name"], [160, 165, "Herb name"]]}], [11064, "Many of these plants have been used ethno-pharmacologically in traditional medicine as antidiabetics, particularly for T2DM [32, 33].", {"entities": [[119, 123, "Pathology"]]}], [11065, "Although many of these plants have been studied experimentally to validate their physiological activity, the chemical and pharmacological properties underpinning the anti-diabetic activity is less well studied.", {"entities": []}], [11066, "Nevertheless, a large number of potentially bio-active molecules have been isolated and identified, among which include complex carbohydrates, alkaloids, glycopeptides, terpenoids, peptides, amines, steroids, flavonoids, lipids, coumarins, sulphur compounds and inorganic ions [32].", {"entities": [[120, 141, "Herb name"], [143, 152, "Herb name"], [169, 179, "Herb name"], [209, 219, "Herb name"], [229, 238, "Herb name"]]}], [11067, "Examples of common herbs and dietary supplements that have been used to treat diabetes include Momordicacharantia, Trigonellafoenum-graceum, Gymnemasylvestre, Azadirachtaindica,  The co-administration of antidiabetic herbs and pharmaceutical agents may result in HDIs leading to enhanced effects (which may be desirable clinically), decreased pharmacological effects, or adverse drug events, such as hypoglycaemia.", {"entities": [[78, 86, "Pathology"], [95, 113, "Herb name"], [115, 139, "Herb name"], [141, 157, "Herb name"], [159, 176, "Herb name"], [371, 390, "Pathology"], [400, 413, "Pathology"]]}], [11068, "The following section provides a brief discussion of common antidiabetic herbs and their potential interactions with antidiabetic agents.", {"entities": [[117, 136, "Drug"]]}], [11069, "Literature searches were conducted with PubMed and Google Scholar up to June 2017.", {"entities": []}], [11070, "The selection of medicinal plants for inclusion is based on their consistent use over long periods and on the strength of available data on effectiveness or adverse/synergistic effects.", {"entities": [[157, 184, "Pathology"]]}], [11071, "Aloe vera is native to Africa and is one of the more than 400 species of the genus Aloe.", {"entities": [[0, 9, "Herb name"], [83, 87, "Herb name"]]}], [11072, "The presumed major active components include carbohydrates (e.g., mannan, galactose-rich polysaccharides), and galacturonic acid [37].", {"entities": [[45, 58, "Herb name"], [66, 104, "Herb name"], [111, 128, "Herb name"]]}], [11073, "Traditional literature reveals a wide range of clinical uses of this plant from cosmeceuticals through to immunity and organ care.", {"entities": []}], [11074, "In diabetes, aloe vera has been shown to significantly reduce blood glucose levels [38].", {"entities": [[3, 11, "Pathology"], [13, 22, "Herb name"], [62, 75, "Parameter"]]}], [11075, "Several studies report potential interactions between aloe vera and antidiabetic drugs.", {"entities": [[54, 63, "Herb name"], [68, 86, "Drug"]]}], [11076, "Of note is its interaction with glibenclamide, a sulphonylurea which exerts its antidiabetic potential by inhibiting ATP sensitive potassium channels in pancreatic \u03b2 cells, resulting in cell membrane depolarization and subsequent insulin release.", {"entities": [[32, 62, "Drug"], [117, 171, "Target"]]}], [11077, "The combination of aloe vera and antidiabetics has generally been shown to have an additive effect.", {"entities": [[19, 28, "Herb name"], [33, 46, "Drug"]]}], [11078, "For instance, aloe has been shown to produce a greater anti-hyperglycaemic effect, when compared to the sole therapy with glibenclamide, pioglitazone or repaglinide [39\u201341].", {"entities": [[14, 18, "Herb name"], [122, 135, "Drug"], [137, 149, "Drug"], [153, 164, "Drug"]]}], [11079, "Both Panax ginseng and Panax quinquefolium, two important members of the ginseng family, have been shown to possess antidiabetic properties affecting insulin dependent and insulin independent pathways [42\u201344].", {"entities": [[5, 18, "Herb name"], [23, 42, "Herb name"], [73, 80, "Herb name"]]}], [11080, "The bioactive constituents responsible for ginseng\u2019s antidiabetic actions are likely to be attributed to its ginsenosides [45, 46].", {"entities": [[43, 50, "Herb name"], [109, 121, "Herb name"]]}], [11081, "Although the precise active components responsible for this anti-diabetic action are unknown, studies with compound K (CK), a final metabolite of protopanaxadiol ginsenosides demonstrate that CK exhibits anti-hyperglycaemic effects through an insulin secreting action similar to metformin.", {"entities": [[107, 122, "Herb name"], [146, 174, "Herb name"], [192, 194, "Herb name"], [279, 288, "Drug"]]}], [11082, "The combined treatment of CK and metformin has been shown to elicit additive effects compared to individual components being used alone.", {"entities": [[26, 28, "Herb name"], [33, 42, "Drug"]]}], [11083, "Significant improvements were observed in plasma glucose and insulin levels, homeostasis model assessment-insulin resistance (HOMA-IR) and in haematoxylin and eosin-stained liver tissues [45, 46].", {"entities": [[42, 56, "Parameter"]]}], [11084, "Karela is also known as bitter melon due to its taste.", {"entities": [[0, 6, "Herb name"], [24, 36, "Herb name"]]}], [11085, "A large number of chemical constituents are found in its juice, including sterols, glucoside mixtures and charantin polypeptides [47].", {"entities": [[57, 62, "Extraction process"], [74, 81, "Herb name"], [83, 101, "Herb name"], [106, 128, "Herb name"]]}], [11086, "Karela is one of the few medicinal plants that has been subjected to extensive clinical studies in combination with common antidiabetics.", {"entities": [[0, 6, "Herb name"], [123, 136, "Drug"]]}], [11087, "Increased efficacy has been reported when used together with metformin, glymidine and glibenclamide.", {"entities": [[61, 70, "Drug"], [72, 81, "Drug"], [86, 99, "Drug"]]}], [11088, "In one clinical trial, 400\u00a0mg of chloroform/benzene karela extract was combined with 50% of the full clinical doses of either metformin or glibenclamide in NIDDM patients.", {"entities": [[23, 29, "Amount"], [33, 66, "Extraction process"], [126, 135, "Drug"], [139, 152, "Drug"], [156, 161, "Pathology"]]}], [11089, "Results showed that the combined interventions elicited a greater hypoglycemic effect when compared to that of full doses of metformin or glibenclaminde alone, indicating a possible additive effect [48].", {"entities": [[125, 134, "Drug"], [138, 152, "Drug"]]}], [11090, "Similar results have also been obtained in animal studies whereby the combined treatments of karela fruit juice/extracts and metformin have been shown to produce greater hypoglycemic effects than either treatment alone in rat models of diabetes [49\u201351].", {"entities": [[43, 57, "Study"], [93, 120, "Extraction process"], [125, 134, "Drug"], [236, 244, "Pathology"]]}], [11091, "Ginger has been widely used as spice as well as medicine for many years.", {"entities": [[0, 6, "Herb name"]]}], [11092, "Crude ginger contains up to 9% lipids or glycolipids and about 5\u20138% oleoresin.", {"entities": [[0, 12, "Herb name"], [68, 77, "Herb name"]]}], [11093, "The pungent principles, accounting for 25% of the oleoresins, consist mainly of gingerols and related phenolic compounds [52].", {"entities": [[50, 60, "Herb name"], [80, 89, "Herb name"], [102, 120, "Herb name"]]}], [11094, "Its aqueous extract is in use as an antidiabetic in many countries as part of traditional therapy.", {"entities": [[4, 19, "Extraction process"]]}], [11095, "It is believed that the antidiabetic effect of ginger is derived from its antioxidant and anti-glycation properties, and its ability to express the glucose transporter Glut 4 [53].", {"entities": [[47, 53, "Herb name"], [148, 174, "Target"]]}], [11096, "In addition, ginger has been shown to have renal protective effects when used with metformin [55, 56].", {"entities": [[13, 19, "Herb name"], [83, 92, "Drug"]]}], [11097, "Prickly pear cactus (Nopal) athough native to Mexico, is now widely used worldwide as food and traditional medicine.", {"entities": [[0, 27, "Herb name"]]}], [11098, "Cacti are divided into several genera, including Opuntia (e.g., Opuntiaaciculata).", {"entities": [[0, 5, "Herb name"], [49, 56, "Herb name"], [64, 80, "Herb name"]]}], [11099, "Opuntia contains a range of phytochemicals in variable quantities, such as polyphenols, dietary minerals and betalains, as well as various compounds including gallic acid, vanillic acid and catechins [57].", {"entities": [[0, 7, "Herb name"], [75, 86, "Herb name"], [109, 118, "Herb name"], [159, 170, "Herb name"], [172, 185, "Herb name"], [190, 199, "Herb name"]]}], [11100, "One study showed a positive interaction between the combined effect of prickly pear cactus pad and glipizide and metformin in T2DM patients.", {"entities": [[71, 90, "Herb name"], [99, 108, "Drug"], [113, 122, "Drug"], [126, 130, "Pathology"]]}], [11101, "In this study a hypoglycaemic reaction was observed, although the authors note that clinical studies are required to support combined therapy of this herb and known diabetic drugs [58].", {"entities": [[84, 100, "Study"], [165, 179, "Drug"]]}], [11102, "It is composed of the following fatty acids: linoleic acid (41% of total), oleic acid (39%), palmitic acid (8%), stearic acid (5%) plus small amounts of other fatty acids [59].", {"entities": [[45, 58, "Herb name"], [75, 85, "Herb name"], [93, 106, "Herb name"], [113, 125, "Herb name"]]}], [11103, "In a landmark clinical study by Sankar et al.", {"entities": [[14, 28, "Study"]]}], [11104, "Fenugreek is commonly used as a spice in south Asia and is known for its hypoglycaemic and hypocholesterolemic properties [62].", {"entities": [[0, 9, "Herb name"]]}], [11105, "The proximate composition of fenugreek (seeds, husk and cotyledons) contains saponin, protein and polyphenols [63].", {"entities": [[29, 38, "Herb name"], [40, 45, "Herb part"], [47, 51, "Herb part"], [56, 66, "Herb part"], [77, 84, "Herb name"], [98, 109, "Herb name"]]}], [11106, "Interactions of fenugreek with known antidiabetics have been evaluated in several chemically induced diabetic animal models.", {"entities": [[16, 25, "Herb name"], [37, 50, "Drug"], [82, 109, "Pathology"]]}], [11107, "The combination of fenugreek (150\u00a0mg/kg) and metformin (100\u00a0mg/kg) produced a significant reduction in plasma glucose level (20.7%) in type 2 diabetes [64].", {"entities": [[19, 28, "Herb name"], [30, 39, "Amount"], [45, 54, "Drug"], [56, 65, "Amount"], [103, 117, "Parameter"], [135, 150, "Pathology"]]}], [11108, "In a similar study, lipid peroxidation (LPO) induced by ferrous sulphate, hydrogen peroxide and carbon tetrachloride in liver were performed.", {"entities": []}], [11109, "Garlic is known for its spectrum of medicinal properties.", {"entities": [[0, 6, "Herb name"]]}], [11110, "It is composed of a large number of sulfur compounds, with suspected bioactive compounds called allyl thiosulfinates (mainly allicin) [65].", {"entities": [[96, 116, "Herb name"]]}], [11111, "Garlic has been reported to possess antidiabetic properties.", {"entities": [[0, 6, "Herb name"]]}], [11112, "Several experimental and clinical studies have been conducted to assess the interaction between garlic and antidiabetic medicines.", {"entities": [[25, 41, "Study"], [96, 102, "Herb name"], [107, 129, "Drug"]]}], [11113, "In a rat model, the effects of garlic on the pharmacokinetic profiles of metformin were investigated.", {"entities": [[31, 37, "Herb name"], [73, 82, "Drug"]]}], [11114, "It was found that garlic increased the peak plasma concentration (C Gymnema is native to South India and its pharmacological properties are mainly attributed to triterpenoidic saponins [71].", {"entities": [[18, 24, "Herb name"], [66, 75, "Herb name"], [161, 184, "Herb name"]]}], [11115, "This herb has been in use for diabetic treatment for almost two millennia [72].", {"entities": [[30, 38, "Pathology"]]}], [11116, "The interaction of gymnema (100 and 500\u00a0mg/kg orally) with metformin (50 and 100\u00a0mg/kg has been studied in STZ-induced diabetic rats.", {"entities": [[19, 26, "Herb name"], [28, 45, "Amount"], [59, 68, "Drug"], [70, 86, "Amount"], [107, 127, "Pathology"]]}], [11117, "The combined treatment was found to decrease the bioavailability of metformin and serum glucose level; the decrease in serum glucose however was not significantly greater than that of metformin itself, although histopathological analyses showed an increase in volume of pancreatic islet cells after combined therapy [73].", {"entities": [[49, 64, "Parameter"], [68, 77, "Drug"], [82, 95, "Parameter"], [119, 132, "Parameter"], [184, 193, "Drug"]]}], [11118, "In an animal study using a chemically-induced diabetic rat model a decrease in plasma metformin concentration and increase in blood glucose levels were seen in animals treated with the combination of gymnema tea and metformin when compared to those receiving metformin alone, suggesting an antagonistic interaction between metformin and gymnema [74].", {"entities": [[6, 18, "Study"], [86, 95, "Drug"], [126, 139, "Parameter"], [200, 207, "Herb name"], [216, 225, "Drug"], [259, 268, "Drug"], [323, 332, "Drug"], [337, 344, "Herb name"]]}], [11119, "In a similar study of chemically-induced diabetic rats, a significant decrease in bioavailability of metformin was observed which was proportional to the dose of gymnema used.", {"entities": [[82, 97, "Parameter"], [101, 110, "Drug"], [162, 169, "Herb name"]]}], [11120, "However, the combined treatment significantly reduced the blood glucose level compared to individual administration of metformin or gymnema [75].", {"entities": [[58, 71, "Parameter"], [119, 128, "Drug"], [132, 139, "Herb name"]]}], [11121, "These findings suggest further research in individuals with diabetes is required to determine the effect of the combination of gymnema tea and metformin on blood sugar levels.", {"entities": [[60, 68, "Pathology"], [127, 134, "Herb name"], [143, 152, "Drug"], [156, 167, "Parameter"]]}], [11122, "Although St John\u2019s wort (SJW) is a medicinal herb with well-established as an antidepressant, it has also been reported to possess antidiabetic properties.", {"entities": [[9, 29, "Herb name"]]}], [11124, "SJW decreased the renal clearance of metformin but had no effects on other pharmacokinetic parameters.", {"entities": [[0, 3, "Herb name"], [18, 33, "Parameter"], [37, 46, "Drug"]]}], [11125, "Nevertheless, SJW treatment improved glucose tolerance by enhancing insulin secretion independent of insulin sensitivity [77].", {"entities": [[14, 17, "Herb name"]]}], [11126, "However, these results differ to that of a study in which pre-treatment with SJW had no effect on blood glucose lowering or the insulin elevating effect of repaglinide [78].", {"entities": [[77, 80, "Herb name"], [98, 111, "Parameter"], [156, 167, "Drug"]]}], [11127, "Further research is required to clarify these findings.", {"entities": []}], [11128, "Astragalus is a frequently used traditional Chinese medicine for diabetes.", {"entities": [[0, 10, "Herb name"], [65, 73, "Pathology"]]}], [11129, "The bioactive constituents of astragalus include polysaccharides, triterpenoids (astragalosides), isoflavones (including kumatakenin, calycosin and formononetin), glycosides and malonates [79].", {"entities": [[30, 40, "Herb name"], [49, 64, "Herb name"], [66, 96, "Herb name"], [98, 109, "Herb name"], [121, 132, "Herb name"], [134, 143, "Herb name"], [148, 160, "Herb name"], [163, 173, "Herb name"], [178, 187, "Herb name"]]}], [11130, "In Chinese herbal medicine astragalus is commonly used as a key herb in antidiabetic formulations.", {"entities": [[27, 37, "Herb name"]]}], [11131, "The effect of astragalus on the pharmacokinetics of pioglitazone has been investigated in a number of clinical and preclinical studies.", {"entities": [[14, 24, "Herb name"], [52, 64, "Drug"], [102, 134, "Study"]]}], [11132, "In healthy human subjects, treatment of astragalus extract significantly reduced the C Scutellaria is a medicinal plant which roots are used to prepare traditional medicines.", {"entities": [[3, 10, "Pathology"], [40, 58, "Extraction process"], [85, 98, "Herb name"], [126, 131, "Herb part"]]}], [11133, "Several chemical compounds have been isolated from the root of scutellaria including baicalein, baicalin, wogonin, norwogonin, oroxylin A and \u03b2-sitosterol [81].", {"entities": [[55, 59, "Herb part"], [63, 74, "Herb name"], [85, 94, "Herb name"], [96, 104, "Herb name"], [106, 113, "Herb name"], [115, 125, "Herb name"], [127, 137, "Herb name"], [142, 154, "Herb name"]]}], [11134, "The effect of combined administration of metformin (500\u00a0mg/kg) and the ethanolic extract of scutellaria (400\u00a0mg/kg) for 30\u00a0days was examined in a rat model of STZ-induced diabetes.", {"entities": [[41, 50, "Drug"], [52, 61, "Amount"], [71, 88, "Extraction process"], [92, 103, "Herb name"], [105, 114, "Amount"], [116, 127, "Duration"], [159, 179, "Pathology"]]}], [11135, "Combination treatment resulted in elevated hepatic activity of antioxidant enzymes compared with metformin alone.", {"entities": [[97, 106, "Drug"]]}], [11136, "Hepatic lipid peroxide concentration was significantly reduced by combination treatment, with a corresponding reduction of plasma and hepatic triglycerides and cholesterol levels.", {"entities": [[123, 171, "Parameter"]]}], [11137, "These results suggest that scutellaria enhances the antidiabetic action of metformin although further research in individuals with diabetes is required to confirm these findings.", {"entities": [[27, 38, "Herb name"], [75, 84, "Drug"], [131, 139, "Pathology"]]}], [11138, "Andrographis paniculata is a herb commonly used by individuals with diabetes [82].", {"entities": [[0, 23, "Herb name"], [68, 76, "Pathology"]]}], [11139, "Potentially additive pharmacological effects are apparent with the use of the herb in combination with antidiabetic medications as the herb has been shown to lead to enhanced uptake of radioactive glucose in the isolated soleus muscle of STZ-diabetic rats in a concentration-dependent manner [83].", {"entities": [[103, 127, "Drug"], [238, 255, "Pathology"]]}], [11141, "Lycium is commonly found in the Himalayan region of India and Pakistan and is traditionally used as a medicinal plant for diabetes.", {"entities": [[0, 6, "Herb name"], [122, 130, "Pathology"]]}], [11142, "Its hypoglycaemic effects are believed to be due to its bioactive polysaccharides and antioxidants.", {"entities": []}], [11143, "Evidence supporting the interaction between Lycium and antidiabetics is experimental only.", {"entities": [[44, 50, "Herb name"], [55, 68, "Drug"]]}], [11144, "The effect of 4\u00a0weeks treatment with Lycium (10\u00a0mg/kg/d) on blood glucose was examined in rats with STZ-induced T2DM [85].", {"entities": [[14, 21, "Duration"], [37, 43, "Herb name"], [45, 53, "Amount"], [60, 73, "Parameter"], [100, 116, "Pathology"]]}], [11145, "Blood glucose levels in Lycium treated rats decreased by 34.9% (P\u00a0<\u00a00.01) compared with controls.", {"entities": [[0, 13, "Parameter"], [24, 30, "Herb name"]]}], [11146, "Findings such as these suggest that Lycium may have an additive effect when used in combination with conventional antidiabetics [86].", {"entities": [[36, 42, "Herb name"], [114, 127, "Drug"]]}], [11147, "However, evidence supporting Lycium\u2019s antidiabetic activity in humans and interaction with antidiabetic medications is essential to determine whether similar effects are observed in human studies.", {"entities": [[29, 35, "Herb name"], [91, 115, "Drug"], [182, 195, "Study"]]}], [11148, "Cassia is an ethnomidicinal plant that is widely used in Indian and Chinese medicine to treat diabetes.", {"entities": [[0, 6, "Herb name"], [94, 102, "Pathology"]]}], [11149, "It has been proposed that the antioxidant and polyphenol content of Cassia fistula and flavonoid content of Cassia occidentalis contribute to their antihyperglycaemic properties [87, 88].", {"entities": [[46, 56, "Herb name"], [68, 82, "Herb name"], [87, 96, "Herb name"], [108, 127, "Herb name"]]}], [11150, "Normal and STZ-induced diabetic rats were administered with 0.45\u00a0g/kg Cassia fistula hexane extract exhibited comparable effects to that of glibenclamide [87].", {"entities": [[0, 36, "Pathology"], [60, 69, "Amount"], [70, 84, "Herb name"], [85, 99, "Extraction process"], [140, 153, "Drug"]]}], [11151, "Similarly, Cassia occidentalis has been shown to have significant antihyperglycaemic activity in normal and alloxan-indiced diabetic rats [88].", {"entities": [[11, 30, "Herb name"], [108, 137, "Pathology"]]}], [11152, "Cassia inhibits enzyme activities of CYP2C9 for which glibenclamide, glimepiride, glipizide, nateglinide, and rosiglitazone are substrates, and CYP3A4 for which pioglitazone and repaglinide are also substrates [89], suggesting there may be an additive effect of this herb with antidiabetic medications.", {"entities": [[0, 6, "Herb name"], [37, 43, "Target"], [54, 67, "Drug"], [69, 80, "Drug"], [82, 91, "Drug"], [93, 104, "Drug"], [110, 123, "Drug"], [144, 150, "Target"], [161, 173, "Drug"], [178, 189, "Drug"], [277, 301, "Drug"]]}], [11153, "Olive tree (Olea europaea L.) leaves have been widely used in traditional remedies in European and Mediterranean countries.", {"entities": [[0, 29, "Herb name"], [30, 36, "Herb part"]]}], [11154, "They have been used as extracts, herbal teas, and powder and contain several potentially bioactive compounds that may have antioxidant, antihypertensive, antiatherogenic, anti-inflammatory, hypoglycemic, and hypocholesterolemic properties.", {"entities": [[23, 31, "Extraction process"], [33, 44, "Extraction process"], [50, 56, "Extraction process"]]}], [11155, "Suggested mechanisms include the effect of olive polyphenols in preventing amylin aggregation in amyloid in pancreatic \u03b2-cells in the pancreas which impairs insulin-secreting cells [92].", {"entities": [[43, 60, "Herb name"]]}], [11156, "Based on the results presented above, it is clear that numerous herbal medicines, when taken in conjunction with antidiabetic pharmaceutical agents, could potentially alter their pharmacokinetic and/or pharmacodynamic properties.", {"entities": [[113, 147, "Drug"]]}], [11157, "These interactions are complex given the large number of pathophysiological/pharmacological targets associated with the disease and the multicomponent properties of herbal medicine.", {"entities": []}], [11158, "The batch-to-batch variation in chemical composition of herbal medicine is also likely to impact on the nature of the interactions, making them unpredictable (Table\u00a01).", {"entities": []}], [11159, "Herb\u2013antidiabetic drug co-administration studies In this review we have found that interactions of antidiabetic drugs and herbs may result in antagonistic or enhancement effects.", {"entities": [[0, 48, "Study"], [99, 117, "Drug"]]}], [11160, "The enhancement of glucose lowering has the possibility of causing hypoglycaemia, hence monitoring of potentially adverse effects is required and hence it is recommended that people with diabetes closely monitor their blood glucose levels when combining the two compounds.", {"entities": [[67, 80, "Pathology"], [114, 129, "Pathology"], [187, 195, "Pathology"], [218, 231, "Parameter"]]}], [11161, "Although the vast majority of available evidence suggests that herbal medicines are relatively safe one case report showed that a patient with T2DM who was treated with the combination of Metformin and Repaglinide experienced hypoglycaemia [93], suggesting that patients and clinicians should indeed be alert to this possibility.", {"entities": [[104, 115, "Study"], [143, 147, "Pathology"], [188, 197, "Drug"], [202, 213, "Drug"], [226, 239, "Pathology"]]}], [11162, "Further research is required to examine the potential for hypoglycaemia in patients who are concurrently administered antidiabetic drugs.", {"entities": [[58, 71, "Pathology"], [118, 136, "Drug"]]}], [11163, "Despite the potential for adverse effects, the combination of these herbs and antidiabetic medications has been more commonly shown to have positive clinical implications as it could lead to enhanced antidiabetic effects, potentially enabling a reduction in dose of antidiabetic agents, thereby minimising their side effects.", {"entities": [[26, 41, "Pathology"], [78, 102, "Drug"], [266, 285, "Drug"], [312, 324, "Pathology"]]}], [11164, "In contrast, antagonism may lead to harmful effects and therefore warrant a cautionary warning or contraindication for the combination.", {"entities": []}], [11165, "Although not discussed in this review, antidiabetic herbs may also interact with other (non-diabetic) medicines when taken concurrently [94].", {"entities": []}], [11166, "These considerations indicate that caution should always be exercised when herbal medicines are combined with pharmaceutical medicines, especially in elderly patients or patients with chronic illnesses due to their compromised body functions (e.g.", {"entities": []}], [11167, "renal and hepatic functions in particular).", {"entities": []}], [11168, "Further research is warranted on the mechanisms of action underlying antidiabetic herb\u2013drug interactions.", {"entities": []}], [11169, "CYP monoxygenase and P-glycoprotein drug transport pathways are of particular interest given that many antidiabetic medications are subject to metabolism by these enzyme systems [95\u201397].", {"entities": [[0, 16, "Target"], [21, 35, "Target"], [103, 127, "Drug"]]}], [11170, "It is worth pointing out however, that most studies presented in this review do not distinguish the difference between synergistic and additive effects.", {"entities": []}], [11171, "A synergistic effect is defined as the total effect produced by a combination of two or more components which is greater than the sum of the individual therapy, whilst an additive effect is simply the sum of individual effects, such that each individual component does not affect the other(s), i.e.", {"entities": []}], [11172, "no interaction [98].", {"entities": []}], [11173, "To this end, it is somewhat problematic to use the term \u2018interaction\u2019 unless synergy is proven.", {"entities": []}], [11174, "Determination of synergism is a complex process especially for HDIs, where numerous bioactive components may be involved.", {"entities": []}], [11175, "The current models such as isobolographic analysis and the combination index are designed to evaluate the interactions of a small number of active components acting on a single biological target [98].", {"entities": []}], [11176, "System-to-system or systems biology methodology is a more appropriate model for the evaluation of more complex interactions but its use is often limited by the availability of the relevant chemical and pharmacological data, especially in complex herbal interventions.", {"entities": []}], [11177, "Research is essential to develop robust and viable models for assessing herb\u2013drug and herb\u2013herb interactions.", {"entities": []}], [11178, "Such information is critical to guide the clinical use of these combinations.", {"entities": []}], [11179, "There are a number of challenges facing herbal medicine including scant information about their active constituents [99], lack of detailed product information [100, 101], complexity due to multiple chemical components and pharmacological targets [102\u2013104], variation in source of herbal material, lack of standardization and batch\u2013batch reproducibility [105, 106] and of certification of authenticity of herbs used in manufacture [107\u2013109].", {"entities": []}], [11180, "Additionally, the existing scientific evidence, particularly clinical, to support the use of herbal medicine remains at the lower levels, and the robustness of the methods used has often been inadequate [110\u2013112].", {"entities": []}], [11181, "This highlights the need for further rigorous scientific research to validate the clinical effectiveness and mechanisms of action of herbal medicine as well as complementary medicine in general.", {"entities": []}], [11182, "Equally important, we need to better our understanding and rigorously document the potential risks associated with herb\u2013drug interactions given the high prevalence of their concurrent use with pharmaceutical medicines, especially for the management of chronic diseases such as diabetes [113\u2013116].", {"entities": [[277, 285, "Pathology"]]}], [11183, "Conversely, it is important to keep in mind that these interactions may also present therapeutic benefits as a result of synergism which may lead to enhanced drug effects or reduced adverse reactions.", {"entities": [[182, 199, "Pathology"]]}], [11184, "In conclusion, interaction between herbal and pharmaceutical agents is a double-edged sword and is of concern to both patients and health care practitioners.", {"entities": []}], [11185, "It is necessary to continue research on potential risks and benefits associated with these interactions, especially in the cohorts of elderly patients and those who are chronically ill.", {"entities": [[123, 130, "Study"]]}], [11186, "Such data is critical for the development of future clinical guidelines in order to better health care outcomes.", {"entities": []}], [11188, "DC and BR have determined the scope of the review article, made substantial revisions and provided new material to the manuscript.", {"entities": []}], [11189, "AB has contributed to determining the overall content of the review and approved the major conclusions.", {"entities": []}], [11190, "SN and KB have contributed expertise in diabetes and herb medicine/nutritional medicine and undertaken final formatting of the manuscript and checking of references.", {"entities": [[40, 48, "Pathology"]]}], [11191, "All authors read and approved the final manuscript.", {"entities": []}], [11192, "As a medical research institute, the National Institute of Complementary Medicine receives research grants and donations from foundations, universities, government agencies, individuals and industry.", {"entities": []}], [11193, "Sponsors and donors provide untied funding for work to advance the vision and mission of the Institute.", {"entities": []}], [11194, "In general NICM respects confidentiality in these arrangements, so as to avoid any likelihood of generating unwelcome further solicitations to the donor or sponsor from outside parties.", {"entities": []}], [11195, "This review was not undertaken as part of a contractual relationship with any organisation and each author who contributed to this manuscript declare that they have no competing interests.", {"entities": []}], [11196, "The authors have received funding support from National Institute of Complementary Medicine (NICM), Western Sydney University for carrying out this work.", {"entities": []}], [11197, "Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.", {"entities": []}], [11198, "Present study investigated the potential effects of Ferula asafetida resin on metabolic activities of human drug metabolizing enzymes: CYP2D6 and CYP3A4.", {"entities": [[52, 68, "Herb name"], [69, 74, "Herb part"], [135, 141, "Target"], [146, 152, "Target"]]}], [11199, "Dextromethorphan (DEX) was used as a marker to assess metabolic activities of these enzymes, based on its CYP2D6 and CYP3A4 mediated metabolism to dextrorphan (DOR) and 3-methoxymorphinan (3-MM), respectively.", {"entities": [[0, 22, "Drug"], [106, 112, "Target"], [117, 123, "Target"]]}], [11200, "For clinical study, healthy human volunteers received a single dose of DEX alone (phase-I) and repeated the same dose after a washout period and four-day Asafetida treatment (phase-II).", {"entities": [[4, 18, "Study"], [20, 27, "Pathology"], [56, 67, "Frequency"], [71, 74, "Drug"], [145, 153, "Duration"], [154, 163, "Herb name"]]}], [11201, "Asafetida showed a concentration dependent inhibition on DOR formation (in vitro) and a 33% increase in DEX/DOR urinary metabolic ratio in clinical study.", {"entities": [[0, 9, "Herb name"], [104, 107, "Drug"], [139, 153, "Study"]]}], [11202, "For CYP3A4, formation of 3-MM in microsomes was increased at low Asafetida concentrations (10, 25 and 50\u00a0\u03bcg/ml) but slightly inhibited at the concentration of 100\u00a0\u03bcg/ml.", {"entities": [[4, 10, "Target"], [65, 74, "Herb name"], [91, 110, "Amount"], [159, 168, "Amount"]]}], [11204, "The findings of this study suggest that Asafetida may have a significant effect on CYP3A4 metabolic activity.", {"entities": [[40, 49, "Herb name"], [83, 89, "Target"]]}], [11205, "Therefore, using Ferula asafetida with CYP3A4 drug substrates should be cautioned especially those with narrow therapeutic index such as cyclosporine, tacrolimus and carbamazepine.", {"entities": [[17, 33, "Herb name"], [39, 45, "Target"], [137, 149, "Drug"], [151, 161, "Drug"], [166, 179, "Drug"]]}], [11206, "Numerous studies have reported that traditional medicines may modulate the metabolic activity of cytochrome P-450 enzymes (CYP).", {"entities": [[97, 127, "Target"]]}], [11207, "Since, the use of traditional medicines is widespread in developing countries, so the extent of modulation of metabolizing enzymes needs to be assessed (Bhattaram et al., 2002; Mukherjee and Wahile, 2006; M\u00fcller and Kanfer, 2011).", {"entities": []}], [11208, "CYP modulating herbs may also influence the metabolism of co-administered CYP drug substrates.", {"entities": []}], [11209, "Such incidences may lead to altered bioavailability and pharmacokinetics of co-administered substrates (M\u00fcller and Kanfer, 2011; Izzo and Ernst, 2001).", {"entities": [[36, 51, "Parameter"]]}], [11210, "Further, the consequences will be more serious with narrow therapeutic index drugs (Barone et al., 2001).", {"entities": []}], [11211, "Several incidences of herb-drug interactions based on modulation of CYP enzymes are reported (Fang et al., 2011; Ho et al., 2011; Han et al., 2011; Boullata, 2005; Doehmer and Eisenbraun, 2012).", {"entities": []}], [11212, "In humans most of the drugs are metabolized by CYP3A4, CYP2D6, CYP2C19, CYP2C9, CYP2E1 and CYP1A2 (Zhou, 2008; Lee et al., 2013a,b).", {"entities": []}], [11213, "Myricetin inhibited the drug metabolizing enzymes CYP3A4 and CYP2C9 (Choi et al., 2010).", {"entities": [[0, 9, "Herb name"], [50, 56, "Target"], [61, 67, "Target"]]}], [11215, "Its oleo-gum resin is obtained by incising or cutting the living roots and rhizomes.", {"entities": [[4, 18, "Herb name"], [65, 70, "Herb part"], [75, 83, "Herb part"]]}], [11216, "The resin is solid or semisolid with alliaceous odor and a bitter acrid taste.", {"entities": [[4, 9, "Herb name"]]}], [11217, "The resinous material comprises ferulic acid, umbelliferone, asaresinotannols, umbelliferone ethers, gums and volatile oils.", {"entities": [[32, 44, "Herb name"], [46, 59, "Herb name"], [61, 77, "Herb name"], [79, 99, "Herb name"], [101, 123, "Herb name"]]}], [11218, "The sulfides of volatile oils are responsible for the characteristic flavor of Asafetida (Sadraei et al., 2003; Kajimoto et al., 1989).", {"entities": [[79, 88, "Herb name"]]}], [11219, "Asafetida has been used as a folk medication for various ailments including flatulence, cough, asthma, bronchitis, hysteria, and convulsions (Eigner and Scholz, 1999).", {"entities": [[0, 9, "Herb name"], [76, 86, "Pathology"], [88, 93, "Pathology"], [95, 101, "Pathology"], [103, 113, "Pathology"], [115, 123, "Pathology"], [129, 140, "Pathology"]]}], [11220, "Present study assesses the potential effects of F. asafetida on the metabolic activities of hepatic metabolizing enzymes CYP3A4 and CYP2D6 using dextromethorphan (DEX) as a probe.", {"entities": [[48, 60, "Herb name"], [121, 127, "Target"], [132, 138, "Target"], [145, 167, "Drug"]]}], [11221, "In vitro investigations were carried out by using human liver microsomes, while an in vivo study was conducted in healthy human subjects.", {"entities": [[86, 96, "Study"], [114, 121, "Pathology"]]}], [11222, "In liver, DEX is mainly metabolized through N- and O-demethylations.", {"entities": [[10, 13, "Drug"]]}], [11223, "The O-demethylation of DEX to dextrorphan (DOR) is predominantly mediated by CYP2D6 (Barnhart, 1980; Schadel et al., 1995).", {"entities": [[23, 26, "Drug"], [77, 83, "Target"]]}], [11224, "Therefore, DEX is commonly used as a marker for CYP2D6 activity (Kerry et al., 1994; Hu et al., 1998; Takashima et al., 2005; Wojtczak et al., 2007).", {"entities": [[11, 14, "Drug"], [48, 54, "Target"]]}], [11225, "The N-demethylation of DEX to 3-methoxymorphinan (3-MM) is mediated by CYP3A4 (Gorski et al., 1994).", {"entities": [[23, 26, "Drug"], [71, 77, "Target"]]}], [11226, "So, DEX has been used as a common probe for both CYP3A and CYP2D6 activities (Spanakis et al., 2009; Yu and Haining, 2001), as well as in vivo in several studies (Ducharme et al., 1996; Funck-Brentano et al., 2005; Jones et al., 1996).", {"entities": [[4, 7, "Drug"], [49, 54, "Parameter"], [59, 65, "Parameter"], [138, 161, "Study"]]}], [11227, "Nicotinamide adenine dinucleotide phosphate (NADPH) and \u03b2-glucuronidase (76,800\u00a0U/ml) were purchased from Helix Pomatia, ICN Biomedicals Inc., Costa Mesa, AC, USA.", {"entities": []}], [11228, "The syrup of dextromethorphan hydrobromide was obtained from Riyadh Pharma, Medical and Cosmetic products Co. Ltd., Riyadh, Saudi Arabia.", {"entities": [[13, 42, "Drug"]]}], [11229, "Dextromethorphan (DEX) hydrobromide, dextrorphan hydrobromide and 3-methoxymorphinan hydrobromide were purchased from ICN Biomedicals Inc., Warrenale, USA.", {"entities": [[0, 35, "Drug"]]}], [11230, "Human liver microsomes having a protein concentration of 20\u00a0mg/ml were purchased from Human Biologics International LLC (HBI, Scottsdale, USA), shipped in small vials with dry ice and stored in a deep freezer at \u221280\u00a0\u00b0C.", {"entities": [[57, 65, "Amount"]]}], [11231, "The internal standards codeine and betaxolol were of USP reference standard.", {"entities": [[23, 30, "Drug"], [35, 44, "Drug"]]}], [11232, "General-purpose reagents (GPR) were used for extraction processes, while HPLC grade solvents were used for HPLC determinations.", {"entities": []}], [11233, "All other materials were of analytical grade.", {"entities": []}], [11234, "This dried resin powder was exhaustively extracted with ethanol for five days by the cold maceration process.", {"entities": [[5, 16, "Extraction process"], [68, 77, "Duration"]]}], [11235, "The ethanolic extract of the resin was filtered and concentrated under reduced pressure using a rotatory evaporator.", {"entities": [[4, 34, "Extraction process"]]}], [11236, "The extract was weighed and its serial dilutions were made with ethyl alcohol (96%) to prepare stock solutions of 1.25, 2.5, 5, 25 and 50\u00a0mg/ml concentrations.", {"entities": []}], [11237, "These stock solutions were stored in a refrigerator until used for incubation.", {"entities": []}], [11238, "Methanolic solution of dextromethorphan (25\u00a0\u03bcM concentration per final incubation mixture) was transferred into eppendorf tubes and dried with the help of nitrogen.", {"entities": [[23, 39, "Drug"]]}], [11239, "The human liver microsomes (comprising 0.25\u00a0mg protein/ml) and appropriate volume of potassium phosphate buffer (0.1\u00a0M, pH 7.4) were added to the DEX loaded tubes and gently mixed.", {"entities": [[39, 57, "Amount"], [146, 149, "Drug"]]}], [11240, "This mixture of DEX, microsomes and buffer was pre-incubated at 37\u00a0\u00b0C for 3\u00a0min in a shaker water bath.", {"entities": [[16, 19, "Drug"]]}], [11241, "The metabolic reaction was initiated by adding 1\u00a0mM NADPH in a final volume of 0.5\u00a0ml.", {"entities": []}], [11242, "Reaction was allowed for 30\u00a0min in the absence (control) or in the presence of 10\u00a0\u03bcl Asafetida resin extract (at concentrations of 10, 25, 50 or 100\u00a0\u03bcg/ml).", {"entities": [[85, 94, "Herb name"]]}], [11243, "The metabolic reaction was terminated by adding 10\u00a0\u03bcl of perchloric acid (70%) with 2\u20133\u00a0min of vigorous shaking.", {"entities": []}], [11244, "The 25\u00a0\u03bcl of internal standard (codeine 50\u00a0\u03bcg/ml) was added to each tube and the tubes were centrifuged at 10,000\u00a0rpm for 15\u00a0min.", {"entities": []}], [11245, "The supernatant was separated and transferred into a clean vial and analyzed by HPLC.", {"entities": []}], [11246, "Study protocol was explained to each volunteer and written informed consent was received from them.", {"entities": []}], [11247, "Study protocol was approved by the Ethics Committee at the College of Medicine, King Saud University; Riyadh (approval number is 1426037).", {"entities": []}], [11248, "The subjects were instructed not to take caffeine or products comprising caffeine, for at least 24\u00a0h before dosing.", {"entities": [[41, 49, "Drug"], [73, 81, "Drug"], [87, 100, "Duration"]]}], [11249, "Further, none of these subjects was receiving any other traditional or conventional medications or grapefruit comprising products for at least 2\u00a0weeks before and during the study.", {"entities": [[134, 150, "Duration"]]}], [11250, "The clinical study was carried out in two phases with a washout period of two weeks.", {"entities": [[4, 18, "Study"], [74, 83, "Duration"]]}], [11251, "In phase-I, all subjects received a single dose of dextromethorphan (10\u00a0ml of DEX hydrobromide syrup (15\u00a0mg/5\u00a0ml).", {"entities": [[34, 47, "Frequency"], [51, 67, "Drug"], [69, 74, "Amount"], [78, 100, "Drug"]]}], [11252, "On the last day of dosing, subjects received 30\u00a0mg DEX (10\u00a0ml of 15\u00a0mg/5\u00a0ml syrup) and Asafetida resin, simultaneously.", {"entities": [[45, 50, "Amount"], [51, 54, "Drug"], [87, 102, "Herb name"]]}], [11253, "The subjects abstained from food for two hours before and after DEX dosing and were instructed to empty their bladder pre-dosing.", {"entities": [[37, 46, "Duration"], [64, 67, "Drug"]]}], [11254, "Urine samples were collected and kept at \u221220\u00a0\u00b0C until analyzed by HPLC.", {"entities": []}], [11256, "The collected urine samples were hydrolyzed by \u03b2-glucuronidase (19,200\u00a0U/ml, incubated for 18\u00a0h) to obtain unconjugated DEX and its metabolites.", {"entities": [[120, 123, "Drug"]]}], [11257, "1\u00a0ml of hydrolyzed urine was vigorously mixed with 5\u00a0ml of extracting solvent mixture (diethyl ether: chloroform: propranolol, 20:9:1 v/v/v) in a clean tube.", {"entities": []}], [11258, "The tube was centrifuged at 14,500g for 10\u00a0min.", {"entities": []}], [11259, "The organic layer was separated and vigorously mixed with 300\u00a0\u03bcl of 0.1\u00a0N hydrochloric acid and centrifuged at 14,500g for 10\u00a0min.", {"entities": []}], [11260, "The aqueous layer was separated and betaxolol (50\u00a0\u03bcl of 50\u00a0\u03bcg/ml) was added as internal standard to each sample.", {"entities": [[36, 45, "Drug"]]}], [11261, "Samples were analyzed by using HPLC.", {"entities": []}], [11262, "DEX and its metabolites were analyzed by Shimadzu Class-VPV 5.02 HPLC instrument using two slightly different analytical methods (Bendriss et al., 2001; Min et al., 1999).", {"entities": [[0, 3, "Drug"]]}], [11263, "The human liver microsomal analytes were eluted on a Nova-Pak\u00ae phenyl column (5\u00a0\u03bcm, 150\u00a0\u00d7\u00a03.9\u00a0mm) using a mobile phase that was composed of an aqueous mixture (1.5% glacial acetic acid and 0.1% triethylamine) and acetonitrile (75:25 v/v), and flowing at a rate of 1\u00a0ml/min.", {"entities": []}], [11264, "Urine samples were eluted on a Zorbax SB-CN column (5\u00a0\u03bcm, 250\u00a0\u00d7\u00a04.6\u00a0mm).", {"entities": []}], [11265, "The mobile phase for analysis of urine samples was composed of the aqueous mixture (1.5% glacial acetic acid and 0.1% triethylamine) and acetonitrile (87.5:12.5 v/v).", {"entities": []}], [11266, "The pH of the mobile phase was adjusted to 3 by orthophosphoric acid.", {"entities": []}], [11267, "Analytes were monitored using a fluorescence detector at excitation and emission wavelengths of 280 and 330\u00a0nm, respectively.", {"entities": []}], [11268, "Concentrations of DEX and its metabolites in samples were estimated based on the calibration curves of the analytes.", {"entities": [[18, 21, "Drug"]]}], [11269, "The in vitro formation of DEX metabolites in the presence of Asafetida was compared with the control by using a one-way analysis of variance (ANOVA), and a Post hoc Scheffe\u2019s multiple comparison test with a significant P value \u2a7d0.05.", {"entities": [[26, 29, "Drug"], [61, 70, "Herb name"]]}], [11270, "Student\u2019s paired t-test was used for statistical analysis of results obtained from clinical study.", {"entities": [[83, 97, "Study"]]}], [11271, "Statistical analysis was performed by using Graph-Pad Prism version 3.0 for Windows (San Diego, CA, USA).", {"entities": []}], [11272, "In the in vitro study, Asafetida resin alcoholic extract inhibited the formation of DOR from DEX in a concentration dependent manner (Fig.", {"entities": [[7, 21, "Study"], [23, 56, "Extraction process"], [93, 96, "Drug"]]}], [11273, "1).", {"entities": []}], [11274, "Formation of 3-MM was potentiated at lower concentrations of the extract, while at the highest Asafetida concentration it did not show any significant effect on 3-MM (Fig.", {"entities": [[95, 104, "Herb name"]]}], [11275, "2).", {"entities": []}], [11276, "The maximum inhibition (about 80% of control) of DOR formation was observed at the highest concentration (100\u00a0\u03bcg/ml) of Asafetida extract.", {"entities": [[106, 115, "Amount"], [120, 129, "Herb name"]]}], [11277, "Order of inhibition of DOR formation was observed as 100\u00a0>\u00a050\u00a0>\u00a025\u00a0\u2a7e\u00a010\u00a0\u03bcg/ml Asafetida extract.", {"entities": [[53, 77, "Amount"], [78, 87, "Herb name"]]}], [11278, "Asafetida resin extract at lower concentrations of 10, 25 and 50\u00a0\u03bcg/ml activates the formation of 3-MM.", {"entities": [[0, 15, "Herb name"], [51, 70, "Amount"]]}], [11279, "The activation was highest at 25\u00a0\u03bcg/ml concentration.", {"entities": [[30, 38, "Amount"]]}], [11280, "The highest concentration (100\u00a0\u03bcg/ml) of Asafetida extract did not produce any remarkable effect on the formation of 3-MM (Fig.", {"entities": [[27, 36, "Amount"], [41, 50, "Herb name"]]}], [11281, "2).", {"entities": []}], [11284, "Almost 75% of DOR was excreted in urine when compared with the control.", {"entities": []}], [11285, "The percent amounts of DOR and 3-MM excreted in the urine in the presence of Asafetida (compared to control) were about 75% and 50%, respectively.", {"entities": [[77, 86, "Herb name"]]}], [11286, "The in vitro as well as in vivo investigations were carried out to study the effect of Asafetida resin (ethanolic extract and powder) on the metabolic activities of CYP2D6 and CYP3A4 hepatic enzymes.", {"entities": [[87, 102, "Herb name"], [104, 132, "Extraction process"], [165, 171, "Target"], [176, 198, "Target"]]}], [11287, "Human liver microsomes were used for in vitro investigation.", {"entities": []}], [11288, "The in vivo study was conducted on healthy human volunteers.", {"entities": [[7, 17, "Study"], [35, 42, "Pathology"]]}], [11289, "Dextromethorphan and its metabolite were measured in urine samples.", {"entities": [[0, 16, "Drug"]]}], [11290, "In vitro microsomal model was used as a rapid screening tool for interaction studies.", {"entities": [[65, 84, "Study"]]}], [11291, "However, in vitro observation does not guarantee whether the same effect will occur in clinical practice, because the contribution of some physiological factors remains unaccounted.", {"entities": []}], [11292, "Therefore, clinical significance of an in vitro study cannot be adopted without in vivo confirmation.", {"entities": [[42, 53, "Study"]]}], [11293, "Thus the formation of DEX metabolites under in vitro and in vivo conditions was used to assess the metabolic activities of CYP2D6 and CYP3A4.", {"entities": [[22, 25, "Drug"], [123, 129, "Target"], [134, 140, "Target"]]}], [11294, "DEX has been used as a probe for CYP2D6 and CYP3A4 enzymes.", {"entities": [[0, 3, "Drug"], [33, 39, "Target"], [44, 50, "Target"]]}], [11295, "It is a non-narcotic antitussive agent, safe, effective and non-invasive marker.", {"entities": [[8, 38, "Drug"]]}], [11296, "It is metabolized by N- and O-demethylations catalyzed by CYP2D6 and CYP3A4 to form metabolites such as DOR and 3-MM, respectively.", {"entities": []}], [11297, "Asafetida significantly inhibited the formation of DOR in liver microsomes.", {"entities": [[0, 9, "Herb name"]]}], [11298, "This in vitro inhibition was observed as concentration dependent and suggested that Asafetida may have the potential to alter the pharmacokinetics of CYP2D6.", {"entities": [[84, 93, "Herb name"], [150, 156, "Target"]]}], [11299, "But on contrary Asafetida potentiates the in vitro activity of CYP3A4 at lower concentrations, but did not produce any remarkable effect at the highest concentration.", {"entities": [[16, 25, "Herb name"], [63, 69, "Target"]]}], [11300, "Although activation of CYP-mediated reactions has been reported in several previous in vitro studies (Atkins et al., 2001; Hutzler et al., 2003; Korzekwa et al., 1998; Tracy, 2006), its in vivo relevance is still unclear.", {"entities": [[87, 100, "Study"]]}], [11301, "Unlike induction, activation is not associated with an increase in the protein level of the activated enzyme but only with its activity.", {"entities": []}], [11302, "One possible mechanism of CYP3A4 activation, which has been previously suggested by several investigators, is the presence of multiple binding sites at the enzyme active site (Atkins et al., 2001; Korzekwa et al., 1998; Tracy, 2006).", {"entities": [[26, 32, "Target"]]}], [11303, "This explanation is supported by the fact that several CYP3A4 activators are also known to be metabolized by this enzyme.", {"entities": [[55, 61, "Target"]]}], [11304, "Based on that, the activation by Asafetida observed in this in vitro study could be due to the ability of at least one of its constituents to bind to the CYP3A4 binding site leading to an increase in the rate of 3-MM formation possibly by inducing conformational changes in the enzyme.", {"entities": [[33, 42, "Herb name"], [60, 74, "Study"], [154, 160, "Target"]]}], [11305, "Activation of CYP3A4 by Asafetida has not been reported before and further in vitro studies that investigate the potential effects of individual Asafetida constituents would be helpful in understanding the mechanism of the observed activation, which is out of the scope of this study.", {"entities": [[14, 20, "Target"], [24, 33, "Herb name"], [78, 91, "Study"], [145, 154, "Herb name"]]}], [11306, "Although in vitro metabolic activation has not been confirmed in vivo before, the opposite significant inhibitory effect on 3-MM observed in the clinical study is difficult to explain.", {"entities": [[124, 128, "Target"], [145, 159, "Study"]]}], [11307, "However, such opposite effects suggest that this interaction may be time and concentration dependent.", {"entities": []}], [11308, "Dose of Asafetida and duration of treatment may influence the outcome of the interaction.", {"entities": [[8, 17, "Herb name"]]}], [11309, "Another possible explanation for the significant in vivo inhibition that was not seen in vitro could be due to the ability of Asafetida to affect CYP3A4 protein expression, which does not occur in the microsomal in vitro model and is considered to be one of its major limitations.", {"entities": [[126, 135, "Herb name"], [146, 171, "Target"]]}], [11310, "Numerous clinical studies have reported the effects of some natural products on the metabolism of conventional drugs.", {"entities": [[9, 25, "Study"]]}], [11311, "Therefore, the clinical study was conducted to confirm the in vitro results.", {"entities": [[15, 29, "Study"]]}], [11313, "Clinical study findings suggest that Asafetida has a significant inhibitory effect on human CYP3A4 and a marginal effect on CYP2D6.", {"entities": [[0, 14, "Study"], [37, 46, "Herb name"], [92, 98, "Target"], [124, 130, "Target"]]}], [11314, "These findings were consistent with animal studies conducted on rats, wherein oral administration of F. asafetida for one week resulted in the reduction of mRNA and protein of CYP3A, in rat liver (Data unpublished).", {"entities": [[36, 50, "Study"], [101, 113, "Herb name"], [118, 126, "Duration"], [176, 181, "Target"]]}], [11315, "In conclusion, the significant Asafetida inhibitory effect on CYP3A4 metabolic activity was an important finding of this study.", {"entities": [[31, 40, "Herb name"], [62, 68, "Target"]]}], [11316, "Based on that, taking Asafetida with CYP3A4 drug substrates should be cautioned, especially those known to have narrow therapeutic index such as cyclosporine, tacrolimus, everolimus, carbamazepine and quinidine.", {"entities": [[22, 31, "Herb name"], [37, 43, "Target"], [145, 157, "Drug"], [159, 169, "Drug"], [171, 181, "Drug"], [183, 196, "Drug"], [201, 210, "Drug"]]}], [11317, "The author(s) declare that they do not have any conflict of interests and approved the final version of this article.", {"entities": []}], [11318, "The authors acknowledge the College of Pharmacy Research Center and the Deanship of Scientific Research in the King Saud University for financial and logistic support.", {"entities": []}], [11319, "Peer review under responsibility of King Saud University.", {"entities": []}], [11320, "Effect of Asafetida on the formation of DOR from DEX in human liver microsomes (n\u00a0=\u00a03, mean\u00a0\u00b1\u00a0SD).", {"entities": [[10, 19, "Herb name"], [49, 52, "Drug"]]}], [11321, "Formation of the metabolite is expressed as nM/mg protein/min.", {"entities": []}], [11322, "Effect of Asafetida on the formation of 3-MM from DEX in human liver microsomes (n\u00a0=\u00a03, mean\u00a0\u00b1\u00a0SD).", {"entities": [[10, 19, "Herb name"], [50, 53, "Drug"]]}], [11323, "Formation of the metabolite is expressed as nM/mg protein/min.", {"entities": []}], [11324, "Urinary metabolic ratio (MR) of DEX with its metabolites in human subjects (n\u00a0=\u00a06).", {"entities": [[32, 35, "Drug"]]}], [11325, "Many cancer patients use integrative therapies with a combination of natural products and diets.", {"entities": [[5, 11, "Pathology"]]}], [11326, "In the Western world, integrative medicine is often not shared with oncologists even during antineoplastic treatments.", {"entities": [[92, 117, "Drug"]]}], [11327, "This behavior stems from the unmet needs of cancer patients who may feel oncologists' underestimation of their symptoms and spiritual aspects.", {"entities": [[44, 50, "Pathology"]]}], [11328, "This case report demonstrates the potential harm of inadequate diet and nutraceutical intake in a 68-year-old woman with metastatic estrogen receptor-positive, human epidermal growth factor receptor-2-negative breast cancer.", {"entities": [[5, 16, "Study"], [98, 109, "Age"], [110, 115, "Sex"], [121, 223, "Pathology"]]}], [11329, "Her care team recommended hormone therapy with abemaciclib plus fulvestrant.", {"entities": [[26, 41, "Drug"], [47, 58, "Drug"], [64, 75, "Drug"]]}], [11330, "Her diarrhea started after 10 days of therapy and did not disappear, despite the use of loperamide, causing a significant reduction in adherence and dose intensity of abemaciclib.", {"entities": [[4, 12, "Pathology"], [21, 34, "Duration"], [88, 98, "Drug"], [167, 178, "Drug"]]}], [11331, "The patient finally disclosed to her oncologist she was following a detoxifying diet and taking several nutraceuticals.", {"entities": []}], [11332, "Her diarrhea was correlated with abemaciclib but most probably exacerbated and prolonged by the diet.", {"entities": [[4, 12, "Pathology"], [33, 44, "Drug"]]}], [11333, "Evaluation of disease after 3 months showed progressive disease.", {"entities": []}], [11334, "Integrative medicine should be in the multidisciplinary management of cancer patients to avoid potentially harmful events and ameliorate patients' quality of life in a holistic approach.", {"entities": [[70, 76, "Pathology"]]}], [11335, "Metastatic breast cancer still represents a major cause of death in women [1].", {"entities": [[0, 24, "Pathology"], [59, 64, "Pathology"], [68, 73, "Sex"]]}], [11336, "To date, patients with estrogen receptor-positive, human epidermal growth factor receptor-2-negative (her-2) breast carcinoma are best managed with a combination of antihormonal agents and cyclin-dependent kinase 4 and 6 inhibitors.", {"entities": [[23, 125, "Pathology"], [165, 184, "Drug"], [189, 231, "Drug"]]}], [11337, "Among the latter class, abemaciclib is the most potent in preclinical studies [2].", {"entities": [[24, 35, "Drug"], [58, 77, "Study"]]}], [11338, "Such combination therapy may achieve a median disease-free survival of 46 months with good tolerability in breast cancer patients progressing during endocrine therapy [3].", {"entities": [[107, 120, "Pathology"], [149, 166, "Drug"]]}], [11339, "Recently, the role of integrative medicine has gained popularity in a more open, multidisciplinary, holistic way of interpreting oncology and unmet patients' needs [4, 5, 6].", {"entities": []}], [11340, "Many patients follow detoxifying or anticancer diets and take nutraceuticals often without discussion with their treating oncologists [7].", {"entities": []}], [11341, "This attitude toward the use of nutraceuticals should be carefully evaluated in a team of integrative medicine since natural products does not always correspond to safety in oncology [8].", {"entities": []}], [11342, "This article reports a negative interaction between detoxifying diet and nutraceuticals with adherence to antihormonal therapy in a woman with advanced estrogen receptor-positive, her-2-negative breast cancer.", {"entities": [[106, 126, "Drug"], [132, 137, "Sex"], [143, 208, "Pathology"]]}], [11343, "Written informed consent was obtained from the patient for publication of this case report and any accompanying images.", {"entities": [[79, 90, "Study"]]}], [11344, "A 68-year-old woman \u2212 a housewife \u2212 presented with suspect progressive breast cancer while taking adjuvant letrozole for 3 years.", {"entities": [[2, 13, "Age"], [14, 19, "Sex"], [59, 84, "Pathology"], [107, 116, "Drug"], [117, 128, "Duration"]]}], [11345, "In February 2018, she was diagnosed with breast cancer and received conservative left breast surgery with axillary dissection after sentinel lymph node analysis was positive for cancer.", {"entities": [[41, 54, "Pathology"], [178, 184, "Pathology"]]}], [11346, "The systemic staging was negative for metastatic disease.", {"entities": [[38, 56, "Pathology"]]}], [11347, "Pathology showed a ductal infiltrating carcinoma estrogen receptor 80%, progestin receptor 35%, her-2 score 1, and Ki67 40%.", {"entities": []}], [11348, "The clinical and pathological stage was pT2, N1, M0.", {"entities": []}], [11349, "She received an adjuvant chemotherapy regimen with epirubicin and cyclophosphamide every 3 weeks for 4 cycles, followed by paclitaxel for 12 weeks, complementary radiotherapy on the left breast and the homolateral axilla, and started adjuvant letrozole.", {"entities": [[16, 37, "Drug"], [51, 61, "Drug"], [66, 82, "Drug"], [83, 109, "Frequency"], [123, 133, "Drug"], [134, 146, "Duration"], [243, 252, "Drug"]]}], [11350, "In May 2020, she was admitted to our outpatients' clinic because of a Ca15.3 increase.", {"entities": [[70, 76, "Parameter"]]}], [11351, "A positron emission tomography/CT (PET/CT) showed progressive disease at nodes, bone, and an unspecific liver uptake.", {"entities": []}], [11352, "Physical examination was nonsignificant, and the patient denied any symptoms of the disease but moderate fatigue.", {"entities": [[105, 112, "Pathology"]]}], [11353, "She was classified as an estrogen receptor-positive, her-2/neu-negative, hormone-resistant breast carcinoma.", {"entities": [[25, 107, "Pathology"]]}], [11354, "The oncologist quitted letrozole.", {"entities": [[23, 32, "Drug"]]}], [11355, "Based on scientific data, the oncologist proposed a systemic treatment with fulvestrant 500 mg every 2 weeks as a loading dose 3 times and then every 4 weeks, plus abemaciclib 150 mg bid on a continuous schedule [3].", {"entities": [[76, 87, "Drug"], [88, 94, "Amount"], [95, 108, "Frequency"], [127, 157, "Frequency"], [164, 175, "Drug"], [176, 182, "Amount"], [183, 186, "Frequency"]]}], [11356, "The patient's performance status was adequate for abemaciclib plus fulvestrant regimen with an Eastern Cooperative Oncology Group Performance Status score of 1.", {"entities": [[50, 61, "Drug"], [67, 78, "Drug"]]}], [11357, "The oncologist carefully interviewed the patient for concomitant gastrointestinal diseases that could contraindicate abemaciclib use and other drug assumptions.", {"entities": [[65, 90, "Pathology"], [117, 128, "Drug"]]}], [11358, "The oncologist performed a drug-drug interaction evaluation employing a drug checker tool and explained in detail abemaciclib to the patient and her daughter, including written precise suggestions concerning potential side effects.", {"entities": [[114, 125, "Drug"], [218, 230, "Pathology"]]}], [11359, "More specifically, the oncologist stressed the precocious use of loperamide and dietary modification in case of diarrhea.", {"entities": [[65, 75, "Drug"], [112, 120, "Pathology"]]}], [11360, "He recommended immediately taking loperamide at first or second liquid stool and contacting the medical oncology team via a WhatsApp messenger system (Fig.", {"entities": [[34, 44, "Drug"]]}], [11361, "1).", {"entities": []}], [11362, "After 10 days, she complained of grade 2 diarrhea, according to the National Cancer Institute Common Toxicity Criteria version 5.0 [9].", {"entities": [[33, 49, "Pathology"]]}], [11363, "Nurses called the patient to assure she was following a correct astringent diet and loperamide assumption.", {"entities": [[84, 94, "Drug"]]}], [11364, "A blood test showed only a mild increase in serum creatinine.", {"entities": [[50, 60, "Parameter"]]}], [11365, "Since she reported intermittent diarrhea, the oncologist reduced the abemaciclib dose to 100 mg bid, but intestinal movements remained unchanged and stopped abemaciclib for 3 days.", {"entities": [[19, 40, "Pathology"], [69, 80, "Drug"], [89, 95, "Amount"], [96, 99, "Frequency"], [157, 168, "Drug"], [169, 179, "Duration"]]}], [11366, "Such drug-free periods occurred every 2 weeks, with no other significant side effects.", {"entities": [[32, 45, "Frequency"], [73, 85, "Pathology"]]}], [11367, "At this point, the patient disclosed she was following a detoxifying diet prescribed by a dietician.", {"entities": []}], [11368, "Oncologists were not aware of it.", {"entities": []}], [11369, "The dietician did not make any effort to contact the managing oncologists.", {"entities": []}], [11370, "Table 1 depicts the diet components.", {"entities": []}], [11371, "As shown in Table 2, she was also taking several integrative agents such as broccoli extracts (250 mg bid), garlic extracts (500 mg bid), high-dose vitamin D, curcumin plus black pepper (526 mg bid), green tea (3 serving/day), vitamin C (500 mg/day), lipoic acid 100 mg/day, coenzyme q10 100 mg/day, vitamin K (250 mcg/day), selenium (75 mcg/day), and iodine (150 mcg/day).", {"entities": [[76, 93, "Extraction process"], [95, 101, "Amount"], [102, 105, "Frequency"], [108, 123, "Extraction process"], [125, 131, "Amount"], [132, 135, "Frequency"], [159, 167, "Herb name"], [173, 185, "Herb name"], [187, 193, "Amount"], [194, 197, "Frequency"], [200, 209, "Herb name"], [211, 224, "Frequency"]]}], [11372, "The dietary prescription also reported that \u201cpeople may experience weakness, stool modification including diarrhea, and generalized pain, which are positive signs of detoxification.\u201d Accordingly, the patient showed evident difficulties in decoding her gastrointestinal symptoms.", {"entities": [[67, 75, "Pathology"], [106, 114, "Pathology"], [120, 136, "Pathology"], [252, 277, "Pathology"]]}], [11373, "The oncologist stopped the diet, and diarrhea frequency reduced in 2 weeks.", {"entities": [[37, 45, "Pathology"]]}], [11374, "The dose intensity of abemaciclib was 68.5% of the planned one, according to the Hyrnuk and Bush formula [10].", {"entities": [[22, 33, "Drug"]]}], [11375, "After 3 months of abemaciclib and fulvestrant, a new PET/CT showed progressive disease according to the RECIST criteria.", {"entities": [[18, 29, "Drug"], [34, 45, "Drug"]]}], [11376, "Besides reversible diarrhea G3 and renal toxicity (creatinine) G1, no other significant adverse events were observed according to the NCCN-CTC criteria [9].", {"entities": [[8, 27, "Pathology"], [35, 49, "Pathology"], [51, 61, "Parameter"], [88, 102, "Pathology"]]}], [11377, "The oncologist's decision was to withheld fulvestrant and abemaciclib and proposed a second-line treatment of everolimus and exemestane.", {"entities": [[42, 53, "Drug"], [58, 69, "Drug"], [110, 120, "Drug"], [125, 135, "Drug"]]}], [11378, "She is still alive during the time of writing.", {"entities": []}], [11379, "Abemaciclib may be administered with or without food, and food-drug interaction analysis showed that diet has modest effects on the pharmacokinetics of abemaciclib [11].", {"entities": [[0, 11, "Drug"], [152, 163, "Drug"]]}], [11380, "A high-fat, high-calorie meal administered to healthy subjects increased the C-max and AUC of abemaciclib plus its active metabolites by 26% and 9%, respectively.", {"entities": [[46, 53, "Pathology"], [77, 82, "Parameter"], [87, 90, "Parameter"], [94, 105, "Drug"]]}], [11381, "Grapefruit juice may increase the plasma concentrations of abemaciclib and therefore should be avoided.", {"entities": [[0, 16, "Extraction process"], [59, 70, "Drug"]]}], [11382, "The possible mechanism is the inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.", {"entities": [[44, 54, "Target"], [134, 144, "Herb name"]]}], [11383, "Inhibition of hepatic CYP450 3A4 may also contribute.", {"entities": [[14, 32, "Target"]]}], [11384, "According to product labeling, abemaciclib systemic exposure (AUC) is predicted to increase up to 16-fold when administered with the potent CYP450 3A4 inhibitor ketoconazole.", {"entities": [[31, 42, "Drug"], [62, 65, "Parameter"], [140, 160, "Target"], [161, 173, "Drug"]]}], [11385, "In this study, we report the inappropriate use of a detoxifying diet with a massive daily administration of herbal and nutraceutical agents in a female patient treated with fulvestrant plus abemaciclib for metastatic breast cancer.", {"entities": [[145, 151, "Sex"], [173, 184, "Drug"], [190, 201, "Drug"], [206, 230, "Pathology"]]}], [11386, "This patient showed poor response to antihormonal therapy, as shown by PET/CT, and reported chronic diarrhea, which hampered treatment adherence and drug dose intensity by one-third of the planned dose.", {"entities": [[37, 57, "Drug"], [92, 108, "Pathology"]]}], [11387, "Neither the patient nor the family caregiver or the dietician informed the oncology center.", {"entities": []}], [11388, "Suspension of the diet by the treating oncologist resulted in the weakening of diarrhea.", {"entities": [[79, 87, "Pathology"]]}], [11389, "Although usual diet habits seem not to influence abemaciclib pharmacokinetics, an incorrect diet may cause gastrointestinal disturbances.", {"entities": [[49, 60, "Drug"], [107, 136, "Pathology"]]}], [11390, "These may favor the occurrence of abemaciclib-related diarrhea, causing dose reductions and poor adherence and eventually negatively influencing patients' outcomes and quality of life.", {"entities": [[34, 45, "Drug"], [54, 62, "Pathology"]]}], [11391, "Our patient was taking many compounds with possible negative interaction on treatment outcome.", {"entities": []}], [11392, "Supplementation with coenzyme q10 and vitamins caused a more unsatisfactory outcome in patients with metastatic breast cancer treated with chemotherapy in a Southwest Oncology Group trial [12].", {"entities": [[101, 125, "Pathology"], [139, 151, "Drug"]]}], [11393, "Although the herb-drug interaction risk for short-term use of garlic is low, prolonged exposure to concentrated garlic extracts may counteract the efficacy of drugs whose disposition depends on the human efflux transporter ABCB1 which may occur in tumor cells [13, 14].", {"entities": [[62, 68, "Herb name"], [99, 127, "Extraction process"], [211, 228, "Target"]]}], [11394, "Even if the check for interactions between the single nutraceuticals and antihormonal agents employed in our patient was negative, knowledge on the possible effects of the whole \u201corchestra\u201d of agents is poor.", {"entities": [[73, 92, "Drug"]]}], [11395, "In clinical practice, oncologists commonly check drug-drug interactions when prescribing modern targeted therapies.", {"entities": []}], [11396, "On the other hand, herb-drug or food/diet-drug is far less explored, even if herb-drug interaction checkers are available [15].", {"entities": []}], [11397, "In this patient, while such a check did not show negative interaction between antihormonal agents and supplements, the diet followed caused a sharpening and prolongation of liquid stools, causing poor adherence and dose reduction of abemaciclib.", {"entities": [[78, 97, "Drug"], [233, 244, "Drug"]]}], [11398, "Moreover, the reckless pieces of information about possible effects of diet, such as fatigue and loose stools, elicited confusion in the patient.", {"entities": [[85, 92, "Pathology"], [97, 109, "Pathology"]]}], [11399, "Today, herbal supplements and nutraceuticals in various forms can be easily purchased over the counter and widely employed by cancer patients, often without discussing with their oncologists.", {"entities": [[126, 132, "Pathology"]]}], [11400, "This hidden behavior is probably related to sometimes justified patients' perception that their needs in terms of quality of life are underweighted by most oncologists far more concentrated on therapy management [16].", {"entities": []}], [11401, "Herbal supplements and nutraceuticals are often self-prescribed or suggested by friends, other patients, or prescribed by professionals other than oncologists.", {"entities": []}], [11402, "Such prescriptions are often not shared, even if patients should discuss its use with the managing oncologist and pharmacist.", {"entities": []}], [11403, "The regulatory agencies do not pay the same attention for pharmaceutical drugs to herbals, dietary supplements, and their manufacturers.", {"entities": []}], [11404, "Although integrative medicine has a significant positive role in managing people affected by cancer, a careful approach is advisable since herbal supplements and nutraceuticals may enhance prescription medications' side effects and block the intended therapeutic drug efficacy.", {"entities": [[93, 99, "Pathology"], [215, 227, "Pathology"]]}], [11405, "It is then advisable that deep and correct information be delivered to patients about the potential benefits but especially about the possible interactions of herbal supplements and nutraceuticals that may occur with the standard therapies administered.", {"entities": []}], [11406, "For this purpose, a multidisciplinary approach is essential to treat this kind of patients.", {"entities": []}], [11407, "The study is exempt from ethics committee approval because every diagnostic and therapeutic action for the primary pathology was performed according to the current standards and guidelines.", {"entities": []}], [11408, "Written informed consent was obtained from the patient for publication of this case report and any accompanying images.", {"entities": []}], [11409, "The authors declared no potential conflicts of interest concerning the research, authorship, and/or publication of this article.", {"entities": []}], [11410, "The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: this study was supported by the Network in Integrative Medicine in Oncology Program of the GSTU Foundation, Palermo, Italy.", {"entities": []}], [11411, "V.G.", {"entities": []}], [11412, "and M.R.V.", {"entities": []}], [11413, "contributed to study concept and design.", {"entities": []}], [11414, "V.G.", {"entities": []}], [11415, "and D.P.", {"entities": []}], [11416, "contributed to drafting of the manuscript.", {"entities": []}], [11417, "All authors contributed to acquisition, analysis, and interpretation of data, critical revision of the manuscript, and read and approved the final manuscript.", {"entities": []}], [11418, "All data generated or analyzed during this study are included in this article.", {"entities": []}], [11419, "Further inquiries can be directed to the corresponding author.", {"entities": []}], [11420, "This study was conducted at the La Maddalena Cancer Center, Palermo, Italy.", {"entities": []}], [11421, "Treatment timeline.", {"entities": []}], [11422, "Diet composition Nutraceuticals", {"entities": []}]]}